10027919	0	(S1 (S (NP (JJ Doc_10027919_0_16_Chemical) (NNS suppresses)) (VP (VBP Doc_10027919_28_57_Disease) (PP (IN without) (S (VP (VBG inducing) (NP (NN Doc_10027919_75_92_Disease)) (PP (IN in) (NP (NP (NNS dogs)) (PP (IN with) (NP (NNP Doc_10027919_106_119_Disease))))))))) (. .)))
10027919	1	(S1 (S (NP (JJ Doc_10027919_133_143_Chemical) (NN therapy)) (VP (VP (VBZ suppresses) (NP (NP (NN serum) (NNS levels)) (PP (IN of) (NP (JJ parathyroid) (NN hormone)))) (PRN (-LRB- -LRB-) (NP (NNP PTH)) (-RRB- -RRB-)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_10027919_222_235_Disease)))))) (CC but) (VP (AUX has) (NP (NP (JJ several) (NNS drawbacks)) (, ,) (PP (VBG including) (NP (NP (JJ Doc_10027919_273_286_Disease) (NN and/or)) (VP (VBD marked) (NP (NNP Doc_10027919_301_329_Disease))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VB lead) (PP (TO to) (NP (NNP Doc_10027919_349_370_Disease)))))))))))) (. .)))
10027919	2	(S1 (S (NP (NP (DT A) (JJ new) (JJ Doc_10027919_378_387_Chemical) (NN analogue)) (, ,) (NP (NP (NNP Doc_10027919_398_414_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_10027919_416_419_Chemical)) (-RRB- -RRB-))) (, ,)) (VP (AUX has) (VP (AUX been) (VP (VBN shown) (S (VP (TO to) (VP (AUX have) (NP (JJ promising) (NNS characteristics)))))))) (. .)))
10027919	3	(S1 (S (NP (DT This) (NN study)) (VP (AUX was) (VP (VBN undertaken) (S (VP (TO to) (VP (VB determine) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NNP OCT))) (PP (IN on) (NP (NP (NP (JJ serum) (JJ PTH) (NNS levels)) (CC and) (NP (NN bone) (NN turnover))) (PP (IN in) (NP (NP (NNS states)) (PP (IN of) (NP (NP (JJ normal)) (CC or) (NP (NNP Doc_10027919_591_614_Disease)))))))))))))) (. .)))
10027919	4	(S1 (S (NP (CD Sixty) (NNS dogs)) (VP (AUX were) (ADJP (ADJP (ADJP (RB either) (JJ nephrectomized)) (PRN (-LRB- -LRB-) (NP (NNP Nx)) (, ,) (NP (NNP N) (SYM =) (CD 38)) (-RRB- -RRB-))) (CC or) (ADJP (ADJP (JJ sham-operated)) (PRN (-LRB- -LRB-) (NP (NNP Sham)) (, ,) (NP (NNP N) (SYM =) (CD 22)) (-RRB- -RRB-))))) (. .)))
10027919	5	(S1 (S (NP (DT The) (NNS animals)) (VP (VBD received) (NP (JJ supplemental) (NNP Doc_10027919_743_752_Chemical)) (S (VP (TO to) (VP (VB enhance) (NP (JJ PTH) (NN secretion)))))) (. .)))
10027919	6	(S1 (S (S (PP (NP (CD Fourteen) (NNS weeks)) (IN after) (NP (NP (DT the) (NN start)) (PP (IN of) (NP (JJ Doc_10027919_813_822_Chemical) (NN supplementation))))) (, ,) (NP (NP (NN half)) (PP (IN of) (NP (DT the) (NNP Nx) (CC and) (NNP Sham) (NNS dogs)))) (VP (VBD received) (NP (NP (NNS doses)) (PP (IN of) (NP (NNP Doc_10027919_887_890_Chemical))) (PRN (-LRB- -LRB-) (NP (NP (CD three) (NNS times)) (PP (IN per) (NP (NN week)))) (-RRB- -RRB-))))) (: ;) (S (NP (DT the) (JJ other) (NN half)) (VP (AUX were) (VP (VBN given) (NP (NN vehicle)) (PP (IN for) (NP (CD 60) (NNS weeks)))))) (. .)))
10027919	7	(S1 (S (ADVP (RB Thereafter)) (, ,) (NP (NP (DT the) (NN treatment) (NNS modalities)) (PP (IN for) (NP (NP (DT a) (NN subset)) (PP (IN of) (NP (NNS animals)))))) (VP (AUX were) (VP (VBN crossed) (PRT (RP over)) (PP (IN for) (NP (DT an) (JJ additional) (CD eight) (NNS months))))) (. .)))
10027919	8	(S1 (S (S (NP (NP (JJ Biochemical) (CC and) (JJ hormonal) (NNS indices)) (PP (IN of) (NP (NP (NNP Doc_10027919_1110_1117_Chemical)) (CC and) (NP (NN bone) (NN metabolism))))) (VP (AUX were) (VP (VBN measured) (PP (IN throughout) (NP (DT the) (NN study)))))) (, ,) (CC and) (S (NP (NN bone) (NNS biopsies)) (VP (AUX were) (VP (AUX done) (PP (PP (IN at) (NP (NP (NN baseline)) (, ,) (NP (NP (NP (CD 60) (NNS weeks)) (PP (IN after) (NP (NNP Doc_10027919_1230_1233_Chemical)))) (CC or) (NP (NN vehicle) (NN treatment))))) (, ,) (CC and) (PP (IN at) (NP (NP (DT the) (NN end)) (PP (IN of) (NP (DT the) (JJ crossover) (NN period))))))))) (. .)))
10027919	9	(S1 (S (PP (IN In) (NP (JJ Nx) (NNS dogs))) (, ,) (NP (NNP Doc_10027919_1317_1320_Chemical)) (ADVP (RB significantly)) (VP (VBD decreased) (NP (NN serum) (NN PTH) (NNS levels)) (PP (ADVP (RB soon)) (IN after) (NP (NP (DT the) (NN induction)) (PP (IN of) (NP (NNP Doc_10027919_1390_1409_Disease)))))) (. .)))
10027919	10	(S1 (S (PP (IN In) (NP (JJ long-standing) (NNP Doc_10027919_1428_1457_Disease))) (, ,) (NP (NP (NNP OCT)) (PRN (-LRB- -LRB-) (NP (CD 0.03) (NN microg/kg)) (-RRB- -RRB-))) (VP (VBD stabilized) (NP (NN serum) (NN PTH) (NNS levels)) (PP (IN during) (NP (DT the) (JJ first) (NNS months)))) (. .)))
10027919	11	(S1 (S (S (NP (NN Serum) (NN PTH) (NNS levels)) (VP (VBD rose) (ADVP (RB thereafter)))) (, ,) (CC but) (S (NP (DT the) (NN rise)) (VP (AUX was) (ADJP (ADJP (RBR less) (JJ pronounced)) (PP (VBN compared) (PP (IN with) (NP (NN baseline)))) (PP (IN than) (NP (NP (DT the) (NN rise)) (VP (VBN seen) (PP (IN in) (NP (JJ Nx) (NN control))))))))) (. .)))
10027919	12	(S1 (S (NP (DT These) (NNS effects)) (VP (AUX were) (VP (VBN accompanied) (PP (IN by) (NP (NP (NNS episodes)) (PP (IN of) (NP (NP (NNP Doc_10027919_1703_1716_Disease)) (CC and) (NP (NNP Doc_10027919_1721_1738_Disease)))))))) (. .)))
10027919	13	(S1 (S (PP (IN In) (NP (NP (NNS animals)) (PP (IN with) (NP (JJ normal) (JJ renal) (NN function))))) (, ,) (NP (NNP OCT)) (VP (VBN induced) (NP (NP (DT a) (JJ transient) (NN decrease)) (PP (IN in) (NP (JJ serum) (JJ PTH) (NNS levels)))) (PP (IN at) (NP (NP (DT a) (NN dose)) (PP (IN of) (NP (CD 0.1) (NN microg/kg))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX was) (RB not) (VP (VBN sustained) (PP (IN with) (NP (NP (VBG lowering)) (PP (IN of) (NP (DT the) (NNS doses)))))))))))) (. .)))
10027919	14	(S1 (S (PP (IN In) (NP (NNP Nx) (NNS dogs))) (, ,) (NP (NNP Doc_10027919_1924_1927_Chemical)) (VP (VP (VBD reversed) (NP (NP (JJ abnormal) (NN bone) (NN formation)) (PRN (, ,) (PP (JJ such) (IN as) (NP (NP (NNP Doc_10027919_1970_1983_Disease)) (CC and) (NP (NNP Doc_10027919_1988_1996_Disease)))) (, ,)))) (CC but) (VP (AUX did) (RB not) (ADVP (RB significantly)) (VP (VB alter) (NP (NP (DT the) (NN level)) (PP (IN of) (NP (NN bone) (NN turnover))))))) (. .)))
10027919	15	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NNP Doc_10027919_2071_2074_Chemical)) (VP (VBD improved) (NP (NN mineralization) (NN lag) (NN time)) (, ,) (PRN (-LRB- -LRB-) (INTJ (DT that) (AUX is)) (, ,) (NP (NP (DT the) (NN rate)) (SBAR (WHPP (IN at) (WHNP (WDT which))) (S (NP (NN osteoid)) (VP (VBZ mineralizes))))) (-RRB- -RRB-)) (PP (IN in) (NP (DT both) (NNP Nx) (CC and) (NNP Sham) (NNS dogs)))) (. .)))
10027919	16	(S1 (S (NP (DT These) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (SBAR (RB even) (IN though) (S (NP (NNP Doc_10027919_2237_2240_Chemical)) (VP (AUX does) (RB not) (ADVP (RB completely)) (VP (VB prevent) (NP (NP (DT the) (NN occurrence)) (PP (IN of) (NP (NNP Doc_10027919_2287_2300_Disease))) (PP (IN in) (NP (NP (JJ experimental) (NNS dogs)) (PP (IN with) (NP (NNP Doc_10027919_2327_2346_Disease)))))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (AUX be) (PP (IN of) (NP (NP (NN use)) (PP (IN in) (NP (NP (DT the) (NN management)) (PP (IN of) (NP (NNP Doc_10027919_2386_2415_Disease))))))) (SBAR (IN because) (S (NP (PRP it)) (VP (VP (AUX does) (RB not) (VP (VB induce) (NP (NNP Doc_10027919_2443_2460_Disease)))) (CC and) (PRN (, ,) (ADVP (RB therefore)) (, ,)) (VP (AUX does) (RB not) (VP (VB increase) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NNP Doc_10027919_2507_2528_Disease)))))))))))))) (. .)))
10074612	0	(S1 (FRAG (NP (NP (NNP Doc_10074612_0_11_Disease)) (, ,) (NP (NNP Doc_10074612_13_24_Disease)) (, ,) (CC and) (NP (NNP Doc_10074612_30_38_Disease))) (PP (IN after) (NP (NP (JJ high-dose) (JJ intravenous) (NN Doc_10074612_67_85_Chemical)) (PP (IN in) (NP (DT a) (JJ monitored) (NN patient))))) (. .)))
10074612	1	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NP (NNP Doc_10074612_130_141_Disease)) (, ,) (NP (NNP Doc_10074612_143_154_Disease)) (, ,) (CC and) (NP (NNP Doc_10074612_160_168_Disease))))) (PP (IN after) (NP (NP (JJ intravenous) (NN administration)) (PP (IN of) (NP (JJ high-dose) (NNP Doc_10074612_215_233_Chemical))))) (PP (IN in) (NP (NP (DT a) (JJ 73-year-old) (NN patient)) (SBAR (WHNP (WP who)) (S (VP (VBD underwent) (NP (JJ electrocardiographic) (PRN (-LRB- -LRB-) (NP (NNP ECG)) (-RRB- -RRB-)) (NN monitoring)) (PP (IN throughout) (NP (DT the) (NN episode))))))))) (. .)))
10074612	2	(S1 (S (NP (EX There)) (VP (AUX was) (NP (NP (DT a) (NN history)) (PP (IN of) (NP (NNP Doc_10074612_358_366_Disease) (NNP Doc_10074612_367_382_Disease))) (ADVP (NP (CD 9) (NNS years)) (RB earlier)))) (. .)))
10074612	3	(S1 (S (NP (DT The) (NN patient)) (VP (AUX was) (VP (VBN admitted) (PP (IN with) (NP (NP (DT a) (NN Doc_10074612_432_456_Disease)) (PP (IN with) (NP (NP (NNP Doc_10074612_462_472_Disease)) (, ,) (ADVP (RB rapidly) (JJ progressive)) (NP (NNP Doc_10074612_494_507_Disease)) (, ,) (CC and) (NP (NNP Doc_10074612_513_522_Disease)))) (SBAR (WHNP (WDT that)) (S (VP (VBD required) (NP (JJ mechanical) (NN ventilation)) (PP (IN in) (NP (DT the) (JJ intensive) (NN care) (NN unit)))))))))) (. .)))
10074612	4	(S1 (S (PP (IN After) (S (VP (VBG receiving) (NP (JJ advanced) (NN cardiopulmonary) (NN resuscitation))))) (, ,) (NP (DT the) (NN patient)) (VP (VBD recovered) (NP (JJ cardiac) (NN rhythm))) (. .)))
10074612	5	(S1 (S (NP (DT The) (NNS ECG)) (VP (VBD showed) (NP (NP (DT a) (JJ junctional) (NN rhythm)) (PP (IN without) (NP (NN Doc_10074612_725_747_Disease))))) (. .)))
10074612	6	(S1 (S (NP (DT This) (NN study)) (VP (VBZ reviews) (NP (NP (DT the) (JJ current) (VBN proposed) (NNS mechanisms)) (PP (IN of) (NP (NNP Doc_10074612_803_815_Disease)))) (PP (IN after) (NP (NP (DT a) (JJ high) (NN dose)) (PP (IN of) (NP (NP (JJ intravenous) (NNP Doc_10074612_849_867_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_10074612_869_873_Chemical)) (-RRB- -RRB-))))))) (. .)))
10074612	7	(S1 (S (NP (DT These) (NNS mechanisms)) (VP (AUX are) (RB not) (ADVP (RB well)) (VP (VBN understood) (SBAR (IN because) (S (, ,) (PP (IN in) (NP (JJS most) (NNS cases))) (, ,) (NP (DT the) (NNS patients)) (VP (AUX were) (RB not) (VP (VBN monitored) (PP (IN at) (NP (NP (DT the) (NN moment)) (PP (IN of) (NP (DT the) (NN event))))))))))) (. .)))
10074612	8	(S1 (S (S (NP (NP (JJ Rapid) (NN infusion)) (CC and) (NP (JJ underlying) (NN Doc_10074612_1031_1046_Disease))) (VP (AUX were) (NP (JJ important) (NN risk) (NNS factors)) (PP (IN in) (NP (NP (DT the) (NN case)) (VP (VBN reported) (ADVP (RB here))))))) (, ,) (CC and) (S (NP (DT the) (NNS authors)) (VP (VB discount) (NP (NNP Doc_10074612_1127_1149_Disease)) (PP (IN as) (NP (DT the) (JJ main) (NN mechanism))))) (. .)))
10091616	0	(S1 (FRAG (S (VP (VBG Worsening) (PP (IN of) (NP (NNP Doc_10091616_13_21_Chemical-induced) (NNP Doc_10091616_30_41_Disease))) (PP (IN by) (NP (UCP (NN motor) (CC and) (JJ mental)) (NNS tasks))))) (. .)))
10091616	1	(S1 (S (NP (NP (CD Ten) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX had) (NP (NNP Doc_10091616_90_109_Disease)))))) (PP (IN with) (S (VP (VBG disabling) (NP (NNP Doc_10091616_125_135_Disease))))) (VP (AUX were) (VP (VBN included) (PP (IN in) (NP (DT this) (NN study) (S (VP (TO to) (VP (VB evaluate) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (JJ mental) (PRN (-LRB- -LRB-) (NP (JJ mental) (NN calculation)) (-RRB- -RRB-)) (CC and) (NN motor) (PRN (-LRB- -LRB-) (S (NP (NP (NP (NN flexion/extension)) (PP (IN of) (NP (JJ right) (NNS fingers)))) (, ,) (NP (NP (NN flexion/extension)) (PP (IN of) (NP (NN left) (NNS fingers)))) (, ,) (NP (NP (NN flexion/extension)) (PP (IN of) (NP (DT the) (NN neck)))) (, ,)) (VP (VBG speaking) (ADVP (RB aloud)))) (-RRB- -RRB-)) (NNS tasks)))) (PP (IN on) (NP (NP (DT the) (VBG worsening)) (PP (IN of) (NP (JJ peak-dose) (NNP Doc_10091616_381_391_Disease))) (PP (VBG following) (NP (NP (NN administration)) (PP (IN of) (NP (NP (DT an) (JJ effective) (JJ single) (NN dose)) (PP (IN of) (NP (NNP Doc_10091616_448_459_Chemical)))))))))))))))) (. .)))
10091616	2	(S1 (S (PP (VBN Compared) (PP (IN with) (NP (NP (DT the) (NN score)) (PP (IN at) (NP (NP (NN rest)) (PRN (-LRB- -LRB-) (NP (CD 1.3+/-0.3)) (-RRB- -RRB-))))))) (, ,) (NP (NP (DT a) (JJ significant) (NN aggravation)) (PP (IN of) (NP (DT the) (NNP Doc_10091616_539_549_Disease) (NN score)))) (VP (AUX was) (VP (VBN observed) (PP (IN during) (S (VP (VP (VBG speaking) (NP (NP (RB aloud)) (PRN (-LRB- -LRB-) (NP (CD 5.2+/-1.1)) (, ,) (NP (CD p<0.05)) (-RRB- -RRB-)) (, ,) (NP (NP (NNS movements)) (PP (IN of) (NP (NN right)))) (PRN (-LRB- -LRB-) (NP (CD 4.5+/-1.0)) (, ,) (NP (CD p<0.05)) (-RRB- -RRB-)))) (CC and) (VP (VBD left) (NP (NP (PRN (-LRB- -LRB-) (NP (CD 3.7+/-0.8)) (, ,) (NP (CD p<0.05)) (-RRB- -RRB-)) (NNS fingers)) (, ,) (NP (NP (NP (NNS movements)) (PP (IN of) (NP (DT the) (NN neck)))) (PRN (-LRB- -LRB-) (NP (CD 5.1+/-1.0)) (, ,) (NP (CD p<0.05)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (JJ mental) (NN calculation)) (PRN (-LRB- -LRB-) (NP (CD 3.1+/-1.0)) (, ,) (NP (CD p<0.05)) (-RRB- -RRB-)))))))))) (. .)))
10091616	3	(S1 (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NN activation) (NNS tasks)) (PP (JJ such) (IN as) (`` ``) (S (VP (VBG speaking) (ADVP (RB aloud)))) ('' ''))) (VP (MD could) (VP (AUX be) (VP (VBN used) (PP (IN for) (NP (NP (JJ objective) (NN assessment)) (PP (IN of) (NP (JJ Doc_10091616_887_897_Disease) (NN severity))))))))))) (. .)))
10193809	0	(S1 (NP (NP (NN Urine) (JJ N-acetyl-beta-D-glucosaminidase--a) (NN marker)) (PP (IN of) (NP (JJ tubular) (NN damage))) (. ?)))
10193809	1	(S1 (S (PP (IN Although) (NP (NP (DT an) (NN indicator)) (PP (IN of) (NP (NNP Doc_10193809_104_129_Disease))))) (, ,) (NP (DT an) (JJ increased) (NN urinary) (NN Doc_10193809_152_160_Chemical-beta-D-glucosaminidase) (-LRB- -LRB-) (NN NAG) (-RRB- -RRB-) (NN activity)) (VP (MD might) (VP (VB reflect) (NP (NP (JJ increased) (JJ lysosomal) (NN activity)) (PP (IN in) (NP (JJ renal) (JJ tubular) (NNS cells)))))) (. .)))
10193809	2	(S1 (S (NP (NP (NNP Doc_10193809_275_300_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_10193809_302_305_Chemical)) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN administered) (PP (TO to) (NP (NNP Sprague) (NNP Dawley) (NNS rats) (S (VP (TO to) (VP (VB induce) (NP (NNP Doc_10193809_357_368_Disease))))))))) (. .)))
10193809	3	(S1 (S (NP (NP (JJ Total) (NN protein)) (, ,) (NP (NN albumin)) (, ,) (NP (NN NAG) (NN activity)) (CC and) (NP (NN protein) (JJ electrophoretic) (NN pattern))) (VP (AUX were) (VP (VBN assessed) (PP (IN in) (NP (NP (JJ daily) (NN urine) (NNS samples)) (PP (IN for) (NP (CD 33) (NNS days))))))) (. .)))
10193809	4	(S1 (S (NP (NP (DT The) (JJ morphological) (NN appearance)) (PP (IN of) (NP (DT the) (NNS kidneys)))) (VP (AUX was) (VP (VBN examined) (PP (IN on) (NP (NP (NNS days) (CD three) (, ,) (CD four) (, ,) (CD six) (, ,) (CD eight) (CC and) (CD thirty) (CD three)) (CC and) (NP (NP (DT the) (NN NAG) (NN isoenzyme) (NNS patterns)) (PP (IN on) (NP (NNS days) (CD zero) (, ,) (CD four) (, ,) (CD eight) (CC and) (CD thirty) (CD three)))))))) (. .)))
10193809	5	(S1 (S (PP (VBG Following) (NP (NP (JJ intravenous) (JJ Doc_10193809_705_708_Chemical) (NN urine) (NN volume)) (CC and) (NP (NN urine)))) (NP (NN NAG) (NN activity)) (VP (VP (VBD increased) (ADVP (RB significantly)) (PP (IN by) (NP (NN day) (CD two)))) (, ,) (CC but) (VP (VBD returned) (PP (TO to) (NP (JJ normal))) (PP (IN by) (NP (NN day) (CD four))))) (. .)))
10193809	6	(S1 (S (PP (IN After) (NP (NN day) (CD four))) (NP (DT all) (VBN treated) (NNS animals)) (VP (VBD exhibited) (NP (NP (DT a) (JJ marked) (NN rise)) (PP (IN in) (NP (NP (NN urine) (NN albumin)) (, ,) (NP (JJ total) (NN protein) (NN excretion)) (CC and) (NP (NN NAG) (NN activity)))))) (. .)))
10193809	7	(S1 (S (NP (NNP Electrophoresis)) (VP (VBD showed) (NP (NP (DT a) (JJ generalised) (NN increase)) (PP (IN in) (NP (NP (NN middle)) (CC and) (NP (JJ high) (JJ molecular) (NN weight) (NN urine) (NNS proteins)))) (PP (IN from) (NP (NN day) (CD four) (NNS onwards))))) (. .)))
10193809	8	(S1 (S (NP (NN Protein) (NNS droplets)) (ADVP (RB first)) (VP (VBD appeared) (ADJP (JJ prominent)) (PP (IN in) (NP (NP (JJ tubular) (NNS cells)) (PP (IN on) (NP (NN day) (CD four)))))) (. .)))
10193809	9	(S1 (S (NP (NP (JJ Peak) (NN urine) (NN NAG) (NN activity)) (CC and) (NP (NP (DT a) (NN change)) (PP (IN in) (NP (NN NAG) (NN isoenzyme) (NN pattern))))) (VP (VBD coincided) (PP (IN with) (NP (PDT both) (NP (DT the) (JJ peak) (NN Doc_10193809_1219_1230_Disease)) (CC and) (NP (NP (DT the) (NN reduction)) (PP (IN in) (NP (NP (JJ intracellular) (NN protein)) (CC and) (NP (NP (NN NAG) (NNS droplets)) (PRN (-LRB- -LRB-) (NP (NN day) (CD six) (NNS onwards)) (-RRB- -RRB-))))))))) (. .)))
10193809	10	(S1 (S (NP (DT This) (NN animal) (NN model)) (VP (VBZ demonstrates) (SBAR (IN that) (S (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (JJ lysosomal) (NN turnover)) (CC and) (ADVP (RB hence)) (NP (NN urine) (NN NAG) (NN activity)) (, ,)))) (VP (VBZ occurs) (SBAR (WHADVP (WRB when)) (S (NP (JJ increased) (NN protein)) (VP (AUX is) (VP (VBN presented) (PP (TO to) (NP (DT the) (JJ tubular) (NNS cells))))))))))) (. .)))
10193809	11	(S1 (S (NP (NN Urine) (NN NAG) (NN activity)) (VP (VP (AUX is) (ADVP (RB thus)) (NP (NP (DT a) (NN measure)) (PP (IN of) (NP (JJ altered) (NN function))) (PP (IN in) (NP (DT the) (JJ renal) (NNS tubules))))) (CC and) (RB not) (ADVP (RB simply)) (NP (NP (DT an) (NN indicator)) (PP (IN of) (NP (NN damage))))) (. .)))
10225068	0	(S1 (NP (NP (NP (NN Doc_10225068_0_21_Disease)) (PP (IN after) (NP (NP (JJ spinal) (NNS anaesthesia)) (PP (IN with) (NP (JJ hyperbaric) (ADJP (CD 5) (NN %)) (NN Doc_10225068_66_76_Chemical)))))) (: :) (NP (NP (DT a) (NN review)) (PP (IN of) (NP (NP (CD six) (NNS cases)) (PP (IN of) (NP (NNP Doc_10225068_103_124_Disease))))) (VP (VBN reported) (PP (TO to) (NP (DT the) (NNP Swedish) (NNP Pharmaceutical) (NNP Insurance) (NN 1993-1997))))) (. .)))
10225068	1	(S1 (S (NP (NP (CD Six) (NNS cases)) (PP (IN of) (NP (NNP Doc_10225068_198_219_Disease))) (PP (IN with) (NP (VBG varying) (NN severity)))) (VP (AUX were) (VP (VBN reported) (PP (TO to) (NP (DT the) (NNP Swedish) (NNP Pharmaceutical) (NNP Insurance))) (PP (IN during) (NP (DT the) (NN period) (CD 1993-1997))))) (. .)))
10225068	2	(S1 (S (NP (DT All)) (VP (AUX were) (VP (VBN associated) (PP (IN with) (NP (NP (JJ spinal) (NNS anaesthesia)) (VP (VBG using) (NP (JJ hyperbaric) (ADJP (CD 5) (NN %)) (NN Doc_10225068_389_399_Chemical))))))) (. .)))
10225068	3	(S1 (S (S (NP (CD Five) (NNS cases)) (VP (AUX had) (NP (JJ single-shot) (NN spinal) (NN anaesthesia)))) (CC and) (S (NP (PRP one)) (VP (AUX had) (NP (NP (DT a) (NN repeat) (NN spinal) (NN anaesthetic)) (ADJP (JJ due) (PP (TO to) (NP (JJ inadequate) (NN block))))))) (. .)))
10225068	4	(S1 (S (NP (NP (DT The) (NN dose)) (PP (IN of) (NP (JJ hyperbaric) (ADJP (CD 5) (NN %)) (JJ Doc_10225068_538_548_Chemical) (VBN administered)))) (VP (VBD ranged) (PP (IN from) (NP (QP (CD 60) (TO to) (CD 120)) (NNS mg)))) (. .)))
10225068	5	(S1 (S (NP (NP (CD Three)) (PP (IN of) (NP (DT the) (NNS cases)))) (VP (AUX were) (ADVP (RBS most) (JJ likely)) (VP (VBN caused) (PP (IN by) (NP (NP (JJ direct) (NN Doc_10225068_641_654_Disease)) (PP (IN of) (NP (JJ hyperbaric) (ADJP (CD 5) (NN %)) (NN Doc_10225068_672_682_Chemical))))))) (. .)))
10225068	6	(S1 (S (PP (IN In) (NP (DT the) (JJ other) (CD 3) (NNS cases))) (, ,) (S (NP (JJ direct) (NN Doc_10225068_713_726_Disease)) (VP (AUX was) (ADVP (RB also)) (ADJP (JJ probable)))) (, ,) (CC but) (S (ADVP (RB unfortunately)) (NP (NN radiological) (NNS investigations)) (VP (AUX were) (RB not) (VP (AUX done) (S (VP (TO to) (ADVP (RB definitely)) (VP (VB exclude) (NP (DT a) (JJ compressive) (NN aetiology)))))))) (. .)))
10225068	7	(S1 (S (NP (DT All) (NNS cases)) (VP (VBD sustained) (NP (JJ permanent) (NN Doc_10225068_883_904_Disease))) (. .)))
10225068	8	(S1 (S (NP (PRP We)) (VP (VBP recommend) (SBAR (IN that) (S (NP (JJ hyperbaric) (NNP Doc_10225068_935_945_Chemical)) (VP (MD should) (VP (AUX be) (VP (VBN administered) (PP (PP (IN in) (NP (NP (NNS concentrations)) (ADJP (ADJP (RB not) (JJR greater)) (PP (IN than) (NP (CD 2) (NN %)))))) (CC and) (PP (IN at) (NP (NP (DT a) (JJ total) (NN dose)) (VP (ADVP (RB preferably) (RB not)) (VBG exceeding) (NP (CD 60) (NN mg)))))))))))) (. .)))
10328196	0	(S1 (NP (NP (NP (JJ Systemic) (JJ Doc_10328196_9_17_Disease) (JJ following) (NN administration)) (PP (IN of) (NP (NP (NNP Doc_10328196_46_55_Chemical)) (PRN (-LRB- -LRB-) (ADVP (RB formerly)) (NP (NNP Doc_10328196_66_75_Chemical)) (-RRB- -RRB-)))) (PP (IN for) (NP (NNP Doc_10328196_81_90_Disease)))) (: :) (NP (NP (NN association)) (PP (IN of) (NP (NNP Doc_10328196_107_130_Disease))) (PP (IN with) (NP (NP (NNS apoptosis)) (PP (IN of) (NP (JJ lesional) (NNS lymphocytes)))))) (. .)))
10328196	1	(S1 (S (NP (NP (NNP Doc_10328196_183_192_Chemical)) (PRN (-LRB- -LRB-) (NP (ADVP (RB formerly)) (NNP Doc_10328196_203_212_Chemical)) (-RRB- -RRB-))) (VP (AUX is) (NP (NP (DT an) (JJ immunosuppressive) (NN agent)) (SBAR (WHNP (WDT that)) (S (VP (VBZ interferes) (PP (IN with) (NP (JJ T-cell) (NN activation)))))))) (. .)))
10328196	2	(S1 (S (SBAR (IN After) (S (NP (NP (CD 2) (NNS individuals)) (PP (IN with) (NP (NNP Doc_10328196_309_318_Disease)))) (VP (VBD developed) (NP (DT a) (NNP Doc_10328196_331_354_Disease) (VBG following) (NN treatment)) (PP (IN with) (NP (NP (JJ oral) (JJ Doc_10328196_385_394_Chemical) (JJ lesional) (NN skin) (NNS cells)) (CC and) (NP (VBN activated) (JJ peripheral) (NN blood) (NNS cells))))))) (VP (AUX were) (VP (VBN analyzed) (PP (IN for) (NP (NP (NN induction)) (PP (IN of) (NP (NN apoptosis))))))) (. .)))
10328196	3	(S1 (S (NP (NP (DT A) (JJ keratome) (NN skin) (NN specimen)) (PP (IN from) (NP (NP (CD 1) (NN patient)) (PP (IN with) (NP (JJ Doc_10328196_553_562_Chemical-induced) (NNP Doc_10328196_571_594_Disease)))))) (VP (AUX had) (NP (NP (DT a) (JJ 2.3-fold) (NN increase)) (PP (IN in) (NP (NP (NN percentage)) (PP (IN of) (NP (NP (JJ apoptotic) (NNS cells)) (PRN (-LRB- -LRB-) (PP (TO to) (NP (CD 48) (NN %))) (-RRB- -RRB-))))))) (PP (VBN compared) (PP (IN with) (NP (NP (DT an) (JJ unaffected) (JJ Doc_10328196_689_698_Chemical-treated) (NN patient)) (PP (IN with) (NP (NP (NNP Doc_10328196_720_729_Disease)) (PRN (-LRB- -LRB-) (NP (CD 21) (NN %)) (-RRB- -RRB-)))))))) (. .)))
10328196	4	(S1 (S (NP (NP (VBN Activated) (JJ peripheral) (NN blood) (NN T) (NNS cells)) (PP (IN from) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_10328196_791_800_Disease)))))) (VP (VBD tended) (S (VP (TO to) (VP (VB exhibit) (NP (NP (JJR greater) (JJ spontaneous) (CC or) (JJ Doc_10328196_842_855_Chemical-induced) (NN apoptosis)) (SBAR (IN than) (S (VP (AUX did) (NP (JJ normal) (NN T) (NNS cells)))))) (, ,) (PP (ADVP (RB particularly)) (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NNP Doc_10328196_931_940_Chemical))))))))) (. .)))
10328196	5	(S1 (S (NP (NP (JJ Severe) (JJ adverse) (NNS effects)) (PP (IN of) (NP (NNP Doc_10328196_981_990_Chemical)))) (VP (VBP include) (NP (NP (NNP Doc_10328196_999_1004_Disease)) (, ,) (NP (NNP Doc_10328196_1006_1012_Disease)) (, ,) (CC and) (NP (NNP Doc_10328196_1018_1041_Disease)))) (. .)))
10328196	6	(S1 (S (NP (DT These) (NNS symptoms)) (VP (MD may) (VP (AUX be) (NP (NP (DT the) (NN result)) (PP (IN of) (NP (NP (JJ drug-induced) (NNS apoptosis)) (PP (IN of) (NP (NP (JJ lesional) (NNS leukocytes)) (, ,) (NP (ADJP (RB especially) (VBN activated)) (NN T) (NNS lymphocytes)) (, ,) (CC and) (ADVP (RB possibly)) (NP (NP (NN release)) (PP (IN of) (NP (JJ inflammatory) (NNS mediators))))))))))) (. .)))
10328196	7	(S1 (S (SBAR (IN Because) (S (NP (NP (NNS patients)) (PP (IN with) (NP (JJ severe) (NNP Doc_10328196_1239_1248_Disease)))) (VP (MD may) (VP (VB develop) (NP (NN Doc_10328196_1261_1275_Disease)) (PP (IN from) (NP (JJ various) (JJ systemic) (NNS therapies))))))) (, ,) (NP (JJ clinical) (NN monitoring)) (VP (AUX is) (ADJP (JJ advisable)) (PP (IN for) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_10328196_1360_1381_Disease))) (SBAR (WHNP (WP who)) (S (VP (AUX are) (VP (VBN treated) (PP (IN with) (NP (JJ immune) (NNS modulators)))))))))) (. .)))
10354657	0	(S1 (NP (NP (NN Effect)) (PP (IN of) (NP (JJ Doc_10354657_10_17_Chemical) (NN maintenance) (NN therapy))) (PP (IN on) (NP (NP (NN thyroid)) (CC and) (NP (NN parathyroid) (NN function)))) (. .)))
10354657	1	(S1 (S (VP (TO To) (VP (VB assess) (NP (NP (NNS changes)) (VP (VBN induced) (PP (IN by) (NP (JJ Doc_10354657_116_123_Chemical) (NN maintenance) (NN therapy))) (PP (IN on) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NN thyroid) (, ,) (NN parathyroid) (CC and) (NN ion) (NNS alterations))))))))) (. .)))
10354657	2	(S1 (S (NP (DT These)) (VP (AUX were) (VP (VBN evaluated) (PP (IN with) (NP (NP (NN respect)) (PP (TO to) (NP (NP (DT the) (NN duration)) (PP (IN of) (NP (NP (JJ Doc_10354657_259_266_Chemical) (NN therapy)) (, ,) (NP (NN age)) (, ,) (NP (NN sex)) (, ,) (CC and) (NP (NP (NN family) (NN history)) (PRN (-LRB- -LRB-) (SBAR (IN whether) (CC or) (RB not) (S (NP (DT the) (NN patient)) (VP (AUX had) (NP (DT a) (JJ first-degree) (NN relative)) (PP (IN with) (NP (NNP Doc_10354657_366_381_Disease)))))) (-RRB- -RRB-))))))))))) (. .)))
10354657	3	(S1 (NP (JJ Prospective) (NN study) (. .)))
10354657	4	(S1 (NP (NP (JJ Affective) (NNS Disorders)) (NP (NP (NNP Clinic)) (PP (IN at) (NP (NP (NP (NNP St.) (NNP Mary) (POS 's)) (NNP Hospital)) (, ,) (NP (NNP Montreal))))) (. .)))
10354657	5	(S1 (NP (NP (NP (QP (CD One) (CD hundred) (CC and) (CD one)) (NNS patients)) (PRN (-LRB- -LRB-) (NP (NP (CD 28) (NNS men)) (CC and) (NP (CD 73) (NNS women))) (-RRB- -RRB-))) (PP (IN with) (S (NP (NNP Doc_10354657_547_563_Disease)) (VP (VBG receiving) (NP (NP (JJ Doc_10354657_574_581_Chemical) (NN maintenance) (NN therapy)) (VP (VBG ranging) (PP (IN from) (NP (CD 1) (NN year) (POS 's))))) (PP (TO to) (NP (NP (CD 32) (NNS years) (POS ')) (NN duration)))))) (. .)))
10354657	6	(S1 (S (NP (DT The) (NN control) (NN group)) (VP (VBD consisted) (PP (IN of) (NP (CD 82) (NNS patients))) (PP (IN with) (NP (NP (DT no) (JJ Doc_10354657_698_709_Disease) (CC or) (JJ endocrinological) (NNS diagnoses)) (PP (IN from) (NP (NP (DT the) (NN hospital) (POS 's)) (JJ out-patient) (NNS clinics)))))) (. .)))
10354657	7	(S1 (S (S (NP (NN OUTCOME)) (VP (VBZ MEASURES))) (: :) (S (NP (NP (NN Laboratory) (NNS analyses)) (PP (IN of) (NP (NNP Doc_10354657_822_829_Chemical) (, ,) (NNP Doc_10354657_831_840_Chemical) (CC and) (JJ thyroid-stimulating) (NN hormone) (NNS levels)))) (VP (VBD performed) (PP (IN before) (S (VP (VP (VBG beginning) (NP (JJ Doc_10354657_907_914_Chemical) (NN therapy))) (CC and) (VP (PP (IN at) (NP (JJ biannual) (NN follow-up))))))))) (. .)))
10354657	8	(S1 (S (NP (NN Doc_10354657_959_973_Disease)) (VP (VBD developed) (PP (IN in) (NP (CD 40) (NNS patients))) (, ,) (S (VP (VBG excluding) (NP (NP (CD 8) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX were) (ADJP (JJ Doc_10354657_1030_1041_Disease)) (PP (IN at) (NP (NN baseline)))))))))) (. .)))
10354657	9	(S1 (S (NP (NP (DT All) (NNS patients)) (VP (AUXG having) (NP (NP (JJ first-degree) (NNS relatives)) (VP (VBN affected) (PP (IN by) (NP (NNP Doc_10354657_1110_1125_Disease))))))) (VP (AUX had) (NP (NP (JJ accelerated) (NN onset)) (PP (IN of) (NP (NP (NNP Doc_10354657_1151_1165_Disease)) (PRN (-LRB- -LRB-) (NP (NP (CD 3.7) (NNS years)) (PP (IN after) (NP (NP (NN onset)) (PP (IN of) (NP (JJ Doc_10354657_1192_1199_Chemical) (NN therapy)))))) (-RRB- -RRB-))))) (PP (VBN compared) (PP (IN with) (NP (NP (NNS patients)) (PP (IN without) (NP (NP (DT a) (NN family) (NN history)) (PRN (-LRB- -LRB-) (NP (NP (CD 8.6) (NNS years)) (PP (IN after) (NP (NP (NN onset)) (PP (IN of) (NP (JJ Doc_10354657_1283_1290_Chemical) (NN therapy)))))) (-RRB- -RRB-)))))))) (. .)))
10354657	10	(S1 (S (NP (NP (NNS Women)) (PP (IN over) (NP (NP (CD 60) (NNS years)) (PP (IN of) (NP (NN age)))))) (VP (AUX were) (VP (ADVP (RBR more) (RB often)) (JJ affected) (PP (IN by) (NP (NNP Doc_10354657_1356_1370_Disease))) (PP (IN than) (NP (NP (NNS women)) (PP (IN under) (NP (NP (NP (CD 60) (NNS years)) (PP (IN of) (NP (NN age)))) (PRN (-LRB- -LRB-) (NP (NP (CD 34.6) (NN %)) (CC versus) (NP (CD 31.9) (NN %))) (-RRB- -RRB-)))))))) (. .)))
10354657	11	(S1 (S (NP (NP (JJ Doc_10354657_1426_1435_Chemical) (NNS levels)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN on) (NP (JJ Doc_10354657_1458_1465_Chemical) (NN treatment)))))) (VP (AUX were) (ADJP (JJ unchanged)) (PP (IN from) (NP (JJ baseline) (NNS levels)))) (. .)))
10354657	12	(S1 (S (PP (IN After) (NP (JJ Doc_10354657_1519_1526_Chemical) (NN treatment))) (, ,) (NP (JJ Doc_10354657_1538_1545_Chemical) (NNS levels)) (VP (AUX were) (ADJP (ADJP (JJR higher)) (PP (IN than) (NP (DT either) (NX (NX (NN baseline) (NNS levels)) (CC or) (NX (NN control) (NNS levels))))))) (. .)))
10354657	13	(S1 (S (ADVP (RB Thus)) (, ,) (NP (JJ Doc_10354657_1618_1625_Chemical) (NN treatment)) (VP (VBN counteracted) (NP (DT the) (NN decrease)) (PP (IN in) (NP (NP (NN plasma) (NN Doc_10354657_1672_1679_Chemical) (NNS levels)) (VP (VBN associated) (PP (IN with) (NP (NN aging))))))) (. .)))
10354657	14	(S1 (S (NP (NNP Familial) (NNP Doc_10354657_1732_1747_Disease)) (VP (AUX is) (NP (NP (DT a) (NN risk) (NN factor)) (PP (IN for) (NP (NP (NNP Doc_10354657_1769_1783_Disease)) (CC and) (NP (NNP Doc_10354657_1788_1801_Disease)))) (PP (IN during) (NP (JJ Doc_10354657_1809_1816_Chemical) (NN therapy))))) (. .)))
10411803	0	(S1 (S (NP (JJ Severe) (JJ immune) (NN Doc_10411803_14_30_Disease)) (VP (VBN associated) (PP (IN with) (NP (NP (JJ prophylactic) (NN use)) (PP (IN of) (NP (NNP Doc_10411803_67_76_Chemical))) (PP (IN in) (NP (NP (NN obstetric)) (CC and) (NP (JJ gynecologic) (NNS procedures))))))) (. .)))
10411803	1	(S1 (S (NP (NP (NN Second-) (CC and) (NN third-generation) (NN Doc_10411803_147_161_Chemical)) (, ,) (NP (RB especially) (NNP Doc_10411803_174_183_Chemical)) (, ,)) (VP (AUX are) (ADVP (RB increasingly)) (VP (VBN associated) (PP (IN with) (NP (JJ severe) (, ,) (ADJP (RB sometimes) (JJ fatal)) (JJ immune) (NN Doc_10411803_249_265_Disease))))) (. .)))
10411803	2	(S1 (S (NP (PRP We)) (VP (VBD noticed) (SBAR (IN that) (S (NP (NP (CD 10)) (PP (IN of) (NP (NP (PRP$ our) (CD 35) (NNS cases)) (PP (IN of) (NP (NNP Doc_10411803_305_314_Chemical-induced) (NNP Doc_10411803_323_340_Disease)))))) (VP (AUX were) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX had) (VP (VBN received) (NP (JJ Doc_10411803_375_384_Chemical) (NN prophylactically)) (PP (IN for) (NP (ADJP (JJ obstetric) (CC and) (JJ gynecologic)) (NNS procedures))))))))))))) (. .)))
10411803	3	(S1 (S (NP (NP (CD Eight)) (PP (IN of) (NP (NP (DT these) (NNS cases)) (PP (IN of) (NP (JJ severe) (JJ immune) (NN Doc_10411803_482_498_Disease)))))) (VP (AUX are) (VP (VBN described))) (. .)))
10414674	0	(S1 (NP (NP (NNS Effects)) (PP (IN of) (NP (JJ nonsteroidal) (JJ anti-inflammatory) (NNS drugs))) (PP (IN on) (NP (NP (NN hemostasis)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_10414674_79_113_Disease))))))) (. .)))
10414674	1	(S1 (S (NP (JJ Platelet) (NN function)) (VP (AUX is) (VP (VBN impaired) (PP (IN by) (NP (NP (JJ nonsteroidal) (JJ anti-inflammatory) (NNS drugs)) (PRN (-LRB- -LRB-) (NP (NNP NSAIDs)) (-RRB- -RRB-)))) (PP (IN with) (NP (JJ prominent) (JJ anti-inflammatory) (NNS properties))))) (. .)))
10414674	2	(S1 (S (NP (NP (PRP$ Their) (NN safety)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG undergoing) (NP (JJ intracranial) (NN surgery)))))) (VP (AUX is) (PP (IN under) (NP (NN debate)))) (. .)))
10414674	3	(S1 (S (NP (NP (NNS Patients)) (PP (IN with) (NP (NP (NNP Doc_10414674_327_361_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_10414674_363_366_Disease)) (-RRB- -RRB-))))) (VP (AUX were) (VP (VBN randomized) (S (VP (TO to) (VP (VB receive) (ADVP (RB either)) (NP (NP (NNP Doc_10414674_402_412_Chemical)) (, ,) (NP (NP (CD 100) (NN mg)) (, ,) (NP (NP (NP (CD three) (NNS times)) (NP (DT a) (NN day))) (PRN (-LRB- -LRB-) (NP (NNP Doc_10414674_441_451_Chemical) (NN group)) (, ,) (NP (NNP n) (SYM =) (CD 9)) (-RRB- -RRB-))) (CC or) (NP (DT a) (JJ weak) (NN NSAID))) (, ,) (NP (NNP Doc_10414674_483_496_Chemical)) (, ,) (NP (CD 1) (NNP g)) (, ,) (NP (NP (CD three) (NNS times)) (NP (DT a) (NN day))))))) (PRN (-LRB- -LRB-) (NP (NNP Doc_10414674_522_535_Chemical) (NN group)) (, ,) (NP (NNP n) (SYM =) (CD 9)) (-RRB- -RRB-)) (S (VP (VBG starting) (PP (ADVP (RB immediately)) (IN after) (NP (NP (DT the) (NN diagnosis)) (PP (IN of) (NP (NNP Doc_10414674_594_604_Disease) (NNP Doc_10414674_605_608_Disease))))))))) (. .)))
10414674	4	(S1 (S (NP (NN Treatment)) (VP (AUX was) (VP (VBN continued) (PP (IN for) (NP (NP (CD 3) (NNS days)) (ADVP (RB postoperatively)))))) (. .)))
10414674	5	(S1 (S (NP (NN Test) (NN blood) (NNS samples)) (VP (AUX were) (VP (VBN taken) (PP (IN before) (NP (NP (NN treatment) (CC and) (NN surgery)) (CONJP (RB as) (RB well) (IN as)))) (PP (IN on) (NP (DT the) (JJ first) (, ,) (ADJP (JJ third) (, ,) (CC and) (JJ fifth)) (JJ postoperative) (NNS mornings))))) (. .)))
10414674	6	(S1 (S (NP (NP (NNP Maximal) (NNP Doc_10414674_795_815_Disease)) (VP (VBN induced) (PP (IN by) (NP (NP (CD 6) (NN microM)) (PP (IN of) (NP (NNP Doc_10414674_839_860_Chemical))))))) (VP (VBD decreased) (PP (IN after) (NP (NP (NN administration)) (PP (IN of) (NP (NNP Doc_10414674_895_905_Chemical)))))) (. .)))
10414674	7	(S1 (S (NP (NN Aggregation)) (VP (AUX was) (ADJP (ADJP (ADJP (ADJP (JJR lower)) (PRN (-LRB- -LRB-) (NP (QP (CD P) (CD <)) (CD .05)) (-RRB- -RRB-))) (PP (IN in) (NP (DT the) (NNP Doc_10414674_946_956_Chemical) (NN group)))) (PP (IN than) (PP (IN in) (NP (DT the) (NNP Doc_10414674_975_988_Chemical) (NN group))))) (PP (RB just) (PP (IN before) (NP (NN surgery))) (CC and) (PP (IN on) (NP (DT the) (JJ third) (JJ postoperative) (NN day))))) (. .)))
10414674	8	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (JJ maximal) (NNP Doc_10414674_1072_1092_Disease)) (VP (VBD increased) (PP (IN in) (NP (NP (DT the) (JJ Doc_10414674_1110_1123_Chemical) (NN group)) (PP (IN on) (NP (DT the) (JJ third) (JJ postoperative) (NN day))))) (SBAR (IN as) (S (VP (VBN compared) (PP (IN with) (NP (NP (DT the) (JJ pretreatment) (NN Doc_10414674_1195_1215_Disease) (NNS results)) (PRN (-LRB- -LRB-) (NP (QP ($ P) (CD <) (CD .05))) (-RRB- -RRB-)))))))) (. .)))
10414674	9	(S1 (S (NP (NP (CD One) (NN patient)) (PP (IN in) (NP (DT the) (NNP Doc_10414674_1254_1264_Chemical) (NN group)))) (VP (VBD developed) (NP (DT a) (JJ postoperative) (NN intracranial) (NN Doc_10414674_1310_1318_Disease))) (. .)))
10414674	10	(S1 (S (NP (NP (NN Coagulation)) (PRN (-LRB- -LRB-) (NP (NP (NN prothrombin) (NN time) (NN -LSB-PT) (NN -RSB-)) (, ,) (NP (VBN activated) (JJ partial) (NN thromboplastin) (NN time) (JJ -LSB-APPT) (NN -RSB-)) (, ,) (NP (NN fibrinogen) (NN concentration)) (, ,) (CC and) (NP (JJ antithrombin) (NNP III) (NN -LSB-AT) (NNP III) (NN -RSB-))) (-RRB- -RRB-))) (VP (AUX was) (ADJP (JJ comparable)) (PP (IN between) (NP (DT the) (CD two) (NNS groups)))) (. .)))
10414674	11	(S1 (S (S (ADJP (ADJP (JJ Doc_10414674_1498_1508_Chemical)) (CC but) (ADJP (RB not) (JJ Doc_10414674_1517_1530_Chemical)))) (VP (VBN impaired) (NP (NN platelet) (NN function)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_10414674_1575_1578_Disease)))))) (. .)))
10414674	12	(S1 (S (SBAR (IN If) (S (NP (NNP Doc_10414674_1583_1593_Chemical)) (VP (AUX is) (VP (VBN used) (PP (IN before) (NP (NN surgery))) (PP (IN on) (NP (JJ cerebral) (NN Doc_10414674_1629_1645_Disease))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB pose) (NP (NP (DT an) (JJ additional) (NN risk) (NN factor)) (PP (IN for) (NP (NN Doc_10414674_1689_1699_Disease)))))) (. .)))
10523326	0	(S1 (NP (NP (JJ Doc_10523326_0_12_Chemical) (NN synthase) (NN expression)) (PP (IN in) (NP (NP (DT the) (NN course)) (PP (IN of) (NP (JJ lead-induced) (NNP Doc_10523326_63_75_Disease))))) (. .)))
10523326	1	(S1 (S (NP (PRP We)) (ADVP (RB recently)) (VP (VP (VBD showed) (NP (NP (JJ elevated) (JJ reactive) (JJ Doc_10523326_114_120_Chemical) (NNS species)) (PRN (-LRB- -LRB-) (NP (NNP ROS)) (-RRB- -RRB-)))) (, ,) (VP (VBD reduced) (NP (NP (JJ urinary) (NN excretion)) (PP (IN of) (NP (NP (JJ Doc_10523326_165_167_Chemical) (NNS metabolites)) (PRN (-LRB- -LRB-) (NP (NNP NOx)) (-RRB- -RRB-)))))) (, ,) (CC and) (VP (VBD increased) (NP (JJ Doc_10523326_201_203_Chemical) (NN sequestration)) (PP (IN as) (NP (NNP Doc_10523326_221_234_Chemical))) (PP (IN in) (NP (NP (JJ various) (NNS tissues)) (PP (IN in) (NP (NP (NNS rats)) (PP (IN with) (NP (NNP Doc_10523326_267_271_Chemical-induced) (NNP Doc_10523326_280_292_Disease))))))))) (. .)))
10523326	2	(S1 (S (NP (DT This) (NN study)) (VP (AUX was) (VP (VBN designed) (S (VP (TO to) (VP (VB discern) (SBAR (IN whether) (S (NP (NP (DT the) (NN reduction)) (PP (IN in) (NP (JJ urinary) (NN NOx))) (PP (IN in) (NP (JJ lead-induced) (NNP Doc_10523326_382_394_Disease)))) (VP (AUX is) (, ,) (PP (IN in) (NP (NN part))) (, ,) (ADJP (JJ due) (PP (TO to) (NP (JJ depressed) (JJ Doc_10523326_425_427_Chemical) (NN synthase) (PRN (-LRB- -LRB-) (NP (NNP NOS)) (-RRB- -RRB-)) (NN expression)))))))))))) (. .)))
10523326	3	(S1 (S (NP (JJ Male) (NNP Sprague-Dawley) (NNS rats)) (VP (AUX were) (ADVP (RB randomly)) (VP (VBN assigned) (PP (TO to) (NP (NP (NP (DT a) (JJ lead-treated) (NN group)) (PRN (-LRB- -LRB-) (VP (VBN given) (NP (NP (NNP Doc_10523326_534_546_Chemical)) (, ,) (NP (CD 100) (NN ppm)) (, ,)) (PP (IN in) (NP (NP (NN drinking) (NN water)) (CC and) (NP (JJ regular) (NN rat) (NN chow))))) (-RRB- -RRB-))) (, ,) (NP (NP (DT a) (NN group)) (VP (VBN given) (NP (ADJP (JJ lead) (CC and) (JJ Doc_10523326_621_630_Chemical-fortified)) (NN chow)))) (, ,) (CC or) (NP (NP (DT a) (JJ normal) (NN control) (NN group)) (VP (VBN given) (NP (NP (DT either) (JJ regular) (NN food) (CC and) (NN water)) (CC or) (NP (JJ Doc_10523326_712_721_Chemical-fortified) (NN food))) (PP (IN for) (NP (CD 12) (NNS weeks))))))))) (. .)))
10523326	4	(S1 (S (NP (NP (JJ Tail) (NN blood) (NN pressure)) (, ,) (NP (JJ urinary) (NN NOx) (NN excretion)) (, ,) (NP (NP (NN plasma)) (SBAR (S (NP (NP (NNP Doc_10523326_802_817_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_10523326_819_822_Chemical)) (-RRB- -RRB-)) (, ,) (CC and) (NP (NP (ADJP (JJ endothelial) (CC and) (JJ inducible)) (NNS NOS)) (PRN (-LRB- -LRB-) (NP (NP (NNS eNOS)) (CC and) (NP (NNS iNOS))) (-RRB- -RRB-)))) (VP (VBZ isotypes) (PP (IN in) (NP (DT the) (NN aorta))))))) (CC and) (NP (NN kidney))) (VP (AUX were) (VP (VBN measured))) (. .)))
10523326	5	(S1 (S (NP (DT The) (JJ lead-treated) (NN group)) (VP (VBD exhibited) (NP (NP (NP (DT a) (NN rise)) (PP (IN in) (NP (NP (NN blood) (NN pressure)) (CC and) (NP (NN plasma) (JJ Doc_10523326_992_995_Chemical) (NN concentration))))) (, ,) (NP (NP (DT a) (NN fall)) (PP (IN in) (NP (JJ urinary) (NN NOx) (NN excretion)))) (, ,) (CC and) (NP (NP (DT a) (JJ paradoxical) (NN rise)) (PP (IN in) (NP (NP (JJ vascular) (CC and) (JJ renal) (NN tissue) (NNS eNOS)) (CC and) (NP (NN iNOS) (NN expression))))))) (. .)))
10523326	6	(S1 (S (NP (JJ Doc_10523326_1122_1131_Chemical) (NN supplementation)) (VP (VP (VBD ameliorated) (NP (NNP Doc_10523326_1160_1172_Disease))) (, ,) (VP (VBD lowered) (NP (NN plasma) (JJ Doc_10523326_1189_1192_Chemical) (NN concentration))) (, ,) (CC and) (VP (VBD raised) (NP (JJ urinary) (NN NOx) (NN excretion)) (SBAR (IN while) (S (VP (ADVP (RB significantly)) (VBG lowering) (NP (NP (NN vascular)) (, ,) (CONJP (CC but) (RB not)) (NP (JJ renal) (, ,) (NN tissue) (NNS eNOS) (CC and) (NNS iNOS) (NN expression)))))))) (. .)))
10523326	7	(S1 (S (NP (JJ Doc_10523326_1328_1337_Chemical) (NN supplementation)) (VP (AUX had) (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (DT either) (NN blood) (NN pressure)) (, ,) (NP (NN plasma) (NN Doc_10523326_1401_1404_Chemical)) (, ,) (CC or) (NP (NN NOS) (NN expression)))) (PP (IN in) (NP (DT the) (NN control) (NN group)))) (. .)))
10523326	8	(S1 (S (NP (DT The) (NN study)) (ADVP (RB also)) (VP (VBD revealed) (NP (NP (JJ significant) (NN inhibition)) (PP (IN of) (NP (NNP NOS) (JJ enzymatic) (NN activity))) (PP (IN by) (NP (NN lead))) (PP (IN in) (NP (JJ cell-free) (NNS preparations))))) (. .)))
10523326	9	(S1 (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NP (JJ lead-induced) (NN Doc_10523326_1582_1594_Disease)) (PP (IN in) (NP (DT this) (NN model)))) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (DT a) (JJ compensatory) (NN upregulation)) (PP (IN of) (NP (NP (ADJP (JJ renal) (CC and) (JJ vascular)) (NNS eNOS)) (CC and) (NP (NN iNOS) (NN expression)))))))) (. .)))
10523326	10	(S1 (S (NP (DT This)) (VP (AUX is) (, ,) (PP (IN in) (NP (NN part))) (, ,) (ADJP (JJ due) (PP (TO to) (NP (NP (JJ ROS-mediated) (JJ Doc_10523326_1743_1745_Chemical) (NN inactivation)) (, ,) (NP (NP (JJ lead-associated) (NN inhibition)) (PP (IN of) (NP (NN NOS) (NN activity)))) (, ,) (CC and) (NP (NP (RB perhaps) (JJ stimulatory) (NNS actions)) (PP (IN of) (NP (NP (VBN increased) (JJ shear) (NN stress)) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_10523326_1878_1890_Disease))))))))))) (. .)))
10524660	0	(S1 (S (NP (NN Doc_10524660_0_19_Chemical)) (VP (VBZ induces) (NP (NP (NNS attacks)) (PP (IN of) (NP (NNP Doc_10524660_39_60_Disease)))) (PP (IN in) (NP (NP (NNS sufferers)) (PP (IN of) (NP (NNP Doc_10524660_77_95_Disease)))))) (. .)))
10524660	1	(S1 (S (NP (NP (NNP Doc_10524660_97_115_Disease)) (CC and) (NP (NNP Doc_10524660_120_141_Disease))) (VP (AUX have) (NP (DT the) (JJ same) (JJ Doc_10524660_156_160_Disease) (NN phase)) (, ,) (S (ADVP (RB thus)) (VP (VBG indicating) (SBAR (IN that) (S (NP (NP (NNP Doc_10524660_189_207_Disease)) (CC and) (NP (NNP Doc_10524660_212_233_Disease))) (VP (NN share) (NP (NP (DT a) (JJ common) (NN pathway)) (PP (IN of) (NP (NN nociception)))))))))) (. .)))
10524660	2	(S1 (S (PP (IN In) (NP (JJ recent) (NNS years))) (, ,) (NP (VBG increasing) (NN evidence)) (VP (AUX has) (VP (VBN suggested) (SBAR (IN that) (S (NP (NP (DT the) (NN messenger) (NN molecule) (NNP Doc_10524660_352_364_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_10524660_366_368_Chemical)) (-RRB- -RRB-))) (VP (AUX is) (VP (VBN involved) (PP (IN in) (NP (NP (JJ Doc_10524660_385_389_Disease) (NNS mechanisms)) (PP (IN of) (NP (NNP Doc_10524660_404_425_Disease))))))))))) (. .)))
10524660	3	(S1 (SBAR (IN In) (NN order) (S (VP (TO to) (VP (VB clarify) (SBAR (S (IN whether) (NP (DT the) (JJ same)) (VP (AUX is) (ADJP (JJ true)) (PP (IN for) (NP (NNP Doc_10524660_476_494_Disease))) (, ,) (PP (IN in) (NP (NP (DT the) (JJ present) (NN study)) (SBAR (S (NP (PRP we)) (VP (VBD examined) (NP (NP (DT the) (JJ Doc_10524660_533_541_Disease) (NN response)) (PP (TO to) (NP (NP (JJ intravenous) (NN infusion)) (PP (IN of) (NP (NP (NNP Doc_10524660_578_597_Chemical) (-LRB- -LRB-) (NNP Doc_10524660_599_602_Chemical) (-RRB- -RRB-)) (PRN (-LRB- -LRB-) (NP (NP (CD 0.5) (NN microg/kg/min)) (PP (IN for) (NP (CD 20) (NN min)))) (-RRB- -RRB-))))))) (PP (IN in) (NP (NP (CD 12) (NNS sufferers)) (PP (IN of) (NP (NNP Doc_10524660_654_672_Disease))))))))))) (. .))))))))
10524660	4	(S1 (S (NP (DT The) (JJ specific) (NN aim)) (VP (AUX was) (S (VP (TO to) (VP (VB elucidate) (SBAR (IN whether) (S (NP (NP (DT an) (NN aura) (NN and/or) (DT an) (NN attack)) (PP (IN of) (NP (NNP Doc_10524660_744_765_Disease)))) (VP (MD could) (VP (AUX be) (VP (VBN induced)))))))))) (. .)))
10524660	5	(S1 (S (NP (CD Fourteen) (JJ healthy) (NNS subjects)) (VP (VBD served) (PP (IN as) (NP (NNS controls)))) (. .)))
10524660	6	(S1 (S (NP (NN Aura) (NNS symptoms)) (VP (AUX were) (RB not) (VP (VBN elicited) (PP (IN in) (NP (DT any) (NN subject))))) (. .)))
10524660	7	(S1 (S (NP (NN Doc_10524660_878_886_Disease)) (VP (AUX was) (ADJP (RBR more) (JJ severe)) (PP (IN in) (NP (NNS migraineurs))) (PP (IN than) (PP (IN in) (NP (NP (DT the) (NNS controls)) (PP (IN during) (CC and) (PP (ADVP (RB immediately)) (IN after) (NP (NP (JJ Doc_10524660_968_971_Chemical) (NN infusion)) (PRN (-LRB- -LRB-) (NP (CD p=0.037)) (-RRB- -RRB-)))) (CONJP (RB as) (RB well) (IN as)) (PP (IN during) (NP (NP (DT the) (JJ following) (CD 11) (NNP h)) (PRN (-LRB- -LRB-) (NP (NNP p) (SYM =) (CD 0.008)) (-RRB- -RRB-))))))))) (. .)))
10524660	8	(S1 (S (PP (IN In) (NP (DT the) (NNS controls))) (, ,) (NP (DT the) (JJ Doc_10524660_1062_1065_Chemical-induced) (NN Doc_10524660_1074_1082_Disease)) (ADVP (RB gradually)) (VP (VBD disappeared) (, ,) (SBAR (IN whereas) (S (PP (IN in) (NP (NNS migraineurs))) (NP (JJ peak) (JJ Doc_10524660_1134_1142_Disease) (NN intensity)) (VP (VBD occurred) (PP (IN at) (NP (NP (DT a) (JJ mean) (NN time)) (PP (IN of) (NP (CD 240) (JJ min) (NN post-infusion))))))))) (. .)))
10524660	9	(S1 (S (PP (IN At) (NP (DT this) (NN time))) (NP (NP (DT the) (VBN induced) (NN Doc_10524660_1228_1236_Disease)) (PP (IN in) (NP (QP (CD 6) (IN of) (CD 12)) (NNS migraineurs)))) (VP (VBD fulfilled) (NP (NP (DT the) (JJ diagnostic) (NNS criteria)) (PP (IN for) (NP (NP (NNP Doc_10524660_1298_1319_Disease)) (PP (IN of) (NP (DT the) (NNP International) (NNP Doc_10524660_1341_1349_Disease) (NNP Society))))))) (. .)))
10524660	10	(S1 (S (NP (DT The) (NNS results)) (ADVP (RB therefore)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NNP Doc_10524660_1394_1396_Chemical)) (VP (AUX is) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (JJ Doc_10524660_1416_1420_Disease) (NNS mechanisms)) (PP (IN of) (NP (NN Doc_10524660_1435_1453_Disease)))))))))) (. .)))
10524660	11	(S1 (S (SBAR (IN Since) (S (NP (JJ cortical) (VBG spreading) (NN Doc_10524660_1480_1490_Disease)) (VP (AUX has) (VP (AUX been) (VP (VBN shown) (S (VP (TO to) (VP (VB liberate) (NP (NNP Doc_10524660_1518_1520_Chemical)) (PP (IN in) (NP (NNS animals))))))))))) (, ,) (NP (DT this) (NN finding)) (VP (MD may) (VP (VB help) (S (NP (NP (PRP$ our) (NN understanding)) (PP (IN of) (NP (NP (DT the) (NN coupling)) (PP (IN between) (NP (NN cortical)))))) (VP (VBG spreading) (NP (NNP Doc_10524660_1616_1626_Disease) (CC and) (NNP Doc_10524660_1631_1639_Disease)) (PP (IN in) (NP (NNP Doc_10524660_1643_1661_Disease))))))) (. .)))
10533019	0	(S1 (NP (NP (JJ Rapid) (NN reversal)) (PP (IN of) (NP (JJ life-threatening) (JJ Doc_10533019_35_44_Chemical-induced) (NN Doc_10533019_53_59_Disease))) (PP (IN with) (NP (NNP Doc_10533019_65_81_Chemical))) (. .)))
10533019	1	(S1 (S (NP (PRP We)) (VP (VBP describe) (NP (NP (DT a) (NN patient)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NN Doc_10533019_119_125_Disease)) (PP (IN with) (NP (JJ sudden) (NN Doc_10533019_138_156_Disease))) (PP (IN after) (NP (NP (DT the) (NN infusion)) (PP (IN of) (NP (JJ intravenous) (NNP Doc_10533019_191_200_Chemical)))))))))) (. .)))
10533019	2	(S1 (S (NP (NP (DT The) (NN administration)) (PP (IN of) (NP (NNP Doc_10533019_224_240_Chemical)))) (ADVP (RB rapidly)) (VP (VBD resolved) (NP (NP (DT the) (NN patient) (POS 's)) (NNP Doc_10533019_272_278_Disease)) (PP (IN with) (NP (NP (JJ prompt) (NN recovery)) (PP (IN of) (NP (NN respiratory) (NN function))))) (, ,) (S (VP (VBG averting) (NP (NP (DT the) (NN need)) (PP (IN for) (NP (NP (ADJP (RBR more) (JJ aggressive)) (NN airway) (NN management)) (CC and) (NP (JJ ventilatory) (NN support)))))))) (. .)))
10533019	3	(S1 (S (NP (DT The) (NN emergency) (NN physician)) (VP (MD should) (VP (AUX be) (ADJP (JJ aware) (SBAR (SBAR (IN that) (S (NP (JJ life-threatening) (NN Doc_10533019_468_474_Disease)) (VP (MD may) (VP (VB accompany) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (JJ intravenous) (NNP Doc_10533019_523_532_Chemical)))))))) (CC and) (SBAR (IN that) (S (NP (NNP Doc_10533019_542_558_Chemical)) (VP (MD may) (VP (AUX be) (NP (DT a) (ADJP (ADJP (JJ rapid)) (CC and) (ADJP (JJ effective))) (NN remedy)))))))))) (. .)))
10539815	0	(S1 (NP (NP (NP (NNS Predictors)) (PP (IN of) (NP (NNP Doc_10539815_14_38_Disease))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_10539815_56_69_Disease))) (PP (IN during) (NP (JJ Doc_10539815_77_88_Chemical-converting) (JJ enzyme) (NN inhibitor) (NN therapy)))))) (: :) (NP (NP (NNS results)) (PP (IN from) (NP (DT the) (NNS studies))) (PP (IN of) (NP (NNP Doc_10539815_154_182_Disease))) (PRN (-LRB- -LRB-) (NP (NNP SOLVD)) (-RRB- -RRB-)))))
10539815	1	(S1 (S (SBAR (IN Although) (S (NP (JJ Doc_10539815_212_223_Chemical-converting) (JJ enzyme) (NN inhibitor) (NN therapy)) (VP (VBZ reduces) (NP (NN mortality) (NNS rates)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NNP Doc_10539815_301_325_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_10539815_327_330_Disease)) (-RRB- -RRB-))))))))) (, ,) (NP (PRP it)) (VP (MD may) (ADVP (RB also)) (VP (VB cause) (NP (NN Doc_10539815_351_375_Disease)))) (. .)))
10539815	2	(S1 (S (NP (JJ Little) (NN information)) (VP (AUX is) (ADJP (JJ available)) (S (VP (TO to) (VP (VB predict) (SBAR (WHNP (WDT which)) (S (NP (NNS patients)) (VP (AUX are) (PP (IN at) (NP (NP (JJS highest) (NN risk)) (PP (IN for) (NP (DT this) (NN complication)))))))))))) (. .)))
10539815	3	(S1 (FRAG (S (VP (TO To) (VP (VB quantify) (NP (NP (JJ specific) (JJ clinical) (NNS predictors)) (PP (IN of) (NP (NNP Doc_10539815_533_560_Disease))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_10539815_578_581_Disease))) (SBAR (WHNP (WP who)) (S (VP (AUX are) (VP (VBN prescribed) (NP (JJ Doc_10539815_601_612_Chemical-converting) (JJ enzyme) (NN inhibitor) (NN therapy)))))))))))) (. .)))
10539815	4	(S1 (S (NP (PRP We)) (VP (VBD analyzed) (NP (NP (NNS data)) (PP (IN from) (NP (NP (DT the) (NNPS Studies)) (PP (IN of) (NP (NP (NP (NNP Doc_10539815_695_723_Disease)) (PRN (-LRB- -LRB-) (NP (NNP SOLVD)) (-RRB- -RRB-))) (, ,) (NP (NP (DT a) (JJ randomized) (, ,) (JJ double-blind) (, ,) (JJ placebo-controlled) (NN trial)) (PP (IN of) (NP (NNP Doc_10539815_789_798_Chemical))) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NNP Doc_10539815_820_823_Disease)))))))))))) (. .)))
10539815	5	(S1 (S (NP (EX There)) (VP (AUX were) (VP (VP (ADVP (NP (CD 3379) (NNS patients)) (RB randomly)) (VBN assigned) (PP (TO to) (NP (NNP Doc_10539815_871_880_Chemical))) (PP (IN with) (NP (NP (DT a) (JJ median) (NN follow-up)) (PP (IN of) (NP (CD 974) (NN days)))))) (CC and) (VP (ADVP (NP (CD 3379) (NNS patients)) (RB randomly)) (VBN assigned) (PP (TO to) (NP (NN placebo))) (PP (IN with) (NP (NP (DT a) (JJ mean) (NN follow-up)) (PP (IN of) (NP (CD 967) (NNS days)))))))) (. .)))
10539815	6	(S1 (S (NP (NN Doc_10539815_999_1023_Disease)) (VP (AUX was) (VP (VBN defined) (PP (IN as) (NP (NP (DT a) (NN rise)) (PP (IN in) (NP (NP (JJ serum) (NNP Doc_10539815_1055_1065_Chemical) (CD >/=0.5) (NNS mg/dL)) (PRN (-LRB- -LRB-) (NP (CD 44) (NNS micromol/L)) (-RRB- -RRB-)))) (PP (IN from) (NP (NN baseline))))))) (. .)))
10539815	7	(S1 (S (NP (PRP We)) (VP (VBD used) (NP (JJ time-to-event) (NN analysis)) (S (VP (TO to) (VP (VB identify) (NP (NP (JJ potential) (NNS predictors)) (PP (IN of) (NP (NP (NN decrease)) (PP (IN in) (NP (NP (JJ renal) (NN function)) (PP (VBG including) (NP (NP (NN age)) (, ,) (NP (JJ baseline) (NN ejection) (NN fraction)) (, ,) (NP (NN baseline) (NN Doc_10539815_1256_1266_Chemical)) (, ,) (NP (JJ low) (JJ systolic) (NN blood) (NN pressure)) (PRN (-LRB- -LRB-) (NP (CD <100) (NN mm) (NNP Hg)) (-RRB- -RRB-)) (, ,) (NP (NP (NN history)) (PP (IN of) (NP (NP (NNP Doc_10539815_1321_1333_Disease)) (, ,) (NP (NNP Doc_10539815_1335_1343_Disease))))) (, ,) (CC and) (NP (NP (NN use)) (PP (IN of) (NP (NP (NN antiplatelet)) (, ,) (NP (NN diuretic)) (, ,) (CC and) (NP (NN beta-blocker) (NN therapy)))))))))))))))) (. .)))
10539815	8	(S1 (S (NP (NP (NNS Patients)) (VP (ADVP (RB randomly)) (VBN assigned) (PP (TO to) (NP (NNP Doc_10539815_1445_1454_Chemical))))) (VP (AUX had) (NP (NP (DT a) (ADJP (CD 33) (NN %)) (JJR greater) (NN likelihood)) (PP (IN of) (NP (NNP Doc_10539815_1487_1511_Disease))) (PP (IN than) (NP (NP (NNS controls)) (PRN (-LRB- -LRB-) (NP (NNP P) (CD =.003)) (-RRB- -RRB-)))))) (. .)))
10539815	9	(S1 (S (PP (IN By) (NP (NN multivariate) (NN analysis))) (, ,) (PP (IN in) (NP (DT both) (DT the) (UCP (NN placebo) (CC and) (JJ Doc_10539815_1587_1596_Chemical)) (NNS groups))) (NP (NP (JJR older) (NN age)) (, ,) (NP (JJ diuretic) (NN therapy)) (, ,) (CC and) (NP (NNP Doc_10539815_1637_1645_Disease))) (VP (AUX were) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_10539815_1667_1691_Disease))) (, ,) (SBAR (IN whereas) (S (NP (NP (NN beta-blocker) (NN therapy)) (CC and) (NP (JJR higher) (NN ejection) (NN fraction))) (VP (AUX were) (ADJP (JJ renoprotective))))))) (. .)))
10539815	10	(S1 (S (NP (JJR Older) (NN age)) (VP (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (DT a) (JJR greater) (NN risk)) (PP (IN of) (S (VP (VBG developing) (NP (NNP Doc_10539815_1831_1855_Disease)) (PP (IN in) (NP (DT both) (NNS groups)))))))))) (, ,) (CC but) (VP (ADVP (RB significantly)) (ADJP (RBR more) (RB so) (PP (IN in) (NP (NP (DT the) (NNP Doc_10539815_1905_1914_Chemical) (NN group)) (PRN (-LRB- -LRB-) (NP (NNP Doc_10539815_1922_1931_Chemical)) (: :) (NP (NP (NP (NP (NN risk) (NN ratio) (NN -LSB-RR)) (JJ -RSB-) (CD 1.42)) (PP (IN per) (NP (CD 10) (NNS years)))) (, ,) (NP (NP (NP (NP (ADJP (CD 95) (NN %)) (NN confidence)) (JJ interval) (JJ -LSB-CI) (JJ -RSB-) (NN 1.32-1.52)) (PP (IN with) (NP (NNP Doc_10539815_2012_2021_Chemical)))) (: ;) (NP (NN placebo)) (: :) (NP (QP (CD RR) (CD 1.18)))) (, ,) (NP (NP (CD 95) (NN %)) (NP (NNP CI) (CD 1.12-1.25)))) (-RRB- -RRB-))))))) (. .)))
10539815	11	(S1 (S (NP (JJ Doc_10539815_2060_2068_Chemical) (NN therapy)) (VP (AUX was) (ADVP (RB likewise)) (VP (VBN associated) (PP (IN with) (NP (NP (DT a) (JJR greater) (NN risk)) (PP (IN of) (NP (NNP Doc_10539815_2124_2148_Disease))) (PP (IN in) (NP (DT the) (NNP Doc_10539815_2156_2165_Chemical) (NN group))))) (PRN (-LRB- -LRB-) (NP (NNP RR) (CD 1.89)) (, ,) (NP (NP (CD 95) (NN %)) (NP (NNP CI) (CD 1.70-2.08))) (-RRB- -RRB-)) (PP (IN than) (PP (IN in) (NP (DT the) (NN placebo) (NN group)))) (PRN (-LRB- -LRB-) (NP (NNP RR) (CD 1.35)) (, ,) (NP (NP (CD 95) (NN %)) (NP (NNP CI) (CD 1.09-1.66))) (-RRB- -RRB-)))) (. .)))
10539815	12	(S1 (S (ADVP (RB Conversely)) (, ,) (NP (NNP Doc_10539815_2267_2276_Chemical)) (VP (AUX had) (NP (NP (DT a) (JJ relative) (JJ renoprotective) (NN effect)) (PRN (-LRB- -LRB-) (NP (NNP RR) (CD 1.33)) (, ,) (NP (CD 95) (NN %) (QP (CD CI) (CD 1.13-1.53))) (-RRB- -RRB-))) (PP (VBN compared) (PP (IN with) (NP (NN placebo)))) (PRN (-LRB- -LRB-) (NP (NNP RR) (CD 1.96)) (, ,) (NP (CD 95) (NN %)) (NP (NNP CI) (CD 1.57-2.44)) (-RRB- -RRB-)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_10539815_2409_2417_Disease)))))) (. .)))
10539815	13	(S1 (S (NP (NP (DT A) (JJR lower) (NN risk)) (PP (IN of) (NP (NNP Doc_10539815_2435_2451_Disease)))) (VP (AUX was) (VP (VBN seen) (PP (IN in) (NP (DT both) (NNS groups))) (PP (IN with) (NP (NP (NP (NN beta-blocker) (NN therapy)) (PRN (-LRB- -LRB-) (NP (NNP RR) (CD 0.70)) (, ,) (NP (CD 95) (NN %) (QP (CD CI) (CD 0.57-0.85))) (-RRB- -RRB-))) (CC and) (NP (NP (JJR higher) (NN baseline) (NN ejection) (NN fraction)) (PRN (-LRB- -LRB-) (NP (NP (QP (CD RR) (CD 0.93)) (IN per) (ADJP (CD 5) (NN %)) (NN increment)) (, ,) (NP (CD 95) (NN %) (QP (RB CI) (CD 0.91-0.) (CD 96)))) (-RRB- -RRB-))))))) (. .)))
10539815	14	(S1 (S (NP (JJ Doc_10539815_2628_2637_Chemical) (NN use)) (VP (VBD caused) (NP (NP (DT a) (ADJP (CD 33) (NN %)) (NN increase)) (PP (IN in) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NNP Doc_10539815_2679_2703_Disease))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_10539815_2721_2724_Disease))))))))) (. .)))
10539815	15	(S1 (S (NP (NP (JJ Doc_10539815_2726_2734_Chemical) (NN use)) (CC and) (NP (JJ advanced) (NN age))) (VP (VBD increased) (NP (DT this) (NN risk))) (. .)))
10539815	16	(S1 (S (S (NP (NN Doc_10539815_2777_2785_Disease)) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (DT an) (VBN increased) (NN risk)) (PP (IN of) (NP (NNP Doc_10539815_2827_2843_Disease))))) (PP (IN in) (NP (DT all) (NNS patients))) (PP (IN with) (NP (NNP Doc_10539815_2865_2868_Disease)))))) (, ,) (CC but) (S (S (NP (DT this) (NN risk)) (VP (AUX was) (VP (VBN reduced) (PP (IN in) (NP (DT the) (NNP Doc_10539815_2903_2912_Chemical) (NN group))) (PP (VBN compared) (PP (IN with) (NP (DT the) (NN placebo) (NN group.) (NN beta-Blocker) (NN therapy))))))) (CC and) (S (NP (JJR higher) (NN ejection) (NN fraction)) (VP (AUX were) (ADJP (JJ renoprotective) (PP (IN in) (NP (DT all) (NNS patients)))) (ADVP (RB regardless) (PP (IN of) (NP (NN therapy))))))) (. .)))
10565806	0	(S1 (S (NP (JJ Hypomania-like) (NN syndrome)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_10565806_35_45_Chemical)))) (. .)))
10565806	1	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT a) (JJ female) (NN patient)) (PP (IN with) (NP (NP (DT a) (NN diagnosis)) (PP (IN of) (NP (NP (DT a) (ADJP (RB not) (RB otherwise) (JJ specified)) (NNP Doc_10565806_120_138_Disease)) (PRN (-LRB- -LRB-) (NP (NNP DSM-IV)) (-RRB- -RRB-)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NN hypomania)) (PP (ADVP (RB shortly)) (IN after) (NP (NP (DT the) (NN introduction)) (PP (IN of) (NP (JJ Doc_10565806_206_216_Chemical) (NN treatment)))))))))))))) (. .)))
10692744	0	(S1 (NP (JJ Doc_10692744_0_13_Chemical-induced) (NN Doc_10692744_22_40_Disease) (. .)))
10692744	1	(S1 (S (NP (NP (JJ Acute) (NN Doc_10692744_48_57_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_10692744_69_82_Chemical))))) (VP (AUX is) (NP (NP (DT a) (ADJP (RB well) (VBN known)) (JJ adverse) (NN drug) (NN reaction)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_10692744_138_154_Disease))))))) (. .)))
10692744	2	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (JJ Doc_10692744_176_189_Chemical-induced) (NN Doc_10692744_198_216_Disease)))) (PP (IN in) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (JJ normal) (JJ renal) (NN function))))) (, ,) (S (VP (TO to) (VP (VB highlight) (NP (NP (JJ predisposing) (NNS factors)) (SBAR (WHNP (WDT that)) (S (VP (AUX are) (ADVP (RB frequently)) (VP (VBN overlooked)))))))))) (. .)))
10728962	0	(S1 (NP (NP (NN Doc_10728962_0_11_Chemical)) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (NNP Doc_10728962_32_41_Chemical-induced) (NNP Doc_10728962_50_61_Disease)) (PP (IN in) (NP (JJ severe) (NNP Doc_10728962_72_85_Disease))))))) (. .)))
10728962	1	(S1 (S (NP (NP (DT The) (NN use)) (PP (IN of) (NP (NP (JJ phosphodiesterase) (NNS inhibitors)) (PP (JJ such) (IN as) (NP (NNP Doc_10728962_135_144_Chemical))))) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (JJ severe) (NNP Doc_10728962_172_185_Disease)))))) (VP (AUX is) (VP (ADVP (RB frequently)) (VBN restricted) (SBAR (IN because) (S (NP (PRP they)) (VP (VBP cause) (NP (NP (NN vasodilation)) (CC and) (NP (NN Doc_10728962_247_258_Disease)))))))) (. .)))
10728962	2	(S1 (S (PP (IN In) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (JJ decompensated) (NN Doc_10728962_291_304_Disease)) (PP (IN with) (NP (NNP Doc_10728962_310_321_Disease))) (PP (IN after) (NP (NN treatment))) (PP (IN with) (NP (NNP Doc_10728962_343_352_Chemical))))))) (, ,) (NP (NP (JJ low) (NNS doses)) (PP (IN of) (NP (NNP Doc_10728962_367_378_Chemical)))) (VP (VBN restored) (NP (NN blood) (NN pressure)) (PP (IN without) (S (VP (VBG inhibiting) (NP (NP (DT the) (JJ inotropic) (NN effect)) (PP (IN of) (NP (NNP Doc_10728962_446_455_Chemical)))))))) (. .)))
10743694	0	(S1 (NP (NP (NN Treatment)) (PP (IN of) (NP (JJ Doc_10743694_13_23_Chemical-related) (JJ adverse) (NNS effects))) (PP (IN by) (NP (NP (NN conversion)) (PP (TO to) (NP (NNP Doc_10743694_65_77_Chemical))) (PP (IN in) (NP (NN liver) (NN transplant) (NNS recipients))))) (. .)))
10743694	1	(S1 (S (SBAR (WHADVP (WRB When)) (S (NP (JJ Doc_10743694_115_125_Chemical) (NN side) (NNS effects)) (VP (VBP persist) (PP (IN despite) (NP (NN dose) (NN reduction)))))) (, ,) (NP (NP (NN conversion)) (PP (TO to) (NP (NP (JJ Doc_10743694_185_197_Chemical-based) (NN immunosuppression)) (PRN (-LRB- -LRB-) (NP (NNP CyA)) (-RRB- -RRB-))))) (VP (AUX is) (ADJP (JJ necessary))) (. .)))
10743694	2	(S1 (S (NP (PRP We)) (VP (VBD characterized) (NP (NP (NP (JJ Doc_10743694_259_269_Chemical) (JJ side) (NNS effects)) (SBAR (WHNP (WDT that)) (S (VP (VBD warranted) (NP (NP (NN discontinuation)) (PP (IN of) (NP (DT the) (NN drug)))))))) (, ,) (CC and) (NP (NNS outcomes))) (PP (IN after) (NP (NN conversion)))) (. .)))
10743694	3	(S1 (S (PP (IN Of) (NP (NP (CD 388) (NN liver) (NNS recipients)) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (NNP Doc_10743694_395_405_Chemical)) (PP (IN as) (NP (JJ primary) (NN immunosuppression)))))))) (, ,) (NP (CD 70)) (VP (VBD required) (NP (NP (NN conversion)) (PP (TO to) (NP (NNP Doc_10743694_462_465_Chemical))))) (. .)))
10743694	4	(S1 (S (NP (PRP We)) (VP (VBD recorded) (NP (NN indication)) (PP (IN for) (NP (NN conversion))) (, ,) (SBAR (IN whether) (S (NP (NN conversion)) (VP (AUX was) (ADJP (JJ early) (CC or) (JJ late)) (PP (IN after) (NP (NP (NN transplantation)) (, ,) (NP (JJ Doc_10743694_566_576_Chemical) (NN dose)) (CC and) (NP (NN trough) (NN blood) (NN level)))) (PP (IN at) (NP (NP (NN conversion)) (, ,) (CC and) (NP (NP (NN incidence)) (PP (IN of) (NP (NN rejection))) (PP (IN after) (NP (NN conversion)))))))))) (. .)))
10743694	5	(S1 (S (NP (NN Conversion)) (VP (AUX was) (ADJP (ADJP (JJ early) (PP (IN in) (NP (NP (CD 29) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 41.4) (NN %)) (-RRB- -RRB-))))) (CC and) (ADJP (JJ late) (PP (IN in) (NP (NP (CD 41)) (PRN (-LRB- -LRB-) (NP (CD 58.6) (NN %)) (-RRB- -RRB-))))))) (. .)))
10743694	6	(S1 (S (S (NP (NP (NNS Indications)) (PP (IN for) (NP (JJ early) (NN conversion)))) (VP (AUX were) (NP (NP (NP (NP (NP (NNP Doc_10743694_771_784_Disease)) (PRN (-LRB- -LRB-) (CD 20) (-RRB- -RRB-))) (, ,) (NP (PRN (-LRB- -LRB-) (JJ insulin-dependent) (-RRB- -RRB-)) (NN diabetes) (NN mellitus))) (-LRB- -LRB-) (NP (NNP Doc_10743694_830_834_Disease)) (-RRB- -RRB-) (-LRB- -LRB-) (NP (CD 5)) (-RRB- -RRB-) (, ,) (NP (NP (NN nephrotoxicity)) (PRN (-LRB- -LRB-) (NP (CD 3)) (-RRB- -RRB-))) (, ,) (NP (NNP Doc_10743694_861_891_Disease)) (PRN (-LRB- -LRB-) (CD 6) (-RRB- -RRB-))) (, ,) (CC and) (NP (NNP Doc_10743694_901_915_Disease)) (PRN (-LRB- -LRB-) (CD 1) (-RRB- -RRB-))))) (, ,) (CC and) (IN for) (S (NP (JJ late) (NN conversion)) (VP (AUX were) (NP (NP (NP (NP (NP (NNP Doc_10743694_950_963_Disease)) (PRN (-LRB- -LRB-) (CD 15) (-RRB- -RRB-)) (, ,) (NP (NNP Doc_10743694_970_974_Disease)) (PRN (-LRB- -LRB-) (CD 12) (-RRB- -RRB-)) (, ,) (NP (NP (NN nephrotoxicity)) (PRN (-LRB- -LRB-) (NP (CD 3)) (-RRB- -RRB-)) (, ,) (NP (NNP Doc_10743694_1001_1012_Disease)) (PRN (-LRB- -LRB-) (CD 5) (-RRB- -RRB-)) (, ,) (NP (NN hepatotoxicity)) (PRN (-LRB- -LRB-) (NP (CD 6)) (-RRB- -RRB-))) (, ,) (NP (NNP Doc_10743694_1038_1078_Disease))) (-LRB- -LRB-) (NP (NNP Doc_10743694_1080_1084_Disease)) (-RRB- -RRB-)) (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-)) (, ,) (NP (NNP Doc_10743694_1091_1105_Disease)) (PRN (-LRB- -LRB-) (CD 1) (-RRB- -RRB-)) (, ,) (NP (NNP Doc_10743694_1111_1127_Disease)) (PRN (-LRB- -LRB-) (CD 1) (-RRB- -RRB-)) (, ,) (CC and) (NP (NNP Doc_10743694_1137_1145_Disease))) (PRN (-LRB- -LRB-) (CD 1) (-RRB- -RRB-)))) (. .)))
10743694	7	(S1 (S (NP (DT All) (JJ early-conversion) (NNS patients)) (VP (VBD showed) (NP (NP (NN improvement/resolution)) (PP (IN of) (NP (NNS symptoms))))) (. .)))
10743694	8	(S1 (S (S (PP (IN Among) (NP (NN late-conversion) (NNS patients))) (, ,) (NP (NP (CD 37)) (PRN (-LRB- -LRB-) (NP (CD 90.2) (NN %)) (-RRB- -RRB-))) (VP (AUX had) (NP (NN improvement/resolution)))) (: ;) (S (PP (IN in) (NP (NP (CD 4)) (PRN (-LRB- -LRB-) (NP (CD 9.8) (NN %)) (-RRB- -RRB-)))) (, ,) (NP (JJ adverse) (NNS effects)) (VP (VBD persisted))) (. .)))
10743694	9	(S1 (S (NP (DT The) (JJ overall) (NN rejection) (NN rate)) (VP (AUX was) (NP (CD 30) (NN %))) (. .)))
10743694	10	(S1 (S (NP (NP (JJ Sixty-two) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 88.6) (NN %)) (-RRB- -RRB-))) (VP (AUX are) (ADJP (JJ alive)) (PP (IN with) (S (VP (VBG functioning) (NP (NNS grafts)) (PP (NP (NP (CD 686) (JJ +/-) (CD 362) (NNS days)) (PRN (-LRB- -LRB-) (NP (NP (NN range)) (, ,) (NP (CD 154-1433) (NNS days))) (-RRB- -RRB-))) (IN after) (NP (NN conversion))))))) (. .)))
10743694	11	(S1 (S (SBAR (WHADVP (WRB When)) (S (NP (JJ Doc_10743694_1495_1505_Chemical) (NN side) (NNS effects)) (VP (AUX are) (ADJP (JJ unresponsive) (PP (TO to) (NP (NN dose) (NN reduction))))))) (, ,) (NP (NP (NN conversion)) (PP (TO to) (NP (NNP Doc_10743694_1569_1572_Chemical)))) (VP (MD can) (VP (AUX be) (VP (VBN accomplished) (ADVP (RB safely)) (, ,) (PP (IN with) (NP (NP (NP (DT no) (VBN increased) (NN risk)) (PP (IN of) (NP (NN rejection)))) (CC and) (NP (JJ excellent) (JJ long-term) (NN outcome))))))) (. .)))
1079693	0	(S1 (NP (NP (JJ Ocular) (NNS manifestations)) (PP (IN of) (NP (NNP Doc_1079693_25_54_Disease))) (. .)))
1079693	1	(S1 (S (NP (PRP We)) (VP (VBD followed) (NP (NP (CD 210) (NNS cases)) (PP (IN of) (NP (NNP Doc_1079693_81_110_Disease)))) (ADVP (RB closely)) (PP (IN for) (NP (CD eleven) (NNS years)))) (. .)))
1079693	2	(S1 (S (NP (NP (NN Thirty-six)) (PP (IN of) (NP (NP (DT the) (CD 210) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 17.2) (NN %)) (-RRB- -RRB-))))) (VP (VBD developed) (NP (NN Doc_1079693_186_199_Disease))) (. .)))
1079693	3	(S1 (S (NP (NN Doc_1079693_201_214_Disease)) (VP (AUX was) (VP (VBN seen) (ADVP (RBS most) (RB frequently)) (PP (IN in) (NP (NP (JJ young) (JJ female) (NNS patients)) (PRN (-LRB- -LRB-) (NP (QP (CD 0) (TO to) (CD 4)) (NNS years)) (-RRB- -RRB-)))) (PP (IN with) (NP (NP (DT the) (JJ monoarticular) (CC or) (JJ pauciatricular) (NN form)) (PP (IN of) (NP (DT the) (NNP Doc_1079693_333_342_Disease))))))) (. .)))
1079693	4	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (CD 30) (NN %)) (PP (IN of) (NP (DT the) (NNS patients)))) (VP (VBD developed) (NP (NN Doc_1079693_383_390_Disease)) (PP (IN after) (NP (NP (CD 16) (NNS years)) (PP (IN of) (NP (NN age)))))) (. .)))
1079693	5	(S1 (S (SBAR (IN Although) (S (NP (NP (CD 61) (NN %)) (PP (IN of) (NP (NNS patients)))) (VP (AUX had) (NP (DT a) (JJ noncontributory) (JJ ocular) (NN history)) (PP (IN on) (NP (NN entry)))))) (, ,) (NP (CD 42) (NN %)) (VP (AUX had) (NP (JJ active) (NN Doc_1079693_501_508_Disease)) (PP (IN on) (NP (NN entry)))) (. .)))
1079693	6	(S1 (S (NP (PRP$ Our) (NN approach)) (VP (AUX was) (ADJP (JJ effective) (PP (IN in) (S (VP (VBG detecting) (NP (NP (NP (NNP Doc_1079693_559_566_Disease)) (PP (IN in) (NP (JJ new) (NNS cases)))) (CC and) (NP (NP (NNS exacerbations)) (PP (IN of) (NP (NP (NNP Doc_1079693_601_608_Disease)) (PP (IN in) (NP (JJ established) (NNS cases)))))))))))) (. .)))
1079693	7	(S1 (S (NP (NP (JJ Forty-four) (NN percent)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_1079693_667_674_Disease)))))) (VP (AUX had) (NP (NP (QP (CD one) (CC or) (JJR more)) (JJ identifiable) (NNS signs)) (CC or) (NP (NP (NNS symptoms)) (, ,) (PP (JJ such) (IN as) (NP (NP (JJ red) (NN eye)) (, ,) (NP (NP (NP (NNP Doc_1079693_740_751_Disease)) (, ,) (NP (NNP Doc_1079693_753_776_Disease)) (, ,) (CC or) (NP (NNP Doc_1079693_781_792_Disease)) (, ,)) (PP (IN in) (NP (NP (NN order)) (PP (IN of) (NP (VBG decreasing) (NN frequency))))))))))) (. .)))
1079693	8	(S1 (S (PP (ADVP (RB Even)) (IN after) (NP (NP (JJ early) (NN detection)) (CC and) (NP (JJ prompt) (NN treatment)))) (, ,) (NP (NP (CD 41) (NN %)) (PP (IN of) (NP (NP (NNS cases)) (PP (IN of) (NP (NNP Doc_1079693_893_900_Disease)))))) (VP (AUX did) (RB not) (VP (VB respond) (PP (TO to) (NP (NP (QP (JJR more) (IN than) (CD six)) (NNS months)) (PP (IN of) (NP (NP (JJ intensive) (JJ topical) (NN treatment)) (PP (IN with) (NP (NP (NNP Doc_1079693_977_992_Chemical)) (CC and) (NP (NNS mydriatics)))))))))) (. .)))
1079693	9	(S1 (S (PP (IN Despite) (NP (DT this))) (, ,) (NP (EX there)) (VP (AUX was) (NP (NP (DT a) (JJ dramatic) (NN decrease)) (PP (IN in) (NP (NP (DT the) (ADJP (CD 50) (NN %)) (NN incidence)) (PP (IN of) (NP (NP (JJ blinding) (NNS complications)) (PP (IN of) (NP (NNP Doc_1079693_1103_1110_Disease))))) (VP (VBN cited) (PP (IN in) (NP (JJR earlier) (NNS studies)))))))) (. .)))
1079693	10	(S1 (S (NP (NP (NNP Doc_1079693_1137_1145_Disease)) (CC and) (NP (NNP Doc_1079693_1150_1166_Disease))) (VP (VBD occurred) (PP (IN in) (NP (NP (QP (RB only) (CD 22) (CC and) (CD 13)) (NN %)) (PP (IN of) (NP (PRP$ our) (NN group))))) (, ,) (ADVP (RB respectively))) (. .)))
1079693	11	(S1 (S (NP (PRP We)) (VP (VP (VBD used) (NP (NP (NNP Doc_1079693_1231_1242_Chemical)) (CC or) (NP (NNP Doc_1079693_1246_1264_Chemical))) (PP (IN in) (NP (NP (CD 173)) (PP (IN of) (NP (CD 210) (NNS cases)))))) (CC and) (VP (VBD found) (NP (NP (QP (RB only) (CD one)) (NN case)) (PP (IN of) (NP (NNP Doc_1079693_1312_1329_Disease))) (ADJP (JJ attributable) (PP (TO to) (NP (DT these) (NNS drugs))))))) (. .)))
1079693	12	(S1 (S (S (NP (ADJP (RB Systemically) (VBN administered)) (NNP Doc_1079693_1385_1400_Chemical)) (VP (AUX were) (VP (VBN used) (PP (IN in) (NP (QP (CD 75) (IN of) (CD 210)) (NNS cases)))))) (: ;) (S (NP (NP (DT a) (JJ significant) (NN number)) (PP (IN of) (NP (JJ posterior) (NN subcapsular) (NN Doc_1079693_1477_1486_Disease)))) (VP (AUX was) (VP (VBN found)))) (. .)))
1079693	13	(S1 (S (NP (JJ Typical) (JJ Doc_1079693_1506_1526_Disease) (NN sicca)) (VP (VBD developed) (PP (IN in) (NP (NP (CD three)) (PP (IN of) (NP (DT the) (JJ Doc_1079693_1559_1566_Disease) (NNS cases)))))) (. .)))
1079693	14	(S1 (S (NP (NP (DT This) (NN association)) (PP (IN with) (NP (NP (NNP Doc_1079693_1596_1603_Disease)) (CC and) (NP (NNP JRA))))) (VP (AUX was) (RB not) (VP (VBN noted) (ADVP (RB previously)))) (. .)))
1079693	15	(S1 (S (NP (NP (JJ Surgical) (NN treatment)) (PP (IN of) (NP (NP (NNP Doc_1079693_1660_1669_Disease)) (, ,) (NP (NNP Doc_1079693_1671_1687_Disease)) (, ,) (CC and) (NP (NNP Doc_1079693_1693_1701_Disease))))) (VP (VBD achieved) (NP (ADJP (RB uniformly) (JJ discouraging)) (NNS results))) (. .)))
10840460	0	(S1 (NP (NP (NP (JJ Doc_10840460_0_16_Chemical-induced) (NN Doc_10840460_25_33_Disease)) (PP (IN in) (NP (JJ freely-moving) (JJ conscious) (NNS rats)))) (: :) (NP (NP (JJ behavioral) (NN approach)) (PP (TO to) (NP (NP (DT a) (JJ new) (NN model)) (PP (IN of) (NP (NNP Doc_10840460_105_118_Disease)))))) (. .)))
10840460	1	(S1 (FRAG (S (VP (TO To) (VP (VB develop) (NP (NP (DT a) (NN model)) (PP (IN of) (NP (NNP Doc_10840460_151_164_Disease)))) (PP (IN in) (NP (NP (NNS rats)) (VP (VBG using) (NP (DT a) (JJ behavioral) (NN approach)))))))) (. .)))
10840460	2	(S1 (S (NP (NP (NP (NNP Doc_10840460_202_218_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_10840460_220_222_Chemical)) (-RRB- -RRB-))) (, ,) (NP (NP (DT an) (JJ antitumoral) (NN agent)) (VP (VBN known) (S (VP (TO to) (VP (VB produce) (NP (NP (JJ toxic) (NNS effects)) (PP (IN on) (NP (DT the) (NN bladder) (NN wall)))) (PP (IN through) (NP (PRP$ its) (JJ main) (JJ toxic) (NN metabolite) (NN Doc_10840460_331_339_Chemical)))))))) (, ,)) (VP (AUX was) (VP (VBN used) (S (VP (TO to) (VP (VB induce) (NP (NNP Doc_10840460_360_368_Disease))))))) (. .)))
10840460	3	(S1 (NP (NP (NNS MATERIALS) (CC AND) (NNS METHODS)) (: :) (S (S (NP (NN CP)) (VP (AUX was) (VP (VBN administered) (PP (IN at) (NP (NP (NNS doses)) (PP (IN of) (NP (NP (CD 50) (, ,) (CD 100) (CC and) (CD 200) (JJ mg./kg.) (NNS i.p.)) (PP (TO to) (NP (JJ male) (NNS rats)))))))))) (, ,) (CC and) (S (NP (PRP$ their) (NN behavior)) (VP (VBD observed) (CC and) (VBD scored)))) (. .)))
10840460	4	(S1 (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NP (NNP Doc_10840460_523_531_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 0.5) (TO to) (CD 4) (CD mg./kg.)) (NN i.v.)) (-RRB- -RRB-)))) (PP (IN on) (NP (JJ Doc_10840460_559_561_Chemical-induced) (JJ behavioral) (NNS modifications)))) (VP (AUX were) (VP (VBN tested) (S (VP (VBN administered) (UCP (ADVP (RB alone)) (CC and) (PP (IN after) (NP (NP (NNP Doc_10840460_636_644_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 1) (RB mg./kg.) (NNP s.c.)) (-RRB- -RRB-))))))))) (. .)))
10840460	5	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (PP (NP (CD 90) (NNS minutes)) (IN after) (NP (NP (CD CP) (NN injection)) (, ,) (SBAR (WHNP (WDT that)) (S (VP (AUX is) (, ,) (PP (IN at) (NP (NP (DT the) (NN time)) (PP (IN of) (NP (NP (NN administration)) (PP (IN of) (NP (NNP Doc_10840460_749_757_Chemical)))))))))))) (, ,) (NP (DT the) (NN bladder)) (VP (AUX was) (VP (VBN removed) (PP (IN in) (NP (NP (DT some) (NNS rats)) (PP (IN for) (NP (JJ histological) (NN examination))))))) (. .)))
10840460	6	(S1 (S (ADVP (RB Finally)) (PRN (, ,) (S (VP (TO to) (VP (VB show) (SBAR (IN that) (S (NP (DT the) (NN bladder)) (VP (AUX is) (ADJP (JJ essential) (PP (IN for) (NP (DT the) (JJ CP-induced) (JJ behavioral) (NNS modifications)))))))))) (, ,)) (NP (JJ female) (NNS rats)) (ADVP (RB also)) (VP (VBD received) (NP (NN CP)) (PP (IN at) (NP (NP (NNS doses)) (PP (IN of) (NP (QP (CD 200) (CD mg./kg.)) (NNS i.p.))))) (PP (CC and) (PP (IN of) (NP (NP (NP (CD 20) (NN mg.)) (PP (IN by) (NP (DT the) (JJ intravesical) (NN route)))) (, ,) (CC and) (NP (NP (NNP Doc_10840460_1021_1029_Chemical)) (PP (IN at) (NP (NP (NNS doses)) (PP (IN of) (NP (NP (CD 0.5) (NN mg.)) (PP (IN by) (NP (DT the) (JJ intravesical) (NN route)))))))))) (CC and) (PP (IN of) (NP (NP (NP (CD 5) (NN mg./kg.)) (NP (NP (JJ i.v.) (NNS RESULTS)) (: :) (NP (NP (CD CP) (ADJP (RB dose-relatedly) (VBN induced)) (JJ marked) (JJ behavioral) (NNS modifications)) (PP (IN in) (NP (JJ male) (NNS rats)))) (: :) (NP (NN breathing) (NN rate) (NN decrease)))) (, ,) (NP (NP (NN closing)) (PP (IN of) (NP (DT the) (NNS eyes)))) (CC and) (NP (NP (NN occurrence)) (PP (IN of) (NP (JJ specific) (NNS postures)))))))) (. .)))
10840460	7	(S1 (S (NP (NN Doc_10840460_1261_1269_Chemical)) (ADVP (RB dose-dependently)) (VP (VBD reversed) (NP (DT these) (NNP Doc_10840460_1302_1322_Disease))) (. .)))
10840460	8	(S1 (S (NP (NP (DT A) (NN dose)) (PP (IN of) (NP (CD 0.5) (NN mg./kg.)))) (VP (VBD produced) (NP (NP (DT a) (NN reduction)) (PP (IN of) (NP (NP (QP (RB almost) (CD 50)) (NN %)) (PP (IN of) (NP (NP (DT the) (JJ behavioral) (NN score)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_10840460_1416_1418_Chemical) (CD 200) (NN mg./kg)))))))))) (. .)))
10840460	9	(S1 (S (NP (DT This) (NN effect)) (VP (AUX was) (ADVP (RB completely)) (VP (VBN prevented) (PP (IN by) (NP (NP (NN pretreatment)) (PP (IN with) (NP (NNP Doc_10840460_1489_1497_Chemical))))))) (. .)))
10840460	10	(S1 (S (PP (IN At) (NP (NP (DT the) (NN time)) (PP (IN of) (NP (NP (NN administration)) (PP (IN of) (NP (NNP Doc_10840460_1532_1540_Chemical))))))) (, ,) (NP (NP (JJ histological) (NNS modifications)) (PP (IN of) (NP (DT the) (NN bladder) (NN wall))) (, ,) (PP (JJ such) (IN as) (NP (NP (NN chorionic)) (CC and) (NP (NN muscle) (NN layer) (NN Doc_10840460_1625_1630_Disease)))) (, ,)) (VP (AUX were) (VP (VBN observed))) (. .)))
10840460	11	(S1 (S (PP (IN In) (NP (JJ female) (NNS rats))) (, ,) (NP (NNP Doc_10840460_1663_1665_Chemical)) (ADVP (NP (CD 200) (NNS mg./kg.)) (RB i.p.)) (VP (VBD produced) (NP (NP (DT the) (JJ same) (JJ marked) (JJ behavioral) (NNS modifications)) (PP (IN as) (NP (NP (DT those)) (VP (VBN observed) (PP (IN in) (NP (JJ male) (NNS rats)))))))) (. .)))
10840460	12	(S1 (S (S (VP (VBN Administered) (PP (IN at) (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (CD 20) (NNS mg.))))) (ADVP (RB intravesically)))) (, ,) (NP (NNP CP)) (VP (AUX did) (RB not) (VP (VB produce) (NP (DT any) (JJ behavioral) (NNS effects)) (, ,) (SBAR (IN whereas) (S (NP (NNP Doc_10840460_1867_1875_Chemical)) (ADVP (NP (QP (IN at) (CD 0.5)) (NNS mg.)) (RB intravesically)) (VP (VBN induced) (NP (NP (JJ behavioral) (NNS modifications)) (ADJP (JJ identical) (PP (TO to) (NP (NP (DT those)) (PP (IN under) (NP (NNP Doc_10840460_1960_1962_Chemical) (CD 200) (NN mg./kg.) (NNS i.p.))))))) (, ,) (PP (IN with) (NP (DT the) (JJ same) (JJ maximal) (NNS levels)))))))) (. .)))
10840460	13	(S1 (S (ADVP (RB Conversely)) (, ,) (NP (NNP Doc_10840460_2023_2031_Chemical) (CD 5)) (VP (VBD mg./kg.) (SBAR (S (NP (NN i.v.)) (VP (AUX did) (RB not) (VP (VB produce) (NP (DT any) (JJ behavioral) (NNS effects)) (ADVP (IN at) (DT all))))))) (. .)))
10840460	14	(S1 (S (ADVP (RB Overall)) (, ,) (NP (DT these) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (DT this) (JJ experimental) (NN model)) (PP (IN of) (NP (JJ CP-induced) (NNP Doc_10840460_2182_2190_Disease)))) (VP (MD may) (VP (AUX be) (NP (NP (DT an) (JJ interesting) (JJ new) (JJ behavioral) (NN model)) (PP (IN of) (NP (JJ inflammatory) (NNP Doc_10840460_2250_2263_Disease)))) (, ,) (S (VP (VBG allowing) (NP (NP (NP (DT a) (JJR better) (NN understanding)) (PP (IN of) (NP (DT these) (NNP Doc_10840460_2306_2323_Disease)))) (CC and) (NP (NP (RB thus) (DT a) (ADJP (RBR better) (JJ therapeutic)) (NN approach)) (PP (TO to) (NP (PRP them)))))))))))) (. .)))
10910842	0	(S1 (S (NP (JJ Doc_10910842_0_12_Chemical-induced) (NN Doc_10910842_21_39_Disease)) (VP (AUX is) (VP (VBN caused) (ADVP (RBR more)) (PP (IN by) (NP (NNP Doc_10910842_58_65_Disease))) (PP (IN than) (PP (IN by) (NP (JJ altered) (JJ Doc_10910842_82_95_Chemical) (NN receptor) (NN expression)))))) (. .)))
10910842	1	(S1 (S (NP (NP (JJ Large) (NNS doses)) (PP (IN of) (NP (NNS glucocorticoids)))) (VP (MD can) (VP (VB alter) (NP (NP (NN muscle)) (UCP (NNP physiology) (CC and) (ADJP (JJ susceptibility) (PP (TO to) (NP (JJ neuromuscular) (VBG blocking) (NNS drugs))) (PP (IN by) (NP (NP (NNS mechanisms)) (VP (RB not) (ADVP (RB clearly)) (VBN understood))))))))) (. .)))
10910842	2	(S1 (S (NP (PRP We)) (VP (VBD investigated) (NP (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (ADJP (JJ moderate) (CC and) (JJ large)) (NNS doses)) (PP (IN of) (NP (NNP Doc_10910842_324_336_Chemical))) (PP (IN on) (NP (NP (NN muscle) (NN function)) (CC and) (NP (NN pharmacology))))))) (, ,) (CC and) (NP (NP (PRP$ their) (NN relationship)) (PP (TO to) (NP (NP (NNS changes)) (PP (IN in) (NP (NP (NN muscle) (NN size)) (CC and) (NP (JJ Doc_10910842_427_440_Chemical) (NN receptor) (PRN (-LRB- -LRB-) (NNP AChR) (-RRB- -RRB-)) (NN expression))))))))) (. .)))
10910842	3	(S1 (S (PP (IN With) (NP (JJ institutional) (NN approval))) (, ,) (NP (CD 35) (NNP Sprague-Dawley) (NNS rats)) (VP (AUX were) (ADVP (RB randomly)) (VP (VBN allocated) (S (VP (TO to) (VP (VB receive) (NP (NP (JJ daily) (JJ subcutaneous) (NNS doses)) (PP (IN of) (NP (NP (NP (QP (CD 10) (CD mg/kg)) (NNP Doc_10910842_593_605_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP P10) (NN group)) (-RRB- -RRB-))) (, ,) (NP (NP (CD 100) (NNS mg/kg)) (NP (NP (NNP Doc_10910842_629_641_Chemical)) (PRN (-LRB- -LRB-) (NP (CD P100) (NN group)) (-RRB- -RRB-)))) (, ,) (CC or) (NP (NP (DT an) (JJ equal) (NN volume)) (PP (IN of) (NP (NN saline))) (PRN (-LRB- -LRB-) (NP (NNP S) (NN group)) (-RRB- -RRB-)))))) (PP (IN for) (NP (CD 7) (NNS days)))))))) (. .)))
10910842	4	(S1 (S (NP (NP (DT A) (JJ fourth) (NN group)) (PP (IN of) (NP (NNS rats)))) (VP (AUX was) (ADJP (NN pair) (VBN fed)) (PRN (-LRB- -LRB-) (S (NP (NN food)) (VP (VBN restricted))) (-RRB- -RRB-)) (PP (IN with) (NP (NP (DT the) (CD P100) (NNS rats)) (PP (IN for) (NP (NP (CD 7) (NNS days)) (PRN (-LRB- -LRB-) (NP (CD FR) (NN group)) (-RRB- -RRB-))))))) (. .)))
10910842	5	(S1 (S (PP (IN On) (NP (NNP Day) (CD 8))) (, ,) (NP (NP (DT the) (JJ nerve-evoked) (NN peak) (VB twitch) (NNS tensions)) (, ,) (NP (JJ tetanic) (NNS tensions)) (, ,) (CC and) (NP (NN fatigability)) (, ,) (CC and) (NP (NP (DT the) (JJ dose-response) (NNS curves)) (PP (IN of) (NP (NNP Doc_10910842_920_934_Chemical))) (PP (IN in) (NP (DT the) (ADJP (FW tibialis) (FW cranialis)) (NN muscle))))) (VP (AUX were) (VP (VP (VBN measured) (PP (IN in) (NP (NN vivo)))) (CC and) (VP (VBN related) (PP (TO to) (NP (NP (NN muscle) (NN mass) (CC or) (NN expression)) (PP (IN of) (NP (NNS AChRs)))))))) (. .)))
10910842	6	(S1 (S (NP (NP (NN Rate)) (PP (IN of) (NP (NN body) (NN weight) (NN gain)))) (VP (AUX was) (VP (VBN depressed) (PP (IN in) (NP (DT the) (NNP P100) (, ,) (NNP FR) (, ,) (CC and) (NNP P10) (NNS groups))) (PP (VBN compared) (PP (IN with) (NP (DT the) (NNP S) (NN group)))))) (. .)))
10910842	7	(S1 (S (NP (NNP Tibialis) (NN muscle) (NN mass)) (VP (AUX was) (ADJP (JJR smaller)) (PP (IN in) (NP (DT the) (NNP P100) (NN group))) (PP (IN than) (PP (IN in) (NP (DT the) (NNP P10) (CC or) (NNP S) (NNS groups))))) (. .)))
10910842	8	(S1 (S (S (S (NP (DT The) (VBN evoked) (NN peak)) (VP (VB twitch))) (CC and) (S (NP (JJ tetanic) (NNS tensions)) (VP (AUX were) (ADJP (ADJP (JJR less) (PP (IN in) (NP (DT the) (NNP P100) (NN group)))) (PP (IN than) (PP (IN in) (NP (DT the) (NNP P10) (CC or) (NNP S) (NNS groups)))))))) (, ,) (ADVP (RB however)) (, ,) (NP (NP (NN tension)) (PP (IN per) (NP (NP (NN milligram)) (PP (IN of) (NP (NN muscle) (NN mass)))))) (VP (AUX was) (ADJP (ADJP (JJR greater)) (PP (IN in) (NP (DT the) (NNP P100) (NN group))) (PP (IN than) (PP (IN in) (NP (DT the) (NNP S) (NN group)))))) (. .)))
10910842	9	(S1 (S (NP (NP (DT The) (ADJP (CD 50) (NN %)) (JJ effective) (NN dose)) (PP (IN of) (NP (NNP Doc_10910842_1443_1457_Chemical))) (PRN (-LRB- -LRB-) (NP (CD microg/kg)) (-RRB- -RRB-)) (PP (IN in) (NP (DT the) (NN tibialis) (NN muscle)))) (VP (AUX was) (ADJP (ADJP (JJR smaller) (PP (IN in) (NP (NP (DT the) (NNP P10)) (PRN (-LRB- -LRB-) (NP (QP (CD 33.6) (CD +/-)) (CD 5.4)) (-RRB- -RRB-))))) (PP (IN than) (PP (IN in) (NP (NP (NP (DT the) (NNP S)) (PRN (-LRB- -LRB-) (NP (QP (CD 61.9) (CD +/-)) (CD 5.0)) (-RRB- -RRB-))) (CC or) (NP (DT the) (NNP P100) (PRN (-LRB- -LRB-) (NP (QP (CD 71.3) (CD +/-)) (CD 9.6)) (-RRB- -RRB-)) (NNS groups))))))) (. .)))
10910842	10	(S1 (S (NP (JJ AChR) (NN expression)) (VP (AUX was) (ADJP (ADJP (JJR less)) (PP (IN in) (NP (DT the) (NNP P10) (NN group))) (PP (IN than) (PP (IN in) (NP (DT the) (NNP S) (NN group)))))) (. .)))
10910842	11	(S1 (S (NP (DT The) (JJ evoked) (NNS tensions)) (VP (VBD correlated) (PP (IN with) (NP (NP (NN muscle) (NN mass)) (PRN (-LRB- -LRB-) (NP (NN r) (-LRB- -LRB-) (CD 2) (-RRB- -RRB-) (SYM =) (CD 0.32)) (, ,) (NP (NNP P) (QP (CD <) (CD 0.001))) (-RRB- -RRB-)))) (, ,) (ADVP (RB however)) (, ,) (PP (RB not) (PP (IN with) (NP (NP (NN expression)) (PP (IN of) (NP (NNP AChR))))))) (. .)))
10910842	12	(S1 (S (NP (NP (DT The) (ADJP (CD 50) (NN %)) (JJ effective) (NN dose)) (PP (IN of) (NP (NNP Doc_10910842_1796_1810_Chemical)))) (VP (AUX did) (RB not) (VP (VB correlate) (PP (IN with) (NP (NP (NN muscle) (NN mass)) (CC or) (NP (NN AChR) (NN expression)))))) (. .)))
10910842	13	(S1 (S (NP (PRP$ Our) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (DT the) (NN Doc_10910842_1895_1920_Disease)) (PP (IN after) (NP (NNP Doc_10910842_1927_1939_Chemical)))) (VP (VP (AUX is) (ADJP (JJ dose-dependent))) (, ,) (CC and) (VP (VP (VBZ derives) (ADVP (RB primarily)) (PP (IN from) (NP (NNP Doc_10910842_1986_2000_Disease)))) (CC and) (VP (VBZ derives) (ADVP (RBR less) (RB so)) (PP (IN from) (NP (NP (NNS changes)) (PP (IN in) (NP (CD AChR) (NN expression))))))))))) (. .)))
10910842	14	(S1 (S (NP (NP (DT The) (NNS mechanisms)) (SBAR (WHPP (IN by) (WHNP (WDT which))) (S (NP (JJ chronic) (NN glucocorticoid) (NN therapy) (NNS alters)) (VP (VBP neuromuscular) (NP (NP (NNP physiology)) (CC and) (NP (NNS pharmacology))))))) (VP (AUX are) (ADJP (JJ unclear))) (. .)))
10910842	15	(S1 (S (NP (PRP We)) (VP (VBP suggest) (SBAR (IN that) (S (NP (DT the) (JJ observed) (NNS effects)) (VP (VP (AUX are) (ADJP (JJ dose-dependent))) (CC and) (VP (VBP derive) (ADVP (RB primarily)) (PP (IN from) (NP (NNP Doc_10910842_2267_2281_Disease)))) (CC and) (VP (VBP derive) (ADVP (RBR less)) (PP (IN from) (NP (NP (NNS changes)) (PP (IN in) (NP (JJ Doc_10910842_2314_2327_Chemical) (NN receptor) (NN expression)))))))))) (. .)))
11009181	0	(S1 (NP (NP (NN Doc_11009181_0_11_Chemical)) (: :) (NP (NP (DT an) (VBN underutilized) (NN therapy)) (PP (IN for) (NP (NNP Doc_11009181_42_61_Disease)))) (. .)))
11009181	1	(S1 (S (NP (NN Doc_11009181_63_74_Chemical)) (VP (AUX was) (NP (NP (DT the) (JJ first) (JJ dopaminergic) (NN drug)) (VP (ADVP (RB ever)) (VBN used) (S (VP (TO to) (VP (VB treat) (NP (NP (NNS symptoms)) (PP (IN of) (NP (NN Doc_11009181_138_157_Disease)))))))))) (. .)))
11009181	2	(S1 (S (SBAR (IN While) (S (NP (JJ powerful) (NN antiparkinsonian) (NNS effects)) (VP (AUX had) (VP (AUX been) (VP (VBN observed) (ADVP (ADVP (RB as) (RB early)) (PP (IN as) (NP (CD 1951))))))))) (, ,) (NP (NP (DT the) (NN potential)) (PP (IN of) (S (VP (VBG treating) (NP (JJ fluctuating) (NNP Doc_11009181_273_292_Disease)) (PP (IN by) (NP (NP (JJ subcutaneous) (NN administration)) (PP (IN of) (NP (NNP Doc_11009181_327_338_Chemical))))))))) (VP (AUX has) (ADVP (RB only)) (ADVP (RB recently)) (VP (VBN become) (NP (NP (DT the) (NN subject)) (PP (IN of) (NP (JJ systematic) (NN study)))))) (. .)))
11009181	3	(S1 (S (NP (NP (DT A) (NN number)) (PP (IN of) (NP (JJ small) (NN scale) (JJ clinical) (NNS trials)))) (VP (AUX have) (ADVP (RB unequivocally)) (VP (VBN shown) (SBAR (IN that) (S (NP (JJ intermittent) (JJ subcutaneous) (NNP Doc_11009181_493_504_Chemical) (NNS injections)) (VP (VBP produce) (NP (JJ antiparkinsonian) (NN benefit)) (ADVP (RB close)) (SBAR (SBAR (IN if) (S (ADJP (RB not) (JJ identical) (PP (TO to) (NP (NP (DT that)) (VP (VBN seen) (PP (IN with) (NP (NNP Doc_11009181_590_598_Chemical))))))))) (CC and) (SBAR (IN that) (S (NP (NNP Doc_11009181_608_619_Chemical) (NN rescue) (NNS injections)) (VP (MD can) (ADVP (RB reliably)) (VP (VB revert) (NP (NNS off-periods)) (PP (ADVP (RB even)) (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ complex) (JJ on-off) (NN motor) (NNS swings))))))))))))))) (. .)))
11009181	4	(S1 (S (NP (ADJP (JJ Continuous) (JJ subcutaneous)) (JJ Doc_11009181_745_756_Chemical) (NNS infusions)) (VP (MD can) (VP (VB reduce) (NP (JJ daily) (NN off-time)) (PP (IN by) (NP (QP (JJR more) (IN than) (CD 50)) (NN %))) (PP (IN in) (NP (NP (DT this) (NN group)) (PP (IN of) (NP (NNS patients))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ appears) (S (VP (TO to) (VP (AUX be) (NP (NP (DT a) (JJR stronger) (NN effect)) (PP (IN than) (NP (NP (DT that)) (VP (ADVP (RB generally)) (VBN seen) (PP (IN with) (NP (NP (JJ add-on) (NN therapy)) (PP (IN with) (NP (NP (JJ oral) (JJ Doc_11009181_930_938_Chemical) (NNS agonists)) (CC or) (NP (JJ COMT) (NNS inhibitors)))))))))))))))))))) (. .)))
11009181	5	(S1 (S (NP (NP (JJ Extended) (JJ follow-up) (NNS studies)) (PP (IN of) (NP (QP (RB up) (TO to) (CD 8)) (NNS years)))) (VP (AUX have) (VP (VBN demonstrated) (NP (NP (JJ long-term) (NN persistence)) (PP (IN of) (NP (JJ Doc_11009181_1055_1066_Chemical) (NN efficacy)))))) (. .)))
11009181	6	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (EX there)) (VP (AUX is) (NP (JJ convincing) (JJ clinical) (NN evidence) (SBAR (IN that) (S (NP (NP (NN monotherapy)) (PP (IN with) (NP (JJ continuous) (JJ subcutaneous) (NNP Doc_11009181_1174_1185_Chemical) (NNS infusions)))) (VP (AUX is) (VP (VBN associated) (PP (IN with) (NP (NP (JJ marked) (NNS reductions)) (PP (IN of) (S (VP (VBG preexisting) (NP (JJ Doc_11009181_1248_1256_Chemical-induced) (NN Doc_11009181_1265_1276_Disease))))))))))))) (. .)))
11009181	7	(S1 (S (NP (NP (DT The) (JJ main) (JJ side) (NNS effects)) (PP (IN of) (NP (JJ subcutaneous) (JJ Doc_11009181_1316_1327_Chemical) (NN treatment)))) (VP (AUX are) (ADJP (JJ related) (PP (TO to) (NP (JJ cutaneous) (NN tolerability) (NNS problems)))) (, ,) (SBAR (IN whereas) (S (NP (NN sedation) (CC and) (NN Doc_11009181_1407_1418_Disease) (NNS complications)) (VP (VBP play) (NP (DT a) (JJR lesser) (NN role)))))) (. .)))
11009181	8	(S1 (S (PP (VBN Given) (NP (NP (DT the) (JJ marked) (NN degree)) (PP (IN of) (NP (NP (NN efficacy)) (PP (IN of) (NP (JJ subcutaneous) (JJ Doc_11009181_1505_1516_Chemical) (NN treatment))))) (PP (IN in) (S (VP (VBG fluctuating) (NP (NNP Doc_11009181_1542_1561_Disease))))))) (, ,) (NP (DT this) (NN approach)) (VP (VBZ seems) (S (VP (TO to) (VP (VB deserve) (NP (ADJP (RBR more) (JJ widespread)) (JJ clinical) (NN use)))))) (. .)))
11022397	0	(S1 (FRAG (S (VP (VBG Probing) (NP (JJ peripheral) (CC and) (JJ central) (JJ cholinergic) (NN system) (NNS responses)))) (. .)))
11022397	1	(S1 (S (S (NP (NP (DT The) (JJ pharmacological) (NN response)) (PP (TO to) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP act) (PP (IN on) (NP (NP (DT the) (JJ cholinergic) (NN system)) (PP (IN of) (NP (DT the) (NN iris))))))))))) (VP (AUX has) (VP (AUX been) (VP (VBN used) (S (VP (TO to) (VP (VB predict) (NP (NNS deficits)) (PP (IN in) (NP (NP (JJ central) (JJ cholinergic) (NN functioning)) (ADJP (JJ due) (PP (TO to) (NP (NP (NNS diseases)) (PP (JJ such) (IN as) (NP (NNP Doc_11022397_250_269_Disease))))))))))))))) (, ,) (CC yet) (S (NP (NP (NNS correlations)) (PP (IN between) (NP (JJ central) (CC and) (JJ peripheral) (NNS responses)))) (VP (AUX have) (RB not) (VP (AUX been) (VP (ADVP (RB properly)) (VBN studied))))) (. .)))
11022397	2	(S1 (S (NP (DT This) (NN study)) (VP (VBD assessed) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (JJ normal) (NN aging))) (PP (IN on) (NP (NP (LST (-LRB- -LRB-) (LS 1) (-RRB- -RRB-)) (NP (DT the) (JJ Doc_11022397_419_430_Chemical-induced) (NN increase)) (PP (IN in) (NP (NN pupil) (NN diameter)))) (, ,) (CC and) (NP (LST (-LRB- -LRB-) (LS 2) (-RRB- -RRB-)) (NP (DT the) (NN reversal)) (PP (IN of) (NP (NP (DT this) (NN effect)) (PP (IN with) (NP (NNP Doc_11022397_508_519_Chemical)))))))))) (. .)))
11022397	3	(S1 (S (NP (NN Doc_11022397_521_532_Chemical)) (VP (AUX was) (VP (VBN used) (PP (IN as) (NP (NP (DT a) (JJ positive) (NN control)) (SBAR (S (VP (TO to) (VP (VB detect) (NP (JJ age-dependent) (NNS changes)) (PP (IN in) (NP (NP (JJ central) (JJ cholinergic) (NN functioning)) (PP (IN in) (NP (DT the) (JJ elderly))))))))))))) (. .)))
11022397	4	(S1 (S (NP (JJ Randomized) (NN double-blind)) (VP (VBD controlled) (NP (NN trial))) (. .)))
11022397	5	(S1 (S (NP (NP (NP (CD Ten) (JJ healthy) (JJ elderly)) (PRN (-LRB- -LRB-) (NP (JJ mean) (NN age) (CD 70)) (-RRB- -RRB-))) (CC and) (NP (CD 9) (JJ young))) (PRN (-LRB- -LRB-) (S (VP (VB mean) (NP (NN age) (CD 33)))) (-RRB- -RRB-)) (VP (NNS volunteers)) (. .)))
11022397	6	(S1 (S (NP (NN Pupil) (NN diameter)) (VP (AUX was) (VP (VBN monitored) (S (VP (VBG using) (NP (NP (DT a) (JJ computerized) (JJ infrared) (NN pupillometer)) (PP (IN over) (NP (CD 4) (NNS hours)))))))) (. .)))
11022397	7	(S1 (S (NP (DT The) (NN study)) (VP (VBD involved) (NP (CD 4) (NNS sessions))) (. .)))
11022397	8	(S1 (S (PP (IN In) (NP (CD 1) (NN session))) (, ,) (NP (NP (NNP Doc_11022397_929_940_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 20) (NN microL)) (, ,) (NP (CD 0.01) (NN %))) (-RRB- -RRB-))) (VP (VP (AUX was) (VP (VBN administered) (PP (TO to) (NP (CD one) (NN eye))))) (CC and) (VP (NP (NN placebo)) (PP (TO to) (NP (DT the) (JJ other))))) (. .)))
11022397	9	(S1 (S (PP (IN In) (NP (DT another) (NN session))) (, ,) (NP (NP (NNP Doc_11022397_1034_1045_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 20) (NN microL)) (, ,) (NP (CD 0.01) (NN %))) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN administered) (PP (TO to) (NP (DT both) (NNS eyes))) (, ,) (S (VP (VBN followed) (ADVP (NP (CD 23) (NNS minutes)) (RB later)) (PP (IN by) (NP (NP (DT the) (NN application)) (PP (IN of) (NP (NP (NNP Doc_11022397_1144_1155_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 20) (NN microL)) (, ,) (NP (CD 0.1) (NN %))) (-RRB- -RRB-)))) (PP (TO to) (NP (NP (CD one) (NN eye)) (CC and) (NP (NP (NN placebo)) (PP (TO to) (NP (DT the) (JJ other)))))))))))) (. .)))
11022397	10	(S1 (S (NP (DT All) (NN eye) (NNS drops)) (VP (AUX were) (VP (VBN given) (PP (IN in) (NP (DT a) (JJ randomized) (NN order))))) (. .)))
11022397	11	(S1 (S (PP (IN In) (NP (CD 2) (JJ separate) (NNS sessions))) (, ,) (S (NP (NP (NP (DT a) (JJ single) (NN dose)) (PP (IN of) (NP (NNP Doc_11022397_1300_1311_Chemical))) (PRN (-LRB- -LRB-) (NP (CD 0.5) (NN mg)) (, ,) (NP (NN intravenously)) (-RRB- -RRB-))) (CC or) (NP (NN placebo))) (VP (AUX was) (VP (VBN administered)))) (, ,) (CC and) (S (NP (NP (DT the) (NNS effects)) (PP (IN on) (NP (NN word) (NN recall)))) (VP (AUX were) (VP (VBN measured) (S (VP (VBG using) (NP (DT the) (JJ Buschke) (JJ Selective) (VBG Reminding) (NN Test)) (PP (IN over) (NP (CD 2) (NNS hours)))))))) (. .)))
11022397	12	(S1 (NP (NP (NN OUTCOME) (NNS MEASURES)) (: :) (NP (NP (NP (NN Pupil) (NN size)) (PP (IN at) (NP (NN time) (NNS points))) (PP (IN after) (NP (NN administration))) (PP (IN of) (NP (NP (NNP Doc_11022397_1535_1546_Chemical)) (CC and) (NP (NNP Doc_11022397_1551_1562_Chemical))))) (: ;) (NP (JJ Doc_11022397_1564_1575_Chemical-induced) (NNP Doc_11022397_1584_1609_Disease))) (. .)))
11022397	13	(S1 (S (NP (EX There)) (VP (AUX was) (NP (NP (DT no) (JJ significant) (NN difference)) (PP (IN between) (NP (NP (NP (JJ elderly) (CC and) (JJ young) (NNS volunteers)) (PP (IN in) (NP (NP (JJ pupillary) (NN response)) (PP (TO to) (NP (NNP Doc_11022397_1718_1729_Chemical))))) (PP (IN at) (NP (DT any) (NN time) (NN point)))) (PRN (-LRB- -LRB-) (NP (QP ($ p) (CD >) (CD 0.05))) (-RRB- -RRB-)))))) (. .)))
11022397	14	(S1 (S (NP (DT The) (JJ elderly) (NN group)) (VP (AUX had) (NP (NP (DT a) (ADJP (RB significantly) (JJR greater)) (JJ Doc_11022397_1806_1817_Chemical-induced) (JJ net) (NN decrease)) (PP (IN in) (NP (NN pupil) (NN size)))) (PP (NP (CD 85) (, ,) (CD 125) (, ,) (CD 165) (CC and) (CD 215) (NNS minutes)) (IN after) (NP (NN administration))) (, ,) (PP (VBN compared) (PP (IN with) (NP (NP (DT the) (JJ young) (NN group)) (PRN (-LRB- -LRB-) (NP (NNP p) (NNP <) (CD 0.05)) (-RRB- -RRB-)))))) (. .)))
11022397	15	(S1 (S (PP (VBN Compared) (PP (IN with) (NP (DT the) (JJ young) (NN group)))) (, ,) (NP (DT the) (JJ elderly) (NN group)) (VP (AUX had) (NP (JJR greater) (JJ Doc_11022397_2007_2018_Chemical-induced) (NNP Doc_11022397_2027_2052_Disease) (CD 60) (, ,) (CD 90) (CC and) (CD 120) (NNS minutes)) (PP (IN after) (NP (NP (NN administration)) (PRN (-LRB- -LRB-) (NP (QP ($ p) (CD <) (CD 0.05))) (-RRB- -RRB-))))) (. .)))
11022397	16	(S1 (S (NP (EX There)) (VP (AUX is) (NP (NP (DT an) (JJ age-related) (JJ pupillary) (NN response)) (PP (TO to) (NP (NNP Doc_11022397_2167_2178_Chemical))) (SBAR (WHNP (WDT that)) (S (VP (AUX is) (RB not) (VP (VBN found) (PP (IN with) (NP (NN Doc_11022397_2202_2213_Chemical))))))))) (. .)))
11022397	17	(S1 (S (ADVP (RB Thus)) (, ,) (NP (NNP Doc_11022397_2221_2232_Chemical)) (VP (MD may) (VP (AUX be) (ADJP (JJ useful) (S (VP (TO to) (VP (VB assess) (NP (NNS variations)) (PP (IN in) (NP (NP (JJ central) (JJ cholinergic) (NN function)) (PP (IN in) (NP (JJ elderly) (NNS patients))))))))))) (. .)))
11027904	0	(S1 (NP (NP (NN Doc_11027904_0_4_Disease) (NNS responses)) (PP (IN in) (NP (JJ Doc_11027904_18_27_Chemical-maintained) (JJ opioid) (NNS abusers))) (. .)))
11027904	1	(S1 (S (S (VP (VBG Providing) (NP (NNP Doc_11027904_65_69_Disease) (NN management)) (PP (IN for) (NP (JJ known) (JJ opioid) (NNS abusers))))) (VP (AUX is) (NP (DT a) (JJ challenging) (JJ clinical) (NN task)) (, ,) (PP (IN in) (NP (NN part))) (SBAR (IN because) (S (NP (RB little)) (VP (AUX is) (VP (VBN known) (PP (IN about) (NP (NP (PRP$ their) (JJ Doc_11027904_182_186_Disease) (NN experience)) (CC and) (NP (JJ analgesic) (NNS requirements))))))))) (. .)))
11027904	2	(S1 (S (NP (DT This) (NN study)) (VP (AUX was) (VP (VBN designed) (S (VP (TO to) (VP (VB describe) (NP (NP (JJ Doc_11027904_262_266_Disease) (NN tolerance)) (CC and) (NP (JJ analgesic) (NN response))) (PP (IN in) (NP (NP (DT a) (NN sample)) (PP (IN of) (NP (NNP Doc_11027904_315_329_Disease))) (VP (VBN stabilized) (PP (IN in) (NP (NP (JJ Doc_11027904_344_353_Chemical-maintenance) (PRN (-LRB- -LRB-) (NP (NNP MM)) (-RRB- -RRB-)) (NN treatment)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 60)) (-RRB- -RRB-)))) (PP (IN in) (NP (NP (NN comparison)) (PP (TO to) (NP (NP (VBN matched) (JJ nondependent) (NN control) (NNS subjects)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 60)) (-RRB- -RRB-)))))))))))))) (. .)))
11027904	3	(S1 (S (PP (IN By) (S (VP (VBG using) (NP (DT a) (JJ placebo-controlled) (, ,) (JJ two-way) (JJ factorial) (NN design))))) (, ,) (NP (NP (NN tolerance)) (PP (TO to) (NP (JJ cold-pressor) (PRN (-LRB- -LRB-) (NP (NNP CP)) (-RRB- -RRB-)) (NNP Doc_11027904_543_547_Disease)))) (VP (AUX was) (VP (VBN examined) (, ,) (PP (DT both) (IN before) (CC and) (IN after) (NP (NP (JJ oral) (NN administration)) (PP (IN of) (NP (NP (NP (NP (JJ therapeutic) (NNS doses)) (PP (IN of) (NP (JJ common) (NN opioid)))) (PRN (-LRB- -LRB-) (NP (NNP Doc_11027904_643_656_Chemical) (CD 2) (CD mg)) (-RRB- -RRB-))) (CC and) (NP (JJ nonsteroidal) (JJ anti-inflammatory) (PRN (-LRB- -LRB-) (NP (NNP Doc_11027904_699_708_Chemical) (CD 10) (CD mg)) (-RRB- -RRB-)) (JJ analgesic) (NNS agents)))))))) (. .)))
11027904	4	(S1 (S (NP (NNS Results)) (VP (VBD showed) (SBAR (IN that) (S (NP (NN MM) (NNS individuals)) (VP (AUX were) (NP (NP (ADJP (RB significantly) (JJR less)) (NN tolerant)) (PP (IN of) (NP (NNP CP) (NNP Doc_11027904_808_812_Disease)))) (PP (IN than) (NP (NN control) (NNS subjects))) (, ,) (S (VP (VBG replicating) (NP (JJ previous) (NN work)))))))) (. .)))
11027904	5	(S1 (S (NP (JJ Analgesic) (NNS effects)) (VP (AUX were) (UCP (ADJP (JJ significant)) (CC neither) (PP (IN for) (NP (NP (NN medication)) (CC nor) (NP (NN group)))))) (. .)))
11027904	6	(S1 (S (NP (DT These) (NNS data)) (VP (VBP indicate) (SBAR (IN that) (S (NP (JJ MM) (NN opioid) (NNS abusers)) (VP (VBP represent) (NP (NP (DT a) (JJ Doc_11027904_987_1002_Disease) (NN subset)) (PP (IN of) (NP (JJ clinical) (NNS patients)))))))) (. .)))
11027904	7	(S1 (S (NP (NP (PRP$ Their) (NNS complaints)) (PP (IN of) (NP (NNP Doc_11027904_1052_1056_Disease)))) (VP (MD should) (VP (AUX be) (VP (VP (VBN evaluated) (ADVP (RB seriously))) (CC and) (VP (VBN managed) (ADVP (RB aggressively)))))) (. .)))
11058428	0	(S1 (S (NP (NNP High-dose) (NNP Doc_11058428_10_28_Chemical)) (VP (MD may) (VP (AUX do) (NP (NP (JJR more) (NN harm)) (PP (IN for) (NP (NNP Doc_11058428_50_68_Disease)))))) (. .)))
11058428	1	(S1 (S (PP (IN Because) (IN of) (NP (NP (DT the) (ADJP (NNP National) (JJ Acute)) (NNP Doc_11058428_100_118_Disease) (NNP Studies)) (PRN (-LRB- -LRB-) (NP (NNP NASCIS)) (-RRB- -RRB-)))) (, ,) (NP (JJ high-dose) (NNP Doc_11058428_147_165_Chemical)) (VP (VBD became) (NP (NP (DT the) (NN standard)) (PP (IN of) (NP (NN care))) (PP (IN for) (NP (DT the) (JJ acute) (NN Doc_11058428_208_226_Disease))))) (. .)))
11058428	2	(S1 (S (PP (IN In) (NP (DT the) (NN NASCIS))) (, ,) (NP (EX there)) (VP (AUX was) (NP (NP (DT no) (NN mention)) (VP (VBG regarding) (NP (NP (DT the) (NN possibility)) (PP (IN of) (NP (JJ acute) (NNP Doc_11058428_299_313_Chemical) (NNP Doc_11058428_314_322_Disease))))) (SBAR (WHNP (WDT that)) (S (VP (VBP high-dose) (SBAR (S (NP (NNP Doc_11058428_338_356_Chemical)) (VP (MD may) (VP (VB cause)))))))))) (. .)))
11058428	3	(S1 (S (NP (NP (DT The) (NN dosage)) (PP (IN of) (NP (NNP Doc_11058428_382_400_Chemical))) (VP (VBN recommended) (PP (IN by) (NP (DT the) (NNP NASCIS) (CD 3))))) (VP (AUX is) (S (NP (NP (DT the) (JJS highest) (NN dose)) (PP (IN of) (NP (NNP Doc_11058428_452_460_Chemical)))) (ADVP (RB ever)) (VP (AUXG being) (VP (VBN used) (PP (IN during) (NP (NP (DT a) (JJ 2-day) (NN period)) (PP (IN for) (NP (DT any) (JJ clinical) (NN condition))))))))) (. .)))
11058428	4	(S1 (S (NP (PRP We)) (VP (VBP hypothesize) (SBAR (IN that) (S (NP (PRP it)) (VP (MD may) (VP (VB cause) (NP (NP (DT some) (NN Doc_11058428_565_585_Disease)) (PP (IN of) (NP (JJ Doc_11058428_589_607_Disease) (NNS patients))))))))) (. .)))
11058428	5	(S1 (S (ADVP (RB Further)) (, ,) (S (NP (NNP Doc_11058428_627_634_Chemical) (NNP Doc_11058428_635_643_Disease)) (VP (VBZ recovers) (ADVP (RB naturally)))) (CC and) (S (NP (NP (DT the) (JJ neurological) (NN improvement)) (VP (VBN shown) (PP (IN in) (NP (DT the) (NN NASCIS))))) (VP (MD may) (VP (AUX be) (NP (NP (NP (RB just) (DT a) (NN recording)) (PP (IN of) (NP (NP (DT this) (JJ natural) (NN motor) (NN recovery)) (PP (IN from) (NP (DT the) (NNP Doc_11058428_780_787_Chemical) (NNP Doc_11058428_788_796_Disease)))))) (, ,) (CONJP (RB instead) (IN of)) (NP (NP (DT any) (NN protection)) (SBAR (WHNP (WDT that)) (S (NP (NNP Doc_11058428_829_847_Chemical)) (VP (VBZ offers) (PP (TO to) (NP (DT the) (NNP Doc_11058428_862_880_Disease))))))))))) (. .)))
11058428	6	(S1 (S (PP (TO To) (NP (PRP$ our) (NN knowledge))) (, ,) (NP (DT this)) (VP (AUX is) (NP (NP (DT the) (JJ first) (NN discussion)) (VP (VBG considering) (NP (DT the) (NN possibility) (SBAR (IN that) (S (NP (NP (DT the) (NNP Doc_11058428_966_984_Chemical)) (VP (VBN recommended) (PP (IN by) (NP (NNP NASCIS))))) (VP (MD may) (VP (VB cause) (NP (JJ acute) (JJ Doc_11058428_1023_1037_Chemical) (NN Doc_11058428_1038_1046_Disease)))))))))) (. .)))
11063349	0	(S1 (NP (NP (NP (NN Conversion)) (PP (TO to) (NP (JJ Doc_11063349_14_23_Chemical) (NN immunosuppression))) (PP (IN in) (NP (JJ renal) (NN transplant) (NNS recipients)))) (: :) (NP (NP (NN report)) (PP (IN of) (NP (DT an) (JJ initial) (NN experience)))) (. .)))
11063349	1	(S1 (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX is) (S (VP (TO to) (VP (VB evaluate) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (JJ Doc_11063349_171_175_Chemical) (NN conversion))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG undergoing) (NP (NP (NP (NNP Doc_11063349_210_222_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11063349_224_227_Chemical)) (-RRB- -RRB-))) (CC or) (NP (NNP Doc_11063349_232_242_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_11063349_244_247_Chemical)) (-RRB- -RRB-)) (NNP Doc_11063349_249_257_Disease))))))))))) (. .)))
11063349	2	(S1 (S (NP (CD Twenty) (JJ renal) (NN transplant) (NNS recipients)) (VP (AUX were) (VP (VBN switched) (PP (TO to) (NP (NP (NP (JJ fixed) (NN dose) (NNP Doc_11063349_331_340_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11063349_342_346_Chemical)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (CD 5) (NN mg/day)) (-RRB- -RRB-)))) (NP (QP (CD 0) (TO to) (CD 204) (NNS months)) (NN posttransplant)))) (. .)))
11063349	3	(S1 (S (NP (NN Drug) (NN monitoring)) (VP (AUX was) (RB not) (ADVP (RB initially)) (VP (VBN used) (S (VP (TO to) (VP (VB adjust) (NP (NNS doses))))))) (. .)))
11063349	4	(S1 (S (NP (NP (DT The) (NNS indications)) (PP (IN for) (NP (NN switch)))) (VP (AUX were) (NP (NP (NP (JJ chronic) (NNP Doc_11063349_487_490_Chemical) (CC or) (NNP Doc_11063349_494_497_Chemical) (NN nephrotoxicity)) (PRN (-LRB- -LRB-) (NP (CD 12)) (-RRB- -RRB-))) (, ,) (NP (JJ acute) (NNP Doc_11063349_525_528_Chemical)) (CC or) (NP (NP (NP (NNP Doc_11063349_532_535_Chemical) (NNP Doc_11063349_536_544_Disease)) (PRN (-LRB- -LRB-) (NP (CD 3)) (-RRB- -RRB-))) (, ,) (NP (JJ severe) (NNP Doc_11063349_557_575_Disease)) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-)) (, ,) (NP (NNP Doc_11063349_581_624_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11063349_626_630_Disease)) (-RRB- -RRB-)))) (PP (IN in) (NP (NP (NP (NN remission)) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NN hepatotoxicity)) (PP (IN in) (NP (CD 1))))))) (. .)))
11063349	5	(S1 (S (NP (NN Follow-up)) (VP (AUX is) (NP (QP (CD 7) (TO to) (CD 24)) (NNS months))) (. .)))
11063349	6	(S1 (S (PP (IN In) (NP (NP (DT the) (CD 12) (NNS patients)) (VP (VBN switched) (PP (IN because) (IN of) (NP (NN chronic) (NN nephrotoxicity)))))) (NP (EX there)) (VP (AUX was) (NP (NP (DT a) (JJ significant) (NN decrease)) (PP (IN in) (NP (JJ serum) (NNP Doc_11063349_817_827_Chemical) (CD -LSB-233+/-34))) (PP (TO to) (NP (CD 210+/-56) (NN micromol/liter)))) (PRN (-LRB- -LRB-) (NP (NNP P<0.05)) (-RRB- -RRB-)) (PP (IN at) (NP (QP (CD 6) (NNS months)) (NN -RSB-)))) (. .)))
11063349	7	(S1 (S (NP (NN Doc_11063349_888_906_Disease)) (VP (VBD improved) (PP (IN in) (NP (CD two) (NNS patients)))) (. .)))
11063349	8	(S1 (S (NP (NP (DT No) (NN relapse)) (PP (IN of) (NP (NNP Doc_11063349_947_951_Disease)))) (VP (AUX was) (VP (VBN observed))) (. .)))
11063349	9	(S1 (S (NP (CD Five) (NNS patients)) (VP (VBD developed) (SBAR (S (NP (NP (NP (NNP Doc_11063349_990_999_Disease)) (PRN (-LRB- -LRB-) (NP (NP (CD two) (NNP Doc_11063349_1005_1035_Disease)) (, ,) (NP (NP (CD one) (NN Doc_11063349_1041_1065_Disease)) (PP (IN with) (NP (JJ polyclonal) (JJ Doc_11063349_1082_1086_Disease) (NN lung) (VB infiltrate))))) (-RRB- -RRB-))) (CC and) (NP (CD two))) (VP (AUX had) (NP (NN Doc_11063349_1116_1140_Disease)))))) (. .)))
11063349	10	(S1 (S (NP (EX There)) (VP (AUX were) (NP (DT no) (NNS deaths))) (. .)))
11063349	11	(S1 (S (NP (NN Doc_11063349_1164_1168_Chemical)) (VP (AUX was) (VP (VBN discontinued) (PP (IN in) (NP (CD four) (NNS patients))) (, ,) (PP (IN because) (IN of) (NP (NP (NP (NNP Doc_11063349_1215_1224_Disease)) (PP (IN in) (NP (CD two)))) (, ,) (NP (NP (NNP Doc_11063349_1233_1237_Disease)) (PP (IN in) (NP (CD one)))) (, ,) (CC and) (NP (NP (JJ oral) (NNP Doc_11063349_1255_1269_Disease)) (PP (IN in) (NP (CD one)))))))) (. .)))
11063349	12	(S1 (S (NP (NN Doc_11063349_1278_1282_Chemical) (NNS levels)) (VP (AUX were) (ADJP (JJ high)) (PRN (-LRB- -LRB-) (NP (CD >15) (NN ng/ml)) (-RRB- -RRB-)) (PP (IN in) (NP (QP (CD 7) (IN of) (CD 13)) (PRN (-LRB- -LRB-) (NP (CD 54) (NN %)) (-RRB- -RRB-)) (NNS patients)))) (. .)))
11063349	13	(S1 (S (NP (JJ Doc_11063349_1352_1356_Chemical) (NN conversion)) (VP (VBZ provides) (NP (JJ adequate) (NN immunosuppression)) (S (VP (TO to) (VP (VB enable) (NP (JJ Doc_11063349_1414_1417_Chemical) (NN withdrawal)))))) (. .)))
11063349	14	(S1 (S (ADVP (RB However)) (, ,) (SBAR (WHADVP (WRB when)) (S (VP (VBG converting) (NP (NNS patients)) (PP (TO to) (NP (JJ Doc_11063349_1467_1471_Chemical) (NN drug) (NNS levels)))))) (VP (MD should) (VP (AUX be) (VP (VBN monitored) (S (VP (TO to) (VP (VB avoid) (SBAR (S (NP (NP (NN over-immunosuppression)) (CC and) (NP (JJ adequate) (ADJP (JJ antiviral) (CC and) (JJ Doc_11063349_1563_1593_Disease)) (NNS prophylaxis))) (VP (MD should) (VP (AUX be) (VP (VBN given)))))))))))) (. .)))
11077455	0	(S1 (NP (NP (NN Electro-oculography)) (, ,) (NP (NN electroretinography)) (, ,) (NP (JJ visual) (JJ evoked) (NNS potentials)) (, ,) (CC and) (NP (NP (JJ multifocal) (NN electroretinography)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_11077455_120_130_Chemical-attributed) (NNP Doc_11077455_142_167_Disease)))))) (. .)))
11077455	1	(S1 (S (NP (NP (NNP Symptomatic) (NNP Doc_11077455_190_215_Disease)) (VP (VBN thought) (S (VP (TO to) (VP (AUX be) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_11077455_246_256_Chemical))))))))) (VP (AUX has) (VP (AUX been) (VP (VBN reported)))) (. .)))
11077455	2	(S1 (S (NP (DT The) (JJ current) (NN study)) (VP (VBD investigated) (NP (NP (DT the) (JJ visual) (NNS fields)) (CC and) (NP (NP (JJ visual) (NN electrophysiology)) (PP (IN of) (NP (CD eight) (NNS patients))) (PP (IN with) (NP (NP (VBN known) (JJ Doc_11077455_383_393_Chemical-attributed) (NNP Doc_11077455_405_422_Disease)) (, ,) (SBAR (WHNP (WHNP (CD three)) (WHPP (IN of) (WHNP (WP whom)))) (S (VP (AUX were) (VP (VBN reported) (ADVP (RB previously))))))))))) (. .)))
11077455	3	(S1 (S (NP (NP (CD Six)) (PP (IN of) (NP (DT the) (NNS patients)))) (VP (AUX were) (ADVP (RB no) (RBR longer)) (VP (VBG receiving) (NP (NN Doc_11077455_509_519_Chemical)))) (. .)))
11077455	4	(S1 (S (NP (DT The) (JJ central) (CC and) (JJ peripheral) (NNS fields)) (VP (AUX were) (VP (VBN examined) (PP (IN with) (NP (DT the) (NNP Humphrey) (JJ Visual) (NN Field) (NN Analyzer))))) (. .)))
11077455	5	(S1 (S (NP (NP (JJ Full) (JJ visual) (NN electrophysiology)) (, ,) (PP (VBG including) (NP (NP (NP (NN flash) (NN electroretinography)) (PRN (-LRB- -LRB-) (NP (NNP ERG)) (-RRB- -RRB-))) (, ,) (NP (NN pattern) (NN electroretinography)) (, ,) (NP (NP (JJ multifocal) (NN ERG)) (VP (VBG using) (NP (DT the) (NN VERIS) (NN system)))) (, ,) (NP (NN electro-oculography)) (, ,) (CC and) (NP (ADJP (NN flash) (CC and) (NN pattern)) (JJ visual) (JJ evoked) (NNS potentials)))) (, ,)) (VP (AUX was) (VP (VBN undertaken))) (. .)))
11077455	6	(S1 (S (NP (CD Seven) (NNS patients)) (VP (VBD showed) (NP (JJ marked) (NN Doc_11077455_884_909_Disease)) (PP (IN with) (NP (NP (DT some) (NN sparing)) (PP (IN of) (NP (DT the) (JJ temporal) (JJ visual) (NN field)))))) (. .)))
11077455	7	(S1 (FRAG (NP (DT The) (JJ eighth) (JJ exhibited) (JJ concentric) (NN constriction)) (. .)))
11077455	8	(S1 (S (S (NP (JJS Most) (JJ electrophysiological) (NNS responses)) (VP (AUX were) (ADVP (RB usually)) (ADVP (RB just)) (PP (IN within) (NP (JJ normal) (NNS limits))))) (: ;) (S (NP (CD two) (NNS patients)) (VP (AUX had) (NP (JJ subnormal) (NNP Arden) (JJ electro-oculography) (NNS indices)))) (: ;) (CC and) (S (NP (CD one) (NN patient)) (VP (VBD showed) (NP (DT an) (ADJP (RB abnormally) (VBN delayed)) (NN photopic) (NN b) (NN wave)))) (. .)))
11077455	9	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (NP (CD five) (NNS patients)) (VP (VBN showed) (NP (JJ delayed) (JJ 30-Hz) (NN flicker) (NN b) (NNS waves)))) (, ,) (CC and) (NP (CD seven) (NNS patients))) (VP (VBD showed) (NP (JJ delayed) (NN oscillatory) (NNS potentials))) (. .)))
11077455	10	(S1 (S (NP (NNP Multifocal) (NNP ERG)) (VP (VBD showed) (NP (NP (NNS abnormalities)) (SBAR (WHNP (WDT that)) (S (ADVP (RB sometimes)) (VP (VP (VBD correlated) (PP (IN with) (NP (DT the) (JJ visual) (NN field) (NN appearance)))) (CC and) (VP (VBD confirmed) (SBAR (IN that) (S (NP (DT the) (NN deficit)) (VP (VBZ occurs) (PP (IN at) (NP (DT the) (JJ retinal) (NN level)))))))))))) (. .)))
11077455	11	(S1 (S (NP (JJ Marked) (NN Doc_11077455_1497_1522_Disease)) (VP (VBZ appears) (S (VP (TO to) (VP (AUX be) (VP (VBN associated) (PP (IN with) (NP (JJ Doc_11077455_1553_1563_Chemical) (NN therapy)))))))) (. .)))
11077455	12	(S1 (S (NP (NP (DT The) (NN field) (NNS defects)) (CC and) (NP (DT some) (NN electrophysiological) (NNS abnormalities))) (VP (VBP persist) (SBAR (WHADVP (WRB when)) (S (NP (JJ Doc_11077455_1648_1658_Chemical) (NN therapy)) (VP (AUX is) (VP (VBN withdrawn)))))) (. .)))
11078231	0	(S1 (S (VP (VBP Doc_11078231_0_19_Disease) (PP (JJ due) (TO to) (NP (NNP Doc_11078231_27_48_Disease))) (PP (IN during) (NP (JJ Doc_11078231_56_66_Chemical) (NN stress) (NN echocardiography)))) (. .)))
11078231	1	(S1 (S (NP (NP (JJ Doc_11078231_92_102_Chemical) (NN stress) (NN echocardiography)) (PRN (-LRB- -LRB-) (NP (NN DSE)) (-RRB- -RRB-))) (VP (AUX is) (NP (NP (DT a) (ADJP (ADJP (JJ useful)) (CC and) (ADJP (JJ safe))) (NN provocation) (NN test)) (PP (IN for) (NP (NNP Doc_11078231_175_194_Disease))))) (. .)))
11078231	2	(S1 (S (PP (IN Until) (NP (RB now))) (, ,) (S (NP (DT the) (NN test)) (VP (AUX has) (VP (AUX been) (VP (VBN focused) (PP (ADVP (RB only)) (IN on) (NP (NP (DT the) (JJ organic) (NN lesion)) (PP (IN in) (NP (DT the) (JJ coronary) (NN artery))))))))) (, ,) (CC and) (S (NP (JJ positive) (NN DSE)) (VP (AUX has) (VP (VBN indicated) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (JJ significant) (JJ fixed) (NN Doc_11078231_349_373_Disease))))))) (. .)))
11078231	3	(S1 (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT the) (JJ present) (NN study)))) (VP (AUX is) (S (VP (TO to) (VP (VB examine) (SBAR (IN whether) (S (NP (NP (JJ Doc_11078231_426_445_Disease) (NN due)) (PP (TO to) (NP (NNP Doc_11078231_453_467_Disease)))) (VP (AUX is) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_11078231_482_492_Chemical))))))))))) (. .)))
11078231	4	(S1 (S (NP (PRP We)) (VP (VBD performed) (NP (NN DSE)) (PP (IN on) (NP (CD 51) (NNS patients))) (PP (PP (IN with) (NP (NNP Doc_11078231_531_554_Disease))) (CC but) (PP (IN without) (NP (JJ significant) (JJ fixed) (NN Doc_11078231_585_609_Disease))))) (. .)))
11078231	5	(S1 (S (NP (DT All) (NNS patients)) (VP (AUX had) (NP (JJ anginal) (NNS attacks)) (PP (IN at) (NP (NP (NN rest)) (PP (IN with) (NP (NP (NNP ST) (NN elevation)) (PP (IN on) (NP (NP (DT the) (NN electrocardiogram)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11078231_696_710_Disease)) (-RRB- -RRB-))))))))) (. .)))
11078231	6	(S1 (S (S (NP (NN Doc_11078231_713_727_Disease)) (VP (AUX was) (VP (VBN induced) (PP (IN by) (NP (NP (NN intracoronary) (NN injection)) (PP (IN of) (NP (NNP Doc_11078231_770_783_Chemical)))))))) (, ,) (CC and) (S (NP (DT no) (JJ fixed) (NN Doc_11078231_798_822_Disease)) (VP (AUX was) (VP (VBN documented) (PP (IN on) (NP (NP (NNS angiograms)) (PP (IN in) (NP (DT all) (NNS patients)))))))) (. .)))
11078231	7	(S1 (S (NP (NN DSE)) (VP (AUX was) (VP (VBN performed) (PP (IN with) (NP (JJ intravenous) (JJ Doc_11078231_904_914_Chemical) (NN infusion))) (PP (IN with) (NP (NP (DT an) (JJ incremental) (NNS doses)) (PP (IN of) (NP (CD 5) (, ,) (CD 10) (, ,) (CD 20) (, ,) (CD 30) (, ,) (CC and) (CD 40) (NN microg/kg/min))))) (NP (DT every) (CD 5) (NNS minutes)))) (. .)))
11078231	8	(S1 (S (PP (IN Of) (NP (DT the) (CD 51) (NNS patients))) (, ,) (NP (CD 7) (NNS patients)) (VP (VBD showed) (NP (NN asynergy)) (PP (IN with) (NP (NNP ST) (NN elevation)))) (. .)))
11078231	9	(S1 (S (S (NP (NP (DT All) (CD 7) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 13.7) (NN %)) (-RRB- -RRB-))) (VP (AUX had) (NP (NN Doc_11078231_1099_1109_Disease)) (PP (IN during) (NP (NN asynergy))))) (, ,) (CC and) (S (NP (DT both) (JJ Doc_11078231_1136_1146_Disease) (CC and) (JJ electrocardiographic) (NNS changes)) (VP (AUX were) (VP (VBN preceded) (PP (IN by) (NP (NN asynergy)))))) (. .)))
11078231	10	(S1 (S (NP (DT These) (NNS findings)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NNP Doc_11078231_1236_1246_Chemical)) (VP (MD can) (VP (VB provoke) (NP (NNP Doc_11078231_1259_1273_Disease)) (PP (IN in) (NP (NP (DT some) (NNS patients)) (PP (IN with) (NP (NNP Doc_11078231_1296_1319_Disease)))))))))) (. .)))
11078231	11	(S1 (S (SBAR (WHADVP (WRB When)) (S (NP (NN DSE)) (VP (AUX is) (VP (VP (VBN performed) (S (VP (TO to) (VP (VB evaluate) (NP (NNP Doc_11078231_1355_1378_Disease)))))) (, ,) (CONJP (RB not) (RB only)) (VP (VBN fixed) (NP (NNP Doc_11078231_1395_1412_Disease))))))) (, ,) (CC but) (ADVP (RB also)) (NP (NNP Doc_11078231_1423_1437_Disease)) (VP (MD should) (VP (AUX be) (VP (VBN considered) (PP (IN as) (NP (NP (DT a) (NN genesis)) (PP (IN of) (NP (NN asynergy)))))))) (. .)))
11079278	0	(S1 (NP (NP (NP (NP (NN Effect)) (PP (IN of) (NP (NP (JJ intravenous) (NNP Doc_11079278_22_32_Chemical)) (CC or) (NP (JJ intravenous) (NNP Doc_11079278_48_58_Chemical))))) (CC plus) (NP (NN glucagon))) (PP (IN on) (NP (NNP Doc_11079278_76_86_Chemical-induced) (NNP Doc_11079278_95_114_Disease))) (. .)))
11079278	1	(S1 (FRAG (NP (NN STUDY) (NN OBJECTIVE)) (: :) (S (S (VP (TO To) (VP (VB determine) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NNP Doc_11079278_160_170_Chemical))) (PP (IN on) (NP (NP (JJ Doc_11079278_174_184_Chemical) (NN stress) (VBG testing)) (PP (IN with) (NP (JJ Doc_11079278_205_229_Chemical) (JJ single-photon) (NN emission) (VBD computed) (JJ tomography) (NN imaging) (CC and) (NN ST-segment) (NN monitoring))))))))) (, ,) (CC and) (S (VP (TO to) (VP (VB assess) (NP (NP (DT the) (NN impact)) (PP (IN of) (NP (JJ intravenous) (NN glucagon))) (PP (IN on) (NP (NP (NNP Doc_11079278_360_370_Chemical) (POS 's)) (NNS effects)))))))) (. .)))
11079278	2	(S1 (NP (NP (NN Randomized)) (, ,) (NP (NN double-blind)) (, ,) (NP (JJ placebo-controlled) (NN trial)) (. .)))
11079278	3	(S1 (FRAG (NP (NN Community) (NN hospital)) (. .)))
11079278	4	(S1 (NP (NP (JJ Twenty-two) (NNS patients)) (PP (IN with) (NP (JJ known) (JJ reversible) (NN perfusion) (NNS defects))) (. .)))
11079278	5	(S1 (S (NP (NNS Patients)) (VP (VBD underwent) (NP (NP (JJ Doc_11079278_575_585_Chemical) (NN stress) (NNS tests)) (PP (IN per) (NP (JJ standard) (NN protocol))))) (. .)))
11079278	6	(S1 (S (SBAR (IN Before) (S (NP (NNP Doc_11079278_629_639_Chemical)) (VP (AUX was) (VP (VBN begun))))) (, ,) (S (NP (DT no) (NN therapy)) (VP (AUX was) (VP (VBN given) (PP (IN during) (NP (DT the) (JJ first) (NN visit)))))) (, ,) (CC and) (S (NP (NNS patients)) (VP (AUX were) (VP (VBN randomized) (PP (IN on) (NP (JJ subsequent) (NNS visits))) (S (VP (TO to) (VP (VP (VB receive) (NP (NNP Doc_11079278_757_767_Chemical) (CC or) (NNP Doc_11079278_771_781_Chemical))) (CC plus) (VP (VB glucagon) (NP (CD 1) (NN mg))))))))) (. .)))
11079278	7	(S1 (S (NP (NN Doc_11079278_802_812_Chemical)) (VP (AUX was) (VP (VBN dosed) (S (VP (TO to) (VP (VB achieve) (NP (DT a) (JJ resting) (NNP Doc_11079278_844_857_Chemical) (NN heart) (NN rate)) (PP (IN below) (NP (NP (CD 65) (NN beats/minute)) (CC or) (NP (NP (DT a) (JJ total) (JJ intravenous) (NN dose)) (PP (IN of) (NP (CD 20) (NN mg))))))))))) (. .)))
11079278	8	(S1 (FRAG (NP (NP (NNS MEASUREMENTS)) (CC AND) (NP (JJ MAIN) (NNS RESULTS))) (: :) (S (NP (NNP Doc_11079278_960_970_Chemical)) (VP (VP (VBD reduced) (NP (NN maximum) (NN heart) (NN rate)) (NP (CD 31) (NN %))) (, ,) (VP (VBD summed) (NP (NN stress) (NNS scores)) (NP (CD 29) (NN %))) (, ,) (CC and) (VP (VBD summed) (NP (NN difference) (NNS scores)) (NP (CD 43) (NN %)) (PP (IN versus) (NP (NN control)))))) (. .)))
11079278	9	(S1 (S (NP (NP (NN Doc_11079278_1078_1088_Chemical)) (CC plus) (NP (NN glucagon))) (ADVP (RB also)) (VP (VBD reduced) (NP (DT the) (NN maximum) (NN heart) (NN rate)) (NP (CD 29) (NN %)) (PP (IN versus) (NP (NN control)))) (. .)))
11079278	10	(S1 (S (VP (VP (VBD Summed) (NP (NN stress))) (CC and) (VP (VBD summed) (SBAR (S (NP (NN difference) (NNS scores)) (VP (AUX were) (RB not) (VP (ADVP (RB significantly)) (VBN reduced) (, ,) (SBAR (IN although) (S (NP (PRP they)) (VP (AUX were) (ADVP (NP (NP (CD 18) (NN %)) (CC and) (NP (CD 30) (NN %))) (JJR lower)) (, ,) (ADVP (RB respectively)) (, ,) (PP (IN than) (NP (NN control)))))))))))) (. .)))
11079278	11	(S1 (S (NP (DT No) (JJ significant) (NNS differences)) (VP (AUX were) (VP (VBN found) (PP (IN in) (NP (NP (DT any) (NN parameter)) (PP (IN between) (NP (NP (NNP Doc_11079278_1363_1373_Chemical)) (CC and) (NP (NNP Doc_11079278_1378_1388_Chemical-glucagon)))))))) (. .)))
11079278	12	(S1 (S (PP (IN During) (NP (JJ Doc_11079278_1418_1428_Chemical) (NN stress) (NN testing))) (, ,) (NP (NNP Doc_11079278_1445_1455_Chemical)) (VP (VP (VBZ attenuates)) (CC or) (VP (VBZ eliminates) (NP (NP (NN evidence)) (PP (IN of) (NP (NN Doc_11079278_1493_1512_Disease)))))) (. .)))
11079278	13	(S1 (S (NP (NN Glucagon) (CD 1) (NN mg)) (, ,) (SBAR (IN although) (S (ADJP (RB somewhat) (JJ effective)))) (, ,) (VP (AUX does) (RB not) (VP (VB correct) (NP (DT this) (NN effect)) (PP (TO to) (NP (DT the) (NN extent) (SBAR (IN that) (S (NP (PRP it)) (VP (MD can) (VP (AUX be) (VP (VBN administered) (ADVP (RB clinically))))))))))) (. .)))
11099450	0	(S1 (NP (NP (NN Evidence)) (PP (IN of) (NP (JJ functional) (NN somatotopy))) (PP (IN in) (NP (NNP GPi))) (PP (IN from) (NP (NP (NNS results)) (PP (IN of) (NP (NN pallidotomy))))) (. .)))
11099450	1	(S1 (S (NP (NP (DT The) (NN objective)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB explore) (NP (NP (DT the) (JJ functional) (NN anatomy)) (PP (IN of) (NP (NP (DT the) (JJ globus) (JJ pallidus) (NNS internus)) (PRN (-LRB- -LRB-) (NP (NNP GPi)) (-RRB- -RRB-))))) (PP (IN by) (S (VP (VBG studying) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (JJ unilateral) (NN pallidotomy))) (PP (IN on) (NP (NP (NP (NNP Doc_11099450_227_239_Disease) (POS ')) (JJ off) ('' ') (NNS signs)) (CC and) (NP (NP (JJ Doc_11099450_256_264_Chemical-induced) (NNS dyskinesias)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11099450_286_289_Disease)) (-RRB- -RRB-))))))))))))) (. .)))
11099450	2	(S1 (S (NP (PRP We)) (VP (VBD found) (NP (NP (JJ significant) (JJ positive) (NNS correlations)) (PP (IN between) (NP (NP (DT the) (JJ preoperative) (NNP Doc_11099450_360_368_Chemical) (NN responsiveness)) (PP (IN of) (NP (NP (NN motor) (NNS signs)) (CC and) (NP (NP (DT the) (NNP Doc_11099450_407_415_Chemical) (NN responsiveness)) (PP (IN of) (NP (NP (NNS scores)) (PP (IN in) (NP (NP (VBN timed) (NNS tests)) (PRN (-LRB- -LRB-) (NP (NP (NNP Core) (NNP Assessment) (NNP Program)) (PP (IN for) (NP (NNP Intracerebral) (NNP Transplantations)))) (-RRB- -RRB-)))))))))))) (PP (IN in) (NP (NP (DT the) (JJ contralateral) (NNS limbs)) (CC and) (NP (NP (DT the) (NN improvement)) (PP (IN in) (NP (DT these) (NNS scores))) (PP (IN after) (NP (NN surgery)))))) (, ,) (SBAR (IN whereas) (S (NP (EX there)) (VP (AUX was) (NP (NP (DT no) (NN correlation)) (PP (IN with) (NP (NP (DT the) (NN improvement)) (PP (IN in) (NP (NNP Doc_11099450_652_655_Disease)))))))))) (. .)))
11099450	3	(S1 (S (NP (PRP We)) (ADVP (RB also)) (VP (VBD found) (NP (NP (DT a) (ADJP (RB highly) (JJ significant)) (NN correlation)) (PRN (-LRB- -LRB-) (NP (NNP P)) (: :) (NP (NP (NNP <) (CD 0.0001)) (, ,) (NP (NN r) (SYM =) (CD 0.8))) (-RRB- -RRB-)) (PP (IN between) (NP (NP (DT the) (NN volume)) (PP (IN of) (NP (NP (NP (DT the) (JJ ventral) (NN lesion)) (PP (IN in) (NP (DT the) (NNP GPi)))) (CC and) (NP (NP (DT the) (NN improvement)) (PP (IN in) (NP (NNP Doc_11099450_802_805_Disease))) (PP (IN in) (NP (DT the) (JJ contralateral) (NNS limbs))))))))) (, ,) (SBAR (IN whereas) (S (NP (EX there)) (VP (AUX was) (NP (NP (DT no) (NN correlation)) (PP (IN between) (NP (NP (DT the) (JJ ventral) (NN volume)) (CC and) (NP (NP (DT the) (NN improvement)) (PP (IN in) (NP (NP (NP (NNP Doc_11099450_917_929_Disease) (POS ')) (ADJP (RB off)) (POS ')) (NNS signs))))))))))) (. .)))
11099450	4	(S1 (S (NP (NP (DT The) (NNS volumes)) (PP (IN of) (NP (NP (DT the) (JJ total) (NN lesion) (NN cylinder)) (CC and) (NP (DT the) (JJ dorsal) (NN lesion))))) (VP (AUX did) (RB not) (VP (VB correlate) (PP (IN with) (NP (NP (DT the) (NN outcome)) (PP (IN of) (NP (NP (DT either) (NNP Doc_11099450_1051_1062_Disease) (CC or) (NNP Doc_11099450_1066_1078_Disease) (POS ')) (JJ off) ('' ') (NNS signs))))))) (. .)))
11099450	5	(S1 (S (S (NP (NP (DT The) (NN differential) (JJ predictive) (NN value)) (PP (IN of) (NP (NNP Doc_11099450_1129_1137_Chemical)))) (VP (VBP responsiveness) (PP (IN for) (NP (NP (DT the) (NN outcome)) (PP (IN of) (NP (NP (NP (NNP Doc_11099450_1172_1184_Disease) (POS ')) (ADJP (RB off)) (POS ')) (NNS signs))))))) (CC and) (S (NP (NP (NNP Doc_11099450_1201_1204_Disease)) (CC and) (NP (NP (DT the) (JJ different) (NNS correlations)) (PP (IN of) (NP (NP (JJ ventral) (NN lesion) (NN volume)) (PP (IN with) (NP (NP (NP (NNP Doc_11099450_1266_1277_Disease) (CC and) (NNP Doc_11099450_1282_1294_Disease) (POS ')) (ADJP (RB off)) (POS ')) (NNS signs))))))) (VP (VBP indicate) (SBAR (IN that) (S (NP (JJ different) (ADJP (JJ anatomical) (CC or) (JJ pathophysiological)) (NNS substrates)) (VP (MD may) (VP (AUX be) (ADJP (JJ responsible) (PP (IN for) (NP (NP (DT the) (NN generation)) (PP (IN of) (NP (NP (NP (NNP Doc_11099450_1416_1428_Disease) (POS ')) (JJ off) ('' ') (NNS signs)) (CC and) (NP (NNP Doc_11099450_1445_1456_Disease))))))))))))) (. .)))
11099450	6	(S1 (S (SBAR (IN Whereas) (S (NP (NP (NNS cells)) (PP (IN in) (NP (NP (DT a) (JJR wider) (NN area)) (PP (IN of) (NP (DT the) (NNP GPi)))))) (VP (MD may) (VP (AUX be) (VP (VBN implicated) (PP (IN in) (NP (NNP Doc_11099450_1520_1532_Disease)))))))) (, ,) (NP (DT the) (JJ ventral) (NNP GPi)) (VP (VBZ seems) (S (VP (TO to) (VP (AUX be) (ADJP (JJ crucial)) (PP (IN for) (NP (NP (DT the) (NN manifestation)) (PP (IN of) (NP (NN Doc_11099450_1595_1598_Disease))))))))) (. .)))
11099450	7	(S1 (S (NP (PRP We)) (VP (VBP suggest) (SBAR (IN that) (S (NP (PRP$ our) (NNS observations)) (VP (AUX are) (NP (NP (JJ additional) (NN proof)) (PP (IN of) (NP (NP (DT the) (JJ functional) (NN somatotopy)) (PP (IN of) (NP (DT the) (NNS systems))) (PP (IN within) (NP (NP (DT the) (NNS GPi)) (SBAR (WHNP (WDT that)) (S (VP (VB mediate) (NP (NP (NNP Doc_11099450_1726_1738_Disease) (CC and) (NNP Doc_11099450_1743_1754_Disease)) (, ,) (ADVP (RB especially))) (PP (IN along) (NP (NP (DT the) (JJ dorsoventral) (NN trajectory)) (VP (VBN used) (PP (IN in) (NP (NN pallidotomy)))))))))))))))))) (. .)))
11099450	8	(S1 (S (NP (NP (DT The) (NN outcome)) (PP (IN of) (NP (NP (NN pallidotomy)) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (DT the) (NN lesion)) (VP (VBZ involves) (NP (DT the) (JJ ventral) (CC and) (JJ dorsal) (NNS GPi)))))))) (VP (MD could) (VP (AUX be) (NP (NP (DT the) (JJ net) (NN effect)) (PP (IN of) (NP (NN alteration)))) (PP (IN in) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (NP (NNS pathways)) (SBAR (WHNP (WDT which)) (S (VP (VP (VB mediate) (NP (JJ different) (NNS symptoms))) (, ,) (CC and) (ADVP (RB hence)) (VP (MD could) (VP (AUX be) (ADJP (JJ variable))))))))))))) (. .)))
11185967	0	(S1 (NP (NP (NN Screening)) (PP (IN for) (NP (NN stimulant) (NN use))) (PP (IN in) (NP (NN adult) (NN emergency) (NN department) (NN Doc_11185967_58_65_Disease) (NNS patients))) (. .)))
11185967	1	(S1 (S (NP (NP (DT The) (NN objective)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB determine) (NP (NP (DT the) (NN prevalence)) (PP (IN of) (NP (JJ positive) (NN plasma) (NN drug) (NN screening))) (PP (IN for) (NP (NNP Doc_11185967_185_192_Chemical) (CC or) (NNP Doc_11185967_196_207_Chemical))) (PP (IN in) (NP (NN adult) (NN emergency) (NN department) (JJ Doc_11185967_238_245_Disease) (NNS patients)))))))) (. .)))
11185967	2	(S1 (S (NP (DT This) (JJ prospective) (NN study)) (VP (VBN evaluated) (NP (NP (JJ consecutive) (NN eligible) (NN Doc_11185967_319_326_Disease) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX had) (NP (NP (DT a) (NN plasma) (NN sample)) (VP (VBN collected) (PP (IN as) (NP (NP (NN part)) (PP (IN of) (NP (PRP$ their) (JJ clinical) (NN evaluation)))))))))))) (. .)))
11185967	3	(S1 (S (NP (NN Plasma)) (VP (AUX was) (VP (VBN tested) (PP (IN for) (NP (NP (NNP Doc_11185967_430_441_Chemical)) (CC and) (NP (NP (DT the) (JJ Doc_11185967_450_457_Chemical) (NN metabolite) (NNP Doc_11185967_469_484_Chemical)) (VP (VBG using) (NP (JJ enzyme-mediated) (NN immunoassay) (NN methodology)))))))) (. .)))
11185967	4	(S1 (S (NP (NP (NN Plasma) (NNS samples)) (PP (IN with) (NP (NP (JJ Doc_11185967_552_567_Chemical) (QP (JJR greater) (IN than) (CD 150) (CD ng/mL))) (CC or) (NP (DT an) (JJ Doc_11185967_597_608_Chemical) (QP (JJR greater) (IN than) (CD 500) (CD ng/mL)))))) (VP (AUX were) (VP (VBN defined) (PP (IN as) (NP (NN positive))))) (. .)))
11185967	5	(S1 (S (S (NP (NP (JJ Patient) (NNS demographics)) (, ,) (NP (NP (NN history)) (PP (IN of) (NP (NP (JJ underlying) (NN drug)) (CC or) (NP (JJ Doc_11185967_710_717_Chemical-related) (JJ Doc_11185967_726_733_Disease) (NN disorder))))) (, ,)) (VP (VBD estimated) (NP (NN time)) (PP (PP (IN from) (NP (NNP Doc_11185967_764_771_Disease))) (PP (TO to) (NP (NP (NN sample) (NN collection)) (, ,) (NP (NN history)) (CC or) (NP (NP (NN suspicion)) (PP (IN of) (NP (NP (NNP Doc_11185967_818_825_Chemical) (CC or) (NNP Doc_11185967_829_840_Chemical) (NN abuse)) (, ,) (NP (NP (NNS results)) (PP (IN of) (NP (NP (JJ clinical) (NN urine) (NN testing)) (PP (IN for) (NP (NNS drugs))) (PP (IN of) (NP (NN abuse)))))))))))))) (, ,) (CC and) (S (NP (JJ assay) (NNS results)) (VP (AUX were) (VP (VBN recorded) (PP (IN without) (NP (NN patient) (NNS identifiers)))))) (. .)))
11185967	6	(S1 (S (S (NP (QP (CD Fourteen) (IN of) (CD 248)) (PRN (-LRB- -LRB-) (NP (NP (CD 5.6) (NN %)) (, ,) (NP (NP (NP (CD 95) (NN %)) (NN CI) (CD 2.7) (NN %)) (NP (CD -8.5) (NN %)))) (-RRB- -RRB-)) (NN plasma) (NNS samples)) (VP (AUX were) (ADJP (JJ positive) (PP (IN by) (NP (NP (JJ immunoassay) (NN testing)) (PP (IN for) (NP (NNP Doc_11185967_1069_1084_Chemical)))))))) (CC and) (S (NP (NP (DT no) (NNS samples)) (PRN (-LRB- -LRB-) (NP (NP (CD 0) (NN %)) (, ,) (NP (NP (CD 95) (NN %)) (NP (QP (CD CI) (CD 0-1.2)) (NN %)))) (-RRB- -RRB-))) (VP (AUX were) (ADJP (JJ positive)) (PP (IN for) (NP (NNP Doc_11185967_1138_1149_Chemical))))) (. .)))
11185967	7	(S1 (S (NP (JJ Positive) (NN test) (NNS results)) (VP (AUX were) (ADJP (RBR more) (JJ common)) (PP (IN in) (NP (NP (JJ patient) (NNS visits)) (SBAR (WHADVP (WRB where)) (S (NP (EX there)) (VP (AUX was) (NP (NP (NP (DT a) (NN history) (CC or) (NN suspicion)) (PP (IN of) (NP (NNP Doc_11185967_1250_1257_Chemical)))) (CC or) (NP (NP (JJ Doc_11185967_1261_1272_Chemical) (NN abuse)) (PRN (-LRB- -LRB-) (NP (QP ($ p) (CD <) (CD 0.0005))) (-RRB- -RRB-)))))))))) (. .)))
11185967	8	(S1 (S (PP (IN During) (NP (DT this) (NN study) (NN period))) (, ,) (NP (NP (JJ routine) (NN plasma) (NN screening)) (PP (IN for) (NP (NP (NNP Doc_11185967_1361_1368_Chemical)) (CC and) (NP (NNP Doc_11185967_1373_1385_Chemical)))) (PP (IN in) (NP (NN adult) (NN Doc_11185967_1395_1402_Disease) (NNS patients)))) (VP (AUX had) (NP (DT a) (JJ low) (NN yield))) (. .)))
11185967	9	(S1 (S (PP (IN As) (NP (DT a) (NN result))) (, ,) (NP (JJ routine) (NN plasma) (NN screening)) (VP (MD would) (VP (VB yield) (NP (NP (JJ few) (NNS cases)) (PP (IN of) (NP (NN stimulant) (NN drug))) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (EX there)) (VP (AUX was) (RB neither) (NP (NP (DT a) (NN history) (CC nor) (NN suspicion)) (PP (IN of) (NP (NNP Doc_11185967_1561_1571_Disease))) (PP (IN in) (NP (DT this) (NN population)))))))))) (. .)))
11195262	0	(S1 (NP (NP (NN Contribution)) (PP (IN of) (NP (NNP Doc_11195262_16_32_Chemical))) (PP (TO to) (NP (DT the) (NNP Doc_11195262_40_99_Disease))) (. .)))
11195262	1	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT the) (NN case)) (PP (IN of) (NP (NP (DT a) (JJ 62-year-old) (NN man)) (SBAR (SBAR (WHNP (WP who)) (S (VP (AUX was) (VP (VBN administered) (NP (NP (NNP Doc_11195262_162_178_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11195262_180_183_Chemical)) (-RRB- -RRB-))))))) (CC and) (SBAR (WHNP (WP who)) (S (ADVP (RB subsequently)) (VP (VBD developed) (NP (NP (DT the) (NNP Doc_11195262_220_279_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11195262_281_286_Disease)) (-RRB- -RRB-))))))))))) (. .)))
11195262	2	(S1 (S (NP (PRP He)) (VP (AUX had) (VP (AUX been) (VP (VBG taking) (NP (NNP Doc_11195262_308_311_Chemical)) (PP (IN for) (NP (NP (NN treatment)) (PP (IN of) (NP (JJ idiopathic) (JJ generalized) (NN Doc_11195262_352_376_Disease))))) (SBAR (IN since) (S (NP (PRP he)) (VP (AUX was) (ADJP (NP (CD 56) (NNS years)) (JJ old)))))))) (. .)))
11195262	3	(S1 (S (PP (IN After) (S (VP (VBG substituting) (NP (NNP Doc_11195262_423_426_Chemical)) (PP (IN with) (NP (NNP Doc_11195262_432_442_Chemical)))))) (, ,) (NP (DT the) (JJ serum) (JJ Doc_11195262_454_460_Chemical) (NN level)) (VP (VBD returned) (PP (TO to) (NP (JJ normal)))) (. .)))
11195262	4	(S1 (S (NP (PRP We)) (VP (VBP consider) (S (NP (NP (DT this) (NN episode)) (PP (IN of) (NP (NNP Doc_11195262_515_520_Disease)))) (VP (TO to) (VP (AUX be) (NP (NP (DT the) (NN result)) (PP (IN of) (NP (NP (DT a) (NN combination)) (PP (IN of) (NP (NP (NNS factors)) (PP (VBG including) (NP (NP (DT a) (NN Doc_11195262_578_616_Disease)) (CC and) (NP (NP (DT the) (JJ long-term) (NN administration)) (PP (IN of) (NP (NNP Doc_11195262_653_656_Chemical))))))))))))))) (. .)))
11208990	0	(S1 (NP (NP (NNP Association)) (PP (IN of) (NP (NP (JJ Doc_11208990_15_27_Chemical) (NN production)) (CC and) (NP (NN apoptosis)))) (PP (IN in) (NP (NP (DT a) (NN model)) (PP (IN of) (NP (JJ experimental) (NNP Doc_11208990_80_91_Disease))))) (. .)))
11208990	1	(S1 (S (PP (IN In) (NP (JJ recent) (NNS studies))) (NP (NP (VBN increased) (NNS amounts)) (PP (IN of) (NP (NP (NP (NNP Doc_11208990_144_156_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11208990_158_160_Chemical)) (-RRB- -RRB-))) (CC and) (NP (NNS apoptosis))))) (VP (AUX have) (VP (AUX been) (VP (VBN implicated) (PP (IN in) (NP (NP (JJ various) (JJ pathological) (NNS conditions)) (PP (IN in) (NP (DT the) (NN kidney)))))))) (. .)))
11208990	2	(S1 (S (NP (PRP We)) (VP (AUX have) (VP (VBN studied) (NP (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NNP Doc_11208990_275_277_Chemical)))) (CC and) (NP (NP (PRP$ its) (NN association)) (PP (IN with) (NP (NNS apoptosis))))) (PP (IN in) (NP (NP (DT an) (JJ experimental) (NN model)) (PP (IN of) (NP (NNP Doc_11208990_341_359_Disease))) (VP (VBN induced) (PP (IN by) (NP (NP (DT a) (JJ single) (NN injection)) (PP (IN of) (NP (NP (NNP Doc_11208990_393_403_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11208990_405_408_Chemical)) (-RRB- -RRB-))))))))))) (. .)))
11208990	3	(S1 (S (NP (NP (DT The) (NN alteration)) (PP (IN in) (NP (DT the) (JJ Doc_11208990_442_444_Chemical) (NN pathway)))) (VP (AUX was) (VP (VBN assessed) (PP (IN by) (S (VP (VBG measuring) (NP (JJ Doc_11208990_479_486_Chemical) (NNS levels)) (PP (PP (IN in) (NP (NN serum/urine))) (CC and) (PP (IN by) (S (VP (VBG evaluating) (NP (NP (DT the) (NNS changes)) (PP (IN in) (NP (NP (JJ vascular) (NN reactivity)) (PP (IN of) (NP (DT the) (VBN isolated) (JJ perfused) (NN rat) (NN kidney) (PRN (-LRB- -LRB-) (NP (NNP IPRK)) (-RRB- -RRB-)) (NN system))))))))))))))) (. .)))
11208990	4	(S1 (S (NP (NNS Rats)) (VP (AUX were) (ADJP (JJ stratified) (PP (IN into) (NP (NP (NN control) (NNS groups)) (CC and) (NP (JJ Doc_11208990_658_661_Chemical-induced) (JJ Doc_11208990_670_681_Disease) (NNS groups)))))) (. .)))
11208990	5	(S1 (S (NP (DT These) (CD two) (NNS groups)) (VP (AUX were) (ADVP (RB then)) (VP (VBN divided) (PP (IN into) (NP (: :) (NP (NP (NN group) (CD 1)) (, ,) (NP (NP (NNS animals)) (VP (VBG receiving) (NP (NN saline))))) (: ;) (CC and) (NP (NP (NN group) (CD 2)) (, ,) (NP (NP (NNS animals)) (VP (VBG receiving) (NP (NP (NNP Doc_11208990_797_811_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP AG)) (-RRB- -RRB-)) (SBAR (WHNP (WDT which)) (S (VP (AUX is) (NP (NP (DT a) (JJ specific) (NN inhibitor)) (PP (IN of) (NP (JJ inducible-Doc_11208990_860_862_Chemical) (NN synthase))))))))))))))) (. .)))
11208990	6	(S1 (S (PP (IN On) (NP (NN day) (CD 21))) (, ,) (NP (NNS rats)) (VP (AUX were) (VP (VBN sacrificed) (PP (IN after) (S (VP (VBG obtaining) (NP (NP (NN material)) (PP (IN for) (NP (JJ biochemical) (NN analysis))))))))) (. .)))
11208990	7	(S1 (S (NP (NP (JJ Histopathological) (NN examination)) (PP (IN of) (NP (NP (DT the) (NNS kidneys)) (PP (IN of) (NP (NP (NNS rats)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_11208990_1031_1034_Chemical))))))))) (VP (VBD revealed) (NP (NP (JJ focal) (NNS areas)) (PP (IN of) (NP (NP (NNP Doc_11208990_1059_1082_Disease)) (CC and) (NP (JJ mild) (NNP Doc_11208990_1092_1123_Disease)))))) (. .)))
11208990	8	(S1 (S (NP (PRP They)) (ADVP (RB also)) (VP (AUX had) (NP (NP (ADJP (RB significantly) (JJR higher)) (NNS levels)) (PP (IN of) (NP (NNP Doc_11208990_1170_1181_Disease)))) (PP (VBN compared) (PP (IN with) (NP (NP (NN control)) (CC and) (NP (NP (NN treatment) (NNS groups)) (PRN (-LRB- -LRB-) (NP (QP ($ P) (CD <) (CD 0.05))) (-RRB- -RRB-))))))) (. .)))
11208990	9	(S1 (S (NP (NN Urine) (NN Doc_11208990_1243_1250_Chemical) (NNS levels)) (VP (AUX were) (ADVP (RB significantly)) (VP (VBN increased) (PP (IN in) (NP (DT the) (JJ Doc_11208990_1294_1297_Chemical-Doc_11208990_1298_1309_Disease) (NN group))) (PRN (-LRB- -LRB-) (S (NP (NNP P)) (VP (VBD <) (NP (CD 0.05)))) (-RRB- -RRB-)))) (. .)))
11208990	10	(S1 (S (PP (IN In) (NP (DT the) (NNP IPRK) (NNP Doc_11208990_1340_1353_Chemical) (CC and) (NNP Doc_11208990_1358_1371_Chemical))) (NP (VBN related) (NNS responses)) (VP (AUX were) (ADVP (RB significantly)) (VP (VBN impaired) (PP (IN in) (NP (DT the) (JJ Doc_11208990_1425_1428_Chemical-Doc_11208990_1429_1440_Disease) (NN group))))) (. .)))
11208990	11	(S1 (S (NP (NN Apoptosis)) (VP (AUX was) (RB not) (VP (VBN detected) (PP (IN in) (NP (NNS controls))))) (. .)))
11208990	12	(S1 (S (ADVP (RB However)) (, ,) (PP (IN in) (NP (DT the) (JJ Doc_11208990_1504_1507_Chemical-Doc_11208990_1508_1519_Disease) (NN group))) (, ,) (NP (JJ numerous) (NN apoptotic) (NNS cells)) (VP (AUX were) (VP (VBN identified) (PP (IN in) (NP (DT the) (JJ tubulointerstitial) (NNS areas))))) (. .)))
11208990	13	(S1 (S (NP (JJ Double) (NN staining)) (VP (VBD revealed) (NP (NP (JJ numerous) (JJ interstitial) (NN apoptotic) (NNS cells)) (SBAR (S (VP (TO to) (VP (VB stain) (PP (IN for) (NP (NP (NNP ED1)) (, ,) (NP (NP (DT a) (NN marker)) (PP (IN for) (NP (NNS monocytes/macrophages)))))))))))) (. .)))
11208990	14	(S1 (S (NP (NP (NN Treatment)) (PP (IN with) (NP (NNP AG)))) (VP (VP (VBD prevented) (NP (NP (DT the) (NN impairment)) (PP (IN of) (NP (JJ renal) (JJ vascular) (NN bed) (NNS responses))))) (CC and) (VP (VBD reduced) (NP (NP (DT both) (NN urine) (JJ Doc_11208990_1816_1823_Chemical) (NNS levels)) (CC and) (NP (NP (NNS apoptosis)) (PP (TO to) (NP (NN control) (NNS levels))))))) (. .)))
11208990	15	(S1 (S (NP (PRP We)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NNS interactions)) (PP (IN between) (NP (NP (NNP Doc_11208990_1913_1915_Chemical)) (CC and) (NP (NNS apoptosis))))) (VP (AUX are) (ADJP (JJ important)) (PP (IN in) (NP (NP (DT the) (NN pathogenesis)) (PP (IN of) (NP (DT the) (JJ Doc_11208990_1971_1974_Chemical-induced) (NN Doc_11208990_1983_1992_Disease))))))))) (. .)))
11226639	0	(S1 (NP (NP (JJ Dual) (NNS effects)) (PP (IN of) (NP (NNP Doc_11226639_16_25_Chemical))) (PP (IN on) (NP (NP (NNP Doc_11226639_29_40_Chemical-induced) (NNP Doc_11226639_49_57_Disease)) (PP (IN in) (NP (NNS rats))))) (. .)))
11226639	1	(S1 (S (S (NP (NN Doc_11226639_67_76_Chemical)) (VP (VBZ affects) (NP (DT the) (NN circadian) (NN sleep/wake) (NN cycle)))) (, ,) (CC but) (S (NP (PRP it)) (VP (AUX is) (RB not) (ADJP (JJ clear)) (SBAR (IN whether) (S (NP (PRP it)) (VP (MD may) (VP (VB influence) (NP (JJ drug-induced) (NN Doc_11226639_175_183_Disease)))))))) (. .)))
11226639	2	(S1 (S (NP (NN Doc_11226639_185_203_Chemical)) (VP (AUX was) (VP (VBN administered) (ADVP (RB intraperitoneally)) (PP (IN into) (NP (NP (JJ male) (NNS rats)) (VP (VBN pre-treated) (PP (IN with) (NP (NP (NNP Doc_11226639_271_280_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 0.05) (, ,) (CD 0.5) (, ,) (CD 5) (CC and) (CD 50) (NN mg/kg)) (-RRB- -RRB-))))))))) (. .)))
11226639	3	(S1 (S (NP (NP (JJ Doc_11226639_310_319_Chemical) (NN pre-treatment)) (VP (VBN affected) (PP (IN in) (NP (DT a) (JJ dual) (NN manner))) (NP (NNP Doc_11226639_360_371_Chemical) (NNP Doc_11226639_372_380_Disease)))) (, ,) (ADVP (RB however)) (, ,) (NP (DT no) (JJ dose-effect) (NN correlation)) (VP (AUX was) (VP (VBN found))) (. .)))
11226639	4	(S1 (S (PP (IN In) (NP (NN particular))) (, ,) (NP (JJ low) (NNS doses)) (VP (VP (VBD reduced) (NP (DT the) (NN latency)) (PP (TO to))) (CC and) (VP (VBN prolonged) (NP (NP (DT the) (NN duration)) (PP (IN of) (NP (NNP Doc_11226639_507_518_Chemical) (NNP Doc_11226639_519_527_Disease)))))) (. .)))
11226639	5	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NP (DT the) (JJS highest) (NN dose)) (PP (IN of) (NP (NP (NNP Doc_11226639_562_571_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 50) (NN mg/kg)) (-RRB- -RRB-))))) (VP (VP (VBD caused) (NP (NP (DT a) (JJ paradoxical) (NN increase)) (PP (IN in) (NP (DT the) (NN latency))))) (CC and) (VP (VBD produced) (NP (NP (NP (DT a) (JJ sustained) (NN reduction)) (PP (IN of) (NP (NP (DT the) (NN duration)) (PP (IN of) (NP (NNP Doc_11226639_682_690_Disease)))))) (, ,) (CC and) (NP (NP (DT a) (NN reduction)) (PP (IN in) (NP (NN mortality) (NN rate))))))) (. .)))
11226639	6	(S1 (S (NP (NNP Doc_11226639_727_736_Chemical) (CD 0.5) (CC and) (CD 5)) (ADVP (RB mg/kg)) (VP (VBD influenced) (NP (NP (DT the) (NN duration)) (CONJP (CC but) (RB not)) (NP (NP (DT the) (NN latency)) (PP (IN of) (NP (NNP Doc_11226639_800_808_Chemical-) (CC or) (NNP Doc_11226639_813_821_Chemical-induced) (NNP Doc_11226639_830_838_Disease)))))) (. .)))
11226639	7	(S1 (S (ADVP (RB Thus)) (, ,) (NP (NP (DT the) (JJ dual) (NN action)) (PP (IN of) (NP (NNP Doc_11226639_865_874_Chemical))) (PP (IN on) (NP (JJ pharmacological) (NNP Doc_11226639_894_902_Disease)))) (VP (VBZ seems) (S (VP (TO to) (VP (AUX be) (ADJP (JJ specific)) (PP (IN for) (NP (NP (DT the) (JJ Doc_11226639_932_943_Chemical) (NN mechanism)) (PP (IN of) (NP (NN action))))))))) (. .)))
11230490	0	(S1 (S (NP (JJ Reduced) (NNP Doc_11230490_8_22_Disease)) (VP (CC and) (VP (VBD preserved) (NP (NP (NN antitumor) (NN efficacy)) (PP (IN of) (NP (JJ liposome-encapsulated) (NNP Doc_11230490_81_92_Chemical) (CC and) (NNP Doc_11230490_97_113_Chemical)))) (PP (VBN compared) (PP (IN with) (NP (NP (JJ conventional) (NNP Doc_11230490_141_152_Chemical)) (CC and) (NP (NNP Doc_11230490_157_173_Chemical))))) (PP (IN in) (NP (NP (DT a) (JJ randomized) (, ,) (JJ multicenter) (NN trial)) (PP (IN of) (NP (NNP Doc_11230490_212_236_Disease))))))) (. .)))
11230490	1	(S1 (S (VP (TO To) (VP (VB determine) (SBAR (IN whether) (S (NP (NP (NNP Doc_11230490_268_274_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (JJ liposome-encapsulated) (NNP Doc_11230490_298_309_Chemical)) (: ;) (NP (NP (NNP The) (NNP Liposome) (NNP Company)) (, ,) (NP (NN Elan) (NN Corporation)) (, ,) (NP (NNP Princeton)))) (, ,) (NP (NNP NJ)) (-RRB- -RRB-)) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NNP Doc_11230490_386_402_Chemical)))))) (ADVP (RB significantly)) (VP (VBZ reduces) (NP (NNP Doc_11230490_425_436_Chemical) (NNP Doc_11230490_437_451_Disease)) (SBAR (IN while) (S (VP (VBG providing) (NP (JJ comparable) (NN antitumor) (NN efficacy)) (PP (IN in) (NP (NP (JJ first-line) (NN treatment)) (PP (IN of) (NP (NP (NNP Doc_11230490_525_549_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11230490_551_554_Disease)) (-RRB- -RRB-)))))))))))))) (. .)))
11230490	2	(S1 (S (NP (NNS PATIENTS) (CC AND) (NNS METHODS)) (: :) (NP (NP (NP (QP (CD Two) (CD hundred)) (JJ ninety-seven) (NNS patients)) (PP (IN with) (NP (NNP Doc_11230490_618_621_Disease)))) (CC and) (NP (NP (DT no) (JJ prior) (NN chemotherapy)) (PP (IN for) (NP (JJ metastatic) (NN disease))))) (VP (AUX were) (VP (VBN randomized) (S (VP (TO to) (VP (VB receive) (NP (NP (DT either) (CD 60) (NNS mg/m)) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-)) (PP (IN of) (NP (NP (NP (NNP Myocet)) (PRN (-LRB- -LRB-) (NP (NNP M)) (-RRB- -RRB-))) (CC or) (NP (JJ conventional) (NNP Doc_11230490_746_757_Chemical))))) (PRN (-LRB- -LRB-) (DT A) (-RRB- -RRB-))))) (, ,) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NP (CD 600) (NNS mg/m)) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-)) (PP (IN of) (NP (NP (NP (NNP Doc_11230490_798_814_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11230490_816_817_Chemical)) (-RRB- -RRB-))) (, ,) (NP (NP (DT every) (CD 3) (NNS weeks)) (PP (IN until) (NP (NN disease) (NN progression)))) (CC or) (NP (JJ unacceptable) (NNP Doc_11230490_876_884_Disease)))))))))) (. .)))
11230490	3	(S1 (S (NP (NN Doc_11230490_886_900_Disease)) (VP (AUX was) (VP (VBN defined) (PP (IN by) (NP (NP (NNS reductions)) (PP (IN in) (NP (JJ left-ventricular) (NN ejection) (NN fraction))) (, ,) (VP (VBN assessed) (PP (IN by) (NP (NP (JJ serial) (JJ multigated) (NN radionuclide) (NN angiography) (NNS scans)) (, ,) (CC or) (NP (NP (NNP Doc_11230490_1031_1055_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11230490_1057_1060_Disease)) (-RRB- -RRB-)))))))))) (. .)))
11230490	4	(S1 (S (NP (JJ Antitumor) (NN efficacy)) (VP (AUX was) (VP (VBN assessed) (PP (IN by) (NP (NP (NP (JJ objective) (NNP Doc_11230490_1108_1113_Disease) (NN response) (NNS rates)) (PRN (-LRB- -LRB-) (NP (NNP World) (NNP Health) (NNP Organization) (NNS criteria)) (-RRB- -RRB-))) (, ,) (NP (NP (NN time)) (PP (TO to) (NP (NP (NN progression)) (, ,) (CC and) (NP (NN survival))))))))) (. .)))
11230490	5	(S1 (S (NP (NP (NP (CD Six) (NN percent)) (PP (IN of) (NP (NNP MC) (NNS patients)))) (CC versus) (NP (NP (NP (CD 21) (NN %)) (PRN (-LRB- -LRB-) (PP (VBG including) (NP (NP (CD five) (NNS cases)) (PP (IN of) (NP (NNP Doc_11230490_1274_1277_Disease))))) (-RRB- -RRB-))) (PP (IN of) (NP (NN AC) (NNS patients))))) (VP (VBD developed) (NP (NP (NNP Doc_11230490_1304_1318_Disease)) (PRN (-LRB- -LRB-) (NP (NNP P) (CD =.0002)) (-RRB- -RRB-)))) (. .)))
11230490	6	(S1 (S (NP (NP (JJ Median) (JJ cumulative) (JJ Doc_11230490_1349_1360_Chemical) (NN dose)) (PP (IN at) (NP (NN onset)))) (VP (AUX was) (NP (NP (QP (JJR more) (IN than) (CD 2,220)) (NN mg/m)) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-)) (PP (IN for) (NP (NP (NNP MC) (CC versus) (CD 480) (NNS mg/m)) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-)) (PP (IN for) (NP (NP (NNP AC)) (PRN (-LRB- -LRB-) (NP (NP (NNP P) (CD =.0001)) (, ,) (NP (NN hazard) (NN ratio)) (, ,) (NP (CD 5.04))) (-RRB- -RRB-)))))))) (. .)))
11230490	7	(S1 (S (NP (NNP MC) (NNS patients)) (ADVP (RB also)) (VP (VBD experienced) (NP (JJR less) (NN grade) (CD 4) (NN Doc_11230490_1510_1521_Disease))) (. .)))
11230490	8	(S1 (UCP (S (NP (NP (JJ Antitumor) (NN efficacy)) (PP (IN of) (NP (NNP MC) (CC versus) (NNP AC)))) (VP (AUX was) (ADJP (JJ comparable)))) (: :) (NP (NP (JJ objective) (NN response) (NNS rates)) (, ,) (NP (NP (NP (NP (CD 43) (NN %)) (PP (IN versus) (NP (CD 43) (NN %)))) (: ;) (NP (NP (JJ median) (NN time)) (PP (TO to) (NP (NP (NN progression)) (, ,) (NP (CD 5.1) (NN %)) (CC versus) (NP (CD 5.5) (NNS months))))) (: ;) (NP (NP (JJ median) (NN time)) (PP (TO to) (NP (NP (NN treatment) (NN failure)) (, ,) (NP (QP (CD 4.6) (CC versus) (CD 4.4)) (NNS months))))) (: ;) (CC and) (NP (JJ median) (NN survival))) (, ,) (NP (QP (CD 19) (CC versus) (CD 16)) (NNS months)))) (. .)))
11230490	9	(S1 (S (NP (NNP Doc_11230490_1779_1785_Chemical)) (VP (VP (VBZ improves) (NP (NP (DT the) (JJ therapeutic) (NN index)) (PP (IN of) (NP (NNP Doc_11230490_1820_1831_Chemical)))) (PP (IN by) (S (VP (VP (ADVP (RB significantly)) (VBG reducing) (NP (NNP Doc_11230490_1858_1872_Disease))) (CC and) (VP (NN grade) (NP (CD 4) (NN Doc_11230490_1885_1896_Disease))))))) (CC and) (VP (VBZ provides) (NP (JJ comparable) (NN antitumor) (NN efficacy)) (, ,) (SBAR (WHADVP (WRB when)) (S (VP (VBN used) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NNP Doc_11230490_1971_1987_Chemical))))) (PP (IN as) (NP (NP (JJ first-line) (NN therapy)) (PP (IN for) (NP (NNP Doc_11230490_2014_2017_Disease)))))))))) (. .)))
11243580	0	(S1 (NP (NP (DT The) (NN role)) (PP (IN of) (NP (JJ nitrergic) (NN system))) (PP (IN in) (NP (NP (NNP Doc_11243580_32_41_Chemical-induced) (NNP Doc_11243580_50_60_Disease)) (PP (IN in) (NP (DT the) (NN mouse))))) (. .)))
11243580	1	(S1 (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NP (NP (NNP Doc_11243580_90_121_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11243580_123_129_Chemical)) (-RRB- -RRB-)) (NP (DT a) (NNP Doc_11243580_133_145_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_11243580_147_149_Chemical)) (-RRB- -RRB-)) (NN synthase) (NN inhibitor))) (CC and) (NP (NP (NNP Doc_11243580_174_184_Chemical)) (, ,) (NP (DT a) (JJ Doc_11243580_188_190_Chemical) (NN precursor)) (, ,))))) (VP (AUX were) (VP (VBN investigated) (PP (IN on) (NP (NNP Doc_11243580_223_232_Chemical-induced) (NNP Doc_11243580_241_252_Disease))))) (. .)))
11243580	2	(S1 (S (PP (IN In) (NP (DT the) (JJ first) (NN experiment))) (, ,) (NP (NP (CD four) (NNS groups)) (PP (IN of) (NP (NNS mice)))) (VP (VBD received) (NP (NP (JJ physiological) (NN saline)) (PRN (-LRB- -LRB-) (NP (CD 0.9) (NN %)) (-RRB- -RRB-)) (, ,) (NP (NP (NP (NNP Doc_11243580_337_347_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 300) (NNS mg/kg)) (, ,) (NP (NNP i.p.)) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Doc_11243580_367_373_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 100) (NN mg/kg)) (, ,) (NP (NNP i.p.)) (-RRB- -RRB-))) (CC and) (NP (NNP Doc_11243580_396_404_Chemical))) (PRN (-LRB- -LRB-) (NP (CD 2) (NN mg/kg)) (-RRB- -RRB-)) (, ,) (ADVP (RB respectively)))) (. .)))
11243580	3	(S1 (S (PP (NP (CD Thirty) (NNS minutes)) (IN after) (NP (DT these) (NNS injections))) (, ,) (NP (DT all) (NNS mice)) (VP (VBD received) (NP (NP (NNP Doc_11243580_487_496_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 50) (NN mg/kg)) (, ,) (NP (NN i.p.))) (-RRB- -RRB-)))) (. .)))
11243580	4	(S1 (S (PP (IN In) (NP (NP (DT the) (JJ second) (NN experiment)) (, ,) (NP (NP (CD four) (NNS groups)) (PP (IN of) (NP (NP (NNS mice)) (VP (VBN received) (NP (JJ similar) (NN treatment)) (PP (IN in) (NP (DT the) (JJ first) (NN experiment))))))) (, ,) (CC and) (NP (NP (CD 30) (NN min)) (PP (IN after) (NP (DT these) (NNS injections)))))) (, ,) (NP (DT all) (NNS mice)) (VP (VBD received) (NP (NP (DT a) (JJR higher) (NN dose)) (PP (IN of) (NP (NP (NNP Doc_11243580_683_692_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 80) (NN mg/kg)) (-RRB- -RRB-)))))) (. .)))
11243580	5	(S1 (S (NP (NP (NP (NNP Doc_11243580_705_711_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 100) (CD mg/kg)) (, ,) (NP (NNP i.p.)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_11243580_734_742_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 2) (NN mg/kg)) (-RRB- -RRB-)))) (ADVP (RB significantly)) (VP (VBD decreased) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NNP Doc_11243580_794_803_Chemical))) (PRN (-LRB- -LRB-) (NP (CD 50) (NN mg/kg)) (-RRB- -RRB-))) (NP (JJ -induced) (NNP Doc_11243580_823_834_Disease))) (. .)))
11243580	6	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (DT the) (JJ Doc_11243580_853_863_Chemical) (NN treatment)) (VP (VBD increased) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (JJ Doc_11243580_901_910_Chemical) (PRN (-LRB- -LRB-) (NP (NP (CD 80) (NN mg/kg)) (, ,) (NP (NNP i.p.))) (-RRB- -RRB-)) (JJ -induced) (NN Doc_11243580_936_947_Disease)))) (ADVP (RB significantly))) (. .)))
11243580	7	(S1 (S (NP (DT These) (NNS results)) (VP (MD may) (VP (VB suggest) (SBAR (IN that) (S (NP (NNP Doc_11243580_994_996_Chemical)) (VP (AUX is) (NP (NP (DT a) (JJ proconvulsant) (NN mediator)) (PP (IN in) (NP (JJ Doc_11243580_1028_1037_Chemical-induced) (NN Doc_11243580_1046_1057_Disease))))))))) (. .)))
11245434	0	(S1 (S (NP (NN Erythropoietin)) (VP (VBZ restores) (NP (NP (DT the) (JJ Doc_11245434_28_34_Disease-induced) (NN reduction)) (PP (IN in) (NP (NP (NNP Doc_11245434_56_72_Chemical) (NNP Doc_11245434_73_85_Disease)) (PP (IN in) (NP (NN rat) (NN Doc_11245434_93_99_Disease))))))) (. .)))
11245434	1	(S1 (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB examine) (NP (NP (DT the) (NN impact)) (PP (IN of) (NP (NN Doc_11245434_152_158_Disease) (NN prevention))) (PP (IN by) (NP (JJ recombinant) (JJ human) (NN erythropoietin) (PRN (-LRB- -LRB-) (NN rHuEPO) (-RRB- -RRB-)) (NN treatment))) (PP (IN on) (NP (NP (DT the) (NNP Doc_11245434_232_244_Disease)) (PP (IN of) (NP (NNP Doc_11245434_248_264_Chemical))) (PP (IN in) (NP (JJ solid) (JJ experimental) (NN Doc_11245434_287_293_Disease)))))))))) (. .)))
11245434	2	(S1 (S (NP (NN Doc_11245434_295_301_Disease)) (VP (AUX was) (VP (VBN induced) (S (VP (VBG using) (NP (NP (DT a) (JJ single) (NN dose)) (PP (IN of) (NP (NP (NNP Doc_11245434_337_348_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 50) (CD mg/kg)) (NN i.v.)) (-RRB- -RRB-)))) (VP (VBG resulting) (PP (IN in) (NP (NP (NP (DT a) (JJ long-lasting) (NN reduction)) (PRN (-LRB- -LRB-) (NP (CD 30) (NN %)) (-RRB- -RRB-))) (PP (IN of) (NP (DT the) (NN hemoglobin) (NN concentration))))))))))) (. .)))
11245434	3	(S1 (S (PP (IN In) (NP (DT a) (JJ second) (NN group))) (, ,) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_11245434_480_486_Disease)))) (VP (AUX was) (VP (VBN prevented) (PP (IN by) (NP (NP (NN rHuEPO)) (PRN (-LRB- -LRB-) (NP (CD 1000) (NN IU/kg)) (-RRB- -RRB-)) (VP (VBN administered) (NP (NNP s.c.) (CD three)) (S (VP (NN times/week) (S (VP (VBG starting) (NP (CD 7) (NNS days)) (PP (IN before) (NP (JJ Doc_11245434_582_593_Chemical) (NN application)))))))))))) (. .)))
11245434	4	(S1 (S (PP (NP (CD Four) (NNS days)) (IN after) (NP (JJ Doc_11245434_623_634_Chemical) (NN treatment))) (, ,) (NP (NP (NNP Doc_11245434_646_652_Disease)) (PRN (-LRB- -LRB-) (NP (NP (NN DS-Doc_11245434_657_664_Disease)) (PP (IN of) (NP (DT the) (NN rat)))) (-RRB- -RRB-))) (VP (AUX were) (VP (VBN implanted) (NP (NNP s.c.)) (PP (IN onto) (NP (DT the) (JJ hind) (NN food) (NN dorsum))))) (. .)))
11245434	5	(S1 (S (NP (CC Neither) (NP (NNP Doc_11245434_732_743_Chemical)) (CC nor) (NP (NN rHuEPO) (NN treatment))) (VP (VBD influenced) (NP (NNP Doc_11245434_776_781_Disease) (NN growth) (NN rate)) (ADVP (FW per) (FW se))) (. .)))
11245434	6	(S1 (S (SBAR (WHADVP (WRB When)) (S (NP (NNP Doc_11245434_807_813_Disease)) (VP (AUX were) (VP (VBN treated) (PP (IN with) (NP (NP (NP (DT a) (JJ single) (NN dose)) (PP (IN of) (NP (NNP Doc_11245434_849_865_Chemical)))) (PRN (-LRB- -LRB-) (NP (CD 60) (NN mg/kg) (NN i.p.)) (-RRB- -RRB-)) (NP (CD 5) (NNS days)))) (PP (IN after) (NP (NN implantation))))))) (, ,) (NP (NP (DT a) (NN growth) (NN delay)) (PP (IN with) (NP (NP (DT a) (JJ subsequent) (NN regrowth)) (PP (IN of) (NP (DT the) (NNP Doc_11245434_958_964_Disease)))))) (VP (AUX was) (VP (VBN observed))) (. .)))
11245434	7	(S1 (S (PP (IN In) (NP (DT the) (NNP Doc_11245434_986_992_Disease) (NN group))) (, ,) (NP (DT the) (NN growth) (NN delay)) (VP (AUX was) (ADJP (RB significantly) (JJR shorter)) (PP (VBN compared) (PP (IN with) (NP (NP (JJ nonanemic) (NNS controls)) (PRN (-LRB- -LRB-) (NP (NP (CD 13.3) (NNS days)) (CC versus) (NP (CD 8.6) (NNS days))) (-RRB- -RRB-)))))) (. .)))
11245434	8	(S1 (S (PP (IN In) (NP (NP (DT the) (NN group)) (SBAR (WHADVP (WRB where)) (S (NP (NNP Doc_11245434_1124_1130_Disease)) (VP (AUX was) (VP (VBN prevented) (PP (IN by) (NP (JJ rHuEPO) (NN treatment))))))))) (, ,) (NP (NN growth) (NN delay)) (VP (AUX was) (ADJP (JJ comparable) (PP (IN with) (NP (NP (DT that)) (PP (IN of) (NP (NP (JJ nonanemic) (NNS controls)) (PRN (-LRB- -LRB-) (NP (CD 13.3) (NNS days)) (-RRB- -RRB-)))))))) (. .)))
11245434	9	(S1 (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (JJ chemotherapy-induced) (NN Doc_11245434_1287_1293_Disease)) (VP (VBZ reduces) (NP (NP (NNP Doc_11245434_1302_1314_Disease)) (PP (IN of) (NP (NNP Doc_11245434_1318_1334_Chemical)))) (PP (IN in) (NP (NNP Doc_11245434_1338_1344_Disease))) (, ,) (SBAR (IN whereas) (S (NP (NP (NN correction)) (PP (IN of) (NP (NNP Doc_11245434_1368_1374_Disease))) (PP (IN by) (NP (NP (JJ rHuEPO) (NN treatment)) (PRN (-LRB- -LRB-) (NP (JJ epoetin) (NN alpha)) (-RRB- -RRB-))))) (VP (VBZ increases) (NP (DT the) (NN sensitivity)) (, ,) (ADVP (RB probably)) (PP (IN as) (NP (NP (DT a) (NN result)) (PP (IN of) (NP (NP (DT an) (VBN improved) (JJ Doc_11245434_1474_1480_Chemical) (NN supply)) (PP (TO to) (NP (NNP Doc_11245434_1491_1496_Disease) (NN tissue)))))))))))))) (. .)))
11271907	0	(S1 (S (NP (JJ Fatal) (NN Doc_11271907_6_30_Disease)) (ADJP (JJ secondary) (PP (TO to) (NP (JJ Doc_11271907_44_60_Chemical) (NN therapy)))) (. .)))
11271907	1	(S1 (S (NP (NN Doc_11271907_70_94_Disease)) (VP (AUX is) (NP (NP (DT a) (ADJP (JJ rare) (CC but) (JJ important)) (NN complication)) (PP (IN of) (NP (JJ Doc_11271907_135_151_Chemical) (NN therapy))))) (. .)))
11271907	2	(S1 (S (NP (NP (JJ Echocardiographic) (NN identification)) (PP (IN of) (NP (DT the) (NN disorder)))) (VP (MD can) (VP (AUX be) (VP (VBN made)))) (. .)))
11271907	3	(S1 (S (NP (PRP We)) (VP (VBP believe) (SBAR (IN that) (S (NP (NP (DT the) (NN ultrasound) (NNS features)) (PP (IN of) (NP (DT this) (NN disorder)))) (VP (AUX have) (RB not) (VP (AUX been) (ADVP (RB previously)) (VP (VBN reported))))))) (. .)))
11282081	0	(S1 (NP (NP (NNS Effects)) (PP (IN of) (NP (NNP Doc_11282081_11_20_Chemical))) (PP (IN on) (NP (NP (NNP Doc_11282081_24_43_Disease)) (CC and) (NP (NP (PRP$ its) (JJ electrophysiological) (NNS determinants)) (PP (IN in) (NP (NNS dogs)))))) (. .)))
11282081	1	(S1 (S (NP (JJ Doc_11282081_107_125_Disease-induced) (NN remodeling)) (VP (VP (VBZ promotes) (NP (NP (DT the) (NN occurrence) (CC and) (NN maintenance)) (PP (IN of) (NP (NP (NNP Doc_11282081_188_207_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11282081_209_211_Disease)) (-RRB- -RRB-)))))) (CC and) (VP (VBZ decreases) (NP (JJ L-type) (JJ Doc_11282081_234_240_Chemical) (NN current)))) (. .)))
11282081	2	(S1 (S (NP (EX There)) (VP (AUX is) (ADVP (RB also)) (NP (NP (DT a) (JJ clinical) (NN suggestion)) (SBAR (WHNP (IN that)) (S (NP (JJ acute) (NNP L-type) (NNP Doc_11282081_304_306_Chemical) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-)) (NN channel) (NN blockade)) (VP (MD can) (VP (VB promote) (NP (NP (NNP Doc_11282081_339_341_Disease)) (, ,) (ADJP (JJ consistent) (PP (IN with) (NP (NP (DT an) (JJ Doc_11282081_362_364_Disease) (VBG promoting) (NN effect)) (PP (IN of) (NP (JJ Doc_11282081_385_391_Chemical) (NN channel) (NN inhibition))))))))))))) (. .)))
11282081	3	(S1 (S (S (VP (TO To) (VP (VB evaluate) (NP (NP (DT the) (JJ potential) (NNS mechanisms)) (PP (IN of) (NP (NNP Doc_11282081_461_463_Disease) (NN promotion))) (PP (IN by) (NP (JJ Doc_11282081_477_483_Chemical) (NN channel) (NNS blockers))))))) (, ,) (NP (PRP we)) (VP (VBN administered) (NP (NNP Doc_11282081_518_527_Chemical)) (PP (TO to) (NP (JJ Doc_11282081_531_539_Chemical-Doc_11282081_540_550_Chemical) (JJ anesthetized) (NNS dogs)))) (. .)))
11282081	4	(S1 (S (S (NP (NN Doc_11282081_570_579_Chemical)) (VP (AUX was) (VP (VBN used) (PP (IN as) (NP (NP (DT a) (NN comparison) (NN drug) (CC and) (NN autonomic) (NN blockade)) (PP (IN with) (NP (NNP Doc_11282081_638_646_Chemical)))))))) (CC and) (S (NP (NNP Doc_11282081_651_658_Chemical)) (VP (AUX was) (VP (VBN applied) (PP (IN in) (NP (DT some) (NNS experiments)))))) (. .)))
11282081	5	(S1 (S (NP (NP (JJ Epicardial) (NN mapping)) (PP (IN with) (NP (CD 240) (JJ epicardial) (NNS electrodes)))) (VP (AUX was) (VP (VBN used) (S (VP (TO to) (VP (VB evaluate) (NP (NN activation)) (PP (IN during) (NP (NN Doc_11282081_781_783_Disease)))))))) (. .)))
11282081	6	(S1 (S (NP (NN Doc_11282081_794_803_Chemical)) (VP (VBD caused) (NP (NNP Doc_11282081_811_813_Disease) (NN promotion)) (PP (IN in) (NP (CD six) (NNS dogs))) (, ,) (S (VP (VBG increasing) (NP (NP (JJ mean) (NN duration)) (PP (IN of) (NP (NNP Doc_11282081_865_867_Disease))) (VP (VBN induced) (PP (IN by) (NP (NN burst) (NN pacing))))))) (, ,) (PP (PP (IN from) (NP (NP (JJ 8+/-4) (NNP s)) (PRN (-LRB- -LRB-) (FW mean+/-S.E.) (-RRB- -RRB-)))) (PP (TO to) (NP (NP (NP (CD 95+/-39) (NNP s)) (PRN (-LRB- -LRB-) (NP (NNP P<0.01) (FW vs.) (NN control)) (-RRB- -RRB-)) (PP (IN at) (NP (NP (DT a) (NN loading) (NN dose)) (PP (IN of) (NP (CD 0.1) (NN mg/kg)))))) (CC and) (NP (NP (CD 228+/-101) (NNP s)) (PRN (-LRB- -LRB-) (NP (NNP P<0.0005) (FW vs.) (NN control)) (-RRB- -RRB-)))))) (PP (IN at) (NP (NP (DT a) (NN dose)) (PP (IN of) (NP (CD 0.2) (NN mg/kg)))))) (. .)))
11282081	7	(S1 (S (NP (JJ Underlying) (NN electrophysiological) (NNS mechanisms)) (VP (AUX were) (VP (VBN studied) (PP (IN in) (NP (NN detail))) (PP (PP (IN in) (NP (NP (CD five) (JJ additional) (NNS dogs)) (PP (IN under) (NP (NN control) (NNS conditions))))) (CC and) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (DT the) (JJR higher) (NN dose)) (PP (IN of) (NP (NNP Doc_11282081_1205_1214_Chemical)))))))))) (. .)))
11282081	8	(S1 (S (PP (IN In) (NP (DT these) (NNS experiments))) (, ,) (NP (NNP Doc_11282081_1238_1247_Chemical)) (VP (VP (VBN shortened) (NP (NP (JJ mean) (JJ effective) (JJ refractory) (NN period)) (PRN (-LRB- -LRB-) (NP (NNP ERP)) (-RRB- -RRB-))) (PP (IN from) (NP (CD 122+/-5))) (PP (TO to) (NP (NP (JJ 114+/-4) (NNS ms)) (PRN (-LRB- -LRB-) (NP (NNP P<0.02)) (-RRB- -RRB-)))) (PP (IN at) (NP (NP (DT a) (NN cycle) (NN length)) (PP (IN of) (NP (CD 300) (NNS ms)))))) (, ,) (VP (VBD decreased) (NP (NP (NNP ERP) (CD heterogeneity)) (PRN (-LRB- -LRB-) (PP (IN from) (ADJP (JJ 15+/-1) (PP (TO to) (NP (CD 10+/-1) (NN %))))) (, ,) (NP (NNP P<0.05)) (-RRB- -RRB-)))) (, ,) (VP (ADVP (RB heterogeneously)) (VBN accelerated) (NP (JJ atrial) (NN conduction))) (CC and) (VP (VBD decreased) (NP (NP (DT the) (NN cycle) (NN length)) (PP (IN of) (NP (NP (NNP Doc_11282081_1504_1506_Disease)) (PRN (-LRB- -LRB-) (NP (NP (NN 94+/-4)) (PP (TO to) (NP (JJ 84+/-3) (NNS ms)))) (, ,) (NP (NNP P<0.005)) (-RRB- -RRB-))))))) (. .)))
11282081	9	(S1 (S (NP (NNP Doc_11282081_1539_1548_Chemical)) (VP (VP (AUX did) (RB not) (VP (VB affect) (NP (NP (NN ERP)) (, ,) (NP (NNP Doc_11282081_1569_1571_Disease) (NN cycle) (NN length)) (CC or) (NP (JJ Doc_11282081_1588_1590_Disease) (NN duration))))) (, ,) (CC but) (VP (VBD produced) (NP (NP (NN conduction) (NN acceleration)) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT that)) (VP (VBN caused) (PP (IN by) (NP (NP (NNP Doc_11282081_1664_1673_Chemical)) (PRN (-LRB- -LRB-) (NP (NN n=5)) (-RRB- -RRB-))))))))))) (. .)))
11282081	10	(S1 (S (PP (IN In) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (JJ autonomic) (NN blockade))))) (, ,) (NP (NNP Doc_11282081_1720_1729_Chemical)) (VP (VP (VBD failed) (S (VP (TO to) (VP (VB promote) (NP (NNP Doc_11282081_1748_1750_Disease)))))) (CC and) (VP (VBD increased)) (, ,) (CONJP (RB rather) (IN than)) (VP (VBG decreasing) (, ,) (NP (NN refractoriness)))) (. .)))
11282081	11	(S1 (S (NP (CC Neither) (NP (NNP Doc_11282081_1814_1823_Chemical)) (CC nor) (NP (NNP Doc_11282081_1828_1837_Chemical))) (VP (VBD affected) (NP (JJ atrial) (NN conduction)) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (JJ autonomic) (NN blockade)))))) (. .)))
11282081	12	(S1 (S (NP (JJ Epicardial) (NN mapping)) (VP (VBD suggested) (SBAR (IN that) (S (NP (NNP Doc_11282081_1938_1947_Chemical)) (VP (VBD promoted) (NP (NNP Doc_11282081_1957_1959_Disease)) (PP (IN by) (S (VP (VBG increasing) (NP (NP (DT the) (NN number)) (PP (IN of) (NP (NP (JJ simultaneous) (NNS wavefronts)) (VP (VBN reflected) (PP (IN by) (NP (NP (JJ separate) (NNS zones)) (PP (IN of) (NP (NN reactivation))))) (PP (IN in) (NP (DT each) (NN cycle)))))))))))))) (. .)))
11282081	13	(S1 (S (NP (NNP Doc_11282081_2084_2093_Chemical)) (VP (VBZ promotes) (NP (NP (NN Doc_11282081_2103_2105_Disease)) (PP (IN in) (NP (JJ normal) (NNS dogs)))) (PP (IN by) (S (VP (VBG promoting) (NP (JJ multiple) (NN circuit) (NN reentry))))) (, ,) (S (NP (DT an) (NN effect)) (ADJP (JJ dependent) (PP (IN on) (NP (NP (JJ intact) (JJ autonomic) (NN tone)) (CC and) (NP (NP (RB not)) (VP (VBN shared) (PP (IN by) (NP (NNP Doc_11282081_2223_2232_Chemical)))))))))) (. .)))
11284996	0	(S1 (S (NP (NNP Calcitonin)) (VP (VBD gene-related) (NP (NN peptide) (NNS levels)) (PP (IN during) (NP (NP (JJ Doc_11284996_46_58_Chemical-induced) (NN Doc_11284996_67_75_Disease)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ chronic) (NNP Doc_11284996_101_122_Disease)))))))) (. .)))
11284996	1	(S1 (S (NP (PRP It)) (VP (AUX has) (VP (AUX been) (VP (VBN proposed) (SBAR (IN that) (S (NP (NP (NNP Doc_11284996_150_162_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11284996_164_166_Chemical)) (-RRB- -RRB-)) (VP (VBN induced) (NP (NNP Doc_11284996_176_184_Disease)) (PP (IN in) (NP (NNP Doc_11284996_188_205_Disease))))) (VP (MD may) (VP (AUX be) (VP (VBN associated) (PP (IN with) (NP (NP (NN release)) (PP (IN of) (NP (NP (JJ calcitonin) (JJ gene-related) (NN peptide)) (PRN (-LRB- -LRB-) (NP (NNP CGRP)) (-RRB- -RRB-)))))))))))))) (. .)))
11284996	2	(S1 (S (PP (IN In) (NP (DT the) (JJ present) (NN study))) (NP (PRP we)) (VP (VBD aimed) (S (VP (TO to) (VP (VB investigate) (NP (NP (NN plasma) (NNS levels)) (PP (IN of) (NP (NNP CGRP)))) (PP (IN during) (NP (NP (NNP Doc_11284996_354_362_Disease)) (VP (VBN induced) (PP (IN by) (NP (NP (DT the) (NNP Doc_11284996_378_380_Chemical) (NN donor) (NNP Doc_11284996_387_406_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11284996_408_411_Chemical)) (-RRB- -RRB-)))) (PP (IN in) (NP (NP (CD 16) (NNS patients)) (PP (IN with) (NP (NP (JJ chronic) (NNP Doc_11284996_441_462_Disease)) (CC and) (NP (CD 16) (JJ healthy) (NNS controls))))))))))))) (. .)))
11284996	3	(S1 (S (NP (DT The) (NNS subjects)) (VP (AUX were) (ADVP (RB randomly)) (VP (VBN allocated) (S (VP (TO to) (VP (VB receive) (NP (CD 0.5) (NN microg/kg/min) (NN Doc_11284996_554_557_Chemical) (CC or) (NN placebo)) (PP (IN over) (NP (NP (CD 20) (NN min)) (PP (IN on) (NP (CD two) (JJ Doc_11284996_588_596_Disease-free) (NNS days)))))))))) (. .)))
11284996	4	(S1 (S (NP (NN Blood) (NNS samples)) (VP (AUX were) (VP (VBN collected) (PP (IN at) (NP (NN baseline) (, ,) (CD 10) (, ,) (CD 20) (CC and) (CD 60) (NN min))) (PP (IN after) (NP (NP (NN start)) (PP (IN of) (NP (NN infusion))))))) (. .)))
11284996	5	(S1 (S (S (NP (DT Both) (NNS patients) (CC and) (NNS controls)) (VP (VBD developed) (NP (ADJP (RB significantly) (JJR stronger)) (JJ immediate) (NN Doc_11284996_763_771_Disease)) (PP (IN on) (NP (NP (DT the) (JJ GTN) (NN day)) (ADVP (IN than) (PP (IN on) (NP (DT the) (NN placebo) (NN day)))))))) (CC and) (S (NP (DT the) (NNP Doc_11284996_819_827_Disease)) (VP (AUX was) (ADJP (ADJP (RB significantly) (RBR more) (JJ pronounced)) (PP (IN in) (NP (NNS patients))) (PP (IN than) (PP (IN in) (NP (NNS controls))))))) (. .)))
11284996	6	(S1 (S (NP (EX There)) (VP (AUX was) (NP (NP (DT no) (NN difference)) (PP (IN between) (NP (NP (DT the) (NN area)) (PP (IN under) (NP (DT the) (NN CGRP) (NN curve)))))) (PRN (-LRB- -LRB-) (NP (NNP AUCCGRP)) (-RRB- -RRB-)) (PP (IN on) (NP (NP (NNP Doc_11284996_967_970_Chemical) (FW vs.) (NN placebo) (NN day)) (PP (IN in) (NP (NP (NP (DT either) (NNS patients)) (PRN (-LRB- -LRB-) (NP (NNP P=0.65)) (-RRB- -RRB-))) (CC or) (NP (NP (NNS controls)) (PRN (-LRB- -LRB-) (NP (NNP P=0.48)) (-RRB- -RRB-)))))))) (. .)))
11284996	7	(S1 (S (NP (NP (DT The) (NNP AUCCGRP)) (VP (VBN recorded) (PP (IN on) (NP (DT the) (JJ Doc_11284996_1065_1068_Chemical) (NN day))))) (VP (AUX did) (RB not) (VP (VB differ) (PP (IN between) (NP (NP (NNS patients)) (CC and) (NP (NP (NNS controls)) (PRN (-LRB- -LRB-) (NP (NNP P=0.36)) (-RRB- -RRB-))))))) (. .)))
11284996	8	(S1 (S (PP (DT Both) (IN in) (NP (NP (NNS patients)) (CC and) (NP (NNS controls)))) (, ,) (NP (NNP CGRP) (NNS levels)) (VP (VBD changed) (ADVP (RB significantly)) (PP (IN over) (NP (NN time))) (, ,) (PP (IN on) (NP (NP (PDT both) (DT the) (JJ Doc_11284996_1216_1219_Chemical) (CC and) (NN placebo) (NNS days)) (PRN (-LRB- -LRB-) (NP (QP ($ P) (CD <) (CD 0.05))) (-RRB- -RRB-))))) (. .)))
11284996	9	(S1 (S (NP (DT The) (JJ present) (NN study)) (VP (VBZ indicates) (SBAR (IN that) (S (NP (JJ Doc_11284996_1282_1284_Chemical-induced) (JJ immediate) (NN Doc_11284996_1303_1311_Disease)) (VP (AUX is) (RB not) (VP (VBN associated) (PP (IN with) (NP (NP (NN release)) (PP (IN of) (NP (NN CGRP)))))))))) (. .)))
11302406	0	(S1 (NP (JJ Doc_11302406_0_11_Chemical-induced) (NN Doc_11302406_20_38_Disease) (. .)))
11302406	1	(S1 (S (VP (TO To) (VP (VP (VB present) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NP (JJ Doc_11302406_72_83_Chemical-associated) (NNP Doc_11302406_95_113_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11302406_115_118_Disease)) (-RRB- -RRB-)))))) (CC and) (VP (VB discuss) (NP (NP (NP (NNP Doc_11302406_132_143_Chemical) (POS 's)) (NN role)) (PP (IN in) (S (VP (VBG causing) (NP (NN Doc_11302406_162_165_Disease))))))))) (. .)))
11302406	2	(S1 (NP (NP (NN CASE) (NN SUMMARY)) (: :) (NP (NP (DT A) (JJ 68-year-old) (JJ white) (NN woman)) (PP (IN with) (NP (NP (NNP Candida) (NNS glabrata)) (VP (VBN isolated) (PP (IN from) (NP (NP (DT a) (JJ presacral) (NN abscess)) (VP (VBN developed) (PP (NP (NNP Doc_11302406_273_276_Disease) (CD eight) (NNS days)) (IN after) (S (VP (VBG commencing) (NP (JJ oral) (NNP Doc_11302406_310_321_Chemical)) (SBAR (S (NP (DT The) (NN patient)) (VP (AUX had) (NP (DT no) (JJ other) (NN risk) (NNS factors)) (PP (IN for) (NP (NNP Doc_11302406_364_367_Disease))) (, ,) (PP (VBG including) (NP (NP (NNP Doc_11302406_379_402_Disease)) (, ,) (NP (NNP Doc_11302406_404_418_Disease)) (, ,) (NP (NNP Doc_11302406_420_444_Disease)) (, ,) (CC and) (NP (NP (JJ electrolyte) (NNS abnormalities)) (SBAR (S (NP (EX There)) (VP (AUX was) (NP (NP (DT a) (JJ temporal) (NN association)) (PP (IN between) (NP (NP (DT the) (NN initiation)) (PP (IN of) (NP (NNP Doc_11302406_535_546_Chemical) (CC and) (NNP Doc_11302406_551_554_Disease))))))))))))))))))))))))) (. .)))
11302406	3	(S1 (S (S (NP (DT The) (NNP Doc_11302406_560_563_Disease)) (VP (VBD resolved) (SBAR (WHADVP (WRB when)) (S (NP (NNP Doc_11302406_578_589_Chemical)) (VP (AUX was) (VP (VBN discontinued))))))) (: ;) (S (ADVP (RB however)) (, ,) (NP (DT the) (NN patient)) (VP (VBD continued) (S (VP (TO to) (VP (AUX have) (NP (NP (NNP Doc_11302406_647_681_Disease) (CC and) (NNP Doc_11302406_686_722_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11302406_724_728_Disease)) (-RRB- -RRB-))) (PP (IN until) (NP (CD six) (NNS days))) (PP (IN after) (NP (NN drug) (NN cessation) (NN DISCUSSION)))))))) (: :) (S (NP (NP (NN Use)) (PP (IN of) (NP (DT the) (NNP Naranjo) (NN probability) (NN scale)))) (VP (VBZ indicates) (NP (NP (NP (DT a) (JJ probable) (NN relationship)) (PP (IN between) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NNP Doc_11302406_868_879_Chemical)))))) (CC and) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_11302406_903_906_Disease))))))) (. .)))
11302406	4	(S1 (S (NP (DT The) (JJ possible) (NN mechanism)) (VP (AUX is) (NP (NP (NN Doc_11302406_934_944_Disease)) (PP (IN of) (NP (ADJP (RB rapidly) (VBG activating)) (JJ delayed) (NNP rectifier) (NNP Doc_11302406_985_994_Chemical) (NNS currents))))) (. .)))
11302406	5	(S1 (S (PP (IN In) (NP (PRP$ our) (NN patient))) (, ,) (NP (EX there)) (VP (AUX was) (NP (NP (DT no) (JJ other) (NN etiology)) (VP (VBN identified) (SBAR (WHNP (WDT that)) (S (VP (MD could) (VP (VB explain) (NP (NNP Doc_11302406_1079_1094_Disease) (CC or) (NNP Doc_11302406_1098_1101_Disease)) (NP (NP (DT The) (JJ complete) (NN disappearance)) (PP (IN of) (NP (NNP Doc_11302406_1132_1136_Disease) (CC and) (NNP Doc_11302406_1141_1175_Disease))) (VP (VBN followed) (PP (IN by) (NP (NP (NN normalization)) (PP (IN of) (NP (CD QT) (NN interval))))) (SBAR (IN after) (S (NP (DT the) (NN drug)) (VP (AUX was) (VP (VBN stopped) (ADVP (RB strongly)) (S (VP (VBZ suggests) (ADJP (JJ Doc_11302406_1262_1273_Chemical) (PP (IN as) (NP (DT the) (NN etiology))))))))))))))))))) (. .)))
11302406	6	(S1 (S (NP (NNS Clinicians)) (VP (MD should) (VP (AUX be) (ADJP (JJ aware) (SBAR (IN that) (S (NP (NNP Doc_11302406_1336_1347_Chemical)) (, ,) (PP (ADVP (RB even)) (IN at) (NP (JJ low) (NNS doses))) (, ,) (VP (MD may) (VP (VB cause) (NP (NN Doc_11302406_1378_1409_Disease)) (, ,) (PP (VBG leading) (PP (TO to) (NP (NNP Doc_11302406_1422_1425_Disease))))))))))) (. .)))
11302406	7	(S1 (S (NP (JJ Serial) (JJ electrocardiographic) (NN monitoring)) (VP (MD may) (VP (AUX be) (VP (VBN considered) (SBAR (WHADVP (WRB when)) (S (NP (NNP Doc_11302406_1489_1500_Chemical)) (VP (AUX is) (VP (VBN administered) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX are) (PP (IN at) (NP (NP (NN risk)) (PP (IN for) (NP (NN Doc_11302406_1549_1572_Disease))))))))))))))))) (. .)))
11337188	0	(S1 (S (NP (NN Doc_11337188_0_37_Disease)) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_11337188_54_63_Chemical)))) (. .)))
11337188	1	(S1 (S (NP (NP (DT A) (JJ 67-year-old) (NN man)) (SBAR (WHNP (WP who)) (S (VP (AUX was) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_11337188_104_113_Chemical))) (PP (IN for) (NP (CD one) (NN week))) (PP (IN because) (IN of) (NP (NNP Doc_11337188_138_170_Disease))))))) (, ,)) (VP (VBD developed) (NP (ADJP (JJ Doc_11337188_182_195_Disease) (CC and) (JJ diffuse) (, ,) (JJ symmetric) (, ,) (JJ palpable)) (NN Doc_11337188_229_245_Disease)) (PP (IN on) (NP (PRP$ his) (NNS feet)))) (. .)))
11337188	2	(S1 (S (NP (NN Doc_11337188_259_276_Disease)) (VP (AUX were) (VP (VBN noted) (PP (IN on) (NP (PRP$ his) (NNS fingers))))) (. .)))
11337188	3	(S1 (S (NP (NN Skin) (NNS biopsies)) (VP (VBD showed) (NP (NP (NNS findings) (JJ diagnostic)) (PP (IN of) (NP (NNP Doc_11337188_348_375_Disease))))) (. .)))
11337188	4	(S1 (S (S (NP (NN Doc_11337188_377_386_Chemical)) (VP (AUX was) (VP (VBN discontinued)))) (CC and) (S (NP (NN patient)) (VP (AUX was) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_11337188_433_448_Chemical)))))) (. .)))
11337188	5	(S1 (S (S (NP (DT The) (NNP Doc_11337188_454_458_Disease)) (VP (VBD disappeared) (PP (IN after) (NP (CD three) (NNS weeks))))) (CC and) (S (NP (JJ renal) (NN function)) (VP (VBD returned) (PP (TO to) (ADJP (JJ normal))))) (. .)))
11337188	6	(S1 (S (NP (NN Doc_11337188_528_555_Disease)) (VP (VBZ presents) (PP (IN as) (NP (NP (JJ palpable) (NN Doc_11337188_577_584_Disease)) (PP (IN of) (NP (NP (DT the) (JJR lower) (NNS extremities)) (VP (ADVP (RB often)) (VBN accompanied) (PP (IN by) (NP (NP (NNP Doc_11337188_631_645_Disease)) (, ,) (NP (NNP Doc_11337188_647_657_Disease)) (, ,) (CC and) (NP (NNP Doc_11337188_663_680_Disease)))))))))) (. .)))
11337188	7	(S1 (S (NP (NP (JJ Etiologic) (NNS factors)) (CC or) (NP (JJ associated) (NNS disorders))) (VP (VBP include) (NP (NP (NNP Doc_11337188_732_742_Disease)) (, ,) (NP (NNP medications)) (, ,) (NP (NNP Doc_11337188_757_782_Disease)) (CC and) (NP (NNP Doc_11337188_787_796_Disease)))) (. .)))
11337188	8	(S1 (S (ADVP (RB However)) (, ,) (PP (IN in) (NP (NP (DT half)) (PP (IN of) (NP (DT the) (NNS cases))))) (NP (DT no) (JJ etiologic) (NN factor)) (VP (AUX is) (VP (VBN identified))) (. .)))
11337188	9	(S1 (S (S (ADVP (RB Usually)) (NP (PRP it)) (VP (AUX is) (NP (DT a) (JJ self-limited) (NN disorder)))) (, ,) (CC but) (S (NP (JJ Doc_11337188_906_920_Chemical) (NN therapy)) (VP (MD may) (VP (AUX be) (VP (VBN needed) (PP (IN in) (NP (JJ life-threatening) (NNS cases))) (SBAR (IN since) (S (NP (NP (JJ early) (NN treatment)) (PP (IN with) (NP (NNP Doc_11337188_996_1011_Chemical))) (PP (IN in) (NP (JJ severe) (NNS cases)))) (VP (MD can) (VP (VB prevent) (NP (NNS complications)))))))))) (. .)))
11337188	10	(S1 (S (NP (NN Doc_11337188_1055_1064_Chemical)) (VP (MD should) (VP (AUX be) (VP (VBN included) (PP (IN among) (NP (NP (DT the) (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (VB cause) (NP (NN Doc_11337188_1115_1142_Disease))))))))))) (. .)))
1141447	0	(S1 (NP (NP (DT The) (JJ renal) (NN pathology)) (PP (IN in) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NNP Doc_1141447_33_40_Chemical-induced) (NNP Doc_1141447_49_67_Disease))))) (. .)))
1141447	1	(S1 (S (NP (NP (DT A) (NN case)) (PP (IN of) (NP (NNP Doc_1141447_79_86_Chemical-induced) (NNP Doc_1141447_95_113_Disease)))) (VP (AUX is) (VP (VBN reported))) (. .)))
1141447	2	(S1 (S (NP (IN At) (JJ necropsy) (NN microscopy)) (VP (VBD shoed) (NP (ADJP (JJ unique) (CC and) (JJ extensive)) (NN damage)) (PP (TO to) (NP (NP (NNS cells)) (VP (VBG lining) (NP (DT the) (JJ distal) (NN nephron)))))) (. .)))
1141447	3	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (VBN suggested) (SBAR (IN that) (S (NP (DT these) (NNS changes)) (VP (VBP represent) (NP (NP (DT a) (JJ specific) (JJ toxic) (NN effect)) (PP (IN of) (NP (NNP Doc_1141447_292_299_Chemical))) (, ,) (VP (VBN reported) (ADVP (RB here)) (PP (IN for) (NP (NP (DT the) (JJ first) (NN time)) (PP (IN in) (NP (NN man)))))))))))) (. .)))
11467664	0	(S1 (S (NP (NN Doc_11467664_0_20_Disease)) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NNP Doc_11467664_48_57_Chemical)))))) (. .)))
11467664	1	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT a) (NN patient)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NN Doc_11467664_93_113_Disease)) (PP (ADVP (RB shortly)) (IN after) (NP (NP (NN initiation)) (PP (IN of) (NP (NN treatment))) (PP (IN with) (NP (NNP Doc_11467664_157_180_Chemical)))))))))) (. .)))
11467664	2	(S1 (S (NP (NP (NN Ultrasound)) (PP (IN of) (NP (DT the) (NN liver) (CC and) (NN abdominal) (NNS CT)))) (VP (AUX were) (ADJP (JJ normal))) (. .)))
11467664	3	(S1 (S (NP (DT An) (NN ERCP)) (VP (VBD showed) (NP (JJ normal) (JJ biliary) (NN anatomy))) (. .)))
11467664	4	(S1 (S (NP (DT A) (JJ percutaneous) (NN liver) (NN biopsy)) (VP (AUX was) (VP (VBN obtained) (S (VP (VBG showing) (NP (JJ marked) (NN Doc_11467664_331_342_Disease)))) (, ,) (PP (IN with) (NP (NP (JJ portal) (NN Doc_11467664_356_361_Disease)) (, ,) (NP (JJ ductular) (NN proliferation)) (, ,) (CC and) (NP (JJ acute) (NN Doc_11467664_397_409_Disease)))))) (. .)))
11467664	5	(S1 (S (S (NP (NN Doc_11467664_411_434_Chemical)) (VP (AUX was) (VP (VBN discontinued)))) (, ,) (CC and) (S (NP (NP (DT the) (NN patient) (POS 's)) (NNP Doc_11467664_471_479_Disease)) (VP (VBD resolved) (ADVP (RB slowly)) (PP (IN over) (NP (NP (DT a) (NN period)) (PP (IN of) (NP (JJ several) (NNS months))))))) (. .)))
11467664	6	(S1 (S (PP (VBN Given) (NP (NP (DT the) (NN onset)) (PP (IN of) (NP (NP (PRP$ his) (NNP Doc_11467664_552_560_Disease) (CD 2) (NN wk)) (PP (IN after) (NP (NP (DT the) (NN initiation)) (PP (IN of) (NP (NNP Doc_11467664_590_599_Chemical))))))))) (, ,) (NP (PRP we)) (VP (VBP believe) (SBAR (IN that) (S (NP (DT this) (NN case)) (VP (VBZ represents) (NP (NP (DT an) (NN example)) (PP (IN of) (NP (NP (JJ Doc_11467664_652_661_Chemical-associated) (NN hepatotoxicity)) (, ,) (NP (NP (DT the) (JJ first) (JJ such) (NN case)) (VP (VBD reported)))))))))) (. .)))
11524350	0	(S1 (NP (NP (NP (JJ Systemic) (NN Doc_11524350_9_17_Disease)) (CC and) (NP (NN resuscitation))) (PP (IN in) (NP (NP (NNP Doc_11524350_39_50_Chemical-)) (, ,) (NP (NNP Doc_11524350_53_68_Chemical-)) (, ,) (CC or) (NP (JJ Doc_11524350_74_85_Chemical-infused) (NNS rats)))) (. .)))
11524350	1	(S1 (S (NP (PRP We)) (VP (VBD compared) (NP (NP (DT the) (JJ systemic) (NN Doc_11524350_125_133_Disease)) (PP (IN of) (NP (NP (NNP Doc_11524350_137_148_Chemical)) (, ,) (NP (NNP Doc_11524350_150_165_Chemical)) (, ,) (CC and) (NP (NNP Doc_11524350_171_182_Chemical)))) (PP (IN in) (NP (JJ anesthetized) (NNS rats))))) (. .)))
11524350	2	(S1 (S (NP (PRP We)) (ADVP (RB also)) (VP (VBD compared) (NP (DT the) (NN ability) (S (VP (TO to) (VP (VB resuscitate) (NP (NNS rats)))))) (PP (IN after) (NP (NP (JJ lethal) (NNS doses)) (PP (IN of) (NP (DT these) (JJ local) (NNS anesthetics)))))) (. .)))
11524350	3	(S1 (S (NP (NNP Doc_11524350_301_312_Chemical) (, ,) (NNP Doc_11524350_314_329_Chemical) (, ,) (CC or) (NNP Doc_11524350_334_345_Chemical)) (VP (AUX was) (VP (VBN infused) (PP (IN at) (NP (NP (DT a) (NN rate)) (PP (IN of) (NP (NP (QP (CD 2) (CD mg.)) (NNS kg)) (PRN (-LRB- -LRB-) (JJ -1) (-RRB- -RRB-)))))) (. .) (VP (VB min) (PRN (-LRB- -LRB-) (NP (NN -1)) (-RRB- -RRB-)) (SBAR (IN while) (S (NP (NP (NN electrocardiogram)) (, ,) (NP (NN electroencephalogram)) (, ,) (CC and) (NP (JJ arterial) (NN pressure))) (VP (AUX were) (ADVP (RB continuously)) (VP (VBN monitored)))))))) (. .)))
11524350	4	(S1 (S (SBAR (WHADVP (WRB When)) (S (NP (NNP Doc_11524350_496_504_Disease)) (VP (AUX was) (VP (VBN recorded))))) (, ,) (S (NP (NN drug) (NN infusion)) (VP (AUX was) (VP (VBN stopped)))) (CC and) (S (NP (DT a) (JJ resuscitation) (NN sequence)) (VP (AUX was) (VP (VBN begun)))) (. .)))
11524350	5	(S1 (S (NP (NN Doc_11524350_585_596_Chemical) (CD 0.01) (NN mg/kg)) (VP (AUX was) (VP (VBN administered) (PP (IN at) (NP (JJ 1-min) (NNS intervals))) (SBAR (IN while) (S (NP (JJ external) (JJ cardiac) (NNS compressions)) (VP (AUX were) (VP (VBN applied))))))) (. .)))
11524350	6	(S1 (S (NP (NN Resuscitation)) (VP (AUX was) (VP (VBN considered) (S (ADJP (JJ successful))) (SBAR (WHADVP (WRB when)) (S (NP (NP (DT a) (JJ systolic) (JJ arterial) (NN pressure) (NN >)) (CC or) (NP (NP (CD =100) (NN mm)) (NP (NNP Hg)))) (VP (AUX was) (VP (VBN achieved) (PP (IN within) (NP (CD 5) (NN min))))))))) (. .)))
11524350	7	(S1 (S (NP (NP (DT The) (JJ cumulative) (NNS doses)) (PP (IN of) (NP (NP (NNP Doc_11524350_835_850_Chemical)) (CC and) (NP (NNP Doc_11524350_855_866_Chemical)))) (SBAR (WHNP (WDT that)) (S (VP (VBD produced) (NP (NN Doc_11524350_881_889_Disease)))))) (VP (VP (AUX were) (ADJP (JJ similar))) (CC and) (VP (AUX were) (ADJP (ADJP (JJR larger)) (PP (IN than) (NP (NP (DT those)) (PP (IN of) (NP (NNP Doc_11524350_933_944_Chemical)))))))) (. .)))
11524350	8	(S1 (S (S (NP (NP (DT The) (JJ cumulative) (NNS doses)) (PP (IN of) (NP (NNP Doc_11524350_970_985_Chemical))) (SBAR (WHNP (WDT that)) (S (VP (VBD produced) (NP (NP (NNP Doc_11524350_1000_1012_Disease)) (CC and) (NP (NNP Doc_11524350_1017_1025_Disease))))))) (VP (AUX were) (ADJP (ADJP (JJR smaller)) (PP (IN than) (NP (NP (DT the) (JJ corresponding) (NNS doses)) (PP (IN of) (NP (NNP Doc_11524350_1071_1082_Chemical)))))))) (, ,) (CC but) (S (NP (PRP they)) (VP (AUX were) (ADJP (ADJP (JJR larger)) (PP (IN than) (NP (NP (DT those)) (PP (IN of) (NP (NNP Doc_11524350_1119_1130_Chemical)))))))) (. .)))
11524350	9	(S1 (S (NP (NP (DT The) (NN number)) (PP (IN of) (NP (JJ successful) (NNS resuscitations)))) (VP (AUX did) (RB not) (VP (VB differ) (PP (IN among) (NP (NNS groups))))) (. .)))
11524350	10	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (DT a) (JJR smaller) (NN dose)) (PP (IN of) (NP (NNP Doc_11524350_1228_1239_Chemical)))) (VP (AUX was) (VP (VBN required) (PP (IN in) (NP (DT the) (NNP Doc_11524350_1260_1271_Chemical) (NN group))) (PP (IN than) (PP (IN in) (NP (DT the) (JJ other) (NNS groups)))))) (. .)))
11524350	11	(S1 (S (NP (PRP We)) (VP (VBP conclude) (SBAR (SBAR (IN that) (S (NP (NP (DT the) (JJ systemic) (NN Doc_11524350_1334_1342_Disease)) (PP (IN of) (NP (NNP Doc_11524350_1346_1361_Chemical)))) (VP (AUX is) (ADJP (JJ intermediate) (PP (IN between) (NP (NP (DT that)) (PP (IN of) (NP (NNP Doc_11524350_1394_1405_Chemical) (CC and) (NNP Doc_11524350_1410_1421_Chemical)))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN administered) (PP (IN at) (NP (DT the) (JJ same) (NN rate))))))))) (CC and) (SBAR (IN that) (S (NP (NNP Doc_11524350_1466_1477_Chemical-induced) (NNP Doc_11524350_1486_1500_Disease)) (VP (VBZ appears) (S (VP (TO to) (VP (AUX be) (ADJP (RBR more) (JJ susceptible) (PP (TO to) (NP (NP (NN treatment)) (PP (IN than) (NP (NP (DT that)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_11524350_1566_1577_Chemical) (CC or) (NNP Doc_11524350_1581_1596_Chemical))))))))))))))))) (. .)))
11573852	0	(S1 (NP (NP (JJ Doc_11573852_0_14_Chemical-induced) (NN Doc_11573852_23_31_Disease)) (PP (IN in) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (NNP Doc_11573852_50_54_Disease))))) (. .)))
11573852	1	(S1 (FRAG (S (VP (TO To) (VP (VB report) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NP (JJ multiple) (NNS episodes)) (PP (IN of) (NP (JJ Doc_11573852_108_115_Disease) (NN activity)))))) (PP (IN in) (NP (NP (DT an) (NNP Doc_11573852_131_135_Disease) (NN patent)) (VP (VBG following) (NP (JJ Doc_11573852_153_167_Chemical) (NN infusion)))))))) (. .)))
11573852	2	(S1 (NP (NP (NN CASE) (NN SUMMARY)) (: :) (NP (NP (DT A) (JJ 46-year-old) (JJ African-American) (NN man)) (VP (VBN experienced) (NP (JJ recurrent) (NNP Doc_11573852_249_267_Disease)) (PP (IN during) (NP (NP (JJ intravenous) (NN infusion)) (PP (IN of) (NP (NP (NNP Doc_11573852_299_313_Chemical)) (, ,) (ADVP (RB then)) (NP (NNP petit) (NN mal) (NN Doc_11573852_330_338_Disease)))))) (SBAR (IN as) (S (S (NP (DT the) (NN infusion)) (VP (AUX was) (VP (VBN stopped)))) (CC and) (S (NP (DT the) (NN drug) (NNS concentrations)) (VP (VBN decreased) (PP (IN with) (NP (NN time))))))))) (. .)))
11573852	3	(S1 (S (NP (NP (DT The) (NNS patients)) (JJ concurrent) (NNS medications)) (VP (VBD included) (NP (NNP Doc_11573852_461_471_Chemical) (, ,) (NNP Doc_11573852_473_484_Chemical) (, ,) (NNP Doc_11573852_486_498_Chemical) (, ,) (NNP Doc_11573852_500_514_Chemical) (, ,) (CC and) (NNP Doc_11573852_520_536_Chemical))) (. .)))
11573852	4	(S1 (S (PP (IN Despite) (NP (NP (NN administration)) (PP (IN of) (NP (NP (NNP Doc_11573852_564_573_Chemical)) (CC and) (NP (NNP Doc_11573852_578_587_Chemical)))))) (, ,) (NP (DT the) (NNP Doc_11573852_593_601_Disease)) (VP (VP (VBD persisted)) (CC and) (VP (VBD occurred) (ADVP (RB only)) (PP (IN during) (NP (NNP Doc_11573852_637_650_Chemical) (NN administration))))) (. .)))
11573852	5	(S1 (S (NP (NP (NP (NNP Doc_11573852_679_683_Disease)) (CC and) (NP (NNP Doc_11573852_688_711_Disease))) (, ,) (SBAR (WHNP (DT both) (WHPP (IN of) (WHNP (WDT which)))) (S (NP (DT the) (NN patient)) (VP (AUX had)))) (, ,)) (VP (MD can) (ADVP (RB potentially)) (VP (VB cause) (NP (NN Doc_11573852_766_774_Disease)))) (. .)))
11573852	6	(S1 (S (S (NP (DT The) (NN patient)) (VP (AUX had) (NP (NP (DT a) (NN history)) (PP (IN of) (NP (JJ Doc_11573852_805_812_Chemical) (NN abuse)))))) (: ;) (S (NP (NP (JJ Doc_11573852_820_827_Chemical) (NN intake)) (CONJP (RB as) (RB well) (IN as)) (NP (NN withdrawal))) (VP (MD can) (ADVP (RB also)) (VP (VB cause) (NP (NN Doc_11573852_872_880_Disease))))) (. .)))
11573852	7	(S1 (S (NP (NN Doc_11573852_882_892_Chemical)) (ADVP (RB also)) (VP (AUX has) (NP (NP (DT a) (NN potential)) (PP (IN for) (S (VP (VBG inducing) (NP (NN Doc_11573852_927_935_Disease))))))) (. .)))
11573852	8	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (DT these) (JJ other) (JJ potential) (NNS causes)) (PP (IN of) (NP (NNP Doc_11573852_978_985_Disease)))) (VP (AUX were) (VP (VBN ruled) (PRT (RP out)))) (. .)))
11573852	9	(S1 (S (NP (NP (DT The) (NN time) (NN course)) (PP (IN of) (NP (NNS events)))) (VP (VBD suggested) (SBAR (IN that) (S (NP (NNP Doc_11573852_1043_1057_Chemical)) (VP (AUX was) (NP (NP (DT the) (NN cause)) (PP (IN of) (NP (DT the) (NNP Doc_11573852_1079_1087_Disease))) (PP (IN in) (NP (DT this) (NNP Doc_11573852_1096_1100_Disease) (NN patient)))))))) (. .)))
11573852	10	(S1 (S (NP (NN Doc_11573852_1123_1137_Chemical)) (VP (VBZ seems) (S (VP (TO to) (VP (AUX be) (NP (NP (DT the) (JJ probable) (NN cause)) (PP (IN of) (NP (DT the) (NNP Doc_11573852_1176_1184_Disease)))))))) (. .)))
11573852	11	(S1 (S (PP (TO To) (NP (NN date))) (, ,) (S (NP (NP (QP (RB only) (CD three)) (NNS cases)) (PP (IN of) (NP (NNP Doc_11573852_1215_1223_Disease))) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_11573852_1240_1254_Chemical))))) (VP (AUX have) (VP (AUX been) (VP (VBN reported) (PP (IN in) (NP (DT the) (NN literature))))))) (, ,) (CC but) (S (NP (NN healthcare) (NNS providers)) (VP (MD should) (VP (AUX be) (ADJP (JJ aware) (PP (IN of) (NP (NP (DT the) (NN potential)) (PP (IN for) (NP (DT this) (JJ rare) (JJ adverse) (NN effect))))))))) (. .)))
11583940	0	(S1 (NP (NP (NP (NNP Doc_11583940_0_9_Chemical)) (CC and) (NP (NNP Doc_11583940_14_35_Chemical))) (PP (IN for) (NP (NP (JJ calcineurin-free) (NN immunosuppression)) (PP (IN in) (NP (JJ renal) (NN transplant) (NNS recipients))))) (. .)))
11583940	1	(S1 (S (NP (NP (JJ Calcineurin) (NNS inhibitors)) (, ,) (PP (JJ such) (IN as) (NP (NP (NNP Doc_11583940_139_151_Chemical)) (CC and) (NP (NNP Doc_11583940_156_166_Chemical)))) (, ,)) (VP (AUX have) (VP (AUX been) (ADJP (JJ available)) (PP (IN for) (NP (QP (RB almost) (CD 20)) (NNS years))))) (. .)))
11583940	2	(S1 (S (SBAR (IN Although) (S (NP (DT these) (NNS drugs)) (VP (VP (AUX are) (ADJP (RB highly) (JJ effective))) (CC and) (VP (VB represent) (NP (NP (DT the) (NN mainstay)) (PP (IN of) (NP (NN transplant) (NN immunosuppression)))))))) (, ,) (NP (PRP they)) (VP (AUX are) (VP (VBN associated) (PP (IN with) (NP (ADJP (ADJP (JJ acute)) (CC and) (ADJP (JJ chronic))) (NN nephrotoxicity))))) (. .)))
11583940	3	(S1 (S (S (NP (NP (JJ Acute) (NN nephrotoxicity)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ occurs) (PP (IN in) (NP (DT the) (JJ early) (NN period))) (PP (IN after) (NP (NN transplantation)))))) (, ,)) (VP (VBZ leads) (PP (TO to) (NP (NP (DT a) (JJR higher) (NN rate)) (PP (IN of) (NP (NN dialysis))))))) (, ,) (CC and) (S (NP (NN chronic) (NN nephrotoxicity)) (VP (MD may) (ADVP (RB eventually)) (VP (VB result) (PP (IN in) (NP (NN graft) (NN loss)))))) (. .)))
11583940	4	(S1 (S (NP (JJ Acute) (CC and) (JJ chronic) (NN nephrotoxicity)) (VP (AUX is) (VP (VBG becoming) (ADJP (RBR more) (JJ common)) (PP (IN as) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (JJ marginal) (NNS kidneys))) (PP (IN for) (NP (NN transplantation) (NNS increases))))))) (. .)))
11583940	5	(S1 (S (NP (NP (CD Two) (ADJP (RB recently) (JJ available)) (NN immunosuppressive) (NNS agents)) (, ,) (NP (NP (NNP Doc_11583940_716_737_Chemical)) (CC and) (NP (NP (NNP Doc_11583940_742_751_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11583940_753_762_Chemical)) (-RRB- -RRB-)))) (, ,)) (VP (AUX have) (NP (DT no) (NN nephrotoxicity))) (. .)))
11583940	6	(S1 (S (NP (NP (DT The) (NN use)) (PP (IN of) (NP (DT these) (NNS drugs))) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (JJ other) (NNS agents)))))) (VP (AUX has) (VP (VBN led) (PP (TO to) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NP (JJ new) (NNS paradigms)) (PP (IN of) (NP (JJ immunosuppressive) (NN therapy))))))))) (. .)))
11583940	7	(S1 (S (NP (DT This) (NN paper)) (VP (VBZ reviews) (NP (NP (DT the) (NNS results)) (PP (IN of) (NP (NP (JJ clinical) (NNS trials)) (SBAR (WHNP (WDT that)) (S (VP (AUX have) (VP (VBN investigated) (NP (NP (DT these) (JJ new) (NNS approaches)) (PP (TO to) (NP (NN immunosuppression)))) (PP (IN in) (NP (JJ renal) (NN transplant) (NNS recipients))))))))))) (. .)))
11694026	0	(S1 (NP (NP (NN Tolerability)) (PP (IN of) (NP (NP (NNP Doc_11694026_16_26_Chemical)) (CC and) (NP (NNP Doc_11694026_31_42_Chemical)))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ NSAID-induced) (NNP Doc_11694026_74_83_Disease/Doc_11694026_84_94_Disease))))) (. .)))
11694026	1	(S1 (S (NP (JJ Previous) (NNS studies)) (VP (VBN evaluated) (NP (NP (DT the) (NN tolerance)) (PP (IN of) (NP (NP (NNP Doc_11694026_140_150_Chemical)) (CC and) (NP (NNP Doc_11694026_155_166_Chemical))))) (PP (IN in) (NP (NP (NNS subjects)) (PP (IN with) (NP (NP (ADJP (JJ cutaneous) (, ,) (JJ respiratory) (CC and) (JJ anaphylactoid)) (NNS reactions)) (VP (VBN induced) (PP (IN by) (NP (NP (JJ nonsteroidal) (JJ anti-inflammatory) (NNS drugs)) (PRN (-LRB- -LRB-) (NP (NNS NSAIDs)) (-RRB- -RRB-)))))))))) (. .)))
11694026	2	(S1 (S (PP (IN In) (NP (DT this) (NN study))) (NP (PRP we)) (VP (VBD investigated) (NP (NP (NN tolerability) (CC and) (NN reliability)) (PP (IN of) (NP (NP (NNP Doc_11694026_355_365_Chemical)) (CC and) (NP (NNP Doc_11694026_370_381_Chemical))))) (PP (IN in) (NP (NP (DT a) (ADJP (RB very) (JJ large)) (NN number)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (DT an) (JJ exclusive) (JJ well-documented) (NN history)) (PP (IN of) (NP (NNP Doc_11694026_462_467_Chemical-induced) (NNP Doc_11694026_476_485_Disease/Doc_11694026_486_496_Disease)))))))))) (. .)))
11694026	3	(S1 (S (ADVP (RB Furthermore)) (, ,) (NP (PRP we)) (VP (VBN evaluated) (SBAR (IN whether) (S (NP (DT some) (NNS factors)) (VP (AUX have) (NP (DT the) (NN potential) (S (VP (TO to) (VP (VB increase) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NN reaction))) (PP (TO to) (NP (NP (NNP Doc_11694026_600_611_Chemical)) (CC and) (NP (NNP Doc_11694026_616_626_Chemical))))))))))))) (. .)))
11694026	4	(S1 (S (NP (NP (DT A) (JJ single-placebo-controlled) (JJ oral) (NN challenge) (NN procedure)) (PP (IN with) (NP (NP (NNP Doc_11694026_686_696_Chemical)) (CC or) (NP (NNP Doc_11694026_700_711_Chemical))))) (VP (AUX was) (VP (VBN applied) (PP (TO to) (NP (CD 829) (NNS patients))) (PP (IN with) (NP (NP (DT a) (NN history)) (PP (IN of) (NP (NNP Doc_11694026_758_763_Chemical-induced) (NNP Doc_11694026_772_781_Disease/Doc_11694026_782_792_Disease))))))) (. .)))
11694026	5	(S1 (S (NP (NP (DT A) (NN total)) (PP (IN of) (NP (CD 75/829) (PRN (-LRB- -LRB-) (NP (CD 9.4) (NN %)) (-RRB- -RRB-)) (NNS patients)))) (VP (VBD experienced) (NP (NP (NNS reactions)) (PP (TO to) (NP (NP (NNP Doc_11694026_853_863_Chemical)) (CC or) (NP (NNP Doc_11694026_867_878_Chemical)))))) (. .)))
11694026	6	(S1 (S (IN Of) (NP (NP (DT the) (CD 715) (NNS patients)) (VP (VBN tested) (PP (IN with) (NP (NP (NNP Doc_11694026_912_922_Chemical) (CD 62)) (PRN (-LRB- -LRB-) (NP (CD 8.6) (NN %)) (-RRB- -RRB-)))))) (VP (VBD showed) (NP (DT a) (JJ positive) (NN test)) (, ,) (SBAR (IN while) (S (NP (NP (QP (IN of) (CD 114)) (NNS subjects)) (VP (VBN submitted) (PP (TO to) (NP (DT the) (NN challenge))) (PP (IN with) (NP (NP (NNP Doc_11694026_1011_1022_Chemical)) (, ,) (NP (NP (CD 13)) (PRN (-LRB- -LRB-) (NP (CD 9.6) (NN %)) (-RRB- -RRB-))))))) (VP (AUX did) (RB not) (VP (VB tolerate) (NP (DT this) (NN drug))))))) (. .)))
11694026	7	(S1 (S (ADVP (RB Furthermore)) (, ,) (NP (NP (NP (CD 18.28) (NN %)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (DT a) (NN history)) (PP (IN of) (NP (JJ chronic) (NNP Doc_11694026_1120_1129_Disease)))))))) (CC and) (NP (NP (CD 11.8) (NN %)) (PP (IN of) (NP (NP (NNS subjects)) (PP (IN with) (NP (NP (DT an) (NN history)) (PP (IN of) (NP (NP (NNP Doc_11694026_1171_1176_Chemical-induced) (NNP Doc_11694026_1185_1194_Disease/Doc_11694026_1195_1205_Disease) (CC or) (NNP Doc_11694026_1209_1219_Disease)) (ADVP (RB alone)))) (PRN (-LRB- -LRB-) (PP (IN with) (CC or) (IN without) (NP (JJ chronic) (NNP Doc_11694026_1251_1260_Disease))) (-RRB- -RRB-)))))))) (VP (VBD resulted) (S (VP (TO to) (VP (AUX be) (ADJP (JJ intolerant) (PP (TO to) (NP (JJ alternative) (NNS drugs)))))))) (. .)))
11694026	8	(S1 (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (NP (PRP$ our) (NNS results)) (VP (VBP confirm) (NP (NP (DT the) (JJ good) (NN tolerability)) (PP (IN of) (NP (NP (NNP Doc_11694026_1371_1381_Chemical)) (CC and) (NP (NNP Doc_11694026_1386_1397_Chemical)))) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD experienced) (NP (NP (NN Doc_11694026_1426_1435_Disease/Doc_11694026_1436_1446_Disease)) (VP (VBN caused) (PP (IN by) (NP (NNS NSAIDs)))))))))))) (. .)))
11694026	9	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NP (NN reaction)) (PP (TO to) (NP (DT these) (JJ alternative) (NN study) (NNS drugs)))))) (VP (AUX is) (ADJP (RB statistically) (JJ increased) (PP (PP (IN by) (NP (NP (DT a) (NN history)) (PP (IN of) (NP (JJ chronic) (NNP Doc_11694026_1579_1588_Disease))))) (CC and) (, ,) (PP (IN above) (NP (DT all))) (, ,) (PP (IN by) (NP (NP (DT a) (NN history)) (PP (IN of) (NP (JJ NSAID-induced) (NNP Doc_11694026_1635_1645_Disease)))))))) (. .)))
11704023	0	(S1 (S (NP (NP (NN Comparison)) (PP (IN of) (NP (NN aqueous) (CC and) (NN gellan)))) (VP (VBP ophthalmic) (ADJP (JJ Doc_11704023_44_51_Chemical) (PP (IN with) (NP (NN placebo)))) (PP (IN on) (NP (NP (DT the) (JJ 24-hour) (NN heart) (NN rate) (NN response)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN on) (NP (NP (NN treatment)) (PP (IN for) (NP (NNP Doc_11704023_129_137_Disease)))))))))) (. .)))
11704023	1	(S1 (S (NP (JJ Topical) (NN beta-blocker) (NN treatment)) (VP (AUX is) (NP (NP (JJ routine) (NN therapy)) (PP (IN in) (NP (NP (DT the) (NN management)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_11704023_233_241_Disease))))))))) (. .)))
11704023	2	(S1 (S (NP (NP (NN Therapy) (NNS results)) (PP (IN in) (NP (JJ systemic) (NN absorption)))) (, ,) (ADVP (RB however)) (, ,) (NP (NP (DT the) (NN degree)) (PP (IN of) (NP (NP (NN reduction)) (PP (IN of) (NP (NP (NN resting)) (CC and) (NP (JJ peak) (NN heart) (NN rate))))))) (VP (AUX has) (RB not) (VP (AUX been) (VP (VBN quantified)))) (. .)))
11704023	3	(S1 (S (NP (DT This) (NN trial)) (VP (VBN evaluated) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (NN placebo)) (, ,) (NP (NP (CD 0.5) (NN %)) (ADJP (JJ aqueous) (NP (NP (NNP Doc_11704023_437_444_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11704023_446_453_Chemical) (NN solution)) (-RRB- -RRB-))))) (CC and) (NP (NP (DT a) (ADJP (CD 0.5) (NN %)) (JJ Doc_11704023_475_482_Chemical) (NN suspension)) (SBAR (WHNP (WDT that)) (S (VP (VBZ forms) (NP (NP (DT a) (NN gel)) (PP (IN on) (NP (NN application))) (PP (TO to) (NP (NP (DT the) (NN conjunctiva)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11704023_546_553_Chemical) (NN gellan)) (-RRB- -RRB-))))) (PP (IN on) (NP (NP (DT the) (JJ 24-hour) (NN heart) (NN rate)) (PP (IN in) (S (NP (NNS patients)) (ADVP (RB currently)) (VP (AUXG being) (VP (VBN treated) (PP (IN for) (NP (NNP Doc_11704023_628_636_Disease))) (S (VP (TO to) (VP (VB quantify) (NP (NP (DT the) (NN reduction)) (PP (IN in) (NP (JJ mean) (NN heart) (NN rate))))))))))))))))))))) (. .)))
11704023	4	(S1 (S (NP (NP (JJ Forty-three) (NNP Caucasian) (NNS patients)) (PP (IN with) (NP (JJ primary) (NNP Doc_11704023_736_755_Disease) (CC or) (NNP Doc_11704023_759_778_Disease))) (PP (IN with) (NP (NP (DT a) (JJ mean) (PRN (-LRB- -LRB-) (JJ +/-SD) (-RRB- -RRB-)) (NN age)) (PP (IN of) (NP (CD 63) (-LRB- -LRB-) (JJ +/-8) (-RRB- -RRB-) (NNS years)))))) (VP (VP (AUX were) (VP (VBN randomized))) (CC and) (VP (VBD crossed) (PP (IN over) (PP (IN in) (NP (NP (DT a) (JJ double-masked) (NN manner)) (PP (TO to) (NP (NP (CD 14) (NNS days)) (PP (IN of) (NP (NP (NN treatment)) (PP (IN with) (NP (NP (NP (NP (NP (NN placebo)) (PRN (-LRB- -LRB-) (NP (NP (NN morning) (CC and) (NN evening)) (PP (IN in) (NP (DT both) (NNS eyes)))) (-RRB- -RRB-)) (, ,)) (NNP Doc_11704023_954_961_Chemical) (NN solution)) (PRN (-LRB- -LRB-) (NP (NP (NN morning) (CC and) (NN evening)) (PP (IN in) (NP (DT both) (NNS eyes)))) (-RRB- -RRB-))) (, ,) (CC or) (NP (NP (JJ Doc_11704023_1010_1017_Chemical) (NN gellan)) (PRN (-LRB- -LRB-) (NP (NP (NN morning)) (PP (IN in) (NP (NP (DT both) (NNS eyes)) (PP (IN with) (NP (NN placebo))) (PP (IN in) (NP (DT the) (NN evening)))))) (-RRB- -RRB-)))))))))))))) (. .)))
11704023	5	(S1 (S (PP (IN On) (NP (NP (DT the) (JJ 13th) (NN day)) (PP (IN of) (NP (DT each) (NN period))))) (, ,) (NP (NN heart) (NN rate)) (VP (AUX was) (VP (VBN recorded) (ADVP (RB continuously)) (PP (IN during) (NP (DT a) (JJ typical) (, ,) (JJ ambulant) (JJ 24-hour) (NN period))))) (. .)))
11704023	6	(S1 (S (S (NP (NP (DT Both) (JJ Doc_11704023_1203_1210_Chemical) (NN solution)) (CC and) (NP (JJ Doc_11704023_1224_1231_Chemical) (NN gellan))) (VP (VBD reduced) (NP (DT the) (JJ mean) (JJ 24-hour) (NN heart) (NN rate)) (PP (VBN compared) (PP (IN with) (NP (NP (NN placebo)) (PRN (-LRB- -LRB-) (NP (NP (JJ P) (NNS <)) (CC or) (NP (SYM =) (CD .001))) (-RRB- -RRB-))))))) (, ,) (CC and) (S (NP (DT this) (NN reduction)) (VP (AUX was) (VP (RBS most) (VBN pronounced) (PP (IN during) (NP (NP (DT the) (JJ daytime)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD -7.5) (NN %)) (NN change)) (PP (IN in) (NP (NP (JJ mean) (NN heart) (NN rate)) (, ,) (NP (CD -5.7) (NN beats/min))))) (-RRB- -RRB-))))))) (. .)))
11704023	7	(S1 (S (NP (JJ Doc_11704023_1423_1430_Chemical) (NN gellan)) (VP (VBD showed) (NP (NP (DT a) (ADJP (RB numerically) (CC but) (RB not) (ADJP (RB significantly) (JJR smaller))) (NN reduction)) (PP (IN in) (NP (JJ 24-hour) (NN heart) (NN rate)))) (, ,) (PP (VBN compared) (PP (IN with) (NP (JJ Doc_11704023_1536_1543_Chemical) (NN solution))))) (. .)))
11704023	8	(S1 (S (S (PP (IN During) (NP (DT the) (NN night))) (, ,) (NP (NP (DT the) (JJ mean) (JJ 12-hour) (NN heart) (NN rate)) (PP (IN on) (NP (NP (NN placebo)) (CC and) (NP (JJ Doc_11704023_1615_1622_Chemical) (NN gellan))))) (VP (AUX were) (ADJP (ADJP (DT both) (RB significantly) (JJR less)) (PP (IN than) (PP (IN on) (NP (JJ Doc_11704023_1667_1674_Chemical) (NN solution))))))) (: ;) (S (NP (NP (DT the) (NN difference)) (PP (IN between) (NP (UCP (NN solution) (CC and) (JJ gellan)) (NNS treatments)))) (VP (AUX was) (ADJP (RB statistically) (JJ significant)) (PRN (-LRB- -LRB-) (NP (NNP P) (SYM =) (CD .01)) (-RRB- -RRB-)))) (. .)))
11704023	9	(S1 (S (NP (NP (DT Both) (JJ Doc_11704023_1798_1805_Chemical) (NN solution)) (CC and) (NP (JJ Doc_11704023_1819_1826_Chemical) (NN gellan) (NN decrease))) (NP (DT the) (JJ mean) (JJ 24-hour) (NN heart) (NN rate)) (VP (VBN compared) (PP (IN with) (NP (NN placebo)))) (. .)))
11704023	10	(S1 (S (NP (DT This) (NN response)) (VP (AUX was) (VP (RBS most) (VBN pronounced) (PP (IN during) (NP (DT the) (JJ active) (JJ daytime) (NN period))))) (. .)))
11704023	11	(S1 (S (NP (DT These) (NNS data)) (VP (VB quantify) (NP (NP (DT the) (JJ modest) (NN Doc_11704023_1993_2004_Disease)) (VP (VBN associated) (PP (IN with) (NP (NP (JJ ophthalmic) (NN beta-blocker) (NN therapy)) (PP (IN in) (NP (NP (DT a) (JJ typical) (JJ patient) (NN population)) (PP (IN on) (NP (NN therapy))) (PP (IN for) (NP (NNP Doc_11704023_2100_2108_Disease)))))))))) (. .)))
11704023	12	(S1 (S (SBAR (IN Although) (S (NP (NN exercise) (NN performance)) (VP (AUX was) (RB not) (VP (VBN assessed) (PP (IN in) (NP (DT this) (NN trial))))))) (, ,) (NP (NP (NNS reductions)) (PP (IN of) (NP (DT this) (NN magnitude)))) (VP (MD should) (RB not) (VP (AUX have) (NP (JJ substantial) (JJ clinical) (NNS consequences)))) (. .)))
11705128	0	(S1 (NP (NP (NP (NN Management) (NNS strategies)) (PP (IN for) (NP (NP (JJ Doc_11705128_26_35_Chemical-induced) (JJ hemolytic) (NN anemia)) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NNP Doc_11705128_81_92_Disease)))))))) (: :) (NP (ADJP (JJ clinical) (CC and) (JJ economic)) (NNS implications)) (. .)))
11705128	1	(S1 (S (ADVP (RB Recently)) (NP (VBN published) (NNS studies)) (VP (AUX have) (VP (VBN demonstrated) (NP (NP (VBN increased) (NN efficacy) (CC and) (NN cost-effectiveness)) (PP (IN of) (NP (NN combination) (NN therapy))) (PP (IN with) (NP (NNP interferon) (CC and) (NNP Doc_11705128_272_280_Chemical/Doc_11705128_281_290_Chemical)))) (PP (VBN compared) (PP (IN with) (NP (NP (JJ Doc_11705128_305_321_Chemical) (NN monotherapy)) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (NNP Doc_11705128_354_373_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11705128_375_378_Disease)) (-RRB- -RRB-))))))))))) (. .)))
11705128	2	(S1 (S (NP (NN Combination) (NN therapy)) (VP (AUX is) (VP (VBN associated) (PP (IN with) (NP (NP (DT a) (ADJP (RB clinically) (JJ important)) (JJ adverse) (NN effect)) (: :) (NP (NP (JJ Doc_11705128_459_468_Chemical-induced) (JJ hemolytic) (NN anemia)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11705128_495_499_Disease)) (-RRB- -RRB-))))))) (. .)))
11705128	3	(S1 (S (NP (NP (DT The) (NN objective)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB evaluate) (NP (NP (DT the) (JJ direct) (NN health-care) (NNS costs)) (CC and) (NP (NP (NN management)) (PP (IN of) (NP (NNP Doc_11705128_593_597_Disease))))) (PP (IN during) (NP (NP (NN treatment)) (PP (IN of) (NP (NNP Doc_11705128_618_621_Disease))) (PP (IN in) (NP (DT a) (JJ clinical) (NN trial) (NN setting))))))))) (. .)))
11705128	4	(S1 (S (NP (DT A) (JJ systematic) (NN literature) (NN review)) (VP (AUX was) (VP (VBN conducted) (S (VP (TO to) (VP (VB synthesize) (NP (NP (NN information)) (PP (IN on) (NP (NP (DT the) (NN incidence) (CC and) (NN management)) (PP (IN of) (NP (NN Doc_11705128_766_770_Disease))))))))))) (. .)))
11705128	5	(S1 (S (NP (JJ Decision-analytic) (NNS techniques)) (VP (AUX were) (VP (VBN used) (S (VP (TO to) (VP (VB estimate) (NP (NP (DT the) (NN cost)) (PP (IN of) (S (VP (VBG treating) (NP (NN Doc_11705128_844_848_Disease))))))))))) (. .)))
11705128	6	(S1 (S (NP (NN Uncertainty)) (VP (AUX was) (VP (VBN evaluated) (S (VP (VBG using) (NP (NN sensitivity) (NNS analyses)))))) (. .)))
11705128	7	(S1 (S (NP (NP (NN Doc_11705128_913_917_Disease)) (, ,) (VP (VBN defined) (PP (IN as) (NP (NP (DT a) (NN reduction)) (PP (IN in) (NP (NN hemoglobin))) (PP (TO to) (NP (QP (JJR less) (IN than) (CD 100)) (NNS g/L)))))) (, ,)) (VP (VBZ occurs) (PP (IN in) (NP (NP (QP (RB approximately) (CD 7) (NN %) (TO to) (CD 9) (NN %))) (PP (IN of) (NP (NP (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NN combination) (NN therapy))))))))) (. .)))
11705128	8	(S1 (S (NP (NP (DT The) (NN standard)) (PP (IN of) (NP (NN care))) (PP (IN for) (NP (NN management))) (PP (IN of) (NP (NNP Doc_11705128_1096_1100_Disease)))) (VP (AUX is) (NP (NP (NP (NN reduction)) (CC or) (NP (NN discontinuation))) (PP (IN of) (NP (DT the) (JJ Doc_11705128_1140_1149_Chemical) (NN dosage))))) (. .)))
11705128	9	(S1 (S (NP (PRP We)) (VP (VBD estimated) (NP (NP (DT the) (JJ direct) (NN cost)) (PP (IN of) (S (VP (VBG treating) (NP (ADJP (RB clinically) (JJ significant)) (NN Doc_11705128_1222_1226_Disease) (S (VP (TO to) (VP (AUX be) (NP (NP (CD 170)) (PP (IN per) (NP (NP (NN patient)) (VP (VBG receiving) (NP (NN combination) (NN therapy)) (PP (IN per) (NP (NP (JJ 48-week) (NN treatment) (NN course)) (PRN (-LRB- -LRB-) (NN range) (NN 68-) (NN 692) (-RRB- -RRB-))))))))))))))))) (. .)))
11705128	10	(S1 (S (NP (NP (DT The) (NNS results)) (PP (IN of) (NP (DT the) (JJ one-way) (NN sensitivity) (NNS analyses)))) (VP (VBD ranged) (PP (IN from) (NP (QP (CD 57) (TO to) (CD 317))))) (. .)))
11705128	11	(S1 (S (PP (IN In) (NP (NN comparison))) (, ,) (NP (NP (DT the) (NN cost)) (PP (IN of) (NP (NP (CD 48) (NNS weeks)) (PP (IN of) (NP (NN combination) (NN therapy)))))) (VP (AUX is) (NP (CD 16,459))) (. .)))
11705128	12	(S1 (S (NP (NP (DT The) (JJ direct) (NN cost)) (PP (IN of) (S (VP (VBG treating) (NP (ADJP (RB clinically) (JJ significant)) (NN Doc_11705128_1535_1539_Disease)))))) (VP (AUX is) (NP (NP (NP (CD 1) (NN %)) (PRN (-LRB- -LRB-) (NP (NN 170/) (CD 16,459)) (-RRB- -RRB-))) (PP (IN of) (NP (NN drug) (NN treatment) (NNS costs))))) (. .)))
11705128	13	(S1 (S (NP (NNS Questions)) (VP (VBP remain) (PP (IN about) (NP (NP (NP (DT the) (JJ optimal) (NN dose)) (PP (IN of) (NP (NNP Doc_11705128_1629_1638_Chemical)))) (CC and) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NNP Doc_11705128_1660_1664_Disease)))))) (PP (IN in) (NP (DT a) (JJ real-world) (NN population)))) (. .)))
11705128	14	(S1 (S (PP (IN Despite) (NP (DT these) (NNS uncertainties))) (, ,) (NP (NP (DT this) (JJ initial) (NN evaluation)) (PP (IN of) (NP (NP (DT the) (JJ direct) (NN cost)) (PP (IN of) (S (VP (VBG treating) (NP (NNP Doc_11705128_1777_1781_Disease)))))))) (VP (VBZ provides) (NP (NP (DT an) (NN estimate)) (PP (IN of) (NP (NP (DT the) (NN cost) (CC and) (NN management) (NNS implications)) (PP (IN of) (NP (DT this) (ADJP (RB clinically) (JJ important)) (JJ adverse) (NN effect))))))) (. .)))
11752998	0	(S1 (NP (NP (JJ Preliminary) (NN efficacy) (NN assessment)) (PP (IN of) (NP (NP (JJ intrathecal) (NN injection)) (PP (IN of) (NP (NP (DT an) (JJ American) (NN formulation)) (PP (IN of) (NP (NNP Doc_11752998_87_96_Chemical))) (PP (IN in) (NP (NNS humans))))))) (. .)))
11752998	1	(S1 (S (NP (NP (JJ Preclinical) (NNS studies)) (PP (IN of) (NP (JJ intrathecal) (NNP Doc_11752998_155_164_Chemical)))) (VP (VBP suggest) (SBAR (S (NP (PRP it)) (VP (MD may) (VP (AUX be) (ADJP (JJ effective)) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (NNP Doc_11752998_213_235_Disease)) (PP (IN in) (NP (NP (NNS humans)) (, ,) (CC and) (NP (JJ preliminary) (NNS studies)))) (PP (IN in) (NP (NNS volunteers) (CC and) (NNS patients))))))) (SBAR (IN with) (S (NP (NP (DT a) (JJ Swedish) (NN formulation)) (PP (IN of) (NP (NNP Doc_11752998_328_337_Chemical)))) (VP (VBZ suggests) (SBAR (S (NP (PRP it)) (VP (MD may) (VP (AUX be) (ADJP (JJ effective) (PP (PP (IN in) (NP (NNP Doc_11752998_370_386_Disease) (NNS states))) (CC but) (RB not) (PP (IN with) (NP (JJ acute) (JJ noxious) (NN stimulation))))))))))))))))) (. .)))
11752998	2	(S1 (S (NP (NP (DT The) (NN purpose)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB screen) (PP (IN for) (NP (NP (NN efficacy)) (PP (IN of) (NP (NP (DT a) (JJ different) (NN formulation)) (PP (IN of) (NP (NNP Doc_11752998_517_526_Chemical))) (VP (VBN marketed) (PP (IN in) (NP (DT the) (NNP US)))))))) (, ,) (S (VP (VBG using) (NP (PDT both) (NP (JJ acute) (JJ noxious) (NN stimulation)) (CC and) (NP (JJ Doc_11752998_588_597_Chemical-evoked) (JJ mechanical) (NN Doc_11752998_616_632_Disease))))))))) (. .)))
11752998	3	(S1 (S (PP (VBG Following) (NP (NP (NNP Food) (CC and) (NNP Drug) (NNP Administration) (CC and) (JJ institutional) (NN review) (NN board) (NN approval)) (CC and) (NP (JJ written) (JJ informed) (NN consent)))) (, ,) (NP (CD 65) (NNS volunteers)) (VP (AUX were) (VP (VBN studied) (PP (IN in) (NP (NP (CD two) (NNS trials)) (: :) (NP (NP (NP (DT an) (JJ open-label) (, ,) (JJ dose-escalating) (NN trial)) (PP (IN with) (NP (NP (JJ intrathecal) (JJ Doc_11752998_848_857_Chemical) (NNS doses)) (PP (IN of) (NP (CD 0.25-2.0) (NN mg)))))) (CC and) (NP (NP (DT a) (JJ double-blind) (, ,) (JJ placebo-controlled) (NN trial)) (PP (IN of) (NP (NP (NNP Doc_11752998_927_936_Chemical)) (, ,) (NP (CD 2) (NN mg)))))))))) (. .)))
11752998	4	(S1 (S (S (NP (JJ Cerebrospinal) (NN fluid)) (VP (AUX was) (VP (VBN obtained) (PP (IN for) (NP (JJ pharmacokinetic) (NN analysis)))))) (, ,) (CC and) (S (NP (NP (JJ Doc_11752998_1011_1015_Disease) (NNS ratings)) (PP (IN in) (NP (NP (NN response)) (PP (TO to) (NP (NP (JJ acute) (NN heat) (NNS stimuli)) (CC and) (NP (NP (NNS areas)) (PP (IN of) (NP (NNP Doc_11752998_1071_1094_Disease) (CC and) (NNP Doc_11752998_1099_1108_Disease))) (PP (IN after) (NP (JJ intradermal) (JJ Doc_11752998_1127_1136_Chemical) (NN injection))))))))) (VP (AUX were) (VP (VBN determined)))) (. .)))
11752998	5	(S1 (S (NP (NNP Doc_11752998_1173_1182_Chemical)) (VP (VP (VBD produced) (NP (NP (DT no) (NN effect)) (PP (IN on) (NP (JJ Doc_11752998_1205_1209_Disease) (NN report)))) (PP (TO to) (NP (JJ acute) (JJ noxious) (JJ thermal) (CC or) (NN chemical) (NN stimulation)))) (CC but) (VP (VBD reduced) (NP (NP (NNP Doc_11752998_1278_1301_Disease)) (CC and) (NP (NNP Doc_11752998_1306_1315_Disease))) (PP (IN from) (NP (NP (JJ intradermal) (JJ Doc_11752998_1333_1342_Chemical) (NN injection)) (PP (IN for) (NP (QP (IN at) (JJS least) (CD 24)) (NNP h))))))) (. .)))
11752998	6	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NP (NN residence) (NN time)) (PP (IN of) (NP (NNP Doc_11752998_1403_1412_Chemical))) (PP (IN in) (NP (JJ cerebrospinal) (NN fluid)))) (VP (AUX was) (ADJP (ADJP (JJ short)) (PRN (-LRB- -LRB-) (VP (VBG <) (NP (CD 4) (NNP h))) (-RRB- -RRB-)))) (. .)))
11752998	7	(S1 (S (NP (DT These) (NNS results)) (VP (VBP show) (NP (NP (JJ selective) (NN inhibition)) (PP (IN by) (NP (NP (JJ intrathecal) (NNP Doc_11752998_1523_1532_Chemical)) (PP (IN of) (NP (NNP Doc_11752998_1536_1552_Disease))))) (, ,) (VP (VBN presumed) (S (VP (TO to) (VP (VB reflect) (NP (NP (JJ central) (NN sensitization)) (PP (IN in) (NP (NNS humans)))) (PP (IN after) (NP (JJ peripheral) (JJ Doc_11752998_1623_1632_Chemical) (NN injection))))))))) (. .)))
11752998	8	(S1 (S (NP (DT The) (JJ long-lasting) (NN effect)) (VP (VP (AUX is) (ADJP (JJ consistent) (PP (IN with) (NP (NP (DT that)) (VP (VBN observed) (PP (IN in) (NP (NP (JJ preliminary) (NNS reports)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ chronic) (NNP Doc_11752998_1749_1765_Disease)))))))))))) (CC and) (VP (AUX is) (RB not) (ADJP (JJ due) (PP (TO to) (NP (NP (JJ prolonged) (NN residence)) (PP (IN of) (NP (NNP Doc_11752998_1807_1816_Chemical))) (PP (IN in) (NP (JJ cerebrospinal) (NN fluid)))))))) (. .)))
11827497	0	(S1 (NP (NNP Delayed-onset) (NNP Doc_11827497_14_21_Chemical-induced) (NNP Doc_11827497_30_46_Disease) (. .)))
11827497	1	(S1 (S (NP (JJ Doc_11827497_60_67_Chemical-induced) (NN Doc_11827497_76_92_Disease)) (VP (VBZ presents) (NP (QP (CD 5) (TO to) (CD 12)) (NNS days)) (PP (IN after) (NP (NNP Doc_11827497_121_128_Chemical) (NN exposure))) (, ,) (PP (PP (IN with)) (CC or) (PP (IN without) (NP (NNP Doc_11827497_155_187_Disease))))) (. .)))
11827497	2	(S1 (S (NP (NP (NP (JJ Delayed) (NN recognition)) (CC and) (NP (NN treatment))) (PP (IN of) (NP (NNP Doc_11827497_226_233_Chemical-induced) (NNP Doc_11827497_242_258_Disease)))) (VP (VBP contribute) (PP (TO to) (NP (JJ poor) (NN patient) (NNS outcomes)))) (. .)))
11827497	3	(S1 (FRAG (S (VP (TO To) (VP (VP (VB describe)) (CC and) (VP (VB increase) (NP (NP (NN awareness)) (PP (IN of) (NP (NP (DT a) (JJ clinical) (NN scenario)) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (NP (DT the) (NN onset) (CC or) (NNS manifestations)) (PP (IN of) (NP (NNP Doc_11827497_405_412_Chemical-induced) (NNP Doc_11827497_421_437_Disease)))) (VP (AUX are) (VP (VBN delayed)))))))))))) (. .)))
11827497	4	(S1 (NP (NN Retrospective) (NN case) (NN series) (. .)))
11827497	5	(S1 (NP (NP (NP (CD Three) (JJ large) (JJ urban) (NNS hospitals)) (-LRB- -LRB-) (PP (IN with) (NP (JJ active) (JJ cardiovascular) (NN surgery) (NNS programs))) (-RRB- -RRB-)) (. .)))
11827497	6	(S1 (S (NP (CD 14) (NNS patients)) (VP (VBN seen) (PP (IN over) (NP (NP (DT a) (JJ 3-year) (NN period)) (SBAR (WHPP (IN in) (WHNP (WP whom))) (S (NP (NNP Doc_11827497_626_633_Chemical-induced) (NNP Doc_11827497_642_658_Disease)) (VP (VBD became) (ADJP (JJ apparent)) (PP (IN on) (NP (NP (VBN delayed) (NN presentation)) (PP (IN with) (NP (JJ Doc_11827497_704_718_Disease) (NNS complications))))))))))) (. .)))
11827497	7	(S1 (NP (NP (NN Platelet) (NNS counts)) (, ,) (NP (NP (NN onset)) (PP (IN of) (NP (ADJP (RB objectively) (VBN determined)) (NNP Doc_11827497_797_812_Disease)))) (, ,) (NP (NP (NNS results)) (PP (IN of) (NP (NP (JJ Doc_11827497_825_832_Chemical-induced) (NN platelet) (NN factor)) (SBAR (S (NP (CD 4) (NN antibody)) (VP (VBZ tests))))))) (, ,) (CC and) (NP (NNS outcomes)) (. .)))
11827497	8	(S1 (S (NP (NNS Patients)) (VP (VBD went) (ADVP (RB home)) (PP (IN after) (NP (NP (NNS hospitalizations)) (SBAR (WHNP (WDT that)) (S (VP (AUX had) (VP (VBN included) (NP (JJ heparin) (JJ exposure--in) (JJS most) (NNS cases)))))))) (, ,) (PP (IN with) (NP (NP (DT no) (NNP Doc_11827497_999_1015_Disease) (NN recognized--only)) (SBAR (S (VP (TO to) (VP (VB return) (PP (TO to) (NP (NP (DT the) (NN hospital)) (PRN (-LRB- -LRB-) (NP (NN median)) (, ,) (NP (NN day) (CD 14)) (-RRB- -RRB-)))) (PP (IN with) (NP (JJ Doc_11827497_1081_1095_Disease) (NNS complications)))))))))) (. .)))
11827497	9	(S1 (S (NP (NNS Thromboemboli)) (VP (AUX were) (ADJP (ADJP (ADJP (JJ venous)) (PRN (-LRB- -LRB-) (NP (NP (CD 12) (NNS patients)) (, ,) (NP (NP (CD 7)) (PP (IN with) (NP (NNP Doc_11827497_1158_1174_Disease))))) (-RRB- -RRB-))) (CC or) (ADJP (ADJP (JJ arterial)) (PRN (-LRB- -LRB-) (NP (CD 4) (NNS patients)) (-RRB- -RRB-))) (CC or) (DT both))) (. .)))
11827497	10	(S1 (S (NP (NN Platelet) (NNS counts)) (VP (AUX were) (ADVP (RB mildly)) (VP (VBN decreased) (PP (IN in) (NP (QP (DT all) (CC but) (CD 2)) (NNS patients))) (PP (IN on) (NP (JJ second) (NN presentation))))) (. .)))
11827497	11	(S1 (S (PP (IN On) (NP (NN readmission))) (, ,) (NP (CD 11) (NNS patients)) (VP (VBD received) (NP (NP (JJ therapeutic) (NN heparin)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VP (VBD worsened) (NP (NP (DT the) (NNS patients) (POS ')) (JJ clinical) (NN condition))) (CC and) (PRN (, ,) (PP (IN in) (NP (QP (DT all) (CD 11)) (NNS cases))) (, ,)) (VP (VBD decreased) (NP (NP (DT the) (JJ platelet) (NN count)) (PRN (-LRB- -LRB-) (S (S (S (VP (VB mean) (PP (IN at) (NP (NN readmission))))) (, ,) (S (NP (NP (CD 143) (NNP x) (CD 10)) (PRN (-LRB- -LRB-) (NP (CD 9)) (-RRB- -RRB-))) (VP (VBZ cells/L))) (: ;) (S (VP (VB mean) (NP (NNP nadir)) (PP (IN after) (NP (JJ Doc_11827497_1511_1518_Chemical) (NN re-exposure)))))) (, ,) (NP (NP (CD 39) (SYM x) (CD 10)) (PRN (-LRB- -LRB-) (NP (CD 9)) (-RRB- -RRB-))) (VP (VBZ cells/L))) (-RRB- -RRB-))))))))) (. .)))
11827497	12	(S1 (S (NP (NP (NNS Results)) (PP (IN of) (NP (JJ serologic) (NNS tests))) (PP (IN for) (NP (JJ Doc_11827497_1584_1591_Chemical-induced) (NNS antibodies)))) (VP (AUX were) (ADJP (JJ positive)) (PP (IN in) (NP (DT all) (NNS patients)))) (. .)))
11827497	13	(S1 (S (NP (JJ Subsequent) (NNS treatments)) (VP (VBD included) (NP (NP (NP (ADJP (NP (NP (NP (JJ alternative) (NNS anticoagulants)) (PRN (-LRB- -LRB-) (NP (CD 11) (NNS patients)) (-RRB- -RRB-))) (, ,) (NP (NP (JJ thrombolytic) (NNS drugs)) (PRN (-LRB- -LRB-) (NP (CD 3) (NNS patients)) (-RRB- -RRB-))) (, ,)) (JJ inferior)) (FW vena) (FW cava) (NNS filters)) (PRN (-LRB- -LRB-) (NP (CD 3) (NNS patients)) (-RRB- -RRB-))) (CC and) (, ,) (ADVP (RB eventually)) (, ,) (NP (NP (NNP Doc_11827497_1805_1813_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 11) (NNS patients)) (-RRB- -RRB-))))) (. .)))
11827497	14	(S1 (S (NP (CD Three) (NNS patients)) (VP (VBD died)) (. .)))
11827497	15	(S1 (S (NP (JJ Delayed-onset) (JJ Doc_11827497_1877_1884_Chemical-induced) (NN Doc_11827497_1893_1909_Disease)) (VP (AUX is) (ADVP (RB increasingly)) (VP (AUXG being) (VP (VBN recognized)))) (. .)))
11827497	16	(S1 (S (S (S (VP (TO To) (VP (VB avoid) (NP (JJ disastrous) (NNS outcomes))))) (, ,) (NP (NNS physicians)) (VP (MD must) (VP (VB consider) (NP (JJ Doc_11827497_1999_2006_Chemical-induced) (NNP Doc_11827497_2015_2031_Disease)) (SBAR (WHADVP (WRB whenever)) (S (NP (DT a) (ADJP (RB recently) (VBN hospitalized)) (NN patient)) (VP (VBZ returns) (PP (IN with) (NP (NN Doc_11827497_2086_2101_Disease))))))))) (: ;) (S (NP (NP (NN therapy)) (PP (IN with) (NP (NP (JJ alternative) (NNS anticoagulants)) (, ,) (ADJP (RB not) (JJ Doc_11827497_2148_2155_Chemical)) (, ,)))) (VP (MD should) (VP (AUX be) (VP (VBN initiated))))) (. .)))
11838826	0	(S1 (NP (NP (NN Treatment)) (PP (IN of) (NP (NNP Doc_11838826_13_24_Chemical-induced) (NNP Doc_11838826_33_51_Disease))) (PP (IN with) (NP (NP (DT a) (JJ Doc_11838826_59_67_Chemical) (NN agonist)) (PP (IN in) (NP (NNS children))))) (. .)))
11838826	1	(S1 (S (NP (NP (NP (NNP Doc_11838826_101_112_Chemical)) (, ,) (NP (NP (DT a) (JJ potent) (NN antagonist)) (PP (IN of) (NP (DT both) (NN serotonergic)))) (PRN (-LRB- -LRB-) (NP (NN 5HT2A)) (-RRB- -RRB-))) (CC and) (NP (JJ dopaminergic) (NNP D2) (NNS receptors))) (VP (AUX is) (VP (VBN associated) (PP (IN with) (NP (NP (NNP Doc_11838826_212_230_Disease)) (PP (IN in) (NP (NNS adults) (CC and) (NNS children))))))) (. .)))
11838826	2	(S1 (S (NP (NP (ADJP (RB Chronically) (JJ elevated)) (NN prolactin) (NNS levels)) (PP (IN in) (NP (NP (NNS children)) (PP (IN with) (NP (NNP Doc_11838826_310_323_Disease)))))) (VP (MD may) (VP (AUX be) (VP (VBN associated) (PP (IN with) (NP (NP (VBN arrested) (NN growth)) (CC and) (NP (NP (NN development)) (VP (VBG resulting) (PP (IN in) (NP (DT either) (JJ Doc_11838826_399_414_Disease) (CC or) (JJ short) (NN stature)))))))))) (. .)))
11838826	3	(S1 (S (NP (DT These) (NNS possibilities)) (VP (VBP stress) (NP (NP (DT the) (NN importance)) (PP (IN of) (S (VP (VBG developing) (NP (NP (DT a) (ADJP (ADJP (JJ safe)) (CC and) (ADJP (JJ effective))) (NN approach)) (PP (TO to) (NP (JJ drug-induced) (NNP Doc_11838826_535_553_Disease))) (PP (IN in) (NP (NN youth))))))))) (. .)))
11838826	4	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT the) (JJ successful) (NN treatment)) (PP (IN of) (NP (NNP Doc_11838826_602_613_Chemical-induced) (NNP Doc_11838826_622_640_Disease))) (PP (IN with) (NP (NP (NNP Doc_11838826_646_657_Chemical)) (PP (IN in) (NP (NN youth))))))) (. .)))
11838826	5	(S1 (S (NP (PRP We)) (VP (VBD undertook) (NP (NP (DT a) (JJ retrospective) (NN case) (NN review)) (PP (IN of) (NP (NP (CD four) (NNS children)) (PP (IN with) (NP (NP (NNP Doc_11838826_740_751_Chemical-induced) (NNP Doc_11838826_760_778_Disease)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_11838826_792_803_Chemical)))))))))) (. .)))
11838826	6	(S1 (S (NP (NP (CD Four) (NNS males)) (PRN (-LRB- -LRB-) (NP (NN age) (NN 6-11) (NNS years)) (-RRB- -RRB-)) (PP (IN with) (NP (NP (NNP Diagnostic) (CC and) (NNP Statistical) (NNP Manual)) (PP (IN of) (NP (NNP Doc_11838826_884_900_Disease) (PRN (-LRB- -LRB-) (NP (JJ fourth) (NN edition)) (-RRB- -RRB-)) (NNP Doc_11838826_918_934_Disease) (CC or) (NNP Doc_11838826_938_947_Disease))))) (, ,) (PP (IN with) (NP (NP (JJ Doc_11838826_954_965_Chemical-induced) (NNS elevations)) (PP (IN in) (NP (NP (JJ serum) (NN prolactin) (NNS levels)) (PRN (-LRB- -LRB-) (NP (CD 57.5-129) (NNS ng/mL)) (, ,) (NP (JJ normal) (NN 5-15) (NNS ng/mL)) (-RRB- -RRB-)))))) (, ,)) (VP (AUX were) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_11838826_1066_1077_Chemical))) (PRN (-LRB- -LRB-) (NP (JJ mean) (NN dose)) (NP (CD 2.13) (NN +/-) (CD 0.09) (NN mg/week)) (-RRB- -RRB-)))) (. .)))
11838826	7	(S1 (S (SBAR (WHADVP (WRB When)) (S (NP (NN serum) (NN prolactin) (NNS levels)) (VP (VBD normalized) (PP (IN in) (NP (DT all) (CD four) (NNS subjects)))))) (PRN (-LRB- -LRB-) (VP (VB mean) (NP (CD 11.2) (NN +/-)) (NP (CD 10.9) (NN ng/mL))) (-RRB- -RRB-)) (, ,) (NP (DT the) (NNP Doc_11838826_1205_1216_Chemical) (NN dose)) (VP (AUX was) (VP (VBN reduced) (PP (TO to) (NP (CD 1) (NN mg/week))) (PP (IN in) (NP (NP (CD three)) (PP (IN of) (NP (CD four) (NNS subjects))))))) (. .)))
11838826	8	(S1 (S (S (NP (NP (DT The) (JJ mean) (NN duration)) (PP (IN of) (NP (NN therapy))) (PP (IN with) (NP (NNP Doc_11838826_1308_1319_Chemical)))) (VP (AUX was) (NP (NP (CD 523.5) (NN +/-)) (NP (CD 129.7) (NNS days))))) (, ,) (CC and) (S (NP (NP (DT the) (JJ mean) (NN duration)) (PP (IN of) (NP (NN therapy))) (PP (IN with) (NP (NNP Doc_11838826_1384_1395_Chemical)))) (VP (AUX was) (NP (NP (CD 788.5) (NN +/-)) (NP (CD 162.5) (NNS days))))) (. .)))
11838826	9	(S1 (S (NP (NN Doc_11838826_1422_1433_Chemical)) (VP (AUX was) (ADVP (RB well)) (VP (VBN tolerated) (PP (IN without) (NP (JJ adverse) (NNS effects))))) (. .)))
11838826	10	(S1 (S (S (NP (NN Doc_11838826_1491_1502_Chemical)) (VP (MD may) (VP (AUX be) (ADJP (JJ useful)) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (NNP Doc_11838826_1538_1549_Chemical-induced) (NNP Doc_11838826_1558_1576_Disease)) (PP (IN in) (NP (NN youth)))))))))) (: ;) (S (ADVP (RB however)) (, ,) (NP (JJ further) (NN research)) (VP (AUX is) (VP (VBN needed)))) (. .)))
11847945	0	(S1 (NP (NP (JJ Acute) (NN Doc_11847945_6_27_Disease)) (PP (IN after) (NP (NP (NN exposure)) (PP (TO to) (NP (NNP Doc_11847945_46_56_Chemical))))) (. .)))
11847945	1	(S1 (FRAG (S (VP (TO To) (VP (VB report) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (JJ acute) (NNP Doc_11847945_95_116_Disease))) (PP (VBG following) (NP (NP (NN exposure)) (PP (TO to) (NP (DT the) (JJ inhalational) (JJ anesthetic) (NN Doc_11847945_167_177_Chemical))))))))) (. .)))
11847945	2	(S1 (NP (NP (NN CASE) (NN SUMMARY)) (: :) (S (NP (NP (DT A) (JJ 70-year-old) (JJ healthy) (NN woman)) (PP (IN from) (NP (NNP Iraq)))) (VP (VBD developed) (NP (JJ acute) (NNP Doc_11847945_247_268_Disease) (CD 3) (NNS weeks)) (PP (VBG following) (NP (NP (NN repair)) (PP (IN of) (NP (DT the) (JJ right) (NN rotator))) (S (VP (VB cuff) (PP (IN under) (NP (JJ general) (NNS anesthesia))))))))) (. .)))
11847945	3	(S1 (S (NP (EX There)) (VP (AUX was) (NP (NP (DT no) (NN evidence)) (PP (IN for) (NP (NP (ADJP (ADJP (JJ viral)) (, ,) (ADJP (JJ autoimmune)) (, ,) (CC or) (ADJP (JJ metabolic))) (NNS causes)) (PP (IN of) (NP (NNP Doc_11847945_414_423_Disease))))))) (. .)))
11847945	4	(S1 (S (NP (DT No) (JJ other) (NNS medications)) (VP (AUX were) (VP (VBN involved) (PP (IN except) (PP (IN for) (NP (NP (NNP Doc_11847945_471_479_Chemical)) (PP (IN for) (NP (NNP Doc_11847945_484_493_Disease)))))))) (. .)))
11847945	5	(S1 (S (NP (DT The) (NNP Doc_11847945_499_506_Chemical) (NN aminotransferase)) (VP (AUX was) (ADJP (JJ elevated) (PP (TO to) (NP (NP (NP (DT a) (JJ peak) (NN concentration)) (PP (IN of) (NP (CD 1533) (NN U/L)))) (CC and) (NP (NP (DT the) (NN serum)) (SBAR (S (NP (NNP Doc_11847945_587_596_Chemical)) (VP (VBD reached) (NP (NP (DT a) (NN peak)) (PP (IN of) (NP (CD 17.0) (NN mg/dL)))))))))))) (. .)))
11847945	6	(S1 (S (NP (EX There)) (VP (AUX was) (NP (NP (JJ slow) (NN improvement)) (PP (IN over) (NP (CD 4) (NNS months))))) (. .)))
11847945	7	(S1 (S (NP (NP (JJ Accidental) (NN reexposure)) (PP (IN by) (NP (DT the) (NN patient))) (PP (TO to) (NP (NNP Doc_11847945_709_717_Chemical)))) (VP (AUX was) (ADJP (JJ uneventful))) (. .)))
11847945	8	(S1 (S (NP (NP (DT The) (ADJP (ADJP (JJ clinical)) (CC and) (ADJP (JJ histologic))) (NN picture)) (PP (IN of) (NP (DT this) (NN case)))) (VP (VBZ resembles) (NP (NP (JJ Doc_11847945_805_814_Chemical) (NN hepatitis)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX has) (NP (DT a) (JJ significant) (NN mortality) (NN rate))))))) (. .)))
11847945	9	(S1 (S (NP (NP (NNP Doc_11847945_879_889_Chemical)) (, ,) (NP (DT a) (JJ common) (JJ anesthetic) (NN agent)) (, ,)) (VP (MD can) (VP (VB cause) (NP (JJ severe) (NN Doc_11847945_935_956_Disease)))) (. .)))
11858397	0	(S1 (S (NP (NN Doc_11858397_0_18_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_11858397_30_44_Chemical))) (PP (IN in) (NP (DT an) (JJ elderly) (NN woman))) (PP (IN with) (S (VP (VBG preexisting) (NP (JJ complete) (NN Doc_11858397_91_115_Disease)))))) (. .)))
11858397	1	(S1 (S (NP (EX There)) (VP (AUX is) (NP (NP (DT a) (VBG growing) (NN list)) (PP (IN of) (NP (NP (NNS drugs)) (VP (VBN implicated) (PP (IN in) (NP (NP (VBN acquired) (NNP Doc_11858397_173_189_Disease)) (CC and) (NP (NNP Doc_11858397_194_212_Disease))))))))) (. .)))
11858397	2	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (JJ torsadogenic) (NN potential)) (PP (IN of) (NP (NP (NNP Doc_11858397_253_267_Chemical)) (, ,) (NP (NP (DT a) (ADJP (RB commonly) (VBN used)) (NN antiemetic)) (CC and) (NP (JJ prokinetic) (NN drug))) (, ,)))) (VP (AUX has) (RB not) (VP (AUX been) (VP (VBN reported) (PP (IN in) (NP (DT the) (NN literature))) (, ,) (PP (IN despite) (NP (NP (PRP$ its) (NN chemical) (NN similarity)) (PP (TO to) (NP (NNP Doc_11858397_393_405_Chemical)))))))) (. .)))
11858397	3	(S1 (S (NP (PRP We)) (VP (VBP report) (PP (IN on) (NP (NP (DT a) (JJ 92-year-old) (NN woman)) (PP (IN with) (S (VP (VBG preexisting) (NP (NP (JJ complete) (NNP Doc_11858397_466_490_Disease)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NN Doc_11858397_505_523_Disease)) (PP (IN after) (NP (NP (JJ intravenous) (CC and) (JJ oral) (NN administration)) (PP (IN of) (NP (NNP Doc_11858397_569_583_Chemical))))))))))))))) (. .)))
11858397	4	(S1 (S (NP (DT This) (NN patient)) (ADVP (RB also)) (VP (VBD developed) (NP (NN Doc_11858397_613_631_Disease)) (SBAR (WHADVP (WRB when)) (S (NP (NP (NNP Doc_11858397_637_646_Chemical)) (CC and) (NP (NNP Doc_11858397_651_663_Chemical))) (VP (AUX were) (VP (VBN given) (ADVP (RB simultaneously))))))) (. .)))
11858397	5	(S1 (S (NP (DT These) (CD two) (NNS episodes)) (VP (AUX were) (VP (VBN suppressed) (ADVP (RB successfully)) (PP (IN after) (S (VP (VP (VBG discontinuing) (NP (DT the) (VBG offending) (NNS drugs))) (CC and) (VP (VBG administering) (NP (NN class) (NN IB) (NNS drugs)))))))) (. .)))
11858397	6	(S1 (S (NP (DT This)) (VP (AUX is) (NP (NP (DT the) (JJ first) (NN documentation)) (SBAR (WHNP (WDT that)) (S (NP (NNP Doc_11858397_850_864_Chemical)) (VP (VBZ provokes) (NP (NNP Doc_11858397_874_892_Disease)) (ADVP (RB clinically))))))) (. .)))
11858397	7	(S1 (S (NP (NN Doc_11858397_905_919_Chemical)) (VP (MD should) (VP (AUX be) (VP (VBN used) (ADVP (RB cautiously)) (PP (IN in) (NP (NNS patients))) (PP (IN with) (NP (NP (DT a) (NN risk)) (PP (IN of) (NP (NNP Doc_11858397_973_991_Disease)))))))) (. .)))
11860278	0	(S1 (S (NP (NNP Doc_11860278_0_8_Chemical) (NNP D2) (NN receptor) (VBG signaling)) (VP (VBZ controls) (NP (NP (JJ neuronal) (NN cell) (NN death)) (VP (VBN induced) (PP (IN by) (NP (NP (NN muscarinic)) (CC and) (NP (JJ glutamatergic) (NNS drugs))))))) (. .)))
11860278	1	(S1 (S (NP (NP (NNP Doc_11860278_107_115_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP DA)) (-RRB- -RRB-))) (, ,) (PP (IN through) (NP (NNP D1/D2) (JJ receptor-mediated) (VBG signaling))) (, ,) (VP (VBZ plays) (NP (DT a) (JJ major) (NN role)) (PP (IN in) (NP (NP (DT the) (NN control)) (PP (IN of) (NP (NNP Doc_11860278_202_220_Disease))) (VP (VBG arising) (PP (IN in) (NP (DT the) (JJ limbic) (NN system))))))) (. .)))
11860278	2	(S1 (S (NP (NP (NN Excitotoxicity)) (VP (VBG leading) (PP (TO to) (NP (NP (JJ neuronal) (NN cell) (NN death)) (PP (IN in) (NP (DT the) (JJ affected) (NNS areas))))))) (VP (AUX is) (NP (NP (DT a) (JJ major) (NN consequence)) (PP (IN of) (NP (NNP Doc_11860278_345_353_Disease))) (PP (IN at) (NP (DT the) (JJ cellular) (NN level))))) (. .)))
11860278	3	(S1 (S (PP (IN In) (NP (DT this) (NN respect))) (, ,) (NP (RB little)) (VP (AUX is) (VP (VBN known) (PP (IN about) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NN DA) (NNS receptors))) (PP (IN in) (NP (NP (DT the) (NN occurrence)) (PP (IN of) (NP (JJ Doc_11860278_462_470_Disease-induced) (JJ neuronal) (NN cell) (NN death))))))))) (. .)))
11860278	4	(S1 (S (ADVP (RB Here)) (NP (PRP we)) (VP (VBP analyze) (NP (NP (DT the) (NN occurrence)) (PP (IN of) (NP (NNP Doc_11860278_534_542_Disease) (CC and) (NNP Doc_11860278_547_560_Disease))) (PP (IN in) (NP (NP (NNP D2R) (JJ -/-) (NNS mice)) (VP (VBN treated) (PP (IN with) (NP (DT the) (JJ cholinergic) (NN agonist) (NN Doc_11860278_614_625_Chemical)))))))) (. .)))
11860278	5	(S1 (S (NP (PRP We)) (VP (VBD compared) (NP (DT these) (NNS results)) (PP (IN with) (NP (NP (DT those)) (VP (ADVP (RB previously)) (VBN obtained) (PP (IN with) (NP (NP (NP (NNP Doc_11860278_689_700_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP KA)) (-RRB- -RRB-))) (, ,) (NP (DT a) (JJ potent) (JJ Doc_11860278_716_725_Chemical) (NN agonist)))))))) (. .)))
11860278	6	(S1 (S (ADVP (RB Importantly)) (, ,) (NP (NNP D2R) (NN -/-) (NNS mice)) (VP (VBP develop) (NP (NNP Doc_11860278_769_777_Disease)) (PP (IN at) (NP (NP (NNS doses)) (PP (IN of) (NP (NP (DT both) (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VP (AUX are) (RB not) (ADJP (JJ epileptogenic)) (PP (IN for) (NP (JJ WT) (NNS littermates)))) (CC and) (VP (VBP show) (NP (JJR greater) (NN Doc_11860278_864_877_Disease))))))))))) (. .)))
11860278	7	(S1 (S (ADVP (RB However)) (, ,) (NP (NNP Doc_11860278_888_899_Chemical-induced) (NNP Doc_11860278_908_916_Disease)) (VP (VBP result) (PP (IN in) (NP (NP (DT a) (ADJP (RBR more) (JJ widespread)) (JJ neuronal) (NN death)) (PP (IN in) (NP (DT both) (NNP WT) (CC and) (NNP D2R) (JJ -/-) (NNS brains))) (PP (IN in) (NP (NP (NN comparison)) (PP (TO to) (NP (CD KA)))))))) (. .)))
11860278	8	(S1 (S (ADVP (RB Thus)) (, ,) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (NNP D2R)))) (VP (VBZ lowers) (NP (NP (DT the) (NN threshold)) (PP (IN for) (NP (NP (NNP Doc_11860278_1061_1069_Disease)) (VP (VBN induced) (PP (IN by) (NP (DT both) (NNP Doc_11860278_1086_1095_Chemical) (CC and) (NNP Doc_11860278_1100_1113_Chemical)))))))) (. .)))
11860278	9	(S1 (S (ADVP (RB Moreover)) (, ,) (NP (NP (DT the) (JJ dopaminergic) (NN control)) (PP (IN of) (NP (JJ Doc_11860278_1153_1161_Disease-induced) (NNP Doc_11860278_1170_1187_Disease)))) (VP (VBZ seems) (S (VP (TO to) (VP (AUX be) (VP (VBN mediated) (PP (IN by) (NP (NP (JJ distinct) (NNS interactions)) (PP (IN of) (NP (NNP D2R) (VBG signaling))) (PP (IN with) (NP (DT these) (CD two) (NNS neurotransmitters)))))))))) (. .)))
11860495	0	(S1 (S (NP (JJ Doc_11860495_0_7_Chemical) (NN structure) (CC and) (NN pharmacological) (NNS properties)) (VP (VBP determine) (NP (NP (DT the) (JJ anti-Doc_11860495_68_75_Disease) (NNS effects)) (PP (IN of) (NP (NNP Doc_11860495_87_108_Chemical))) (PP (IN in) (NP (NP (DT the) (JJ passive) (NN avoidance) (NN task)) (PP (IN in) (NP (NNS rats))))))) (. .)))
11860495	1	(S1 (S (NP (NP (NNP Doc_11860495_148_169_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11860495_171_176_Chemical)) (-RRB- -RRB-))) (VP (AUX has) (VP (VBN generated) (NP (NN interest)) (SBAR (IN as) (S (NP (NP (CD one)) (PP (IN of) (NP (DT the) (ADJP (RBS most) (JJ potent)) (NN memory-enhancing)))) (VP (VBZ neurosteroids) (S (VP (TO to) (VP (AUX be) (VP (VBN examined) (PP (IN in) (NP (JJ rodent) (VBG learning) (NNS studies))))))) (, ,) (PP (IN with) (NP (JJ particular) (NN importance))) (PP (IN in) (NP (DT the) (JJ ageing) (NN process)))))))) (. .)))
11860495	2	(S1 (S (NP (NP (DT The) (NN mechanism)) (SBAR (WHPP (IN by) (WHNP (WDT which))) (S (NP (DT this) (JJ endogenous) (NN Doc_11860495_390_397_Chemical)) (VP (VBZ enhances) (NP (NN memory) (NN formation)))))) (VP (AUX is) (VP (VBN hypothesized) (S (VP (TO to) (VP (VB involve) (NP (NP (NNS actions)) (PP (IN on) (NP (ADJP (JJ glutamatergic) (CC and) (JJ GABAergic)) (NNS systems))))))))) (. .)))
11860495	3	(S1 (S (NP (DT This) (NN hypothesis)) (VP (VBZ stems) (PP (IN from) (NP (NNS findings))) (SBAR (IN that) (S (NP (NNP Doc_11860495_540_545_Chemical)) (VP (AUX is) (NP (NP (NP (DT a) (JJ potent) (JJ positive) (NN modulator)) (PP (IN of) (NP (NP (JJ Doc_11860495_580_600_Chemical) (NNS receptors)) (PRN (-LRB- -LRB-) (NP (NNS NMDARs)) (-RRB- -RRB-))))) (CC and) (NP (NP (DT a) (JJ negative) (NN modulator)) (PP (IN of) (NP (NP (NNP Doc_11860495_648_671_Chemical) (PRN (-LRB- -LRB-) (NP (DT A)) (-RRB- -RRB-)) (NNS receptors)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11860495_686_690_Chemical)) (-LRB- -LRB-) (NP (DT A) (-RRB- -RRB-) (NNP Rs)) (-RRB- -RRB-)))))))))) (. .)))
11860495	4	(S1 (S (ADVP (RB Moreover)) (, ,) (NP (NNP Doc_11860495_708_713_Chemical)) (VP (AUX is) (ADJP (JJ able) (S (VP (TO to) (VP (VB reverse) (NP (NP (DT the) (JJ Doc_11860495_737_744_Disease-like) (NNS effects)) (PP (IN of) (NP (ADJP (ADJP (JJ NMDAR) (CC and) (JJ Doc_11860495_771_775_Chemical)) (PRN (-LRB- -LRB-) (NP (DT A)) (-RRB- -RRB-))) (NN R) (NNS ligands))))))))) (. .)))
11860495	5	(S1 (S (S (VP (TO To) (VP (VB investigate) (NP (DT this) (NN hypothesis))))) (, ,) (NP (NP (DT the) (JJ present) (NN study)) (PP (IN in) (NP (NNS rats)))) (VP (VBD examined) (NP (NP (DT the) (JJ memory-altering) (NNS abilities)) (PP (IN of) (NP (NP (JJ structural) (NNS analogs)) (PP (IN of) (NP (NP (NNP Doc_11860495_911_916_Chemical)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBP differ) (PP (IN in) (NP (NP (PRP$ their) (NN modulation)) (PP (IN of) (NP (NNP NMDAR) (FW and/or) (NNP Doc_11860495_967_971_Chemical))))) (PRN (-LRB- -LRB-) (NP (DT A)) (-RRB- -RRB-)) (NP (NN R) (NN function))))))))))) (. .)))
11860495	6	(S1 (S (NP (NP (DT The) (NNS analogs)) (VP (VBN tested))) (VP (AUX were) (: :) (NP (NP (NNP Doc_11860495_1011_1039_Chemical) (PRN (-LRB- -LRB-) (NP (NP (DT an) (NN agent)) (SBAR (WHNP (WDT that)) (S (VP (AUX is) (ADJP (JJ inactive) (PP (IN at) (NP (NP (NP (NNP Doc_11860495_1070_1074_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (DT A) (-RRB- -RRB-) (NNP Rs)) (CC and) (NP (NNS NMDARs))) (-RRB- -RRB-))) (, ,) (NP (NNP Doc_11860495_1093_1108_Chemical))))) (PRN (-LRB- -LRB-) (NP (NNP Doc_11860495_1110_1155_Chemical)) (, ,) (NP (NP (NP (DT an) (NN inhibitor)) (PP (IN of) (NP (NP (DT both) (NNP Doc_11860495_1178_1182_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (DT A) (-RRB- -RRB-) (NNP Rs)) (CC and) (NP (NNS NMDARs))) (-RRB- -RRB-))))) (, ,) (CC and) (NP (DT a) (ADJP (ADJP (RB newly) (VBN synthesized)) (-LRB- -LRB-)))) (: -)))))) (-RRB- -RRB-)) (NNP Doc_11860495_1229_1234_Chemical) (NN enantiomer)) (PRN (-LRB- -LRB-) (SBAR (WHNP (WDT which)) (S (VP (AUX is) (ADJP (JJ identical) (PP (TO to) (NP (NP (NNP Doc_11860495_1269_1274_Chemical)) (PP (IN in) (NP (NP (NNS effects)) (PP (IN on) (NP (NNP Doc_11860495_1289_1293_Chemical))) (PRN (-LRB- -LRB-) (NP (NP (DT A) (-RRB- -RRB-) (NNP Rs)) (CC and) (NP (NNS NMDARs))) (-RRB- -RRB-))))))))))))) (. .)))
11860495	7	(S1 (S (NP (NP (DT The) (JJ memory-enhancing) (NNS effects)) (PP (IN of) (NP (NP (NNP Doc_11860495_1344_1349_Chemical)) (CC and) (NP (PRP$ its) (NNS analogs))))) (VP (AUX were) (VP (VBN tested) (PP (IN in) (NP (NP (DT the) (JJ passive) (NN avoidance) (NN task)) (VP (VBG using) (NP (NP (DT the) (NN model)) (PP (IN of) (NP (JJ Doc_11860495_1427_1438_Chemical-induced) (NN Doc_11860495_1447_1454_Disease))))))))) (. .)))
11860495	8	(S1 (S (NP (CC Both) (NP (NNP Doc_11860495_1461_1466_Chemical)) (CC and) (NP (PRP$ its) (-LRB- -LRB-) (: -) (-RRB- -RRB-) (NN enantiomer))) (VP (VBD blocked) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NNP Doc_11860495_1513_1524_Chemical))))) (. .)))
11860495	9	(S1 (S (NP (DT The) (NNS results)) (VP (VBP show) (SBAR (IN that) (S (, ,) (PP (IN unlike) (NP (NNP Doc_11860495_1556_1561_Chemical))) (, ,) (NP (NP (NNP Doc_11860495_1563_1591_Chemical)) (CC and) (NP (NNP Doc_11860495_1596_1620_Chemical))) (VP (VBD failed) (S (VP (TO to) (VP (VB block) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NNP Doc_11860495_1651_1662_Chemical))))))) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (S (VP (VBG altering) (NP (NP (DT the) (NN modulation)) (PP (IN of) (NP (JJ Doc_11860495_1707_1711_Chemical) (NNS receptors)))))) (VP (VBZ diminishes) (NP (NP (DT the) (JJ memory-enhancing) (NNS effects)) (PP (IN of) (NP (NNP Doc_11860495_1765_1770_Chemical))))))))))))) (. .)))
11860495	10	(S1 (S (ADVP (RB Moreover)) (, ,) (NP (NN enantioselectivity)) (VP (AUX was) (VP (VBN demonstrated) (PP (IN by) (NP (NP (DT the) (NN ability)) (PP (IN of) (NP (JJ natural) (NNP Doc_11860495_1844_1849_Chemical))) (S (VP (TO to) (VP (AUX be) (ADJP (NP (NP (DT an) (NN order)) (PP (IN of) (NP (NN magnitude)))) (RBR more) (JJ effective) (PP (IN than) (NP (NP (PRP$ its) (JJ synthetic) (NN enantiomer)) (PP (IN in) (S (VP (VBG reversing) (NP (JJ Doc_11860495_1936_1947_Chemical-induced) (NN Doc_11860495_1956_1963_Disease))))))))))))))) (. .)))
11860495	11	(S1 (S (NP (DT These) (NNS results)) (VP (VBP identify) (NP (NP (DT a) (JJ novel) (NN neuropharmacological) (NN site)) (PP (IN for) (NP (NP (DT the) (NN modulation)) (PP (IN of) (NP (NN memory) (NNS processes))) (PP (IN by) (NP (JJ neuroactive) (NNP Doc_11860495_2076_2084_Chemical))))))) (. .)))
11861791	0	(S1 (S (NP (NP (NN Activation)) (PP (IN of) (NP (JJ Doc_11861791_14_30_Chemical) (NN polymerase)))) (VP (VBZ contributes) (PP (TO to) (NP (NP (NN development)) (PP (IN of) (NP (NNP Doc_11861791_72_83_Chemical-induced) (NNP Doc_11861791_92_105_Disease)))))) (. .)))
11861791	1	(S1 (S (NP (NP (NN Activation)) (PP (IN of) (NP (NP (DT the) (JJ nuclear) (JJ enzyme) (JJ Doc_11861791_140_156_Chemical) (NN polymerase)) (PRN (-LRB- -LRB-) (NP (NNP PARP)) (-RRB- -RRB-)))) (PP (IN by) (NP (JJ oxidant-mediated) (NN DNA) (NN damage)))) (VP (AUX is) (NP (NP (DT an) (JJ important) (NN pathway)) (PP (IN of) (NP (NP (NN cell) (NN dysfunction)) (CC and) (NP (NN tissue) (NN injury))))) (PP (IN in) (NP (NP (NNS conditions)) (VP (VBN associated) (PP (IN with) (NP (JJ oxidative) (NN stress))))))) (. .)))
11861791	2	(S1 (S (NP (VBN Increased) (NN oxidative) (NN stress)) (VP (AUX is) (NP (NP (DT a) (JJ major) (NN factor)) (VP (VBN implicated) (PP (IN in) (NP (NP (DT the) (NNP Doc_11861791_379_393_Disease)) (PP (IN of) (NP (NP (NP (NNP Doc_11861791_397_408_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11861791_410_413_Chemical)) (-RRB- -RRB-))) (, ,) (NP (NP (DT a) (ADJP (RB widely) (VBN used)) (NN antitumor)) (ADJP (NNP Doc_11861791_440_453_Chemical) (JJ antibiotic)))))))))) (. .)))
11861791	3	(S1 (S (ADVP (RB Thus)) (, ,) (NP (PRP we)) (VP (VBN hypothesized) (SBAR (IN that) (S (NP (NP (DT the) (NN activation)) (PP (IN of) (NP (NNP PARP)))) (VP (MD may) (VP (VB contribute) (PP (TO to) (NP (DT the) (JJ Doc_11861791_538_541_Chemical-induced) (NN Doc_11861791_550_564_Disease)))))))) (. .)))
11861791	4	(S1 (S (S (VP (VBG Using) (NP (NP (DT a) (JJ dual) (NN approach)) (PP (IN of) (NP (JJ PARP-1) (NN suppression)))) (, ,) (PP (IN by) (NP (NP (JJ genetic) (NN deletion)) (CC or) (NP (JJ pharmacological) (NN inhibition)))) (PP (IN with) (NP (DT the) (NNP Doc_11861791_670_686_Chemical) (NNP PARP) (NN inhibitor) (NNP Doc_11861791_702_706_Chemical))))) (, ,) (NP (PRP we)) (ADVP (RB now)) (VP (VBP demonstrate) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NNP PARP))) (PP (IN in) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NP (NNP Doc_11861791_766_785_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_11861791_797_800_Chemical)))))))))) (. .)))
11861791	5	(S1 (S (NP (NN PARP-1+/+) (CC and) (NN PARP-1-/-) (NNS mice)) (VP (VBD received) (NP (NP (DT a) (JJ single) (NN injection)) (PP (IN of) (NP (NP (NNP Doc_11861791_862_865_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 25) (CD mg/kg)) (NNS i.p)) (-RRB- -RRB-)))))) (. .)))
11861791	6	(S1 (S (PP (NP (CD Five) (NNS days)) (IN after) (NP (NNP Doc_11861791_898_901_Chemical) (NN administration))) (, ,) (NP (JJ left) (NN ventricular) (NN performance)) (VP (VP (AUX was) (VP (ADVP (RB significantly)) (VBN depressed) (PP (IN in) (NP (JJ PARP-1+/+) (NNS mice))))) (, ,) (CC but) (VP (ADJP (RB only) (PP (TO to) (NP (DT a) (JJR smaller) (NN extent)))) (PP (IN in) (NP (JJ PARP-1-/-) (NNS ones))))) (. .)))
11861791	7	(S1 (S (NP (JJ Similar) (NNS experiments)) (VP (AUX were) (VP (VBN conducted) (PP (IN in) (NP (NP (JJ BALB/c) (NNS mice)) (VP (VBN treated) (PP (IN with) (NP (NP (NN Doc_11861791_1105_1109_Chemical)) (CC or) (NP (NN vehicle))))))))) (. .)))
11861791	8	(S1 (S (NP (NP (NN Treatment)) (PP (IN with) (NP (DT a) (NN Doc_11861791_1139_1143_Chemical)))) (VP (VP (ADVP (RB significantly)) (VBN improved) (NP (NNP Doc_11861791_1167_1186_Disease))) (CC and) (VP (VBD increased) (NP (NP (DT the) (NN survival)) (PP (IN of) (NP (DT the) (NNS animals)))))) (. .)))
11861791	9	(S1 (S (PP (IN In) (NP (NN addition))) (NP (NNP Doc_11861791_1242_1246_Chemical)) (VP (ADVP (RB significantly)) (VBD reduced) (NP (NP (NP (DT the) (JJ Doc_11861791_1273_1276_Chemical-induced) (NN increase)) (PP (IN in) (NP (NP (DT the) (JJ serum) (JJ Doc_11861791_1307_1314_Chemical) (NN dehydrogenase)) (CC and) (NP (JJ Doc_11861791_1333_1341_Chemical) (NN kinase) (NNS activities))))) (CC but) (NP (NP (RB not) (JJ metalloproteinase) (NN activation)) (PP (IN in) (NP (DT the) (NN heart)))))) (. .)))
11861791	10	(S1 (S (ADVP (RB Thus)) (, ,) (NP (NNP PARP) (NN activation)) (VP (VBZ contributes) (PP (TO to) (NP (NP (DT the) (NNP Doc_11861791_1452_1466_Disease)) (PP (IN of) (NP (NNP Doc_11861791_1470_1473_Chemical)))))) (. .)))
11861791	11	(S1 (S (NP (NN PARP) (NNS inhibitors)) (VP (MD may) (VP (VB exert) (NP (JJ protective) (NNS effects)) (PP (IN against) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (JJ severe) (NNP Doc_11861791_1554_1575_Disease))) (VP (VBN associated) (PP (IN with) (NP (DT the) (JJ Doc_11861791_1596_1599_Chemical) (NN treatment)))))))) (. .)))
11868798	0	(S1 (NP (NP (NN Doc_11868798_0_14_Chemical)) (: :) (SQ (AUX is) (NP (PRP it)) (NP (NP (DT a) (JJ novel) (NN drug)) (PP (IN for) (NP (NP (DT the) (NN prevention)) (PP (IN of) (NP (NNP Doc_11868798_57_71_Chemical-related) (NNP Doc_11868798_80_91_Disease))) (PP (IN in) (NP (NNP Doc_11868798_95_101_Disease) (NNS patients)))))) (. ?))))
11868798	1	(S1 (S (NP (NN Nephrotoxicity)) (VP (AUX is) (NP (NP (DT the) (JJ major) (JJ adverse) (NN effect)) (PP (IN of) (NP (NP (NNP Doc_11868798_169_183_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11868798_185_188_Chemical)) (-RRB- -RRB-))))) (, ,) (S (ADVP (RB often)) (VP (VBG limiting) (NP (NP (NN administration)) (PP (IN of) (NP (JJ full) (NN dosage))))))) (. .)))
11868798	2	(S1 (S (NP (JJ Selective) (JJ distal) (JJ tubular) (NN epithelial) (NN Doc_11868798_273_281_Disease)) (VP (VBZ seems) (S (VP (TO to) (VP (AUX be) (ADJP (JJ responsible) (PP (IN for) (NP (NP (DT the) (JJ profound) (JJ Doc_11868798_323_332_Chemical) (NN wasting)) (SBAR (WHNP (WDT that)) (S (VP (AUX is) (NP (NP (DT a) (JJ major) (JJ clinical) (NN side) (NN effect)) (PP (IN of) (NP (NN treatment))) (PP (IN with) (NP (NNP Doc_11868798_396_399_Chemical)))))))))))))) (. .)))
11868798	3	(S1 (S (NP (JJ Doc_11868798_401_410_Chemical) (NN depletion)) (ADVP (RB also)) (VP (VBZ potentiates) (NP (NP (DT the) (JJ tubular) (NN Doc_11868798_450_458_Disease)) (PP (IN of) (NP (NNP Doc_11868798_462_465_Chemical))))) (. .)))
11868798	4	(S1 (S (NP (DT This) (NN study)) (VP (AUX was) (VP (VBN designed) (S (VP (TO to) (VP (VB assess) (NP (NP (DT the) (NN ability)) (PP (IN of) (NP (NNP Doc_11868798_516_530_Chemical))) (S (VP (VP (TO to) (VP (VB reduce) (NP (JJ Doc_11868798_541_550_Chemical) (NNS requirements)))) (CC and) (VP (TO to) (VP (VB prevent) (NP (NP (NN Doc_11868798_579_590_Disease)) (PP (IN in) (NP (NP (JJ Doc_11868798_594_605_Disease) (NNS patients)) (PP (IN on) (NP (JJ Doc_11868798_618_621_Chemical) (NN treatment)))))))))))))))) (. .)))
11868798	5	(S1 (S (PP (IN In) (NP (DT this) (NN study))) (NP (NP (CD 26) (NNS patients)) (PP (IN with) (NP (JJ various) (NNP Doc_11868798_681_704_Disease)))) (VP (AUX were) (VP (VBN randomized) (S (VP (TO to) (VP (VP (VB receive) (NP (DT either) (JJ intravenous) (NN Doc_11868798_751_754_Chemical)) (ADVP (RB alone))) (CC or) (VP (NP (NP (NNP Doc_11868798_764_767_Chemical)) (CC and) (NP (JJ oral) (NNP Doc_11868798_777_791_Chemical) (CD 100))) (S (VP (VBG mg) (ADVP (RB twice) (RB daily)) (SBAR (WHADVP (WRB when)) (S (VP (VBG developing) (NP (DT a) (VBN proven) (CC or) (VBN suspected) (NN Doc_11868798_849_865_Disease))))))))))))) (. .)))
11868798	6	(S1 (S (NP (NP (NNS Patients)) (VP (VBG receiving) (NP (JJ concomitant) (NNP Doc_11868798_907_910_Chemical) (CC and) (NNP Doc_11868798_915_929_Chemical)))) (VP (AUX had) (NP (NP (ADJP (RB significantly) (JJR higher)) (NN plasma) (NN Doc_11868798_962_971_Chemical) (NNS levels)) (PP (IN than) (NP (NP (DT those)) (VP (VBG receiving) (NP (NNP Doc_11868798_1000_1003_Chemical)) (ADVP (RB alone)) (PRN (-LRB- -LRB-) (FRAG (X (FW P) (SYM =)) (NP (CD 0.0027))) (-RRB- -RRB-))))))) (. .)))
11868798	7	(S1 (S (NP (NP (DT Those) (NNS patients)) (VP (VBG receiving) (NP (NP (NNP Doc_11868798_1049_1052_Chemical)) (CC and) (NP (NNP Doc_11868798_1057_1071_Chemical))))) (VP (VBD required) (NP (ADJP (RB significantly) (JJR less)) (JJ Doc_11868798_1100_1109_Chemical) (NN supplementation)) (S (VP (TO to) (VP (VB maintain) (NP (PRP$ their) (NN plasma) (NN Doc_11868798_1151_1160_Chemical)) (PP (IN within) (NP (NP (DT the) (JJ normal) (NN range)) (PRN (-LRB- -LRB-) (NP (NNP P) (SYM =) (CD 0.022)) (-RRB- -RRB-)))))))) (. .)))
11868798	8	(S1 (S (ADVP (RB Moreover)) (, ,) (NP (JJ urinary) (JJ Doc_11868798_1216_1225_Chemical) (NNS losses)) (VP (AUX were) (ADJP (ADJP (RB significantly) (JJR less) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (NNP Doc_11868798_1279_1282_Chemical)) (CC and) (NP (NNP Doc_11868798_1287_1301_Chemical))))))) (PP (IN than) (NP (NP (DT those)) (VP (VBG receiving) (NP (NNP Doc_11868798_1323_1326_Chemical)) (ADVP (RB alone)))))) (PRN (-LRB- -LRB-) (NP (NNP P) (SYM =) (CD 0.040)) (-RRB- -RRB-))) (. .)))
11868798	9	(S1 (S (NP (DT This) (NN study)) (VP (VBD showed) (SBAR (IN that) (S (NP (NNP Doc_11868798_1381_1395_Chemical)) (VP (MD can) (VP (VP (VB reduce) (NP (JJ Doc_11868798_1407_1416_Chemical) (NNS requirements))) (CC and) (VP (VB prevent) (NP (NN Doc_11868798_1442_1453_Disease)) (PP (IN by) (S (VP (VBG reducing) (NP (NP (JJ urinary) (JJ Doc_11868798_1474_1483_Chemical) (NN loss)) (PP (IN in) (NP (NNP Doc_11868798_1492_1503_Disease) (NNS patients))) (PP (IN on) (NP (JJ Doc_11868798_1516_1519_Chemical) (NN treatment))))))))))))) (. .)))
11890511	0	(S1 (S (NP (NN Doc_11890511_0_20_Disease)) (VP (VBZ occurs) (NP (JJ following) (NN substantia) (NN nigra) (NNS lesions)) (PP (IN in) (NP (DT the) (NN rat)))) (. .)))
11890511	1	(S1 (S (NP (JJ Erectile) (NN function)) (VP (AUX was) (VP (VBN assessed) (NP (CD 6) (NNS weeks)) (PP (VBG following) (NP (NP (JJ uni-) (CC and) (JJ bilateral) (NNS injections)) (PP (IN of) (NP (NNP Doc_11890511_157_174_Chemical))) (PP (IN in) (NP (NP (DT the) (NN substantia) (NN nigra) (NN nucleus)) (PP (IN of) (NP (DT the) (NN brain))))))))) (. .)))
11890511	2	(S1 (S (NP (JJ Behavioral) (JJ Doc_11890511_232_243_Chemical-induced) (NN penile) (NNS erections)) (VP (VP (AUX were) (VP (VBN reduced) (PRN (-LRB- -LRB-) (NP (NN 5/8)) (-RRB- -RRB-)))) (CC and) (VP (VBD increased) (PRN (-LRB- -LRB-) (ADVP (RB 3/8)) (-RRB- -RRB-)) (PP (IN in) (NP (ADJP (JJ uni-) (CC and) (JJ bilateral)) (JJ lesioned) (NNS animals))))) (. .)))
11890511	3	(S1 (S (NP (NP (JJ Intracavernous) (NNS pressures)) (, ,) (PP (VBG following) (NP (NP (JJ electrical) (NN stimulation)) (PP (IN of) (NP (DT the) (JJ cavernous) (NN nerve))))) (, ,)) (VP (VBN decreased) (PP (IN in) (NP (JJ lesioned) (NNS animals)))) (. .)))
11890511	4	(S1 (S (NP (NP (NNS Lesions)) (PP (IN of) (NP (DT the) (JJ substantia) (NNS nigra)))) (VP (AUX were) (VP (VBN confirmed) (PP (IN by) (NP (NN histology))))) (. .)))
11890511	5	(S1 (S (NP (NP (NN Concentration)) (PP (IN of) (NP (NP (NNP Doc_11890511_540_548_Chemical)) (CC and) (NP (PRP$ its) (NNS metabolites))))) (VP (AUX were) (VP (VBN decreased) (PP (IN in) (NP (NP (DT the) (NN striatum)) (PP (IN of) (NP (NN substantia) (NN nigra) (JJ lesioned) (NNS rats))))))) (. .)))
11890511	6	(S1 (S (NP (NP (NNS Lesions)) (PP (IN of) (NP (DT the) (NN substantia) (NN nigra)))) (VP (VP (AUX are) (ADVP (RB therefore)) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_11890511_697_717_Disease))) (PP (IN in) (NP (NNS rats))))) (CC and) (VP (MD may) (VP (VB serve) (PP (IN as) (NP (NP (DT a) (NN model)) (SBAR (S (VP (TO to) (VP (VB study) (NP (NP (NN Doc_11890511_760_780_Disease)) (PP (IN in) (NP (NNP Doc_11890511_784_803_Disease))))))))))))) (. .)))
11900788	0	(S1 (NP (NP (JJ Doc_11900788_0_8_Chemical) (NN potentiation)) (PP (IN of) (NP (NP (NNP Doc_11900788_25_33_Chemical-induced) (NNP Doc_11900788_42_51_Disease)) (PP (IN in) (NP (NNS mice))))) (. .)))
11900788	1	(S1 (S (PP (IN In) (NP (DT the) (JJ present) (NN study))) (, ,) (NP (NP (NNS effects)) (PP (IN of) (NP (NNP Doc_11900788_94_102_Chemical))) (PP (IN on) (NP (NNP Doc_11900788_106_115_Disease))) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_11900788_127_135_Chemical))) (PP (IN in) (NP (NNS mice))))) (VP (AUX have) (VP (AUX been) (VP (VBN investigated)))) (. .)))
11900788	2	(S1 (S (S (ADJP (ADJP (JJ Doc_11900788_168_176_Chemical)) (CC but) (ADJP (RB not) (JJ Doc_11900788_185_193_Chemical)))) (VP (VBN induced) (NP (DT a) (JJ dose-dependent) (NN Doc_11900788_219_228_Disease))) (. .)))
11900788	3	(S1 (S (NP (NP (DT The) (NN response)) (PP (IN of) (NP (NNP Doc_11900788_246_254_Chemical)))) (VP (AUX was) (VP (VBN potentiated) (PP (IN by) (NP (NNP Doc_11900788_274_282_Chemical))))) (. .)))
11900788	4	(S1 (S (NP (NP (JJ Intraperitoneal) (NN administration)) (PP (IN of) (NP (NNP Doc_11900788_318_326_Chemical) (, ,) (NNP Doc_11900788_328_336_Chemical) (, ,) (NNP Doc_11900788_338_350_Chemical) (, ,) (CC and) (NNP Doc_11900788_356_369_Chemical))) (PP (TO to) (NP (NNS mice)))) (VP (VBD reduced) (NP (NP (NN Doc_11900788_386_395_Disease)) (VP (VBN induced) (PP (IN by) (NP (NP (DT a) (NN combination)) (PP (IN of) (NP (NP (NNP Doc_11900788_424_432_Chemical)) (PP (IN with) (NP (NNP Doc_11900788_438_446_Chemical)))))))))) (. .)))
11900788	5	(S1 (S (NP (NP (JJ Intracerebroventricular) (NN injection)) (PP (IN of) (NP (NP (NNP Doc_11900788_485_493_Chemical)) (, ,) (NP (NNP Doc_11900788_495_508_Chemical)) (, ,) (CC and) (NP (NNP Doc_11900788_514_522_Chemical))))) (ADVP (RB also)) (VP (VBD decreased) (NP (NP (NN Doc_11900788_538_547_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_11900788_559_567_Chemical) (CC plus) (NNP Doc_11900788_573_581_Chemical)))))) (. .)))
11900788	6	(S1 (S (NP (NP (NP (JJ Intraperitoneal) (NN administration)) (PP (IN of) (NP (NNP Doc_11900788_617_625_Chemical)))) (, ,) (CC but) (NP (NP (RB not) (JJ intraperitoneal) (CC or) (JJ intracerebroventricular) (NN injection)) (PP (IN of) (NP (NNP Doc_11900788_691_704_Chemical)))) (, ,)) (VP (VBD decreased) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (DT a) (JJ single) (NN dose)) (PP (IN of) (NP (NNP Doc_11900788_747_755_Chemical))))))) (. .)))
11900788	7	(S1 (S (NP (PRP It)) (VP (AUX was) (VP (VBN concluded) (SBAR (IN that) (S (S (NP (NNP Doc_11900788_779_787_Chemical) (NNP Doc_11900788_788_797_Disease)) (VP (MD can) (VP (AUX be) (VP (VBN elicited) (PP (IN by) (NP (NP (NN opioid)) (CC and) (NP (JJ cholinergic) (NNS receptors)))))))) (, ,) (CC and) (S (NP (NP (DT the) (NN potentiation)) (PP (IN of) (NP (NNP Doc_11900788_875_883_Chemical))) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_11900788_895_903_Chemical))))) (VP (MD may) (ADVP (RB also)) (VP (AUX be) (VP (VBN mediated) (PP (IN through) (NP (JJ cholinergic) (NN receptor) (NNS mechanisms))))))))))) (. .)))
11912119	0	(S1 (NP (NP (NP (NN Force) (NN overflow)) (CC and) (NP (JJ Doc_11912119_19_27_Chemical-induced) (NNS dyskinesias))) (PP (IN in) (NP (NNP Doc_11912119_51_70_Disease))) (. .)))
11912119	1	(S1 (S (NP (PRP We)) (VP (VBD assessed) (NP (NP (NP (NN force) (NN coordination)) (PP (IN of) (NP (NP (DT the) (NN hand)) (PP (IN in) (NP (NNP Doc_11912119_118_137_Disease)))))) (CC and) (NP (NP (PRP$ its) (NN relationship)) (PP (TO to) (NP (NP (NN motor) (NNS complications)) (PP (IN of) (NP (JJ Doc_11912119_185_193_Chemical) (NN therapy))))))) (, ,) (PP (ADVP (RB particularly)) (TO to) (NP (NP (JJ Doc_11912119_219_227_Chemical-induced) (NNS dyskinesias)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11912119_249_252_Disease)) (-RRB- -RRB-))))) (. .)))
11912119	2	(S1 (S (NP (PRP We)) (VP (VBD studied) (NP (NP (CD two) (NNS groups)) (PP (IN of) (NP (NNP Doc_11912119_280_299_Disease) (NNS patients)))) (PP (IN with) (PRN (-LRB- -LRB-) (NP (NP (NNP Doc_11912119_315_334_Disease) (NNP +) (NNP Doc_11912119_337_340_Disease)) (, ,) (NP (NNP n) (SYM =) (CD 23))) (-RRB- -RRB-)) (CC and) (PP (IN without) (NP (NP (NP (JJ Doc_11912119_362_370_Chemical-induced) (NNS dyskinesias)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11912119_392_411_Disease)) (: -) (NP (NP (NNP Doc_11912119_414_417_Disease)) (, ,) (NP (NNP n) (SYM =) (CD 10))) (-RRB- -RRB-))) (, ,) (CC and) (NP (JJ age-matched) (JJ healthy) (NNS controls)))))) (. .)))
11912119	3	(S1 (S (NP (NP (DT The) (NN motor) (NN score)) (PP (IN of) (NP (NP (DT the) (JJ Unified) (NNP Doc_11912119_493_512_Disease) (NN Rating) (NN Scale)) (, ,) (NP (DT a) (NNP Doc_11912119_529_539_Disease) (NN score)) (CC and) (NP (NN force)))) (PP (IN in) (NP (DT a) (JJ grip-lift) (NN paradigm)))) (VP (AUX were) (VP (VBN assessed) (PP (IN ON) (CC and) (IN OFF) (NP (NNP Doc_11912119_605_613_Chemical))))) (. .)))
11912119	4	(S1 (S (NP (NP (DT A) (JJ pathological) (NN increase)) (PP (IN of) (NP (NNS forces)))) (VP (AUX was) (VP (VBN seen) (PP (IN in) (NP (NN ON-state))) (PP (IN in) (NP (NP (NNP Doc_11912119_673_692_Disease) (NNP +) (NNP Doc_11912119_695_698_Disease)) (ADVP (RB only)))))) (. .)))
11912119	5	(S1 (S (PP (IN In) (NP (NNP Doc_11912119_708_727_Disease) (NNP +) (NNP Doc_11912119_730_733_Disease))) (, ,) (NP (NP (DT the) (NN force)) (VP (VBN involved) (PP (IN in) (S (VP (VBG pressing) (PRT (RP down)) (NP (DT the) (NN object)) (PP (IN before) (NP (NN lifting)))))))) (VP (AUX was) (ADVP (RB significantly)) (VP (VBN increased) (PP (IN by) (NP (NP (NNP Doc_11912119_828_836_Chemical)) (PRN (-LRB- -LRB-) (PP (IN by) (NP (CD 61) (NN %))) (, ,) (NP (NNP P) (NNP <) (CD 0.05)) (-RRB- -RRB-)))))) (. .)))
11912119	6	(S1 (S (NP (NP (DT An) (NN overshooting)) (PP (IN of) (NP (JJ peak) (NN grip) (NN force))) (PP (PP (IN by) (NP (NP (CD 51) (NN %)) (PRN (-LRB- -LRB-) (NP (QP (CD P) (CD <)) (CD 0.05)) (-RRB- -RRB-)))) (CC and) (PP (IN of) (NP (JJ static) (NN grip) (NN force)))) (PP (IN by) (NP (CD 45) (NN %))) (PRN (-LRB- -LRB-) (NP (QP (CD P) (CD <)) (CD 0.01)) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN observed) (PP (IN in) (NP (DT the) (NN ON-))) (PP (VBN compared) (PP (IN with) (NP (DT the) (JJ OFF-drug) (NN condition)))))) (. .)))
11912119	7	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (DT no) (JJ excessive) (NN force)) (VP (AUX was) (VP (VBN found) (PP (IN in) (NP (NP (NNP Doc_11912119_1060_1079_Disease)) (: -) (NP (NNP Doc_11912119_1082_1085_Disease)))))) (. .)))
11912119	8	(S1 (S (NP (NP (JJ Peak) (NN grip) (NN force)) (PP (IN in) (NP (NN ON-state)))) (VP (AUX was) (ADVP (NP (NP (CD 140) (NN %)) (PRN (-LRB- -LRB-) (NP (QP ($ P) (CD <) (CD 0.05))) (-RRB- -RRB-))) (JJR higher)) (PP (IN in) (NP (NNP Doc_11912119_1145_1164_Disease) (NNP +) (NNP Doc_11912119_1167_1170_Disease))) (PP (IN than) (PP (IN in) (NP (NP (NNP Doc_11912119_1179_1198_Disease)) (: -) (NP (NNP Doc_11912119_1201_1204_Disease))))) (, ,) (SBAR (IN while) (S (NP (JJ static) (NN grip) (NN force)) (VP (AUX was) (VP (VBN increased) (PP (IN by) (NP (NP (CD 138) (NN %)) (PRN (-LRB- -LRB-) (NP (QP ($ P) (CD <) (CD 0.01))) (-RRB- -RRB-)))) (PP (IN between) (NP (NNS groups)))))))) (. .)))
11912119	9	(S1 (S (NP (NP (NN Severity)) (PP (IN of) (NP (JJ peak-dose) (NNP Doc_11912119_1301_1312_Disease)))) (VP (AUX was) (ADVP (RB strongly)) (VP (VBN correlated) (PP (IN with) (NP (NN grip) (NN force))) (PP (IN in) (NP (NP (NN ON-state)) (PRN (-LRB- -LRB-) (NP (NP (NP (SYM r)) (NP (SYM =) (CD 0.79))) (PP (IN with) (NP (NN peak) (NN force)))) (, ,) (NP (QP ($ P) (CD <) (CD 0.01))) (-RRB- -RRB-)))))) (. .)))
11912119	10	(S1 (S (NP (DT No) (NN correlation)) (VP (AUX was) (VP (VBN observed) (PP (IN between) (NP (NP (NNS forces)) (CC and) (NP (DT the) (NN motor) (NN score)))) (PP (CONJP (RB as) (RB well) (IN as)) (PP (IN with) (NP (NP (DT the) (JJ daily) (NN dose)) (PP (IN of) (NP (JJ dopaminergic) (NN medication)))))))) (. .)))
11912119	11	(S1 (S (NP (NN Force) (NN excess)) (VP (AUX was) (ADVP (RB only)) (VP (VBN observed) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NNP Doc_11912119_1573_1576_Disease)) (CC and) (NP (NN motor) (NNS fluctuations)))))))) (. .)))
11912119	12	(S1 (S (NP (DT A) (JJ close) (NN relationship)) (VP (AUX was) (VP (VBN seen) (PP (IN between) (NP (NP (DT the) (NN overshooting)) (PP (IN of) (NP (NP (NNS forces)) (CC and) (NP (NNP Doc_11912119_1670_1681_Disease)))) (PP (IN in) (NP (DT the) (JJ ON-drug) (NN condition))))))) (. .)))
11912119	13	(S1 (S (NP (PRP We)) (VP (VBP postulate) (SBAR (IN that) (S (NP (DT both) (NP (NNP Doc_11912119_1731_1734_Disease)) (CC and) (NP (NN grip))) (VP (VBP force) (NP (NP (JJ excess) (NN share) (JJ common) (JJ pathophysiological) (NNS mechanisms)) (VP (VBN related) (PP (TO to) (NP (NN motor) (NNS fluctuations))))))))) (. .)))
11999899	0	(S1 (NP (NP (NP (JJ Behavioral) (NNS effects)) (PP (IN of) (NP (NNP Doc_11999899_22_28_Chemical))) (PP (IN on) (NP (JJ Doc_11999899_32_41_Chemical-treated) (NNS mice)))) (. .)))
11999899	1	(S1 (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NP (NP (NNP Doc_11999899_71_82_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11999899_84_90_Chemical)) (-RRB- -RRB-))) (, ,) (NP (DT a) (JJ noncompetitive) (NNP Doc_11999899_110_130_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_11999899_132_136_Chemical)) (-RRB- -RRB-)) (NN receptor) (NN antagonist)) (, ,)))) (VP (AUX were) (VP (VBN studied) (PP (IN on) (NP (NP (JJ Doc_11999899_175_183_Chemical-related) (NNS behaviors)) (VP (VBN induced) (PP (IN by) (NP (JJ Doc_11999899_213_222_Chemical) (NNS treatments)))))))) (. .)))
11999899	2	(S1 (S (NP (DT This) (NN study)) (VP (VBZ focuses) (PP (IN on) (NP (NP (JJ behavioral) (NNS syndromes)) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VBN used) (PP (IN as) (NP (NP (NP (NNS models)) (PP (IN for) (NP (NP (NNP Doc_11999899_306_325_Disease)) (, ,) (CC or) (NP (NNP Doc_11999899_330_348_Disease)) (, ,)))) (CC and) (NP (NP (PRP$ its) (NN response)) (PP (IN after) (NP (JJ glutamatergic) (NN blockage))))))))))))) (. .)))
11999899	3	(S1 (S (NP (NP (NNP Doc_11999899_397_406_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 1) (NN mg/kg)) (-RRB- -RRB-)) (, ,) (VP (VBN administered) (PP (IN once) (NP (NP (DT every) (JJ other) (NN day)) (PP (IN for) (NP (CD 4) (NNS days)))))) (, ,)) (VP (VBD produced) (NP (NP (NNS increases)) (PP (IN in) (NP (NP (NNP Doc_11999899_486_506_Disease)) (, ,) (NP (NP (NP (NN tongue) (NN protrusion)) (CC and) (NP (JJ vacuous) (VBG chewing))) (PP (IN in) (NP (NNS mice)))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX are) (NP (NP (NNS signs)) (ADJP (JJ indicative) (PP (IN of) (NP (NNP Doc_11999899_585_603_Disease)))))))))))) (. .)))
11999899	4	(S1 (S (NP (NN Doc_11999899_605_614_Chemical)) (ADVP (RB also)) (VP (VBD produced) (NP (NP (NP (NNP Doc_11999899_629_635_Disease)) (CC and) (NP (NNP Doc_11999899_640_649_Disease))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX are) (NP (NP (NNS signs)) (PP (JJ suggestive) (IN of) (NP (NNP Doc_11999899_681_700_Disease))))))))) (. .)))
11999899	5	(S1 (S (NP (NP (NN Doc_11999899_702_708_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 0.1) (NN mg/kg)) (-RRB- -RRB-))) (, ,) (S (VP (VBN administered) (NP (CD 30) (NN min)) (PP (IN before) (NP (DT the) (JJ observation) (NN test))))) (, ,) (VP (VBD prevented) (NP (NP (DT the) (JJ vacuous) (VBG chewing) (NNS movements)) (, ,) (NP (NN tongue) (NNS protrusions)) (CC and) (NP (NP (NNP Doc_11999899_835_844_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_11999899_856_865_Chemical))))))) (. .)))
11999899	6	(S1 (S (ADVP (RB However)) (, ,) (NP (JJ Doc_11999899_876_882_Chemical) (NN injection)) (VP (VBD produced) (NP (NP (DT a) (JJ significant) (NN increase)) (PP (IN of) (NP (NNP Doc_11999899_928_934_Disease))) (PP (IN in) (NP (JJ Doc_11999899_938_947_Chemical-treated) (NNS mice))))) (. .)))
11999899	7	(S1 (S (NP (NP (NP (NNP Doc_11999899_962_971_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 1) (CD mg/kg))) (-RRB- -RRB-))) (, ,) (VP (VP (VBN administered) (NP (CD 90) (NN min)) (PP (IN before) (NP (DT the) (NN test)))) (CC and) (VP (VBN followed) (PP (IN by) (NP (NP (JJ Doc_11999899_1035_1045_Chemical) (NN injection)) (PRN (-LRB- -LRB-) (NP (CD 0.1) (NN mg/kg)) (-RRB- -RRB-)))) (NP (CD 5) (NN min)) (PP (IN before) (NP (DT the) (NN test))))) (, ,)) (VP (AUX did) (RB not) (VP (VB produce) (NP (NNP Doc_11999899_1107_1122_Disease)) (PP (IN in) (NP (NNS mice))))) (. .)))
11999899	8	(S1 (S (PP (IN On) (NP (DT the) (JJ other) (NN hand))) (, ,) (NP (NP (NNP Doc_11999899_1151_1160_Chemical) (VBN induced) (NNS increases)) (PP (IN in) (NP (NP (NNP Doc_11999899_1182_1188_Disease)) (CC and) (NP (NNP Doc_11999899_1193_1202_Disease))))) (VP (VBN compared) (S (VP (TO to) (VP (VB control) (NP (NNS mice)))))) (. .)))
11999899	9	(S1 (S (NP (JJ Doc_11999899_1229_1235_Chemical) (PRN (-LRB- -LRB-) (NP (CD 0.1) (NN mg/kg)) (-RRB- -RRB-)) (NN administration)) (VP (VBD attenuated) (NP (NP (DT the) (NNP Doc_11999899_1278_1287_Disease) (CC and) (NNP Doc_11999899_1292_1298_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_11999899_1310_1319_Chemical)))))) (. .)))
11999899	10	(S1 (S (NP (NP (NP (NN Pretreatment)) (PP (IN with) (NP (NNP Doc_11999899_1339_1348_Chemical)))) (PRN (-LRB- -LRB-) (NP (CD 1) (NN mg/kg)) (-RRB- -RRB-)) (NP (CD 24) (NNP h)) (PP (IN before) (NP (DT the) (NN observation) (NN test)))) (VP (VBD produced) (NP (NP (NP (NNS increases)) (PP (IN in) (NP (NP (JJ vacuous) (VBG chewing) (NNS movements)) (CC and) (NP (NN tongue) (NN protrusion))))) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (NP (NNS increases)) (PP (IN in) (NP (NNP Doc_11999899_1487_1493_Disease) (CC and) (NNP Doc_11999899_1498_1507_Disease)))) (, ,)) (PP (IN whereas) (NP (NNP Doc_11999899_1517_1523_Chemical) (PRN (-LRB- -LRB-) (NP (CD 0.1) (NNS mg/kg)) (-RRB- -RRB-)) (NN injection))) (NP (CD 90) (NN min)) (SBAR (IN before) (S (NP (DT the) (NN test)) (VP (VBD reversed) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NNP Doc_11999899_1593_1602_Chemical)))))))) (. .)))
11999899	11	(S1 (S (NP (DT These) (NNS results)) (VP (VBP show) (SBAR (IN that) (S (NP (NNP Doc_11999899_1628_1637_Chemical)) (VP (VBZ produces) (ADJP (ADJP (JJ different)) (CC and) (ADJP (JJ Doc_11999899_1661_1679_Disease))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VP (AUX are) (ADJP (VBN related) (PP (TO to) (NP (NP (NN dose) (CC and) (NN schedule)) (VP (VBN employed)))))) (CC and) (VP (MD can) (VP (AUX be) (VP (VBN considered) (PP (IN as) (NP (NNP Doc_11999899_1754_1766_Disease-like) (CC and) (NNP Doc_11999899_1776_1794_Disease) (NNS signs))))))))))))) (. .)))
11999899	12	(S1 (S (NP (NP (DT The) (JJ glutamatergic) (NN blockage)) (VP (VBN produced) (PP (IN by) (NP (NNP Doc_11999899_1841_1845_Chemical))))) (VP (MD can) (VP (VB restore) (NP (NP (DT these) (NNS signs)) (, ,) (PP (JJ such) (IN as) (NP (NP (JJ vacuous) (VBG chewing) (NNS movements)) (, ,) (NP (NN tongue) (NNS protrusions)) (, ,) (NP (NNP Doc_11999899_1926_1935_Disease)) (CC and) (NP (NNP Doc_11999899_1940_1946_Disease))))) (PP (VBG according) (PP (TO to) (NP (DT the) (VBN employed) (NN model)))))) (. .)))
12013711	0	(S1 (NP (NP (JJ Doc_12013711_0_11_Chemical-associated) (, ,) (JJ benign) (JJ transient) (NNP Doc_12013711_41_60_Disease)) (PP (IN in) (NP (NP (JJ Doc_12013711_64_77_Disease) (NNS patients)) (PP (IN with) (NP (NP (DT a) (JJ past) (NN history)) (PP (IN of) (NP (NN LSD) (NN abuse))))))) (. .)))
12013711	1	(S1 (S (NP (NP (CD Two) (JJ Doc_12013711_125_138_Disease) (NNS patients)) (, ,) (SBAR (SBAR (WHNP (WP who)) (S (VP (AUX had) (NP (NP (DT a) (JJ prior) (NN history)) (PP (IN of) (NP (CD LSD) (NN abuse))))))) (CC and) (SBAR (WHNP (WP who)) (S (VP (AUX had) (ADVP (RB previously)) (VP (VBN developed) (NP (NNP Doc_12013711_219_222_Disease)) (PP (IN with) (NP (JJ classic) (NNS antipsychotics)))))))) (, ,)) (VP (AUX were) (ADVP (RB successfully)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_12013711_283_294_Chemical))))) (. .)))
12013711	2	(S1 (S (NP (PRP They)) (DT both) (VP (VBD reported) (NP (NP (JJ short) (NNS episodes)) (PP (IN of) (NP (JJ transient) (NNP Doc_12013711_343_362_Disease))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD appeared) (ADVP (RB immediately)) (PP (IN after) (S (VP (VBG starting) (NP (NN treatment)) (PP (IN with) (NP (NNP Doc_12013711_421_432_Chemical))))))))))) (. .)))
12013711	3	(S1 (S (NP (DT This) (NN imagery)) (VP (VBD resembled) (SBAR (S (NP (NNP Doc_12013711_457_476_Disease)) (ADVP (RB previously)) (VP (VBN experienced) (PP (IN as) (NP (NP (`` ``) (NNS flashbacks) ('' '')) (VP (VBN related) (PP (TO to) (NP (JJ prior) (NN LSD) (NN consumption)))))))))) (. .)))
12013711	4	(S1 (S (S (NP (JJ Doc_12013711_550_561_Chemical) (NN administration)) (VP (AUX was) (VP (VBN continued)))) (CC and) (S (NP (DT the) (NN Doc_12013711_599_618_Disease)) (ADVP (RB gradually)) (VP (VBD wore) (PRT (RP off)))) (. .)))
12013711	5	(S1 (S (PP (IN During) (NP (DT a) (JJ six-month) (JJ follow-up) (NN period))) (, ,) (NP (EX there)) (VP (AUX was) (NP (NP (DT no) (NN recurrence)) (PP (IN of) (NP (NNP Doc_12013711_703_722_Disease))))) (. .)))
12013711	6	(S1 (S (NP (DT This) (NN phenomenon)) (VP (MD may) (VP (AUX be) (VP (VBN interpreted) (PP (IN as) (NP (NP (DT a) (ADJP (ADJP (JJ benign)) (, ,) (ADJP (JJ short-term)) (CC and) (ADJP (JJ self-limiting))) (NN side) (NN effect)) (SBAR (WHNP (WDT which)) (S (VP (AUX does) (RB not) (VP (VP (VB contraindicate) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NNP Doc_12013711_854_865_Chemical))))) (CC or) (VP (VB interfere) (PP (IN with) (NP (NN treatment))))))))))))) (. .)))
12013711	7	(S1 (S (NP (NP (NNS Conclusions)) (VP (VBN based) (PP (IN on) (NP (CD two) (NN case) (NNS reports))))) (VP (MD should) (VP (AUX be) (VP (VBN taken) (PP (IN with) (NP (JJ appropriate) (NN caution)))))) (. .)))
12042105	0	(S1 (NP (JJ Doc_12042105_0_10_Chemical-induced) (NN Doc_12042105_19_34_Disease) (. .)))
12042105	1	(S1 (S (NP (NN Doc_12042105_36_46_Chemical)) (VP (AUX is) (NP (NP (DT a) (ADJP (RB recently) (VBN developed)) (JJ antiepileptic) (NN medication)) (SBAR (WHNP (WDT that)) (S (VP (AUX is) (VP (VBG becoming) (NP (NP (JJR more)) (VP (ADVP (RB widely)) (VBN prescribed) (PP (IN because) (IN of) (NP (PRP$ its) (NN efficacy))) (PP (IN in) (S (VP (VBG treating) (NP (NNP Doc_12042105_172_191_Disease))))))))))))) (. .)))
12042105	2	(S1 (S (NP (NNS Urologists)) (VP (MD should) (VP (AUX be) (ADJP (JJ aware) (SBAR (IN that) (S (NP (DT this) (NN medication)) (VP (MD can) (VP (VB cause) (NP (NN Doc_12042105_251_269_Disease)) (PP (IN in) (NP (NP (NNS patients)) (ADJP (JJ secondary) (PP (TO to) (NP (NP (NN inhibition)) (PP (IN of) (NP (JJ carbonic) (NN anhydrase))))))))))))))) (. .)))
12042105	3	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (DT a) (JJ distal) (JJ tubular) (NN acidification) (NN defect)) (VP (MD may) (VP (VB result) (, ,) (S (ADVP (RB thus)) (VP (VBG impairing) (NP (NP (DT the) (JJ normal) (JJ compensatory) (NN drop)) (PP (IN in) (NP (NN urine) (NNP pH.))) (SBAR (S (NP (DT These) (NNS factors)) (VP (MD can) (VP (VB lead) (PP (TO to) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_12042105_494_511_Chemical) (NNP Doc_12042105_512_527_Disease)))))))))))))) (. .)))
12042105	4	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT the) (JJ first) (CD two) (NNS cases)) (PP (IN of) (NP (NNP Doc_12042105_562_572_Chemical-induced) (NNP Doc_12042105_581_596_Disease))) (PP (IN in) (NP (DT the) (JJ urologic) (NN literature))))) (. .)))
12091028	0	(S1 (NP (NP (NN Doc_12091028_0_8_Chemical)) (PP (IN in) (NP (NP (JJ war/tropical) (NN surgery)) (PRN (-LRB- -LRB-) (NP (NP (DT a) (JJ final) (NN tribute)) (PP (TO to) (NP (DT the) (JJ racemic) (NN mixture)))) (-RRB- -RRB-)))) (. .)))
12091028	1	(S1 (S (NP (NP (DT A) (NN technique)) (PP (IN of) (NP (NP (JJ continuous) (JJ intravenous) (NNS anaesthesia)) (PP (IN with) (NP (NNP Doc_12091028_130_138_Chemical)))))) (VP (VP (AUX was) (VP (VBN used) (ADVP (RB successfully)) (PP (IN during) (NP (DT the) (NNP Somalia) (JJ civil) (NN war))) (PP (IN in) (NP (CD 1994))))) (CC and) (VP (PP (IN in) (NP (JJ north) (NNP Uganda))) (PP (IN in) (NP (CD 1999))) (PP (IN for) (NP (NP (CD 64) (NNS operations)) (PP (IN in) (NP (CD 62) (NNS patients))) (, ,) (VP (VBN aged) (PP (IN from) (NP (QP (CD 6) (NNS weeks) (TO to) (CD 70)) (NNS years)))) (, ,) (PP (VBG undergoing) (NP (NP (NN limb) (CC and) (NN abdominal) (NN surgery)) (PP (VBG including) (NP (NP (JJ caesarian) (NNS sections)) (CC and) (NP (NP (NNS interventions)) (PP (IN in) (NP (NNS neonates)))))))))))) (. .)))
12091028	2	(S1 (S (NP (NP (NNS Operations)) (VP (VBG lasting) (PRT (RP up)) (PP (TO to) (NP (CD 2h))))) (VP (MD could) (VP (AUX be) (VP (VBN performed) (PP (IN in) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (NP (JJ sophisticated) (NN equipment)) (PP (JJ such) (IN as) (NP (NP (NN pulse) (NNS oximeters)) (CC or) (NP (NP (NNS ventilators)) (PP (IN in) (NP (NNS patients)))))))))) (PP (IN on) (NP (NP (JJ spontaneous) (NN ventilation) (NN breathing) (NN air/Doc_12091028_570_576_Chemical)) (ADVP (RB only))))))) (. .)))
12091028	3	(S1 (S (PP (IN After) (NP (NP (NP (NN premedication)) (PP (IN with) (NP (NP (NNP Doc_12091028_608_616_Chemical)) (, ,) (NP (NNP Doc_12091028_618_632_Chemical)) (CC and) (NP (JJ local) (NNS anaesthesia))))) (, ,) (CC and) (NP (NP (NN induction)) (PP (IN with) (NP (NP (JJ standard) (NNS doses)) (PP (IN of) (NP (NNP Doc_12091028_693_701_Chemical)))))))) (, ,) (NP (NP (DT a) (NN maintenance) (NN dose)) (PP (IN of) (NP (NP (CD 10-20) (NN microg/kg/min)) (PP (IN of) (NP (NNP Doc_12091028_748_756_Chemical)))))) (VP (VBD proved) (ADJP (JJ safe) (CC and) (JJ effective))) (. .)))
12091028	4	(S1 (S (NP (NN Emphasis)) (VP (AUX was) (VP (VBN placed) (PP (IN on) (NP (JJ bedside) (JJ clinical) (NN monitoring))) (, ,) (S (VP (VBG relying) (ADVP (RB heavily)) (PP (IN on) (NP (DT the) (NN heart) (NN rate))))))) (. .)))
12091028	5	(S1 (S (NP (NP (NN Doc_12091028_871_879_Chemical)) (, ,) (SBAR (IN unless) (FRAG (ADJP (JJ contraindicated) (CC or) (JJ risky)))) (, ,)) (VP (VBZ remains) (NP (NP (DT the) (RB only) (JJ necessary) (JJ complementary) (NN drug)) (PP (TO to) (NP (NNP Doc_12091028_963_971_Chemical)))) (SBAR (IN as) (S (NP (PRP it)) (VP (VP (VBZ buffers) (NP (PRP$ its) (JJ cardiovascular) (NN response))) (CC and) (VP (VBZ decreases) (NP (NP (DT the) (NN duration) (CC and) (NN intensity)) (PP (IN of) (NP (ADJP (JJ operative) (CC and) (JJ postoperative)) (NNP Doc_12091028_1086_1100_Disease))))))))) (. .)))
12091028	6	(S1 (S (NP (JJ Local) (JJ anaesthetic) (NNS blocks)) (VP (AUX were) (ADJP (JJ useful)) (PP (IN in) (S (VP (VBG decreasing) (NP (NP (DT the) (NN requirement)) (PP (IN for) (NP (JJ postoperative) (NN Doc_12091028_1187_1196_Disease)))))))) (. .)))
12091028	7	(S1 (S (NP (DT An) (NN antisialogue)) (VP (AUX was) (ADJP (RB usually) (JJ unnecessary)) (PP (IN in) (NP (NP (NNS operations)) (VP (VBG lasting) (NP (QP (RB up) (TO to) (CD 2)) (NNP h))))) (, ,) (S (NP (NNP Doc_12091028_1271_1285_Chemical)) (VP (AUXG being) (NP (NP (DT the) (JJS best) (NN choice)) (PP (IN for) (NP (NP (PRP$ its) (JJS lowest) (NN psychotropic)) (CC and) (NP (JJ chronotropic) (NNS effects))))))) (, ,) (PP (ADVP (RB especially)) (IN in) (NP (DT a) (JJ hot) (NN climate)))) (. .)))
12091028	8	(S1 (S (NP (NP (NN Experience)) (PP (IN in) (NP (JJ war/tropical) (NNS settings)))) (VP (VBZ suggests) (SBAR (S (NP (DT this) (NN technique)) (VP (MD could) (VP (AUX be) (ADJP (JJ useful) (PP (PP (IN in) (NP (NP (JJ civilian) (NNS contexts)) (PP (JJ such) (IN as) (NP (JJ outdoor) (JJ life-saving) (NN emergency) (NN surgery))))) (CC or) (PP (IN in) (NP (NP (NN mass) (NNS casualties)) (SBAR (WHADVP (WRB where)) (, ,) (S (NP (NP (JJ e.g.) (NN amputation)) (CC and) (NP (JJ rapid) (NN extrication))) (VP (AUX were) (VP (VBN required)))))))))))))) (. .)))
12093990	0	(S1 (NP (NP (JJ Intravenous) (JJ Doc_12093990_12_21_Chemical) (NN treatment)) (PP (IN for) (NP (NP (JJ severe) (NN Doc_12093990_43_61_Disease)) (PP (IN in) (NP (JJ immunocompromised) (NNS children))))) (. .)))
12093990	1	(S1 (S (NP (NN Adenovirus)) (VP (AUX is) (NP (NP (DT an) (JJ important) (NN cause)) (PP (IN of) (NP (NP (NN morbidity)) (CC and) (NP (NN mortality))))) (PP (IN in) (NP (DT the) (JJ immunocompromised) (NN host)))) (. .)))
12093990	2	(S1 (S (NP (NP (DT The) (NN incidence)) (PP (IN of) (NP (JJ severe) (NNP Doc_12093990_220_238_Disease))) (PP (IN in) (NP (NNS pediatrics)))) (VP (AUX is) (VP (VBG increasing) (PP (IN in) (NP (NP (NN association)) (PP (IN with) (NP (NP (VBG growing) (NNS numbers)) (PP (IN of) (NP (JJ immunocompromised) (NNS children))))) (, ,) (SBAR (WHADVP (WRB where)) (S (NP (NP (NN case) (NN fatality) (NNS rates)) (ADJP (RB as) (JJ high) (PP (IN as) (NP (QP (CD 50) (NN %) (TO to) (CD 80) (NN %)))))) (VP (AUX have) (VP (AUX been) (VP (VBN reported)))))))))) (. .)))
12093990	3	(S1 (S (NP (EX There)) (VP (VP (AUX are) (NP (DT no) (JJ approved) (JJ antiviral) (NNS agents)) (PP (IN with) (NP (NP (VBN proven) (NN efficacy)) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (JJ severe) (NNP Doc_12093990_490_508_Disease)))))))) (, ,) (CC nor) (VP (AUX are) (ADVP (RB there)) (NP (NP (DT any) (JJ prospective) (JJ randomized) (, ,) (JJ controlled) (NNS trials)) (PP (IN of) (NP (ADJP (RB potentially) (JJ useful)) (JJ anti-adenovirus) (NNS therapies)))))) (. .)))
12093990	4	(S1 (S (NP (NP (JJ Apparent) (JJ clinical) (NN success)) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (JJ severe) (NNP Doc_12093990_672_690_Disease)))))) (VP (AUX is) (VP (VBN limited) (PP (TO to) (NP (NP (DT a) (JJ few) (NN case) (NNS reports)) (CC and) (NP (JJ small) (NNS series)))))) (. .)))
12093990	5	(S1 (S (NP (NN Experience)) (VP (AUX is) (ADJP (JJS greatest) (PP (IN with) (NP (JJ intravenous) (NNP Doc_12093990_782_791_Chemical) (CC and) (NNP Doc_12093990_796_805_Chemical))))) (. .)))
12093990	6	(S1 (S (NP (NP (NNP Doc_12093990_807_816_Chemical)) (, ,) (NP (DT a) (JJ Doc_12093990_820_829_Chemical) (NN analogue)) (, ,)) (VP (AUX has) (NP (NP (JJ broad) (JJ antiviral) (NN activity)) (PP (IN against) (NP (DT both) (NNP RNA) (CC and) (NNP DNA) (NNS viruses)))) (, ,) (PP (VBG including) (NP (NP (VBN documented) (NN activity)) (PP (IN against) (NP (NN adenovirus))) (PP (IN in) (NP (NN vitro)))))) (. .)))
12093990	7	(S1 (S (NP (NN Doc_12093990_962_971_Chemical)) (VP (AUX is) (VP (VP (VBN licensed) (PP (IN in) (NP (JJ aerosol) (NN form))) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NNP Doc_12093990_1021_1058_Disease)))))) (, ,) (CC and) (VP (ADVP (RB orally)) (PP (IN in) (NP (NN combination))) (PP (IN with) (NP (NNP interferon))) (S (VP (TO to) (VP (VB treat) (SBAR (S (NP (ADJP (NNP Doc_12093990_1111_1122_Disease.) (JJ Intravenous)) (NNP Doc_12093990_1136_1145_Chemical)) (VP (AUX is) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NN choice))) (PP (IN for) (NP (NNP Doc_12093990_1177_1217_Disease))))))))))))) (. .)))
12093990	8	(S1 (S (NP (NP (DT The) (ADJP (RBS most) (JJ common)) (JJ adverse) (NN effect)) (PP (IN of) (NP (JJ intravenous) (NNP Doc_12093990_1265_1274_Chemical)))) (VP (AUX is) (NP (JJ reversible) (JJ mild) (NN Doc_12093990_1294_1300_Disease))) (. .)))
12093990	9	(S1 (S (NP (NP (DT The) (NN use)) (PP (IN of) (NP (NNP Doc_12093990_1313_1322_Chemical))) (PP (IN in) (NP (JJ severe) (NNP Doc_12093990_1333_1353_Disease)))) (VP (AUX has) (VP (AUX been) (VP (VBN limited) (PP (IN by) (NP (NP (JJ adverse) (NNS effects)) (, ,) (SBAR (WHNP (WHNP (DT the) (RBS most) (JJ significant)) (WHPP (IN of) (WHNP (WDT which)))) (S (VP (AUX is) (NP (NN nephrotoxicity)))))))))) (. .)))
12093990	10	(S1 (S (NP (PRP We)) (VP (VP (VBP report) (NP (NP (PRP$ our) (NN experience)) (PP (IN with) (NP (JJ intravenous) (JJ Doc_12093990_1493_1502_Chemical) (NN therapy))) (PP (IN for) (NP (JJ severe) (NN Doc_12093990_1522_1540_Disease)))) (PP (IN in) (NP (NP (DT a) (NN series)) (PP (IN of) (NP (JJ immunocompromised) (NNS children)))))) (CC and) (VP (VB review) (NP (DT the) (NN literature)))) (. .)))
12093990	11	(S1 (NP (NP (NNS DESIGN/METHODS)) (: :) (S (NP (PRP We)) (ADVP (RB retrospectively)) (VP (VBN reviewed) (NP (NP (DT the) (JJ medical) (NNS records)) (PP (IN of) (NP (NP (CD 5) (NNS children)) (VP (VBN treated) (PP (IN with) (NP (JJ intravenous) (NNP Doc_12093990_1713_1722_Chemical))) (PP (IN for) (NP (VBN documented) (JJ severe) (NN Doc_12093990_1745_1763_Disease))))))))) (. .)))
12093990	12	(S1 (S (NP (CD Two) (NNS patients)) (VP (VBD developed) (NP (JJ adenovirus) (NN Doc_12093990_1799_1819_Disease)) (PP (IN after) (NP (NP (JJ cardiac)) (CC and) (NP (NN bone) (NN marrow) (NNS transplants)))) (, ,) (ADVP (RB respectively))) (. .)))
12093990	13	(S1 (S (NP (DT The) (NN bone) (NN marrow) (NN transplant) (NN patient)) (ADVP (RB also)) (VP (VBD received) (NP (NP (JJ intravenous) (NN Doc_12093990_1938_1947_Chemical)) (PP (IN for) (NP (JJ progressive) (VBN disseminated) (NN disease))))) (. .)))
12093990	14	(S1 (S (S (NP (DT An) (JJ additional) (CD 3) (NNS children)) (VP (VBD developed) (NP (NNP Doc_12093990_2021_2041_Disease)))) (: ;) (S (NP (CD 2)) (VP (AUX were) (NP (NP (NNS neonates)) (, ,) (SBAR (WHNP (CD 1) (WHPP (IN of) (WHNP (WP whom)))) (S (VP (AUX had) (NP (JJ partial) (NN Doc_12093990_2082_2099_Disease)))))))) (. .)))
12093990	15	(S1 (S (NP (DT The) (VBG remaining) (NN infant)) (VP (AUX had) (ADVP (RB recently)) (VP (VBN undergone) (NP (DT a) (JJ cardiac) (NN transplant)))) (. .)))
12093990	16	(S1 (S (NP (JJ Intravenous) (NNP Doc_12093990_2179_2188_Chemical)) (VP (AUX was) (VP (VBN administered) (PP (IN on) (NP (DT a) (JJ compassionate-use) (NN protocol))))) (. .)))
12093990	17	(S1 (S (NP (NP (JJ Complete) (JJ clinical) (NN recovery)) (VP (VBN followed) (ADVP (RB later)) (PP (IN by) (NP (JJ viral) (NN clearance))))) (VP (AUX was) (VP (VBN observed) (PP (IN in) (NP (NP (CD 2) (NNS children)) (: :) (NP (NP (NP (DT the) (JJ cardiac) (NN transplant) (NN recipient)) (PP (IN with) (NP (JJ adenovirus) (NN Doc_12093990_2386_2406_Disease)))) (CC and) (NP (NP (DT the) (JJ immunocompetent) (NN neonate)) (PP (IN with) (NP (NNP Doc_12093990_2444_2464_Disease))))))))) (. .)))
12093990	18	(S1 (S (NP (DT The) (JJ remaining) (CD 3) (NNS children)) (VP (VBD died) (PP (IN of) (NP (NNP Doc_12093990_2499_2517_Disease)))) (. .)))
12093990	19	(S1 (S (NP (JJ Intravenous) (JJ Doc_12093990_2531_2540_Chemical) (NN therapy)) (VP (AUX was) (ADVP (RB well)) (VP (VBN tolerated))) (. .)))
12093990	20	(S1 (S (NP (NP (NN Use)) (PP (IN of) (NP (NNP Doc_12093990_2576_2585_Chemical))) (PP (IN in) (NP (CD 1) (NN child)))) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (NNP Doc_12093990_2617_2642_Disease)) (CC and) (NP (NNP Doc_12093990_2647_2658_Disease)))))) (. .)))
12093990	21	(S1 (S (NP (NP (PRP$ Our) (NN series)) (PP (IN of) (NP (NNS patients)))) (VP (AUX is) (NP (NP (NN representative)) (PP (IN of) (NP (NP (DT the) (NN spectrum)) (PP (IN of) (NP (NP (JJ immunocompromised) (NNS children)) (PP (IN at) (NP (NP (JJS greatest) (NN risk)) (PP (IN for) (NP (NP (JJ severe) (NN Doc_12093990_2787_2805_Disease)) (, ,) (NP (RB namely) (JJ solid-organ) (CC and) (NN bone) (NN marrow) (NN transplant) (NNS recipients)) (, ,) (NP (NNS neonates)) (, ,) (CC and) (NP (NP (NNS children)) (PP (IN with) (NP (NNP Doc_12093990_2893_2909_Disease)))))))))))))) (. .)))
12093990	22	(S1 (S (SBAR (IN Although) (S (NP (JJ intravenous) (NNP Doc_12093990_2932_2941_Chemical)) (VP (AUX was) (RB not) (ADJP (JJ effective)) (PP (IN for) (NP (NP (DT all) (NNS children)) (PP (IN with) (NP (JJ severe) (NNP Doc_12093990_2989_3007_Disease))))) (PP (PP (IN in) (NP (DT this) (NN series))) (CC or) (PP (IN in) (NP (DT the) (NN literature))))))) (, ,) (NP (NN therapy)) (VP (AUX is) (ADJP (JJ unlikely) (S (VP (TO to) (VP (AUX be) (PP (IN of) (NP (NN benefit))) (SBAR (IN if) (S (VP (VBN begun) (ADVP (RB late)) (PP (IN in) (NP (NP (DT the) (NN course)) (PP (IN of) (NP (DT the) (NNP Doc_12093990_3117_3126_Disease))))))))))))) (. .)))
12093990	23	(S1 (S (NP (NP (JJ Early) (NN identification)) (, ,) (VP (VBN eg) (PP (IN by) (NP (NP (NN polymerase) (NN chain) (NN reaction)) (PP (IN of) (NP (DT those) (NNS patients))))) (PP (IN at) (NP (NP (NN risk)) (PP (IN of) (NP (VBN disseminated) (NN Doc_12093990_3224_3242_Disease))))))) (VP (MD may) (VP (VB permit) (NP (NP (RBR earlier) (JJ antiviral) (NN treatment)) (CC and) (NP (NP (JJR better) (NN evaluation)) (PP (IN of) (NP (JJ therapeutic) (NN response))))))) (. .)))
12093990	24	(S1 (S (NP (NP (CD Two)) (PP (IN of) (NP (NP (CD 5) (NNS children)) (PP (IN with) (NP (JJ severe) (NNP Doc_12093990_3372_3390_Disease))) (VP (VBN treated) (PP (IN with) (NP (JJ intravenous) (NN Doc_12093990_3416_3425_Chemical))))))) (VP (VBD recovered)) (. .)))
12093990	25	(S1 (S (NP (NP (DT The) (NN availability)) (PP (IN of) (NP (NP (JJR newer) (JJ rapid) (JJ diagnostic) (NNS techniques)) (, ,) (PP (JJ such) (IN as) (NP (NN polymerase) (NN chain) (NN reaction))) (, ,)))) (VP (MD may) (VP (VB make) (NP (NP (JJR earlier) (, ,) (ADJP (RBR more) (JJ effective)) (NN treatment)) (PP (IN of) (NP (JJ Doc_12093990_3573_3593_Disease) (JJ possible)))))) (. .)))
12093990	26	(S1 (S (PP (VBN Given) (NP (NP (DT the) (NN seriousness)) (CC and) (NP (NP (VBG increasing) (NN prevalence)) (PP (IN of) (NP (NNP Doc_12093990_3655_3673_Disease))) (PP (IN in) (NP (NP (JJ certain) (NNS hosts)) (, ,) (ADVP (RB especially)) (NP (NNS children))))))) (, ,) (NP (NP (DT a) (JJ large) (, ,) (JJ multicenter) (JJ clinical) (NN trial)) (PP (IN of) (NP (NP (ADJP (RB potentially) (JJ useful)) (JJ anti-adenoviral) (NNS therapies)) (, ,) (PP (JJ such) (IN as) (NP (JJ intravenous) (NNP Doc_12093990_3818_3827_Chemical))) (, ,)))) (VP (AUX is) (ADVP (RB clearly)) (VP (VBN required) (S (VP (TO to) (VP (VB demonstrate) (NP (DT the) (ADJP (ADJP (RBS most) (JJ effective)) (CC and) (ADJP (RBS least) (JJ toxic))) (NN therapy))))))) (. .)))
12101159	0	(S1 (S (S (VP (VBN Delayed) (NP (NNP Doc_12101159_8_17_Disease) (NNP Doc_12101159_18_32_Disease)) (PP (IN after) (NP (NNP Doc_12101159_39_48_Chemical) (NNP Doc_12101159_49_57_Disease))))) (: ;) (S (NP (NP (NN resuscitation)) (PP (IN with) (NP (JJ high) (NN dose)))) (ADJP (JJ intravenous) (JJ Doc_12101159_100_107_Chemical))) (. .)))
12101159	1	(S1 (S (NP (DT A) (CD 51) (NN year) (JJ old) (NN man)) (VP (VBD took) (NP (DT a) (JJ mixed) (NN Doc_12101159_140_148_Disease)) (PP (VBG including) (NP (NP (CD 1.8-3.6) (NNP g)) (PP (IN of) (NP (NNP Doc_12101159_172_181_Chemical) (, ,) (NNP Doc_12101159_183_194_Chemical) (, ,) (NNP Doc_12101159_196_203_Chemical) (, ,) (NNP Doc_12101159_205_223_Chemical) (, ,) (CC and) (NNP Doc_12101159_229_236_Chemical)))))) (. .)))
12101159	2	(S1 (S (NP (PRP He)) (ADVP (RB initially)) (VP (VP (VBD presented) (PP (TO to) (NP (NN hospital))) (PP (IN after) (NP (NP (CD six) (NNS hours)) (PP (IN with) (NP (JJ mild) (NN Doc_12101159_299_310_Disease)))))) (CC and) (VP (AUX was) (VP (VBN treated) (PP (IN with) (NP (NP (VBN activated) (NN charcoal)) (CC and) (NP (JJ intravenous) (NNS fluids))))))) (. .)))
12101159	3	(S1 (S (PP (NP (CD Eighteen) (NNS hours)) (IN after) (NP (DT the) (NNP Doc_12101159_400_408_Disease))) (NP (PRP he)) (VP (AUX had) (NP (CD two) (JJ generalised) (NN Doc_12101159_432_453_Disease))) (. .)))
12101159	4	(S1 (S (NP (DT The) (NN patient)) (VP (VP (VBD remained) (ADJP (JJ unresponsive) (PP (IN with) (NP (NP (JJ junctional) (NNP Doc_12101159_505_516_Disease)) (, ,) (NP (JJ unrecordable) (NN blood) (NN pressure)) (, ,))))) (CC and) (VP (ADVP (RB then)) (VBD became) (NP (NNP Doc_12101159_563_572_Disease)))) (. .)))
12101159	5	(S1 (S (NP (PRP He)) (VP (AUX was) (VP (VBN resuscitated) (S (PP (IN with) (NP (JJ high) (NN dose))) (-LRB- -LRB-) (NP (CD 13.5) (NNP g)) (-RRB- -RRB-) (NP (NP (JJ intravenous) (NNP Doc_12101159_630_637_Chemical)) (CC and) (NP (NP (NNP Doc_12101159_642_652_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12101159_654_665_Chemical)) (-RRB- -RRB-))))))) (. .)))
12101159	6	(S1 (S (NP (PRP He)) (VP (VBD required) (NP (NP (JJ inotropic) (NN support)) (CC and) (NP (JJ temporary) (NN pacing))) (PP (IN over) (NP (DT the) (JJ next) (CD 48) (NNS hours)))) (. .)))
12101159	7	(S1 (S (NP (DT This) (NN case)) (VP (VBZ suggests) (SBAR (S (NP (EX there)) (VP (AUX is) (NP (NP (DT a) (NN role)) (PP (IN for) (NP (JJ aggressive) (JJ high) (NN dose) (JJ intravenous) (JJ Doc_12101159_815_822_Chemical) (NN therapy))) (PP (IN in) (NP (JJ severe) (NNP Doc_12101159_841_850_Chemical) (NNP Doc_12101159_851_859_Disease)))) (, ,) (PP (ADVP (RB particularly)) (IN with) (NP (NP (DT the) (NN onset)) (PP (IN of) (NP (NNP Doc_12101159_892_900_Disease))))))))) (. .)))
12101159	8	(S1 (S (NP (PRP It)) (VP (MD should) (VP (AUX be) (VP (VBN considered) (ADVP (RB early)) (PP (IN in) (NP (NP (NNS cases)) (PP (IN of) (NP (NNP Doc_12101159_944_958_Disease))))) (PP (IN after) (NP (NNP Doc_12101159_965_974_Chemical) (NNP Doc_12101159_975_983_Disease)))))) (. .)))
12101159	9	(S1 (S (NP (DT The) (NN case)) (ADVP (RB also)) (VP (VBZ highlights) (NP (NP (DT the) (NNS problems)) (PP (IN with) (NP (JJ delayed) (NN Doc_12101159_1036_1044_Disease)))) (SBAR (WHADVP (WRB when)) (S (NP (JJ whole) (NN bowel) (NN irrigation)) (VP (AUX is) (RB not) (VP (VBN administered)))))) (. .)))
12109865	0	(S1 (NP (NP (JJ Low-molecular-weight) (NN heparin)) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ mechanical) (NN heart) (NNS valves))))))) (. .)))
12109865	1	(S1 (S (NP (NP (DT The) (NN interruption)) (PP (IN of) (NP (JJ oral) (NN anticoagulant) (PRN (-LRB- -LRB-) (NP (NNP OAC)) (-RRB- -RRB-)) (NN administration)))) (VP (AUX is) (ADVP (RB sometimes)) (VP (VBN indicated) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ mechanical) (NN heart) (NNS valves))))) (, ,) (PP (ADVP (RB mainly)) (IN before) (NP (NP (NN noncardiac) (NN surgery)) (, ,) (NP (JJ non-surgical) (NNS interventions)) (, ,) (CC and) (NP (NN pregnancy)))))) (. .)))
12109865	2	(S1 (S (NP (NP (JJ Unfractionated) (NN heparin)) (PRN (-LRB- -LRB-) (INTJ (UH UH)) (-RRB- -RRB-))) (VP (AUX is) (ADVP (RB currently)) (NP (NP (DT the) (NN substitute)) (PP (IN for) (NP (VBN selected) (NNS patients))))) (. .)))
12109865	3	(S1 (S (NP (NP (NNP Doc_12109865_382_410_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP LMWH)) (-RRB- -RRB-))) (VP (VP (VBZ offers) (NP (NP (JJ theoretical) (NNS advantages)) (PP (IN over) (NP (NNP UH))))) (, ,) (CC but) (VP (AUX is) (RB not) (ADVP (RB currently)) (VP (VBN considered) (PP (IN in) (NP (JJ clinical) (NNS guidelines))) (PP (IN as) (NP (NP (DT an) (NN alternative)) (PP (TO to) (NP (UH UH))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ prosthetic) (NNS valves)))))))))) (. .)))
12109865	4	(S1 (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT the) (JJ present) (NN study)))) (VP (AUX was) (S (VP (VP (TO to) (VP (VB review) (NP (NP (DT the) (NNS data)) (VP (VBN accumulated) (ADVP (RB so) (RB far)) (PP (IN on) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NNP Doc_12109865_669_673_Chemical))) (PP (IN in) (NP (DT this) (JJ patient) (NN population))))))))) (CC and) (VP (TO to) (VP (VB discuss) (NP (NP (PRP$ its) (NN applicability)) (PP (IN in) (NP (JJ common) (NN practice))))))))) (. .)))
12109865	5	(S1 (S (PP (IN For) (NP (DT this) (NN paper))) (, ,) (NP (NP (DT the) (JJ current) (JJ medical) (NN literature)) (PP (IN on) (NP (NN LMWH))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ mechanical) (NN heart) (NNS valves)))))) (VP (AUX was) (ADVP (RB extensively)) (VP (VBN reviewed))) (. .)))
12109865	6	(S1 (S (NP (EX There)) (VP (AUX were) (NP (NP (CD eight) (NN series)) (CC and) (NP (CD six) (NN case) (NNS reports)))) (. .)))
12109865	7	(S1 (S (S (NP (NP (NN None)) (PP (IN of) (NP (DT the) (NNS studies)))) (VP (AUX was) (VP (VBN randomized)))) (, ,) (CC and) (S (NP (RB only) (CD one)) (VP (AUX was) (ADJP (JJ prospective)))) (. .)))
12109865	8	(S1 (S (NP (NP (NNS Data)) (SBAR (S (VP (TO to) (VP (VB establish) (NP (DT the) (JJ Doc_12109865_1028_1042_Disease) (NN risk))))))) (VP (AUX were) (ADJP (JJ incomplete))) (. .)))
12109865	9	(S1 (S (PP (IN After) (NP (VBG excluding) (NN case) (NNS reports))) (, ,) (NP (DT the) (JJ following) (NNS groups)) (VP (AUX were) (VP (VBN constructed) (UCP (: :) (ADJP (ADJP (NP (NP (LST (-LRB- -LRB-) (DT a) (-RRB- -RRB-)) (NP (JJ short-term) (NN administration)) (, ,) (PP (IN after) (NP (NN valve) (NN insertion)))) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 212)) (-RRB- -RRB-)) (: ;) (NP (NP (PRN (-LRB- -LRB-) (NP (NNP b)) (-RRB- -RRB-)) (JJ short-term) (, ,) (JJ perioperative) (PRN (-LRB- -LRB-) (NP (NN noncardiac)) (-RRB- -RRB-)) (JJ /periprocedural)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 114)) (-RRB- -RRB-)) (: ;)) (-LRB- -LRB-) (NP (NNP c)) (-RRB- -RRB-)) (JJ long-term)) (, ,) (ADJP (JJ due) (S (VP (TO to) (VP (VB intolerance) (PP (TO to) (NP (NP (NNP OAC)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 16)) (-RRB- -RRB-)) (: ;) (ADJP (PRN (-LRB- -LRB-) (NP (NNP d)) (-RRB- -RRB-)) (JJ long-term)) (, ,))) (PP (IN in) (NP (NN pregnancy))))))) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 10)) (-RRB- -RRB-)))))) (. .)))
12109865	10	(S1 (S (S (NP (NP (DT The) (NN incidence) (NN rate)) (PP (IN of) (NP (NNP Doc_12109865_1378_1393_Disease)))) (VP (AUX was) (NP (NP (NP (CD 0.9) (NN %)) (PP (IN for) (NP (PDT all) (DT the) (NNS studies) (CC and) (CD 0.5) (, ,) (CD 0) (, ,) (CD 20)))) (, ,) (CC and) (NP (NP (CD 0) (NN %)) (PP (IN in) (NP (NNS groups)))) (DT a)) (, ,) (NP (NP (NNP b)) (, ,) (NP (NNP c)) (, ,) (CC and) (NP (NNP d)) (, ,) (ADVP (RB respectively))))) (: ;) (S (PP (IN for) (NP (NNP Doc_12109865_1490_1500_Disease))) (, ,) (NP (DT the) (JJ overall) (NN rate)) (VP (AUX was) (NP (NP (CD 3.4) (NN %)) (PRN (-LRB- -LRB-) (NP (NP (CD 3.8)) (, ,) (NP (CD 2.6)) (, ,) (NP (CD 10)) (, ,) (CC and) (NP (NP (CD 0) (NN %)) (PP (IN for) (NP (DT the) (JJ respective) (NNS groups))))) (-RRB- -RRB-))))) (. .)))
12109865	11	(S1 (S (PP (IN In) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ mechanical) (NN heart) (NNS valves))))) (, ,) (NP (JJ short-term) (JJ Doc_12109865_1644_1648_Chemical) (NN therapy)) (VP (VBZ compares) (ADVP (RB favorably)) (PP (IN with) (NP (NNP UH)))) (. .)))
12109865	12	(S1 (S (NP (NP (NNS Data)) (PP (IN on) (NP (NP (NN mid-)) (CC and) (NP (JJ long-term) (JJ Doc_12109865_1712_1716_Chemical) (NN administration)))) (PP (IN in) (NP (DT these) (NNS patients)))) (VP (AUX are) (ADJP (JJ sparse))) (. .)))
12109865	13	(S1 (S (NP (JJ Further) (JJ randomized) (NNS studies)) (VP (AUX are) (VP (VBN needed) (S (VP (TO to) (VP (VB confirm) (NP (NP (DT the) (NN safety)) (CC and) (NP (JJ precise) (NNS indications))) (PP (IN for) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NNP LMWH))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ mechanical) (NN heart) (NNS valves)))))))))))) (. .)))
12139551	0	(S1 (NP (NP (NP (NN Doc_12139551_0_14_Disease)) (PP (IN after) (NP (JJ intravenous) (NNP Doc_12139551_33_47_Chemical)))) (: -) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NP (CD five) (JJ repeated) (NNS injections)) (PP (IN of) (NP (NNP Doc_12139551_88_102_Chemical))))) (VP (VBG causing) (NP (NP (CD five) (NNS episodes)) (PP (IN of) (NP (NNP Doc_12139551_128_142_Disease)))))) (. .)))
12139551	1	(S1 (S (NP (PRP We)) (VP (VBP describe) (NP (NP (DT a) (NN patient)) (SBAR (WHADVP (WRB where)) (S (NP (NP (JJ intravenous) (NN injection)) (PP (IN of) (NP (NNP Doc_12139551_197_211_Chemical)))) (VP (AUX was) (ADVP (RB immediately)) (VP (VBN followed) (PP (IN by) (NP (NNP Doc_12139551_240_248_Disease))) (ADVP (RB repeatedly)))))))) (. .)))
12139551	2	(S1 (S (NP (DT The) (NN patient)) (VP (VBD received) (NP (NNP Doc_12139551_282_296_Chemical) (CD 10) (NNS mg)) (PP (IN i.v.) (NP (CD five) (NNS times))) (PP (IN during) (NP (NP (CD 48)) (NP (NNP h))))) (. .)))
12139551	3	(S1 (S (PP (IN After) (S (VP (VP (VBG interviewing) (NP (DT the) (VBG attending) (NNS nurses))) (CC and) (VP (VBG reviewing) (NP (DT the) (VBN written) (NN documentation)))))) (, ,) (NP (PRP it)) (VP (AUX is) (ADJP (JJ clear)) (SBAR (IN that) (S (NP (NP (DT every) (NN administration)) (PP (IN of) (NP (NNP Doc_12139551_454_468_Chemical)))) (VP (AUX was) (ADVP (RB immediately)) (PRN (-LRB- -LRB-) (PP (IN within) (NP (PRP s))) (-RRB- -RRB-)) (VP (VBN followed) (PP (IN by) (NP (NNP Doc_12139551_508_516_Disease)))))))) (. .)))
12139551	4	(S1 (S (S (NP (DT The) (NNP Doc_12139551_522_530_Disease)) (VP (VBD lasted) (SBAR (S (NP (NN 15-30)) (VP (VBZ s) (PP (IN on) (NP (CD four) (NNS occasions)))))))) (, ,) (S (PP (IN on) (NP (CD one) (NN occasion))) (NP (PRP it)) (VP (VBD lasted) (NP (CD 2) (NN min)))) (. .)))
12139551	5	(S1 (S (NP (DT The) (NN patient)) (VP (VBD received) (NP (NP (JJ Doc_12139551_619_627_Chemical) (JJ 0.5-1) (NN mg)) (CC and) (NP (NN chest) (NNS compressions))) (, ,) (SBAR (IN before) (S (NP (JJ sinus) (NN rhythm)) (ADVP (RB again)) (VP (VBD took) (PRT (RP over)))))) (. .)))
12139551	6	(S1 (S (NP (PRP We)) (VP (VB interpret) (NP (DT this)) (PP (IN as) (NP (NP (NNS episodes)) (PP (IN of) (NP (NNP Doc_12139551_731_745_Disease))) (VP (VBN caused) (PP (IN by) (NP (NNP Doc_12139551_756_770_Chemical))))))) (. .)))
12139551	7	(S1 (S (NP (NP (NP (DT The) (JJ rapid) (NN injection)) (PP (IN via) (NP (DT the) (JJ central) (JJ venous) (NN route)))) (CC and) (NP (NP (DT the) (JJ concomitant) (VBG tapering)) (PP (IN of) (NP (JJ Doc_12139551_853_861_Chemical) (NN infusion))))) (VP (MD might) (VP (AUX have) (VP (VBN contributed) (PP (IN in) (S (VP (VBG precipitating) (NP (DT the) (JJ adverse) (NN drug) (NN reaction)))))))) (. .)))
12180796	0	(S1 (S (NP (NP (JJ Immunohistochemical) (NN study)) (PP (IN on) (NP (NP (JJ inducible) (NN type)) (PP (IN of) (NP (NP (NP (NNP Doc_12180796_47_59_Chemical)) (PRN (-LRB- -LRB-) (NP (NNS iNOS)) (-RRB- -RRB-))) (, ,) (NP (NP (JJ basic) (NN fibroblast) (NN growth) (NN factor)) (PRN (-LRB- -LRB-) (NP (CD bFGF)) (-RRB- -RRB-)) (CC and) (NP (NNP Doc_12180796_110_115_Disease) (NN growth) (NN factor-beta1)) (PRN (-LRB- -LRB-) (JJ TGF-beta1) (-RRB- -RRB-)) (PP (IN in) (NP (NP (NNP Doc_12180796_151_160_Disease)) (VP (VBN induced) (PP (IN in) (NP (NNS rats))) (PP (IN by) (NP (NNP Doc_12180796_180_190_Chemical) (CC and) (NNP Doc_12180796_195_207_Chemical))))))) (, ,)))))) (VP (VBZ vasodilators)) (. .)))
12180796	1	(S1 (S (NP (NP (NP (NN Doc_12180796_223_232_Disease)) (VP (VBN induced) (PP (IN in) (NP (NNS rats))) (PP (IN by) (NP (NNS vasodilators))))) (, ,) (NP (NNP Doc_12180796_266_276_Chemical) (CC and) (NNP Doc_12180796_281_293_Chemical)) (, ,)) (VP (AUX was) (VP (VBN examined) (ADVP (RB immunohistochemically)) (PP (IN for) (NP (NP (NNS expressions)) (PP (IN of) (NP (NP (JJ inducible) (NN type)) (PP (IN of) (NP (NP (NP (NNP Doc_12180796_367_379_Chemical) (NN synthase)) (PRN (-LRB- -LRB-) (NP (NNS iNOS)) (-RRB- -RRB-))) (, ,) (NP (NP (JJ basic) (JJ fibroblast) (NN growth) (NN factor)) (PRN (-LRB- -LRB-) (NP (CD bFGF)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_12180796_439_444_Disease) (NN growth) (NNS factor-beta1)) (PRN (-LRB- -LRB-) (NP (NNP TGF-beta1)) (-RRB- -RRB-))))))))))) (. .)))
12180796	2	(S1 (S (NP (NNS Rats)) (VP (AUX were) (VP (VP (VBN administered) (NP (NNP Doc_12180796_501_511_Chemical)) (PP (IN for) (NP (CD 24) (NNS hours))) (PP (IN by) (NP (JJ intravenous) (NN infusion))) (PP (IN with))) (CC or) (VP (PP (IN without) (S (VP (VBG following) (NP (NP (JJ repeated) (JJ daily) (JJ oral) (NNS administrations)) (PP (IN of) (NP (NNP Doc_12180796_614_626_Chemical)))))))))) (. .)))
12180796	3	(S1 (S (S (ADVP (RB Irrespective) (PP (IN of) (NP (NNP Doc_12180796_644_656_Chemical) (NN administration)))) (, ,) (NP (NNS iNOS) (NNS antigens)) (VP (AUX were) (ADJP (RB remarkably) (JJ abundant)) (PP (IN in) (NP (NP (NP (JJ ED-1-positive) (NNS cells)) (PP (IN on) (NP (NN day) (CD 5)))) (CC and) (NP (NP (CD 8) (NN post-Doc_12180796_755_765_Chemical-infusion)) (PRN (-LRB- -LRB-) (NP (NNP DPI)) (-RRB- -RRB-))))))) (: ;) (S (NP (CD bFGF) (NNS antigens)) (VP (AUX were) (ADJP (RB remarkably) (JJ abundant)) (PP (IN in) (NP (NP (JJ ED-1-positive) (NNS cells)) (PP (IN on) (NP (QP (CD 1) (CC and) (CD 3)) (NNP DPI))))))) (: ;) (S (NP (JJ TGF-beta1) (NNS antigens)) (VP (AUX were) (VP (VBN observed) (PP (IN in) (NP (JJ ED-1-positive) (NNS cells))) (PP (IN on) (CC and) (IN after) (NP (CD 5) (NNP DPI)))))) (. .)))
12180796	4	(S1 (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (S (NP (NP (DT the) (JJ peak) (NN expression)) (PP (IN of) (NP (NN iNOS) (NN antigen)))) (VP (AUX was) (VP (VBN followed) (PP (IN by) (NP (NP (DT that)) (PP (IN of) (NP (CD bFGF) (NN antigen)))))))) (, ,) (CC and) (S (NP (NNS bFGF)) (VP (MD may) (VP (AUX have) (NP (NP (DT a) (JJ suppressive) (NN effect)) (PP (IN on) (NP (NP (NNS iNOS) (NN expression)) (PP (IN in) (NP (DT these) (NN rat) (NNP Doc_12180796_1108_1117_Disease) (NNS models)))))))))))) (. .)))
12180796	5	(S1 (S (PP (IN On) (NP (DT the) (JJ other) (NN hand))) (, ,) (NP (NN TGF-beta1)) (VP (AUX was) (RB not) (VP (VBN considered) (S (VP (TO to) (VP (AUX have) (NP (NP (DT a) (JJ suppressive) (NN effect)) (PP (IN on) (NP (NP (NN iNOS) (NN expression)) (PP (IN in) (NP (DT these) (NNS models))))))))))) (. .)))
12231232	0	(S1 (NP (NP (DT The) (NN striatum)) (PP (IN as) (NP (NP (DT a) (NN target)) (PP (IN for) (NP (NP (JJ anti-rigor) (NNS effects)) (PP (IN of) (NP (NP (NP (DT an) (NN antagonist)) (PP (IN of) (NP (NN mGluR1)))) (, ,) (CONJP (CC but) (RB not)) (NP (NP (DT an) (NN agonist)) (PP (IN of) (NP (NN group) (NNP II) (JJ metabotropic) (NN Doc_12231232_120_129_Chemical) (NNS receptors)))))))))) (. .)))
12231232	1	(S1 (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT the) (JJ present) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB find) (PRT (RP out)) (SBAR (IN whether) (S (NP (NP (NP (NP (DT the) (JJ metabotropic) (NN receptor) (CD 1)) (PRN (-LRB- -LRB-) (NP (NN mGluR1)) (-RRB- -RRB-))) (CC and) (NP (NN group) (NNP II) (NNS mGluRs))) (, ,) (VP (VBN localized) (PP (IN in) (NP (DT the) (NN striatum)))) (, ,)) (VP (AUX are) (VP (VBN involved) (PP (IN in) (NP (NP (JJ antiparkinsonian-like) (NNS effects)) (PP (IN in) (NP (NNS rats))))))))))))) (. .)))
12231232	2	(S1 (S (NP (NP (NP (NNP Doc_12231232_334_345_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 1) (CD mg/kg)) (NN ip)) (-RRB- -RRB-)) (VP (VBN induced) (NP (NP (NP (NNP Doc_12231232_367_379_Disease-like) (NNP Doc_12231232_385_400_Disease)) (, ,) (VP (VBN measured) (PP (IN as) (NP (NP (DT an) (VBN increased) (NN resistance)) (PP (IN of) (NP (NP (DT a) (NN rat) (POS 's)) (JJ hind) (NN foot))) (PP (TO to) (NP (NP (JJ passive) (NN flexion)) (CC and) (NP (NP (NN extension)) (PP (IN at) (NP (NP (NP (DT the) (JJ ankle) (NN joint.) (NNP Doc_12231232_512_551_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP AIDA)) (: ;) (NP (QP (CD 0.5-15) (CD microg/0.5)) (NN microl)) (-RRB- -RRB-))) (, ,) (NP (DT a) (JJ potent) (CC and) (JJ selective) (NN mGluR1) (NN antagonist)))))))))) (, ,)) (CC or) (NP (NP (NNP Doc_12231232_631_675_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12231232_677_687_Chemical)) (: ;) (NP (QP (CD 7.5-15) (CD microg/0.5)) (NN microl)) (-RRB- -RRB-)))))) (, ,) (NP (DT a) (JJ selective) (NN group) (NNP II) (NN agonist)) (, ,)) (VP (AUX was) (VP (VBN injected) (ADVP (RB bilaterally)) (PP (IN into) (NP (NP (DT the) (NN striatum)) (PP (IN of) (NP (JJ Doc_12231232_792_803_Chemical-treated) (NNS animals))))))) (. .)))
12231232	3	(S1 (S (NP (NP (NN AIDA)) (PP (IN in) (NP (NP (NNS doses)) (PP (IN of) (NP (QP (CD 7.5-15) (CD microg/0.5)) (NN microl)))))) (VP (VBD diminished) (NP (DT the) (JJ Doc_12231232_878_889_Chemical-induced) (NNP Doc_12231232_898_913_Disease))) (. .)))
12231232	4	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NNP Doc_12231232_928_938_Chemical) (NNS injections)) (VP (AUX were) (ADJP (JJ ineffective))) (. .)))
12231232	5	(S1 (S (NP (DT The) (JJ present) (NNS results)) (VP (MD may) (VP (VB suggest) (SBAR (IN that) (S (NP (NP (DT the) (NN blockade)) (PP (IN of) (NP (NP (JJ striatal) (NNS mGluR1)) (, ,) (CONJP (CC but) (RB not)) (NP (NP (DT the) (NN stimulation)) (PP (IN of) (NP (NN group) (NNP II) (NNS mGluRs)))) (, ,)))) (VP (MD may) (VP (VB ameliorate) (NP (NNP Doc_12231232_1097_1109_Disease) (NNP Doc_12231232_1110_1125_Disease)))))))) (. .)))
12448656	0	(S1 (NP (NP (DT A) (NN phase) (NNP II) (NN study)) (PP (IN of) (NP (NNP Doc_12448656_20_31_Chemical))) (PP (IN in) (NP (JJ advanced) (JJ metastatic) (NN Doc_12448656_55_75_Disease))) (. .)))
12448656	1	(S1 (FRAG (S (VP (VP (TO To) (VP (VB evaluate) (NP (NP (DT the) (NN Doc_12448656_105_113_Disease) (CC and) (NN activity)) (PP (IN of) (NP (NNP Doc_12448656_130_141_Chemical))) (PP (IN in) (NP (NNS patients)))) (PP (IN with) (NP (JJ advanced) (JJ metastatic) (NN Doc_12448656_179_196_Disease))))) (CC and) (VP (TO to) (VP (VB measure) (NP (NP (NNS changes)) (PP (IN of) (NP (CD one) (JJ angiogenic) (NN factor)))))))) (, ,) (NP (NP (NP (JJ vascular) (JJ endothelial) (NN growth) (NN factor)) (PRN (-LRB- -LRB-) (NP (NNP VEGF)) (-RRB- -RRB-))) (NP (CD 165))) (, ,) (PP (IN with) (NP (NN therapy))) (. .)))
12448656	2	(S1 (S (NP (NP (NP (NNS PATIENTS)) (CC AND) (NP (NNS METHODS))) (: :) (NP (CD 29) (NNS patients))) (VP (AUX were) (VP (VBD enrolled) (PP (IN on) (NP (NP (DT a) (NN study)) (PP (IN of) (NP (NNP Doc_12448656_368_379_Chemical))))) (S (VP (VBG using) (NP (DT an) (JJ intra-patient) (NN dose) (NN escalation) (NN schedule)))))) (. .)))
12448656	3	(S1 (S (NP (NNS Patients)) (VP (VP (VBD began) (NP (NNP Doc_12448656_444_455_Chemical)) (PP (IN at) (NP (CD 400) (NN mg/d)))) (CC and) (VP (VBD escalated) (SBAR (IN as) (S (VP (VBN tolerated) (PP (TO to) (NP (CD 1200) (NN mg/d))) (PP (IN by) (NP (NN day) (CD 54)))))))) (. .)))
12448656	4	(S1 (S (S (NP (NP (NN Fifty-nine)) (PP (IN per) (NP (NP (NN cent)) (PP (IN of) (NP (NNS patients)))))) (VP (AUX had) (VP (AUX had) (NP (NP (JJ previous) (NN therapy)) (PP (IN with) (NP (NN IL-2))))))) (CC and) (S (NP (CD 52) (NN %)) (VP (AUX were) (NP (NN performance) (NN status) (CD 2) (CC or) (CD 3)))) (. .)))
12448656	5	(S1 (S (NP (JJ Systemic) (NN plasma) (NN VEGF165) (NNS levels)) (VP (AUX were) (VP (VBN measured) (PP (IN by) (NP (NP (JJ dual) (JJ monoclonal) (NNP ELISA)) (PP (IN in) (NP (CD 8) (NNS patients))))))) (. .)))
12448656	6	(S1 (S (NP (CD 24) (NNS patients)) (VP (AUX were) (ADJP (ADJP (JJ evaluable) (PP (IN for) (NP (NP (NN response)) (PP (IN with) (NP (NP (CD one) (JJ partial) (NN response)) (PP (IN of) (NP (NP (CD 11) (NNS months) (NN duration)) (PP (IN of) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (NP (NP (ADJP (JJ hepatic) (CC and) (JJ pulmonary)) (NNP Doc_12448656_848_858_Disease)) (PRN (-LRB- -LRB-) (NP (CD 4) (NN %)) (-RRB- -RRB-))) (, ,) (NP (CD one) (JJ minor) (NN response)) (, ,)))))))))))) (CC and) (ADJP (NP (CD 2) (NNS patients)) (JJ stable))) (PP (IN for) (NP (IN over) (CD 6) (NNS months)))) (. .)))
12448656	7	(S1 (S (S (NP (NP (NNP Doc_12448656_926_936_Disease)) (CC and) (NP (NNP Doc_12448656_941_953_Disease))) (VP (AUX were) (NP (JJ prominent) (NNP Doc_12448656_969_979_Disease)))) (CC and) (S (NP (JJS most) (NNS patients)) (VP (MD could) (RB not) (VP (VB tolerate) (NP (DT the) (CD 1200) (NN mg/day) (NN dose) (NN level))))) (. .)))
12448656	8	(S1 (S (NP (JJ Systemic) (NN plasma) (NN VEGF165) (NNS levels)) (VP (AUX did) (RB not) (VP (VB change) (PP (IN with) (NP (NN therapy))))) (. .)))
12448656	9	(S1 (S (NP (DT These) (NNS results)) (VP (AUX are) (ADJP (JJ consistent) (PP (IN with) (NP (NP (DT a) (JJ low) (NN level)) (PP (IN of) (NP (NP (NN activity)) (PP (IN of) (NP (NNP Doc_12448656_1178_1189_Chemical))) (PP (IN in) (NP (NNP Doc_12448656_1193_1213_Disease))))))))) (. .)))
12448656	10	(S1 (S (S (NP (NP (NN Administration)) (PP (IN of) (NP (NNS doses))) (PP (IN over) (NP (CD 800) (NN mg/day)))) (VP (AUX was) (ADJP (JJ difficult) (SBAR (S (VP (TO to) (VP (VB achieve) (PP (IN in) (NP (DT this) (JJ patient) (NN population)))))))))) (, ,) (ADVP (RB however)) (S (NP (JJR lower) (NNS doses)) (VP (AUX were) (ADJP (JJ practical)))) (. .)))
12448656	11	(S1 (S (NP (NP (NP (DT The) (JJ dose-response) (NN relationship)) (PRN (, ,) (PP (IN if) (NP (DT any))) (, ,))) (PP (IN of) (NP (NNP Doc_12448656_1387_1398_Chemical))) (PP (IN for) (NP (NNP Doc_12448656_1403_1423_Disease)))) (VP (AUX is) (ADJP (JJ unclear))) (. .)))
12452237	0	(S1 (SQ (MD Can) (NP (NNP Doc_12452237_4_13_Chemical)) (VP (VB reduce) (NP (JJ Doc_12452237_21_36_Chemical) (VBN induced) (NN Doc_12452237_45_66_Disease))) (. ?)))
12452237	1	(S1 (S (NP (DT This) (NN study)) (VP (AUX was) (VP (VBN undertaken) (S (VP (TO to) (VP (VB determine) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (JJ Doc_12452237_121_130_Chemical) (NN pretreatment))) (PP (IN on) (NP (NP (NN reduction)) (PP (IN of) (NP (NNP Doc_12452237_160_175_Chemical-induced) (NNP Doc_12452237_184_191_Disease))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG undergoing) (NP (NP (JJ general) (NN anesthesia)) (PP (IN for) (NP (JJ gynecological) (NN surgery))))))))))))))) (. .)))
12452237	2	(S1 (S (NP (NP (QP (CD One) (CD hundred))) (CC and) (NP (JJ thirty-five) (NNS patients))) (VP (AUX were) (VP (VBN assigned) (PP (TO to) (NP (NP (CD one)) (PP (IN of) (NP (NP (CD three) (NNS groups)) (PP (IN in) (NP (DT a) (JJ prospective) (, ,) (JJ double) (JJ blind) (, ,) (JJ randomized) (NN manner))))))))) (. .)))
12452237	3	(S1 (S (NP (NP (NNP Group) (NNP PS)) (, ,) (NP (DT the) (NN control) (NN group)) (, ,)) (VP (VBD received) (NP (NP (JJ normal) (NN saline)) (CC and) (NP (NNP Doc_12452237_442_457_Chemical) (CD 1.5) (NN mg))) (NP (NP (NP (NNP x) (CD kg)) (PRN (-LRB- -LRB-) (NP (NN -1)) (-RRB- -RRB-))) (: ;) (NP (NP (NNP Group) (NNP LS)) (, ,) (NP (NP (NNP Doc_12452237_485_494_Chemical) (CD 1.5) (NN mg)) (X (SYM x) (NP (NP (NP (NNS kg)) (PRN (-LRB- -LRB-) (JJ -1) (-RRB- -RRB-))) (CC and) (NP (NNP Doc_12452237_515_530_Chemical) (CD 1.5) (NNS mg))) (X (SYM x)) (NP (NP (NN kg)) (PRN (-LRB- -LRB-) (NP (NN -1)) (-RRB- -RRB-)))))) (: ;) (NP (NP (NNP Group) (NNP PR)) (, ,) (NP (JJ normal) (NN saline))) (CC and) (NP (NNP Doc_12452237_576_586_Chemical) (CD 0.6))) (S (VP (VBG mg) (NP (NP (NNP x) (NNS kg)) (PRN (-LRB- -LRB-) (JJ -1) (-RRB- -RRB-)))))) (. .)))
12452237	4	(S1 (S (NP (JJ Doc_12452237_604_612_Chemical) (CD 0.1) (NN mg)) (ADVP (LS x)) (VP (VBZ kg) (SBAR (S (S (NP (-LRB- -LRB-) (JJ -1) (-RRB- -RRB-) (NNP iv)) (VP (AUX was) (VP (VBN given) (PP (IN for) (NP (NN premedication)))))) (CC and) (S (NP (DT all) (NNS patients)) (VP (AUX were) (VP (VBN monitored) (PP (IN with) (NP (NP (DT a) (JJ noninvasive) (NN blood) (NN pressure) (NN monitor)) (, ,) (NP (NN ECG)) (CC and) (NP (NN pulse) (NN oximetry)))))))))) (. .)))
12452237	5	(S1 (S (NP (NNP Anesthesia)) (VP (AUX was) (VP (VBN induced) (PP (IN with) (NP (NP (CD 5) (JJ mg.kg) (-LRB- -LRB-) (NN -1) (-RRB- -RRB-) (JJ Doc_12452237_799_809_Chemical) (NN iv.)) (VP (VBN followed) (PP (IN by) (NP (NP (NP (NNP Doc_12452237_826_841_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Group) (NNP PS)) (, ,) (NP (NNP LS)) (-RRB- -RRB-))) (CC or) (NP (NP (NNP Doc_12452237_860_870_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Group) (NNP PR)) (-RRB- -RRB-)))))))) (PP (IN for) (NP (JJ tracheal) (NN intubation))))) (. .)))
12452237	6	(S1 (S (PP (VBG Following) (NP (NP (NN administration)) (PP (IN of) (NP (DT these) (NNS agents))))) (, ,) (NP (NP (DT the) (NN presence)) (, ,) (CC and) (NP (NP (NN degree)) (PP (IN of) (NP (NNP Doc_12452237_977_990_Disease))))) (VP (AUX were) (VP (VBN assessed) (ADVP (RB visually)) (PP (IN on) (NP (DT a) (CD four) (NN point) (NN scale))) (PP (IN by) (NP (NP (CD one) (NN investigator)) (SBAR (WHNP (WP who)) (S (VP (AUX was) (VP (VBN blinded) (PP (TO to) (NP (NP (DT the) (NN drug)) (VP (VBN administered)))))))))))) (. .)))
12452237	7	(S1 (S (NP (NP (DT The) (NN blood) (NN pressure) (CC and) (NN heart) (NN rate)) (PP (IN of) (NP (DT each) (NN patient)))) (VP (AUX were) (VP (VBN monitored) (PP (IN on) (NP (CD nine) (NNS occasions))))) (. .)))
12452237	8	(S1 (S (ADVP (NP (JJ Twenty-four) (NNS hours)) (RB later)) (, ,) (NP (NP (DT any) (NN Doc_12452237_1211_1218_Disease)) (VP (VBN experienced))) (VP (AUX was) (VP (VP (VBN assessed) (PP (VBG according) (PP (TO to) (NP (DT a) (JJ structured) (NN questionaire))))) (CC and) (VP (VBN graded) (PP (IN by) (NP (NP (DT a) (ADJP (CD four) (NN point)) (NN scale)) (PP (IN by) (NP (NP (CD one) (NN investigator)) (VP (VBN blinded) (PP (TO to) (NP (DT the) (JJ intraoperative) (NN management))))))))))) (. .)))
12452237	9	(S1 (S (NP (DT The) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NNP Doc_12452237_1404_1424_Disease)) (VP (AUX was) (RB not) (VP (VBN found) (PP (IN in) (NP (NNP Group) (NNP PR))) (SBAR (IN while) (S (NP (NP (DT the) (NNS patients)) (PP (IN in) (NP (NNP Group) (NNP LS)))) (VP (AUX had) (NP (NP (DT a) (JJR lower) (NN incidence)) (PP (IN of) (NP (NNP Doc_12452237_1507_1527_Disease))) (PP (IN than) (NP (NP (DT those)) (PP (IN in) (NP (NP (NNP Group) (NNP PS)) (PRN (-LRB- -LRB-) (NP (NNP p) (QP (CD <) (CD 0.001))) (-RRB- -RRB-))))))))))))))) (. .)))
12452237	10	(S1 (S (PP (IN At) (NP (CD 24))) (NP (NNP h)) (, ,) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NNP Doc_12452237_1590_1597_Disease)))) (VP (AUX was) (ADJP (ADJP (JJR higher) (PP (IN in) (NP (NNP Group) (NNP PS)))) (PP (IN than) (PP (IN in) (NP (NP (NNP Group) (NNP LS)) (CC and) (NP (NP (NNP PR)) (PRN (-LRB- -LRB-) (NP (NNP p) (NNP <) (CD 0.05)) (-RRB- -RRB-)))))))) (. .)))
12452237	11	(S1 (S (NP (DT A) (NN correlation)) (VP (AUX was) (RB not) (VP (VBN found) (PP (IN between) (NP (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NNP Doc_12452237_1710_1717_Disease)))) (CC and) (NP (NP (DT the) (NN occurrence)) (PP (IN of) (NP (NNP Doc_12452237_1740_1760_Disease)))))))) (. .)))
12452237	12	(S1 (S (NP (NP (DT The) (NNS changes)) (PP (IN in) (NP (NP (JJ systolic) (CC and) (JJ diastolic) (NN blood) (NN pressure)) (CC and) (NP (NN heart) (NN rate))))) (VP (AUX were) (RB not) (ADJP (JJ significant)) (PP (IN among) (NP (DT the) (CD three) (NNS groups)))) (. .)))
12452237	13	(S1 (S (PP (IN In) (NP (NP (NN conclusion)) (, ,) (SBAR (WHADVP (WRB where)) (S (NP (NNP Doc_12452237_1896_1911_Chemical)) (VP (AUX is) (VP (VBN used))))))) (, ,) (NP (NNP Doc_12452237_1921_1930_Chemical)) (VP (AUX is) (VP (VBN proven) (S (VP (TO to) (VP (AUX be) (NP (NP (DT the) (JJ useful) (NN pretreatment) (NN agent)) (PP (IN for) (NP (NP (DT the) (NN reduction)) (PP (IN of) (NP (NN Doc_12452237_1998_2019_Disease))))))))))) (. .)))
12481039	0	(S1 (S (NP (JJ Reduced) (JJ Doc_12481039_8_14_Chemical) (NN channel) (NN density)) (, ,) (VP (VP (VBD altered) (NP (NP (NN voltage) (NN dependence)) (PP (IN of) (NP (NN inactivation))))) (, ,) (CC and) (VP (VBD increased) (NP (NN susceptibility)) (PP (TO to) (NP (NNP Doc_12481039_108_116_Disease))) (PP (IN in) (NP (NP (NNS mice)) (VP (VBG lacking) (NP (JJ Doc_12481039_133_139_Chemical) (NN channel) (NN beta) (NNS 2-subunits))))))) (. .)))
12481039	1	(S1 (S (NP (JJ Doc_12481039_165_171_Chemical) (NN channel) (NNS beta-subunits)) (VP (VBP modulate) (NP (NP (NP (NN channel) (NN gating)) (, ,) (NP (NN assembly)) (, ,) (CC and) (NP (NN cell) (NN surface) (NN expression))) (PP (IN in) (NP (JJ heterologous) (NN cell) (NNS systems))))) (. .)))
12481039	2	(S1 (S (NP (PRP We)) (VP (VBD generated) (NP (JJ beta2) (PRN (-LRB- -LRB-) (JJ -/-) (-RRB- -RRB-)) (NNS mice)) (S (VP (TO to) (VP (VB investigate) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NN beta2))) (PP (IN in) (NP (NP (NN control)) (PP (IN of) (NP (NP (JJ Doc_12481039_363_369_Chemical) (NN channel) (NN density)) (, ,) (NP (NN localization)) (, ,) (CC and) (NP (NP (NN function)) (PP (IN in) (NP (NP (NNS neurons)) (PP (IN in) (NP (NN vivo))))))))))))))) (. .)))
12481039	3	(S1 (S (NP (NP (NNS Measurements)) (PP (IN of) (NP (NNP Doc_12481039_450_465_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_12481039_467_470_Chemical)) (-RRB- -RRB-)) (JJ binding)))) (VP (VBD showed) (NP (NP (DT a) (JJ significant) (NN reduction)) (PP (IN in) (NP (NP (DT the) (NN level)) (PP (IN of) (NP (NN plasma) (NN membrane) (JJ Doc_12481039_543_549_Chemical) (NNS channels))) (PP (IN in) (NP (JJ beta2) (PRN (-LRB- -LRB-) (JJ -/-) (-RRB- -RRB-)) (NNS neurons))))))) (. .)))
12481039	4	(S1 (S (NP (NP (DT The) (NN loss)) (PP (IN of) (NP (NNS beta2)))) (VP (VBD resulted) (PP (IN in) (NP (NP (NP (JJ negative) (NNS shifts)) (PP (IN in) (NP (NP (DT the) (JJ voltage) (NN dependence)) (PP (IN of) (NP (NN inactivation)))))) (CONJP (RB as) (RB well) (IN as)) (NP (NP (JJ significant) (NNS decreases)) (PP (IN in) (NP (NP (JJ Doc_12481039_706_712_Chemical) (JJ current) (NN density)) (PP (IN in) (NP (ADJP (RB acutely) (VBN dissociated)) (JJ hippocampal) (NNS neurons))))))))) (. .)))
12481039	5	(S1 (S (S (NP (NP (DT The) (JJ integral)) (PP (IN of) (NP (NP (DT the) (JJ compound) (NN action) (NN potential)) (PP (IN in) (NP (JJ optic) (NN nerve)))))) (VP (AUX was) (VP (ADVP (RB significantly)) (VBN reduced)))) (, ,) (CC and) (S (NP (NP (DT the) (NN threshold)) (PP (IN for) (NP (NN action) (JJ potential) (NN generation)))) (VP (AUX was) (VP (VBN increased) (, ,) (S (VP (VBG indicating) (NP (NP (DT a) (NN reduction)) (PP (IN in) (NP (NP (DT the) (NN level)) (PP (IN of) (NP (JJ functional) (NN plasma) (NN membrane) (JJ Doc_12481039_992_998_Chemical) (NNS channels))))))))))) (. .)))
12481039	6	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NP (NP (NP (DT the) (NN conduction) (NN velocity)) (, ,) (NP (NP (DT the) (NN number) (CC and) (NN size)) (PP (IN of) (NP (NP (NNS axons)) (PP (IN in) (NP (DT the) (JJ optic) (NN nerve)))))) (, ,) (CC and) (NP (NP (DT the) (JJ specific) (NN localization)) (PP (IN of) (NP (NP (NNP Doc_12481039_1129_1131_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP v)) (-RRB- -RRB-)))))) (NP (CD 1.6) (NNS channels))) (PP (IN in) (NP (DT the) (NNS nodes))) (PP (IN of) (NP (NNP Ranvier)))) (VP (AUX were) (VP (VBN unchanged.) (S (NP (JJ beta2) (PRN (-LRB- -LRB-) (JJ -/-) (-RRB- -RRB-)) (NNS mice)) (VP (VP (VBN displayed) (NP (NP (VBN increased) (NN susceptibility)) (PP (TO to) (NP (NNP Doc_12481039_1241_1249_Disease))))) (, ,) (VP (ADVP (RB as)) (VBN indicated) (PP (IN by) (NP (NP (VBN reduced) (NN latency) (CC and) (NN threshold)) (PP (IN for) (NP (JJ Doc_12481039_1301_1312_Chemical-induced) (NNP Doc_12481039_1321_1329_Disease)))))) (, ,) (CC but) (VP (VBD seemed) (ADJP (JJ normal)) (PP (IN in) (NP (JJ other) (JJ neurological) (NNS tests)))))))) (. .)))
12481039	7	(S1 (S (NP (PRP$ Our) (NNS observations)) (VP (VBP show) (SBAR (IN that) (S (NP (NNS beta2-subunits)) (VP (VP (VBP play) (NP (NP (DT an) (JJ important) (NN role)) (PP (IN in) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (NP (NP (JJ Doc_12481039_1464_1470_Chemical) (NN channel) (NN density)) (CC and) (NP (NN function))) (PP (IN in) (NP (NP (NNS neurons)) (PP (IN in) (NP (NN vivo))))))))))) (CC and) (VP (AUX are) (VP (VBN required) (PP (IN for) (NP (NP (JJ normal) (NN action) (JJ potential) (NN generation)) (CC and) (NP (NP (NN control)) (PP (IN of) (NP (NN excitability)))))))))))) (. .)))
12549952	0	(S1 (S (VP (VB Doc_12549952_0_19_Disease) (PP (IN with) (NP (NP (JJ concurrent) (NN Doc_12549952_36_45_Chemical)) (CC and) (NP (JJ Doc_12549952_50_61_Chemical) (NN therapy))))) (. .)))
12549952	1	(S1 (S (S (VP (TO To) (VP (VB report) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (JJ fatal) (NN Doc_12549952_108_121_Disease)))) (ADVP (RB possibly))))) (VP (VBN associated) (PP (IN with) (NP (NP (JJ concurrent) (NN use)) (PP (IN of) (NP (NP (NNP Doc_12549952_165_174_Chemical)) (CC and) (NP (NNP Doc_12549952_179_190_Chemical))))))) (. .)))
12549952	2	(S1 (NP (NP (NN CASE) (NN SUMMARY)) (: :) (NP (NP (DT A) (JJ 41-year-old) (JJ Chinese) (NN man)) (PP (IN with) (NP (NP (DT a) (NN history)) (PP (IN of) (NP (NNP Doc_12549952_250_265_Disease))) (SBAR (S (VP (AUX had) (VP (AUX been) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_12549952_288_299_Chemical)) (CC and) (NP (NNP Doc_12549952_304_315_Chemical)))) (PP (IN for) (NP (DT the) (JJ past) (CD 5) (NNS years))))))))))) (. .)))
12549952	3	(S1 (S (NP (PRP He)) (VP (VBD received) (NP (NP (DT a) (JJ 10-day) (NN course)) (PP (IN of) (NP (NNP Doc_12549952_369_378_Chemical)))) (PP (IN as) (NP (NP (DT an) (NN aid)) (PP (IN for) (S (VP (VBG smoking) (NP (NN cessation)) (ADVP (NP (CD 10) (NNS weeks)) (RB prior)) (PP (TO to) (NP (NN presentation))))))))) (. .)))
12549952	4	(S1 (S (NP (PRP He)) (VP (VBD developed) (NP (NN Doc_12549952_456_475_Disease)) (PP (IN with) (NP (NP (JJ rapid) (NN deterioration)) (PP (IN of) (NP (JJ renal) (NN function)))))) (. .)))
12549952	5	(S1 (S (NP (NN Liver) (NNS biopsy)) (VP (VBD showed) (NP (NP (NN evidence)) (PP (IN of) (NP (JJ nonspecific) (NNP Doc_12549952_564_595_Disease))))) (. .)))
12549952	6	(S1 (S (NP (JJ Doc_12549952_597_600_Chemical) (NN condition)) (VP (AUX was) (VP (RBR further) (VBN complicated) (PP (IN by) (NP (NP (NNP Doc_12549952_638_644_Disease)) (CC and) (NP (NNP Doc_12549952_649_661_Disease)))))) (. .)))
12549952	7	(S1 (S (NP (NN Death)) (VP (VBD resulted) (PP (NP (CD 19) (NNS days)) (IN after) (NP (NP (DT the) (NN onset)) (PP (IN of) (NP (NNS symptoms)))))) (. .)))
12549952	8	(S1 (S (NP (NP (DT The) (NN likelihood)) (SBAR (WHNP (IN that)) (S (NP (NNP Doc_12549952_735_744_Chemical)) (VP (VBN induced) (NP (NN hepatotoxicity)) (PP (IN in) (NP (PRP$ our) (NN patient))))))) (VP (AUX was) (ADJP (JJ possible)) (, ,) (PP (VBN based) (PP (IN on) (NP (DT the) (NNP Naranjo) (NN probability) (NN scale))))) (. .)))
12549952	9	(S1 (S (SBAR (IN Although) (S (NP (EX there)) (VP (AUX is) (NP (NP (JJ increasing) (NN evidence)) (PP (IN of) (NP (NP (NN hepatotoxicity)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_12549952_916_925_Chemical)))))))))) (, ,) (NP (DT this)) (VP (AUX is) (NP (NP (DT the) (JJ first) (NN case)) (PP (IN of) (NP (NN fatality))) (SBAR (WHNP (WDT that)) (S (VP (MD could) (VP (AUX have) (VP (VBN resulted) (PP (IN from) (NP (NNP Doc_12549952_992_1011_Disease))) (PP (IN in) (NP (NP (DT a) (NN patient)) (VP (VBG receiving) (NP (JJ Doc_12549952_1035_1044_Chemical) (NN while)) (PP (IN on) (NP (NP (JJ concomitant) (NN treatment)) (PP (IN with) (NP (NNP Doc_12549952_1081_1092_Chemical))))))))))))))) (. .)))
12549952	10	(S1 (S (NP (NNS Clinicians)) (VP (MD should) (VP (AUX be) (ADJP (JJ aware) (PP (IN of) (NP (NP (DT the) (NN possibility)) (PP (IN of) (NP (NNP Doc_12549952_1156_1174_Disease))) (VP (VBN induced) (PP (IN by) (NP (NP (JJ Doc_12549952_1186_1195_Chemical) (VBN given) (NN concurrently)) (PP (IN with) (NP (JJ other) (JJ hepatotoxic) (NNS drugs))))))))))) (. .)))
1255900	0	(S1 (NP (NP (NP (JJ Pyeloureteral) (VBG filling) (NNS defects)) (VP (VBN associated) (PP (IN with) (NP (JJ systemic) (NN anticoagulation))))) (: :) (NP (NP (DT a) (NN case)) (SBAR (S (VP (VBP report))))) (. .)))
1255900	1	(S1 (S (NP (NP (DT The) (NN etiology)) (PP (IN of) (NP (NNP Doc_1255900_103_126_Disease)))) (VP (AUX has) (ADVP (RB long)) (VP (AUX been) (VP (VBN attributed) (PP (TO to) (NP (NP (NN chronic) (NN Doc_1255900_163_172_Disease)) (CC and) (NP (NN Doc_1255900_177_189_Disease))))))) (. .)))
1255900	2	(S1 (S (NP (DT A) (NN case)) (VP (AUX is) (VP (VBN presented) (SBAR (IN that) (S (VP (AUX is) (ADJP (JJ unique)) (SBAR (IN in) (IN that) (S (NP (NP (NP (DT the) (JJ acute) (NN onset)) (CC and) (NP (DT the) (JJ rapid) (NN resolution))) (PP (IN of) (NP (JJ pyeloureteral) (VBG filling) (NNS defects))) (PP (IN in) (NP (DT this) (NN patient)))) (VP (AUX were) (VP (VBN documented) (PP (IN by) (NP (NN radiography)))))))))))) (. .)))
1255900	3	(S1 (S (NP (EX There)) (VP (AUX is) (NP (NP (DT no) (NN evidence)) (PP (IN of) (NP (NP (NN antecedent)) (CC or) (NP (JJ concurrent) (NN Doc_1255900_405_414_Disease))))) (PP (IN in) (NP (DT this) (NN patient)))) (. .)))
1255900	4	(S1 (S (NP (DT The) (NN disease)) (VP (VP (VBD occurred) (ADVP (JJ subsequent) (PP (TO to) (NP (NP (DT the) (NN initiation)) (PP (IN of) (NP (JJ Doc_1255900_485_492_Chemical) (NN therapy)))))) (PP (IN for) (NP (VBN suspected) (JJ pelvic) (NN Doc_1255900_522_538_Disease)))) (CC and) (VP (VBD cleared) (ADVP (RB rapidly) (JJ subsequent)) (PP (TO to) (NP (PRP$ its) (NN discontinuation))))) (. .)))
1255900	5	(S1 (S (NP (NP (DT The) (NN rate)) (PP (IN of) (NP (NP (NN resolution)) (PP (IN of) (NP (DT the) (JJ radiographic) (NNS findings)))))) (VP (MD may) (VP (AUX be) (ADJP (JJ helpful) (PP (IN in) (NP (NP (NN distinguishing)) (PP (IN between) (NP (NP (JJ true) (NNP Doc_1255900_692_715_Disease)) (CC and) (NP (NNP Doc_1255900_720_741_Disease))))))))) (. .)))
12571256	0	(S1 (NP (NP (JJ Nephrotoxic) (NNS effects)) (PP (IN in) (NP (NP (JJ high-risk) (NNS patients)) (VP (VBG undergoing) (NP (NN angiography))))) (. .)))
12571256	1	(S1 (S (NP (NP (DT The) (NN use)) (PP (IN of) (NP (JJ iodinated) (NN contrast) (NN medium)))) (VP (MD can) (VP (VB result) (PP (IN in) (NP (NNP Doc_12571256_129_140_Disease))))) (. .)))
12571256	2	(S1 (S (SBAR (IN Whether) (S (NP (JJ iso-osmolar) (NN contrast) (NN medium)) (VP (AUX is) (ADJP (ADJP (RBR less) (JJ nephrotoxic)) (PP (IN than) (NP (NP (JJ low-osmolar) (NN contrast) (NN medium)) (PP (IN in) (NP (JJ high-risk) (NNS patients))))))))) (VP (AUX is) (ADJP (JJ uncertain))) (. .)))
12571256	3	(S1 (S (NP (PRP We)) (VP (VBD conducted) (NP (DT a) (JJ randomized) (, ,) (JJ double-blind) (, ,) (JJ prospective) (, ,) (NN multicenter) (NN study)) (S (VP (VBG comparing) (NP (NP (DT the) (JJ nephrotoxic) (NNS effects)) (PP (IN of) (NP (NP (DT an) (JJ iso-osmolar) (, ,) (JJ dimeric) (, ,) (JJ nonionic) (NNP Doc_12571256_419_434_Chemical)) (, ,) (NP (NNP Doc_12571256_436_445_Chemical)) (, ,)))) (PP (IN with) (NP (NP (DT those)) (PP (IN of) (NP (NP (DT a) (JJ low-osmolar) (, ,) (JJ nonionic) (, ,) (JJ monomeric) (NN contrast) (NN medium)) (, ,) (NP (NNP Doc_12571256_513_520_Chemical))))))))) (. .)))
12571256	4	(S1 (S (NP (DT The) (NN study)) (VP (VBD involved) (NP (CD 129) (NNS patients)) (PP (IN with) (NP (NNP Doc_12571256_559_567_Disease))) (PP (IN with) (NP (NP (JJ serum) (JJ Doc_12571256_579_589_Chemical) (NNS concentrations)) (PP (IN of) (NP (QP (CD 1.5) (TO to) (CD 3.5)) (NNS mg))) (PP (IN per) (NP (NP (NN deciliter)) (SBAR (WHNP (WP who)) (S (VP (VBD underwent) (NP (ADJP (JJ coronary) (CC or) (JJ aortofemoral)) (NN angiography)))))))))) (. .)))
12571256	5	(S1 (S (NP (DT The) (JJ primary) (NN end) (NN point)) (VP (AUX was) (NP (NP (DT the) (JJ peak) (NN increase)) (PP (IN from) (NP (NN base) (NN line))) (PP (IN in) (NP (NP (DT the) (JJ Doc_12571256_754_764_Chemical) (NN concentration)) (PP (IN during) (NP (DT the) (CD three) (NNS days))) (PP (IN after) (NP (NN angiography))))))) (. .)))
12571256	6	(S1 (S (NP (JJ Other) (NN end) (NNS points)) (VP (AUX were) (NP (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (DT the) (JJ Doc_12571256_861_871_Chemical) (NN concentration)) (PP (IN of) (NP (CD 0.5) (NN mg))) (PP (IN per) (NP (JJR deciliter) (CC or) (JJR more)))))) (, ,) (NP (NP (DT an) (NN increase)) (PP (IN of) (NP (NP (CD 1.0) (NNS mg)) (PP (IN per) (NP (JJR deciliter) (CC or) (JJR more)))))) (, ,) (CC and) (NP (NP (DT a) (NN change)) (PP (IN in) (NP (NP (DT the) (JJ Doc_12571256_984_994_Chemical) (NN concentration)) (PP (IN from) (NP (NN day) (CD 0))) (PP (TO to) (NP (NN day) (CD 7)))))))) (. .)))
12571256	7	(S1 (S (NP (DT The) (NNP Doc_12571256_1043_1053_Chemical) (NN concentration)) (VP (VBD increased) (ADVP (RB significantly) (RBR less)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (NN Doc_12571256_1122_1131_Chemical)))))))) (. .)))
12571256	8	(S1 (S (PP (PP (IN From) (NP (NN day) (CD 0))) (PP (TO to) (NP (NN day) (CD 3)))) (, ,) (NP (NP (DT the) (JJ mean) (JJ peak) (NN increase)) (PP (IN in) (NP (NNP Doc_12571256_1180_1190_Chemical)))) (VP (AUX was) (NP (NP (CD 0.13) (NN mg)) (PP (IN per) (NP (NP (NP (NN deciliter)) (PP (IN in) (NP (DT the) (NNP Doc_12571256_1224_1233_Chemical) (NN group)))) (CC and) (NP (NP (CD 0.55) (NNS mg)) (PP (IN per) (NP (NP (NN deciliter)) (PP (IN in) (NP (NP (DT the) (JJ Doc_12571256_1273_1280_Chemical) (NN group)) (PRN (-LRB- -LRB-) (NP (NP (NNP P=0.001)) (: ;) (NP (NP (NP (DT the) (NN increase)) (PP (IN with) (NP (NNP Doc_12571256_1315_1324_Chemical)))) (CC minus) (NP (NP (DT the) (NN increase)) (PP (IN with) (NP (NNP Doc_12571256_1349_1356_Chemical)))))) (, ,) (NP (NP (CD -0.42) (NNS mg)) (PP (IN per) (NP (NN deciliter) (CD -LSB-95) (NN percent) (NN confidence) (NN interval)))) (, ,) (NP (QP (CD -0.73) (TO to) (CD -0.22)) (NNS -RSB-)) (-RRB- -RRB-))))))))))) (. .)))
12571256	9	(S1 (S (NP (NP (CD Two)) (PP (IN of) (NP (NP (DT the) (CD 64) (NNS patients)) (PP (IN in) (NP (DT the) (NNP Doc_12571256_1462_1471_Chemical) (NN group)))))) (PRN (-LRB- -LRB-) (NP (CD 3) (NN percent)) (-RRB- -RRB-)) (VP (AUX had) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (DT the) (JJ Doc_12571256_1513_1523_Chemical) (NN concentration)) (PP (IN of) (NP (CD 0.5) (NNS mg)) (PP (IN per) (NP (NP (ADJP (JJR deciliter) (CC or) (JJR more)) (PRN (, ,) (SBAR (IN as) (S (VP (VBN compared) (PP (IN with) (NP (NP (CD 17)) (PP (IN of) (NP (NP (DT the) (CD 65) (NNS patients)) (PP (IN in) (NP (NP (NP (DT the) (NNP Doc_12571256_1617_1624_Chemical) (NN group)) (PRN (-LRB- -LRB-) (NP (CD 26) (NN percent)) (-RRB- -RRB-))) (-LRB- -LRB-) (NP (NNP P=0.002)) (: ;) (NP (NP (NNS odds) (NN ratio)) (PP (IN for) (NP (NP (PDT such) (DT an) (NN increase)) (PP (IN in) (NP (DT the) (NNP Doc_12571256_1693_1702_Chemical) (NN group))))))))))))))) (, ,)) (ADJP (QP (CD 0.09) (CD -LSB-95)) (NN percent)) (NN confidence) (NN interval)) (, ,) (NP (QP (CD 0.02) (TO to) (CD 0.41)) (NNS -RSB-)) (-RRB- -RRB-)))))))) (. .)))
12571256	10	(S1 (S (S (NP (NP (DT No) (NN patient)) (VP (VBG receiving) (NP (NNP Doc_12571256_1785_1794_Chemical)))) (VP (AUX had) (NP (NP (DT an) (NN increase)) (PP (IN of) (NP (NP (CD 1.0) (NNS mg)) (PP (IN per) (NP (NP (NN deciliter)) (CC or) (NP (JJR more))))))))) (, ,) (CC but) (S (NP (NP (CD 10) (NNS patients)) (PP (IN in) (NP (DT the) (NNP Doc_12571256_1867_1874_Chemical) (NN group))) (PRN (-LRB- -LRB-) (NP (CD 15) (NN percent)) (-RRB- -RRB-))) (VP (AUX did))) (. .)))
12571256	11	(S1 (S (NP (NP (DT The) (JJ mean) (NN change)) (PP (IN in) (NP (NP (DT the) (JJ Doc_12571256_1922_1932_Chemical) (NN concentration)) (PP (IN from) (NP (NN day) (CD 0))) (PP (TO to) (NP (NN day) (CD 7)))))) (VP (AUX was) (NP (NP (QP (CD 0.07) (CD mg))) (PP (IN per) (NP (NP (NP (NN deciliter)) (PP (IN in) (NP (DT the) (NNP Doc_12571256_2000_2009_Chemical) (NN group)))) (CC and) (NP (NP (CD 0.24) (NN mg)) (PP (IN per) (NP (NP (NN deciliter)) (PP (IN in) (NP (NP (DT the) (JJ Doc_12571256_2049_2056_Chemical) (NN group)) (PRN (-LRB- -LRB-) (NP (NP (NNP P=0.003)) (: ;) (NP (NP (NP (NN value)) (PP (IN in) (NP (DT the) (NNP Doc_12571256_2086_2095_Chemical) (NN group)))) (CC minus) (NP (NP (DT the) (NN value)) (PP (IN in) (NP (DT the) (NNP Doc_12571256_2125_2132_Chemical) (NN group)))))) (, ,) (NP (NP (CD -0.17) (NNS mg)) (PP (IN per) (NP (NN deciliter) (CD -LSB-95) (NN percent) (NN confidence) (NN interval)))) (, ,) (NP (QP (CD -0.34) (TO to) (CD -0.07)) (NNS -RSB-)) (-RRB- -RRB-))))))))))) (. .)))
12571256	12	(S1 (S (NP (NP (NN Doc_12571256_2227_2238_Disease)) (VP (VBN induced) (PP (IN by) (NP (NN contrast) (NN medium))))) (VP (MD may) (VP (AUX be) (ADJP (RBR less) (JJ likely) (S (VP (TO to) (VP (VB develop) (PP (IN in) (NP (JJ high-risk) (NNS patients))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP Doc_12571256_2323_2332_Chemical)) (VP (AUX is) (VP (VBN used) (PP (RB rather) (IN than) (NP (DT a) (JJ low-osmolar) (, ,) (JJ nonionic) (NN contrast) (NN medium))))))))) (. .)))
12600698	0	(S1 (NP (NP (JJ Protective) (NN effect)) (PP (IN of) (NP (NNP Doc_12600698_21_30_Chemical))) (PP (IN against) (NP (NP (JJ Doc_12600698_39_51_Chemical-induced) (NN vestibulotoxicity)) (PP (IN in) (NP (DT the) (NN guinea) (NN pig))))) (. .)))
12600698	1	(S1 (S (NP (DT This) (NN study)) (VP (VBD investigated) (NP (NP (NN alleviation)) (PP (IN of) (NP (JJ Doc_12600698_136_148_Chemical-induced) (NN vestibulotoxicity))) (PP (IN by) (NP (NNP Doc_12600698_178_187_Chemical))) (PP (IN in) (NP (NN guinea) (NNS pigs))))) (. .)))
12600698	2	(S1 (S (NP (NP (NNP Doc_12600698_204_213_Chemical)) (, ,) (NP (DT a) (JJ free) (JJ radical) (NN scavenger)) (, ,)) (VP (VP (AUX has) (NP (JJ potent) (JJ free) (JJ radical) (NN quenching) (NN action))) (CC and) (VP (AUX is) (VP (VBN used) (PP (IN in) (NP (JJ clinical) (NN practice))) (S (VP (TO to) (VP (VB treat) (NP (NN Doc_12600698_324_343_Disease)))))))) (. .)))
12600698	3	(S1 (S (S (NP (NNP Doc_12600698_345_357_Chemical)) (VP (AUX was) (VP (VBN administered) (PP (TO to) (NP (DT the) (JJ inner) (NN ear))) (PP (IN by) (NP (NP (JJ osmotic) (NN pump)) (PP (IN for) (NP (NP (CD 24) (NNP h)) (, ,) (CC and) (NP (NP (NNP Doc_12600698_422_431_Chemical)) (PRN (-LRB- -LRB-) (NP (NN n=8)) (-RRB- -RRB-)))))))))) (CC or) (S (NP (NP (NN saline)) (PRN (-LRB- -LRB-) (NP (NN n=6)) (-RRB- -RRB-))) (VP (AUX was) (ADVP (RB intraperitoneally)) (VP (VBN injected) (ADVP (RB once) (NP (DT a) (NN day)) (PP (IN for) (NP (CD 7) (NNS days))))))) (. .)))
12600698	4	(S1 (S (NP (PRP We)) (VP (VBD observed) (NP (NP (JJ horizontal) (NN vestibulo-ocular)) (ADJP (JJ reflex) (PP (IN as) (NP (NP (DT a) (NN marker)) (PP (IN of) (NP (JJ postoperative) (NN vestibular) (NN function)))))))) (. .)))
12600698	5	(S1 (S (NP (NP (NNS Animals)) (VP (VBN injected) (PP (IN with) (NP (NN saline))))) (VP (VBD showed) (NP (NP (ADJP (RB statistically) (JJR smaller)) (NNS gains)) (PP (IN than) (NP (NP (DT those)) (VP (VBN injected) (PP (IN with) (NP (NNP Doc_12600698_694_703_Chemical)))))))) (. .)))
12600698	6	(S1 (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NNP Doc_12600698_732_741_Chemical)) (VP (VBZ suppresses) (NP (JJ Doc_12600698_753_765_Chemical-induced) (NN vestibulotoxicity)))))) (. .)))
12691807	0	(S1 (NP (NP (JJ Doc_12691807_0_8_Chemical-induced) (JJ oromandibular) (NN Doc_12691807_31_39_Disease)) (PP (IN in) (NP (NNP Doc_12691807_43_73_Disease))) (. .)))
12691807	1	(S1 (S (NP (JJ Doc_12691807_75_83_Chemical-induced) (NNP Doc_12691807_92_103_Disease)) (VP (AUX have) (VP (AUX been) (VP (VBN reported) (PP (IN in) (NP (NP (NNP Doc_12691807_126_145_Disease)) (CC and) (NP (NNP Doc_12691807_150_173_Disease))))))) (. .)))
12691807	2	(S1 (S (NP (NNP Cranial) (NNP Doc_12691807_183_192_Disease)) (VP (AUX are) (ADJP (JJ rare)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NNP Doc_12691807_219_249_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12691807_251_254_Disease)) (-RRB- -RRB-))))))) (. .)))
12691807	3	(S1 (S (PP (IN In) (NP (DT this) (NN report))) (NP (PRP we)) (VP (VBP describe) (NP (NP (DT an) (JJ unusual) (NN case)) (PP (IN of) (NP (NP (JJ reversible) (JJ Doc_12691807_314_322_Chemical-induced) (NNP Doc_12691807_331_353_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12691807_355_358_Disease)) (-RRB- -RRB-))))) (PP (IN in) (NP (NP (DT a) (JJ Doc_12691807_365_368_Disease) (NN patient)) (SBAR (S (VP (TO to) (VP (VP (VB highlight) (NP (NP (DT the) (NN importance)) (PP (IN of) (S (VP (VBG recognizing) (NP (DT this) (NN drug) (JJ related) (NN complication)) (PP (IN in) (NP (NP (DT the) (NN management)) (PP (IN of) (NP (NNP Doc_12691807_472_475_Disease)))))))))) (, ,) (CC and) (VP (VB discuss) (NP (DT the) (JJ possible) (JJ underlying) (NN pathophysiology)))))))))) (. .)))
12734532	0	(S1 (NP (NP (NN Case) (NN report)) (: :) (NP (NP (NP (NNP Doc_12734532_13_21_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12734532_23_42_Chemical)) (-RRB- -RRB-))) (PP (IN as) (NP (NP (DT a) (NN cause)) (PP (IN of) (NP (NNP Doc_12734532_58_79_Disease)))))) (. .)))
12734532	1	(S1 (S (NP (NP (NNP Doc_12734532_81_100_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12734532_102_105_Chemical)) (-RRB- -RRB-))) (VP (AUX is) (NP (NP (DT a) (JJ sympathetic) (NN Doc_12734532_124_129_Chemical)) (VP (VBN used) (PP (IN in) (NP (NP (JJ over-the-counter) (JJ cold) (NNS remedies)) (CC and) (NP (JJ weight-control) (NNS preparations) (NX (NNP worldwide)))))))) (. .)))
12734532	2	(S1 (S (NP (PRP$ Its) (NN use)) (VP (AUX has) (VP (AUX been) (VP (VBN associated) (PP (IN with) (NP (NP (JJ Doc_12734532_245_257_Disease) (NNS episodes)) (CC and) (NP (NP (NNP Doc_12734532_271_290_Disease)) (PP (IN in) (NP (JJR younger) (NNS women))))))))) (. .)))
12734532	3	(S1 (S (NP (JJ Several) (NNS reports)) (VP (AUX have) (VP (VBN linked) (NP (NP (DT the) (NN abuse)) (PP (IN of) (NP (NNP Doc_12734532_350_353_Chemical))) (PP (IN with) (NP (NNP Doc_12734532_359_376_Disease)))) (, ,) (SBAR (ADVP (RB especially)) (WHADVP (WRB when)) (S (NP (NNP Doc_12734532_394_402_Disease)) (VP (AUX is) (VP (VBN involved))))))) (. .)))
12734532	4	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (ADVP (RB here)) (DT the) (JJ first) (NN case)) (PP (IN of) (NP (JJ Doc_12734532_449_457_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_12734532_459_462_Chemical)) (-RRB- -RRB-)) (JJ -induced) (NN Doc_12734532_472_489_Disease)))) (PP (IN in) (NP (NP (DT a) (JJ young) (NN woman)) (SBAR (WHNP (WP who)) (S (VP (AUX was) (VP (VBG using) (NP (PRP it)) (PP (IN at) (NP (NP (JJ recommended) (NNS doses)) (PP (IN for) (NP (NN weight) (NN control)))))))))))) (. .)))
12734532	5	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (PRP we)) (VP (VBP review) (NP (NP (DT the) (CD 7) (JJ other) (NNS cases)) (PP (IN of) (NP (JJ Doc_12734532_609_612_Chemical) (JJ related) (NN Doc_12734532_621_638_Disease))) (SBAR (WHNP (WDT that)) (S (VP (AUX have) (VP (AUX been) (VP (VBN reported) (ADVP (RB so) (RB far))))))))) (. .)))
12734532	6	(S1 (S (NP (NP (NNS Physicians)) (CC and) (NP (NNS patients))) (VP (MD should) (VP (AUX be) (ADJP (JJ alert) (PP (TO to) (NP (NP (DT the) (JJ potential) (JJ cardiac) (NN risk)) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NNP Doc_12734532_768_771_Chemical))))))))) (, ,) (PP (ADVP (RB even)) (IN at) (NP (NP (NNS doses)) (VP (ADVP (RB generally)) (VBN considered) (S (VP (TO to) (VP (AUX be) (ADJP (JJ safe)))))))))) (. .)))
12739036	0	(S1 (NP (NP (NN Differential) (NN diagnosis)) (PP (IN of) (NP (NP (JJ high) (JJ serum) (JJ Doc_12739036_37_45_Chemical) (NN kinase) (NNS levels)) (PP (IN in) (NP (NNP Doc_12739036_63_91_Disease))))) (. .)))
12739036	1	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT the) (JJ clinical) (CC and) (JJ bioptic) (NNS findings)) (PP (IN for) (NP (NP (DT a) (JJ 57-year-old) (NN woman)) (PP (IN with) (NP (JJ severe) (JJ Doc_12739036_173_184_Chemical-induced) (NN Doc_12739036_193_201_Disease))))))) (. .)))
12739036	2	(S1 (S (PP (IN Since) (NP (CD 1989))) (, ,) (NP (PRP she)) (VP (AUX had) (VP (AUX been) (VP (VBG suffering) (PP (IN from) (NP (NP (NNP Doc_12739036_243_271_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12739036_273_276_Disease)) (-RRB- -RRB-)))) (PP (IN with) (NP (NP (NNP Doc_12739036_283_300_Disease) (CC and) (VBN undergone) (NNS periods)) (PP (IN of) (NP (NN treatment))) (PP (IN with) (NP (NP (NNP Doc_12739036_341_353_Chemical)) (CC and) (NP (NNP Doc_12739036_358_374_Chemical))))))))) (. .)))
12739036	3	(S1 (S (NP (NP (JJ Additional) (NN therapy)) (PP (IN with) (NP (NP (NNP Doc_12739036_400_411_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP CQ)) (-RRB- -RRB-))))) (VP (AUX was) (VP (VBN started) (PP (IN because) (IN of) (NP (NN Doc_12739036_440_450_Disease))))) (. .)))
12739036	4	(S1 (S (PP (IN At) (NP (DT the) (JJ same) (NN time))) (, ,) (NP (ADJP (RB slightly) (VBN increased)) (JJ Doc_12739036_489_497_Chemical) (NN kinase) (PRN (-LRB- -LRB-) (NP (NNP CK)) (-RRB- -RRB-)) (NNS levels)) (VP (AUX were) (VP (VBN noted))) (. .)))
12739036	5	(S1 (S (S (NP (NN Doc_12739036_529_537_Disease)) (VP (AUX was) (VP (VBN suspected)))) (, ,) (CC and) (S (NP (DT the) (NN patient)) (VP (AUX was) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_12739036_586_594_Chemical)))))) (. .)))
12739036	6	(S1 (S (S (NP (DT The) (NN CK) (NN increase)) (VP (VBD persisted) (, ,) (ADVP (RB however)))) (, ,) (CC and) (S (NP (PRP she)) (VP (VBD developed) (NP (NP (JJ progressive) (NN Doc_12739036_662_679_Disease)) (CC and) (NP (NNP Doc_12739036_684_700_Disease))))) (. .)))
12739036	7	(S1 (S (NP (JJ Routine) (NNS controls)) (VP (VBD revealed) (NP (NP (ADJP (RB markedly) (JJ elevated)) (NN CK) (NNS levels)) (PP (IN of) (NP (CD 1,700) (NN U/l))))) (. .)))
12739036	8	(S1 (S (NP (DT The) (JJ neurological) (CC and) (JJ electrophysiological) (NNS findings)) (VP (AUX were) (RB not) (ADJP (JJ typical) (PP (IN of) (NP (NNP Doc_12739036_841_849_Disease))))) (. .)))
12739036	9	(S1 (S (ADVP (RB Thus)) (, ,) (NP (NP (NN muscle) (NN biopsy)) (PP (IN of) (NP (DT the) (JJ deltoid) (NN muscle)))) (VP (AUX was) (VP (VBN performed) (SBAR (IN in) (NN order) (S (VP (TO to) (VP (VB exclude) (NP (NP (NN Doc_12739036_927_939_Disease)) (CC or) (NP (JJ toxic) (NN Doc_12739036_949_957_Disease))))))))) (. .)))
12739036	10	(S1 (S (SBAR (IN As) (S (NP (PRP it)) (VP (VBD revealed) (NP (JJ Doc_12739036_974_985_Chemical-induced) (NN Doc_12739036_994_1002_Disease))))) (, ,) (NP (NN medication)) (VP (AUX was) (VP (VBN stopped))) (. .)))
12739036	11	(S1 (S (S (VP (VBG Discriminating) (PP (IN between) (NP (NP (JJ primary) (JJ Doc_12739036_1059_1062_Disease-induced) (NN Doc_12739036_1071_1110_Disease)) (CC and) (NP (JJ drug-induced) (NN side) (NNS effects)))))) (VP (AUX is) (ADJP (JJ important) (PP (IN for) (NP (NP (JJ appropriate) (NN treatment)) (PP (IN of) (NP (JJ Doc_12739036_1183_1186_Disease) (NNS patients))))))) (. .)))
12745515	0	(S1 (S (NP (NN Doc_12745515_0_7_Disease)) (VP (VBN associated) (PP (IN with) (NP (NP (NNP Doc_12745515_24_41_Disease)) (CC and) (NP (JJ sustained-release) (NNP Doc_12745515_64_73_Chemical))))) (. .)))
12745515	1	(S1 (S (NP (DT This) (NN case) (NN report)) (VP (VBZ describes) (NP (NP (DT a) (JJ generalized) (NN Doc_12745515_116_123_Disease)) (VP (VBN associated) (PP (IN with) (NP (NP (JJ sustained-release) (JJ Doc_12745515_158_167_Chemical) (NN use)) (CC and) (NP (NN Doc_12745515_176_193_Disease))))))) (. .)))
12745515	2	(S1 (S (NP (NP (DT The) (NN subject)) (, ,) (NP (DT a) (JJ 31-year-old) (NN female) (NN smoker)) (, ,)) (VP (AUX was) (VP (VBG participating) (PP (IN in) (NP (NP (DT a) (JJ clinical) (NN trial)) (VP (VBG evaluating) (NP (NP (DT an) (JJ investigational) (NN medication)) (PP (IN for) (S (VP (VBG smoking) (NP (NP (NN cessation)) (SBAR (WHNP (WDT that)) (S (VP (VBD used) (NP (JJ sustained-release) (NNP Doc_12745515_366_375_Chemical)) (PP (IN as) (NP (DT an) (JJ active) (NN control)))))))))))))))) (. .)))
12745515	3	(S1 (S (PP (IN After) (NP (NP (CD 5) (NNS weeks)) (PP (IN of) (NP (JJ Doc_12745515_415_424_Chemical) (NN use))))) (, ,) (NP (DT the) (NN subject)) (VP (VBD experienced) (NP (DT a) (JJ generalized) (NN tonic) (NN clonic) (NN Doc_12745515_481_488_Disease)) (PP (IN after) (S (VP (VP (VBG staying) (PRT (RP up)) (NP (QP (RB nearly) (PDT all)) (NN night) (NN packing))) (CC and) (VP (VBG moving) (PP (TO to) (NP (DT a) (JJ new) (NN residence)))))))) (. .)))
12745515	4	(S1 (S (NP (DT The) (NN patient)) (VP (AUX had) (NP (DT no) (JJ other) (NN risk) (NNS factors)) (PP (IN for) (NP (NNP Doc_12745515_604_612_Disease)))) (. .)))
12745515	5	(S1 (S (NP (PRP We)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NNP Doc_12745515_630_647_Disease)) (VP (MD may) (VP (VB add) (PP (TO to) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (JJ Doc_12745515_671_680_Chemical-associated) (NN Doc_12745515_692_700_Disease)))))))))) (. .)))
12760988	0	(S1 (NP (NP (NP (NN Doc_12760988_0_21_Disease)) (PP (IN after) (NP (NNP Doc_12760988_28_43_Chemical)))) (: :) (NP (NP (DT no) (NN evidence)) (PP (IN for) (NP (DT an) (JJ inflammatory) (NN origin)))) (. .)))
12760988	1	(S1 (S (NP (NP (DT A) (JJ common) (NN side) (NN effect)) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_12760988_122_137_Chemical))))) (VP (AUX is) (ADJP (JJ Doc_12760988_141_162_Disease))) (. .)))
12760988	2	(S1 (S (S (NP (NP (DT The) (NN pathogenesis)) (PP (IN of) (NP (DT this) (NN Doc_12760988_189_196_Disease)))) (VP (AUX is) (ADVP (RB still)) (ADJP (JJ unclear)))) (: ;) (S (NP (NNP Doc_12760988_215_227_Disease)) (VP (VP (AUX has) (VP (AUX been) (VP (VBN suggested)))) (CC but) (VP (PP (IN without) (NP (JJ convincing) (NN evidence)))))) (. .)))
12760988	3	(S1 (S (NP (PRP We)) (VP (VBD designed) (NP (NP (DT the) (JJ present) (NN study)) (SBAR (S (VP (TO to) (VP (VB investigate) (SBAR (IN whether) (S (NP (DT an) (JJ inflammatory) (NN reaction)) (VP (VBZ contributes) (PP (TO to) (NP (DT this) (NN Doc_12760988_378_385_Disease)))))))))))) (. .)))
12760988	4	(S1 (S (NP (NP (DT The) (NN incidence) (CC and) (NN severity)) (PP (IN of) (NP (JJ Doc_12760988_417_432_Chemical-associated) (NNP Doc_12760988_444_451_Disease)))) (VP (AUX was) (VP (VBN determined) (PP (IN in) (NP (NP (CD 64) (NNS patients)) (VP (VBN pretreated) (PP (IN with) (NP (NP (NN saline)) (CC or) (NP (NNP Doc_12760988_508_521_Chemical)))) (PP (IN before) (NP (NP (NNP Doc_12760988_529_544_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (NNP n) (SYM =) (CD 32)) (PP (IN for) (NP (DT each)))) (-RRB- -RRB-))))))))) (. .)))
12760988	5	(S1 (S (S (NP (NP (NN Incidence) (CC and) (NN severity)) (PP (IN of) (NP (NNP Doc_12760988_590_597_Disease)))) (VP (AUX did) (RB not) (VP (VB differ) (ADVP (RB significantly)) (PP (IN between) (NP (DT the) (CD two) (NNS groups)))))) (: :) (S (NP (NP (CD 15) (NNS patients)) (PP (IN in) (NP (DT the) (NNP Doc_12760988_670_683_Chemical) (NN group)))) (VP (VBD complained) (PP (IN of) (NP (NNP Doc_12760988_704_711_Disease))) (PP (VBN compared) (PP (IN with) (NP (NP (CD 18) (NNS patients)) (PP (IN in) (NP (DT the) (NN saline) (NN group)))))))) (, ,) (CC and) (S (NP (JJ severe) (NNP Doc_12760988_770_777_Disease)) (VP (AUX was) (VP (VBN reported) (PP (IN by) (NP (NP (CD five) (NNS patients)) (CC and) (NP (NP (CD three) (NNS patients)) (PRN (, ,) (ADVP (RB respectively)) (-LRB- -LRB-) (ADJP (RB not) (JJ significant)) (-RRB- -RRB-)))))))) (. .)))
12760988	6	(S1 (S (PP (IN At) (NP (CD 48))) (NP (NNP h)) (PP (IN after) (NP (NN surgery))) (, ,) (NP (NP (CD 12) (NNS patients)) (PP (IN in) (NP (DT both) (NNS groups)))) (ADVP (RB still)) (VP (VBN suffered) (PP (IN from) (NP (NNP Doc_12760988_930_937_Disease))) (PRN (-LRB- -LRB-) (RB not) (ADJP (JJ significant)) (-RRB- -RRB-))) (. .)))
12760988	7	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (NN interleukin-6)) (PRN (-LRB- -LRB-) (NP (NN IL-6)) (-RRB- -RRB-)) (PP (IN as) (NP (NP (DT an) (JJ early) (NN marker)) (PP (IN of) (NP (NNP Doc_12760988_1013_1025_Disease)))))) (VP (AUX was) (VP (VBN assessed) (PP (IN in) (NP (NP (DT a) (NN subgroup)) (PP (IN of) (NP (NP (CD 10) (NNS patients)) (VP (VBN pretreated) (PP (IN with) (NP (NN saline)))))))))) (. .)))
12760988	8	(S1 (S (S (NP (PRP We)) (VP (VBD found) (NP (NP (DT an) (NN increase)) (PP (IN of) (NP (NN IL-6))) (PP (IN for) (NP (QP (RB only) (CD three)) (NNS patients)))))) (, ,) (CC but) (S (NP (QP (RB only) (CD one)) (NN patient)) (VP (VBD reported) (NP (NNP Doc_12760988_1176_1183_Disease)))) (: ;) (S (NP (NP (NP (DT no) (NN relationship)) (PP (IN between) (NP (NNP Doc_12760988_1209_1216_Disease)))) (CC and) (NP (NP (DT the) (NN increase)) (PP (IN of) (NP (NN IL-6))))) (VP (AUX was) (VP (VBN found)))) (. .)))
12760988	9	(S1 (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (EX there)) (VP (AUX is) (NP (NP (DT no) (NN evidence)) (PP (IN for) (NP (NP (DT an) (JJ inflammatory) (NN origin)) (PP (IN of) (NP (NNP Doc_12760988_1319_1334_Chemical-associated) (NNP Doc_12760988_1346_1353_Disease))))))) (. .)))
12760988	10	(S1 (S (NP (NP (NN Administration)) (PP (IN of) (NP (NNP Doc_12760988_1387_1400_Chemical))) (PP (IN before) (NP (NNP Doc_12760988_1408_1423_Chemical)))) (VP (AUX was) (RB not) (ADJP (JJ effective) (PP (IN in) (S (VP (VBG decreasing) (NP (NP (NP (DT the) (NN incidence)) (CC or) (NP (DT the) (NN severity))) (PP (IN of) (NP (NNP Doc_12760988_1489_1504_Chemical-induced) (NNP Doc_12760988_1513_1534_Disease))))))))) (. .)))
12760988	11	(S1 (S (ADVP (RB Furthermore)) (, ,) (NP (EX there)) (VP (AUX was) (NP (NP (DT no) (JJ significant) (NN relationship)) (PP (IN between) (NP (NP (NP (NP (NNP Doc_12760988_1595_1616_Disease)) (CC and) (NP (NN time) (NN course))) (PP (IN of) (NP (JJ interleukin-6) (NNS concentrations)))) (, ,) (NP (NP (DT a) (NN marker)) (PP (IN of) (NP (NNP Doc_12760988_1678_1690_Disease)))))))) (. .)))
12760988	12	(S1 (S (NP (NP (NN Pretreatment)) (PP (IN with) (NP (NNP Doc_12760988_1710_1723_Chemical)))) (VP (AUX is) (RB not) (VP (VBN justified) (S (VP (TO to) (VP (VB prevent) (NP (NNP Doc_12760988_1752_1773_Disease)) (PP (IN after) (NP (NN Doc_12760988_1780_1795_Chemical)))))))) (. .)))
12842176	0	(S1 (NP (NP (NN Effect)) (PP (IN of) (NP (NNP Doc_12842176_10_17_Chemical))) (PP (IN on) (NP (NP (JJ hepatic) (CC and) (NN brain) (NN cytochrome) (NNS P450s)) (CC and) (NP (NP (NN influence)) (PP (IN of) (NP (NP (CD P450) (NN modulation)) (PP (IN in) (NP (NP (NNP Doc_12842176_92_99_Chemical)) (VP (VBN induced) (NP (NNP Doc_12842176_108_121_Disease)))))))))) (. .)))
12842176	1	(S1 (S (NP (NP (JJ Oral) (NN administration)) (PP (IN of) (NP (NNP Doc_12842176_146_153_Chemical))) (PRN (-LRB- -LRB-) (NP (CD 2.5) (, ,) (CD 5) (, ,) (CD 10) (CC and) (CD 15) (NN mg/kg)) (, ,) (NP (NN body) (NN weight)) (-RRB- -RRB-)) (PP (IN for) (NP (CD 5) (NNS days)))) (VP (AUX was) (VP (VBN found) (S (VP (TO to) (VP (VB produce) (NP (NP (DT a) (JJ dose-dependent) (NN increase)) (PP (IN in) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (NP (NP (NP (CD P450) (JJ dependent) (NNP Doc_12842176_285_302_Chemical-Doc_12842176_303_304_Chemical-deethylase) (PRN (-LRB- -LRB-) (NNP EROD) (-RRB- -RRB-) (, ,)) (NNP Doc_12842176_324_342_Chemical-Doc_12842176_343_344_Chemical-dealkylase)) (PRN (-LRB- -LRB-) (VB PROD) (-RRB- -RRB-))) (CC and) (NP (JJ Doc_12842176_367_389_Chemical) (NN demethylase))) (PRN (-LRB- -LRB-) (NP (NNP Doc_12842176_403_407_Chemical-d)) (-RRB- -RRB-)))))) (PP (IN in) (NP (NN rat) (NN brain) (CC and) (NN liver))))))))) (. .)))
12842176	2	(S1 (S (NP (NP (DT A) (JJ significant) (NN increase)) (PP (IN in) (NP (DT the) (JJ hepatic) (CC and) (NN brain) (NN P450) (NNS monooxygenases)))) (VP (AUX was) (VP (ADVP (RB also)) (VBN observed) (SBAR (WHADVP (WRB when)) (S (NP (NP (DT the) (NN duration)) (PP (IN of) (NP (NP (NN exposure)) (PP (IN of) (NP (JJ low) (NN dose))))) (PRN (-LRB- -LRB-) (NP (QP (CD 2.5) (CD mg/kg))) (-RRB- -RRB-)) (PP (IN of) (NP (NNP Doc_12842176_578_585_Chemical)))) (VP (AUX was) (VP (VBN increased) (PP (IN from) (NP (CD 5) (NNS days))) (PP (TO to) (NP (QP (CD 15) (CC or) (CD 21)) (NNS days))))))))) (. .)))
12842176	3	(S1 (S (NP (NNP Doc_12842176_630_632_Chemical)) (VP (VBD observed) (SBAR (S (PP (IN with) (NP (JJ different) (NNS doses))) (, ,) (NP (NP (DT the) (NN magnitude)) (PP (IN of) (NP (NN induction))) (PP (IN in) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (CD P450) (NNS monooxygenases)))))) (VP (AUX was) (ADJP (JJ several) (VB fold) (JJR higher)) (PP (IN in) (NP (NN liver) (NNS microsomes))) (SBAR (WHADVP (WRB when)) (S (VP (VBN compared) (PP (IN with) (NP (DT the) (NN brain)))))))))) (. .)))
12842176	4	(S1 (S (NP (JJ Western) (VBG blotting) (NNS studies)) (VP (AUX have) (VP (VBN indicated) (SBAR (IN that) (S (NP (NP (DT the) (NN increase)) (PP (IN in) (NP (DT the) (CD P450) (NNS enzymes)))) (VP (MD could) (VP (AUX be) (ADJP (JJ due) (PP (TO to) (NP (NP (DT the) (NN increase)) (PP (IN in) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP (JJ P450) (NNS 1A1/1A2)) (, ,) (NP (NNS 2B1/2B2)) (CC and) (NP (JJ 2E1) (NNS isoenzymes))))))))))))))) (. .)))
12842176	5	(S1 (S (PP (IN In) (NP (NN vitro) (NNS studies))) (S (VP (VBG using) (NP (NP (JJ organic) (NNS inhibitors)) (PP (JJ specific) (IN for) (NP (NP (JJ individual) (JJ P450) (NNS isoenzymes)) (CC and) (NP (NN antibody) (NN inhibition) (NNS experiments))))))) (VP (AUX have) (ADVP (RB further)) (VP (VBN demonstrated) (SBAR (IN that) (S (NP (NP (DT the) (NN increase)) (PP (IN in) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (S (VP (VB PROD))) (, ,) (NNP Doc_12842176_1161_1165_Chemical) (CC and) (NNP Doc_12842176_1170_1174_Chemical-d)))))) (VP (AUX are) (ADJP (JJ due) (PP (TO to) (NP (NP (DT the) (NN increase)) (PP (IN in) (NP (NP (DT the) (NNS levels)) (PP (IN of) (NP (CD P450) (CD 2B1/2B2) (, ,) (CD 1A1/1A2) (CC and) (CD 2E1) (NNS isoenzymes)))))))) (, ,) (ADVP (RB respectively))))))) (. .)))
12842176	6	(S1 (S (NP (NN Induction) (NNS studies)) (VP (AUX have) (ADVP (RB further)) (VP (VBN shown) (SBAR (IN that) (S (SBAR (IN while) (S (NP (NP (NN pretreatment)) (PP (IN of) (NP (NP (NP (NNP Doc_12842176_1338_1358_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP MC)) (-RRB- -RRB-))) (, ,) (NP (NP (DT an) (NN inducer)) (PP (IN of) (NP (NNP P4501A1/1A2)))) (, ,)))) (VP (AUX did) (RB not) (VP (VB produce) (NP (DT any) (JJ significant) (NN effect)) (PP (IN in) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NP (NNP Doc_12842176_1451_1458_Chemical)) (VP (VBN induced) (NP (NNP Doc_12842176_1467_1478_Disease))))))))))) (, ,) (NP (NP (NN pretreatment)) (PP (IN with) (NP (NP (NP (NNP Doc_12842176_1498_1511_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP PB)) (-RRB- -RRB-))) (, ,) (NP (NP (DT an) (NN inducer)) (PP (IN of) (NP (CD P450) (NNS 2B1/2B2)))) (CC or) (NP (NP (NNP Doc_12842176_1548_1555_Chemical)) (, ,) (NP (NP (DT an) (NN inducer)) (PP (IN of) (NP (QP (CD P450) (CD 2E1)) (JJ catalysed) (NNS reactions)))) (, ,))))) (VP (ADVP (RB significantly)) (VBD increased) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NNP Doc_12842176_1642_1649_Chemical))) (VP (VBN induced) (NP (NNP Doc_12842176_1658_1669_Disease))))))))) (. .)))
12842176	7	(S1 (S (ADVP (RB Similarly)) (, ,) (SBAR (WHADVP (WRB when)) (S (NP (NP (DT the) (JJ P450-mediated) (NN metabolism)) (PP (IN of) (NP (NNP Doc_12842176_1719_1726_Chemical)))) (VP (AUX was) (VP (VBN blocked) (PP (IN by) (NP (NNP Doc_12842176_1742_1757_Chemical))))))) (NP (NP (NN incidence)) (PP (IN of) (NP (NNP Doc_12842176_1771_1782_Disease)))) (VP (AUX was) (VP (VBN increased) (PP (IN in) (NP (NP (NNS animals)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_12842176_1821_1828_Chemical))) (S (VP (VBG indicating) (SBAR (IN that) (S (NP (NP (JJ Doc_12842176_1845_1852_Chemical) (FW per) (FW se)) (CC or) (NP (NP (PRP$ its) (NNS metabolites)) (VP (VBN formed) (PP (IN by) (NP (NNP PB) (CC or) (NNP Doc_12842176_1895_1902_Chemical)))))) (VP (VBP inducible) (SBAR (S (NP (JJ P450) (NNS isoenzymes)) (VP (AUX are) (VP (VBN involved) (PP (IN in) (NP (PRP$ its) (JJ neurobehavioral) (NN Doc_12842176_1965_1973_Disease))))))))))))))))) (. .)))
12851669	0	(S1 (NP (NP (ADJP (JJ Absolute) (CC and) (JJ attributable)) (NN risk)) (PP (IN of) (NP (NNP Doc_12851669_34_56_Disease))) (PP (IN in) (NP (NNS women))) (PP (IN on) (NP (JJ combined) (NNP Doc_12851669_78_97_Chemical) (CC and) (NNP Doc_12851669_102_118_Chemical))) (. .)))
12851669	1	(S1 (FRAG (S (VP (TO To) (VP (VB achieve) (NP (NP (JJ absolute) (NN risk) (NNS estimates)) (PP (IN of) (NP (NP (NNP Doc_12851669_169_191_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12851669_193_196_Disease)) (-RRB- -RRB-))))) (PP (PP (IN among) (NP (NP (NNS women)) (PP (IN on) (NP (NP (NNP Doc_12851669_213_232_Chemical)) (CC plus) (NP (NP (NNP Doc_12851669_238_254_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12851669_256_259_Chemical/Doc_12851669_260_262_Chemical)) (-RRB- -RRB-))))))) (, ,) (CC and) (PP (IN among) (NP (NP (NNS women)) (PP (IN on) (NP (NP (JJ combined) (NNP Doc_12851669_293_312_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12851669_314_318_Chemical)) (-RRB- -RRB-)))))))))) (. .)))
12851669	2	(S1 (S (PP (IN From) (NP (NP (NP (NP (DT the) (JJ Danish) (NNP National) (NNP Register)) (PP (IN of) (NP (NNS Patients)))) (PRN (-LRB- -LRB-) (NP (NNP NRP)) (-RRB- -RRB-))) (, ,) (NP (CD 1996) (TO to) (CD 1998)))) (, ,) (NP (NP (DT the) (NNS records)) (PP (IN of) (NP (NP (QP (CD 1.1) (CD million)) (JJ Danish) (NNS women)) (, ,) (NP (NP (NNS ages)) (NP (QP (CD 15) (TO to) (CD 44)) (NNS years))) (, ,)))) (VP (AUX were) (VP (VBD searched) (PP (IN for) (NP (NP (NN evidence)) (PP (IN of) (NP (NNP Doc_12851669_489_492_Disease))))))) (. .)))
12851669	3	(S1 (S (NP (JJ Doc_12851669_494_497_Chemical) (NN use)) (VP (AUX was) (VP (VBN ascertained) (PP (IN through) (NP (VBN mailed) (NNS questionnaires))))) (. .)))
12851669	4	(S1 (S (NP (NP (JJ Sales) (NNS statistics)) (PP (IN of) (NP (NP (NNP Doc_12851669_569_573_Chemical)) (CC and) (NP (NNP Doc_12851669_578_581_Chemical/Doc_12851669_582_584_Chemical))))) (VP (AUX were) (VP (VBN provided) (PP (IN through) (NP (JJ Danish) (NN Drug) (NNS Statistics))))) (. .)))
12851669	5	(S1 (S (PP (IN During) (NP (NP (DT the) (NN time) (NN frame)) (PP (IN of) (NP (DT the) (NN study))))) (, ,) (NP (CD 330) (NNS women)) (VP (AUX were) (VP (VBN found) (S (VP (TO to) (VP (AUX have) (VP (AUX had) (ADJP (JJ Doc_12851669_709_712_Disease)) (SBAR (IN while) (S (PP (IN on) (NP (NN Doc_12851669_722_726_Chemical))))))))))) (. .)))
12851669	6	(S1 (S (PP (IN Of) (NP (DT these) (NNS women))) (, ,) (NP (CD 67)) (VP (AUX were) (PP (IN on) (NP (NNP Doc_12851669_755_769_Chemical-containing) (NNP Doc_12851669_781_785_Chemical)))) (. .)))
12851669	7	(S1 (S (NP (CD Eleven)) (VP (AUX were) (PP (IN on) (NP (NNP Doc_12851669_802_805_Chemical/Doc_12851669_806_808_Chemical)))) (. .)))
12851669	8	(S1 (S (NP (NP (DT The) (JJ corresponding) (JJ absolute) (NN risk)) (PP (IN of) (NP (NNP Doc_12851669_845_848_Disease)))) (VP (AUX was) (NP (NP (NP (CD 3.4)) (PRN (-LRB- -LRB-) (NP (NN range)) (, ,) (NP (CD 3.1-3.8)) (-RRB- -RRB-)) (PP (IN per) (NP (NP (QP (CD 10) (CD 000)) (NNS women) (NNS years)) (PP (IN among) (NP (NP (DT the) (NNS women)) (PP (IN on) (NP (NNP Doc_12851669_916_920_Chemical)))))))) (, ,) (NP (NP (CD 4.2)) (PRN (-LRB- -LRB-) (NP (NN range)) (, ,) (NP (CD 3.2-5.2)) (-RRB- -RRB-)) (PP (IN per) (NP (NP (QP (CD 10) (CD 000)) (NNS women) (NNS years)) (PP (IN among) (NP (NP (NNS women)) (PP (IN on) (NP (NNP Doc_12851669_981_995_Chemical-containing) (NNP Doc_12851669_1007_1011_Chemical)))))))) (, ,) (CC and) (NP (NP (CD 3.1)) (PRN (-LRB- -LRB-) (NP (NN range)) (, ,) (NP (CD 1.3-4.9)) (-RRB- -RRB-)) (PP (IN per) (NP (NP (QP (CD 10) (CD 000)) (NNS women) (NNS years)) (PP (IN among) (NP (NP (DT the) (NNS women)) (PP (IN on) (NP (NNP Doc_12851669_1080_1083_Chemical/Doc_12851669_1084_1086_Chemical)))))))))) (. .)))
12851669	9	(S1 (S (NP (PRP$ Our) (NNS results)) (VP (VBP suggest) (SBAR (S (NP (NP (DT the) (JJ absolute) (NN risk)) (PP (IN of) (NP (NNP Doc_12851669_1141_1144_Disease))) (PP (IN among) (NP (JJ Danish) (NNS women))) (PP (IN on) (NP (NNP Doc_12851669_1167_1171_Chemical)))) (VP (AUX is) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT that)) (PP (IN among) (NP (NP (NNS women)) (VP (VBG taking) (NP (NNP Doc_12851669_1210_1213_Chemical/Doc_12851669_1214_1216_Chemical)))))))))))) (. .)))
12852481	0	(S1 (S (NP (NP (NN Comparison)) (PP (IN of) (NP (NP (JJ developmental) (NN toxicology)) (PP (IN of) (NP (NP (NNP Doc_12852481_42_49_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12852481_51_71_Chemical)) (-RRB- -RRB-)))))) (PP (IN in) (NP (NP (NNS rats)) (VP (VBG using) (NP (JJ selected) (NN dosing)))))) (VP (VBZ paradigms)) (. .)))
12852481	1	(S1 (S (NP (NP (NN Analysis)) (PP (IN of) (NP (DT the) (NN literature))) (PP (IN for) (NP (NP (JJ nonsteroidal) (JJ anti-inflammatory) (NNS drugs)) (PRN (-LRB- -LRB-) (NP (NNS NSAIDs)) (-RRB- -RRB-))))) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NP (DT a) (JJ low) (NN incidence)) (PP (IN of) (NP (NNP Doc_12852481_236_259_Disease)))) (VP (VBZ occurs) (PP (IN in) (NP (NP (NNS rats)) (VP (VBN given) (PP (ADVP (RB NSAIDs)) (IN on) (NP (JJ specific) (NNS days))) (PP (IN during) (NP (NN organogenesis)))))))))) (. .)))
12852481	2	(S1 (S (NP (NP (NP (NNP Doc_12852481_327_334_Chemical)) (PRN (-LRB- -LRB-) (NP (JJ Doc_12852481_336_356_Chemical) (JJ -LSB-Doc_12852481_358_361_Chemical) (NN -RSB-)) (-RRB- -RRB-))) (, ,) (NP (DT an) (JJ irreversible) (ADJP (VB cyclooxygenase) (CD 1) (CC and) (CD 2)) (NN inhibitor)) (, ,)) (VP (VBZ induces) (NP (NP (NP (NP (NNP Doc_12852481_423_446_Disease)) (SBAR (WHADVP (WRB when)) (S (VP (VBN administered) (PP (TO to) (NP (NNP Wistar) (NNS rats))) (PP (IN on) (NP (JJ gestational) (NN day))))))) (PRN (-LRB- -LRB-) (NP (NNP GD)) (-RRB- -RRB-)) (NP (CD 9) (, ,) (CD 10) (, ,) (CC or) (CD 11))) (-LRB- -LRB-) (NP (NNP Kimmel) (MD CA)) (, ,) (NP (NNP Wilson) (NNP JG)) (, ,) (NP (NNP Schumacher) (NNP HJ)))) (. .)))
12852481	3	(S1 (NP (NP (NNP Teratology) (CD 4:15-24)) (, ,) (NP (CD 1971)) (-RRB- -RRB-) (. .)))
12852481	4	(S1 (S (NP (EX There)) (VP (AUX are) (NP (NP (DT no) (VBN published) (NNP Doc_12852481_605_608_Chemical) (NNS studies)) (VP (VBG using) (NP (NP (DT the) (JJ multiple) (NN dosing) (NN paradigm)) (PP (IN of) (NP (QP (RB GDs) (CD 6) (TO to) (CD 17)))))))) (. .)))
12852481	5	(S1 (S (NP (NP (NNS Objectives)) (PP (IN of) (NP (DT the) (JJ current) (NN study)))) (VP (AUX were) (S (S (VP (TO to) (VP (VB compare) (NP (NNS results)) (PP (IN between) (NP (NP (NP (NNP Sprague-Dawley)) (PRN (-LRB- -LRB-) (NP (NNP SD)) (-RRB- -RRB-))) (CC and) (NP (NNP Wistar) (NNS strains)))) (SBAR (WHADVP (WRB when)) (S (NP (NNP Doc_12852481_776_779_Chemical)) (VP (AUX is) (VP (VBN administered) (PP (IN on) (NP (NNP GD) (CD 9) (, ,) (CD 10) (, ,) (CC or) (CD 11)))))))))) (: ;) (S (VP (TO to) (VP (VB compare) (NP (DT the) (NN malformation) (NNS patterns)) (PP (VBG following) (NP (NP (ADJP (JJ single) (CC and) (JJ multiple)) (NNS dosings)) (PP (IN during) (NP (NP (NNS organogenesis)) (PP (IN in) (NP (JJ SD) (NNS rats)))))))))) (: ;) (CC and) (S (VP (TO to) (VP (VB test) (NP (DT the) (NN hypothesis) (SBAR (IN that) (S (NP (JJ maternal) (NNP Doc_12852481_965_990_Disease)) (VP (VBZ confounds) (NP (NP (DT the) (NN detection)) (PP (IN of) (NP (JJ low) (NN incidence) (NN Doc_12852481_1032_1045_Disease)))) (PP (IN with) (NP (NNP Doc_12852481_1051_1054_Chemical))) (SBAR (WHADVP (WRB when)) (S (NP (DT a) (JJ multiple) (NN dosing) (NN paradigm)) (VP (AUX is) (VP (VBN used)))))))))))))) (. .)))
12852481	6	(S1 (S (NP (NNP Doc_12852481_1105_1108_Chemical)) (VP (AUX was) (VP (VBN administered) (PP (PP (IN as) (NP (NP (DT a) (JJ single) (NN dose)) (PP (IN on) (NP (NP (NP (NNP GD) (CD 9)) (PRN (-LRB- -LRB-) (NP (NP (CD 0)) (, ,) (NP (CD 250)) (, ,) (NP (CD 500)) (, ,) (CC or) (NP (CD 625) (NNS mg/kg))) (-RRB- -RRB-))) (, ,) (NP (NP (NP (CD 10)) (PRN (-LRB- -LRB-) (NP (NP (CD 0)) (, ,) (NP (CD 500)) (, ,) (NP (CD 625)) (, ,) (CC or) (NP (CD 750) (NNS mg/kg))) (-RRB- -RRB-))) (, ,) (CC or) (NP (NP (CD 11)) (PRN (-LRB- -LRB-) (NP (NP (CD 0)) (, ,) (NP (CD 500)) (, ,) (NP (CD 750)) (, ,) (CC or) (NP (CD 1000) (NN mg/kg))) (-RRB- -RRB-)))))))) (CC and) (PP (IN from) (NP (NNP GD) (CD 6)))) (S (VP (TO to) (VP (VB GD) (NP (NP (CD 17)) (PRN (-LRB- -LRB-) (NP (NP (CD 0)) (, ,) (NP (CD 50)) (, ,) (NP (CD 125)) (, ,) (CC or) (NP (NP (CD 250) (NNS mg/kg)) (NP (DT a) (NN day)))) (-RRB- -RRB-))) (PP (IN in) (NP (DT the) (JJ multiple) (NN dose) (NN study))) (PP (TO to) (NP (CD SD) (NNS rats)))))))) (. .)))
12852481	7	(S1 (S (S (NP (NNS Animals)) (VP (AUX were) (VP (VBN killed) (PP (IN on) (NP (NNP GD) (CD 21)))))) (, ,) (CC and) (S (NP (NNS fetuses)) (VP (AUX were) (VP (VBN examined) (ADVP (RB viscerally))))) (. .)))
12852481	8	(S1 (S (S (NP (DT The) (NN literature) (NN evaluation)) (VP (VBD suggested) (SBAR (IN that) (S (NP (NNS NSAIDs)) (VP (VB induce) (NP (NP (NP (NP (NP (NP (NP (NP (NNP Doc_12852481_1474_1500_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12852481_1502_1506_Disease)) (-RRB- -RRB-))) (CC and) (NP (NNP Doc_12852481_1512_1527_Disease))) (PRN (-LRB- -LRB-) (NP (NNP Doc_12852481_1529_1532_Disease)) (-RRB- -RRB-))) (PP (IN in) (NP (NNS rats)))) (CC and) (NP (NNP Doc_12852481_1546_1566_Disease))) (PRN (-LRB- -LRB-) (NP (NNP Doc_12852481_1568_1570_Disease)) (-RRB- -RRB-))) (, ,) (NP (NNP Doc_12852481_1573_1576_Disease)) (, ,) (CC and) (NP (NNP Doc_12852481_1582_1586_Disease))) (PP (IN in) (NP (NP (NNS rabbits)) (PRN (-LRB- -LRB-) (NP (NNP Cook) (NNP JC) (CC et) (NNP al.)) (, ,) (NP (CD 2003)) (-RRB- -RRB-))))))))) (: ;) (S (ADVP (RB hence)) (, ,) (NP (DT the) (JJ present) (NN study)) (VP (VBD focused) (PP (IN on) (NP (DT these) (NNP Doc_12852481_1664_1677_Disease))) (, ,) (SBAR (RB even) (IN though) (S (NP (NNP Doc_12852481_1691_1694_Chemical)) (VP (VBZ induces) (NP (JJ several) (JJ other) (NN low-incidence) (NNP Doc_12852481_1731_1744_Disease))))))) (. .)))
12852481	9	(S1 (S (PP (IN In) (NP (JJ single) (NN dose) (NNS studies))) (, ,) (NP (NP (NNP Doc_12852481_1770_1772_Disease)) (, ,) (NP (NNP Doc_12852481_1774_1776_Disease)) (, ,) (CC and) (NP (NNP Doc_12852481_1782_1785_Disease))) (VP (AUX were) (VP (VBN induced) (PP (IN on) (NP (NNP GDs) (CD 9) (CC and) (CD 10))))) (. .)))
12852481	10	(S1 (S (NP (NN Doc_12852481_1816_1819_Disease)) (ADVP (RB also)) (VP (AUX was) (VP (VBN noted) (PP (VBG following) (NP (NP (NN treatment)) (PP (IN on) (NP (NNP GD) (CD 11))))))) (. .)))
12852481	11	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (S (NP (NP (NNP Doc_12852481_1878_1880_Disease)) (CC and) (NP (NNP Doc_12852481_1885_1887_Disease))) (VP (AUX were) (VP (VBN noted) (PP (IN in) (NP (NP (DT the) (JJ multiple) (NN dose) (NN study) (NN design)) (PP (ADVP (RB only)) (IN in) (NP (DT the) (JJ high-dose) (NN group)))))))) (, ,) (CC and) (S (NP (NNP Doc_12852481_1966_1969_Disease)) (VP (AUX was) (VP (VBN noted) (PP (IN across) (NP (DT all) (NN dose) (NNS groups)))))) (. .)))
12852481	12	(S1 (S (NP (NP (JJ High) (NN concordance)) (PP (IN in) (NP (NP (JJ major) (NN Doc_12852481_2043_2066_Disease)) (PP (IN between) (NP (NNP Wistar) (CC and) (NNP SD) (NNS rats)))))) (VP (AUX were) (VP (VBN noted) (PP (IN with) (NP (NP (DT the) (NN exception)) (PP (IN of) (NP (NP (NP (NNP Doc_12852481_2127_2130_Disease)) (PP (IN in) (NP (DT the) (CD SD) (NNS rats)))) (CC and) (NP (NP (NNP Doc_12852481_2150_2163_Disease)) (PP (IN in) (NP (DT the) (JJ Wistar) (NNS rats)))))))))) (. .)))
12852481	13	(S1 (S (NP (NNS Variations) (CC and) (NNP Doc_12852481_2199_2212_Disease)) (VP (AUX were) (UCP (JJ similar) (SBAR (WHADVP (WRB when)) (S (NP (NNP Doc_12852481_2231_2234_Chemical)) (VP (AUX was) (VP (VBN administered) (PP (IN as) (NP (DT a) (JJ single) (NN dose))))))) (CC or) (PP (IN during) (NP (NP (DT the) (NN period)) (PP (IN of) (NP (NP (NNS organogenesis)) (PRN (-LRB- -LRB-) (NP (QP (RB GDs) (CD 6) (TO to) (CD 17))) (-RRB- -RRB-)))))))) (. .)))
12852481	14	(S1 (S (NP (PRP It)) (VP (AUX was) (ADVP (RB also)) (ADJP (JJ evident)) (SBAR (IN that) (S (, ,) (PP (IN by) (S (VP (VBG titrating) (NP (DT the) (NN dose) (S (VP (TO to) (VP (VB achieve) (NP (NP (DT a) (JJ maximum) (JJ tolerated) (NN dose)) (, ,) (NP (NP (NNP Doc_12852481_2407_2420_Disease)) (SBAR (WHNP (WDT that)) (S (ADVP (RB normally)) (VP (VBP occur) (PP (IN at) (NP (JJ low) (NN incidence))))))) (, ,)) (SBAR (IN as) (S (VP (VBN reported) (PP (IN from) (NP (JJ previous) (JJ single) (NN dose) (NNS studies))))))))))))) (, ,) (VP (MD could) (ADVP (RB also)) (VP (AUX be) (VP (VBN induced) (PP (IN with) (NP (NP (NNP Doc_12852481_2533_2536_Chemical)) (VP (VBN given) (PP (IN at) (NP (JJ multiple) (NNS doses)))))))))))) (. .)))
1286498	0	(S1 (NP (NP (NP (NN Reversal)) (PP (IN of) (NP (JJ central) (JJ Doc_1286498_20_34_Chemical) (NNS effects))) (PP (IN by) (NP (NNP Doc_1286498_46_56_Chemical))) (PP (IN after) (NP (NP (JJ intravenous) (JJ conscious) (NN sedation)) (PP (IN with) (NP (NP (NNP Doc_1286498_99_107_Chemical)) (CC and) (NP (NNS opioids))))))) (: :) (NP (NP (NN report)) (PP (IN of) (NP (DT a) (JJ double-blind) (NN multicenter) (NN study)))) (. .)))
1286498	1	(S1 (NP (NP (DT The) (NNP Doc_1286498_169_179_Chemical)) (PP (IN in) (NP (NP (JJ Intravenous) (JJ Conscious) (NN Sedation)) (PP (IN with) (NP (NNP Doc_1286498_219_227_Chemical) (NNP Multicenter) (NNP Study) (NNP Group) (NNP II))))) (. .)))
1286498	2	(S1 (S (NP (NP (DT The) (NN efficacy) (CC and) (NN safety)) (PP (IN of) (NP (NP (DT a) (JJ new) (JJ Doc_1286498_289_303_Chemical) (NN antagonist)) (, ,) (NP (NNP Doc_1286498_316_326_Chemical)) (, ,)))) (VP (AUX were) (VP (VBN assessed) (PP (IN in) (NP (DT a) (JJ double-blind) (NN multicenter) (NN study))))) (. .)))
1286498	3	(S1 (S (NP (NP (NP (NNP Doc_1286498_379_389_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (JJ mean) (NN dose)) (, ,) (NP (CD 0.76) (NN mg))) (-RRB- -RRB-))) (CC or) (NP (NP (NN placebo)) (PRN (-LRB- -LRB-) (NP (NP (JJ mean) (NN dose)) (, ,) (NP (CD 8.9) (NN ml))) (-RRB- -RRB-)))) (VP (AUX was) (VP (VBN administered) (ADVP (RB intravenously)) (PP (TO to) (NP (NP (QP (CD 130) (CC and) (CD 67)) (NNS patients)) (, ,) (ADVP (RB respectively)) (, ,) (SBAR (WHNP (WP who)) (S (VP (AUX had) (VP (AUX been) (VP (VBN given) (NP (NNP Doc_1286498_530_538_Chemical)) (PP (IN in) (NP (NP (NN conjunction)) (PP (IN with) (NP (NP (DT an) (JJ opioid)) (PRN (-LRB- -LRB-) (NP (NNP Doc_1286498_570_578_Chemical) (, ,) (NNP Doc_1286498_580_590_Chemical) (, ,) (CC or) (NNP Doc_1286498_595_603_Chemical)) (-RRB- -RRB-)))))) (PP (IN for) (NP (NP (DT the) (NN induction) (CC and) (NN maintenance)) (PP (IN of) (NP (NP (JJ intravenous) (JJ conscious) (NN sedation)) (PP (IN for) (NP (ADJP (JJ diagnostic) (CC or) (JJ therapeutic)) (JJ surgical) (NNS procedures)))))))))))))))) (. .)))
1286498	4	(S1 (S (NP (NP (DT The) (NN group) (NN assessable)) (PP (IN for) (NP (NN efficacy)))) (VP (VBN comprised) (NP (NP (NP (CD 122) (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_1286498_794_804_Chemical))))) (CC and) (NP (NP (CD 64) (NNS patients)) (VP (VBN given) (NP (NN placebo)))))) (. .)))
1286498	5	(S1 (S (PP (IN After) (NP (CD 5) (NNS minutes))) (, ,) (NP (NP (NP (CD 80/115)) (PRN (-LRB- -LRB-) (NP (CD 70) (NN %)) (-RRB- -RRB-)) (JJ Doc_1286498_866_876_Chemical-treated) (NNS patients)) (, ,) (PP (VBN compared) (PP (IN with) (NP (NP (CD 21/63)) (PRN (-LRB- -LRB-) (NP (CD 33) (NN %)) (-RRB- -RRB-)) (JJ placebo-treated) (NNS patients)))) (, ,)) (VP (AUX were) (ADJP (RB completely) (JJ awake) (CC and) (JJ alert)) (, ,) (SBAR (IN as) (S (VP (VBN indicated) (PP (IN by) (NP (DT a) (NN score))) (PP (IN of) (NP (NP (CD 5)) (PP (IN on) (NP (NP (NP (DT the) (NNP Observer) (POS 's)) (NN Assessment)) (PP (IN of) (NP (NNP Alertness/Sedation) (NN Scale))))))))))) (. .)))
1286498	6	(S1 (S (NP (NP (JJ Ninety-five) (NN percent)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN in) (NP (NP (DT each) (NN group)) (SBAR (WHNP (WP who)) (S (VP (VBN attained) (NP (NP (DT a) (NN score)) (PP (IN of) (NP (CD 5)))) (PP (IN at) (NP (DT the) (JJ 5-minute) (NN assessment))))))))))) (VP (VBD showed) (NP (NP (DT no) (NN loss)) (PP (IN of) (NP (NN alertness)))) (PP (IN throughout) (NP (DT the) (JJ 180-minute) (NN assessment) (NN period)))) (. .)))
1286498	7	(S1 (S (NP (JJ Doc_1286498_1239_1249_Chemical-treated) (NNS patients)) (ADVP (RB also)) (VP (VBD performed) (ADVP (RB significantly)) (ADVP (RB better)) (PP (IN on) (NP (NP (DT the) (JJ Finger-to-Nose) (NN Test)) (CC and) (NP (NP (DT the) (NN recall)) (PP (IN of) (NP (NP (NNS pictures)) (VP (VBN shown) (PP (IN at) (NP (DT the) (JJ 5-minute) (NN assessment)))))))))) (. .)))
1286498	8	(S1 (S (NP (NN Doc_1286498_1391_1401_Chemical)) (VP (AUX was) (ADVP (RB well)) (VP (VBN tolerated) (, ,) (PP (IN with) (NP (NP (DT no) (JJ serious) (JJ adverse) (NNS effects)) (VP (VBN reported)))))) (. .)))
1286498	9	(S1 (S (NP (NP (NN Thirty-nine)) (PRN (-LRB- -LRB-) (NP (CD 30) (NN %)) (-RRB- -RRB-)) (PP (IN of) (NP (JJ Doc_1286498_1485_1495_Chemical-treated) (NNS patients))) (, ,) (PP (VBN compared) (PP (IN with) (NP (NP (NP (CD 17)) (PRN (-LRB- -LRB-) (NP (CD 25) (NN %)) (-RRB- -RRB-))) (PP (IN of) (NP (JJ placebo-treated) (NNS patients))))))) (VP (AUX had) (NP (QP (CD one) (CC or) (JJR more)) (JJ drug-related) (JJ adverse) (NNS experiences))) (. .)))
1286498	10	(S1 (S (NP (DT The) (JJS most) (JJ common) (JJ adverse) (NNS effects)) (VP (AUX were) (NP (NP (NP (NP (NNP Doc_1286498_1652_1658_Disease)) (CC and) (NP (NNP Doc_1286498_1663_1671_Disease))) (PP (IN in) (NP (DT the) (NNP Doc_1286498_1679_1689_Chemical) (NN group)))) (CC and) (NP (NP (NP (NNP Doc_1286498_1700_1706_Disease)) (CC and) (NP (JJ injection-site) (NNP Doc_1286498_1726_1730_Disease))) (PP (IN in) (NP (DT the) (NN placebo) (NN group)))))) (. .)))
1286498	11	(S1 (S (NP (NN Doc_1286498_1753_1763_Chemical)) (VP (AUX was) (VP (VBN found) (S (VP (TO to) (ADVP (RB promptly)) (VP (VB reverse) (NP (NP (NN sedation)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_1286498_1814_1822_Chemical))) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NNS opioids)))))))))))) (. .)))
12907924	0	(S1 (NP (NP (JJ Doc_12907924_0_15_Chemical-induced) (NNP Doc_12907924_24_53_Disease)) (PP (IN in) (NP (DT an) (JJ elderly) (NN man))) (. .)))
12907924	1	(S1 (S (NP (NP (DT An) (JJ 82-year-old) (NN man)) (PP (IN with) (NP (NP (NNP Doc_12907924_97_127_Disease)) (CC and) (NP (JJ early) (NNP Doc_12907924_138_157_Disease))))) (VP (AUX was) (VP (VBN started) (PP (IN on) (NP (NNP Doc_12907924_173_188_Chemical))))) (. .)))
12907924	2	(S1 (S (NP (JJ Significant) (NN Doc_12907924_202_231_Disease)) (VP (VP (VBD ensued)) (CC but) (VP (VBN diminished) (PP (IN over) (NP (JJ several) (NNS weeks))) (SBAR (WHADVP (WRB when)) (S (NP (NNP Doc_12907924_278_293_Chemical)) (VP (AUX was) (VP (VBN replaced) (PP (IN by) (NP (NN Doc_12907924_310_321_Chemical))))))))) (. .)))
12907924	3	(S1 (S (S (NP (DT The) (NN patient)) (VP (AUX had) (NP (DT no) (JJ prior) (JJ Doc_12907924_348_359_Disease) (NN history)))) (, ,) (CC but) (S (NP (PRP he)) (VP (AUX had) (NP (NP (DT a) (NN sister)) (PP (IN with) (NP (NNP Doc_12907924_394_423_Disease)))))) (. .)))
12907924	4	(S1 (S (NP (PRP It)) (VP (VBZ appears) (SBAR (IN that) (S (NP (NNP Doc_12907924_441_456_Chemical)) (VP (VBD precipitated) (NP (NP (DT the) (NN patient) (POS 's)) (JJ pathological) (NN behavior)))))) (. .)))
12911170	0	(S1 (NP (JJ Doc_12911170_0_13_Chemical-induced) (JJ acute) (NNP Doc_12911170_28_50_Disease) (CC and) (NNP Doc_12911170_55_82_Disease) (. .)))
12911170	1	(S1 (S (NP (NN Doc_12911170_84_97_Chemical)) (VP (AUX has) (VP (AUX been) (VP (VBN associated) (PP (IN with) (NP (NP (JJ several) (JJ side) (NNS effects)) (PP (VBG including) (NP (NP (NNP Doc_12911170_154_176_Disease)) (CC and) (NP (NNP Doc_12911170_181_197_Disease))))))))) (. .)))
12911170	2	(S1 (S (NP (NP (DT The) (NN combination)) (PP (IN of) (NP (DT both) (NN side) (NNS effects)))) (VP (AUX is) (ADJP (RB extremely) (JJ rare))) (. .)))
12911170	3	(S1 (S (PP (IN In) (NP (DT this) (NN report))) (, ,) (NP (PRP we)) (VP (VBP describe) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NNP Doc_12911170_293_306_Chemical-induced) (NNP Doc_12911170_315_337_Disease) (CC and) (NNP Doc_12911170_342_369_Disease))))) (. .)))
12911170	4	(S1 (S (NP (NN Doc_12911170_371_387_Disease)) (VP (VBD improved) (PP (IN after) (S (VP (VBG stopping) (NP (NP (DT the) (NN drug) (CC and) (NN initiation)) (PP (IN of) (NP (JJ Doc_12911170_439_446_Chemical) (NN therapy)))))))) (. .)))
12911170	5	(S1 (S (ADVP (RB Unfortunately)) (, ,) (S (NP (JJ acute) (NN Doc_12911170_477_499_Disease)) (VP (AUX was) (ADJP (JJ irreversible)))) (CC and) (S (NP (DT the) (NN patient)) (VP (VBD developed) (NP (NN Doc_12911170_543_566_Disease)))) (. .)))
1300436	0	(S1 (NP (NP (JJ Potential) (JJ deleterious) (NN effect)) (PP (IN of) (NP (NNP Doc_1300436_32_42_Chemical))) (PP (IN in) (NP (NN radiocontrast) (NN Doc_1300436_60_71_Disease))) (. .)))
1300436	1	(S1 (S (NP (NP (DT The) (NN purpose)) (PP (IN of) (NP (DT the) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB determine) (NP (NP (DT the) (NN efficacy)) (PP (IN of) (NP (NNP Doc_1300436_131_141_Chemical)))) (PP (IN in) (NP (NP (NN addition)) (PP (TO to) (NP (NP (JJ intravenous) (NNS fluids)) (PP (IN in) (NP (NP (DT the) (NN prevention)) (PP (IN of) (NP (JJ radiocontrast) (NNP Doc_1300436_211_222_Disease.) (CD 18) (NNS patients))))))))) (, ,) (PP (VBN referred) (PP (TO to) (NP (NP (DT a) (JJ radiocontrast) (NN study)) (, ,) (VP (VBN considered) (PP (IN at) (NP (NN risk))) (SBAR (IN because) (S (PP (IN of) (NP (JJ preexisting) (NNP Doc_1300436_314_333_Disease))) (, ,) (VP (AUX were) (VP (VBD enrolled) (PP (IN in) (NP (NP (DT a) (JJ prospective) (, ,) (JJ randomized) (, ,) (JJ controlled) (NN trial)) (, ,) (VP (VBN performed) (PP (IN at) (NP (NP (DT the) (JJ secondary) (NN care) (NN center)) (PP (IN of) (NP (DT a) (JJ 1,100-bed) (JJ private) (NN university) (NN hospital)))))))))))))))))))) (. .)))
1300436	2	(S1 (S (PP (IN In) (NP (NP (NN addition)) (PP (TO to) (NP (NNS fluids))))) (, ,) (NP (DT the) (NN treatment) (NN group)) (VP (VBD received) (NP (NP (NNP Doc_1300436_532_542_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (JJ mean) (NN dose)) (NP (CD 110) (NNS mg))) (-RRB- -RRB-))) (ADVP (RB intravenously)) (NP (CD 30) (NN min)) (ADVP (RB prior) (PP (TO to) (NP (NP (DT the) (NN injection)) (PP (IN of) (NP (NN contrast) (NN material))))))) (. .)))
1300436	3	(S1 (S (NP (DT The) (NN control) (NN group)) (VP (VBD received) (NP (NP (NNS fluids)) (PRN (-LRB- -LRB-) (NP (JJ mean) (CD 3) (NNS liters)) (-RRB- -RRB-)))) (. .)))
1300436	4	(S1 (S (NP (JJ Radiological) (NNS studies)) (VP (AUX were) (ADVP (RB mostly)) (NP (NP (NNS angiographies)) (VP (VBN performed) (PP (IN with) (NP (DT both) (ADJP (JJ ionic) (CC and) (JJ non-ionic)) (NN contrast) (NN material))))) (, ,) (PP (IN at) (NP (NP (DT an) (JJ average) (NN dose)) (PP (IN of) (NP (QP (CD 245) (CD ml))))))) (. .)))
1300436	5	(S1 (S (NP (NP (NN Doc_1300436_815_856_Disease)) (PP (IN in) (NP (DT the) (NN group)))) (VP (VBD pretreated) (PP (IN with) (NP (NP (NNP Doc_1300436_886_896_Chemical)) (PRN (-LRB- -LRB-) (VP (VBN p) (NP (NNP <) (CD 0.005)) (PP (IN by) (NP (NNP ANOVA)))) (-RRB- -RRB-)))) (, ,) (PP (IN with) (NP (NP (DT a) (NN rise)) (PP (IN in) (NP (JJ serum) (NNP Doc_1300436_940_950_Chemical))) (PP (IN from) (NP (NP (NP (CD 145) (NN +/-)) (NP (QP (CD 13) (TO to) (CD 182)) (JJ +/-) (CD 16) (NNS mumol/l))) (PP (IN at) (NP (CD 24))) (NP (NNP h)))))) (, ,) (SBAR (IN while) (S (NP (DT no) (NN change)) (VP (VBD occurred) (PP (IN in) (NP (NP (DT the) (NN control) (NN group)) (PRN (-LRB- -LRB-) (PP (IN from) (NP (NP (CD 141) (NN +/-)) (NP (QP (CD 6) (TO to) (CD 142)) (JJ +/-) (CD 7) (NNS mumol/l)))) (-RRB- -RRB-)))))))) (. .)))
1300436	6	(S1 (S (NP (NN Doc_1300436_1083_1096_Disease)) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (NNP Doc_1300436_1117_1128_Disease)) (PP (IN in) (NP (DT the) (JJ Doc_1300436_1136_1146_Chemical-treated) (NN group))))))) (. .)))
1300436	7	(S1 (S (NP (NN Doc_1300436_1162_1172_Chemical)) (VP (MD may) (VP (AUX be) (ADJP (JJ deleterious)) (PP (IN in) (NP (NP (DT the) (NN prevention)) (PP (IN of) (NP (NN radiocontrast) (NN Doc_1300436_1227_1238_Disease))))))) (. .)))
133615	0	(S1 (NP (JJ Progestational) (NNS agents) (CC and) (NNP Doc_133615_26_43_Disease) (. .)))
133615	1	(S1 (NP (NNP VII) (. .)))
133615	2	(S1 (NP (NP (NP (NP (NN Doc_133615_50_64_Disease)) (CC and) (NP (JJ other) (NNS complications))) (PP (IN of) (NP (JJ Doc_133615_92_110_Chemical) (NN therapy))) (PP (IN in) (NP (NN relationship))) (PP (TO to) (NP (NP (JJ pretreatment) (NNS levels)) (PP (IN of) (NP (JJ Doc_133615_161_178_Disease) (NNS factors)))))) (: :) (NP (NP (NN summary) (NN report)) (PP (IN of) (NP (DT a) (JJ ten-year) (NN study)))) (. .)))
133615	3	(S1 (S (PP (IN During) (NP (DT a) (JJ ten-year) (NN period))) (, ,) (NP (CD 348) (NNS women)) (VP (AUX were) (VP (VBN studied) (PP (IN for) (NP (NP (DT a) (NN total)) (PP (IN of) (NP (CD 5,877) (JJ patient) (NNS months))) (PP (IN in) (NP (NP (CD four) (JJ separate) (NNS studies)) (VP (VBG relating) (NP (NNP Doc_133615_343_362_Chemical)) (PP (TO to) (NP (NP (NNS changes)) (PP (IN in) (NP (JJ hematologic) (NNS parameters)))))))))))) (. .)))
133615	4	(S1 (S (NP (NP (JJ Significant) (NNS increases)) (PP (IN in) (NP (NP (NP (JJ certain) (NNS factors)) (PP (IN of) (NP (DT the) (NNP Doc_133615_449_466_Disease)))) (CC and) (NP (NN fibrinolysin) (NNS systems)))) (PRN (-LRB- -LRB-) (NP (NP (NP (NNS factors)) (NP (PRP I))) (, ,) (NP (NP (NNP II)) (, ,) (NP (NNP VII)) (, ,) (NP (NNP VIII)) (, ,) (NP (CD IX)) (, ,) (CC and) (NP (NP (SYM X)) (CC and) (NP (NNS plasminogen))))) (-RRB- -RRB-))) (VP (AUX were) (VP (VBN observed) (PP (IN in) (NP (DT the) (VBN treated) (NNS groups))))) (. .)))
133615	5	(S1 (S (NP (JJ Severe) (NNS complications)) (VP (VBD developed) (PP (IN in) (NP (CD four) (NNS patients)))) (. .)))
133615	6	(S1 (S (NP (DT All) (CD four)) (VP (AUX had) (NP (DT an) (JJ abnormal) (NN Doc_133615_653_670_Disease) (NN profile)) (, ,) (S (VP (VBG suggesting) (`` ``) (NP (NNP Doc_133615_692_710_Disease)) ('' '') (PP (IN before) (NP (NP (NN initiation)) (PP (IN of) (NP (NN therapy)))))))) (. .)))
133615	7	(S1 (S (S (NP (NP (DT Some)) (PP (IN of) (NP (DT these) (NNS findings)))) (VP (VBD represented) (NP (NP (DT the) (ADJP (RBS most) (JJ extreme)) (NNS abnormalities)) (VP (VBN seen) (PP (IN in) (NP (NP (DT the) (JJ entire) (NN group)) (PP (IN of) (NP (NNS patients))))))))) (: ;) (S (NP (DT some)) (VP (VBD increased) (ADVP (RB further)) (PP (IN during) (NP (NN therapy))))) (. .)))
133615	8	(S1 (S (NP (NP (CD One)) (PP (IN of) (NP (DT these) (NNS patients)))) (VP (VBD developed) (NP (DT a) (NN Doc_133615_919_940_Disease)) (PP (IN before) (S (VP (VBG receiving) (NP (DT any) (NN medication))))) (, ,) (SBAR (ADVP (RB shortly)) (IN after) (S (NP (DT the) (JJ base-line) (NNS values)) (VP (AUX were) (VP (VBN obtained)))))) (. .)))
133615	9	(S1 (S (NP (CD One) (NN patient)) (VP (VBD developed) (SBAR (NP (NNP Doc_133615_1046_1057_Disease) (CD 19) (NNS months)) (IN after) (S (S (NP (PRP she)) (VP (VBD began) (NP (NN therapy)))) (, ,) (CC and) (S (NP (DT another)) (VP (VBD developed) (NP (NNP Doc_133615_1115_1131_Disease)) (PP (IN after) (NP (NP (CD 27) (NNS months)) (PP (IN of) (NP (NN therapy)))))))))) (. .)))
133615	10	(S1 (S (NP (DT The) (JJ fourth) (NN patient)) (VP (VBD developed) (NP (NNP Doc_133615_1189_1205_Disease) (CD 14) (NNS days)) (PP (IN after) (NP (NP (NN initiation)) (PP (IN of) (NP (JJ contraceptive) (NN therapy)))))) (. .)))
133615	11	(S1 (S (NP (DT All) (CD four) (NNS patients)) (VP (AUX were) (PP (IN of) (NP (DT the) (NNP A) (CC or) (NNP AB) (NN blood) (NN group)))) (. .)))
133615	12	(S1 (S (NP (JJ Previous) (NNS studies)) (VP (VBD suggested) (NP (NP (DT the) (NN possiblility)) (PP (IN of) (NP (VBN increased) (NN propensity))) (PP (IN for) (NP (NNP Doc_133615_1380_1394_Disease) (NNS episodes))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG possessing) (NP (DT the) (NNP A) (NN antigen))))))) (. .)))
133615	13	(S1 (S (NP (PRP It)) (VP (VBZ appears) (PP (IN from) (NP (DT these) (NNS data))) (SBAR (IN that) (S (NP (JJ hematologic) (NNS work-ups)) (VP (MD may) (VP (AUX be) (ADJP (JJ useful)) (PP (IN in) (NP (NP (NNS women)) (SBAR (WHNP (WP who)) (S (VP (AUX are) (VP (IN about) (S (VP (TO to) (VP (VB start) (NP (JJ long-term) (JJ Doc_133615_1551_1569_Chemical) (NN therapy)))))))))))))))) (. .)))
1355091	0	(S1 (S (NP (NN Doc_1355091_0_23_Disease)) (VP (VBZ occurs) (PP (VBG following) (NP (NP (NN alpha) (NN 2-adrenoceptor) (NN blockade)) (PP (IN in) (NP (JJ chronic) (JJ Doc_1355091_82_90_Chemical-pretreated) (JJ conscious) (ADJP (RB spontaneously) (JJ Doc_1355091_126_138_Disease)) (NN rats.) (CD 1)))))) (. .)))
1355091	1	(S1 (S (NP (NNS Studies)) (VP (AUX were) (VP (VBN performed) (S (VP (TO to) (VP (VB evaluate) (SBAR (IN whether) (S (NP (JJ chronic) (JJ Doc_1355091_199_207_Chemical) (NN treatment)) (VP (VBZ alters) (NP (NP (DT the) (NN alpha) (NN 2-adrenoceptor) (NN function)) (PP (IN for) (NP (NP (JJ orthostatic) (NN control)) (PP (IN of) (NP (NP (JJ arterial) (NN blood) (NN pressure)) (PP (IN in) (NP (NP (JJ conscious) (ADJP (RB spontaneously) (JJ Doc_1355091_337_349_Disease)) (NNS rats)) (PRN (-LRB- -LRB-) (NP (NNP SHR)) (-RRB- -RRB-)) (. .) (CD 2)))))))))))))))) (. .)))
1355091	2	(S1 (S (NP (NP (JJ Conscious) (NNP SHR)) (PRN (-LRB- -LRB-) (NP (JJ male) (JJ 300-350) (NNP g)) (-RRB- -RRB-))) (VP (AUX were) (VP (VBN subjected) (PP (TO to) (NP (NP (CD 90) (NNS degrees)) (SBAR (S (NP (NN head-up)) (VP (VBZ tilts) (PP (IN for) (NP (NP (CD 60) (NNP s) (JJ following) (JJ acute) (NN administration)) (PP (IN of) (NP (NP (NP (NNP Doc_1355091_482_490_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 0.1) (JJ mg) (JJ kg-1) (NN i.p.)) (-RRB- -RRB-))) (CC or) (NP (NP (NNP Doc_1355091_513_524_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 3) (CD mg)) (JJ kg-1) (NNS i.v.)) (-RRB- -RRB-)))))))))))))) (. .)))
1355091	3	(S1 (S (NP (NN Doc_1355091_543_566_Disease)) (VP (AUX was) (VP (VBN determined) (PP (IN by) (NP (NP (DT the) (JJ average) (NN decrease)) (PRN (-LRB- -LRB-) (NP (NN %)) (-RRB- -RRB-)))) (PP (IN in) (NP (JJ mean) (JJ arterial) (NN pressure))) (PRN (-LRB- -LRB-) (NP (NN MAP) (NN femoral)) (-RRB- -RRB-)) (PP (IN over) (NP (DT the) (NN 60-s) (NN tilt) (NN period))))) (. .)))
1355091	4	(S1 (S (NP (NP (DT The) (JJ basal) (NN MAP)) (PP (IN of) (NP (JJ conscious) (NNP SHR)))) (VP (AUX was) (VP (VBN reduced) (PP (TO to) (NP (DT a) (JJ similar) (NN extent))) (PP (IN by) (NP (NP (NNP Doc_1355091_743_751_Chemical) (PRN (-LRB- -LRB-) (NP (CD -23) (NN %)) (-LRB- -LRB-) (NP (LST (: -) (-RRB- -RRB-)) (NP (CD -26) (NN %)) (NN MAP)) (-RRB- -RRB-))) (CC and) (NP (NNP Doc_1355091_774_785_Chemical) (PRN (-LRB- -LRB-) (NP (CD -16) (NN %)) (-LRB- -LRB-) (NP (LST (: -) (-RRB- -RRB-)) (NP (CD -33) (NN %)) (NN MAP)) (-RRB- -RRB-))))))) (. .)))
1355091	5	(S1 (S (ADVP (RB However)) (, ,) (NP (DT the) (JJ head-up) (NN tilt)) (VP (VBN induced) (NP (NNP Doc_1355091_839_862_Disease)) (PP (IN in) (NP (NP (DT the) (NNP SHR)) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_1355091_887_895_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD -16) (NN %)) (NN MAP)) (, ,) (NP (NNP n) (SYM =) (CD 6)) (-RRB- -RRB-))))))) (, ,) (FRAG (CC but) (RB not) (PP (IN in) (NP (NP (DT the) (NNP SHR)) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_1355091_947_958_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (NP (QP (JJR less) (IN than) (CD +2)) (NN %)) (NN MAP)) (, ,) (NP (NNP n) (SYM =) (CD 6))) (-RRB- -RRB-)) (. .) (CD 3)))))))) (. .)))
1355091	6	(S1 (S (NP (JJ Conscious) (NNS SHR)) (VP (AUX were) (VP (VBN treated) (PP (IN for) (NP (NP (CD 4) (NNS days)) (PP (IN with) (NP (NNP Doc_1355091_1033_1041_Chemical))))) (PP (IN at) (NP (NP (CD 2) (JJ mg) (JJ kg-1) (JJ day-1) (NN i.p.)) (PP (IN for) (NP (JJ chronic) (NN alpha) (NN 1-adrenoceptor) (NN blockade))))))) (. .)))
1355091	7	(S1 (S (NP (NP (NN MAP)) (PP (IN in) (NP (JJ conscious) (NNS SHR))) (PP (IN after) (NP (JJ chronic) (JJ Doc_1355091_1144_1152_Chemical) (NN treatment)))) (VP (AUX was) (ADJP (ADJP (NP (CD 14) (NN %)) (JJR lower)) (PP (IN than) (PP (IN in) (NP (NP (DT the) (JJ untreated) (NNP SHR)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 8)) (-RRB- -RRB-))))))) (. .)))
1355091	8	(S1 (S (NP (NP (NN Head-up) (VBZ tilts)) (PP (IN in) (NP (DT these) (NNS rats)))) (VP (AUX did) (RB not) (VP (VB produce) (NP (NNP Doc_1355091_1256_1279_Disease)) (SBAR (WHADVP (WRB when)) (S (VP (VBD performed) (ADVP (RB either)) (PP (ADVP (RB prior)) (TO to) (CC or) (IN after) (NP (NP (JJ acute) (NN dosing)) (PP (IN of) (NP (NNP Doc_1355091_1336_1344_Chemical))) (PRN (-LRB- -LRB-) (NP (CD 0.1) (JJ mg) (JJ kg-1) (NNS i.p.)) (-RRB- -RRB-))))))))) (. .)))
1355091	9	(S1 (S (ADVP (RB Conversely)) (, ,) (NP (NP (NN administration)) (PP (IN of) (NP (NNP Doc_1355091_1395_1406_Chemical))) (PRN (-LRB- -LRB-) (NP (QP (CD 3) (CD mg)) (JJ kg-1) (NNS i.v.)) (-RRB- -RRB-)) (PP (IN in) (NP (JJ chronic) (NNP Doc_1355091_1435_1443_Chemical)))) (VP (VBD treated) (SBAR (S (S (NP (NNP SHR)) (VP (VBD decreased) (NP (NP (DT the) (JJ basal) (NN MAP)) (PP (IN by) (NP (CD 12-31) (NN %)))) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 4)) (-RRB- -RRB-)))) (, ,) (CC and) (S (NP (JJ subsequent)) (VP (VBZ tilts) (S (VP (VBN induced) (NP (NP (JJ further) (NNS drops)) (PP (IN of) (NP (NN MAP)))) (PP (IN by) (NP (CD 19-23) (NN %))) (PP (IN in) (NP (DT these) (JJ rats.) (CD 4)))))))))) (. .)))
1355091	10	(S1 (S (NP (NP (DT The) (NN pressor) (NNS responses)) (CC and) (NP (NP (NP (NP (NNP Doc_1355091_1603_1614_Disease)) (PP (TO to) (NP (NP (NP (DT the) (NN alpha) (NN 1-agonist) (NNP Doc_1355091_1638_1648_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 0.6) (CC and) (CD 2) (NNS micrograms)) (NP (JJ kg-1) (NN i.v.))) (-RRB- -RRB-))) (, ,) (NP (DT the) (NN alpha) (NN 2-agonist))))) (NP (NP (NNP Doc_1355091_1703_1715_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 1) (CC and) (CD 3) (NNS micrograms)) (JJ kg-1) (NNS i.v.)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NNP Doc_1355091_1752_1765_Chemical))) (PRN (-LRB- -LRB-) (NP (NP (CD 0.1) (CC and) (CD 1.0) (NNS micrograms)) (NP (JJ kg-1) (NN i.v.))) (-RRB- -RRB-)))) (VP (AUX were) (VP (VBN determined) (PP (IN in) (NP (NP (JJ conscious) (NNP SHR)) (PP (IN with) (CC and) (PP (IN without) (NP (JJ chronic) (JJ Doc_1355091_1859_1867_Chemical) (NN pretreatment)))))))) (. .)))
1355091	11	(S1 (S (NP (NP (PDT Both) (DT the) (JJ pressor) (CC and) (JJ Doc_1355091_1903_1914_Disease) (NNS effects)) (PP (IN of) (NP (NNP Doc_1355091_1926_1936_Chemical)))) (VP (AUX were) (VP (VBN abolished) (PP (IN in) (NP (NP (JJ chronic) (JJ Doc_1355091_1963_1971_Chemical) (VBN treated) (NNS SHR)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 4)) (-RRB- -RRB-)))) (PP (IN as) (PP (VBN compared) (PP (TO to) (NP (NP (DT the) (JJ untreated) (NNS SHR)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 4)) (-RRB- -RRB-)))))))) (. .)))
1355091	12	(S1 (S (PP (IN On) (NP (DT the) (JJ other) (NN hand))) (, ,) (S (NP (NP (DT the) (JJ pressor) (NNS effects)) (PP (IN of) (NP (NNP Doc_1355091_2076_2088_Chemical)))) (VP (AUX were) (ADJP (JJ similar)) (PP (IN in) (NP (NP (DT both) (NNS groups)) (PP (IN of) (NP (NNP SHR))))))) (, ,) (CC but) (S (NP (DT the) (JJ accompanying) (NN Doc_1355091_2146_2157_Disease)) (VP (AUX was) (ADJP (ADJP (ADJP (JJR greater)) (PP (IN in) (NP (NNP SHR))) (PP (IN with) (NP (JJ chronic) (JJ Doc_1355091_2190_2198_Chemical) (NN treatment)))) (PP (IN than) (PP (IN without) (NP (JJ such) (NN treatment))))))) (. .)))
1355091	13	(S1 (S (ADVP (RB Furthermore)) (, ,) (NP (NP (DT the) (NNP Doc_1355091_2255_2266_Disease)) (SBAR (WHNP (WDT that)) (S (VP (VBD accompanied) (SBAR (S (NP (NP (DT the) (JJ Doc_1355091_2288_2301_Chemical-induced) (JJ pressor) (NN effect)) (PP (IN in) (NP (NNP SHR)))) (VP (AUX was) (ADJP (JJ similar)) (PP (IN with) (CC and) (IN without) (NP (JJ chronic) (JJ Doc_1355091_2369_2377_Chemical) (NN treatment))) (PP (IN despite) (NP (NP (DT a) (ADJP (CD 47-71) (NN %)) (NN reduction)) (PP (IN of) (NP (DT the) (NN pressor) (NN effect))) (PP (IN in) (NP (JJ chronic) (NN alpha) (NN 1-receptor)))))))))))) (VP (VBD blocked) (NP (NP (NNP SHR.)) (PRN (-LRB- -LRB-) (NP (NP (JJ ABSTRACT)) (VP (VBN TRUNCATED) (PP (IN AT) (NP (CD 400) (NNS WORDS))))) (-RRB- -RRB-))))))
1415380	0	(S1 (S (NP (NN Doc_1415380_0_25_Disease)) (VP (VBN associated) (PP (IN with) (NP (NP (NN ingestion)) (PP (IN of) (NP (NNP Doc_1415380_55_62_Chemical)))))) (. .)))
1415380	1	(S1 (S (NP (JJ Doc_1415380_64_89_Disease) (JJ following) (JJ Doc_1415380_100_107_Chemical) (NN ingestion)) (VP (AUX is) (NP (NP (DT a) (ADJP (RB newly) (VBN described)) (NN phenomenon)) (, ,) (PP (IN with) (NP (NP (QP (RB just) (CD two)) (JJ previous) (NNS descriptions)) (PP (IN of) (NP (NP (CD 4) (NNS cases)) (PP (IN in) (NP (DT the) (NN literature))))))))) (. .)))
1415380	2	(S1 (S (NP (PRP We)) (VP (VBP describe) (NP (DT a) (JJ 5th) (NN case))) (. .)))
1415380	3	(S1 (S (NP (DT The) (NN reaction)) (VP (MD may) (VP (AUX be) (VP (VBN mediated) (PP (IN by) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NNS antibodies))))) (ADVP (RB reactive)) (PP (IN against) (NP (NNS platelets))) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NNP Doc_1415380_346_353_Chemical)))))))) (. .)))
1415380	4	(S1 (S (NP (NN Treatment)) (VP (AUX has) (VP (VBN included) (NP (NP (NN use)) (PP (IN of) (NP (NN plasma) (NN exchange)))) (, ,) (NP (NP (NNP Doc_1415380_402_412_Chemical)) (, ,) (NP (NNP Doc_1415380_414_421_Chemical)) (, ,) (CC and) (NP (NNP Doc_1415380_427_439_Chemical))))) (. .)))
1415380	5	(S1 (S (NP (DT The) (NNS patients)) (VP (AUX have) (DT all) (VP (VBN regained) (NP (NP (DT some) (NN degree)) (PP (IN of) (NP (JJ renal) (NN function)))))) (. .)))
1415380	6	(S1 (S (ADVP (RB However)) (, ,) (NP (PRP it)) (VP (AUX is) (ADJP (JJ unclear)) (SBAR (IN whether) (S (NP (NP (JJ pharmacological) (NN treatment)) (CC or) (NP (JJ spontaneous) (NN resolution))) (VP (AUX is) (ADJP (JJ responsible) (PP (IN for) (NP (DT the) (NN improvement)))))))) (. .)))
1415380	7	(S1 (S (NP (JJ Doc_1415380_622_629_Chemical-associated) (NN Doc_1415380_641_666_Disease)) (ADVP (RB probably)) (VP (VBZ occurs) (ADVP (ADVP (RBR more) (RB often)) (SBAR (IN than) (S (VP (AUX is) (VP (VBN recognized))))))) (. .)))
1415380	8	(S1 (S (NP (PRP It)) (VP (AUX is) (ADJP (JJ important)) (S (VP (VP (TO to) (VP (VB recognize) (NP (DT this) (NN reaction)) (SBAR (WHADVP (WRB when)) (S (NP (PRP it)) (VP (VBZ occurs)))))) (CC and) (VP (TO to) (VP (VB avoid) (NP (JJ further) (JJ Doc_1415380_793_800_Chemical) (NN exposure)))))) (, ,) (SBAR (IN since) (S (NP (DT the) (NN reaction)) (VP (VBZ seems) (S (VP (TO to) (VP (AUX be) (ADJP (JJ recurrent))))))))) (. .)))
1423339	0	(S1 (NP (NP (NP (NN Doc_1423339_0_17_Disease)) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_1423339_34_45_Chemical) (NNP Doc_1423339_46_54_Disease))))) (: :) (NP (DT a) (NN case) (NN report)) (. .)))
1423339	1	(S1 (S (NP (DT An) (JJ elderly) (NN woman)) (VP (VBD developed) (NP (DT an) (JJ Doc_1423339_101_110_Disease-like) (NN subacute) (NN Doc_1423339_125_133_Disease)) (PP (IN as) (NP (NP (DT a) (NN result)) (PP (IN of) (NP (NNP Doc_1423339_149_160_Chemical) (NNP Doc_1423339_161_169_Disease)))))) (. .)))
1423339	2	(S1 (S (NP (NP (NN Analysis)) (PP (IN of) (NP (DT the) (NNS manifestations)))) (VP (VBD showed) (SBAR (S (NP (NP (DT that) (JJ severe) (NN impairment)) (PP (IN of) (NP (NN memory)))) (VP (VBD accounted) (PP (IN for) (NP (NP (RB virtually) (DT all)) (PP (IN of) (NP (DT the) (NNS abnormalities))))))))) (. .)))
1423339	3	(S1 (S (NP (EX There)) (VP (AUX is) (NP (NN evidence) (SBAR (IN that) (S (NP (NP (JJ cerebral) (NNS reactions)) (PP (TO to) (NP (NN drug) (NN Doc_1423339_342_350_Disease)))) (VP (MD can) (VP (VB exhibit) (NP (NP (NNS patterns)) (SBAR (WHNP (WDT that)) (S (VP (VBP suggest) (NP (NP (ADJP (RB highly) (JJ selective)) (NN involvement)) (PP (IN of) (NP (NP (JJ functional) (NNS subdivisions)) (PP (IN of) (NP (DT the) (NN brain)))))))))))))))) (. .)))
1445986	0	(S1 (FRAG (NP (JJ Doc_1445986_0_9_Chemical-induced) (JJ immune) (NN Doc_1445986_25_41_Disease)) (. .)))
1445986	1	(S1 (S (NP (NNP Immune) (NNP Doc_1445986_50_66_Disease)) (PP (JJ due) (TO to) (NP (DT a) (JJ drug-adsorption) (NN mechanism))) (VP (AUX has) (VP (AUX been) (VP (VBN described) (ADVP (RB primarily)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (NNP Doc_1445986_153_164_Chemical)) (CC and) (NP (JJ first-generation) (NNP Doc_1445986_186_200_Chemical))))))))) (. .)))
1445986	2	(S1 (S (NP (PRP We)) (VP (VBP describe) (NP (NP (DT a) (NN patient)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NNP Doc_1445986_238_244_Disease)) (PP (IN while) (S (VP (VBG receiving) (NP (JJ intravenous) (NN Doc_1445986_273_282_Chemical)))))))))) (. .)))
1445986	3	(S1 (S (NP (JJ Doc_1445986_284_293_Chemical-dependent) (NNS antibodies)) (VP (AUX were) (VP (VBN detected) (PP (PP (IN in) (NP (NP (DT the) (NN patient) (POS 's)) (NN serum))) (CC and) (PP (IN in) (NP (NP (DT an) (NN eluate)) (VP (VBN prepared) (PP (IN from) (NP (PRP$ his) (JJ red) (NN blood) (NNS cells))))))))) (. .)))
1445986	4	(S1 (S (NP (DT The) (NN eluate)) (ADVP (RB also)) (VP (VBD reacted) (ADVP (RB weakly)) (PP (IN with) (NP (NP (JJ red) (NN blood) (NNS cells)) (PP (IN in) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (NNP Doc_1445986_474_483_Chemical))))))) (, ,) (S (VP (VBG suggesting) (NP (NP (DT the) (JJ concomitant) (NN formation)) (PP (IN of) (NP (JJ warm-reactive) (NNS autoantibodies))))))) (. .)))
1445986	5	(S1 (S (NP (DT These) (NNS observations)) (, ,) (PP (IN in) (NP (NP (NN conjunction)) (PP (IN with) (NP (NP (JJ clinical) (CC and) (NN laboratory) (NN evidence)) (PP (IN of) (NP (JJ extravascular) (NNP Doc_1445986_645_654_Disease))))))) (, ,) (VP (AUX are) (ADJP (JJ consistent) (PP (IN with) (NP (NP (JJ drug-induced) (NN Doc_1445986_689_705_Disease)) (, ,) (VP (ADVP (RB possibly)) (VBG involving) (NP (DT both) (NN drug-adsorption) (CC and) (JJ autoantibody) (NN formation) (NNS mechanisms))))))) (. .)))
1445986	6	(S1 (S (NP (DT This) (NN case)) (VP (VBZ emphasizes) (NP (NP (DT the) (NN need)) (PP (IN for) (NP (NP (VBN increased) (NN awareness)) (PP (IN of) (NP (NP (JJ hemolytic) (NNS reactions)) (PP (TO to) (NP (DT all) (NNP Doc_1445986_870_884_Chemical))))))))) (. .)))
14633084	0	(S1 (NP (NP (NN Use)) (PP (IN of) (NP (NNP Doc_14633084_7_20_Chemical))) (PP (IN with) (NP (NNP Doc_14633084_26_31_Chemical))) (PP (IN for) (NP (NP (DT the) (NN prevention)) (PP (IN of) (NP (NNP Doc_14633084_54_64_Chemical-induced) (NNP Doc_14633084_73_93_Disease))))) (. .)))
14633084	1	(S1 (S (NP (NP (NN Doc_14633084_100_120_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_14633084_122_124_Disease)) (-RRB- -RRB-))) (VP (AUX is) (NP (NP (DT a) (VBG limiting) (NN side-effect)) (PP (IN of) (NP (NN chemotherapy))) (PP (IN with) (NP (NP (NNP Doc_14633084_173_183_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_14633084_185_188_Chemical)) (-RRB- -RRB-)))))) (. .)))
14633084	2	(S1 (S (PP (IN In) (NP (NP (DT the) (NN study)) (VP (VBN presented) (ADVP (RB here))))) (, ,) (NP (PRP we)) (VP (VBD investigated) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NNP Doc_14633084_247_260_Chemical))) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NNP Doc_14633084_281_286_Chemical))))) (PP (IN for) (NP (NP (DT the) (NN prevention)) (PP (IN of) (NP (NNP Doc_14633084_309_312_Chemical-induced) (NNP Doc_14633084_321_323_Disease))))))) (. .)))
14633084	3	(S1 (S (NP (NP (JJ Male) (JJ Wistar) (NNS rats)) (PRN (-LRB- -LRB-) (NP (NP (CD 150-200) (NNP g)) (: ;) (NP (NP (CD 6) (NNS rats)) (PP (IN per) (NP (NN group))))) (-RRB- -RRB-))) (VP (AUX were) (VP (VBN treated) (PP (IN with) (NP (NP (NN saline)) (CC or) (NP (NP (NNP Doc_14633084_409_414_Chemical) (CD 5) (NN min)) (PRN (-LRB- -LRB-) (NP (NN i.p.)) (-RRB- -RRB-))))) (PP (IN before) (NP (NP (CC and) (CD 2) (CC and) (CD 6)) (NP (NNP h)))) (PP (IN after) (NP (NP (-LRB- -LRB-) (JJ v.o.) (-RRB- -RRB-) (NN administration)) (PP (IN of) (NP (NNP Doc_14633084_480_483_Chemical))))))) (. .)))
14633084	4	(S1 (S (NP (NP (CD One)) (, ,) (NP (NP (QP (CD two) (CC or) (CD three)) (NNS doses)) (PP (IN of) (NP (NNP Doc_14633084_512_517_Chemical))))) (VP (AUX were) (VP (VBN replaced) (PP (PP (IN with) (NP (NP (NNP Doc_14633084_537_550_Chemical)) (ADVP (RB alone)))) (CC or) (PP (IN with) (NP (NP (NNP Doc_14633084_565_578_Chemical)) (CC plus) (NP (NNP Doc_14633084_584_589_Chemical))))))) (. .)))
14633084	5	(S1 (S (NP (NN Doc_14633084_591_599_Disease)) (VP (AUX was) (VP (VBN evaluated) (NP (CD 24) (NNP h)) (PP (IN after) (NP (PRP$ its) (NN induction))) (PP (PP (IN by) (NP (NP (DT the) (NNS changes)) (PP (IN in) (NP (NN bladder) (JJ wet) (NN weight))))) (CC and) (PP (IN by) (NP (NP (NN macroscopic)) (CC and) (NP (JJ microscopic) (NN analysis))))))) (. .)))
14633084	6	(S1 (S (NP (NP (NP (DT The) (NN replacement)) (PP (IN of) (NP (DT the) (JJ last) (NN dose)))) (CC or) (NP (NP (DT the) (JJ last) (CD two) (NNS doses)) (PP (IN of) (NP (NP (NNP Doc_14633084_788_793_Chemical)) (PP (IN with) (NP (NNP Doc_14633084_799_812_Chemical))))))) (VP (VBD reduced) (NP (DT the) (NN increase)) (PP (IN in) (NP (NP (NN bladder) (JJ wet) (NN weight)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_14633084_867_870_Chemical))) (PP (IN by) (NP (NP (CD 84.79) (NN %)) (CC and) (NP (CD 89.13) (NN %)) (, ,) (ADVP (RB respectively)))))))) (. .)))
14633084	7	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (PRP it)) (ADVP (RB almost)) (VP (VBD abolished) (NP (NP (DT the) (JJ macroscopic) (CC and) (JJ microscopic) (NNS alterations)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_14633084_995_998_Chemical)))))) (. .)))
14633084	8	(S1 (S (ADVP (RB Moreover)) (, ,) (NP (NP (DT the) (NN addition)) (PP (IN of) (NP (NNP Doc_14633084_1026_1039_Chemical))) (PP (TO to) (NP (NP (DT the) (JJ last) (CD two) (NNS doses)) (PP (IN of) (NP (NNP Doc_14633084_1065_1070_Chemical)))))) (VP (AUX was) (ADJP (ADJP (RBR more) (JJ efficient)) (PP (IN than) (NP (NP (CD three) (NNS doses)) (PP (IN of) (NP (NNP Doc_14633084_1110_1115_Chemical)))))) (ADVP (RB alone)) (SBAR (WHADVP (WRB when)) (S (VP (VBN evaluated) (ADVP (RB microscopically)))))) (. .)))
14633084	9	(S1 (S (NP (NP (NN Doc_14633084_1166_1179_Chemical)) (PP (IN in) (NP (NN combination))) (PP (IN with) (NP (NNP Doc_14633084_1200_1205_Chemical)))) (VP (AUX was) (ADJP (JJ efficient)) (PP (IN in) (S (VP (VBG blocking) (NP (JJ Doc_14633084_1232_1235_Chemical-induced) (NNP Doc_14633084_1244_1246_Disease)))))) (. .)))
14633084	10	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (NN replacement)) (PP (IN of) (NP (NP (NP (JJ last) (CD two) (NNS doses)) (PP (IN of) (NP (NNP Doc_14633084_1294_1299_Chemical))) (PP (IN with) (NP (NN saline)))) (CC or) (NP (NP (DT all)) (PP (IN of) (NP (NP (DT the) (JJ Doc_14633084_1326_1331_Chemical) (NNS doses)) (PP (IN with) (NP (NNP Doc_14633084_1343_1356_Chemical))))))))) (VP (AUX did) (RB not) (VP (VB prevent) (NP (NNP Doc_14633084_1373_1375_Disease)))) (. .)))
14648024	0	(S1 (NP (NP (JJ Doc_14648024_0_24_Chemical-induced) (NN Doc_14648024_33_49_Disease)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_14648024_67_95_Disease))))) (. .)))
14648024	1	(S1 (S (NP (NP (NN Doc_14648024_97_113_Disease)) (VP (VBN associated) (PP (IN with) (NP (NP (NNP Doc_14648024_130_154_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_14648024_156_160_Chemical)) (-RRB- -RRB-)))) (PP (IN for) (NP (NP (NNP Doc_14648024_166_194_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_14648024_196_199_Disease)) (-RRB- -RRB-)))))) (VP (AUX is) (ADJP (RB very) (JJ rare))) (. .)))
14648024	2	(S1 (S (NP (PRP We)) (VP (VBP describe) (NP (NP (CD four) (NNS patients)) (PP (IN with) (NP (NP (JJ classic) (NNP Doc_14648024_254_257_Disease)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NN Doc_14648024_272_288_Disease)) (PP (IN during) (NP (JJ Doc_14648024_296_300_Chemical) (NN therapy)))))))))) (. .)))
14648024	3	(S1 (S (NP (NP (NNP Doc_14648024_310_315_Disease)) (CC and) (NP (NP (JJ subsequent) (NN multiple) (NNP Doc_14648024_340_347_Disease) (NNP Doc_14648024_348_368_Disease)) (PP (IN over) (NP (NNS extremities))))) (VP (VBD developed) (PP (IN on) (NP (NP (NNP D11)) (, ,) (NP (NNP D16)) (, ,) (NP (NNP D17)) (, ,) (CC and) (NP (NNP D19)) (, ,) (ADVP (RB respectively)))) (, ,) (PP (IN after) (NP (JJ Doc_14648024_443_447_Chemical) (NN therapy)))) (. .)))
14648024	4	(S1 (S (NP (NP (DT The) (NN skin) (NN biopsy)) (VP (VBN taken) (PP (IN from) (NP (DT each) (NN patient))))) (VP (AUX was) (ADJP (JJ consistent) (PP (IN with) (NP (NNP Doc_14648024_517_533_Disease))))) (. .)))
14648024	5	(S1 (S (NP (DT All) (NNS patients)) (VP (VBD received) (NP (NP (JJ short) (NN course)) (PP (IN of) (NP (NNP Doc_14648024_573_581_Chemical))))) (. .)))
14648024	6	(S1 (S (S (NP (NN Doc_14648024_583_588_Disease)) (VP (VBD subsided) (ADVP (RB rapidly)))) (CC and) (S (NP (DT the) (NN skin) (NNS lesions)) (VP (VBD regressed) (ADVP (RB completely)))) (. .)))
14648024	7	(S1 (S (NP (DT All) (NNS patients)) (VP (VBD achieved) (NP (JJ complete) (NN remission)) (PP (IN without) (NP (NP (NN withdrawal)) (PP (IN of) (NP (NNP Doc_14648024_712_716_Chemical)))))) (. .)))
14648024	8	(S1 (S (NP (NN Doc_14648024_718_722_Chemical)) (VP (VBD seemed) (S (VP (TO to) (VP (AUX be) (NP (NP (DT the) (ADJP (RBS most) (JJ possible)) (NN etiology)) (PP (IN of) (NP (NNP Doc_14648024_766_782_Disease))) (PP (IN in) (NP (PRP$ our) (NNS patients)))))))) (. .)))
14648024	9	(S1 (S (NP (NP (JJ Short-term) (NN use)) (PP (IN of) (NP (NNP Doc_14648024_818_825_Chemical)))) (VP (AUX is) (ADJP (RB very) (JJ effective) (PP (IN in) (NP (NNP Doc_14648024_847_851_Chemical-induced) (NNP Doc_14648024_860_876_Disease))))) (. .)))
14704468	0	(S1 (NP (NP (NN Effect)) (PP (IN of) (NP (DT some) (NNS convulsants))) (PP (IN on) (NP (NP (NP (DT the) (JJ protective) (NN activity)) (PP (IN of) (NP (NNP Doc_14704468_57_68_Chemical)))) (CC and) (NP (NP (PRP$ its) (NNS combinations)) (PP (IN with) (NP (NP (NP (NNP Doc_14704468_95_104_Chemical)) (CC or) (NP (NNP Doc_14704468_108_118_Chemical))) (PP (IN in) (NP (JJ amygdala-kindled) (NNS rats)))))))) (. .)))
14704468	1	(S1 (S (NP (NP (NN Doc_14704468_145_156_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 5) (NN mg/kg)) (-RRB- -RRB-))) (VP (VBN exerted) (NP (DT a) (JJ significant) (JJ protective) (NN action)) (PP (IN in) (NP (JJ amygdala-kindled) (NNS rats))) (, ,) (S (VP (VBG reducing) (NP (DT both) (JJ Doc_14704468_247_254_Disease) (CC and) (JJ afterdischarge) (NNS durations))))) (. .)))
14704468	2	(S1 (S (NP (NP (DT The) (NNS combinations)) (PP (IN of) (NP (NP (NNP Doc_14704468_305_316_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 2.5) (NN mg/kg)) (-RRB- -RRB-)))) (PP (IN with) (NP (NP (NNP Doc_14704468_334_343_Chemical)) (, ,) (NP (NNP Doc_14704468_345_355_Chemical)) (, ,) (CC or) (NP (NP (NNP Doc_14704468_360_373_Chemical)) (PRN (-LRB- -LRB-) (VP (VBN applied) (PP (IN at) (NP (PRP$ their) (JJ subprotective) (NNS doses)))) (-RRB- -RRB-)))))) (ADVP (RB also)) (VP (VBD exhibited) (NP (JJ antiseizure) (NN effect)) (PP (IN in) (NP (DT this) (NN test)))) (. .)))
14704468	3	(S1 (S (ADVP (RB However)) (, ,) (NP (QP (RB only) (CD two)) (JJ first) (NNS combinations)) (VP (VBD occurred) (S (VP (TO to) (VP (AUX be) (PP (IN of) (NP (JJ pharmacodynamic) (NN nature))))))) (. .)))
14704468	4	(S1 (S (PP (IN Among) (NP (JJ several) (NNS chemoconvulsants))) (, ,) (NP (NP (NNP Doc_14704468_572_583_Chemical) (, ,) (NNP Doc_14704468_585_609_Chemical) (CC and) (NNP Doc_14704468_614_624_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (DT the) (NN opener)) (PP (IN of) (NP (JJ L-type) (NNP Doc_14704468_647_654_Chemical) (NNS channels)))) (-RRB- -RRB-))) (VP (VBD reversed) (NP (NP (NP (DT the) (JJ protective) (NN activity)) (PP (IN of) (NP (NP (NNP Doc_14704468_701_712_Chemical)) (ADVP (RB alone))))) (CC and) (NP (NP (PRP$ its) (NN combination)) (PP (IN with) (NP (NNP Doc_14704468_744_753_Chemical)))))) (. .)))
14704468	5	(S1 (S (PP (IN On) (NP (DT the) (JJ other) (NN hand))) (, ,) (NP (NNP Doc_14704468_774_785_Chemical) (, ,) (NNP Doc_14704468_787_800_Chemical) (CC and) (NNP Doc_14704468_805_815_Chemical)) (VP (VBD inhibited) (NP (NP (DT the) (JJ anticonvulsive) (NN action)) (PP (IN of) (NP (NP (NNP Doc_14704468_855_866_Chemical)) (VP (VBN combined) (PP (IN with) (NP (NNP Doc_14704468_881_891_Chemical)))))))) (. .)))
14704468	6	(S1 (S (NP (DT The) (NNS results)) (VP (VBP support) (NP (DT the) (NN hypothesis) (SBAR (IN that) (S (NP (NP (NP (DT the) (JJ protective) (NN activity)) (PP (IN of) (NP (NNP Doc_14704468_960_971_Chemical)))) (CC and) (NP (NP (PRP$ its) (NNS combinations)) (PP (IN with) (NP (JJ other) (NNS antiepileptics))))) (VP (MD may) (VP (VB involve) (NP (NP (NN potentiation)) (PP (IN of) (NP (NP (JJ GABAergic) (NN neurotransmission) (CC and) (NN blockade)) (PP (IN of) (NP (NP (NNP L-type)) (PP (IN of) (NP (NNP Doc_14704468_1101_1108_Chemical) (NNS channels)))))))))))))) (. .)))
14736955	0	(S1 (S (NP (NP (JJ Mitochondrial) (NN DNA)) (CC and) (NP (PRP$ its) (JJ respiratory) (NN chain) (NNS products))) (VP (AUX are) (ADJP (JJ defective)) (PP (IN in) (NP (NNP Doc_14736955_70_81_Chemical) (NNP Doc_14736955_82_91_Disease)))) (. .)))
14736955	1	(S1 (S (NP (NN Doc_14736955_105_116_Chemical)) (VP (VBZ induces) (NP (NP (DT a) (JJ self-perpetuating) (NN Doc_14736955_145_156_Disease)) (VP (VBN characterized) (PP (IN by) (NP (NP (JJ early) (NNP Doc_14736955_180_221_Disease)) (PP (IN in) (NP (NNS rats)))))))) (. .)))
14736955	2	(S1 (S (NP (PRP We)) (VP (VBD investigated) (NP (NP (DT the) (JJ potential) (NN role)) (PP (IN of) (NP (NNP Doc_14736955_269_289_Disease))) (PP (IN in) (NP (NP (DT the) (NN onset)) (PP (IN of) (NP (DT these) (NNS lesions))))))) (. .)))
14736955	3	(S1 (S (NP (NNS Rats)) (VP (VP (AUX were) (VP (VBN treated) (PP (IN with) (NP (NP (JJ intravenous) (NNP Doc_14736955_365_376_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 1) (NN mg) (NN kg) (PRN (-LRB- -LRB-) (JJ -1) (-RRB- -RRB-)) (NN week)) (PRN (-LRB- -LRB-) (JJ -1) (-RRB- -RRB-))) (-RRB- -RRB-)))) (PP (IN for) (NP (CD 7) (NNS weeks))))) (CC and) (VP (AUX were) (VP (VBN sacrificed) (ADVP (RB either) (NP (NP (NP (NP (CD 1) (NN week)) (PRN (-LRB- -LRB-) ('' ') (NP (NN short-term) (POS ')) (-RRB- -RRB-))) (CC or) (NP (NP (CD 30) (NNS weeks)) (PRN (-LRB- -LRB-) (: ') (ADJP (JJ long-term)) ('' ') (-RRB- -RRB-)))) (VP (VBG following) (NP (DT the) (JJ last) (NN dose)))))))) (. .)))
14736955	4	(S1 (S (NP (JJ Additional) (NNS rats)) (VP (VBD received) (NP (NP (NP (DT a) (JJ single) (NN dose)) (NP (QP (RB either) (CD 6)) (NNS days))) (CC or) (NP (NP (CD 2) (NNP h)) (ADVP (RB prior) (PP (TO to) (NP (NN euthanasia))))))) (. .)))
14736955	5	(S1 (S (NP (DT All) (NNS rats)) (VP (AUX were) (VP (VBN killed) (PP (IN at) (NP (NP (CD 48) (NNS weeks)) (PP (IN of) (NP (NN age))))))) (. .)))
14736955	6	(S1 (S (NP (NN Doc_14736955_634_663_Disease)) (VP (VP (AUX was) (VP (VBN monitored))) (CC and) (VP (VBD correlated) (PP (TO to) (NP (NP (DT the) (NN activity) (CC or) (NN expression)) (PP (IN of) (NP (JJ respiratory) (NN chain) (NNS components))))))) (. .)))
14736955	7	(S1 (S (ADVP (RB Finally)) (, ,) (NP (PRP we)) (VP (VBN quantified) (NP (NP (NP (DT both) (JJ nuclear) (CC and) (JJ mitochondrial) (NN DNA)) (PRN (-LRB- -LRB-) (NP (NN mtDNA)) (-RRB- -RRB-))) (CONJP (RB as) (RB well) (IN as)) (NP (NP (JJ Doc_14736955_833_843_Chemical) (NN production)) (CC and) (NP (NP (DT the) (CD 4834) (NN base) (NN pair) (POS ')) (JJ common) ('' ') (NN mtDNA) (NN deletion))))) (. .)))
14736955	8	(S1 (S (NP (DT The)) (VP (POS ') (SBAR (S (NP (NP (NNS long-term) (POS ')) (NN group)) (VP (AUX had) (NP (NP (JJ significant) (NN Doc_14736955_950_980_Disease)) (, ,) (NP (NP (JJ depressed) (NNS activities)) (PP (IN of) (NP (NP (JJ mtDNA-encoded) (JJ Doc_14736955_1020_1024_Chemical) (NN dehydrogenase)) (CC and) (NP (NP (JJ cytochrome-c) (NN oxidase)) (PRN (-LRB- -LRB-) (NP (NNP COX)) (-RRB- -RRB-)))))) (CC and) (NP (VBN increased) (JJ Doc_14736955_1084_1091_Chemical) (NN synthase) (NN activity))))))) (. .)))
14736955	9	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (NN expression)) (PP (IN of) (NP (DT the) (JJ mtDNA-encoded) (NNP COX)))) (VP (VBD subunit) (SBAR (S (S (NP (PRP I)) (VP (AUX was) (VP (VBN reduced)))) (CC and) (S (NP (NN mtDNA) (NNS levels)) (VP (AUX were) (VP (VBN decreased))))))) (. .)))
14736955	10	(S1 (S (PP (IN In) (NP (: ') (JJ short-term) ('' ') (NNS rats))) (, ,) (NP (EX there)) (VP (AUX were) (UCP (ADJP (RBR fewer) (JJ Doc_14736955_1254_1269_Disease)) (, ,) (CC but) (NP (NP (JJ similar) (NNS numbers)) (PP (IN of) (NP (JJ Doc_14736955_1294_1312_Disease) (NN activity)))))) (. .)))
14736955	11	(S1 (S (PP (IN Among) (NP (DT all) (NNS animals))) (, ,) (NP (NNP Doc_14736955_1342_1371_Disease)) (VP (AUX were) (ADVP (RB inversely)) (VP (VBN correlated) (PP (IN with) (NP (NP (NN mtDNA) (NNS levels)) (, ,) (NP (JJ mtDNA-encoded) (JJ respiratory) (NN chain) (NNS activities)) (CC and) (PP (IN with) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (DT the) (JJ mtDNA-encoded) (NN respiratory) (NN chain))))) (NP (JJ subunit) (NNS COX-I)))))) (. .)))
14736955	12	(S1 (S (NP (NN Injury)) (VP (AUX was) (ADVP (RB positively)) (VP (VBN correlated) (PP (IN with) (NP (NP (JJ Doc_14736955_1576_1586_Chemical) (NN production)) (CC and) (NP (NP (DT the) (NNS activities)) (PP (IN of) (NP (NP (JJ nucleus-encoded) (NN mitochondrial)) (CC or) (NP (JJ cytoplasmic) (NNS enzymes))))))))) (. .)))
14736955	13	(S1 (S (S (NP (NP (NNS Kidneys)) (PP (IN from) (NP (DT the) ('' ') (JJ long-term) ('' ') (NN group)))) (VP (VBD showed) (NP (JJR more) (NN mtDNA) (NNS deletions)) (PP (IN than) (PP (IN in))))) (: ') (S (NP (NP (JJ short-term) ('' ') (NNS animals)) (CC and) (NP (DT these))) (VP (AUX were) (RB not) (VP (VBN observed) (PP (IN in) (NP (DT the) (JJ other) (NNS groups)))))) (. .)))
14736955	14	(S1 (S (NP (DT These) (NNS results)) (VP (VBP suggest) (NP (NP (DT an) (JJ important) (NN role)) (PP (IN for) (NP (JJ quantitative) (CC and) (JJ qualitative) (NN mtDNA) (NNS alterations)))) (PP (IN through) (NP (NP (DT the) (NN reduction)) (PP (IN of) (NP (NP (JJ mtDNA-encoded) (JJ respiratory) (NN chain) (NN function)) (CC and) (NP (NP (NN induction)) (PP (IN of) (NP (NNP Doc_14736955_2002_2012_Chemical))) (PP (IN in) (NP (NNP Doc_14736955_2016_2027_Chemical-induced) (NNP Doc_14736955_2036_2049_Disease))))))))) (. .)))
14742097	0	(S1 (NP (NP (DT A) (JJ randomized) (, ,) (JJ placebo-controlled) (, ,) (JJ crossover) (NN study)) (PP (IN of) (NP (NNP Doc_14742097_53_62_Chemical))) (PP (IN for) (NP (JJ Doc_14742097_67_71_Chemical-induced) (NN female) (NN Doc_14742097_87_105_Disease))) (. .)))
14742097	1	(S1 (S (NP (NP (DT The) (NN objective)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB determine) (SBAR (IN whether) (S (NP (NP (NNP Doc_14742097_160_169_Chemical)) (, ,) (NP (NP (DT an) (ADJP (JJ alpha-) (CC and) (JJ beta-adrenergic)) (NN agonist)) (VP (ADVP (RB previously)) (VBN shown) (S (VP (TO to) (VP (VB enhance) (NP (NP (JJ genital) (NN blood) (NN flow)) (PP (IN in) (NP (NNS women))))))))) (, ,)) (VP (AUX has) (NP (JJ beneficial) (NNS effects)) (PP (IN in) (S (VP (VBG reversing) (NP (JJ antidepressant-induced) (NN Doc_14742097_325_343_Disease)))))))))))) (. .)))
14742097	2	(S1 (S (NP (NNP Nineteen) (NNP Doc_14742097_354_376_Disease) (NNS women)) (VP (VBG receiving) (NP (DT either) (NNP Doc_14742097_400_410_Chemical) (, ,) (NNP Doc_14742097_412_422_Chemical))) (, ,) (CC or) (S (NP (NNP Doc_14742097_427_437_Chemical)) (VP (VBD participated) (PP (IN in) (NP (NP (DT an) (JJ eight-week) (, ,) (JJ double-blind) (, ,) (JJ placebo-controlled) (, ,) (JJ cross-over) (NN study)) (PP (IN of) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (NNP Doc_14742097_538_547_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 50) (NN mg)) (-RRB- -RRB-)))) (PP (IN on) (NP (NP (JJ self-report) (NNS measures)) (PP (IN of) (NP (NP (JJ sexual) (NN desire)) (, ,) (NP (NN arousal)) (, ,) (NP (NN orgasm)) (, ,) (CC and) (NP (JJ sexual) (NN satisfaction)))))))))))) (. .)))
14742097	3	(S1 (S (SBAR (IN Although) (S (NP (EX there)) (VP (AUX were) (NP (NP (JJ significant) (NNS improvements)) (ADJP (JJ relative) (PP (TO to) (NP (NP (NN baseline)) (PP (IN in) (NP (NP (JJ sexual) (NN desire)) (CC and) (NP (NN orgasm) (NN intensity/pleasure)))))))) (PP (IN on) (NP (NP (QP (CD 50) (CD mg)) (JJ Doc_14742097_762_771_Chemical) (NNS 1-hr)) (PP (ADVP (RB prior)) (TO to) (NP (JJ sexual) (NN activity)))))))) (, ,) (NP (NP (JJ significant) (NNS improvements)) (PP (PP (IN in) (NP (DT these) (NNS measures))) (, ,) (CONJP (RB as) (RB well) (IN as)) (PP (IN in) (NP (NP (JJ sexual) (NN arousal)) (CC and) (NP (JJ orgasmic) (NN ability)))))) (ADVP (RB also)) (VP (AUX were) (VP (VBN noted) (PP (IN with) (NP (NN placebo))))) (. .)))
14742097	4	(S1 (S (NP (DT These) (NNS findings)) (VP (VB highlight) (NP (NP (DT the) (NN importance)) (PP (IN of) (S (VP (VBG conducting) (NP (JJ placebo-controlled) (NNS trials)) (PP (IN for) (NP (DT this) (NN condition)))))))) (. .)))
14745746	0	(S1 (SQ (AUX Does) (NP (NP (NN hormone) (NN therapy)) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NNP Doc_14745746_42_55_Disease)))))) (VP (AUX have) (NP (DT a) (NN Doc_14745746_63_105_Disease))) (. ?)))
14745746	1	(S1 (FRAG (NP (DT A) (NN pilot) (NN study)) (. .)))
14745746	2	(S1 (S (NP (DT This) (NN pilot) (NN study)) (VP (VBZ examines) (SBAR (IN whether) (S (NP (NP (NN hormone) (NN therapy)) (PP (IN for) (NP (NNP Doc_14745746_176_189_Disease)))) (VP (VBZ affects) (NP (NN cognition)))))) (. .)))
14745746	3	(S1 (S (NP (NP (NNS Patients)) (VP (VBG participating) (PP (IN in) (NP (NP (NP (DT a) (JJ randomised) (NN trial)) (PP (IN of) (NP (NP (NNP Doc_14745746_257_268_Chemical)) (, ,) (NP (NP (NNP Doc_14745746_270_279_Chemical)) (ADVP (RB alone))) (CC or) (NP (NP (JJ combined) (-LRB- -LRB-) (NNP ATAC) (-RRB- -RRB-)) (PRN (-LRB- -LRB-) (NP (CD n=94)) (-RRB- -RRB-)))))) (CC and) (NP (NP (DT a) (NN group)) (PP (IN of) (NP (NNS women)))))) (PP (IN without) (NP (NP (NNP Doc_14745746_341_354_Disease)) (PRN (-LRB- -LRB-) (NP (CD n=35)) (-RRB- -RRB-)))))) (VP (VBD completed) (NP (NP (DT a) (NN battery)) (PP (IN of) (NP (JJ neuropsychological) (NNS measures))))) (. .)))
14745746	4	(S1 (S (PP (VBN Compared) (PP (IN with) (NP (DT the) (NN control) (NN group)))) (, ,) (NP (DT the) (NNS patients)) (VP (AUX were) (VP (VBN impaired) (PP (PP (IN on) (NP (NP (DT a) (NN processing) (NN speed) (NN task)) (PRN (-LRB- -LRB-) (NP (CD p=0.032)) (-RRB- -RRB-)))) (CC and) (PP (IN on) (NP (NP (DT a) (NN measure)) (PP (IN of) (NP (NP (JJ immediate) (JJ verbal) (NN memory)) (PRN (-LRB- -LRB-) (NP (CD p=0.026)) (-RRB- -RRB-))))))) (PP (IN after) (S (VP (VBG controlling) (PP (IN for) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NN hormone) (NN replacement) (NN therapy))) (PP (IN in) (NP (DT both) (NNS groups)))))))))) (. .)))
14745746	5	(S1 (S (NP (JJ Patient) (NN group) (NN performance)) (VP (AUX was) (RB not) (ADJP (RB significantly) (JJ related) (PP (TO to) (NP (NP (NP (NN length)) (PP (IN of) (NP (NN treatment)))) (CC or) (NP (NP (NNS measures)) (PP (IN of) (NP (JJ psychological) (NN morbidity)))))))) (. .)))
14745746	6	(S1 (S (NP (DT The) (NNS results)) (VP (VBD showed) (NP (JJ specific) (NNS impairments)) (PP (IN in) (S (VP (VBG processing) (NP (NP (NP (NN speed)) (CC and) (NP (JJ verbal) (NN memory))) (PP (IN in) (NP (NP (NNS women)) (VP (VBG receiving) (NP (JJ hormonal) (NN therapy)) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NNP Doc_14745746_896_909_Disease))))))))))))) (. .)))
14745746	7	(S1 (S (NP (JJ Verbal) (NN memory)) (VP (MD may) (VP (AUX be) (ADJP (RB especially) (JJ sensitive) (PP (TO to) (NP (NP (NNS changes)) (PP (IN in) (NP (NP (JJ Doc_14745746_967_976_Chemical) (NNS levels)) (, ,) (NP (NP (DT a) (NN finding)) (VP (ADVP (RB commonly)) (VBN reported) (PP (IN in) (NP (NP (NNS studies)) (PP (IN of) (NP (NN hormone) (NN replacement) (NN therapy))) (PP (IN in) (NP (JJ healthy) (NNS women)))))))))))))) (. .)))
14745746	8	(S1 (S (PP (IN In) (NP (NP (NP (NN view)) (PP (IN of) (NP (NP (DT the) (VBN increased) (NN use)) (PP (IN of) (NP (NN hormone) (NNS therapies))) (PP (IN in) (NP (DT an) (NN adjuvant)))))) (CC and) (NP (JJ preventative) (NN setting)))) (NP (NP (PRP$ their) (NN impact)) (PP (IN on) (NP (JJ cognitive) (NN functioning)))) (VP (MD should) (VP (AUX be) (VP (VBN investigated) (ADVP (RBR more) (RB thoroughly))))) (. .)))
14975762	0	(S1 (S (NP (NP (NN Expression)) (PP (IN of) (NP (CD p300)))) (VP (VBZ protects) (NP (NP (JJ cardiac) (NNS myocytes)) (PP (IN from) (NP (NP (NNS apoptosis)) (PP (IN in) (NP (NN vivo))))))) (. .)))
14975762	1	(S1 (S (NP (NN Doc_14975762_69_80_Chemical)) (VP (AUX is) (NP (NP (DT an) (JJ anti-Doc_14975762_92_97_Disease) (NN agent)) (SBAR (WHNP (WDT that)) (S (VP (VP (VBZ represses) (NP (JJ cardiac-specific) (NN gene) (NN expression))) (CC and) (VP (VBZ induces) (NP (JJ myocardial) (NN cell) (NN apoptosis)))))))) (. .)))
14975762	2	(S1 (S (NP (NN Doc_14975762_191_202_Chemical)) (VP (VBZ depletes) (NP (NP (JJ cardiac) (NN p300)) (, ,) (NP (NP (DT a) (JJ transcriptional) (NN coactivator)) (SBAR (WHNP (WDT that)) (S (VP (AUX is) (VP (VBN required) (PP (IN for) (NP (NP (DT the) (NN maintenance)) (PP (IN of) (NP (NP (DT the) (JJ differentiated) (NN phenotype)) (PP (IN of) (NP (JJ cardiac) (NNS myocytes)))))))))))))) (. .)))
14975762	3	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (CD p300))) (PP (IN in) (NP (NP (NN protection)) (PP (IN against) (NP (JJ Doc_14975762_394_405_Chemical-induced) (NNS apoptosis)))))) (VP (AUX is) (ADJP (JJ unknown))) (. .)))
14975762	4	(S1 (S (NP (NP (NNP Transgenic) (NNS mice)) (VP (VBG overexpressing) (NP (CD p300)) (PP (IN in) (NP (DT the) (NN heart) (CC and) (NN wild-type) (NNS mice))))) (VP (AUX were) (VP (VBN subjected) (PP (TO to) (NP (JJ Doc_14975762_522_533_Chemical) (NN treatment))))) (. .)))
14975762	5	(S1 (S (PP (VBN Compared) (PP (IN with) (NP (JJ wild-type) (NNS mice)))) (, ,) (NP (NNP transgenic) (NNS mice)) (VP (VBD exhibited) (NP (NP (JJR higher) (NN survival) (NN rate)) (CONJP (RB as) (RB well) (IN as)) (NP (NP (NP (JJR more) (VBN preserved) (JJ left) (NN ventricular) (NN function)) (CC and) (NP (JJ cardiac) (NN expression))) (PP (IN of) (NP (JJ alpha-sarcomeric) (NN actin)))))) (. .)))
14975762	6	(S1 (FRAG (NP (NP (JJ Doc_14975762_724_735_Chemical) (VBN induced) (JJ myocardial) (NN cell) (NN apoptosis)) (PP (IN in) (NP (JJ wild-type) (NNS mice)))) (CC but) (RB not) (PP (IN in) (NP (NNP transgenic) (NNS mice))) (. .)))
14975762	7	(S1 (S (NP (NP (NN Expression)) (PP (IN of) (NP (CD p300)))) (VP (VBD increased) (NP (NP (NP (DT the) (JJ cardiac) (NN level)) (PP (IN of) (NP (NP (NN bcl-2)) (CC and) (NP (NN mdm-2))))) (, ,) (CC but) (RB not) (NP (NP (DT that)) (PP (IN of) (NP (NN p53)))) (CC or) (NP (NP (JJ other) (NNS members)) (PP (IN of) (NP (DT the) (JJ bcl-2) (NN family)))))) (. .)))
14975762	8	(S1 (S (NP (DT These) (NNS findings)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP (NP (NN overexpression)) (PP (IN of) (NP (CD p300)))) (VP (VP (VBZ protects) (NP (NP (JJ cardiac) (NNS myocytes)) (PP (IN from) (NP (JJ Doc_14975762_1027_1038_Chemical-induced) (NNS apoptosis))))) (CC and) (VP (VBZ reduces) (NP (NP (DT the) (NN extent)) (PP (IN of) (NP (NP (JJ acute) (NNP Doc_14975762_1089_1102_Disease)) (PP (IN in) (NP (NP (NN adult) (NNS mice)) (PP (IN in) (NP (NN vivo))))))))))))) (. .)))
14982270	0	(S1 (NP (JJ Doc_14982270_0_11_Chemical-induced) (NN Doc_14982270_20_40_Disease) (. .)))
14982270	1	(S1 (S (NP (NN Doc_14982270_42_53_Chemical)) (VP (AUX is) (NP (DT a) (ADJP (ADJP (RB widely) (JJ used)) (CC and) (ADJP (RB generally) (JJ well-tolerated))) (NN antithyroid) (NN agent))) (. .)))
14982270	2	(S1 (S (NP (DT A) (JJ 43-year-old) (NN woman)) (VP (AUX had) (NP (NP (JJ severe) (NN Doc_14982270_150_158_Disease)) (CC and) (NP (NNP Doc_14982270_163_170_Disease) (CD 1) (NN month))) (PP (IN after) (S (VP (VBG receiving) (NP (NP (NP (NNP Doc_14982270_195_206_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 10) (CD mg)) (NN tid)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_14982270_223_234_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 20) (CD mg)) (NN tid)) (-RRB- -RRB-)))) (PP (IN for) (NP (NP (NN treatment)) (PP (IN of) (NP (NNP Doc_14982270_264_279_Disease))))))))) (. .)))
14982270	3	(S1 (S (NP (DT The) (NN patient)) (VP (VBD continued) (NP (NN treatment)) (PP (IN for) (NP (DT another) (CD 4) (NNS days))) (PP (IN after) (NP (NP (DT the) (NN appearance)) (PP (IN of) (NP (NNP Doc_14982270_356_364_Disease))))) (SBAR (IN until) (S (NP (PRP she)) (VP (VBD finished) (NP (DT both) (NNS medications)))))) (. .)))
14982270	4	(S1 (S (S (SBAR (WHADVP (WRB When)) (S (VP (VBN seen) (PP (IN at) (NP (DT the) (NN emergency) (NN department))) (ADVP (NP (CD 2) (NNS weeks)) (RB later))))) (, ,) (NP (PRP she)) (ADVP (RB still)) (VP (AUX had) (NP (JJ severe) (NN Doc_14982270_476_483_Disease)))) (, ,) (NP (NP (NNP Doc_14982270_485_493_Disease)) (, ,) (CC and) (NP (NNP Doc_14982270_499_517_Disease)) (, ,)) (VP (VBD formed) (NP (NP (RB mainly)) (PP (IN of) (NP (DT the) (JJ conjugated) (NN fraction))))) (. .)))
14982270	5	(S1 (S (S (NP (JJ Doc_14982270_561_572_Chemical-induced) (NN Doc_14982270_581_592_Disease)) (VP (AUX was) (VP (VBN diagnosed)))) (, ,) (CC and) (S (NP (JJ Doc_14982270_612_623_Chemical) (NN therapy)) (VP (AUX was) (VP (VBN resumed)))) (. .)))
14982270	6	(S1 (S (PP (IN Over) (NP (DT the) (JJ following) (CD 9) (NNS days))) (, ,) (S (NP (DT the) (NNS symptoms)) (VP (VBN improved))) (CC and) (S (NP (NN plasma) (NN Doc_14982270_705_714_Chemical) (NNS levels)) (VP (AUX were) (ADVP (RB normal)) (PP (IN after) (NP (CD 12) (NNS weeks))) (PP (IN without) (NP (NNP Doc_14982270_757_768_Chemical))))) (. .)))
14982270	7	(S1 (S (PP (IN In) (NP (NP (JJ rare) (NNS cases)) (PP (IN within) (NP (NP (DT the) (JJ first) (JJ few) (NNS weeks)) (PP (IN of) (NP (NN therapy))))))) (, ,) (NP (DT this) (NN drug)) (VP (MD can) (VP (VB cause) (NP (ADJP (JJ severe) (CC and) (JJ reversible)) (NN Doc_14982270_865_885_Disease)))) (. .)))
14982270	8	(S1 (S (NP (NP (NNS Physicians)) (CC and) (NP (NNS patients))) (VP (MD should) (VP (AUX be) (ADJP (JJ aware) (PP (IN of) (NP (DT this) (JJ adverse) (NN effect)))) (SBAR (IN so) (IN that) (S (, ,) (PP (IN upon) (NP (NN occurrence))) (, ,) (NP (PRP they)) (VP (MD can) (VP (VP (VB discontinue) (NP (JJ Doc_14982270_997_1008_Chemical) (NN therapy))) (CC and) (VP (VB avoid) (NP (JJ unnecessary) (NN invasive) (NNS procedures))))))))) (. .)))
15042318	0	(S1 (S (NP (NP (JJ Doc_15042318_0_19_Disease) (JJ following) (NN chemotherapy)) (PP (IN for) (NP (NN stage)))) (VP (VBP IIIE) (NP (JJ diffuse) (JJ large) (NNP B-cell) (NNP Doc_15042318_79_95_Disease)) (PP (IN in) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (NP (NNP Doc_15042318_114_132_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_15042318_134_152_Disease)) (-RRB- -RRB-))))))) (. .)))
15042318	1	(S1 (S (NP (DT The) (NNS authors)) (VP (VBP describe) (NP (NP (DT the) (JJ unusual) (NN association)) (PP (IN between) (NP (NP (NP (NNP diffuse) (NNP B-cell) (NNP Doc_15042318_223_239_Disease) (CC and) (NNP Doc_15042318_244_262_Disease)) (, ,) (NP (NP (DT the) (ADJP (RBS most) (JJ common)) (NN form)) (PP (IN of) (NP (JJ adult) (NNP Doc_15042318_294_312_Disease)))) (, ,)) (CC and) (NP (JJ sudden) (NNP Doc_15042318_325_344_Disease))))) (PP (VBG following) (NP (NP (CD one) (NN cycle)) (PP (IN of) (NP (JJ Doc_15042318_368_379_Chemical-based) (NN chemotherapy))) (PP (IN in) (NP (DT the) (JJ same) (NN patient)))))) (. .)))
15042318	2	(S1 (S (NP (NP (NN Doc_15042318_420_439_Disease)) (CC or) (NP (JJ other) (NN Doc_15042318_449_468_Disease))) (VP (AUX are) (NP (NP (JJ unusual) (NNS complications)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NN chemotherapy)))))))) (. .)))
15042318	3	(S1 (S (NP (NP (DT The) (NN Doc_15042318_538_554_Disease)) (VP (ADVP (RB intrinsically)) (VBN associated) (PP (IN with) (NP (NP (DT the) (JJ aggressive) (NN chemotherapy)) (VP (VBN employed)))))) (VP (MD could) (VP (VB function) (PP (IN as) (NP (NP (DT a) (VBG triggering) (NN factor)) (PP (IN for) (NP (NP (DT the) (NNP Doc_15042318_668_678_Disease)) (PP (IN in) (NP (NP (DT the) (JJ predisposed) (NN myocardium)) (PP (IN of) (NP (DT this) (NN patient))))))))))) (. .)))
1504402	0	(S1 (S (VP (VBP Doc_1504402_0_16_Disease) (NP (JJ immune) (NN reaction)) (PP (IN as) (NP (NP (DT a) (NN mechanism)) (PP (IN for) (NP (NNP Doc_1504402_52_61_Chemical-associated) (NNP Doc_1504402_73_82_Disease)))))) (. .)))
1504402	1	(S1 (FRAG (S (VP (TO To) (VP (VB assess) (NP (JJ lymphocyte) (NN reactivity)) (PP (PP (TO to) (NP (NNP Doc_1504402_130_139_Chemical))) (CC and) (PP (TO to) (NP (NP (NN serum)) (VP (VBG containing) (NP (NP (JJ putative) (ADJP (FW ex) (FW vivo)) (JJ Doc_1504402_181_190_Chemical) (NNS antigens)) (CC or) (NP (NP (NNS metabolites)) (PP (IN in) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (JJ Doc_1504402_228_237_Chemical-induced) (NNP Doc_1504402_246_258_Disease)))))))))))))) (. .)))
1504402	2	(S1 (NP (NP (DT A) (JJ 58-year-old) (NN woman)) (PP (IN with) (NP (NP (DT a) (JJ clinical) (NN diagnosis)) (PP (IN of) (NP (NNP Doc_1504402_318_327_Chemical-induced) (NNP Doc_1504402_336_348_Disease))))) (. .)))
1504402	3	(S1 (S (NP (NP (JJ Peripheral) (NN blood) (NN mononuclear) (NNS cells)) (VP (VBN collected) (PP (IN from) (NP (DT the) (NN patient))))) (VP (AUX were) (VP (VBN cultured) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (DT a) (NN solution)) (PP (IN of) (NP (NNP Doc_1504402_468_477_Chemical))))))) (PP (CONJP (CC and) (RB also)) (PP (IN with) (NP (NP (NNS sera)) (VP (VBN collected) (PP (IN from) (NP (NP (DT a) (NN volunteer)) (ADVP (IN before))))))) (CC and) (PP (IN after) (NP (JJ Doc_1504402_541_550_Chemical) (NN intake)))))) (. .)))
1504402	4	(S1 (S (NP (DT A) (JJ similar) (NN protocol)) (VP (AUX was) (VP (VBN performed) (PP (IN with) (NP (NP (NNS lymphocytes)) (PP (IN from) (NP (DT a) (JJ healthy) (NN subject))))))) (. .)))
1504402	5	(S1 (S (NP (DT No) (JJ lymphocyte) (NN proliferation)) (VP (AUX was) (VP (VBN observed) (PP (CC either) (PP (IN in) (NP (DT the) (NN patient))) (CC or) (PP (IN in) (NP (NP (DT the) (JJ healthy) (NN volunteer)) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (JJ Doc_1504402_752_761_Chemical) (NNS solutions)))))))))) (. .)))
1504402	6	(S1 (S (NP (NP (DT A) (JJ significant) (JJ proliferative) (NN response)) (PP (TO to) (NP (NN serum))) (VP (VBN collected) (PP (IN after) (NP (JJ Doc_1504402_835_844_Chemical) (NN intake))))) (VP (AUX was) (VP (VBN observed) (PP (IN in) (NP (NP (DT the) (NN case)) (PP (IN of) (NP (DT the) (NN patient))))) (PP (VBN compared) (PP (IN with) (NP (NP (DT the) (JJ proliferative) (NN response)) (PP (TO to) (NP (NP (DT the) (NN serum)) (VP (VBN collected) (PP (IN before) (NP (DT the) (NN drug) (NN intake))))))))))) (. .)))
1504402	7	(S1 (S (NP (DT No) (NN reactivity)) (VP (AUX was) (VP (VBN found) (SBAR (WHADVP (WRB when)) (S (NP (NP (NNS lymphocytes)) (PP (IN from) (NP (DT the) (JJ healthy) (NN subject)))) (VP (AUX were) (VP (VBN tested) (PP (IN under) (NP (JJ similar) (NNS conditions))))))))) (. .)))
1504402	8	(S1 (S (NP (NP (DT The) (NN methodology)) (VP (VBN used))) (VP (VBD allowed) (NP (NP (DT the) (NN detection)) (PP (IN of) (NP (JJ lymphocyte) (NN sensitization)))) (PP (TO to) (NP (NP (NNS sera)) (VP (VBG containing) (ADVP (FW ex)) (NP (JJ vivo-prepared) (JJ Doc_1504402_1204_1213_Chemical) (NNS antigens))))) (, ,) (S (VP (VBG suggesting) (NP (NP (DT the) (NN involvement)) (PP (IN of) (NP (NP (DT an) (JJ immunologic) (NN mechanism)) (PP (IN in) (NP (JJ Doc_1504402_1282_1291_Chemical-induced) (NNP Doc_1504402_1300_1312_Disease))))))))) (. .)))
15075188	0	(S1 (S (NP (NP (JJ Increased) (NN expression)) (CC and) (NP (NN apical))) (VP (VBG targeting) (PP (IN of) (NP (NP (JJ renal) (JJ ENaC) (NNS subunits)) (PP (IN in) (NP (NP (NNP Doc_15075188_68_93_Chemical-induced) (NNP Doc_15075188_102_120_Disease)) (PP (IN in) (NP (NNS rats)))))))) (. .)))
15075188	1	(S1 (S (NP (NN Doc_15075188_130_148_Disease)) (VP (AUX is) (ADVP (RB often)) (VP (VBN accompanied) (PP (IN by) (NP (NP (JJ Doc_15075188_173_179_Chemical) (NN retention)) (CC and) (NP (JJ generalized) (NN Doc_15075188_206_211_Disease)))))) (. .)))
15075188	2	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (JJ molecular) (NN basis)) (PP (IN for) (NP (DT the) (VBN decreased) (JJ renal) (JJ Doc_15075188_266_272_Chemical) (NN excretion)))) (VP (VBZ remains) (ADJP (JJ undefined))) (. .)))
15075188	3	(S1 (S (NP (PRP We)) (VP (VBN hypothesized) (SBAR (IN that) (S (NP (NP (NN epithelial)) (SBAR (S (VP (TO Na) (VP (VB channel) (NP (-LRB- -LRB-) (NNP ENaC) (-RRB- -RRB-) (NN subunit) (NN dysregulation))))))) (VP (MD may) (VP (AUX be) (ADJP (JJ responsible) (PP (IN for) (NP (DT the) (VBN increased) (NNP Doc_15075188_411_417_Chemical) (NN retention))))))))) (. .)))
15075188	4	(S1 (S (NP (NP (DT An) (JJ experimental) (NN group)) (PP (IN of) (NP (NNS rats)))) (VP (AUX was) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_15075188_476_501_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (NNP Doc_15075188_503_506_Chemical)) (: ;) (NP (CD 180) (NN mg/kg) (NNP iv))) (-RRB- -RRB-)))) (, ,) (SBAR (IN whereas) (S (NP (DT the) (NN control) (NN group)) (VP (VBD received) (NP (JJ only) (NN vehicle))))))) (. .)))
15075188	5	(S1 (S (PP (IN After) (NP (CD 7) (NNS days))) (, ,) (NP (NP (NP (JJ Doc_15075188_586_589_Chemical) (NN treatment)) (VP (VBN induced) (NP (JJ significant) (NNP Doc_15075188_620_631_Disease)))) (, ,) (NP (NNP Doc_15075188_633_648_Disease)) (, ,)) (VP (VBD decreased) (NP (NP (JJ urinary) (JJ Doc_15075188_668_674_Chemical) (NN excretion)) (, ,) (CC and) (NP (JJ extensive) (NN Doc_15075188_700_707_Disease)))) (. .)))
15075188	6	(S1 (S (NP (NP (DT The) (NN protein) (NN abundance)) (PP (IN of) (NP (NN alpha-ENaC) (CC and) (NN beta-ENaC)))) (VP (VP (AUX was) (VP (VBN increased) (PP (PP (IN in) (NP (NP (DT the) (JJ inner) (NN stripe)) (PP (IN of) (NP (NP (DT the) (JJ outer) (NN medulla)) (PRN (-LRB- -LRB-) (NP (NNP ISOM)) (-RRB- -RRB-)))))) (CC and) (PP (IN in) (NP (NP (DT the) (JJ inner) (NN medulla)) (PRN (-LRB- -LRB-) (NP (NNP IM)) (-RRB- -RRB-))))))) (CC but) (VP (AUX was) (RB not) (VP (VBN altered) (SBAR (IN in) (S (NP (DT the) (JJ cortex.) (JJ gamma-ENaC) (NN abundance)) (VP (AUX was) (VP (VBN increased) (PP (IN in) (NP (NP (DT the) (NN cortex)) (, ,) (NP (NN ISOM)) (, ,) (CC and) (NP (NN IM))))))))))) (. .)))
15075188	7	(S1 (S (NP (NP (JJ Immunoperoxidase) (NN brightfield-)) (CC and) (NP (JJ laser-scanning) (JJ confocal) (NN fluorescence) (NN microscopy))) (VP (VBD demonstrated) (NP (NP (NP (VBN increased) (VBG targeting)) (PP (IN of) (NP (NN alpha-ENaC)))) (, ,) (NP (NN beta-ENaC)) (, ,) (CC and) (NP (JJ gamma-ENaC) (NNS subunits))) (PP (TO to) (NP (DT the) (JJ apical) (NN plasma) (NN membrane))) (PP (IN in) (NP (NP (DT the) (JJ distal) (JJ convoluted) (NN tubule)) (PRN (-LRB- -LRB-) (NP (NNP DCT2)) (-RRB- -RRB-)))) (, ,) (S (VP (VBG connecting) (NP (NP (NN tubule)) (, ,) (CC and) (NP (JJ cortical) (CC and) (JJ medullary) (NN collecting) (NN duct) (NNS segments)))))) (. .)))
15075188	8	(S1 (S (NP (JJ Immunoelectron) (NN microscopy)) (ADVP (RB further)) (VP (VBD revealed) (NP (NP (DT an) (JJ increased) (VBG labeling)) (PP (IN of) (NP (NP (ADJP (JJ alpha-ENaC) (PP (IN in) (NP (NP (DT the) (JJ apical) (NN plasma) (NN membrane)) (PP (IN of) (NP (JJ cortical) (NN collecting)))))) (JJ duct) (NN principal) (NNS cells)) (PP (IN of) (NP (JJ Doc_15075188_1413_1416_Chemical-treated) (NNS rats)))))) (, ,) (S (VP (VBG indicating) (NP (NP (VBN enhanced) (NN apical) (VBG targeting)) (PP (IN of) (NP (JJ alpha-ENaC) (NNS subunits))))))) (. .)))
15075188	9	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NP (DT the) (NN protein) (NNS abundances)) (PP (IN of) (NP (NP (JJ Doc_15075188_1531_1536_Chemical/Doc_15075188_1537_1541_Chemical) (NN exchanger) (NN type)) (NP (CD 3) (-LRB- -LRB-) (NN NHE3) (-RRB- -RRB-)) (, ,) (NP (NP (JJ Doc_15075188_1567_1584_Chemical) (NN cotransporter)) (PRN (-LRB- -LRB-) (JJ BSC-1) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (JJ Doc_15075188_1612_1620_Chemical-sensitive) (JJ Doc_15075188_1631_1642_Chemical) (NN cotransporter)) (PRN (-LRB- -LRB-) (NP (NNP TSC)) (-RRB- -RRB-)))))) (VP (AUX were) (VP (VBN decreased))) (. .)))
15075188	10	(S1 (S (S (ADVP (RB Moreover)) (, ,) (NP (NP (DT the) (NN abundance)) (PP (IN of) (NP (NP (DT the) (NN alpha) (-LRB- -LRB-) (CD 1) (-RRB- -RRB-) (NN -subunit)) (PP (IN of) (NP (DT the) (NNP Doc_15075188_1734_1736_Chemical-Doc_15075188_1737_1738_Chemical-ATPase)))))) (VP (AUX was) (VP (VBN decreased) (PP (IN in) (NP (DT the) (NN cortex) (CC and) (NN ISOM)))))) (, ,) (CC but) (S (NP (PRP it)) (VP (VBD remained) (ADJP (JJ unchanged)) (PP (IN in) (NP (DT the) (NN IM))))) (. .)))
15075188	11	(S1 (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NP (DT the) (ADJP (VBN increased) (CC or) (VBN sustained)) (NN expression)) (PP (IN of) (NP (NP (JJ ENaC) (NNS subunits)) (VP (VBN combined) (PP (IN with) (S (NP (VBN increased) (NN apical)) (VP (VP (VBG targeting) (PP (IN in) (NP (DT the) (NN DCT2)))) (, ,) (VP (VBG connecting) (NP (NN tubule))) (, ,) (CC and) (VP (VBG collecting) (NP (NN duct)))))))))) (VP (AUX are) (ADJP (JJ likely) (S (VP (TO to) (VP (VB play) (NP (DT a) (NN role)) (PP (IN in) (NP (NP (DT the) (JJ Doc_15075188_2017_2023_Chemical) (NN retention)) (VP (VBN associated) (PP (IN with) (NP (JJ Doc_15075188_2050_2053_Chemical-induced) (NNP Doc_15075188_2062_2080_Disease))))))))))) (. .)))
15075188	12	(S1 (S (NP (NP (DT The) (VBN decreased) (NN abundance)) (PP (IN of) (NP (NP (NNP NHE3)) (, ,) (NP (NNP BSC-1)) (, ,) (NP (NNP TSC)) (, ,) (CC and) (NP (NNP Doc_15075188_2131_2133_Chemical-Doc_15075188_2134_2135_Chemical-ATPase))))) (VP (MD may) (VP (VB play) (NP (NP (DT a) (JJ compensatory) (NN role)) (SBAR (S (VP (TO to) (VP (VB promote) (NP (JJ Doc_15075188_2183_2189_Chemical) (NN excretion))))))))) (. .)))
15096016	0	(S1 (NP (NP (JJ Pallidal) (NN stimulation)) (: :) (NP (NP (DT an) (NN alternative)) (PP (TO to) (NP (NN pallidotomy)))) (. ?)))
15096016	1	(S1 (S (NP (NP (DT A) (NN resurgence)) (PP (IN of) (NP (NP (NN interest)) (PP (IN in) (NP (NP (DT the) (JJ surgical) (NN treatment)) (PP (IN of) (NP (NP (NNP Doc_15096016_107_126_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_15096016_128_130_Disease)) (-RRB- -RRB-))))))))) (VP (VBD came) (PP (IN with) (NP (NP (DT the) (NN rediscovery)) (PP (IN of) (NP (JJ posteroventral) (NN pallidotomy))) (PP (IN by) (NP (NP (NNP Laitinen)) (PP (IN in) (NP (CD 1985)))))))) (. .)))
15096016	2	(S1 (S (NP (NP (NNP Laitinen) (POS 's)) (NN procedure)) (VP (VBD improved) (NP (JJS most) (NNS symptoms)) (PP (IN in) (NP (NP (JJ drug-resistant) (NNP Doc_15096016_271_273_Disease)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD engendered) (NP (NP (JJ wide) (NN interest)) (PP (IN in) (NP (DT the) (JJ neurosurgical) (NN community)))))))))) (. .)))
15096016	3	(S1 (S (NP (NP (DT Another) (JJ lesioning) (NN procedure)) (, ,) (NP (JJ ventrolateral) (NN thalamotomy)) (, ,)) (VP (AUX has) (VP (VBN become) (NP (NP (DT a) (JJ powerful) (NN alternative)) (SBAR (S (VP (TO to) (VP (VB stimulate) (NP (DT the) (NN nucleus) (NN ventralis) (NN intermedius))))))) (, ,) (S (VP (VBG producing) (NP (NP (JJ high) (JJ long-term) (NN success) (NNS rates)) (CC and) (NP (JJ low) (NN morbidity) (NNS rates))))))) (. .)))
15096016	4	(S1 (S (NP (JJ Pallidal) (NN stimulation)) (VP (AUX has) (RB not) (VP (VBN met) (PP (IN with) (NP (DT the) (JJ same) (NN success))))) (. .)))
15096016	5	(S1 (S (PP (VBG According) (PP (TO to) (NP (DT the) (NN literature)))) (NP (NN pallidotomy)) (VP (VBZ improves) (NP (NP (DT the) (`` ``) (ADJP (RB on)) ('' '') (NNS symptoms)) (PP (IN of) (NP (NNP Doc_15096016_666_668_Disease))) (, ,) (PP (JJ such) (IN as) (NP (NP (NNP Doc_15096016_678_689_Disease)) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (NP (DT the) (`` ``) (ADJP (RB off)) ('' '') (NNS symptoms)) (, ,) (PP (JJ such) (IN as) (NP (NP (NNP Doc_15096016_730_738_Disease)) (, ,) (NP (NNP Doc_15096016_740_752_Disease)) (, ,) (CC and) (NP (JJ on-off) (NNS fluctuations))))))))) (. .)))
15096016	6	(S1 (S (S (NP (JJ Pallidal) (NN stimulation)) (VP (VBZ improves) (NP (NP (NNP Doc_15096016_809_821_Disease)) (CC and) (NP (NNP Doc_15096016_826_834_Disease))) (PP (TO to) (NP (DT a) (JJ minor) (NN extent))))) (: ;) (S (ADVP (RB however)) (, ,) (NP (PRP$ its) (NN strength)) (VP (VBZ seems) (S (VP (TO to) (VP (AUX be) (PP (IN in) (S (VP (VBG improving) (NP (JJ Doc_15096016_901_909_Chemical-induced) (NN Doc_15096016_918_929_Disease)))))))))) (. .)))
15096016	7	(S1 (S (NP (NN Stimulation)) (ADVP (RB often)) (VP (VP (VBZ produces) (NP (NP (DT an) (NN improvement)) (PP (IN in) (NP (DT the) (JJ Doc_15096016_980_1000_Disease) (JJ upper) (NNS limbs))))) (, ,) (CC but) (VP (VBZ increases) (NP (NP (DT the) (`` ``) (NN freezing) ('' '') (NN phenomenon)) (PP (IN in) (NP (DT the) (JJR lower) (NNS limbs))) (PP (IN at) (NP (DT the) (JJ same) (NN time)))))) (. .)))
15096016	8	(S1 (S (S (VP (VBG Considering) (NP (NP (NP (DT the) (JJ small) (NN increase)) (PP (IN in) (NP (NP (DT the) (NN patient) (POS 's)) (NN independence)))) (, ,) (NP (NP (DT the) (JJ high) (NNS costs)) (PP (IN of) (NP (JJ bilateral) (NNS implants)))) (, ,) (CC and) (NP (NP (NP (DT the) (NN difficulty)) (JJS most) (NNS patients) (NN experience)) (PP (IN in) (S (VP (VBG handling) (NP (DT the) (NNS devices))))))))) (, ,) (NP (DT the) (NN question)) (VP (VBZ arises) (PP (IN as) (PP (TO to) (SBAR (IN whether) (S (NP (JJ bilateral) (JJ pallidal) (NN stimulation)) (VP (AUX is) (NP (NP (DT a) (JJ real) (NN alternative)) (PP (TO to) (NP (NN pallidotomy)))))))))) (. .)))
15266215	0	(S1 (NP (NP (NP (NP (NNS Effects)) (PP (IN of) (NP (DT the) (JJ cyclooxygenase-2) (JJ specific) (NN inhibitor) (JJ Doc_15266215_51_61_Chemical) (CC versus) (JJ nonsteroidal) (NN antiinflammatory) (NNS agents)))) (CC and) (NP (NN placebo))) (PP (IN on) (NP (NP (JJ cardiovascular) (JJ Doc_15266215_136_146_Disease) (NNS events)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_15266215_171_180_Disease))))))) (. .)))
15266215	1	(S1 (S (NP (EX There)) (VP (AUX have) (VP (AUX been) (NP (NNS concerns) (SBAR (IN that) (S (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (JJ cardiovascular) (JJ Doc_15266215_239_249_Disease) (NNS events)))) (VP (MD may) (VP (AUX be) (ADJP (ADJP (JJR higher) (PP (IN with) (NP (JJ cyclooxygenase) (PRN (-LRB- -LRB-) (NP (NNP COX)) (-RRB- -RRB-)) (JJ -2-specific) (NNS inhibitors)))) (PP (IN than) (NP (NP (JJ nonselective) (JJ nonsteroidal) (NN antiinflammatory) (NNS drugs)) (PRN (-LRB- -LRB-) (NP (NNS NSAIDs)) (-RRB- -RRB-)))))))))))) (. .)))
15266215	2	(S1 (S (NP (PRP We)) (VP (VBN evaluated) (NP (NP (JJ cardiovascular) (NN event) (NNS data)) (PP (IN for) (NP (NP (NNP Doc_15266215_426_436_Chemical)) (, ,) (NP (NP (DT a) (JJ new) (JJ COX-2-specific) (NN inhibitor)) (PP (IN in) (NP (QP (RB approximately) (CD 8000)) (NNS patients))) (PP (IN with) (NP (NP (NNP Doc_15266215_505_519_Disease) (CC and) (NNP Doc_15266215_524_544_Disease)) (VP (VBN treated) (PP (IN with) (NP (NP (DT this) (NN agent)) (PP (IN in) (NP (JJ randomized) (JJ clinical) (NNS trials))))))))))))) (. .)))
15266215	3	(S1 (S (NP (NP (DT The) (NN incidence)) (PP (IN of) (NP (NP (JJ cardiovascular) (JJ Doc_15266215_632_642_Disease) (NNS events)) (PRN (-LRB- -LRB-) (NP (NP (JJ cardiac)) (, ,) (NP (NP (NN cerebrovascular)) (CC and) (NP (JJ peripheral) (NN vascular))) (, ,) (CC or) (NP (JJ arterial) (NNP Doc_15266215_713_723_Disease))) (-RRB- -RRB-))))) (VP (AUX was) (VP (VBN determined) (PP (IN by) (S (VP (VBG analyzing) (NP (NP (NP (VBN pooled) (NNP Doc_15266215_760_770_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 10-80) (CD mg)) (NN daily)) (-RRB- -RRB-))) (, ,) (NP (NP (JJ nonselective) (NN NSAID)) (PRN (-LRB- -LRB-) (NP (NNP Doc_15266215_809_819_Chemical) (CD 75) (NN mg) (NN bid)) (, ,) (NP (NP (NNP Doc_15266215_831_840_Chemical) (CD 800) (NN mg) (NN tid)) (, ,) (CC or) (NP (NNP Doc_15266215_856_864_Chemical) (CD 500) (NN mg) (NN bid))) (-RRB- -RRB-))) (CC and) (NP (NP (NN placebo) (NNS data)) (PP (IN from) (NP (CD 10) (JJ randomized) (NNP Doc_15266215_913_927_Disease) (CC and) (NNP Doc_15266215_932_952_Disease) (NNS trials))) (SBAR (WHNP (WDT that)) (S (VP (AUX were) (NP (JJ 6-52) (NNS weeks)) (PP (IN in) (NP (NN duration))))))))))))) (. .)))
15266215	4	(S1 (S (NP (NP (DT The) (NN incidence) (NNS rates)) (PP (IN of) (NP (NNS events)))) (VP (AUX were) (VP (VBN determined) (PP (PP (IN in) (NP (NP (DT all) (NNS patients)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 7934)) (-RRB- -RRB-)))) (CC and) (PP (IN in) (NP (NP (NP (NNS users)) (PP (IN of) (NP (NP (JJ low-dose) (PRN (-LRB- -LRB-) (NP (QP (CD <) (CC or) (CD =325) (CD mg)) (NN daily)) (-RRB- -RRB-)) (NNP Doc_15266215_1113_1120_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 1051)) (-RRB- -RRB-))))) (CC and) (NP (NP (NNS nonusers)) (PP (IN of) (NP (NP (NNP Doc_15266215_1148_1155_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 6883)) (-RRB- -RRB-)))))))))) (. .)))
15266215	5	(S1 (S (NP (NP (JJ Crude) (CC and) (JJ exposure-adjusted) (NNS incidences)) (PP (IN of) (NP (JJ Doc_15266215_1210_1220_Disease) (NNS events)))) (VP (AUX were) (ADJP (JJ similar) (PP (IN for) (NP (NP (NNP Doc_15266215_1245_1255_Chemical)) (, ,) (NP (NNP NSAIDs)) (, ,) (CC and) (NP (NN placebo)))))) (. .)))
15266215	6	(S1 (S (NP (NP (DT The) (NN risk)) (PP (IN of) (NP (JJ serious) (JJ Doc_15266215_1298_1308_Disease) (NNS events)))) (VP (AUX was) (ADVP (RB also)) (ADJP (JJ similar)) (PP (IN for) (NP (DT each) (JJ Doc_15266215_1342_1352_Chemical) (NN dose)))) (. .)))
15266215	7	(S1 (S (NP (NN Doc_15266215_1359_1369_Disease) (NN risk)) (VP (AUX was) (ADJP (ADJP (RB consistently) (JJR higher) (PP (IN for) (NP (NP (NNS users)) (PP (IN of) (NP (JJ Doc_15266215_1412_1419_Chemical) (NNS users)))))) (PP (IN than) (NP (NP (NNS nonusers)) (PP (IN of) (NP (NP (NNP Doc_15266215_1443_1450_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (NN placebo)) (, ,) (NP (NP (NP (NP (QP (CD 1.4) (NN %) (CC vs.) (CD 0) (NN %))) (: ;) (NP (NP (NNP Doc_15266215_1474_1484_Chemical)) (, ,) (NP (NP (CD 1.7) (NN %)) (CC vs.) (NP (CD 0.2) (NN %)))) (: ;)) (ADVP (RB NSAIDs))) (, ,) (NP (CD 1.9) (NN %)) (CC vs.) (NP (CD 0.5) (NN %)))) (-RRB- -RRB-)))))))) (. .)))
15266215	8	(S1 (S (NP (NP (DT The) (NNS rates)) (PP (IN of) (NP (NNS events))) (PP (IN in) (NP (NP (NNS users)) (PP (IN of) (NP (NNP Doc_15266215_1557_1564_Chemical)))))) (VP (AUX were) (ADJP (JJ similar) (PP (PP (IN for) (NP (DT all) (CD 3) (NN treatment) (NNS groups))) (CC and) (PP (IN across) (NP (JJ Doc_15266215_1616_1626_Chemical) (NNS doses)))))) (. .)))
15266215	9	(S1 (S (NP (NP (NN Short-)) (CC and) (NP (NP (JJ intermediate-term) (NN treatment)) (PP (IN with) (NP (NP (NP (JJ therapeutic)) (PRN (-LRB- -LRB-) (NP (QP (CD 10) (CC or) (CD 20)) (NN mg) (NN daily)) (-RRB- -RRB-))) (CC and) (NP (JJ supratherapeutic) (PRN (-LRB- -LRB-) (NP (QP (CD 40) (CC or) (CD 80)) (NN mg) (NN daily)) (-RRB- -RRB-)) (JJ Doc_15266215_1751_1761_Chemical) (NNS doses)))))) (VP (AUX was) (RB not) (VP (VBN associated) (PP (IN with) (NP (NP (DT an) (VBN increased) (NN incidence)) (PP (IN of) (NP (NP (NNP Doc_15266215_1818_1828_Disease) (NNS events)) (ADJP (JJ relative) (PP (TO to) (NP (NP (JJ nonselective) (NNS NSAIDs)) (CC or) (NP (NP (NN placebo)) (PP (IN in) (NP (NP (NNP Doc_15266215_1882_1896_Disease) (CC and) (NNP Doc_15266215_1901_1921_Disease) (NNS patients)) (PP (IN in) (NP (JJ controlled) (JJ clinical) (NNS trials))))))))))))))) (. .)))
15266362	0	(S1 (S (NP (NNP Doc_15266362_0_16_Disease) (NNP Doc_15266362_17_28_Disease)) (VP (VBD complicating) (NP (JJ Doc_15266362_42_69_Disease) (NN heart))) (. .)))
15266362	1	(S1 (S (NP (DT The) (JJ present) (NN report)) (VP (VBZ describes) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (JJ Doc_15266362_116_140_Disease) (NN complicating) (NN Doc_15266362_154_181_Disease))))) (. .)))
15266362	2	(S1 (S (NP (NP (DT The) (JJ 47-year-old) (NN female) (NN patient)) (, ,) (VP (VBN known) (S (VP (TO to) (VP (AUX have) (NP (NN Doc_15266362_229_256_Disease)))))) (, ,)) (VP (VP (AUX was) (VP (VBN admitted) (PP (IN with) (NP (NNP Doc_15266362_276_297_Disease))))) (CC and) (VP (VBD managed) (ADVP (RB aggressively)) (PP (IN with) (NP (NP (JJ Doc_15266362_328_338_Chemical) (NN infusion)) (CC and) (NP (JJ other) (NNS drugs)))) (SBAR (IN while) (S (VP (AUXG being) (VP (VBN assessed) (PP (IN for) (NP (NN heart) (NN transplantation))))))))) (. .)))
15266362	3	(S1 (S (PP (IN On) (NP (JJ transthoracic) (NN echocardiogram))) (, ,) (NP (PRP she)) (VP (AUX had) (NP (JJ moderate) (NN Doc_15266362_462_490_Disease)) (PP (IN with) (NP (NP (JJ regional) (NN variability)) (CC and) (NP (JJ moderate) (NN Doc_15266362_530_550_Disease))))) (. .)))
15266362	4	(S1 (S (NP (NP (DT The) (NN recipient) (POS 's)) (NN heart)) (VP (VBD showed) (NP (NP (DT the) (NNS features)) (PP (IN of) (NP (JJ apical) (NNP Doc_15266362_604_631_Disease) (CC and) (NNP Doc_15266362_636_647_Disease))) (PP (IN with) (NP (JJ abundant) (NNS eosinophils))))) (. .)))
15266362	5	(S1 (S (S (NP (NN Doc_15266362_675_686_Disease)) (VP (AUX is) (ADJP (JJ rare)))) (CC and) (S (NP (NNP Doc_15266362_699_723_Disease)) (VP (AUX is) (NP (NN rarer)))) (. .)))
15266362	6	(S1 (S (NP (PRP It)) (VP (AUX is) (ADJP (JJ likely)) (SBAR (IN that) (S (NP (DT the) (NNP Doc_15266362_756_772_Disease) (PRN (-LRB- -LRB-) (NP (NNP Doc_15266362_774_786_Disease)) (-RRB- -RRB-)) (NNP Doc_15266362_788_799_Disease)) (VP (AUX was) (VP (VBN related) (PP (TO to) (NP (JJ Doc_15266362_815_825_Chemical) (NN infusion) (NN therapy)))))))) (. .)))
15266362	7	(S1 (S (NP (NNP Doc_15266362_844_868_Disease)) (VP (VP (AUX has) (VP (AUX been) (VP (VBN reported) (PP (IN with) (NP (NP (DT an) (NN incidence)) (PP (IN of) (NP (CD 2.4) (NN %))) (PP (TO to) (NP (CD 7.2) (NN %))))) (PP (IN in) (NP (VBN explanted) (NNS hearts)))))) (CC and) (VP (MD may) (VP (AUX be) (VP (VBN related) (PP (TO to) (NP (JJ multidrug) (NN therapy))))))) (. .)))
15276120	0	(S1 (NP (NP (NN Time) (NNS trends)) (PP (IN in) (NP (NNP Doc_15276120_15_23_Chemical-associated) (NNP Doc_15276120_35_45_Disease))) (. .)))
15276120	1	(S1 (S (NP (NP (DT The) (JJ annual) (NN incidence)) (PP (IN of) (NP (NP (NNP Doc_15276120_71_79_Chemical-related) (NNP Doc_15276120_88_96_Disease)) (PP (IN at) (NP (NP (NNP Brigham) (CC and) (NNP Women) (POS 's)) (NNP Hospital)))))) (VP (VBD increased) (PP (IN from) (NP (CD 0.97/1,000) (JJ patient) (NNS admissions))) (PP (IN in) (NP (NP (DT the) (JJ first) (NN time) (NN period)) (PRN (-LRB- -LRB-) (NP (NP (NNP January) (CD 1995)) (PP (TO to) (NP (NNP October) (CD 1998)))) (-RRB- -RRB-)))) (PP (TO to) (NP (NP (CD 1.19/1,000) (JJ patient) (NNS admissions)) (PP (IN in) (NP (NP (DT the) (JJ second) (NN time) (NN period)) (PRN (-LRB- -LRB-) (NP (NP (NNP November) (CD 1998)) (PP (TO to) (NP (NNP August) (CD 2002)))) (-RRB- -RRB-)) (PP (IN of) (NP (DT this) (NN study)))))))) (. .)))
15276120	2	(S1 (S (NP (NP (DT The) (NN proportion)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ major) (CC and) (NNP Doc_15276120_377_398_Disease)))))) (VP (VBD increased) (PP (IN from) (NP (NP (CD 20.2) (NN %)) (CC and) (NP (CD 1.9) (NN %)))) (, ,) (ADVP (RB respectively)) (, ,) (PP (IN in) (NP (DT the) (JJ first) (NN time) (NN period))) (, ,) (PP (TO to) (NP (NP (NP (CD 33.3) (NN %)) (CC and) (NP (CD 7.8) (NN %)) (, ,) (ADVP (RB respectively)) (, ,)) (PP (IN in) (NP (DT the) (JJ second)))))) (. .)))
1535072	0	(S1 (NP (NP (JJ Doc_1535072_0_9_Chemical) (NN treatment)) (PP (IN of) (NP (NNP Doc_1535072_23_42_Disease))) (VP (VBN induced) (PP (IN by) (NP (JJ Doc_1535072_54_63_Chemical) (JJ reuptake) (NNS blockers)))) (. .)))
1535072	1	(S1 (S (NP (JJ Preclinical) (CC and) (JJ clinical) (NNS studies)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NNP Doc_1535072_141_150_Chemical)) (VP (VP (VBZ facilitates) (NP (JJ sexual) (NN behavior))) (CC and) (VP (MD may) (VP (AUX be) (ADJP (JJ helpful)) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NN Doc_1535072_218_232_Disease))))))))))) (. .)))
1535072	2	(S1 (S (NP (DT A) (JJ single) (NN case) (NN report)) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NNP Doc_1535072_269_278_Chemical)) (VP (MD may) (VP (AUX be) (VP (VBN used) (S (VP (TO to) (VP (VB treat) (NP (NP (DT the) (NN Doc_1535072_304_323_Disease)) (PP (IN of) (NP (NN Doc_1535072_327_339_Chemical))))))))))))) (. .)))
1535072	3	(S1 (S (NP (DT This) (NN study)) (VP (VBN evaluated) (NP (NNP Doc_1535072_362_371_Chemical)) (PP (IN as) (NP (NP (DT a) (NN treatment)) (PP (IN for) (NP (NP (DT the) (NNP Doc_1535072_395_414_Disease)) (VP (VBN caused) (PP (IN by) (NP (JJ Doc_1535072_425_434_Chemical) (JJ reuptake) (NNS blockers))))))))) (. .)))
1535072	4	(S1 (S (NP (NP (CD Six) (NNS patients)) (PP (IN with) (NP (NP (DT either) (NNP Doc_1535072_487_516_Disease)) (, ,) (NP (NNP Doc_1535072_518_534_Disease)) (, ,) (NP (NNP Doc_1535072_536_543_Disease)) (, ,) (CC or) (NP (NNP Doc_1535072_548_567_Disease)))) (SBAR (WHNP (WP who)) (S (VP (VBD suffered) (NP (NNP Doc_1535072_581_600_Disease)) (PP (IN after) (NP (NN treatment))) (PP (IN with) (NP (JJ Doc_1535072_622_631_Chemical) (NN reuptake) (NNS blockers))))))) (VP (AUX were) (VP (VBN given) (NP (NNP Doc_1535072_661_670_Chemical)) (PP (IN on) (NP (NP (DT a) (JJ p.r.n.) (NN basis)) (PP (IN in) (NP (DT an) (JJ open) (JJ clinical) (NN trial))))))) (. .)))
1535072	5	(S1 (S (NP (NP (JJ Various) (NNS doses)) (PP (IN of) (NP (NNP Doc_1535072_733_742_Chemical)))) (VP (AUX were) (VP (VBN used) (S (VP (TO to) (VP (VB determine) (NP (NP (DT the) (JJ ideal) (NN dose)) (PP (IN for) (NP (DT each) (NN patient))))))))) (. .)))
1535072	6	(S1 (S (NP (NP (CD Five)) (PP (IN of) (NP (DT the) (CD six) (NNS patients)))) (VP (VBD experienced) (NP (VBN improved) (JJ sexual) (NN functioning)) (PP (IN after) (S (VP (VBG taking) (NP (NN Doc_1535072_886_895_Chemical)))))) (. .)))
1535072	7	(S1 (S (NP (NP (CD One) (NN patient)) (SBAR (WHNP (WP who)) (S (VP (VBD failed) (S (VP (TO to) (VP (VB comply) (PP (IN with) (NP (JJ Doc_1535072_935_944_Chemical) (NN treatment)))))))))) (VP (AUX had) (NP (DT no) (JJ therapeutic) (NNS effects))) (. .)))
1535072	8	(S1 (S (NP (NP (JJ Side) (NNS effects)) (PP (IN of) (NP (NNP Doc_1535072_999_1008_Chemical)))) (VP (VBD included) (NP (NP (JJ excessive) (NN sweating)) (, ,) (NP (JJ increased) (NN Doc_1535072_1048_1055_Disease)) (, ,) (CC and) (NP (NP (DT a) (JJ wound-up) (NN feeling)) (PP (IN in) (NP (DT some) (NNS patients)))))) (. .)))
1535072	9	(S1 (S (NP (NP (DT The) (NNS results)) (PP (IN of) (NP (DT this) (NN study)))) (VP (VBP indicate) (SBAR (IN that) (S (NP (NNP Doc_1535072_1150_1159_Chemical)) (VP (MD may) (VP (AUX be) (NP (NP (DT an) (JJ effective) (NN treatment)) (PP (IN for) (NP (NP (DT the) (NNP Doc_1535072_1198_1217_Disease)) (VP (VBN caused) (PP (IN by) (NP (JJ Doc_1535072_1228_1237_Chemical) (JJ reuptake) (NNS blockers)))))))))))) (. .)))
1535072	10	(S1 (S (NP (JJ Future) (JJ controlled) (NNS studies)) (VP (AUX are) (VP (VBN needed) (S (VP (TO to) (VP (ADVP (RB further)) (VB investigate) (NP (NP (NP (DT the) (NN effectiveness)) (CC and) (NP (NN safety))) (PP (IN of) (NP (NNP Doc_1535072_1349_1358_Chemical))) (PP (IN for) (NP (DT this) (NN indication))))))))) (. .)))
1545575	0	(S1 (S (VP (VB Doc_1545575_0_20_Disease) (S (VP (VBG complicating) (NP (NN bone) (NN marrow) (NN transplantation))))) (. .)))
1545575	1	(S1 (S (NP (NN Doc_1545575_63_83_Disease)) (VP (AUX is) (NP (NP (DT a) (ADJP (RB potentially) (JJ serious)) (NN complication)) (PP (IN of) (NP (NP (JJ high-dose) (JJ Doc_1545575_135_151_Chemical) (NN therapy)) (VP (VBN administered) (PP (IN before) (NP (NN bone) (NN marrow) (NN transplantation)))))))) (. .)))
1545575	2	(S1 (S (PP (IN As) (NP (NP (JJ standard) (NN practice)) (PP (IN at) (NP (PRP$ our) (NN institution))))) (, ,) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX are) (VP (VBN scheduled) (S (VP (TO to) (VP (VB receive) (NP (DT a) (NN bone) (NN marrow) (NN transplant)))))))))) (VP (AUX are) (VP (VBN treated) (ADVP (RB prophylactically)) (PP (IN with) (NP (NP (JJ forced) (NN hydration)) (CC and) (NP (NN bladder) (NN irrigation)))))) (. .)))
1545575	3	(S1 (S (PP (IN In) (NP (DT an) (NN attempt) (S (VP (TO to) (VP (VB obviate) (NP (NP (DT the) (NN inconvenience)) (PP (IN of) (NP (NN bladder) (NN irrigation))))))))) (, ,) (NP (PRP we)) (VP (VBD conducted) (NP (NP (DT a) (NN feasibility) (NN trial)) (PP (IN of) (NP (NN uroprophylaxis))) (PP (IN with) (NP (NP (NNP Doc_1545575_510_515_Chemical)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ neutralizes) (NP (NP (DT the) (JJ hepatic) (NN metabolite)) (PP (IN of) (NP (NNP Doc_1545575_561_577_Chemical))) (SBAR (WHNP (WDT that)) (S (VP (VBZ causes) (NP (NN Doc_1545575_590_610_Disease))))))))))))) (. .)))
1545575	4	(S1 (S (PP (IN Of) (NP (NP (CD 97) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (JJ standard) (NN prophylaxis))))))) (, ,) (NP (CD 4)) (VP (AUX had) (NP (JJ symptomatic) (NN Doc_1545575_680_700_Disease))) (. .)))
1545575	5	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NP (CD two)) (PP (IN of) (NP (CD four) (JJ consecutive) (NNS patients))) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (JJ Doc_1545575_761_766_Chemical) (NN uroprophylaxis)) (PP (IN before) (NP (JJ allogeneic) (NN bone) (NN marrow) (NN transplantation))))))) (VP (AUX had) (NP (NP (JJ severe) (NN Doc_1545575_839_859_Disease)) (PP (IN for) (NP (QP (IN at) (JJS least) (CD 2)) (NNS weeks))))) (. .)))
1545575	6	(S1 (S (PP (IN Because) (IN of) (NP (DT this) (JJ suboptimal) (NN result))) (, ,) (NP (PRP we)) (VP (VP (VBD resumed) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NN bladder) (NN irrigation))))) (CC and) (VP (VBD forced) (NP (NN hydration)) (S (VP (TO to) (VP (VB minimize) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NNP Doc_1545575_1003_1023_Disease))))))))) (. .)))
15517007	0	(S1 (S (NP (NP (NN Consensus) (NN statement)) (VP (VBG concerning) (NP (NNP Doc_15517007_31_45_Disease)))) (VP (VBG occurring) (PP (IN during) (NP (NP (JJ haematopoietic) (NN stem) (NN cell) (NN transplantation)) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NNP Doc_15517007_124_143_Disease))))))) (, ,) (PP (IN with) (NP (NP (JJ special) (NN reference)) (PP (TO to) (NP (NP (NNP Doc_15517007_171_189_Disease)) (CC and) (NP (NNP Doc_15517007_194_212_Disease))))))) (. .)))
15517007	1	(S1 (S (NP (JJ Autologous) (JJ haematopoietic) (NN stem) (NN cell) (NN transplantation)) (VP (AUX is) (ADVP (RB now)) (NP (NP (DT a) (ADJP (JJ feasible) (CC and) (JJ effective)) (NN treatment)) (PP (IN for) (NP (NP (JJ selected) (NNS patients)) (PP (IN with) (NP (JJ severe) (NN Doc_15517007_342_361_Disease))))))) (. .)))
15517007	2	(S1 (S (ADVP (NNP Worldwide)) (, ,) (NP (QP (IN over) (CD 650)) (NNS patients)) (VP (AUX have) (VP (AUX been) (VP (VBN transplanted) (PP (IN in) (NP (NP (DT the) (NN context)) (PP (IN of) (NP (NP (NN phase) (NN I)) (CC and) (NP (NNP II) (JJ clinical) (NNS trials))))))))) (. .)))
15517007	3	(S1 (S (NP (DT The) (NNS results)) (VP (AUX are) (ADJP (JJ encouraging) (RB enough) (S (VP (TO to) (VP (VB begin) (NP (JJ randomised) (NN phase) (NNP III) (NNS trials))))))) (. .)))
15517007	4	(S1 (S (ADVP (RB However)) (, ,) (SBAR (IN as) (S (VP (VBN predicted)))) (, ,) (NP (NP (JJ significant) (JJ transplant-related) (NN morbidity)) (CC and) (NP (NN mortality))) (VP (AUX have) (VP (AUX been) (VP (VBN observed)))) (. .)))
15517007	5	(S1 (S (NP (DT This)) (VP (AUX is) (ADVP (RB primarily)) (ADJP (JJ due) (PP (PP (TO to) (NP (NP (NNS complications)) (VP (VBN related) (PP (TO to) (NP (NP (RB either) (DT the) (NN stage)) (PP (IN of) (NP (DT the) (NN disease))))) (PP (IN at) (NP (NN transplant)))))) (CC or) (RB due) (PP (TO to) (NP (NNP Doc_15517007_742_752_Disease)))))) (. .)))
15517007	6	(S1 (S (NP (NP (DT The) (NN number)) (PP (IN of) (NP (NP (NNS deaths)) (VP (VBN related) (PP (TO to) (NP (NNP Doc_15517007_786_802_Disease))))))) (VP (AUX is) (ADJP (JJ low))) (. .)))
15517007	7	(S1 (S (ADVP (RB However)) (, ,) (NP (NN caution)) (VP (AUX is) (VP (VBN required) (SBAR (WHADVP (WRB when)) (S (NP (NP (NNP Doc_15517007_845_861_Chemical) (CC or) (NNP Doc_15517007_865_879_Chemical)) (PP (JJ such) (IN as) (NP (NNP Doc_15517007_888_900_Chemical)))) (VP (AUX are) (VP (VBN used) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (DT a) (JJ possible) (JJ underlying) (NN Doc_15517007_949_961_Disease))))) (, ,) (PP (IN for) (NP (NN example))) (, ,) (NP (NNP Doc_15517007_976_994_Disease) (NNS patients)))))))) (. .)))
15517007	8	(S1 (S (PP (IN In) (NP (NNP November) (CD 2002))) (, ,) (NP (DT a) (NN meeting)) (VP (AUX was) (VP (VBN held) (PP (IN in) (NP (NNP Florence))) (, ,) (S (VP (VBG bringing) (ADVP (RB together)) (NP (NP (DT a) (NN number)) (PP (IN of) (NP (NP (NNS experts)) (PP (IN in) (NP (JJ various) (NNS fields))))) (, ,) (PP (VBG including) (NP (NN rheumatology) (, ,) (NN cardiology) (, ,) (NN neurology) (, ,) (NN pharmacology) (CC and) (NN transplantation) (NN medicine)))))))) (. .)))
15517007	9	(S1 (S (NP (NP (DT The) (NN object)) (PP (IN of) (NP (DT the) (NN meeting)))) (VP (AUX was) (S (VP (VP (TO to) (VP (VB analyse) (NP (NP (JJ existing) (NNS data)) (, ,) (ADJP (DT both) (JJ published) (CC or) (JJ available)) (, ,) (PP (IN in) (NP (DT the) (NNP European) (NNP Group))) (PP (IN for) (NP (NP (NNP Blood)) (CC and) (NP (NNP Marrow) (NNP Transplantation) (NNP Doc_15517007_1346_1364_Disease) (NN database))))))) (, ,) (CC and) (VP (TO to) (VP (VB propose) (NP (NP (DT a) (JJ safe) (NN approach)) (PP (TO to) (NP (JJ such) (NNS patients))))))))) (. .)))
15517007	10	(S1 (S (NP (NP (DT A) (JJ full) (JJ cardiological) (NN assessment)) (PP (IN before) (CC and) (IN during) (NP (DT the) (NN transplant)))) (VP (VBD emerged) (PP (IN as) (NP (DT the) (JJ major) (NN recommendation)))) (. .)))
15531665	0	(S1 (SQ (AUX Does) (NP (JJ supplemental) (JJ Doc_15531665_18_27_Chemical) (NN increase)) (VP (VBP Doc_15531665_37_59_Disease) (NP (NN risk)) (PP (IN in) (NP (NP (NNS women)) (PP (IN with) (NP (NNP Doc_15531665_79_87_Disease)))))) (. ?)))
15531665	1	(S1 (S (S (NP (NN Doc_15531665_101_110_Chemical)) (VP (VBZ acts) (PP (IN as) (NP (DT a) (JJ potent) (NN antioxidant))))) (: ;) (S (ADVP (RB however)) (, ,) (NP (PRP it)) (VP (MD can) (ADVP (RB also)) (VP (AUX be) (NP (NP (DT a) (NN prooxidant)) (CC and) (NP (JJ glycate) (NN protein))) (PP (IN under) (NP (JJ certain) (NNS circumstances))) (PP (IN in) (NP (NN vitro)))))) (. .)))
15531665	2	(S1 (S (NP (DT These) (NNS observations)) (VP (VBD led) (NP (PRP us)) (S (VP (TO to) (VP (VB hypothesize) (SBAR (IN that) (S (NP (NP (DT a) (JJ high) (NN intake)) (PP (IN of) (NP (NNP Doc_15531665_299_308_Chemical))) (PP (IN in) (NP (JJ Doc_15531665_312_320_Disease) (NNS persons)))) (VP (MD might) (VP (VB promote) (NP (NNP Doc_15531665_343_358_Disease)))))))))) (. .)))
15531665	3	(S1 (S (NP (DT The) (NN objective)) (VP (AUX was) (S (VP (TO to) (VP (VB examine) (NP (NP (DT the) (NN relation)) (PP (IN between) (NP (NP (JJ Doc_15531665_421_430_Chemical) (NN intake)) (CC and) (NP (NP (NN mortality)) (PP (IN from) (NP (NNP Doc_15531665_457_479_Disease))))))))))) (. .)))
15531665	4	(S1 (S (NP (PRP We)) (VP (VBD studied) (NP (NP (DT the) (NN relation)) (PP (IN between) (NP (NP (JJ Doc_15531665_521_530_Chemical) (NN intake)) (CC and) (NP (NN mortality))))) (PP (IN from) (NP (NP (NP (JJ total) (NNP Doc_15531665_563_585_Disease)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 281)) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Doc_15531665_597_620_Disease)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 175)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NNP Doc_15531665_636_642_Disease)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 57)) (-RRB- -RRB-))))) (PP (IN in) (NP (NP (CD 1923) (JJ postmenopausal) (NNS women)) (SBAR (WHNP (WP who)) (S (VP (VBD reported) (S (VP (AUXG being) (ADJP (JJ Doc_15531665_700_708_Disease)) (PP (IN at) (NP (NN baseline))))))))))) (. .)))
15531665	5	(S1 (S (S (S (NP (NNP Diet)) (VP (AUX was) (VP (VBN assessed) (PP (IN with) (NP (NP (DT a) (JJ food-frequency) (NN questionnaire)) (PP (IN at) (NP (NN baseline)))))))) (, ,) (CC and) (S (NP (NP (NNS subjects)) (ADJP (RB initially) (JJ free) (PP (IN of) (NP (NNP Doc_15531665_820_843_Disease))))) (VP (AUX were) (ADVP (RB prospectively)) (VP (VBN followed) (PP (IN for) (NP (CD 15) (NNP y.) (NNS RESULTS))))))) (: :) (S (PP (IN After) (NP (NP (NN adjustment)) (PP (IN for) (NP (NNP Doc_15531665_912_934_Disease) (NN risk) (NNS factors))))) (, ,) (NP (NP (NN type)) (PP (IN of) (NP (NNP Doc_15531665_957_965_Disease) (NN medication)))) (VP (VP (VBD used)) (, ,) (NP (NP (NP (NN duration)) (PP (IN of) (NP (NNP Doc_15531665_995_1003_Disease)))) (, ,) (CC and) (NP (NP (NNS intakes)) (PP (IN of) (NP (NNP Doc_15531665_1020_1026_Chemical) (, ,) (NNP Doc_15531665_1028_1037_Chemical) (, ,) (CC and) (NNP Doc_15531665_1043_1056_Chemical)))) (, ,) (SBAR (S (NP (NP (DT the) (VBN adjusted) (JJ relative) (NNS risks)) (PP (IN of) (NP (JJ total) (NNP Doc_15531665_1095_1117_Disease) (NN mortality)))) (VP (AUX were) (NP (CD 1.0) (, ,) (CD 0.97) (, ,) (CD 1.11) (, ,) (CD 1.47) (, ,) (CC and) (CD 1.84)) (PRN (-LRB- -LRB-) (NP (NP (NNP P)) (PP (IN for) (NP (NN trend)))) (NP (NNP <) (CD 0.01)) (-RRB- -RRB-)) (PP (IN across) (NP (NP (NNS quintiles)) (PP (IN of) (NP (NP (JJ total) (JJ Doc_15531665_1212_1221_Chemical) (NN intake)) (PP (IN from) (NP (NN food) (CC and) (NNS supplements))))))))))))) (. .)))
15531665	6	(S1 (S (S (NP (NP (VBN Adjusted) (JJ relative) (NNS risks)) (PP (IN of) (NP (NNP Doc_15531665_1283_1306_Disease)))) (VP (AUX were) (NP (CD 1.0)))) (, ,) (NP (NP (CD 0.81) (, ,) (CD 0.99) (, ,) (CD 1.26) (, ,) (CC and) (CD 1.91) (-LRB- -LRB-) (NN P)) (PP (IN for) (NP (NN trend)))) (VP (SYM =) (NP (CD 0.01)) (-RRB- -RRB-) (PP (CC and) (PP (IN of) (NP (NNP Doc_15531665_1372_1378_Disease) (AUX were) (CD 1.0) (, ,) (CD 0.52) (, ,) (CD 1.23) (, ,) (CD 2.22) (, ,) (CC and) (CD 2.57))) (PRN (-LRB- -LRB-) (VP (VBN P) (PP (IN for) (NP (NN trend) (NN <) (CD 0.01)))) (-RRB- -RRB-)))) (. .)))
15531665	7	(S1 (S (SBAR (WHADVP (WRB When)) (S (NP (NP (NN dietary)) (CC and) (NP (JJ supplemental) (NNP Doc_15531665_1468_1477_Chemical))) (VP (AUX were) (VP (VBN analyzed) (ADVP (RB separately)))))) (, ,) (NP (RB only) (JJ supplemental) (NNP Doc_15531665_1522_1531_Chemical)) (VP (VBD showed) (NP (NP (DT a) (JJ positive) (NN association)) (PP (IN with) (NP (NN mortality) (NNS endpoints))))) (. .)))
15531665	8	(S1 (S (NP (JJ Doc_15531665_1588_1597_Chemical) (NN intake)) (VP (AUX was) (ADJP (JJ unrelated) (PP (TO to) (NP (NP (NN mortality)) (PP (IN from) (NP (NNP Doc_15531665_1637_1659_Disease)))))) (PP (IN in) (NP (DT the) (JJ nondiabetic) (NNS subjects))) (PP (IN at) (NP (NN baseline)))) (. .)))
15531665	9	(S1 (S (NP (NP (DT A) (JJ high) (JJ Doc_15531665_1720_1729_Chemical) (NN intake)) (PP (IN from) (NP (NNS supplements)))) (VP (AUX is) (VP (VBN associated) (PP (IN with) (NP (NP (DT an) (VBN increased) (NN risk)) (PP (IN of) (NP (NN Doc_15531665_1794_1816_Disease) (NN mortality))) (PP (IN in) (NP (NP (JJ postmenopausal) (NNS women)) (PP (IN with) (NP (NNP Doc_15531665_1856_1864_Disease))))))))) (. .)))
15565293	0	(S1 (S (NP (JJ Optical) (NN coherence) (NN tomography)) (VP (MD can) (VP (VB measure) (NP (NP (JJ axonal) (NN loss)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_15565293_70_80_Chemical-induced) (NNP Doc_15565293_89_105_Disease)))))))) (. .)))
15565293	1	(S1 (S (TO To) (VP (VBP map) (CC and) (VBP identify) (NP (NP (DT the) (NN pattern)) (, ,) (PP (IN in) (NP (NN vivo))) (, ,) (PP (IN of) (NP (NP (NNP Doc_15565293_161_180_Disease)) (PP (IN in) (NP (NNP Doc_15565293_184_194_Chemical-induced) (NNP Doc_15565293_203_219_Disease)))))) (S (VP (VBG using) (NP (NP (JJ optical) (NN coherence) (NN tomography)) (PRN (-LRB- -LRB-) (NP (NNP OCT)) (-RRB- -RRB-)))))) (. .)))
15565293	2	(S1 (S (NP (NN Doc_15565293_262_272_Chemical)) (VP (AUX is) (NP (NP (DT an) (JJ antimycobacterial) (NN agent)) (VP (ADVP (RB often)) (VBN used) (S (VP (TO to) (VP (VB treat) (NP (NN Doc_15565293_323_335_Disease)))))))) (. .)))
15565293	3	(S1 (S (NP (NP (DT A) (JJ serious) (NN complication)) (PP (IN of) (NP (NNP Doc_15565293_363_373_Chemical)))) (VP (AUX is) (NP (NP (DT an) (NN Doc_15565293_380_396_Disease)) (SBAR (WHNP (WDT that)) (S (VP (VBZ impairs) (NP (NP (JJ visual) (NN acuity)) (, ,) (NP (NN contrast) (NN sensitivity)) (, ,) (CC and) (NP (NN color) (NN vision)))))))) (. .)))
15565293	4	(S1 (S (ADVP (RB However)) (, ,) (ADVP (RB early) (RB on)) (, ,) (SBAR (WHADVP (WRB when)) (S (NP (DT the) (JJ toxic) (NN Doc_15565293_499_515_Disease)) (VP (AUX is) (ADJP (ADJP (JJ mild)) (CC and) (ADJP (RB partly) (JJ reversible)))))) (, ,) (NP (DT the) (JJ funduscopic) (NNS findings)) (VP (AUX are) (ADVP (RB often)) (ADJP (JJ subtle) (CC and) (JJ easy) (S (VP (TO to) (VP (VB miss)))))) (. .)))
15565293	5	(S1 (S (NP (NP (CD Three) (NNS subjects)) (PP (IN with) (NP (NP (DT a) (NN history)) (PP (IN of) (NP (NP (NNP Doc_15565293_649_659_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_15565293_661_664_Chemical)) (-RRB- -RRB-))))))) (VP (VBD -induced) (SBAR (S (NP (NP (NNP Doc_15565293_674_690_Disease)) (PP (IN of) (NP (ADJP (JJ short-) (, ,) (JJ intermediate-) (, ,) (CC and) (JJ long-term)) (NNP Doc_15565293_731_746_Disease)))) (VP (AUX were) (VP (VBN administered) (NP (NP (DT a) (JJ full) (JJ neuro-ophthalmologic) (NN examination)) (PP (VBG including) (NP (NP (JJ visual) (NN acuity)) (, ,) (NP (NN color) (NN vision)) (, ,) (NP (NN contrast) (NN sensitivity)) (, ,) (CC and) (NP (JJ fundus) (NN examination)))))))))) (. .)))
15565293	6	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (NNP OCT)) (PRN (-LRB- -LRB-) (NP (NNP OCT) (CD 3000)) (, ,) (NP (NP (NNP Humphrey-Zeiss)) (, ,) (NP (NNP Dublin)) (, ,) (NP (MD CA))) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN performed) (PP (IN on) (NP (NP (DT both) (NNS eyes)) (PP (IN of) (NP (DT each) (NN subject))) (VP (VBG using) (NP (DT the) (JJ retinal) (NN nerve) (NN fiber) (NN layer) (-LRB- -LRB-) (NN RNFL) (-RRB- -RRB-) (NN analysis) (NN protocol))))))) (. .)))
15565293	7	(S1 (S (NP (NNP OCT)) (VP (VBZ interpolates) (NP (NP (NNS data)) (PP (IN from) (NP (CD 100) (NNS points)))) (PP (IN around) (NP (NP (DT the) (JJ optic) (NN nerve)) (SBAR (S (VP (TO to) (ADVP (RB effectively)) (VP (NN map) (PRT (RP out)) (NP (DT the) (NNS RNFL))))))))) (. .)))
15565293	8	(S1 (S (NP (DT The) (NNS results)) (VP (AUX were) (VP (VBN compared) (PP (TO to) (NP (NP (DT the) (JJ calculated) (NN average) (NN RNFL)) (PP (IN of) (NP (NP (JJ normal) (NNS eyes)) (VP (VBN accumulated) (PP (IN from) (NP (NP (CD four) (JJ prior) (NNS studies)) (VP (VBG using) (NP (NP (NNP OCT)) (, ,) (NP (CD n=661))))))))))))) (. .)))
15565293	9	(S1 (S (PP (IN In) (NP (NP (DT all) (NNS subjects)) (PP (IN with) (NP (NP (NN history)) (PP (IN of) (NP (JJ Doc_15565293_1312_1315_Chemical-induced) (NNP Doc_15565293_1324_1340_Disease))))))) (, ,) (NP (EX there)) (VP (AUX was) (NP (NP (DT a) (JJ mean) (NN loss)) (PP (IN of) (NP (NP (NP (CD 72) (NN %)) (NN nerve) (NN fiber) (NN layer) (NN thickness)) (PP (IN in) (NP (NP (DT the) (JJ temporal) (NNP quadrant)) (PRN (-LRB- -LRB-) (NP (NP (NP (NN patient) (DT A)) (, ,) (PP (IN with) (NP (NP (JJ eventual) (NN recovery)) (PP (IN of) (NP (NP (JJ visual) (NN acuity)) (CC and) (NP (NP (NP (NP (NNS fields)) (, ,) (NP (NP (ADJP (CD 58) (NN %)) (NN loss)) (: ;) (NP (NN patient) (NNP B))) (, ,)) (PP (IN with) (NP (JJ intermediate) (NNP Doc_15565293_1527_1542_Disease)))) (, ,) (NP (NP (ADJP (CD 68) (NN %)) (NN loss)) (: ;) (NP (NN patient)) (X (SYM C)))))))) (, ,) (PP (IN with) (NP (JJ chronic) (NNP Doc_15565293_1578_1593_Disease)))) (, ,) (NP (ADJP (CD 90) (NN %)) (NN loss))) (-RRB- -RRB-))))))) (, ,) (PP (IN with) (NP (NP (DT an) (JJ average) (JJ mean) (JJ optic) (NN nerve) (NN thickness)) (PP (IN of) (NP (CD 26+/-16) (NN microm)))))) (. .)))
15565293	10	(S1 (S (NP (EX There)) (VP (AUX was) (NP (NP (DT a) (JJ combined) (JJ mean) (NN loss)) (PP (IN of) (NP (NP (CD 46) (NN %)) (PP (IN of) (NP (NP (NNS fibers)) (PP (IN from) (NP (NP (DT the) (JJ superior) (, ,) (JJ inferior) (, ,) (CC and) (JJ nasal) (NNS quadrants)) (PP (IN in) (NP (NP (DT the) (-LRB- -LRB-) (CD six) (-RRB- -RRB-) (NNS eyes)) (PP (IN of) (NP (NP (DT all) (CD three) (NNS subjects)) (PRN (-LRB- -LRB-) (S (VP (VB mean) (NP (NP (JJ average) (NN thickness)) (PP (IN of) (NP (CD 55+/-29) (NN microm)))))) (-RRB- -RRB-)))))))))))))) (. .)))
15565293	11	(S1 (S (PP (IN In) (NP (NP (DT both) (NNS sets)) (PRN (-LRB- -LRB-) (NP (CD four)) (-RRB- -RRB-)) (PP (IN of) (NP (NP (NNS eyes)) (PP (IN of) (NP (NP (DT the) (NNS subjects)) (PP (IN with) (NP (NP (JJ persistent) (NNP Doc_15565293_1909_1924_Disease)) (PRN (-LRB- -LRB-) (NP (NNS patients) (NNP B) (CC and) (NNP C)) (-RRB- -RRB-)))))))))) (, ,) (NP (EX there)) (VP (AUX was) (NP (NP (DT an) (JJ average) (NN loss)) (PP (IN of) (NP (NP (CD 79) (NN %)) (PP (IN of) (NP (NN nerve) (NN fiber) (NN thickness))))) (PP (IN in) (NP (DT the) (JJ temporal) (NNP quadrant))))) (. .)))
15565293	12	(S1 (S (NP (NP (DT The) (NNP OCT) (NNS results)) (PP (IN in) (NP (NP (DT these) (NNS patients)) (PP (IN with) (NP (NNP Doc_15565293_2081_2084_Chemical-induced) (NNP Doc_15565293_2093_2109_Disease)))))) (VP (VBP show) (NP (NP (JJ considerable) (NN loss)) (ADVP (RB especially)) (PP (IN of) (NP (DT the) (JJ temporal) (NNS fibers))))) (. .)))
15565293	13	(S1 (S (NP (DT This)) (VP (AUX is) (ADJP (JJ consistent) (PP (IN with) (NP (NP (JJ prior) (JJ histopathological) (NNS studies)) (SBAR (WHNP (WDT that)) (S (VP (VBP show) (NP (NP (JJ predominant) (NN loss)) (PP (IN of) (NP (NP (JJ parvo-cellular) (NNS axons)) (-LRB- -LRB-) (CC or) (NP (JJ small-caliber) (NNS axons)) (-RRB- -RRB-)))) (PP (IN within) (NP (NP (DT the) (JJ papillo-macular) (NN bundle)) (PP (IN in) (NP (ADJP (JJ toxic) (CC or) (JJ hereditary)) (NNP Doc_15565293_2357_2375_Disease)))))))))))) (. .)))
15565293	14	(S1 (S (NP (NN Doc_15565293_2377_2380_Chemical)) (VP (MD can) (VP (AUX be) (NP (NP (DT a) (JJ valuable) (NN tool)) (PP (IN in) (NP (NP (DT the) (JJ quantitative) (NN analysis)) (PP (IN of) (NP (NN Doc_15565293_2436_2454_Disease)))))))) (. .)))
15565293	15	(S1 (S (ADVP (RB Additionally)) (, ,) (PP (IN in) (NP (NP (NNS terms)) (PP (IN of) (NP (NP (NN management)) (PP (IN of) (NP (NNP Doc_15565293_2496_2499_Chemical-induced) (NNP Doc_15565293_2508_2524_Disease))))))) (, ,) (NP (PRP it)) (VP (AUX is) (ADJP (JJ important) (S (VP (VP (TO to) (ADVP (RB properly)) (VP (VB manage) (NP (NP (JJ Doc_15565293_2561_2571_Chemical) (NN dosing)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_15565293_2596_2612_Disease)))))))) (CC and) (VP (TO to) (VP (VB achieve) (NP (NP (JJ proper) (NN transition)) (PP (TO to) (NP (DT a) (NN maintenance) (NN dose)))) (SBAR (IN once) (S (NP (DT an) (JJ appropriate) (NN loading) (NN dose)) (VP (AUX has) (VP (AUX been) (VP (VBN reached)))))))))))) (. .)))
15579441	0	(S1 (NP (NP (NN Doc_15579441_0_7_Disease)) (PP (IN in) (NP (NNP Doc_15579441_11_24_Disease))) (PP (IN with) (NP (NNP Doc_15579441_30_41_Disease) (NN and/or) (NN glomerular) (NNP Doc_15579441_60_72_Disease))) (. .)))
15579441	1	(S1 (S (PP (IN Despite) (NP (NP (DT the) (VBG increasing) (NN need)) (SBAR (S (VP (TO to) (VP (VB identify) (CC and) (VB quantify) (NP (NN tissue) (NN oxygenation)) (PP (IN at) (NP (DT the) (JJ cellular) (NN level))))))))) (, ,) (NP (ADJP (RB relatively) (JJ few)) (NNS methods)) (VP (AUX have) (VP (AUX been) (ADJP (JJ available)))) (. .)))
15579441	2	(S1 (S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP (PRP we)) (VP (VP (VBD developed) (NP (NP (DT a) (JJ new) (JJ Doc_15579441_247_254_Disease-responsive) (NN reporter) (NN vector)) (VP (VBG using) (NP (NP (DT a) (JJ Doc_15579441_290_297_Disease-responsive) (NN element)) (PP (IN of) (NP (NP (DT the) (CD 5) (POS ')) (JJ vascular) (JJ endothelial) (NN growth) (NN factor) (JJ untranslated) (NN region))))))) (CC and) (VP (VBD generated) (NP (DT a) (JJ novel) (NNP Doc_15579441_404_411_Disease-sensing) (NNP transgenic) (NN rat)))) (. .)))
15579441	3	(S1 (S (NP (PRP We)) (ADVP (RB then)) (VP (VBD applied) (NP (DT this) (NN animal) (NN model)) (PP (TO to) (NP (NP (DT the) (NN detection)) (PP (IN of) (NP (JJ tubulointerstitial) (NN Doc_15579441_509_516_Disease))) (PP (IN in) (NP (DT the) (JJ diseased) (NN kidney)))))) (. .)))
15579441	4	(S1 (S (PP (IN With) (NP (DT this) (NN model))) (, ,) (NP (PRP we)) (VP (AUX were) (ADJP (JJ able) (S (VP (TO to) (VP (VB identify) (NP (JJ diffuse) (JJ cortical) (NN Doc_15579441_600_607_Disease)) (PP (IN in) (NP (NP (DT the) (JJ Doc_15579441_615_640_Chemical-induced) (UCP (NNP Doc_15579441_649_667_Disease) (CC and) (JJ focal) (CC and) (JJ segmental)) (NN Doc_15579441_692_699_Disease)) (PP (IN in) (NP (DT the) (JJ remnant) (NN kidney) (NN model)))))))))) (. .)))
15579441	5	(S1 (S (NP (NP (NN Expression)) (PP (IN of) (NP (DT the) (JJ Doc_15579441_747_754_Disease-responsive) (NN transgene)))) (VP (VBD increased) (PP (IN throughout) (NP (DT the) (JJ observation) (NN period))) (, ,) (S (VP (VBG reaching) (NP (NN 2.2-fold)) (PP (IN at) (NP (NP (CD 2) (NNS weeks)) (PP (IN in) (NP (DT the) (JJ Doc_15579441_857_882_Chemical) (NN model) (CC and) (NN 2.6-fold))))) (PP (IN at) (NP (NP (CD 4) (NNS weeks)) (PP (IN in) (NP (DT the) (JJ remnant) (NN kidney) (NN model))))))) (, ,) (SBAR (IN whereas) (S (NP (NP (DT that)) (PP (IN of) (NP (JJ vascular) (JJ endothelial) (NN growth) (NN factor)))) (VP (VBD showed) (NP (DT a) (JJ mild) (NN decrease)) (, ,) (S (VP (VBG reflecting) (NP (NP (JJ distinct) (NNS behaviors)) (PP (IN of) (NP (DT the) (CD two) (NNS genes)))))))))) (. .)))
15579441	6	(S1 (S (NP (NP (DT The) (NN degree)) (PP (IN of) (NP (NNP Doc_15579441_1079_1086_Disease)))) (VP (VBD showed) (NP (NP (DT a) (JJ positive) (NN correlation)) (PP (IN with) (NP (NP (JJ microscopic) (NNP Doc_15579441_1134_1159_Disease)) (PP (IN in) (NP (DT both) (NNS models))))))) (. .)))
15579441	7	(S1 (S (ADVP (RB Finally)) (, ,) (NP (PRP we)) (VP (VBD identified) (NP (NP (DT the) (NN localization)) (PP (IN of) (NP (VBG proliferating) (NN cell) (JJ nuclear) (ADJP (JJ antigen-positive) (, ,) (JJ ED-1-positive) (, ,) (CC and) (JJ terminal)) (JJ Doc_15579441_1292_1296_Chemical) (JJ nick-end) (JJ labeled-positive) (NNS cells))) (PP (IN in) (NP (NP (DT the) (JJ Doc_15579441_1336_1343_Disease) (JJ cortical) (NN area)) (PP (IN in) (NP (DT the) (JJ remnant) (NN kidney) (NN model))))))) (. .)))
15579441	8	(S1 (S (NP (PRP We)) (VP (VB propose) (ADVP (RB here)) (NP (NP (DT a) (JJ possible) (JJ pathological) (NN tie)) (PP (IN between) (NP (NP (JJ chronic) (JJ tubulointerstitial) (NN Doc_15579441_1466_1473_Disease)) (CC and) (NP (JJ progressive) (NN Doc_15579441_1490_1509_Disease)))))) (. .)))
15580403	0	(S1 (S (NP (NP (JJ Adequate) (NN timing)) (PP (IN of) (NP (NNP Doc_15580403_19_28_Chemical)))) (VP (NN reduction) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_15580403_56_65_Disease))))) (PP (IN during) (NP (NP (NN combination) (NN therapy)) (PP (IN of) (NP (NP (NNP Doc_15580403_96_106_Chemical)) (CC and) (NP (NNP Doc_15580403_111_120_Chemical)))) (PP (IN for) (NP (NNP Doc_15580403_125_144_Disease)))))) (. .)))
15580403	1	(S1 (S (NP (NN Doc_15580403_158_174_Disease)) (VP (AUX is) (NP (NP (CD one)) (PP (IN of) (NP (NP (DT the) (JJ major) (JJ adverse) (NNS events)) (PP (IN of) (NP (NP (DT the) (NN combination) (NN therapy)) (PP (IN of) (NP (NP (NNP Doc_15580403_240_250_Chemical)) (CC and) (NP (NNP Doc_15580403_255_264_Chemical)))))))))) (. .)))
15580403	2	(S1 (S (PP (IN Because) (IN of) (NP (JJ Doc_15580403_277_286_Chemical-related) (NN Doc_15580403_295_311_Disease))) (, ,) (NP (NN dose) (NN reduction)) (VP (AUX is) (NP (NP (DT a) (JJ common) (NN event)) (PP (IN in) (NP (DT this) (NN therapy))))) (. .)))
15580403	3	(S1 (S (PP (IN In) (NP (DT this) (JJ clinical) (NN retrospective) (NN cohort) (NN study))) (NP (PRP we)) (VP (AUX have) (VP (VBN examined) (NP (NP (DT the) (JJ suitable) (NN timing)) (PP (IN of) (NP (NP (JJ Doc_15580403_447_456_Chemical) (NN reduction)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NNP Doc_15580403_484_493_Disease)) (PP (IN during) (NP (NN combination) (NN therapy)))))))))))) (. .)))
15580403	4	(S1 (S (NP (NP (NNS Thirty-seven)) (PP (IN of) (NP (NP (CD 160) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VP (AUX had) (NP (JJ HCV-genotype) (NNS 1b))) (, ,) (VP (AUX had) (NP (JJ high) (NN virus) (NN load))) (, ,) (CC and) (VP (VBN received) (NP (JJ 24-week) (NN combination) (NN therapy))))))))) (VP (VBD developed) (NP (NNP Doc_15580403_657_663_Disease)) (PP (IN with) (NP (NP (NP (NN hemoglobin) (NN level)) (NP (CD <10) (NNS g/dl))) (CC or) (NP (JJ Doc_15580403_698_704_Disease-related) (NNS signs)))) (PP (IN during) (NP (NN therapy)))) (. .)))
15580403	5	(S1 (S (PP (IN After) (NP (DT that))) (, ,) (NP (DT these) (CD 37) (NNS patients)) (VP (AUX were) (VP (VBN reduced) (NP (NP (CD one) (NN tablet)) (PP (IN of) (NP (NP (NNP Doc_15580403_792_801_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 200) (NN mg)) (-RRB- -RRB-))))) (PP (IN per) (NP (NN day))))) (. .)))
15580403	6	(S1 (S (PP (IN After) (NP (NP (NN reduction)) (PP (IN of) (NP (NNP Doc_15580403_839_848_Chemical))))) (, ,) (NP (NP (CD 27)) (PP (IN of) (NP (CD 37) (NNS patients)))) (VP (MD could) (VP (VB continue) (NP (NP (NN combination) (NN therapy)) (PP (IN for) (NP (NP (DT a) (NN total)) (PP (IN of) (NP (NP (CD 24) (NNS weeks)) (PRN (-LRB- -LRB-) (NP (NN group) (NN A)) (-RRB- -RRB-))))))))) (. .)))
15580403	7	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (QP (CD 10) (IN of) (CD 37)) (NNS patients)) (PP (IN with) (NP (NP (NN reduction)) (PP (IN of) (NP (NNP Doc_15580403_983_992_Chemical)))))) (VP (MD could) (RB not) (VP (VB continue) (NP (NN combination) (NN therapy)) (SBAR (IN because) (S (NP (NP (NP (PRP$ their) (CD <8.5) (JJ g/dl) (NN hemoglobin) (NNS values)) (VP (VBN decreased) (PP (TO to)))) (CC or) (NP (JJ Doc_15580403_1090_1096_Disease-related) (JJ severe) (NN side) (NNS effects))) (VP (VBD occurred) (PRN (-LRB- -LRB-) (NP (NN group) (NN B)) (-RRB- -RRB-))))))) (. .)))
15580403	8	(S1 (S (S (NP (PRP We)) (VP (VBD assessed) (NP (DT the) (JJ final) (NN efficacy) (CC and) (NN safety)) (PP (IN after) (NP (NP (NN reduction)) (PP (IN of) (NP (NP (NNP Doc_15580403_1206_1215_Chemical)) (PP (IN in) (NP (NP (NP (NNS groups)) (NP (DT A))) (CC and) (NP (NNP B.) (NNS RESULTS)))))))))) (: :) (S (NP (NP (DT A) (JJ sustained) (JJ virological) (NN response)) (PRN (-LRB- -LRB-) (NP (NNP SVR)) (-RRB- -RRB-))) (VP (AUX was) (NP (NP (CD 29.6) (NN %)) (PRN (-LRB- -LRB-) (CD 8/27) (-RRB- -RRB-)) (PP (IN in) (NP (NP (NN group) (DT A)) (CC and) (NP (NP (NP (CD 10) (NN %)) (PRN (-LRB- -LRB-) (NP (CD 1/10)) (-RRB- -RRB-))) (PP (IN in) (NP (NN group) (NN B))))))) (, ,) (ADVP (RB respectively)))) (. .)))
15580403	9	(S1 (S (NP (NP (DT A) (ADJP (CD 34.4) (NN %) (PRN (-LRB- -LRB-) (NP (CD 12/27)) (-RRB- -RRB-)) (PP (IN of) (NP (JJ SVR) (NNS +)))) (JJ biological) (NN response)) (PP (IN in) (NP (NN group) (DT A)))) (VP (AUX was) (ADJP (ADJP (JJR higher)) (PP (IN than) (NP (CD 10) (NN %)))) (PRN (-LRB- -LRB-) (NP (CD 1/10)) (-RRB- -RRB-)) (PP (IN in) (NP (NN group) (NN B))) (PRN (-LRB- -LRB-) (NP (NNP P) (SYM =) (CD 0.051)) (-RRB- -RRB-)) (, ,) (PP (IN with) (NP (JJ slight) (NN significance)))) (. .)))
15580403	10	(S1 (S (PP (IN With) (NP (NP (NN respect)) (PP (TO to) (NP (NN hemoglobin) (NN level))))) (PP (IN at) (NP (NP (DT the) (NN time)) (PP (IN of) (NP (NNP Doc_15580403_1534_1543_Chemical))))) (NP (NN reduction)) (, ,) (NP (NP (DT a) (NN rate)) (PP (IN of) (NP (NP (NN continuation)) (PP (IN of) (NP (NN therapy))))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (QP (CD >) (CC or) (CD =10) (CD g/dl)) (NN hemoglobin)))))) (VP (AUX was) (ADJP (ADJP (JJR higher)) (PP (IN than) (NP (NP (DT that)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (CD <10) (NNS g/dl)) (PRN (-LRB- -LRB-) (NP (NNP P) (SYM =) (CD 0.036)) (-RRB- -RRB-)))))))))) (. .)))
15580403	11	(S1 (S (NP (NP (NP (NN Reduction)) (PP (IN of) (NP (NNP Doc_15580403_1718_1727_Chemical))) (PP (IN at) (NP (NN hemoglobin) (NN level) (CD >)))) (CC or) (NP (CD =10) (NN g/dl))) (VP (AUX is) (ADJP (JJ suitable)) (PP (IN in) (NP (NP (NNS terms)) (PP (IN of) (NP (NN efficacy) (CC and) (NN side) (NNS effects)))))) (. .)))
15638391	0	(S1 (S (NP (NP (VBG Aging) (NN process)) (PP (IN of) (NP (NP (JJ epithelial) (NNS cells)) (PP (IN of) (NP (DT the) (NN rat) (NN prostate) (NN lateral)))))) (VP (VBP lobe) (PP (IN in) (NP (NP (JJ experimental) (NN Doc_15638391_83_101_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_15638391_113_124_Chemical))))))) (. .)))
15638391	1	(S1 (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT the) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VP (VB examine) (NP (NP (DT the) (NN influence)) (PP (IN of) (NP (NP (NNP Doc_15638391_179_197_Disease)) (, ,) (VP (VBN induced) (PP (IN by) (NP (NP (NNP Doc_15638391_210_221_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP HAL)) (-RRB- -RRB-)))) (PP (IN on) (NP (NN age) (JJ related) (NN morphology)))))))) (CC and) (VP (VB function) (NP (NP (NNS changes)) (PP (IN of) (NP (JJ epithelial) (NNS cells))) (PP (IN in) (NP (NN rat) (NN prostate) (NN lateral) (NN lobe))))))))) (. .)))
15638391	2	(S1 (S (NP (DT The) (NN study)) (VP (AUX was) (VP (VBN performed) (PP (IN on) (NP (ADJP (RB sexually) (JJ mature)) (NN male) (NNS rats))))) (. .)))
15638391	3	(S1 (S (NP (NP (JJ Serum) (NNS concentrations)) (PP (IN of) (NP (NP (NP (NNP prolactin)) (PRN (-LRB- -LRB-) (NP (NNP PRL)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_15638391_423_435_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP T)) (-RRB- -RRB-)))))) (VP (AUX were) (VP (VBN measured))) (. .)))
15638391	4	(S1 (S (NP (NN Tissue) (NNS sections)) (VP (AUX were) (VP (VBN evaluated) (PP (IN with) (NP (NP (NN light)) (CC and) (NP (NNP electron) (NN microscopy)))))) (. .)))
15638391	5	(S1 (S (NP (NP (JJ Immunohistochemical) (NNS reactions)) (PP (IN for) (NP (NP (JJ Anti-Proliferating) (NN Cell) (JJ Nuclear) (NN Antigen)) (PRN (-LRB- -LRB-) (NP (NNP PCNA)) (-RRB- -RRB-))))) (VP (AUX were) (VP (VBN performed))) (. .)))
15638391	6	(S1 (S (PP (IN In) (NP (NP (NNS rats)) (PP (IN of) (NP (DT the) (JJ experimental) (NN group))))) (, ,) (NP (NP (DT the) (JJ mean) (NN concentration)) (PP (IN of) (NP (: :) (NN PRL)))) (VP (AUX was) (ADVP (RBR more) (IN than)) (ADJP (RB twice) (JJR higher)) (, ,) (SBAR (IN whereas) (S (NP (JJ T) (NN concentration)) (VP (AUX was) (ADJP (ADJP (RB almost) (RB twice) (JJR lower)) (PP (IN than) (NP (NP (DT that)) (PP (IN in) (NP (DT the) (NN control) (NN group)))))))))) (. .)))
15638391	7	(S1 (S (NP (JJ Light) (NN microscopy)) (VP (VBD visualized) (NP (NP (DT the) (NN following)) (: :) (NP (NP (NN Doc_15638391_835_846_Disease) (CC and) (NN epithelium) (NN Doc_15638391_862_873_Disease)) (PP (IN of) (NP (NP (DT the) (JJ glandular) (NNS ducts)) (, ,) (VP (VBN associated) (PP (IN with) (NP (VBN increased) (NNP PCNA) (NN expression))))))))) (. .)))
15638391	8	(S1 (S (NP (NNP Electron) (NN microscopy)) (VP (VBD revealed) (NP (NP (NNS changes)) (PP (IN in) (NP (JJ columnar) (NN epithelial) (NNS cells))) (, ,) (VP (VBG concerning) (NP (NNS organelles))) (, ,) (VP (VBN engaged) (PP (IN in) (NP (NP (NN protein) (NN synthesis)) (CC and) (NP (NN secretion))))))) (. .)))
1564236	0	(S1 (NP (NP (NP (NN Relation)) (PP (IN of) (NP (NN perfusion) (NNS defects))) (VP (VBN observed) (PP (IN with) (NP (NP (JJ myocardial) (NN contrast)) (ADJP (JJ echocardiography) (PP (TO to) (NP (NP (DT the) (NN severity)) (PP (IN of) (NP (NNP Doc_1564236_100_117_Disease)))))))))) (: :) (NP (NP (NN correlation)) (PP (IN with) (NP (JJ Doc_1564236_136_144_Chemical-201) (NN single-photon) (NN emission) (NN tomography)))) (. .)))
1564236	1	(S1 (S (NP (PRP It)) (VP (AUX has) (VP (AUX been) (VP (ADVP (RB previously)) (VBN shown) (SBAR (IN that) (S (NP (JJ myocardial) (NN contrast) (NN echocardiography)) (VP (AUX is) (NP (NP (DT a) (JJ valuable) (NN technique)) (PP (IN for) (NP (NP (JJ delineating) (NNS regions)) (PP (IN of) (NP (JJ myocardial) (NN underperfusion) (JJ secondary))) (PP (PP (TO to) (NP (NNP Doc_1564236_345_363_Disease))) (CC and) (PP (TO to) (NP (NP (JJ critical) (NNP Doc_1564236_380_397_Disease)) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (JJ hyperemic) (NN stimulation))))))))))))))))) (. .)))
1564236	2	(S1 (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB determine) (SBAR (IN whether) (S (NP (NP (JJ myocardial) (NN contrast) (NN echocardiography)) (VP (VBN performed) (PP (IN with) (NP (NP (DT a) (JJ stable) (NN solution)) (PP (IN of) (NP (JJ sonicated) (NN albumin))))))) (VP (MD could) (VP (VB detect) (NP (NP (NNS regions)) (PP (IN of) (NP (NP (JJ myocardial) (NNS underperfusion)) (VP (VBG resulting) (PP (IN from) (NP (NP (JJ various) (NNS degrees)) (PP (IN of) (NP (NNP Doc_1564236_662_679_Disease))))))))))))))))) (. .)))
1564236	3	(S1 (S (NP (NP (DT The) (NN perfusion) (NN defect)) (VP (VBN produced) (PP (IN in) (NP (CD 16) (JJ open) (NN chest) (NNS dogs))))) (VP (AUX was) (PP (VBN compared) (PP (PP (IN with) (NP (NP (DT the) (JJ anatomic) (NN area)) (PP (IN at) (NP (NN risk))) (VP (VBN measured) (PP (IN by) (NP (DT the) (NN postmortem) (NN dual-perfusion) (NN technique)))))) (CC and) (PP (IN with) (NP (NP (JJ Doc_1564236_838_846_Chemical-201) (JJ single-photon) (NN emission) (NN tomography)) (PRN (-LRB- -LRB-) (NP (NN SPECT)) (-RRB- -RRB-))))))) (. .)))
1564236	4	(S1 (S (PP (IN During) (NP (DT a) (JJ transient) (-LRB- -LRB-) (NN 20-s) (-RRB- -RRB-) (NN Doc_1564236_920_938_Disease))) (, ,) (NP (DT a) (NN perfusion) (NN defect)) (VP (AUX was) (VP (VBN observed) (PP (IN with) (NP (NN contrast) (NN echocardiography))) (PP (IN in) (NP (NP (CD 14)) (PP (IN of) (NP (DT the) (CD 15) (NNS dogs))) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (DT the) (NN occlusion)) (VP (AUX was) (VP (VBN produced))))))))) (. .)))
1564236	5	(S1 (S (NP (DT The) (NN perfusion) (NN defect)) (VP (VBD correlated) (ADVP (RB significantly)) (PP (IN with) (NP (DT the) (JJ anatomic) (NN area))) (PP (IN at) (NP (NP (NN risk)) (PRN (-LRB- -LRB-) (NP (SYM r) (X (SYM =)) (CD 0.74)) (: ;) (NP (NNP p) (QP (JJR less) (IN than) (CD 0.002))) (-RRB- -RRB-))))) (. .)))
1564236	6	(S1 (S (PP (IN During) (NP (NNP Doc_1564236_1176_1188_Chemical-induced) (NNP Doc_1564236_1197_1206_Disease))) (, ,) (NP (NP (CD 12)) (PP (IN of) (NP (NP (DT the) (CD 16) (NNS dogs)) (PP (IN with) (NP (DT a) (JJ partial) (NN Doc_1564236_1241_1258_Disease)))))) (VP (AUX had) (NP (NP (DT a) (JJ visible) (NN area)) (PP (IN of) (NP (NN hypoperfusion)))) (PP (IN by) (NP (NN contrast) (JJ echocardiography)))) (. .)))
1564236	7	(S1 (S (NP (NP (DT The) (CD four) (NNS dogs)) (PP (IN without) (NP (DT a) (JJ perfusion) (NN defect)))) (VP (AUX had) (NP (NP (DT a) (NN stenosis)) (SBAR (WHNP (WDT that)) (S (VP (VBD resulted) (PP (IN in) (NP (NP (DT a) (JJ mild) (ADJP (-LRB- -LRB-) (NP (CD 0) (NN %) (TO to) (CD 50) (NN %)) (-RRB- -RRB-)) (NN reduction)) (PP (IN in) (NP (NNP Doc_1564236_1430_1442_Chemical-induced) (NNP Doc_1564236_1451_1460_Disease)))))))))) (. .)))
1564236	8	(S1 (S (NP (NP (DT The) (NN size)) (PP (IN of) (NP (NP (DT the) (JJ perfusion) (NN defect)) (PP (IN during) (NP (NNS stenosis)))))) (VP (VBD correlated) (ADVP (RB significantly)) (PP (IN with) (NP (DT the) (JJ anatomic) (NN area))) (PP (IN at) (NP (NP (NN risk)) (PRN (-LRB- -LRB-) (NP (SYM r) (X (SYM =)) (CD 0.61)) (: ;) (S (NP (NN p)) (VP (SYM =) (NP (CD 0.02)))) (-RRB- -RRB-))))) (. .)))
1564236	9	(S1 (S (S (NP (CD Doc_1564236_1589_1597_Chemical-201) (NN SPECT)) (VP (VBD demonstrated) (NP (DT a) (JJ perfusion) (NN defect)) (PP (IN in) (NP (NP (DT all) (CD 14) (NNS dogs)) (VP (VBN analyzed) (PP (IN during) (NP (JJ Doc_1564236_1671_1683_Chemical-induced) (NNP Doc_1564236_1692_1701_Disease)))))))) (: ;) (S (NP (NP (DT the) (NN size)) (PP (IN of) (NP (DT the) (NN perfusion) (NN defect)))) (VP (VBD correlated) (PP (IN with) (NP (DT the) (JJ anatomic) (NN area)) (PP (IN at) (NP (NN risk))) (PRN (-LRB- -LRB-) (NP (NN r) (SYM =) (CD 0.58)) (: ;) (NP (NNP p) (QP (JJR less) (IN than) (CD 0.03))) (-RRB- -RRB-)) (CC and) (PP (IN with) (NP (DT the) (NN perfusion) (NN defect)))) (PP (IN by) (NP (NP (NN contrast) (JJ echocardiography)) (PRN (-LRB- -LRB-) (NP (NP (SYM r)) (NP (SYM =) (CD 0.58))) (: ;) (NP (NNP p) (QP (JJR less) (IN than) (CD 0.03))) (-RRB- -RRB-)))))) (. .)))
1564236	10	(S1 (S (ADVP (RB Thus)) (, ,) (NP (JJ myocardial) (NN contrast) (NN echocardiography)) (VP (MD can) (VP (AUX be) (VP (VBN used) (S (VP (TO to) (VP (VB visualize) (CC and) (VB quantitate) (NP (NP (DT the) (NN amount)) (PP (IN of) (NP (JJ jeopardized) (NN myocardium)))) (PP (IN during) (NP (NP (ADJP (JJ moderate) (TO to) (JJ severe)) (NNS degrees)) (PP (IN of) (NP (NNP Doc_1564236_2053_2070_Disease))))))))))) (. .)))
1564236	11	(S1 (S (NP (NP (DT The) (NNS results)) (VP (VBN obtained))) (VP (VBP show) (NP (NP (DT a) (NN correlation)) (PP (IN with) (NP (NP (DT the) (JJ anatomic) (NN area)) (PP (IN at) (NP (NN risk))) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT that)) (VP (VBN obtained) (PP (IN with) (NP (JJ Doc_1564236_2173_2181_Chemical-201) (NN SPECT))))))))))) (. .)))
15673851	0	(S1 (S (NP (NP (DT The) (NN activation)) (PP (IN of) (NP (JJ spinal) (JJ Doc_15673851_25_45_Chemical) (NNS receptors)))) (VP (MD may) (VP (VB contribute) (PP (TO to) (NP (NP (NN degeneration)) (PP (IN of) (NP (NP (JJ spinal) (NN motor) (NNS neurons)) (VP (VBN induced) (PP (IN by) (NP (JJ neuraxial) (NN Doc_15673851_132_140_Chemical))) (PP (IN after) (NP (NP (DT a) (JJ noninjurious) (NN interval)) (PP (IN of) (NP (NNP Doc_15673851_174_194_Disease)))))))))))) (. .)))
15673851	1	(S1 (S (NP (PRP We)) (VP (VBD investigated) (NP (NP (DT the) (NN relationship)) (PP (IN between) (NP (NP (NP (DT the) (NN degeneration)) (PP (IN of) (NP (JJ spinal) (NN motor) (NNS neurons)))) (CC and) (NP (NP (NN activation)) (PP (IN of) (NP (NNP Doc_15673851_296_316_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_15673851_318_322_Chemical)) (-RRB- -RRB-)) (NNS receptors))))))) (PP (IN after) (NP (JJ neuraxial) (NNP Doc_15673851_350_358_Chemical))) (PP (VBG following) (NP (NP (DT a) (JJ noninjurious) (NN interval)) (PP (IN of) (NP (NP (NNP Doc_15673851_396_412_Disease)) (PP (IN in) (NP (NNS rats)))))))) (. .)))
15673851	2	(S1 (S (NP (NN Doc_15673851_422_442_Disease)) (VP (AUX was) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_15673851_458_474_Disease))) (PP (IN for) (NP (NP (CD 6) (NN min)) (PP (IN with) (NP (DT a) (NN balloon) (NN catheter))))))) (. .)))
15673851	3	(S1 (S (PP (IN In) (NP (DT a) (NN microdialysis) (NN study))) (, ,) (S (NP (NP (CD 10) (NN muL)) (PP (IN of) (NP (NP (NP (NN saline)) (PRN (-LRB- -LRB-) (NP (NP (NN group)) (X (SYM C)) (: ;) (NP (NNP n) (SYM =) (CD 8))) (-RRB- -RRB-))) (CC or) (NP (NP (CD 30) (NN mug)) (PP (IN of) (NP (NNP Doc_15673851_583_591_Chemical))) (PRN (-LRB- -LRB-) (NP (NNP group) (NNP M)) (: ;) (NP (NNP n) (SYM =) (CD 8)) (-RRB- -RRB-)))))) (VP (AUX was) (VP (VBN injected) (ADVP (RB intrathecally)) (PRN (-LRB- -LRB-) (PRP IT) (-RRB- -RRB-)) (NP (CD 0.5) (NNP h)) (PP (IN after) (NP (NN reflow)))))) (, ,) (CC and) (S (NP (NP (NP (CD 30) (NN mug)) (PP (IN of) (NP (NNP Doc_15673851_675_683_Chemical))) (PRN (-LRB- -LRB-) (NP (NN group) (CD SM)) (: ;) (NP (NNP n) (SYM =) (CD 8)) (-RRB- -RRB-))) (CC or) (NP (NP (CD 10) (NN muL)) (PP (IN of) (NP (NN saline))) (PRN (-LRB- -LRB-) (NP (NP (NN group) (NN SC)) (: ;) (NP (NNP n) (SYM =) (CD 8))) (-RRB- -RRB-)))) (VP (AUX was) (VP (VBN injected) (S (NP (PRP IT)) (NP (NP (CD 0.5) (NNP h)) (PP (IN after) (NP (JJ sham) (NN operation)))))))) (. .)))
15673851	4	(S1 (S (NP (NN Microdialysis) (NNS samples)) (VP (AUX were) (VP (VBN collected) (NP (NN preischemia)) (, ,) (PP (PP (IN before) (NP (PRP IT) (NN injection))) (, ,) (CC and) (PP (IN at) (NP (CD 2) (, ,) (CD 4) (, ,) (CD 8) (, ,) (CD 24) (, ,) (CC and) (NP (NP (NP (CD 48) (NNP h)) (PP (IN of) (NP (NN reperfusion)))) (PRN (-LRB- -LRB-) (PP (IN after) (NP (PRP IT) (NN injection))) (-RRB- -RRB-)))))))) (. .)))
15673851	5	(S1 (S (ADVP (JJ Second)) (, ,) (NP (PRP we)) (VP (VBD investigated) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (NP (PRP IT)) (NNP Doc_15673851_962_968_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 30) (NN mug)) (-RRB- -RRB-)))) (PP (IN on) (NP (NP (DT the) (JJ histopathologic) (NNS changes)) (PP (IN in) (NP (NP (DT the) (JJ spinal) (NN cord)) (PP (IN after) (NP (JJ Doc_15673851_1034_1042_Chemical-induced) (NN Doc_15673851_1051_1070_Disease))))))))) (. .)))
15673851	6	(S1 (S (PP (IN After) (NP (PRP IT))) (NP (NNP Doc_15673851_1081_1089_Chemical)) (, ,) (NP (DT the) (JJ cerebrospinal) (NN fluid) (PRN (-LRB- -LRB-) (NP (NNP CSF)) (-RRB- -RRB-)) (NNP Doc_15673851_1121_1130_Chemical) (NN concentration)) (VP (AUX was) (VP (VBN increased) (PP (IN in) (NP (NN group))) (ADVP (NNP M) (JJ relative) (PP (TO to) (NP (NP (DT both) (NN baseline) (CC and) (NN group) (NN C)) (PRN (-LRB- -LRB-) (NP (QP (CD P) (CD <)) (CD 0.05)) (-RRB- -RRB-))))))) (. .)))
15673851	7	(S1 (S (NP (DT This) (NN increase)) (VP (VBD persisted) (PP (IN for) (NP (CD 8) (NNS hrs)))) (. .)))
15673851	8	(S1 (S (NP (PRP IT)) (NP (NNP Doc_15673851_1258_1264_Chemical)) (ADVP (RB significantly)) (VP (VBD reduced) (NP (NP (DT the) (NN number)) (PP (IN of) (NP (JJ dark-stained) (NNS alpha-motoneurons)))) (PP (IN after) (NP (NNP Doc_15673851_1338_1346_Chemical-induced) (NNP Doc_15673851_1355_1374_Disease))) (PP (VBN compared) (PP (IN with) (NP (DT the) (NN saline) (NN group))))) (. .)))
15673851	9	(S1 (S (NP (DT These) (NNS data)) (VP (VBP indicate) (SBAR (IN that) (S (NP (PRP IT)) (ADVP (NNP Doc_15673851_1435_1443_Chemical)) (VP (VBZ induces) (NP (NNP Doc_15673851_1452_1471_Disease)) (PP (IN with) (NP (NP (DT a) (JJ concomitant) (NN increase)) (PP (IN in) (NP (NNP CSF) (NNP Doc_15673851_1507_1516_Chemical))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX is) (VP (VBN involved) (PP (IN in) (NP (JJ Doc_15673851_1539_1543_Chemical) (NN receptor) (NN activation))))))))))))) (. .)))
15673851	10	(S1 (S (NP (PRP We)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NNS opioids)) (VP (MD may) (VP (AUX be) (ADJP (JJ Doc_15673851_1596_1606_Disease)) (PP (IN in) (NP (NP (DT the) (NN setting)) (PP (IN of) (NP (NNP Doc_15673851_1625_1645_Disease))))) (PP (IN via) (NP (JJ Doc_15673851_1650_1654_Chemical) (NN receptor) (NN activation)))))))) (. .)))
15686794	0	(S1 (NP (NP (NP (JJ Acute) (NN Doc_15686794_6_19_Disease)) (PP (IN during) (NP (NP (JJ intravenous) (NN administration)) (PP (IN of) (NP (NNP Doc_15686794_57_67_Chemical)))))) (: :) (NP (NP (DT a) (NN report)) (PP (IN of) (NP (CD two) (NNS cases)))) (. .)))
15686794	1	(S1 (S (NP (NN Doc_15686794_92_102_Chemical)) (VP (VBZ represents) (NP (NP (DT an) (JJ effective) (JJ antiarrhythmic) (NN drug)) (PP (IN for) (NP (NP (NP (NN cardioversion)) (PP (IN of) (NP (NP (JJ recent-onset) (NNP Doc_15686794_181_200_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_15686794_202_204_Disease)) (-RRB- -RRB-))))) (CC and) (NP (NP (NN maintenance)) (PP (IN of) (NP (JJ sinus) (NN rhythm)))))))) (. .)))
15686794	2	(S1 (S (NP (PRP We)) (ADVP (RB briefly)) (VP (VBP describe) (NP (NP (CD two) (NNS patients)) (VP (VBG suffering) (PP (IN from) (NP (JJ recent-onset) (NNP Doc_15686794_300_319_Disease)))) (, ,) (SBAR (WHNP (WP who)) (S (VP (VBD experienced) (NP (DT an) (JJ acute) (JJ devastating) (NN Doc_15686794_358_371_Disease)) (PP (NP (DT a) (JJ few) (NNS minutes)) (IN after) (NP (NP (NN initiation)) (PP (IN of) (NP (JJ intravenous) (JJ Doc_15686794_418_428_Chemical) (NN loading)))))))))) (. .)))
15686794	3	(S1 (S (ADVP (RB Notably)) (, ,) (NP (DT this) (NN side) (NN effect)) (VP (AUX has) (RB not) (VP (AUX been) (ADVP (RB ever)) (VP (VBN reported) (PP (IN in) (NP (DT the) (JJ medical) (NN literature)))))) (. .)))
15686794	4	(S1 (S (NP (NNS Clinicians)) (VP (MD should) (VP (AUX be) (ADJP (JJ aware) (PP (IN of) (NP (DT this) (NN reaction)))) (SBAR (IN since) (S (NP (NP (JJ prompt) (NN termination)) (PP (IN of) (NP (JJ parenteral) (NN administration)))) (VP (VBZ leads) (S (VP (TO to) (VP (VB complete) (NP (NN resolution)))))))))) (. .)))
15764424	0	(S1 (NP (NP (NP (JJ Quantitative) (NN drug) (NNS levels)) (PP (IN in) (NP (NN stimulant) (NN Doc_15764424_38_47_Disease)))) (: :) (NP (NP (NN relationship)) (PP (TO to) (NP (NP (NN symptom) (NN severity)) (, ,) (NP (NP (NNP Doc_15764424_83_97_Chemical)) (CC and) (NP (NNP Doc_15764424_102_114_Disease)))))) (. .)))
15764424	1	(S1 (S (S (S (VP (TO To) (VP (VB examine) (NP (NP (DT the) (NN relationship)) (PP (IN between) (NP (NP (JJ quantitative) (NN stimulant) (NN drug) (NNS levels)) (, ,) (NP (NP (NNP Doc_15764424_188_202_Chemical)) (, ,) (CC and) (NP (NNP Doc_15764424_208_226_Disease))))))))) (, ,) (NP (NP (JJ nineteen) (NNS patients)) (PP (IN in) (NP (NP (DT a) (JJ Doc_15764424_251_262_Disease) (NN emergency) (NN service)) (PP (IN with) (NP (NP (DT a) (NN diagnosis)) (PP (IN of) (NP (NNP Doc_15764424_301_312_Chemical-) (CC or) (NNP Doc_15764424_317_324_Chemical-induced) (NNP Doc_15764424_333_342_Disease)))))))) (VP (AUX were) (VP (VBN interviewed)))) (, ,) (CC and) (S (NP (NP (NN plasma)) (CC and) (NP (NN urine))) (VP (AUX were) (VP (VBN collected) (PP (IN for) (NP (NP (JJ quantitative) (NNS assays)) (PP (IN of) (NP (NN stimulant) (NN drug) (CC and) (JJ Doc_15764424_443_456_Chemical) (NN metabolite) (NNS levels)))))))) (. .)))
15764424	2	(S1 (S (NP (JJ Doc_15764424_476_491_Chemical) (CC or) (JJ Doc_15764424_495_506_Chemical) (NNS levels)) (VP (AUX were) (VP (VBN related) (PP (TO to) (NP (NP (JJ several) (NN psychopathology) (NNS scores)) (CC and) (NP (DT the) (JJ global) (NN Doc_15764424_576_588_Disease) (NN rating)))))) (. .)))
15764424	3	(S1 (S (NP (JJ Doc_15764424_597_600_Chemical) (NNS levels)) (VP (AUX were) (VP (VBN related) (PP (TO to) (NP (JJ global) (NN Doc_15764424_631_643_Disease))) (FRAG (CC but) (RB not) (PP (TO to) (NP (NN psychopathology) (NNS ratings)))))) (. .)))
15764424	4	(S1 (S (SBAR (IN Although) (S (NP (NP (JJ many) (JJ other) (NNS factors)) (PP (JJ such) (IN as) (NP (NN sensitization)))) (VP (MD may) (VP (VB play) (NP (DT a) (NN role)))))) (, ,) (NP (NP (NN intensity)) (PP (IN of) (NP (NP (JJ stimulant-induced) (NN Doc_15764424_778_796_Disease)) (CC and) (NP (NNS stereotypies))))) (VP (VBZ appears) (S (VP (TO to) (VP (AUX be) (ADVP (IN at) (JJS least)) (PP (IN in) (NP (NN part) (JJ dose-related))))))) (. .)))
15811908	0	(S1 (S (NP (NN Doc_15811908_0_16_Disease)) (VP (VBN unmasked) (PP (IN by) (NP (NP (NNP Doc_15811908_29_40_Chemical)) (CC and) (NP (NNP Doc_15811908_45_53_Chemical))))) (. .)))
15811908	1	(S1 (FRAG (S (VP (TO To) (VP (VB describe) (NP (NP (DT the) (NN unmasking)) (PP (IN of) (NP (NNP Doc_15811908_95_111_Disease)))) (PP (IN in) (NP (NP (DT a) (NN patient)) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_15811908_138_149_Chemical)) (CC and) (NP (NNP Doc_15811908_154_162_Chemical)))))))))) (. .)))
15811908	2	(S1 (NP (NP (NN CASE) (NN SUMMARY)) (: :) (NP (NP (DT A) (JJ 42-year-old) (JJ white) (NN man)) (VP (VBN developed) (NP (JJ acute) (NNP Doc_15811908_218_230_Disease)) (PP (IN with) (NP (NP (JJ severe) (NN Doc_15811908_243_251_Disease)) (CC and) (NP (NP (NNP Doc_15811908_256_264_Disease) (CD 2) (NNS hours)) (PP (IN after) (NP (NP (DT the) (JJ first) (NNS doses)) (PP (IN of) (NP (NP (NNP Doc_15811908_298_309_Chemical) (CD 100) (NNS mg)) (CC and) (NP (NNP Doc_15811908_321_329_Chemical) (CD 100) (NNS mg))))))))))) (. .)))
15811908	3	(S1 (S (S (NP (DT Both) (NNS drugs)) (VP (AUX were) (ADVP (RB immediately)) (VP (VBN discontinued)))) (, ,) (CC and) (S (NP (DT the) (NN patient)) (VP (VBD recovered) (PP (IN after) (NP (NP (JJ subsequent) (NN Doc_15811908_423_434_Chemical)) (CC and) (NP (JJ Doc_15811908_439_448_Chemical) (NN treatment)))))) (. .)))
15811908	4	(S1 (S (S (NP (JJ Abdominal) (NN ultrasound)) (VP (VBD showed) (NP (DT an) (JJ adrenal) (NN mass)))) (, ,) (CC and) (S (NP (JJ postoperative) (JJ histologic) (NN examination)) (VP (VBD confirmed) (NP (NP (DT the) (NN diagnosis)) (PP (IN of) (NP (NNP Doc_15811908_573_589_Disease)))))) (. .)))
15811908	5	(S1 (S (S (NP (NP (JJ Drug-induced) (NNS symptoms)) (PP (IN of) (NP (NNP Doc_15811908_628_644_Disease)))) (VP (AUX are) (ADVP (RB often)) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (VBN substituted) (JJ Doc_15811908_694_703_Chemical) (NNS drugs)))))))) (, ,) (CC but) (S (NP (DT the) (JJ underlying) (NN mechanism)) (VP (AUX is) (ADJP (JJ unknown)))) (. .)))
15811908	6	(S1 (S (PP (IN In) (NP (PRP$ our) (NN case))) (, ,) (NP (NP (NN use)) (PP (IN of) (NP (DT the) (NNP Naranjo) (NN probability) (NN scale)))) (VP (VBD indicated) (NP (NP (DT a) (JJ possible) (NN relationship)) (PP (IN between) (NP (NP (DT the) (JJ Doc_15811908_848_860_Disease) (NN crisis)) (CC and) (NP (NNP Doc_15811908_872_883_Chemical) (CC and) (NNP Doc_15811908_888_896_Chemical) (NN therapy)))))) (. .)))
15811908	7	(S1 (S (PP (IN As) (PP (IN of) (NP (NNP March) (CD 24) (, ,) (CD 2005)))) (, ,) (NP (DT this)) (VP (AUX is) (NP (NP (DT the) (JJ first) (JJ reported) (NN case)) (PP (IN of) (NP (NNP Doc_15811908_976_987_Chemical-) (CC and) (NNP Doc_15811908_993_1001_Chemical-induced) (NNP Doc_15811908_1010_1022_Disease) (NN crisis))) (PP (IN in) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (NNP Doc_15811908_1048_1064_Disease))))))) (. .)))
15811908	8	(S1 (S (NP (NP (NNS Physicians)) (CC and) (NP (JJ other) (NN healthcare) (NNS professionals))) (VP (MD should) (VP (AUX be) (ADJP (JJ aware) (PP (IN of) (NP (NP (DT this) (JJ potential) (JJ adverse) (NN effect)) (PP (IN of) (NP (NP (NNP Doc_15811908_1164_1172_Chemical)) (CC and) (NP (NNP Doc_15811908_1177_1188_Chemical))))))))) (. .)))
15814210	0	(S1 (NP (NP (NP (JJ Minor) (NN Doc_15814210_6_30_Disease)) (, ,) (NP (JJ cognitive) (NN development)) (, ,) (CC and) (NP (JJ somatic) (NN development))) (PP (IN at) (NP (NP (DT the) (NN age)) (PP (IN of) (NP (QP (CD 3) (TO to) (CD 7)) (NNS years))))) (PP (IN after) (NP (NP (JJ Doc_15814210_112_125_Chemical) (NN treatment)) (PP (IN in) (NP (JJ very-low) (JJ birth-weight) (NNS infants))))) (. .)))
15814210	1	(S1 (S (NP (NP (DT The) (NN objective)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB assess) (NP (NP (JJ minor) (NN Doc_15814210_218_242_Disease)) (, ,) (NP (JJ cognitive) (NN development)) (, ,) (CC and) (NP (JJ somatic) (NN development))) (PP (IN after) (NP (NP (JJ Doc_15814210_297_310_Chemical) (NN therapy)) (PP (IN in) (NP (JJ very-low-birthweight) (NNS infants))))))))) (. .)))
15814210	2	(S1 (S (NP (NP (JJ Thirty-three) (NNS children)) (PP (IN after) (NP (JJ Doc_15814210_380_393_Chemical) (NN treatment)))) (VP (AUX were) (VP (VBN matched) (PP (TO to) (NP (CD 33) (NNS children))) (PP (IN without) (NP (JJ Doc_15814210_440_453_Chemical) (NN treatment))))) (. .)))
15814210	3	(S1 (S (NP (NNS Data)) (VP (AUX were) (VP (VBN assessed) (PP (IN at) (NP (NP (DT the) (NN age)) (PP (IN of) (NP (JJ 3-7) (NNS years))))))) (. .)))
15814210	4	(S1 (S (NP (NN Doc_15814210_509_522_Chemical)) (VP (AUX was) (VP (VBN started) (PP (IN between) (NP (NP (DT the) (NN 7th)) (CC and) (NP (NP (DT the) (JJ 28th) (NN day)) (PP (IN of) (NP (NN life))) (PP (IN over) (NP (NP (CD 7) (NNS days)) (PP (IN with) (NP (NP (DT a) (JJ total) (NN dose)) (PP (IN of) (NP (CD 2.35) (NN mg/kg/day)))))))))))) (. .)))
15814210	5	(S1 (S (NP (NN Exclusion) (NNS criteria)) (VP (AUX were) (NP (NP (NNP Doc_15814210_649_657_Disease)) (, ,) (NP (NNP Doc_15814210_659_672_Disease)) (, ,) (NP (JJ major) (JJ surgical) (NNS interventions)) (, ,) (ADJP (JJ small) (PP (IN for) (NP (JJ gestational) (NN age)))) (, ,) (NP (JJ intraventricular) (NN Doc_15814210_748_759_Disease) (NNS grades) (NNP III) (CC and) (NNP IV)) (, ,) (NP (NNP Doc_15814210_779_807_Disease)) (, ,) (CC and) (NP (JJ severe) (NNP Doc_15814210_820_843_Disease)))) (. .)))
15814210	6	(S1 (S (NP (DT Each) (NN child)) (VP (AUX was) (VP (VP (VBN examined) (PP (IN by) (NP (NP (DT a) (NN neuropediatrician)) (PP (IN for) (NP (JJ minor) (NNP Doc_15814210_902_927_Disease)))))) (CC and) (VP (VBN tested) (PP (IN by) (NP (NP (DT a) (NN psychologist)) (PP (IN for) (NP (NP (JJ cognitive) (NN development)) (PP (IN with) (NP (NP (DT a) (NNP Kaufman) (NNP Assessment) (NNP Battery)) (PP (IN for) (NP (NP (NNS Children)) (CC and) (NP (DT a) (JJ Draw-a-Man) (NN Test))))))))))))) (. .)))
15814210	7	(S1 (S (NP (EX There)) (VP (AUX were) (NP (NP (DT no) (NNS differences)) (PP (IN in) (NP (NP (JJ demographic) (NNS data)) (, ,) (NP (NN growth)) (, ,) (CC and) (NP (JJ socio-economic) (NN status)))) (PP (IN between) (NP (DT the) (CD two) (NNS groups))))) (. .)))
15814210	8	(S1 (S (NP (NP (JJ Fine) (NN motor) (NNS skills)) (CC and) (NP (JJ gross) (NN motor) (NN function))) (VP (AUX were) (ADJP (ADJP (RB significantly) (JJR better) (PP (IN in) (NP (DT the) (NN control) (NN group)))) (PRN (-LRB- -LRB-) (NP (CD p<0.01)) (-RRB- -RRB-)))) (. .)))
15814210	9	(S1 (S (PP (IN In) (NP (DT the) (JJ Draw-a-Man) (NN Test))) (, ,) (NP (DT the) (NN control) (NN group)) (VP (VBD showed) (NP (NP (JJR better) (NNS results)) (PRN (-LRB- -LRB-) (NP (CD p<0.001)) (-RRB- -RRB-)))) (. .)))
15814210	10	(S1 (S (NP (EX There)) (VP (AUX were) (NP (NP (DT no) (NNS differences)) (PP (IN in) (NP (NP (NP (NN development)) (PP (IN of) (NP (NN speech)))) (, ,) (NP (JJ social) (NN development)) (, ,) (CC and) (NP (NP (DT the) (NNP Kaufman) (NNP Assessment) (NNP Battery)) (PP (IN for) (NP (NNS Children)))))))) (. .)))
15814210	11	(S1 (S (PP (IN After) (NP (JJ Doc_15814210_1460_1473_Chemical) (NN treatment))) (, ,) (NP (NNS children)) (VP (VBD showed) (NP (NP (DT a) (JJR higher) (NN rate)) (PP (IN of) (NP (JJ minor) (NN Doc_15814210_1524_1549_Disease))))) (. .)))
15814210	12	(S1 (S (NP (JJ Neurological) (NN development)) (VP (AUX was) (VP (VBN affected) (PP (ADVP (RB even)) (IN without) (NP (JJ neurological) (NN diagnosis))))) (. .)))
15814210	13	(S1 (S (NP (JJ Further) (JJ long-term) (NN follow-up) (NNS studies)) (VP (MD will) (VP (AUX be) (ADJP (JJ necessary) (S (VP (TO to) (ADVP (RB fully)) (VP (VB evaluate) (NP (NP (DT the) (NN impact)) (PP (IN of) (NP (NNP Doc_15814210_1712_1725_Chemical))) (PP (IN on) (NP (NP (NN neurological)) (CC and) (NP (JJ cognitive) (NN development))))))))))) (. .)))
15858223	0	(S1 (NP (NP (JJ Doc_15858223_0_13_Chemical) (NN I)) (: :) (NP (NP (NN time) (NN course)) (PP (IN of) (NP (NP (NN lipid) (NN peroxidation) (NNS biomarkers)) (, ,) (NP (NN Doc_15858223_63_77_Disease)) (, ,) (CC and) (NP (JJ Doc_15858223_83_96_Chemical) (JJ metabolite) (NNS levels)))) (PP (IN in) (NP (NNS rats)))) (. .)))
15858223	1	(S1 (S (NP (NP (DT A) (JJ single) (NN dose)) (PP (IN of) (NP (NP (NNP Doc_15858223_141_154_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_15858223_156_159_Chemical)) (-RRB- -RRB-)))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX is) (NP (DT a) (ADJP (RB widely) (VBN used)) (JJ antiepileptic) (NN drug))))) (, ,)) (VP (AUX is) (VP (VBN associated) (PP (IN with) (NP (NP (JJ oxidative) (NN stress)) (PP (IN in) (NP (NNS rats))))) (, ,) (SBAR (IN as) (S (ADVP (RB recently)) (VP (VBN demonstrated) (PP (IN by) (NP (NP (JJ elevated) (NNS levels)) (PP (IN of) (NP (NP (NNP Doc_15858223_297_317_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_15858223_319_332_Chemical)) (-RRB- -RRB-))))))))))) (. .)))
15858223	2	(S1 (S (VP (TO To) (VP (VB determine) (SBAR (IN whether) (S (NP (EX there)) (VP (AUX was) (NP (NP (DT a) (JJ temporal) (NN relationship)) (PP (IN between) (NP (NP (NP (NP (JJ Doc_15858223_398_401_Chemical-associated) (JJ oxidative) (NN stress)) (CC and) (NP (NN hepatotoxicity))) (PRN (, ,) (S (NP (JJ adult) (JJ male) (NNP Sprague-Dawley) (NNS rats)) (VP (AUX were) (VP (VBN treated) (PP (VBG ip) (PP (IN with) (NP (NP (NP (NP (NNP Doc_15858223_502_505_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 500) (NN mg/kg)) (-RRB- -RRB-))) (CC or) (NP (NP (CD 0.9) (NN %) (NN saline)) (PRN (-LRB- -LRB-) (NP (NN vehicle)) (-RRB- -RRB-)))) (RB once) (RB daily) (IN for) (CD 2) (, ,) (CD 4) (, ,) (CD 7) (, ,) (CD 10))))))) (, ,))) (CC or) (NP (CD 14) (NNS days)))))))))) (. .)))
15858223	3	(S1 (S (NP (JJ Oxidative) (NN stress)) (VP (AUX was) (VP (VBN assessed) (PP (IN by) (S (VP (VBG determining) (NP (NP (NN plasma) (CC and) (NN liver) (NNS levels)) (PP (IN of) (NP (NP (NNP Doc_15858223_655_668_Chemical)) (, ,) (NP (NP (NN lipid) (NNP Doc_15858223_676_690_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP LPO)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (JJ Doc_15858223_702_721_Chemical) (JJ reactive) (NNS substances)) (PRN (-LRB- -LRB-) (NP (NNS TBARs)) (-RRB- -RRB-))))))))))) (. .)))
15858223	4	(S1 (S (NP (NN Plasma) (CC and) (NN liver) (NN Doc_15858223_768_781_Chemical)) (VP (VP (AUX were) (ADJP (JJ elevated))) (CC and) (VP (VBD reached) (NP (DT a) (NN plateau)) (PP (IN after) (NP (NP (NN day) (CD 2)) (PP (IN of) (NP (JJ Doc_15858223_833_836_Chemical) (NN treatment))) (PP (VBN compared) (PP (TO to) (NP (NN control)))))))) (. .)))
15858223	5	(S1 (S (NP (NN Liver) (NN LPO) (NNS levels)) (VP (AUX were) (ADJP (RB not) (JJ elevated)) (PP (IN until) (NP (NP (NN day) (CD 7)) (PP (IN of) (NP (NN treatment))) (PRN (-LRB- -LRB-) (NP (NP (NN 1.8-fold) (CC versus) (NN control)) (, ,) (NP (NNP p) (NNP <) (CD 0.05))) (-RRB- -RRB-))))) (. .)))
15858223	6	(S1 (S (NP (NN Liver) (CC and) (NN plasma) (NNS TBARs)) (VP (AUX were) (RB not) (VP (VBN increased) (PP (IN until) (NP (NP (CD 14) (NNS days)) (PRN (-LRB- -LRB-) (NP (NP (NN 2-fold)) (CC vs.) (NP (NN control))) (, ,) (NP (NP (CD p) (NNS <)) (NP (CD 0.05))) (-RRB- -RRB-)))))) (. .)))
15858223	7	(S1 (S (NP (NN Doc_15858223_1053_1067_Disease)) (VP (AUX was) (VP (VBN evaluated) (PP (VBN based) (PP (IN on) (NP (NP (NN serum) (NNS levels)) (PP (IN of) (NP (NP (JJ alpha-Doc_15858223_1113_1124_Chemical) (NN Doc_15858223_1125_1126_Chemical-transferase)) (PRN (-LRB- -LRB-) (NP (NN alpha-GST)) (-RRB- -RRB-)))))) (CC and) (PP (IN by) (NP (NN histology)))))) (. .)))
15858223	8	(S1 (S (NP (NN Serum) (NN alpha-GST) (NNS levels)) (VP (AUX were) (ADJP (RB significantly) (JJ elevated) (PP (IN by) (NP (NN day) (CD 4)))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD corresponded) (PP (TO to) (NP (NN hepatotoxicity))) (SBAR (IN as) (S (VP (VBN shown) (PP (IN by) (NP (NP (DT the) (VBG increasing) (NN incidence)) (PP (IN of) (NP (NP (NP (NNP Doc_15858223_1307_1319_Disease)) (PP (IN of) (NP (DT the) (NN liver) (NN capsule)))) (, ,) (NP (NNP Doc_15858223_1342_1350_Disease)) (, ,) (CC and) (NP (NNP Doc_15858223_1356_1365_Disease)))) (PP (IN throughout) (NP (DT the) (NN study)))))))))))) (. .)))
15858223	9	(S1 (S (NP (NP (DT The) (NN liver) (NNS levels)) (PP (IN of) (NP (NP (JJ beta-oxidation) (NNS metabolites)) (PP (IN of) (NP (NNP Doc_15858223_1438_1441_Chemical)))))) (VP (AUX were) (VP (VBN decreased) (PP (IN by) (NP (NN day) (CD 14))) (, ,) (SBAR (IN while) (S (NP (NP (DT the) (NNS levels)) (PP (IN of) (NP (NP (NNP Doc_15858223_1488_1497_Chemical)) (CC and) (NP (NNP Doc_15858223_1502_1515_Chemical-Doc_15858223_1516_1519_Chemical))))) (VP (AUX were) (RB not) (ADJP (JJ elevated)) (PP (IN throughout) (NP (DT the) (NN study)))))))) (. .)))
15858223	10	(S1 (S (ADVP (RB Overall)) (, ,) (NP (DT these) (NNS findings)) (VP (VBP indicate) (SBAR (IN that) (S (NP (JJ Doc_15858223_1598_1601_Chemical) (NN treatment)) (VP (VBZ results) (PP (IN in) (NP (JJ oxidative) (NN stress))) (, ,) (SBAR (IN as) (S (VP (VBN measured) (PP (IN by) (NP (NP (NNS levels)) (PP (IN of) (NP (NP (NNP Doc_15858223_1666_1679_Chemical)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ precedes) (NP (NP (DT the) (NN onset)) (PP (IN of) (NP (NP (NNP Doc_15858223_1709_1717_Disease)) (, ,) (NP (NNP Doc_15858223_1719_1728_Disease)) (, ,) (CC and) (NP (NP (JJ elevated) (NNS levels)) (PP (IN of) (NP (JJ serum) (NN alpha-GST))))))))))))))))))))) (. .)))
15867025	0	(S1 (NP (NP (NP (NN Assessment)) (PP (IN of) (NP (JJ perinatal) (NNP Doc_15867025_24_35_Disease) (CC and) (NNP Doc_15867025_40_47_Disease) (NN prevention))) (PP (IN in) (NP (NNP New) (NNP Hampshire)))) (NP (NN delivery) (NNS hospitals)) (. .)))
15867025	1	(S1 (FRAG (S (VP (TO To) (VP (VB evaluate) (NP (JJ current) (NN performance)) (PP (IN on) (NP (NP (JJ recommended) (NN perinatal) (NNP Doc_15867025_164_175_Disease) (CC and) (NNP Doc_15867025_180_187_Disease) (NN prevention) (NNS practices)) (PP (IN in) (NP (NNP New) (NNP Hampshire)))))))) (. .)))
15867025	2	(S1 (S (NP (NNS Data)) (VP (AUX were) (VP (VBN extracted) (PP (IN from) (NP (NP (JJ 2021) (VBN paired) (NN mother-infant) (NNS records)) (PP (IN for) (NP (DT the) (NN year) (CD 2000) (NN birth) (NN cohort))) (PP (IN in) (NP (NP (NNP New) (NNP Hampshire) (POS 's)) (CD 25) (NN delivery) (NNS hospitals))))))) (. .)))
15867025	3	(S1 (S (NP (NN Assessment)) (VP (AUX was) (VP (AUX done) (PP (IN on) (NP (NP (DT the) (JJ following)) (: :) (NP (NP (NP (JJ prenatal) (NN screening)) (PP (IN for) (NP (NNP Doc_15867025_429_440_Disease) (CC and) (NNP Doc_15867025_445_452_Disease)))) (, ,) (NP (NP (NN administration)) (PP (IN of) (NP (DT the) (NNP Doc_15867025_476_487_Disease) (NN vaccine) (NN birth) (NN dose))) (PP (TO to) (NP (DT all) (NNS infants)))) (, ,) (NP (NP (NN administration)) (PP (IN of) (NP (NNP Doc_15867025_541_552_Disease) (JJ immune) (NN globulin))) (PP (TO to) (NP (NP (NNS infants)) (SBAR (WHNP (WP who)) (S (VP (AUX were) (VP (VBN born) (PP (TO to) (NP (JJ Doc_15867025_597_624_Chemical-positive) (NNS mothers)))))))))) (, ,) (NP (NNP Doc_15867025_643_650_Disease) (NN immunity)) (, ,) (CC and) (NP (NP (NN administration)) (PP (IN of) (NP (NP (JJ in-hospital) (NN postpartum) (NNP Doc_15867025_706_713_Disease) (NN vaccine)) (PP (TO to) (NP (JJ Doc_15867025_725_732_Disease) (NN nonimmune) (NNS women))))))))))) (. .)))
15867025	4	(S1 (S (NP (NP (JJ Prenatal) (NN screening) (NNS rates)) (PP (IN for) (NP (NP (NP (NNP Doc_15867025_788_799_Disease)) (PRN (-LRB- -LRB-) (NP (CD 98.8) (NN %)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_15867025_812_819_Disease)) (PRN (-LRB- -LRB-) (NP (CD 99.4) (NN %)) (-RRB- -RRB-)))))) (VP (AUX were) (ADJP (JJ high))) (. .)))
15867025	5	(S1 (S (NP (JJ Doc_15867025_839_850_Disease) (NN vaccine) (NN birth) (NN dose)) (VP (AUX was) (VP (VBN administered) (PP (TO to) (NP (NP (CD 76.2) (NN %)) (PP (IN of) (NP (DT all) (NNS infants))))))) (. .)))
15867025	6	(S1 (S (NP (NP (DT All) (NNS infants)) (SBAR (WHNP (WP who)) (S (VP (AUX were) (VP (VBN born) (PP (TO to) (NP (JJ Doc_15867025_941_968_Chemical-positive) (NNS mothers)))))))) (ADVP (RB also)) (VP (VBD received) (NP (NNP Doc_15867025_1000_1011_Disease) (JJ immune) (NN globulin))) (. .)))
15867025	7	(S1 (S (NP (JJ Multivariate) (JJ logistic) (NN regression)) (VP (VBD showed) (SBAR (IN that) (S (NP (NP (DT the) (NN month)) (PP (IN of) (NP (NP (NN delivery)) (CC and) (NP (NN infant) (NN birth) (NN weight))))) (VP (AUX were) (NP (NP (JJ independent) (NNS predictors)) (PP (IN of) (NP (JJ Doc_15867025_1151_1162_Disease) (NN vaccination)))))))) (. .)))
15867025	8	(S1 (S (NP (NP (DT The) (NN proportion)) (PP (IN of) (NP (NP (NNS infants)) (SBAR (WHNP (WP who)) (S (VP (AUX were) (VP (VBN vaccinated) (PP (IN in) (NP (NP (NNP January)) (CC and) (NP (NP (NNP February) (CD 2000)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 48.5) (NN %)) (CC and) (NP (CD 67.5) (NN %))) (, ,) (NP (RB respectively))) (-RRB- -RRB-)))))))))))) (VP (AUX was) (ADJP (ADJP (JJR less)) (PP (IN than) (NP (DT any) (JJ other) (NNS months)))) (, ,) (SBAR (IN whereas) (S (NP (NP (DT the) (NN proportion)) (SBAR (WHNP (WP who)) (S (VP (AUX were) (VP (VBN vaccinated) (PP (IN in) (NP (NNP December) (CD 2000))))))) (PRN (-LRB- -LRB-) (NP (CD 88.2) (NN %)) (-RRB- -RRB-))) (VP (AUX was) (NP (DT the) (JJS highest)))))) (. .)))
15867025	9	(S1 (S (NP (NP (NNS Women)) (SBAR (WHNP (WP who)) (S (VP (AUX were) (VP (VBN born) (PP (IN between) (NP (NP (CD 1971)) (CC and) (NP (CD 1975))))))))) (VP (AUX had) (NP (NP (DT the) (JJS highest) (NN rate)) (PP (IN of) (NP (NP (JJ Doc_15867025_1466_1473_Disease) (NN nonimmunity)) (PRN (-LRB- -LRB-) (NP (CD 9.5) (NN %)) (-RRB- -RRB-)))))) (. .)))
15867025	10	(S1 (S (NP (JJ In-hospital) (NN postpartum) (NN Doc_15867025_1517_1524_Disease) (NN vaccine) (NN administration)) (VP (AUX was) (VP (VBN documented) (PP (IN for) (NP (NP (CD 75.6) (NN %)) (PP (IN of) (NP (JJ nonimmune) (NNS women))))))) (. .)))
15867025	11	(S1 (S (NP (DT This) (NN study)) (VP (VP (VBZ documents) (NP (NP (JJ good) (NN compliance)) (PP (IN in) (NP (NP (NNP New) (NNP Hampshire) (POS 's)) (VBG birthing) (NNS hospitals))) (PP (IN with) (NP (NP (JJ national) (NNS guidelines)) (PP (IN for) (NP (JJ perinatal) (NNP Doc_15867025_1719_1730_Disease) (CC and) (NNP Doc_15867025_1735_1742_Disease) (NN prevention))))))) (CC and) (VP (VBZ highlights) (NP (NP (JJ potential) (NNS areas)) (PP (IN for) (NP (NN improvement)))))) (. .)))
15893386	0	(S1 (NP (NP (JJ Doc_15893386_0_15_Chemical-induced) (NN Doc_15893386_24_48_Disease)) (PP (IN during) (NP (NP (JJ bronchoscopic) (NN removal)) (PP (IN of) (NP (DT a) (JJ tracheal) (JJ foreign) (NN body))))) (. .)))
15893386	1	(S1 (S (NP (NP (NN Doc_15893386_106_130_Disease)) (PP (IN during) (NP (JJ general) (NNS anesthesia)))) (VP (AUX is) (VP (VBN considered) (S (NP (NP (DT an) (JJ early) (NN warning) (NN sign)) (PP (IN of) (NP (NP (DT a) (JJ possible) (NN episode)) (PP (IN of) (NP (NN Doc_15893386_218_240_Disease))))))))) (. .)))
15893386	2	(S1 (S (NP (DT The) (NN decision) (SBAR (IN whether) (S (VP (VP (TO to) (VP (VB continue))) (CC or) (VP (VB discontinue) (NP (DT the) (NN procedure))))))) (VP (VBZ depends) (PP (IN on) (NP (NP (DT the) (NN urgency)) (PP (IN of) (NP (NP (DT the) (NN surgery) (CC and) (NN severity)) (PP (IN of) (NP (NNP Doc_15893386_358_382_Disease)))))))) (. .)))
15893386	3	(S1 (S (ADVP (RB Here)) (, ,) (NP (PRP we)) (VP (VBP describe) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NP (JJ severe) (NNP Doc_15893386_419_443_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_15893386_445_457_Disease)) (-RRB- -RRB-))))) (PP (IN after) (NP (NNP Doc_15893386_465_480_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_15893386_482_485_Chemical)) (-RRB- -RRB-)) (NN administration))) (PP (IN during) (NP (NP (JJ general) (JJ anesthetic) (NN management)) (PP (IN for) (NP (NP (JJ rigid) (JJ bronchoscopic) (NN removal)) (PP (IN of) (NP (DT a) (JJ tracheal) (JJ foreign) (NN body)))))))) (. .)))
15893386	4	(S1 (S (NP (NN Anesthesia)) (VP (AUX was) (VP (VBN continued) (ADVP (RB uneventfully)) (PP (IN with) (NP (JJ Doc_15893386_642_650_Chemical) (NN infusion))) (SBAR (IN while) (S (NP (DT all) (NNS facilities)) (VP (AUX were) (ADJP (JJ available) (S (VP (TO to) (VP (VB detect) (CC and) (VB treat) (NP (NN Doc_15893386_716_738_Disease))))))))))) (. .)))
15897593	0	(S1 (S (NP (NNP Doc_15897593_0_11_Chemical)) (VP (VBZ protects) (PP (IN against) (NP (NN myelosuppression))) (PP (IN from) (NP (NP (DT the) (NN DNA) (NN cleavage-enhancing) (NNS drugs)) (ADJP (ADJP (NNP Doc_15897593_84_93_Chemical) (CC and) (NNP Doc_15897593_98_110_Chemical)) (CC but) (ADJP (RB not) (JJ Doc_15897593_119_130_Chemical)))))) (. .)))
15897593	1	(S1 (S (S (NP (NP (DT The) (NNP Doc_15897593_145_159_Chemical) (NNP Doc_15897593_160_172_Chemical) (CC and) (NNP Doc_15897593_177_188_Chemical)) (CC and) (NP (DT the) (NNP Doc_15897593_197_215_Chemical) (NNP Doc_15897593_216_225_Chemical))) (VP (AUX are) (NP (NP (JJ potent) (NN DNA) (NN cleavage-enhancing) (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (AUX are) (ADVP (RB widely)) (VP (VBN used) (PP (IN in) (NP (JJ clinical) (NN oncology)))))))))) (: ;) (S (ADVP (RB however)) (, ,) (NP (NP (NN myelosuppression)) (CC and) (NP (NNP Doc_15897593_339_355_Disease))) (VP (VBP limit) (NP (PRP$ their) (NN use)))) (. .)))
15897593	2	(S1 (S (NP (NP (NNP Doc_15897593_373_384_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_15897593_386_394_Chemical)) (-RRB- -RRB-))) (VP (AUX is) (VP (VBN recommended) (PP (IN for) (NP (NP (NN protection)) (PP (IN against) (NP (NNP Doc_15897593_434_447_Chemical-induced) (NNP Doc_15897593_456_470_Disease))))))) (. .)))
15897593	3	(S1 (NP (NP (JJ EXPERIMENTAL) (NN DESIGN)) (: :) (S (S (PP (IN Because) (IN of) (NP (PRP$ their) (JJ widespread) (NN use))) (, ,) (NP (NP (NP (DT the) (JJ Doc_15897593_530_550_Disease) (JJ following) (NN coadministration)) (PP (IN of) (NP (NNP Doc_15897593_581_592_Chemical)))) (CC and) (NP (DT these) (CD three) (ADJP (RB structurally) (JJ different)) (NN DNA) (NN cleavage) (NNS enhancers))) (VP (AUX was) (VP (VBN investigated)))) (: :) (S (NP (NP (NN Sensitivity)) (PP (IN of) (NP (JJ human) (CC and) (JJ murine) (NN blood) (NN progenitor) (NNS cells))) (PP (TO to) (NP (NP (NNP Doc_15897593_731_740_Chemical)) (, ,) (NP (NNP Doc_15897593_742_754_Chemical)) (, ,) (CC and) (NP (NNP Doc_15897593_760_771_Chemical) (NN +/-) (NNP Doc_15897593_776_787_Chemical))))) (VP (AUX was) (VP (VBN determined) (PP (IN in) (NP (NP (JJ granulocyte-macrophage) (NN colony)) (VP (VBG forming) (NP (NNS assays))))))))) (. .)))
15897593	4	(S1 (S (S (ADVP (RB Likewise)) (, ,) (PP (IN in) (NP (NN vivo))) (, ,) (NP (NNP B6D2F1) (NNS mice)) (VP (AUX were) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_15897593_901_910_Chemical)) (, ,) (NP (NNP Doc_15897593_912_924_Chemical)) (, ,) (CC and) (NP (NNP Doc_15897593_930_941_Chemical)))) (, ,) (PP (IN with) (CC or) (IN without) (NP (NNP Doc_15897593_959_970_Chemical))) (PP (IN over) (NP (NP (DT a) (JJ wide) (NN range)) (PP (IN of) (NP (NNS doses)))))))) (: :) (S (NP (NP (NN posttreatment)) (, ,) (NP (DT a) (JJ full) (JJ hematologic) (NN evaluation))) (VP (AUX was) (VP (AUX done)))) (. .)))
15897593	5	(S1 (S (S (NP (NP (JJ Nontoxic) (NNS doses)) (PP (IN of) (NP (NNP Doc_15897593_1081_1092_Chemical)))) (VP (VP (VBD reduced) (NP (NP (NN myelosuppression)) (CC and) (NP (NNP Doc_15897593_1122_1133_Disease))) (PP (IN from) (NP (NNP Doc_15897593_1139_1151_Chemical) (CC and) (NNP Doc_15897593_1156_1165_Chemical))) (PP (IN in) (NP (NNS mice)))) (CC and) (VP (VBD antagonized) (NP (PRP$ their) (JJ antiproliferative) (NNS effects)) (PP (IN in) (NP (DT the) (NN colony) (NN assay)))))) (: ;) (S (ADVP (RB however)) (, ,) (NP (NNP Doc_15897593_1252_1263_Chemical)) (ADVP (RB neither)) (VP (VBD reduced) (NP (NP (NN myelosuppression)) (, ,) (NP (NN Doc_15897593_1298_1309_Disease)) (, ,) (CC nor) (NP (NP (DT the)) (PP (IN in) (NP (NNP vitro) (NNP Doc_15897593_1328_1340_Disease))))) (PP (IN from) (NP (NNP Doc_15897593_1346_1357_Chemical))))) (. .)))
15897593	6	(S1 (S (S (SBAR (IN Although) (S (NP (PRP$ our) (NNS findings)) (VP (VBP support) (NP (NP (DT the) (NN observation)) (SBAR (WHNP (WDT that)) (S (NP (NNP Doc_15897593_1422_1433_Chemical)) (VP (VBZ reduces) (NP (NP (DT neither) (JJ hematologic) (NN activity) (CC nor) (NN antitumor) (NN activity)) (PP (IN from) (NP (NNP Doc_15897593_1499_1510_Chemical)))) (ADVP (RB clinically))))))))) (, ,) (NP (NP (DT the) (JJ potent) (NN antagonism)) (PP (IN of) (NP (JJ Doc_15897593_1548_1560_Chemical) (NN activity)))) (VP (VBZ raises) (NP (NN concern)))) (: ;) (S (NP (NP (DT a) (JJ possible) (NN interference)) (PP (IN with) (NP (NN anticancer) (NN efficacy)))) (ADVP (RB certainly)) (VP (MD would) (VP (VB call) (PP (IN for) (NP (VBN renewed) (NN attention)))))) (. .)))
15897593	7	(S1 (S (NP (PRP$ Our) (NNS data)) (ADVP (RB also)) (VP (VBP suggest) (SBAR (IN that) (S (NP (JJ significant) (JJ Doc_15897593_1718_1727_Chemical) (NN dose) (NN escalation)) (VP (AUX is) (ADVP (RB perhaps)) (ADJP (JJ possible)) (PP (IN by) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NNP Doc_15897593_1778_1789_Chemical))))))))) (. .)))
15897593	8	(S1 (S (NP (NP (JJ Clinical) (NNS trials)) (PP (IN in) (NP (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NN brain) (NN Doc_15897593_1830_1840_Disease)) (VP (VBG combining) (NP (NNP Doc_15897593_1851_1862_Chemical)))))) (CC and) (NP (NP (JJ high) (NNS doses)) (PP (IN of) (NP (NNP Doc_15897593_1881_1890_Chemical))))))) (VP (AUX is) (ADJP (JJ ongoing) (PP (IN with) (NP (NP (DT the) (NN aim)) (PP (IN of) (S (VP (VBG improving) (NP (NN efficacy)) (PP (IN without) (S (VP (VBG aggravating) (NP (NNP Doc_15897593_1957_1977_Disease)))))))))))) (. .)))
15897593	9	(S1 (S (SBAR (IN If) (ADJP (JJ successful))) (, ,) (NP (DT this)) (VP (VBZ represents) (NP (NP (DT an) (JJ exciting) (NN mechanism)) (PP (IN for) (NP (NP (JJ pharmacologic) (NN regulation)) (PP (IN of) (NP (NP (JJ side) (NNS effects)) (PP (IN from) (NP (JJ cytotoxic) (NNS chemotherapy))))))))) (. .)))
15930398	0	(S1 (NP (NP (NP (NP (NN Assessment)) (PP (IN of) (NP (DT the) (NN onset)))) (CC and) (NP (NP (NN persistence)) (PP (IN of) (NP (NNP Doc_15930398_43_50_Disease))))) (PP (IN during) (NP (NP (JJ procedural) (NN sedation)) (PP (IN with) (NP (NNP Doc_15930398_83_91_Chemical))))) (. .)))
15930398	1	(S1 (S (VP (TO To) (VP (VP (VB assess) (NP (NP (NNS patients) (POS ')) (NN ability) (S (VP (TO to) (VP (VB repeat) (CC and) (VB recall) (NP (NP (NNS words)) (VP (VBN presented) (PP (TO to) (NP (PRP them))))) (SBAR (IN while) (S (VP (VBG undergoing) (NP (JJ procedural) (NN sedation)) (PP (IN with) (NP (NNP Doc_15930398_220_228_Chemical))))))))))) (, ,) (CC and) (VP (VB correlate) (NP (PRP$ their) (NN recall)) (PP (IN with) (NP (NP (PRP$ their) (NN level)) (PP (IN of) (NP (NN awareness))))) (SBAR (IN as) (S (VP (VBN measured) (PP (IN by) (NP (JJ bispectral) (NN index) (PRN (-LRB- -LRB-) (NP (NNP BIS)) (-RRB- -RRB-)) (NN monitoring))))))))) (. .)))
15930398	2	(S1 (S (NP (DT This)) (VP (AUX was) (NP (NP (DT a) (JJ prospective) (, ,) (JJ single-intervention) (NN study)) (PP (IN of) (S (VP (VBG consenting) (NP (NP (NN adult) (NNS patients)) (VP (VBG undergoing) (NP (NP (JJ procedural) (NN sedation)) (PP (IN with) (NP (NNP Doc_15930398_461_469_Chemical))) (PP (IN between) (NP (NP (NNP December) (CD 28) (, ,) (CD 2002)) (, ,) (CC and) (NP (NNP October) (CD 31) (, ,) (CD 2003)))))))))))) (. .)))
15930398	3	(S1 (S (NP (NN BIS) (NN monitoring)) (VP (AUX was) (VP (VBN initiated) (S (VP (VP (VBG starting) (NP (NP (CD 3) (NNS minutes)) (PP (IN before) (NP (DT the) (NN procedure))))) (CC and) (VP (VBG continuing) (SBAR (IN until) (S (NP (DT the) (NN patient)) (VP (AUX had) (VP (VBN regained) (NP (JJ baseline) (JJ mental) (NN status))))))))))) (. .)))
15930398	4	(S1 (S (PP (IN At) (NP (JJ 1-minute) (NNS intervals))) (PP (IN during) (NP (DT the) (JJ procedural) (NN sedation))) (, ,) (SBAR (IN until) (S (NP (DT the) (NN patient)) (VP (VBD regained) (NP (JJ baseline) (JJ mental) (NN status)) (PP (IN at) (NP (NP (DT the) (NN end)) (PP (IN of) (NP (DT the) (NN procedure)))))))) (, ,) (S (NP (NP (DT a) (NN word)) (PP (IN from) (NP (DT a) (JJ standardized) (NN list)))) (VP (AUX was) (VP (VBN read) (ADVP (RB aloud))))) (, ,) (CC and) (S (NP (DT the) (NN patient)) (VP (AUX was) (VP (VBN asked) (S (VP (TO to) (ADVP (RB immediately)) (VP (VB repeat) (NP (DT the) (NN word)) (PP (TO to) (NP (DT the) (NN investigator))))))))) (. .)))
15930398	5	(S1 (S (NP (DT The) (NNS BIS)) (VP (VBP score) (PP (IN at) (NP (DT the) (NN time))) (SBAR (S (S (NP (DT the) (NN word)) (VP (AUX was) (VP (VBN read)))) (CC and) (S (NP (NP (DT the) (NN patient) (POS 's)) (NN ability) (S (VP (TO to) (VP (VB repeat) (NP (DT the) (NN word)))))) (VP (AUX were) (VP (VBN recorded))))))) (. .)))
15930398	6	(S1 (S (PP (IN After) (NP (DT the) (NN procedure))) (, ,) (S (NP (DT the) (NN patient)) (VP (AUX was) (VP (VBN asked) (S (VP (TO to) (VP (VB state) (NP (NP (DT all)) (PP (IN of) (NP (DT the) (NNS words)))) (PP (IN from) (NP (DT the) (NN list))) (SBAR (IN that) (S (NP (PRP he) (CC or) (PRP she)) (VP (MD could) (VP (VP (VB recall)) (, ,) (CC and) (VP (TO to) (VP (VB identify) (NP (NP (DT the) (JJ last) (NN word)) (VP (VBN recalled) (PP (PP (IN from) (ADVP (RB prior))) (PP (TO to) (NP (NP (DT the) (NN start)) (PP (IN of) (NP (DT the) (NN procedure)))))))))))))))))))) (CC and) (S (NP (NP (DT the) (JJ first) (NN word)) (VP (VBN recalled) (PP (IN from) (PP (IN after) (NP (DT the) (NN procedure)))))) (VP (AUX was) (VP (VBN completed)))) (. .)))
15930398	7	(S1 (S (S (NP (JJ Seventy-five) (VBG consenting) (NNS patients)) (VP (AUX were) (VP (VBD enrolled)))) (: ;) (S (NP (CD one) (NN patient)) (VP (AUX was) (VP (VBN excluded) (PP (IN from) (NP (NN data) (NN analysis))) (PP (IN for) (NP (DT a) (NN protocol) (NN violation)))))) (. .)))
15930398	8	(S1 (S (NP (DT No) (JJ serious) (JJ adverse) (NNS events)) (VP (AUX were) (VP (VBN noted) (PP (IN during) (NP (DT the) (JJ procedural) (NNS sedations))))) (. .)))
15930398	9	(S1 (S (NP (NP (DT The) (JJ mean) (-LRB- -LRB-) (JJ +/-standard) (NN deviation) (-RRB- -RRB-) (NN time)) (PP (IN of) (NP (NN data) (NN collection)))) (VP (AUX was) (NP (NP (CD 16.4) (NNS minutes)) (PRN (-LRB- -LRB-) (NP (CD +/-7.1)) (: ;) (S (VP (VB range) (NP (QP (CD 5) (TO to) (CD 34)) (NNS minutes)))) (-RRB- -RRB-)))) (. .)))
15930398	10	(S1 (S (NP (DT The) (JJ mean) (JJ initial) (-LRB- -LRB-) (NN preprocedure) (-RRB- -RRB-) (NN BIS) (NN score)) (VP (AUX was) (NP (NP (CD 97.1)) (PRN (-LRB- -LRB-) (NP (NP (CD +/-2.3)) (: ;) (NP (NN range) (QP (CD 92) (TO to) (CD 99)))) (-RRB- -RRB-)))) (. .)))
15930398	11	(S1 (S (NP (NP (DT The) (JJ mean) (JJS lowest) (NN BIS) (NN score)) (VP (VBG occurring) (PP (IN during) (NP (DT these) (JJ procedural) (NNS sedations))))) (VP (AUX was) (NP (NP (CD 66.9)) (PRN (-LRB- -LRB-) (NP (NP (CD +/-14.4)) (: ;) (NP (NN range) (CD 33) (TO to) (CD 91))) (-RRB- -RRB-)))) (. .)))
15930398	12	(S1 (S (NP (NP (DT The) (JJ mean) (JJS lowest) (NN BIS) (NN score)) (VP (VBG corresponding) (PP (TO to) (NP (NP (DT the) (NN ability)) (PP (IN of) (NP (DT the) (NN patient))) (S (VP (TO to) (ADVP (RB immediately)) (VP (VB repeat) (NP (NP (NNS words)) (VP (VBN read) (PP (IN from) (NP (DT the) (NN list)))))))))))) (VP (AUX was) (NP (NP (CD 77.1)) (PRN (-LRB- -LRB-) (NP (CD 95) (NN %) (QP (CD CI) (SYM =) (CD 74.3) (TO to) (CD 80.0))) (-RRB- -RRB-)))) (. .)))
15930398	13	(S1 (S (NP (NP (DT The) (JJ mean) (JJS highest) (NN BIS) (NN score)) (VP (VBG corresponding) (PP (TO to) (NP (DT the) (NNP Doc_15930398_1967_1992_Disease))))) (VP (AUX was) (NP (NP (CD 81.5)) (PRN (-LRB- -LRB-) (NP (CD 95) (NN %) (QP (CD CI) (SYM =) (CD 78.1) (TO to) (CD 84.8))) (-RRB- -RRB-)))) (. .)))
15930398	14	(S1 (S (NP (NP (DT The) (JJ mean) (NN BIS) (NN score)) (VP (VBG corresponding) (PP (TO to) (NP (NP (DT the) (JJ last) (NN word)) (VP (VBD recalled) (PP (IN from) (ADVP (RB prior))) (PP (TO to) (NP (NP (DT the) (NN initiation)) (PP (IN of) (NP (DT the) (NN sedation)))))))))) (VP (AUX was) (NP (NP (CD 96.7)) (PRN (-LRB- -LRB-) (NP (NP (CD +/-2.4)) (: ;) (NP (NN range) (CD 84) (TO to) (CD 98))) (-RRB- -RRB-)))) (. .)))
15930398	15	(S1 (S (NP (NP (DT The) (JJ mean) (NN BIS) (NN score)) (VP (VBG corresponding) (PP (TO to) (NP (DT the) (JJ first) (NN word))))) (VP (VBD recalled) (SBAR (IN after) (S (S (NP (DT the) (NN procedure)) (VP (AUX was) (VP (VBN completed)))) (VP (AUX was) (NP (NP (CD 91.2)) (PRN (-LRB- -LRB-) (NP (CD 95) (NN %) (QP (CD CI) (SYM =) (CD 88.1) (TO to) (CD 94.3))) (-RRB- -RRB-))))))) (. .)))
15930398	16	(S1 (S (NP (DT All) (NNS patients)) (VP (VBD recalled) (NP (NP (QP (IN at) (JJS least) (CD one)) (NN word)) (SBAR (WHNP (WDT that)) (S (VP (AUX had) (VP (AUX been) (VP (VBN read) (PP (TO to) (NP (PRP them))) (PP (IN during) (NP (DT the) (NN protocol)))))))))) (. .)))
15930398	17	(S1 (S (NP (NP (DT The) (JJ mean) (JJS lowest) (NN BIS) (NN score)) (PP (IN for) (NP (DT any)))) (VP (VBD recalled) (SBAR (S (S (NP (NN word)) (VP (AUX was) (NP (NP (CD 91.5)) (PRN (-LRB- -LRB-) (NP (NP (CD +/-11.1)) (: ;) (NP (NN range) (QP (CD 79) (TO to) (CD 98)))) (-RRB- -RRB-))))) (, ,) (CC and) (S (NP (DT no) (NNS words)) (VP (AUX were) (VP (VBN recalled) (SBAR (WHADVP (WRB when)) (S (NP (DT the) (JJ corresponding) (NN BIS) (NN score)) (VP (AUX was) (NP (QP (JJR less) (IN than) (CD 90)))))))))))) (. .)))
15930398	18	(S1 (S (NP (EX There)) (VP (AUX is) (NP (NP (DT a) (NN range)) (PP (IN of) (NP (NN BIS) (NNS scores))) (SBAR (WHPP (IN during) (WHNP (WDT which))) (S (NP (JJ sedated) (NNS patients)) (VP (VP (AUX are) (ADJP (JJ able) (S (VP (TO to) (VP (VB repeat) (NP (NP (NNS words)) (VP (VBN read) (PP (TO to) (NP (PRP them)))))))))) (CC but) (VP (AUX are) (RB not) (ADJP (JJ able) (S (VP (TO to) (ADVP (RB subsequently)) (VP (VB recall) (NP (DT these) (NNS words)))))))))))) (. .)))
15930398	19	(S1 (S (ADVP (RB Furthermore)) (, ,) (NP (NNS patients)) (VP (AUX had) (NP (NP (DT no) (NN recall)) (PP (IN of) (NP (NNS words)))) (VP (VBD repeated) (ADVP (RB prior) (PP (TO to) (NP (JJ procedural) (NN sedation)))) (PP (IN in) (NP (NP (NN BIS) (NNS ranges)) (VP (VBN associated) (PP (IN with) (NP (NP (NN recall)) (PP (IN after) (NP (NP (JJ procedural) (NN sedation)) (, ,) (NP (NP (NN suggestive)) (PP (IN of) (NP (NNP Doc_15930398_2870_2888_Disease))))))))))))) (. .)))
1595783	0	(S1 (NP (NNP Doc_1595783_0_10_Chemical) (NNP Doc_1595783_11_29_Disease) (. .)))
1595783	1	(S1 (S (NP (NN Doc_1595783_31_41_Chemical)) (VP (AUX is) (NP (NP (NP (DT an) (JJ effective) (NN antiarrhythmic) (NN agent)) (SBAR (WHNP (WP$ whose) (NN utility)) (S (VP (AUX is) (VP (VBN limited) (PP (IN by) (NP (JJ many) (NNS side-effects)))))))) (, ,) (NP (DT the) (ADJP (RBS most) (JJ problematic)) (NN being) (NNP Doc_1595783_153_164_Disease)))) (. .)))
1595783	2	(S1 (S (NP (NP (DT The) (NNP Doc_1595783_170_188_Disease)) (PP (IN of) (NP (NNP Doc_1595783_192_202_Chemical)))) (VP (AUX is) (VP (VBN thought) (S (VP (TO to) (VP (VB result) (PP (IN from) (NP (NP (JJ direct) (NN injury)) (VP (VBN related) (PP (TO to) (NP (NP (DT the) (JJ intracellular) (NN accumulation)) (PP (IN of) (NP (NP (NN phospholipid)) (CC and) (NP (JJ T) (JJ cell-mediated) (NN Doc_1595783_321_349_Disease)))))))))))))) (. .)))
1595783	3	(S1 (S (NP (NP (DT The) (ADJP (ADJP (JJ clinical)) (CC and) (ADJP (JJ radiographic))) (NNS features)) (PP (IN of) (NP (NNP Doc_1595783_393_403_Chemical-induced) (NNP Doc_1595783_412_430_Disease)))) (VP (AUX are) (ADJP (ADJP (JJ characteristic)) (CC but) (ADJP (JJ nonspecific)))) (. .)))
1595783	4	(S1 (S (NP (DT The) (NN diagnosis)) (VP (VBZ depends) (PP (IN on) (NP (NP (NN exclusion)) (PP (IN of) (NP (NP (JJ other) (NNS entities)) (, ,) (PP (JJ such) (IN as) (NP (NP (NNP Doc_1595783_529_542_Disease)) (, ,) (NP (NNP Doc_1595783_544_553_Disease)) (, ,) (CC and) (NP (NNP Doc_1595783_559_569_Disease))))))))) (. .)))
1595783	5	(S1 (S (SBAR (IN While) (S (NP (NP (NN withdrawal)) (PP (IN of) (NP (NNP Doc_1595783_591_601_Chemical)))) (VP (VBZ leads) (PP (TO to) (NP (JJ clinical) (NN improvement))) (PP (IN in) (NP (NP (NN majority)) (PP (IN of) (NP (NNS cases)))))))) (, ,) (NP (DT this)) (VP (AUX is) (RB not) (ADVP (RB always)) (ADJP (ADJP (JJ possible)) (CC or) (ADJP (JJ advisable)))) (. .)))
1595783	6	(S1 (S (NP (NP (NN Dose) (NN reduction)) (CC or) (NP (JJ concomitant) (JJ Doc_1595783_726_733_Chemical) (NN therapy))) (VP (MD may) (VP (AUX have) (NP (NP (DT a) (NN role)) (PP (IN in) (NP (JJ selected) (NNS patients)))))) (. .)))
15974569	0	(S1 (S (NP (NP (CD Two) (NNS prodrugs)) (PP (IN of) (NP (ADJP (ADJP (JJ potent)) (CC and) (ADJP (JJ selective))) (NNP GluR5) (NNP Doc_15974569_43_50_Chemical) (NN receptor) (NNS antagonists)))) (VP (NNS actives) (PP (IN in) (NP (NP (CD three) (JJ animal) (NNS models)) (PP (IN of) (NP (NNP Doc_15974569_106_110_Disease)))))) (. .)))
15974569	1	(S1 (S (NP (NP (NNP Doc_15974569_112_123_Chemical) (CD 5) (CC and) (CD 7)) (, ,) (NP (CD two) (ADJP (JJ potent) (CC and) (JJ selective)) (JJ competitive) (NNP GluR5) (NNP KA) (NN receptor) (NNS antagonists)) (, ,)) (VP (VBD exhibited) (NP (NP (JJ high) (JJ GluR5) (NN receptor) (NN affinity)) (PP (IN over) (NP (JJ other) (JJ Doc_15974569_251_260_Chemical) (NNS receptors))))) (. .)))
15974569	2	(S1 (S (NP (NP (PRP$ Their) (JJ Doc_15974569_278_283_Chemical) (NNS prodrugs)) (ADVP (CD 6) (CC and) (CD 8))) (VP (AUX were) (ADJP (RB orally) (JJ active) (PP (IN in) (NP (NP (CD three) (NNS models)) (PP (IN of) (NP (NNP Doc_15974569_339_343_Disease)))))) (: :) (NP (NP (NN reversal)) (PP (IN of) (NP (NP (JJ Doc_15974569_357_365_Chemical-induced) (NN paw) (VBG licking)) (, ,) (NP (JJ carrageenan-induced) (NN Doc_15974569_407_427_Disease)) (, ,) (CC and) (NP (JJ Doc_15974569_433_442_Chemical-induced) (NN Doc_15974569_451_474_Disease)))))) (. .)))
15985056	0	(S1 (FRAG (NP (JJ Possible) (JJ Doc_15985056_9_21_Chemical-associated) (NN Doc_15985056_33_40_Disease)) (. .)))
15985056	1	(S1 (S (VP (TO To) (VP (VB report) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NP (JJ persistent) (NN Doc_15985056_84_91_Disease)) (VP (VBN associated) (PP (IN by) (NP (JJ Doc_15985056_106_118_Chemical) (NN therapy))))))))) (. .)))
15985056	2	(S1 (NP (NP (NN CASE) (NN SUMMARY)) (: :) (NP (NP (DT A) (JJ 76-year-old) (NN man)) (VP (VBN presented) (PP (IN with) (NP (JJ persistent) (NN Doc_15985056_186_193_Disease))) (PP (IN after) (S (VP (VBG beginning) (NP (NNP Doc_15985056_210_222_Chemical)) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NNP Doc_15985056_244_255_Disease)))))))))) (. .)))
15985056	3	(S1 (S (NP (NN Doc_15985056_257_264_Disease)) (VP (AUX were) (ADJP (ADJP (JJ persistent)) (CC and) (ADJP (JJ exhausting)))) (. .)))
15985056	4	(S1 (S (NP (NP (NP (NN Discontinuation)) (PP (IN of) (NP (NNP Doc_15985056_316_328_Chemical)))) (CC and) (NP (NP (NN therapy)) (PP (IN with) (NP (NNP Doc_15985056_346_354_Chemical))))) (ADVP (RB finally)) (VP (VBD resolved) (NP (NNP Doc_15985056_372_379_Disease))) (. .)))
15985056	5	(S1 (S (NP (NP (DT No) (JJ organic) (NN cause)) (PP (IN of) (NP (NNP Doc_15985056_401_408_Disease)))) (VP (AUX was) (VP (VBN identified) (PP (IN despite) (NP (JJ extensive) (NN investigation))))) (. .)))
15985056	6	(S1 (S (NP (JJ Pharmacotherapeutic) (NNS agents)) (VP (AUX have) (VP (AUX been) (ADVP (RB uncommonly)) (VP (VBN associated) (PP (IN with) (NP (NN Doc_15985056_533_540_Disease)))))) (. .)))
15985056	7	(S1 (S (NP (NP (NP (NNP Doc_15985056_542_557_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_15985056_559_572_Chemical) (CC and) (NNP Doc_15985056_577_595_Chemical)) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Doc_15985056_598_613_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_15985056_615_624_Chemical)) (-RRB- -RRB-))) (CC and) (NP (JJ general) (NNS anaesthesia))) (VP (AUX have) (VP (AUX been) (NP (NP (DT the) (JJ specific) (NNS agents)) (VP (VBN mentioned) (ADVP (RBS most) (RB frequently)) (PP (IN in) (NP (DT the) (NN literature))) (PP (IN as) (S (VP (AUXG being) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_15985056_768_775_Disease))))))))))))) (. .)))
15985056	8	(S1 (S (NP (NP (JJ Few) (NNS cases)) (PP (IN of) (NP (JJ drug-induced) (NNP Doc_15985056_803_810_Disease)))) (VP (AUX have) (VP (AUX been) (VP (VBN reported) (PP (VBN related) (PP (TO to) (NP (JJ Doc_15985056_841_850_Chemical) (NNS antimicrobials))))))) (. .)))
15985056	9	(S1 (S (S (VP (VBG Using) (NP (DT the) (NNP Naranjo) (JJ adverse) (NN effect) (NN reaction) (NN probability) (NN scale)) (NP (DT this) (NN event)))) (VP (MD could) (VP (AUX be) (VP (VBN classified) (PP (IN as) (NP (NP (JJ possible)) (PRN (-LRB- -LRB-) (NP (NN score) (CD 5) (NNS points)) (-RRB- -RRB-)))) (, ,) (PP (ADVP (RB mostly)) (IN because) (IN of) (NP (NP (DT the) (JJ close) (JJ temporal) (NN sequence)) (, ,) (NP (NP (JJ previous) (NNS reports)) (PP (IN on) (NP (NP (DT this) (NN reaction)) (PP (IN with) (NP (JJ other) (NNP Doc_15985056_1080_1090_Chemical)))))) (CC and) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (NP (DT any) (JJ alternative) (NN explanation)) (PP (IN for) (NP (NNP Doc_15985056_1142_1149_Disease))))))))))) (. .)))
15985056	10	(S1 (S (NP (PRP$ Our) (NN hypothesis)) (VP (AUX is) (SBAR (IN that) (S (NP (NP (DT a) (JJ vagal) (NN mechanism)) (VP (VBN mediated) (PP (IN by) (NP (NNP Doc_15985056_1204_1216_Chemical))))) (VP (MD could) (VP (AUX be) (NP (NP (DT the) (NN pathogenesis)) (PP (IN of) (NP (NNP Doc_15985056_1246_1253_Disease))) (PP (IN in) (NP (PRP$ our) (NN patient))))))))) (. .)))
15985056	11	(S1 (S (NP (NP (NN Diagnosis)) (PP (IN of) (NP (JJ drug-induced) (NNP Doc_15985056_1309_1316_Disease)))) (VP (VP (AUX is) (ADJP (JJ difficult))) (CC and) (ADVP (RB often)) (VP (VBN achieved) (ADVP (RB only)) (PP (IN by) (NP (NP (DT a) (NN process)) (PP (IN of) (NP (NN elimination))))))) (. .)))
15985056	12	(S1 (S (ADVP (RB However)) (, ,) (NP (NNP Doc_15985056_1392_1401_Chemical) (NNS antimicrobials)) (VP (AUX have) (VP (AUX been) (VP (VBN reported) (S (VP (TO to) (VP (AUX be) (VP (VBN associated) (SBAR (IN with) (S (NP (NP (NNP Doc_15985056_1458_1465_Disease)) (CC and) (NP (JJ vagal) (NN mechanism))) (VP (MD could) (VP (VB explain) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (DT this) (NN side-effect))))))))))))))) (. .)))
16006300	0	(S1 (NP (NP (NNP Doc_16006300_0_17_Chemical) (NNP Doc_16006300_18_26_Disease)) (: :) (NP (DT the) (VBN updated) (NNP Doc_16006300_40_60_Disease)) (: ;) (NP (NP (NN report)) (PP (IN of) (NP (NP (CD 3) (NNS cases)) (CC and) (NP (NP (NN review)) (PP (IN of) (NP (DT the) (NN literature))))))) (. .)))
16006300	1	(S1 (FRAG (S (VP (TO To) (VP (VP (VB describe) (NP (NP (CD 3) (NNS patients)) (PP (IN with) (NP (NNP Doc_16006300_149_166_Chemical-induced) (NNP Doc_16006300_175_188_Disease))))) (CC and) (VP (VB gain) (NP (NP (NNS insights)) (PP (IN into) (NP (NP (DT the) (NN cause) (CC and) (NN management)) (PP (IN of) (NP (DT the) (NNP Doc_16006300_244_264_Disease)))))))))) (. .)))
16006300	2	(S1 (S (NP (PRP We)) (VP (VP (VBP report) (NP (NP (DT the) (JJ clinical) (CC and) (NN laboratory) (NNS data)) (PP (IN in) (NP (NP (CD 3) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD presented) (PP (IN with) (NP (JJ severe) (NNP Doc_16006300_358_371_Disease)))))) (PRN (-LRB- -LRB-) (VP (VBN corrected) (NP (NP (NN serum) (JJ Doc_16006300_389_396_Chemical) (NN >)) (CC or) (NP (QP (SYM =) (CD 14) (CD mg/dL))))) (-RRB- -RRB-)))))) (CC and) (VP (VBP review) (NP (NP (DT the) (JJ pertinent) (NN literature)) (PP (IN on) (NP (NNP Doc_16006300_453_473_Disease)))))) (. .)))
16006300	3	(S1 (S (NP (DT The) (CD 3) (NNS patients)) (VP (AUX had) (NP (NP (NN Doc_16006300_503_528_Disease)) (, ,) (NP (JJ relative) (NN Doc_16006300_539_558_Disease)) (, ,) (CC and) (NP (NP (JJ low) (NN parathyroid) (NN hormone)) (PRN (-LRB- -LRB-) (NP (NNP PTH)) (-RRB- -RRB-))) (, ,) (NP (JJ PTH-related) (NN peptide)) (, ,) (CC and) (NP (JJ Doc_16006300_620_643_Chemical) (NNS concentrations)))) (. .)))
16006300	4	(S1 (S (NP (DT No) (JJ malignant) (NN lesion)) (VP (AUX was) (VP (VBN found))) (. .)))
16006300	5	(S1 (S (NP (NN Treatment)) (VP (VBD included) (NP (NP (JJ aggressive) (NN hydration)) (CC and) (NP (NP (JJ varied) (NNS amounts)) (PP (IN of) (NP (NNP Doc_16006300_753_763_Chemical)))))) (. .)))
16006300	6	(S1 (S (NP (NP (DT The) (CD 2) (NNS patients)) (PP (IN with) (NP (DT the) (JJR higher) (NN serum) (JJ Doc_16006300_802_809_Chemical) (NNS concentrations)))) (VP (VBD received) (NP (NP (JJ Doc_16006300_834_845_Chemical) (NN intravenously)) (PRN (-LRB- -LRB-) (NP (NP (CD 60) (CC and) (CD 30) (NNS mg)) (, ,) (ADVP (RB respectively))) (-RRB- -RRB-)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD caused) (NP (JJ severe) (NN Doc_16006300_910_922_Disease))))))) (. .)))
16006300	7	(S1 (S (PP (IN Of) (NP (DT the) (CD 3) (NNS patients))) (, ,) (NP (CD 2)) (VP (AUX were) (VP (VBG ingesting) (NP (NP (JJ acceptable) (NNS doses)) (PP (IN of) (NP (NP (JJ elemental) (NNP Doc_16006300_990_997_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 1) (NNP g)) (CC and) (NP (NP (CD 2) (NNP g) (NNP daily)) (, ,) (ADVP (RB respectively)))) (-RRB- -RRB-))))) (PP (IN in) (NP (NP (DT the) (NN form)) (PP (IN of) (NP (NNP Doc_16006300_1047_1064_Chemical))))))) (. .)))
16006300	8	(S1 (S (PP (IN In) (NP (NP (NN addition)) (PP (TO to) (NP (PRP$ our) (VBN highlighted) (NNS cases))))) (, ,) (NP (PRP we)) (VP (VP (VBP review) (NP (NP (DT the) (NN history) (, ,) (NN classification) (, ,) (JJ pathophysiologic) (NNS features)) (, ,) (CC and) (NP (NP (NN treatment)) (PP (IN of) (NP (NNP Doc_16006300_1187_1207_Disease)))))) (CC and) (VP (VB summarize) (NP (NP (DT the) (NNS cases)) (VP (VBN reported) (PP (IN from) (NP (JJ early) (CD 1995))) (PP (TO to) (NP (NNP November) (CD 2003))))))) (. .)))
16006300	9	(S1 (S (NP (NN Doc_16006300_1287_1307_Disease)) (VP (VP (MD may) (VP (AUX be) (NP (NP (DT a) (JJ common) (NN cause)) (PP (IN of) (NP (JJ unexplained) (NN Doc_16006300_1345_1358_Disease)))))) (CC and) (VP (MD can) (VP (AUX be) (VP (VBD precipitated) (PP (IN by) (NP (NP (JJ small) (NNS amounts)) (PP (IN of) (NP (NP (ADJP (RB orally) (VBN ingested)) (NNP Doc_16006300_1419_1436_Chemical)) (PP (IN in) (NP (JJ susceptible) (NNS persons))))))))))) (. .)))
16006300	10	(S1 (S (NP (NP (NP (NN Treatment)) (PP (IN with) (NP (NN hydration)))) (, ,) (NP (NP (NNP Doc_16006300_1487_1497_Chemical) (, ,) (CC and) (NN discontinuation)) (PP (IN of) (NP (DT the) (NNP Doc_16006300_1526_1533_Chemical)))) (CC and) (NP (JJ Doc_16006300_1538_1547_Chemical) (NN source))) (VP (AUX is) (ADJP (JJ adequate))) (. .)))
16006300	11	(S1 (S (NP (JJ Doc_16006300_1568_1579_Chemical) (NN treatment)) (VP (AUX is) (VP (VBN associated) (PP (IN with) (NP (NP (JJ considerable) (NN risk)) (PP (IN for) (NP (NNP Doc_16006300_1631_1643_Disease))))) (, ,) (PP (ADVP (RB even)) (IN in) (NP (NP (NNS cases)) (PP (IN of) (NP (ADJP (RB initially) (JJ severe)) (NNP Doc_16006300_1679_1692_Disease))))))) (. .)))
16047871	0	(S1 (NP (JJ Doc_16047871_0_8_Chemical-induced) (NN Doc_16047871_17_44_Disease) (. .)))
16047871	1	(S1 (S (NP (NP (NN Skin) (NNS reactions)) (VP (VBN associated) (PP (IN with) (NP (JJ oral) (JJ Doc_16047871_82_90_Chemical-derived) (NNS anticoagulants))))) (VP (AUX are) (NP (DT an) (JJ uncommon) (NN occurrence))) (. .)))
16047871	2	(S1 (S (NP (NP (NN Doc_16047871_142_169_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_16047871_171_173_Disease)) (-RRB- -RRB-))) (VP (AUX is) (ADVP (RB primarily)) (NP (DT a) (NN Doc_16047871_190_223_Disease)) (, ,) (SBAR (IN though) (S (NP (JJ systemic) (NN involvement)) (VP (MD may) (VP (AUX be) (VP (VBN encountered))))))) (. .)))
16047871	3	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (CD 4) (NNS patients)) (PP (IN with) (NP (JJ late-onset) (NN Doc_16047871_310_312_Disease)))) (PP (ADVP (RB probably)) (JJ due) (PP (TO to) (NP (NNP Doc_16047871_329_337_Chemical))))) (. .)))
16047871	4	(S1 (S (NP (DT All) (CD 4) (NNS patients)) (VP (VBD presented) (PP (IN with) (NP (NP (NN Doc_16047871_369_383_Disease)) (SBAR (WHNP (WDT that)) (S (VP (VBD developed) (PP (IN after) (S (VP (VBG receiving) (NP (NN Doc_16047871_415_423_Chemical)) (PP (IN for) (NP (JJ several) (NNS years)))))))))))) (. .)))
16047871	5	(S1 (S (NP (NP (DT The) (NNS results)) (PP (IN of) (NP (JJ Doc_16047871_458_469_Disease) (NNS biopsies)))) (VP (AUX were) (ADJP (JJ available)) (PP (IN in) (NP (CD 3) (NNS patients))) (, ,) (S (VP (VBG confirming) (NP (NP (NNP Doc_16047871_520_540_Disease)) (VP (VBN resolved) (PP (IN in) (NP (DT all) (NNS patients))) (SBAR (IN after) (S (NP (NNP Doc_16047871_572_580_Chemical)) (VP (AUX was) (VP (VBN discontinued)))))))))) (. .)))
16047871	6	(S1 (S (PP (IN In) (NP (NP (CD 2)) (PP (IN of) (NP (DT the) (CD 4) (NNS patients))))) (, ,) (NP (NP (NN rechallenge)) (PP (IN with) (NP (NNP Doc_16047871_640_648_Chemical)))) (VP (VBD led) (PP (TO to) (NP (NP (NN recurrence)) (PP (IN of) (NP (DT the) (NNS lesions)))))) (. .)))
16047871	7	(S1 (S (NP (NN Doc_16047871_683_685_Disease)) (VP (MD may) (VP (AUX be) (NP (NP (DT a) (JJ late-onset) (JJ adverse) (NN reaction)) (VP (VBN associated) (PP (IN with) (NP (JJ Doc_16047871_739_747_Chemical) (NN therapy))))))) (. .)))
1610717	0	(S1 (S (NP (JJ Doc_1610717_0_7_Chemical-induced)) (VP (VBP brainstem) (NP (NP (NN Doc_1610717_26_34_Disease)) (CC and) (NP (NN behavior)))) (. .)))
1610717	1	(S1 (S (NP (NP (DT A) (NN variety)) (PP (IN of) (NP (NP (JJ abnormal) (NN sensory/motor) (NNS behaviors)) (VP (VBN associated) (PP (IN with) (NP (NP (JJ electrical) (NNS discharges)) (VP (VBN recorded) (PP (IN from) (NP (DT the) (JJ bilateral) (NN brainstem)))))))))) (VP (AUX were) (VP (VBN induced) (PP (IN in) (NP (JJ adult) (JJ WKY) (NNS rats))) (PP (PP (IN by) (NP (NP (JJ mechanical) (-LRB- -LRB-) (JJ electrode) (NNS implants) (-RRB- -RRB-)) (CC and) (NP (JJ DC) (JJ electrical) (JJ current) (NNS stimulations)))) (CC and) (PP (IN by) (NP (NP (ADJP (JJ acute) (CC and) (JJ chronic)) (NN administration)) (PP (IN of) (NP (NNP Doc_1610717_319_326_Chemical)))))))) (. .)))
1610717	2	(S1 (S (S (NP (DT The) (NN electrode) (NN implant)) (VP (VBN implicated) (NP (NP (NP (CD one) (NN side)) (CC or) (NP (DT the) (JJ other))) (PP (IN of) (NP (NP (DT the) (JJ reticular) (NN system)) (PP (IN of) (NP (DT the) (NN brainstem)))))))) (CC but) (S (NP (NNS subjects)) (VP (AUX were) (RB not) (VP (VBN incapacitated) (PP (IN by) (NP (DT the) (NNS stimulations)))))) (. .)))
1610717	3	(S1 (S (NP (NP (NN Doc_1610717_481_488_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 40) (NN mg/kg)) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN injected) (ADVP (RB subcutaneously)) (PP (IN for) (NP (NP (DT an) (JJ acute) (NN experiment)) (CC and) (NP (JJ subsequent) (ADJP (CD 20) (NN mg/kg)) (NNS doses)))) (ADVP (RB twice) (RB daily)) (PP (IN for) (NP (CD 3) (NNS days))) (PP (IN in) (NP (DT a) (JJ chronic) (NN study))))) (. .)))
1610717	4	(S1 (S (NP (NN Doc_1610717_625_632_Chemical)) (VP (VBD generated) (NP (ADJP (RBR more) (JJ abnormal)) (NNS behaviors)) (PP (IN in) (NP (DT the) (NN brainstem) (NN perturbation) (NN group))) (, ,) (NP (RB especially) (DT the) (ADJP (RB electrically) (JJ perturbated)) (NNS subjects))) (. .)))
1610717	5	(S1 (S (NP (DT The) (JJ abnormal) (NNS behaviors)) (VP (AUX were) (VP (VBG yawning) (, ,) (S (NP (NP (NN retrocollis)) (, ,) (NP (NP (NNP Doc_1610717_804_817_Disease)) (, ,) (NP (NNP Doc_1610717_819_835_Disease))) (, ,)) (VP (`` ``) (NN beating) (VB drum) ('' '') (NP (NP (NN behavior)) (, ,) (NP (NN squealing)) (, ,) (NP (NN head) (NN bobbing)) (, ,) (NP (NN circling)) (, ,) (NP (VBG sniffing)) (, ,) (NP (JJ abnormal) (NN posturing)) (, ,) (CC and) (NP (JJ facial) (NN twitching))))))) (. .)))
1610717	6	(S1 (S (NP (NP (NNS Shifts)) (PP (IN in) (NP (NP (DT the) (NN power) (NN frequency) (NNP spectra)) (PP (IN of) (NP (DT the) (NN discharge) (NNS patterns)))))) (VP (AUX were) (VP (VBN noted) (PP (IN between) (NP (UCP (JJ quiet) (CC and) (NN pacing)) (JJ behavioral) (NNS states))))) (. .)))
1610717	7	(S1 (S (S (NP (NP (NN Doc_1610717_1068_1084_Disease)) (PP (TO to) (NP (NP (JJ various) (NN auditory)) (, ,) (NP (NN tactile)) (, ,) (CC and) (NP (JJ visual) (NN stimulation))))) (VP (AUX was) (ADJP (JJ present)))) (CC and) (S (NP (NP (NNS shifts)) (PP (IN in) (NP (DT the) (NN brainstem) (NN ambient) (NN power) (NN spectral) (NN frequency)))) (VP (VBD occurred) (PP (IN in) (NP (NP (NN response)) (PP (TO to) (NP (JJ tactile) (NN stimulation))))))) (. .)))
1610717	8	(S1 (S (NP (DT These) (NNS findings)) (VP (VBP suggest) (SBAR (IN that) (S (NP (DT the) (NN brainstem)) (VP (VBZ generates) (CC and) (VBZ propagates) (NP (NP (JJ pathological) (NNS discharges)) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (AUX be) (VP (VBN elicited) (PP (IN by) (NP (JJ mechanical) (CC and) (JJ DC) (JJ electrical) (NN perturbation))))))))))))) (. .)))
1610717	9	(S1 (S (NP (NN Doc_1610717_1414_1421_Chemical)) (VP (AUX was) (VP (VBN found) (S (VP (TO to) (VP (VBP activate) (NP (DT the) (NN discharge) (NN system))) (CC and) (ADVP (RB thus)) (VP (VB induce) (NP (NP (JJ abnormal) (NNS behaviors)) (SBAR (WHNP (WDT that)) (S (VP (AUX are) (VP (VBN generated) (PP (PP (IN at) (NP (DT the) (NN discharge) (NN site))) (CC and) (PP (IN at) (NP (NP (JJ distant) (NNS sites)) (SBAR (WHPP (TO to) (WHNP (WDT which))) (S (NP (DT the) (NN discharge)) (VP (VBZ propagates))))))))))))))))) (. .)))
1610717	10	(S1 (S (S (NP (JJ Cognitive) (NNS functions)) (VP (MD may) (ADVP (RB also)) (VP (AUX be) (VP (VBN involved) (PP (IN since) (NP (NN dopaminergic))))))) (CC and) (S (NP (NP (JJ serotonergic) (JJ cellular) (NNS elements)) (PP (IN at) (NP (DT the) (NN brainstem) (NN level)))) (VP (AUX are) (ADVP (RB also)) (VP (VBN implicated)))) (. .)))
16116131	0	(S1 (S (NP (NP (NNS rTMS)) (PP (IN of) (NP (NN supplementary) (NN motor) (NN area) (NNS modulates)))) (VP (VBD therapy-induced) (NP (NNP Doc_16116131_59_70_Disease)) (PP (IN in) (NP (NNP Doc_16116131_74_91_Disease)))) (. .)))
16116131	1	(S1 (S (NP (NP (NP (DT The) (JJ neural) (NNS mechanisms)) (CC and) (NP (NN circuitry))) (VP (VBN involved) (PP (IN in) (NP (NNP Doc_16116131_141_149_Chemical-induced) (NNP Doc_16116131_158_168_Disease))))) (VP (AUX are) (ADJP (JJ unclear))) (. .)))
16116131	2	(S1 (S (S (VP (VBG Using) (NP (NP (JJ repetitive) (JJ transcranial) (JJ magnetic) (NN stimulation)) (PRN (-LRB- -LRB-) (NP (NNS rTMS)) (-RRB- -RRB-))) (PP (IN over) (NP (NP (DT the) (JJ supplementary) (NN motor) (NN area)) (PRN (-LRB- -LRB-) (NP (NNP SMA)) (-RRB- -RRB-)))) (PP (IN in) (NP (NP (DT a) (NN group)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ advanced) (NNP Doc_16116131_317_334_Disease))))))))) (, ,) (NP (DT the) (NNS authors)) (VP (VBD investigated) (SBAR (IN whether) (S (NP (NP (NN modulation)) (PP (IN of) (NP (NN SMA) (NN excitability)))) (VP (MD may) (VP (VB result) (PP (IN in) (NP (NP (DT a) (NN modification)) (PP (IN of) (NP (NP (DT a) (JJ Doc_16116131_434_444_Disease) (NN state)) (VP (VBN induced) (PP (IN by) (NP (JJ continuous) (JJ Doc_16116131_473_484_Chemical) (NN infusion))))))))))))) (. .)))
16116131	3	(S1 (S (NP (NP (NNS rTMS)) (PP (IN at) (NP (CD 1) (NN Hz)))) (VP (AUX was) (VP (VBN observed) (S (VP (TO to) (VP (ADVP (RB markedly)) (VB reduce) (NP (NNP Doc_16116131_540_564_Disease))))) (, ,) (SBAR (IN whereas) (S (NP (NN 5-Hz) (NNS rTMS)) (VP (VBN induced) (UCP (DT a) (ADJP (JJ slight)) (CC but) (RB not) (NP (JJ significant) (NN increase)))))))) (. .)))
16132524	0	(S1 (NP (NP (NP (NP (JJ Intracavitary) (JJ chemotherapy)) (PRN (-LRB- -LRB-) (NP (JJ Doc_16132524_28_38_Chemical/Doc_16132524_39_50_Chemical) (JJ liquid) (JJ crystalline) (JJ cubic) (NNS phases)) (-RRB- -RRB-))) (PP (IN for) (NP (JJ recurrent) (NNP Doc_16132524_98_110_Disease)))) (: --) (NP (JJ clinical) (NNS observations)) (. .)))
16132524	1	(S1 (S (NP (JJ Human) (JJ malignant) (NN Doc_16132524_153_165_Disease)) (VP (AUX have) (NP (DT a) (JJ poor) (NN prognosis)) (PP (IN in) (NP (NP (NN spite)) (PP (IN of) (NP (NP (NN surgery)) (CC and) (NP (NN radiation) (NN therapy))))))) (. .)))
16132524	2	(S1 (S (NP (JJ Cubic) (NNS phases)) (VP (VBP consist) (PP (IN of) (NP (JJ curved) (JJ biocontinuous) (NN lipid) (NNS bilayers))) (, ,) (S (VP (VBG separating) (NP (NP (CD two) (JJ congruent) (NNS networks)) (PP (IN of) (NP (NN water) (NNS channels))))))) (. .)))
16132524	3	(S1 (S (S (VP (VBN Used) (PP (IN as) (NP (NP (DT a) (NN host)) (PP (IN for) (NP (JJ cytotoxic) (NNS drugs))))))) (, ,) (NP (DT the) (JJ gel-like) (NNP matrix)) (VP (MD can) (ADVP (RB easily)) (VP (AUX be) (VP (VBN applied) (PP (TO to) (NP (NP (DT the) (NNS walls)) (PP (IN of) (NP (DT a) (JJ surgical) (NN resection) (NN cavity)))))))) (. .)))
16132524	4	(S1 (S (PP (IN For) (NP (JJ human) (JJ Doc_16132524_478_490_Disease) (NNS recurrences))) (, ,) (NP (NP (DT the) (NN feasibility) (, ,) (NN safety) (, ,) (CC and) (JJ short-term) (NNS effects)) (PP (IN of) (NP (NP (DT a) (JJ surgical) (NN intracavitary) (NN application)) (PP (IN of) (NP (NP (NNP Doc_16132524_595_605_Chemical)) (CC and) (NP (NNP Doc_16132524_610_621_Chemical)))) (VP (VBN encapsulated) (PP (IN by) (NP (JJ liquid) (JJ crystalline) (JJ cubic) (NNS phases))))))) (VP (AUX are) (VP (VBN examined) (PP (IN in) (NP (DT a) (NN pilot) (NN study))))) (. .)))
16132524	5	(S1 (S (NP (NP (DT A) (NN total)) (PP (IN of) (NP (NP (CD 12) (NNS patients)) (PP (IN with) (NP (NP (DT a) (NN recurrence)) (PP (IN of) (NP (DT a) (NNP Doc_16132524_747_759_Disease) (NN multiforme)))))))) (VP (VP (VBD underwent) (NP (NN re-resection))) (CC and) (VP (VBD received) (NP (NP (DT an) (JJ intracavitary) (NN application)) (PP (IN of) (NP (NP (NNP Doc_16132524_839_849_Chemical)) (CC and) (NP (JJ Doc_16132524_854_865_Chemical) (JJ cubic) (NNS phases)))) (PP (IN in) (NP (JJ different) (NNS dosages)))))) (. .)))
16132524	6	(S1 (S (NP (NP (CD Six)) (PP (IN of) (NP (DT the) (NNS patients)))) (VP (VP (VBD received) (NP (QP (JJR more) (IN than) (CD 15)) (NNS mg)) (NP (NNP Doc_16132524_946_956_Chemical))) (CC and) (VP (VBD suffered) (PP (IN from) (ADJP (JJ moderate) (TO to) (JJ severe))) (NP (NNP Doc_16132524_994_1005_Disease)) (, ,) (SBAR (IN while) (S (NP (DT the) (JJ remaining) (NNS patients)) (VP (VBD received) (NP (NP (RB only) (DT a) (NN total)) (PP (IN of) (NP (CD 15) (NN mg) (NNP Doc_16132524_1067_1077_Chemical))))))))) (. .)))
16132524	7	(S1 (S (PP (IN In) (NP (DT the) (JJ latter) (NN group))) (, ,) (NP (NNP Doc_16132524_1100_1111_Disease)) (VP (VP (AUX was) (ADVP (RB markedly)) (VP (VBN reduced))) (CC and) (VP (VBD dealt) (ADVP (RB medically)))) (. .)))
16132524	8	(S1 (S (S (NP (NP (JJ Intracavitary) (NN chemotherapy)) (PP (IN in) (NP (JJ recurrent) (NNP Doc_16132524_1194_1206_Disease))) (VP (VBG using) (NP (JJ cubic) (NNS phases)))) (VP (AUX is) (ADJP (ADJP (JJ feasible)) (CC and) (ADJP (JJ safe))))) (, ,) (CC yet) (S (NP (DT the) (JJ clinical) (NN benefit)) (VP (VBZ remains) (S (VP (TO to) (VP (AUX be) (VP (VBN examined) (PP (IN in) (NP (DT a) (JJ clinical) (NN phase) (NNP II) (NN study))))))))) (. .)))
16157917	0	(S1 (S (NP (NN Doc_16157917_0_11_Chemical)) (VP (VBN associated) (PP (PP (IN with) (NP (NN exacerbation))) (CC or) (PP (IN de) (NP (NP (NNP novo) (NNP Doc_16157917_52_61_Disease)) (PP (IN in) (NP (NNP Doc_16157917_65_98_Disease))))))) (. .)))
16157917	1	(S1 (S (NP (NP (CD Five) (NNS patients)) (PP (IN with) (NP (NP (NNP Doc_16157917_119_152_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_16157917_154_157_Disease)) (-RRB- -RRB-)))) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_16157917_172_183_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_16157917_185_188_Chemical)) (-RRB- -RRB-)))))) (VP (VBD experienced) (NP (NP (NN exacerbation)) (CC or) (NP (NP (FW de) (FW novo) (NN appearance)) (PP (IN of) (NP (NP (NNP Doc_16157917_240_255_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_16157917_257_259_Disease)) (-RRB- -RRB-))))))) (. .)))
16157917	2	(S1 (S (PP (IN In) (NP (CD three) (NNS patients))) (, ,) (NP (NNP Doc_16157917_281_284_Chemical)) (VP (VBD exacerbated) (NP (NNP Doc_16157917_297_299_Disease)) (PP (IN in) (NP (DT a) (JJ dose-dependent) (NN manner))) (PP (IN with) (NP (JJ early) (NN aggravation))) (PP (IN during) (NP (NN titration)))) (. .)))
16157917	3	(S1 (S (NP (NN Doc_16157917_368_370_Disease)) (VP (VBD disappeared) (SBAR (WHADVP (WRB when)) (S (NP (JJ Doc_16157917_388_391_Chemical) (NN dose)) (VP (AUX was) (VP (VBN decreased) (PP (IN by) (NP (QP (CD 25) (TO to) (CD 50)) (NN %)))))))) (. .)))
16157917	4	(S1 (S (PP (IN In) (NP (CD two) (NNS patients))) (, ,) (NP (NNP Doc_16157917_442_445_Chemical)) (VP (VBD exacerbated) (NP (NNP Doc_16157917_458_460_Disease)) (PP (IN in) (NP (DT a) (ADJP (ADJP (VBN delayed)) (CC but) (ADJP (RBR more) (JJ severe))) (NN manner))) (, ,) (PP (IN with) (NP (NP (NN Doc_16157917_503_519_Disease)) (SBAR (WHNP (WDT that)) (S (ADVP (RB only)) (VP (VBD ceased) (PP (IN after) (S (VP (VBG LTG) (NP (NN withdrawal))))))))))) (. .)))
16174948	0	(S1 (NP (NP (NN Absence)) (PP (IN of) (NP (JJ acute) (JJ cerebral) (NN vasoconstriction))) (PP (IN after) (NP (NNP Doc_16174948_49_56_Chemical-associated) (NNP Doc_16174948_68_91_Disease))) (. .)))
16174948	1	(S1 (S (NP (JJ Doc_16174948_107_114_Chemical) (NN use)) (VP (AUX has) (VP (AUX been) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_16174948_144_171_Disease))) (, ,) (PP (VBG including) (NP (NP (JJ arterial) (NN vasoconstriction)) (CC and) (NP (NN Doc_16174948_213_223_Disease))))))) (. .)))
16174948	2	(S1 (S (ADVP (RB However)) (, ,) (NP (EX there)) (VP (AUX are) (NP (NP (JJ few) (NNS studies)) (PP (IN of) (NP (NP (JJ angiographic) (NNS effects)) (PP (IN of) (NP (NNP Doc_16174948_283_290_Chemical))))) (PP (IN on) (NP (JJ human) (JJ cerebral) (NNS arteries))))) (. .)))
16174948	3	(S1 (S (NP (NP (NN Information)) (PP (IN on) (NP (DT these) (NNS effects)))) (VP (MD could) (VP (AUX be) (VP (VBN obtained) (PP (IN from) (NP (NP (NNS angiograms)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NNP Doc_16174948_399_406_Chemical-associated) (NNP Doc_16174948_418_441_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_16174948_443_446_Disease)) (-RRB- -RRB-)))) (SBAR (WHNP (WP who)) (S (VP (VBD underwent) (NP (NN angiography)) (PP (ADVP (RB shortly)) (IN after) (NP (JJ Doc_16174948_488_495_Chemical) (NN use))))))))))))) (. .)))
16174948	4	(S1 (S (NP (PRP We)) (VP (VP (VBD screened) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_16174948_536_539_Disease) (NN retrospectively))))) (CC and) (VP (VBD identified) (NP (NP (DT those)) (PP (IN with) (NP (NP (JJ positive) (NN urine) (NN toxicology)) (PP (IN for) (NP (NP (NNP Doc_16174948_612_619_Chemical)) (CC or) (NP (PRP$ its) (NNS metabolites))))))))) (. .)))
16174948	5	(S1 (S (NP (NP (JJ Quantitative) (JJ arterial) (NN diameter) (NNS measurements)) (PP (IN from) (NP (NP (NNS angiograms)) (PP (IN of) (NP (DT these) (NNS patients)))))) (VP (AUX were) (VP (VBN compared) (PP (TO to) (NP (NP (NNS measurements)) (PP (IN from) (NP (NN control) (NNS patients))) (PP (IN with) (NP (NP (NNP Doc_16174948_775_778_Disease)) (SBAR (WHNP (WP who)) (S (VP (AUX were) (VP (VBN matched) (PP (IN for) (NP (NP (NNS factors)) (VP (VBN known) (S (VP (TO to) (VP (VB influence) (NP (JJ arterial) (NN diameter)))))))))))))))))) (. .)))
16174948	6	(S1 (S (NP (NP (JJ Qualitative) (NNS comparisons)) (PP (IN of) (NP (JJ small) (NN artery) (NNS changes)))) (ADVP (RB also)) (VP (AUX were) (VP (VBN made))) (. .)))
16174948	7	(S1 (S (NP (NP (JJ Thirteen) (NNS patients)) (PP (IN with) (NP (JJ positive) (JJ Doc_16174948_951_958_Chemical) (NN toxicology)))) (VP (AUX were) (VP (VBN compared) (PP (TO to) (NP (CD 26) (NNS controls))))) (. .)))
16174948	8	(S1 (S (NP (EX There)) (VP (AUX were) (NP (NP (DT no) (JJ significant) (NNS differences)) (PP (IN between) (NP (NP (NNS groups)) (PP (IN in) (NP (NP (NP (DT the) (JJ mean) (NNS diameters)) (PP (IN of) (NP (DT the) (JJ intradural) (JJ internal) (NN carotid)))) (, ,) (NP (NP (JJ sphenoidal) (NN segment)) (PP (IN of) (NP (NP (DT the) (JJ middle) (JJ cerebral) (, ,) (JJ precommunicating) (NN segment)) (PP (IN of) (NP (DT the) (NNP anterior) (NN cerebral)))))) (, ,) (CC or) (NP (NP (NN basilar) (NNS arteries)) (PRN (-LRB- -LRB-) (NP (NP (NNS p)) (NP (NP (QP (JJR greater) (IN than) (CD 0.05))) (PP (IN for) (NP (DT all) (NNS comparisons)))) (, ,) (NP (JJ unpaired) (NNS t-tests))) (-RRB- -RRB-))))))))) (. .)))
16174948	9	(S1 (S (NP (EX There)) (ADVP (RB also)) (VP (AUX were) (NP (NP (DT no) (JJ significant) (NNS differences)) (PP (IN between) (NP (NP (NNS groups)) (SBAR (WHADVP (WRB when)) (S (VP (VBG expressing) (NP (NNS diameters)) (PP (IN as) (NP (NP (DT the) (NN sum)) (PP (IN of) (NP (NP (DT the) (JJ precommunicating) (NN segment)) (PP (IN of) (NP (NP (DT the) (NNP anterior) (JJ cerebral) (NN +) (NN sphenoidal) (NN segment)) (PP (IN of) (NP (DT the) (JJ middle) (JJ cerebral) (NNS +))) (NP (NP (JJ Doc_16174948_1484_1496_Chemical) (JJ internal) (JJ carotid) (NN artery)) (VP (VBG +) (NP (NP (JJ basilar) (NN artery)) (VP (VBN divided) (PP (IN by) (NP (NP (DT the) (NN diameter)) (PP (IN of) (NP (NP (DT the) (JJ petrous) (JJ internal) (NN carotid) (NN artery)) (PRN (-LRB- -LRB-) (NP (NNP p) (QP (JJR greater) (IN than) (CD 0.05))) (, ,) (NP (JJ unpaired) (NNS t-tests)) (-RRB- -RRB-))))))))))))))))))))))) (. .)))
16174948	10	(S1 (S (NP (JJ Qualitative) (NNS assessments)) (VP (VBD showed) (NP (NP (CD two) (JJ arterial) (NNS irregularities)) (PP (IN in) (NP (NP (DT the) (JJ distal) (NN vasculature)) (PP (IN in) (NP (DT each) (NN group))))))) (. .)))
16174948	11	(S1 (S (NP (NP (DT No) (JJ quantitative) (NN evidence)) (PP (IN for) (NP (NP (NN narrowing)) (PP (IN of) (NP (NP (JJ large) (JJ cerebral) (NNS arteries)) (CC or) (NP (JJ qualitative) (JJ angiographic) (NN evidence)))) (PP (IN for) (NP (NP (JJ distal) (NN narrowing)) (CC or) (NP (NNP Doc_16174948_1881_1891_Disease))))))) (VP (MD could) (VP (AUX be) (VP (VBN found) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD underwent) (NP (NN angiography)) (PP (IN after) (NP (NP (NNP Doc_16174948_1951_1961_Disease) (NNP Doc_16174948_1962_1965_Disease)) (VP (VBN associated) (PP (IN with) (NP (JJ Doc_16174948_1982_1989_Chemical) (NN use)))))))))))))) (. .)))
16192988	0	(S1 (S (NP (NP (JJ Doc_16192988_0_15_Chemical) (NNS causes) (NNS alterations)) (PP (IN in) (NP (DT the) (NN MAP)))) (VP (VBD kinase-related) (ADVP (RB pathways)) (PP (IN in) (NP (NP (DT the) (NNS brains)) (PP (IN of) (NP (NNS mice))))) (SBAR (IN that) (S (NP (NN display)) (VP (VBD increased) (NP (NNP Doc_16192988_115_129_Disease)))))) (. .)))
16192988	1	(S1 (S (NP (NNP Doc_16192988_131_151_Disease)) (VP (VP (AUX have) (VP (AUX been) (VP (VBN reported) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBP suffer) (PP (IN from) (NP (DT some) (NN Doc_16192988_204_225_Disease))))))))))) (, ,) (CC and) (VP (AUX are) (ADJP (JJ common) (PP (IN in) (NP (NNP Doc_16192988_245_260_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_16192988_262_266_Chemical)) (-RRB- -RRB-)) (NNS abusers)))))) (. .)))
16192988	2	(S1 (S (NP (NN Herein)) (, ,) (NP (PRP we)) (VP (VBP report) (SBAR (IN that) (S (NP (NP (JJ multiple) (PRN (-LRB- -LRB-) (CC but) (ADJP (RB not) (JJ single)) (-RRB- -RRB-)) (NNS injections)) (PP (IN of) (NP (NNP Doc_16192988_340_344_Chemical)))) (ADVP (RB significantly)) (VP (VBD increased) (NP (NNP Doc_16192988_369_383_Disease)) (PP (IN in) (NP (JJ male) (JJ CD-1) (NNS mice))))))) (. .)))
16192988	3	(S1 (S (NP (NP (DT This) (NN increase)) (PP (IN in) (NP (NNP Doc_16192988_420_434_Disease)))) (VP (AUX was) (RB not) (ADJP (JJ secondary) (PP (TO to) (NP (NNP Doc_16192988_456_460_Chemical-induced) (NNP Doc_16192988_469_482_Disease))))) (. .)))
16192988	4	(S1 (S (NP (NP (NN Analysis)) (PP (IN of) (NP (NP (NN protein) (NN expression)) (VP (VBG using) (NP (NP (NN antibody) (NNS microarrays)) (CC and) (NP (JJ Western) (VBG blotting))))))) (VP (VBD revealed) (NP (NN differential) (NNS changes)) (PP (IN in) (NP (NN MAP) (JJ kinase-related) (NNS pathways))) (PP (IN after) (NP (NP (NN multiple)) (CC and) (NP (JJ single) (JJ Doc_16192988_650_654_Chemical) (NNS injections))))) (. .)))
16192988	5	(S1 (S (S (NP (EX There)) (VP (AUX were) (ADJP (RB statistically) (JJ significant)) (PRN (-LRB- -LRB-) (NP (CD p<0.05)) (-RRB- -RRB-)))) (VP (VP (VBZ decreases) (PP (IN in) (NP (NP (NNP MEK1)) (, ,) (NP (NAC (NNP Erk2p) (, ,) (NNP GSK3alpha) (, ,)) (NN 14-3-3e)) (, ,)))) (CC and) (VP (VBZ MEK7) (PP (IN in) (NP (NP (DT the) (NN striata)) (PP (IN of) (NP (NNS mice))))) (PP (IN after) (NP (NP (JJ multiple) (NNS injections)) (PP (IN of) (NP (NNP Doc_16192988_820_824_Chemical))))))) (. .)))
16192988	6	(S1 (S (NP (NN MEK1)) (VP (AUX was) (ADVP (RB significantly)) (VP (VBN decreased) (ADVP (RB also)) (PP (PP (IN after) (NP (NP (DT a) (JJ single) (NN injection)) (PP (IN of) (NP (NNP Doc_16192988_892_896_Chemical))))) (, ,) (CC but) (PP (TO to) (NP (NP (DT a) (ADJP (RB much) (JJR lesser)) (NN degree)) (PP (IN than) (PP (IN after) (NP (NP (JJ multiple) (NNS injections)) (PP (IN of) (NP (NNP Doc_16192988_960_964_Chemical))))))))))) (. .)))
16192988	7	(S1 (S (PP (IN In) (NP (DT the) (JJ frontal) (NN cortex))) (, ,) (NP (EX there)) (VP (AUX was) (NP (NP (DT a) (ADJP (RB statistically) (JJ significant)) (NN decrease)) (PP (IN in) (NP (NN GSK3alpha))) (PP (IN after) (NP (NP (JJ multiple) (PRN (-LRB- -LRB-) (CONJP (CC but) (RB not)) (ADJP (JJ single)) (-RRB- -RRB-)) (NNS injections)) (PP (IN of) (NP (NNP Doc_16192988_1095_1099_Chemical))))))) (. .)))
16192988	8	(S1 (S (NP (DT These) (NNS findings)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NNS alterations)) (PP (IN in) (NP (NP (NN MAP) (JJ kinase-related) (NNS pathways)) (PP (IN in) (NP (DT the) (JJ prefronto-striatal) (NNS circuitries)))))) (VP (MD might) (VP (AUX be) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (NN manifestation)) (PP (IN of) (NP (NNP Doc_16192988_1252_1272_Disease))) (PP (IN in) (NP (NNS mice))))))))))) (. .)))
16225977	0	(S1 (S (NP (NN Doc_16225977_0_11_Chemical)) (VP (VBD related) (NP (NNP Doc_16225977_20_37_Disease)) (PP (IN in) (NP (DT an) (JJ adolescent) (NN Doc_16225977_55_68_Disease)))) (. .)))
16225977	1	(S1 (S (NP (NN Doc_16225977_70_83_Disease)) (VP (MD can) (VP (AUX be) (ADVP (RB effectively)) (VP (VBN treated) (PP (IN by) (NP (NP (JJ atypical) (NNS antipsychotics)) (PP (JJ such) (IN as) (NP (NP (NNP Doc_16225977_146_157_Chemical)) (, ,) (NP (NNP Doc_16225977_159_169_Chemical)) (CC and) (NP (NNP Doc_16225977_174_185_Chemical))))))))) (. .)))
16225977	2	(S1 (S (ADVP (RB However)) (, ,) (NP (EX there)) (VP (AUX are) (NP (NP (CD two) (NN case) (NNS reports)) (SBAR (WHNP (WDT that)) (S (VP (VBP show) (NP (NN Doc_16225977_233_250_Disease))))) (, ,) (PP (VBG including) (NP (UCP (NN motor) (CC and) (JJ phonic)) (NNS variants))) (, ,) (VP (VBG occurring) (PP (IN during) (NP (NN treatment))) (PP (IN with) (NP (NNP Doc_16225977_321_331_Chemical) (CC or) (NNP Doc_16225977_335_344_Chemical)))))) (. .)))
16225977	3	(S1 (S (NP (PRP We)) (VP (VBP present) (NP (NP (DT a) (JJ 15-year-old) (NN girl) (NN Doc_16225977_376_389_Disease)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (JJ frequent) (NN Doc_16225977_413_447_Disease)) (PP (IN after) (NP (NP (CD 5) (NNS months)) (PP (IN of) (NP (NP (JJ Doc_16225977_466_477_Chemical) (NN treatment)) (PRN (-LRB- -LRB-) (NP (NP (CD 1000) (NN mg)) (PP (IN per) (NP (NN day)))) (-RRB- -RRB-))))))))))) (. .)))
16225977	4	(S1 (S (NP (DT The) (NNP Doc_16225977_511_528_Disease)) (VP (VBD resolved) (ADVP (RB completely)) (SBAR (IN after) (S (NP (PRP we)) (VP (VBD reduced) (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (NNP Doc_16225977_578_589_Chemical)))) (ADVP (RB down)) (PP (TO to) (NP (NP (CD 800) (NNS mg)) (PP (IN per) (NP (NN day))))))))) (. .)))
16225977	5	(S1 (S (ADVP (RB However)) (, ,) (NP (PRP her) (NNP Doc_16225977_627_636_Disease)) (VP (VBD recurred) (PP (IN after) (NP (DT the) (NN dose) (NN reduction)))) (. .)))
16225977	6	(S1 (S (NP (PRP We)) (ADVP (RB then)) (VP (VBD placed) (NP (PRP her)) (PP (IN on) (NP (NP (DT an) (JJ additional) (CD 100) (NNS mg)) (PP (IN per) (NP (NP (NN day)) (PP (IN of) (NP (NNP Doc_16225977_726_736_Chemical)))))))) (. .)))
16225977	7	(S1 (S (NP (PRP She)) (VP (VP (AUX has) (VP (AUX been) (PP (IN in) (NP (JJ complete) (NN remission))) (PP (IN under) (NP (NP (DT the) (VBN combined) (NNS medications)) (PP (IN for) (NP (QP (JJR more) (IN than) (CD one)) (NN year))))))) (CC and) (VP (VBZ maintains) (NP (DT a) (JJ fair) (NN role) (NN function)))) (. .)))
16225977	8	(S1 (S (NP (DT No) (JJR more) (UCP (NNP Doc_16225977_871_888_Disease) (CC or) (JJ other)) (NN side) (NNS effects)) (VP (AUX have) (VP (AUX been) (VP (VBN reported)))) (. .)))
16225977	9	(S1 (S (ADVP (RB Together) (PP (IN with) (NP (ADJP (RB previously) (VBN reported)) (NNS cases)))) (, ,) (NP (PRP$ our) (NN patient)) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NNP Doc_16225977_998_1015_Disease)) (VP (MD might) (VP (VB occur) (PP (IN in) (NP (JJ certain) (JJ vulnerable) (NNS individuals))) (PP (IN during) (NP (NP (NN treatment)) (PP (IN with) (NP (NP (JJ atypical) (NNS antipsychotics)) (PP (JJ such) (IN as) (NP (NP (NNP Doc_16225977_1116_1126_Chemical)) (, ,) (NP (NNP Doc_16225977_1128_1137_Chemical)) (, ,) (CC or) (NP (NNP Doc_16225977_1142_1153_Chemical))))))))))))) (. .)))
1628552	0	(S1 (NP (NP (NP (JJ Doc_1628552_0_11_Chemical) (JJ related) (JJ complete) (NN Doc_1628552_29_40_Disease)) (PP (IN with) (NP (NNP Doc_1628552_46_55_Disease)))) (: :) (NP (NN case) (NN report)) (. .)))
1628552	1	(S1 (S (NP (NP (DT A) (JJ 27-year) (ADJP (JJ old) (JJ African)) (NN woman)) (PP (IN with) (NP (NP (NN history)) (PP (IN of) (NP (JJ regular) (JJ Doc_1628552_122_133_Chemical) (NN ingestion)))))) (VP (VBD presented) (PP (IN with) (NP (NP (JJ progressive) (NN Doc_1628552_171_194_Disease)) (, ,) (NP (JJ easy) (NN Doc_1628552_201_214_Disease)) (, ,) (NP (NN dyspnoea)) (, ,))) (NP (NNP Doc_1628552_226_235_Disease)) (PP (VBG progressing) (PP (TO to) (NP (NNP Doc_1628552_251_267_Disease))))) (. .)))
1628552	2	(S1 (S (NP (JJ Ophthalmological) (NN assessment)) (VP (VBD revealed) (NP (NP (NP (NNS features)) (PP (IN of) (NP (NNP Doc_1628552_318_329_Chemical) (NNP Doc_1628552_330_341_Disease)))) (, ,) (NP (NP (JJ cardiac) (NN assessment) (VBN revealed) (NNS features)) (PP (IN of) (NP (NNP Doc_1628552_383_396_Disease)))) (CC and) (NP (NP (DT a) (JJ complete) (NN Doc_1628552_412_423_Disease)) (PP (IN with) (NP (NNP Doc_1628552_429_454_Disease) (NN pattern)))))) (. .)))
1628552	3	(S1 (S (S (NP (DT The) (NNP Doc_1628552_468_479_Disease)) (VP (AUX was) (VP (VBN treated) (PP (IN by) (NP (NN pacemaker) (NN insertion)))))) (CC and) (S (NP (DT the) (NNP Doc_1628552_523_536_Disease)) (VP (VBD resolved) (ADVP (RB spontaneously)) (PP (VBG following) (NP (JJ Doc_1628552_570_581_Chemical) (NN discontinuation))))) (. .)))
1628552	4	(S1 (S (NP (PRP She)) (ADVP (RB however)) (VP (VBZ remains) (NP (NN Doc_1628552_619_624_Disease))) (. .)))
1636026	0	(S1 (NP (NP (NNS Effects)) (PP (IN of) (NP (NNP Doc_1636026_11_19_Chemical))) (PP (IN on) (NP (DT the) (VBN isolated) (JJ perfused) (NN rat) (NN kidney))) (. .)))
1636026	1	(S1 (S (SBAR (IN Although) (S (NP (NNP Doc_1636026_66_74_Chemical)) (VP (AUX has) (VP (AUX been) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_1636026_119_138_Disease))) (PP (IN in) (NP (QP (JJR greater) (IN than) (CD 100)) (NNS subjects)))))))))) (, ,) (NP (NP (DT the) (NN mechanism)) (PP (IN of) (NP (NN damage)))) (VP (VBZ remains) (ADJP (JJ unclear))) (. .)))
1636026	2	(S1 (S (NP (NP (DT The) (JJ direct) (JJ nephrotoxic) (NNS effects)) (PP (IN of) (NP (NP (DT a) (JJ single) (NN dose)) (PP (IN of) (NP (NP (CD 15) (NN mg)) (PP (IN of) (NP (NNP Doc_1636026_270_278_Chemical)))))))) (VP (AUX were) (VP (VBN compared) (PP (IN in) (NP (DT the) (JJ recirculating) (JJ isolated) (NN rat) (NN kidney))) (PP (VBN perfused) (PP (IN with) (NP (JJ cell-free) (NN buffer)))) (PP (PP (IN with)) (CC or) (PP (IN without) (NP (NP (DT the) (NN addition)) (PP (IN of) (NP (NP (CD 5) (NN mg/dL)) (PP (IN of) (NP (NNP Doc_1636026_408_417_Chemical)))))))))) (. .)))
1636026	3	(S1 (S (NP (EX There)) (VP (AUX were) (NP (NP (DT no) (JJ significant) (NNS differences)) (PP (IN in) (NP (NP (NP (JJ renal) (JJ Doc_1636026_466_472_Chemical) (NN excretion)) (, ,) (NP (JJ Doc_1636026_484_490_Chemical) (NN consumption)) (, ,) (CC or) (NP (JJ urinary) (NN flow) (NNS rates))) (PP (IN in) (NP (NP (NNS kidneys)) (VP (VBN perfused) (PP (IN with) (NP (NNP Doc_1636026_551_559_Chemical))))))))) (PP (VBN compared) (PP (IN with) (NP (DT the) (JJ drug-free) (NN control) (NNS groups))))) (. .)))
1636026	4	(S1 (S (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NP (DT a) (JJ significant) (NN decline)) (PP (IN in) (NP (JJ glomerular) (NN filtration) (NN rate)))) (VP (AUX was) (VP (VBN found) (PP (IN after) (NP (NP (DT the) (NN introduction)) (PP (IN of) (NP (NNP Doc_1636026_705_713_Chemical))) (PP (TO to) (NP (NP (DT the) (NN kidney)) (VP (VBN perfused) (PP (IN with) (NP (NNP Doc_1636026_742_751_Chemical))))))))))) (: ;) (S (NP (DT no) (NNS changes)) (VP (AUX were) (VP (VBN found) (PP (IN with) (NP (NNP Doc_1636026_780_788_Chemical))) (PP (IN in) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (NNP Doc_1636026_807_816_Chemical)))))))) (. .)))
1636026	5	(S1 (S (NP (NP (DT A) (JJ significant) (NN decrease)) (PP (IN in) (NP (NP (DT the) (JJ baseline) (NN excretion) (NN rate)) (PP (IN of) (NP (NNP Doc_1636026_875_884_Chemical)))))) (VP (AUX was) (VP (VBN found) (PP (IN in) (NP (NP (NNS rats)) (VP (VBN given) (NP (NNP Doc_1636026_909_917_Chemical))))) (, ,) (PP (VBN compared) (PP (IN with) (NP (JJ drug-free) (NNS controls)))))) (. .)))
1636026	6	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (JJ fractional) (NN excretion)) (PP (IN of) (NP (NNP Doc_1636026_990_999_Chemical)))) (VP (AUX was) (ADJP (JJ unchanged)) (PP (IN between) (NP (NP (DT the) (NNS groups)) (PP (IN over) (NP (DT the) (JJ experimental) (NN period)))))) (. .)))
1636026	7	(S1 (S (PP (IN In) (NP (NN summary))) (, ,) (NP (NNP Doc_1636026_1075_1083_Chemical)) (VP (VBZ causes) (NP (NP (NNP Doc_1636026_1091_1123_Disease)) (, ,) (ADJP (RBS most) (JJ likely))) (PP (IN by) (S (VP (ADVP (RB directly)) (VBG altering) (NP (NP (DT the) (JJ intrarenal) (NN distribution)) (PP (IN of) (NP (NN Doc_1636026_1189_1198_Chemical)))))))) (. .)))
16364460	0	(S1 (S (NP (NP (NN Microinjection)) (PP (IN of) (NP (NNP Doc_16364460_18_28_Chemical))) (PP (IN into) (NP (NP (DT the) (JJ CA1) (NN region)) (PP (IN of) (NP (NNS hippocampus)))))) (VP (VBZ improves) (NP (NP (JJ Doc_16364460_73_84_Chemical-induced) (NN Doc_16364460_93_100_Disease)) (PP (IN in) (NP (NN adult) (NN male) (NNS rats))))) (. .)))
16364460	1	(S1 (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NP (NNP Doc_16364460_135_145_Chemical)) (PRN (-LRB- -LRB-) (NP (JJ 5-HT2) (NN antagonist)) (-RRB- -RRB-)))) (PP (IN on) (NP (NP (JJ Doc_16364460_168_179_Chemical) (PRN (-LRB- -LRB-) (NP (JJ muscarinic) (JJ cholinergic) (NN antagonist)) (-RRB- -RRB-)) (JJ -induced) (NNP Doc_16364460_224_231_Disease)) (PP (IN in) (NP (NNP Morris) (NN water) (NN maze))) (PRN (-LRB- -LRB-) (NP (NNP MWM)) (-RRB- -RRB-))))) (VP (AUX was) (VP (VBN investigated))) (. .)))
16364460	2	(S1 (S (NP (NNS Rats)) (VP (VP (AUX were) (VP (VBN divided) (PP (IN into) (NP (CD eight) (NNS groups))))) (CC and) (VP (ADVP (RB bilaterally)) (VBN cannulated) (PP (IN into) (NP (NP (JJ CA1) (NN region)) (PP (IN of) (NP (DT the) (NN hippocampus))))))) (. .)))
16364460	3	(S1 (S (ADVP (NP (CD One) (NN week)) (RB later)) (, ,) (NP (PRP they)) (VP (VBD received) (ADVP (RB repeatedly)) (NP (NP (NP (NNS vehicles)) (PRN (-LRB- -LRB-) (NP (NN saline)) (, ,) (NP (NNP Doc_16364460_435_439_Chemical)) (, ,) (NP (NN saline+Doc_16364460_448_452_Chemical)) (-RRB- -RRB-))) (, ,) (NP (NP (NP (NNP Doc_16364460_455_466_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 2) (CD microg/0.5)) (NN microl) (NN saline/side)) (: ;) (NP (NP (CD 30) (NN min)) (PP (IN before) (NP (NN training)))) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Doc_16364460_526_536_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 2)) (, ,) (NP (NP (QP (CD 4) (CC and) (CD 8) (CD microg/0.5)) (JJ microl) (NNP Doc_16364460_567_571_Chemical/side)) (: ;) (NP (NP (CD 20) (NN min)) (PP (IN before) (NP (NN training))))) (-RRB- -RRB-))) (CC and) (NP (NNP Doc_16364460_606_617_Chemical) (PRN (-LRB- -LRB-) (NP (NP (QP (CD 2) (CD microg/0.5)) (NN microl)) (: ;) (NP (NP (CD 30) (NN min)) (PP (IN before) (NP (JJ Doc_16364460_654_664_Chemical) (NN injection))))) (-RRB- -RRB-)) (NN +Doc_16364460_676_686_Chemical)))) (PRN (-LRB- -LRB-) (NP (NP (QP (CD 4) (CD microg/0.5)) (NN microl)) (NP (NNP Doc_16364460_708_712_Chemical))) (-RRB- -RRB-)) (PP (IN through) (NP (NP (NNS cannulae)) (NP (DT each) (NN day))))) (. .)))
16364460	4	(S1 (S (NP (NNS Animals)) (VP (AUX were) (VP (VBN tested) (PP (IN for) (NP (NP (CD four) (JJ consecutive) (NNS days)) (PRN (-LRB- -LRB-) (NP (CD 4) (NN trial/day)) (-RRB- -RRB-)))) (PP (IN in) (NP (NP (CD MWM)) (SBAR (WHPP (IN during) (WHNP (WDT which))) (S (NP (NP (DT the) (NN position)) (PP (IN of) (NP (JJ hidden) (NN platform)))) (VP (AUX was) (ADJP (JJ unchanged))))))))) (. .)))
16364460	5	(S1 (S (PP (IN In) (NP (DT the) (JJ fifth) (NN day))) (, ,) (NP (DT the) (NN platform)) (VP (AUX was) (VP (VBD elevated) (PP (IN above) (NP (NP (DT the) (NN water) (NN surface)) (PP (IN in) (NP (NP (DT another) (NN position)) (SBAR (S (VP (TO to) (VP (VB evaluate) (NP (NP (DT the) (NN function)) (PP (IN of) (NP (UCP (NN motor) (, ,) (JJ motivational) (CC and) (JJ visual)) (NNS systems)))))))))))))) (. .)))
16364460	6	(S1 (S (NP (DT The) (NNS results)) (VP (VP (VBD showed) (NP (NP (DT a) (JJ significant) (NN increase)) (PP (IN in) (NP (NN escape) (NNS latencies))))) (CC and) (VP (VBD traveled) (NP (NP (NNS distances)) (SBAR (S (VP (TO to) (VP (VB find) (NP (NN platform)) (PP (IN in) (NP (JJ Doc_16364460_1129_1140_Chemical-treated) (NN group))) (SBAR (IN as) (S (VP (VBN compared) (PP (TO to) (NP (JJ saline) (NN group))))))))))))) (. .)))
16364460	7	(S1 (S (NP (NP (JJ Doc_16364460_1184_1194_Chemical-treated) (NNS rats)) (PRN (-LRB- -LRB-) (NP (QP (CD 4) (CD microg/0.5)) (NN microl/side)) (-RRB- -RRB-))) (VP (VBD showed) (NP (NP (DT a) (JJ significant) (NN decrease)) (PP (IN in) (NP (DT the) (VBN mentioned) (NNS parameters)))) (SBAR (IN as) (S (VP (VBN compared) (PP (TO to) (NP (JJ Doc_16364460_1308_1312_Chemical-treated) (NN group))))))) (. .)))
16364460	8	(S1 (S (ADVP (RB However)) (, ,) (NP (NNP Doc_16364460_1337_1348_Chemical) (CC and) (NNP Doc_16364460_1353_1363_Chemical) (NN co-administration)) (VP (VP (VBD resulted) (PP (IN in) (NP (NP (DT a) (JJ significant) (NN decrease)) (PP (IN in) (NP (NN escape) (NNS latencies)))))) (CC and) (VP (VBD traveled) (NP (NNS distances)) (ADVP (RB as)) (PP (VBN compared) (PP (TO to) (NP (DT the) (JJ Doc_16364460_1479_1490_Chemical-treated) (NNS rats)))))) (. .)))
16364460	9	(S1 (S (NP (PRP$ Our) (NNS findings)) (VP (VBP show) (SBAR (IN that) (S (NP (NP (NN microinjection)) (PP (IN of) (NP (NNP Doc_16364460_1546_1556_Chemical))) (PP (IN into) (NP (NP (DT the) (JJ CA1) (NN region)) (PP (IN of) (NP (DT the) (NNS hippocampus)))))) (VP (VBZ improves) (NP (DT the) (JJ Doc_16364460_1609_1620_Chemical-induced) (NN Doc_16364460_1629_1636_Disease)))))) (. .)))
16418614	0	(S1 (NP (NP (JJ Doc_16418614_0_3_Chemical-associated) (NN Doc_16418614_15_25_Disease)) (PP (IN in) (NP (NP (DT a) (NN girl)) (PP (IN with) (NP (NP (NNP Doc_16418614_41_56_Disease)) (CC and) (NP (NNP Doc_16418614_61_76_Disease)))))) (. .)))
16418614	1	(S1 (S (NP (NNP Palpable) (NNP Doc_16418614_87_94_Disease)) (VP (VP (AUX is) (NP (NP (DT a) (VBG concerning) (JJ clinical) (NN finding)) (PP (IN in) (NP (JJ pediatric) (NNS patients))))) (CC and) (VP (MD can) (VP (AUX have) (NP (NP (JJ many) (NNS causes)) (, ,) (PP (VBG including) (NP (JJ infectious) (CC and) (JJ autoimmune) (NNS processes))))))) (. .)))
16418614	2	(S1 (S (NP (NP (DT A) (JJ rare) (NN cause)) (, ,) (NP (JJ drug-induced) (NNP Doc_16418614_250_260_Disease)) (, ,)) (VP (MD may) (VP (VB result) (PP (IN from) (NP (NP (DT the) (NN production)) (PP (IN of) (NP (NP (JJ antineutrophil) (JJ cytoplasmic) (NNS antibodies)) (PRN (-LRB- -LRB-) (NP (NNP ANCAs)) (-RRB- -RRB-)))))) (PP (IN in) (NP (NP (NN response)) (PP (TO to) (NP (DT a) (NN medication))))))) (. .)))
16418614	3	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT a) (NN girl)) (PP (IN with) (NP (NP (NNP Doc_16418614_393_408_Disease)) (CC and) (NP (NNP Doc_16418614_413_428_Disease)))) (SBAR (WHNP (WP who)) (S (VP (VBD presented) (PP (IN with) (NP (JJ palpable) (NN Doc_16418614_457_473_Disease)))))))) (. .)))
16418614	4	(S1 (S (NP (NP (DT The) (NN diagnosis)) (PP (IN of) (NP (NP (NNP Doc_16418614_492_508_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_16418614_510_513_Chemical)) (-RRB- -RRB-))))) (VP (VBD -associated) (SBAR (S (NP (NNP Doc_16418614_526_536_Disease)) (VP (AUX was) (VP (VBN made) (PP (IN by) (NP (NP (NP (NN observation)) (PP (IN of) (NP (JJ consistent) (JJ clinical) (NNS features)))) (, ,) (NP (NP (DT the) (NN detection)) (PP (IN of) (NP (NP (JJ elevated) (NNP ANA)) (CC and) (NP (NNP ANCA)))) (PP (IN in) (NP (DT the) (NN blood)))) (, ,) (CC and) (NP (NP (DT the) (JJ observed) (JJ clinical) (NN resolution)) (PP (IN of) (NP (NNS symptoms))) (PP (VBG following) (NP (NP (NN withdrawal)) (PP (IN of) (NP (NNP Doc_16418614_720_723_Chemical))))))))))))) (. .)))
16418614	5	(S1 (S (NP (NP (JJ Subsequent) (NN treatment)) (PP (IN of) (NP (JJ persistent) (NNP Doc_16418614_760_775_Disease))) (PP (IN with) (NP (NN radioablation)))) (VP (AUX did) (RB not) (VP (VB result) (PP (IN in) (NP (NP (NP (DT an) (NN exacerbation)) (PP (IN of) (NP (DT the) (NNP Doc_16418614_836_846_Disease)))) (, ,) (NP (NP (DT a) (NN complication)) (VP (VBN described) (PP (IN in) (NP (JJ prior) (NN case) (NNS reports))))))))) (. .)))
16428827	0	(S1 (S (NP (NN Doc_16428827_0_8_Chemical)) (VP (VP (VBZ activates) (NP (NP (JJ Doc_16428827_19_26_Chemical) (NN acetyltransferase)) (PP (IN from) (NP (JJ MC-IXC) (NNS cells))))) (CC and) (VP (VBZ improves) (NP (JJ drug-induced) (NN Doc_16428827_89_96_Disease)))) (. .)))
16428827	1	(S1 (S (NP (NP (DT The) (JJ Doc_16428827_102_109_Chemical) (NN acetyltransferase) (-LRB- -LRB-) (VB ChAT) (-RRB- -RRB-) (NN activator)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ enhances) (NP (JJ cholinergic) (NN transmission)) (PP (IN via) (NP (NP (DT an) (NN augmentation)) (PP (IN of) (NP (NP (DT the) (JJ enzymatic) (NN production)) (PP (IN of) (NP (NP (NNP Doc_16428827_237_250_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_16428827_252_255_Chemical)) (-RRB- -RRB-))))))))))) (, ,)) (VP (AUX is) (NP (NP (DT an) (JJ important) (NN factor)) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (NNP Doc_16428827_301_320_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_16428827_322_324_Disease)) (-RRB- -RRB-)))))))) (. .)))
16428827	2	(S1 (S (NP (NP (JJ Methanolic) (NNS extracts)) (PP (IN from) (NP (NNP Pueraria) (NNS thunbergiana)))) (VP (VBD exhibited) (NP (NP (DT an) (JJ activation) (NN effect)) (PRN (-LRB- -LRB-) (NP (CD 46) (NN %)) (-RRB- -RRB-))) (PP (IN on) (NP (NP (VB ChAT)) (PP (IN in) (NP (NN vitro)))))) (. .)))
16428827	3	(S1 (S (PP (IN Via) (NP (NP (DT the) (JJ sequential) (NN isolation)) (PP (IN of) (NP (NNP Pueraria) (NNS thunbergiana))))) (, ,) (NP (DT the) (JJ active) (NN component)) (VP (AUX was) (ADVP (RB ultimately)) (VP (VBN identified) (PP (IN as) (NP (NP (NNP Doc_16428827_534_542_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_16428827_544_569_Chemical)) (-RRB- -RRB-)))))) (. .)))
16428827	4	(S1 (S (SBAR (IN In) (NN order) (S (VP (TO to) (VP (VB investigate) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NNP Doc_16428827_611_619_Chemical))) (PP (IN from) (NP (NNP Pueraria) (NNS thunbergiana))) (PP (IN on) (NP (NNP Doc_16428827_650_661_Chemical-induced) (NNP Doc_16428827_670_704_Disease)))))))) (, ,) (NP (PRP we)) (VP (VBD conducted) (NP (NP (DT a) (NN series)) (PP (IN of) (PP (IN in) (NP (NN vivo) (NNS tests)))))) (. .)))
16428827	5	(S1 (S (NP (NP (NN Administration)) (PP (IN of) (NP (NP (NNP Doc_16428827_764_772_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 4.5) (NN mg/kg) (NN body) (NN weight)) (-RRB- -RRB-)))) (PP (TO to) (NP (NNS mice)))) (VP (AUX was) (VP (VBN shown) (ADVP (RB significantly)) (S (VP (TO to) (VP (VB reverse) (NP (JJ Doc_16428827_840_851_Chemical-induced) (NNP Doc_16428827_860_867_Disease))))) (, ,) (PP (VBG according) (PP (TO to) (NP (NP (DT the) (NNS results)) (PP (IN of) (NP (DT a) (JJ Y-maze) (NN test)))))))) (. .)))
16428827	6	(S1 (S (NP (NP (NNS Injections)) (PP (IN of) (NP (NNP Doc_16428827_926_937_Chemical))) (PP (IN into) (NP (NNS mice)))) (VP (VBD resulted) (PP (IN in) (NP (NP (VBN impaired) (NN performance)) (PP (IN on) (NP (NP (JJ Y-maze) (NNS tests)) (PRN (-LRB- -LRB-) (NP (NP (DT a) (CD 37) (NN %) (NNS decreases)) (PP (IN in) (NP (JJ alternation) (NN behavior)))) (-RRB- -RRB-))))))) (. .)))
16428827	7	(S1 (S (PP (IN By) (NP (NP (NN way)) (PP (IN of) (NP (NN contrast))))) (, ,) (NP (NP (NNS mice)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_16428827_1078_1086_Chemical))))) (ADVP (RB prior) (PP (TO to) (NP (DT the) (JJ Doc_16428827_1100_1111_Chemical) (NNS injections)))) (VP (AUX were) (ADVP (RB noticeably)) (VP (VBN protected) (PP (IN from) (NP (NP (DT this) (NN performance) (NN impairment)) (PRN (-LRB- -LRB-) (NP (NP (DT an) (ADJP (QP (RB approximately) (CD 12)) (NN %)) (ADJP (CD -21) (NN %)) (NN decrease)) (PP (IN in) (NP (JJ alternation) (NN behavior)))) (-RRB- -RRB-)))))) (. .)))
16428827	8	(S1 (S (NP (DT These) (NNS results)) (VP (VBP indicate) (SBAR (SBAR (IN that) (S (NP (NNP Doc_16428827_1271_1279_Chemical)) (VP (MD might) (VP (VB play) (NP (NP (DT a) (NN role)) (PP (IN in) (NP (NP (JJ Doc_16428827_1301_1314_Chemical) (NNS biosynthesis)) (PP (IN as) (NP (DT a) (VB ChAT) (NN activator)))))))))) (, ,) (CC and) (SBAR (IN that) (S (NP (PRP it)) (ADVP (RB also)) (VP (VBZ ameliorates) (NP (JJ Doc_16428827_1378_1389_Chemical-induced) (NN Doc_16428827_1398_1405_Disease))))))) (. .)))
16471092	0	(S1 (NP (NP (NP (JJ Urinary) (NNS symptoms)) (CC and) (NP (NP (NN quality)) (PP (IN of) (NP (NN life) (NNS changes))))) (PP (IN in) (NP (NP (NNP Thai) (NNS women)) (PP (IN with) (NP (NNP Doc_16471092_64_82_Disease))))) (PP (IN after) (NP (JJ Doc_16471092_89_100_Chemical) (NN treatment))) (. .)))
16471092	1	(S1 (FRAG (S (VP (TO To) (VP (VB study) (NP (NP (DT the) (NN urinary) (NNS symptoms) (CC and) (NN quality)) (PP (IN of) (NP (NP (NN life) (NNS changes)) (PP (IN in) (NP (NP (NNP Thai) (NNS women)) (PP (IN with) (NP (NP (NNP Doc_16471092_201_219_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_16471092_221_224_Disease)) (-RRB- -RRB-))))))))) (PP (IN after) (NP (JJ Doc_16471092_232_243_Chemical) (NN treatment)))))) (. .)))
16471092	2	(S1 (NP (NP (NP (NN MATERIAL)) (CC AND) (NP (NN METHOD))) (: :) (S (NP (NP (CD Thirty) (NNS women) (PRN (-LRB- -LRB-) (VP (VBN aged) (NP (CD 30-77) (NNS years))) (-RRB- -RRB-))) (VP (VBN diagnosed) (PP (IN as) (S (VP (AUXG having) (NP (NP (NP (NN Doc_16471092_328_331_Disease)) (PP (IN at) (NP (DT the) (NNP Gynecology) (NNP Clinic)))) (, ,) (NP (NNP King) (NNP Chulalongkorn) (NNP Memorial) (NNP Hospital))) (PP (IN from) (NP (NNP January))) (PP (TO to) (NP (NNP April) (CD 2004)))))))) (VP (AUX were) (VP (VBN included) (PP (IN in) (NP (DT the) (JJ present) (NN study)))))) (. .)))
16471092	3	(S1 (S (NP (NP (NN Doc_16471092_458_469_Chemical) (CD 2) (NN mg)) (, ,) (RB twice) (RB daily)) (VP (AUX was) (VP (VBN given))) (. .)))
16471092	4	(S1 (S (PP (IN After) (NP (CD 8) (NNS weeks) (NN treatment))) (, ,) (NP (NP (NNS changes)) (PP (IN in) (NP (NP (NN micturition) (NN diary) (NNS variables)) (CC and) (NP (NN tolerability))))) (VP (AUX were) (VP (VBN determined))) (. .)))
16471092	5	(S1 (S (NP (NP (JJ Short) (NN form) (CD 36) (-LRB- -LRB-) (CD SF36) (-RRB- -RRB-) (NNS questionaires)) (PRN (-LRB- -LRB-) (NP (NNP Thai) (NN version)) (-RRB- -RRB-))) (VP (AUX were) (VP (VBN given) (PP (IN before) (CC and) (IN after) (NP (NP (CD 8) (NNS weeks)) (PP (IN of) (NP (NN treatment))))))) (. .)))
16471092	6	(S1 (S (PP (IN At) (NP (CD 8) (NNS weeks))) (, ,) (NP (NP (DT all) (NN micturition)) (PP (IN per) (NP (NN day)))) (VP (VBD decreased) (PP (IN from) (S (VP (VBG 16.) (NP (NP (CD 7) (NN +/-)) (VP (VBG 5.) (NP (NP (NP (QP (CD 3) (TO to) (CD 6.) (CD 7) (NN +/-))) (NP (CD 2.4) (NNS times))) (PP (IN per) (NP (NN day)))))))))) (. .)))
16471092	7	(S1 (S (NP (NP (DT The) (NN number)) (PP (IN of) (NP (JJ Doc_16471092_817_825_Disease) (NNS episodes)))) (VP (VBD decreased) (PP (IN from) (NP (NP (QP (CD 5.4) (JJ +/-) (CD 4.2) (TO to) (CD 1.1)) (JJ +/-) (CD 1.0) (NNS times)) (PP (IN per) (NP (NN night)))))) (. .)))
16471092	8	(S1 (S (NP (DT The) (ADJP (RBS most) (JJ common)) (NN side) (NN effect)) (VP (AUX was) (ADJP (JJ Doc_16471092_926_935_Disease)) (PP (IN in) (NP (NP (CD 5) (NNS cases)) (PRN (-LRB- -LRB-) (NP (CD 16.7) (NN %)) (-RRB- -RRB-)))) (PP (IN with) (NP (NP (CD 2) (NNS cases)) (VP (VBG reporting) (NP (NP (DT a) (JJ moderate) (NN degree)) (CC and) (NP (NP (CD 1) (NN case)) (PP (IN with) (NP (JJ severe) (NN degree))))))))) (. .)))
16471092	9	(S1 (S (NP (NP (QP (RB Only) (CD one)) (NN case)) (PRN (-LRB- -LRB-) (NP (CD 3.3) (NN %)) (-RRB- -RRB-))) (VP (VBD withdrew) (PP (IN from) (NP (DT the) (JJ present) (NN study))) (ADVP (RB due)) (PP (TO to) (NP (DT a) (JJ severe) (NN Doc_16471092_1096_1105_Disease)))) (. .)))
16471092	10	(S1 (S (NP (DT The) (CD SF-36) (NNS scores)) (VP (VBD changed) (ADVP (RB significantly)) (PP (IN in) (NP (NP (DT the) (NNS domains)) (PP (IN of) (NP (NP (JJ physical) (NN functioning)) (, ,) (NP (NN role) (NN function) (JJ emotional)) (, ,) (NP (JJ social) (NN function)) (CC and) (NP (JJ mental) (NN heath))))))) (. .)))
16471092	11	(S1 (S (S (NP (NN Doc_16471092_1257_1268_Chemical)) (VP (AUX was) (VP (ADVP (RB well)) (VBN tolerated)))) (CC and) (S (NP (PRP$ its) (NNS effects)) (VP (VBD improved) (NP (NP (DT the) (NN quality)) (PP (IN of) (NP (NN life)))) (PP (IN in) (NP (NP (NNP Thai) (NNS women)) (PP (IN with) (NP (NNP Doc_16471092_1352_1355_Disease))))))) (. .)))
16563323	0	(S1 (S (NP (JJ Doc_16563323_0_12_Chemical) (NN pretreatment)) (VP (VBZ reduces) (NP (NN Doc_16563323_34_43_Disease)) (PP (IN after) (NP (NNP Doc_16563323_50_59_Chemical)))) (. .)))
16563323	1	(S1 (S (S (VP (VB STUDY) (NP (NN OBJECTIVE)))) (: :) (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT the) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB compare) (NP (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (ADJP (JJ pretreatment) (PP (IN with) (NP (NNP Doc_16563323_146_158_Chemical) (CD 1)))) (NNS microg/kg)))) (CC and) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN gender))) (PP (IN on) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NNP Doc_16563323_216_225_Disease))))))) (PP (IN after) (NP (NP (NN anesthesia) (NN induction)) (PP (IN with) (NP (NNP Doc_16563323_258_267_Chemical)))))))))) (. .)))
16563323	2	(S1 (S (NP (DT This)) (VP (AUX was) (NP (DT a) (JJ randomized) (, ,) (JJ double-blind) (NN study))) (. .)))
16563323	3	(S1 (S (NP (DT The) (NN study)) (VP (AUX was) (VP (VBN conducted) (PP (IN at) (NP (DT a) (NN university) (NN hospital))))) (. .)))
16563323	4	(S1 (S (NP (CD Sixty) (NNS patients)) (VP (AUX were) (VP (VBN pretreated) (PP (IN in) (NP (NP (DT a) (JJ randomized) (JJ double-blinded) (NN fashion)) (PP (IN with) (NP (NP (NNP Doc_16563323_464_476_Chemical) (CD 1) (NN microg/kg)) (CC or) (NP (NN placebo)))))))) (. .)))
16563323	5	(S1 (S (PP (NP (CD Two) (NNS minutes)) (IN after) (NP (NP (NN Doc_16563323_519_531_Chemical)) (CC or) (NP (NN placebo) (NN injection)))) (, ,) (NP (NNP Doc_16563323_554_563_Chemical) (CD 0.3) (NN mg/kg)) (VP (AUX was) (VP (VBN given))) (. .)))
16563323	6	(S1 (S (NP (NN Doc_16563323_599_608_Disease)) (VP (AUX was) (VP (VBN recorded) (PP (IN with) (NP (NP (DT a) (NN scale)) (PP (IN of) (NP (NP (CD 0)) (PP (TO to) (NP (CD 3))))))))) (. .)))
16563323	7	(S1 (S (NP (NP (DT The) (NN grade)) (PP (IN of) (NP (NP (NP (NNP sedation)) (PRN (-LRB- -LRB-) (NP (NP (NN none)) (, ,) (ADJP (JJ mild) (, ,) (JJ moderate) (, ,) (JJ severe))) (-RRB- -RRB-))) (, ,) (NP (NNP Doc_16563323_700_706_Disease)) (, ,) (NP (NNP Doc_16563323_708_716_Disease)) (, ,) (CC and) (NP (NNP Doc_16563323_722_727_Disease))))) (VP (AUX were) (VP (VBN recorded) (PP (IN after) (NP (NP (NN injection)) (PP (IN of) (NP (DT both) (NNS drugs))))))) (. .)))
16563323	8	(S1 (NP (NP (JJ MAIN) (NNS RESULTS)) (: :) (S (NP (NP (DT The) (NN incidence)) (PP (IN of) (NP (NNP Doc_16563323_804_813_Disease)))) (VP (AUX was) (ADJP (ADJP (ADJP (RB significantly) (JJR lower) (PP (IN in) (NP (DT the) (NNP Doc_16563323_845_857_Chemical) (NN group)))) (PRN (-LRB- -LRB-) (NP (CD 6.7) (NN %)) (-RRB- -RRB-))) (PP (IN than) (PP (IN in) (NP (NP (NP (DT the) (NN placebo) (NN group)) (PRN (-LRB- -LRB-) (NP (CD 70) (NN %)) (-RRB- -RRB-))) (-LRB- -LRB-) (NP (NNP P) (NNP <) (CD 0.001)) (-RRB- -RRB-))))))) (. .)))
16563323	9	(S1 (S (NP (NP (NN None)) (PP (IN of) (NP (DT the) (NNS patients)))) (VP (VBD experienced) (NP (NP (NNP sedation)) (, ,) (NP (NNP Doc_16563323_959_964_Disease)) (, ,) (NP (NNP Doc_16563323_966_972_Disease)) (, ,) (CC or) (NP (NNP Doc_16563323_977_985_Disease))) (PP (IN after) (NP (NP (NN injection)) (PP (IN of) (NP (DT both) (NNS drugs)))))) (. .)))
16563323	10	(S1 (S (PP (IN In) (NP (DT the) (NN placebo) (NN group))) (, ,) (NP (JJ male) (NNS patients)) (VP (AUX were) (VP (VBN associated) (PP (IN with) (NP (NP (ADJP (RB significantly) (JJ increased)) (NN incidence)) (PP (IN of) (NP (NNP Doc_16563323_1111_1120_Disease))) (PP (IN after) (NP (NNP Doc_16563323_1127_1136_Chemical) (NN administration))))))) (. .)))
16563323	11	(S1 (S (NP (NP (NN Pretreatment)) (PP (IN with) (NP (NNP Doc_16563323_1183_1195_Chemical) (CD 1)))) (ADVP (RB microg/kg)) (VP (VBD reduced) (NP (NNP Doc_16563323_1216_1225_Disease)) (PP (IN after) (NP (NP (JJ Doc_16563323_1232_1241_Chemical) (NN induction)) (PP (IN without) (NP (NP (JJ side) (NNS effects)) (PP (JJ such) (IN as) (NP (NP (NN sedation)) (, ,) (NP (NNP Doc_16563323_1291_1296_Disease) (, ,) (NNP Doc_16563323_1298_1304_Disease) (, ,) (CC or) (NNP Doc_16563323_1309_1317_Disease))))))))) (. .)))
16563323	12	(S1 (S (NP (NNS Men)) (VP (VBP experience) (NP (NP (JJ increased) (NN incidence)) (PP (IN of) (NP (NNP Doc_16563323_1357_1366_Disease))) (PP (IN than) (NP (NP (NNS women)) (PP (IN after) (NP (NNP Doc_16563323_1384_1393_Chemical) (NN administration))))))) (. .)))
16574713	0	(S1 (S (NP (NP (NN Memory) (NN function)) (CC and) (NP (JJ Doc_16574713_20_29_Chemical) (NN transporter) (NN promoter) (NN gene))) (VP (VBD polymorphism) (PP (IN in) (NP (NNP Doc_16574713_72_79_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_16574713_81_85_Chemical)) (-RRB- -RRB-)) (NNS users)))) (. .)))
16574713	1	(S1 (S (SBAR (IN Although) (S (NP (NP (NNP Doc_16574713_103_136_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_16574713_138_142_Chemical) (CC or) (NNP Doc_16574713_146_153_Chemical)) (-RRB- -RRB-))) (VP (AUX has) (VP (AUX been) (VP (VBN shown) (S (VP (TO to) (VP (VB damage) (NP (NN brain) (NNP Doc_16574713_186_195_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_16574713_197_201_Chemical)) (-RRB- -RRB-)) (NNS neurons)) (PP (IN in) (NP (NP (NNS animals)) (CC and) (ADVP (RB possibly)) (NP (NNS humans)))))))))))) (, ,) (NP (JJ little)) (VP (AUX is) (VP (VBN known) (PP (IN about) (NP (NP (DT the) (JJ long-term) (NNS consequences)) (PP (IN of) (NP (NP (NNP Doc_16574713_295_299_Chemical-induced) (NNP Doc_16574713_308_312_Chemical) (NNP Doc_16574713_313_331_Disease)) (PP (IN on) (NP (NP (NNS functions)) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (NNP Doc_16574713_354_358_Chemical)) (VP (AUX is) (VP (VBN involved))))) (, ,) (PP (JJ such) (IN as) (NP (JJ cognitive) (NN function))))))))))) (. .)))
16574713	2	(S1 (S (SBAR (IN Because) (S (NP (JJ Doc_16574713_408_412_Chemical) (NNS transporters)) (VP (VBP play) (NP (NP (DT a) (JJ key) (NN element)) (PP (IN in) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (JJ synaptic) (JJ Doc_16574713_475_479_Chemical) (NN transmission))))))))) (NP (PRP it)) (VP (MD may) (VP (AUX be) (ADJP (JJ important) (S (VP (TO to) (VP (VB control) (PP (IN for) (NP (NP (DT the) (JJ potential) (JJ covariance) (NN effect)) (PP (IN of) (NP (NP (DT a) (NN polymorphism)) (PP (IN in) (NP (NP (DT the) (JJ Doc_16574713_585_589_Chemical) (NN transporter) (NN promoter) (NN gene) (NN region)) (PRN (-LRB- -LRB-) (JJ 5-HTTLPR) (-RRB- -RRB-)))))))) (ADVP (WRB when)) (S (VP (VBG studying) (NP (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NNP Doc_16574713_663_667_Chemical)))) (CONJP (RB as) (RB well) (IN as)) (NP (JJ cognitive) (NN functioning))))))))))) (. .)))
16574713	3	(S1 (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT the) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB investigate) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (JJ moderate) (CC and) (JJ heavy) (JJ Doc_16574713_776_780_Chemical) (NN use))) (PP (IN on) (NP (NP (JJ cognitive) (NN function)) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (JJ long-term) (NN abstention)) (PP (IN from) (NP (NNP Doc_16574713_860_864_Chemical))))))))) (, ,) (PP (IN in) (NP (NP (NNS subjects)) (VP (VBN genotyped) (PP (IN for) (NP (NN 5-HTTLPR)))))))))) (. .)))
16574713	4	(S1 (S (NP (NP (DT A) (JJ second) (NN aim)) (PP (IN of) (NP (DT the) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB determine) (SBAR (IN whether) (S (NP (DT these) (NNS effects)) (VP (VBP differ) (PP (IN for) (NP (NP (NNS females)) (CC and) (NP (NNS males))))))))))) (. .)))
16574713	5	(S1 (S (NP (NP (NP (JJ Fifteen) (JJ moderate) (NNP Doc_16574713_1014_1018_Chemical) (NNS users)) (PRN (-LRB- -LRB-) (NP (CD <55) (NN lifetime) (NNS tablets)) (-RRB- -RRB-))) (, ,) (NP (NP (CD 22) (JJ heavy) (NNP Doc_16574713_1058_1062_Chemical+) (NNS users)) (PRN (-LRB- -LRB-) (NP (CD >55) (NN lifetime) (NNS tablets)) (-RRB- -RRB-))) (, ,) (NP (NP (CD 16) (JJ ex-Doc_16574713_1100_1104_Chemical+) (NNS users)) (PRN (-LRB- -LRB-) (S (NP (JJ last) (NN tablet)) (VP (VBD >) (NP (CD 1) (NN year)) (ADVP (RB ago)))) (-RRB- -RRB-))) (CC and) (NP (CD 13) (NNS controls))) (VP (AUX were) (VP (VBN compared) (PP (IN on) (NP (NP (DT a) (NN battery)) (PP (IN of) (NP (JJ neuropsychological) (NNS tests))))))) (. .)))
16574713	6	(S1 (S (NP (NP (NN DNA)) (PP (IN from) (NP (JJ peripheral) (JJ nuclear) (NN blood) (NNS cells)))) (VP (AUX was) (VP (VBN genotyped) (PP (IN for) (NP (NP (NNS 5-HTTLPR)) (VP (VBG using) (NP (NP (JJ standard) (NN polymerase) (NN chain) (NN reaction)) (SBAR (S (NP (CD methods.A) (JJ significant) (NN group) (NN effect)) (VP (AUX was) (VP (VBN observed) (PP (RB only) (PP (IN on) (NP (NP (NN memory) (NN function) (NNS tasks)) (PRN (-LRB- -LRB-) (NP (NNP p) (SYM =) (CD 0.04)) (-RRB- -RRB-)))) (CC but) (RB not) (PP (IN on) (NP (NP (NP (NN reaction) (NNS times)) (PRN (-LRB- -LRB-) (NP (NNP p) (SYM =) (CD 0.61)) (-RRB- -RRB-))) (CC or) (NP (NP (JJ attention/executive) (NN functioning)) (PRN (-LRB- -LRB-) (NP (NNP p) (SYM =) (CD 0.59)) (-RRB- -RRB-)))))))))))))))) (. .)))
16574713	7	(S1 (S (NP (JJ Heavy) (CC and) (JJ ex-Doc_16574713_1505_1509_Chemical+) (NNS users)) (VP (VBD performed) (ADVP (RB significantly) (JJR poorer)) (PP (IN on) (NP (NP (NN memory) (NNS tasks)) (PP (IN than) (NP (NNS controls)))))) (. .)))
16574713	8	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NP (DT no) (NN evidence)) (PP (IN of) (NP (NNP Doc_16574713_1607_1624_Disease)))) (VP (AUX was) (VP (VBN observed) (PP (IN in) (NP (JJ moderate) (JJ Doc_16574713_1650_1654_Chemical) (NNS users))))) (. .)))
16574713	9	(S1 (S (NP (NP (DT No) (JJ significant) (NN effect)) (PP (IN of) (NP (NP (NN 5-HTTLPR)) (CC or) (NP (NN gender))))) (VP (AUX was) (VP (VBN observed))) (. .)))
16574713	10	(S1 (S (SBAR (IN While) (S (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NNP Doc_16574713_1737_1741_Chemical))) (PP (IN in) (NP (NP (NNS quantities)) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (AUX be) (VP (VBN considered) (S (`` ``) (ADJP (JJ moderate)) ('' '')))))))))) (VP (AUX is) (RB not) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_16574713_1813_1840_Disease))))))) (, ,) (NP (NP (JJ heavy) (NN use)) (PP (IN of) (NP (JJ Doc_16574713_1855_1859_Chemical) (NN use)))) (VP (MD may) (VP (VB lead) (PP (TO to) (NP (JJ long) (JJ lasting) (NN Doc_16574713_1889_1907_Disease))))) (. .)))
16574713	11	(S1 (S (NP (NP (DT No) (NN effect)) (PP (IN of) (NP (NN 5-HTTLPR) (CC or) (NN gender))) (PP (IN on) (NP (NP (NN memory) (NN function)) (CC or) (NP (NN Doc_16574713_1963_1967_Chemical) (NN use))))) (VP (AUX was) (VP (VBN observed))) (. .)))
16584858	0	(S1 (NP (NP (NN Role)) (PP (IN of) (NP (NNP Doc_16584858_8_18_Chemical))) (PP (IN on) (NP (NP (JJ biochemical) (NNS alterations)) (CC and) (NP (JJ antioxidant) (NN status)))) (PP (IN in) (NP (NP (NNP Doc_16584858_72_85_Chemical-induced) (NNP Doc_16584858_94_115_Disease)) (PP (IN in) (NP (NNS rats))))) (. .)))
16584858	1	(S1 (S (NP (NP (DT The) (JJ current) (NN study)) (VP (VBN dealt) (PP (IN with) (NP (NP (DT the) (JJ protective) (NN role)) (PP (IN of) (NP (NP (NNP Doc_16584858_177_187_Chemical)) (, ,) (NP (NP (DT a) (JJ Doc_16584858_191_201_Chemical)) (PP (IN from) (NP (NP (NNP Mangifera) (NNP indica) (NNP Linn) (. .)) (PRN (-LRB- -LRB-) (NP (NNP Anacardiaceae)) (-RRB- -RRB-))))) (, ,))))) (PP (IN on) (NP (NP (NNP Doc_16584858_250_263_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_16584858_265_269_Chemical)) (-RRB- -RRB-)))))) (VP (VBD -induced) (NP (NP (NNP Doc_16584858_279_300_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_16584858_302_304_Disease)) (-RRB- -RRB-))) (PP (IN in) (NP (NNS rats))) (PP (IN through) (NP (PRP$ its) (JJ antioxidative) (NN mechanism)))) (. .)))
16584858	2	(S1 (S (NP (NP (JJ Subcutaneous) (NN injection)) (PP (IN of) (NP (NP (NNP Doc_16584858_377_381_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (QP (CD 200) (CD mg/kg)) (NN body) (NN weight)) (PP (IN in) (NP (QP (CD 1) (CD ml)) (NN saline)))) (-RRB- -RRB-)))) (PP (TO to) (NP (NNS rats))) (PP (IN for) (NP (CD 2) (JJ consecutive) (NNS days)))) (VP (VBD caused) (SBAR (S (NP (NP (NNP Doc_16584858_459_476_Disease)) (PP (IN in) (NP (NN rat) (NN heart))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX was) (VP (VBN determined) (PP (IN by) (NP (NP (DT the) (JJ increased) (NN activity)) (PP (IN of) (NP (NP (NP (JJ serum) (JJ Doc_16584858_547_554_Chemical) (NN dehydrogenase)) (PRN (-LRB- -LRB-) (NP (NNP LDH)) (-RRB- -RRB-))) (CC and) (NP (NP (JJ Doc_16584858_579_587_Chemical) (NN phosphokinase) (NNS isoenzymes)) (PRN (-LRB- -LRB-) (NP (NNP CK-MB)) (-RRB- -RRB-))))))))))) (, ,)) (VP (VP (VBD increased) (NP (NNP Doc_16584858_632_641_Chemical) (NN level))) (CC and) (VP (VBD reduced) (NP (NN plasma)) (NP (JJ Doc_16584858_667_671_Chemical) (VBG binding) (NN capacity))))))) (. .)))
16584858	3	(S1 (S (NP (NP (DT The) (JJ protective) (NN role)) (PP (IN of) (NP (NNP Doc_16584858_713_723_Chemical)))) (VP (AUX was) (VP (VBN analyzed) (PP (IN by) (NP (NP (NNP Doc_16584858_740_770_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_16584858_772_775_Chemical)) (-RRB- -RRB-)) (NN test)) (VP (VBN used) (PP (IN for) (NP (NP (JJ macroscopic) (JJ enzyme) (NN mapping) (NN assay)) (PP (IN of) (NP (DT the) (NNP Doc_16584858_831_850_Disease)))))))))) (. .)))
16584858	4	(S1 (S (NP (NP (DT The) (NN heart) (NN tissue) (NN antioxidant) (NNS enzymes)) (PP (JJ such) (IN as) (NP (NP (JJ Doc_16584858_897_907_Chemical) (NN dismutase)) (, ,) (NP (NN catalase)) (, ,) (NP (JJ Doc_16584858_929_940_Chemical) (NN peroxidase)) (, ,) (NP (JJ Doc_16584858_953_964_Chemical) (NN transferase)) (CC and) (NP (NP (JJ Doc_16584858_981_992_Chemical) (NN reductase) (NNS activities)) (, ,) (NP (NP (JJ non-enzymic) (NNS antioxidants)) (PP (JJ such) (IN as) (NP (NN cerruloplasmin)))) (, ,) (NP (NNP Doc_16584858_1064_1073_Chemical) (, ,) (NNP Doc_16584858_1075_1084_Chemical) (CC and) (NNP Doc_16584858_1089_1100_Chemical) (NNS levels)))))) (VP (AUX were) (VP (VBN altered) (PP (IN in) (NP (JJ Doc_16584858_1124_1126_Disease) (NNS rats))))) (. .)))
16584858	5	(S1 (S (S (PP (IN Upon) (NP (NP (NN pretreatment)) (PP (IN with) (NP (NNP Doc_16584858_1156_1166_Chemical))))) (-LRB- -LRB-) (NP (NP (QP (CD 100) (CD mg/kg)) (NN body) (NN weight)) (VP (VBN suspended) (PP (IN in) (NP (NP (CD 2) (NN ml)) (PP (IN of) (NP (NNP Doc_16584858_1211_1230_Chemical))))))) (-RRB- -RRB-) (VP (VBN given) (ADVP (RB intraperitoneally)) (PP (IN for) (NP (CD 28) (NNS days))) (PP (TO to) (NP (NNP Doc_16584858_1271_1273_Disease) (NNS rats))))) (VP (VBD protected) (NP (NP (DT the) (JJ above-mentioned) (NNS parameters)) (SBAR (S (VP (TO to) (VP (VB fall) (PP (IN from) (NP (DT the) (JJ normal) (NNS levels))))))))) (. .)))
16584858	6	(S1 (S (NP (NP (NNS Activities)) (PP (IN of) (NP (NP (NN heart) (NN tissue) (NN enzymic) (NNS antioxidants)) (CC and) (NP (JJ serum) (JJ non-enzymic) (NNS antioxidants) (NNS levels))))) (VP (VBD rose) (ADVP (RB significantly)) (PP (IN upon) (NP (NNP Doc_16584858_1466_1476_Chemical) (NN administration))) (SBAR (IN as) (S (VP (VBN compared) (PP (TO to) (NP (JJ Doc_16584858_1507_1511_Chemical-induced) (JJ Doc_16584858_1520_1522_Disease) (NNS rats))))))) (. .)))
16584858	7	(S1 (S (PP (IN From) (NP (DT the) (JJ present) (NN study))) (NP (PRP it)) (VP (AUX is) (VP (VBN concluded) (SBAR (IN that) (S (NP (NNP Doc_16584858_1573_1583_Chemical)) (VP (VBZ exerts) (NP (NP (DT a) (JJ beneficial) (NN effect)) (PP (IN against) (NP (NNP Doc_16584858_1619_1623_Chemical-induced) (NNP Doc_16584858_1632_1634_Disease)))) (ADVP (RB due) (PP (TO to) (NP (NP (PRP$ its) (JJ antioxidant) (NN potential)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBN regulated) (NP (DT the) (NNS tissues) (NN defense) (NN system)) (PP (IN against) (NP (NNP Doc_16584858_1720_1734_Disease)))))))))))))) (. .)))
16586083	0	(S1 (NP (NP (NP (JJ Cardiovascular) (NN risk)) (PP (IN with) (NP (JJ cyclooxygenase) (NNS inhibitors)))) (: :) (NP (NP (JJ general) (NN problem)) (PP (IN with) (NP (NN substance) (NN specific) (NNS differences)))) (. ?)))
16586083	1	(S1 (S (NP (NP (JJ Randomised) (JJ clinical) (NNS trials)) (CC and) (NP (JJ observational) (NNS studies))) (VP (AUX have) (VP (VBN shown) (NP (NP (DT an) (VBN increased) (NN risk)) (PP (IN of) (NP (NNP Doc_16586083_190_211_Disease) (, ,) (NNP Doc_16586083_213_219_Disease) (, ,) (NNP Doc_16586083_221_233_Disease) (CC and) (NNP Doc_16586083_238_251_Disease)))) (PP (IN during) (NP (NP (NN treatment)) (PP (IN with) (NP (JJ cyclooxygenase) (NNS inhibitors))))))) (. .)))
16586083	2	(S1 (S (NP (JJ Adverse) (JJ cardiovascular) (NNS effects)) (VP (VBD occurred) (ADVP (RB mainly)) (, ,) (FRAG (CC but) (RB not) (ADVP (RB exclusively)) (, ,) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ concomitant) (NN risk) (NNS factors))))))) (. .)))
16586083	3	(S1 (S (NP (NN Cyclooxygenase) (NNS inhibitors)) (VP (VBP cause) (NP (NP (JJ complex) (NNS changes)) (PP (IN in) (NP (ADJP (JJ renal) (, ,) (JJ vascular) (CC and) (JJ cardiac)) (NN prostanoid) (NNS profiles)))) (S (VP (ADVP (RB thereby)) (VBG increasing) (NP (NP (JJ vascular) (NN resistance)) (CC and) (NP (JJ fluid) (NN retention)))))) (. .)))
16586083	4	(S1 (S (NP (NP (DT The) (NN incidence)) (PP (IN of) (NP (JJ cardiovascular) (JJ adverse) (NNS events)))) (VP (VBZ tends) (S (VP (TO to) (VP (VB increase) (PP (IN with) (NP (NP (DT the) (JJ daily) (NN dose)) (CC and) (NP (JJ total) (NN exposure) (NN time)))))))) (. .)))
16586083	5	(S1 (S (NP (NP (DT A) (NN comparison)) (PP (IN of) (NP (JJ individual) (UCP (JJ selective) (CC and) (JJ unselective)) (NN cyclooxygenase) (NNS inhibitors)))) (VP (VBZ suggests) (NP (NP (JJ substance-specific) (NNS differences)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VP (MD may) (VP (VB depend) (PP (IN on) (NP (NP (NNS differences)) (PP (IN in) (NP (NP (JJ pharmacokinetic) (NNS parameters)) (CC or) (NP (JJ inhibitory) (NN potency)))))))) (CC and) (VP (MD may) (VP (AUX be) (VP (VBN contributed) (PP (IN by) (NP (JJ Doc_16586083_912_925_Chemical-independent) (NNS effects))))))))))) (. .)))
16586083	6	(S1 (S (NP (NP (JJ Diagnostic) (NNS markers)) (PP (JJ such) (IN as) (NP (NP (NP (JJ Doc_16586083_974_975_Chemical-terminal) (JJ pro) (NN brain) (NN natriuretic) (NN peptide)) (PRN (-LRB- -LRB-) (NP (NN NT-proBNP)) (-RRB- -RRB-))) (CC or) (NP (JJ high-sensitive) (JJ C-reactive) (NN protein))))) (VP (MD might) (VP (VB help) (PP (IN in) (NP (NP (DT the) (JJ early) (NN identification)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN at) (NP (NN risk))))))) (, ,) (S (ADVP (RB thus)) (VP (VBG avoiding) (NP (NP (DT the) (NN occurrence)) (PP (IN of) (NP (JJ serious) (NNP Doc_16586083_1164_1187_Disease)))))))) (. .)))
16596970	0	(S1 (S (NP (NNP Doc_16596970_0_11_Chemical) (NNP Doc_16596970_12_20_Disease)) (VP (VB cause) (NP (JJ age-dependent) (NN Doc_16596970_41_87_Disease))) (. .)))
16596970	1	(S1 (S (NP (NP (NNS Children)) (SBAR (WHNP (WP who)) (S (VP (AUX have) (NP (NN Doc_16596970_107_125_Disease)))))) (VP (AUX have) (UCP (ADJP (JJ continuous)) (CC or) (VP (ADVP (RB rapidly)) (VBG repeating) (NP (NP (NN Doc_16596970_163_171_Disease)) (SBAR (WHNP (WDT that)) (S (VP (VP (MD may) (VP (AUX be) (ADJP (JJ life-threatening)))) (CC and) (VP (MD may) (VP (VB cause) (NP (NP (JJ life-long) (NNS changes)) (PP (IN in) (NP (NN brain) (CC and) (NN behavior))))))))))))) (. .)))
16596970	2	(S1 (S (NP (NP (DT The) (NN extent)) (SBAR (WHPP (TO to) (WHNP (WDT which))) (S (NP (NNP Doc_16596970_276_294_Disease)) (VP (VBZ causes) (NP (NN Doc_16596970_302_337_Disease)))))) (VP (AUX is) (ADJP (JJ unknown))) (. .)))
16596970	3	(S1 (S (NP (DT A) (JJ naturalistic) (NN auditory) (NN location) (NN discrimination) (NN method)) (VP (AUX was) (VP (VBN used) (S (VP (TO to) (VP (VB evaluate) (NP (DT this) (NN question)) (S (VP (VBG using) (NP (NP (DT an) (NN animal) (NN model)) (PP (IN of) (NP (NNP Doc_16596970_465_483_Disease))))))))))) (. .)))
16596970	4	(S1 (S (NP (JJ Male) (JJ Sprague-Dawley) (NNS rats)) (VP (AUX were) (VP (VBN injected) (PP (IN with) (NP (NP (NP (NN saline)) (PP (IN on) (NP (JJ postnatal) (NN day))) (PRN (-LRB- -LRB-) (NP (NNP P)) (-RRB- -RRB-)) (CD 20)) (, ,) (CC or) (NP (NP (DT a) (JJ convulsant) (NN dose)) (PP (IN of) (NP (NNP Doc_16596970_585_596_Chemical))) (PP (IN on) (NP (NNP P20) (CC or) (NNP P45)))))))) (. .)))
16596970	5	(S1 (S (S (NP (NP (NN Doc_16596970_612_623_Chemical)) (PP (IN on) (NP (DT either) (NN day)))) (VP (VBN induced) (NP (NNP Doc_16596970_646_664_Disease)))) (: ;) (S (NP (NP (NNP Doc_16596970_666_684_Disease)) (PP (IN at) (NP (NNP P45)))) (VP (VBD resulted) (PP (IN in) (NP (NP (JJ CA3) (NN cell) (NN loss)) (CC and) (NP (JJ spontaneous) (NN Doc_16596970_734_742_Disease)))) (, ,) (SBAR (IN whereas) (S (NP (NNP P20) (NNS rats)) (VP (AUX had) (NP (NP (DT no) (NN cell) (NN loss)) (CC or) (NP (JJ spontaneous) (NN Doc_16596970_793_801_Disease)))))))) (. .)))
16596970	6	(S1 (S (NP (JJ Mature) (NNS rats)) (VP (AUX were) (VP (VBN trained) (PP (IN with) (NP (NP (JJ sound-source) (NN location)) (CC and) (NP (JJ sound-silence) (NNS discriminations)))))) (. .)))
16596970	7	(S1 (S (NP (NNP Control) (PRN (-LRB- -LRB-) (NP (NN saline) (CD P20)) (-RRB- -RRB-)) (NNS rats)) (VP (VBD acquired) (NP (DT both) (NNS discriminations)) (ADVP (RB immediately))) (. .)))
16596970	8	(S1 (S (PP (IN In) (NP (NNP Doc_16596970_962_980_Disease) (PRN (-LRB- -LRB-) (NP (NNP P20)) (-RRB- -RRB-)) (NNS rats))) (, ,) (NP (NP (NN acquisition)) (PP (IN of) (NP (DT the) (JJ sound-source) (NN location) (NN discrimination)))) (VP (AUX was) (ADJP (RB moderately) (JJ impaired))) (. .)))
16596970	9	(S1 (S (NP (JJ Doc_16596970_1074_1092_Disease) (PRN (-LRB- -LRB-) (NP (NNP P45)) (-RRB- -RRB-)) (NNS rats)) (VP (VBD failed) (S (VP (TO to) (VP (VB acquire) (NP (DT either) (NN sound-source) (NN location) (CC or) (NN sound-silence) (NNS discriminations)))))) (. .)))
16596970	10	(S1 (S (NP (NP (NN Doc_16596970_1185_1203_Disease)) (PP (IN in) (NP (NN rat)))) (VP (VBZ causes) (NP (DT an) (JJ age-dependent) (, ,) (JJ long-term) (NN Doc_16596970_1246_1283_Disease))) (. .)))
16596970	11	(S1 (S (NP (DT This) (NN impairment)) (VP (MD may) (VP (VB explain) (NP (NP (CD one) (NN cause)) (PP (IN of) (NP (NP (NNP Doc_16596970_1326_1367_Disease)) (PP (IN in) (NP (NNS humans)))))))) (. .)))
16600756	0	(S1 (NP (NP (NP (NN Nerve) (NN growth) (NN factor)) (CC and) (NP (NN Doc_16600756_24_38_Chemical))) (PP (IN in) (NP (NP (DT the) (NN urine)) (PP (IN of) (NP (NP (JJ female) (NNS patients)) (PP (IN with) (NP (NNP Doc_16600756_76_94_Disease))))))) (. .)))
16600756	1	(S1 (S (S (NP (NP (NP (NN NGF)) (CC and) (NP (NNP Doc_16600756_113_116_Chemical))) (PP (IN in) (NP (DT the) (NN bladder)))) (VP (MD can) (VP (AUX be) (VP (VBN affected) (PP (IN by) (NP (NP (JJ pathological) (NNS changes)) (PP (IN in) (NP (DT the) (NN bladder))))))))) (CC and) (S (NP (DT these) (NNS changes)) (VP (MD can) (VP (AUX be) (VP (VBN detected) (PP (IN in) (NP (NN urine))))))) (. .)))
16600756	2	(S1 (S (NP (PRP We)) (VP (VBD investigated) (NP (NP (NNS changes)) (PP (IN in) (NP (NP (JJ urinary) (NN NGF)) (CC and) (NP (NNP Doc_16600756_274_277_Chemical)))) (PP (IN in) (NP (NP (NNS women)) (PP (IN with) (NP (NN OAB))))))) (. .)))
16600756	3	(S1 (FRAG (NP (NNS MATERIALS) (CC AND) (NNS METHODS)) (: :) (S (NP (DT The) (NN study) (NNS groups)) (VP (VBD included) (NP (NP (NP (NP (CD 65) (NNS women)) (PP (IN with) (NP (NN OAB)))) (CC and) (NP (NP (CD 20)) (PP (IN without) (NP (NN bladder) (NNS symptoms))))) (SBAR (WHNP (WP who)) (S (VP (VBD served) (PP (IN as) (NP (NNS controls))))))))) (. .)))
16600756	4	(S1 (S (NP (NN Evaluation)) (VP (VBD included) (NP (NP (JJ patient) (NN history)) (, ,) (NP (NN urinalysis)) (, ,) (NP (DT a) (JJ voiding) (NN diary)) (CC and) (NP (JJ urodynamic) (NNS studies)))) (. .)))
16600756	5	(S1 (S (NP (NN Urine) (NNS samples)) (VP (AUX were) (VP (VBN collected))) (. .)))
16600756	6	(S1 (S (NP (NNP NGF) (, ,) (NNP Doc_16600756_544_548_Chemical) (, ,) (NNP Doc_16600756_550_559_Chemical) (CC and) (NNP Doc_16600756_564_568_Chemical)) (VP (VP (AUX were) (VP (VBN measured) (S (VP (VBG using) (NP (JJ enzyme-linked) (NN immunosorbent) (NN assay)))))) (CC and) (VP (VBN compared) (PP (IN between) (NP (DT the) (NNS groups))))) (. .)))
16600756	7	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (NP (NNS correlations)) (PP (IN between) (NP (NP (JJ urinary) (NNP NGF)) (CC and) (NP (NNP Doc_16600756_706_708_Chemical))))) (, ,) (CC and) (NP (NP (JJ urodynamic) (NNS parameters)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NN OAB))))))) (VP (AUX were) (VP (VBN examined))) (. .)))
16600756	8	(S1 (S (NP (NP (NNP Urinary) (NNP NGF)) (, ,) (NP (NNP Doc_16600756_794_798_Chemical)) (CC and) (NP (NNP Doc_16600756_803_812_Chemical))) (VP (AUX were) (ADVP (RB significantly)) (VP (VBN increased) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NN OAB))))) (PP (VBN compared) (PP (IN with) (NP (NP (NNS controls)) (PRN (-LRB- -LRB-) (NP (NNP p) (CD <0.05)) (-RRB- -RRB-))))))) (. .)))
16600756	9	(S1 (S (ADVP (RB However)) (, ,) (NP (JJ urinary) (NNP Doc_16600756_914_918_Chemical)) (VP (AUX was) (RB not) (ADJP (JJ different)) (PP (IN between) (NP (NP (NNS controls)) (CC and) (NP (NP (NNS patients)) (PP (IN with) (NP (NN OAB))))))) (. .)))
16600756	10	(S1 (S (PP (IN In) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ OAB) (NN urinary))))) (NP (NNP Doc_16600756_1006_1010_Chemical)) (VP (ADVP (RB positively)) (VBD correlated) (PP (IN with) (NP (NN volume))) (PP (IN at) (NP (NP (JJ first) (NN desire)) (PP (TO to) (NP (NP (NP (VB void)) (CC and) (NP (NN maximum) (JJ cystometric) (NN capacity))) (PRN (-LRB- -LRB-) (NP (NNP p) (CD <0.05)) (-RRB- -RRB-))))))) (. .)))
16600756	11	(S1 (S (NP (NP (NNP Urinary) (NNP NGF)) (, ,) (NP (NNP Doc_16600756_1126_1135_Chemical)) (CC and) (NP (NNP Doc_16600756_1140_1144_Chemical))) (VP (AUX did) (RB not) (VP (VB correlate) (PP (IN with) (NP (NP (JJ urodynamic) (NNS parameters)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NN OAB))))))))) (. .)))
16600756	12	(S1 (S (NP (NP (NNP NGF)) (CC and) (NP (NNP Doc_16600756_1233_1236_Chemical))) (VP (AUX have) (NP (JJ important) (NNS roles)) (PP (IN in) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (JJ OAB) (NNS symptoms))) (PP (IN in) (NP (JJ female) (NNS patients)))))) (. .)))
16600756	13	(S1 (S (NP (NP (JJ Urinary) (NNS levels)) (PP (IN of) (NP (DT these) (NNS factors)))) (VP (MD may) (VP (AUX be) (VP (VBN used) (PP (IN as) (NP (NNS markers))) (S (VP (TO to) (VP (VB evaluate) (NP (JJ OAB) (NNS symptoms)))))))) (. .)))
16629641	0	(S1 (NP (NP (NP (NP (NN Definition)) (CC and) (NP (NN management))) (PP (IN of) (NP (NNP Doc_16629641_29_35_Disease))) (PP (IN in) (NP (NNS patients)))) (NP (NNP Doc_16629641_48_79_Disease)) (. .)))
16629641	1	(S1 (S (NP (NP (NN Doc_16629641_81_121_Disease)) (PRN (-LRB- -LRB-) (NP (NN HCV)) (-RRB- -RRB-))) (VP (MD can) (VP (VB progress) (PP (TO to) (NP (NP (NNP Doc_16629641_144_153_Disease)) (, ,) (NP (NNP Doc_16629641_155_179_Disease)) (, ,) (CC and) (NP (NNP Doc_16629641_185_208_Disease)))))) (. .)))
16629641	2	(S1 (S (NP (NP (DT The) (JJ current) (JJS best) (NN treatment)) (PP (IN for) (NP (NNP Doc_16629641_241_254_Disease)))) (VP (AUX is) (NP (NP (NN combination) (NN therapy)) (PP (IN with) (NP (NP (NNP Doc_16629641_283_303_Chemical)) (CC and) (NP (NNP Doc_16629641_308_317_Chemical)))))) (. .)))
16629641	3	(S1 (S (SBAR (IN Although) (S (NP (DT this) (NN regimen)) (VP (VBZ produces) (NP (NP (JJ sustained) (JJ virologic) (NNS responses)) (PRN (-LRB- -LRB-) (NP (NNP SVRs)) (-RRB- -RRB-))) (PP (IN in) (NP (NP (QP (RB approximately) (CD 50)) (NN %)) (PP (IN of) (NP (NNS patients)))))))) (, ,) (NP (PRP it)) (VP (MD can) (VP (AUX be) (VP (VBN associated) (PP (IN with) (NP (DT a) (ADJP (RB potentially) (JJ dose-limiting)) (NN Doc_16629641_475_491_Disease)))))) (. .)))
16629641	4	(S1 (S (S (NP (NN Hemoglobin) (NNS concentrations)) (VP (VB decrease) (ADVP (RB mainly)) (PP (IN as) (NP (NP (DT a) (NN result)) (PP (IN of) (NP (JJ Doc_16629641_550_559_Chemical-induced) (NNP Doc_16629641_568_577_Disease))))))) (, ,) (CC and) (S (NP (DT this) (NN Doc_16629641_588_594_Disease)) (VP (MD can) (VP (AUX be) (ADJP (JJ problematic)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NNP Doc_16629641_631_644_Disease) (, ,) (RB especially) (DT those)) (SBAR (WHNP (WP who)) (S (VP (AUX have) (VP (VBN comorbid) (NP (NNP Doc_16629641_681_714_Disease))))))))))))) (. .)))
16629641	5	(S1 (S (PP (IN In) (ADJP (JJ general))) (, ,) (NP (NNP Doc_16629641_728_734_Disease)) (VP (VP (MD can) (VP (VB increase) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NP (NN morbidity)) (CC and) (NP (NN mortality))))))) (, ,) (CC and) (VP (MD may) (VP (AUX have) (NP (NP (JJ negative) (NNS effects)) (PP (IN on) (NP (NP (JJ cerebral) (NN function)) (CC and) (NP (NP (NN quality)) (PP (IN of) (NP (NN life)))))))))) (. .)))
16629641	6	(S1 (S (SBAR (IN Although) (S (NP (NNP Doc_16629641_866_875_Chemical-associated) (NNP Doc_16629641_887_893_Disease)) (VP (MD can) (VP (AUX be) (VP (VBN reversed) (PP (IN by) (NP (NP (NN dose) (NN reduction)) (CC or) (NP (NN discontinuation))))))))) (, ,) (NP (DT this) (NN approach)) (VP (VBZ compromises) (NP (NNS outcomes)) (PP (IN by) (S (VP (ADVP (RB significantly)) (VBG decreasing) (NP (NN SVR) (NNS rates)))))) (. .)))
16629641	7	(S1 (S (NP (JJ Recombinant) (JJ human) (NN erythropoietin)) (VP (VP (AUX has) (VP (AUX been) (VP (VBN used) (S (VP (TO to) (VP (VB manage) (NP (JJ Doc_16629641_1079_1088_Chemical-associated) (NN Doc_16629641_1100_1106_Disease)))))))) (CC but) (VP (AUX has) (NP (JJ other) (JJ potential) (NNS disadvantages)))) (. .)))
16629641	8	(S1 (S (NP (NP (NNP Doc_16629641_1146_1156_Chemical)) (, ,) (NP (NP (DT a) (JJ liver-targeting) (NN prodrug)) (PP (IN of) (NP (NNP Doc_16629641_1187_1196_Chemical)))) (, ,)) (VP (AUX has) (NP (DT the) (NN potential) (S (VP (TO to) (VP (VB maintain) (NP (NP (DT the) (JJ virologic) (NN efficacy)) (PP (IN of) (NP (NNP Doc_16629641_1254_1263_Chemical)))) (SBAR (IN while) (S (VP (VBG decreasing) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NNP Doc_16629641_1293_1309_Disease)))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NN Doc_16629641_1327_1346_Disease))))))))))))) (. .)))
16634859	0	(S1 (NP (NP (NN Impact)) (PP (IN of) (NP (NNP Doc_16634859_10_17_Chemical) (NN exposure))) (PP (IN after) (NP (NN pregnancy) (NN recognition))) (PP (IN on) (NP (JJ ultrasonographic) (JJ fetal) (NN growth) (NNS measures))) (. .)))
16634859	1	(S1 (S (SBAR (NP (QP (JJR More) (IN than) (CD 3)) (NNS decades)) (IN after) (S (NP (NP (NNP Jones) (CC and) (NNP Smith)) (PRN (-LRB- -LRB-) (NP (CD 1973)) (-RRB- -RRB-))) (VP (VBD reported) (PP (IN on) (NP (NP (DT the) (NN devastation)) (VP (VBN caused) (PP (IN by) (NP (NNP Doc_16634859_197_204_Chemical) (NN exposure))) (PP (IN on) (NP (JJ fetal) (NN development))))))))) (, ,) (NP (NP (DT the) (NNS rates)) (PP (IN of) (NP (NP (JJ heavy) (NN drinking)) (PP (IN during) (NP (NN pregnancy)))))) (VP (VBP remain) (ADJP (RB relatively) (JJ unchanged))) (. .)))
16634859	2	(S1 (S (NP (NP (JJ Early) (NN identification)) (PP (IN of) (NP (NP (JJ fetal) (JJ Doc_16634859_340_347_Chemical) (NN exposure)) (CC and) (NP (JJ maternal) (NN abstinence))))) (VP (VBD led) (PP (TO to) (NP (JJR better) (NN infant) (NNS outcomes)))) (. .)))
16634859	3	(S1 (S (NP (DT This) (NN study)) (VP (VBD examined) (NP (NP (DT the) (NN utility)) (PP (IN of) (NP (NN biometry))) (PP (IN for) (S (VP (VBG detecting) (NP (JJ Doc_16634859_470_477_Chemical-related) (JJ fetal) (NN Doc_16634859_492_509_Disease))))))) (. .)))
16634859	4	(S1 (S (NP (PRP We)) (VP (VBD obtained) (NP (JJ fetal) (NN ultrasound) (NNS measures)) (PP (IN from) (NP (JJ routine) (NN ultrasound) (NNS examinations))) (PP (IN for) (NP (NP (CD 167) (JJ pregnant) (JJ hazardous) (NNS drinkers)) (SBAR (WHNP (WP who)) (S (VP (AUX were) (VP (VBD enrolled) (PP (IN in) (NP (DT a) (JJ brief) (JJ Doc_16634859_660_667_Chemical) (NN intervention) (NN study)))))))))) (. .)))
16634859	5	(S1 (S (NP (NP (DT The) (JJ fetal) (NNS measures)) (PP (IN for) (NP (NP (NNS women)) (SBAR (WHNP (WP who)) (S (VP (VBP quit) (PP (IN after) (NP (NP (NN learning)) (PP (IN of) (NP (PRP$ their) (NNS pregnancies))))))))))) (VP (AUX were) (PP (VBN compared) (PP (IN with) (NP (NP (NNS measures)) (PP (IN for) (NP (NP (NNS women)) (SBAR (WHNP (WP who)) (S (VP (VBD continued) (NP (DT some) (NN drinking)) (PP (IN throughout) (NP (NP (DT the) (NN course)) (PP (IN of) (NP (PRP$ their) (NNS pregnancies)))))))))))))) (. .)))
16634859	6	(S1 (S (SBAR (IN Because) (S (NP (NP (NN intensity)) (PP (IN of) (NP (JJ Doc_16634859_893_900_Chemical) (NN consumption)))) (VP (AUX is) (VP (VBN associated) (PP (IN with) (NP (JJR poorer) (JJ fetal) (NNS outcomes))))))) (, ,) (NP (JJ separate) (NNS analyses)) (VP (AUX were) (VP (VBN conducted) (PP (IN for) (NP (DT the) (JJ heavy) (PRN (-LRB- -LRB-) (NP (NP (JJ average)) (PP (IN of) (NP (JJ >or=5) (NNS drinks))) (PP (IN per) (NP (NN drinking) (NN day)))) (-RRB- -RRB-)) (JJ Doc_16634859_1045_1052_Chemical) (NNS consumers))))) (. .)))
16634859	7	(S1 (S (NP (NP (JJ Fetal) (NNS measures)) (PP (IN from) (NP (DT the) (JJ heavy-exposed) (NNS fetuses)))) (VP (AUX were) (ADVP (RB also)) (PP (VBN compared) (PP (IN with) (NP (NP (NNS measures)) (PP (IN from) (NP (NP (DT a) (JJ nondrinking) (NN group)) (SBAR (WHNP (WDT that)) (S (VP (AUX was) (NP (NP (NN representative)) (PP (IN of) (NP (NP (JJ normal) (, ,) (JJ uncomplicated) (NNS pregnancies)) (PP (IN from) (NP (PRP$ our) (NNS clinics))))))))))))))) (. .)))
16634859	8	(S1 (S (NP (NP (NNS Analyses)) (PP (IN of) (NP (NN covariance)))) (VP (AUX were) (VP (VBN used) (S (VP (TO to) (VP (VB determine) (SBAR (IN whether) (S (NP (EX there)) (VP (AUX were) (NP (NP (NNS differences)) (PP (IN between) (NP (NNS groups)))) (PP (IN after) (S (VP (VBG controlling) (PP (IN for) (NP (NP (NNS influences)) (PP (IN of) (NP (NP (JJ gestational) (NN age)) (CC and) (NP (NN Doc_16634859_1395_1405_Disease))))))))))))))))) (. .)))
16634859	9	(S1 (S (NP (NP (RB Nearly) (NN half)) (PP (IN of) (NP (DT the) (JJ pregnant) (NNS drinkers)))) (VP (VBD abstained) (PP (IN after) (NP (NP (NN learning)) (PP (IN of) (NP (PRP$ their) (NNS pregnancies)))))) (. .)))
16634859	10	(S1 (S (SBAR (WHADVP (WRB When)) (S (NP (NNS women)) (ADVP (RB reportedly)) (VP (VB quit) (NP (NN drinking)) (ADVP (RB early)) (PP (IN in) (NP (PRP$ their) (NNS pregnancies)))))) (, ,) (NP (JJ fetal) (NN growth) (NNS measures)) (VP (AUX were) (RB not) (ADJP (RB significantly) (JJ different) (PP (IN from) (NP (DT a) (JJ non-Doc_16634859_1630_1637_Chemical-exposed) (NN group)))) (, ,) (ADVP (RB regardless) (PP (IN of) (NP (JJ prior) (NN drinking) (NNS patterns))))) (. .)))
16634859	11	(S1 (S (NP (NP (DT Any) (JJ Doc_16634859_1696_1703_Chemical) (NN consumption) (NN postpregnancy) (NN recognition)) (PP (IN among) (NP (DT the) (JJ heavy) (NNS drinkers)))) (VP (VBD resulted) (PP (IN in) (NP (NNP Doc_16634859_1779_1804_Disease) (CONJP (RB as) (RB well) (IN as)) (NNP Doc_16634859_1816_1848_Disease))) (PP (IN in) (NP (NP (NN comparison)) (PP (IN with) (NP (NP (NNS women)) (SBAR (SBAR (WHNP (WP who)) (S (ADVP (RB either)) (VP (VBP quit) (NP (NN drinking))))) (CC or) (SBAR (WHNP (WP who)) (S (VP (AUX were) (NP (NNS nondrinkers))))))))))) (. .)))
16634859	12	(S1 (S (NP (JJ Doc_16634859_1924_1935_Chemical) (NN abuse)) (VP (AUX was) (ADJP (JJ predictive) (PP (IN of) (NP (JJR larger) (NN cranial))) (PP (TO to) (NP (NN body) (NN growth) (NNS ratios))))) (. .)))
16634859	13	(S1 (S (NP (NP (NNS Alterations)) (PP (IN in) (NP (JJ fetal) (JJ biometric) (NNS measurements)))) (VP (AUX were) (VP (VBN observed) (PP (IN among) (NP (NP (DT the) (JJ heavy) (NNS drinkers)) (SBAR (WHADVP (RB only) (WRB when)) (S (NP (PRP they)) (VP (VBD continued) (NP (NN drinking)) (PP (IN after) (S (VP (VBG becoming) (ADJP (JJ aware) (PP (IN of) (NP (PRP$ their) (NNS pregnancies)))))))))))))) (. .)))
16634859	14	(S1 (S (SBAR (IN Although) (S (NP (NP (DT the) (NN reliance)) (PP (IN on) (NP (JJ self-reported) (NN drinking)))) (VP (AUX is) (NP (NP (DT a) (NN limitation)) (PP (IN in) (NP (DT this) (NN study))))))) (, ,) (NP (DT these) (NNS findings)) (VP (VBP support) (NP (NP (NP (DT the) (NNS benefits)) (PP (IN of) (NP (JJ early) (NN abstinence)))) (CC and) (NP (NP (DT the) (NN potential)) (PP (IN for) (NP (NN ultrasound) (NNS examinations))))) (PP (IN in) (NP (NP (DT the) (NN detection)) (PP (IN of) (NP (JJ fetal) (JJ Doc_16634859_2378_2385_Chemical) (NNS effects)))))) (. .)))
16710500	0	(S1 (NP (JJ Doc_16710500_0_10_Chemical-associated) (NN Doc_16710500_22_38_Disease) (. .)))
16710500	1	(S1 (S (NP (NN Doc_16710500_54_64_Chemical)) (VP (VP (AUX is) (VP (VBN used) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (NNP Doc_16710500_93_105_Disease)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX is) (ADVP (RB still)) (ADJP (JJ prevalent)) (PP (IN in) (NP (NNP Southeast) (NNP Asia)))))))))))) (, ,) (CC and) (VP (MD can) (VP (AUX be) (VP (VBN associated) (PP (IN with) (NP (JJ permanent) (NN Doc_16710500_188_199_Disease))))))) (. .)))
16710500	2	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (CD 3) (NNS cases)) (SBAR (WHNP (WDT which)) (S (VP (VBD presented) (PP (IN with) (NP (NN Doc_16710500_240_261_Disease)))))))) (. .)))
16710500	3	(S1 (NP (JJ CLINICAL) (NN PICTURE) (: :) (S (NP (NP (CD Three) (NNS patients)) (PP (IN with) (NP (JJ Doc_16710500_301_311_Chemical-associated) (JJ toxic) (NN Doc_16710500_329_345_Disease)))) (VP (AUX are) (VP (VBN described)))) (. .)))
16710500	4	(S1 (S (NP (DT All) (CD 3) (NNS patients)) (VP (AUX had) (NP (NN Doc_16710500_380_452_Disease))) (. .)))
16710500	5	(S1 (S (NP (DT The) (NNP Doc_16710500_458_475_Disease)) (VP (AUX had) (NP (DT a) (JJ bitemporal) (NN flavour)) (, ,) (S (VP (VBG suggesting) (NP (NP (NN involvement)) (PP (IN of) (NP (DT the) (JJ optic) (NN chiasm))))))) (. .)))
16710500	6	(S1 (S (PP (IN Despite) (S (VP (VBG stopping) (NP (NNP Doc_16710500_574_584_Chemical)) (PP (IN on) (NP (NN diagnosis)))))) (, ,) (NP (JJ visual) (NN function)) (VP (VBD continued) (S (VP (TO to) (VP (VB deteriorate) (PP (IN for) (NP (DT a) (JJ few) (NNS months))))))) (. .)))
16710500	7	(S1 (S (NP (JJ Subsequent) (NN improvement)) (VP (AUX was) (ADJP (JJ mild)) (PP (IN in) (NP (CD 2) (NNS cases)))) (. .)))
16710500	8	(S1 (S (PP (IN In) (NP (DT the) (JJ third) (NN case))) (, ,) (S (NP (NP (JJ visual) (NN acuity)) (CC and) (NP (JJ colour) (NN vision))) (VP (VBD normalised))) (CC but) (S (NP (DT the) (JJ optic) (NNS discs)) (VP (AUX were) (ADJP (JJ pale)))) (. .)))
16710500	9	(S1 (S (NP (DT All) (CD 3) (NNS patients)) (VP (AUX had) (NP (DT some) (JJ permanent) (NN Doc_16710500_838_861_Disease))) (. .)))
16710500	10	(S1 (S (NP (JJ Doc_16710500_876_886_Chemical) (NN usage)) (VP (VP (AUX is) (VP (VBN associated) (PP (IN with) (NP (JJ permanent) (NNP Doc_16710500_922_933_Disease))))) (CC and) (VP (MD should) (VP (AUX be) (VP (VBN avoided) (SBAR (IN if) (FRAG (ADJP (ADJP (ADJP (JJ possible)) (CC or) (ADJP (JJ used))) (PP (IN with) (NP (NP (NN caution)) (CC and) (NP (JJ proper) (JJ ophthalmological) (NN follow-up))))))))))) (. .)))
16710500	11	(S1 (S (NP (DT The) (NN author)) (VP (VBZ postulates) (SBAR (IN that) (S (PP (IN in) (NP (NP (NNS cases)) (PP (IN of) (NP (JJ Doc_16710500_1067_1077_Chemical) (JJ associated) (NN chiasmopathy))))) (, ,) (NP (NNP Doc_16710500_1103_1113_Chemical)) (VP (MD may) (ADVP (RB initially)) (VP (VP (VB affect) (NP (DT the) (JJ optic) (NNS nerves))) (CC and) (VP (ADVP (RB subsequently)) (VB progress) (S (VP (TO to) (VP (VB involve) (NP (DT the) (JJ optic) (NN chiasm))))))))))) (. .)))
16720068	0	(S1 (S (NP (JJ Possible) (NN Doc_16720068_9_39_Disease)) (VP (VBD related) (PP (TO to) (NP (NP (JJ concomitant) (NN treatment)) (PP (IN with) (NP (NP (NNP Doc_16720068_78_88_Chemical)) (CC and) (NP (NNP Doc_16720068_93_103_Chemical))))))) (. .)))
16720068	1	(S1 (S (NP (NP (DT A) (JJ 74-year-old) (NN man)) (PP (IN with) (NP (NNP Doc_16720068_128_147_Disease)))) (VP (AUX was) (VP (VBN admitted) (PP (TO to) (NP (NP (DT a) (NNP Doc_16720068_166_177_Disease) (NN hospital)) (ADJP (JJ due) (PP (TO to) (NP (NP (NNP Doc_16720068_194_202_Disease)) (, ,) (NP (NNP Doc_16720068_204_220_Disease)) (, ,) (NP (NN exhaustion)) (, ,) (CC and) (NP (NNP Doc_16720068_238_247_Disease))))))))) (. .)))
16720068	2	(S1 (S (NP (JJ Medical) (NN treatment)) (VP (AUX was) (VP (VBN initiated) (PP (IN at) (NP (NP (DT a) (JJ daily) (NN dose)) (PP (IN of) (NP (QP (CD 20) (CD mg) (NN Doc_16720068_306_316_Chemical) (CC and) (CD 1.2) (CD mg)) (NNP Doc_16720068_328_338_Chemical))))))) (. .)))
16720068	3	(S1 (S (PP (IN On) (NP (NP (DT the) (JJ 10th) (NN day)) (PP (IN of) (NP (NNP Doc_16720068_359_369_Chemical) (CC and) (NNP Doc_16720068_374_384_Chemical) (NN treatment))))) (, ,) (NP (DT the) (NN patient)) (VP (VBD exhibited) (SBAR (S (VP (VBD marked) (NP (NP (NN Doc_16720068_425_448_Disease)) (, ,) (NP (NN disorientation)) (, ,) (CC and) (NP (NP (JJ severe) (NN Doc_16720068_477_492_Disease)) (PP (IN with) (NP (NNP Doc_16720068_498_505_Disease))))))))) (. .)))
16720068	4	(S1 (S (NP (DT The) (NN patient)) (VP (AUX had) (NP (NP (DT a) (NN Doc_16720068_525_530_Disease)) (PRN (-LRB- -LRB-) (NP (NP (CD 38.2) (NNS degrees)) (NP (SYM C))) (-RRB- -RRB-))) (, ,) (S (VP (VBG fluctuating) (NP (NP (NN blood) (NN pressure)) (PRN (-LRB- -LRB-) (NP (NP (QP (IN between) (CD 165/90) (CC and) (CD 130/70) (CD mg)) (NNS mm)) (NP (NNP Hg))) (-RRB- -RRB-)) (, ,) (CC and) (NP (JJ severe) (NN Doc_16720068_625_648_Disease)))))) (. .)))
16720068	5	(S1 (S (NP (NN Laboratory) (NNS tests)) (VP (VBD showed) (NP (NP (NP (DT an) (NN elevation)) (PP (IN of) (NP (JJ Doc_16720068_690_698_Chemical) (NN phosphokinase)))) (PRN (-LRB- -LRB-) (NP (CD 2218) (NN IU/L)) (-RRB- -RRB-)) (, ,) (NP (JJ Doc_16720068_726_735_Chemical) (NN aminotransferase)) (PRN (-LRB- -LRB-) (NP (CD 134) (NN IU/L)) (-RRB- -RRB-)) (, ,) (NP (JJ Doc_16720068_765_772_Chemical) (NN aminotransferase)) (PRN (-LRB- -LRB-) (NP (CD 78) (NN IU/L)) (-RRB- -RRB-)) (, ,) (CC and) (NP (JJ BUN) (PRN (-LRB- -LRB-) (NP (CD 27.9) (NNS mg/ml)) (-RRB- -RRB-)) (NNS levels)))) (. .)))
16720068	6	(S1 (S (S (NP (DT The) (NN patient)) (VP (VBD received) (NP (NP (NNP Doc_16720068_851_864_Chemical)) (CC and) (NP (NNP Doc_16720068_869_877_Chemical))) (S (VP (TO to) (VP (VB treat) (NP (PRP$ his) (NN symptoms.)) (ADVP (NP (CD 7) (NNS days)) (RB later))))))) (, ,) (S (NP (DT the) (NNP Doc_16720068_919_924_Disease)) (VP (VBD disappeared))) (CC and) (S (NP (NP (DT the) (NN patient) (POS 's)) (NN serum) (NN CPK) (NNS levels)) (VP (AUX were) (VP (VBN normalized) (PRN (-LRB- -LRB-) (NP (CD 175) (NN IU/L)) (-RRB- -RRB-))))) (. .)))
16720068	7	(S1 (S (NP (DT This) (NN patient)) (VP (VBD presented) (PP (IN with) (NP (NP (NNS symptoms)) (PP (IN of) (NP (NP (NNP Doc_16720068_1040_1070_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_16720068_1072_1075_Disease)) (-RRB- -RRB-)))))) (, ,) (S (ADVP (RB thus)) (VP (VBG demonstrating) (SBAR (IN that) (S (NP (JJ Doc_16720068_1102_1105_Disease-like) (NNS symptoms)) (VP (MD can) (VP (VB occur) (PP (IN after) (NP (NP (JJ combined) (NN Doc_16720068_1145_1155_Chemical)) (CC and) (NP (JJ Doc_16720068_1160_1170_Chemical) (NN treatment))))))))))) (. .)))
16720068	8	(S1 (S (NP (NP (DT The) (JJ adverse) (NN drug) (NN reaction) (NN score)) (VP (VBN obtained) (PP (IN by) (NP (DT the) (NNP Naranjo) (NN algorithm))))) (VP (AUX was) (NP (CD 6)) (PP (IN in) (NP (PRP$ our) (NN case))) (, ,) (S (VP (VBG indicating) (NP (NP (DT a) (JJ probable) (NN relationship)) (PP (IN between) (NP (NP (NP (DT the) (NN patient) (POS 's)) (JJ Doc_16720068_1324_1327_Disease-like) (JJ adverse) (NNS symptoms)) (CC and) (NP (NP (DT the) (VBN combined) (NN treatment)) (VP (VBN used) (PP (IN in) (NP (DT this) (NN case))))))))))) (. .)))
16720068	9	(S1 (S (NP (NP (DT The) (NN involvement)) (PP (IN of) (NP (NP (ADJP (JJ physiologic) (CC and) (JJ environmental)) (NNS aspects)) (ADJP (JJ specific) (PP (TO to) (NP (DT this) (NN patient))))))) (VP (AUX was) (VP (VBN suspected))) (. .)))
16720068	10	(S1 (S (NP (NP (JJ Several) (NN risk) (NNS factors)) (PP (IN for) (NP (NNP Doc_16720068_1518_1521_Disease)))) (VP (MD should) (VP (AUX be) (VP (VBN noted) (PP (IN in) (NP (NP (JJ elderly) (JJ Doc_16720068_1549_1559_Disease) (NNS patients)) (SBAR (WHNP (WP$ whose) (NNS symptoms)) (S (ADVP (RB often)) (VP (VBP include) (NP (NP (NNP Doc_16720068_1598_1609_Disease)) (, ,) (NP (NNP Doc_16720068_1611_1620_Disease)) (, ,) (NP (NNP Doc_16720068_1622_1634_Disease)) (, ,) (CC and) (NP (NN exhaustion))))))))))) (. .)))
16720068	11	(S1 (S (NP (JJ Careful) (JJ therapeutic) (NN intervention)) (VP (AUX is) (ADJP (JJ necessary)) (PP (IN in) (NP (NP (NNS cases)) (VP (VBG involving) (NP (NP (JJ elderly) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBP suffer) (PP (IN from) (NP (NN Doc_16720068_1750_1760_Disease))))))))))) (. .)))
16725121	0	(S1 (S (NP (NP (NN Down-regulation)) (PP (IN of) (NP (JJ Doc_16725121_19_33_Chemical) (NN transporter) (NN function)))) (VP (VBN induced) (PP (IN by) (NP (NP (NN chronic) (NN administration)) (PP (IN of) (NP (NNP Doc_16725121_92_103_Chemical))) (VP (VBG linking) (PP (TO to) (NP (NP (NP (DT the) (NN alteration)) (PP (IN of) (NP (NP (NN sensitivity)) (PP (IN of) (NP (JJ local-anesthetics-induced) (NNP Doc_16725121_174_185_Disease)))))) (CC and) (NP (NP (DT the) (NN counteraction)) (PP (IN by) (NP (NP (NN co-administration)) (PP (IN with) (NP (JJ local) (NNS anesthetics)))))))))))) (. .)))
16725121	1	(S1 (S (S (NP (NP (NNS Alterations)) (PP (IN of) (NP (JJ Doc_16725121_268_282_Chemical) (NN transporter))) (PRN (-LRB- -LRB-) (JJ NET) (-RRB- -RRB-))) (VP (VBP function) (PP (IN by) (NP (NP (JJ chronic) (NN inhibition)) (PP (IN of) (NP (NP (NN NET)) (PP (IN in) (NP (NP (NN relation)) (PP (TO to) (NP (NN sensitization))) (PP (TO to) (NP (NNP Doc_16725121_371_379_Disease))))))))) (S (VP (VB induce) (PP (IN by) (NP (NNP Doc_16725121_390_397_Chemical))))))) (CC and) (S (NP (JJ local) (NNS anesthetics)) (VP (AUX were) (VP (VBN studied) (PP (IN in) (NP (NNS mice)))))) (. .)))
16725121	2	(S1 (S (NP (NP (JJ Daily) (NN administration)) (PP (IN of) (NP (NP (NNP Doc_16725121_466_477_Chemical)) (, ,) (NP (NP (DT an) (NN inhibitor)) (PP (IN of) (NP (DT the) (NN NET)))) (, ,))) (PP (IN for) (NP (CD 5) (NNS days)))) (VP (VBD decreased) (NP (JJ -LSB-) (PRN (-LRB- -LRB-) (CD 3) (-RRB- -RRB-)) (NNP H) (NNS -RSB-)) (NP (JJ Doc_16725121_531_545_Chemical) (NN uptake)) (PP (IN in) (NP (NP (DT the) (NNP P2) (NNS fractions)) (PP (IN of) (NP (NP (NNS hippocampus)) (CONJP (CC but) (RB not)) (NP (NN cortex) (, ,) (NN striatum) (CC or) (NNS amygdalae))))))) (. .)))
16725121	3	(S1 (S (NP (NP (NN Co-administration)) (PP (IN of) (NP (NP (NNP Doc_16725121_648_657_Chemical)) (, ,) (NP (NNP Doc_16725121_659_670_Chemical)) (CC or) (NP (NNP Doc_16725121_674_682_Chemical)))) (PP (IN with) (NP (NNP Doc_16725121_688_699_Chemical)))) (VP (VBD reversed) (NP (DT this) (NN effect))) (. .)))
16725121	4	(S1 (S (NP (NP (JJ Daily) (NN treatment)) (PP (IN of) (NP (NP (NP (JJ Doc_16725121_741_748_Chemical) (JJ increased) (NNS -LSB-)) (PRN (-LRB- -LRB-) (NP (CD 3)) (-RRB- -RRB-))) (NP (NNP H) (NN -RSB-) (NNP Doc_16725121_765_779_Chemical))))) (VP (VBD uptake) (PP (IN into) (NP (DT the) (NN hippocampus)))) (. .)))
16725121	5	(S1 (S (NP (NP (JJ Daily) (NN administration)) (PP (IN of) (NP (NNP Doc_16725121_833_844_Chemical)))) (VP (VP (VBD increased) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NP (NN appearance)) (PP (IN of) (NP (JJ Doc_16725121_886_895_Chemical-induced) (NNP Doc_16725121_904_915_Disease))))))) (CC and) (VP (VBD decreased) (NP (NP (DT that)) (PP (IN of) (NP (NNP Doc_16725121_938_945_Chemical-induced) (NNP Doc_16725121_954_965_Disease)))))) (. .)))
16725121	6	(S1 (S (NP (NP (NN Co-administration)) (PP (IN of) (NP (NNP Doc_16725121_988_997_Chemical))) (PP (IN with) (NP (NNP Doc_16725121_1003_1014_Chemical)))) (VP (VBD reversed) (NP (NP (DT the) (NNS changes)) (PP (IN of) (NP (NP (JJ Doc_16725121_1039_1049_Disease) (NN activity)) (PP (IN of) (NP (NP (NNP Doc_16725121_1062_1071_Chemical)) (CC and) (NP (NNP Doc_16725121_1076_1083_Chemical)))) (VP (VBN induced) (PP (IN by) (NP (NP (VBN repeated) (NN administration)) (PP (IN of) (NP (NNP Doc_16725121_1122_1133_Chemical)))))))))) (. .)))
16725121	7	(S1 (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NN down-regulation)) (PP (IN of) (NP (NP (JJ hippocampal) (NN NET)) (VP (VBN induced) (PP (IN by) (NP (NP (NN chronic) (NN administration)) (PP (IN of) (NP (NNP Doc_16725121_1234_1245_Chemical))))))))) (VP (MD may) (VP (AUX be) (ADJP (JJ relevant) (PP (TO to) (NP (NP (JJ Doc_16725121_1265_1276_Chemical-induced) (NN sensitization)) (PP (IN of) (NP (NNP Doc_16725121_1302_1311_Chemical) (NNP Doc_16725121_1312_1323_Disease))))))))))) (. .)))
16725121	8	(S1 (S (NP (NP (NN Inhibition)) (PP (IN of) (NP (NNP Doc_16725121_1339_1344_Chemical) (NNS channels))) (PP (IN by) (NP (JJ local) (NNS anesthetics)))) (VP (MD may) (VP (VB regulate) (NP (NP (JJ Doc_16725121_1388_1399_Chemical-induced) (NN down-regulation)) (PP (IN of) (NP (JJ NET) (NN function)))))) (. .)))
16725121	9	(S1 (S (NP (NP (VBN Repeated) (NN administration)) (PP (IN of) (NP (NNP Doc_16725121_1468_1475_Chemical)))) (VP (VBZ induces) (NP (NP (NN up-regulation)) (PP (IN of) (NP (JJ hippocampal) (JJ NET) (NN function))))) (. .)))
16725121	10	(S1 (S (NP (NP (JJ Doc_16725121_1527_1538_Chemical-induced) (NN sensitization)) (PP (IN of) (NP (NNP Doc_16725121_1564_1573_Chemical) (NNP Doc_16725121_1574_1582_Disease)))) (VP (MD may) (VP (AUX have) (NP (NP (DT a) (NN mechanism)) (ADJP (JJ distinct) (PP (IN from) (NP (NP (NN kindling)) (VP (VBG resulting) (PP (IN from) (NP (NP (VBN repeated) (NN administration)) (PP (IN of) (NP (NNP Doc_16725121_1669_1676_Chemical)))))))))))) (. .)))
16820346	0	(S1 (S (NP (NN Doc_16820346_0_12_Chemical)) (VP (VP (VBD prevented)) (CC and) (VP (VBD reversed) (NP (JJ Doc_16820346_36_49_Chemical-induced) (NN Doc_16820346_58_70_Disease)) (PP (IN in) (NP (DT the) (NN rat))))) (. .)))
16820346	1	(S1 (S (S (VP (TO To) (VP (VB assess) (NP (NP (DT the) (JJ antioxidant) (NNS effects)) (PP (IN of) (NP (NP (NNP Doc_16820346_120_132_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_16820346_134_140_Chemical)) (-RRB- -RRB-)))) (PP (IN on) (NP (JJ Doc_16820346_145_158_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_16820346_160_163_Chemical)) (-RRB- -RRB-)) (JJ -induced) (NN Doc_16820346_173_185_Disease))))))) (, ,) (NP (CD 60) (JJ male) (NNP Sprague-Dawley) (NNS rats)) (VP (AUX were) (VP (VP (VBN treated) (PP (IN with) (NP (NNP Doc_16820346_233_239_Chemical) (CD 30) (NN mg/kg/day)))) (CC or) (VP (VB tap) (NP (NN water)) (PP (IN for) (NP (CD 15) (NNS days)))))) (. .)))
16820346	2	(S1 (S (NP (NNP Doc_16820346_279_282_Chemical)) (VP (VBD increased) (NP (JJ systolic) (NN blood) (NN pressure)) (PRN (-LRB- -LRB-) (ADVP (RB SBP)) (-RRB- -RRB-)) (PP (IN from) (NP (NP (NP (CD 109) (NN +/-)) (NP (QP (CD 1.8) (TO to) (CD 135)) (JJ +/-) (CD 0.6) (NNS mmHg))) (CC and) (NP (NN plasma) (NN Doc_16820346_371_381_Chemical)))) (PRN (-LRB- -LRB-) (NP (CD 5711) (NN +/-) (CD 284.9) (NN saline)) (, ,) (NP (CD 7931) (NN +/-) (CD 392.8) (NNP U/ml) (NN dex)) (, ,) (NP (NNP P)) (NP (NN <) (CD 0.001)) (-RRB- -RRB-))) (. .)))
16820346	3	(S1 (S (PP (IN In) (NP (DT this) (NN prevention) (NN study))) (, ,) (S (NP (NP (NN SBP)) (PP (IN in) (NP (DT the) (NNP Doc_16820346_480_486_Chemical) (NNP +) (NNP Doc_16820346_489_492_Chemical) (NN group)))) (VP (AUX was) (VP (VBN increased) (PP (IN from) (NP (NP (CD 115) (NN +/-)) (NP (QP (CD 0.4) (TO to) (CD 124)) (JJ +/-) (CD 1.5) (NNS mmHg))))))) (, ,) (CC but) (S (NP (DT this)) (VP (AUX was) (ADJP (ADJP (RB significantly) (JJR lower)) (PP (IN than) (PP (IN in) (NP (DT the) (JJ Doc_16820346_596_599_Chemical-only) (NN group))))) (PRN (-LRB- -LRB-) (S (NP (NNP P) (POS ')) (VP (VBG <) (NP (CD 0.05)))) (-RRB- -RRB-)))) (. .)))
16820346	4	(S1 (S (NP (NNP Doc_16820346_624_630_Chemical)) (VP (VBD reversed) (NP (NP (NP (NNP Doc_16820346_640_643_Chemical-induced) (NNP Doc_16820346_652_664_Disease)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 129) (NN +/-)) (NP (CD 0.6) (NNS mmHg))) (, ,) (CC vs.) (NP (NP (CD 135) (NN +/-)) (NP (NP (CD 0.6) (JJ mmHg) (NNS P) (POS ')) (NNP <) (CD 0.05)))) (-RRB- -RRB-))) (CC and) (NP (NP (VBN decreased) (NN plasma) (NNP Doc_16820346_737_747_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 7931) (NN +/-) (CD 392.8) (NNP Doc_16820346_764_767_Chemical)) (, ,) (NP (CD 1187) (CD +/-) (CD 441.2) (NNP Doc_16820346_784_790_Chemical) (NNP +) (NNP Doc_16820346_793_796_Chemical))) (, ,) (NP (NNP P) (QP (CD <) (CD 0.0001))) (-RRB- -RRB-))))) (. .)))
16820346	5	(S1 (S (NP (NP (NN Plasma) (NNP Doc_16820346_818_825_Chemical/Doc_16820346_826_833_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP NOx)) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN decreased) (PP (IN in) (NP (JJ Doc_16820346_857_860_Chemical-treated) (NNS rats))) (PP (VBN compared) (PP (TO to) (NP (NP (JJ saline-treated) (NNS rats)) (PRN (-LRB- -LRB-) (NP (NP (CD 11.2) (NN +/-) (CD 1.08) (NN microm)) (, ,) (NP (NP (CD 15.3) (NN +/-)) (NP (CD 1.17) (NN microm)) (, ,) (ADVP (RB respectively)))) (, ,) (NP (NP (CD P) (NNS <)) (NP (CD 0.05))) (-RRB- -RRB-))))))) (. .)))
16820346	6	(S1 (S (NP (NN Doc_16820346_976_982_Chemical)) (VP (VBD affected) (NP (DT neither) (NN plasma) (NN NOx) (CC nor) (NN thymus) (NN weight))) (. .)))
16820346	7	(S1 (S (ADVP (RB Thus)) (, ,) (NP (NNP Doc_16820346_1036_1048_Chemical)) (VP (VP (VBD prevented)) (CC and) (VP (VBD reversed) (NP (JJ Doc_16820346_1072_1085_Chemical-induced) (NN Doc_16820346_1094_1106_Disease)) (PP (IN in) (NP (DT the) (NN rat))))) (. .)))
16826348	0	(S1 (S (NP (NN Doc_16826348_0_21_Disease)) (VP (VBD caused) (PP (IN by) (NP (JJ high-dose) (JJ Doc_16826348_42_62_Chemical) (NN treatment))) (PP (IN in) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (NNP Doc_16826348_91_113_Disease)))))) (. .)))
16826348	1	(S1 (S (S (NP (NP (DT The) (ADJP (JJ central) (JJ nervous)) (NN system) (NN Doc_16826348_142_150_Disease)) (PP (IN of) (NP (JJ high-dose) (NNP Doc_16826348_164_184_Chemical)))) (VP (AUX is) (VP (ADVP (RB well)) (VBN recognized)))) (, ,) (CC but) (S (NP (NP (DT the) (NNP Doc_16826348_213_221_Disease)) (PP (IN of) (NP (NNP Doc_16826348_225_245_Chemical))) (PP (IN in) (NP (DT the) (JJ peripheral) (JJ nervous) (NN system)))) (VP (AUX has) (VP (AUX been) (ADVP (RB infrequently)) (VP (VBN reported))))) (. .)))
16826348	2	(S1 (S (NP (DT A) (JJ 49-year-old) (JJ Japanese) (NN man)) (VP (AUX was) (VP (VBN diagnosed) (PP (IN with) (NP (NNP Doc_16826348_357_379_Disease))))) (. .)))
16826348	3	(S1 (S (SBAR (IN After) (S (NP (PRP he)) (VP (VBD achieved) (NP (JJ complete) (NN remission))))) (, ,) (NP (PRP he)) (VP (VBD received) (NP (NP (JJ high-dose) (JJ Doc_16826348_441_461_Chemical) (NN treatment)) (PRN (-LRB- -LRB-) (NP (NP (NP (NP (CD 2) (NN g/m2)) (NP (RB twice) (DT a) (NN day))) (PP (IN for) (NP (CD 5) (NNS days)))) (: ;) (NP (NN total)) (, ,) (NP (CD 20) (NN g/m2))) (-RRB- -RRB-))) (PP (IN as) (NP (NN consolidation) (NN therapy)))) (. .)))
16826348	4	(S1 (S (S (NP (NP (DT The) (JJ first) (NN course)) (PP (IN of) (NP (JJ high-dose) (NNP Doc_16826348_576_596_Chemical)))) (VP (VBD resulted) (PP (IN in) (NP (DT no) (JJ unusual) (NNS symptoms))))) (, ,) (CC but) (S (PP (IN on) (NP (NP (NN day) (CD 21)) (PP (IN of) (NP (NP (DT the) (JJ second) (NN course)) (PP (IN of) (NP (NN treatment))))))) (, ,) (NP (DT the) (NN patient)) (VP (VBD complained) (PP (IN of) (NP (NNP Doc_16826348_705_713_Disease))) (PP (IN in) (NP (PRP$ his) (JJ right) (NN foot))))) (. .)))
16826348	5	(S1 (S (NP (NP (NN Electromyogram)) (CC and) (NP (NN nerve-conduction) (NNS studies))) (VP (VBD showed) (NP (NNP Doc_16826348_784_805_Disease)) (PP (IN in) (NP (DT both) (JJ peroneal) (NNS nerves)))) (. .)))
16826348	6	(S1 (S (S (NP (DT This) (NN Doc_16826348_836_846_Disease)) (VP (AUX was) (ADVP (RB gradually)) (VP (VBG resolving)))) (: ;) (S (ADVP (RB however)) (, ,) (SBAR (IN after) (S (NP (DT the) (NN patient)) (VP (VBD received) (NP (JJ allogeneic) (NN bone) (NN marrow) (NN transplantation))))) (, ,) (NP (DT the) (NNS symptoms)) (VP (VBD worsened) (, ,) (PP (IN with) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_16826348_995_1020_Disease))))) (, ,) (SBAR (S (CC and) (NP (DT the) (NNS symptoms)) (ADVP (RB subsequently)) (VP (VBD responded) (PP (TO to) (NP (NNP Doc_16826348_1065_1083_Chemical)))))))) (. .)))
16826348	7	(S1 (S (S (SBAR (IN Although) (S (NP (NP (DT the) (NNS mechanisms)) (PP (IN of) (NP (NNP Doc_16826348_1112_1133_Disease)))) (VP (AUX are) (ADVP (RB still)) (ADJP (JJ unclear))))) (, ,) (NP (JJ high-dose) (NNP Doc_16826348_1163_1183_Chemical)) (VP (AUX is) (NP (NP (DT a) (NN therapy)) (SBAR (WHNP (WDT that)) (S (VP (AUX is) (ADJP (RB potentially) (JJ toxic) (PP (TO to) (NP (DT the) (JJ peripheral) (JJ nervous) (NN system)))))))))) (, ,) (CC and) (S (NP (NN auto/alloimmunity)) (VP (MD may) (VP (VB play) (NP (DT an) (JJ important) (NN role)) (PP (IN in) (NP (DT these) (NNS mechanisms)))))) (. .)))
16844102	0	(S1 (NP (NP (NN Effect)) (PP (IN of) (NP (NP (NNP Doc_16844102_10_26_Chemical)) (CC and) (NP (NNP Doc_16844102_31_43_Chemical)))) (PP (IN on) (NP (NNP Doc_16844102_47_62_Chemical-induced) (NNP Doc_16844102_71_84_Disease))) (. .)))
16844102	1	(S1 (S (NP (NP (NNP Doc_16844102_86_101_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_16844102_103_105_Chemical)) (-RRB- -RRB-))) (VP (VBD -induced) (SBAR (S (NP (JJ dopaminergic) (NN Doc_16844102_128_141_Disease)) (VP (AUX is) (VP (VBN believed) (S (VP (TO to) (VP (AUX be) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (VBN increased) (NN formation)) (PP (IN of) (NP (JJ free) (NNS radicals)))))))))))))) (. .)))
16844102	2	(S1 (S (NP (DT This) (NN study)) (VP (VBD examined) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (NP (NP (NNP Doc_16844102_252_268_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_16844102_270_278_Chemical)) (-RRB- -RRB-))) (, ,) (NP (NP (DT a) (NN scavenger)) (PP (IN of) (NP (JJ reactive) (JJ Doc_16844102_305_311_Chemical) (NNS species)))) (, ,)) (CC and) (NP (NP (NP (NNP Doc_16844102_325_337_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_16844102_339_342_Chemical)) (-RRB- -RRB-))) (, ,) (NP (DT an) (NNP Doc_16844102_348_352_Chemical) (NN chelator)) (, ,)))) (PP (IN on) (NP (DT the) (JJ MA-induced) (NNP Doc_16844102_381_394_Disease))))) (. .)))
16844102	3	(S1 (S (NP (JJ Male) (NNS rats)) (VP (AUX were) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_16844102_424_426_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 10) (NN mg/kg)) (, ,) (NP (NP (DT every) (CD 2) (NNP h)) (PP (IN for) (NP (CD four) (NNS injections))))) (-RRB- -RRB-)))))) (. .)))
16844102	4	(S1 (S (NP (DT The) (NN rat)) (VP (VBD received) (NP (NP (DT either) (NNP Doc_16844102_494_502_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 20) (NN mg/kg)) (-RRB- -RRB-))) (PP (RB intraperitoneally) (PP (IN for) (NP (CD 3) (NNS days))) (CC and) (ADVP (NP (CD 30) (NN min)) (RB prior)) (PP (TO to) (NP (NP (NNP MA) (NN administration)) (CC or) (NP (NP (NNP Doc_16844102_584_587_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 50) (NN mg/kg)) (-RRB- -RRB-)))))) (ADVP (RB subcutaneously)) (NP (CD 30) (NN min)) (PP (IN before) (NP (NNP MA) (NN administration)))) (. .)))
16844102	5	(S1 (S (NP (NP (DT The) (NNS concentrations)) (PP (IN of) (NP (NP (NP (NNP Doc_16844102_669_677_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP DA)) (-RRB- -RRB-))) (, ,) (NP (NNP Doc_16844102_684_693_Chemical)) (CC and) (NP (PRP$ their) (NNS metabolites))))) (VP (VBD decreased) (ADVP (RB significantly)) (SBAR (IN after) (S (NP (NP (NNP MA) (NN administration)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX was) (VP (VBD inhibited) (PP (IN by) (NP (DT the) (NNP Doc_16844102_792_800_Chemical) (CC and) (NNP Doc_16844102_805_808_Chemical) (NN pretreatment.) (NNP Doc_16844102_823_831_Chemical) (CC and) (NNP Doc_16844102_836_839_Chemical)))))))) (VP (VBD attenuated) (NP (NP (DT the) (JJ Doc_16844102_855_857_Chemical-induced) (NN Doc_16844102_866_878_Disease)) (CONJP (RB as) (RB well) (IN as)) (NP (NP (DT the) (NNS alterations)) (PP (IN in) (NP (DT the) (NN locomotor) (NN activity))))))))) (. .)))
16844102	6	(S1 (S (S (NP (NP (DT The) (NN level)) (PP (IN of) (NP (NN lipid) (NN peroxidation)))) (VP (AUX was) (ADJP (JJR higher)))) (CC and) (S (NP (DT the) (VBN reduced) (JJ Doc_16844102_992_1003_Chemical) (NN concentration)) (VP (AUX was) (ADJP (JJR lower)) (PP (IN in) (NP (DT the) (JJ MA-treated) (NNS rats))))) (. .)))
16844102	7	(S1 (S (NP (DT These) (NNS changes)) (VP (AUX were) (ADVP (RB significantly)) (VP (VBN attenuated) (PP (IN by) (NP (NP (NNP Doc_16844102_1099_1107_Chemical)) (CC and) (NP (NNP Doc_16844102_1112_1115_Chemical)))))) (. .)))
16844102	8	(S1 (S (NP (DT This)) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NP (NNP Doc_16844102_1136_1144_Chemical)) (CC and) (NP (NNP Doc_16844102_1149_1152_Chemical))) (VP (VBP ameliorate) (NP (DT the) (JJ MA-induced) (NN Doc_16844102_1179_1194_Disease)) (PP (IN by) (S (VP (VBG decreasing) (NP (NP (DT the) (NN level)) (PP (IN of) (NP (JJ oxidative) (NN stress))))))))))) (. .)))
1687392	0	(S1 (S (NP (NP (NN Blockade)) (PP (IN of) (NP (DT both) (JJ D-1) (CC and) (JJ D-2) (JJ Doc_1687392_29_37_Chemical) (NNS receptors)))) (VP (MD may) (VP (VB induce) (NP (NN Doc_1687392_59_68_Disease)) (PP (IN in) (NP (NNP mice.) (CD 1))))) (. .)))
1687392	1	(S1 (S (S (NP (NP (DT The) (NNP Doc_1687392_85_94_Disease)) (VP (VBN induced) (PP (IN by) (NP (JJ Doc_1687392_106_114_Chemical) (NNS antagonists))))) (VP (AUX has) (VP (AUX been) (VP (VBN tested))))) (CC and) (S (NP (NP (DT the) (JJ possible) (JJ Doc_1687392_160_168_Chemical) (NNS subtypes)) (VP (VBN involved) (PP (IN in) (NP (NNP Doc_1687392_190_199_Disease))))) (VP (AUX was) (VP (VBN determined.) (NP (CD 2))))) (. .)))
1687392	2	(S1 (S (NP (NP (JJ Doc_1687392_219_227_Chemical) (NN antagonist) (NNP Doc_1687392_239_251_Chemical)) (, ,) (NP (JJ D-1) (NN antagonist) (NNP Doc_1687392_268_277_Chemical)) (CC or) (NP (JJ D-2) (NN antagonist) (NNP Doc_1687392_296_305_Chemical))) (VP (VBN induced) (NP (NNP Doc_1687392_314_323_Disease))) (. .)))
1687392	3	(S1 (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NP (NNP Doc_1687392_339_351_Chemical)) (CC and) (NP (NNP Doc_1687392_356_365_Chemical))))) (VP (AUX was) (ADJP (JJ dose-dependent))) (. .)))
1687392	4	(S1 (S (NP (NP (NN Combination)) (PP (IN of) (NP (NNP Doc_1687392_401_410_Chemical))) (PP (IN with) (NP (NNP Doc_1687392_416_425_Chemical)))) (VP (AUX did) (RB not) (VP (VB induce) (NP (NN Doc_1687392_441_450_Disease) (NN potentiation.) (CD 3)))) (. .)))
1687392	5	(S1 (S (NP (JJ D-1) (JJ agonist) (ADJP (JJ Doc_1687392_480_489_Chemical) (CC or) (JJ D-2)) (NN agonist) (NN Doc_1687392_505_515_Chemical)) (VP (VBD decreased) (NP (NP (DT the) (NN Doc_1687392_530_539_Disease)) (VP (VBN induced) (PP (IN by) (NP (NP (NNP Doc_1687392_551_563_Chemical)) (, ,) (NP (NNP Doc_1687392_565_574_Chemical)) (CC or) (NP (NNP Doc_1687392_578_587_Chemical.) (CD 4))))))) (. .)))
1687392	6	(S1 (S (NP (NP (NN Combination)) (PP (IN of) (NP (NNP Doc_1687392_607_616_Chemical))) (PP (IN with) (NP (NNP Doc_1687392_622_632_Chemical)))) (VP (AUX did) (RB not) (VP (VB cause) (NP (NP (JJ potentiated) (JJ inhibitory) (NN effect)) (PP (IN on) (NP (NP (NNP Doc_1687392_680_689_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_1687392_701_709_Chemical) (NN antagonists.) (CD 5))))))))) (. .)))
1687392	7	(S1 (S (NP (DT The) (NNS data)) (VP (MD may) (VP (VB indicate) (SBAR (IN that) (S (SBAR (IN although) (S (NP (JJ D-2) (NN receptor) (NN blockade)) (VP (AUX is) (VP (VBN involved) (PP (IN in) (NP (NNP Doc_1687392_799_808_Disease))))))) (, ,) (NP (DT the) (JJ D-1) (NN receptor)) (VP (MD may) (VP (VB plan) (NP (DT a) (NN role)))))))) (. .)))
16960342	0	(S1 (S (NP (NP (JJ Sustained) (JJ clinical) (NN improvement)) (PP (IN of) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (JJ decompensated) (NNP Doc_16960342_63_74_Disease)))))) (VP (VBD virus-related) (NP (NNP Doc_16960342_89_98_Disease)) (PP (IN after) (NP (NP (NN treatment)) (PP (IN with) (NP (NNP Doc_16960342_120_130_Chemical) (CD monotherapy)))))) (. .)))
16960342	1	(S1 (S (NP (NP (NN Doc_16960342_144_177_Disease)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ causes) (NP (NP (NNP Doc_16960342_192_207_Disease)) (CC and) (NP (NNP Doc_16960342_212_236_Disease)))))) (, ,)) (VP (VBZ remains) (NP (NP (DT a) (JJ major) (NN health) (NN problem)) (PP (IN in) (NP (JJ Asian) (NNS countries))))) (. .)))
16960342	2	(S1 (S (NP (NP (JJ Recent) (NN development)) (PP (IN of) (NP (NN vaccine))) (PP (IN for) (NP (NN prevention)))) (VP (AUX is) (VP (VBN reported) (S (VP (TO to) (VP (AUX be) (ADJP (JJ successful) (PP (IN in) (S (VP (VBG reducing) (NP (NP (DT the) (NN size)) (PP (IN of) (NP (RB chronically) (JJ infected) (NNS carriers))))))))))) (, ,) (SBAR (IN although) (S (NP (DT the) (JJ standard) (JJ medical) (NNS therapies)) (VP (AUX have) (RB not) (VP (AUX been) (VP (VBN established) (PRT (RP up)) (PP (TO to) (NP (RB now)))))))))) (. .)))
16960342	3	(S1 (S (PP (IN In) (NP (DT this) (NN report))) (, ,) (NP (PRP we)) (VP (VBD encountered) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (NP (JJ decompensated) (JJ HBV-related) (NN Doc_16960342_567_576_Disease)) (SBAR (WHNP (WP who)) (S (VP (VBD exhibited) (NP (DT the) (JJ dramatic) (NNS improvements)) (PP (IN after) (NP (JJ antiviral) (NN therapy)))))))))) (. .)))
16960342	4	(S1 (S (NP (DT The) (NN patient)) (VP (AUX was) (NP (DT a) (JJ 50-year-old) (NN woman))) (. .)))
16960342	5	(S1 (S (S (NP (JJ Previous) (JJ conventional) (JJ medical) (NNS treatments)) (VP (AUX were) (RB not) (ADJP (JJ effective)) (PP (IN for) (NP (DT this) (NN patient))))) (, ,) (S (ADVP (RB thus)) (NP (DT this) (NN patient)) (VP (AUX had) (VP (AUX been) (VP (VBN referred) (PP (TO to) (NP (PRP$ our) (NN hospital))))))) (. .)))
16960342	6	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NP (NNP Doc_16960342_841_851_Chemical)) (, ,) (NP (DT a) (JJ reverse) (NN transcriptase) (NN inhibitor)) (, ,))) (PP (IN for) (NP (CD 23) (NNS months)))) (ADVP (RB dramatically)) (VP (VBD improved) (NP (PRP$ her) (NN liver) (NN severity))) (. .)))
16960342	7	(S1 (S (PP (IN During) (NP (DT this) (NN period))) (, ,) (S (NP (DT no) (NN drug) (NN resistant) (JJ mutant) (NN HBV)) (VP (VBD emerged))) (, ,) (CC and) (S (NP (DT the) (JJ serum) (NN HBV-DNA) (NN level)) (VP (AUX was) (ADVP (RB continuously)) (VP (VBN suppressed)))) (. .)))
16960342	8	(S1 (S (NP (DT These) (JJ virological) (NNS responses)) (VP (AUX were) (ADVP (RB also)) (VP (VBN maintained) (SBAR (RB even) (IN after) (S (NP (DT the) (JJ antiviral) (NN therapy)) (VP (AUX was) (VP (VBN discontinued))))))) (. .)))
16960342	9	(S1 (S (ADVP (RB Moreover)) (, ,) (NP (DT both) (NNP Doc_16960342_1174_1185_Disease) (NN surface) (NN antigen) (CC and) (NN e) (NN antigen)) (VP (AUX were) (VP (VBN observed) (S (VP (TO to) (VP (AUX have) (VP (VBN disappeared) (PP (IN in) (NP (DT this) (NN patient))))))))) (. .)))
16960342	10	(S1 (S (NP (NP (DT The) (NN administration)) (PP (IN of) (NP (NNP Doc_16960342_1289_1299_Chemical))) (PP (TO to) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ HBV-related) (NNP Doc_16960342_1329_1338_Disease)))))) (, ,) (PP (IN like) (NP (PRP$ our) (JJ present) (NN case))) (, ,) (VP (MD should) (VP (AUX be) (VP (VBN considered) (PP (IN as) (NP (DT an) (JJ initial) (JJ medical) (JJ therapeutic) (NN option))) (, ,) (PP (ADVP (RB especially)) (IN in) (NP (NP (NNS countries)) (SBAR (WHADVP (WRB where)) (S (NP (NN liver) (NN transplantation)) (VP (AUX is) (RB not) (ADVP (RB reliably)) (ADJP (JJ available)))))))))) (. .)))
1700207	0	(S1 (S (NP (NP (JJ Antiarrhythmic) (NNS effects)) (PP (IN of) (NP (NP (JJ optical) (NNS isomers)) (PP (IN of) (NP (NNP Doc_1700207_45_56_Chemical))))) (PP (IN on) (NP (NN canine)))) (VP (VBP Doc_1700207_67_90_Disease)) (. .)))
1700207	1	(S1 (S (NP (NP (NP (JJ Antiarrhythmic) (NNS effects)) (PP (IN of) (NP (PRN (-LRB- -LRB-) (NP (NNP +)) (-RRB- -RRB-)) (NN -Doc_1700207_122_133_Chemical)))) (CC and) (NP (LST (-LRB- -LRB-) (: -) (-RRB- -RRB-)) (NN -Doc_1700207_142_153_Chemical))) (VP (AUX were) (VP (VBN examined) (S (VP (VBG using) (NP (CD two) (JJ canine) (NNP Doc_1700207_185_207_Disease) (NNS models)))))) (. .)))
1700207	2	(S1 (S (NP (NP (NNP Digitalis) (NNP Doc_1700207_226_236_Disease)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX is) (VP (VBN suppressed) (PP (IN by) (NP (JJ Doc_1700207_261_263_Chemical) (NN channel) (NNS blockers))))))) (, ,)) (VP (AUX was) (VP (VBN induced) (PP (IN by) (NP (NP (JJ intermittent) (JJ intravenous) (PRN (-LRB- -LRB-) (NP (NN i.v.)) (-RRB- -RRB-)) (NN injection)) (PP (IN of) (NP (NNP Doc_1700207_342_349_Chemical))) (PP (IN in) (NP (JJ Doc_1700207_353_366_Chemical-anesthetized) (NNS dogs))))))) (. .)))
1700207	3	(S1 (S (NP (NP (JJ Doc_1700207_386_396_Chemical) (NN arrhythmia)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX is) (VP (VBN suppressed) (PP (IN by) (NP (JJ Doc_1700207_432_434_Chemical) (NN channel) (NNS blockers))))))) (, ,)) (VP (AUX was) (VP (VBN induced) (PP (IN by) (NP (JJ Doc_1700207_468_478_Chemical) (NN infusion))) (PP (IN in) (NP (JJ Doc_1700207_491_500_Chemical-anesthetized) (NNS dogs))))) (. .)))
1700207	4	(S1 (S (NP (NP (NN Doc_1700207_520_523_Chemical)) (CC and) (NP (ADJP (CD 5) (NN mg/kg)) (NN i.v.) (PRN (-LRB- -LRB-) (NNP +) (-RRB- -RRB-)) (NN -Doc_1700207_545_556_Chemical))) (VP (VBD suppressed) (NP (NP (NNP Doc_1700207_568_577_Chemical-)) (CC and) (NP (NP (NNP Doc_1700207_583_593_Chemical-induced) (NNP Doc_1700207_602_613_Disease)) (, ,) (ADVP (RB respectively))))) (. .)))
1700207	5	(S1 (S (NP (NP (DT The) (JJ minimum) (JJ effective) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (PRN (-LRB- -LRB-) (NP (NNP +)) (-RRB- -RRB-)) (JJ -Doc_1700207_680_691_Chemical))) (PP (IN for) (NP (NP (NNP Doc_1700207_696_705_Chemical-)) (CC and) (NP (NNP Doc_1700207_711_721_Chemical-induced) (NNP Doc_1700207_730_741_Disease))))) (VP (AUX were) (NP (CD 1.4) (ADJP (JJ +/-) (NP (CD 0.4) (CC and) (CD 2.0))) (JJ +/-) (CD 0.6) (NN micrograms/ml)) (, ,) (ADVP (RB respectively)) (PRN (-LRB- -LRB-) (NP (JJ mean) (JJ +/-) (NNS SD)) (, ,) (NP (NNP n) (SYM =) (CD 6)) (-RRB- -RRB-))) (. .)))
1700207	6	(S1 (S (NP (NP (DT A) (JJR lower) (NN dose)) (PP (IN of) (NP (NP (QP (CD 1) (CD mg/kg)) (NNS i.v.)) (PP (IN of) (S (LST (-LRB- -LRB-) (: -)) (-RRB- -RRB-) (NP (NN -Doc_1700207_861_872_Chemical))))))) (VP (VBD suppressed) (NP (DT the) (JJ Doc_1700207_888_897_Chemical-induced) (NN Doc_1700207_906_916_Disease)) (, ,) (SBAR (IN whereas) (S (NP (CD 5) (JJ mg/kg) (NN i.v.)) (VP (AUX was) (VP (VBN needed) (S (VP (TO to) (VP (VB suppress) (NP (JJ Doc_1700207_962_972_Chemical-induced) (NN Doc_1700207_981_992_Disease)))))))))) (. .)))
1700207	7	(S1 (S (NP (NP (DT The) (JJ minimum) (JJ effective) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (LST (-LRB- -LRB-) (: -) (-RRB- -RRB-)) (NP (JJ -Doc_1700207_1045_1056_Chemical)) (PP (IN for) (NP (NNP Doc_1700207_1061_1070_Chemical-) (CC and) (NNP Doc_1700207_1076_1086_Chemical-induced) (NNP Doc_1700207_1095_1105_Disease)))))) (VP (AUX were) (NP (NP (CD 0.06) (JJ +/-) (NNS 0.04)) (CC and) (NP (NP (NP (CD 0.7) (NNS +/-)) (NP (CD 0.1) (NN micrograms/ml)) (, ,) (ADVP (RB respectively))) (PRN (-LRB- -LRB-) (NP (NP (JJ mean) (JJ +/-) (NNS SD)) (, ,) (NP (NNP n) (SYM =) (CD 6))) (-RRB- -RRB-))))) (. .)))
1700207	8	(S1 (S (NP (NP (DT The) (JJR stronger) (JJ antiarrhythmic) (NN effect)) (PP (IN of) (NP (NP (NP (LST (-LRB- -LRB-) (: -) (-RRB- -RRB-)) (NP (ADJP (JJ -Doc_1700207_1233_1244_Chemical) (SBAR (S (VP (VBZ indicates) (SBAR (IN that) (S (LST (-LRB- -LRB-) (: -) (-RRB- -RRB-)) (NP (NN -isomer)) (VP (MD may) (VP (AUX have) (NP (DT an) (NN effect))))))))) (QP (RB nearly) (CD 5-20) (NNS times))) (JJR stronger)) (PP (IN in) (NP (JJ suppressing) (NNP Doc_1700207_1332_1334_Chemical) (NNS channels)))) (, ,) (CC but) (NP (NNS effects))) (PP (IN of) (NP (NP (DT both) (NNS drugs)) (PP (IN on) (NP (NNP Doc_1700207_1374_1376_Chemical) (NNS channels)))))))) (VP (MD may) (VP (AUX be) (ADJP (RB almost) (JJ equipotent)))) (. .)))
17019386	0	(S1 (NP (NP (NP (NN Passage)) (PP (IN of) (NP (NNP Doc_17019386_11_19_Chemical))) (PP (IN into) (NP (DT the) (NN brain))) (PP (IN around) (NP (NNP Doc_17019386_42_49_Disease)))) (: :) (NP (NP (DT a) (JJ potential) (NN cause)) (PP (IN of) (NP (NN rebound) (NN phenomenon)))) (. .)))
17019386	1	(S1 (NP (NP (DT A) (NN study)) (PP (IN on) (NP (CD 21) (NNS patients))) (. .)))
17019386	2	(S1 (S (NP (NP (JJ Widespread) (NN use)) (PP (IN of) (NP (NNP Doc_17019386_139_147_Chemical))) (S (VP (TO to) (VP (VP (VB reduce) (NP (NNP Doc_17019386_158_169_Disease))) (CC and) (VP (VB lower) (NP (NP (NN Doc_17019386_180_192_Disease)) (PP (IN in) (NP (NNP Doc_17019386_196_207_Disease) (NNS patients))))))))) (VP (VBZ continues) (S (VP (TO to) (VP (AUX be) (VP (VBN afflicted) (PP (IN by) (NP (DT the) (JJ so-called) (NN rebound) (NN phenomenon)))))))) (. .)))
17019386	3	(S1 (S (NP (NP (NN Leakage)) (PP (IN of) (NP (NNP Doc_17019386_291_299_Chemical))) (PP (IN into) (NP (DT the) (NN brain) (NN parenchyma))) (PP (IN through) (NP (NP (DT an) (JJ altered) (NNP BBB) (CC and) (JJ secondary) (NN reversal)) (PP (IN of) (NP (JJ osmotic) (NN gradient)))))) (VP (AUX is) (VP (VBN considered) (S (NP (NP (DT the) (JJ major) (NN cause)) (PP (IN of) (NP (NN rebound))))))) (. .)))
17019386	4	(S1 (S (NP (DT This)) (VP (AUX has) (ADVP (RB only)) (VP (AUX been) (VP (VBN demonstrated) (ADVP (RB experimentally)) (PP (IN in) (NP (NNS animals)))))) (. .)))
17019386	5	(S1 (S (PP (IN As) (NP (NP (DT a) (NN contribution)) (PP (TO to) (NP (DT this) (NN issue))))) (NP (PRP we)) (VP (VBD decided) (S (VP (TO to) (VP (VB research) (NP (NP (DT the) (JJ possible) (NN passage)) (PP (IN of) (NP (NNP Doc_17019386_573_581_Chemical)))) (PP (IN into) (NP (DT the) (NN brain))) (PP (IN after) (NP (NN administration))) (PP (TO to) (NP (CD 21) (NNP Doc_17019386_624_635_Disease) (NNS patients))))))) (. .)))
17019386	6	(S1 (S (NP (NP (NNP Doc_17019386_655_663_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (ADJP (CD 18) (NN %)) (NN solution)) (: ;) (NP (CD 1) (NN g/kg))) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN administered) (PP (IN as) (NP (NP (DT a) (NN bolus)) (PP (TO to) (NP (NP (NNS patients)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD ten)) (VP (AUX had) (ADJP (JJ Doc_17019386_736_752_Disease)))) (, ,) (NP (NP (CD seven) (NN brain)) (NP (NNP Doc_17019386_766_776_Disease))) (CC and) (NP (NP (CD four)) (NP (NNP Doc_17019386_786_796_Disease)))) (-RRB- -RRB-)))))) (PP (IN about) (NP (NP (CD 30) (NNS minutes)) (PP (IN before) (NP (NN craniotomy))))))) (. .)))
17019386	7	(S1 (S (PP (IN During) (NP (NN resection))) (, ,) (NP (NP (DT a) (NN sample)) (PP (IN of) (NP (DT the) (VBG surrounding) (NNP Doc_17019386_880_889_Disease) (JJ white) (NN matter)))) (VP (AUX was) (VP (VBN taken) (PP (IN at) (NP (DT the) (JJ same) (NN time))) (PP (IN as) (NP (DT a) (CD 10) (NN ml) (NN venous) (NN blood) (NN sample))))) (. .)))
17019386	8	(S1 (S (NP (JJ Doc_17019386_962_970_Chemical) (NNS concentrations)) (VP (AUX were) (VP (VBN measured) (PP (IN in) (NP (NP (NN plasma)) (CC and) (NP (JJ white) (NN matter)))) (PP (IN by) (NP (NP (DT a) (VBN modified) (NN version)) (PP (IN of) (NP (NP (DT the) (JJ enzyme) (NN assay)) (PP (IN of) (NP (NP (NNP Blonquist)) (CC et) (NP (NNP al)))))))))) (. .)))
17019386	9	(S1 (S (PP (IN In) (NP (JJS most) (NNP Doc_17019386_1106_1112_Disease) (NNS patients))) (, ,) (NP (NP (JJ Doc_17019386_1123_1131_Chemical) (NNS concentrations)) (PP (IN in) (NP (JJ white) (NN matter)))) (VP (AUX were) (ADJP (ADJP (QP (CD 2) (TO to) (CD 6) (NNS times)) (JJR higher)) (PP (IN than) (PP (IN in) (NP (NN plasma))))) (PRN (-LRB- -LRB-) (S (VP (VB mean) (NP (CD 3.5) (NNS times)))) (-RRB- -RRB-))) (. .)))
17019386	10	(S1 (S (PP (IN In) (NP (NNP Doc_17019386_1224_1234_Disease) (CC and) (NNP Doc_17019386_1239_1249_Disease))) (NP (NP (NNS patients) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NNP Doc_17019386_1284_1292_Chemical)))) (VP (AUX were) (ADJP (ADJP (JJR higher)) (PP (IN than) (NP (JJ white) (NN matter) (NNS concentrations)))) (PP (IN except) (PP (IN in) (NP (NP (CD three) (NNS cases)) (PP (IN with) (NP (NP (NN infiltration)) (PP (IN by) (NP (JJ neoplastic) (NNS cells))))))))) (. .)))
17019386	11	(S1 (S (NP (NP (DT The) (NNS results)) (PP (IN of) (NP (PRP$ our) (NN study)))) (VP (VBP show) (SBAR (IN that) (S (PP (ADVP (RB even)) (IN after) (NP (DT a) (JJ single) (NN bolus))) (, ,) (NP (NNP Doc_17019386_1474_1482_Chemical)) (VP (MD may) (VP (VB leak) (PP (IN through) (NP (NP (DT the) (VBN altered) (NNP BBB)) (PP (IN near) (NP (NNP Doc_17019386_1521_1528_Disease))))) (, ,) (S (VP (VP (VBG reversing) (NP (DT the) (JJ initial) (NN plasma-to-blood) (NN osmotic) (NN gradient))) (, ,) (VP (VBG aggravating) (NP (JJ peritumoral) (NNP Doc_17019386_1610_1615_Disease))) (CC and) (VP (VBG promoting) (NP (NP (NN rebound)) (PP (IN of) (NP (NNP ICP)))))))))))) (. .)))
17042884	0	(S1 (NP (NP (JJ Placebo-level) (NN incidence)) (PP (IN of) (NP (NP (NNP Doc_17042884_27_50_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_17042884_52_55_Disease)) (-RRB- -RRB-)))) (PP (IN with) (NP (NP (NNP Doc_17042884_62_72_Chemical)) (PP (IN in) (NP (NP (JJ controlled) (NNS studies)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_17042884_112_125_Disease))))))))) (. .)))
17042884	1	(S1 (FRAG (S (VP (TO To) (VP (VB evaluate) (NP (NP (NN Doc_17042884_151_174_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_17042884_176_179_Disease)) (-RRB- -RRB-)) (, ,) (PP (VBG including) (NP (NNP Doc_17042884_192_201_Disease))) (, ,) (PP (IN with) (NP (NP (NNP Doc_17042884_208_218_Chemical)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_17042884_236_249_Disease))))))))))) (. .)))
17042884	2	(S1 (S (NP (NNS Data)) (VP (AUX were) (VP (VBN analyzed) (PP (IN from) (NP (CD four) (ADJP (RB similarly) (VBN designed)) (, ,) (ADJP (JJ randomized) (, ,) (JJ double-blind) (, ,) (JJ 3-) (TO to) (JJ 12-week)) (NNS studies))))) (. .)))
17042884	3	(S1 (S (NP (CD Two) (NNS studies)) (VP (VBN evaluated) (NP (NP (NP (NP (JJ Doc_17042884_380_390_Chemical) (NN monotherapy)) (PRN (-LRB- -LRB-) (NP (QP (IN up) (TO to) (CD 800)) (NN mg/day)) (-RRB- -RRB-))) (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 209)) (-RRB- -RRB-)) (CC versus) (NP (NP (NN placebo)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 198)) (-RRB- -RRB-)))) (, ,) (PP (IN with) (NP (NP (NNP Doc_17042884_463_470_Chemical) (CC or) (NNP Doc_17042884_474_485_Chemical) (NN monotherapy)) (PP (IN as) (NP (JJ respective) (JJ active) (NNS controls)))))) (. .)))
17042884	4	(S1 (S (NP (CD Two) (NNS studies)) (VP (VBN evaluated) (NP (NP (NNP Doc_17042884_551_561_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (IN up) (TO to) (CD 800)) (NN mg/day)) (-RRB- -RRB-))) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NP (DT a) (NN mood) (NN stabilizer) (-LRB- -LRB-) (NNP Doc_17042884_620_627_Chemical) (CC or) (NNP Doc_17042884_631_641_Chemical)) (, ,) (NP (NNP Doc_17042884_643_646_Chemical) (NNP +) (NNP Doc_17042884_649_651_Chemical/Doc_17042884_652_655_Chemical)) (-RRB- -RRB-) (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 196)) (-RRB- -RRB-))))) (PP (VBN compared) (PP (TO to) (NP (NP (NP (NN placebo) (CC and) (NN mood) (NN stabilizer)) (-LRB- -LRB-) (NP (NNP Doc_17042884_708_711_Chemical) (NNP +) (NNP Doc_17042884_714_716_Chemical/Doc_17042884_717_720_Chemical)) (-RRB- -RRB-)) (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 203)) (-RRB- -RRB-))))) (. .)))
17042884	5	(S1 (S (NP (NN Doc_17042884_733_756_Disease)) (VP (AUX were) (VP (VBN evaluated) (S (VP (VBG using) (NP (NP (NP (DT the) (JJ Simpson-Angus) (NN Scale)) (PRN (-LRB- -LRB-) (NP (NNP SAS)) (-RRB- -RRB-))) (, ,) (NP (NP (DT the) (NNP Barnes) (NNP Akathisia) (NNP Rating) (NNP Scale)) (PRN (-LRB- -LRB-) (NP (NNS BARS)) (-RRB- -RRB-))) (, ,) (NP (JJ adverse) (NN event) (NNS reports)) (CC and) (NP (JJ anticholinergic) (NN drug) (NN usage))))))) (. .)))
17042884	6	(S1 (S (NP (NP (DT The) (NN incidence)) (PP (IN of) (NP (NP (JJ Doc_17042884_931_934_Disease-related) (JJ adverse) (NNS events)) (, ,) (PP (VBG including) (NP (NNP Doc_17042884_969_978_Disease))) (, ,)))) (VP (AUX was) (ADJP (RB no) (JJ different) (PP (IN with) (NP (NP (JJ Doc_17042884_1002_1012_Chemical) (NN monotherapy)) (PRN (-LRB- -LRB-) (NP (CD 12.9) (NN %)) (-RRB- -RRB-)))) (PP (IN than) (PP (IN with) (NP (NN placebo))))) (PRN (-LRB- -LRB-) (NP (CD 13.1) (NN %)) (-RRB- -RRB-))) (. .)))
17042884	7	(S1 (S (ADVP (RB Similarly)) (, ,) (NP (NP (JJ Doc_17042884_1071_1074_Disease-related) (JJ adverse) (NNS events)) (PP (IN with) (NP (NP (NNP Doc_17042884_1103_1106_Chemical) (NNP +) (NNP Doc_17042884_1109_1111_Chemical/Doc_17042884_1112_1115_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 21.4) (NN %)) (-RRB- -RRB-))))) (VP (AUX were) (ADJP (RB no) (JJ different) (PP (IN than) (PP (IN with) (NP (NP (NNP Doc_17042884_1152_1155_Chemical) (NNP +) (NNP Doc_17042884_1158_1160_Chemical/Doc_17042884_1161_1164_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 19.2) (NN %)) (-RRB- -RRB-))))))) (. .)))
17042884	8	(S1 (S (NP (NP (JJ Adverse) (NNS events)) (VP (VBN related) (PP (TO to) (NP (NNP Doc_17042884_1200_1203_Disease))))) (VP (VBD occurred) (PP (IN in) (NP (NP (CD 59.6) (NN %)) (PP (IN of) (NP (NP (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_17042884_1247_1258_Chemical) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 99)) (-RRB- -RRB-)) (NN monotherapy)))))))) (, ,) (SBAR (IN whereas) (S (NP (NP (CD 26.5) (NN %)) (PP (IN of) (NP (NNS patients)))) (VP (VP (VBD treated) (PP (IN with) (NP (NNP Doc_17042884_1320_1327_Chemical)))) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 98)) (-RRB- -RRB-)) (VP (VB monotherapy) (NP (NP (JJ experienced) (JJ adverse) (NNS events)) (VP (VBN related) (PP (TO to) (NP (NNP Doc_17042884_1387_1390_Disease)))))))))) (. .)))
17042884	9	(S1 (S (NP (NP (DT The) (NN incidence)) (PP (IN of) (NP (NNP Doc_17042884_1409_1418_Disease)))) (VP (AUX was) (ADJP (ADJP (JJ low)) (CC and) (ADJP (JJ similar))) (PP (PP (IN with) (NP (NP (NNP Doc_17042884_1444_1454_Chemical) (JJ monotherapy) (PRN (-LRB- -LRB-) (NP (CD 3.3) (NN %)) (-RRB- -RRB-))) (CC and) (NP (NP (NN placebo)) (PRN (-LRB- -LRB-) (NP (CD 6.1) (NN %)) (-RRB- -RRB-))))) (, ,) (CC and) (PP (IN with) (NP (NP (NP (NNP Doc_17042884_1503_1506_Chemical) (NNP +) (NNP Doc_17042884_1509_1511_Chemical/Doc_17042884_1512_1515_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 3.6) (NN %)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_17042884_1527_1530_Chemical) (NNP +) (NNP Doc_17042884_1533_1535_Chemical/Doc_17042884_1536_1539_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 4.9) (NN %)) (-RRB- -RRB-))))))) (. .)))
17042884	10	(S1 (S (NP (NNP Doc_17042884_1548_1555_Chemical)) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (DT a) (ADJP (RB significantly) (JJR higher)) (NN incidence)) (PRN (-LRB- -LRB-) (NP (NNP p) (NNP <) (CD 0.05)) (-RRB- -RRB-)) (PP (IN of) (NP (NNP Doc_17042884_1623_1629_Disease))))) (PRN (-LRB- -LRB-) (NP (CD 18.4) (NN %)) (-RRB- -RRB-)) (SBAR (IN than) (S (NP (NP (NNP Doc_17042884_1643_1653_Chemical) (PRN (-LRB- -LRB-) (NP (CD 5.6) (NN %)) (-RRB- -RRB-)) (: ;) (NP (JJ cerebellar) (NNP Doc_17042884_1673_1679_Disease))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX is) (NP (NP (DT a) (JJ known) (JJ adverse) (NN effect)) (PP (IN of) (NP (NNP Doc_17042884_1716_1723_Chemical))))))) (, ,)) (VP (MD may) (VP (AUX have) (VP (VBN contributed) (PP (TO to) (NP (NP (DT the) (JJ elevated) (NN rate)) (PP (IN of) (NP (NNP Doc_17042884_1770_1776_Disease))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (JJ Doc_17042884_1799_1806_Chemical) (NN therapy)))))))))))))) (. .)))
17042884	11	(S1 (S (NP (NNP Doc_17042884_1816_1827_Chemical)) (VP (VBN induced) (NP (NP (NP (DT a) (ADJP (RB significantly) (JJR higher)) (NN incidence)) (PRN (-LRB- -LRB-) (NP (NNP p) (NNP <) (CD 0.001)) (-RRB- -RRB-))) (PP (IN of) (NP (NP (NP (NNP Doc_17042884_1884_1893_Disease)) (PRN (-LRB- -LRB-) (NP (QP (CD 33.3) (NN %) (CC versus) (CD 5.9) (NN %))) (-RRB- -RRB-))) (, ,) (NP (NNP Doc_17042884_1915_1921_Disease) (PRN (-LRB- -LRB-) (NP (NP (CD 30.3) (NN %)) (CC versus) (NP (CD 7.8) (NN %))) (-RRB- -RRB-))) (, ,) (CC and) (NP (NNP Doc_17042884_1947_1970_Disease) (PRN (-LRB- -LRB-) (NP (NP (CD 35.4) (NN %)) (CC versus) (NP (CD 5.9) (NN %))) (-RRB- -RRB-))))) (PP (IN than) (NP (NNP Doc_17042884_1996_2006_Chemical))))) (. .)))
17042884	12	(S1 (S (NP (DT No) (JJ significant) (NNS differences)) (VP (AUX were) (VP (VBN observed) (PP (IN between) (NP (NP (NNP Doc_17042884_2057_2067_Chemical)) (CC and) (NP (NN placebo)))) (PP (IN on) (NP (NP (NNP SAS)) (CC and) (NP (NNS BARS) (NNS scores)))))) (. .)))
17042884	13	(S1 (S (NP (JJ Anticholinergic) (NN use)) (VP (AUX was) (ADJP (ADJP (JJ low)) (CC and) (ADJP (JJ similar))) (PP (IN with) (NP (NP (NN Doc_17042884_2149_2159_Chemical)) (CC or) (NP (NN placebo))))) (. .)))
17042884	14	(S1 (S (PP (IN In) (NP (NNP Doc_17042884_2188_2201_Disease))) (, ,) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NNP Doc_17042884_2220_2223_Disease))) (, ,) (PP (VBG including) (NP (NNP Doc_17042884_2235_2244_Disease))) (, ,) (PP (IN with) (NP (JJ Doc_17042884_2251_2261_Chemical) (NN therapy)))) (VP (AUX is) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT that)) (PP (IN with) (NP (NN placebo))))))) (. .)))
17049862	0	(S1 (SQ (AUX Is) (NP (NNP Doc_17049862_3_12_Chemical) (NN administration)) (ADJP (JJ safe) (PP (IN in) (NP (DT a) (JJ hypothermic) (NN child)))) (. ?)))
17049862	1	(S1 (S (NP (NP (DT A) (JJ male) (NN neonate)) (PP (IN with) (NP (NP (DT a) (NN Doc_17049862_79_98_Disease)) (CC and) (NP (DT a) (VBG leaking) (NN myelomeningocoele))))) (VP (VBD underwent) (NP (NP (JJ ventriculoperitoneal) (NN shunt) (NN insertion)) (VP (VBN followed) (PP (IN by) (NP (NP (NN repair)) (PP (IN of) (NP (NN myelomeningocoele)))))))) (. .)))
17049862	2	(S1 (S (PP (IN During) (NP (NP (NN anaesthesia)) (CC and) (NP (NN surgery)))) (, ,) (NP (PRP he)) (ADVP (RB inadvertently)) (VP (VBD became) (ADJP (RB moderately) (JJ hypothermic))) (. .)))
17049862	3	(S1 (S (NP (JJ Intravenous) (NNP Doc_17049862_311_320_Chemical)) (VP (AUX was) (VP (VBN administered) (PP (IN during) (NP (NP (DT the) (JJ later) (NN part)) (PP (IN of) (NP (NP (DT the) (NN surgery)) (PP (IN for) (NP (JJ Doc_17049862_379_386_Disease) (NNS prophylaxis))))))))) (. .)))
17049862	4	(S1 (S (PP (VBG Following) (NP (NNP Doc_17049862_410_419_Chemical) (NN administration))) (, ,) (NP (DT the) (NN patient)) (VP (VBD developed) (NP (NP (JJ acute) (JJ severe) (NN Doc_17049862_471_482_Disease)) (, ,) (ADJP (JJ refractory) (PP (TO to) (NP (NP (NNP Doc_17049862_498_506_Chemical)) (CC and) (NP (NNP Doc_17049862_511_521_Chemical))))))) (. .)))
17049862	5	(S1 (S (NP (NP (DT The) (JJ cardiac) (NN depressant) (NNS actions)) (PP (IN of) (NP (NP (NNP Doc_17049862_557_566_Chemical)) (CC and) (NP (NNP Doc_17049862_571_582_Disease))))) (VP (MD can) (VP (AUX be) (ADJP (JJ additive)))) (. .)))
17049862	6	(S1 (S (NP (NP (NN Administration)) (PP (IN of) (NP (NNP Doc_17049862_618_627_Chemical))) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NNP Doc_17049862_647_658_Disease)))))) (VP (MD may) (VP (VB lead) (PP (TO to) (NP (NP (DT an) (JJ adverse) (JJ cardiac) (NN event)) (PP (IN in) (NP (NNS children))))))) (. .)))
17049862	7	(S1 (S (SBAR (IN As) (S (NP (NNP Doc_17049862_712_721_Chemical)) (VP (AUX is) (NP (DT a) (ADJP (RB commonly) (VBN used)) (NN drug))))) (, ,) (NP (NNS clinicians)) (VP (AUX need) (S (VP (TO to) (VP (AUX be) (ADJP (JJ aware) (PP (IN of) (NP (DT this) (NN interaction)))))))) (. .)))
17074608	0	(S1 (NP (NP (NP (JJ Doc_17074608_0_9_Chemical-induced) (NN Doc_17074608_18_24_Disease)) (CC and) (NP (NNP Doc_17074608_29_43_Disease))) (PP (IN in) (NP (JJ atypical) (NNP Doc_17074608_56_82_Disease))) (. .)))
17074608	1	(S1 (S (NP (NN Doc_17074608_84_110_Disease)) (VP (AUX is) (NP (NP (DT a) (NN disorder)) (PP (IN of) (NP (NP (JJ Doc_17074608_128_138_Chemical) (NN metabolism)) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (NP (DT a) (NN defect)) (PP (IN in) (NP (DT the) (JJ Doc_17074608_175_182_Chemical) (NN cleavage) (NN system)))) (VP (VBZ leads) (PP (TO to) (NP (NP (DT an) (NN accumulation)) (PP (IN of) (NP (NNP Doc_17074608_227_234_Chemical))) (PP (IN in) (NP (DT the) (NN brain) (CC and) (JJ other) (NN body) (NNS compartments)))))))))))) (. .)))
17074608	2	(S1 (S (PP (IN In) (NP (DT the) (JJ classical) (NN form))) (NP (PRP it)) (VP (VBZ presents) (PP (IN as) (NP (NP (JJ neonatal) (NN Doc_17074608_323_328_Disease)) (, ,) (NP (JJ intractable) (NN Doc_17074608_342_350_Disease)) (, ,) (CC and) (NP (NP (NNP Doc_17074608_356_365_Disease)) (, ,) (VP (VBN followed) (PP (IN by) (NP (JJ significant) (NNP Doc_17074608_391_414_Disease)))))))) (. .)))
17074608	3	(S1 (S (NP (NP (DT An) (JJ important) (NN subset)) (PP (IN of) (NP (NP (NNS children)) (PP (IN with) (NP (NNP Doc_17074608_453_479_Disease)))))) (VP (AUX are) (NP (NP (JJ atypical) (NNS variants)) (SBAR (WHNP (WP who)) (S (VP (VBP present) (PP (IN in) (NP (DT a) (JJ heterogeneous) (NN manner)))))))) (. .)))
17074608	4	(S1 (S (NP (DT This) (NN report)) (VP (VBZ describes) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (NP (JJ mild) (NNP Doc_17074608_583_597_Disease) (CC and) (NNP Doc_17074608_602_620_Disease)) (, ,) (SBAR (WHNP (WP who)) (S (VP (AUX was) (VP (VBN found) (S (VP (TO to) (VP (AUX have) (VP (NNP Doc_17074608_644_670_Disease) (PP (VBG following) (NP (NP (PRP$ her) (NN presentation)) (PP (IN with) (NP (NP (JJ acute) (NNP Doc_17074608_709_723_Disease)) (CC and) (NP (NNP Doc_17074608_728_734_Disease)))))) (PP (ADVP (RB shortly)) (IN after) (NP (NP (NN initiation)) (PP (IN of) (NP (JJ Doc_17074608_763_772_Chemical) (NN therapy))))))))))))))))) (. .)))
1711760	0	(S1 (NP (NP (NP (JJ Delayed) (NN institution)) (PP (IN of) (NP (NNP Doc_1711760_23_35_Disease))) (PP (IN during) (NP (JJ focal) (NN Doc_1711760_49_66_Disease)))) (: :) (NP (NP (NN effect)) (PP (IN on) (NP (NNP Doc_1711760_78_89_Disease)))) (. .)))
1711760	1	(S1 (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NP (VBN induced) (NNP Doc_1711760_113_125_Disease)) (VP (VBN instituted) (PP (IN after) (NP (NP (DT a) (JJ 2-h) (NN delay)) (PP (VBG following) (NP (NP (NNP Doc_1711760_165_197_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_1711760_199_203_Disease)) (-RRB- -RRB-))))))))) (PP (IN on) (NP (NP (JJ Doc_1711760_208_219_Disease) (NN formation)) (CC and) (NP (JJ histochemical) (NN injury))))) (VP (AUX was) (VP (VBN studied))) (. .)))
1711760	2	(S1 (S (PP (IN Under) (NP (JJ Doc_1711760_274_284_Chemical) (NN anesthesia))) (, ,) (NP (NP (DT the) (NNP MCA)) (PP (IN of) (NP (CD 14) (ADJP (RB spontaneously) (JJ Doc_1711760_325_337_Disease)) (NNS rats)))) (VP (AUX was) (VP (VBN occluded))) (. .)))
1711760	3	(S1 (S (PP (IN In) (NP (NP (DT the) (NN control) (NN group)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 7)) (-RRB- -RRB-)))) (, ,) (NP (NP (DT the) (JJ mean) (NN arterial) (NN pressure)) (PRN (-LRB- -LRB-) (NP (NN MAP)) (-RRB- -RRB-))) (VP (AUX was) (RB not) (VP (VBN manipulated))) (. .)))
1711760	4	(S1 (S (PP (IN In) (NP (NP (DT the) (NNP Doc_1711760_448_460_Disease) (NN group)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 7)) (-RRB- -RRB-)))) (, ,) (NP (DT the) (NN MAP)) (VP (AUX was) (ADJP (JJ elevated) (PP (IN by) (NP (NP (CD 25-30) (JJ mm) (NNP Hg) (NN beginning)) (, 2) (NP (NNP h) (IN after) (NNP Doc_1711760_532_536_Disease)))))) (. .)))
1711760	5	(S1 (S (PP (NP (CD Four) (NNS hours)) (IN after) (NP (NNP Doc_1711760_555_559_Disease))) (, ,) (S (NP (DT the) (NNS rats)) (VP (AUX were) (VP (VBN killed)))) (CC and) (S (NP (DT the) (NNS brains)) (VP (VBN harvested))) (. .)))
1711760	6	(S1 (S (NP (DT The) (NNS brains)) (VP (AUX were) (VP (VBN sectioned) (PP (IN along) (NP (NP (JJ coronal) (NNS planes)) (VP (VBG spanning) (NP (NP (DT the) (NN distribution)) (PP (IN of) (NP (NP (NNP Doc_1711760_684_692_Disease)) (VP (VBN produced) (PP (IN by) (NP (NNP Doc_1711760_705_709_Disease)))))))))))) (. .)))
1711760	7	(S1 (S (NP (NP (JJ Specific) (NN gravity)) (PRN (-LRB- -LRB-) (NP (NN SG)) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN determined) (PP (PP (IN in) (NP (DT the) (NN subcortex))) (CC and) (PP (IN in) (NP (NP (CD two) (NNS sites)) (PP (IN in) (NP (DT the) (NN cortex))) (PRN (-LRB- -LRB-) (NP (NP (NP (NN core)) (CC and) (NP (NN periphery))) (PP (IN of) (NP (DT the) (NNP Doc_1711760_823_831_Disease) (NN territory)))) (-RRB- -RRB-))))))) (. .)))
1711760	8	(S1 (S (NP (NP (DT The) (NN extent)) (PP (IN of) (NP (NNP Doc_1711760_858_873_Disease)))) (VP (AUX was) (VP (VBN determined) (PP (IN by) (NP (JJ Doc_1711760_892_918_Chemical) (NN staining))))) (. .)))
1711760	9	(S1 (S (PP (IN In) (NP (DT the) (NNP Doc_1711760_936_944_Disease) (NN core))) (, ,) (NP (EX there)) (VP (AUX was) (NP (NP (DT no) (NN difference)) (PP (IN in) (NP (NNS SG)))) (PP (IN in) (NP (NP (DT the) (NN subcortex) (CC and) (NN cortex)) (PP (IN in) (NP (DT the) (CD two) (NNS groups)))))) (. .)))
1711760	10	(S1 (S (PP (IN In) (NP (NP (DT the) (NN periphery)) (PP (IN of) (NP (DT the) (NNP Doc_1711760_1052_1060_Disease) (NN territory))))) (, ,) (NP (NP (NN SG)) (PP (IN in) (NP (DT the) (NN cortex)))) (VP (AUX was) (ADJP (JJR greater)) (PRN (-LRB- -LRB-) (NP (JJR less) (NNP Doc_1711760_1107_1112_Disease) (NN accumulation)) (-RRB- -RRB-)) (PP (IN in) (NP (DT the) (NNP Doc_1711760_1134_1146_Disease) (NN group))) (PRN (-LRB- -LRB-) (NP (NP (CD 1.041) (JJ +/-) (CD 0.001) (NNP vs) (CD 1.039) (NN +/-)) (NP (CD 0.001))) (, ,) (NP (NNP P)) (NP (QP (JJR less) (IN than) (CD 0.05))) (-RRB- -RRB-))) (. .)))
1711760	11	(S1 (S (NP (NP (DT The) (NN area)) (PP (IN of) (NP (JJ histochemical) (NN injury)))) (PRN (-LRB- -LRB-) (PP (IN as) (NP (NP (DT a) (NN percent)) (PP (IN of) (NP (NP (DT the) (JJ cross-sectional) (NN area)) (PP (IN of) (NP (DT the) (NN hemisphere))))))) (-RRB- -RRB-)) (VP (AUX was) (ADJP (JJR less)) (PP (IN in) (NP (NP (DT the) (NNP Doc_1711760_1319_1331_Disease) (NN group)) (PRN (-LRB- -LRB-) (NP (NP (CD 33) (JJ +/-) (NP (CD 3) (NN %)) (NNP vs) (CD 21) (NN +/-) (CD 2) (NN %)) (, ,) (VP (VBD P) (NP (QP (JJR less) (IN than) (CD 0.05))))) (-RRB- -RRB-))))) (. .)))
1711760	12	(S1 (S (NP (DT The) (NNS data)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NNP Doc_1711760_1405_1418_Chemical-induced) (NNP Doc_1711760_1427_1439_Disease)) (VP (VBD instituted) (NP (CD 2)) (NP (NNP h)) (SBAR (SBAR (IN after) (S (NP (NNP Doc_1711760_1461_1465_Disease)) (VP (AUX does) (RB not) (VP (VB aggravate) (NP (NNP Doc_1711760_1485_1490_Disease)) (PP (IN in) (NP (DT the) (NNP Doc_1711760_1498_1506_Disease) (NN core))))))) (, ,) (SBAR (IN that) (S (NP (PRP it)) (VP (VBZ improves) (NP (NNP Doc_1711760_1530_1535_Disease)) (PP (IN in) (NP (NP (DT the) (NN periphery)) (PP (IN of) (NP (DT the) (NNP Doc_1711760_1560_1568_Disease) (NN territory)))))))) (, ,) (CC and) (SBAR (IN that) (S (NP (PRP it)) (VP (VBZ reduces) (NP (NP (DT the) (NN area)) (PP (IN of) (NP (JJ histochemical) (NNP Doc_1711760_1626_1646_Disease)))))))))))) (. .)))
17194457	0	(S1 (S (NP (NP (JJ Behavioral) (NNS effects)) (PP (IN of) (NP (NN pubertal)))) (VP (VBP anabolic) (NP (NP (JJ androgenic) (JJ Doc_17194457_51_58_Chemical) (NN exposure)) (PP (IN in) (NP (NP (JJ male) (NNS rats)) (PP (IN with) (NP (JJ low) (NNP Doc_17194457_90_99_Chemical))))))) (. .)))
17194457	1	(S1 (S (NP (NP (DT The) (NN goal)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB assess) (NP (NP (DT the) (JJ interactive) (NNS effects)) (PP (IN of) (NP (NP (JJ chronic) (JJ anabolic) (NN androgenic) (NNP Doc_17194457_193_200_Chemical) (PRN (-LRB- -LRB-) (NP (NNP AAS)) (-RRB- -RRB-)) (NN exposure)) (CC and) (NP (NN brain) (NNP Doc_17194457_226_235_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_17194457_237_256_Chemical)) (, ,) (NP (NNP Doc_17194457_258_262_Chemical)) (-RRB- -RRB-)) (NN depletion)))) (PP (IN on) (NP (NP (NN behavior)) (PP (IN of) (NP (JJ pubertal) (JJ male) (NNS rats)))))))))) (. .)))
17194457	2	(S1 (S (S (NP (NN Doc_17194457_309_318_Chemical)) (VP (AUX was) (VP (VBN depleted) (S (VP (VBG beginning) (PP (IN on) (NP (NN postnatal) (NN day) (CD 26))) (PP (IN with) (NP (NNP Doc_17194457_367_390_Chemical))) (PRN (-LRB- -LRB-) (NP (NNP Doc_17194457_392_396_Chemical) (QP (CD 100) (CD mg/kg))) (, ,) (NP (DT every) (JJ other) (NN day)) (-RRB- -RRB-))))))) (: ;) (S (NP (NNS controls)) (VP (VBD received) (NP (NN saline)))) (. .)))
17194457	3	(S1 (S (PP (IN At) (NP (NP (NN puberty)) (PRN (-LRB- -LRB-) (NP (NNP P40)) (-RRB- -RRB-)))) (, ,) (NP (NP (PDT half) (DT the) (JJ Doc_17194457_479_483_Chemical-treated) (NNS rats)) (CC and) (NP (PDT half) (DT the) (JJ saline-treated) (NNS rats))) (VP (VBD began) (NP (NN treatment)) (PP (IN with) (NP (NP (NNP Doc_17194457_551_563_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP T)) (, ,) (NP (CD 5) (NN mg/kg)) (, ,) (NP (CD 5) (NN days/week)) (-RRB- -RRB-))))) (. .)))
17194457	4	(S1 (S (NP (JJ Behavioral) (NNS measures)) (VP (VBD included) (NP (NP (NN locomotion)) (, ,) (NP (NN Doc_17194457_632_644_Disease)) (, ,) (NP (NN copulation)) (, ,) (NP (NN partner) (NN preference)) (, ,) (CC and) (NP (NNP Doc_17194457_682_692_Disease)))) (. .)))
17194457	5	(S1 (S (NP (NNS Animals)) (VP (AUX were) (VP (VBN tested) (PP (IN for) (NP (NNP Doc_17194457_718_728_Disease))) (PP (IN in) (NP (PRP$ their) (NN home) (NN cage))) (, ,) (PP (DT both) (PP (IN with)) (CC and) (PP (IN without) (NP (NP (JJ physical) (NN provocation)) (PRN (-LRB- -LRB-) (NP (JJ mild) (NN tail) (NN pinch)) (-RRB- -RRB-))))))) (. .)))
17194457	6	(S1 (S (NP (NP (NN Brain) (NNS levels)) (PP (IN of) (NP (NP (NNP Doc_17194457_827_831_Chemical)) (CC and) (NP (NP (PRP$ its) (NN metabolite)) (, ,) (NP (NP (NNP Doc_17194457_852_878_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_17194457_880_886_Chemical)) (-RRB- -RRB-))) (, ,))))) (VP (AUX were) (VP (VBN determined) (S (VP (VBG using) (NP (NN HPLC)))))) (. .)))
17194457	7	(S1 (S (NP (NN Doc_17194457_917_921_Chemical)) (ADVP (RB significantly) (CC and) (RB substantially)) (VP (VBD depleted) (NP (NP (NNP Doc_17194457_963_967_Chemical)) (CC and) (NP (NNP Doc_17194457_972_978_Chemical))) (PP (IN in) (NP (NP (DT all) (NN brain) (NNS regions)) (VP (VBN examined))))) (. .)))
17194457	8	(S1 (S (NP (JJ Chronic) (JJ T) (NN treatment)) (VP (VP (ADVP (RB significantly)) (VBD decreased) (NP (NP (NNP Doc_17194457_1054_1058_Chemical)) (CC and) (NP (NNP Doc_17194457_1063_1069_Chemical))) (PP (IN in) (NP (JJ certain) (NN brain) (NNS areas)))) (, ,) (CC but) (PP (TO to) (NP (NP (DT a) (ADJP (RB much) (JJR lesser)) (NN extent)) (PP (IN than) (NP (NNP Doc_17194457_1127_1131_Chemical)))))) (. .)))
17194457	9	(S1 (S (NP (NP (JJ Chronic) (NN exposure)) (PP (TO to) (NP (NNP Doc_17194457_1153_1157_Chemical)))) (ADVP (RB alone)) (ADVP (RB significantly)) (VP (VBD decreased) (SBAR (S (NP (NN locomotor) (NN activity)) (VP (CC and) (VP (VBD increased) (NP (NNP Doc_17194457_1221_1233_Disease))) (CC but) (VP (AUX had) (NP (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (JJ sexual) (NN behavior)) (, ,) (NP (NN partner) (NN preference)) (, ,) (CC or) (NP (NNP Doc_17194457_1295_1305_Disease)))))))))) (. .)))
17194457	10	(S1 (S (NP (NP (NNS T)) (ADVP (RB alone))) (VP (VP (AUX had) (NP (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (NN locomotion)) (, ,) (NP (NNP Doc_17194457_1344_1356_Disease)) (, ,) (CC or) (NP (JJ sexual) (NN behavior)))))) (CC but) (VP (VBD increased) (NP (NP (NN partner) (NN preference)) (CC and) (NP (NN Doc_17194457_1414_1424_Disease))))) (. .)))
17194457	11	(S1 (S (NP (NP (DT The) (ADJP (RBS most) (JJ striking)) (NN effect)) (PP (IN of) (NP (VBG combining) (NNP T+Doc_17194457_1466_1470_Chemical)))) (VP (AUX was) (NP (NP (NP (DT a) (JJ significant) (NN increase)) (PP (IN in) (NP (NN attack) (NN frequency)))) (CONJP (RB as) (RB well) (IN as)) (NP (NP (DT a) (JJ significant) (NN decrease)) (PP (IN in) (NP (NP (DT the) (NN latency)) (PP (TO to) (NP (NN attack))) (, ,) (PP (ADVP (RB particularly)) (VBG following) (NP (JJ physical) (NN provocation)))))))) (. .)))
17194457	12	(S1 (S (PP (VBN Based) (PP (IN on) (NP (DT these) (NNS data)))) (, ,) (NP (PRP it)) (VP (MD can) (VP (AUX be) (VP (VBN speculated) (SBAR (IN that) (S (NP (NP (JJ pubertal) (NN AAS) (NNS users)) (PP (IN with) (NP (JJ low) (JJ central) (NN Doc_17194457_1706_1710_Chemical)))) (VP (MD may) (VP (AUX be) (ADJP (RB especially) (JJ prone) (PP (TO to) (NP (NN exhibit) (NN Doc_17194457_1746_1765_Disease))))))))))) (. .)))
17241657	0	(S1 (NP (NP (NP (NP (NNS Effects)) (PP (IN of) (NP (NNP Doc_17241657_11_16_Chemical)))) (CC and) (PRN (-LRB- -LRB-) (JJ +/-) (-RRB- -RRB-)) (NP (JJ -Doc_17241657_27_32_Chemical) (, ,) (JJ putative) (JJ sigma2-preferring) (NNS antagonists)) (, ,)) (PP (IN on) (NP (NP (JJ behavioral) (NN toxic) (CC and) (NN stimulant) (NNS effects)) (PP (IN of) (NP (NP (NNP Doc_17241657_119_126_Chemical)) (PP (IN in) (NP (NNS mice))))))) (. .)))
17241657	1	(S1 (S (NP (JJR Earlier) (NNS studies)) (VP (AUX have) (VP (VBN demonstrated) (SBAR (IN that) (S (NP (NP (NN antagonism)) (PP (IN of) (NP (NN sigma1) (NNS receptors)))) (VP (VBZ attenuates) (NP (NP (DT the) (JJ Doc_17241657_221_231_Disease) (, ,) (JJ lethal) (, ,) (NN locomotor) (NN stimulatory) (CC and) (JJ rewarding) (NNS actions)) (PP (IN of) (NP (NP (NNP Doc_17241657_288_295_Chemical)) (PP (IN in) (NP (NNS mice))))))))))) (. .)))
17241657	2	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NP (DT the) (NN contribution)) (PP (IN of) (NP (JJ sigma2) (NNS receptors)))) (VP (AUX is) (ADJP (JJ unclear)) (SBAR (IN because) (S (NP (NP (JJ experimental) (NNS tools)) (SBAR (S (VP (TO to) (ADVP (RB selectively)) (VP (VB target) (NP (DT this) (NN subtype))))))) (VP (AUX are) (ADJP (JJ unavailable)))))) (. .)))
17241657	3	(S1 (S (S (VP (TO To) (VP (VB begin) (S (VP (VBG addressing) (NP (DT this) (NN need))))))) (, ,) (NP (PRP we)) (VP (VBD characterized) (NP (NP (NP (NNP Doc_17241657_493_498_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_17241657_500_540_Chemical)) (-RRB- -RRB-))) (CC and) (NP (NP (-LRB- -LRB-) (JJ +/-) (-RRB- -RRB-) (NN -SM) (CD 21)) (PRN (-LRB- -LRB-) (NP (NNP Doc_17241657_559_601_Chemical)) (-RRB- -RRB-)))) (PP (IN in) (NP (NP (NN receptor) (VBG binding)) (CC and) (NP (JJ behavioral) (NNS studies))))) (. .)))
17241657	4	(S1 (S (NP (NN Receptor) (JJ binding) (NNS studies)) (VP (VBD confirmed) (NP (DT that) (ADJP (JJ Doc_17241657_687_692_Chemical) (CC and) (PRN (-LRB- -LRB-) (JJ +/-) (-RRB- -RRB-)) (JJ -Doc_17241657_703_708_Chemical)) (NN display) (JJ preferential) (NN affinity)) (PP (IN for) (S (VP (VBG sigma2) (PP (IN over) (NP (JJ sigma1) (NNS receptors))))))) (. .)))
17241657	5	(S1 (S (PP (IN In) (NP (JJ behavioral) (NNS studies))) (, ,) (NP (NP (NN pretreatment)) (PP (IN of) (NP (NP (NP (NNP Swiss) (NNP Webster) (NNS mice)) (PP (IN with) (NP (NNP Doc_17241657_836_841_Chemical)))) (CC or) (PRN (-LRB- -LRB-) (JJ +/-) (-RRB- -RRB-)) (NP (NN -Doc_17241657_851_856_Chemical))))) (VP (VP (ADVP (RB significantly)) (VBD attenuated) (NP (JJ Doc_17241657_882_889_Chemical-induced) (NN Doc_17241657_898_909_Disease) (CC and) (NN locomotor) (NN activity))) (, ,) (CC but) (RB not) (VP (NN lethality))) (. .)))
17241657	6	(S1 (S (S (SBAR (WHADVP (WRB When)) (S (VP (VBN administered) (ADVP (RB alone))))) (, ,) (NP (-LRB- -LRB-) (NN +/-) (-RRB- -RRB-) (NN -Doc_17241657_984_989_Chemical)) (VP (VBD produced) (NP (NP (DT no) (JJ significant) (NNS effects)) (VP (VBN compared) (S (VP (TO to) (VP (VB control) (NP (NP (NNS injections)) (PP (IN of) (NP (NN saline))))))))))) (, ,) (CC but) (S (NP (NNP Doc_17241657_1068_1073_Chemical)) (VP (AUX had) (NP (NN locomotor) (NN depressant) (NNS actions)))) (. .)))
17241657	7	(S1 (S (ADVP (RB Together)) (, ,) (NP (DT the) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (S (NP (JJ sigma2) (NN receptor) (NNS antagonists)) (VP (AUX have) (NP (DT the) (NN potential) (S (VP (TO to) (VP (VB attenuate) (NP (NP (DT some)) (PP (IN of) (NP (NP (DT the) (JJ behavioral) (NNS effects)) (PP (IN of) (NP (NNP Doc_17241657_1234_1241_Chemical)))))))))))) (, ,) (CC and) (S (NP (NP (JJ further) (NN development)) (PP (IN of) (NP (ADJP (RBR more) (JJ selective)) (, ,) (JJ high) (NN affinity) (NNS ligands)))) (VP (AUX are) (VP (VBN warranted))))))) (. .)))
17263743	0	(S1 (S (VP (VB Doc_17263743_0_14_Disease) (PP (IN in) (NP (NP (DT a) (NN child)) (PP (IN with) (NP (NNP Doc_17263743_31_45_Disease))) (VP (VBG undergoing) (NP (NP (JJ Doc_17263743_57_68_Chemical) (NN induction)) (PP (IN of) (NP (NN anesthesia)))) (PP (IN after) (NP (JJ preoperative) (NN Doc_17263743_112_121_Chemical))))))) (. .)))
17263743	1	(S1 (S (NP (NN Doc_17263743_123_132_Chemical)) (VP (AUX is) (NP (NP (DT a) (ADJP (RB frequently) (VBN administered)) (NN alpha2-adrenergic) (NN agonist)) (SBAR (WHNP (WDT which)) (S (VP (MD can) (VP (VB decrease) (NP (NP (NN heart) (NN rate)) (CC and) (NP (NN blood) (NN pressure))))))))) (. .)))
17263743	2	(S1 (S (NP (PRP We)) (VP (VBP present) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NP (DT a) (JJ 5-year-old) (NN child)) (PP (IN with) (NP (NP (NNP Doc_17263743_283_297_Disease)) (CC and) (NP (NNP Doc_17263743_302_318_Disease)))))) (, ,) (VP (VBG receiving) (NP (NNP Doc_17263743_330_339_Chemical)) (PP (IN for) (NP (NP (NNP Doc_17263743_344_356_Disease)) (, ,) (SBAR (WHNP (WP who)) (S (VP (VBD presented) (PP (IN for) (NP (NP (NN placement)) (PP (IN of) (NP (DT a) (JJ Doc_17263743_391_399_Chemical) (NN pump))))))))))))) (. .)))
17263743	3	(S1 (S (PP (IN Without) (NP (NP (DT the) (NN knowledge)) (PP (IN of) (NP (DT the) (JJ medical) (NNS personnel))))) (, ,) (NP (NP (DT the) (NN patient) (POS 's)) (NN mother)) (VP (VBN administered) (NP (NP (CD three) (NNS doses)) (PP (IN of) (NP (NNP Doc_17263743_503_512_Chemical)))) (PP (IN during) (NP (DT the) (NN evening))) (PP (IN before) (NP (NP (CC and) (NN morning)) (PP (IN of) (NP (NN surgery))))) (S (VP (TO to) (VP (VB reduce) (NP (NN Doc_17263743_572_579_Disease)))))) (. .)))
17263743	4	(S1 (S (PP (IN During) (NP (NP (NN induction)) (PP (IN of) (NP (NN anesthesia))))) (, ,) (NP (DT the) (NN patient)) (VP (VBD developed) (NP (NP (NNP Doc_17263743_635_646_Disease)) (CC and) (NP (NNP Doc_17263743_651_662_Disease))) (S (VP (VBG requiring) (NP (JJ cardiac) (NN resuscitation))))) (. .)))
17263743	5	(S1 (S (NP (EX There)) (VP (AUX are) (NP (NP (DT no) (JJ previous) (NNS reports)) (PP (IN of) (NP (NNP Doc_17263743_729_738_Chemical-associated) (NNP Doc_17263743_750_764_Disease)))) (PP (IN in) (NP (NP (DT a) (NN child) (VBG undergoing) (NN induction)) (PP (IN of) (NP (NN anesthesia)))))) (. .)))
17285209	0	(S1 (NP (NP (NP (JJ Doc_17285209_0_11_Chemical-converting) (JJ enzyme) (-LRB- -LRB-) (NN ACE) (-RRB- -RRB-) (JJ inhibitor-associated) (NN Doc_17285209_57_67_Disease)) (PP (IN of) (NP (DT the) (NN stomach) (CC and) (JJ small) (NN intestine)))) (: :) (NP (DT a) (NN case) (NN report)) (. .)))
17285209	1	(S1 (S (NP (DT This)) (VP (AUX is) (NP (NP (DT a) (NN case) (NN report)) (PP (IN on) (NP (NP (DT a) (JJ 45-year) (JJ old) (JJ African-American) (NN female)) (PP (IN with) (NP (NP (ADJP (RB newly) (VBN diagnosed)) (NNP Doc_17285209_203_215_Disease)) (, ,) (SBAR (WHNP (WP who)) (S (VP (AUX was) (VP (VBN started) (PP (IN on) (NP (NP (DT a) (NN combination) (NN pill)) (PP (IN of) (NP (JJ Doc_17285209_258_268_Chemical/Doc_17285209_269_279_Chemical) (JJ 10/5) (NN mg))))))))))))))) (. .)))
17285209	2	(S1 (S (NP (DT The) (JJ very) (JJ next) (NN day)) (, ,) (NP (PRP she)) (VP (VBD presented) (PP (IN at) (NP (NP (DT the) (NN emergency) (NN room)) (PRN (-LRB- -LRB-) (NP (NNP ER)) (-RRB- -RRB-)))) (PP (IN with) (NP (NP (NNP Doc_17285209_354_368_Disease)) (, ,) (NP (NNP Doc_17285209_370_376_Disease)) (CC and) (NP (NNP Doc_17285209_381_389_Disease))))) (. .)))
17285209	3	(S1 (S (NP (NP (JJ Physical) (NN exam)) (, ,) (NP (JJ complete) (JJ metabolic) (NN panel)) (, ,) (CC and) (NP (NN hemogram))) (VP (AUX were) (PP (IN in) (NP (DT the) (JJ normal) (NN range)))) (. .)))
17285209	4	(S1 (S (NP (PRP She)) (VP (AUX was) (VP (VBN discharged) (PP (IN from) (NP (DT the) (NN ER))) (PP (IN after) (NP (NP (DT a) (JJ few) (NNS hours)) (PP (IN of) (NP (NN treatment))) (PP (IN with) (NP (NN fluid) (CC and) (NNS analgesics))))))) (. .)))
17285209	5	(S1 (S (ADVP (RB However)) (, ,) (NP (PRP she)) (VP (VBD returned) (PP (TO to) (NP (DT the) (NN ER))) (NP (DT the) (JJ next) (NN day)) (PP (IN with) (NP (DT the) (JJ same) (NNS complaints)))) (. .)))
17285209	6	(S1 (S (NP (DT This) (NN time)) (NP (DT the) (JJ physical) (NN exam)) (VP (AUX was) (ADJP (JJ significant) (PP (IN for) (NP (NP (DT a) (JJ distended) (NN abdomen)) (PP (IN with) (NP (NN dullness))) (PP (TO to) (NP (NNP percussion))))))) (. .)))
17285209	7	(S1 (S (NP (NNS CT) (S (VP (VB scan) (PP (IN of) (NP (DT the) (NNS abdomen)))))) (VP (VBD revealed) (NP (NP (ADJP (RB markedly) (VBN thickened)) (NN antrum)) (PP (IN of) (NP (DT the) (NN stomach) (, ,) (NN duodenum) (CC and) (NN jejunum))) (, ,) (ADVP (IN along) (PP (IN with) (NP (NN fluid))))) (PP (IN in) (NP (DT the) (JJ abdominal) (CC and) (JJ pelvic) (NN cavity)))) (. .)))
17285209	8	(S1 (S (NP (NP (JJ Doc_17285209_877_888_Chemical-converting) (NN enzyme) (NN inhibitor)) (PRN (-LRB- -LRB-) (NP (NNP ACEI)) (-RRB- -RRB-))) (VP (VBD -induced) (SBAR (S (S (NP (NNP Doc_17285209_932_942_Disease)) (VP (AUX was) (VP (VBN suspected)))) (, ,) (CC and) (S (NP (JJ anti-Doc_17285209_967_979_Disease) (NNS medications)) (VP (AUX were) (VP (VBN discontinued))))))) (. .)))
17285209	9	(S1 (S (S (NP (PRP$ Her) (NNS symptoms)) (VP (VBD improved) (PP (IN within) (NP (DT the) (JJ next) (CD 24) (NNS hours))))) (, ,) (CC and) (S (NP (NP (NN repeat) (NN CT)) (PP (IN after) (NP (CD 72) (NNS hours)))) (VP (VBD revealed) (NP (NP (JJ marked) (NN improvement)) (PP (IN in) (NP (NP (NN stomach) (CC and) (JJ small) (NN bowel) (NN thickening)) (CC and) (NP (NP (NN resolution)) (PP (IN of) (NP (NNP Doc_17285209_1172_1179_Disease))))))))) (. .)))
17285209	10	(S1 (S (NP (NP (DT The) (NN recognition)) (PP (IN of) (NP (NP (NP (JJ Doc_17285209_1200_1211_Chemical-converting) (NN enzyme)) (PRN (-LRB- -LRB-) (NP (NN ACE)) (-RRB- -RRB-))) (CC and) (NP (NP (NN angiotensin) (NN receptor) (NN blocker)) (PRN (-LRB- -LRB-) (NP (NN ARB)) (-RRB- -RRB-)))))) (NP (NNP Doc_17285209_1275_1296_Disease)) (VP (VBZ constitutes) (NP (NP (DT a) (NN challenge)) (PP (TO to) (NP (NP (JJ primary) (NN care) (NNS physicians)) (, ,) (NP (NNS internists)) (, ,) (NP (NN emergency) (NN room) (NN personal)) (CC and) (NP (NNS surgeons)))))) (. .)))
1728915	0	(S1 (NP (JJ Doc_1728915_0_13_Chemical-induced) (NN Doc_1728915_22_41_Disease) (. .)))
1728915	1	(S1 (NP (NP (NN Characterization)) (PP (IN of) (NP (CD two) (JJ distinct) (JJ clinical) (NNS syndromes))) (. .)))
1728915	2	(S1 (S (NP (NP (DT A) (NN patient)) (PP (IN with) (NP (NP (JJ sinus) (NNP Doc_1728915_117_128_Disease)) (CC and) (NP (NP (NNP Doc_1728915_133_155_Disease)) (, ,) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_1728915_168_181_Chemical)))) (, ,))))) (VP (VBD prompted) (NP (NP (DT an) (JJ extensive) (NN literature) (NN review)) (PP (IN of) (NP (DT all) (ADJP (RB previously) (VBN reported)) (NNS cases))))) (. .)))
1728915	3	(S1 (S (PP (IN From) (NP (NP (DT the) (NN analysis)) (PP (IN of) (NP (DT these) (NNS cases))))) (, ,) (NP (NP (CD two) (JJ distinct) (NNS forms)) (PP (IN of) (NP (NNP Doc_1728915_313_326_Chemical-associated) (NNP Doc_1728915_338_357_Disease)))) (VP (VBD emerged)) (. .)))
1728915	4	(S1 (S (NP (CD One) (JJ patient) (NN group)) (VP (VBD developed) (NP (NN Doc_1728915_395_413_Disease)) (PP (IN in) (NP (NP (DT the) (NN setting)) (PP (IN of) (NP (DT a) (JJ massive) (JJ Doc_1728915_442_455_Chemical) (NN Doc_1728915_456_464_Disease)))))) (. .)))
1728915	5	(S1 (S (NP (DT The) (JJ second) (NN group)) (VP (VBD consisted) (ADVP (RB almost) (RB exclusively)) (PP (IN of) (NP (NP (JJ elderly) (NNS women)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (ADJP (RB potentially) (JJ life-threatening)) (NNP Doc_1728915_572_588_Disease) (CC or) (NNP Doc_1728915_592_625_Disease))))))) (, ,) (S (VP (VBN associated) (PP (IN with) (NP (ADJP (ADJP (RB either) (JJ therapeutic)) (CC or) (ADJP (RB modestly) (JJ elevated))) (JJ Doc_1728915_683_696_Chemical) (NN serum) (NNS levels)))))) (. .)))
1728915	6	(S1 (S (SBAR (IN Because) (S (NP (NNP Doc_1728915_719_732_Chemical)) (VP (AUX is) (ADVP (RB widely)) (VP (VBN used) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (JJ many) (UCP (JJ neurologic) (CC and) (JJ Doc_1728915_788_799_Disease)) (NNS conditions))))))))) (, ,) (NP (NP (DT the) (NN recognition)) (PP (IN of) (NP (DT the) (JJ latter) (NN syndrome)))) (VP (AUX has) (NP (NP (JJ important) (NNS implications)) (PP (IN for) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (DT this) (NN drug))) (PP (IN in) (NP (JJ elderly) (NNS patients))))))) (. .)))
1732442	0	(S1 (NP (NP (NN Detection)) (PP (IN of) (NP (NP (JJ abnormal) (JJ cardiac) (NN adrenergic) (NN neuron) (NN activity)) (PP (IN in) (NP (NP (JJ Doc_1732442_60_70_Chemical-induced) (NN Doc_1732442_79_93_Disease)) (PP (IN with) (NP (NNP Doc_1732442_99_133_Chemical))))))) (. .)))
1732442	1	(S1 (S (NP (NP (NP (NNP Doc_1732442_135_171_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_1732442_173_177_Chemical)) (-RRB- -RRB-))) (, ,) (NP (NP (DT an) (NN analog)) (PP (IN of) (NP (NP (NNP Doc_1732442_193_207_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP NE)) (-RRB- -RRB-))))) (, ,)) (VP (VBZ serves) (PP (IN as) (NP (NP (DT an) (NN index)) (PP (IN of) (NP (NP (JJ adrenergic) (NN neuron) (NN integrity)) (CC and) (NP (NN function))))))) (. .)))
1732442	2	(S1 (S (S (VP (VBG Using) (NP (NP (DT a) (NN rat) (NN model)) (PP (IN of) (NP (JJ Doc_1732442_299_309_Chemical-induced) (NNP Doc_1732442_318_332_Disease)))))) (, ,) (NP (PRP we)) (VP (VBD tested) (NP (DT the) (NN hypothesis) (SBAR (IN that) (S (NP (JJ abnormal) (JJ cardiac) (JJ adrenergic) (NN neuron) (NN activity)) (VP (MD may) (VP (VP (VB appear)) (CC and) (AUX be) (VP (VBN exacerbated) (ADVP (RB dose-dependently)) (PP (IN in) (NP (NNP Doc_1732442_458_468_Chemical) (NNP Doc_1732442_469_483_Disease)))))))))) (. .)))
1732442	3	(S1 (S (NP (NP (DT The) (NN degree)) (PP (IN of) (NP (NNP Doc_1732442_499_540_Disease)))) (VP (AUX was) (VP (VBN analyzed) (PP (IN in) (NP (NP (NN relation)) (PP (TO to) (NP (NP (DT the) (NN duration)) (PP (IN of) (NP (NP (JJ Doc_1732442_585_595_Chemical) (NN treatment)) (PRN (-LRB- -LRB-) (NP (NP (CD 2) (NN mg/kg)) (, ,) (ADVP (RB once)) (NP (DT a) (NN week))) (-RRB- -RRB-)))))))))) (. .)))
1732442	4	(S1 (S (NP (EX There)) (VP (AUX were) (NP (NP (DT no) (NNS abnormalities)) (CC or) (NP (JJ only) (JJ isolated) (NN degeneration))) (PP (IN in) (NP (NP (DT the) (ADJP (JJ 1-) (CC or) (JJ 2-wk)) (NN treatment) (NNS groups)) (, ,) (VP (VBN isolated) (CC or) (VBN scattered) (NP (NN degeneration)) (PP (IN in) (NP (NP (NP (NN half)) (PP (IN of) (NP (DT the) (NN 3-wk) (NN group)))) (, ,) (NP (NP (JJ frequent) (JJ scattered) (NN degeneration)) (PP (IN in) (NP (DT the) (NN 4-wk) (NN group)))) (, ,) (NP (NP (JJ scattered) (CC or) (JJ focal) (NN degeneration)) (PP (IN in) (NP (DT the) (NN 5-wk) (NN group)))) (, ,) (CC and) (NP (NP (JJ extensive) (NN degeneration)) (PP (IN in) (NP (DT the) (NN 8-wk) (NN group)))))))))) (. .)))
1732442	5	(S1 (S (NP (NP (JJ Myocardial) (NN accumulation)) (PP (IN of) (NP (NNP Doc_1732442_961_971_Chemical) (CD 4)))) (VP (VBD hr) (SBAR (IN after) (S (NP (JJ intravenous) (NN injection)) (VP (AUX did) (RB not) (VP (VB differ) (SBAR (IN between) (S (NP (NP (DT the) (NNS controls)) (CC and) (NP (DT the) (NNS groups))) (VP (VBD treated) (NP (QP (CD 3) (CD wk) (CC or) (JJR less))))))))))) (. .)))
1732442	6	(S1 (S (ADVP (RB However)) (, ,) (NP (DT the) (NN 4-wk) (NN group)) (VP (AUX had) (ADJP (ADJP (NP (NP (NP (DT a) (ADJP (RB slightly) (JJR lower)) (NN accumulation)) (PP (IN in) (NP (NP (NP (DT the) (JJ right) (NN ventricular) (NN wall)) (PRN (-LRB- -LRB-) (NP (NP (CD 82) (NN %)) (PP (IN of) (NP (DT the) (NN control)))) (-RRB- -RRB-))) (CC and) (NP (NP (ADJP (RB significantly) (JJR lower)) (NN accumulation)) (PP (IN in) (NP (DT the) (JJ left) (NN ventricular) (NN wall))))))) (-LRB- -LRB-) (NP (NP (QP (RB about) (CD 66)) (NN %)) (PP (IN of) (NP (DT the) (NN control)))) (: :) (NP (NN p))) (JJR less) (PP (IN than) (NP (CD 0.05)))) (-RRB- -RRB-))) (. .)))
1732442	7	(S1 (S (PP (IN In) (NP (DT the) (JJ 5-wk) (NN group))) (, ,) (NP (NP (JJ Doc_1732442_1318_1322_Chemical) (NN accumulation)) (PP (IN in) (NP (DT the) (JJ right) (CC and) (JJ left) (NN ventricular) (NN wall)))) (VP (AUX was) (NP (NP (NP (CD 35) (NN %)) (CC and) (NP (NP (CD 27) (NN %)) (PP (IN of) (NP (NP (DT that)) (PP (IN in) (NP (NNS controls)))))) (, ,) (ADVP (RB respectively))) (PRN (-LRB- -LRB-) (NP (NNP p) (QP (JJR less) (IN than) (CD 0.001))) (-RRB- -RRB-)))) (. .)))
1732442	8	(S1 (S (PP (IN In) (NP (DT the) (JJ 8-wk) (NN group))) (, ,) (NP (NP (JJ Doc_1732442_1465_1469_Chemical) (NN accumulation)) (PP (IN in) (NP (DT the) (JJ right) (CC and) (JJ left) (NN ventricular) (NN wall)))) (VP (AUX was) (NP (NP (NP (CD 18) (NN %)) (CC and) (NP (NP (CD 14) (NN %)) (PP (IN of) (NP (NP (DT that)) (PP (IN in) (NP (NNS controls)))))) (, ,) (ADVP (RB respectively))) (PRN (-LRB- -LRB-) (NP (NNP p) (QP (JJR less) (IN than) (CD 0.001))) (-RRB- -RRB-)))) (. .)))
1732442	9	(S1 (S (ADVP (RB Thus)) (, ,) (NP (NP (JJ Doc_1732442_1599_1603_Chemical) (NN accumulation)) (PP (IN in) (NP (DT the) (NN myocardium)))) (VP (VBD decreased) (PP (IN in) (NP (DT an) (JJ Doc_1732442_1651_1661_Chemical) (JJ dose-dependent) (NN manner)))) (. .)))
1732442	10	(S1 (S (NP (NP (DT The) (NN appearance)) (PP (IN of) (NP (NP (VBN impaired) (JJ cardiac) (NN adrenergic) (NN neuron) (NN activity)) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (JJ slight) (NNP Doc_1732442_1773_1794_Disease)) (PRN (-LRB- -LRB-) (ADVP (JJ scattered) (CC or) (JJ focal)) (NP (NNP Doc_1732442_1815_1836_Disease)) (-RRB- -RRB-))))))))) (VP (VBZ indicates) (SBAR (IN that) (S (NP (JJ Doc_1732442_1853_1857_Chemical) (NN scintigraphy)) (VP (MD may) (VP (AUX be) (NP (NP (DT a) (JJ useful) (NN method)) (PP (IN for) (NP (NP (NN detection)) (PP (IN of) (NP (JJ Doc_1732442_1911_1921_Chemical-induced) (NNP Doc_1732442_1930_1944_Disease))))))))))) (. .)))
17344330	0	(S1 (NP (NP (NNP Doc_17344330_0_7_Disease) (CC and) (NNP Doc_17344330_12_27_Disease)) (PP (IN among) (NP (NNS patients))) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_17344330_56_65_Chemical))) (PP (IN for) (NP (NP (JJ Doc_17344330_70_76_Chemical) (NN dependence)) (PP (IN in) (NP (NP (DT the) (NN city)) (PP (IN of) (NP (NNP Copenhagen)))))))) (. .)))
17344330	1	(S1 (S (NP (NN Doc_17344330_127_136_Chemical)) (VP (AUX is) (VP (VBN prescribed) (S (VP (TO to) (VP (NNP Doc_17344330_154_160_Chemical) (S (NP (NNS addicts)) (VP (TO to) (VP (VB decrease) (NP (JJ illicit) (JJ opioid) (NN use)))))))))) (. .)))
17344330	2	(S1 (S (NP (NP (NN Prolongation)) (PP (IN of) (NP (NP (DT the) (JJ QT) (NN interval)) (PP (IN in) (NP (NP (DT the) (NNS ECG)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NNP Doc_17344330_261_279_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_17344330_281_284_Disease)) (-RRB- -RRB-))))))))))) (VP (AUX has) (VP (AUX been) (VP (VBN reported) (PP (IN in) (NP (JJ Doc_17344330_307_316_Chemical) (NNS users)))))) (. .)))
17344330	3	(S1 (S (PP (IN As) (NP (NP (JJ Doc_17344330_327_333_Chemical) (NNS addicts)) (ADJP (RB sometimes) (JJ faint) (PP (IN while) (S (VP (VBG using) (NP (JJ illicit) (NNS drugs)))))))) (, ,) (S (NP (NNS doctors)) (VP (MD might) (VP (VP (VB attribute) (NP (NP (ADJP (RB too) (JJ many)) (NNS episodes)) (PP (IN of) (NP (NNP Doc_17344330_430_437_Disease)))) (PP (TO to) (NP (JJ illicit) (NN drug) (NN use)))) (CC and) (VP (ADVP (RB thereby)) (VB underestimate) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NNP Doc_17344330_501_504_Disease))) (PP (IN in) (NP (DT this) (JJ special) (NN population)))))))) (, ,) (CC and) (S (NP (NP (DT the) (JJ high) (NN mortality)) (PP (IN in) (NP (DT this) (NN population)))) (VP (MD may) (, ,) (PP (IN in) (NP (NN part))) (, ,) (VP (AUX be) (VP (VBN caused) (PP (IN by) (NP (NP (DT the) (JJ proarrhythmic) (NN effect)) (PP (IN of) (NP (NNP Doc_17344330_630_639_Chemical))))))))) (. .)))
17344330	4	(S1 (S (PP (IN In) (NP (DT this) (JJ cross-sectional) (NN study) (NN interview))) (, ,) (NP (NNS ECGs) (CC and) (NN blood) (NNS samples)) (VP (AUX were) (VP (VBN collected) (PP (IN in) (NP (NP (DT a) (NN population)) (PP (IN of) (NP (NP (JJ adult) (JJ Doc_17344330_754_760_Chemical) (NNS addicts)) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_17344330_782_791_Chemical)) (CC or) (NP (NNP Doc_17344330_795_808_Chemical)))) (PP (IN on) (NP (DT a) (JJ daily) (NN basis)))))))))) (. .)))
17344330	5	(S1 (S (PP (IN Of) (NP (NP (DT the) (NNS patients)) (PP (IN at) (NP (DT the) (NNP Drug) (NN Addiction) (NN Service))) (PP (IN in) (NP (NP (DT the) (JJ municipal)) (PP (IN of) (NP (NNP Copenhagen))))))) (, ,) (NP (NP (CD 450)) (PRN (-LRB- -LRB-) (NP (QP (RB approximately) (CD 52)) (NN %)) (-RRB- -RRB-))) (VP (AUX were) (VP (VBN included))) (. .)))
17344330	6	(S1 (S (NP (DT The) (JJ QT) (NN interval)) (VP (AUX was) (VP (VBN estimated) (PP (IN from) (NP (CD 12) (JJ lead) (NNS ECGs))))) (. .)))
17344330	7	(S1 (S (NP (DT All) (NNS participants)) (VP (AUX were) (VP (VBN interviewed) (PP (IN about) (NP (NP (DT any) (NN experience)) (PP (IN of) (NP (NNP Doc_17344330_1051_1058_Disease))))))) (. .)))
17344330	8	(S1 (S (NP (NP (DT The) (NN association)) (PP (IN between) (NP (NP (NP (JJ opioid) (NN dose)) (CC and) (NP (NN QT))) (, ,) (CC and) (NP (JJ Doc_17344330_1108_1117_Chemical) (NN dose)) (CC and) (NP (NP (NN reporting)) (PP (IN of) (NP (NNP Doc_17344330_1140_1147_Disease))))))) (VP (AUX was) (VP (VBN assessed) (S (VP (VBG using) (NP (NP (JJ multivariate) (JJ linear) (NN regression)) (CC and) (NP (NP (JJ logistic) (NN regression)) (, ,) (ADVP (RB respectively)))))))) (. .)))
17344330	9	(S1 (S (NP (JJ Doc_17344330_1246_1255_Chemical) (NN dose)) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (ADJP (RB longer) (JJ QT)) (NN interval)) (PP (IN of) (NP (NP (CD 0.140) (NNS ms/mg)) (PRN (-LRB- -LRB-) (NP (NNP p) (SYM =) (CD 0.002)) (-RRB- -RRB-)))))))) (. .)))
17344330	10	(S1 (S (NP (NP (DT No) (NN association)) (PP (IN between) (NP (NP (NNP Doc_17344330_1351_1364_Chemical)) (CC and) (NP (NNP QTc))))) (VP (AUX was) (VP (VBN found))) (. .)))
17344330	11	(S1 (S (PP (IN Among) (NP (NP (DT the) (NNS subjects)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_17344330_1416_1425_Chemical)))))) (, ,) (NP (NP (ADJP (CD 28) (NN %)) (NNS men)) (CC and) (NP (ADJP (CD 32) (NN %)) (NNS women))) (VP (AUX had) (NP (NN Doc_17344330_1453_1475_Disease))) (. .)))
17344330	12	(S1 (S (NP (NP (NN None)) (PP (IN of) (NP (NP (DT the) (NNS subjects)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_17344330_1511_1524_Chemical))))))) (VP (AUX had) (VP (VBN QTc) (NP (JJ interval) (NX (NX (CD >0.440) (NNP s)) (PRN (-LRB- -LRB-) (-LRB- -LRB-) (NNP 1/2) (-RRB- -RRB-) (-RRB- -RRB-)))))) (. .)))
17344330	13	(S1 (S (NP (DT A) (ADJP (NP (CD 50) (NN mg)) (JJR higher)) (JJ Doc_17344330_1574_1583_Chemical) (NN dose)) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (DT a) (CD 1.2) (ADJP (ADJP (-LRB- -LRB-) (NP (CD 95) (NN %) (QP (CD CI) (CD 1.1) (TO to) (CD 1.4))) (-RRB- -RRB-)) (CC times) (ADJP (JJR higher))) (NNS odds)) (PP (IN for) (NP (NNP Doc_17344330_1657_1664_Disease))))))) (. .)))
17344330	14	(S1 (S (NP (NN Doc_17344330_1679_1688_Chemical)) (VP (AUX is) (VP (VBN associated) (PP (IN with) (NP (NP (NP (NNP Doc_17344330_1708_1723_Disease)) (CC and) (NP (NP (JJR higher) (NN reporting)) (PP (IN of) (NP (NNP Doc_17344330_1748_1755_Disease))))) (PP (IN in) (NP (NP (DT a) (NN population)) (PP (IN of) (NP (JJ Doc_17344330_1775_1781_Chemical) (NNS addicts))))))))) (. .)))
17366349	0	(S1 (S (NP (NN Doc_17366349_0_30_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_17366349_42_53_Chemical))) (PP (IN on) (NP (NP (DT the) (JJ second) (NN day)) (PP (IN of) (NP (NN treatment)))))) (. .)))
17366349	1	(S1 (S (NP (NP (NN Doc_17366349_86_116_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_17366349_118_121_Disease)) (-RRB- -RRB-))) (VP (AUX is) (NP (NP (DT the) (ADJP (ADJP (JJS rarest)) (CC and) (ADJP (RBS most) (JJ serious)))) (PP (IN of) (NP (DT the) (JJ neuroleptic-induced) (NN Doc_17366349_181_199_Disease))))) (. .)))
17366349	2	(S1 (S (NP (PRP We)) (VP (VBP describe) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NP (NNP Doc_17366349_223_253_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_17366349_255_258_Disease)) (-RRB- -RRB-)))) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NNP Doc_17366349_287_298_Chemical)))))))) (. .)))
17366349	3	(S1 (S (SBAR (IN Although) (S (NP (JJ conventional) (NNS neuroleptics)) (VP (AUX are) (ADVP (RBR more) (RB frequently)) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_17366349_371_374_Disease))))))) (, ,) (NP (NP (JJ atypical) (JJ antipsychotic) (NNS drugs)) (PP (IN like) (NP (NNP Doc_17366349_410_421_Chemical)))) (VP (MD may) (ADVP (RB also)) (VP (AUX be) (NP (DT a) (NN cause)))) (. .)))
17366349	4	(S1 (S (NP (DT The) (NN patient)) (VP (AUX is) (NP (NP (DT a) (JJ 24-year-old) (NN male)) (PP (IN with) (NP (NP (DT a) (NN history)) (PP (IN of) (NP (NNP Doc_17366349_495_508_Disease))))) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NP (NP (NNS signs)) (CC and) (NP (NNS symptoms))) (PP (IN of) (NP (NNP Doc_17366349_545_548_Disease)))) (PP (IN after) (NP (NP (CD 2) (NNS days)) (PP (IN of) (NP (NN treatment))))) (PP (IN with) (NP (NP (DT an) (JJ 80-mg/day) (NN dose)) (PP (IN of) (NP (ADJP (RB orally) (VBN administrated)) (NNP Doc_17366349_622_633_Chemical)))))))))) (. .)))
17366349	5	(S1 (S (NP (DT This) (NN case)) (VP (AUX is) (NP (NP (DT the) (JJS earliest) (PRN (-LRB- -LRB-) (NP (NP (JJ second) (NN day)) (PP (IN of) (NP (NN treatment)))) (-RRB- -RRB-)) (ADJP (NNP Doc_17366349_687_690_Disease) (JJ due) (PP (TO to) (NP (NNP Doc_17366349_698_709_Chemical))))) (VP (VBN reported) (PP (IN in) (NP (DT the) (NN literature)))))) (. .)))
17490790	0	(S1 (S (NP (JJ Peripheral) (NNP Doc_17490790_11_23_Chemical)) (VP (VBN induced) (NP (NNP Doc_17490790_32_68_Disease)) (PP (IN in) (NP (NN rat) (NN substantia) (NNS nigra)))) (. .)))
17490790	1	(S1 (S (NP (JJ Doc_17490790_94_98_Chemical) (NN accumulation)) (VP (AUX is) (VP (VBN considered) (S (VP (TO to) (VP (AUX be) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (NNS pathogenesis)) (PP (IN of) (NP (NN Doc_17490790_164_183_Disease))))))))))) (. .)))
17490790	2	(S1 (S (S (VP (TO To) (VP (VB demonstrate) (NP (NP (DT the) (NN relationship)) (PP (IN between) (NP (NP (JJ peripheral) (JJ Doc_17490790_236_240_Chemical) (NN overload)) (CC and) (NP (JJ dopaminergic) (NN neuron) (NN loss))))) (PP (IN in) (NP (NP (NN rat) (NN substantia) (NN nigra)) (PRN (-LRB- -LRB-) (NP (NNP SN)) (-RRB- -RRB-))))))) (, ,) (PP (IN in) (NP (DT the) (JJ present) (NN study))) (NP (PRP we)) (VP (VBD used) (NP (NP (JJ fast) (JJ cyclic) (NN voltammetry)) (, ,) (NP (NNP Doc_17490790_363_371_Chemical) (FW hydroxylase) (PRN (-LRB- -LRB-) (NP (NNP TH)) (-RRB- -RRB-)) (NN immunohistochemistry)) (, ,) (NP (NP (NNP Perls) (POS ')) (JJ Doc_17490790_418_422_Chemical) (NN staining)) (, ,) (CC and) (NP (JJ high) (NN performance) (NN liquid) (JJ chromatography-electrochemical) (NN detection))) (S (VP (TO to) (VP (VP (VB study) (NP (DT the) (NNP Doc_17490790_515_551_Disease))) (CC and) (VP (VBD increased) (NP (JJ Doc_17490790_566_570_Chemical) (NN content)) (PP (IN in) (NP (NP (DT the) (NN SN)) (PP (IN of) (NP (JJ Doc_17490790_592_604_Chemical) (JJ overloaded) (NNS animals)))))))))) (. .)))
17490790	3	(S1 (S (NP (DT The) (NNS findings)) (VP (VBD showed) (SBAR (IN that) (S (NP (JJ peripheral) (JJ Doc_17490790_661_673_Chemical) (NN overload)) (VP (VP (VBD increased) (NP (DT the) (JJ Doc_17490790_697_701_Chemical) (JJ staining) (JJ positive) (NNS cells))) (CC and) (VP (VBD reduced) (NP (NP (DT the) (NN number)) (PP (IN of) (NP (NP (JJ TH-immunoreactive) (NNS neurons)) (PP (IN in) (NP (DT the) (NN SN))))))))))) (. .)))
17490790	4	(S1 (S (PP (IN As) (NP (DT a) (NN result))) (, ,) (NP (NP (JJ Doc_17490790_802_810_Chemical) (NN release)) (CC and) (NP (NP (NN content)) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (PRP$ its) (NNS metabolites) (NNS contents)))) (VP (AUX were) (VP (VBN decreased) (PP (IN in) (NP (JJ caudate) (NNS putamen))))) (. .)))
17490790	5	(S1 (S (NP (ADJP (RB Even) (RBR more) (JJ dramatic)) (NNS changes)) (VP (AUX were) (VP (VBN found) (PP (IN in) (NP (JJ chronic) (NN overload) (NN group))))) (. .)))
17490790	6	(S1 (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (JJ peripheral) (NNP Doc_17490790_1006_1018_Chemical)) (VP (MD can) (VP (VB increase) (NP (NP (DT the) (JJ Doc_17490790_1036_1040_Chemical) (NN level)) (PP (IN in) (NP (NP (DT the) (NNP SN)) (, ,) (SBAR (WHADVP (WRB where)) (S (NP (JJ excessive) (NN Doc_17490790_1074_1078_Chemical)) (VP (VBZ causes) (NP (DT the) (NNP Doc_17490790_1090_1126_Disease))))))))))))) (. .)))
17490790	7	(S1 (S (NP (DT The) (JJ chronic) (JJ Doc_17490790_1140_1144_Chemical) (NN overload)) (VP (MD may) (VP (AUX be) (ADJP (RBR more) (JJ destructive) (PP (TO to) (NP (JJ dopaminergic) (NNS neurons))) (PP (IN than) (NP (DT the) (JJ acute) (JJ Doc_17490790_1217_1221_Chemical) (NN overload)))))) (. .)))
17490864	0	(S1 (NP (NP (JJ Attenuated) (NN disruption)) (PP (IN of) (NP (NN prepulse) (NN inhibition))) (PP (IN by) (NP (JJ dopaminergic) (NN stimulation))) (PP (IN after) (NP (NP (NP (JJ maternal) (NN deprivation)) (CC and) (NP (JJ adolescent) (JJ Doc_17490864_115_129_Chemical) (NN treatment))) (PP (IN in) (NP (NNS rats))))) (. .)))
17490864	1	(S1 (S (NP (NP (DT The) (NN development)) (PP (IN of) (NP (NNP Doc_17490864_168_181_Disease)))) (VP (MD may) (VP (VB include) (NP (NP (DT an) (JJ early) (JJ neurodevelopmental) (NN stress) (NN component)) (SBAR (WHNP (WDT which)) (S (VP (VBZ increases) (NP (NN vulnerability)) (PP (TO to) (NP (RBR later) (JJ stressful) (NN life) (NNS events))))))) (, ,) (PP (IN in) (NP (NP (NN combination)) (VP (VBG leading) (PP (TO to) (NP (NN overt) (NN disease)))))))) (. .)))
17490864	2	(S1 (S (NP (PRP We)) (VP (VBD investigated) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (DT an) (JJ early) (NN stress)) (, ,) (PP (IN in) (NP (NP (DT the) (NN form)) (PP (IN of) (NP (JJ maternal) (NN deprivation))))) (, ,) (VP (VBN combined) (PP (IN with) (NP (DT a) (JJ later) (NN stress)))) (, ,) (ADJP (JJ simulated) (PP (IN by) (NP (JJ chronic) (JJ periadolescent) (JJ Doc_17490864_492_506_Chemical) (NN treatment)))) (, ,))) (PP (IN on) (NP (NP (NN behaviour)) (PP (IN in) (NP (NNS rats))))))) (. .)))
17490864	3	(S1 (S (NP (NP (JJ Acute) (NN treatment)) (PP (IN with) (NP (NNP Doc_17490864_561_572_Chemical)))) (VP (VBD caused) (NP (NP (NN disruption)) (PP (IN of) (NP (NP (JJ prepulse) (NN inhibition)) (PRN (-LRB- -LRB-) (NP (NNP PPI)) (-RRB- -RRB-)))) (PP (PP (IN in) (NP (NNS controls))) (CC and) (PP (IN in) (NP (NP (NNS rats)) (SBAR (WHNP (WDT that)) (S (VP (VP (AUX had) (VP (VBN undergone) (NP (NP (DT either) (JJ maternal) (NN deprivation)) (CC or) (NP (JJ Doc_17490864_694_708_Chemical) (NN treatment))))) (, ,) (CC but) (VP (AUX was) (ADJP (RB surprisingly) (JJ absent)) (PP (IN in) (NP (NP (NNS rats)) (SBAR (WHNP (WDT that)) (S (VP (AUX had) (VP (VBN undergone) (NP (DT the) (JJ combined) (JJ early) (CC and) (JJ late) (NN stress))))))))))))))))) (. .)))
17490864	4	(S1 (S (NP (JJ Doc_17490864_811_822_Chemical) (NN treatment)) (ADVP (RB significantly)) (VP (VP (VBD disrupted) (NP (NNP PPI)) (PP (IN in) (NP (DT both) (JJ non-deprived) (NNS groups)))) (, ,) (CC but) (VP (AUX was) (ADJP (JJ absent)) (PP (IN in) (NP (DT both) (JJ maternally) (VBN deprived) (NNS groups))))) (. .)))
17490864	5	(S1 (S (NP (NP (DT The) (JJ Doc_17490864_945_954_Chemical-1A) (NN receptor) (NN agonist)) (, ,) (NP (NNP Doc_17490864_976_985_Chemical)) (, ,)) (VP (VBN induced) (NP (NP (DT a) (JJ significant) (NN disruption)) (PP (IN of) (NP (NNP PPI)))) (PP (IN in) (NP (DT all) (NNS groups)))) (. .)))
17490864	6	(S1 (S (NP (JJ Doc_17490864_1042_1053_Chemical-induced) (NN Doc_17490864_1062_1085_Disease)) (VP (AUX was) (ADJP (JJ similar)) (PP (IN in) (NP (DT all) (NNS groups)))) (. .)))
17490864	7	(S1 (S (NP (DT These) (NNS results)) (VP (VBP show) (NP (NP (DT an) (JJ inhibitory) (NN interaction)) (PP (IN of) (NP (JJ early) (NN stress))) (, ,) (VP (VBN caused) (PP (IN by) (NP (JJ maternal) (NN deprivation)))) (, ,) (VP (VBN combined) (PP (IN with) (NP ('' ') (JJ adolescent) ('' ') (NN stress)))) (, ,) (ADJP (JJ simulated) (PP (IN by) (NP (JJ Doc_17490864_1255_1269_Chemical) (NN treatment)))) (, ,)) (PP (IN on) (NP (NP (JJ dopaminergic) (NN regulation)) (PP (IN of) (NP (NNP PPI)))))) (. .)))
17490864	8	(S1 (S (NP (NP (DT The) (JJ altered) (NNS effects)) (PP (IN of) (NP (NNP Doc_17490864_1339_1350_Chemical) (CC and) (NNP Doc_17490864_1355_1366_Chemical)))) (VP (MD could) (VP (VB indicate) (NP (NP (NN differential) (NNS changes)) (PP (IN in) (NP (NP (JJ Doc_17490864_1406_1414_Chemical) (NN receptor) (NN signalling)) (VP (VBG leading) (PP (TO to) (NP (NP (JJ functional) (NN desensitisation)) (, ,) (CC or) (NP (NP (JJ altered) (NN modulation)) (PP (IN of) (NP (NP (JJ sensory) (NN gating)) (PP (IN in) (NP (NP (DT the) (NN nucleus) (NNS accumbens)) (PP (IN by) (NP (JJ limbic) (NNS structures))) (PP (JJ such) (IN as) (NP (DT the) (NN hippocampus)))))))))))))))) (. .)))
17511042	0	(S1 (NP (NP (DT An) (ADJP (RB extremely) (JJ rare)) (NN case)) (PP (IN of) (NP (NNP Doc_17511042_26_48_Disease))) (PP (IN in) (NP (NP (DT a) (JJ Doc_17511042_54_73_Disease) (NN patient)) (PP (IN during) (NP (NNP Doc_17511042_89_118_Chemical) (CC and) (NNP Doc_17511042_123_132_Chemical) (NN treatment))))) (. .)))
17511042	1	(S1 (S (PP (IN During) (NP (NP (NN treatment)) (PP (IN of) (NP (NP (JJ Doc_17511042_164_183_Disease) (NNS patients)) (PP (IN with) (NP (NP (NNP interferon)) (CC and) (NP (NNP Doc_17511042_213_222_Chemical)))))))) (, ,) (NP (NP (DT a) (NN lot)) (PP (IN of) (NP (NN side) (NNS effects)))) (VP (AUX are) (VP (VBN described))) (. .)))
17511042	2	(S1 (S (NP (NP (JJ Twenty-three) (NN percent) (TO to) (CD 44) (NN %)) (PP (IN of) (NP (NNS patients)))) (VP (VBP develop) (NP (NN Doc_17511042_309_319_Disease))) (. .)))
17511042	3	(S1 (S (NP (NP (DT A) (NN minority)) (PP (IN of) (NP (NNS patients)))) (VP (VB evolve) (S (VP (TO to) (VP (VB Doc_17511042_354_363_Disease))))) (. .)))
17511042	4	(S1 (S (PP (TO To) (NP (NP (DT the) (JJS best)) (PP (IN of) (NP (PRP$ our) (NN knowledge))))) (, ,) (NP (NP (DT no) (NNS cases)) (PP (IN of) (NP (NNP Doc_17511042_407_430_Disease))) (VP (VBG occurring) (PP (IN during) (NP (NNP interferon) (NN therapy))))) (VP (AUX have) (VP (AUX been) (VP (VBN described) (PP (IN in) (NP (DT the) (NN literature)))))) (. .)))
17511042	5	(S1 (S (NP (PRP We)) (VP (VBP present) (NP (NP (DT a) (JJ 49-year-old) (NN woman)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (DT a) (NN Doc_17511042_553_575_Disease)) (PP (IN during) (NP (NN treatment))) (PP (IN with) (NP (NNP Doc_17511042_598_627_Chemical) (NNP weekly) (CC and) (NNP Doc_17511042_639_648_Chemical)))))))) (. .)))
17511042	6	(S1 (S (NP (PRP She)) (VP (VBD complained) (PP (IN of) (S (VP (VBG seeing) (NP (NP (NNS parasites)) (CC and) (NP (NP (DT the) (NNS larvae)) (PP (IN of) (NP (NNS fleas))))) (PP (IN in) (NP (PRP$ her) (NNS stools))))))) (. .)))
17511042	7	(S1 (S (NP (DT This)) (VP (MD could) (RB not) (VP (AUX be) (VP (VBN confirmed) (PP (IN by) (NP (DT any) (JJ technical) (NN examination)))))) (. .)))
17511042	8	(S1 (S (NP (PDT All) (DT the) (NNS complaints)) (VP (VP (VBD disappeared) (PP (IN after) (S (VP (VBG stopping) (NP (NNP Doc_17511042_828_857_Chemical)))))) (CC and) (VP (VBD reappeared) (PP (IN after) (S (VP (VBG restarting) (NP (PRP it))))))) (. .)))
17511042	9	(S1 (S (NP (PRP She)) (VP (AUX had) (NP (DT a) (JJ complete) (JJ sustained) (JJ viral) (NN response))) (. .)))
17574447	0	(S1 (S (NP (NP (NNP Hepatonecrosis)) (CC and) (NP (NNP Doc_17574447_19_30_Disease))) (VP (VBD related) (PP (TO to) (NP (JJ long-term) (JJ Doc_17574447_52_65_Chemical) (NN therapy))) (: :) (NP (NP (DT an) (JJ autopsy) (NN report)) (PP (IN of) (NP (CD two) (NNS patients))))) (. .)))
17574447	1	(S1 (S (S (NP (NP (NNP Doc_17574447_110_123_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP PB)) (-RRB- -RRB-))) (VP (AUX has) (NP (NP (DT a) (NN reputation)) (PP (IN for) (NP (NN safety)))))) (, ,) (CC and) (S (NP (PRP it)) (VP (AUX is) (VP (ADVP (RB commonly)) (VBN believed) (SBAR (IN that) (S (NP (NP (JJ PB-related) (NNS increases)) (PP (IN in) (NP (JJ serum) (NN aminotransferase) (NNS levels)))) (VP (AUX do) (RB not) (VP (VP (VB indicate)) (CC or) (VP (VB predict) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (JJ significant) (JJ chronic) (NN Doc_17574447_311_324_Disease)))))))))))) (. .)))
17574447	2	(S1 (S (ADVP (RB Here)) (NP (PRP we)) (VP (VBP report) (PP (IN of) (NP (NP (NP (CD two) (NN adult) (NNS patients)) (PP (IN with) (NP (NP (DT a) (JJ long) (NN history)) (PP (IN of) (NP (NNP Doc_17574447_386_394_Disease))) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_17574447_408_410_Chemical)))))) (SBAR (WHNP (WP who)) (S (VP (VBD died) (ADVP (RB suddenly)))))) (: :) (NP (CD one)))) (PP (IN as) (NP (NP (NN consequence)) (PP (IN of) (NP (NP (NNP Doc_17574447_452_466_Disease)) (, ,) (NP (NP (DT the) (JJ other)) (PP (IN of) (NP (JJ acute) (NNP Doc_17574447_487_503_Disease))))))))) (. .)))
17574447	3	(S1 (S (PP (IN At) (NP (NN autopsy))) (, ,) (NP (NP (NN analysis)) (PP (IN of) (NP (NN liver) (NN parenchyma)))) (VP (VBD revealed) (NP (NP (JJ rich) (NN portal) (JJ inflammatory) (VB infiltrate)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD consisted) (PP (IN of) (NP (JJ mixed) (NN eosinophil) (CC and) (NN monocyte) (NNS cells)))))) (, ,) (VP (VBN associated) (PP (IN with) (NP (NP (JJ several) (NNS foci)) (PP (IN of) (NP (NNP Doc_17574447_680_688_Disease))) (VP (VBN surrounded) (PP (IN by) (NP (NP (DT a) (JJ hard) (NN ring)) (PP (IN of) (NP (JJ non-specific) (JJ granulomatous) (NN tissue))))))))))) (. .)))
17574447	4	(S1 (S (NP (NP (JJ Inflammatory) (NNS reactions)) (PP (IN of) (NP (ADJP (JJ internal) (CC and) (JJ external)) (JJ hepatic) (NN biliary) (NNS ducts)))) (VP (AUX were) (ADVP (RB also)) (VP (VBN seen))) (. .)))
17574447	5	(S1 (S (NP (PRP$ Our) (NNS findings)) (VP (VBP illustrate) (SBAR (IN that) (S (NP (NNS PB)) (VP (MD may) (VP (AUX be) (VP (VBN associated) (PP (IN with) (NP (NP (JJ chronic) (NNP Doc_17574447_902_914_Disease)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VB lead) (PP (TO to) (NP (ADJP (ADJP (RBR more) (JJ serious)) (CC and) (ADJP (JJ deleterious))) (NNS consequences))))))))))))))) (. .)))
17574447	6	(S1 (S (PP (IN For) (NP (DT this) (NN reason))) (, ,) (NP (DT each) (NN clinician)) (VP (MD should) (VP (VB recognize) (NP (DT this) (NN entity)) (PP (IN in) (NP (NP (DT the) (NN differential) (NN diagnosis)) (PP (IN of) (NP (JJ PB-related) (JJ asymptomatic) (NN Doc_17574447_1095_1129_Disease))))))) (. .)))
17682013	0	(S1 (S (VP (VBN Delayed) (NP (NN Doc_17682013_8_27_Disease)) (PP (IN with) (NP (NP (JJ Doc_17682013_33_39_Disease-like) (NN presentation)) (PP (IN in) (NP (JJ chemotherapy) (NNS recipients)))))) (. .)))
17682013	1	(S1 (S (NP (DT A) (JJ transient) (NNP Doc_17682013_110_129_Disease) (NN mimicking) (NN Doc_17682013_140_164_Disease)) (VP (AUX has) (VP (AUX been) (VP (VBN described) (PP (IN as) (NP (NP (DT a) (NN complication)) (PP (IN of) (NP (NN chemotherapy))))) (, ,) (ADVP (RBS most) (RB commonly)) (PP (IN in) (NP (NP (NNS recipients)) (PP (IN of) (NP (JJ intrathecal) (NNP Doc_17682013_262_274_Chemical))) (PP (IN for) (NP (NN childhood) (NN Doc_17682013_289_298_Disease)))))))) (. .)))
17682013	2	(S1 (S (NP (ADJP (RB Recently) (VBN published)) (NN neuroimaging) (NNS data)) (VP (VBP suggest) (NP (NP (DT a) (JJ common) (NN pathophysiology)) (VP (VBN associated) (PP (IN with) (NP (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (JJ chemotherapy) (NNS agents)))) (CC and) (NP (NP (NNS modes)) (PP (IN of) (NP (NN administration))))))))) (. .)))
17682013	3	(S1 (S (NP (PRP We)) (VP (VBN reviewed) (NP (NP (DT the) (JJ medical) (NN literature)) (PP (IN for) (NP (NP (JJ single) (NNS reports) (CC and) (NN case) (NNS series)) (PP (IN of) (NP (NP (NNS patients)) (VP (VBG presenting) (PP (IN with) (NP (JJ Doc_17682013_555_561_Disease-like) (NNS episodes))) (SBAR (IN while) (S (VP (VBG receiving) (NP (JJ systemic) (CC or) (JJ intrathecal) (NN chemotherapy)))))))))))) (. .)))
17682013	4	(S1 (S (NP (PRP We)) (ADVP (RB only)) (VP (VBD included) (NP (NP (NNS studies)) (VP (VBG providing) (NP (JJ detailed) (JJ neuroimaging) (NNS data))))) (. .)))
17682013	5	(S1 (S (NP (NP (NNS Patients)) (PP (IN with) (NP (NNP Doc_17682013_707_732_Disease)))) (VP (AUX were) (VP (VBN excluded))) (. .)))
17682013	6	(S1 (S (NP (PRP We)) (VP (VBD identified) (NP (NP (CD 27) (NNS reports)) (PP (IN of) (NP (JJ toxic) (NNP Doc_17682013_791_810_Disease)))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NP (NP (NNP Doc_17682013_836_848_Chemical)) (PRN (-LRB- -LRB-) (ADJP (JJ intrathecal) (, ,) (JJ systemic)) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Doc_17682013_874_888_Chemical)) (CC and) (NP (PRP$ its) (JJ derivative) (NNP Doc_17682013_908_916_Chemical))) (, ,) (CC and) (NP (NNP Doc_17682013_922_934_Chemical)))))))) (. .)))
17682013	7	(S1 (S (NP (NP (NN Diffusion) (JJ weighted) (NN imaging)) (PRN (-LRB- -LRB-) (NP (NNP DWI)) (-RRB- -RRB-)) (PP (IN of) (NP (DT all) (NNS patients)))) (VP (VBD revealed) (NP (NP (ADJP (RB well) (VBN demarcated)) (NN hyperintense) (NN Doc_17682013_1023_1066_Disease)) (PP (IN of) (NP (NP (DT the) (JJ cerebral) (NNS hemispheres)) (CC and) (NP (DT the) (JJ corpus) (NN callosum))))) (, ,) (PP (VBG corresponding) (PP (TO to) (NP (NP (NNS areas)) (PP (IN of) (NP (NP (VBN decreased) (NN proton) (NN diffusion)) (PP (IN on) (NP (NP (JJ apparent) (NN diffusion) (NN coefficient) (PRN (-LRB- -LRB-) (NP (NNP ADC)) (-RRB- -RRB-)) (NNS maps)) (PRN (-LRB- -LRB-) (ADJP (JJ available) (PP (IN in) (NP (CD 21/27) (NNS patients)))) (-RRB- -RRB-)))))))))) (. .)))
17682013	8	(S1 (S (NP (NNS Lesions)) (VP (VBD exceeded) (NP (NP (DT the) (NNS confines)) (PP (IN of) (NP (JJ adjacent) (JJ vascular) (NNS territories))))) (. .)))
17682013	9	(S1 (S (NP (NP (JJ Complete) (NN resolution)) (PP (IN of) (NP (NNS symptoms))) (PP (IN within) (NP (JJ 1-4) (NNS days)))) (VP (AUX was) (VP (VBN accompanied) (PP (IN by) (NP (NP (NN normalisation)) (PP (IN of) (NP (JJ ADC) (NNS abnormalities))))))) (. .)))
17682013	10	(S1 (S (ADVP (RB However)) (, ,) (NP (JJ fluid) (JJ attenuated) (NN inversion) (NN recovery) (PRN (-LRB- -LRB-) (NP (NN FLAIR)) (-RRB- -RRB-)) (NNS sequences)) (ADVP (RB frequently)) (VP (VBD revealed) (NP (JJ persistent) (NNP Doc_17682013_1510_1536_Disease))) (. .)))
17682013	11	(S1 (S (NP (NP (JJ Several) (JJ pathophysiological) (NNS models)) (PP (IN of) (NP (JJ delayed) (NNP Doc_17682013_1596_1615_Disease))) (PP (IN after) (NP (NP (NN exposure)) (PP (TO to) (NP (NP (NN intrathecal)) (CC or) (NP (JJ systemic) (NN chemotherapy))))))) (VP (AUX have) (VP (AUX been) (VP (VBN proposed)))) (. .)))
17682013	12	(S1 (S (NP (NP (NN DWI) (NNS findings)) (PP (IN in) (NP (DT this) (NN cohort)))) (VP (VP (AUX are) (ADJP (JJ indicative) (PP (IN of) (NP (NNP Doc_17682013_1737_1782_Disease))))) (CC and) (VP (VB lend) (NP (NN support)) (PP (TO to) (NP (NP (DT an) (ADJP (ADVP (IN at) (JJS least)) (RB partially) (JJ reversible)) (JJ metabolic) (NN derangement)) (PP (IN as) (NP (NP (DT the) (NN basis)) (PP (IN for) (NP (DT this) (NN syndrome))))))))) (. .)))
17702969	0	(S1 (S (NP (NP (JJ Prenatal) (NN exposure)) (PP (TO to) (NP (NNP Doc_17702969_21_31_Chemical)))) (VP (VBZ induces) (NP (NN Doc_17702969_40_68_Disease)) (PP (IN in) (NP (DT the) (NN rat)))) (. .)))
17702969	1	(S1 (S (NP (NN Doc_17702969_92_102_Chemical)) (VP (AUX is) (NP (NP (DT a) (JJ selective) (JJ Doc_17702969_118_127_Chemical) (NN reuptake) (NN inhibitor) (NN antidepressant)) (VP (ADVP (RB widely)) (VBN used) (PP (IN by) (NP (JJ pregnant) (NNS women)))))) (. .)))
17702969	2	(S1 (S (NP (JJ Epidemiological) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (NP (JJ Doc_17702969_227_237_Chemical) (NN exposure)) (ADVP (RB prenatally)) (VP (VBZ increases) (NP (NP (DT the) (NN prevalence)) (PP (IN of) (NP (NP (JJ persistent) (NN Doc_17702969_297_328_Disease)) (PP (IN of) (NP (DT the) (JJ newborn)))))))))) (. .)))
17702969	3	(S1 (S (NP (NP (DT The) (NN mechanism)) (ADJP (JJ responsible) (PP (IN for) (NP (DT this) (NN effect))))) (VP (AUX is) (ADJP (ADJP (JJ unclear)) (CC and) (ADJP (JJ paradoxical))) (, ,) (S (VP (VBG considering) (NP (NP (DT the) (JJ current) (NN evidence)) (PP (IN of) (NP (NP (DT a) (JJ Doc_17702969_453_475_Disease) (JJ protective) (JJ Doc_17702969_487_497_Chemical) (NN effect)) (PP (IN in) (NP (JJ adult) (NNS rodents))))))))) (. .)))
17702969	4	(S1 (S (S (VP (TO To) (VP (VB evaluate) (NP (NP (DT the) (JJ Doc_17702969_551_561_Chemical) (NN effect)) (PP (IN on) (NP (JJ fetal) (NN rat))))))) (VP (VBP pulmonary) (NP (NP (JJ vascular) (JJ smooth) (NN muscle) (JJ mechanical) (NNS properties)) (CC and) (NP (NN cell) (NN proliferation) (NN rate)))) (. .)))
17702969	5	(S1 (S (NP (JJ Pregnant) (NNS rats)) (VP (AUX were) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_17702969_707_717_Chemical))) (PRN (-LRB- -LRB-) (NP (CD 10) (NN mg/kg)) (-RRB- -RRB-)) (PP (IN from) (NP (NNP Day) (CD 11))) (PP (IN through) (NP (NP (NNP Day) (CD 21)) (PP (IN of) (NP (NN gestation))))))) (. .)))
17702969	6	(S1 (NP (NP (NP (NNS MEASUREMENTS)) (CC AND) (NP (JJ MAIN) (NNS RESULTS))) (: :) (S (NP (NNS Fetuses)) (VP (AUX were) (VP (VBN delivered) (PP (IN by) (NP (JJ cesarean) (NN section)))))) (. .)))
17702969	7	(S1 (S (SBAR (IN As) (S (VP (VBN compared) (PP (IN with) (NP (NNS controls)))))) (, ,) (NP (JJ Doc_17702969_872_882_Chemical) (NN exposure)) (VP (VBD resulted) (PP (IN in) (NP (NNP Doc_17702969_904_932_Disease))) (SBAR (IN as) (S (VP (VBN evidenced) (PP (PP (IN by) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (DT the) (NN weight) (NN ratio)) (PP (IN of) (NP (DT the) (JJ right) (NN ventricle))) (PP (TO to) (NP (DT the) (JJ left) (NN ventricle) (CC plus) (NN septum))))) (PRN (-LRB- -LRB-) (NP (NNP P) (SYM =) (CD 0.02)) (-RRB- -RRB-)))) (CC and) (PP (IN by) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (JJ pulmonary) (JJ arterial) (JJ medial) (NN thickness))) (PRN (-LRB- -LRB-) (NP (QP (CD P) (CD <)) (CD 0.01)) (-RRB- -RRB-))))))))) (. .)))
17702969	8	(S1 (S (S (NP (JJ Postnatal) (NN mortality)) (VP (AUX was) (VP (VBN increased) (PP (IN among) (NP (JJ experimental) (NNS animals)))))) (, ,) (CC and) (S (NP (JJ arterial) (JJ Doc_17702969_1194_1200_Chemical) (NN saturation)) (VP (VP (AUX was) (NP (NP (CD 96) (NN +/-)) (ADJP (CD 1) (NN %))) (PP (IN in) (NP (JJ 1-day-old) (NN control) (NNS animals)))) (CC and) (VP (ADJP (ADJP (RB significantly) (JJR lower)) (PRN (-LRB- -LRB-) (ADJP (QP ($ P) (CD <) (CD 0.01))) (-RRB- -RRB-))) (PP (IN in) (NP (NP (JJ Doc_17702969_1293_1303_Chemical-exposed) (NNS pups)) (PRN (-LRB- -LRB-) (NP (CD 79) (NN +/-) (CD 2) (NN %)) (-RRB- -RRB-))))))) (. .)))
17702969	9	(S1 (S (PP (IN In) (NP (NN vitro))) (, ,) (NP (NNP Doc_17702969_1340_1350_Chemical)) (VP (VBN induced) (NP (JJ pulmonary) (JJ arterial) (NN muscle) (NN contraction)) (PP (IN in) (NP (NP (JJ fetal) (, ,) (CONJP (CC but) (RB not)) (NP (NN adult))) (, ,) (NP (NP (NNS animals)) (PRN (-LRB- -LRB-) (NP (QP ($ P) (CD <) (CD 0.01))) (-RRB- -RRB-))) (CC and) (NP (JJ reduced) (JJ Doc_17702969_1453_1462_Chemical-induced) (NN contraction)))) (PP (IN at) (NP (NP (DT both) (NNS ages)) (PRN (-LRB- -LRB-) (NP (QP ($ P) (CD <) (CD 0.01))) (-RRB- -RRB-))))) (. .)))
17702969	10	(S1 (S (PP (IN After) (PP (IN in) (NP (NP (NN utero) (NN exposure)) (PP (TO to) (NP (DT a) (JJ low) (JJ Doc_17702969_1541_1551_Chemical) (NN concentration)))))) (NP (DT the) (JJ pulmonary) (JJ arterial) (JJ smooth) (NN muscle) (NN cell) (NN proliferation) (NN rate)) (VP (AUX was) (ADVP (RB significantly)) (VP (VBN increased) (PP (IN in) (NP (NP (ADJP (JJ fetal) (, ,) (CC but) (ADJP (RB not) (JJ adult)) (, ,)) (NNS cells)) (PRN (-LRB- -LRB-) (NP (QP ($ P) (CD <) (CD 0.01))) (-RRB- -RRB-)))))) (. .)))
17702969	11	(S1 (S (PP (IN In) (NP (NP (NN contrast)) (PP (TO to) (NP (DT the) (NN adult))))) (, ,) (NP (NP (JJ Doc_17702969_1737_1747_Chemical) (NN exposure)) (PP (IN in) (NP (NN utero)))) (VP (VBZ induces) (NP (NN Doc_17702969_1774_1796_Disease)) (PP (IN in) (NP (DT the) (JJ fetal) (NN rat))) (PP (IN as) (NP (NP (DT a) (NN result)) (PP (IN of) (NP (NP (DT a) (ADJP (RB developmentally) (VBN regulated)) (NN increase)) (PP (IN in) (NP (JJ pulmonary) (JJ vascular) (JJ smooth) (NN muscle) (NN proliferation)))))))) (. .)))
17786501	0	(S1 (NP (NP (JJ Doc_17786501_0_10_Chemical-induced) (JJ transient) (NN Doc_17786501_29_60_Disease)) (: :) (NP (DT a) (NN case) (NN report)) (. .)))
17786501	1	(S1 (FRAG (S (VP (TO To) (VP (VB report) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NNP Doc_17786501_102_133_Disease)))) (PP (IN after) (NP (NP (JJ chronic) (NN use)) (PP (IN of) (NP (NNP Doc_17786501_155_165_Chemical))) (PP (IN for) (NP (JJ Doc_17786501_170_177_Chemical) (NN dependence) (NN management)))))))) (. .)))
17786501	2	(S1 (NP (NP (NP (NNS MATERIALS)) (CC AND) (NP (NNS METHODS))) (: :) (NP (DT A) (NN case) (NN report)) (. .)))
17786501	3	(S1 (S (NP (DT A) (JJ 57-year-old) (NN male)) (VP (VBD presented) (PP (IN with) (NP (JJ gradual) (NNP Doc_17786501_290_304_Disease))) (PP (IN in) (NP (DT both) (NNS eyes))) (PP (IN with) (NP (NP (JJ intermittent) (NN Doc_17786501_336_345_Disease)) (PP (IN for) (NP (CD 2) (NNS months)))))) (. .)))
17786501	4	(S1 (S (NP (NN Doc_17786501_360_362_Chemical)) (ADVP (RB also)) (VP (VBD complained) (PP (IN of) (NP (NN paraesthesia))) (PP (IN with) (NP (NP (NNP Doc_17786501_400_408_Disease)) (PP (IN in) (NP (DT both) (NNS feet)))))) (. .)))
17786501	5	(S1 (S (NP (JJ Doc_17786501_423_426_Chemical) (NN vision)) (VP (AUX was) (NP (NP (CD 6/15)) (CC and) (NP (CD 2/60))) (PP (IN in) (NP (DT the) (JJ right) (CC and) (JJ left) (NNS eyes))) (, ,) (ADVP (RB respectively))) (. .)))
17786501	6	(S1 (S (NP (NN Fundoscopy)) (VP (VBD revealed) (NP (JJ bilaterally) (JJ swollen) (JJ optic) (NN nerve) (NNS heads))) (. .)))
17786501	7	(S1 (S (NP (JJ Visual) (NN field) (NN testing)) (VP (VBD confirmed) (NP (JJ bilateral) (JJ central-caecal) (NN scotomata))) (. .)))
17786501	8	(S1 (S (NP (PRP He)) (VP (AUX had) (VP (AUX been) (VP (VBG taking) (NP (NN Doc_17786501_639_649_Chemical)) (PP (IN for) (NP (NP (JJ Doc_17786501_654_661_Chemical) (NN dependence)) (PP (IN for) (NP (DT the) (JJ preceding) (CD 3) (NNS years)))))))) (. .)))
17786501	9	(S1 (S (NP (JJ Doc_17786501_700_710_Chemical) (NN discontinuation)) (VP (VBP lead) (PP (TO to) (NP (DT an) (JJ immediate) (NN symptomatic) (NN improvement)))) (. .)))
17786501	10	(S1 (S (NP (NP (NNS Physicians)) (VP (VBG initiating) (NP (JJ long-term) (NN Doc_17786501_817_827_Chemical) (NN therapy)))) (VP (MD should) (VP (AUX be) (ADJP (JJ aware) (PP (IN of) (NP (DT these) (JJ adverse) (NNS effects)))))) (. .)))
17786501	11	(S1 (S (NP (PRP They)) (VP (MD should) (VP (VB recommend) (NP (JJ annual) (JJ ophthalmic) (NNS reviews)) (PP (IN with) (NP (JJ visual) (NN field) (NN testing))))) (. .)))
17786501	12	(S1 (S (NP (NNS Patients)) (VP (MD should) (VP (AUX be) (VP (VBN reassured) (PP (IN with) (NP (NP (NN respect)) (PP (TO to) (NP (NP (DT the) (NN reversibility)) (PP (IN of) (NP (DT these) (JJ adverse) (NNS effects)))))))))) (. .)))
17923537	0	(S1 (S (NP (NP (JJ Intraocular) (NN pressure)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_17923537_38_45_Disease)))))) (VP (VBN treated) (PP (IN with) (NP (JJ Doc_17923537_59_81_Chemical) (NNS implants)))) (. .)))
17923537	1	(S1 (S (S (VP (TO To) (VP (VB report) (NP (NP (DT the) (NN incidence) (CC and) (NN management)) (PP (IN of) (NP (NP (NNP Doc_17923537_145_174_Disease)) (PRN (-LRB- -LRB-) (NP (NNP IOP)) (-RRB- -RRB-)))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_17923537_198_205_Disease))))))))) (VP (VBN treated) (PP (IN with) (NP (DT the) (JJ Doc_17923537_223_245_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_17923537_247_249_Chemical)) (-RRB- -RRB-)) (JJ intravitreal) (NN implant)))) (. .)))
17923537	2	(S1 (S (NP (NP (VBN Pooled) (NNS data)) (PP (IN from) (NP (CD 3) (NN multicenter))) (, ,) (ADJP (JJ double-masked) (, ,) (JJ randomized) (, ,) (JJ controlled)) (, ,)) (VP (VB phase) (SBAR (S (NP (NP (CD 2b/3) (JJ clinical) (NNS trials)) (VP (VBG evaluating) (NP (NP (DT the) (NN safety) (CC and) (NN efficacy)) (PP (IN of) (NP (NP (DT the) (ADJP (JJ 0.59-mg) (CC or) (JJ 2.1-mg)) (NN FA) (NN intravitreal) (NN implant)) (CC or) (NP (JJ standard) (NN therapy))))))) (VP (AUX were) (VP (VBN analyzed)))))) (. .)))
17923537	3	(S1 (S (PP (IN During) (NP (DT the) (JJ 3-year) (NN follow-up))) (, ,) (NP (NP (CD 71.0) (NN %)) (PP (IN of) (NP (VBN implanted) (NNS eyes)))) (VP (AUX had) (NP (NP (NP (DT an) (JJ IOP) (NN increase)) (PP (IN of) (NP (QP (CD 10) (CD mm)) (NP (NP (NNP Hg) (CC or) (NP (NP (NP (QP (JJR more) (IN than) (NN baseline) (CC and) (CD 55.1) (NN %))) (, ,) (NP (CD 24.7) (NN %)) (, ,)) (CC and) (NP (NP (CD 6.2) (NN %)) (PP (IN of) (NP (NNS eyes)))))) (VP (VBD reached) (NP (NP (DT an) (NN IOP)) (PP (IN of) (NP (CD 30) (NN mm) (NNP Hg)))))) (CC or) (NP (JJR more))))) (, ,) (NP (CD 40) (JJ mm) (NNP Hg) (CC or) (JJR more)) (, ,) (CC and) (NP (CD 50) (JJ mm) (NNP Hg) (CC or) (JJR more))) (, ,) (ADVP (RB respectively))) (. .)))
17923537	4	(S1 (S (S (NP (JJ Topical) (NN IOP-lowering) (NN medication)) (VP (AUX was) (VP (VBN administered) (PP (IN in) (NP (NP (CD 74.8) (NN %)) (PP (IN of) (NP (VBN implanted) (NNS eyes)))))))) (, ,) (CC and) (S (NP (NP (JJ IOP-lowering) (NNS surgeries)) (, ,) (SBAR (WHNP (JJS most) (WHPP (IN of) (WHNP (WDT which)))) (S (VP (AUX were) (NP (NP (NNS trabeculectomies)) (PRN (-LRB- -LRB-) (NP (CD 76.2) (NN %)) (-RRB- -RRB-)))))) (, ,)) (VP (AUX were) (VP (VBN performed) (PP (IN on) (NP (NP (CD 36.6) (NN %)) (PP (IN of) (NP (VBN implanted) (NNS eyes)))))))) (. .)))
17923537	5	(S1 (S (NP (JJ Intraocular) (JJ pressure-lowering) (NNS surgeries)) (VP (AUX were) (VP (VBN considered) (S (NP (NP (DT a) (NN success)) (PRN (-LRB- -LRB-) (NP (NP (JJ postoperative) (NN IOP)) (PP (IN of) (NP (JJ 6-21) (NN mm) (NNP Hg))) (PP (PP (IN with)) (CC or) (PP (IN without) (NP (JJ additional) (JJ IOP-lowering) (NN medication))))) (-RRB- -RRB-))) (PP (IN in) (NP (NP (CD 85.1) (NN %)) (PP (IN of) (NP (NP (NNS eyes)) (PP (IN at) (NP (CD 1) (NN year)))))))))) (. .)))
17923537	6	(S1 (S (NP (NP (DT The) (NN rate)) (PP (IN of) (NP (NNP Doc_17923537_1123_1131_Disease)))) (-LRB- -LRB-) (VP (VB IOP) (NP (NP (QP (CD </=) (CD 5)) (NNS mm)) (SBAR (S (NP (NNP Hg)) (-RRB- -RRB-) (VP (VBG following) (SBAR (S (NP (NP (NN IOP-lowering) (NN surgery)) (PRN (-LRB- -LRB-) (NP (CD 42.5) (NN %)) (-RRB- -RRB-))) (VP (AUX was) (ADJP (RB not) (JJ different) (PP (IN from) (NP (NP (DT that)) (PP (IN of) (NP (VBN implanted) (NNS eyes))))))))))))) (RB not) (VP (VBN subjected) (PP (TO to) (NP (NP (NP (NN surgery)) (PRN (-LRB- -LRB-) (NP (CD 35.4) (NN %)) (-RRB- -RRB-))) (-LRB- -LRB-) (NP (NNP P) (SYM =) (CD .09)) (-RRB- -RRB-))))) (. .)))
17923537	7	(S1 (S (NP (JJ Elevated) (NN IOP)) (VP (VP (AUX is) (NP (NP (DT a) (JJ significant) (NN complication)) (PP (IN with) (NP (DT the) (JJ FA) (JJ intravitreal) (NN implant))))) (CC but) (VP (MD may) (VP (AUX be) (VP (VBN controlled) (PP (IN with) (NP (NP (NN medication)) (CC and) (NP (NN surgery)))))))) (. .)))
17943461	0	(S1 (S (NP (JJ Myocardial) (NNP Fas) (JJ ligand) (NN expression)) (VP (VBZ increases) (NP (NN susceptibility)) (PP (TO to) (NP (NNP Doc_17943461_61_64_Chemical-induced) (NNP Doc_17943461_73_87_Disease)))) (. .)))
17943461	1	(S1 (S (NP (NP (NP (NNP Doc_17943461_101_123_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_17943461_125_128_Disease)) (-RRB- -RRB-))) (CC and) (NP (NNP Doc_17943461_134_145_Disease))) (VP (VBP occur) (PP (IN in) (NP (JJ many) (NNP Doc_17943461_160_172_Disease) (NNS individuals))) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (JJ symptomatic) (NNP Doc_17943461_211_224_Disease))) (PP (IN in) (NP (NP (QP (RB up) (TO to) (CD 5)) (NN %)) (PP (IN of) (NP (NNS patients)))))))) (. .)))
17943461	2	(S1 (S (NP (NP (ADJP (RB Highly) (JJ active)) (NN antiretroviral) (NN therapy)) (PRN (-LRB- -LRB-) (NP (NN HAART)) (-RRB- -RRB-))) (VP (VP (AUX has) (VP (ADVP (RB significantly)) (VBN reduced) (NP (NP (NP (NN morbidity)) (CC and) (NP (NN mortality))) (PP (IN of) (NP (NP (NNP Doc_17943461_348_382_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_17943461_384_388_Disease)) (-RRB- -RRB-))))))) (, ,) (CC but) (VP (AUX has) (VP (VBN resulted) (PP (IN in) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NNP Doc_17943461_426_457_Disease)))))))) (. .)))
17943461	3	(S1 (FRAG (NP (NNS METHODS) (CC AND) (NNS RESULTS)) (: :) (S (SBAR (IN In) (NN order) (S (VP (TO to) (VP (VP (VB investigate) (PP (IN whether) (NP (DT the) (NN HAART) (NN component))) (SBAR (S (NP (NP (NNP Doc_17943461_532_542_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_17943461_544_573_Chemical)) (: ;) (NP (NNP Doc_17943461_575_578_Chemical)) (-RRB- -RRB-))) (VP (VBZ triggers) (NP (DT the) (JJ Fas-dependent) (JJ cell-death) (NN pathway)))))) (CC and) (VP (VB cause) (NP (NP (JJ cytoskeletal) (NN disruption)) (PP (IN in) (NP (NP (DT a) (JJ murine) (NN model)) (PP (IN of) (NP (NNP Doc_17943461_681_684_Disease))))))))))) (, ,) (NP (NP (NP (JJ 8-week-old) (NNP transgenic)) (PRN (-LRB- -LRB-) (VP (VBG expressing) (NP (NP (NP (NNP Fas) (NN ligand)) (PP (IN in) (NP (DT the) (NN myocardium)))) (: :) (NP (NNP FasL) (NNP Tg)))) (-RRB- -RRB-))) (CC and) (NP (JJ non-transgenic) (PRN (-LRB- -LRB-) (NP (NNP NTg)) (-RRB- -RRB-)) (NNS mice))) (VP (VBD received) (NP (NP (NN water) (NN ad) (NN libitum)) (VP (VBG containing) (NP (NP (JJ different) (NNS concentrations)) (PP (IN of) (NP (NP (NNP Doc_17943461_854_857_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 0)) (, ,) (NP (CD 0.07)) (, ,) (NP (CD 0.2)) (, ,) (CC and) (NP (CD 0.7) (NN mg/ml))) (-RRB- -RRB-))))))))) (. .)))
17943461	4	(S1 (S (PP (IN After) (NP (CD 6) (NNS weeks))) (, ,) (S (NP (JJ cardiac) (NN function)) (VP (AUX was) (VP (VBN assessed) (PP (IN by) (NP (NN echocardiography)))))) (CC and) (S (NP (NN morphology)) (VP (AUX was) (VP (VBN assessed) (PP (IN by) (NP (NP (NN histopathologic)) (CC and) (NP (JJ immunohistochemical) (NNS methods))))))) (. .)))
17943461	5	(S1 (S (NP (ADJP (JJ NTg) (CC and) (JJ untreated)) (NNP FasL) (NNP Tg) (NNS mice)) (VP (VBD showed) (NP (NP (ADJP (JJ little) (CC or) (DT no)) (NN change)) (PP (IN in) (NP (NP (JJ cardiac) (NN structure)) (CC or) (NP (NN function)))))) (. .)))
17943461	6	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NNP Doc_17943461_1139_1142_Chemical-treated) (NNP FasL) (NNP Tg) (NNS mice)) (VP (VBD developed) (NP (NP (NN Doc_17943461_1174_1190_Disease)) (CC and) (NP (JJ depressed) (JJ cardiac) (NN function))) (PP (IN in) (NP (DT a) (JJ dose-dependent) (NN manner))) (, ,) (PP (IN with) (NP (NP (JJ concomitant) (JJ inflammatory) (NN infiltration)) (PP (IN of) (NP (DT both) (NNS ventricles)))))) (. .)))
17943461	7	(S1 (S (NP (DT These) (NNS changes)) (VP (AUX were) (VP (VBN associated) (PP (IN with) (NP (NP (NP (DT an) (VBN increased) (JJ sarcolemmal) (NN expression)) (PP (IN of) (NP (NNP Fas) (CC and) (NNP FasL)))) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (NP (VBN increased) (NN activation)) (PP (IN of) (NP (NN caspase) (CD 3)))) (, ,) (NP (NP (NN translocation)) (PP (IN of) (NP (NN calpain) (CD 1))) (PP (TO to) (NP (DT the) (NN sarcolemma) (CC and) (NN sarcomere)))) (, ,) (CC and) (NP (NP (VBN increased) (NNS numbers)) (PP (IN of) (NP (NP (NNS cells)) (VP (VBG undergoing) (NP (NN apoptosis)))))))))) (. .)))
17943461	8	(S1 (S (NP (DT These)) (VP (AUX were) (VP (VBN associated) (PP (IN with) (NP (NP (NP (NNS changes)) (PP (IN in) (NP (NP (NN dystrophin)) (CC and) (NP (JJ cardiac) (NN troponin) (NN I) (NN localization))))) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (NP (NN loss)) (PP (IN of) (NP (JJ sarcolemmal) (NN integrity)))))))) (. .)))
17943461	9	(S1 (S (NP (NP (DT The) (NN expression)) (PP (IN of) (NP (NNP Fas) (CD ligand))) (PP (IN in) (NP (DT the) (NN myocardium)))) (PRN (, ,) (SBAR (IN as) (S (VP (VBN identified) (PP (IN in) (NP (JJ HIV-positive) (NNS patients)))))) (, ,)) (VP (MD might) (VP (VB increase) (NP (DT the) (NN susceptibility)) (PP (TO to) (NP (JJ HAART-induced) (NNP Doc_17943461_1840_1854_Disease))) (PP (JJ due) (TO to) (NP (NP (NN activation)) (PP (IN of) (NP (NP (JJ apoptotic) (NNS pathways)) (, ,) (VP (VBG resulting) (PP (IN in) (NP (NNP Doc_17943461_1909_1941_Disease)))))))))) (. .)))
17965424	0	(S1 (NP (NP (NP (JJ Gastrointestinal) (NN tolerability)) (PP (IN of) (NP (NNP Doc_17965424_33_43_Chemical))) (PP (IN in) (NP (NNP Doc_17965424_47_67_Disease) (NNS patients)))) (: :) (NP (NP (NP (NNS results)) (PP (IN of) (NP (DT the) (NNP Doc_17965424_93_103_Chemical) (NNP vs) (NNP Doc_17965424_107_124_Chemical) (JJ gastrointestinal) (NN tolerability)))) (CC and) (NP (NP (NN effectiveness) (NN trial)) (PRN (-LRB- -LRB-) (NP (NNP EDGE-II)) (-RRB- -RRB-)))) (. .)))
17965424	1	(S1 (S (NP (DT A) (JJ randomised) (, ,) (JJ double-blind) (NN study)) (VP (TO to) (VP (VB compare) (NP (NP (NP (DT the) (JJ gastrointestinal) (PRN (-LRB- -LRB-) (NP (NNP GI)) (-RRB- -RRB-)) (NN tolerability)) (, ,) (NP (NN safety)) (CC and) (NP (NN efficacy))) (PP (IN of) (NP (NNP Doc_17965424_308_318_Chemical) (CC and) (NNP Doc_17965424_323_333_Chemical))) (PP (IN in) (NP (NNS patients)))) (PP (IN with) (NP (NP (NNP Doc_17965424_351_371_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_17965424_373_375_Disease)) (-RRB- -RRB-)))))) (. .)))
17965424	2	(S1 (NP (NP (NNS PATIENTS) (CC AND) (NNS METHODS)) (: :) (NP (NP (DT A) (NN total)) (PP (IN of) (NP (NP (NP (CD 4086) (NNS patients)) (PRN (-LRB- -LRB-) (NP (NP (JJ mean) (NN age)) (NP (CD 60.8) (NNS years))) (-RRB- -RRB-)) (VP (VP (VBN diagnosed) (SBAR (IN with) (S (NP (NNP Doc_17965424_462_464_Disease) (AUX were)) (VP (VBD enrolled))))) (CC and) (VP (VBD received) (NP (NNP Doc_17965424_492_502_Chemical)) (ADVP (NP (CD 90) (NNS mg)) (RB daily)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 2032)) (-RRB- -RRB-))))) (CC or) (NP (NP (NNP Doc_17965424_529_539_Chemical) (CD 75) (NNS mg)) (ADJP (ADJP (RB twice) (JJ daily)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 2054)) (-RRB- -RRB-))))))) (. .)))
17965424	3	(S1 (S (NP (NP (NP (NN Use)) (PP (IN of) (NP (JJ gastroprotective) (NNS agents)))) (CC and) (NP (JJ low-dose) (NN Doc_17965424_614_621_Chemical))) (VP (AUX was) (VP (VBN allowed))) (. .)))
17965424	4	(S1 (S (NP (DT The) (JJ prespecified) (JJ primary) (NN end) (NN point)) (VP (VBD consisted) (PP (IN of) (NP (NP (DT the) (JJ cumulative) (NN rate)) (PP (IN of) (NP (NP (JJ patient) (NNS discontinuations)) (ADJP (JJ due) (PP (TO to) (NP (NP (JJ clinical) (CC and) (NN laboratory) (NN GI) (JJ adverse) (NNS experiences)) (PRN (-LRB- -LRB-) (NP (NNP AEs)) (-RRB- -RRB-)))))))))) (. .)))
17965424	5	(S1 (S (NP (JJ General) (NN safety)) (VP (AUX was) (ADVP (RB also)) (VP (VBN assessed) (, ,) (PP (VBG including) (NP (JJ adjudicated) (NNP Doc_17965424_848_873_Disease) (NN event) (NNS data))))) (. .)))
17965424	6	(S1 (S (NP (NN Efficacy)) (VP (AUX was) (VP (VBN evaluated) (S (VP (VBG using) (NP (NP (DT the) (JJ Patient) (JJ Global) (NN Assessment)) (PP (IN of) (NP (NN Disease) (NN Status))) (PRN (-LRB- -LRB-) (NP (NP (NNP PGADS)) (: ;) (NP (JJ 0-4) (NN point) (NN scale))) (-RRB- -RRB-))))))) (. .)))
17965424	7	(S1 (S (NP (NP (JJ Mean) (PRN (-LRB- -LRB-) (NP (NNP SD)) (: ;) (NP (NN maximum)) (-RRB- -RRB-)) (NN duration)) (PP (IN of) (NP (NN treatment)))) (VP (AUX was) (NP (NP (NP (CD 19.3)) (PRN (-LRB- -LRB-) (NP (NP (CD 10.3)) (: ;) (NP (CD 32.9))) (-RRB- -RRB-))) (CC and) (NP (NP (CD 19.1)) (PRN (-LRB- -LRB-) (NP (NP (CD 10.4)) (: ;) (NP (CD 33.1))) (-RRB- -RRB-)))) (NP (NP (NNS months)) (PP (IN in) (NP (DT the) (NNP Doc_17965424_1097_1107_Chemical) (CC and) (NNP Doc_17965424_1112_1122_Chemical) (NNS groups)))) (, ,) (ADVP (RB respectively))) (. .)))
17965424	8	(S1 (S (NP (NP (DT The) (JJ cumulative) (NN discontinuation) (NN rate)) (ADJP (JJ due) (PP (TO to) (NP (NNP Doc_17965424_1188_1194_Disease))))) (VP (AUX was) (ADJP (ADJP (RB significantly) (JJR lower) (PP (IN with) (NP (NNP Doc_17965424_1224_1234_Chemical)))) (PP (IN than) (NP (NNP Doc_17965424_1240_1250_Chemical)))) (PRN (-LRB- -LRB-) (NP (NP (CD 5.2) (NNP vs) (CD 8.5) (NNS events)) (PP (IN per) (NP (NP (CD 100) (NNS patient-years)) (, ,) (ADVP (RB respectively)) (NP (NP (: ;) (NN hazard) (NN ratio) (NN 0.62)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 95) (NN %)) (ADVP (RB CI))) (: :) (NP (NP (CD 0.47)) (, ,) (NP (CD 0.81))) (: ;) (NP (CD p<or=0.001))) (-RRB- -RRB-)))))) (-RRB- -RRB-))) (. .)))
17965424	9	(S1 (S (NP (NP (DT The) (NN incidence)) (PP (IN of) (NP (NP (NNS discontinuations)) (PP (IN for) (NP (JJ Doc_17965424_1398_1410_Disease-related) (CC and) (JJ Doc_17965424_1423_1429_Disease-related) (NNS AEs)))))) (VP (AUX were) (ADJP (RB significantly) (JJR higher)) (PP (IN with) (NP (NNP Doc_17965424_1473_1483_Chemical))) (PRN (-LRB- -LRB-) (NP (NP (CD 2.5) (NN %)) (CC and) (NP (CD 1.1) (NN %) (RB respectively))) (-RRB- -RRB-)) (PP (VBN compared) (PP (IN with) (NP (NNP Doc_17965424_1527_1537_Chemical)))) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 1.5) (NN %)) (CC and) (NP (NP (CD 0.4) (NN %)) (ADVP (RB respectively)))) (: ;) (NP (NP (NP (CD p<0.001)) (PP (IN for) (NP (NNP Doc_17965424_1579_1591_Disease)))) (CC and) (NP (NP (CD p<0.01)) (PP (IN for) (NP (NNP Doc_17965424_1607_1613_Disease)))))) (-RRB- -RRB-))) (. .)))
17965424	10	(S1 (S (NP (NP (NN Doc_17965424_1616_1626_Chemical)) (CC and) (NP (JJ Doc_17965424_1631_1641_Chemical) (NN treatment))) (VP (VBD resulted) (PP (IN in) (NP (NP (JJ similar) (NN efficacy)) (PRN (-LRB- -LRB-) (S (NP (NNS PGADS)) (VP (VBP mean) (NP (NP (NNS changes)) (PP (IN from) (NP (NN baseline) (NN -0.62)))) (NP (NNP vs) (CD -0.58)) (, ,) (ADVP (RB respectively)))) (-RRB- -RRB-))))) (. .)))
17965424	11	(S1 (S (NP (JJ Doc_17965424_1759_1769_Chemical) (CD 90) (NN mg)) (VP (VBD demonstrated) (NP (NP (DT a) (ADJP (RB significantly) (JJR lower)) (NN risk)) (PP (IN for) (S (VP (VBG discontinuing) (NP (NN treatment)) (PP (JJ due) (TO to) (NP (NNP Doc_17965424_1851_1857_Disease))) (PP (VBN compared) (PP (IN with) (NP (NNP Doc_17965424_1872_1882_Chemical) (CD 150) (NNS mg))))))))) (. .)))
17965424	12	(S1 (S (NP (NP (NNS Discontinuations)) (PP (IN from) (NP (NP (JJ renovascular) (NNS AEs)) (, ,) (SBAR (IN although) (S (ADJP (RBR less) (JJ common) (PP (IN than) (NP (NP (NNS discontinuations)) (PP (IN from) (NP (NNP Doc_17965424_1979_1985_Disease)))))))) (, ,)))) (VP (AUX were) (ADJP (RB significantly) (JJR higher)) (PP (IN with) (NP (NNP Doc_17965424_2018_2028_Chemical)))) (. .)))
17975693	0	(S1 (NP (NP (JJ Anxiogenic) (NN potential)) (PP (IN of) (NP (NP (NNP Doc_17975693_24_37_Chemical)) (CC and) (NP (NNP Doc_17975693_42_53_Chemical)))) (PP (IN in) (NP (NNS rats))) (. .)))
17975693	1	(S1 (S (S (NP (NP (NP (DT The) (JJ possible) (JJ anxiogenic) (NNS effects)) (PP (IN of) (NP (NNP Doc_17975693_112_128_Chemical)))) (, ,) (ADVP (RB namely)) (NP (NP (NNP Doc_17975693_137_150_Chemical)) (CC and) (NP (NNP Doc_17975693_155_166_Chemical))) (, ,)) (VP (AUX were) (VP (VBN investigated) (PP (IN in) (NP (NP (JJ adult) (NNP Charles) (NNP Foster) (NN albino) (NNS rats)) (PP (IN of) (NP (DT either) (NN sex))))) (, ,) (S (VP (VBG weighing) (NP (CD 150-200) (NNP g.) (NNS METHODS))))))) (: :) (S (S (NP (DT The) (NNS drugs)) (VP (AUX were) (VP (VBN given) (ADVP (RB orally)) (, ,) (PP (IN in) (NP (NP (NNS doses)) (PP (IN of) (NP (NP (CD 50) (NNS mg/kg)) (PP (IN for) (NP (CD five) (JJ consecutive) (NNS days)))))))))) (CC and) (S (NP (DT the) (NNS experiments)) (VP (AUX were) (VP (VBN performed) (PP (IN on) (NP (DT the) (JJ fifth) (NN day))))))) (. .)))
17975693	2	(S1 (S (NP (DT The) (NNS tests)) (VP (VBD included) (NP (NP (JJ open-field) (JJ exploratory) (NN behaviour)) (, ,) (NP (JJ elevated) (JJ plus) (NN maze)) (CC and) (NP (NP (JJ elevated) (NN zero) (NN maze)) (, ,) (NP (JJ social) (NN interaction)) (CC and) (NP (JJ novelty-suppressed) (NN feeding) (NN latency) (NN behaviour))))) (. .)))
17975693	3	(S1 (S (NP (DT The) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (NNP Doc_17975693_595_608_Chemical-)) (CC and) (NP (JJ Doc_17975693_614_625_Chemical-treated) (NNS rats))) (VP (VBD showed) (NP (JJ anxious) (NN behaviour)) (PP (IN in) (NP (NP (NN comparison)) (PP (TO to) (NP (NN control) (NNS rats))))) (PP (IN in) (NP (NP (PDT all) (DT the) (NNS parameters)) (VP (VBN studied)))))))) (. .)))
17975693	4	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (NNP Doc_17975693_734_747_Chemical-)) (CC and) (NP (JJ Doc_17975693_753_764_Chemical-treated) (NNS rats))) (VP (AUX did) (RB not) (VP (VB differ) (ADVP (RB significantly)) (PP (IN from) (NP (DT each) (JJ other))) (PP (IN in) (NP (JJ various) (JJ behavioural) (NNS parameters))))) (. .)))
17975693	5	(S1 (S (NP (DT The) (JJ present) (JJ experimental) (NNS findings)) (VP (VB substantiate) (NP (NP (DT the) (ADJP (RB clinically) (JJ observed)) (NN anxiogenic) (NN potential)) (PP (IN of) (NP (NP (NNP Doc_17975693_965_978_Chemical)) (CC and) (NP (NNP Doc_17975693_983_994_Chemical)))))) (. .)))
18006530	0	(S1 (NP (NP (NN Reduction)) (PP (IN of) (NP (NNP Doc_18006530_13_17_Disease))) (PP (IN during) (NP (NP (NN induction)) (PP (IN with) (NP (NP (JJ target-controlled) (NNP Doc_18006530_58_66_Chemical)) (CC and) (NP (NNP Doc_18006530_71_83_Chemical)))))) (. .)))
18006530	1	(S1 (S (NP (NP (NN Doc_18006530_97_101_Disease)) (PP (IN on) (NP (NN injection))) (PP (IN of) (NP (NNP Doc_18006530_118_126_Chemical)))) (VP (AUX is) (ADJP (JJ unpleasant))) (. .)))
18006530	2	(S1 (S (NP (PRP We)) (VP (VBN hypothesized) (SBAR (IN that) (S (NP (NNP Doc_18006530_163_171_Chemical) (NN infusion) (NNP Doc_18006530_181_185_Disease)) (VP (MD might) (VP (AUX be) (VP (VBN prevented) (PP (IN by) (S (VP (VBG infusing) (NP (NNP Doc_18006530_217_229_Chemical)) (PP (IN before) (S (VP (VBG starting) (NP (DT the) (JJ Doc_18006530_250_258_Chemical) (NN infusion)) (PP (IN in) (NP (NP (DT a) (JJ clinical) (NN setting)) (SBAR (WHADVP (WRB where)) (S (NP (NP (NP (JJ target-controlled) (NNS infusions)) (PRN (-LRB- -LRB-) (NP (NNP TCI)) (-RRB- -RRB-))) (PP (IN of) (NP (DT both) (NNS drugs)))) (VP (AUX were) (VP (VBN used))))))))))))))))))) (. .)))
18006530	3	(S1 (S (NP (DT A) (JJ prospective) (, ,) (JJ randomized) (, ,) (JJ double-blind) (, ,) (JJ placebo-controlled) (NN trial)) (VP (AUX was) (VP (VBN performed) (S (VP (TO to) (VP (VB determine) (NP (NP (DT the) (JJ effect-site) (NN concentration)) (PRN (-LRB- -LRB-) (NP (NNP Ce)) (-RRB- -RRB-)) (PP (IN of) (NP (NNP Doc_18006530_486_498_Chemical))) (S (VP (TO to) (VP (VB prevent) (NP (DT the) (NNP Doc_18006530_514_518_Disease)) (PP (IN without) (NP (VBG producing) (NNS complications)))))))))))) (. .)))
18006530	4	(S1 (S (S (NP (NP (DT A) (NN total)) (PP (IN of) (NP (CD 128) (NNS patients)))) (VP (VBG undergoing) (NP (JJ general) (NN surgery)))) (VP (AUX were) (ADVP (RB randomly)) (VP (VBN allocated) (S (VP (TO to) (VP (VB receive) (NP (NP (JJ normal) (NN saline) (PRN (-LRB- -LRB-) (NN control) (-RRB- -RRB-))) (CC or) (NP (NNP Doc_18006530_674_686_Chemical))) (PP (TO to) (NP (NP (NP (NP (NP (NP (NP (DT a) (NN target) (NNP Ce)) (PP (IN of) (NP (QP (CD 2) (CD ng)) (NNS ml)))) (PRN (-LRB- -LRB-) (JJ -1) (-RRB- -RRB-)) (PRN (-LRB- -LRB-) (NP (NNP R2)) (-RRB- -RRB-)) (, ,) (CD 4)) (NN ng) (NNS ml)) (PRN (-LRB- -LRB-) (JJ -1) (-RRB- -RRB-)) (PRN (-LRB- -LRB-) (NP (NNP R4)) (-RRB- -RRB-)) (, ,) (CC or) (NP (QP (CD 6) (CD ng)) (NNS ml))) (PRN (-LRB- -LRB-) (JJ -1) (-RRB- -RRB-)) (PRN (-LRB- -LRB-) (NP (NNP R6)) (-RRB- -RRB-))) (VP (VBN administered) (PP (IN via) (NP (NNP TCI))))))))))) (. .)))
18006530	5	(S1 (S (SBAR (IN After) (S (NP (DT the) (NN target) (NN Ce)) (VP (AUX was) (VP (VBN achieved))))) (, ,) (NP (NP (DT the) (NN infusion)) (PP (IN of) (NP (NNP Doc_18006530_833_841_Chemical)))) (VP (AUX was) (VP (VBN started))) (. .)))
18006530	6	(S1 (S (S (NP (JJ Doc_18006530_855_867_Chemical-related) (NNS complications)) (VP (AUX were) (VP (VBN assessed) (PP (IN during) (NP (DT the) (JJ Doc_18006530_915_927_Chemical) (NN infusion)))))) (, ,) (CC and) (S (NP (NP (NN Doc_18006530_942_946_Disease)) (VP (VBN caused) (PP (IN by) (NP (NNP Doc_18006530_957_965_Chemical))))) (VP (AUX was) (VP (VBN evaluated) (S (VP (VBG using) (NP (NP (DT a) (JJ four-point) (NN scale)) (PP (IN during) (NP (DT the) (JJ Doc_18006530_1016_1024_Chemical) (NN infusion))))))))) (. .)))
18006530	7	(S1 (S (NP (NP (DT The) (NN incidence)) (PP (IN of) (NP (NNP Doc_18006530_1061_1065_Disease)))) (VP (AUX was) (ADJP (ADJP (RB significantly) (JJR lower)) (PP (IN in) (NP (NNS Groups) (NNP R4) (CC and) (NNP R6))) (PP (IN than) (PP (IN in) (NP (NP (DT the) (NN control)) (CC and) (NP (NP (JJ R2) (NNS groups)) (PRN (-LRB- -LRB-) (NP (NP (QP (CD 12/32) (CC and) (CD 6/31)) (NNP vs) (CD 26/31) (CC and) (CD 25/32)) (, ,) (ADVP (RB respectively))) (, ,) (NP (NNP P<0.001)) (-RRB- -RRB-)))))))) (. .)))
18006530	8	(S1 (S (NP (NN Doc_18006530_1204_1208_Disease)) (VP (AUX was) (ADJP (RBR less) (JJ severe)) (PP (IN in) (NP (NNS Groups) (NNP R4) (CC and) (NNP R6))) (PP (IN than) (PP (IN in) (NP (NP (DT the) (NN control)) (CC and) (NP (NP (JJ R2) (NNS groups)) (PRN (-LRB- -LRB-) (NP (NNP P<0.001)) (-RRB- -RRB-))))))) (. .)))
18006530	9	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (DT both) (NN incidence) (CC and) (NN severity)) (PP (IN of) (NP (NNP Doc_18006530_1330_1334_Disease)))) (VP (AUX were) (RB not) (ADJP (JJ different)) (PP (IN between) (NP (NNS Groups) (NNP R4) (CC and) (NNP R6)))) (. .)))
18006530	10	(S1 (S (NP (DT No) (JJ significant) (NNS complications)) (VP (AUX were) (VP (VBN observed) (PP (IN during) (NP (DT the) (NN study))))) (. .)))
18006530	11	(S1 (S (PP (IN During) (NP (NP (NN induction)) (PP (IN of) (NP (NN anaesthesia))) (PP (IN with) (NP (NNP TCI))) (PP (IN of) (NP (NNP Doc_18006530_1498_1506_Chemical) (CC and) (NNP Doc_18006530_1511_1523_Chemical))))) (, ,) (NP (NP (DT a) (JJ significant) (NN reduction)) (PP (IN in) (NP (NNP Doc_18006530_1552_1560_Chemical) (NN infusion) (NNP Doc_18006530_1570_1574_Disease)))) (VP (AUX was) (VP (VBN achieved) (PP (IN without) (NP (JJ significant) (NNS complications))) (PP (IN by) (NP (NP (JJ prior) (NN administration)) (PP (IN of) (NP (NNP Doc_18006530_1649_1661_Chemical))) (PP (IN at) (NP (NP (DT a) (NN target) (NN Ce)) (PP (IN of) (NP (NP (QP (CD 4) (CD ng)) (NNS ml)) (PRN (-LRB- -LRB-) (JJ -1) (-RRB- -RRB-)))))))))) (. .)))
18086064	0	(S1 (NP (NP (NP (NN Doc_18086064_0_15_Chemical) (CC and) (JJ cardiac) (NN protection)) (PP (IN for) (NP (JJ non-cardiac) (NN surgery)))) (: :) (NP (NP (DT a) (NN meta-analysis)) (PP (IN of) (NP (JJ randomised) (JJ controlled) (NNS trials)))) (. .)))
18086064	1	(S1 (S (NP (PRP We)) (VP (VBD conducted) (NP (NP (DT a) (JJ systematic) (NN review)) (PP (IN of) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NNP Doc_18086064_164_179_Chemical))) (PP (IN on) (NP (NP (JJ cardiac) (NNS outcomes)) (PP (VBG following) (NP (NN non-cardiac) (NN surgery))))))))) (. .)))
18086064	2	(S1 (S (NP (PRP We)) (VP (VBD included) (NP (NP (JJ prospective) (, ,) (JJ randomised) (JJ peri-operative) (NNS studies)) (PP (IN of) (NP (NNP Doc_18086064_293_308_Chemical))) (SBAR (WHNP (WDT that)) (S (VP (VBD reported) (NP (NP (NN mortality)) (, ,) (NP (JJ cardiac) (NN morbidity)) (CC or) (NP (JJ adverse) (NN drug) (NNS events)))))))) (. .)))
18086064	3	(S1 (S (NP (DT A) (NNP PubMed) (NNP Central) (CC and) (NNP EMBASE) (NN search)) (VP (AUX was) (VP (VBN conducted) (PP (IN up) (PP (TO to) (NP (NNP July) (CD 2007)))))) (. .)))
18086064	4	(S1 (S (NP (NP (DT The) (NN reference) (NNS lists)) (PP (IN of) (NP (VBN identified) (NNS papers)))) (VP (AUX were) (VP (VBN examined) (PP (IN for) (NP (JJ further) (NNS trials))))) (. .)))
18086064	5	(S1 (S (PP (IN Of) (NP (NP (CD 425) (NNS studies)) (VP (VBN identified)))) (, ,) (NP (CD 20)) (VP (AUX were) (VP (VBN included) (PP (IN in) (NP (NP (DT the) (NNS meta-analysis)) (PRN (-LRB- -LRB-) (NP (CD 840) (NNS patients)) (-RRB- -RRB-)))))) (. .)))
18086064	6	(S1 (S (NP (NNP Doc_18086064_598_613_Chemical)) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (NP (DT a) (NN trend)) (PP (IN towards) (NP (JJ improved) (JJ cardiac) (NNS outcomes)))) (: ;) (NP (NP (JJ all-cause) (NN mortality)) (PRN (-LRB- -LRB-) (CC OR) (S (NP (NP (CD 0.27)) (, ,) (NP (CD 95) (NN %) (QP (CD CI) (CD 0.01-7.13))) (, ,) (NP (CD p))) (VP (SYM =) (NP (CD 0.44)))) (-RRB- -RRB-)) (, ,) (NP (JJ non-fatal) (NNP Doc_18086064_746_767_Disease)) (PRN (-LRB- -LRB-) (NP (NP (QP (CC OR) (CD 0.26))) (, ,) (NP (NP (CD 95) (NN %) (QP (CD CI) (CD 0.04-1.60))) (, ,) (NP (NNP p) (SYM =) (CD 0.14)))) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NNP Doc_18086064_811_831_Disease)) (PRN (-LRB- -LRB-) (NP (NP (QP (CC OR) (CD 0.65))) (, ,) (NP (CD 95) (NN %) (QP (CD CI) (CD 0.26-1.63))) (, ,) (NP (NP (NNP p) (SYM =)) (NP (CD 0.36)))) (-RRB- -RRB-))))))) (. .)))
18086064	7	(S1 (S (NP (NP (NP (JJ Peri-operative) (NNP Doc_18086064_886_897_Disease)) (PRN (-LRB- -LRB-) (NP (NP (CD 26) (NN %)) (, ,) (CC OR) (NP (CD 3.80)) (, ,) (NP (NP (NP (CD 95) (NN %)) (NP (NNP CI) (CD 1.91-7.54) (, ,) (CD p))) (X (SYM =)) (CD 0.0001))) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_18086064_947_958_Disease)) (PRN (-LRB- -LRB-) (NP (NP (CD 17) (NN %)) (, ,) (CC OR) (NP (CD 5.45)) (, ,) (NP (CD 95) (NN %) (QP (CD CI) (CD 2.98-9.95)))) (, ,) (NP (NNP p) (QP (CD <) (CD 0.00001))) (-RRB- -RRB-)))) (VP (AUX were) (VP (ADVP (RB significantly)) (VBN increased))) (. .)))
18086064	8	(S1 (S (NP (DT An) (NN anticholinergic)) (VP (AUX did) (RB not) (VP (VB reduce) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NNP Doc_18086064_1086_1097_Disease)))) (PRN (-LRB- -LRB-) (S (NP (NN p)) (VP (SYM =) (NP (CD 0.43)))) (-RRB- -RRB-)))) (. .)))
18086064	9	(S1 (S (NP (NP (DT A) (JJ randomised) (JJ placebo-controlled) (NN trial)) (PP (IN of) (NP (NNP Doc_18086064_1151_1166_Chemical)))) (VP (AUX is) (VP (VBN warranted))) (. .)))
18161408	0	(S1 (NP (NP (NP (NN Doc_18161408_0_21_Disease)) (PP (IN in) (NP (NN pregnancy))) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_18161408_51_69_Chemical))) (PP (IN for) (NP (NN ovulation) (NN induction))))) (: :) (NP (DT a) (NN case) (NN report)) (. .)))
18161408	1	(S1 (S (NP (NP (NNP Doc_18161408_122_140_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_18161408_142_144_Chemical)) (-RRB- -RRB-))) (VP (AUX is) (ADVP (RB commonly)) (VP (VBN prescribed) (PP (IN for) (NP (NN ovulation) (NN induction))))) (. .)))
18161408	2	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (VBN considered) (S (ADJP (JJ safe))) (, ,) (PP (IN with) (NP (JJ minimal) (NN side) (NNS effects))))) (. .)))
18161408	3	(S1 (S (NP (NN Doc_18161408_244_259_Disease)) (VP (AUX is) (NP (NP (DT a) (ADJP (JJ rare) (CC but) (JJ life-threatening)) (NN complication)) (SBAR (WHNP (WDT that)) (S (VP (AUX has) (VP (AUX been) (VP (VBN reported) (PP (IN after) (NP (NP (NN ovulation) (NN induction)) (PP (IN with) (NP (NNS CC)))))))))))) (. .)))
18161408	4	(S1 (S (NP (NP (JJ Spontaneous) (NNP Doc_18161408_374_393_Disease) (CC or) (NNP Doc_18161408_397_412_Disease)) (PP (IN with) (NP (JJ subsequent) (NN clot) (NNS lysis)))) (VP (AUX has) (VP (AUX been) (VP (VBN suggested) (PP (IN as) (NP (NP (CD one)) (PP (IN of) (NP (NP (DT the) (ADJP (RBS most) (JJ common)) (NNS causes)) (PP (IN of) (NP (NP (NNP Doc_18161408_495_516_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_18161408_518_520_Disease)) (-RRB- -RRB-)))))))) (PP (IN during) (NP (NN pregnancy))) (, ,) (PP (IN with) (NP (DT a) (ADJP (RB subsequently) (JJ normal)) (JJ coronary) (NN angiogram)))))) (. .)))
18161408	5	(S1 (S (NP (NP (DT A) (JJ 33-year-old) (NN woman)) (PP (IN with) (NP (DT a) (JJ 5-week) (NN gestation)))) (VP (VP (AUX had) (ADVP (RB recently)) (VP (VBN received) (NP (NNP Doc_18161408_659_661_Chemical)) (PP (IN for) (NP (NN ovulation) (NN induction))))) (CC and) (VP (VBD presented) (PP (IN with) (NP (NNP Doc_18161408_705_715_Disease))))) (. .)))
18161408	6	(S1 (S (NP (DT An) (NN electrocardiogram)) (VP (VBD showed) (NP (NP (DT a) (NN lateral)) (CC and) (NP (NNP anterior) (NNP wall) (NNP Doc_18161408_773_794_Disease)))) (. .)))
18161408	7	(S1 (S (NP (JJ Cardiac) (NNS enzymes)) (VP (VBD showed) (NP (NP (DT a) (JJ peak) (NN rise)) (PP (IN in) (S (VP (VBG troponin) (NP (PRP I)) (PP (TO to) (NP (QP (CD 9.10) (CD ng/mL))))))))) (. .)))
18161408	8	(S1 (S (NP (DT An) (JJ initial) (NN exercise) (NN stress) (NN test)) (VP (AUX was) (ADJP (JJ normal))) (. .)))
18161408	9	(S1 (S (PP (IN At) (NP (NP (DT the) (NN time)) (PP (IN of) (NP (NN admission))))) (, ,) (S (NP (DT the) (NN patient)) (VP (AUX was) (PP (IN at) (NP (NP (JJ high) (NN risk)) (PP (IN of) (NP (NNP Doc_18161408_962_978_Disease))) (PP (TO to) (NP (DT the) (NN fetus))))))) (, ,) (CC so) (S (NP (DT a) (JJ coronary) (NN angiogram)) (VP (AUX was) (VP (VBN postponed) (PP (IN until) (NP (DT the) (JJ second) (NN trimester)))))) (. .)))
18161408	10	(S1 (S (NP (PRP It)) (VP (VBD showed) (NP (JJ normal) (JJ coronary) (NNS vessels))) (. .)))
18161408	11	(S1 (S (NP (DT This)) (VP (VBZ appears) (S (VP (TO to) (VP (AUX be) (NP (NP (DT the) (JJ first) (JJ reported) (NN case)) (VP (VBG documenting) (NP (NP (DT a) (JJ possible) (NN association)) (PP (IN between) (NP (NP (NNP Doc_18161408_1192_1194_Chemical)) (CC and) (NP (NNP Doc_18161408_1199_1220_Disease))))))))))) (. .)))
18161408	12	(S1 (S (NP (NN Doc_18161408_1222_1232_Disease)) (VP (MD might) (VP (AUX be) (NP (NP (DT a) (ADJP (JJ rare) (CC but) (JJ hazardous)) (NN complication)) (PP (IN of) (NP (NNP Doc_18161408_1279_1281_Chemical)))))) (. .)))
18161408	13	(S1 (S (PP (VBN Given) (NP (DT this) (JJ life-threatening) (NN complication))) (, ,) (NP (JJ appropriate) (JJ prophylactic) (NNS measures)) (VP (MD should) (VP (AUX be) (VP (VBN used) (PP (IN in) (NP (JJ high-risk) (NN woman) (VBG undergoing) (NN ovarian) (NN stimulation)))))) (. .)))
18177388	0	(S1 (S (VP (VP (VB Reverse)) (CC or) (VP (VBN inverted) (NP (NP (NNP Doc_18177388_20_63_Disease)) (PRN (-LRB- -LRB-) (NP (JJ reverse) (NN Doc_18177388_73_97_Disease)) (-RRB- -RRB-))) (PP (IN in) (NP (NP (DT a) (JJ young) (NN woman)) (PP (IN in) (NP (NP (DT the) (NN setting)) (PP (IN of) (NP (JJ Doc_18177388_134_145_Chemical) (NN use))))))))) (. .)))
18177388	1	(S1 (S (NP (JJ Transient) (NN Doc_18177388_161_204_Disease)) (VP (AUX was) (ADVP (RB first)) (VP (VBN described) (PP (IN in) (NP (NNP Japan))) (PP (IN as) (`` ``) (NP (NNP Doc_18177388_238_262_Disease))))) (. .) ('' '')))
18177388	2	(S1 (S (NP (DT This) (NN syndrome)) (VP (AUX has) (VP (AUX been) (VP (VBN identified) (PP (IN in) (NP (JJ many) (JJ other) (NNS countries)))))) (. .)))
18177388	3	(S1 (S (NP (NP (JJ Many) (NNS variations)) (PP (IN of) (NP (DT this) (NN syndrome)))) (VP (AUX have) (VP (AUX been) (VP (ADVP (RB recently)) (VBN described) (PP (IN in) (NP (DT the) (NN literature)))))) (. .)))
18177388	4	(S1 (S (NP (NP (CD One)) (PP (IN of) (NP (DT the) (NN rarest)))) (VP (AUX is) (NP (NP (DT the) (JJ reverse) (NN type)) (PP (IN of) (NP (DT this) (NN syndrome)))) (, ,) (PP (IN with) (NP (NP (NP (JJ hyperdynamic) (NN apex)) (CC and) (NP (JJ complete) (NN Doc_18177388_497_505_Disease))) (PP (IN of) (NP (NP (DT the) (NN base)) (PRN (-LRB- -LRB-) (SBAR (IN as) (S (VP (VBN opposed) (PP (TO to) (NP (DT the) (JJ classic) (NN Doc_18177388_545_562_Disease)))))) (-RRB- -RRB-))))))) (. .)))
18177388	5	(S1 (S (PP (IN In) (NP (DT this) (NN article))) (, ,) (NP (PRP we)) (VP (VBP report) (NP (NP (DT an) (JJ interesting) (NN case)) (PP (IN of) (NP (NP (DT a) (JJ young) (NN woman)) (SBAR (WHNP (WP who)) (S (VP (VBD presented) (PP (IN with) (S (NP (NP (DT this) (JJ rare) (NN type)) (PP (IN of) (NP (JJ reverse) (NNP Doc_18177388_674_700_Disease)))) (VP (VBG occurring) (PP (IN after) (NP (JJ Doc_18177388_717_728_Chemical) (NN use))))))))))))) (. .)))
18177388	6	(S1 (S (NP (DT This) (NN report)) (VP (AUX is) (VP (VBN followed) (PP (IN by) (NP (NP (NN review)) (PP (IN of) (NP (DT the) (NN literature))))))) (. .)))
18201582	0	(S1 (S (NP (NP (NNS Results)) (PP (IN of) (NP (NP (DT a) (JJ comparative) (, ,) (ADJP (NN phase) (NNP III) (, ,) (JJ 12-week) (, ,) (JJ multicenter) (, ,) (JJ prospective) (, ,) (JJ randomized)) (, ,) (JJ double-blind) (NN assessment)) (PP (IN of) (NP (NP (DT the) (NN efficacy) (CC and) (NN tolerability)) (PP (IN of) (NP (NP (DT a) (JJ fixed-dose) (NN combination)) (PP (IN of) (NP (NP (NNP Doc_18201582_172_183_Chemical)) (CC and) (NP (NNP Doc_18201582_188_198_Chemical) (CC versus) (NNP Doc_18201582_206_216_Chemical))))))))))) (VP (VB monotherapy) (PP (IN in) (NP (NP (JJ Indian) (NNS adults)) (PP (IN with) (NP (NN stage) (NNP II) (NNP Doc_18201582_260_272_Disease)))))) (. .)))
18201582	1	(S1 (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB evaluate) (NP (NP (DT the) (NN efficacy) (CC and) (NN tolerability)) (PP (IN of) (NP (NP (NP (DT a) (JJ new) (JJ fixed-dose) (NN combination)) (PRN (-LRB- -LRB-) (NP (NNP FDC)) (-RRB- -RRB-)) (PP (IN of) (NP (NNP Doc_18201582_394_405_Chemical) (CD 40)))) (JJ mg) (CD +) (NNP Doc_18201582_414_424_Chemical) (NP (NP (CD 5) (NN mg)) (PRN (-LRB- -LRB-) (NP (NNP T+A)) (-RRB- -RRB-)) (VP (VBN compared) (PP (IN with) (NP (NP (JJ Doc_18201582_450_460_Chemical) (JJ 5-mg) (NN monotherapy)) (PRN (-LRB- -LRB-) (NP (DT A)) (-RRB- -RRB-)))) (PP (IN in) (NP (JJ adult) (NNP Indian) (NNS patients))) (PP (IN with) (NP (NN stage))))) (NNP II) (NNP Doc_18201582_521_533_Disease)))))))) (. .)))
18201582	2	(S1 (S (NP (DT This) (JJ comparative) (, ,) (ADJP (NN Phase) (NNP III) (, ,) (JJ 12-week) (, ,) (JJ multicenter) (, ,) (JJ prospective) (, ,) (JJ randomized) (, ,) (JJ double-blind)) (NN study)) (VP (AUX was) (VP (VBN conducted) (PP (IN in) (NP (NP (JJ Indian) (NNS patients)) (VP (VBN aged) (NP (QP (CD 18) (TO to) (CD 65)) (NNS years)) (PP (IN with) (NP (JJ established) (NN stage) (NNP II) (NNP Doc_18201582_718_730_Disease)))))))) (. .)))
18201582	3	(S1 (S (S (NP (NNS Patients)) (VP (AUX were) (VP (VBN treated) (PP (IN with) (NP (NP (NP (JJ oral) (NN FDC)) (PP (IN of) (NP (NNP T+A)))) (CC or) (NP (NP (DT A) (NN QD)) (PP (IN before) (NP (NN breakfast)))))) (PP (IN for) (NP (CD 12) (NNS weeks)))))) (: ;) (S (NP (NP (NP (NN blood) (NN pressure)) (PRN (-LRB- -LRB-) (NP (NNP BP)) (-RRB- -RRB-))) (CC and) (NP (NN heart) (NN rate))) (VP (AUX were) (VP (VBN measured) (PP (IN in) (NP (DT the) (VBG sitting) (NN position)))))) (. .)))
18201582	4	(S1 (S (NP (JJ Primary) (NN efficacy) (NN end) (NNS points)) (VP (AUX were) (S (NP (NP (NN reduction)) (PP (IN in) (NP (NP (JJ clinical) (JJ systolic) (NNP BP) (PRN (-LRB- -LRB-) (NP (NNP SBP)) (-RRB- -RRB-)) (NNP /) (NN diastolic) (NNP BP)) (PRN (-LRB- -LRB-) (NP (NNP DBP)) (-RRB- -RRB-)))) (PP (IN from) (NP (NN baseline)))) (VP (TO to) (VP (VB study) (NP (NP (NN end) (CC and) (NN number)) (PP (IN of) (NP (NP (NNS responders)) (PRN (-LRB- -LRB-) (NP (NN ie)) (, ,) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD achieved) (SBAR (S (NP (NN target) (NNS SBP/)) (VP (VBD DBP) (NP (CD <130/<80) (NN mm)) (NP (NNP Hg))))))))) (-RRB- -RRB-))))) (PP (IN at) (NP (NP (NN end)) (PP (IN of) (NP (NN study))))))))) (. .)))
18201582	5	(S1 (S (NP (NN Tolerability)) (VP (AUX was) (VP (VBN assessed) (PP (IN by) (NP (NP (JJ treatment-emergent) (JJ adverse) (NNS events)) (, ,) (VP (VBN identified) (S (VP (VBG using) (NP (NP (NN physical) (NN examination)) (, ,) (NP (NN laboratory) (NN analysis)) (, ,) (CC and) (NP (NN electrocardiography)))))))))) (. .)))
18201582	6	(S1 (S (S (NP (NP (DT A) (NN total)) (PP (IN of) (NP (CD 210) (NNS patients)))) (VP (AUX were) (VP (VBD enrolled) (PP (IN in) (NP (DT the) (NN study)))))) (: ;) (S (NP (NP (CD 203) (NNS patients) (PRN (-LRB- -LRB-) (NP (CD 143) (NNS men)) (, ,) (NP (CD 60) (NNS women)) (-RRB- -RRB-))) (VP (VBN completed) (NP (DT the) (NN study)) (PP (IN while) (NP (CD 7))))) (VP (AUX were) (VP (VP (VBN lost) (PP (TO to) (NP (NN follow-up))) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 4) (NNS patients)) (PP (IN in) (NP (DT the) (NNP T+A) (NN group)))) (CC and) (NP (NP (CD 3)) (PP (IN in) (NP (DT the) (DT A) (NN group))))) (-RRB- -RRB-))) (CC and) (VP (VBN considered) (S (ADJP (JJ with-drawn))))))) (. .)))
18201582	7	(S1 (S (PP (IN At) (NP (NN study) (NN end))) (, ,) (NP (NP (ADJP (RB statistically) (JJ significant)) (NN percentage) (NNS reductions)) (PP (PP (IN from) (NP (NP (NN baseline)) (PP (IN within) (NP (NNS groups))))) (CC and) (PP (IN between) (NP (NNS groups))))) (VP (AUX were) (VP (VBN observed) (PP (IN in) (NP (NP (NP (NNP SBP)) (PRN (-LRB- -LRB-) (NP (NP (NNP T+A) (CD -LSB--27.4) (NN %) (NN -RSB-)) (: ;) (NP (DT A) (ADJP (CD -LSB--16.6) (NN %)) (NN -RSB-))) (-RRB- -RRB-))) (CC and) (NP (NP (NP (NNP DBP)) (PRN (-LRB- -LRB-) (NP (NP (NNP T+A) (ADJP (CD -LSB--20.1) (NN %)) (NN -RSB-)) (: ;) (NP (DT A) (ADJP (CD -LSB--13.3) (NN %)) (NN -RSB-))) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (NP (DT all)) (, ,) (NP (NP (NN P)) (QP (CD <) (CD 0.05)))) (-RRB- -RRB-))))))) (. .)))
18201582	8	(S1 (S (NP (NN Response) (NNS rates)) (VP (AUX were) (NP (NP (NP (NP (CD 87.3) (NN %)) (PRN (-LRB- -LRB-) (NP (CD 89/102)) (-RRB- -RRB-))) (PP (IN in) (NP (DT the) (NNP T+A) (NN group)))) (CC and) (NP (NP (NP (CD 69.3) (NN %)) (PRN (-LRB- -LRB-) (NP (CD 70/101)) (-RRB- -RRB-))) (PP (IN in) (NP (NP (DT the) (NNP A) (NN group)) (PRN (-LRB- -LRB-) (NP (QP (CD P) (CD <)) (CD 0.05)) (-RRB- -RRB-))))))) (. .)))
18201582	9	(S1 (S (NP (NP (DT The) (NNS prevalences)) (PP (IN of) (NP (JJ adverse) (NNS events)))) (VP (AUX were) (RB not) (ADJP (RB significantly) (JJ different) (PP (IN between) (NP (NP (DT the) (CD 2) (NN treatment) (NNS groups)) (PRN (-LRB- -LRB-) (NP (NP (NNP T+A)) (, ,) (NP (NP (CD 16.0) (NN %)) (NP (CD -LSB-17/106) (NN -RSB-)))) (: ;) (NP (NP (DT A)) (, ,) (NP (NP (CD 15.4) (NN %)) (NP (CD -LSB-16/104) (NNS -RSB-)))) (-RRB- -RRB-)))))) (. .)))
18201582	10	(S1 (S (S (S (NP (JJ Peripheral) (NNP Doc_18201582_1939_1944_Disease)) (VP (AUX was) (VP (VBN reported) (PP (IN in) (NP (NP (CD 8.5) (NN %) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 9/106)) (-RRB- -RRB-)))) (PP (IN in) (NP (DT the) (NNP T+A) (NN group))) (PP (VBN compared) (PP (IN with) (NP (NP (CD 13.5) (NN %)) (PRN (-LRB- -LRB-) (NP (CD 14/104)) (-RRB- -RRB-))))) (PP (IN in) (NP (DT the) (DT A) (NN group)))))) (, ,) (CC and) (S (NP (NN cough)) (VP (AUX was) (VP (VBN reported) (PP (IN in) (NP (NP (NP (CD 3.8) (NN %) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 4/106)) (-RRB- -RRB-)) (PP (IN in) (NP (DT the) (NNP T+A) (NN group)))) (CC and) (NP (NP (ADJP (CD 1.0) (NN %)) (PRN (-LRB- -LRB-) (NP (CD 1/104)) (-RRB- -RRB-)) (NNS patients)) (PP (IN in) (NP (DT the) (DT A) (NN group)))))))))) (: ;) (S (NP (DT these) (NNS differences)) (VP (AUX did) (RB not) (VP (VB reach) (NP (JJ statistical) (NN significance))))) (. .)))
18201582	11	(S1 (S (NP (NP (DT The) (NNS incidences)) (PP (IN of) (NP (NP (NNP Doc_18201582_2228_2236_Disease)) (, ,) (NP (NNP Doc_18201582_2238_2247_Disease)) (, ,) (CC and) (NP (NNP Doc_18201582_2253_2261_Disease))))) (VP (AUX were) (ADJP (JJ similar)) (PP (IN between) (NP (DT the) (CD 2) (NNS groups)))) (. .)))
18201582	12	(S1 (S (PP (IN Among) (NP (NP (DT these) (JJ Indian) (NNS patients)) (PP (IN with) (NP (NN stage) (NNP II) (NNP Doc_18201582_2352_2364_Disease))))) (, ,) (S (NP (NP (DT the) (NNP FDC)) (PP (IN of) (NP (NNP T+A)))) (VP (AUX was) (VP (VBN found) (S (VP (TO to) (VP (AUX be) (ADJP (RB significantly) (RBR more) (JJ effective))))) (, ,) (PP (IN with) (NP (NP (NN regard)) (PP (TO to) (NP (NNP BP) (NNS reductions))))) (, ,) (ADVP (IN than) (DT A))))) (, ,) (CC and) (S (NP (DT both) (NNS treatments)) (VP (AUX were) (VP (ADVP (RB well)) (VBN tolerated)))) (. .)))
18239197	0	(S1 (S (NP (NP (VBN Increased) (NN Doc_18239197_10_24_Disease)) (VP (VBN associated) (PP (IN with) (NP (DT the) (NNP APOE) (NN epsilon4))))) (VP (VBD allele) (PP (IN after) (NP (JJ Doc_18239197_72_87_Chemical) (JJ oral) (NN anticholinergic) (NN challenge))) (PP (IN in) (NP (JJ healthy) (JJ elderly)))) (. .)))
18239197	1	(S1 (S (NP (NP (DT The) (NNS objectives)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX were) (S (VP (VP (TO to) (VP (VB examine) (NP (NP (DT the) (NN relationship)) (PP (IN between) (NP (NP (NN APOE) (NNS epsilon4)) (CC and) (NP (NP (JJ subjective) (NNS effects)) (PP (IN of) (NP (NP (NP (NNP Doc_18239197_261_276_Chemical)) (PP (IN on) (NP (NP (NNS measures)) (VP (VBG reflecting) (NP (NN sedation)))))) (CC and) (NP (NNP Doc_18239197_313_322_Disease)))))))))) (CC and) (VP (TO to) (VP (VB investigate) (NP (NP (DT the) (NN relationship)) (PP (IN between) (NP (NP (JJ Doc_18239197_367_382_Chemical-induced) (JJ subjective) (NNS effects)) (CC and) (NP (JJ objective) (NN memory) (NN performance)))))))))) (. .)))
18239197	2	(S1 (S (NP (DT This) (NN study)) (VP (VBN comprised) (NP (NP (CD 24) (ADJP (RB cognitively) (JJ intact)) (, ,) (ADJP (NN health) (JJ elderly)) (NNS adults)) (PRN (-LRB- -LRB-) (NP (CD 12) (NNP APOE) (NN epsilon4) (NNS carriers)) (-RRB- -RRB-))) (PP (IN at) (NP (DT an) (NN outpatient) (NN geriatric) (NN psychiatry) (NN research) (NN clinic)))) (. .)))
18239197	3	(S1 (S (NP (DT This)) (VP (AUX was) (NP (DT a) (JJ randomized) (, ,) (JJ double) (JJ blind) (, ,) (JJ placebo-controlled) (, ,) (JJ three-way) (, ,) (JJ crossover) (JJ experimental) (NN design))) (. .)))
18239197	4	(S1 (S (NP (DT All) (NNS participants)) (VP (VBD received) (NP (NP (QP (CD 1.0) (CD mg) (CC or) (CD 2.0) (CD mg)) (NN Doc_18239197_744_759_Chemical)) (CC or) (NP (NP (NN placebo)) (VP (VBN administered) (PP (IN in) (NP (JJ counterbalanced) (NNS sequences))) (PP (IN over) (NP (NP (DT a) (NN period)) (PP (IN of) (NP (CD three) (JJ consecutive) (NNS weeks))))))))) (. .)))
18239197	5	(S1 (S (NP (NP (NP (NNP Bond) (CC and) (NNP Lader) (POS 's)) (JJ visual) (JJ analog) (NNS scales)) (CC and) (NP (NP (JJ alternate) (NNS versions)) (PP (IN of) (NP (DT the) (JJ Buschke) (JJ Selective) (VBG Reminding) (NN Test))))) (VP (AUX were) (VP (VBN administered) (PP (IN in) (NP (DT a) (VBN repeated) (NNS measures) (NN design))) (PP (IN at) (NP (NN baseline) (, ,) (CD 1) (, ,) (CD 2.5) (, ,) (CC and) (CD 5) (NNS hours) (NN postdrug) (NN administration))))) (. .)))
18239197	6	(S1 (S (NP (NP (DT A) (JJ 2.0-mg) (JJ oral) (NN dose)) (PP (IN of) (NP (NNP Doc_18239197_1093_1108_Chemical)))) (VP (VBD resulted) (PP (IN in) (NP (NP (JJ increased) (JJ subjective) (NNS ratings)) (PP (IN of) (NP (NNP Doc_18239197_1153_1168_Disease))))) (PP (IN in) (NP (NP (NNS carriers)) (PP (IN of) (NP (DT the) (NNP APOE) (NN epsilon4) (NN allele))))) (ADVP (RB only))) (. .)))
18239197	7	(S1 (S (NP (NN Drug) (NNS effects)) (SBAR (IN as) (S (VP (VBN determined) (PP (IN by) (NP (NP (NN difference) (NNS scores)) (PP (IN between) (NP (QP (CD 2.0) (CD mg))))))))) (NP (NP (NNP Doc_18239197_1278_1293_Chemical)) (CC and) (NP (NP (NN placebo)) (PP (IN on) (NP (NP (NNS ratings)) (PP (IN of) (NP (NNP Doc_18239197_1320_1335_Disease))))))) (VP (VP (ADVP (RB significantly)) (VBD correlated) (PP (IN with) (NP (NN total)))) (CC and) (VP (VBD delayed) (NP (NN recall)) (PP (IN on) (NP (NP (DT the) (JJ Buschke) (JJ Selective) (VBG Reminding) (NN Test)) (PP (IN in) (NP (NP (NNS carriers)) (PP (IN of) (NP (DT the) (NNP APOE) (NN epsilon4) (NN allele))))))) (ADVP (RB only)))) (. .)))
18239197	8	(S1 (S (ADVP (RB However)) (, ,) (NP (DT no) (JJ significant) (NNS effects)) (VP (AUX were) (VP (VBN found) (PP (IN with) (NP (NP (JJ other) (JJ visual) (NN analog) (NNS scales)) (VP (VBG reflecting) (NP (NP (JJ subjective) (NN sedation)) (CC and) (NP (NN clear-headedness)))))))) (. .)))
18239197	9	(S1 (S (NP (NP (DT The) (JJ epsilon4) (NN allele)) (PP (IN in) (NP (JJ healthy) (JJ elderly)))) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (VBN increased) (JJ subjective) (NN Doc_18239197_1697_1711_Disease)) (PP (IN after) (NP (JJ Doc_18239197_1718_1733_Chemical) (JJ anticholinergic) (NN challenge))))))) (. .)))
18356633	0	(S1 (NP (NP (DT An) (NN evaluation)) (PP (IN of) (NP (NNP Doc_18356633_17_25_Chemical) (CD nephrotoxicity))) (PP (IN in) (NP (DT the) (JJ hematology/oncology) (NN population))) (. .)))
18356633	1	(S1 (S (NP (NN Doc_18356633_80_88_Chemical)) (VP (AUX is) (NP (NP (DT an) (NN Doc_18356633_95_109_Chemical)) (VP (ADVP (RB commonly)) (VBN used) (S (VP (TO to) (VP (VB provide) (NP (NP (JJ empirical) (JJ double) (JJ gram-negative) (NN treatment)) (PP (IN for) (NP (NP (NNP Doc_18356633_180_199_Disease)) (CC and) (NP (JJ other) (JJ suspected) (NNP Doc_18356633_220_230_Disease))))))))))) (. .)))
18356633	2	(S1 (S (S (NP (NP (NNS Strategies)) (PP (IN of) (NP (NP (NN extended-interval)) (CC and) (NP (JJ conventional) (NN dosing))))) (VP (AUX have) (VP (AUX been) (VP (VBN utilized) (ADVP (RB extensively)) (PP (IN in) (NP (DT the) (JJ general) (JJ medical) (NN population))))))) (: ;) (S (ADVP (RB however)) (, ,) (NP (NNS data)) (VP (AUX are) (VP (VBG lacking) (S (VP (TO to) (VP (VB support) (NP (NP (DT a) (VBG dosing) (NN strategy)) (PP (IN in) (NP (DT the) (JJ hematology/oncology) (NN population)))))))))) (. .)))
18356633	3	(S1 (S (S (VP (TO To) (VP (VB evaluate) (NP (JJ Doc_18356633_460_468_Chemical-associated) (NN nephrotoxicity)) (PP (IN in) (NP (DT an) (JJ adult) (NN hematology/oncology) (NN population)))))) (, ,) (NP (DT a) (JJ prospective) (, ,) (JJ randomized) (, ,) (JJ open-label) (NN trial)) (VP (AUX was) (VP (VBN conducted) (PP (IN at) (NP (DT a) (JJ university-affiliated) (JJ medical) (NN center))))) (. .)))
18356633	4	(S1 (S (NP (NP (CD Forty) (NNS patients)) (PP (IN with) (NP (NP (DT a) (NN diagnosis)) (ADJP (JJ consistent) (PP (IN with) (NP (NP (DT a) (NN Doc_18356633_690_720_Disease)) (SBAR (WHNP (WDT that)) (S (VP (VBD required) (NP (NN treatment)) (PP (IN with) (NP (DT an) (NNP Doc_18356633_753_767_Chemical)))))))))))) (VP (AUX were) (VP (VBN randomized) (PP (TO to) (NP (DT either) (JJ conventional) (CC or) (JJ extended-interval) (NN Doc_18356633_828_836_Chemical))))) (. .)))
18356633	5	(S1 (S (NP (NP (DT The) (NN occurrence)) (PP (IN of) (NP (NN nephrotoxicity))) (PP (IN by) (NP (NP (NNS means)) (PP (IN of) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (JJ serum) (NN Doc_18356633_904_914_Chemical) (CC and) (NN evaluation)) (PP (IN of) (NP (NN efficacy))))) (PP (IN via) (NP (NP (JJ Doc_18356633_946_954_Chemical) (NN serum) (NNS concentrations)) (PP (IN with) (NP (JJ respective) (NNS pathogens)))))))))) (VP (AUX were) (VP (VBN assessed))) (. .)))
18356633	6	(S1 (S (S (NP (NP (DT The) (NN occurrence)) (PP (IN of) (NP (NN nephrotoxicity)))) (VP (AUX was) (ADJP (JJ similar)) (PP (IN between) (NP (DT the) (JJ conventional) (CC and) (JJ extended-interval) (NNS groups))) (, ,) (PP (IN at) (NP (NP (CD 10) (NN %)) (CC and) (NP (CD 5) (NN %)))) (, ,) (ADVP (RB respectively)))) (PRN (-LRB- -LRB-) (NP (NNP P) (SYM =) (CD 1.00)) (-RRB- -RRB-)) (. .)))
18356633	7	(S1 (S (NP (NP (CD Six) (NNS patients)) (PP (IN in) (NP (DT the) (JJ conventional) (NN group)))) (VP (AUX had) (NP (DT a) (JJ positive) (NN culture)) (, ,) (PP (VBN compared) (PP (IN with) (NP (NP (NN none)) (PP (IN in) (NP (NP (DT the) (JJ extended-interval) (NN group)) (PRN (-LRB- -LRB-) (NP (NNP P) (SYM =) (CD 0.002)) (-RRB- -RRB-)))))))) (. .)))
18356633	8	(S1 (S (S (NP (NP (DT The) (NN occurrence)) (PP (IN of) (NP (NN nephrotoxicity)))) (VP (AUX was) (ADJP (JJ similar)) (PP (IN between) (NP (DT the) (CD two) (JJ dosing) (NNS regimens))))) (, ,) (CC but) (S (NP (NP (DT the) (NN distribution)) (PP (IN of) (NP (NN risk) (NNS factors)))) (VP (AUX was) (ADJP (JJ variable)) (PP (IN between) (NP (DT the) (CD two) (NNS groups))))) (. .)))
18356633	9	(S1 (S (NP (NN Efficacy)) (VP (MD could) (RB not) (VP (AUX be) (VP (VBN assessed)))) (. .)))
18363626	0	(S1 (NP (NP (JJ High) (NN dose)) (ADJP (JJ Doc_18363626_10_25_Chemical) (PP (IN as) (NP (NP (DT the) (JJ sole) (NN sedative)) (PP (IN for) (NP (JJ pediatric) (NNP MRI)))))) (. .)))
18363626	1	(S1 (S (NP (DT This) (JJ large-scale) (NN retrospective) (NN review)) (VP (VBZ evaluates) (NP (NP (DT the) (NN sedation) (NN profile)) (PP (IN of) (NP (NNP Doc_18363626_149_164_Chemical))))) (. .)))
18363626	2	(S1 (S (S (VP (TO To) (VP (VB determine) (NP (DT the) (JJ hemodynamic) (NNS responses))))) (, ,) (NP (NP (NN efficacy)) (CC and) (NP (JJ adverse) (NNS events))) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (JJ high) (NN dose))) (PP (JJ Doc_18363626_276_291_Chemical) (IN as) (NP (NP (DT the) (JJ sole) (NN sedative)) (PP (IN for) (NP (JJ magnetic) (NN resonance) (NN imaging) (PRN (-LRB- -LRB-) (NP (NNP MRI)) (-RRB- -RRB-)) (NNS studies)))))))) (. .)))
18363626	3	(S1 (S (NP (NN Doc_18363626_371_386_Chemical)) (VP (AUX has) (VP (AUX been) (VP (VBN used) (PP (IN at) (NP (PRP$ our) (NN institution))) (PP (IN since) (NP (CD 2005))) (S (VP (TO to) (VP (VB provide) (NP (NN sedation)) (PP (IN for) (NP (JJ pediatric) (JJ radiological) (NN imaging) (NNS studies))))))))) (. .)))
18363626	4	(S1 (S (PP (IN Over) (NP (NN time))) (, ,) (NP (NP (DT an) (JJ effective) (NN protocol)) (VP (VBG utilizing) (NP (JJ high) (NN dose) (NN Doc_18363626_548_563_Chemical)) (PP (IN as) (NP (DT the) (JJ sole) (NN sedative) (NN agent))))) (VP (AUX has) (VP (VBN evolved))) (. .)))
18363626	5	(S1 (NP (NP (NNS METHODS/MATERIALS)) (: :) (S (PP (IN As) (NP (NP (NN part)) (PP (IN of) (NP (DT the) (JJ ongoing) (NNP Quality) (NNP Assurance) (NN process))))) (, ,) (S (NP (NP (NNS data)) (PP (IN on) (NP (DT all) (NNS sedations)))) (VP (AUX are) (VP (VBN reviewed) (ADVP (RB monthly))))) (CC and) (S (NP (NNS protocols)) (VP (VBN modified) (SBAR (IN as) (S (VP (VBN needed))))))) (. .)))
18363626	6	(S1 (S (NP (NNS Data)) (VP (AUX were) (VP (VBN analyzed) (PP (IN from) (NP (NP (DT all) (CD 747) (JJ consecutive) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (NNP Doc_18363626_816_831_Chemical)) (PP (IN for) (NP (NNP MRI) (NN sedation))) (PP (PP (IN from) (NP (NNP April) (CD 2005))) (PP (TO to) (NP (NNP April) (CD 2007))))))))))) (. .)))
18363626	7	(S1 (S (PP (IN Since) (NP (CD 2005))) (, ,) (S (NP (NP (DT the) (JJ 10-min) (NN loading) (NN dose)) (PP (IN of) (NP (PRP$ our) (JJ Doc_18363626_932_947_Chemical) (NN protocol)))) (VP (VBD increased) (PP (IN from) (NP (NP (QP (CD 2) (TO to) (CD 3)) (NNS microg.kg)) (PRN (-LRB- -LRB-) (JJ -1) (-RRB- -RRB-)))))) (, ,) (CC and) (S (NP (DT the) (NN infusion) (NN rate)) (VP (VBD increased) (PP (IN from) (NP (QP (CD 1) (TO to) (CD 1.5)))) (PP (TO to) (NP (QP (CD 2) (CD microg.kg)) (PRN (-LRB- -LRB-) (JJ -1) (-RRB- -RRB-)) (NNS .h))) (PRN (-LRB- -LRB-) (NP (NN -1)) (-RRB- -RRB-)))) (. .)))
18363626	8	(S1 (S (NP (DT The) (JJ current) (NN sedation) (NN protocol)) (VP (VP (ADVP (RB progressively)) (VBD increased) (NP (NP (DT the) (NN rate)) (PP (IN of) (S (NP (NP (JJ successful) (NN sedation)) (PRN (-LRB- -LRB-) (S (NP (JJ able)) (VP (TO to) (VP (VB complete) (NP (DT the) (NN imaging) (NN study))))) (-RRB- -RRB-))) (ADVP (WRB when)) (VP (VBG using) (NP (NNP Doc_18363626_1200_1215_Chemical)) (ADVP (RB alone) (PP (IN from) (NP (CD 91.8) (NN %)))) (PP (TO to) (NP (CD 97.6) (NN %))) (PRN (-LRB- -LRB-) (NP (NNP P) (SYM =) (CD 0.009)) (-RRB- -RRB-)))))) (, ,) (S (VP (VBG reducing) (NP (NP (DT the) (NN requirement)) (PP (IN for) (NP (JJ adjuvant) (NNP Doc_18363626_1293_1306_Chemical)))) (PP (IN in) (NP (NP (DT the) (NN event)) (PP (IN of) (NP (NN sedation) (NN failure))) (PP (IN with) (NP (NNP Doc_18363626_1345_1360_Chemical))) (ADVP (RB alone))))))) (CC and) (VP (VBD decreased) (NP (DT the) (JJ mean) (NN recovery) (NN time)) (PP (IN by) (NP (NP (CD 10) (NN min)) (PRN (-LRB- -LRB-) (NP (NNP P) (NNP <) (CD 0.001)) (-RRB- -RRB-)))))) (. .)))
18363626	9	(S1 (S (SBAR (IN Although) (S (NP (JJ Doc_18363626_1436_1451_Chemical) (NN sedation)) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (DT a) (ADJP (CD 16) (NN %)) (NN incidence)) (PP (IN of) (NP (NNP Doc_18363626_1500_1511_Disease))))))))) (, ,) (S (NP (DT all) (JJ concomitant) (JJ mean) (JJ arterial) (NN blood) (NNS pressures)) (VP (AUX were) (PP (IN within) (NP (NP (CD 20) (NN %)) (PP (IN of) (NP (JJ age-adjusted) (JJ normal) (NN range))))))) (CC and) (S (NP (NNP Doc_18363626_1608_1614_Chemical) (NNS saturations)) (VP (AUX were) (ADJP (CD 95) (NN %) (CC or) (JJR higher)))) (. .)))
18363626	10	(S1 (S (NP (NP (NN Doc_18363626_1659_1674_Chemical)) (PP (IN in) (NP (JJ high) (NNS doses)))) (VP (VBZ provides) (NP (NP (JJ adequate) (NN sedation)) (PP (IN for) (NP (JJ pediatric) (NNP MRI) (NNS studies))))) (. .)))
18363626	11	(S1 (S (SBAR (IN While) (S (NP (NP (NN use)) (PP (IN of) (NP (JJ high) (NN dose) (NN Doc_18363626_1766_1781_Chemical)))) (VP (AUX is) (VP (VBN associated) (PP (IN with) (NP (NP (NNS decreases)) (PP (IN in) (NP (NP (NN heart) (NN rate)) (CC and) (NP (NN blood) (NN pressure)))) (PP (IN outside) (NP (NP (DT the) (VBN established) (POS ')) (JJ awake) ('' ') (NNS norms))))))))) (, ,) (NP (DT this) (NN deviation)) (VP (VP (AUX is) (ADVP (RB generally)) (PP (IN within) (NP (NP (CD 20) (NN %)) (PP (IN of) (NP (NNS norms)))))) (, ,) (CC and) (VP (AUX is) (RB not) (VP (VBN associated) (PP (IN with) (NP (JJ adverse) (NNS sequelae)))))) (. .)))
18363626	12	(S1 (S (NP (NN Doc_18363626_1977_1992_Chemical)) (VP (AUX is) (ADJP (JJ useful) (PP (IN as) (NP (NP (DT the) (JJ sole) (NN sedative)) (PP (IN for) (NP (JJ pediatric) (NNP MRI))))))) (. .)))
18405372	0	(S1 (NP (NP (NP (NN Hepatotoxicity)) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_18405372_31_44_Chemical))) (PP (IN in) (NP (JJ inflammatory) (NN Doc_18405372_61_70_Disease))))) (: :) (NP (NP (DT A) (NN case) (NN series)) (PP (IN from) (NP (NP (DT a) (JJ local) (NN surveillance)) (PP (IN of) (NP (JJ serious) (JJ adverse) (NNS events)))))) (. .)))
18405372	1	(S1 (S (NP (NP (JJ Spontaneous) (NN reporting) (NNS systems)) (PP (IN for) (NP (JJ adverse) (NN drug) (NNS reactions))) (PRN (-LRB- -LRB-) (NP (NNPS ADRs)) (-RRB- -RRB-))) (VP (AUX are) (VP (VBN handicapped) (PP (IN by) (NP (NP (NN under-reporting)) (CC and) (NP (JJ limited) (NN detail)))) (PP (IN on) (NP (JJ individual) (NNS cases))))) (. .)))
18405372	2	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT an) (NN investigation)) (PP (IN from) (NP (NP (DT a) (JJ local) (NN surveillance)) (PP (IN for) (NP (NP (JJ serious) (JJ adverse) (NN drug) (NNS reactions)) (VP (VBN associated) (PP (IN with) (NP (NP (NN disease)) (VP (VBG modifying) (NP (NP (JJ anti-rheumatic) (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (AUX was) (VP (VBN triggered) (PP (IN by) (NP (NP (DT the) (NN occurrence)) (PP (IN of) (NP (NNP Doc_18405372_473_486_Disease))) (PP (IN in) (NP (NP (CD two)) (PP (IN of) (NP (PRP$ our) (NNS patients)))))))))))))))))))))) (. .)))
18405372	3	(S1 (S (NP (JJ Serious) (NN ADR) (NNS reports)) (VP (AUX have) (VP (AUX been) (VP (VBN solicited) (PP (IN from) (NP (JJ local) (NNS clinicians))) (PP (IN by) (NP (JJ regular) (NNS postcards))) (PP (IN over) (NP (DT the) (JJ past) (CD seven) (NNS years)))))) (. .)))
18405372	4	(S1 (S (NP (NP (NNS Patients) (POS ')) (, ,) (SBAR (WHNP (WP who)) (S (VP (VP (AUX had) (NP (NN hepatotoxicity)) (PP (IN on) (NP (NNP Doc_18405372_667_680_Chemical)))) (CC and) (VP (VBD met) (NP (NP (DT a) (NN definition)) (PP (IN of) (NP (DT a) (JJ serious) (NN Doc_18405372_715_718_Chemical)))))))) (, ,)) (VP (AUX were) (VP (VBN identified))) (. .)))
18405372	5	(S1 (S (NP (NP (CD Two) (NNS clinicians)) (VP (VBN reviewed))) (VP (VP (VBD structured) (NP (NN case) (NNS reports))) (CC and) (VP (VBN assessed) (NP (NN causality)) (PP (PP (IN by) (NP (NN consensus))) (CC and) (PP (IN by) (S (VP (VBG using) (NP (DT a) (JJ causality) (NN assessment) (NN instrument)))))))) (. .)))
18405372	6	(S1 (S (NP (NP (DT The) (JJ likely) (NN frequency)) (PP (IN of) (NP (NN hepatotoxicity))) (PP (IN with) (NP (NNP Doc_18405372_913_926_Chemical)))) (VP (AUX was) (VP (VBN estimated) (PP (IN by) (S (VP (VBG making) (NP (NP (DT a) (NN series)) (PP (IN of) (NP (JJ conservative) (NNS assumptions))))))))) (. .)))
18405372	7	(S1 (S (S (NP (CD Ten) (NNS cases)) (VP (AUX were) (VP (VBN identified)))) (: :) (S (NP (CD eight)) (VP (VBD occurred) (PP (IN during) (NP (NN surveillance))))) (. .)))
18405372	8	(S1 (S (S (NP (CD Eight) (NNS patients)) (VP (AUX were) (VP (VBN hospitalised) (, ,) (NP (NP (CD two)) (PP (IN in) (NP (NNP Doc_18405372_1102_1117_Disease))))))) (: -) (S (NP (CD one)) (VP (VBD died) (PP (IN after) (NP (DT a) (NN liver) (NN transplant))))) (. .)))
18405372	9	(S1 (S (NP (NP (DT All)) (PP (IN but) (NP (CD one) (NN event)))) (VP (VBD occurred) (PP (IN within) (NP (NP (CD 6) (NNS weeks)) (PP (IN of) (NP (NN treatment)))))) (. .)))
18405372	10	(S1 (S (NP (CD Seven) (NNS patients)) (VP (AUX had) (NP (NP (DT a) (NN Doc_18405372_1232_1241_Disease)) (, ,) (NP (NP (CD three) (NN Doc_18405372_1249_1261_Disease)) (CC and) (NP (CD one) (NN Doc_18405372_1270_1292_Disease))))) (. .)))
18405372	11	(S1 (S (NP (CD Five) (NNS patients)) (VP (AUX were) (PP (IN of) (NP (NP (NNP Black) (NNPS British)) (PP (IN of) (NP (NNP African) (CC or) (NNP Caribbean) (NN descent)))))) (. .)))
18405372	12	(S1 (S (NP (NN Liver) (NNS enzymes)) (VP (VBD showed) (NP (NP (NP (DT a) (JJ hepatocellular) (NN pattern)) (PP (IN in) (NP (CD four) (NNS cases)))) (CC and) (NP (NP (DT a) (JJ mixed) (NN pattern)) (PP (IN in) (NP (CD six)))))) (. .)))
18405372	13	(S1 (S (NP (JJ Drug-related) (NN hepatotoxicity)) (VP (AUX was) (VP (VBN judged) (UCP (ADJP (JJ probable)) (CC or) (ADJP (RB highly) (JJ probable) (PP (IN in) (NP (CD 8) (NNS patients))))))) (. .)))
18405372	14	(S1 (S (NP (NP (DT The) (JJ likely) (NN frequency)) (PP (IN of) (NP (JJ serious) (NN hepatotoxicity))) (PP (IN with) (NP (NNP Doc_18405372_1585_1598_Chemical)))) (VP (AUX was) (VP (VBN estimated) (PP (IN at) (NP (NP (CD 0.4) (NN %)) (PP (IN of) (NP (VBN treated) (NNS patients))))))) (. .)))
18405372	15	(S1 (S (S (NP (NP (JJ Serious) (NN hepatotoxicity)) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_18405372_1693_1706_Chemical))))) (VP (VBZ appears) (S (VP (TO to) (VP (AUX be) (ADJP (JJ under-appreciated))))))) (CC and) (S (NP (NP (NP (JJ intensive) (NN monitoring)) (CC and) (NP (NN vigilance))) (PP (IN in) (NP (NP (DT the) (JJ first) (CD 6) (NNS weeks)) (PP (IN of) (NP (NN treatment)))))) (VP (AUX is) (ADJP (RB especially) (JJ important)))) (. .)))
18441470	0	(S1 (S (NP (JJ Complete) (NN Doc_18441470_9_31_Disease)) (ADJP (JJ secondary) (PP (TO to) (NP (JJ Doc_18441470_45_52_Chemical) (NN therapy)))) (. .)))
18441470	1	(S1 (S (NP (NN Doc_18441470_62_84_Disease)) (VP (AUX has) (VP (AUX been) (VP (VBN reported) (ADVP (RBS most) (RB frequently)) (PP (IN among) (NP (NP (DT the) (JJ adverse) (JJ cardiovascular) (NNS effects)) (PP (IN of) (NP (NNP Doc_18441470_163_170_Chemical)))))))) (. .)))
18441470	2	(S1 (S (PP (IN In) (NP (DT the) (JJ present) (NN case))) (, ,) (NP (NP (JJ complete) (NN Doc_18441470_202_229_Disease)) (PP (IN with) (NP (NNP Doc_18441470_235_251_Disease)))) (VP (VBD developed) (ADVP (JJ secondary)) (PP (TO to) (NP (JJ Doc_18441470_275_282_Chemical) (NN therapy))) (, ,) (S (VP (VBG necessitating) (NP (JJ permanent) (NN pacemaker) (NN implantation))))) (. .)))
18441470	3	(S1 (S (NP (NNP Serum) (NNP Doc_18441470_346_353_Chemical) (NNS levels)) (VP (VBD remained) (PP (IN under) (CC or) (PP (IN within) (NP (DT the) (JJ therapeutic) (NN range)))) (PP (IN during) (NP (DT the) (NNP Doc_18441470_419_435_Disease)))) (. .)))
18441470	4	(S1 (S (NP (NN Doc_18441470_437_444_Chemical)) (VP (MD should) (VP (AUX be) (VP (VBN used) (PP (IN with) (NP (JJ extreme) (NN caution))) (, ,) (PP (ADVP (RB especially)) (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (JJ mild) (NN disturbance)) (PP (IN of) (NP (CD AV) (NN conduction)))))))))) (. .)))
18483878	0	(S1 (S (NP (NP (JJ Exaggerated) (NN expression)) (PP (IN of) (NP (JJ inflammatory) (NNS mediators))) (PP (IN in) (NP (NP (JJ vasoactive) (JJ intestinal) (NN polypeptide) (NN knockout) (PRN (-LRB- -LRB-) (JJ VIP-/-) (-RRB- -RRB-)) (NNS mice)) (PP (IN with) (NP (NP (NNP Doc_18483878_114_130_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP CYP)) (-RRB- -RRB-))))))) (VP (VBD -induced) (NP (NNP Doc_18483878_145_153_Disease))) (. .)))
18483878	1	(S1 (S (NP (NP (JJ Vasoactive) (JJ intestinal) (NN polypeptide)) (PRN (-LRB- -LRB-) (NP (NN VIP)) (-RRB- -RRB-))) (VP (AUX is) (NP (NP (DT an) (JJ immunomodulatory) (NN neuropeptide)) (VP (VBN distributed) (PP (IN in) (NP (JJ micturition) (NNS pathways)))))) (. .)))
18483878	2	(S1 (S (NP (JJ VIP) (PRN (-LRB- -LRB-) (JJ -/-) (-RRB- -RRB-)) (NNS mice)) (VP (VB exhibit) (NP (NP (JJ altered) (NN bladder) (NN function)) (CC and) (NP (JJ neurochemical) (NNS properties))) (PP (IN in) (NP (NN micturition) (NNS pathways))) (SBAR (IN after) (S (NP (NP (NNP Doc_18483878_374_390_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP CYP)) (-RRB- -RRB-))) (VP (VBD -induced) (NP (NNP Doc_18483878_405_413_Disease)))))) (. .)))
18483878	3	(S1 (S (PP (VBN Given) (NP (NP (NP (NN VIP) (POS 's)) (NN role)) (PP (IN as) (NP (DT an) (JJ anti-inflammatory) (NN mediator))))) (, ,) (NP (PRP we)) (VP (VBN hypothesized) (SBAR (IN that) (S (NP (JJ VIP) (PRN (-LRB- -LRB-) (JJ -/-) (-RRB- -RRB-)) (NNS mice)) (VP (MD would) (VP (VB exhibit) (NP (JJ enhanced) (JJ inflammatory) (NN mediator) (NN expression)) (PP (IN after) (NP (NNP Doc_18483878_563_571_Disease)))))))) (. .)))
18483878	4	(S1 (S (NP (NP (DT A) (NN mouse) (JJ inflammatory) (NN cytokine)) (CC and) (NP (NN receptor) (NN RT2) (NN profiler) (NN array))) (VP (AUX was) (VP (VBN used) (S (VP (TO to) (VP (VP (VB determine) (NP (NP (JJ regulated) (NNS transcripts)) (PP (IN in) (NP (NP (DT the) (JJ urinary) (NN bladder)) (PP (IN of) (NP (NP (JJ wild) (NN type)) (PRN (-LRB- -LRB-) (NP (NNP WT)) (-RRB- -RRB-)))))))) (CC and) (VP (VB VIP) (NP (NP (PRN (-LRB- -LRB-) (JJ -/-) (-RRB- -RRB-)) (NNS mice)) (PP (IN with) (CC or) (IN without) (NP (NP (JJ Doc_18483878_754_757_Chemical-induced) (NNP Doc_18483878_766_774_Disease)) (PRN (-LRB- -LRB-) (NP (NP (QP (CD 150) (CD mg/kg))) (: ;) (NP (CD i.p.)) (: ;) (NP (CD 48) (NNP h))) (-RRB- -RRB-))))))))))) (. .)))
18483878	5	(S1 (S (S (NP (CD Four) (JJ binary) (NNS comparisons)) (VP (AUX were) (VP (VBN made)))) (: :) (S (NP (NP (NP (CD WT) (NN control)) (PP (IN versus) (NP (NP (NP (CD CYP) (NN treatment)) (PRN (-LRB- -LRB-) (NP (CD 48) (NNP h)) (-RRB- -RRB-))) (, ,) (NP (NNP VIP) (PRN (-LRB- -LRB-) (JJ -/-) (-RRB- -RRB-)) (NN control)) (CC versus) (NP (NP (CD CYP) (NN treatment)) (PRN (-LRB- -LRB-) (NP (CD 48) (NNP h)) (-RRB- -RRB-)))))) (, ,) (NP (NNP WT) (NN control) (CC versus) (NN VIP) (PRN (-LRB- -LRB-) (JJ -/-) (-RRB- -RRB-)) (NN control)) (, ,) (CC and) (CD WT)) (PP (IN with) (NP (NP (NP (CD CYP) (NN treatment)) (-LRB- -LRB-) (NP (CD 48) (NNP h)) (-RRB- -RRB-)) (CC versus) (NP (NP (NP (NN VIP)) (PRN (-LRB- -LRB-) (JJ -/-) (-RRB- -RRB-)) (PP (IN with) (NP (JJ CYP) (NN treatment)))) (-LRB- -LRB-) (NP (CD 48) (NNP h)) (-RRB- -RRB-))))) (. .)))
18483878	6	(S1 (S (NP (NP (DT The) (NNS genes)) (VP (VBN presented))) (VP (VBP represent) (PRN (-LRB- -LRB-) (NP (CD 1)) (-RRB- -RRB-)) (NP (NP (JJR greater)) (SBAR (IN than) (S (NP (NP (NP (JJ 1.5-fold) (NN change)) (PP (IN in) (NP (DT either) (NN direction)))) (CC and) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-)) (NP (DT the) (JJ p) (NN value))) (VP (AUX is) (NP (QP (JJR less) (IN than) (CD 0.05))))))) (PP (IN for) (NP (NP (DT the) (NN comparison)) (VP (AUXG being) (VP (VBN made)))))) (. .)))
18483878	7	(S1 (S (NP (JJ Several) (JJ regulated) (NNS genes)) (VP (AUX were) (VP (VBN validated) (S (VP (VBG using) (NP (NP (JJ enzyme-linked) (NNS immunoassays)) (PP (VBG including) (NP (NP (NN IL-1beta)) (CC and) (NP (NN CXCL1))))))))) (. .)))
18483878	8	(S1 (S (S (NP (NNP CYP) (NN treatment)) (ADVP (RB significantly)) (-LRB- -LRB-) (NP (NNP p) (NNP <) (CC or) (SYM =) (CD 0.001)) (-RRB- -RRB-) (VP (VBD increased) (NP (NP (NN expression)) (PP (IN of) (NP (NNP CXCL1) (CC and) (NNP IL-1beta))) (PP (IN in) (NP (NP (DT the) (JJ urinary) (NN bladder)) (PP (IN of) (NP (NNP WT) (CC and) (NNP VIP) (PRN (-LRB- -LRB-) (JJ -/-) (-RRB- -RRB-)) (NNS mice)))))))) (, ,) (CC but) (S (VP (NN expression) (PP (IN in) (NP (NP (JJ VIP) (PRN (-LRB- -LRB-) (JJ -/-) (-RRB- -RRB-)) (NNS mice)) (PP (IN with) (NP (JJ CYP) (NN treatment))))) (VP (AUX was) (ADVP (RB significantly)) (S (-LRB- -LRB-) (NP (NNP p) (NNP <) (CC or) (SYM =) (CD 0.001)) (-RRB- -RRB-) (NP (NP (JJR greater) (PRN (-LRB- -LRB-) (ADJP (JJ 4.2-) (PP (TO to) (NP (JJ 13-fold) (NN increase)))) (-RRB- -RRB-))) (PP (IN than) (SBAR (WHNP (WDT that)) (S (VP (VBD observed) (PP (IN in) (NP (NP (JJ WT) (NN urinary) (NN bladder)) (PRN (-LRB- -LRB-) (ADJP (JJ 3.6-) (PP (TO to) (NP (JJ 5-fold) (NN increase)))) (-RRB- -RRB-))))))))))))) (. .)))
18483878	9	(S1 (S (NP (DT The) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (PP (IN in) (NP (NP (JJ VIP) (PRN (-LRB- -LRB-) (JJ -/-) (-RRB- -RRB-)) (NNS mice)) (PP (IN with) (NP (NNP Doc_18483878_1656_1676_Disease))))) (, ,) (NP (JJ inflammatory) (NNS mediators)) (VP (AUX are) (VP (VBN increased) (PP (IN above) (NP (NP (DT that)) (VP (VBN observed) (PP (IN in) (S (VP (VBG WT) (PP (IN with) (NP (NN CYP)))))))))))))) (. .)))
18483878	10	(S1 (S (NP (NP (DT This) (NN shift)) (PP (IN in) (NP (NN balance)))) (VP (MD may) (VP (VB contribute) (PP (TO to) (NP (NP (NP (VBN increased) (NN Doc_18483878_1801_1820_Disease)) (PP (IN in) (NP (NP (JJ VIP) (PRN (-LRB- -LRB-) (JJ -/-) (-RRB- -RRB-)) (NNS mice)) (PP (IN with) (NP (NNP Doc_18483878_1843_1863_Disease)))))) (CC and) (NP (NP (VBN altered) (JJ neurochemical) (NN expression)) (PP (IN in) (NP (NN micturition) (NNS pathways)))))))) (. .)))
1848636	0	(S1 (NP (NP (NP (JJ Doc_1848636_0_12_Chemical) (NN phenotype)) (CC and) (NP (DT the) (NNS pharmacokinetics)) (CC and) (NP (JJ beta-2) (NN receptor) (NNS pharmacodynamics))) (PP (IN of) (NP (NP (NNP Doc_1848636_88_98_Chemical)) (CC and) (NP (PRP$ its) (NNS enantiomers)))) (. .)))
1848636	1	(S1 (S (NP (NP (DT The) (NN metabolism)) (PP (IN of) (NP (DT the) (JJ cardioselective) (NN beta-blocker) (NN Doc_1848636_171_181_Chemical)))) (VP (AUX is) (PP (IN under) (NP (NP (JJ genetic) (NN control)) (PP (IN of) (NP (DT the) (JJ Doc_1848636_214_226_Chemical/Doc_1848636_227_236_Chemical) (NN type)))))) (. .)))
1848636	2	(S1 (S (NP (NP (DT The) (CD two) (JJ metabolic) (NNS phenotypes)) (, ,) (NP (NP (NP (JJ extensive)) (PRN (-LRB- -LRB-) (NP (NNP EM)) (-RRB- -RRB-))) (CC and) (NP (NP (JJ poor) (NNS metabolizers)) (PRN (-LRB- -LRB-) (NP (NNP PM)) (-RRB- -RRB-)))) (, ,)) (VP (VBP show) (NP (NP (JJ different) (JJ stereoselective) (NN metabolism)) (, ,) (VP (VBG resulting) (PP (IN in) (NP (NP (ADJP (RB apparently) (JJR higher)) (JJ beta-1) (JJ adrenoceptor) (JJ antagonistic) (NN potency)) (PP (IN of) (NP (NP (JJ racemic) (NNP Doc_1848636_442_452_Chemical)) (PP (IN in) (NP (NNP EMs)))))))))) (. .)))
1848636	3	(S1 (S (NP (PRP We)) (VP (VBD investigated) (SBAR (IN if) (S (NP (DT the) (NN latter)) (ADVP (RB also)) (VP (VBZ applies) (PP (TO to) (NP (DT the) (JJ beta-2) (NN adrenoceptor) (NN antagonism))) (PP (IN by) (NP (NNP Doc_1848636_545_555_Chemical))))))) (. .)))
1848636	4	(S1 (S (NP (NP (DT The) (NN drug) (NN effect)) (VP (VBN studied))) (VP (AUX was) (NP (NP (DT the) (NN antagonism)) (PP (IN by) (NP (NP (NNP Doc_1848636_603_613_Chemical)) (PP (IN of) (NP (NNP Doc_1848636_617_628_Chemical-induced) (NNP Doc_1848636_637_648_Disease))))))) (. .)))
1848636	5	(S1 (S (PP (IN By) (S (VP (VBG using) (NP (JJ pharmacokinetic) (JJ pharmacodynamic) (NN modeling))))) (NP (NP (DT the) (NNS pharmacodynamics)) (PP (IN of) (NP (NP (JJ racemic) (NNP Doc_1848636_732_742_Chemical)) (CC and) (NP (DT the) (JJ active) (NNP S-isomer)) (, ,)))) (VP (AUX were) (VP (VBN quantitated) (PP (IN in) (NP (NP (NNP EMs)) (CC and) (NP (NNP PMs)))) (PP (IN in) (NP (NP (NNS terms)) (PP (IN of) (NP (CD IC50) (NNS values))))) (, ,) (S (VP (VBG representing) (NP (NP (JJ Doc_1848636_838_848_Chemical) (NN plasma) (NNS concentrations)) (VP (VBG resulting) (PP (IN in) (NP (JJ half-maximum) (NN receptor) (NN occupancy))))))))) (. .)))
1848636	6	(S1 (S (S (NP (CD Six) (NNP EMs)) (VP (VBD received) (NP (NP (CD 0.5) (NN mg)) (PP (IN of) (NP (NNP Doc_1848636_944_955_Chemical) (NNP s.c.)))) (PP (IN on) (NP (CD two) (JJ different) (NNS occasions))))) (: :) (S (LST (LS 1)) (-RRB- -RRB-) (NP (NP (NP (QP (CD 1) (CD hr))) (PP (IN after) (NP (NP (NN administration)) (PP (IN of) (NP (DT a) (NN placebo)))))) (CC and) (NP (CD 2))) (-RRB- -RRB-) (NP (CD 1) (NN hr) (SBAR (IN after) (S (NP (NP (CD 150) (NNS mg)) (PP (IN of) (NP (NNP Doc_1848636_1059_1069_Chemical)))) (VP (VBD p.o.) (SBAR (S (NP (CD Five) (NNS PMs)) (VP (AUX were) (VP (VBN studied) (PP (VBG according) (PP (TO to) (NP (DT the) (JJ same) (NN protocol)))) (, ,) (PP (IN except) (PP (IN for) (NP (NP (DT a) (JJR higher) (NNP Doc_1848636_1149_1160_Chemical) (NN dose)) (PRN (-LRB- -LRB-) (NP (CD 0.75) (NN mg)) (-RRB- -RRB-)) (PP (IN on) (NP (NN day) (CD 2))))))))))))))) (. .)))
1848636	7	(S1 (S (NP (NP (NN Blood) (NNS samples)) (PP (IN for) (NP (NP (NP (DT the) (NN analysis)) (PP (IN of) (NP (NP (NN plasma) (NNP Doc_1848636_1227_1236_Chemical)) (, ,) (NP (NP (NNP Doc_1848636_1238_1249_Chemical)) (, ,) (NP (NP (NNP Doc_1848636_1251_1261_Chemical)) (PRN (-LRB- -LRB-) (NP (JJ racemic)) (, ,) (NP (NNP R-) (CC and) (NNP S-isomer)) (-RRB- -RRB-)))) (, ,)))) (CC and) (NP (JJ Doc_1848636_1294_1317_Chemical) (NNS concentrations))))) (VP (AUX were) (VP (VBN taken) (PP (IN at) (NP (JJ regular) (NN time) (NNS intervals))) (, ,) (PP (IN during) (NP (NP (CD 8) (NN hr)) (PP (IN after) (NP (NNP Doc_1848636_1389_1399_Chemical))))))) (. .)))
1848636	8	(S1 (S (PP (IN In) (NP (NNP PMs))) (, ,) (NP (NNP Doc_1848636_1409_1419_Chemical)) (VP (VBD increased) (NP (DT the) (JJ Doc_1848636_1434_1445_Chemical) (NN area)) (PP (IN under) (NP (NP (DT the) (NN plasma) (NN concentration)) (CC vs.) (NP (NP (NN time) (NN curve)) (PRN (-LRB- -LRB-) (NP (CD +67) (NN %)) (-RRB- -RRB-)))))) (. .)))
1848636	9	(S1 (S (NP (NP (JJR Higher) (NNP Doc_1848636_1512_1522_Chemical/Doc_1848636_1523_1546_Chemical) (NNS ratios)) (PP (IN in) (NP (NNS PMs)))) (VP (AUX were) (ADJP (JJ predictive)) (PP (IN for) (NP (NP (JJR higher) (NN R-/S-isomer) (NNS ratios)) (PP (IN of) (NP (JJ unchanged) (NN drug)))))) (. .)))
1848636	10	(S1 (S (NP (EX There)) (VP (AUX was) (NP (NP (DT a) (NN difference)) (PP (IN in) (NP (JJ Doc_1848636_1652_1662_Chemical) (NN potency))) (PP (IN with) (NP (JJR higher) (JJ racemic) (NNP Doc_1848636_1691_1701_Chemical) (CD IC50) (NNS values))) (PP (IN in) (NP (NP (NNS PMs)) (PRN (-LRB- -LRB-) (NP (NP (CD 72) (NNS +/-)) (NP (CD 7) (NN ng.ml-1))) (-RRB- -RRB-)))) (PP (IN than) (NP (NP (NNP EMs)) (PRN (-LRB- -LRB-) (NP (NP (CD 42) (NNS +/-)) (NP (CD 8) (NN ng.ml-1))) (, ,) (NP (NNP P) (QP (JJR less) (IN than) (CD .001))) (-RRB- -RRB-)))) (. .)) (PRN (-LRB- -LRB-) (NP (NP (JJ ABSTRACT)) (VP (VBN TRUNCATED) (PP (IN AT) (NP (CD 250) (NNS WORDS))))) (-RRB- -RRB-)))))
18513945	0	(S1 (NP (NP (NP (DT The) (NNS hemodynamics)) (PP (IN of) (NP (NP (NNP Doc_18513945_20_28_Chemical)) (CC and) (NP (JJ other) (JJ vasoactive) (NNS agents)))) (PP (IN during) (NP (NP (JJ neuraxial) (NNS anesthesia)) (PP (IN for) (NP (JJ cesarean) (NN delivery)))))) (: :) (NP (NP (NNS findings)) (PP (IN in) (NP (CD six) (NNS cases)))) (. .)))
18513945	1	(S1 (S (NP (NN Doc_18513945_131_139_Chemical)) (VP (AUX is) (NP (NP (DT a) (ADJP (RB commonly) (VBN used)) (NN uterotonic)) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (VB cause) (NP (ADJP (ADJP (JJ significant)) (CC and) (ADJP (RB even) (JJ fatal))) (NN Doc_18513945_212_223_Disease)) (, ,) (SBAR (ADVP (RB particularly)) (WHADVP (WRB when)) (S (VP (VBN given) (PP (IN as) (NP (DT a) (NN bolus)))))))))))) (. .)))
18513945	2	(S1 (S (NP (DT The) (JJ resulting) (NN Doc_18513945_275_286_Disease)) (VP (MD can) (VP (AUX be) (VP (VBN produced) (PP (IN by) (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (NP (JJ systemic) (JJ vascular) (NN resistance)) (CC or) (NP (JJ cardiac) (NN output)))))) (PP (IN through) (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (JJ venous) (NN return)))))))) (. .)))
18513945	3	(S1 (S (NP (NP (NNS Parturients)) (PP (IN with) (NP (NP (JJ normal) (NN volume) (NN status)) (, ,) (NP (NN heart) (NNS valves)) (CC and) (NP (JJ pulmonary) (NN vasculature))))) (ADVP (RBS most) (RB often)) (VP (VB respond) (PP (TO to) (NP (DT this) (NN Doc_18513945_509_520_Disease))) (PP (IN with) (NP (NP (DT a) (JJ compensatory) (NN increase)) (PP (IN in) (NP (NP (NN heart) (NN rate)) (CC and) (NP (NN Doc_18513945_568_574_Disease) (NN volume))))))) (. .)))
18513945	4	(S1 (S (NP (NP (JJ Doc_18513945_583_591_Chemical-induced) (NN Doc_18513945_600_611_Disease)) (PP (IN at) (NP (JJ cesarean) (NN delivery)))) (VP (MD may) (VP (AUX be) (VP (ADVP (RB incorrectly)) (VBN attributed) (PP (TO to) (NP (NNP Doc_18513945_666_676_Disease)))))) (. .)))
18513945	5	(S1 (S (NP (NP (NN Pulse) (NN power) (NN analysis)) (PRN (-LRB- -LRB-) (VP (ADVP (RB also)) (VBN called) (S (`` ``) (NP (NN pulse) (NN contour) (NN analysis)) ('' ''))) (-RRB- -RRB-)) (PP (IN of) (NP (DT an) (JJ arterial) (NN pressure) (NN wave) (NN form)))) (VP (VBZ allows) (NP (NP (JJ continuous) (NN evaluation)) (PP (IN of) (NP (NP (JJ systemic) (JJ vascular) (NN resistance)) (CC and) (NP (JJ cardiac) (NN output))))) (PP (IN in) (NP (JJ real) (NN time))) (, ,) (S (ADVP (RB thereby)) (VP (VBG elucidating) (NP (NP (DT the) (JJ causative) (NNS factors)) (PP (IN behind) (NP (NP (NNS changes)) (PP (IN in) (NP (NN blood) (NN pressure))))))))) (. .)))
18513945	6	(S1 (S (NP (NN Pulse) (NN power) (NN analysis)) (VP (AUX was) (VP (VBN conducted) (PP (IN in) (NP (NP (CD six) (NNS cases)) (PP (IN of) (NP (JJ cesarean) (NN delivery))) (VP (VBN performed) (PP (IN under) (NP (JJ neuraxial) (NN anesthesia)))))))) (. .)))
18513945	7	(S1 (S (NP (NP (NN Doc_18513945_1049_1060_Disease)) (PP (IN in) (NP (NP (NN response)) (PP (TO to) (NP (NNP Doc_18513945_1076_1084_Chemical)))))) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (JJ systemic) (NN vascular) (NN resistance)))) (CC and) (NP (NP (DT a) (JJ compensatory) (NN increase)) (PP (IN in) (NP (NP (NN Doc_18513945_1179_1185_Disease) (NN volume)) (, ,) (NP (NN heart) (NN rate)) (CC and) (NP (JJ cardiac) (NN output))))))))) (. .)))
18513945	8	(S1 (S (NP (NN Pulse) (NN power) (NN analysis)) (VP (MD may) (VP (AUX be) (ADJP (JJ helpful) (PP (IN in) (S (VP (VP (VBG determining) (NP (DT the) (NN etiology)) (PP (IN of))) (CC and) (VP (VBG treating) (NP (NNP Doc_18513945_1305_1316_Disease)) (PP (IN during) (NP (NP (JJ cesarean) (NN delivery)) (PP (IN under) (NP (JJ neuraxial) (NNS anesthesia)))))))))))) (. .)))
18541230	0	(S1 (NP (NP (JJ Protective) (NNS effects)) (PP (IN of) (NP (NN antithrombin))) (PP (IN on) (NP (NP (NNP Doc_18541230_38_63_Chemical) (NNP Doc_18541230_64_73_Disease)) (PP (IN in) (NP (NNS rats))))) (. .)))
18541230	1	(S1 (S (NP (PRP We)) (VP (VBD investigated) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (FW antithrombin)) (, ,) (NP (NP (DT a) (NN plasma) (NN inhibitor)) (PP (IN of) (NP (NN coagulation) (NNS factors)))) (, ,))) (PP (IN in) (NP (NP (NNS rats)) (PP (IN with) (NP (NP (NNP Doc_18541230_184_209_Chemical-induced) (NNP Doc_18541230_218_227_Disease)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX is) (NP (NP (DT an) (JJ experimental) (NN model)) (PP (IN of) (NP (JJ human) (NNP Doc_18541230_269_287_Disease))))))))))))) (. .)))
18541230	2	(S1 (S (NP (NP (NN Antithrombin)) (PRN (-LRB- -LRB-) (NP (QP (CD 50) (CC or) (CD 500)) (NNS IU/kg/i.v.)) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN administered) (PP (TO to) (NP (NNS rats))) (ADVP (RB once) (NP (DT a) (NN day))) (PP (IN for) (NP (CD 10) (NNS days))) (PP (ADVP (RB immediately)) (IN after) (NP (NP (DT the) (NN injection)) (PP (IN of) (NP (NP (NNP Doc_18541230_408_433_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 50) (NN mg/kg/i.v.)) (-RRB- -RRB-)))))))) (. .)))
18541230	3	(S1 (S (NP (NP (NN Treatment)) (PP (IN with) (NP (NN antithrombin)))) (VP (VBD attenuated) (NP (DT the) (JJ Doc_18541230_494_519_Chemical-induced) (NNP Doc_18541230_528_555_Disease))) (. .)))
18541230	4	(S1 (S (NP (NP (JJ Doc_18541230_557_582_Chemical-induced) (NNP Doc_18541230_591_608_Disease)) (CC and) (NP (NNP Doc_18541230_613_627_Disease))) (VP (AUX were) (ADVP (RB also)) (VP (VBN suppressed))) (. .)))
18541230	5	(S1 (S (NP (JJ Histopathological) (NN examination)) (VP (VBD revealed) (NP (NP (JJ severe) (NN Doc_18541230_696_708_Disease)) (PP (JJ such) (IN as) (NP (NP (NP (NN proteinaceous) (VBZ casts)) (PP (IN in) (NP (NNS tubuli)))) (CC and) (NP (NP (JJ tubular) (NN expansion)) (PP (IN in) (NP (NP (DT the) (NN kidney)) (PP (IN of) (NP (NN control) (NNS rats))))))))) (, ,) (SBAR (IN while) (S (NP (NP (DT an) (NN improvement)) (PP (IN of) (NP (DT the) (NN damage)))) (VP (AUX was) (VP (VBN seen) (PP (IN in) (NP (JJ antithrombin-treated) (NNS rats)))))))) (. .)))
18541230	6	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (JJ antithrombin) (NN treatment)) (ADVP (RB markedly)) (VP (VBD suppressed) (NP (NP (JJ Doc_18541230_930_955_Chemical-induced) (NN apoptosis)) (PP (IN of) (NP (JJ renal) (JJ tubular) (NN epithelial) (NNS cells))))) (. .)))
18541230	7	(S1 (S (ADVP (RB Furthermore)) (, ,) (NP (NP (JJ Doc_18541230_1022_1047_Chemical-induced) (NNS increases)) (PP (IN in) (NP (JJ renal) (NN cytokine) (NN content)))) (VP (AUX were) (ADVP (RB also)) (VP (VBN decreased))) (. .)))
18541230	8	(S1 (S (NP (DT These) (NNS findings)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NN thrombin)) (VP (VBZ plays) (NP (DT an) (JJ important) (NN role)) (PP (IN in) (NP (NP (DT the) (NN pathogenesis)) (PP (IN of) (NP (JJ Doc_18541230_1197_1222_Chemical-induced) (NN Doc_18541230_1231_1249_Disease))))))))) (. .)))
18541230	9	(S1 (S (NP (NP (NN Treatment)) (PP (IN with) (NP (NN antithrombin)))) (VP (MD may) (VP (AUX be) (ADJP (RB clinically) (JJ effective)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_18541230_1324_1342_Disease))))))) (. .)))
18589141	0	(S1 (NP (NP (JJ Doc_18589141_0_7_Chemical-induced) (NN thrombocytopenia)) (PP (IN after) (NP (NN liver) (NN transplantation))) (. .)))
18589141	1	(S1 (S (NP (NP (NP (NNP Doc_18589141_74_103_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_18589141_105_108_Chemical)) (-RRB- -RRB-))) (CC or) (NP (NP (JJ low-molecular) (NN weight) (NN heparin)) (PRN (-LRB- -LRB-) (NP (NNP LMWH)) (-RRB- -RRB-)))) (VP (AUX is) (VP (VBN used) (PP (IN in) (NP (JJ anticoagulant) (NNS protocols))) (PP (IN at) (NP (JJ several) (NNS institutions))) (S (VP (TO to) (VP (VB prevent) (NP (NNP Doc_18589141_219_229_Disease)) (PP (IN after) (NP (NN liver) (NN transplantation)))))))) (. .)))
18589141	2	(S1 (S (NP (NP (JJ Doc_18589141_259_266_Chemical-induced) (NN thrombocytopenia)) (PRN (-LRB- -LRB-) (NP (NNP Doc_18589141_293_296_Disease)) (-RRB- -RRB-))) (VP (AUX is) (NP (NP (DT an) (JJ adverse) (JJ immune-mediated) (NN reaction)) (PP (TO to) (NP (NNP Doc_18589141_340_347_Chemical))) (, ,) (VP (VBG resulting) (PP (IN in) (NP (NP (JJ platelet) (NN count) (NNS decreases)) (PP (IN of) (NP (QP (JJR more) (IN than) (CD 50)) (NN %)))))))) (. .)))
18589141	3	(S1 (S (NP (NP (DT The) (NNS frequencies)) (PP (IN of) (NP (NNP Doc_18589141_424_427_Disease))) (PP (IN after) (NP (NP (NP (NP (NN liver) (NN transplantation)) (CC and) (NP (NN platelet) (NN factor))) (JJ 4/heparin-reactive) (NN antibody) (PRN (-LRB- -LRB-) (NNP Doc_18589141_505_508_Disease) (NN antibody) (-RRB- -RRB-)) (NN positivity)) (PP (IN in) (NP (NN liver) (NN transplantation) (NNS patients)))))) (, ,) (ADVP (RB however)) (, ,) (VP (AUX are) (ADJP (JJ unknown))) (. .)))
18589141	4	(S1 (NP (NP (NNS PATIENTS) (CC AND) (NNS METHODS)) (: :) (S (NP (NP (DT The) (CD 32) (NNS men)) (CC and) (NP (CD 20) (NNS women))) (VP (VBD underwent) (S (VP (VBG living) (NP (NN donor) (NN liver) (NN transplantation)))))) (. .)))
18589141	5	(S1 (S (NP (PRP We)) (VP (VBD started) (NP (NP (NNP LMWH)) (PRN (-LRB- -LRB-) (NP (CD 25) (NN IU/kg/h)) (-RRB- -RRB-))) (PP (IN on) (NP (NP (JJ postoperative) (NN day)) (PRN (-LRB- -LRB-) (NP (NN POD)) (-RRB- -RRB-)))) (NP (CD 1)) (, ,) (S (VP (VBG switching) (PP (TO to) (NP (NP (NNP Doc_18589141_751_754_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 5000) (NN U/d)) (-RRB- -RRB-)))) (PP (IN on) (NP (NN POD) (QP (CD 2) (CC or) (CD 3))))))) (. .)))
18589141	6	(S1 (S (NP (NP (DT The) (NN dose)) (PP (IN of) (NP (NNP Doc_18589141_793_796_Chemical)))) (VP (AUX was) (VP (VBN changed) (PP (VBG according) (PP (TO to) (NP (DT the) (VBN activated) (NN clotting) (NN time) (NN level)))))) (. .)))
18589141	7	(S1 (S (NP (NN Doc_18589141_857_860_Disease) (NN antibody) (NNS levels)) (VP (AUX were) (VP (VBN measured) (NP (NP (DT the) (NN day)) (PP (PP (IN before) (NP (NN surgery))) (CC and) (PP (IN on) (NP (NN POD) (CD 7) (CC and) (CD 14))))))) (. .)))
18589141	8	(S1 (S (NP (JJ Platelet) (NN count)) (VP (AUX was) (VP (VBN measured) (ADVP (RB daily)) (PP (IN for) (NP (CD 3) (NNS weeks))))) (. .)))
18589141	9	(S1 (S (S (NP (DT The) (JJ average) (NN platelet)) (VP (VBZ counts) (ADVP (RB preoperatively)))) (, ,) (CC and) (S (PP (IN on) (NP (NN POD) (CD 7))) (, ,) (NP (NP (CD 14)) (, ,) (CC and) (NP (CD 21))) (VP (AUX were) (NP (NP (NP (CD 65)) (, ,) (NP (CD 88)) (, ,) (NP (CD 149)) (, ,) (CC and) (NP (CD 169))) (NNP x) (CD 10) (-LRB- -LRB-) (CD 9) (-RRB- -RRB-) (NNS /L)) (, ,) (ADVP (RB respectively)))) (. .)))
18589141	10	(S1 (S (NP (CD Two) (NNS patients)) (VP (VBD developed) (NP (JJ hepatic) (NN artery) (NN Doc_18589141_1149_1159_Disease)) (PP (IN on) (NP (NN POD) (CD 11) (CC and) (CD 19))) (, ,) (ADVP (RB respectively)) (, ,) (SBAR (IN although) (S (S (NP (PRP they)) (VP (AUX were) (ADJP (NNP Doc_18589141_1211_1214_Disease) (JJ antibody-negative)))) (CC and) (S (NP (PRP$ their) (JJ platelet) (NNS counts)) (VP (AUX were) (ADJP (JJ stable))))))) (. .)))
18589141	11	(S1 (S (S (PP (IN In) (NP (CD 2) (JJ other) (NNS patients))) (, ,) (NP (DT the) (NN platelet) (NN count)) (VP (VBD decreased) (ADVP (RB suddenly)) (PP (IN from) (NP (CD 107))))) (NP (NP (NNP x) (CD 10)) (PRN (-LRB- -LRB-) (NP (CD 9)) (-RRB- -RRB-))) (VP (VBD /L) (PP (IN on) (NP (NN POD))) (SBAR (S (NP (NP (QP (CD 4) (TO to) (CD 65)) (SYM x) (CD 10)) (PRN (-LRB- -LRB-) (NP (CD 9)) (-RRB- -RRB-))) (VP (VBZ /L) (PP (PP (IN on) (NP (NN POD) (CD 6))) (CC and) (PP (IN from) (NP (NP (CD 76) (NNP x) (CD 10)) (PRN (-LRB- -LRB-) (NP (CD 9)) (-RRB- -RRB-)) (VP (VBN /L) (PP (IN on) (NP (NP (NN POD)) (SBAR (S (NP (NP (QP (CD 7) (TO to) (CD 33)) (SYM x) (CD 10)) (PRN (-LRB- -LRB-) (NP (CD 9)) (-RRB- -RRB-))) (VP (VBD /L) (PP (IN on) (NP (NN POD) (CD 9))) (, ,) (ADVP (RB respectively))))))))))))))) (. .)))
18589141	12	(S1 (S (NP (DT The) (JJ Doc_18589141_1459_1466_Chemical-induced) (NN Doc_18589141_1475_1495_Disease) (NN test)) (VP (AUX was) (ADJP (JJ negative)) (PP (IN in) (NP (DT these) (NNS patients)))) (. .)))
18589141	13	(S1 (S (NP (NP (DT The) (NN percentage)) (PP (IN of) (NP (JJ Doc_18589141_1551_1554_Disease) (JJ antibody-positive) (NNS patients)))) (VP (AUX was) (NP (NP (NP (CD 0.5) (NN %)) (ADVP (RB preoperatively))) (, ,) (NP (NP (CD 5.6) (NN %)) (PP (IN on) (NP (NN POD) (CD 7)))) (, ,) (CC and) (NP (NP (CD 5.6) (NN %)) (PP (IN on) (NP (NN POD) (CD 14)))))) (. .)))
18589141	14	(S1 (S (NP (NP (NN None)) (PP (IN of) (NP (DT the) (NNS subjects/patients)))) (VP (VBD developed) (NP (JJ UFH-related) (NN Doc_18589141_1694_1697_Disease))) (. .)))
18589141	15	(S1 (S (PP (IN In) (NP (PRP$ our) (NN series))) (, ,) (NP (NP (DT the) (NN occurrence)) (PP (IN of) (NP (NNP Doc_18589141_1745_1748_Disease))) (PP (IN after) (NP (NN liver) (NN transplantation)))) (VP (AUX was) (ADJP (JJ uncommon))) (. .)))
18627295	0	(S1 (S (NP (NP (JJ Doc_18627295_0_11_Chemical) (JJ Doc_18627295_12_26_Disease-induced) (NN Doc_18627295_35_47_Disease)) (CC and) (NP (NN apoptosis))) (VP (AUX are) (VP (VBN attenuated) (PP (IN by) (NP (NP (NN gene) (NN deletion)) (PP (IN of) (NP (DT the) (JJ kinin) (JJ B1) (NN receptor))))))) (. .)))
18627295	1	(S1 (S (NP (NP (JJ Clinical) (NN use)) (PP (IN of) (NP (NP (DT the) (NNP Doc_18627295_140_153_Chemical) (NNP Doc_18627295_154_165_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_18627295_167_170_Chemical)) (-RRB- -RRB-))))) (VP (AUX is) (VP (VBN limited) (PP (IN by) (NP (NP (PRP$ its) (JJ Doc_18627295_190_201_Disease) (NNS effects)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX are) (VP (VBN attributed) (PP (TO to) (NP (NP (DT the) (NN induction)) (PP (IN of) (NP (NNS apoptosis))))))))))))) (. .)))
18627295	2	(S1 (S (S (VP (TO To) (VP (VB elucidate) (NP (NP (DT the) (JJ possible) (NN role)) (PP (IN of) (NP (NP (DT the) (JJ kinin) (JJ B1) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NNP B1R)) (-RRB- -RRB-))))) (PP (IN during) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_18627295_351_354_Chemical) (NNP Doc_18627295_355_369_Disease)))))))) (, ,) (NP (PRP we)) (VP (VBD studied) (NP (NP (NNP B1R) (NN knockout) (NNS mice)) (PRN (-LRB- -LRB-) (NP (NP (NNP B1R)) (PRN (-LRB- -LRB-) (NP (NN -/-)) (-RRB- -RRB-))) (-RRB- -RRB-))) (PP (IN by) (S (VP (VBG investigating) (NP (JJ cardiac) (NN Doc_18627295_436_448_Disease) (CC and) (NN apoptosis)) (PP (IN after) (NP (NP (NN induction)) (PP (IN of) (NP (JJ Doc_18627295_482_485_Chemical-induced) (NNP Doc_18627295_494_508_Disease))))))))) (. .)))
18627295	3	(S1 (S (NP (JJ Doc_18627295_510_513_Chemical) (NN control) (NNS mice)) (VP (VBD showed) (NP (NP (NN Doc_18627295_534_553_Disease)) (VP (VBN measured) (PP (IN by) (NP (NP (JJ pressure-volume) (NNS loops)) (PP (IN in) (NP (NN vivo)))))))) (. .)))
18627295	4	(S1 (S (NP (DT This)) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (DT a) (VBN reduced) (NN activation) (NN state)) (PP (IN of) (NP (NP (NNP AKT)) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (NP (DT an) (VBN increased) (NN bax/bcl2) (NN ratio)) (PP (IN in) (NP (JJ Western) (NNS blots)))))))) (, ,) (S (VP (VBG indicating) (NP (NNP Doc_18627295_725_742_Disease)))))) (. .)))
18627295	5	(S1 (S (ADVP (RB Furthermore)) (, ,) (NP (NP (NN mRNA) (NNS levels)) (PP (IN of) (NP (DT the) (NN proinflammatory) (NN cytokine) (NN interleukin) (CD 6)))) (VP (AUX were) (VP (VBN increased) (PP (IN in) (NP (DT the) (JJ cardiac) (NN tissue))))) (. .)))
18627295	6	(S1 (S (PP (IN In) (NP (NNP DOX) (NNP B1R) (PRN (-LRB- -LRB-) (JJ -/-) (-RRB- -RRB-)) (NNS mice))) (, ,) (NP (NNP Doc_18627295_875_894_Disease)) (VP (AUX was) (VP (VBN improved) (PP (VBN compared) (PP (TO to) (NP (NP (JJ Doc_18627295_920_923_Chemical) (NN control) (NNS mice)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (NP (NP (NN normalization)) (PP (IN of) (NP (DT the) (JJ bax/bcl-2) (NN ratio)))) (CC and) (NP (NN interleukin) (CD 6))) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (JJ AKT) (NN activation) (NN state))))))))))))) (. .)))
18627295	7	(S1 (S (NP (DT These) (NNS findings)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NNP B1R)) (VP (AUX is) (ADJP (JJ detrimental)) (PP (IN in) (NP (NP (NNP Doc_18627295_1103_1106_Chemical) (NNP Doc_18627295_1107_1121_Disease)) (SBAR (WHPP (IN in) (WHNP (WDT that))) (S (NP (PRP it)) (VP (VBZ mediates) (NP (DT the) (JJ inflammatory) (NN response) (CC and) (NN apoptosis))))))))))) (. .)))
18627295	8	(S1 (S (NP (DT These) (NNS insights)) (VP (MD might) (VP (AUX have) (NP (NP (JJ useful) (NNS implications)) (PP (IN for) (NP (NP (JJ future) (NNS studies)) (VP (VBG utilizing) (NP (NNP B1R) (NNS antagonists)) (PP (IN for) (NP (NP (NN treatment)) (PP (IN of) (NP (JJ human) (NNP Doc_18627295_1297_1300_Chemical) (NNP Doc_18627295_1301_1315_Disease))))))))))) (. .)))
18657397	0	(S1 (NP (NP (JJ Detailed) (JJ spectral) (NN profile) (NN analysis)) (PP (IN of) (NP (NP (NNP Doc_18657397_38_48_Chemical-induced) (NNP Doc_18657397_57_78_Disease)) (PP (IN in) (NP (JJ anesthetized) (NNS rats))))) (. .)))
18657397	1	(S1 (S (NP (JJ Doc_18657397_101_111_Chemical) (NN model)) (VP (AUX is) (NP (NP (DT a) (ADJP (RB widely) (VBN used)) (JJ experimental) (NN model)) (PP (IN for) (NP (JJ Doc_18657397_158_166_Disease) (NN research))))) (. .)))
18657397	2	(S1 (S (PP (IN In) (NP (DT the) (JJ present) (NN study))) (NP (PRP we)) (VP (VBD aimed) (S (VP (TO to) (VP (VB portray) (NP (NP (DT a) (JJ detailed) (JJ spectral) (NN analysis)) (PP (IN of) (NP (NNP Doc_18657397_250_260_Chemical-induced) (NNP Doc_18657397_269_290_Disease)))) (PP (IN in) (NP (NP (NN comparison)) (PP (IN with) (NP (NP (JJ basal) (NN brain) (NN activity)) (PP (IN in) (NP (JJ anesthetized) (JJ Wistar) (NNS rats))))))))))) (. .)))
18657397	3	(S1 (S (NP (JJ Male) (JJ Wistar) (NNS rats)) (VP (AUX were) (ADJP (ADJP (JJ anesthetized) (PP (IN with) (NP (NNP i.p.) (NNP Doc_18657397_405_413_Chemical)))) (CC and) (ADJP (JJ connected) (PP (TO to) (NP (DT an) (JJ electrocorticogram) (NN setup)))))) (. .)))
18657397	4	(S1 (S (PP (IN After) (NP (NP (DT a) (JJ short) (NN period)) (PP (IN of) (NP (JJ basal) (NN activity) (VBG recording))))) (, ,) (NP (NNP Doc_18657397_510_519_Disease) (NN focus)) (VP (AUX was) (VP (VBN induced) (PP (IN by) (S (VP (VBG injecting) (NP (CD 400IU/2) (NN microl) (JJ Doc_18657397_566_578_Chemical) (NN potassium)) (PP (IN into) (NP (DT the) (JJ left) (JJ lateral) (NN ventricle))) (SBAR (IN while) (S (NP (DT the) (JJ cortical) (NN activity)) (VP (AUX was) (ADVP (RB continuously)) (VP (VBN recorded)))))))))) (. .)))
18657397	5	(S1 (S (NP (NP (JJ Basal) (NN activity)) (, ,) (NP (NN latent) (NN period)) (CC and) (NP (DT the) (JJ Doc_18657397_714_724_Chemical-induced) (NN Doc_18657397_733_754_Disease) (NNS periods))) (VP (AUX were) (ADVP (RB then)) (VP (VBN analyzed) (S (VP (VBG using) (NP (NP (DT both) (JJ conventional) (NNS methods)) (CC and) (NP (JJ spectral) (NN analysis))))))) (. .)))
18657397	6	(S1 (S (NP (JJ Spectral) (NNS analyses)) (VP (AUX were) (VP (VBN conducted) (PP (IN by) (S (VP (VBG dividing) (NP (DT the) (JJ whole) (NN spectrum)) (PP (IN into) (NP (NP (JJ different) (NN frequency) (NNS bands)) (VP (VBG including) (NP (NP (NP (NN delta)) (, ,) (NP (NN theta)) (PRN (-LRB- -LRB-) (ADJP (JJ slow) (CC and) (JJ fast)) (-RRB- -RRB-)) (, ,) (NP (NN alpha-sigma)) (, ,) (NP (NP (NN beta)) (PRN (-LRB- -LRB-) (NP (CD 1) (CC and) (CD 2)) (-RRB- -RRB-))) (CC and) (NP (NP (NN gamma)) (PRN (-LRB- -LRB-) (NP (CD 1) (CC and) (CD 2)) (-RRB- -RRB-)))) (NNS bands)))))))))) (. .)))
18657397	7	(S1 (S (NP (PRP$ Our) (NNS results)) (VP (VBP show) (SBAR (IN that) (S (S (NP (DT the) (JJS most) (JJ affected) (NN frequency) (NNS bands)) (VP (AUX were) (NP (NN delta) (, ,) (NN theta) (, ,) (NN beta-2) (CC and) (NN gamma-2) (NNS bands)) (PP (IN during) (NP (DT the) (NNP Doc_18657397_1138_1159_Disease))))) (CC and) (S (NP (EX there)) (VP (AUX were) (NP (NP (JJ marked) (NNS differences)) (PP (IN in) (NP (NP (NNS terms)) (PP (IN of) (NP (NP (JJ spectral) (NNS densities)) (PP (IN between) (NP (NP (CD three) (VBN investigated) (NNS episodes)) (PRN (-LRB- -LRB-) (NP (NP (JJ basal) (NN activity)) (, ,) (NP (NN latent) (NN period)) (CC and) (NP (NNP Doc_18657397_1296_1317_Disease))) (-RRB- -RRB-)))))))))))))) (. .)))
18657397	8	(S1 (S (NP (PRP$ Our) (NNS results)) (VP (MD may) (VP (VB help) (S (VP (TO to) (VP (VB analyze) (NP (NP (JJ novel) (NNS data)) (VP (VBN obtained) (S (VP (VBG using) (SBAR (S (NP (NP (NP (JJ similar) (JJ experimental) (NNS models)) (CC and) (NP (DT the) (JJ simple) (NN analysis) (NN method))) (VP (VBD described) (ADVP (RB here)))) (VP (MD can) (VP (AUX be) (VP (VBN used) (PP (IN in) (NP (JJ similar) (NNS studies))) (S (VP (TO to) (VP (VB investigate) (NP (NP (DT the) (JJ basic) (JJ neuronal) (NN mechanism)) (PP (IN of) (NP (NP (DT this)) (CC or) (NP (NP (JJ other) (NNS types)) (PP (IN of) (NP (JJ experimental) (NN Doc_18657397_1566_1576_Disease)))))))))))))))))))))))) (. .)))
18674790	0	(S1 (S (NP (JJ High) (JJ fat) (JJ diet-fed) (NN Doc_18674790_18_23_Disease) (NNS rats)) (VP (AUX are) (ADJP (RB highly) (JJ sensitive) (PP (TO to) (NP (NNP Doc_18674790_53_64_Chemical-induced) (NNP Doc_18674790_73_87_Disease))))) (. .)))
18674790	1	(S1 (S (ADVP (RB Often)) (, ,) (NP (NP (NN chemotherapy)) (PP (IN by) (NP (NP (NNP Doc_18674790_112_123_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_18674790_125_135_Chemical)) (-RRB- -RRB-))))) (VP (AUX is) (VP (VBN limited) (PP (JJ due) (TO to) (NP (NP (NN life)) (VP (VBG threatening) (NP (NNP Doc_18674790_172_186_Disease)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN during) (CC and) (NP (NN posttherapy)))))))))) (. .)))
18674790	2	(S1 (S (ADVP (RB Recently)) (, ,) (NP (PRP we)) (VP (AUX have) (VP (VBN shown) (SBAR (IN that) (S (NP (JJ moderate) (NN diet) (NN restriction)) (ADVP (RB remarkably)) (VP (VBZ protects) (PP (IN against) (NP (NNP Doc_18674790_306_317_Chemical-induced) (NNP Doc_18674790_326_340_Disease)))))))) (. .)))
18674790	3	(S1 (S (NP (DT This) (NN cardioprotection)) (VP (AUX is) (VP (VBN accompanied) (PP (IN by) (NP (NP (NP (VBN decreased) (JJ cardiac) (NN oxidative) (NN stress)) (CC and) (NP (ADJP (JJ Doc_18674790_421_434_Chemical) (CC and) (JJ increased)) (JJ cardiac) (JJ Doc_18674790_457_467_Chemical) (NN oxidation))) (, ,) (NP (JJ Doc_18674790_479_482_Chemical) (NN synthesis)) (, ,) (CC and) (NP (JJ upregulated) (JJ JAK/STAT3) (NN pathway)))))) (. .)))
18674790	4	(S1 (S (PP (IN In) (NP (DT the) (JJ current) (NN study))) (, ,) (NP (PRP we)) (VP (VBD investigated) (SBAR (IN whether) (S (NP (NP (DT a) (JJ physiological) (NN intervention)) (PP (IN by) (S (VP (VBG feeding) (NP (NP (ADJP (CD 40) (NN %)) (JJ high) (JJ fat) (NN diet)) (PRN (-LRB- -LRB-) (NP (NNP HFD)) (-RRB- -RRB-)))))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ induces) (NP (NNP Doc_18674790_654_661_Disease)) (PP (IN in) (NP (NP (JJ male) (JJ Sprague-Dawley) (NNS rats)) (PRN (-LRB- -LRB-) (NP (CD 250-275) (NNP g)) (-RRB- -RRB-))))))) (, ,)) (VP (VBZ sensitizes) (PP (TO to) (NP (NNP Doc_18674790_717_728_Chemical-induced) (NNP Doc_18674790_737_751_Disease))))))) (. .)))
18674790	5	(S1 (S (NP (NP (DT A) (JJ LD) (PRN (-LRB- -LRB-) (NP (CD 10)) (-RRB- -RRB-)) (NN dose)) (PRN (-LRB- -LRB-) (NP (QP (CD 8) (CD mg)) (NN Doc_18674790_773_784_Chemical/kg)) (, ,) (NP (NN ip)) (-RRB- -RRB-)) (VP (VBN administered) (PP (IN on) (NP (NP (NN day) (CD 43)) (PP (IN of) (NP (DT the) (NNP HFD) (NN feeding) (NN regimen))))))) (VP (VBD led) (PP (TO to) (NP (NP (JJR higher) (NN Doc_18674790_857_871_Disease)) (, ,) (NP (NNP Doc_18674790_873_892_Disease)) (, ,) (NP (NN lipid) (NN peroxidation)) (, ,) (CC and) (NP (NP (ADJP (CD 80) (NN %)) (NN mortality)) (PP (IN in) (NP (NP (DT the) (NNP Doc_18674790_939_944_Disease) (PRN (-LRB- -LRB-) (NNP Doc_18674790_946_948_Disease) (-RRB- -RRB-)) (NNS rats)) (PP (IN in) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (DT any) (JJ significant) (NN Doc_18674790_989_1014_Disease))))))))))) (. .)))
18674790	6	(S1 (S (NP (JJ Doc_18674790_1016_1027_Chemical) (NN toxicokinetics) (NNS studies)) (VP (VBD revealed) (NP (NP (DT no) (NN change)) (PP (IN in) (NP (NP (NN accumulation)) (PP (IN of) (NP (NP (NNP Doc_18674790_1089_1100_Chemical)) (CC and) (NP (NP (NNP Doc_18674790_1105_1118_Chemical)) (PRN (-LRB- -LRB-) (NP (JJ toxic) (NN metabolite)) (-RRB- -RRB-))))))) (PP (IN in) (NP (DT the) (JJ normal) (JJ diet-fed) (PRN (-LRB- -LRB-) (CD ND) (-RRB- -RRB-)) (CC and) (NNP Doc_18674790_1170_1172_Disease) (NNS hearts))))) (. .)))
18674790	7	(S1 (S (NP (JJ Mechanistic) (NNS studies)) (VP (VBD revealed) (SBAR (IN that) (S (NP (NNP Doc_18674790_1215_1217_Disease) (NNS rats)) (VP (AUX are) (VP (VBN sensitized) (S (ADJP (JJ due) (PP (TO to) (NP (NP (: :) (LST (-LRB- -LRB-) (LS 1) (-RRB- -RRB-)) (NP (JJR higher) (JJ oxyradical) (NN stress)) (VP (VBG leading) (PP (TO to) (NP (NN upregulation)) (PP (IN of) (NP (NP (VBG uncoupling) (NNS proteins)) (SBAR (S (NP (NP (CD 2) (CC and) (CD 3) (, ,) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-)) (NN downregulation)) (PP (IN of) (NP (JJ cardiac) (NN peroxisome) (NNS proliferators))) (VP (VBN activated) (NP (NN receptor-alpha)) (PRN (, ,) (-LRB- -LRB-) (NP (CD 3)) (-RRB- -RRB-)))) (VP (VBD decreased) (SBAR (S (NP (NP (NN plasma) (NN adiponectin) (NNS levels)) (PRN (, ,) (-LRB- -LRB-) (NP (CD 4)) (-RRB- -RRB-))) (VP (VBD decreased) (NP (JJ cardiac) (JJ fatty-acid) (NN oxidation))))))))))))) (-LRB- -LRB-) (NP (NP (QP (CD 666.9+/-14.0) (CD nmol/min/g)) (NN heart)) (PP (IN in) (NP (NNP ND)))) (CC versus) (NP (NP (QP (CD 400.2+/-11.8) (CD nmol/min/g)) (NN heart)) (PP (IN in) (NP (NNP Doc_18674790_1573_1575_Disease)))) (-RRB- -RRB-))))) (, ,) (PRN (-LRB- -LRB-) (NP (CD 5)) (-RRB- -RRB-)) (VP (VBN decreased) (NP (NP (JJ mitochondrial) (JJ Doc_18674790_1606_1609_Chemical-alpha2) (NN protein) (NN kinase)) (, ,) (CC and) (PRN (-LRB- -LRB-) (NP (CD 6)) (-RRB- -RRB-)) (NP (CD 86) (NN %) (NN drop))) (PP (IN in) (NP (NP (JJ cardiac) (JJ Doc_18674790_1661_1664_Chemical) (NNS levels)) (VP (VBN accompanied) (PP (IN by) (NP (NP (VBN decreased) (JJ Doc_18674790_1697_1700_Chemical/Doc_18674790_1701_1704_Chemical) (NN ratio)) (PP (IN after) (NP (NNP Doc_18674790_1717_1728_Chemical) (NN administration)))))))))))))) (. .)))
18674790	8	(S1 (S (NP (NP (VBN Decreased) (JJ cardiac) (NN erythropoietin)) (CC and) (NP (VBN increased) (NNS SOCS3))) (ADVP (RB further)) (VP (VBD downregulated) (NP (DT the) (JJ cardioprotective) (NN JAK/STAT3) (NN pathway))) (. .)))
18674790	9	(S1 (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (JJ HFD-induced) (NNP Doc_18674790_1887_1892_Disease) (NNS rats)) (VP (AUX are) (ADVP (RB highly)) (VP (VBN sensitized) (PP (TO to) (NP (NNP Doc_18674790_1923_1934_Chemical-induced) (NNP Doc_18674790_1943_1957_Disease))) (PP (IN by) (S (VP (VP (ADVP (RB substantially)) (VBG downregulating) (NP (JJ cardiac) (JJ mitochondrial) (JJ Doc_18674790_2012_2015_Chemical) (NN generation))) (, ,) (VP (VBG increasing) (NP (JJ oxidative) (NN stress))) (CC and) (VP (VBG downregulating) (NP (DT the) (JJ JAK/STAT3) (NN pathway)))))))) (. .)))
18808529	0	(S1 (S (NP (NN Doc_18808529_0_13_Chemical)) (VP (VBZ induces) (NP (NP (NP (JJ primary) (NN loss)) (PP (IN of) (NP (NN dystrophin))) (PP (IN in) (NP (NN rat) (NNS hearts)))) (: :) (NP (NP (NN correlation)) (PP (IN with) (NP (NNP Doc_18808529_81_98_Disease)))))) (. .)))
18808529	1	(S1 (S (S (NP (NP (DT The) (NN mechanism)) (PP (IN of) (NP (NNP Doc_18808529_117_130_Chemical-induced) (NNP Doc_18808529_139_156_Disease)))) (VP (AUX is) (ADJP (JJ unknown)))) (, ,) (CC but) (S (NP (NP (DT a) (NN mismatch)) (PP (IN of) (NP (NP (JJ Doc_18808529_187_193_Chemical) (NN supply)) (CC vs.) (NP (NP (NN demand)) (PP (VBG following) (NP (NP (JJ coronary) (NNP Doc_18808529_231_242_Disease)) (CC and) (NP (NNP Doc_18808529_247_271_Disease)))))))) (VP (AUX is) (NP (NP (DT the) (JJS best) (NN explanation)) (PP (IN for) (NP (NP (DT the) (JJ complex) (JJ morphological) (NNS alterations)) (VP (VBN observed))))))) (. .)))
18808529	2	(S1 (S (NP (NP (JJ Severe) (NNS alterations)) (PP (IN in) (NP (NP (DT the) (JJ structural) (NN integrity)) (PP (IN of) (NP (NP (DT the) (NN sarcolemma)) (PP (IN of) (NP (NNS cardiomyocytes)))))))) (VP (AUX have) (VP (AUX been) (VP (VBN demonstrated) (S (VP (TO to) (VP (AUX be) (VP (VBN caused) (PP (IN by) (NP (NN Doc_18808529_470_483_Chemical)))))))))) (. .)))
18808529	3	(S1 (S (S (VP (VBG Taking) (PP (IN into) (NP (NN account))) (SBAR (IN that) (S (NP (DT the) (JJ sarcolemmal) (NN integrity)) (VP (AUX is) (VP (VBN stabilized) (PP (PP (IN by) (NP (NP (DT the) (JJ dystrophin-glycoprotein) (NN complex)) (PRN (-LRB- -LRB-) (NP (NNP DGC)) (-RRB- -RRB-)) (SBAR (WHNP (WDT that)) (S (VP (VBZ connects) (NP (NN actin) (CC and) (NN laminin)) (PP (IN in) (NP (NP (JJ contractile) (NN machinery)) (CC and) (NP (JJ extracellular) (NNP matrix))))))))) (CC and) (PP (IN by) (NP (NNS integrins)))))))))) (, ,) (NP (DT this) (NN study)) (VP (VBZ tests) (NP (NP (DT the) (NN hypothesis)) (SBAR (WHNP (WDT that)) (S (NP (NNP Doc_18808529_732_745_Chemical)) (VP (VBZ affects) (NP (JJ sarcolemmal) (NN stability)) (PP (IN through) (NP (NP (NNS changes)) (PP (IN in) (NP (DT the) (NNS DGC) (CC and) (NNS integrins)))))))))) (. .)))
18808529	4	(S1 (S (NP (PRP We)) (VP (VBD found) (NP (NP (JJ different) (NN sensitivity)) (PP (IN of) (NP (DT the) (NN DGC) (CC and) (NN integrin)))) (PP (TO to) (NP (JJ Doc_18808529_876_889_Chemical) (NN subcutaneous) (NN administration)))) (. .)))
18808529	5	(S1 (S (NP (JJ Immunofluorescent) (NN staining)) (VP (VBD revealed) (SBAR (IN that) (S (NP (NN dystrophin)) (VP (AUX is) (NP (NP (DT the) (RBS most) (JJ sensitive)) (PP (IN among) (NP (NP (DT the) (NNS structures)) (VP (VBG connecting) (NP (DT the) (NN actin)) (PP (IN in) (NP (NP (DT the) (JJ cardiomyocyte) (NN cytoskeleton)) (CC and) (NP (DT the) (JJ extracellular) (NNP matrix)))))))))))) (. .)))
18808529	6	(S1 (S (NP (DT The) (JJ sarcomeric) (NN actin) (NN dissolution)) (VP (VBD occurred) (PP (IN after) (NP (NP (DT the) (NN reduction) (CC or) (NN loss)) (PP (IN of) (NP (NN dystrophin)))))) (. .)))
18808529	7	(S1 (S (ADVP (RB Subsequently)) (, ,) (PP (IN after) (NP (NP (NN lysis)) (PP (IN of) (NP (NNS myofilaments))))) (, ,) (NP (NP (JJ gamma-sarcoglycan)) (, ,) (NP (JJ beta-dystroglycan)) (, ,) (NP (JJ beta1-integrin)) (, ,) (CC and) (NP (JJ laminin) (JJ alpha-2) (NNS expressions))) (VP (AUX were) (VP (VBN reduced) (PP (VBN followed) (PP (IN by) (NP (PRP$ their) (NN breakdown)))) (, ,) (PP (IN as) (NP (NP (NN epiphenomena)) (PP (IN of) (NP (DT the) (JJ myocytolytic) (NN process))))))) (. .)))
18808529	8	(S1 (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NP (NN administration)) (PP (IN of) (NP (NNP Doc_18808529_1433_1446_Chemical))) (PP (TO to) (NP (NNS rats)))) (VP (VBZ results) (PP (IN in) (NP (NP (JJ primary) (NN loss)) (PP (IN of) (NP (NN dystrophin))))) (, ,) (S (NP (NP (DT the) (RBS most) (JJ sensitive)) (PP (IN among) (NP (NP (DT the) (JJ structural) (NNS proteins)) (SBAR (WHNP (WDT that)) (S (VP (VBP form) (NP (NP (DT the) (NN DGC)) (SBAR (WHNP (WDT that)) (S (VP (VBZ connects) (NP (NP (DT the) (JJ extracellular) (NNP matrix)) (CC and) (NP (NP (DT the) (NN cytoskeleton)) (PP (IN in) (NP (NN cardiomyocyte))))))))))))))))) (. .)))
18808529	9	(S1 (S (NP (NP (DT These) (NNS changes)) (, ,) (VP (VBN related) (PP (TO to) (NP (NNP Doc_18808529_1665_1681_Disease)))) (, ,)) (VP (VBP explain) (NP (NP (NP (DT the) (JJ severe) (NNS alterations)) (PP (IN in) (NP (NP (DT the) (JJ structural) (NN integrity)) (PP (IN of) (NP (NP (DT the) (NN sarcolemma)) (PP (IN of) (NP (NNS cardiomyocytes)))))))) (CC and) (NP (NP (RB hence) (JJ severe) (CC and) (JJ irreversible) (NN injury)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_18808529_1830_1843_Chemical))))))) (. .)))
188339	0	(S1 (S (NP (NP (JJ Etiologic) (NNS factors)) (PP (IN in) (NP (NP (DT the) (NNS pathogenesis)) (PP (IN of) (NP (NNP Doc_188339_41_53_Disease)))))) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_188339_70_89_Chemical)))) (. .)))
188339	1	(S1 (S (PP (IN Within) (NP (DT the) (JJ last) (JJ several) (NNS years))) (, ,) (NP (ADJP (RB previously) (JJ rare)) (NNP Doc_188339_138_150_Disease)) (VP (AUX have) (VP (AUX been) (VP (VBN seen) (PP (IN in) (NP (NP (JJ young) (NNS women)) (VP (VBG using) (NP (NNP Doc_188339_187_205_Chemical) (NNP Doc_188339_206_214_Chemical)))))))) (. .)))
188339	2	(S1 (S (NP (NP (DT The) (NNP Registry)) (PP (IN for) (NP (NP (NP (NNP Doc_188339_233_245_Disease) (NNP Associated)) (PP (IN with) (NP (NNP Doc_188339_262_281_Chemical))) (PP (IN at) (NP (NP (DT the) (NNP University)) (PP (IN of) (NP (NNP California)))))) (, ,) (NP (NNP Irvine)) (, ,)))) (VP (AUX has) (ADVP (RB clearly)) (VP (VBN identified) (NP (CD 27) (NNS cases)))) (. .)))
188339	3	(S1 (S (NP (DT The) (JJ recent) (NN literature)) (VP (VBZ contains) (NP (CD 44) (NN case) (NNS reports))) (. .)))
188339	4	(S1 (S (NP (NP (NN Common)) (PP (TO to) (NP (DT these) (CD 71) (NNS cases)))) (VP (AUX has) (VP (AUX been) (NP (NP (DT a) (JJ histopathologic) (NN diagnosis)) (PP (IN of) (NP (NP (NNP Doc_188339_469_494_Disease)) (, ,) (NP (NNP Doc_188339_496_503_Disease)) (, ,) (NP (NNP Doc_188339_505_514_Disease)) (, ,) (CC and) (NP (NNP Doc_188339_520_528_Disease))))))) (. .)))
188339	5	(S1 (S (NP (JJ Significant) (JJ statistical) (JJ etiologic) (NNS factors)) (VP (VBP include) (NP (NP (JJ prolonged) (JJ uninterrupted) (NN usage)) (PP (IN of) (NP (NNP Doc_188339_613_631_Chemical) (NNP Doc_188339_632_640_Chemical))))) (. .)))
188339	6	(S1 (S (NP (NP (NP (CD Eight) (NNS deaths)) (CC and) (NP (NN liver) (NN Doc_188339_665_672_Disease))) (PP (IN in) (NP (CD 18) (NNS patients)))) (VP (VB attest) (PP (TO to) (NP (NP (DT the) (NN seriousness)) (PP (IN of) (NP (DT this) (JJ new) (ADJP (RB potentially) (JJ lethal)) (JJ adverse) (NN phenomenon)))))) (. .)))
1899352	0	(S1 (NP (NP (JJ Doc_1899352_0_10_Chemical) (JJ continuous) (NN infusion)) (PP (IN without) (NP (NNP Doc_1899352_39_44_Chemical))) (. .)))
1899352	1	(S1 (NP (NP (DT A) (NN phase) (NN I) (NN trial)) (PP (IN of) (NP (DT a) (JJ 14-day) (NN cycle))) (. .)))
1899352	2	(S1 (S (NP (CD Twenty) (NNS patients)) (VP (VBD received) (NP (NP (CD 27) (NNS courses)) (PP (IN of) (NP (NNP Doc_1899352_120_130_Chemical))) (VP (VBN administered) (PP (IN as) (NP (NP (DT a) (JJ 24-hour) (JJ continuous) (NN infusion)) (PP (IN for) (NP (NP (CD 14) (NNS days)) (PP (IN without) (NP (NNP Doc_1899352_197_202_Chemical)))))))))) (. .)))
1899352	3	(S1 (S (NP (NP (DT The) (NN goal)) (PP (IN of) (NP (DT the) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB deliver) (NP (NP (DT a) (NN dose) (NN rate)) (CC and) (NP (NP (JJ total) (JJ cumulative) (NN dose)) (PP (IN of) (NP (NNP Doc_1899352_282_292_Chemical))) (SBAR (WHNP (WDT that)) (S (VP (MD would) (VP (AUX be) (ADJP (JJ comparable) (PP (TO to) (NP (NP (NP (JJ standard) (NNS bolus)) (CC or) (NP (JJ short-term) (NNS infusions))) (VP (VBN administered) (PP (IN with) (NP (NNP Doc_1899352_378_383_Chemical))))))))))))))))) (. .)))
1899352	4	(S1 (S (NP (NN Dose) (NNS escalations)) (VP (VBD proceeded) (PP (IN from) (NP (NP (QP (CD 200) (TO to) (CD 300))) (, ,) (NP (CD 400)) (, ,) (NP (CD 450)) (, ,) (NP (CD 500)) (, ,) (CC and) (NP (QP (CD 550) (CD mg/m2/d)))))) (. .)))
1899352	5	(S1 (S (NP (CD Four) (NNS patients)) (VP (VBD developed) (NP (JJ transient) (JJ microscopic) (NN Doc_1899352_507_516_Disease)) (PP (IN at) (NP (NP (CD 400)) (, ,) (NP (CD 450)) (, ,) (CC and) (NP (CD 500) (NN mg/m2/d))))) (. .)))
1899352	6	(S1 (S (NP (EX There)) (VP (AUX were) (NP (NP (DT no) (NNS instances)) (PP (IN of) (NP (JJ macroscopic) (NNP Doc_1899352_586_595_Disease))))) (. .)))
1899352	7	(S1 (S (PP (IN At) (NP (CD 550) (CD mg/m2/d))) (, ,) (NP (CD three) (NNS patients)) (VP (VBD experienced) (NP (NP (JJ nonurologic) (NNP Doc_1899352_652_660_Disease)) (: ;) (NP (NP (NNP Doc_1899352_662_671_Disease)) (PRN (-LRB- -LRB-) (NP (CD 1)) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Doc_1899352_677_683_Disease)) (PRN (-LRB- -LRB-) (NP (CD 1)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NNP Grade) (CD 2) (NNP Doc_1899352_701_711_Disease)) (PRN (-LRB- -LRB-) (NP (CD 1)) (-RRB- -RRB-))))) (. .)))
1899352	8	(S1 (S (NP (NP (DT The) (JJ recommended) (NN dose)) (PP (IN of) (NP (CD 500) (NNS mg/m2/d)))) (VP (VBZ delivers) (NP (NP (DT a) (JJ total) (NN dose)) (PP (IN of) (NP (CD 7) (NN g/m2))) (PP (IN per) (NP (NP (NN cycle)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX is) (ADJP (JJ comparable) (PP (TO to) (NP (NP (DT that)) (VP (VBN delivered) (PP (IN in) (NP (NP (JJ clinical) (NN practice)) (PP (IN for) (NP (NP (NN bolus)) (CC or) (NP (JJ short-term) (NN infusion))))))))))))))))) (. .)))
1899352	9	(S1 (S (PP (IN Because) (NP (NP (JJ few) (NNS patients)) (VP (VBN received) (NP (JJ multiple) (NNS courses)) (PP (IN over) (NP (NN time)))))) (, ,) (NP (DT the) (JJ cumulative) (NNS effects)) (VP (AUX are) (ADJP (JJ indeterminate)) (PP (IN in) (NP (DT the) (JJ present) (NN trial)))) (. .)))
1899352	10	(S1 (S (S (NP (NP (DT The) (NN frequency) (CC and) (NN predictability)) (PP (IN of) (NP (NNP Doc_1899352_1046_1055_Disease)))) (VP (AUX are) (RB not) (ADJP (JJ precise)))) (, ,) (CC and) (S (NP (NP (ADVP (IN at) (JJS least)) (JJ daily) (NN monitoring)) (PP (IN by) (NP (NN urine) (NN Hematest)))) (VP (AUX is) (ADJP (JJ essential)) (, ,) (S (VP (VBG adding) (NP (NN Doc_1899352_1142_1147_Chemical)) (PP (TO to) (NP (NP (DT the) (NN infusate)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ persistent) (NNP Doc_1899352_1192_1201_Disease))))))))))) (. .)))
1899352	11	(S1 (S (NP (NP (DT The) (JJ protracted) (NN infusion) (NN schedule)) (PP (IN for) (NP (NNP Doc_1899352_1240_1250_Chemical)))) (VP (VP (VBZ permits) (NP (JJ convenient) (NN outpatient) (NN administration)) (PP (IN without) (NP (NNP Doc_1899352_1304_1309_Chemical)))) (CC and) (VP (VBZ reduces) (NP (NP (DT the) (NN drug) (NN cost)) (PP (IN of) (NP (NP (JJ clinical) (NN usage)) (PP (IN of) (NP (DT this) (NN agent)))))) (PP (IN by) (NP (NP (QP (IN up) (TO to) (CD 890))) (PP (IN per) (NP (NN cycle))))))) (. .)))
1899352	12	(S1 (S (S (NP (JJ Clinical) (NN activity)) (VP (AUX was) (VP (VBN demonstrated) (PP (IN in) (NP (DT a) (JJ single) (NN patient)))))) (, ,) (CC but) (S (NP (NP (DT a) (JJ comparative) (NN trial)) (PP (IN of) (NP (JJ standard) (JJ bolus) (NNS schedules))) (PP (IN with) (NP (DT the) (JJ protracted) (NN infusion) (NN schedule)))) (VP (MD will) (VP (AUX be) (ADJP (JJ necessary) (S (VP (TO to) (VP (VB determine) (SBAR (IN if) (S (NP (NP (DT the) (JJ clinical) (NN effectiveness)) (PP (IN of) (NP (DT the) (NN drug)))) (VP (AUX is) (VP (VBN maintained)))))))))))) (. .)))
18997632	0	(S1 (NP (NP (DT A) (NN case)) (PP (IN of) (NP (NNP Doc_18997632_10_33_Disease))) (VP (VBN related) (PP (TO to) (NP (JJ Doc_18997632_45_53_Chemical) (NN pretreatment)))) (. .)))
18997632	1	(S1 (S (NP (JJ Suboptimal) (NN Doc_18997632_79_86_Disease) (NN duration)) (VP (AUX is) (ADVP (RB commonly)) (VP (VBN encountered) (PP (IN in) (NP (JJ electroconvulsive) (NN therapy) (NN practice))) (, ,) (PP (ADVP (RB especially)) (IN in) (NP (NP (JJR older) (NNS patients)) (PP (IN with) (NP (JJR higher) (NNP Doc_18997632_200_207_Disease) (NNS thresholds))))))) (. .)))
18997632	2	(S1 (S (NP (JJ Intravenous) (NNP Doc_18997632_232_240_Chemical)) (VP (VP (AUX is) (ADVP (RB commonly)) (VP (VBN used) (S (VP (TO to) (VP (VB improve) (NP (NP (NNP Doc_18997632_269_276_Disease) (NN duration) (CC and) (NN quality)) (PP (IN in) (NP (JJ such) (NNS patients))))))))) (CC and) (VP (AUX is) (ADVP (RB generally)) (VP (ADVP (RB well)) (VBN tolerated) (PRT (RP aside)) (PP (IN from) (NP (NP (JJ occasional) (NNS reports)) (PP (IN of) (NP (ADJP (RB relatively) (JJ benign)) (NNP Doc_18997632_398_416_Disease)))))))) (. .)))
18997632	3	(S1 (S (NP (PRP We)) (VP (VBP describe) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (NP (DT no) (JJ previous) (NN history)) (PP (IN of) (NP (NP (NNP Doc_18997632_468_483_Disease) (CC or) (NNP Doc_18997632_487_497_Disease)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NP (NP (JJ sustained) (NN bigeminy)) (CC and) (NP (CD 2) (JJ brief) (NNS runs))) (PP (IN of) (NP (NNP Doc_18997632_551_574_Disease)))) (PP (IN after) (NP (NNP Doc_18997632_581_589_Chemical) (NN administration)))))))))))) (. .)))
18997632	4	(S1 (S (SBAR (IN Although) (S (NP (JJ intravenous) (NNP Doc_18997632_627_635_Chemical)) (VP (AUX is) (ADVP (RB generally)) (VP (ADVP (RB well)) (VBN tolerated))))) (, ,) (NP (DT the) (NN clinician)) (VP (MD should) (VP (AUX be) (ADJP (JJ aware) (PP (IN of) (NP (NP (DT the) (NN potential)) (PP (IN for) (NP (ADJP (JJ unpredictable) (CC and) (JJ serious)) (NNP Doc_18997632_742_765_Disease)))))))) (. .)))
19058474	0	(S1 (NP (NP (NP (JJ Fatal) (NN haemopericardium)) (CC and) (NP (NN Doc_19058474_27_55_Disease))) (ADJP (JJ due) (PP (TO to) (NP (NP (JJ possible) (NN interaction)) (PP (IN of) (NP (NN cranberry) (NN juice))) (PP (IN with) (NP (NNP Doc_19058474_108_116_Chemical)))))) (. .)))
19058474	1	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (JJ fatal) (JJ internal) (NN Doc_19058474_153_164_Disease)))) (PP (IN in) (NP (NP (DT an) (JJ elderly) (NN man)) (SBAR (WHNP (WP who)) (S (VP (VBD consumed) (NP (ADJP (RB only) (JJ cranberry)) (NN juice)) (PP (IN for) (NP (CD two) (NNS weeks))) (SBAR (IN while) (S (VP (VBG maintaining) (NP (NP (PRP$ his) (JJ usual) (NN dosage)) (PP (IN of) (NP (NNP Doc_19058474_269_277_Chemical))))))))))))) (. .)))
19058474	2	(S1 (S (NP (PRP We)) (VP (VB propose) (SBAR (IN that) (S (NP (NP (ADJP (RB naturally) (VBG occurring)) (NNS compounds)) (PP (JJ such) (IN as) (NP (NP (NNP Doc_19058474_333_343_Chemical)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX are) (ADJP (JJ present)) (PP (IN in) (NP (NN fruit) (NNS juices)))))) (, ,)))) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN potency)) (PP (IN of) (NP (NNP Doc_19058474_408_416_Chemical)))) (PP (IN by) (S (VP (VBG competing) (PP (IN for) (NP (NP (DT the) (NNS enzymes)) (SBAR (WHNP (WDT that)) (S (ADVP (RB normally)) (VP (VBP inactivate) (NP (NNP Doc_19058474_471_479_Chemical))))))))))))))) (. .)))
19058474	3	(S1 (S (SBAR (IN While) (S (ADVP (RB traditionally)) (VP (VBN regarded) (PP (IN as) (NP (NNS foodstuffs)))))) (, ,) (NP (NP (NN consumption)) (PP (IN of) (NP (NN fruit) (NNS juices)))) (VP (MD should) (VP (AUX be) (VP (VBN considered) (SBAR (WHADVP (WRB when)) (S (NP (NNS patients)) (VP (VBP develop) (NP (JJ adverse) (NN drug) (NNS reactions)))))))) (. .)))
19105845	0	(S1 (NP (NP (NN Effect)) (PP (IN of) (NP (VBG increasing) (JJ intraperitoneal) (NN infusion) (NNS rates))) (PP (IN on) (NP (NP (NNP Doc_19105845_55_78_Chemical-induced) (NNP Doc_19105845_87_95_Disease)) (PP (IN in) (NP (NNS mice))))) (. .)))
19105845	1	(S1 (S (NP (PRP It)) (VP (AUX is) (RB not) (VP (VBN known) (SBAR (IN if) (S (NP (EX there)) (VP (AUX is) (NP (NP (DT a) (NN relationship)) (PP (IN between) (NP (NP (NN input) (NN rate) (CC and) (NN incidence)) (PP (IN of) (NP (JJ Doc_19105845_196_205_Chemical-induced) (NN Doc_19105845_214_222_Disease))))))))))) (. .)))
19105845	2	(S1 (S (NP (DT This)) (VP (AUX is) (ADJP (JJ important)) (, ,) (SBAR (IN since) (S (NP (NP (JJ different) (JJ controlled) (NN release) (NNS formulations)) (PP (IN of) (NP (NNP Doc_19105845_294_303_Chemical)))) (VP (VBP release) (NP (DT the) (JJ active) (NN drug)) (PP (IN at) (NP (JJ different) (NNS rates))))))) (. .)))
19105845	3	(S1 (S (NP (PRP We)) (VP (VBD investigated) (NP (NP (DT the) (NN effect)) (PP (IN of) (S (VP (VBG varying) (NP (NP (DT the) (JJ intraperitoneal) (NN infusion) (NNS rates)) (PP (IN of) (NP (NP (NNP Doc_19105845_433_446_Chemical) (QP (CD 120) (CD mg/kg))) (, ,) (NP (NP (DT a) (JJ known) (NNP Doc_19105845_466_476_Disease) (NN dose) (CD 50)) (PRN (-LRB- -LRB-) (NP (CD CD50)) (-RRB- -RRB-))) (, ,)))) (PP (IN on) (NP (NP (DT the) (NN incidence) (CC and) (NN severity)) (PP (IN of) (NP (NP (NNP Doc_19105845_526_535_Chemical-induced) (NNP Doc_19105845_544_555_Disease)) (PP (IN in) (NP (DT the) (NNP Swiss) (NN albino) (NNS mice)))))))))))) (. .)))
19105845	4	(S1 (S (NP (NP (DT A) (NN total)) (PP (IN of) (NP (NP (CD 69) (NNS mice)) (, ,) (NP (NP (QP (RB approximately) (CD 7)) (NNS weeks)) (PP (IN of) (NP (NN age))))))) (, ,) (CC and) (S (PP (VBG weighing) (NP (QP (CD 21.0) (TO to) (CD 29.1)))) (NP (NNP g)) (VP (AUX were) (ADVP (RB randomly)) (VP (VBN assigned) (S (VP (TO to) (VP (VB Doc_19105845_686_699_Chemical) (NP (QP (CD 120) (CD mg/kg)) (NN treatment)) (PP (IN by) (NP (NP (JJ intraperitoneal) (PRN (-LRB- -LRB-) (NP (NNP IP)) (-RRB- -RRB-)) (NN administration)) (PP (IN in) (NP (NP (CD 7) (NNS groups)) (PRN (-LRB- -LRB-) (NP (NP (QP (CD 9) (TO to) (CD 10)) (NNS animals)) (PP (IN per) (NP (NN group)))) (-RRB- -RRB-)))))))))))) (. .)))
19105845	5	(S1 (S (NP (NNP Doc_19105845_800_813_Chemical)) (VP (AUX was) (VP (VBN infused) (PP (IN through) (NP (NP (DT a) (ADJP (RB surgically) (VBN implanted)) (NN IP)) (VP (VBG dosing) (NP (NN catheter)) (PP (IN with) (NP (NP (NNS infusions)) (PP (IN in) (NP (NP (DT each) (NN group)) (PP (IN of) (NP (NP (CD 0) (NN min)) (, ,) (NP (CD 15) (NN min)) (, ,) (NP (CD 30) (NN min)) (, ,) (NP (CD 60) (NN min)) (, ,) (NP (CD 90) (NN min)) (, ,) (NP (CD 120) (NN min)) (, ,) (CC and) (NP (CD 240) (NN min))))))))))))) (. .)))
19105845	6	(S1 (S (NP (NP (DT The) (NN number)) (, ,) (NP (NP (NN time)) (PP (IN of) (NP (NP (NN onset)) (, ,) (NP (NN duration)) (CC and) (NP (NP (DT the) (NN intensity)) (PP (IN of) (NP (DT the) (NN Doc_19105845_1030_1041_Disease))))))) (CC or) (NP (NP (NN absence)) (PP (IN of) (NP (NNP Doc_19105845_1056_1067_Disease))))) (VP (AUX were) (VP (VBN recorded))) (. .)))
19105845	7	(S1 (S (NP (DT The) (NNS results)) (VP (VBD showed) (SBAR (IN that) (S (NP (NP (NN IP) (NN administration)) (PP (IN of) (NP (NP (NNP Doc_19105845_1137_1150_Chemical) (CD 120) (NNS mg/kg)) (PP (IN by) (NP (JJ bolus) (NN injection)))))) (VP (VBN induced) (NP (NNP Doc_19105845_1188_1199_Disease)) (PP (IN in) (NP (CD 6))) (PP (IN out) (PP (IN of) (NP (CD 10) (NNS mice)))) (PRN (-LRB- -LRB-) (NP (NP (CD 60) (NN %)) (PP (IN of) (NP (JJ convulsing) (NNS mice)))) (-RRB- -RRB-)) (PP (IN in) (NP (NN group) (CD 1))))))) (. .)))
19105845	8	(S1 (S (NP (JJ Logistic) (JJ regression) (NN analysis)) (VP (VBD revealed) (SBAR (IN that) (S (NP (NN infusion) (NN time)) (VP (AUX was) (ADJP (JJ significant)) (PRN (-LRB- -LRB-) (NP (NP (NNP p) (SYM =) (CD 0.0004)) (: ;) (NP (NNS odds) (NN ratio)) (X (SYM =)) (CD 0.974)) (-RRB- -RRB-)) (CC and) (VP (VBG increasing) (NP (NP (DT the) (ADJP (CD IP) (NN infusion)) (NN time)) (PP (IN of) (NP (NNP Doc_19105845_1402_1415_Chemical))) (SBAR (S (NP (CD 120) (NN mg/kg)) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (DT a) (ADJP (CD 91) (NN %)) (VBN reduced) (NNS odds)) (PP (IN of) (NP (NNP Doc_19105845_1468_1479_Disease))))) (PP (IN at) (NP (NP (NN infusion) (NNS times)) (PP (IN of) (NP (NP (QP (CD 15) (TO to) (CD 90)) (NN min)) (PP (VBN compared) (PP (TO to) (NP (JJ bolus) (NN injection)))))))))))))))))) (. .)))
19105845	9	(S1 (S (NP (NP (JJ Further) (NN increase)) (PP (IN in) (NP (NN infusion) (NN time)))) (VP (VBD resulted) (PP (IN in) (NP (NP (JJ further) (NN reduction)) (PP (IN in) (NP (NP (DT the) (NNS odds)) (PP (IN of) (NP (NNP Doc_19105845_1622_1633_Disease))))) (PP (TO to) (NP (ADJP (CD 99.8) (NN %)) (NN reduction))) (PP (IN at) (NP (CD 240) (NN min)))))) (. .)))
19105845	10	(S1 (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NP (NP (DT the) (NN demonstration)) (PP (IN of) (NP (NP (DT an) (NN inverse) (NN relationship)) (PP (IN between) (NP (NP (NN infusion) (NN time)) (PP (IN of) (NP (NP (DT a) (ADJP (JJ fixed) (CC and) (JJ Doc_19105845_1774_1784_Disease)) (NN dose)) (PP (IN of) (NP (NNP Doc_19105845_1793_1802_Chemical)))))))))) (CC and) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NNP Doc_19105845_1819_1830_Disease))) (PP (IN in) (NP (DT a) (JJ prospective) (NN study))))) (VP (AUX is) (ADJP (JJ novel))) (. .)))
19135948	0	(S1 (NP (NP (NP (JJ Doc_19135948_0_25_Disease) (NNS prophylaxis)) (PP (IN with) (NP (NNP Doc_19135948_43_53_Chemical) (CC and) (NNP Doc_19135948_58_68_Chemical))) (SBAR (S (VP (AUX is) (VP (VBN associated) (PP (IN with) (NP (NP (DT a) (JJ high) (NN incidence)) (PP (IN of) (NP (NNP Doc_19135948_108_139_Disease) (CC and) (NNP Doc_19135948_144_159_Disease)))))))))) (: :) (NP (NP (NNS results)) (PP (IN of) (NP (DT the) (NNP EVTAC) (NN trial)))) (. .)))
19135948	1	(S1 (S (NP (NP (DT A) (JJ calcineurin) (NN inhibitor)) (VP (VBN combined) (PP (IN with) (NP (NNP Doc_19135948_227_239_Chemical))))) (VP (AUX is) (NP (NP (DT the) (JJ standard) (NN prophylaxis)) (PP (IN for) (NP (NP (NNP Doc_19135948_272_297_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_19135948_299_303_Disease)) (-RRB- -RRB-)))) (PP (IN after) (NP (NP (JJ allogeneic) (JJ hematopoietic) (NN stem) (NN cell) (NN transplantation)) (PRN (-LRB- -LRB-) (NP (NN HSCT)) (-RRB- -RRB-)))))) (. .)))
19135948	2	(S1 (S (NP (NP (NNP Doc_19135948_370_380_Chemical)) (, ,) (NP (NP (DT a) (NN derivative)) (PP (IN of) (NP (NNP Doc_19135948_398_407_Chemical)))) (, ,)) (VP (VBZ seems) (S (VP (TO to) (VP (VB mediate) (NP (NN antileukemia) (NNS effects)))))) (. .)))
19135948	3	(S1 (S (NP (PRP We)) (VP (VBP report) (PP (IN on) (NP (NP (DT a) (NN combination)) (PP (IN of) (NP (NP (NP (NP (NNP Doc_19135948_478_488_Chemical) (CC and) (NNP Doc_19135948_493_503_Chemical)) (PP (IN in) (NP (NP (CD 24) (NNS patients)) (PRN (-LRB- -LRB-) (NP (NP (JJ median) (NN age)) (, ,) (NP (CD 62) (NNS years))) (-RRB- -RRB-)))) (PP (IN with) (NP (DT either) (NNP Doc_19135948_554_578_Disease)))) (PRN (-LRB- -LRB-) (NP (NNP Doc_19135948_580_583_Disease)) (: ;) (NP (NNP n) (SYM =) (CD 17)) (-RRB- -RRB-))) (CC or) (NP (NP (NNP Doc_19135948_596_618_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_19135948_620_623_Disease)) (: ;) (NP (NNP n) (SYM =) (CD 7)) (-RRB- -RRB-))))) (VP (VBG undergoing) (NP (NP (JJ intensive) (NN conditioning)) (VP (VBN followed) (PP (IN by) (NP (NP (NN HSCT)) (PP (IN from) (NP (ADJP (VBN related) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 4)) (-RRB- -RRB-)) (CC or) (ADJP (JJ unrelated)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 20)) (-RRB- -RRB-))) (NNS donors))))))))))) (. .)))
19135948	4	(S1 (S (S (NP (DT All) (NNS patients)) (VP (VBD engrafted))) (, ,) (CC and) (S (NP (QP (RB only) (CD 1)) (NN patient)) (VP (VBD experienced) (NP (NN grade)) (NP (NNP IV) (NNP Doc_19135948_798_807_Disease)))) (. .)))
19135948	5	(S1 (S (NP (NP (NP (CD Nine) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 37) (NN %)) (-RRB- -RRB-)) (VP (VBN developed) (NP (JJ acute) (NN grade) (NNP II-IV) (NNP Doc_19135948_857_861_Disease)))) (, ,) (CC and) (NP (NP (QP (CD 11) (IN of) (CD 17)) (JJ evaluable) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 64) (NN %)) (-RRB- -RRB-)))) (VP (VBD developed) (NP (JJ chronic) (JJ extensive) (NN Doc_19135948_929_933_Disease))) (. .)))
19135948	6	(S1 (S (NP (NP (NN Doc_19135948_935_977_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_19135948_979_982_Disease)) (-RRB- -RRB-))) (VP (VBD occurred) (PP (IN in) (NP (NP (CD 7) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 29) (NN %)) (-RRB- -RRB-)))) (, ,) (PP (IN with) (NP (NP (CD 2) (NNS cases)) (PP (IN of) (NP (NNP Doc_19135948_1030_1049_Disease)))))) (. .)))
19135948	7	(S1 (S (NP (DT The) (NN study)) (VP (AUX was) (VP (VBN terminated) (ADVP (RB prematurely)) (SBAR (IN because) (S (NP (NP (DT an) (JJ additional) (CD 6) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 25) (NN %)) (-RRB- -RRB-))) (VP (VBD developed) (NP (NP (NP (NNP Doc_19135948_1137_1168_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_19135948_1170_1173_Disease)) (-RRB- -RRB-))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX was) (ADJP (JJ fatal)) (PP (IN in) (NP (CD 2) (NNS cases)))))))))))) (. .)))
19135948	8	(S1 (S (PP (IN With) (NP (NP (DT a) (JJ median) (NN follow-up)) (PP (IN of) (NP (CD 26) (NNS months))))) (, ,) (NP (DT the) (JJ 2-year) (JJ overall) (NN survival) (NN rate)) (VP (AUX was) (NP (CD 47) (NN %))) (. .)))
19135948	9	(S1 (S (SBAR (IN Although) (S (NP (DT this) (JJ new) (NN combination)) (VP (VBZ appears) (S (VP (TO to) (VP (AUX be) (ADJP (JJ effective) (PP (IN as) (NP (NP (DT a) (JJ prophylactic) (NN regimen)) (PP (IN for) (NP (JJ acute) (NNP Doc_19135948_1374_1378_Disease)))))))))))) (, ,) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NP (NNP Doc_19135948_1397_1400_Disease)) (CC and) (NP (NNP Doc_19135948_1405_1408_Disease))))) (VP (AUX is) (ADJP (ADJP (RB considerably) (JJR higher)) (SBAR (IN than) (S (VP (VBN seen) (PP (IN with) (NP (JJ other) (NNS regimens)))))))) (. .)))
19139001	0	(S1 (S (NP (NP (JJ Longitudinal) (NN assessment)) (PP (IN of) (NP (NN air) (NN conduction)))) (VP (VBZ audiograms) (PP (IN in) (NP (NP (DT a) (NN phase) (NNP III) (JJ clinical) (NN trial)) (PP (IN of) (NP (NP (NNP Doc_19139001_86_109_Chemical)) (CC and) (NP (NNP Doc_19139001_114_122_Chemical)))) (PP (IN for) (NP (NP (NN prevention)) (PP (IN of) (NP (JJ sporadic) (NNP Doc_19139001_150_169_Disease)))))))) (. .)))
19139001	1	(S1 (S (NP (DT A) (NN phase) (NNP III) (JJ clinical) (NN trial)) (VP (VBD assessed) (NP (NP (DT the) (NN recurrence)) (PP (IN of) (NP (NNP Doc_19139001_225_243_Disease)))) (PP (IN after) (NP (NN treatment))) (PP (IN for) (NP (NP (CD 36) (NNS months)) (PP (IN with) (NP (NP (NP (NP (NNP Doc_19139001_279_302_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_19139001_304_308_Chemical)) (-RRB- -RRB-))) (CC plus) (NP (NNP Doc_19139001_315_323_Chemical))) (CC or) (NP (VBN matched) (NNS placebos))))))) (. .)))
19139001	2	(S1 (S (NP (JJ Temporary) (NN Doc_19139001_355_367_Disease)) (VP (AUX is) (NP (NP (DT a) (JJ known) (NN Doc_19139001_379_387_Disease)) (PP (IN of) (NP (NN treatment))) (PP (IN with) (NP (NP (NNP Doc_19139001_406_410_Chemical)) (, ,) (SBAR (RB thus) (S (NP (DT a) (JJ comprehensive) (NN approach)) (VP (AUX was) (VP (VBN developed) (S (VP (TO to) (VP (VB analyze) (NP (JJ serial) (NN air) (NN conduction) (NNS audiograms))))))))))))) (. .)))
19139001	3	(S1 (S (NP (DT The) (JJ generalized) (NN estimating) (NN equation) (NN method)) (VP (VBD estimated) (NP (NP (DT the) (JJ mean) (NN difference)) (PP (IN between) (NP (NN treatment) (NNS arms))) (PP (IN with) (NP (NP (NN regard)) (PP (TO to) (NP (NP (NN change)) (PP (IN in) (NP (NP (NN air) (NN conduction)) (SBAR (S (NP (JJ pure) (NN tone)) (VP (VBZ thresholds) (SBAR (IN while) (S (VP (VBG accounting) (PP (IN for) (NP (NP (JJ within-subject) (NN correlation)) (ADJP (JJ due) (PP (TO to) (NP (NP (VBN repeated) (NNS measurements)) (PP (IN at) (NP (NNS frequencies)))))))))))))))))))))) (. .)))
19139001	4	(S1 (S (PP (VBN Based) (PP (IN on) (NP (CD 290) (NNS subjects)))) (, ,) (NP (EX there)) (VP (AUX was) (NP (NP (DT an) (JJ average) (NN difference)) (PP (IN of) (NP (CD 0.50) (NN dB))) (PP (IN between) (NP (NP (NNS subjects)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_19139001_847_851_Chemical) (CC plus) (NNP Doc_19139001_857_865_Chemical))))))) (PP (VBN compared) (PP (IN with) (NP (NP (DT those)) (VP (VBN treated) (PP (IN with) (NP (NP (NN placebo)) (PRN (-LRB- -LRB-) (NP (NP (ADJP (CD 95) (NN %)) (NN confidence) (NN interval)) (, ,) (NP (NP (QP (CD -0.64) (TO to) (CD 1.63)) (NNS dB)) (: ;) (NP (NNP P) (SYM =) (CD 0.39)))) (-RRB- -RRB-)) (, ,) (VP (VBN adjusted) (PP (IN for) (NP (NP (NN baseline) (NNS values)) (, ,) (NP (NN age)) (, ,) (CC and) (NP (NNS frequencies)))))))))))) (. .)))
19139001	5	(S1 (S (PP (IN In) (NP (NP (DT the) (JJ normal) (NN speech) (NN range)) (PP (IN of) (NP (QP (CD 500) (TO to) (CD 3,000)) (NNPS Hz))))) (, ,) (NP (NP (DT an) (VBN estimated) (NN difference)) (PP (IN of) (NP (NP (CD 0.99) (NNS dB)) (PRN (-LRB- -LRB-) (NP (NP (QP (CD -0.17) (TO to) (CD 2.14)) (NNS dB)) (: ;) (NP (NNP P) (SYM =) (CD 0.09))) (-RRB- -RRB-))))) (VP (AUX was) (VP (VBN detected))) (. .)))
19139001	6	(S1 (S (NP (NN Dose) (NN intensity)) (VP (AUX did) (RB not) (VP (VB add) (NP (NN information)) (PP (TO to) (NP (NNS models))))) (. .)))
19139001	7	(S1 (S (NP (EX There)) (VP (AUX were) (NP (NP (NP (NP (CD 14)) (PP (IN of) (NP (NP (CD 151)) (PRN (-LRB- -LRB-) (NP (CD 9.3) (NN %)) (-RRB- -RRB-)))) (PP (IN in) (NP (DT the) (NNP Doc_19139001_1224_1228_Chemical) (CC plus) (NNP Doc_19139001_1234_1242_Chemical) (NN group)))) (CC and) (NP (NP (CD 4)) (PP (IN of) (NP (NP (CD 139)) (PRN (-LRB- -LRB-) (NP (CD 2.9) (NN %)) (-RRB- -RRB-)))))) (PP (IN in) (NP (DT the) (NN placebo) (NN group))) (SBAR (WHNP (WP who)) (S (VP (VBD experienced) (NP (QP (IN at) (JJS least) (CD 15) (CD dB)) (NN hearing) (NN reduction)) (PP (IN from) (NP (NN baseline))) (PP (IN in) (NP (QP (CD 2) (CC or) (JJR more)) (JJ consecutive) (NNS frequencies))) (PP (IN across) (NP (NP (DT the) (JJ entire) (NN range)) (VP (VBN tested) (PRN (-LRB- -LRB-) (NP (NNP P) (SYM =) (CD 0.02)) (-RRB- -RRB-)))))))))) (. .)))
19139001	8	(S1 (S (NP (JJ Follow-up) (NN air) (NN conduction)) (VP (AUX done) (SBAR (NP (QP (IN at) (JJS least) (CD 6)) (NNS months)) (IN after) (S (NP (NP (NN end)) (PP (IN of) (NP (NN treatment)))) (VP (VBD showed) (NP (NP (DT an) (VBN adjusted) (JJ mean) (NN difference)) (PP (IN in) (NP (NP (NN hearing) (NNS thresholds)) (PP (IN of) (NP (NP (CD 1.08) (NNS dB)) (PRN (-LRB- -LRB-) (NP (NP (QP (CD -0.81) (TO to) (CD 2.96)) (NNS dB)) (: ;) (NP (NNP P) (SYM =) (CD 0.26))) (-RRB- -RRB-)))))) (PP (IN between) (NP (NN treatment) (NNS arms)))))))) (. .)))
19139001	9	(S1 (S (NP (EX There)) (VP (AUX was) (NP (DT no) (JJ significant) (NN difference)) (PP (IN in) (NP (NP (DT the) (NN proportion)) (PP (IN of) (NP (NP (NNS subjects)) (PP (IN in) (NP (DT the) (NNP Doc_19139001_1698_1702_Chemical) (CC plus) (NNP Doc_19139001_1708_1716_Chemical) (NN group))) (SBAR (WHNP (WP who)) (S (VP (VBD experienced) (NP (ADJP (RB clinically) (JJ significant)) (NN Doc_19139001_1762_1774_Disease)) (PP (VBN compared) (PP (IN with) (NP (DT the) (NN placebo) (NN group)))))))))))) (. .)))
19139001	10	(S1 (S (NP (NP (DT The) (VBN estimated) (JJ attributable) (NN risk)) (PP (IN of) (NP (NNP Doc_19139001_1843_1854_Disease))) (PP (IN from) (NP (NP (NN exposure)) (PP (TO to) (NP (DT the) (NN drug)))))) (VP (AUX is) (NP (NP (CD 8.4) (NN %)) (PRN (-LRB- -LRB-) (NP (NP (ADJP (CD 95) (NN %)) (NN confidence) (NN interval)) (, ,) (NP (NP (QP (CD -2.0) (NN %) (TO to) (CD 18.8) (NN %))) (: ;) (NP (NNP P) (SYM =) (CD 0.12)))) (-RRB- -RRB-)))) (. .)))
19139001	11	(S1 (S (NP (EX There)) (VP (AUX is) (NP (NP (DT a) (JJ <2) (JJ dB) (NN difference)) (PP (IN in) (NP (NP (JJ mean) (NN threshold)) (PP (IN for) (NP (NP (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_19139001_2014_2018_Chemical)) (CC plus) (NP (NNP Doc_19139001_2024_2032_Chemical)))) (PP (VBN compared) (PP (IN with) (NP (NP (DT those)) (VP (VBN treated) (PP (IN with) (NP (NN placebo)))))))))))))) (. .)))
19203554	0	(S1 (S (VP (VB Proteinase) (NP (NP (JJ 3-antineutrophil) (JJ cytoplasmic) (NN antibody-)) (PRN (-LRB- -LRB-) (NP (NNP PR3-ANCA)) (-RRB- -RRB-))) (NP (JJ positive) (JJ necrotizing) (NN Doc_19203554_81_99_Disease)) (PP (IN after) (S (VP (VBG restarting) (NP (JJ Doc_19203554_117_131_Chemical) (NN treatment)))))) (. .)))
19203554	1	(S1 (S (NP (NP (DT A) (JJ 59-year-old) (NN woman)) (PP (IN with) (NP (NNP Doc_19203554_168_186_Disease)))) (VP (VBD developed) (NP (NNP Doc_19203554_197_205_Disease) (, ,) (NNP Doc_19203554_207_223_Disease) (, ,) (NNP Doc_19203554_225_237_Disease) (CC and) (NNP Doc_19203554_242_263_Disease)) (PP (IN after) (NP (NP (NN restarting)) (PP (IN of) (NP (JJ Doc_19203554_284_298_Chemical) (NN treatment)))))) (. .)))
19203554	2	(S1 (S (NP (NP (JJ Light) (NN microscopy)) (PP (IN of) (NP (DT a) (NN kidney) (NN biopsy)))) (VP (VBD revealed) (NP (NNP Doc_19203554_355_395_Disease)) (PP (IN without) (NP (NP (NN deposition)) (PP (IN of) (NP (NP (NN immunoglobulin)) (CC or) (NP (VB complement))))))) (. .)))
19203554	3	(S1 (S (S (NP (JJ Proteinase) (JJ 3-antineutrophil) (JJ cytoplasmic) (NN antibody) (PRN (-LRB- -LRB-) (NNP PR3-ANCA) (-RRB- -RRB-)) (NN titer)) (VP (AUX was) (ADJP (JJ elevated)) (PP (IN at) (NP (CD 183) (NNP ELISA) (NNS units))) (PRN (-LRB- -LRB-) (NP (NNP EU)) (-RRB- -RRB-)) (PP (IN in) (NP (NN sera))) (PRN (-LRB- -LRB-) (NP (JJ normal) (NN range)) (NP (QP (JJR less) (IN than) (CD 10)) (NN EU)) (-RRB- -RRB-)))) (, ,) (S (NP (NN myeloperoxidase-ANCA)) (VP (AUX was) (ADJP (JJ negative)))) (. .)))
19203554	4	(S1 (S (NP (NN PR3-ANCA) (NN titer)) (VP (AUX was) (NP (NP (QP (CD 250) (CC and) (CD 1,070)) (NN EU)) (PP (IN in) (NP (NNP Doc_19203554_665_682_Disease))) (PP (IN on) (NP (JJ right) (CC and) (JJ left) (NN side)))) (, ,) (ADVP (RB respectively))) (. .)))
19203554	5	(S1 (S (SBAR (IN Although) (S (NP (NP (NN cessation)) (PP (IN of) (NP (JJ Doc_19203554_743_757_Chemical) (NN treatment)))) (VP (VBD resulted) (PP (IN in) (NP (NP (NNS improvements)) (PP (IN in) (NP (NP (NNP Doc_19203554_796_801_Disease) (, ,) (NNP Doc_19203554_803_811_Disease) (, ,) (NNP Doc_19203554_813_823_Disease)) (, ,) (NP (NP (NP (NN titer)) (PP (IN of) (NP (JJ C-reactive) (NN protein)))) (CC and) (NP (NP (NN volume)) (PP (IN of) (NP (DT the) (NNP Doc_19203554_871_888_Disease)))))))))))) (, ,) (NP (PRP we)) (VP (VBD initiated) (NP (JJ Doc_19203554_903_910_Chemical) (NN therapy)) (, ,) (SBAR (IN because) (S (S (NP (NNP PR3-ANCA) (NN titer)) (VP (VBD rose) (PP (TO to) (NP (QP (CD 320) (CD EU)))))) (, ,) (S (NP (NN eosinophil) (NN count)) (VP (VBD increased) (PP (TO to) (NP (CD 1,100) (NN cells/microl))))) (, ,) (CC and) (S (NP (DT the) (NNP Doc_19203554_1017_1033_Disease)) (VP (VBD remained)))))) (. .)))
19203554	6	(S1 (S (S (NP (NP (CD One) (NN month)) (PP (IN after) (NP (JJ Doc_19203554_1060_1067_Chemical) (NN therapy))) (, ,) (NP (DT the) (NNP Doc_19203554_1081_1097_Disease))) (VP (VBD disappeared))) (, ,) (CC and) (S (NP (JJ PR3-ANCA) (NN titer)) (VP (VBD normalized) (ADVP (NP (CD 3) (NNS months)) (RB later)))) (. .)))
19203554	7	(S1 (S (NP (DT This) (NN case)) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NNP Doc_19203554_1181_1195_Chemical)) (VP (MD can) (VP (VB induce) (NP (JJ PR3-ANCA-positive) (JJ necrotizing) (NN Doc_19203554_1237_1255_Disease))))))) (. .)))
19234905	0	(S1 (NP (NP (NN Comparison)) (PP (IN of) (NP (NP (JJ unilateral) (NN pallidotomy) (CC and) (NN subthalamotomy) (NNS findings)) (PP (IN in) (NP (JJ advanced) (NNP Doc_19234905_77_107_Disease))))) (. .)))
19234905	1	(S1 (S (NP (NP (DT A) (JJ prospective) (, ,) (JJ randomized) (, ,) (JJ double-blind) (NN pilot) (NN study)) (SBAR (S (VP (TO to) (VP (VB compare) (NP (NP (DT the) (NNS results)) (PP (IN of) (NP (NP (JJ stereotactic) (JJ unilateral) (NN pallidotomy)) (CC and) (NP (NN subthalamotomy)))) (PP (IN in) (NP (JJ advanced) (NNP Doc_19234905_254_284_Disease) (PRN (-LRB- -LRB-) (NP (NNP Doc_19234905_286_288_Disease)) (-RRB- -RRB-)) (JJ refractory)))) (PP (TO to) (NP (JJ medical) (NN treatment)))))))) (VP (AUX was) (VP (VBN designed))) (. .)))
19234905	2	(S1 (S (NP (NP (NP (CD Ten) (JJ consecutive) (NNS patients)) (PRN (-LRB- -LRB-) (NP (JJ mean) (NN age)) (, ,) (NP (NP (CD 58.4) (JJ +/-) (CD 6.8) (NNS years)) (PRN (: ;) (NP (CD 7) (NNS men)) (, ,) (NP (CD 3) (NNS women)) (-RRB- -RRB-)) (PP (IN with) (NP (NP (JJ similar) (NNS characteristics)) (PP (IN at) (NP (NP (DT the) (NN duration)) (PP (IN of) (NP (NN disease)))))))) (-LRB- -LRB-) (NP (NP (JJ mean) (NN disease) (NN time)) (, ,) (NP (NP (CD 8.4) (NN +/-)) (NP (CD 3.5) (NNS years)))) (-RRB- -RRB-))) (, ,) (NP (NP (VBG disabling) (NN motor) (NNS fluctuations)) (PRN (-LRB- -LRB-) (NP (NP (NNP Hoehn) (NNP _) (NNP Yahr) (NN stage) (NN 3-5)) (PP (IN in) (NP (JJ off-drug) (NNS phases)))) (-RRB- -RRB-))) (CC and) (NP (JJ Doc_19234905_581_589_Chemical-induced) (NN Doc_19234905_598_609_Disease))) (VP (AUX were) (VP (VBN selected))) (. .)))
19234905	3	(S1 (S (S (NP (DT All) (NNS patients)) (VP (AUX had) (NP (JJ bilateral) (NNS symptoms)))) (CC and) (S (NP (PRP$ their) (JJ Doc_19234905_671_679_Chemical) (JJ equivalent) (NN dosing)) (VP (AUX were) (VP (VBN analysed)))) (. .)))
19234905	4	(S1 (S (NP (CD Six) (NNS patients)) (VP (AUX were) (VP (VBN operated) (PRT (RP on)) (PP (IN in) (NP (NP (NP (DT the) (JJ globus) (JJ pallidus) (NNS interna)) (PRN (-LRB- -LRB-) (NP (NNP GPi)) (-RRB- -RRB-))) (CC and) (NP (NP (CD four)) (PP (IN in) (NP (DT the) (JJ subthalamic) (NN nucleus))) (PRN (-LRB- -LRB-) (NP (NNP STN)) (-RRB- -RRB-))))))) (. .)))
19234905	5	(S1 (S (NP (JJ Clinical) (NN evaluation)) (VP (VP (VBD included) (NP (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NP (DT the) (JJ Unified) (NNP Doc_19234905_875_894_Disease) (NNP Rating) (NNP Scale)) (PRN (-LRB- -LRB-) (NP (NNP UPDRS)) (-RRB- -RRB-))))) (, ,) (NP (NNP Hoehn_Yahr) (NN score)) (CC and) (NP (NP (NNP Schwab) (NNP England) (NNS activities)) (PP (IN of) (NP (JJ daily) (VBG living) (-LRB- -LRB-) (NNP ADL) (-RRB- -RRB-) (NN score))))) (PP (IN in) ('' ') (NP (NN on'-)))) (CC and) (VP ('' ') (NP (NP (NP (JJ off'-drug) (NNS conditions)) (PP (IN before) (NP (NN surgery)))) (CC and) (NP (CD 6) (NNS months))) (PP (IN after) (NP (NN surgery))))) (. .)))
19234905	6	(S1 (S (NP (EX There)) (VP (AUX was) (ADJP (RB statistically) (JJ significant)) (NP (NN improvement)) (PP (IN in) (NP (NP (DT all) (JJ contralateral) (JJ major) (JJ Doc_19234905_1145_1157_Disease) (NN motor) (NNS signs)) (PP (IN in) (NP (NP (DT all) (NNS patients)) (VP (VBN followed) (PP (IN for) (NP (CD 6) (NNS months))))))))) (. .)))
19234905	7	(S1 (S (NP (JJ Doc_19234905_1209_1217_Chemical) (JJ equivalent) (JJ daily) (NN intake)) (VP (AUX was) (VP (ADVP (RB significantly)) (VBN reduced) (PP (IN in) (NP (DT the) (JJ STN) (NN group))))) (. .)))
19234905	8	(S1 (S (NP (NP (NNS Changes)) (PP (IN in) (NP (NP (NNP UPDRS)) (, ,) (NP (NNP Hoehn) (NNP _) (NNP Yahr)) (CC and) (NP (NNP Schwab) (NNP England) (NNP ADL) (NNS scores))))) (VP (AUX were) (ADJP (JJ similar)) (PP (IN in) (NP (DT both) (NNS groups)))) (. .)))
19234905	9	(S1 (S (NP (JJ Cognitive) (NNS functions)) (VP (AUX were) (ADJP (JJ unchanged)) (PP (IN in) (NP (DT both) (NNS groups)))) (. .)))
19234905	10	(S1 (S (S (NP (NNS Complications)) (VP (AUX were) (VP (VBN observed) (PP (IN in) (NP (CD two) (NNS patients)))))) (: :) (S (NP (PRP one)) (VP (AUX had) (NP (DT a) (JJ left) (NN Doc_19234905_1487_1509_Disease)) (SBAR (IN after) (S (NP (NP (NN pallidotomy)) (CC and) (NP (NP (DT another) (NN one)) (VP (VBN developed)))) (VP (VBD left) (NP (JJ hemiballistic) (NNS movements)) (PP (NP (CD 3) (NNS days)) (IN after) (NP (NP (NN subthalamotomy)) (SBAR (WHNP (WDT which)) (S (ADVP (RB partly)) (VP (VBD improved) (PP (IN within) (NP (NP (CD 1) (NN month)) (PP (IN with) (NP (NNP Doc_19234905_1653_1662_Chemical))) (NP (CD 1000) (NN mg/day)))))))))))))) (. .)))
19234905	11	(S1 (S (NP (NP (DT The) (NNS findings)) (PP (IN of) (NP (DT this) (NN study)))) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NNS lesions)) (PP (IN of) (NP (DT the) (JJ unilateral) (NNP STN) (CC and) (NNP GPi)))) (VP (AUX are) (NP (NP (ADJP (RB equally) (JJ effective)) (NN treatment)) (PP (IN for) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ advanced) (NN Doc_19234905_1813_1815_Disease))) (ADJP (JJ refractory) (PP (TO to) (NP (JJ medical) (NN treatment))))))))))) (. .)))
19274460	0	(S1 (NP (NP (CD DSMM) (CD XI) (NN study)) (: :) (NP (NP (NN dose) (NN definition)) (PP (IN for) (NP (NP (JJ intravenous) (NNP Doc_19274460_47_63_Chemical)) (PP (IN in) (NP (NN combination))))) (PP (IN with) (NP (NNP Doc_19274460_84_94_Chemical/Doc_19274460_95_108_Chemical))) (PP (IN for) (NP (NP (NN remission) (NN induction)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (ADJP (RB newly) (VBN diagnosed)) (NNP Doc_19274460_166_173_Disease)))))))) (. .)))
19274460	1	(S1 (S (NP (DT A) (JJ clinical) (NN trial)) (VP (AUX was) (VP (VBN initiated) (S (VP (TO to) (VP (VB evaluate) (NP (NP (DT the) (JJ recommended) (NN dose)) (PP (IN of) (NP (NNP Doc_19274460_242_258_Chemical))) (PP (IN in) (NP (NN combination))) (PP (IN with) (NP (NNP Doc_19274460_279_289_Chemical) (CC and) (NNP Doc_19274460_294_307_Chemical)))) (PP (IN as) (NP (NP (JJ induction) (NN treatment)) (PP (IN before) (NP (NP (NN stem) (NN cell) (NN transplantation)) (PP (IN for) (NP (NP (JJR younger) (NNS patients)) (PP (IN with) (NP (NP (ADJP (RB newly) (VBN diagnosed)) (NNP Doc_19274460_406_422_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_19274460_424_426_Disease)) (-RRB- -RRB-))))))))))))))) (. .)))
19274460	2	(S1 (S (NP (CD Thirty) (NNS patients)) (VP (AUX were) (VP (VBN treated) (PP (IN with) (NP (NP (CD three) (JJ 21-day) (NNS cycles)) (PP (IN of) (NP (NP (NNP Doc_19274460_486_496_Chemical) (CD 1.3) (NNS mg/m)) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-)))) (PP (IN on) (NP (NNS days) (CD 1) (, ,) (CD 4) (, ,) (CD 8) (, ,) (CC and) (NP (CD 11)) (CC plus) (NP (NP (NNP Doc_19274460_538_551_Chemical) (CD 40) (NNS mg)) (PP (IN on) (NP (NP (DT the) (NN day)) (PP (IN of) (NP (NP (JJ Doc_19274460_572_582_Chemical) (NN injection)) (CC and) (NP (NP (DT the) (NN day)) (PP (IN after) (NP (JJ plus) (NNP Doc_19274460_616_632_Chemical))) (PP (IN at) (NP (NP (CD 900)) (, ,) (NP (CD 1,200)) (, ,) (CC or) (NP (CD 1,500) (NN mg/m)) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-)) (PP (IN on) (NP (NN day) (CD 1))))))))))))))))) (. .)))
19274460	3	(S1 (S (NP (NP (DT The) (JJ maximum) (JJ tolerated) (NN dose)) (PP (IN of) (NP (NNP Doc_19274460_705_721_Chemical)))) (VP (AUX was) (VP (VBN defined) (PP (IN as) (NP (NP (CD 900) (NN mg/m)) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-)))))) (. .)))
19274460	4	(S1 (S (PP (IN At) (NP (DT this) (NN dose) (NN level))) (, ,) (NP (NP (CD 92) (NN %)) (PP (IN of) (NP (NNS patients)))) (VP (VBD achieved) (NP (ADVP (IN at) (JJS least)) (DT a) (JJ partial) (NN response))) (. .)))
19274460	5	(S1 (S (NP (NP (NP (NP (DT The) (JJ overall) (NN response) (NN rate)) (NP (JJ -LSB-complete) (NN response))) (PRN (-LRB- -LRB-) (NP (NNP CR)) (-RRB- -RRB-))) (CC plus) (NP (NP (JJ partial) (NN response) (PRN (-LRB- -LRB-) (NNP PR) (-RRB- -RRB-)) (NN -RSB-)) (PP (IN across) (NP (DT all) (NN dose) (NNS levels))))) (VP (AUX was) (NP (CD 77) (NN %)) (, ,) (PP (IN with) (NP (DT a) (ADJP (CD 10) (NN %)) (JJ CR) (NN rate)))) (. .)))
19274460	6	(S1 (S (NP (DT No) (NN patient)) (VP (VBD experienced) (NP (JJ progressive) (NN disease))) (. .)))
19274460	7	(S1 (S (NP (DT The) (JJS most) (JJ frequent) (JJ adverse) (NNS events)) (VP (AUX were) (ADJP (JJ Doc_19274460_1036_1081_Disease) (CONJP (RB as) (RB well) (IN as)) (JJ Doc_19274460_1093_1103_Disease))) (. .)))
19274460	8	(S1 (S (NP (DT The) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NP (NNP Doc_19274460_1130_1140_Chemical)) (PP (IN in) (NP (NN combination))) (PP (IN with) (NP (NNP Doc_19274460_1161_1177_Chemical))) (PP (IN at) (NP (NP (QP (CD 900) (CD mg/m))) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-))))) (CC and) (NP (NNP Doc_19274460_1197_1210_Chemical))) (VP (AUX is) (NP (NP (DT an) (JJ effective) (NN induction) (NN treatment)) (PP (IN for) (NP (NP (NNS patients)) (PP (IN with) (NP (ADJP (RB newly) (VBN diagnosed)) (NNP Doc_19274460_1281_1283_Disease))))) (SBAR (WHNP (WDT that)) (S (VP (VBZ warrants) (NP (JJ further) (NN investigation)))))))))) (. .)))
1928887	0	(S1 (NP (NP (JJ Doc_1928887_0_8_Chemical) (NN reversal)) (PP (IN of) (NP (NNP Doc_1928887_21_32_Disease))) (PP (JJ due) (TO to) (NP (NNP Doc_1928887_40_49_Chemical) (NNP Doc_1928887_50_58_Disease))) (. .)))
1928887	1	(S1 (S (NP (NP (DT The) (JJ hemodynamic) (NNS effects)) (PP (IN of) (NP (NP (NNP Doc_1928887_87_96_Chemical)) (CC and) (NP (JJ other) (JJ Doc_1928887_107_118_Chemical-converting) (NN enzyme) (NNS inhibitors))))) (VP (MD may) (VP (AUX be) (VP (VBN mediated) (PP (IN by) (NP (DT the) (JJ endogenous) (NN opioid) (NN system)))))) (. .)))
1928887	2	(S1 (S (NP (DT The) (NN opioid) (NN antagonist) (NN Doc_1928887_219_227_Chemical)) (VP (AUX has) (VP (AUX been) (VP (VBN shown) (S (VP (TO to) (VP (VB block) (CC or) (VB reverse) (NP (NP (DT the) (JJ Doc_1928887_267_278_Disease) (NNS actions)) (PP (IN of) (NP (NNP Doc_1928887_290_299_Chemical)))))))))) (. .)))
1928887	3	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NP (DT an) (JJ intentional) (JJ Doc_1928887_336_345_Chemical) (NN Doc_1928887_346_354_Disease)) (, ,) (VP (VBN manifested) (PP (IN by) (NP (JJ marked) (NNP Doc_1928887_377_388_Disease)))) (, ,) (SBAR (WHNP (WDT that)) (S (VP (VBD resolved) (ADVP (RB promptly)) (PP (IN with) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NNP Doc_1928887_440_448_Chemical)))))))))))) (. .)))
1928887	4	(S1 (S (PP (TO To) (NP (PRP$ our) (NN knowledge))) (, ,) (NP (DT this)) (VP (AUX is) (NP (NP (DT the) (JJ first) (JJ reported) (NN case)) (PP (IN of) (NP (NP (NNP Doc_1928887_503_512_Chemical-induced) (NNP Doc_1928887_521_532_Disease)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_1928887_546_554_Chemical)))))))) (. .)))
1928887	5	(S1 (S (NP (PRP$ Our) (NN experience)) (VP (VBZ demonstrates) (NP (NP (DT a) (JJ possible) (NN role)) (PP (IN of) (NP (NNP Doc_1928887_603_611_Chemical))) (PP (IN in) (NP (NP (DT the) (NN reversal)) (PP (IN of) (NP (NP (NNP Doc_1928887_631_642_Disease)) (VP (VBG resulting) (PP (IN from) (NP (NNP Doc_1928887_658_667_Chemical)))))))))) (. .)))
19289093	0	(S1 (NP (NP (NN Identification)) (PP (IN of) (NP (NP (DT a) (ADJP (JJ simple) (CC and) (JJ sensitive)) (NN microplate) (NN method)) (PP (IN for) (NP (NP (DT the) (NN detection)) (PP (IN of) (NP (JJ oversulfated) (NNP Doc_19289093_93_112_Chemical))) (PP (IN in) (NP (JJ Doc_19289093_116_123_Chemical) (NNS products))))))) (. .)))
19289093	1	(S1 (S (NP (NN Doc_19289093_134_141_Chemical)) (VP (AUX is) (NP (NP (DT a) (ADJP (RB commonly) (VBN implemented)) (NN anticoagulant)) (VP (VBN used) (S (VP (TO to) (VP (VB treat) (NP (ADJP (RB critically) (JJ ill)) (NNS patients)))))))) (. .)))
19289093	2	(S1 (S (ADVP (RB Recently)) (, ,) (NP (NP (DT a) (NN number)) (PP (IN of) (NP (NP (JJ commercial) (NNS lots)) (PP (IN of) (NP (NNP Doc_19289093_262_269_Chemical) (NNS products)))))) (VP (AUX were) (VP (VBN found) (S (VP (TO to) (VP (AUX be) (VP (VBN contaminated) (PP (IN with) (NP (NP (DT an) (JJ oversulfated) (NNP Doc_19289093_330_349_Chemical) (PRN (-LRB- -LRB-) (NP (NNP OSCS)) (-RRB- -RRB-)) (NN derivative)) (SBAR (WHNP (WDT that)) (S (VP (MD could) (VP (VB elicit) (NP (DT a) (JJ Doc_19289093_388_399_Disease) (NN response)) (PP (IN in) (S (NP (NNS pigs)) (VP (VBG following) (NP (DT a) (JJ single) (JJ high-dose) (NN infusion))))))))))))))))) (. .)))
19289093	3	(S1 (S (S (VP (VBG Using) (NP (NP (DT both) (VBN contaminated) (NN heparin) (NNS products)) (CC and) (NP (DT the) (ADJP (RB synthetically) (VBN produced)) (NN derivative))))) (, ,) (NP (PRP we)) (VP (VBD showed) (SBAR (IN that) (S (NP (DT the) (NN OSCS)) (VP (VBZ produces) (NP (NP (JJ dose-dependent) (NN Doc_19289093_588_599_Disease)) (PP (IN in) (NP (NNS pigs)))))))) (. .)))
19289093	4	(S1 (S (NP (NP (DT The) (ADJP (RB no) (JJ observed)) (NN effect) (NN level)) (PRN (-LRB- -LRB-) (NP (NNP NOEL)) (-RRB- -RRB-)) (PP (IN for) (NP (DT this) (NN contaminant)))) (VP (VBZ appears) (S (VP (TO to) (VP (AUX be) (ADJP (RB approximately) (JJ 1mg/kg)) (, ,) (S (VP (VBG corresponding) (PP (TO to) (NP (NP (DT a) (NN contamination) (NN level)) (PP (IN of) (NP (QP (RB approximately) (CD 3)) (NN %))))))))))) (. .)))
19289093	5	(S1 (S (NP (PRP We)) (ADVP (RB also)) (VP (VBD demonstrated) (SBAR (IN that) (S (NP (NNS OSCS)) (VP (MD can) (VP (AUX be) (VP (VBN identified) (PP (IN in) (NP (NP (JJ heparin) (NNS products)) (VP (VBG using) (NP (NP (DT a) (JJ simple) (, ,) (JJ inexpensive) (, ,) (ADJP (RB commercially) (JJ available)) (NN heparin) (NN enzyme) (NN immunoassay) (-LRB- -LRB-) (NN EIA) (-RRB- -RRB-) (NN kit)) (SBAR (WHNP (WDT that)) (S (VP (AUX has) (NP (NP (DT a) (NN limit)) (PP (IN of) (NP (NP (NN detection)) (PP (IN of) (NP (QP (RB approximately) (CD 0.1)) (NN %)))))) (, ,) (PP (ADVP (RB well)) (IN below) (NP (DT the) (NNP NOEL)))))))))))))))) (. .)))
19289093	6	(S1 (S (NP (DT This) (NN kit)) (VP (MD may) (VP (VB provide) (NP (NP (DT a) (JJ useful) (NN method)) (SBAR (S (VP (TO to) (VP (VB test) (NP (NP (JJ Doc_19289093_1039_1046_Chemical) (NNS products)) (PP (IN for) (NP (NP (NN contamination)) (PP (IN with) (NP (JJ oversulfated) (NN GAG) (NNS derivatives))))))))))))) (. .)))
19300240	0	(S1 (NP (NP (CD 5) (JJ Doc_19300240_2_14_Chemical-induced) (NN Doc_19300240_23_49_Disease)) (: :) (NP (DT a) (NN case) (NN report)) (. .)))
19300240	1	(S1 (S (NP (NP (DT The) (NNP Doc_19300240_70_96_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_19300240_98_101_Disease)) (-RRB- -RRB-))) (VP (AUX is) (NP (NP (DT a) (ADJP (RB recently) (VBN described)) (JJ stress-mediated) (NN Doc_19300240_143_165_Disease)) (VP (VBN characterized) (PP (IN by) (NP (NP (JJ transient) (NN wall-motion) (NNS abnormalities)) (VP (VBG involving) (NP (NP (DT the) (NN apex) (CC and) (NN midventricle)) (PP (IN with) (NP (NP (NNP Doc_19300240_260_272_Disease)) (PP (IN of) (NP (NP (DT the) (JJ basal) (NN left) (NN ventricular) (PRN (-LRB- -LRB-) (NP (NNP LV)) (-RRB- -RRB-)) (NNS segments)) (PP (IN without) (NP (JJ obstructive) (NNP Doc_19300240_337_364_Disease)))))))))))))) (. .)))
19300240	2	(S1 (S (NP (NN Doc_19300240_366_380_Disease)) (VP (AUX is) (RB not) (NP (NP (DT an) (JJ uncommon) (JJ adverse) (NN effect)) (PP (IN of) (NP (JJ chemotherapeutic) (NNS agents))))) (. .)))
19300240	3	(S1 (S (ADVP (RB However)) (, ,) (NP (EX there)) (VP (AUX are) (NP (NP (DT no) (NNS reports)) (PP (IN of) (NP (ADJP (NNP Doc_19300240_476_479_Disease) (JJ secondary) (TO to) (JJ chemotherapeutic)) (NNS agents))))) (. .)))
19300240	4	(S1 (S (NP (PRP We)) (VP (VBP describe) (NP (NP (DT the) (NN case)) (PP (IN of) (NP (NP (DT a) (NN woman)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (DT the) (NN syndrome)) (PP (IN after) (S (VP (VBG chemotherapy) (PP (IN for) (NP (JJ metastatic) (NN Doc_19300240_611_617_Disease))))))))))))) (. .)))
19300240	5	(S1 (S (NP (NP (DT A) (JJ 79-year-old) (NN woman)) (VP (VBN presented) (PP (IN with) (NP (JJ typical) (NNP Doc_19300240_662_670_Disease) (NNP Doc_19300240_671_681_Disease))))) (, ,) (VP (VBD elevated) (NP (NP (JJ cardiac) (NNS enzymes)) (PP (IN with) (NP (NP (JJ significant) (JJ ST-segment) (NNS abnormalities)) (PP (IN on) (NP (PRP$ her) (NN electrocardiogram))))))) (. .)))
19300240	6	(S1 (S (NP (PRP She)) (VP (VBD underwent) (NP (NP (JJ recent) (NN chemotherapy)) (PP (IN with) (NP (NNP Doc_19300240_815_827_Chemical))) (PP (IN for) (NP (JJ metastatic) (NN Doc_19300240_843_860_Disease))))) (. .)))
19300240	7	(S1 (S (NP (NN Echocardiography)) (VP (VBD revealed) (NP (NP (DT a) (JJ wall-motion) (NN abnormality)) (VP (VBG involving) (NP (NP (DT the) (ADJP (JJ apical) (CC and) (JJ periapical)) (NNS segments)) (SBAR (WHNP (WDT which)) (S (VP (VBD appeared) (NP (NNP Doc_19300240_974_982_Disease))))))))) (. .)))
19300240	8	(S1 (S (NP (JJ Coronary) (NN angiography)) (VP (VBD revealed) (NP (DT no) (JJ obstructive) (JJ coronary) (NNS lesions))) (. .)))
19300240	9	(S1 (S (NP (DT The) (NN patient)) (VP (AUX was) (VP (VBN stabilized) (PP (IN with) (NP (JJ medical) (NN therapy))))) (. .)))
19300240	10	(S1 (S (ADVP (NP (CD Four) (NNS weeks)) (RB later)) (NP (PRP she)) (VP (VBD remained) (ADJP (RB completely) (JJ asymptomatic))) (. .)))
19300240	11	(S1 (S (NP (NN Echocardiogram)) (VP (VBD revealed) (NP (NP (DT a) (JJ normal) (NN ejection) (NN fraction)) (CC and) (NP (NP (DT a) (NN resolution)) (PP (IN of) (NP (DT the) (JJ apical) (NNS akinesis)))))) (. .)))
19300240	12	(S1 (S (NP (NP (JJ Pathogenetic) (NNS mechanisms)) (PP (IN of) (NP (NNP Doc_19300240_1270_1291_Disease))) (PP (IN in) (NP (NP (JJ Doc_19300240_1295_1301_Disease) (NNS patients)) (VP (VBG undergoing) (NP (NN chemotherapy)))))) (VP (VBP include) (NP (NP (NNP Doc_19300240_1343_1361_Disease)) (, ,) (NP (NN endothelial) (NN damage)) (CC and) (NP (JJ consequent) (NN Doc_19300240_1397_1405_Disease) (NN formation)))) (. .)))
19300240	13	(S1 (S (PP (IN In) (NP (PRP$ our) (NN patient))) (, ,) (NP (NP (DT both) (JJ supraphysiologic) (NNS levels)) (PP (IN of) (NP (NP (NN plasma) (UCP (JJ Doc_19300240_1472_1486_Chemical) (CC and) (NN stress)) (JJ related) (NNS neuropeptides)) (VP (VBN caused) (PP (IN by) (NP (NP (JJ Doc_19300240_1530_1536_Disease) (NN diagnosis)) (CONJP (RB as) (RB well) (IN as)) (NP (NN chemotherapy)))))))) (VP (MD may) (VP (AUX have) (VP (VBN contributed) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_19300240_1611_1614_Disease))))))) (. .)))
19319147	0	(S1 (S (NP (NP (JJ Rapid) (NN reversal)) (PP (IN of) (NP (NN anticoagulation)))) (VP (VBZ reduces) (NP (NN Doc_19319147_42_52_Disease) (NN volume)) (PP (IN in) (NP (NP (DT a) (NN mouse) (NN model)) (PP (IN of) (NP (NNP Doc_19319147_80_88_Chemical-associated) (NNP Doc_19319147_100_124_Disease)))))) (. .)))
19319147	1	(S1 (S (NP (NP (JJ Doc_19319147_126_134_Chemical-associated) (NNP Doc_19319147_146_170_Disease)) (PRN (-LRB- -LRB-) (NP (NNP W-ICH)) (-RRB- -RRB-))) (VP (AUX is) (NP (NP (DT a) (JJ severe) (NN type)) (PP (IN of) (NP (NN Doc_19319147_199_205_Disease))))) (. .)))
19319147	2	(S1 (S (NP (EX There)) (VP (AUX is) (NP (NP (DT no) (NN consensus)) (PP (IN on) (NP (NP (DT the) (JJ optimal) (NN treatment)) (PP (IN for) (NP (NN W-ICH))))))) (. .)))
19319147	3	(S1 (S (S (VP (VBG Using) (NP (DT a) (NN mouse) (NN model)))) (, ,) (NP (PRP we)) (VP (VBD tested) (SBAR (IN whether) (S (NP (NP (DT the) (JJ rapid) (NN reversal)) (PP (IN of) (NP (NP (NN anticoagulation)) (VP (VBG using) (NP (NP (JJ human) (JJ prothrombin) (JJ complex) (NN concentrate)) (PRN (-LRB- -LRB-) (NP (NNP Doc_19319147_387_390_Chemical)) (-RRB- -RRB-))))))) (VP (MD can) (VP (VB reduce) (NP (JJ hemorrhagic) (NN blood) (NN volume))))))) (. .)))
19319147	4	(S1 (S (NP (JJ Male) (JJ CD-1) (NNS mice)) (VP (AUX were) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_19319147_462_470_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 2) (CD mg/kg) (IN over) (CD 24)) (NNP h)) (-RRB- -RRB-)))) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (NP (DT a) (JJ mean) (PRN (-LRB- -LRB-) (JJ +/-s.d.) (-RRB- -RRB-)) (JJ International) (JJ Normalized) (NN Ratio)) (PP (IN of) (NP (CD 3.5+/-0.9))))))))) (. .)))
19319147	5	(S1 (S (ADVP (RB First)) (, ,) (NP (PRP we)) (VP (VBD showed) (SBAR (IN that) (S (NP (NP (DT an) (JJ intravenous) (NN administration)) (PP (IN of) (NP (JJ human) (NN Doc_19319147_628_631_Chemical)))) (ADVP (RB rapidly)) (VP (VBD reversed) (NP (NN anticoagulation)) (PP (IN in) (NP (NNS mice))))))) (. .)))
19319147	6	(S1 (S (ADVP (JJ Second)) (, ,) (NP (NP (DT a) (JJ stereotactic) (NN injection)) (PP (IN of) (NP (NN collagenase)))) (VP (AUX was) (VP (VBN administered) (S (VP (TO to) (VP (VB induce) (NP (NN Doc_19319147_749_759_Disease)) (PP (IN in) (NP (DT the) (JJ right) (NN striatum)))))))) (. .)))
19319147	7	(S1 (S (ADVP (NP (JJ Forty-five) (NNS minutes)) (RB later)) (, ,) (NP (DT the) (NNS animals)) (VP (AUX were) (ADVP (RB randomly)) (VP (VBN treated) (PP (IN with) (NP (NP (NP (NNP Doc_19319147_848_851_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 100) (NN U/kg)) (-RRB- -RRB-))) (CC or) (NP (NP (JJ saline) (NNS i.v.)) (PRN (-LRB- -LRB-) (NP (NP (CD n=12)) (PP (IN per) (NP (NN group)))) (-RRB- -RRB-))))))) (. .)))
19319147	8	(S1 (S (PP (NP (JJ Twenty-four) (NNS hours)) (IN after) (NP (NNP Doc_19319147_920_930_Disease) (NN induction))) (, ,) (NP (JJ hemorrhagic) (NN blood) (NN volume)) (VP (AUX was) (VP (VBN quantified) (S (VP (VBG using) (NP (DT a) (JJ photometric) (NN hemoglobin) (NN assay)))))) (. .)))
19319147	9	(S1 (S (NP (DT The) (JJ mean) (JJ hemorrhagic) (NN blood) (NN volume)) (VP (AUX was) (VP (VBN reduced) (PP (IN in) (NP (NP (JJ Doc_19319147_1069_1072_Chemical-treated) (NNS animals)) (PRN (-LRB- -LRB-) (NP (CD 6.5+/-3.1) (NN microL)) (-RRB- -RRB-)))) (PP (VBN compared) (PP (IN with) (NP (NP (JJ saline) (NNS controls)) (PRN (-LRB- -LRB-) (NP (NP (CD 15.3+/-11.2) (NN microL)) (, ,) (NP (NNP P=0.015))) (-RRB- -RRB-))))))) (. .)))
19319147	10	(S1 (S (PP (IN In) (NP (DT the) (JJ saline) (NN group))) (, ,) (NP (NP (CD 45) (NN %)) (PP (IN of) (NP (DT the) (NNS mice)))) (VP (VBD developed) (NP (NP (JJ large) (NN Doc_19319147_1222_1231_Disease)) (PRN (-LRB- -LRB-) (FW i.e.) (, ,) (ADJP (CD >15) (NN microL)) (-RRB- -RRB-)))) (. .)))
19319147	11	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (JJ such) (JJ extensive) (NNS lesions)) (VP (AUX were) (ADVP (RB never)) (VP (VBN found) (PP (IN in) (NP (DT the) (NNP PCC) (NN group))))) (. .)))
19319147	12	(S1 (S (NP (PRP We)) (VP (VBP provide) (NP (NP (JJ experimental) (NNS data)) (VP (VBG suggesting) (NP (NNP Doc_19319147_1363_1366_Chemical)) (S (VP (TO to) (VP (AUX be) (NP (NP (DT an) (JJ effective) (JJ acute) (NN treatment)) (PP (IN for) (NP (NNP W-ICH)))) (PP (IN in) (NP (NP (NNS terms)) (PP (IN of) (S (VP (VBG reducing) (NP (JJ hemorrhagic) (NN blood) (NN volume))))))))))))) (. .)))
19319147	13	(S1 (S (NP (JJ Future) (NNS studies)) (VP (AUX are) (VP (VBN needed) (S (VP (TO to) (VP (VB assess) (NP (NP (DT the) (JJ therapeutic) (NN potential)) (VP (VBG emerging) (PP (IN from) (NP (PRP$ our) (NN finding))) (PP (IN for) (NP (JJ human) (NN W-ICH)))))))))) (. .)))
19370593	0	(S1 (NP (NP (JJ Long) (NN term) (NN hormone) (NN therapy)) (PP (IN for) (NP (JJ perimenopausal) (CC and) (JJ postmenopausal) (NNS women))) (. .)))
19370593	1	(S1 (S (NP (NP (NN Hormone) (NN therapy)) (PRN (-LRB- -LRB-) (NP (NN HT)) (-RRB- -RRB-))) (VP (VP (AUX is) (ADVP (RB widely)) (VP (VBN used) (PP (IN for) (S (VP (VBG controlling) (NP (JJ menopausal) (NNS symptoms))))))) (CC and) (VP (AUX has) (ADVP (RB also)) (VP (AUX been) (VP (VBN used) (PP (IN for) (NP (NP (DT the) (NN management) (CC and) (NN prevention)) (PP (IN of) (NP (NNP Doc_19370593_215_237_Disease) (, ,) (NNP Doc_19370593_239_251_Disease) (CC and) (NNP Doc_19370593_256_264_Disease))) (PP (IN in) (NP (JJR older) (NNS women))))))))) (. .)))
19370593	2	(S1 (S (NP (DT This)) (VP (AUX is) (NP (NP (DT an) (VBN updated) (NN version)) (PP (IN of) (NP (NP (DT the) (JJ original) (JJ Cochrane) (NN review)) (VP (ADVP (RB first)) (VBN published) (PP (IN in) (NP (CD 2005)))))))) (. .)))
19370593	3	(S1 (FRAG (S (VP (TO To) (VP (VB assess) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (JJ long-term) (NNS HT))) (PP (IN on) (NP (NP (NN mortality)) (, ,) (NP (JJ cardiovascular) (NNS outcomes)) (, ,) (NP (NP (NNP Doc_19370593_453_459_Disease) (, ,) (NNP Doc_19370593_461_480_Disease) (, ,) (NN cognition) (, ,) (NN Doc_19370593_493_502_Disease) (CC and) (NN quality)) (PP (IN of) (NP (NN life)))))))))) (. .)))
19370593	4	(S1 (NP (NP (NN SEARCH) (NN STRATEGY)) (: :) (S (NP (PRP We)) (VP (VBD searched) (NP (NP (NP (DT the) (JJ following) (NNS databases)) (PP (TO to) (NP (NNP November) (CD 2007)))) (: :) (NP (NP (NP (NNS Trials) (NNP Register)) (PP (IN of) (NP (DT the) (NNP Cochrane) (NNP Doc_19370593_627_646_Disease) (CC and) (NNP Subfertility) (NNP Group)))) (, ,) (NP (NP (NNP Cochrane) (NNP Central) (NNP Register)) (PP (IN of) (NP (JJ Controlled) (NNS Trials)))) (, ,) (NP (NNP MEDLINE)) (, ,) (NP (NNP EMBASE)) (, ,) (NP (JJ Biological) (NNS Abstracts)))))) (. .)))
19370593	5	(S1 (FRAG (ADVP (RB Also)) (NP (NP (JJ relevant) (JJ non-indexed) (NNS journals)) (CC and) (NP (NN conference) (NNS abstracts))) (. .)))
19370593	6	(S1 (NP (NP (NN SELECTION) (NNS CRITERIA)) (: :) (NP (NP (JJ Randomised) (JJ double-blind) (NNS trials)) (PP (IN of) (NP (NN HT))) (PP (IN versus) (NP (NN placebo))) (, ,) (VP (VBN taken) (PP (IN for) (NP (QP (IN at) (JJS least) (CD one)) (NN year))) (PP (IN by) (NP (JJ perimenopausal) (CC or) (JJ postmenopausal) (NNS women))))) (. .)))
19370593	7	(S1 (S (NP (NNS HT)) (VP (VBD included) (NP (NNP Doc_19370593_975_985_Chemical)) (, ,) (PP (IN with) (CC or) (PP (IN without) (NP (NNS progestogens)))) (, ,) (PP (IN via) (NP (ADJP (JJ oral) (, ,) (JJ transdermal) (, ,) (JJ subcutaneous) (CC or) (JJ transnasal)) (NNS routes)))) (. .)))
19370593	8	(S1 (NP (NP (NP (NNS DATA) (NN COLLECTION)) (CC AND) (NP (NN ANALYSIS))) (: :) (NP (NP (CD Two) (NNS authors)) (VP (VP (ADVP (RB independently)) (VBN assessed) (NP (NN trial) (NN quality))) (CC and) (VP (VBN extracted) (NP (NN data))))) (. .)))
19370593	9	(S1 (NP (NP (JJ MAIN) (NNS RESULTS)) (: :) (S (NP (NP (JJ Nineteen) (NNS trials)) (VP (VBG involving) (NP (CD 41,904) (NNS women)))) (VP (AUX were) (VP (VBN included)))) (. .)))
19370593	10	(S1 (S (PP (IN In) (NP (ADJP (RB relatively) (JJ healthy)) (NNS women))) (, ,) (NP (VBN combined) (JJ continuous) (NNS HT)) (VP (ADVP (RB significantly)) (VBD increased) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NP (NP (NP (NNP Doc_19370593_1330_1353_Disease)) (CC or) (NP (JJ coronary) (NN event))) (PRN (-LRB- -LRB-) (PP (IN after) (NP (NP (CD one) (NN year) (POS 's)) (NN use))) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Doc_19370593_1396_1402_Disease)) (PRN (-LRB- -LRB-) (PP (IN after) (NP (CD three) (NNS years))) (-RRB- -RRB-))) (, ,) (NP (NNP Doc_19370593_1424_1437_Disease)) (CC and) (NP (NNP Doc_19370593_1442_1461_Disease)))))) (. .)))
19370593	11	(S1 (S (NP (JJ Long-term) (JJ Doc_19370593_1473_1482_Chemical-only) (NNS HT)) (VP (VP (ADVP (RB significantly)) (VBD increased) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NP (NNP Doc_19370593_1527_1550_Disease)) (, ,) (NP (NP (NNP Doc_19370593_1552_1558_Disease) (CC and) (NNP Doc_19370593_1563_1582_Disease)) (PRN (-LRB- -LRB-) (PP (IN after) (NP (NP (NP (QP (CD one) (TO to) (CD two)) (NNS years)) (, ,) (NP (CD three) (NNS years))) (CC and) (NP (NP (CD seven) (NNS years) (POS ')) (NN use))) (ADVP (RB respectively))) (-RRB- -RRB-))) (, ,))))) (CC but) (VP (AUX did) (RB not) (VP (ADVP (RB significantly)) (VB increase) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NNP Doc_19370593_1703_1716_Disease))))))) (. .)))
19370593	12	(S1 (S (NP (NP (DT The) (ADJP (RB only) (RB statistically) (JJ significant)) (NNS benefits)) (PP (IN of) (NP (NN HT)))) (VP (AUX were) (NP (NP (DT a) (VBN decreased) (NN incidence)) (PP (IN of) (NP (NP (NNP Doc_19370593_1798_1807_Disease)) (CC and) (PRN (-LRB- -LRB-) (PP (IN for) (NP (JJ combined) (NNS HT))) (-RRB- -RRB-)) (NP (NNP Doc_19370593_1830_1842_Disease))))) (, ,) (PP (IN with) (NP (JJ long-term) (NN use)))) (. .)))
19370593	13	(S1 (S (PP (IN Among) (NP (NP (NNS women)) (VP (VBN aged) (PP (IN over) (NP (CD 65)))) (SBAR (WHNP (WP who)) (S (VP (AUX were) (ADJP (RB relatively) (JJ healthy)) (PRN (-LRB- -LRB-) (FW i.e.) (ADVP (RB generally)) (NP (NN fit)) (, ,) (PP (IN without) (NP (NN overt) (NN disease))) (-RRB- -RRB-)) (CC and) (VP (VBG taking) (NP (JJ continuous) (JJ combined) (NNS HT)))))))) (, ,) (NP (EX there)) (VP (AUX was) (NP (NP (DT a) (ADJP (RB statistically) (JJ significant)) (NN increase)) (PP (IN in) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NNP Doc_19370593_2063_2071_Disease))))))) (. .)))
19370593	14	(S1 (S (PP (IN Among) (NP (NP (NNS women)) (PP (IN with) (NP (NNP Doc_19370593_2090_2112_Disease))))) (, ,) (NP (NP (JJ long-term) (NN use)) (PP (IN of) (NP (JJ combined) (JJ continuous) (NNS HT)))) (VP (ADVP (RB significantly)) (VBN increased) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NNP Doc_19370593_2190_2213_Disease))))) (. .)))
19370593	15	(S1 (S (NP (CD One) (NN trial)) (VP (VBD analysed) (NP (NP (NNS subgroups)) (PP (IN of) (NP (NP (CD 2839) (ADJP (RB relatively) (JJ healthy) (QP (CD 50) (TO to) (CD 59)) (NN year)) (JJ old) (NNS women)) (VP (VBG taking) (NP (NP (JJ combined) (JJ continuous) (NN HT)) (CC and) (NP (NP (CD 1637)) (VP (VBG taking) (NP (NP (JJ Doc_19370593_2340_2349_Chemical-only) (NNS HT)) (, ,) (CC versus) (NP (JJ similar-sized) (NN placebo) (NNS groups))))))))))) (. .)))
19370593	16	(S1 (S (S (NP (NP (DT The) (JJ only) (ADJP (RB significantly) (JJ increased)) (NN risk)) (VP (VBD reported))) (VP (AUX was) (PP (IN for) (NP (NNP Doc_19370593_2451_2474_Disease))) (PP (IN in) (NP (NP (NNS women)) (VP (VBG taking) (NP (JJ combined) (JJ continuous) (NNS HT))))))) (: :) (S (NP (PRP$ their) (JJ absolute) (NN risk)) (VP (VBD remained) (ADJP (JJ low)) (, ,) (PP (IN at) (NP (QP (JJR less) (IN than) (CD 1/500)))))) (. .)))
19370593	17	(S1 (S (ADVP (RB However)) (, ,) (NP (DT this) (NN study)) (VP (AUX was) (RB not) (VP (VBN powered) (S (VP (TO to) (VP (VB detect) (NP (NP (NNS differences)) (PP (IN between) (NP (NP (NNS groups)) (PP (IN of) (NP (JJR younger) (NNS women))))))))))) (. .)))
19370593	18	(S1 (NP (NP (NP (NNS AUTHORS) (POS ')) (NNS CONCLUSIONS)) (: :) (S (NP (NN HT)) (VP (AUX is) (RB not) (VP (VBN indicated) (PP (IN for) (NP (NP (DT the) (JJ routine) (NN management)) (PP (IN of) (NP (NN chronic) (NN disease)))))))) (. .)))
19370593	19	(S1 (S (NP (PRP We)) (VP (AUX need) (NP (NP (JJR more) (NN evidence)) (PP (IN on) (NP (NP (DT the) (NN safety)) (PP (IN of) (NP (NP (NNS HT)) (PP (IN for) (NP (JJ menopausal) (NN symptom) (NN control)))))))) (, ,) (SBAR (IN though) (S (NP (JJ short-term) (NN use)) (VP (VBZ appears) (S (VP (TO to) (VP (AUX be) (ADJP (RB relatively) (JJ safe)) (PP (IN for) (NP (JJ healthy) (JJR younger) (NNS women)))))))))) (. .)))
19642243	0	(S1 (S (VP (VB Doc_19642243_0_19_Disease) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_19642243_37_41_Disease))))) (PP (IN on) (NP (NNP Doc_19642243_45_54_Chemical))) (PP (IN while) (S (VP (VBG receiving) (NP (JJ prolonged) (JJ Doc_19642243_81_91_Chemical) (NN course)) (PP (IN for) (NP (NNP Doc_19642243_103_116_Disease))))))) (. .)))
19642243	1	(S1 (S (NP (NN Doc_19642243_118_131_Disease)) (VP (VBD developed) (PP (IN after) (NP (NP (DT a) (JJ prolonged) (NN course)) (PP (IN of) (NP (JJ Doc_19642243_170_180_Chemical) (NN therapy))))) (PP (IN in) (NP (NP (CD 2) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX were) (S (VP (VBG receiving) (NP (NNP Doc_19642243_222_251_Chemical)) (PP (IN as) (NP (NP (NN part)) (PP (IN of) (NP (DT an) (JJ antiretroviral) (NN regimen))))))))))))) (. .)))
19642243	2	(S1 (S (NP (NN Doc_19642243_290_299_Chemical)) (VP (AUX has) (VP (AUX been) (VP (VBN implicated) (PP (IN in) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NP (NNP Doc_19642243_342_358_Disease)) (CC and) (NP (NNP Doc_19642243_363_382_Disease)))))) (PP (IN because) (IN of) (NP (NP (PRP$ its) (NNS effects)) (PP (IN on) (NP (DT the) (JJ proximal) (JJ renal) (NN tubule)))))))) (. .)))
19642243	3	(S1 (S (NP (JJ Doc_19642243_436_446_Chemical) (NN nephrotoxicity)) (VP (VP (AUX is) (ADJP (JJ infrequent))) (CC but) (VP (MD may) (VP (VB result) (PP (IN from) (NP (NN coadministration))) (PP (IN with) (NP (DT a) (JJ nephrotoxic) (NN agent)))))) (. .)))
19642243	4	(S1 (S (NP (NNS Clinicians)) (VP (MD should) (VP (AUX be) (ADJP (JJ aware) (SBAR (IN that) (S (NP (NNP Doc_19642243_571_580_Chemical)) (VP (MD may) (VP (VB raise) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NNP Doc_19642243_603_616_Disease)))) (PP (IN during) (NP (NP (VBN prolonged) (NN administration)) (PP (IN of) (NP (NN Doc_19642243_652_662_Chemical)))))))))))) (. .)))
19674115	0	(S1 (S (NP (NNP Recurrent) (NNP Doc_19674115_10_18_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_19674115_30_42_Chemical)))) (. .)))
19674115	1	(S1 (S (NP (NN Doc_19674115_44_56_Chemical)) (VP (MD can) (VP (AUX have) (NP (NP (JJ adverse) (NNS effects)) (PP (JJ such) (IN as) (NP (NP (NNP Doc_19674115_90_106_Disease)) (, ,) (NP (NNP Doc_19674115_108_121_Disease)) (CC or) (NP (JJ digestive) (NNS disorders))))))) (. .)))
19674115	2	(S1 (S (PP (IN In) (NP (JJ rare) (NNS cases))) (, ,) (NP (NP (NNS alterations)) (PP (IN in) (NP (NP (NN taste)) (CC and) (NP (NN smell) (NN function))))) (VP (AUX have) (VP (AUX been) (VP (VBN reported) (PP (IN for) (NP (NNP Doc_19674115_224_236_Chemical))) (SBAR (WHADVP (WRB when)) (S (VP (VBN combined) (PP (IN with) (NP (JJ other) (NNS drugs))))))))) (. .)))
19674115	3	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (JJ reversible) (NNP Doc_19674115_300_318_Disease))) (VP (VBN related) (PP (TO to) (NP (NNP Doc_19674115_330_342_Chemical))))) (PP (IN in) (NP (DT a) (NN woman))) (, ,) (PP (IN with) (NP (DT a) (JJ positive) (NN rechallenge)))) (. .)))
19674115	4	(S1 (S (NP (DT The) (NN patient)) (VP (VBD presented) (NP (DT every) (NN day)) (NP (NP (DT a) (NN sensation)) (PP (IN of) (S (VP (VBG smelling) (NP (NP (NN something)) (VP (VBG burning) (NP (CD 15) (NN min)) (PP (IN after) (NP (NN drug) (NN intake)))))))))) (. .)))
19674115	5	(S1 (S (NP (NN Doc_19674115_484_492_Disease)) (VP (VP (VBD disappeared) (ADVP (RB completely)) (PP (IN after) (NP (JJ Doc_19674115_522_534_Chemical) (NN withdrawal)))) (CC and) (VP (VBD recurred) (PP (IN after) (NP (PRP$ its) (NN rechallenge))))) (. .)))
19674115	6	(S1 (S (NP (DT The) (NN case)) (VP (AUX was) (VP (VBN reported) (PP (TO to) (NP (NP (DT the) (NNP Tunisian) (NNP Centre)) (PP (IN of) (NP (NN Pharmacovigilance))))))) (. .)))
19692487	0	(S1 (S (NP (NP (NNS Mice)) (VP (VBG lacking) (NP (NN mPGES-1)))) (VP (AUX are) (ADJP (JJ resistant) (PP (TO to) (NP (NNP Doc_19692487_38_45_Chemical-induced) (NNP Doc_19692487_54_62_Disease))))) (. .)))
19692487	1	(S1 (S (NP (NN Cyclooxygenase-2) (NN activity)) (VP (AUX is) (VP (VBN required) (PP (IN for) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_19692487_125_132_Chemical-induced) (NNP Doc_19692487_141_149_Disease))))))) (. .)))
19692487	2	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (NN involvement)) (PP (IN of) (NP (DT a) (JJ specific) (, ,) (JJ terminal) (NNP Doc_19692487_200_213_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_19692487_215_217_Chemical)) (-RRB- -RRB-)) (NN isomerase)))) (VP (AUX has) (RB not) (VP (AUX been) (VP (VBN evaluated)))) (. .)))
19692487	3	(S1 (S (NP (DT The) (JJ present) (NN study)) (VP (AUX was) (VP (VBN undertaken) (S (VP (TO to) (VP (VB assess) (NP (NP (JJ Doc_19692487_296_303_Chemical-induced) (NN Doc_19692487_312_320_Disease)) (PP (IN in) (NP (NP (NNS mice)) (VP (VBN deficient) (PP (IN in) (NP (NP (JJ microsomal) (JJ Doc_19692487_353_368_Chemical) (NN synthase-1)) (PRN (-LRB- -LRB-) (NP (JJ mPGES-1)) (-RRB- -RRB-))))))))))))) (. .)))
19692487	4	(S1 (S (NP (NP (DT A) (NN 2-wk) (NN administration)) (PP (IN of) (NP (NNP Doc_19692487_416_420_Chemical))) (PRN (-LRB- -LRB-) (NP (QP (CD 4) (CD mmol.kg)) (ADJP (ADJP (PRN (-LRB- -LRB-) (JJ -1) (-RRB- -RRB-)) (JJ .day)) (PRN (-LRB- -LRB-) (ADJP (JJ -1)) (-RRB- -RRB-))) (NNS ip)) (-RRB- -RRB-)) (PP (IN in) (NP (JJ mPGES-1) (NN +/+) (NNS mice)))) (VP (VBD led) (PP (TO to) (NP (DT a) (VBN marked) (NNP Doc_19692487_484_492_Disease))) (PP (IN with) (NP (JJ hyposmotic) (NN urine)))) (. .)))
19692487	5	(S1 (S (NP (DT This)) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (JJ elevated) (JJ renal) (JJ mPGES-1) (NN protein) (NN expression)) (CC and) (NP (VBN increased) (NN urine) (NN Doc_19692487_603_609_Chemical) (NN excretion)))))) (. .)))
19692487	6	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (JJ mPGES-1) (JJ -/-) (NNS mice)) (VP (AUX were) (ADJP (RB largely) (JJ resistant) (PP (TO to) (NP (NP (JJ Doc_19692487_677_684_Chemical-induced) (NN Doc_19692487_693_701_Disease)) (CC and) (NP (NP (DT a) (NN urine)) (VP (VBG concentrating) (NP (NN defect))))))) (, ,) (S (VP (VBN accompanied) (PP (IN by) (NP (NP (ADJP (RB nearly) (JJ complete)) (NN blockade)) (PP (IN of) (NP (JJ high) (NN urine) (NNP Doc_19692487_790_796_Chemical) (CC and) (NNP Doc_19692487_801_805_Chemical) (NN output)))))))) (. .)))
19692487	7	(S1 (S (NP (ADJP (JJ Immunoblotting) (, ,) (JJ immunohistochemistry) (, ,) (CC and) (JJ quantitative)) (PRN (-LRB- -LRB-) (NP (NNP q)) (-RRB- -RRB-)) (NNP RT-PCR)) (ADVP (RB consistently)) (VP (VBD detected) (NP (NP (NP (DT a) (JJ significant) (NN decrease)) (PP (IN in) (NP (NP (JJ aquaporin-2) (PRN (-LRB- -LRB-) (NP (NNP AQP2)) (-RRB- -RRB-)) (NN protein) (NN expression)) (PP (IN in) (NP (PDT both) (DT the) (JJ renal) (NN cortex)))))) (CC and) (NP (NP (NN medulla)) (PP (IN of) (NP (JJ Doc_19692487_1006_1013_Chemical-treated) (NN +/+) (NNS mice)))))) (. .)))
19692487	8	(S1 (S (NP (DT This) (NN decrease)) (VP (AUX was) (ADVP (RB significantly)) (VP (VBN attenuated) (PP (IN in) (NP (DT the) (JJ -/-) (NNS mice))))) (. .)))
19692487	9	(S1 (S (NP (NNP qRT-PCR)) (VP (VBD detected) (NP (NP (JJ similar) (NNS patterns)) (PP (IN of) (NP (NP (NNS changes)) (PP (IN in) (NP (JJ AQP2) (NNS mRNA)))))) (PP (PP (IN in) (NP (DT the) (NN medulla))) (CC but) (PP (RB not) (IN in) (NP (DT the) (NN cortex))))) (. .)))
19692487	10	(S1 (S (ADVP (RB Similarly)) (, ,) (NP (NP (DT the) (JJ total) (NN protein) (NN abundance)) (PP (IN of) (NP (DT the) (JJ Doc_19692487_1234_1236_Chemical-Doc_19692487_1237_1242_Chemical) (NN cotransporter))) (PRN (-LRB- -LRB-) (NP (NNP NKCC2)) (-RRB- -RRB-)) (PP (IN in) (NP (NP (DT the) (NN medulla) (CC but) (RB not)) (PP (IN in) (NP (NP (DT the) (NN cortex)) (PP (IN of) (NP (DT the) (JJ +/+) (NNS mice)))))))) (VP (AUX was) (VP (ADVP (RB significantly)) (VBN reduced) (PP (IN by) (NP (JJ Doc_19692487_1347_1354_Chemical) (NN treatment))))) (. .)))
19692487	11	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NP (DT the) (NN dowregulation)) (PP (IN of) (NP (JJ renal) (JJ medullary) (NN NKCC2) (NN expression)))) (VP (AUX was) (ADVP (RB significantly)) (VP (VBN attenuated) (PP (IN in) (NP (DT the) (JJ -/-) (NNS mice))))) (. .)))
19692487	12	(S1 (S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (S (NP (JJ mPGES-1-derived) (NNP Doc_19692487_1512_1518_Chemical)) (VP (VBZ mediates) (NP (JJ Doc_19692487_1528_1535_Chemical-induced) (NNP Doc_19692487_1544_1552_Disease)) (ADVP (RB likely)) (PP (IN via) (NP (NP (NN inhibition)) (PP (IN of) (NP (NP (NN AQP2)) (CC and) (NP (JJ NKCC2) (NN expression)))))))))) (. .)))
1969772	0	(S1 (S (NP (NP (NN Preservation)) (PP (IN of) (NP (JJ renal) (NN blood)))) (VP (VBP flow) (PP (IN during) (NP (NP (NN Doc_1969772_40_51_Disease)) (VP (VBN induced) (PP (IN with) (NP (NNP Doc_1969772_65_75_Chemical))) (PP (IN in) (NP (NNS dogs))))))) (. .)))
1969772	1	(S1 (S (NP (NP (DT The) (NN introduction)) (PP (IN of) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (MD could) (VP (VB induce) (NP (NN Doc_1969772_129_140_Disease)) (PP (IN with) (NP (JJ different) (JJ pharmacological) (NNS actions)))))))))) (VP (MD would) (VP (AUX be) (ADJP (JJ advantageous)) (SBAR (IN because) (S (NP (NP (JJ side) (NNS effects)) (ADJP (JJ unique) (PP (TO to) (NP (DT a) (JJ specific) (NN drug))))) (VP (MD could) (VP (AUX be) (VP (VBN minimized) (PP (IN by) (S (VP (VBG selecting) (NP (JJ appropriate) (NN therapy)))))))))))) (. .)))
1969772	2	(S1 (S (NP (NP (NP (JJ Specific) (NNP Doc_1969772_311_319_Chemical-1)) (, ,) (PRN (-LRB- -LRB-) (NP (NNP DA1)) (-RRB- -RRB-))) (CC and) (NP (JJ Doc_1969772_333_341_Chemical-2) (PRN (-LRB- -LRB-) (JJ DA2) (-RRB- -RRB-)) (NN receptor) (NNS agonists))) (VP (AUX are) (ADVP (RB now)) (PP (IN under) (NP (JJ clinical) (NN investigation)))) (. .)))
1969772	3	(S1 (S (NP (NN Doc_1969772_406_425_Chemical)) (VP (AUX is) (NP (NP (DT a) (JJ specific) (NN DA1) (NN receptor) (NN agonist)) (SBAR (WHNP (WDT that)) (S (VP (VBZ lowers) (NP (NN blood) (NN pressure)) (PP (IN by) (NP (NN vasodilatation)))))))) (. .)))
1969772	4	(S1 (S (NP (NP (DT The) (NN hypothesis)) (SBAR (WHNP (WDT that)) (S (NP (NNP Doc_1969772_527_537_Chemical)) (VP (MD could) (VP (VP (AUX be) (VP (VBN used) (S (VP (TO to) (VP (VB induce) (NP (NNP Doc_1969772_562_573_Disease))))))) (CC and) (VP (VB preserve) (NP (NN blood) (NN flow)) (PP (TO to) (NP (DT the) (NN kidney))))))))) (VP (AUX was) (VP (VBN tested))) (. .)))
1969772	5	(S1 (S (NP (NP (JJ Systemic) (JJ aortic) (NN blood) (NN pressure)) (CC and) (NP (JJ renal) (NN blood) (NN flow))) (VP (AUX were) (VP (VBN measured) (ADVP (RB continuously)) (PP (IN with) (NP (NP (DT a) (JJ carotid) (NN arterial) (NN catheter)) (CC and) (NP (NP (DT an) (JJ electromagnetic) (NN flow) (NN probe)) (ADVP (RB respectively))))) (, ,) (SBAR (IN in) (NN order) (S (VP (TO to) (VP (VB compare) (NP (NP (DT the) (ADJP (JJ cardiovascular) (CC and) (JJ renal)) (JJ vascular) (NNS effects)) (PP (IN of) (NP (NNP Doc_1969772_853_863_Chemical) (CC and) (NNP Doc_1969772_868_888_Chemical))) (PP (IN in) (NP (CD ten) (NNS dogs)))) (PP (IN under) (NP (JJ Doc_1969772_907_916_Chemical) (JJ general) (NN anaesthesia))))))))) (. .)))
1969772	6	(S1 (S (NP (JJ Mean) (JJ arterial) (NN pressure)) (VP (AUX was) (VP (VBN decreased) (NP (NP (CD 30) (JJ +/-) (CD 8)) (PP (IN per) (NP (NN cent)))) (PP (IN from) (NP (NP (NN control)) (PP (IN with) (NP (NP (NN infusion)) (PP (IN of) (NP (NP (NP (NNP Doc_1969772_1023_1033_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 3.4) (NN +/-) (QP (CD 2.0) (CD micrograms.kg-1.min-1))) (-RRB- -RRB-))) (CC and) (NP (NP (CD 34) (NNS +/-)) (NP (NP (CD 4)) (PP (IN per) (NP (NP (NN cent)) (PP (IN with) (NP (NP (NN infusion)) (PP (IN of) (NP (NP (NNP Doc_1969772_1109_1129_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 5.9) (NN micrograms.kg-1.min-1)) (-RRB- -RRB-)) (PRN (-LRB- -LRB-) (NP (NNP NS)) (-RRB- -RRB-)))))))))))))))))) (. .)))
1969772	7	(S1 (S (NP (NP (JJ Renal) (NN blood) (NN flow)) (PRN (-LRB- -LRB-) (NP (NN RBF)) (-RRB- -RRB-))) (VP (VP (VBD increased) (PP (IN during) (NP (NP (JJ Doc_1969772_1204_1214_Chemical-induced) (NNP Doc_1969772_1223_1234_Disease) (CD 11) (NN +/-) (CD 7)) (PP (IN per) (NP (NN cent)))))) (CC and) (VP (VBD decreased) (NP (CD 21) (NN +/-)) (NP (NP (CD 8)) (PP (IN per) (NP (NN cent)))) (PP (IN during) (NP (NP (NNP Doc_1969772_1292_1312_Chemical-induced) (NNP Doc_1969772_1321_1332_Disease)) (PRN (-LRB- -LRB-) (NP (NNP P) (QP (JJR less) (IN than) (CD 0.01))) (-RRB- -RRB-)))))) (. .)))
1969772	8	(S1 (S (NP (NNP Doc_1969772_1353_1373_Chemical)) (VP (AUX is) (NP (NP (NP (DT a) (JJ non-selective) (NN arteriolar)) (CC and) (NP (JJ venous) (NN vasodilator))) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (VB produce) (NP (NP (NN redistribution)) (PP (IN of) (NP (NN blood) (NN flow)))) (ADVP (RB away) (PP (IN from) (NP (DT the) (NN kidney) (SBAR (IN during) (S (VP (VBN induced) (NP (NNP Doc_1969772_1509_1520_Disease)))))))))))))) (. .)))
1969772	9	(S1 (S (NP (NNP Doc_1969772_1522_1532_Chemical)) (VP (AUX is) (NP (NP (DT a) (JJ selective) (JJ Doc_1969772_1548_1556_Chemical-1) (PRN (-LRB- -LRB-) (NP (NNP DA1)) (-RRB- -RRB-)) (NN receptor) (NN agonist)) (SBAR (WHNP (WDT that)) (S (VP (VP (VBZ causes) (NP (NN vasodilatation)) (PP (TO to) (NP (NP (DT the) (NN kidney) (CC and) (JJ other) (NNS organs)) (PP (IN with) (NP (JJ DA1) (NNS receptors)))))) (CC and) (VP (VBZ preserves) (NP (NN blood) (NN flow)) (PP (TO to) (NP (DT the) (NN kidney) (SBAR (IN during) (S (VP (VBN induced) (S (NP (NNP Doc_1969772_1713_1724_Disease)))))))))))))) (. .)))
19707748	0	(S1 (NP (NP (NP (NN Doc_19707748_0_8_Disease)) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_19707748_25_37_Chemical))))) (: :) (NP (NP (NN case) (NN presentation)) (CC and) (NP (NN literature) (NN review))) (. .)))
19707748	1	(S1 (S (NP (PRP We)) (VP (VBP present) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NP (DT a) (NN patient)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NNP Doc_19707748_134_142_Disease)) (PP (ADVP (RB shortly)) (IN after) (S (VP (VP (VBG initiating) (NP (NN treatment)) (PP (IN with) (NP (NNP Doc_19707748_183_195_Chemical)))) (CC and) (VP (TO to) (VP (VB discuss) (NP (NP (DT the) (JJ potential) (NN drug-drug) (NNS interactions)) (VP (VBN related) (PP (TO to) (NP (NP (DT the) (NN inhibition)) (PP (IN of) (NP (NP (JJ cytochrome) (NNP P450) (PRN (-LRB- -LRB-) (NP (NNP CYP)) (-RRB- -RRB-)) (NNS 1A2)) (PP (PP (IN in) (NP (DT this) (NN case))) (, ,) (CONJP (RB as) (RB well) (IN as)) (PP (IN in) (NP (JJ other) (NNS cases)))))) (, ,) (PP (IN of) (NP (JJ Doc_19707748_347_359_Chemical-induced) (NNP Doc_19707748_368_376_Disease))))))))))))))))))) (. .)))
19707748	2	(S1 (S (NP (JJ Several) (JJ biomedical) (NNS databases)) (VP (AUX were) (VP (VBD searched) (PP (VBG including) (NP (NP (NNP MEDLINE)) (, ,) (NP (NNP Cochrane)) (CC and) (NP (NNP Ovid)))))) (. .)))
19707748	3	(S1 (S (NP (NP (DT The) (JJ main) (NN search) (NNS terms)) (VP (VBN utilized))) (VP (AUX were) (NP (NP (NN case) (NN report)) (CC and) (NP (NN Doc_19707748_520_532_Chemical)))) (. .)))
19707748	4	(S1 (S (NP (DT The) (NN search)) (VP (AUX was) (ADJP (JJ limited) (PP (TO to) (NP (NP (NNS studies)) (VP (VBN published) (PP (IN in) (NP (NNP English)))))))) (. .)))
19707748	5	(S1 (S (NP (NP (CD Six) (NNS cases)) (PP (IN of) (NP (NNP Doc_19707748_612_624_Chemical-induced) (NNP Doc_19707748_633_641_Disease)))) (VP (AUX have) (VP (AUX been) (VP (VBN reported) (PP (IN in) (NP (DT the) (NN literature)))))) (. .)))
19707748	6	(S1 (S (NP (NP (JJ Drug-drug) (NNS interactions)) (VP (VBN related) (PP (TO to) (NP (NP (DT the) (NN inhibition)) (PP (IN of) (NP (NN CYP1A2))) (PP (IN by) (NP (NNP Doc_19707748_742_754_Chemical))))))) (VP (AUX are) (ADVP (RB likely)) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (JJ clinical) (NN outcome)) (PP (IN of) (NP (DT these) (NNS cases))))))) (. .)))
19707748	7	(S1 (S (NP (NNS Clinicians)) (VP (AUX are) (VP (VBN exhorted) (S (VP (TO to) (VP (VB pay) (NP (JJ close) (NN attention)) (SBAR (WHADVP (WRB when)) (S (VP (VBG initiating) (NP (JJ Doc_19707748_891_903_Chemical) (NN therapy)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG taking) (NP (NP (NNS medications)) (PP (IN with) (NP (JJ epileptogenic) (NNS properties))) (SBAR (WHNP (WDT that)) (S (VP (AUX are) (VP (VBG CYP1A2) (NP (NNS substrates)))))))))))))))))) (. .)))
19719056	0	(S1 (NP (NP (JJ Doc_19719056_0_7_Chemical-Doc_19719056_8_16_Chemical) (NNS conjugates)) (: :) (NP (NP (NN synthesis)) (, ,) (PP (PP (IN in) (NP (NN vitro))) (CC and) (PP (IN in) (NP (NN vivo) (NN evaluation))))) (. .)))
19719056	1	(S1 (S (NP (NP (NN Doc_19719056_73_81_Chemical)) (PRN (-LRB- -LRB-) (NP (NN E)) (-RRB- -RRB-))) (, ,) (VP (AUX is) (NP (DT a) (JJ non-narcotic) (ADJP (JJ analgesic) (CC and) (JJ antiinflammatory)) (NN drug))) (. .)))
19719056	2	(S1 (S (NP (DT A) (JJ biodegradable) (NN polymer) (NN dextran)) (VP (AUX has) (VP (AUX been) (VP (VBN utilized) (PP (IN as) (NP (NP (DT a) (NN carrier)) (PP (IN for) (NP (NP (NN synthesis)) (PP (IN of) (NP (NP (JJ Doc_19719056_222_230_Chemical-Doc_19719056_231_238_Chemical) (NNS conjugates)) (PRN (-LRB- -LRB-) (NP (NNP ED)) (-RRB- -RRB-)))))))) (S (VP (TO to) (VP (VP (VB improve) (NP (PRP$ its) (JJ aqueous) (NN solubility))) (CC and) (VP (VB reduce) (NP (JJ gastrointestinal) (NN side) (NNS effects))))))))) (. .)))
19719056	3	(S1 (S (NP (NP (DT An) (VBN activated) (NN moiety)) (, ,) (PP (FW i.e.) (NP (NP (JJ Doc_19719056_357_372_Chemical) (NN derivative)) (PP (IN of) (NP (NP (NNP Doc_19719056_387_395_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_19719056_397_400_Chemical)) (-RRB- -RRB-)))))) (, ,)) (VP (AUX was) (ADJP (JJ condensed) (PP (IN with) (NP (NP (DT the) (JJ polysaccharide) (NN polymer) (NN dextran)) (PP (IN of) (NP (JJ different) (JJ molecular) (NNS weights)))))) (PRN (-LRB- -LRB-) (NP (CD 40000) (, ,) (CD 60000) (, ,) (CD 110000) (CC and) (CD 200000)) (-RRB- -RRB-))) (. .)))
19719056	4	(S1 (S (NP (JJ IR) (NN spectral) (NNS data)) (VP (VBD confirmed) (NP (NP (NN formation)) (PP (IN of) (NP (JJ Doc_19719056_563_568_Chemical) (NN bonding)))) (PP (IN in) (NP (DT the) (NNS conjugates)))) (. .)))
19719056	5	(S1 (S (NP (JJ Doc_19719056_596_604_Chemical) (NNS contents)) (VP (AUX were) (VP (VBN evaluated) (PP (IN by) (NP (JJ UV-spectrophotometric) (NN analysis))))) (. .)))
19719056	6	(S1 (S (NP (DT The) (JJ molecular) (NNS weights)) (VP (AUX were) (VP (VBN determined) (PP (IN by) (S (VP (VBG measuring) (NP (NP (NN viscosity)) (VP (VBG using) (NP (DT the) (NNP Mark-Howink-Sakurada) (NN equation))))))))) (. .)))
19719056	7	(S1 (SINV (PP (IN In) (NP (NP (NN vitro) (NNS hydrolysis)) (PP (IN of) (NP (NNP ED))))) (VP (AUX was) (VP (AUX done) (PP (PP (IN in) (NP (NP (JJ aqueous) (NNS buffers)) (PRN (-LRB- -LRB-) (NP (CD pH) (CD 1.2) (, ,) (CD 7.4) (, ,) (CD 9)) (-RRB- -RRB-)))) (CC and) (PP (IN in) (NP (NP (CD 80) (NN %)) (PRN (-LRB- -LRB-) (NP (NN v/v)) (-RRB- -RRB-))))))) (NP (NP (JJ human) (NN plasma)) (PRN (-LRB- -LRB-) (NP (NN pH) (CD 7.4)) (-RRB- -RRB-))) (. .)))
19719056	8	(S1 (S (PP (IN At) (NP (NN pH) (CD 9))) (, ,) (NP (NP (DT a) (JJR higher) (NN rate)) (PP (IN of) (NP (NP (JJ Doc_19719056_903_911_Chemical) (NN release)) (PP (IN from) (NP (NNP ED)))))) (VP (AUX was) (VP (VBN observed) (PP (IN as) (PP (VBN compared) (PP (TO to) (NP (NP (NP (JJ aqueous) (NN buffer)) (PP (IN of) (NP (NN pH) (CD 7.4)))) (CC and) (NP (NP (NP (CD 80) (NN %)) (NP (JJ human) (NN plasma))) (PRN (-LRB- -LRB-) (NP (NN pH) (CD 7.4)) (-RRB- -RRB-))))))) (, ,) (PP (VBG following) (NP (JJ first-order) (NNS kinetics))))) (. .)))
19719056	9	(S1 (S (PP (IN In) (NP (NN vivo))) (NP (NNS investigations)) (VP (AUX were) (VP (VBN performed) (PP (IN in) (NP (NNS animals))))) (. .)))
19719056	10	(S1 (S (NP (JJ Acute) (JJ analgesic) (CC and) (JJ antiinflammatory) (NNS activities)) (VP (AUX were) (VP (VBN ascertained) (S (VP (VBG using) (S (S (NP (NNP Doc_19719056_1165_1176_Chemical)) (VP (VBN induced) (S (VP (VBG writhing) (NP (NP (NN model)) (PRN (-LRB- -LRB-) (NP (NNS mice)) (-RRB- -RRB-))))))) (CC and) (S (NP (JJ carrageenan-induced) (NN rat)) (VP (VBD paw) (NP (NNP Doc_19719056_1239_1244_Disease) (NN model)) (, ,) (ADVP (RB respectively))))))))) (. .)))
19719056	11	(S1 (S (PP (IN In) (NP (NP (NN comparison)) (PP (TO to) (NP (NN control))))) (, ,) (NP (NP (NNP E)) (CC and) (NP (NNP ED1-ED4))) (VP (VBD showed) (NP (NP (ADJP (RB highly) (JJ significant)) (JJ analgesic) (CC and) (JJ antiinflammatory) (NNS activities)) (PRN (-LRB- -LRB-) (NP (NNP p) (CD <0.001)) (-RRB- -RRB-)))) (. .)))
19719056	12	(S1 (S (NP (JJ Biological) (NN evaluation)) (VP (VBD suggested) (SBAR (IN that) (S (NP (NP (NNS conjugates)) (PRN (-LRB- -LRB-) (NP (NN ED1-ED4)) (-RRB- -RRB-))) (VP (VBD retained) (NP (JJ comparable) (JJ analgesic) (CC and) (JJ antiinflammatory) (NNS activities)) (PP (IN with) (NP (ADJP (RB remarkably) (VBN reduced)) (NN ulcerogenicity))) (SBAR (IN as) (S (VP (VBN compared) (PP (TO to) (NP (PRP$ their) (NN parent) (NN drug--Doc_19719056_1579_1587_Chemical)))))))))) (. .)))
19721134	0	(S1 (NP (NP (NP (DT The) (JJ antiarrhythmic) (NN effect)) (CC and) (NP (JJ possible) (JJ ionic) (NNS mechanisms))) (PP (IN of) (NP (NNP Doc_19721134_59_70_Chemical))) (PP (IN on) (NP (NN animal) (NNS models))) (. .)))
19721134	1	(S1 (S (NP (DT This) (NN study)) (VP (AUX was) (VP (VBN designed) (S (VP (TO to) (VP (VP (VB evaluate) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NNP Doc_19721134_140_151_Chemical))))) (CC and) (VP (VB explore) (NP (DT the) (JJ underlying) (JJ ionic) (NN mechanism)))))) (, ,) (S (VP (VBG using) (NP (DT both) (JJ Doc_19721134_207_216_Chemical-induced) (NN rat) (CC and) (JJ Doc_19721134_233_240_Chemical-induced) (NN guinea) (NN pig)) (NP (NNP Doc_19721134_260_270_Disease) (NNS models)))))) (. .)))
19721134	2	(S1 (S (NP (JJ Confocal) (NN microscopy)) (VP (AUX was) (VP (VBN used) (S (VP (TO to) (VP (VB measure) (NP (NP (JJ intracellular) (JJ free-Doc_19721134_338_345_Chemical) (NNS concentrations)) (PRN (-LRB- -LRB-) (NP (NP (JJ -LSB-Doc_19721134_363_369_Chemical) (NNS -RSB-)) (PRN (-LRB- -LRB-) (NP (PRP i)) (-RRB- -RRB-))) (-RRB- -RRB-))) (PP (IN in) (NP (JJ isolated) (NNS myocytes)))))))) (. .)))
19721134	3	(S1 (S (NP (DT The) (JJ current) (NN data)) (VP (VBD showed) (SBAR (IN that) (S (NP (NNP Doc_19721134_426_437_Chemical)) (ADVP (RB significantly)) (VP (VP (VBD delayed) (NP (NP (NN onset)) (PP (IN of) (NP (NNP Doc_19721134_469_480_Disease))))) (, ,) (VP (VBD decreased) (NP (NP (DT the) (NN time) (NN course)) (PP (IN of) (NP (NNP Doc_19721134_511_551_Disease))))) (, ,) (VP (VBD reduced) (NP (NNP Doc_19721134_561_571_Disease) (NN score))) (, ,) (CC and) (VP (VBD increased) (SBAR (S (NP (NP (DT the) (NN survival) (NN time)) (PP (IN of) (NP (NP (JJ arrhythmic) (NNS rats)) (CC and) (NP (NP (NN guinea) (JJ pigs.) (JJ -LSB-Doc_19721134_648_654_Chemical) (NN -RSB-) (PRN (-LRB- -LRB-) (NP (PRP i)) (-RRB- -RRB-)) (NN overload)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_19721134_679_688_Chemical) (CC or) (NNP Doc_19721134_692_699_Chemical)))))))) (VP (AUX was) (VP (VBN reduced) (PP (IN in) (NP (NP (JJ isolated) (NNS myocytes)) (VP (VBN pretreated) (PP (IN with) (NP (NNP Doc_19721134_749_760_Chemical))))))))))))))) (. .)))
19721134	4	(S1 (S (ADVP (RB Moreover)) (, ,) (NP (NP (NP (NP (NNP M)) (PRN (-LRB- -LRB-) (NP (CD 3)) (-RRB- -RRB-))) (NP (JJ -muscarinic) (JJ Doc_19721134_788_801_Chemical) (NN receptor) (PRN (-LRB- -LRB-) (NP (NN mAChR)) (-RRB- -RRB-)) (NN antagonist)) (NNP Doc_19721134_830_836_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_19721134_838_885_Chemical)) (-RRB- -RRB-))) (ADVP (RB partially)) (VP (VBD abolished) (NP (NP (DT the) (JJ beneficial) (NNS effects)) (PP (IN of) (NP (NNP Doc_19721134_933_944_Chemical))))) (. .)))
19721134	5	(S1 (S (NP (DT These) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NNP Doc_19721134_970_981_Chemical)) (VP (VBD produced) (NP (NP (JJ antiarrhythmic) (NNS actions)) (PP (IN on) (NP (NP (JJ arrhythmic) (NN rat) (CC and) (NN guinea) (NN pig) (NNS models)) (VP (VBN induced) (PP (IN by) (NP (NP (NNP Doc_19721134_1065_1074_Chemical)) (CC or) (NP (NNP Doc_19721134_1078_1085_Chemical)))) (PP (IN via) (S (VP (VBG stimulating) (NP (DT the) (JJ cardiac) (NNP M) (PRN (-LRB- -LRB-) (NP (CD 3)) (-RRB- -RRB-)) (NN -mAChR))))))))))))) (. .)))
19721134	6	(S1 (S (NP (DT The) (NN mechanism)) (VP (MD may) (VP (AUX be) (ADJP (JJ related) (PP (TO to) (NP (NP (DT the) (NN improvement)) (PP (IN of) (NP (JJ Doc_19721134_1177_1183_Chemical) (NN handling)))))))) (. .)))
19761039	0	(S1 (NP (NP (NN Effect)) (PP (IN of) (NP (NNP Doc_19761039_10_32_Chemical))) (PP (IN on) (NP (NP (NP (JJ Doc_19761039_36_45_Chemical-induced) (NN neurobehavioral)) (CC and) (NP (JJ biochemical) (NNS alterations))) (PP (IN in) (NP (NNS rats))))) (. .)))
19761039	1	(S1 (S (NP (NP (NN Effect)) (PP (IN of) (NP (NP (NP (JJ methanolic) (VB extract)) (PP (IN of) (NP (NNP Doc_19761039_139_161_Chemical)))) (PRN (-LRB- -LRB-) (NP (CD 100-300) (NN mg/kg)) (-RRB- -RRB-))))) (VP (AUX was) (VP (VBN studied) (PP (IN on) (NP (NP (JJ Doc_19761039_193_202_Chemical-induced) (JJ orofacial) (NN Doc_19761039_221_231_Disease)) (CC and) (NP (JJ neurochemical) (NNS alterations)))))) (. .)))
19761039	2	(S1 (S (NP (DT The) (NNS rats)) (VP (AUX were) (VP (VBN treated) (PP (IN with) (NP (NP (JJ intraperitoneal) (NNP Doc_19761039_306_315_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 1) (NN mg/kg)) (, ,) (NP (NN ip))) (-RRB- -RRB-)))) (PP (IN for) (NP (NP (CD 3) (NNS days)) (NP (DT every) (JJ other) (NN day)))))) (. .)))
19761039	3	(S1 (S (PP (IN On) (NP (NN day) (CD 5))) (, ,) (NP (NP (JJ vacuous) (VBG chewing) (NNS movements)) (CC and) (NP (NN tongue) (NNS protrusions))) (VP (AUX were) (VP (VBN counted) (PP (IN for) (NP (CD 5) (NN min))))) (. .)))
19761039	4	(S1 (S (NP (JJ Doc_19761039_441_450_Chemical) (VBN treated) (NNS rats)) (ADVP (RB significantly)) (VP (VBD developed) (NP (NP (JJ vacuous) (VBG chewing) (NNS movements)) (CC and) (NP (NN tongue) (NNS protrusions))) (ADVP (RB however)) (, ,) (S (NP (NP (NN coadministration)) (PP (IN of) (NP (JJ Doc_19761039_566_588_Chemical) (NNS roots)))) (VP (VB extract) (PRN (-LRB- -LRB-) (NP (NP (CD 100) (, ,) (CD 200) (CC and) (CD 300) (NNS mg/kg)) (, ,) (PP (IN per) (NP (RB orally)))) (-RRB- -RRB-)) (VP (VBN attenuated) (NP (DT the) (NNS effects)))))) (. .)))
19761039	5	(S1 (S (NP (NP (JJ Biochemical) (NN analysis)) (PP (IN of) (NP (NN brain)))) (VP (VBD revealed) (SBAR (IN that) (S (NP (DT the) (JJ Doc_19761039_712_721_Chemical) (NN treatment)) (VP (VP (ADVP (RB significantly)) (VBD increased) (NP (NN lipid) (NN peroxidation))) (CC and) (VP (VBD decreased) (NP (NP (NNS levels)) (PP (IN of) (NP (NP (NP (JJ Doc_19761039_799_809_Chemical) (NN dismutase)) (PRN (-LRB- -LRB-) (NP (NNP SOD)) (-RRB- -RRB-))) (, ,) (NP (NP (NN catalase)) (PRN (-LRB- -LRB-) (NP (NN CAT)) (-RRB- -RRB-))) (CC and) (NP (NP (JJ Doc_19761039_846_857_Chemical) (NN reductase)) (PRN (-LRB- -LRB-) (NP (NNP Doc_19761039_869_872_Chemical)) (-RRB- -RRB-)) (, ,) (NP (NP (DT an) (NN index)) (PP (IN of) (NP (JJ oxidative) (NN stress) (NN process))))))))))))) (. .)))
19761039	6	(S1 (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (VB extract)))) (VP (VP (ADVP (RB significantly)) (VBD reduced) (NP (DT the) (NN lipid) (NN peroxidation))) (CC and) (VP (VBD reversed) (NP (DT the) (NN decrease)) (PP (IN in) (NP (NP (NN brain) (NN SOD)) (, ,) (NP (NN CAT)) (CC and) (NP (JJ Doc_19761039_1034_1037_Chemical) (NNS levels)))))) (. .)))
19761039	7	(S1 (S (NP (NP (DT The) (NNS results)) (PP (IN of) (NP (DT the) (JJ present) (NN study)))) (VP (VBD suggested) (SBAR (IN that) (S (NP (NNP Doc_19761039_1094_1116_Chemical)) (VP (AUX had) (NP (DT a) (JJ protective) (NN role)) (PP (IN against) (NP (NP (JJ Doc_19761039_1147_1156_Chemical-induced) (JJ orofacial) (NN Doc_19761039_1175_1185_Disease)) (CC and) (NP (JJ oxidative) (NN stress)))))))) (. .)))
19893084	0	(S1 (NP (NP (JJ Dynamic) (NN response)) (PP (IN of) (NP (NP (NN blood) (NN vessel)) (PP (IN in) (NP (NNP Doc_19893084_36_55_Disease))))) (. .)))
19893084	1	(S1 (S (PP (IN In) (NP (DT this) (NN study))) (NP (PRP we)) (VP (VBD postulated) (SBAR (SBAR (IN that) (S (PP (IN during) (NP (NP (NNP Doc_19893084_97_116_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_19893084_128_138_Chemical)))))) (NP (NP (DT the) (ADJP (ADJP (JJ transient)) (CC or) (ADJP (JJ dynamic))) (NN response)) (PP (IN of) (NP (NN blood) (NNS vessels)))) (VP (MD could) (VP (AUX be) (VP (VBN affected)))))) (, ,) (CC and) (SBAR (IN that) (S (NP (NNS antioxidants)) (VP (MD can) (VP (VB prevent) (NP (NP (DT the) (NNS changes)) (PP (IN in) (NP (NP (JJ dynamic) (NNS responses)) (PP (IN of) (NP (NN blood) (NNS vessels)))))))))))) (. .)))
19893084	2	(S1 (S (NP (NP (DT The) (JJ new) (NN approach)) (PP (TO to) (NP (FW ex) (FW vivo) (NN blood) (NN vessel) (NNS experiments))) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (ADVP (RB not) (RB only)) (NP (NP (DT the) (NN end) (NNS points)) (PP (IN of) (NP (NP (NP (NNS vessels)) (SBAR (S (NP (NP (NN response)) (PP (IN within) (NP (DT the) (NN time) (NN interval)))) (VP (AUX is) (VP (VBN considered)))))) (, ,) (CONJP (CC but) (RB also)) (NP (NP (NNS dynamics)) (PP (IN of) (NP (DT this) (NN response))))))))) (, ,)) (VP (AUX was) (VP (VBN used) (PP (IN in) (NP (DT this) (NN paper))))) (. .)))
19893084	3	(S1 (S (NP (PRP$ Our) (NNS results)) (VP (VBP confirm) (NP (DT the) (NN alteration)) (PP (IN in) (NP (NP (JJ dynamic) (NN response)) (PP (IN of) (NP (NN blood) (NNS vessels))))) (PP (IN during) (NP (NP (DT the) (NN change)) (PP (IN of) (NP (NN pressure))) (PP (IN in) (NP (JJ Doc_19893084_605_615_Chemical-treated) (NNS animals)))))) (. .)))
19893084	4	(S1 (S (NP (NP (DT The) (JJ beneficial) (NNS effects)) (PP (IN of) (NP (NNP Doc_19893084_659_668_Chemical) (NN administration))) (PP (TO to) (NP (JJ Doc_19893084_687_697_Chemical-treated) (NNS animals)))) (VP (AUX are) (ADVP (RB also)) (VP (VBN confirmed) (PP (IN through) (NP (: :) (NP (NP (NP (JJR lower) (NN level)) (PP (IN of) (NP (NN blood) (NNP Doc_19893084_763_767_Chemical) (CC and) (NNP Doc_19893084_772_782_Chemical)))) (CC and) (NP (NP (JJR higher) (NN level)) (PP (IN of) (NP (NNP Doc_19893084_803_812_Chemical))))))))) (. .)))
19893084	5	(S1 (S (NP (NP (DT The) (NN pressure) (JJ dynamic) (NNS responses)) (PP (IN of) (NP (JJ isolated) (NN blood) (NNS vessels)))) (VP (VBP show) (NP (NP (DT a) (JJR faster) (NN pressure) (NN change)) (PP (IN in) (NP (JJ Doc_19893084_904_914_Chemical-treated) (NNS animals)))) (PRN (-LRB- -LRB-) (NP (CD 8.07) (NN +/-) (CD 1.7) (NNP s) (CC vs.) (CD 5.64) (NN +/-) (CD 0.18)) (PRP s) (-RRB- -RRB-))) (. .)))
19893084	6	(S1 (S (NP (NP (JJ Doc_19893084_969_978_Chemical) (NN administration) (VBN induced) (NN slowdown)) (PP (IN of) (NP (NN pressure)))) (VP (VBP change) (ADVP (RB back)) (PP (TO to) (NP (DT the) (NN control) (NNS values)))) (. .)))
19893084	7	(S1 (S (NP (NP (DT The) (NN pressure) (JJ dynamic) (NNS properties)) (, ,) (VP (ADVP (RB quantitatively)) (VBN defined) (PP (IN by) (NP (NP (JJ comparative) (NN pressure) (NN dynamic)) (CC and) (NP (JJ total) (NN pressure) (NN dynamic))))) (, ,)) (VP (VBP confirm) (NP (DT the) (NN alteration)) (PP (IN in) (NP (NP (JJ dynamic) (NN response)) (PP (IN of) (NP (NN blood) (NNS vessels))))) (PP (IN during) (NP (NP (NP (DT the) (NN change)) (PP (IN of) (NP (NN pressure))) (PP (IN in) (NP (JJ Doc_19893084_1267_1277_Chemical-treated) (NNS animals)))) (CC and) (NP (NP (JJ beneficial) (NNS effects)) (PP (IN of) (NP (NNP Doc_19893084_1320_1329_Chemical) (NN administration))))))) (. .)))
19917396	0	(S1 (NP (NP (NP (JJ Reversible) (NN Doc_19917396_11_33_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_19917396_45_55_Chemical))) (PP (IN in) (NP (DT a) (JJ pediatric) (NN heart) (NN transplant) (NN recipient))))) (: :) (NP (NN case) (NN report)) (. .)))
19917396	1	(S1 (S (NP (NN Doc_19917396_112_122_Chemical)) (VP (AUX is) (NP (NP (DT a) (JJ potent) (NN immunosuppressant)) (SBAR (WHNP (WDT that)) (S (VP (AUX is) (ADVP (RB frequently)) (VP (VBN used) (PP (IN in) (NP (NN organ) (NN transplantation))))))))) (. .)))
19917396	2	(S1 (S (ADVP (RB However)) (, ,) (NP (JJ adverse) (NNS effects)) (VP (VBP include) (NP (NN Doc_19917396_236_252_Disease))) (. .)))
19917396	3	(S1 (S (ADVP (RB Herein)) (NP (PRP we)) (VP (VBP describe) (NP (NP (JJ transient) (NNP Doc_19917396_283_305_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_19917396_317_327_Chemical))) (PP (IN after) (NP (NN heart) (NN transplantation)))))) (. .)))
19917396	4	(S1 (S (NP (DT The) (NNP Doc_19917396_361_372_Disease)) (VP (VP (VBD caused) (NP (DT no) (JJ clinical) (NNS symptoms))) (CC but) (VP (AUX was) (VP (VP (VBN noted) (PP (IN because) (IN of) (NP (NP (NN elevation)) (PP (IN of) (NP (NN plasma) (NN brain) (NN natriuretic) (NN peptide) (NN concentration)))))) (CC and) (VP (VBN confirmed) (PP (IN at) (NP (NN echocardiography))))))) (. .)))
19917396	5	(S1 (S (S (ADVP (RB Initially)) (, ,) (NP (NN allograft) (NN rejection)) (VP (AUX was) (VP (VBN feared)))) (: ;) (S (ADVP (RB however)) (, ,) (NP (JJ myocardial) (NN biopsy) (NNS samples)) (VP (VBD revealed) (NP (NP (JJ only) (JJ interstitial) (NN Doc_19917396_626_631_Disease)) (CC and) (NP (JJ mild) (NN Doc_19917396_641_663_Disease))))) (: ;) (S (NP (DT neither) (JJ cellular) (CC nor) (JJ humoral) (NN rejection)) (VP (AUX was) (VP (VBN detected)))) (. .)))
19917396	6	(S1 (S (S (NP (DT The) (NN blood) (JJ Doc_19917396_728_738_Chemical) (NN concentration)) (VP (AUX was) (ADJP (ADJP (JJR higher)) (PP (IN than) (NP (JJ usual)))) (PP (IN at) (NP (DT that) (NN time))))) (: ;) (S (ADVP (RB thus)) (, ,) (NP (JJ Doc_19917396_795_805_Chemical) (NN dosage)) (VP (AUX was) (VP (VBN reduced)))) (. .)))
19917396	7	(S1 (S (NP (NN Doc_19917396_826_848_Disease)) (VP (ADVP (RB completely)) (VBN resolved) (PP (IN upon) (S (VP (VP (VBG reducing) (NP (NP (DT the) (NN target) (NN concentration)) (PP (IN of) (NP (NNP Doc_19917396_911_921_Chemical))))) (CC and) (VP (AUX did) (RB not) (VP (VB recur)))))) (, ,) (SBAR (IN as) (S (VP (VBN confirmed) (PP (IN at) (NP (NP (NN echocardiography)) (CC and) (NP (JJ myocardial) (NN biopsy)))))))) (. .)))
19917396	8	(S1 (S (ADVP (RB Thus)) (, ,) (NP (PRP we)) (VP (VBP conclude) (SBAR (IN that) (S (NP (NNP Doc_19917396_1020_1030_Chemical)) (VP (VBZ induces) (NP (JJ reversible) (NN Doc_19917396_1050_1072_Disease)))))) (. .)))
19917396	9	(S1 (S (PP (IN In) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (JJ Doc_19917396_1096_1106_Chemical) (NN therapy))))) (, ,) (NP (NN blood) (NN concentration)) (VP (MD should) (VP (AUX be) (VP (VP (ADVP (RB carefully)) (VBN controlled)) (CC and) (VP (NP (JJ extreme) (NN attention)) (VBD paid) (PP (TO to) (NP (JJ cardiac) (NN involvement))))))) (. .)))
19923525	0	(S1 (S (NP (NN Doc_19923525_0_10_Chemical)) (VP (VBZ prevents) (NP (NP (NN Doc_19923525_20_37_Disease)) (VP (VBN caused) (PP (IN by) (NP (NP (NNP Doc_19923525_48_61_Chemical-induced) (NNP Doc_19923525_70_81_Disease)) (PP (IN in) (NP (NN adult) (NNS mice)))))))) (. .)))
19923525	1	(S1 (S (NP (NP (NN Doc_19923525_109_120_Disease)) (CC and) (NP (NP (DT a) (JJ resultant) (NN decrease)) (PP (IN in) (NP (JJ cerebral) (NN blood) (NN flow))))) (VP (AUX have) (VP (AUX been) (VP (VBN implicated) (PP (IN in) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_19923525_212_233_Disease)))))))) (. .)))
19923525	2	(S1 (S (NP (PRP We)) (VP (VBD tested) (NP (DT the) (NN hypothesis)) (SBAR (IN that) (S (NP (NP (NNP Doc_19923525_265_275_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_19923525_277_281_Chemical)) (-RRB- -RRB-)) (VP (VBN administered) (PP (IN at) (NP (NP (DT the) (NN onset)) (PP (IN of) (NP (NP (NNP Doc_19923525_312_325_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_19923525_327_330_Chemical)) (-RRB- -RRB-)))))))) (VP (VBD -induced) (SBAR (S (NP (NNP Doc_19923525_340_351_Disease)) (VP (MD would) (VP (VB preserve) (NP (JJ long-term) (JJ associative) (NN memory)))))))))) (. .)))
19923525	3	(S1 (S (NP (DT The) (NN passive) (NN avoidance) (PRN (-LRB- -LRB-) (NP (NNP PA)) (-RRB- -RRB-)) (NN paradigm)) (VP (AUX was) (VP (VBN used) (S (VP (TO to) (VP (VB assess) (NP (NN memory) (NN retention))))))) (. .)))
19923525	4	(S1 (S (PP (IN For) (NP (NNP PA) (NN training))) (, ,) (NP (NP (NNS latencies)) (PRN (-LRB- -LRB-) (NP (NNS seconds)) (-RRB- -RRB-))) (VP (AUX were) (VP (VBN recorded) (PP (IN for) (NP (NN entry))) (PP (IN from) (NP (DT a) (VBN suspended) (NN platform))) (PP (IN into) (NP (NP (DT a) (NNP Plexiglas) (NN tube)) (SBAR (WHADVP (WRB where)) (S (NP (DT a) (NN shock)) (VP (AUX was) (ADVP (RB automatically)) (VP (VBN delivered))))))))) (. .)))
19923525	5	(S1 (S (NP (NNS Latencies)) (VP (AUX were) (VP (VBN recorded) (NP (CD 48) (NNP h)) (ADVP (RB later)) (PP (IN for) (NP (DT a) (NN testing) (NN trial))))) (. .)))
19923525	6	(S1 (S (NP (NP (NNP Ninety-six) (NNP Swiss-Webster) (PRN (S (NP (NP (NNS mice)) (PRN (-LRB- -LRB-) (NP (CD 30-35) (NNP g)) (, ,) (NP (JJ 6-8) (NNS wk)) (-RRB- -RRB-)) (, ,)) (VP (AUX were) (VP (VBN randomized) (PP (IN into) (NP (CD 6) (NNS groups))) (NP (NP (CD 1) (-RRB- -RRB-) (NN saline)) (PRN (-LRB- -LRB-) (NP (NN control)) (-RRB- -RRB-)))))) (, ,) (NP (CD 2)) (-RRB- -RRB-)) (NNP Doc_19923525_790_793_Chemical)) (PRN (PP (ADVP (RB immediately)) (IN after) (S (VP (VBG learning)))) (, ,) (NP (CD 3)) (-RRB- -RRB-))) (VP (VBZ NTG) (NP (CD 3) (NNP h)) (PP (IN after) (S (VP (VBG learning) (PRN (, ,) (NP (NP (CD 4) (-RRB- -RRB-) (NNP Doc_19923525_852_855_Chemical)) (CC and) (NP (NNP Doc_19923525_860_864_Chemical))) (, ,) (NP (CD 5)) (-RRB- -RRB-)) (NP (NP (NN vehicle)) (, ,) (CC and) (NP (NP (CD 6) (-RRB- -RRB-) (NNP Doc_19923525_885_889_Chemical)) (ADVP (RB alone)))))))) (. .)))
19923525	7	(S1 (S (NP (NP (NP (DT The) (NN extent)) (PP (IN of) (NP (NNP Doc_19923525_911_922_Disease)))) (CC and) (NP (NP (NNS changes)) (PP (PP (IN in) (NP (NP (NN brain) (NN tissue) (NN oxygenation)) (PRN (-LRB- -LRB-) (NP (NP (NNP PbtO)) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-))) (-RRB- -RRB-)))) (CC and) (PP (IN in) (NP (JJ cerebral) (NN blood) (NN flow)))))) (VP (AUX were) (VP (VBN studied) (PP (IN in) (NP (NP (DT a) (JJ separate) (NN group)) (PP (IN of) (NP (NNS animals))))))) (. .)))
19923525	8	(S1 (S (NP (DT All) (NNS groups)) (VP (VBD exhibited) (NP (NP (JJ similar) (NN training) (NNS latencies)) (PRN (-LRB- -LRB-) (NP (CD 17.0) (NN +/-) (CD 4.6)) (PRP s) (-RRB- -RRB-)))) (. .)))
19923525	9	(S1 (S (NP (NP (NNS Mice)) (VP (VBN subjected) (PP (TO to) (NP (NNP Doc_19923525_1138_1149_Disease) (NNS episodes))))) (VP (VBD showed) (NP (NP (DT a) (JJ significant) (NN decrease)) (PP (IN in) (NP (NP (NN latency) (NN time)) (PRN (-LRB- -LRB-) (NP (QP (CD 178) (CD +/-)) (CD 156)) (PRP s) (-RRB- -RRB-))))) (PP (VBN compared) (PP (IN with) (NP (NP (DT those)) (VP (VP (VBN injected) (PP (IN with) (NP (NP (NN saline)) (, ,) (NP (NNP Doc_19923525_1263_1266_Chemical) (NNP +) (NNP Doc_19923525_1269_1273_Chemical)) (, ,)))) (CC or) (VP (VBN delayed) (NP (NNP Doc_19923525_1286_1289_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 580) (JJ +/-) (NX (NX (CD 81) (NNP s)) (, ,) (NX (CD 557) (JJ +/-) (CD 67) (NNP s)) (, ,) (CC and) (NX (CD 493) (JJ +/-) (CD 146)))) (NP (NP (PRP s)) (, ,) (ADVP (RB respectively))) (-RRB- -RRB-)))))))) (. .)))
19923525	10	(S1 (S (NP (NP (DT A) (JJ Kruskal-Wallis) (JJ 1-way) (NN analysis)) (PP (IN of) (NP (NN variance)))) (VP (VBD indicated) (NP (NP (DT a) (JJ significant) (NN difference)) (PP (IN among) (NP (NP (DT the) (CD 4) (NN treatment) (NNS groups)) (PRN (-LRB- -LRB-) (NP (NNP H) (SYM =) (CD 15.34)) (: ;) (NP (QP ($ P) (CD <) (CD 0.001))) (-RRB- -RRB-)))))) (. .)))
19923525	11	(S1 (S (PP (IN In) (NP (NP (DT a) (JJ separate) (NN group)) (PP (IN of) (NP (NNS mice))) (VP (RB not) (VBN subjected) (PP (TO to) (NP (JJ behavioral) (NNS studies)))))) (, ,) (NP (NP (DT the) (JJ same) (NN dose)) (PP (IN of) (NP (NP (NP (NNP Doc_19923525_1567_1570_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 3)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_19923525_1583_1586_Chemical) (NNP +) (NNP Doc_19923525_1589_1593_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 3)) (-RRB- -RRB-)))))) (VP (VBD caused) (NP (JJ mean) (JJ arterial) (NN blood) (NN pressure)) (S (VP (TO to) (VP (VB decrease) (PP (PP (IN from) (NP (NP (CD 85.9) (JJ +/-) (ADJP (CD 3.8) (NN mm)) (NNP Hg) (NN sem)) (PP (TO to) (NP (NP (CD 31.6) (NN +/-)) (NP (CD 0.8) (JJ mm) (NNP Hg) (NN sem)))))) (CC and) (PP (IN from) (NP (NP (CD 86.2) (NN +/-)) (NP (CD 3.7) (JJ mm) (NNP Hg) (NN sem))))) (PP (TO to) (NP (NP (CD 32.6) (NNS +/-)) (NP (CD 0.2) (JJ mm) (NNP Hg) (NN sem)) (, ,) (ADVP (RB respectively)))))))) (. .)))
19923525	12	(S1 (S (NP (NP (JJ Mean) (JJ arterial) (NN blood) (NN pressure)) (PP (IN in) (NP (NP (NNS mice)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_19923525_1827_1831_Chemical))))))) (ADVP (RB alone)) (VP (VBD decreased) (PP (IN from) (NP (QP (CD 88.1) (CD +/-)) (QP (CD 3.8) (CD mm)))) (NP (NNP Hg)) (PP (TO to) (NP (NP (CD 80.0) (NNS +/-)) (NP (CD 2.9) (NN mm) (NNP Hg))))) (. .)))
19923525	13	(S1 (S (S (NP (DT The) (NNP intergroup) (NN difference)) (VP (AUX was) (ADJP (RB statistically) (JJ significant)))) (PRN (-LRB- -LRB-) (S (NP (NNP P)) (VP (VBD <) (NP (CD 0.05)))) (-RRB- -RRB-)) (. .)))
19923525	14	(S1 (S (NP (NN Doc_19923525_1963_1970_Chemical)) (VP (VBD decreased) (PP (PP (IN from) (NP (NP (CD 51.7) (NN +/-)) (NP (CD 4.5) (JJ mm) (NNP Hg) (NN sem)))) (PP (TO to) (NP (NP (NP (CD 33.8) (NN +/-)) (NP (CD 5.2) (JJ mm) (NNP Hg) (NN sem))) (PP (IN in) (NP (DT the) (JJ NTG) (NN group))))) (CC and) (PP (IN from) (NP (NP (CD 38.6) (JJ +/-) (ADJP (CD 6.1) (NN mm)) (NNP Hg) (NN sem)) (PP (TO to) (NP (NP (CD 25.4) (JJ +/-) (ADJP (CD 2.0) (NN mm)) (NNP Hg) (NN sem)) (PP (IN in) (NP (DT the) (NNP Doc_19923525_2117_2120_Chemical) (NNP +) (NNP Doc_19923525_2123_2127_Chemical) (NNS groups)))))))) (, ,) (ADVP (RB respectively))) (. .)))
19923525	15	(S1 (S (NP (EX There)) (VP (AUX were) (NP (DT no) (JJ significant) (NNS differences)) (PP (IN among) (NP (NNS groups)))) (. .)))
19923525	16	(S1 (S (PP (IN In) (NP (DT a) (NNP PA) (NN retention) (NN paradigm))) (, ,) (NP (NP (DT the) (NN injection)) (PP (IN of) (NP (NNP Doc_19923525_2259_2262_Chemical))) (PP (ADVP (RB immediately)) (IN after) (NP (NN learning)))) (VP (VBD produced) (NP (NP (DT a) (JJ significant) (NN impairment)) (PP (IN of) (NP (JJ long-term) (JJ associative) (NN memory)))) (PP (IN in) (NP (NNS mice))) (, ,) (SBAR (IN whereas) (S (NP (JJ delayed) (VBN induced) (NN Doc_19923525_2389_2400_Disease)) (VP (AUX had) (NP (DT no) (NN effect)))))) (. .)))
19923525	17	(S1 (S (NP (NN Doc_19923525_2416_2420_Chemical)) (VP (VP (VBD attenuated) (NP (DT the) (NN disruption)) (PP (IN in) (NP (NP (NN consolidation)) (PP (IN of) (NP (JJ long-term) (NN memory))) (VP (VBN caused) (PP (IN by) (NP (NNP Doc_19923525_2494_2497_Chemical))))))) (CC but) (VP (AUX did) (RB not) (VP (VB improve) (NP (NN latency)) (PP (IN in) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (NNP Doc_19923525_2544_2555_Disease)))))))) (. .)))
19923525	18	(S1 (S (NP (NP (DT The) (JJ observed) (NN effect)) (PP (IN of) (NP (NNP Doc_19923525_2580_2584_Chemical)))) (VP (MD may) (VP (AUX have) (VP (AUX been) (ADJP (JJ attributable) (PP (TO to) (NP (NP (DT the) (NN preservation)) (PP (IN of) (NP (JJ Doc_19923525_2635_2642_Chemical) (NNS homeostasis))) (PP (IN during) (NP (NNP Doc_19923525_2662_2673_Disease)))))) (, ,) (SBAR (IN because) (S (NP (EX there)) (VP (AUX were) (NP (NP (DT no) (NNS differences)) (PP (IN in) (NP (NP (DT the) (NNP PbtO) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-)) (NNS indices)) (PP (IN among) (NP (NNS groups)))))))))))) (. .)))
19940105	0	(S1 (S (NP (JJ Metabotropic) (NNP Doc_19940105_13_22_Chemical) (CD 7) (NN receptor) (NN subtype)) (VP (VBZ modulates) (NP (NN motor) (NNS symptoms)) (PP (IN in) (NP (NP (JJ rodent) (NNS models)) (PP (IN of) (NP (NNP Doc_19940105_87_106_Disease)))))) (. .)))
19940105	1	(S1 (S (NP (NNP Metabotropic) (NNP Doc_19940105_121_130_Chemical) (PRN (-LRB- -LRB-) (NP (NN mGlu)) (-RRB- -RRB-)) (NNS receptors)) (VP (VP (VBP modulate) (NP (NP (JJ synaptic) (NN transmission)) (PP (IN in) (NP (DT the) (JJ central) (JJ nervous) (NN system))))) (CC and) (VP (VBP represent) (NP (NP (JJ promising) (JJ therapeutic) (NNS targets)) (PP (IN for) (NP (NP (JJ symptomatic) (NN treatment)) (PP (IN of) (NP (NP (NNP Doc_19940105_282_301_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_19940105_303_305_Disease)) (-RRB- -RRB-))))))))) (. .)))
19940105	2	(S1 (S (PP (IN Among) (NP (DT the) (CD eight) (NN mGlu) (NN receptor) (NNS subtypes))) (, ,) (S (NP (NN mGlu7) (NN receptor)) (VP (AUX is) (ADVP (RB prominently)) (VP (VBN expressed) (PP (IN in) (NP (DT the) (JJ basal) (NN ganglia)))))) (, ,) (CC but) (S (NP (NP (PRP$ its) (NN role)) (PP (IN in) (S (VP (VBG restoring) (NP (NN motor) (NN function)) (PP (IN in) (NP (NP (NN animal) (NNS models)) (PP (IN of) (NP (NNP Doc_19940105_471_473_Disease))))))))) (VP (AUX is) (RB not) (VP (VBN known)))) (. .)))
19940105	3	(S1 (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NP (NP (NNP Doc_19940105_503_554_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_19940105_556_562_Chemical)) (-RRB- -RRB-))) (, ,) (NP (NP (DT the) (JJ first) (JJ selective) (NN allosteric) (NN activator)) (PP (IN of) (NP (JJ mGlu7) (NNS receptors)))) (, ,)))) (VP (AUX were) (ADVP (RB thus)) (VP (VBN tested) (PP (IN in) (NP (NP (JJ different) (JJ rodent) (NNS models)) (PP (IN of) (NP (NNP Doc_19940105_673_675_Disease))))))) (. .)))
19940105	4	(S1 (S (ADVP (RB Here)) (, ,) (NP (PRP we)) (VP (VBP show) (SBAR (IN that) (S (NP (NP (NP (NP (JJ oral)) (PRN (-LRB- -LRB-) (NP (CD 5) (NN mg/kg)) (-RRB- -RRB-))) (CC or) (NP (NP (JJ intrastriatal) (NN administration)) (PRN (-LRB- -LRB-) (NP (CD 0.1) (CC and) (CD 0.5) (NN nmol)) (-RRB- -RRB-)))) (PP (IN of) (NP (NNP Doc_19940105_765_771_Chemical)))) (VP (VBZ reverses) (NP (NP (JJ Doc_19940105_781_792_Chemical-induced) (NN Doc_19940105_801_810_Disease)) (PP (IN in) (NP (NNS rats)))))))) (. .)))
19940105	5	(S1 (S (NP (NP (NN Doc_19940105_820_826_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 2.5) (CC and) (CD 5)) (NN mg/kg)) (-RRB- -RRB-))) (VP (VBZ reduces) (NP (NP (JJ Doc_19940105_853_864_Chemical-induced) (NNS rotations)) (PP (IN in) (NP (JJ unilateral) (NNP Doc_19940105_897_914_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_19940105_916_922_Chemical)) (-RRB- -RRB-)) (JJ -lesioned) (NNS rats))))) (. .)))
19940105	6	(S1 (S (PP (IN In) (NP (NP (DT a) (ADJP (RBR more) (JJ complex)) (NN task)) (VP (ADVP (RB commonly)) (VBN used) (S (VP (TO to) (VP (VB evaluate) (NP (NP (JJ major) (JJ Doc_19940105_994_1002_Disease) (NNS symptoms)) (PP (IN of) (NP (NNP Doc_19940105_1015_1017_Disease) (NNS patients)))))))))) (, ,) (NP (CD 5) (JJ mg/kg) (NN Doc_19940105_1036_1042_Chemical)) (VP (VBZ reverses) (NP (NP (DT the) (VBN increased) (NN reaction) (NN time)) (SBAR (S (VP (TO to) (VP (VB respond) (PP (TO to) (NP (NP (DT a) (NN cue)) (PP (IN of) (NP (JJ bilateral) (JJ Doc_19940105_1113_1119_Chemical-lesioned) (NNS rats))))))))))) (. .)))
19940105	7	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NNP Doc_19940105_1148_1154_Chemical)) (VP (VP (VBZ reduces) (NP (NP (DT the) (NN duration)) (PP (IN of) (NP (NNP Doc_19940105_1179_1190_Chemical-induced) (NNP Doc_19940105_1199_1208_Disease)))) (PP (IN in) (NP (NP (DT a) (JJ mGlu7) (JJ receptor-dependent) (NN manner)) (PP (IN in) (NP (NN wild-type)))))) (CC but) (RB not) (VP (VBZ mGlu7) (NP (NN receptor) (NN knockout) (NNS mice)))) (. .)))
19940105	8	(S1 (S (NP (NP (JJR Higher) (NNS doses)) (PP (IN of) (NP (NNP Doc_19940105_1313_1319_Chemical))) (PRN (-LRB- -LRB-) (NP (QP (CD 10) (CC and) (CD 20)) (JJ mg/kg) (NNS p.o.)) (-RRB- -RRB-))) (VP (AUX have) (NP (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (DT the) (JJ same) (NNS models)) (PP (IN of) (NP (NNP Doc_19940105_1380_1382_Disease))))))) (. .)))
19940105	9	(S1 (S (ADVP (JJ Overall)) (NP (DT these) (NNS findings)) (VP (VBP suggest) (SBAR (IN that) (S (NP (JJ mGlu7) (NN receptor) (NN activation)) (VP (MD can) (VP (VB reverse) (NP (NP (NN motor) (NN dysfunction)) (VP (VBN associated) (PP (IN with) (NP (JJ reduced) (JJ Doc_19940105_1500_1508_Chemical) (NN activity)))))))))) (. .)))
19940105	10	(S1 (S (NP (NP (JJ Selective) (NNS ligands)) (PP (IN of) (NP (NN mGlu7) (NN receptor) (NNS subtypes)))) (VP (MD may) (ADVP (RB thus)) (VP (AUX be) (VP (VBN considered) (PP (IN as) (NP (NP (JJ promising) (NNS compounds)) (PP (IN for) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (JJ antiparkinsonian) (JJ therapeutic) (NNS strategies)))))))))) (. .)))
19944333	0	(S1 (FRAG (NP (JJ Doc_19944333_0_9_Chemical-induced) (NNP Doc_19944333_18_45_Disease)) (PP (JJ due) (TO to) (NP (NNP Doc_19944333_53_74_Disease))) (. .)))
19944333	1	(S1 (S (NP (NP (DT A) (JJ 65-year-old) (NN man)) (PP (IN with) (NP (JJ advanced) (NNP Doc_19944333_108_128_Disease)))) (VP (AUX was) (VP (VBN admitted) (PP (JJ due) (TO to) (S (VP (VBG continuing) (NP (NN Doc_19944333_160_170_Disease)) (PP (IN at) (NP (NN rest)))))))) (. .)))
19944333	2	(S1 (S (PP (NP (CD Two) (NNS weeks)) (IN before) (NP (PRP$ his) (NN admission))) (, ,) (NP (NNP Doc_19944333_212_221_Chemical)) (VP (AUX had) (VP (AUX been) (VP (VBN started)))) (. .)))
19944333	3	(S1 (S (NP (PRP He)) (VP (AUX was) (VP (VBN diagnosed) (PP (IN with) (NP (JJ non-ST-elevation) (NN Doc_19944333_279_300_Disease))) (PP (IN by) (NP (NP (NN laboratory) (NNS data)) (CC and) (NP (NN electrocardiogram)))))) (. .)))
19944333	4	(S1 (S (NP (JJ Enhanced) (NN heart) (JJ magnetic) (NN resonance) (NN imaging)) (ADVP (RB also)) (VP (VBD showed) (NP (NN Doc_19944333_397_422_Disease))) (. .)))
19944333	5	(S1 (S (ADVP (RB However)) (, ,) (NP (EX there)) (VP (AUX was) (NP (NP (DT no) (NN stenosis)) (PP (IN in) (NP (NP (JJ coronary) (NNS arteries)) (PP (IN on) (NP (NN angiography))))))) (. .)))
19944333	6	(S1 (S (NP (NN Doc_19944333_492_513_Disease)) (VP (AUX was) (VP (VBN induced) (PP (IN by) (NP (DT a) (JJ provocative) (NN test))))) (. .)))
19944333	7	(S1 (S (S (NP (NP (NP (NN Cessation)) (PP (IN of) (NP (NNP Doc_19944333_562_571_Chemical)))) (CC and) (NP (NP (NN administration)) (PP (IN of) (NP (NP (JJ Doc_19944333_594_596_Chemical-channel) (NN blocker)) (CC and) (NP (NNP Doc_19944333_617_625_Chemical)))))) (VP (VBD ameliorated) (NP (PRP$ his) (NNS symptoms)))) (, ,) (CC but) (S (NP (NN relapse)) (VP (VBD occurred) (PP (IN after) (NP (NP (NN resumption)) (PP (IN of) (NP (NNP Doc_19944333_693_702_Chemical))))))) (. .)))
19944333	8	(S1 (S (NP (NP (NN Addition)) (PP (IN of) (NP (JJ oral) (NNP Doc_19944333_721_731_Chemical)))) (VP (VP (VBD reduced) (NP (PRP$ his) (NNS symptoms))) (CC and) (VP (VBD maintained) (NP (JJ Doc_19944333_768_781_Disease) (NN status)))) (. .)))
19944333	9	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT the) (JJ first) (NN case)) (PP (IN of) (NP (JJ Doc_19944333_818_827_Chemical-induced) (NN Doc_19944333_836_857_Disease))))) (. .)))
19944333	10	(S1 (S (NP (NN Doc_19944333_859_868_Chemical)) (VP (AUX is) (NP (NP (DT a) (JJ multikinase) (NN inhibitor)) (SBAR (WHNP (WDT that)) (S (VP (VBZ targets) (NP (NP (VBG signaling) (NNS pathways)) (ADJP (JJ necessary) (PP (IN for) (NP (NP (JJ cellular) (NN proliferation)) (CC and) (NP (NN survival))))))))))) (. .)))
19944333	11	(S1 (S (PP (IN On) (NP (DT the) (JJ other) (NN hand))) (, ,) (NP (DT the) (NNP Rho/ROCK) (NN pathway)) (VP (AUX has) (NP (NP (DT an) (JJ important) (NN role)) (PP (IN in) (NP (NP (DT the) (NNS pathogenesis)) (PP (IN of) (NP (NNP Doc_19944333_1064_1085_Disease))))))) (. .)))
19944333	12	(S1 (S (NP (PRP$ Our) (NN report)) (VP (MD may) (VP (VB show) (NP (NP (DT an) (JJ adverse) (NN effect)) (PP (IN on) (NP (NP (DT the) (JJ Rho/ROCK) (NN pathway)) (PP (IN by) (NP (JJ Doc_19944333_1152_1161_Chemical) (NN use)))))))) (. .)))
19944736	0	(S1 (S (NP (DT A) (JJ novel) (NN animal) (NN model)) (VP (TO to) (VP (VB evaluate) (NP (NP (DT the) (NN ability)) (PP (IN of) (NP (DT a) (NN drug) (NN delivery) (NN system))) (S (VP (TO to) (VP (VB promote) (NP (DT the) (NN passage)) (PP (IN through) (NP (DT the) (NNP BBB))))))))) (. .)))
19944736	1	(S1 (S (NP (NP (DT The) (NN purpose)) (PP (IN of) (NP (DT this) (NN investigation)))) (VP (AUX was) (S (VP (TO to) (VP (VB explore) (NP (NP (DT the) (NN potentiality)) (PP (IN of) (NP (NP (DT a) (JJ novel) (NN animal) (NN model)) (SBAR (S (VP (TO to) (VP (AUX be) (VP (VBN used) (PP (IN for) (NP (NP (DT the)) (PP (IN in) (NP (NP (NN vivo) (NN evaluation)) (PP (IN of) (NP (NP (DT the) (NN ability)) (PP (IN of) (NP (DT a) (NN drug) (NN delivery) (NN system))) (S (VP (TO to) (VP (VB promote) (NP (DT the) (NN passage)) (PP (IN through) (NP (NP (DT the) (JJ blood-brain) (NN barrier) (PRN (-LRB- -LRB-) (NP (NNP BBB)) (-RRB- -RRB-)) (NN and/or)) (SBAR (S (VP (TO to) (VP (VB improve) (NP (NP (DT the) (NN brain) (NN localization)) (PP (IN of) (NP (DT a) (JJ bioactive) (NN compound))))))))))))))))))))))))))))))) (. .)))
19944736	2	(S1 (S (NP (DT A) (JJ Doc_19944736_409_417_Chemical-coated) (JJ Doc_19944736_425_443_Chemical) (NN nanoparticles)) (VP (AUX was) (VP (VBN used) (PP (IN as) (NP (NP (DT a) (NN model)) (PP (IN of) (NP (JJ colloidal) (NN drug) (NN delivery) (NN system))))) (, ,) (ADJP (JJ able) (PP (TO to) (NP (NN trespass)) (NP (DT the) (NNP BBB)))))) (. .)))
19944736	3	(S1 (S (NP (NP (NN Doc_19944736_539_546_Chemical)) (, ,) (VP (VBN administered) (PP (IN in) (NP (JJ Doc_19944736_564_568_Chemical) (JJ pre-treated) (NNS rats)))) (, ,)) (VP (VBZ induces) (NP (NP (JJ electrocorticographic) (NN Doc_19944736_617_625_Disease)) (CC and) (NP (JJ delayed) (NN Doc_19944736_638_656_Disease)))) (. .)))
19944736	4	(S1 (S (NP (NP (NP (DT The) (JJ toxic) (NNS effects)) (PP (IN of) (NP (JJ Doc_19944736_679_686_Chemical-loaded) (JJ Doc_19944736_694_712_Chemical) (NNS nanoparticles)))) (PRN (-LRB- -LRB-) (NP (CD 5mg/kg)) (-RRB- -RRB-)) (, ,) (NP (NP (DT a) (JJ saline) (NN solution)) (PP (IN of) (NP (NP (NNP Doc_19944736_758_765_Chemical)) (PRN (-LRB- -LRB-) (NP (NN 5mg/kg)) (-RRB- -RRB-))))) (CC and) (NP (DT an) (JJ empty) (JJ colloidal) (JJ nanoparticle) (NN suspension))) (VP (AUX were) (VP (VBN compared) (PP (VBG following) (NP (NP (NN i.p.) (NN administration)) (PP (IN in) (NP (JJ Doc_19944736_869_873_Chemical-pre-treated) (NNP Wistar) (NNS rats))))))) (. .)))
19944736	5	(S1 (S (NP (NP (PDT All) (DT the) (NNS animals)) (VP (VBN treated) (PP (IN with) (NP (JJ Doc_19944736_928_935_Chemical-loaded) (NNS nanoparticles))))) (VP (VBD showed) (NP (NP (DT an) (JJR earlier) (NN outcome)) (PP (IN of) (NP (NP (NNP CNS) (JJ adverse) (NNS symptoms)) (, ,) (NP (FW i.e.) (FW Doc_19944736_1013_1022_Disease) (NN onset)) (, ,)))) (PP (IN with) (NP (NP (NN respect)) (PP (TO to) (NP (NP (DT those) (NNS animals)) (VP (VBN treated) (PP (IN with) (NP (NP (DT the) (JJ free) (NN compound)) (PRN (-LRB- -LRB-) (NP (NP (CD 10) (NN min)) (PP (IN vs.) (ADVP (NP (CD 22) (NN min)) (RB respectively)))) (-RRB- -RRB-)))))))))) (. .)))
19944736	6	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (JJ Doc_19944736_1138_1145_Chemical-loaded) (NNS nanoparticles) (NN administration)) (VP (VBN induced) (NP (NNP Doc_19944736_1190_1214_Disease)) (PP (IN in) (NP (NP (CD CA1) (NN field)) (PP (IN of) (NP (NP (DT the) (NNS hippocampus)) (PP (IN in) (NP (DT all) (VBN treated) (NNS animals))))))) (, ,) (SBAR (IN while) (S (NP (NP (DT the) (JJ saline) (NN solution)) (PP (IN of) (NP (NP (NNP Doc_19944736_1300_1307_Chemical)) (PP (ADVP (RB only)) (IN in) (NP (NP (CD 60) (NN %)) (PP (IN of) (NP (NNS animals))))))))))) (. .)))
19944736	7	(S1 (S (NP (JJ Empty) (NNS nanoparticles)) (VP (VBD provided) (NP (JJ similar) (NNS results)) (S (VP (TO to) (VP (VB control) (NP (NP (-LRB- -LRB-) (JJ saline-treated) (-RRB- -RRB-) (NN group)) (PP (IN of) (NP (NNS animals)))))))) (. .)))
19944736	8	(S1 (S (PP (IN In) (NP (NP (NN conclusion)) (, ,) (NP (NP (DT the) (NN evaluation)) (PP (IN of) (NP (NP (NN time-to-onset)) (PP (IN of) (NP (NNS symptoms)))))) (CC and) (NP (NP (DT the) (NN severity)) (PP (IN of) (NP (NP (JJ neurodegenerative) (NNS processes)) (VP (VBN induced) (PP (IN by) (NP (NP (DT the) (JJ Doc_19944736_1545_1552_Chemical-Doc_19944736_1553_1560_Chemical) (NN model)) (PP (IN of) (NP (NNP Doc_19944736_1570_1578_Disease))) (PP (IN in) (NP (DT the) (NN rat))))))))))) (, ,) (VP (MD could) (VP (AUX be) (VP (VBN used) (S (VP (TO to) (VP (VB evaluate) (NP (NP (RB preliminarily) (DT the) (NN capability)) (PP (IN of) (NP (DT a) (NN drug) (NN delivery) (NN system)))) (PP (TO to) (NP (NN trespass))) (PRN (-LRB- -LRB-) (CC or) (RB not) (-RRB- -RRB-)) (S (NP (DT the) (NNP BBB)) (PP (IN in) (NP (NN vivo)))))))))) (. .)))
19996135	0	(S1 (S (NP (NNP High-dose) (NNP Doc_19996135_10_25_Chemical)) (VP (AUX is) (VP (VBN associated) (PP (IN with) (NP (NP (JJ nonischemic) (JJ clinical) (NN Doc_19996135_66_74_Disease)) (PP (IN in) (NP (JJ cardiac) (JJ surgical) (NNS patients))))))) (. .)))
19996135	1	(S1 (S (PP (IN In) (NP (CD 2) (JJ separate) (NNS centers))) (, ,) (NP (PRP we)) (VP (VBD observed) (NP (NP (DT a) (JJ notable) (NN increase)) (PP (IN in) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (JJ postoperative) (NNP Doc_19996135_205_215_Disease) (NNP Doc_19996135_216_224_Disease))))) (PP (IN from) (NP (CD 1.3) (NN %)))) (PP (TO to) (NP (CD 3.8) (NN %))) (PP (IN in) (NP (NP (NNS patients)) (VP (AUXG having) (VP (VBN undergone) (NP (JJ major) (JJ cardiac) (JJ surgical) (NNS procedures))))))) (. .)))
19996135	2	(S1 (S (NP (DT These) (NNS events)) (VP (AUX were) (ADJP (RB temporally) (JJ coincident) (PP (IN with) (NP (NP (DT the) (JJ initial) (NN use)) (PP (IN of) (NP (JJ high-dose) (NNP Doc_19996135_381_396_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_19996135_398_401_Chemical)) (-RRB- -RRB-)) (NN therapy))) (PP (IN after) (NP (NP (NN withdrawal)) (PP (IN of) (NP (NN aprotinin))) (PP (IN from) (NP (JJ general) (JJ clinical) (NN usage))))))))) (. .)))
19996135	3	(S1 (S (NP (NP (DT The) (NN purpose)) (PP (IN of) (NP (DT this) (NN review)))) (VP (AUX was) (S (VP (TO to) (VP (VB perform) (NP (NP (DT a) (JJ retrospective) (NN analysis)) (SBAR (S (VP (TO to) (VP (VB examine) (SBAR (IN whether) (S (NP (EX there)) (VP (AUX was) (NP (NP (DT a) (NN relation)) (PP (IN between) (NP (NP (JJ Doc_19996135_585_588_Chemical) (NN usage)) (CC and) (NP (NN Doc_19996135_599_607_Disease))))) (PP (IN after) (NP (JJ cardiac) (NN surgery))))))))))))))) (. .)))
19996135	4	(S1 (S (NP (DT An) (JJ in-depth) (NN chart) (NN review)) (VP (AUX was) (VP (VBN undertaken) (PP (IN in) (NP (NP (DT all) (CD 24) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (JJ perioperative) (NN Doc_19996135_727_735_Disease))))))))) (. .)))
19996135	5	(S1 (S (S (NP (JJ Electroencephalographic) (NN activity)) (VP (AUX was) (VP (VBN recorded) (PP (IN in) (NP (NP (CD 11)) (PP (IN of) (NP (DT these) (NNS patients)))))))) (, ,) (CC and) (S (NP (DT all) (NNS patients)) (VP (AUX had) (NP (NP (DT a) (JJ formal) (NN neurological) (NN evaluation)) (CC and) (NP (NN brain) (NN imaging) (NNS studies))))) (. .)))
19996135	6	(S1 (S (S (NP (NP (CD Twenty-one)) (PP (IN of) (NP (DT the) (CD 24) (NNS patients)))) (VP (AUX did) (RB not) (VP (AUX have) (NP (NP (NN evidence)) (PP (IN of) (NP (JJ new) (NNP Doc_19996135_957_981_Disease))))))) (, ,) (CC but) (S (NP (NNP Doc_19996135_987_995_Disease)) (VP (AUX were) (ADJP (RB likely) (JJ due) (PP (TO to) (NP (NNP Doc_19996135_1015_1036_Disease)))) (PP (IN in) (NP (CD 3) (NNS patients))))) (. .)))
19996135	7	(S1 (S (NP (NP (DT All) (NNS patients)) (PP (IN with) (NP (NNP Doc_19996135_1070_1078_Disease)))) (VP (AUX did) (RB not) (VP (AUX have) (NP (JJ permanent) (NN Doc_19996135_1102_1128_Disease)))) (. .)))
19996135	8	(S1 (S (NP (NP (DT All) (CD 24) (NNS patients)) (PP (IN with) (NP (NNP Doc_19996135_1151_1159_Disease)))) (VP (VBD received) (NP (NP (JJ high) (NNS doses)) (PP (IN of) (NP (NNP Doc_19996135_1183_1186_Chemical)))) (ADVP (RB intraoperatively)) (SBAR (S (S (S (VP (VBG ranging) (PP (IN from) (NP (QP (CD 61) (TO to) (CD 259)) (NNS mg/kg))))) (, ,) (VP (AUX had) (NP (NP (DT a) (JJ mean) (NN age)) (PP (IN of) (NP (CD 69.9) (NNS years)))))) (, ,) (CC and) (S (NP (NP (CD 21)) (PP (IN of) (NP (CD 24)))) (VP (AUX had) (VP (VBN undergone) (NP (NP (JJ open) (NN chamber)) (CONJP (RB rather) (IN than)) (NP (JJ coronary) (NN bypass) (NNS procedures))))))))) (. .)))
19996135	9	(S1 (S (NP (NP (DT All)) (PP (IN but) (NP (CD one) (NN patient)))) (VP (AUX were) (VP (VBN managed) (S (VP (VBG using) (NP (NN cardiopulmonary) (NN bypass)))))) (. .)))
19996135	10	(S1 (S (NP (NP (DT No) (NN evidence)) (PP (IN of) (NP (NP (NN Doc_19996135_1422_1436_Disease)) (, ,) (NP (NN metabolic)) (, ,) (CC or) (NP (NP (JJ Doc_19996135_1452_1464_Disease-induced) (NNS causes)) (PP (IN for) (NP (PRP$ their) (NN Doc_19996135_1490_1498_Disease))))))) (VP (AUX was) (ADJP (JJ apparent))) (. .)))
19996135	11	(S1 (S (NP (PRP$ Our) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NN use)) (PP (IN of) (NP (JJ high-dose) (NNP Doc_19996135_1567_1570_Chemical))) (PP (IN in) (NP (NP (JJR older) (NNS patients)) (PP (IN in) (NP (NP (NN conjunction)) (PP (IN with) (NP (NP (JJ cardiopulmonary) (NN bypass)) (CC and) (NP (JJ open-chamber) (JJ cardiac) (NN surgery))))))))) (VP (AUX is) (VP (VBN associated) (PP (IN with) (NP (NP (JJ clinical) (NN Doc_19996135_1693_1701_Disease)) (PP (IN in) (NP (JJ susceptible) (NNS patients)))))))))) (. .)))
2004	0	(S1 (S (NP (NP (NP (JJ Electrocardiographic) (NNS changes)) (CC and) (NP (NN Doc_2004_33_52_Disease))) (PP (IN in) (NP (NNS patients)))) (VP (VBG receiving) (NP (JJ psychotropic) (NNS drugs))) (. .)))
2004	1	(S1 (S (NP (CD Eight) (NNS patients)) (VP (AUX had) (NP (NP (NP (JJ cardiac) (NNS manifestations)) (SBAR (WHNP (WDT that)) (S (VP (AUX were) (ADJP (JJ life-threatening)) (PP (IN in) (NP (CD five))) (SBAR (IN while) (S (VP (VBG taking) (NP (JJ psychotropic) (NNS drugs))))))))) (, ,) (CC either) (NP (ADJP (JJ Doc_2004_212_226_Chemical) (CC or) (JJ tricyclic)) (NNS antidepressants)))) (. .)))
2004	2	(S1 (S (SBAR (IN Although) (S (NP (JJS most) (NNS patients)) (VP (AUX were) (VP (VBG receiving) (NP (JJ several) (NNS drugs)))))) (, ,) (NP (NP (NNP Doc_2004_310_318_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2004_320_332_Chemical)) (-RRB- -RRB-))) (VP (VBD appeared) (S (VP (TO to) (VP (AUX be) (ADJP (JJ responsible) (PP (IN for) (NP (NP (CD five) (NNS cases)) (PP (IN of) (NP (NNP Doc_2004_379_402_Disease))) (, ,) (SBAR (WHNP (CD one) (WHPP (IN of) (WHNP (WDT which)))) (S (VP (AUX was) (ADJP (JJ fatal)) (PP (IN in) (NP (DT a) (CD 35) (NN year) (JJ old) (NN woman))))))))))))) (. .)))
2004	3	(S1 (S (NP (NN Doc_2004_451_479_Disease)) (VP (VBD developed) (PP (IN in) (NP (NP (CD one) (NN patient)) (VP (VBG receiving) (NP (NP (NNP Doc_2004_515_524_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2004_526_540_Chemical)) (-RRB- -RRB-))))))) (. .)))
2004	4	(S1 (S (NP (NP (NP (NNP Doc_2004_543_550_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2004_552_565_Chemical)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_2004_571_577_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2004_579_592_Chemical)) (-RRB- -RRB-)))) (DT each) (VP (VBD produced) (NP (NNP Doc_2004_608_632_Disease)) (PP (IN in) (NP (DT a) (CD 73) (NN year) (JJ old) (NN woman)))) (. .)))
2004	5	(S1 (S (NP (NP (JJ Electrocardiographic) (NNS T)) (CC and) (NP (NNP U) (NN wave) (NNS abnormalities))) (VP (AUX were) (ADJP (JJ present)) (PP (IN in) (NP (JJS most) (NNS patients)))) (. .)))
2004	6	(S1 (S (S (NP (DT The) (NNP Doc_2004_740_763_Disease)) (VP (VBD responded) (PP (PP (TO to) (NP (NP (JJ intravenous) (NN administration)) (PP (IN of) (NP (NNP Doc_2004_807_816_Chemical))))) (CC and) (PP (TO to) (NP (JJ direct) (JJ current) (JJ electric) (NN shock)))))) (: ;) (S (NP (JJ ventricular) (NN pacing)) (VP (AUX was) (VP (VBN required) (PP (IN in) (NP (NP (NP (DT some) (NNS instances)) (CC and) (NP (JJ intravenous) (NN administration))) (PP (IN of) (NP (NNP Doc_2004_939_950_Chemical))) (VP (VBN combined) (PP (IN with) (NP (NP (JJ ventricular) (NN pacing)) (PP (IN in) (NP (CD one))))))))))) (. .)))
2004	7	(S1 (S (NP (NP (DT The) (NN Doc_2004_996_1012_Disease)) (VP (ADVP (RB generally)) (VBN subsided) (PP (IN within) (NP (CD 48) (NNS hours))) (PP (IN after) (NP (NP (NN administration)) (PP (IN of) (NP (DT the) (NNS drugs))))))) (VP (AUX was) (VP (VBN stopped))) (. .)))
2004	8	(S1 (S (S (NP (NP (CD Five)) (PP (IN of) (NP (DT the) (CD eight) (NNS patients)))) (VP (AUX were) (NP (NP (NP (CD 50) (NNS years)) (PP (IN of) (NP (NN age)))) (CC or) (NP (JJR younger))))) (: ;) (S (NP (QP (RB only) (CD one))) (ADVP (RB clearly)) (VP (AUX had) (NP (JJ antecedent) (NN Doc_2004_1187_1200_Disease)))) (. .)))
2004	9	(S1 (S (NP (NNP Major) (NNP Doc_2004_1208_1227_Disease)) (VP (AUX are) (NP (NP (DT a) (JJ potential) (NN hazard)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN without) (NP (NNP Doc_2004_1271_1284_Disease))))) (SBAR (WHNP (WP who)) (S (VP (AUX are) (VP (VBG receiving) (NP (NP (JJ customary) (JJ therapeutic) (NNS doses)) (PP (IN of) (NP (JJ psychotropic) (NNS drugs)))))))))) (. .)))
2004	10	(S1 (S (NP (DT A) (JJ prospective) (JJ clinical) (NN trial)) (VP (AUX is) (VP (VBN suggested) (S (VP (TO to) (VP (VB quantify) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NNP Doc_2004_1420_1441_Disease))) (PP (TO to) (NP (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NNP Doc_2004_1464_1478_Chemical)))) (CC or) (NP (JJ tricyclic) (JJ antidepressant) (NNS drugs)))))))))) (. .)))
2004015	0	(S1 (NP (NP (NN Sensitivity)) (PP (IN of) (NP (JJ erythroid) (NN progenitor) (NNS colonies))) (PP (TO to) (NP (NP (NN erythropoietin)) (PP (IN in) (NP (JJ Doc_2004015_66_80_Chemical) (VBN treated) (NN Doc_2004015_89_104_Disease) (NNS mice))))) (. .)))
2004015	1	(S1 (S (NP (NP (NP (DT The) (NNP Doc_2004015_115_122_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_2004015_134_161_Chemical))))) (PRN (-LRB- -LRB-) (NP (NNP Doc_2004015_163_166_Chemical)) (-RRB- -RRB-))) (VP (AUX is) (ADVP (RB poorly)) (VP (VBN understood))) (. .)))
2004015	2	(S1 (S (NP (PRP We)) (VP (AUX have) (VP (VBN used) (NP (NP (DT a) (JJ murine) (NN model)) (PP (IN of) (NP (NP (NNP Doc_2004015_221_225_Disease)) (, ,) (NP (NP (NNP Doc_2004015_227_236_Disease)) (PP (IN of) (NP (NP (JJ female) (NNP C57BL/6) (NNS mice)) (PP (IN with) (NP (JJ LP-BM5) (NN murine) (NNP Doc_2004015_279_288_Disease) (PRN (-LRB- -LRB-) (NP (NNP MuLV)) (-RRB- -RRB-)) (NN virus)))))) (, ,)))) (S (VP (TO to) (VP (VB determine) (SBAR (S (IN if) (NP (NNP Doc_2004015_319_322_Chemical-induced) (NNP Doc_2004015_331_338_Disease)) (VP (AUX is) (ADJP (JJ due)) (, ,) (PP (IN in) (NP (NN part))) (, ,) (PP (TO to) (NP (NP (VBN decreased) (NN responsiveness)) (PP (IN of) (NP (NP (JJ erythropoietic) (NNS precursors)) (PRN (-LRB- -LRB-) (NP (NNP BFU-e)) (-RRB- -RRB-)))) (PP (TO to) (NP (NP (NN erythropoietin)) (PRN (-LRB- -LRB-) (NP (NNP EPO)) (-RRB- -RRB-)))))))))))))) (. .)))
2004015	3	(S1 (S (NP (NP (NNS Mice)) (PP (IN in) (NP (NP (DT the) (JJ early) (NN stage)) (PP (IN of) (NP (JJ LP-BM5) (JJ MuLV) (NN disease)))))) (VP (AUX were) (VP (VBN given) (NP (NNP Doc_2004015_504_507_Chemical)) (PP (IN in) (NP (PRP$ their) (NN drinking) (NN water))) (PP (IN at) (NP (QP (CD 1.0) (CC and) (CD 2.5) (CD mg/ml)))))) (. .)))
2004015	4	(S1 (S (NP (NN Doc_2004015_554_557_Chemical)) (VP (VBD produced) (NP (NNP Doc_2004015_567_574_Disease)) (PP (IN in) (NP (DT both) (NNS groups))) (, ,) (PP (IN in) (NP (DT a) (JJ dose-dependent) (NN fashion)))) (. .)))
2004015	5	(S1 (S (PP (IN Despite) (NP (DT the) (NNP Doc_2004015_632_639_Disease))) (, ,) (NP (NP (DT the) (NN number)) (PP (IN of) (NP (NP (NN splenic) (CC and) (NN bone) (NN marrow) (NN BFU-e)) (PP (IN in) (NP (JJ Doc_2004015_688_691_Chemical) (VBN treated) (NNS mice)))))) (VP (VBD increased) (PRT (RP up)) (S (VP (TO to) (VP (VB five-fold) (PP (IN over) (NP (NP (NNS levels)) (VP (VBN observed) (PP (IN in) (NP (JJ infected) (JJ untreated) (NNS animals))) (PP (IN after) (NP (NP (CD 15) (NNP d)) (PP (IN of) (NP (NN treatment)))))))))))) (. .)))
2004015	6	(S1 (S (NP (NP (NN Colony) (NN formation)) (PP (IN by) (NP (NP (NN splenic)) (CC and) (NP (NN bone) (NN marrow) (NN BFUe))))) (VP (AUX was) (VP (VBN stimulated) (PP (IN at) (NP (NP (JJR lower) (NNS concentrations)) (PP (IN of) (NP (NNP EPO))) (PP (IN in) (NP (NP (NNS mice)) (VP (VBG receiving) (NP (NNP Doc_2004015_920_923_Chemical)) (PP (IN for) (NP (NP (CD 15) (NNP d)) (PP (IN than) (PP (IN for) (NP (JJ infected) (, ,) (JJ untreated) (NNS mice))))))))))))) (. .)))
2004015	7	(S1 (S (PP (IN By) (NP (NN day) (CD 30))) (, ,) (NP (NP (NN sensitivity)) (PP (IN of) (NP (NP (DT both) (NN splenic) (CC and) (NN bone) (NN marrow) (NNS BFU-e)) (PP (IN of) (NP (VBN treated) (NNS animals)))))) (VP (VBD returned) (PP (TO to) (NP (DT that))) (PP (VBN observed) (PP (IN from) (NP (NP (NNS cells)) (PP (IN of) (NP (JJ infected) (JJ untreated) (NNS animals))))))) (. .)))
2004015	8	(S1 (S (NP (NP (DT The) (JJ mean) (NN plasma) (NNS levels)) (PP (IN of) (NP (NNP EPO)))) (VP (VBD observed) (SBAR (IN in) (S (NP (NNP Doc_2004015_1158_1161_Chemical)) (VP (VBD treated) (SBAR (S (NP (NNS mice)) (VP (AUX were) (ADJP (JJ appropriate) (PP (IN for) (NP (NP (DT the) (NN degree)) (PP (IN of) (NP (NNP Doc_2004015_1210_1217_Disease))) (VP (VBD observed) (SBAR (WHADVP (WRB when)) (S (VP (VBN compared) (PP (IN with) (NP (NP (NP (NNP Doc_2004015_1246_1261_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2004015_1263_1266_Chemical)) (-RRB- -RRB-))) (VBN treated) (NNS mice))))))))))))))))) (. .)))
2004015	9	(S1 (S (NP (NP (NP (DT The) (NNS numbers)) (PP (IN of) (NP (NNP BFU-e)))) (CC and) (NP (NP (DT the) (NN percentage)) (PP (IN of) (NP (NN bone) (NN marrow) (NNS erythroblasts))))) (VP (VBD observed) (SBAR (S (VP (AUX were) (ADJP (JJ comparable) (PP (IN in) (NP (NP (NNP Doc_2004015_1379_1382_Chemical) (CC and) (NNP Doc_2004015_1387_1390_Chemical) (VBN treated) (NNS mice)) (PP (IN with) (NP (NP (JJ similar) (NNS degrees)) (PP (IN of) (NP (NNP Doc_2004015_1428_1435_Disease)))))))))))) (. .)))
2004015	10	(S1 (S (ADVP (RB However)) (, ,) (NP (NNP Doc_2004015_1446_1461_Disease)) (VP (AUX was) (ADJP (JJ inappropriate) (PP (IN for) (NP (NP (DT the) (NN degree)) (PP (IN of) (NP (NNP Doc_2004015_1498_1505_Disease))) (VP (VBN observed) (PP (IN in) (NP (JJ Doc_2004015_1518_1521_Chemical) (VBN treated) (JJ infected) (NNS mice)))))))) (. .)))
2004015	11	(S1 (S (NP (NP (NP (JJ Doc_2004015_1545_1548_Chemical-induced) (JJ peripheral) (NN Doc_2004015_1568_1575_Disease)) (PP (IN in) (NP (NP (DT the) (NN face)) (PP (IN of) (NP (NP (VBN increased) (NNS numbers)) (PP (IN of) (NP (NNP BFU-e)))))))) (CC and) (NP (NP (VBN increased) (NNS levels)) (PP (IN of) (NP (NN plasma) (NNP EPO))))) (VP (VBP suggest) (NP (NP (DT a) (NN lesion)) (PP (IN in) (NP (JJ terminal) (NN differentiation))))) (. .)))
20042557	0	(S1 (S (NP (NN Sedation)) (VP (NN depth) (PP (IN during) (NP (NP (JJ spinal) (NN anesthesia)) (CC and) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_20042557_63_85_Disease)))))) (PP (IN in) (NP (NP (JJ elderly) (NNS patients)) (VP (VBG undergoing) (NP (JJ Doc_20042557_117_129_Disease) (NN repair)))))) (. .)))
20042557	1	(S1 (S (S (VP (TO To) (VP (VB determine) (SBAR (IN whether) (S (VP (VBG limiting) (NP (JJ intraoperative) (NN sedation) (NN depth)) (PP (IN during) (NP (NP (JJ spinal) (NNS anesthesia)) (PP (IN for) (NP (NP (NN Doc_20042557_238_250_Disease) (NN repair)) (PP (IN in) (NP (JJ elderly) (NNS patients))))))))))))) (VP (MD can) (VP (VB decrease) (NP (NP (DT the) (NN prevalence)) (PP (IN of) (NP (NNP Doc_20042557_309_331_Disease)))))) (. .)))
20042557	2	(S1 (FRAG (NP (NNS PATIENTS) (CC AND) (NNS METHODS)) (: :) (S (NP (PRP We)) (VP (VBD performed) (NP (DT a) (JJ double-blind) (, ,) (JJ randomized) (JJ controlled) (NN trial)) (PP (IN at) (NP (NP (DT an) (JJ academic) (JJ medical) (NN center)) (PP (IN of) (NP (NP (JJ elderly) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD >or=65) (NNS years)) (-RRB- -RRB-)))))) (PP (IN without) (NP (NP (JJ preoperative) (NN Doc_20042557_498_506_Disease)) (CC or) (NP (NP (JJ severe) (NN Doc_20042557_517_525_Disease)) (SBAR (WHNP (WP who)) (S (VP (VBD underwent) (NP (NNP Doc_20042557_540_552_Disease) (NN repair)) (PP (IN under) (NP (NP (JJ spinal) (NNS anesthesia)) (PP (IN with) (NP (JJ Doc_20042557_589_597_Chemical) (NN sedation))))))))))))) (. .)))
20042557	3	(S1 (S (S (NP (JJ Sedation) (NN depth)) (VP (AUX was) (VP (VBN titrated) (S (VP (VBG using) (NP (NP (VBN processed) (NN electroencephalography)) (PP (IN with) (NP (DT the) (JJ bispectral) (NN index))) (PRN (-LRB- -LRB-) (NP (NNP BIS)) (-RRB- -RRB-)))))))) (, ,) (CC and) (S (NP (NNS patients)) (VP (AUX were) (VP (VBN randomized) (S (VP (TO to) (VP (VB receive) (NP (DT either) (ADJP (ADJP (JJ deep)) (PRN (-LRB- -LRB-) (NP (NNP BIS)) (, ,) (NP (QP (RB approximately) (CD 50))) (-RRB- -RRB-)) (CC or) (ADJP (JJ light)) (PRN (-LRB- -LRB-) (NP (NNP BIS)) (, ,) (NP (CD >or=80)) (-RRB- -RRB-))) (NN sedation)))))))) (. .)))
20042557	4	(S1 (S (NP (NN Doc_20042557_817_839_Disease)) (VP (AUX was) (VP (VBN assessed) (SBAR (IN as) (S (VP (VBN defined) (PP (IN by) (NP (NP (NNP Diagnostic) (CC and) (NNP Statistical) (NNP Manual)) (PP (IN of) (NP (NP (NNP Doc_20042557_904_920_Disease) (PRN (-LRB- -LRB-) (NP (JJ Third) (NN Edition) (JJ Revised)) (-RRB- -RRB-)) (NNS criteria)) (VP (VBG using) (NP (NP (DT the) (NN Confusion) (NN Assessment) (NN Method)) (VP (VBG beginning) (PP (IN at) (NP (DT any) (NN time))) (PP (IN from) (NP (NP (DT the) (JJ second) (NN day)) (PP (IN after) (NP (NN surgery))))))))))))))))) (. .)))
20042557	5	(S1 (S (PP (IN From) (NP (NNP April) (CD 2) (, ,) (CD 2005))) (, ,) (PP (IN through) (NP (NNP October) (CD 30) (, ,) (CD 2008))) (, ,) (NP (NP (DT a) (NN total)) (PP (IN of) (NP (CD 114) (NNS patients)))) (VP (AUX were) (VP (VBN randomized))) (. .)))
20042557	6	(S1 (S (NP (NP (DT The) (NN prevalence)) (PP (IN of) (NP (NNP Doc_20042557_1163_1185_Disease)))) (VP (AUX was) (ADJP (RB significantly) (JJR lower)) (PP (IN in) (NP (NP (DT the) (JJ light) (NN sedation) (NN group)) (PRN (-LRB- -LRB-) (NP (NP (NP (NP (QP (CD 11/57) (CD -LSB-19)) (NN %)) (JJ -RSB-) (NNP vs) (CD 23/57) (ADJP (CD -LSB-40) (NN %)) (NN -RSB-)) (PP (IN in) (NP (DT the) (JJ deep) (NN sedation) (NN group)))) (: ;) (NP (NNP P=.02))) (-RRB- -RRB-)))) (, ,) (S (VP (VBG indicating) (SBAR (IN that) (S (NP (NP (CD 1) (NN incident)) (PP (IN of) (NP (NNP Doc_20042557_1332_1340_Disease)))) (VP (MD will) (VP (AUX be) (VP (VBN prevented) (PP (IN for) (NP (NP (DT every) (CD 4.7) (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (JJ light) (NN sedation)))))))))))))) (. .)))
20042557	7	(S1 (S (NP (NP (DT The) (JJ mean) (JJ +/-) (NN SD) (NN number)) (PP (IN of) (NP (NP (NNS days)) (PP (IN of) (NP (NNP Doc_20042557_1445_1453_Disease))))) (PP (IN during) (NP (NN hospitalization)))) (VP (AUX was) (ADJP (ADJP (JJR lower) (PP (IN in) (NP (DT the) (JJ light) (NN sedation) (NN group)))) (PP (IN than) (PP (IN in) (NP (NP (DT the) (JJ deep) (NN sedation) (NN group)) (PRN (-LRB- -LRB-) (NP (NP (CD 0.5+/-1.5) (NNS days)) (NP (NNP vs) (CD 1.4+/-4.0) (NNS days)) (: ;) (NP (NNP P=.01))) (-RRB- -RRB-))))))) (. .)))
20042557	8	(S1 (S (NP (NP (DT The) (NN use)) (PP (IN of) (NP (JJ light) (JJ Doc_20042557_1619_1627_Chemical) (NN sedation)))) (VP (VBD decreased) (NP (NP (DT the) (NN prevalence)) (PP (IN of) (NP (NNP Doc_20042557_1665_1687_Disease))) (PP (IN by) (NP (CD 50) (NN %)))) (PP (VBN compared) (PP (IN with) (NP (JJ deep) (NN sedation))))) (. .)))
20042557	9	(S1 (S (S (VP (VBG Limiting) (NP (NP (NN depth)) (PP (IN of) (NP (NN sedation)))) (PP (IN during) (NP (JJ spinal) (NNS anesthesia))))) (VP (AUX is) (NP (NP (DT a) (ADJP (JJ simple) (, ,) (JJ safe) (, ,) (CC and) (JJ cost-effective)) (NN intervention)) (PP (IN for) (S (VP (VBG preventing) (NP (NNP Doc_20042557_1842_1864_Disease)) (PP (IN in) (NP (NP (JJ elderly) (NNS patients)) (SBAR (WHNP (WDT that)) (S (VP (MD could) (VP (AUX be) (VP (ADVP (RB widely) (CC and) (RB readily)) (VBN adopted))))))))))))) (. .)))
20103708	0	(S1 (NP (NP (DT The) (JJ protective) (NN role)) (PP (IN of) (NP (NNP Nrf2))) (PP (IN in) (NP (NNP Doc_20103708_31_45_Chemical-induced) (NNP Doc_20103708_54_74_Disease))) (. .)))
20103708	1	(S1 (S (NP (NN Doc_20103708_87_107_Disease)) (VP (AUX is) (NP (NP (CD one)) (PP (IN of) (NP (NP (DT the) (JJ major) (NNS causes)) (PP (IN of) (NP (NP (NNP Doc_20103708_138_151_Disease)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX is) (VP (VBN accompanied) (PP (IN by) (NP (NP (DT the) (NN production)) (PP (IN of) (NP (NP (JJ reactive) (JJ Doc_20103708_204_210_Chemical) (NNS species)) (PRN (-LRB- -LRB-) (NP (NNS ROS)) (-RRB- -RRB-)))))))))))))))) (. .)))
20103708	2	(S1 (S (NP (NN Nrf2)) (VP (AUX is) (NP (NP (DT the) (JJ primary) (NN transcription) (NN factor)) (SBAR (WHNP (WDT that)) (S (VP (VBZ controls) (S (NP (DT the) (JJ antioxidant) (NN response)) (ADJP (JJ essential) (PP (IN for) (S (VP (VBG maintaining) (NP (JJ cellular) (NN redox) (NNS homeostasis)))))))))))) (. .)))
20103708	3	(S1 (S (ADVP (RB Here)) (, ,) (NP (PRP we)) (VP (VBP report) (NP (NP (PRP$ our) (NNS findings)) (VP (VBG demonstrating) (NP (NP (DT a) (JJ protective) (NN role)) (PP (IN of) (NP (NNP Nrf2))) (PP (IN against) (NP (NNP Doc_20103708_437_457_Disease))))))) (. .)))
20103708	4	(S1 (NP (NP (NN RESEARCH) (NN DESIGN) (CC AND) (NNS METHODS)) (: :) (S (NP (PRP We)) (VP (VB explore) (NP (NP (DT the) (JJ protective) (NN role)) (PP (IN of) (NP (NNP Nrf2))) (PP (IN against) (NP (NNP Doc_20103708_535_555_Disease)))) (S (VP (VBG using) (NP (JJ human) (NN kidney) (NN biopsy) (NNS tissues)) (PP (IN from) (NP (NP (JJ Doc_20103708_595_615_Disease) (NNS patients)) (, ,) (NP (NP (DT a) (JJ Doc_20103708_628_642_Chemical-induced) (NNP Doc_20103708_651_671_Disease) (NN model)) (PP (IN in) (NP (JJ Nrf2) (PRN (-LRB- -LRB-) (JJ -/-) (-RRB- -RRB-)) (NNS mice)))) (, ,) (CC and) (NP (JJ cultured) (JJ human) (JJ mesangial) (NNS cells)))))))) (. .)))
20103708	5	(S1 (S (NP (NP (DT The) (NNS glomeruli)) (PP (IN of) (NP (JJ human) (NNP Doc_20103708_765_785_Disease) (NNS patients)))) (VP (VP (AUX were) (PP (IN under) (NP (JJ oxidative) (NN stress)))) (CC and) (VP (AUX had) (NP (JJ elevated) (JJ Nrf2) (NNS levels)))) (. .)))
20103708	6	(S1 (S (PP (IN In) (NP (DT the) (NN animal) (NN study))) (, ,) (NP (NNP Nrf2)) (VP (AUX was) (VP (VBN demonstrated) (S (VP (TO to) (VP (AUX be) (ADJP (JJ crucial)) (PP (IN in) (S (VP (VBG ameliorating) (NP (JJ Doc_20103708_926_940_Chemical-induced) (NN Doc_20103708_949_961_Disease)))))))))) (. .)))
20103708	7	(S1 (S (NP (DT This)) (VP (AUX is) (ADJP (JJ evident) (PP (IN by) (NP (NP (NNP Nrf2) (PRN (-LRB- -LRB-) (JJ -/-) (-RRB- -RRB-)) (NNS mice)) (VP (VP (AUXG having) (NP (JJR higher) (NN ROS) (NN production))) (CC and) (VP (VBG suffering) (PP (IN from) (NP (NP (JJR greater) (JJ oxidative) (NN DNA) (NN damage)) (CC and) (NP (NNP Doc_20103708_1078_1090_Disease)))) (PP (VBN compared) (PP (IN with) (NP (NNP Nrf2) (-LRB- -LRB-) (CD +/+) (-RRB- -RRB-) (NNS mice)))))))))) (. .)))
20103708	8	(S1 (S (NP (NP (JJ Mechanistic) (NNS studies)) (PP (PP (IN in) (NP (NP (DT both)) (PP (IN in) (NP (NN vivo))))) (CC and) (PP (IN in) (NP (NN vitro) (NNS systems))))) (VP (VBD showed) (SBAR (IN that) (S (NP (NP (DT the) (JJ Nrf2-mediated) (NN protection)) (PP (IN against) (NP (NNP Doc_20103708_1227_1247_Disease)))) (VP (AUX is) (, ,) (ADVP (IN at) (JJS least)) (, ,) (PP (ADVP (RB partially)) (IN through) (NP (NP (NP (NN inhibition)) (PP (IN of) (NP (NP (VBG transforming) (NN growth) (NNS factor-beta1)) (PRN (-LRB- -LRB-) (JJ TGF-beta1) (-RRB- -RRB-))))) (CC and) (NP (NP (NN reduction)) (PP (IN of) (NP (JJ extracellular) (NNP matrix) (NN production)))))))))) (. .)))
20103708	9	(S1 (S (PP (IN In) (NP (JJ human) (JJ renal) (NN mesangial) (NNS cells))) (, ,) (NP (JJ high) (NNP Doc_20103708_1426_1433_Chemical)) (VP (VP (VBN induced) (NP (NNP ROS) (NN production))) (CC and) (VP (VBN activated) (NP (NP (NN expression)) (PP (IN of) (NP (NP (NNP Nrf2)) (CC and) (NP (PRP$ its) (JJ downstream) (NNS genes))))))) (. .)))
20103708	10	(S1 (S (ADVP (RB Furthermore)) (, ,) (NP (NP (NN activation) (CC or) (NN overexpression)) (PP (IN of) (NP (NNP Nrf2)))) (VP (VBD inhibited) (NP (NP (DT the) (NN promoter) (NN activity)) (PP (IN of) (NP (NN TGF-beta1)))) (PP (IN in) (NP (DT a) (JJ dose-dependent) (NN manner))) (, ,) (SBAR (IN whereas) (S (VP (VBN knockdown) (PP (IN of) (NP (NNP Nrf2))) (PP (IN by) (S (VP (VBG siRNA) (NP (NP (JJ enhanced) (JJ TGF-beta1) (NN transcription)) (CC and) (NP (JJ fibronectin) (NN production)))))))))) (. .)))
20103708	11	(S1 (S (NP (DT This) (NN work)) (ADVP (RB clearly)) (VP (VBZ indicates) (NP (NP (DT a) (JJ protective) (NN role)) (PP (IN of) (NP (NNP Nrf2))) (PP (IN in) (NP (NNP Doc_20103708_1805_1825_Disease)))) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP (NP (NP (NN dietary)) (CC or) (NP (JJ therapeutic) (NN activation))) (PP (IN of) (NP (NNP Nrf2)))) (VP (MD could) (VP (AUX be) (VP (VBN used) (PP (IN as) (NP (NP (DT a) (NN strategy)) (SBAR (S (VP (TO to) (VP (VP (VB prevent)) (CC or) (VP (VB slow) (PRT (RP down)) (NP (NP (DT the) (NN progression)) (PP (IN of) (NP (NNP Doc_20103708_1956_1976_Disease))))))))))))))))))) (. .)))
20164825	0	(S1 (S (NP (NN Doc_20164825_0_9_Chemical)) (VP (VBZ prevents) (NP (JJ experimental) (JJ Doc_20164825_32_42_Chemical-induced) (NN Doc_20164825_51_62_Disease)) (PP (IN by) (NP (DT a) (JJ mitochondria-dependent) (NN pathway)))) (. .)))
20164825	1	(S1 (S (NP (DT The) (JJ antidiabetic) (NN drug) (NN Doc_20164825_122_131_Chemical)) (VP (MD can) (VP (VP (VB diminish) (NP (NP (NNS apoptosis)) (VP (VBN induced) (PP (IN by) (NP (JJ oxidative) (NN stress))) (PP (IN in) (NP (JJ endothelial) (NNS cells)))))) (CC and) (VP (VB prevent) (NP (NNP Doc_20164825_216_236_Disease)) (PP (ADVP (RB even)) (IN in) (NP (JJ nondiabetic) (NNS patients)))))) (. .)))
20164825	2	(S1 (S (ADVP (RB Here)) (NP (PRP we)) (VP (VBD tested) (SBAR (IN whether) (S (NP (PRP it)) (VP (AUX has) (NP (DT a) (JJ beneficial) (NN effect)) (PP (IN in) (NP (NP (DT a) (NN rat) (NN model)) (PP (IN of) (NP (NNP Doc_20164825_335_345_Chemical) (NNP Doc_20164825_346_354_Disease))))))))) (. .)))
20164825	3	(S1 (S (NP (NP (JJ Mitochondrial) (NN analysis)) (, ,) (NP (NN respiration) (NN intensity)) (, ,) (NP (NP (NNS levels)) (PP (IN of) (NP (JJ reactive) (JJ Doc_20164825_422_428_Chemical) (NNS species)))) (, ,) (NP (NN permeability) (NN transition)) (, ,) (CC and) (NP (JJ cytochrome) (NN c) (NN release))) (VP (AUX were) (VP (VBN assessed) (PP (NP (QP (CD 3) (CC and) (CD 6)) (NNS days)) (IN after) (NP (NNP Doc_20164825_521_531_Chemical) (NN administration))))) (. .)))
20164825	4	(S1 (S (NP (JJ Doc_20164825_548_557_Chemical) (NN treatment)) (ADVP (RB fully)) (VP (VBD blocked) (NP (JJ Doc_20164825_582_592_Chemical-mediated) (NNP Doc_20164825_602_621_Disease))) (. .)))
20164825	5	(S1 (S (NP (DT This)) (VP (AUX was) (VP (VBN accompanied) (PP (IN by) (NP (NP (DT a) (JJR lower) (NN activity)) (PP (IN of) (NP (NNP Doc_20164825_667_675_Chemical-beta-D-glucosaminidase))))) (, ,) (ADVP (RB together) (PP (IN with) (NP (NP (NP (DT a) (NN decrease)) (PP (IN of) (NP (NN lipid) (NN peroxidation)))) (CC and) (NP (NP (NN increase)) (PP (IN of) (NP (NN antioxidant) (NNS systems))))))))) (. .)))
20164825	6	(S1 (S (NP (NN Doc_20164825_784_793_Chemical)) (ADVP (RB also)) (VP (VBD protected) (NP (DT the) (NN kidney)) (PP (IN from) (NP (JJ histological) (NN damage))) (PP (NP (CD 6) (NNS days)) (IN after) (NP (NNP Doc_20164825_858_868_Chemical) (NN administration)))) (. .)))
20164825	7	(S1 (S (NP (NP (NP (DT These)) (PP (IN in) (NP (NP (NN vivo) (NNS markers)) (PP (IN of) (NP (NNP Doc_20164825_910_928_Disease)))))) (CC and) (NP (NP (PRP$ their) (NN correction)) (PP (IN by) (NP (NNP Doc_20164825_953_962_Chemical))))) (VP (AUX were) (VP (VBN complemented) (PP (IN by) (NP (NP (ADJP (IN in) (NN vitro)) (NNS studies)) (PP (IN of) (NP (JJ mitochondrial) (NN function))))))) (. .)))
20164825	8	(S1 (S (NP (PRP We)) (VP (VBD found) (SBAR (IN that) (S (NP (JJ Doc_20164825_1042_1052_Chemical) (NN treatment)) (VP (VBD depleted) (NP (NP (JJ respiratory) (NNS components)) (PRN (-LRB- -LRB-) (NP (NP (NN cytochrome) (NN c)) (, ,) (NP (NNP Doc_20164825_1110_1114_Chemical))) (-RRB- -RRB-))) (, ,) (PP (ADVP (RB probably)) (JJ due) (PP (TO to) (NP (NP (DT the) (NN opening)) (PP (IN of) (NP (JJ mitochondrial) (NN transition) (VBZ pores)))))))))) (. .)))
20164825	9	(S1 (S (NP (NP (DT These) (NNS injuries)) (, ,) (VP (ADVP (RB partly)) (VBN mediated) (PP (IN by) (NP (NP (DT a) (NN rise)) (PP (IN in) (NP (NP (JJ reactive) (JJ Doc_20164825_1234_1240_Chemical) (NNS species)) (PP (IN from) (NP (DT the) (NNP electron) (NN transfer) (NN chain)))))))) (, ,)) (VP (AUX were) (ADVP (RB significantly)) (VP (VBN decreased) (PP (IN by) (NP (NNP Doc_20164825_1315_1324_Chemical))))) (. .)))
20164825	10	(S1 (S (ADVP (RB Thus)) (, ,) (NP (PRP$ our) (NN study)) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NP (JJ pleiotropic) (NNS effects)) (PP (IN of) (NP (NNP Doc_20164825_1379_1388_Chemical)))) (VP (MD can) (VP (VP (VB lessen) (NP (JJ Doc_20164825_1400_1410_Chemical) (NN nephrotoxicity))) (CC and) (VP (VB improve) (NP (JJ mitochondrial) (NN homeostasis)))))))) (. .)))
20195852	0	(S1 (NP (NP (NP (NN Risk)) (PP (IN of) (NP (NNP Doc_20195852_8_19_Disease))) (PP (IN after) (NP (NP (NN consumption)) (PP (IN of) (NP (JJ nonionic) (NN contrast) (NNS media))) (PP (IN by) (NP (NP (NNS children)) (VP (VBG undergoing) (NP (JJ cardiac) (NN angiography)))))))) (: :) (NP (DT a) (JJ prospective) (NN study)) (. .)))
20195852	1	(S1 (S (PP (IN Despite) (S (VP (VBG increasing) (NP (NP (NNS reports)) (PP (IN on) (NP (NP (JJ nonionic) (NNP Doc_20195852_169_203_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_20195852_205_208_Disease)) (-RRB- -RRB-))))) (PP (IN in) (NP (VBN hospitalized) (NN adult) (NNS patients))) (PP (IN during) (NP (JJ cardiac) (NNS procedures)))))) (, ,) (NP (NP (DT the) (NNS studies)) (PP (IN in) (NP (NNS pediatrics)))) (VP (AUX are) (ADJP (JJ limited)) (, ,) (PP (IN with) (NP (NP (ADJP (RB even) (JJR less)) (NN focus)) (PP (IN on) (NP (NP (JJ possible) (JJ predisposing) (NNS factors)) (CC and) (NP (JJ preventive) (NNS measures)))) (PP (IN for) (NP (NP (NNS patients)) (VP (VBG undergoing) (NP (JJ cardiac) (NN angiography)))))))) (. .)))
20195852	2	(S1 (S (NP (DT This) (JJ prospective) (NN study)) (VP (VP (VBD determined) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NNP Doc_20195852_481_484_Disease))) (PP (IN for) (NP (NP (NP (CD two) (JJ nonionic) (NN contrast) (NNS media)) (PRN (-LRB- -LRB-) (NP (NNP CM)) (-RRB- -RRB-))) (, ,) (NP (NNP Doc_20195852_523_532_Chemical) (CC and) (NNP Doc_20195852_537_544_Chemical)) (, ,)))) (PP (IN among) (NP (QP (CD 80) (NNS patients) (JJR younger) (IN than) (CD 18)) (NNS years)))) (CC and) (VP (VBD compared) (NP (NP (DT the) (NNS rates)) (PP (IN for) (NP (DT this) (NN complication)))) (PP (IN in) (NP (NP (NN relation)) (PP (TO to) (NP (NP (NP (NP (DT the) (NN type)) (CC and) (NP (NN dosage))) (PP (IN of) (NP (NNS CM)))) (CC and) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NNP Doc_20195852_692_700_Disease)))))))))) (. .)))
20195852	3	(S1 (S (NP (NP (DT The) (CD 80) (NNS patients)) (PP (IN in) (NP (DT the) (NN study)))) (ADVP (RB consecutively)) (VP (VBD received) (NP (NP (NP (DT either) (NNP Doc_20195852_761_770_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (NN group) (NN A)) (, ,) (NP (NNP n) (SYM =) (CD 40))) (-RRB- -RRB-))) (CC or) (NP (NP (NNP Doc_20195852_792_799_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (NN group) (NNP B)) (, ,) (NP (NNP n) (SYM =) (CD 40))) (-RRB- -RRB-))))) (. .)))
20195852	4	(S1 (S (NP (NP (NNP Serum) (NNP Doc_20195852_825_831_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_20195852_833_835_Chemical)) (-RRB- -RRB-)) (, ,) (NP (NNP Doc_20195852_838_847_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_20195852_849_850_Chemical)) (-RRB- -RRB-)) (, ,) (CC and) (NP (NP (NNP Doc_20195852_857_867_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_20195852_869_871_Chemical)) (-RRB- -RRB-)))) (VP (AUX were) (VP (VP (VBN measured) (NP (CD 24) (NNP h)) (PP (IN before) (NP (NN angiography))) (PP (IN as) (NP (NN baseline) (NNS values)))) (, ,) (VP (ADVP (RB then)) (VBN measured) (ADVP (RB again)) (PP (IN at) (NP (ADJP (JJ 12-) (, ,) (JJ 24-) (, ,) (CC and) (JJ 48-h)) (NNS intervals))) (PP (IN after) (NP (JJ CM) (NN use)))))) (. .)))
20195852	5	(S1 (S (NP (NP (NN Urine) (NNS samples)) (PP (IN for) (NP (NP (NNP Doc_20195852_1015_1017_Chemical)) (CC and) (NP (NNP Doc_20195852_1022_1024_Chemical))))) (ADVP (RB also)) (VP (AUX were) (VP (VBN checked) (PP (IN at) (NP (DT the) (JJ same) (NNS intervals))))) (. .)))
20195852	6	(S1 (S (NP (NP (NN Risk)) (PP (IN of) (NP (NP (NP (NNP Doc_20195852_1074_1087_Disease)) (, ,) (NP (NNP Doc_20195852_1089_1109_Disease) (, ,) (NNP Doc_20195852_1111_1137_Disease) (, ,) (NNP Doc_20195852_1139_1162_Disease)) (, ,)) (CC and) (NP (NP (NNP End-stage) (NNP Doc_20195852_1178_1190_Disease)) (PRN (-LRB- -LRB-) (NP (NNP RIFLE) (NNS criteria)) (-RRB- -RRB-)))))) (VP (AUX were) (VP (VBN used) (S (VP (TO to) (VP (VB define) (NP (NP (NNP Doc_20195852_1228_1231_Disease)) (CC and) (NP (PRP$ its) (NN incidence))) (PP (IN in) (NP (DT the) (NN study) (NN population)))))))) (. .)))
20195852	7	(S1 (S (ADVP (RB Accordingly)) (, ,) (PP (IN among) (NP (NP (DT the) (CD 15) (JJ Doc_20195852_1301_1304_Disease) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 18.75) (NN %)) (-RRB- -RRB-)))) (, ,) (NP (NP (CD 7.5) (NN %)) (PP (IN of) (NP (NP (DT the) (NNS patients)) (PP (IN in) (NP (NN group) (DT A)))))) (VP (AUX had) (VP (VBN increased) (NP (NP (NN risk)) (CC and) (NP (NP (CD 3.75) (NN %)) (SBAR (S (VP (AUX had) (NP (NNP Doc_20195852_1389_1401_Disease))))))) (, ,) (SBAR (IN whereas) (S (NP (NP (CD 5) (NN %)) (PP (IN of) (NP (NN group) (NN B)))) (VP (AUX had) (VP (VBN increased) (NP (NP (NN risk)) (CC and) (NP (NP (CD 2.5) (NN %)) (SBAR (S (VP (AUX had) (NP (NNP Doc_20195852_1457_1469_Disease))))))))))))) (. .)))
20195852	8	(S1 (S (SBAR (IN Whereas) (S (NP (NP (CD 33.3) (NN %)) (PP (IN of) (NP (NP (DT the) (NNS patients)) (PP (IN with) (NP (NNP Doc_20195852_1506_1509_Disease)))))) (VP (AUX were) (PP (IN among) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (NP (DT the) (JJ proper) (NN dosage)) (PP (IN of) (NP (NNS CM)))))))))))) (, ,) (NP (DT the) (NN percentage)) (VP (VBN increased) (PP (TO to) (NP (CD 66.6) (NN %))) (PP (IN among) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (JJR larger) (NNS doses))))))) (, ,) (PP (IN with) (NP (NP (DT a) (JJ significant) (NN difference)) (PP (IN in) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NNP Doc_20195852_1688_1691_Disease))) (VP (VBN related) (PP (TO to) (NP (NP (DT the) (JJ different) (NNS dosages)) (PP (IN of) (NP (NP (NNS CM)) (PRN (-LRB- -LRB-) (NP (NNP p) (SYM =) (CD 0.014)) (-RRB- -RRB-)))))))))))) (. .)))
20195852	9	(S1 (S (PP (IN Among) (NP (NP (DT the) (CD 15) (NNS patients)) (PP (IN with) (NP (NNP Doc_20195852_1771_1774_Disease))))) (, ,) (S (NP (CD 6)) (VP (AUX had) (NP (JJ cyanotic) (NN Doc_20195852_1791_1816_Disease)))) (, ,) (CC but) (S (NP (DT the) (NN incidence)) (VP (AUX did) (RB not) (VP (VB differ) (ADVP (RB significantly)) (PP (IN from) (NP (NP (DT that)) (PP (IN for) (NP (DT the) (JJ noncyanotic) (NNS patients))))) (PRN (-LRB- -LRB-) (NP (NNP p) (SYM =) (CD 0.243)) (-RRB- -RRB-))))) (. .)))
20195852	10	(S1 (S (SBAR (IN Although) (S (ADJP (RB clinically) (JJ silent)))) (, ,) (NP (NNP Doc_20195852_1945_1948_Disease)) (VP (AUX is) (RB not) (ADJP (JJ rare)) (PP (IN in) (NP (NN pediatrics)))) (. .)))
20195852	11	(S1 (S (S (NP (DT The) (NN incidence)) (VP (VBZ depends) (PP (PP (IN on) (NP (NN dosage))) (CC but) (RB not) (PP (IN on) (NP (NP (DT the) (NN type)) (PP (IN of) (NP (VBN consumed) (JJ nonionic) (NNP Doc_20195852_2049_2051_Chemical))))) (, ,) (CC nor) (PP (IN on) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NNP Doc_20195852_2076_2084_Disease)))))))) (, ,) (CC and) (S (SBAR (IN although) (S (NP (NNP Doc_20195852_2099_2102_Disease)) (ADVP (RB usually)) (VP (AUX is) (ADJP (JJ reversible))))) (, ,) (NP (JJR more) (NN concern)) (VP (AUX is) (VP (VBN needed) (PP (IN for) (NP (NP (DT the) (NN prevention)) (PP (IN of) (NP (PDT such) (DT a) (NN complication))) (PP (IN in) (NP (NNS children)))))))) (. .)))
2021202	0	(S1 (NP (NP (NP (JJ Renal) (NN function)) (CC and) (NP (NNS hemodynamics))) (PP (IN during) (NP (NP (VBN prolonged) (JJ Doc_2021202_49_59_Chemical-induced) (NN Doc_2021202_68_79_Disease)) (PP (IN in) (NP (NNS humans))))) (. .)))
2021202	1	(S1 (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NNP Doc_2021202_105_115_Chemical-induced) (NNP Doc_2021202_124_135_Disease))) (PP (IN on) (NP (NP (JJ glomerular) (NN function)) (CC and) (NP (JJ renal) (NN blood) (NN flow))))) (VP (AUX was) (VP (VBN investigated) (PP (IN in) (NP (CD 20) (JJ human) (NNS subjects))))) (. .)))
2021202	2	(S1 (S (NP (NP (NP (JJ Glomerular) (NN filtration) (NN rate)) (PRN (-LRB- -LRB-) (NP (SYM GFR)) (-RRB- -RRB-))) (CC and) (NP (NP (JJ effective) (JJ renal) (NN plasma) (NN flow)) (PRN (-LRB- -LRB-) (NP (NNP ERPF)) (-RRB- -RRB-)))) (VP (AUX were) (VP (VBN measured) (PP (IN by) (NP (NP (NN inulin)) (CC and) (NP (NNP Doc_2021202_319_338_Chemical) (PRN (-LRB- -LRB-) (NNP Doc_2021202_340_343_Chemical) (-RRB- -RRB-)) (NN clearance)))) (, ,) (ADVP (RB respectively)))) (. .)))
2021202	3	(S1 (S (NP (NN Anesthesia)) (VP (AUX was) (VP (VBN maintained) (PP (IN with) (NP (NP (NNP Doc_2021202_401_409_Chemical)) (, ,) (NP (NNP Doc_2021202_411_424_Chemical)) (, ,) (NP (NNP Doc_2021202_426_432_Chemical)) (, ,) (CC and) (NP (NNP Doc_2021202_438_448_Chemical)))))) (. .)))
2021202	4	(S1 (S (NP (NNP Doc_2021202_450_461_Disease)) (VP (AUX was) (VP (VBN induced) (PP (IN for) (NP (CD 236.9) (NN +/-))) (NP (CD 15.1) (NN min)) (PP (IN by) (S (VP (VBG increasing) (NP (DT the) (ADJP (NNP Doc_2021202_515_525_Chemical) (JJ inspired)) (NN concentration) (S (VP (TO to) (VP (VB maintain) (NP (NP (DT a) (JJ mean) (JJ arterial) (NN pressure)) (PP (IN of) (NP (CD 59.8) (JJ +/-) (CD 0.4) (NNS mmHg))))))))))))) (. .)))
2021202	5	(S1 (S (NP (NP (NNP GFR)) (CC and) (NP (NNP ERPF))) (VP (VBD decreased) (UCP (PP (IN with) (NP (NP (DT the) (NN induction)) (PP (IN of) (NP (NN anesthesia))))) (CC but) (RB not) (ADJP (RB significantly) (JJR more))) (PP (IN during) (NP (NNP Doc_2021202_698_709_Disease)))) (. .)))
2021202	6	(S1 (S (ADVP (RB Postoperatively)) (, ,) (NP (NNP ERPF)) (VP (VBD returned) (S (VP (TO to) (VP (VB preoperative) (NP (NNS values))))) (, ,) (SBAR (IN whereas) (S (NP (SYM GFR)) (VP (AUX was) (ADJP (ADJP (JJR higher)) (PP (IN than) (NP (JJ preoperative) (NNS values)))))))) (. .)))
2021202	7	(S1 (S (NP (JJ Renal) (JJ vascular) (NN resistance)) (VP (VP (VBD increased) (PP (IN during) (NP (NN anesthesia)))) (CC but) (VP (VBD decreased) (SBAR (WHADVP (WRB when)) (S (NP (NNP Doc_2021202_888_899_Disease)) (VP (AUX was) (VP (VBN induced)))))) (, ,) (S (VP (VBG allowing) (NP (NP (DT the) (NN maintenance)) (PP (IN of) (NP (JJ renal) (NN blood) (NN flow))))))) (. .)))
2021202	8	(S1 (S (NP (PRP We)) (VP (VBP conclude) (SBAR (SBAR (IN that) (S (NP (JJ renal) (JJ compensatory) (NNS mechanisms)) (VP (AUX are) (VP (VBN preserved) (PP (IN during) (NP (JJ Doc_2021202_1027_1037_Chemical-induced) (NN Doc_2021202_1046_1057_Disease))))))) (CC and) (SBAR (IN that) (S (NP (NP (JJ renal) (NN function)) (CC and) (NP (NNS hemodynamics))) (ADVP (RB quickly)) (VP (VBP return) (PP (TO to) (ADJP (JJ normal))) (SBAR (WHADVP (WRB when)) (S (NP (NN normotension)) (VP (AUX is) (VP (VBN resumed)))))))))) (. .)))
20304337	0	(S1 (S (NP (NP (NN Doc_20304337_0_20_Disease)) (PP (IN in) (NP (DT an) (NN infant)))) (ADVP (RB prenatally)) (VP (VBD exposed) (PP (TO to) (NP (NNP Doc_20304337_56_63_Chemical)))) (. .)))
20304337	1	(S1 (S (NP (JJ Many) (NNS authors)) (VP (VBD described) (NP (NP (DT the) (NNS effects)) (PP (IN on) (NP (NP (DT the) (NN fetus)) (PP (IN of) (NP (NP (JJ maternal) (JJ Doc_20304337_125_132_Chemical) (NN abuse)) (PP (IN during) (NP (NN pregnancy))))))))) (. .)))
20304337	2	(S1 (S (NP (NN Vasoconstriction)) (VP (VBZ appears) (S (VP (TO to) (VP (AUX be) (NP (NP (DT the) (JJ common) (NN mechanism)) (PP (IN of) (NP (NP (NN action)) (VP (VBG leading) (PP (TO to) (NP (NP (DT a) (JJ wide) (NN range)) (PP (IN of) (NP (NN Doc_20304337_246_261_Disease))))))))))))) (. .)))
20304337	3	(S1 (S (NP (PRP We)) (VP (VBP report) (PP (IN on) (NP (NP (DT an) (NN infant)) (PP (IN with) (NP (NNP Doc_20304337_291_325_Disease))) (ADJP (JJ attributable) (PP (TO to) (NP (NNP Doc_20304337_342_362_Disease)))) (, ,) (VP (VBN born) (PP (TO to) (NP (DT a) (JJ Doc_20304337_374_381_Chemical-addicted) (NN mother))))))) (. .)))
20331935	0	(S1 (NP (NP (DT A) (JJ cross-sectional) (NN evaluation)) (PP (IN of) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (NNP Doc_20331935_46_57_Chemical)) (CC and) (NP (JJ selective) (JJ Doc_20331935_72_81_Chemical) (JJ reuptake) (NNS inhibitors)))) (PP (IN on) (NP (NP (NN bone) (NN mineral) (NN density)) (PP (IN in) (NP (NNS boys))))))) (. .)))
20331935	1	(S1 (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT the) (JJ present) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB investigate) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NNP Doc_20331935_208_219_Chemical-induced) (NNP Doc_20331935_228_246_Disease))) (PP (IN on) (NP (NP (JJ trabecular) (NN bone) (NN mineral) (NN density)) (PRN (-LRB- -LRB-) (NP (NNP BMD)) (-RRB- -RRB-)) (PP (IN in) (NP (NP (NNS children)) (CC and) (NP (NNS adolescents))))))))))) (. .)))
20331935	2	(S1 (S (NP (NP (ADJP (RB Medically) (JJ healthy)) (NNS 7-)) (PP (TO to) (NP (NP (JJ 17-year-old) (NNS males)) (ADJP (RB chronically) (VBN treated)) (, ,) (PP (IN in) (NP (DT a) (JJ naturalistic) (NN setting))) (, ,) (PP (IN with) (NP (NNP Doc_20331935_420_431_Chemical)))))) (VP (AUX were) (VP (VBN recruited) (PP (IN for) (NP (DT this) (JJ cross-sectional) (NN study))) (PP (IN through) (NP (NP (NN child) (NN psychiatry) (NN outpatient) (NNS clinics)) (PP (IN between) (NP (NNP November) (CD 2005) (CC and) (NP (NNP June) (CD 2007)))))))) (. .)))
20331935	3	(S1 (S (NP (NP (JJ Anthropometric) (NNS measurements)) (CC and) (NP (NN laboratory) (NN testing))) (VP (AUX were) (VP (VBN conducted))) (. .)))
20331935	4	(S1 (S (S (NP (DT The) (JJ clinical) (NNS diagnoses)) (VP (AUX were) (VP (VBN based) (PP (IN on) (NP (NN chart) (NN review)))))) (, ,) (CC and) (S (NP (NP (NN developmental)) (CC and) (NP (NN treatment) (NN history))) (VP (AUX was) (VP (VBN obtained) (PP (IN from) (NP (DT the) (JJ medical) (NN record)))))) (. .)))
20331935	5	(S1 (S (S (NP (NP (JJ Volumetric) (NN BMD)) (PP (IN of) (NP (DT the) (JJ ultradistal) (NNS radius)))) (VP (AUX was) (VP (VBN measured) (S (VP (VBG using) (NP (JJ peripheral) (JJ quantitative) (JJ computed) (NN tomography))))))) (, ,) (CC and) (S (NP (NP (JJ areal) (NN BMD)) (PP (IN of) (NP (DT the) (JJ lumbar) (NN spine)))) (VP (AUX was) (VP (VBN estimated) (S (VP (VBG using) (NP (JJ dual-energy) (NN x-ray) (NN absorptiometry))))))) (. .)))
20331935	6	(S1 (S (NP (NN Doc_20331935_957_975_Disease)) (VP (AUX was) (ADJP (JJ present) (PP (IN in) (NP (NP (CD 49) (NN %)) (PP (IN of) (NP (NP (NP (CD 83) (NNS boys)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 41)) (-RRB- -RRB-))) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_20331935_1028_1039_Chemical))) (PP (IN for) (NP (NP (DT a) (NN mean)) (PP (IN of) (NP (CD 2.9) (NNS years)))))))))))) (. .)))
20331935	7	(S1 (S (NP (JJ Serum) (JJ Doc_20331935_1071_1083_Chemical) (NN concentration)) (VP (VP (VBD increased) (PP (IN with) (NP (JJ pubertal) (NN status)))) (CC but) (VP (AUX was) (RB not) (VP (VBN affected) (PP (IN by) (NP (NNP Doc_20331935_1153_1171_Disease)))))) (. .)))
20331935	8	(S1 (S (SBAR (IN As) (S (VP (VBN expected)))) (, ,) (NP (NP (NN bone) (NN mineral) (NN content)) (CC and) (NP (NNS BMD))) (VP (VBN increased) (PP (IN with) (NP (JJ sexual) (NN maturity)))) (. .)))
20331935	9	(S1 (S (PP (IN After) (S (VP (VBG adjusting) (PP (IN for) (NP (NP (NP (DT the) (NN stage)) (PP (IN of) (NP (NP (JJ sexual) (NN development)) (CC and) (NP (NN height))))) (CC and) (NP (NNP BMI) (NN z) (NNS scores))))))) (, ,) (NP (NN serum) (NN prolactin)) (VP (AUX was) (ADVP (RB negatively)) (VP (VBN associated) (PP (IN with) (NP (NP (JJ trabecular) (JJ volumetric) (NNS BMD)) (PP (IN at) (NP (NP (DT the) (JJ ultradistal) (NNS radius)) (PRN (-LRB- -LRB-) (NP (QP ($ P) (CD <) (CD .03))) (-RRB- -RRB-)))))))) (. .)))
20331935	10	(S1 (S (PP (VBG Controlling) (PP (IN for) (NP (JJ relevant) (NNS covariates)))) (, ,) (NP (PRP we)) (ADVP (RB also)) (VP (VBD found) (NP (NN treatment)) (PP (IN with) (NP (NP (JJ selective) (NNP Doc_20331935_1514_1523_Chemical) (NN reuptake) (NNS inhibitors)) (PRN (-LRB- -LRB-) (NP (NNP SSRIs)) (-RRB- -RRB-)))) (S (VP (TO to) (VP (AUX be) (VP (VBN associated) (PP (IN with) (NP (NP (JJR lower) (NN trabecular)) (VP (VBN BMD) (PP (IN at) (NP (DT the) (JJ radius) (PRN (-LRB- -LRB-) (NP (NNP P) (SYM =) (CD .03)) (-RRB- -RRB-)) (CC and) (NNP BMD) (NNP z) (NN score))) (PP (IN at) (NP (NP (DT the) (JJ lumbar) (NN spine)) (PRN (-LRB- -LRB-) (NP (QP (CD P) (CD <)) (CD .05)) (-RRB- -RRB-)))))))))))) (. .)))
20331935	11	(S1 (S (NP (DT These) (NNS findings)) (VP (VBD became) (ADJP (RBR more) (JJ marked)) (SBAR (WHADVP (WRB when)) (S (NP (DT the) (NN analysis)) (VP (AUX was) (VP (VBN restricted) (PP (TO to) (NP (JJ non-Hispanic) (JJ white) (NNS patients)))))))) (. .)))
20331935	12	(S1 (S (PP (IN Of) (NP (CD 13) (VBN documented) (NNP Doc_20331935_1782_1791_Disease))) (, ,) (NP (CD 3)) (VP (VBD occurred) (SBAR (IN after) (S (S (NP (NP (NNP Doc_20331935_1810_1821_Chemical)) (CC and) (NP (NNP SSRIs))) (VP (AUX were) (VP (VBN started)))) (, ,) (CC and) (S (NP (NN none)) (VP (VBD occurred) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_20331935_1881_1899_Disease)))))))))) (. .)))
20331935	13	(S1 (S (NP (DT This)) (VP (AUX is) (NP (NP (DT the) (JJ first) (NN study)) (SBAR (S (VP (TO to) (VP (VB link) (NP (NNP Doc_20331935_1946_1957_Chemical-induced) (NNP Doc_20331935_1966_1984_Disease) (CC and) (NNP SSRI) (NN treatment)) (PP (TO to) (NP (NP (JJR lower) (NNS BMD)) (PP (IN in) (NP (NP (NNS children)) (CC and) (NP (NNS adolescents)))))))))))) (. .)))
20331935	14	(S1 (S (NP (JJ Future) (NN research)) (VP (MD should) (VP (VP (VB evaluate) (NP (NP (DT the) (JJ longitudinal) (NN course)) (PP (IN of) (NP (DT this) (JJ adverse) (NN event)))) (S (VP (TO to) (VP (VB determine) (NP (PRP$ its) (JJ temporal) (NN stability)))))) (CC and) (VP (PP (IN whether) (NP (DT a) (JJR higher) (JJ fracture) (NN rate) (NNS ensues)))))) (. .)))
20394767	0	(S1 (S (NP (NP (JJ Fear-potentiated) (NN Doc_20394767_17_24_Disease)) (, ,) (CC but) (NP (RB not) (JJ light-enhanced) (NN Doc_20394767_49_56_Disease)) (, ,)) (VP (AUX is) (VP (VBN enhanced) (PP (IN by) (NP (JJ anxiogenic) (NNS drugs))))) (. .)))
20394767	1	(S1 (NP (NP (NP (NN RATIONALE)) (CC AND) (NP (NNS OBJECTIVES))) (: :) (S (NP (NP (DT The) (JJ light-enhanced) (NNP Doc_20394767_136_143_Disease) (CD paradigm)) (PRN (-LRB- -LRB-) (NP (NNP LES)) (-RRB- -RRB-))) (VP (AUX is) (VP (VBN suggested) (S (VP (TO to) (VP (VB model) (NP (NNP Doc_20394767_181_188_Disease))))) (, ,) (PP (IN because) (IN of) (NP (NP (DT the) (JJ non-specific) (NN cue)) (CC and) (NP (DT the) (JJ long-term) (NN effect))))))) (. .)))
20394767	2	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NP (DT the) (JJ fear-potentiated) (NNP Doc_20394767_282_289_Disease)) (PRN (-LRB- -LRB-) (NP (NNP FPS)) (-RRB- -RRB-))) (VP (AUX is) (VP (VBN suggested) (S (VP (TO to) (VP (VB model) (NP (VBN conditioned) (NN fear))))))) (. .)))
20394767	3	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (JJ pharmacological) (NNS profiles)) (PP (IN of) (NP (DT these) (CD two) (NNS paradigms)))) (VP (AUX are) (ADJP (RB very) (JJ similar))) (. .)))
20394767	4	(S1 (S (NP (DT The) (JJ present) (NN study)) (VP (VP (VBD investigated) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (JJ putative) (JJ anxiogenic) (NNS drugs))) (PP (IN on) (NP (NNP LES) (CC and) (NNP FPS))))) (CC and) (VP (VBD aimed) (PP (IN at) (S (VP (VP (VBG determining) (NP (NP (DT the) (NN sensitivity)) (PP (IN of) (NP (NNP LES)))) (PP (IN for) (NP (JJ anxiogenic) (NNS drugs)))) (CC and) (VP (TO to) (ADVP (RB potentially)) (VP (VBG showing) (NP (NP (DT a) (JJ pharmacological) (NN differentiation)) (PP (IN between) (NP (DT these) (CD two) (NNS paradigms))))))))))) (. .)))
20394767	5	(S1 (S (NP (JJ Male) (NNP Wistar) (NNS rats)) (VP (VP (VBD received) (NP (NP (DT each) (NN dose)) (PP (IN of) (NP (NP (NP (NP (DT the) (NN alpha)) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-))) (NN -adrenoceptor) (NN antagonist) (NP (NP (NP (NP (NNP Doc_20394767_746_755_Chemical)) (PRN (-LRB- -LRB-) (NP (NN 0.25-1.0mg/kg)) (-RRB- -RRB-))) (, ,) (NP (NP (DT the) (JJ Doc_20394767_777_781_Chemical) (PRN (-LRB- -LRB-) (NP (CD 2C)) (-RRB- -RRB-)) (NN receptor) (NN agonist) (NNP Doc_20394767_803_827_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_20394767_829_833_Chemical)) (, ,) (NP (NN 0.5-2.0mg/kg)) (-RRB- -RRB-))) (CC or) (NP (DT the) (NNP Doc_20394767_856_860_Chemical))) (PRN (-LRB- -LRB-) (DT A) (-RRB- -RRB-))) (NN inverse) (NN receptor) (NN agonist) (NNP Doc_20394767_889_907_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_20394767_909_912_Chemical)) (, ,) (NP (NN 3-30mg/kg)) (-RRB- -RRB-)))))) (CC and) (VP (AUX were) (ADVP (RB subsequently)) (VP (VBN tested) (PP (IN in) (NP (DT either) (NNP LES) (CC or) (NNP FPS)))))) (. .)))
20394767	6	(S1 (S (NP (NP (NN None)) (PP (IN of) (NP (DT the) (NNS drugs)))) (VP (VBD enhanced) (NP (NNP LES)) (, ,) (PP (IN whereas) (NP (NP (JJ Doc_20394767_1025_1029_Chemical) (VBN increased) (NN percentage) (NNS FPS)) (CC and) (NP (JJ Doc_20394767_1059_1068_Chemical) (JJ increased) (JJ absolute) (NNS FPS) (NNS values))))) (. .)))
20394767	7	(S1 (S (ADVP (RB Furthermore)) (, ,) (NP (NNP Doc_20394767_1113_1122_Chemical)) (VP (VBD increased) (NP (JJ baseline) (JJ Doc_20394767_1142_1149_Disease) (NN amplitude)) (PP (IN in) (NP (DT the) (NNP LES))) (, ,) (SBAR (IN while) (S (S (NP (NNP Doc_20394767_1178_1182_Chemical)) (VP (VBD suppressed) (NP (JJ baseline) (NN Doc_20394767_1203_1210_Disease)) (PP (IN in) (NP (DT both) (DT the) (NNP LES) (CC and) (NNP FPS))))) (CC and) (S (NP (NNP Doc_20394767_1239_1242_Chemical)) (VP (VBD suppressed) (NP (JJ baseline) (NNP Doc_20394767_1263_1270_Disease)) (PP (IN in) (NP (DT the) (NNS FPS)))))))) (. .)))
20394767	8	(S1 (S (PP (IN In) (NP (NP (NN contrast)) (PP (TO to) (NP (NP (NNS findings)) (PP (IN in) (NP (DT the) (JJ FPS) (NNS paradigm))))))) (, ,) (NP (NP (NN none)) (PP (IN of) (NP (DT the) (NNS drugs)))) (VP (AUX were) (ADJP (JJ able) (S (VP (TO to) (VP (VB exacerbate) (NP (DT the) (NNP LES) (NN response))))))) (. .)))
20394767	9	(S1 (S (ADVP (RB Thus)) (, ,) (NP (DT a) (JJ clear) (NN pharmacological) (NN differentiation)) (VP (AUX was) (VP (VBN found) (PP (IN between) (NP (NP (NNP LES)) (CC and) (NP (NNP FPS)))))) (. .)))
20466178	0	(S1 (S (NP (NNP Rosaceiform) (NNP Doc_20466178_12_22_Disease)) (VP (VBN associated) (PP (IN with) (NP (JJ topical) (JJ Doc_20466178_47_57_Chemical) (NN treatment)))) (. .)))
20466178	1	(S1 (S (NP (PRP We)) (VP (VBP describe) (NP (NP (QP (RB herein) (CD 3)) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NNP Doc_20466178_113_120_Disease-like) (NNP Doc_20466178_126_136_Disease) (NNP Doc_20466178_137_146_Disease)))))) (PP (IN while) (S (VP (VBG using) (NP (NP (NP (NP (CD 0.03) (NN %)) (CC or) (NP (CD 0.1) (NN %))) (NNP Doc_20466178_173_183_Chemical) (NN ointment)) (PP (IN for) (NP (NNP Doc_20466178_197_214_Disease)))))))) (. .)))
20466178	2	(S1 (S (NP (NN Skin) (NN biopsy) (NNS specimens)) (VP (VBD showed) (NP (NP (NN Doc_20466178_245_259_Disease)) (CC and) (NP (JJ noncaseating) (JJ epithelioid) (JJ granulomatous) (NN tissue) (NN formation))) (PP (IN in) (NP (NP (DT the) (NN papillary)) (PP (TO to) (NP (NNP mid) (NNS dermis)))))) (. .)))
20466178	3	(S1 (S (NP (NP (JJ Continuous) (JJ topical) (NN use)) (PP (IN of) (NP (NP (NNS immunomodulators)) (PP (JJ such) (IN as) (NP (NP (NNP Doc_20466178_403_413_Chemical)) (CC or) (NP (NNP Doc_20466178_417_429_Chemical))))))) (VP (MD should) (VP (AUX be) (VP (VBN regarded) (PP (IN as) (NP (NP (DT a) (JJ potential) (NN cause)) (PP (IN of) (NP (JJ rosaceiform) (NNP Doc_20466178_485_495_Disease))))) (, ,) (SBAR (IN although) (S (NP (JJ many) (NNS cases)) (VP (AUX have) (RB not) (VP (AUX been) (VP (VBN reported))))))))) (. .)))
20510337	0	(S1 (S (NP (JJ Doc_20510337_0_12_Chemical) (NN treatment)) (VP (VBZ ameliorates) (NP (NP (JJ acute) (JJ Doc_20510337_41_50_Chemical) (NN nephrotoxicity)) (PP (IN in) (NP (NNS mice))))) (. .)))
20510337	1	(S1 (S (NP (NP (DT The) (JJ nephroprotective) (NN effect)) (PP (IN of) (NP (NNP Doc_20510337_106_118_Chemical)))) (VP (AUX was) (VP (VBN investigated) (PP (IN in) (NP (NP (NNS mice)) (PP (IN with) (NP (NNP Doc_20510337_149_167_Disease))) (VP (VBN induced) (PP (IN by) (NP (NP (DT a) (JJ single) (NN i.p.) (NN injection)) (PP (IN of) (NP (NP (NNP Doc_20510337_206_215_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 5) (NN mg/kg)) (-RRB- -RRB-))))))))))) (. .)))
20510337	2	(S1 (S (NP (NP (JJ Doc_20510337_227_239_Chemical) (NN treatment)) (PRN (-LRB- -LRB-) (NP (NP (CD 10) (NN mg/kg/day)) (, ,) (NP (NN i.p.))) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN applied) (PP (IN for) (NP (CD 6) (JJ consecutive) (NNS days))) (, ,) (S (VP (VBG starting) (NP (NP (CD 1) (NN day)) (PP (IN before) (NP (NNP Doc_20510337_329_338_Chemical) (NN administration)))))))) (. .)))
20510337	3	(S1 (S (NP (NN Doc_20510337_355_367_Chemical)) (ADVP (RB significantly)) (VP (VBD reduced) (NP (NP (ADJP (JJ Doc_20510337_390_409_Chemical) (CC and) (JJ serum)) (JJ Doc_20510337_420_430_Chemical) (NNS levels)) (SBAR (WHNP (WDT which)) (S (VP (AUX were) (VP (VBN increased) (PP (IN by) (NP (NNP Doc_20510337_462_471_Chemical))))))))) (. .)))
20510337	4	(S1 (S (NP (NP (JJ Doc_20510337_473_485_Chemical) (ADJP (RB significantly) (VBN compensated)) (NNS deficits)) (PP (IN in) (NP (NP (DT the) (JJ antioxidant) (NN defense) (NNS mechanisms)) (PRN (-LRB- -LRB-) (NP (NP (JJ reduced) (JJ Doc_20510337_568_579_Chemical) (NN level)) (CC and) (NP (JJ Doc_20510337_590_600_Chemical) (JJ dismutase) (NN activity))) (-RRB- -RRB-)))) (, ,) (VP (VBN suppressed) (NP (NN lipid) (NN peroxidation))) (, ,)) (VP (VP (VBD decreased) (NP (NP (DT the) (NNS elevations)) (PP (IN of) (NP (NP (NNP Doc_20510337_681_686_Disease) (NNP Doc_20510337_687_695_Disease) (NN factor-alpha)) (, ,) (NP (NNP Doc_20510337_710_722_Chemical) (CC and) (NNP Doc_20510337_727_735_Chemical) (NN ion) (NN concentration)) (, ,))))) (CC and) (VP (VBD attenuated) (SBAR (S (NP (NP (DT the) (NNS reductions)) (PP (IN of) (NP (NP (NNP Doc_20510337_788_796_Chemical) (CC and) (NNP Doc_20510337_801_805_Chemical) (NNS ions)) (PP (IN in) (NP (JJ renal) (NN tissue)))))) (VP (VBD resulted) (PP (IN from) (NP (NNP Doc_20510337_841_850_Chemical) (NN administration)))))))) (. .)))
20510337	5	(S1 (S (ADVP (RB Also)) (, ,) (NP (NP (JJ histopathological) (NN Doc_20510337_891_910_Disease)) (VP (VBN mediated) (PP (IN by) (NP (NNP Doc_20510337_923_932_Chemical))))) (VP (AUX was) (VP (VBN ameliorated) (PP (IN by) (NP (JJ Doc_20510337_952_964_Chemical) (NN treatment))))) (. .)))
20510337	6	(S1 (S (NP (JJ Immunohistochemical) (NN analysis)) (VP (VBD revealed) (SBAR (IN that) (S (NP (NNP Doc_20510337_1019_1031_Chemical)) (ADVP (RB significantly)) (VP (VBD decreased) (NP (NP (DT the) (JJ Doc_20510337_1060_1069_Chemical-induced) (NN overexpression)) (PP (IN of) (NP (NP (JJ inducible) (JJ Doc_20510337_1106_1118_Chemical) (NN synthase)) (, ,) (NP (JJ nuclear) (NN factor-kappaB)) (, ,) (NP (NN caspase-3)) (CC and) (NP (NN p53)))) (PP (IN in) (NP (JJ renal) (NN tissue)))))))) (. .)))
20510337	7	(S1 (S (NP (PRP It)) (VP (AUX was) (VP (VBN concluded) (SBAR (IN that) (S (NP (NNP Doc_20510337_1209_1221_Chemical)) (VP (VBZ represents) (NP (NP (DT a) (JJ potential) (JJ therapeutic) (NN option)) (SBAR (S (VP (TO to) (VP (VB protect) (PP (IN against) (NP (NP (JJ acute) (JJ Doc_20510337_1289_1298_Chemical) (NN nephrotoxicity)) (VP (ADVP (RB commonly)) (VBN encountered) (PP (IN in) (NP (JJ clinical) (NN practice)))))))))))))))) (. .)))
2051906	0	(S1 (NP (NP (JJ Reversible) (NNP Doc_2051906_11_22_Disease)) (PP (IN with) (NP (NP (NNP Doc_2051906_28_44_Disease)) (VP (VBG following) (NP (JJ Doc_2051906_55_67_Chemical) (NN therapy))))) (. .)))
2051906	1	(S1 (S (NP (DT A) (NN case)) (VP (VBP report)) (. .)))
2051906	2	(S1 (S (NP (NP (DT A) (JJ 67-year-old) (NN patient)) (, ,) (PP (PP (IN with) (NP (JJ primary) (NNP Doc_2051906_128_140_Disease))) (CC and) (PP (IN without) (NP (NP (JJ previous) (NN evidence)) (PP (IN of) (NP (NNP Doc_2051906_174_187_Disease)))))) (, ,)) (VP (VBD developed) (NP (NP (JJ clinical) (CC and) (JJ biochemical) (NNS features)) (PP (IN of) (NP (JJ severe) (NNP Doc_2051906_243_254_Disease) (CD 3) (NNS months)))) (PP (IN after) (NP (NP (NN initiation)) (PP (IN of) (NP (JJ Doc_2051906_284_296_Chemical) (NN therapy)))))) (. .)))
2051906	3	(S1 (S (NP (NN Liver) (NN biopsy)) (VP (VBD showed) (NP (NN Doc_2051906_326_337_Disease)) (PP (IN with) (NP (NP (DT both) (JJ cytological) (CC and) (JJ architectural) (NNS alterations)) (PP (IN of) (NP (JJ interlobular) (JJ bile) (NNS ducts)))))) (. .)))
2051906	4	(S1 (S (NP (JJ Doc_2051906_418_430_Chemical) (NN withdrawal)) (VP (VBD resulted) (PP (IN after) (NP (CD 7) (NNS weeks))) (PP (IN in) (NP (NP (DT the) (NN resolution)) (PP (IN of) (NP (ADJP (ADJP (JJ clinical)) (CC and) (ADJP (JJ biochemical))) (NNS abnormalities)))))) (. .)))
2051906	5	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (VBN believed) (SBAR (IN that) (S (NP (DT this)) (VP (AUX is) (NP (NP (DT the) (JJ first) (JJ reported) (NN case)) (PP (IN of) (NP (NP (JJ reversible) (JJ Doc_2051906_592_604_Chemical-induced) (NN Doc_2051906_613_624_Disease)) (VP (VBN associated) (PP (IN with) (NP (NP (JJ histological) (NN evidence)) (PP (IN of) (NP (NN Doc_2051906_666_682_Disease)))))))))))))) (. .)))
20533999	0	(S1 (S (NP (NN Doc_20533999_0_8_Chemical)) (VP (AUX is) (RB not) (ADJP (JJ essential)) (PP (IN for) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_20533999_49_64_Chemical-induced) (NNP Doc_20533999_73_86_Disease)))))) (. .)))
20533999	1	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (ADVP (RB widely)) (VBN believed) (SBAR (IN that) (S (NP (NP (NNP Doc_20533999_115_123_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_20533999_125_127_Chemical)) (-RRB- -RRB-))) (VP (VBZ mediates) (SBAR (S (NP (NP (NNP Doc_20533999_138_153_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_20533999_155_159_Chemical)) (-RRB- -RRB-))) (VP (VBD -induced) (NP (NNP Doc_20533999_169_177_Disease)) (PP (TO to) (NP (NN brain) (NN dopaminergic) (NNS neurons))) (, ,) (PP (IN because) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP interfere) (PP (IN with) (NP (NNP DA) (NN neurotransmission) (NN decrease) (NNP Doc_20533999_273_281_Disease)))))))) (, ,) (PP (IN whereas) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP increase) (NP (NN DA) (NN neurotransmission)) (VP (VB enhance) (NP (NNP Doc_20533999_340_348_Disease)))))))))))))))) (. .)))
20533999	2	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (NN temperature) (NNS effects)) (PP (IN of) (NP (NNS drugs))) (SBAR (WHNP (WDT that)) (S (VP (AUX have) (VP (AUX been) (VP (VBN used) (S (VP (TO to) (VP (VB manipulate) (NP (NN brain) (JJ Doc_20533999_428_430_Chemical) (NN neurotransmission))))))))))) (VP (VBP confound) (NP (NP (NN interpretation)) (PP (IN of) (NP (DT the) (NNS data))))) (. .)))
20533999	3	(S1 (S (ADVP (RB Here)) (NP (PRP we)) (VP (VBP show) (SBAR (IN that) (S (NP (NP (DT the) (ADJP (RB recently) (VBN reported)) (NN ability)) (PP (IN of) (NP (NNP Doc_20533999_537_561_Chemical))) (S (VP (TO to) (VP (VB reverse) (NP (NP (DT the) (JJ protective) (NN effect)) (PP (IN of) (NP (NNP Doc_20533999_598_624_Chemical))) (PP (IN on) (NP (NNP Doc_20533999_628_632_Chemical-induced) (NNP DA) (NNP Doc_20533999_644_657_Disease)))))))) (VP (AUX is) (ADVP (RB also)) (VP (VBN confounded) (PP (IN by) (NP (NP (NN drug) (NNS effects)) (PP (IN on) (NP (NN body) (NN temperature)))))))))) (. .)))
20533999	4	(S1 (S (ADVP (RB Further)) (, ,) (NP (PRP we)) (VP (VBP show) (SBAR (IN that) (S (NP (NP (NNS mice)) (VP (ADVP (RB genetically)) (VBN engineered) (S (VP (TO to) (VP (AUX be) (ADJP (JJ deficient)) (PP (IN in) (NP (NN brain) (NN DA)))))))) (VP (VBP develop) (NP (NNP Doc_20533999_800_804_Chemical) (NNP Doc_20533999_805_818_Disease)) (, ,) (ADVP (ADVP (RB as) (RB long)) (SBAR (IN as) (S (NP (NP (DT the) (JJ thermic) (NNS effects)) (PP (IN of) (NP (NNP Doc_20533999_854_858_Chemical)))) (VP (AUX are) (VP (VBN preserved)))))))))) (. .)))
20533999	5	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (PRP we)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP (NP (NNS mice)) (ADJP (RB genetically) (VBN engineered))) (VP (TO to) (VP (AUX have) (S (NP (JJ unilateral) (NN brain) (NN Doc_20533999_960_962_Chemical) (NNS deficits)) (VP (VB develop) (NP (NP (JJ Doc_20533999_980_984_Chemical-induced) (NN Doc_20533999_993_1014_Disease)) (SBAR (WHNP (WDT that)) (S (VP (AUX are) (PP (IN of) (NP (JJ comparable) (NN magnitude))) (PP (IN on) (NP (NP (DT both) (NNS sides)) (PP (IN of) (NP (DT the) (NN brain)))))))))))))))) (. .)))
20533999	6	(S1 (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (NP (DT these) (NNS findings)) (VP (VP (VBP demonstrate) (SBAR (IN that) (S (NP (NN DA)) (VP (AUX is) (RB not) (ADJP (JJ essential)) (PP (IN for) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (JJ Doc_20533999_1167_1171_Chemical-induced) (JJ dopaminergic) (NN Doc_20533999_1193_1206_Disease))))))))) (CC and) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NNS mechanisms)) (ADJP (JJ independent) (PP (IN of) (NP (NN DA))))) (VP (VBP warrant) (NP (ADJP (RBR more) (JJ intense)) (NN investigation))))))) (. .)))
20552622	0	(S1 (FRAG (NP (NP (NN Doc_20552622_0_41_Disease)) (VP (VBN triggered) (PP (IN by) (NP (NNP Doc_20552622_55_65_Chemical))))) (: :) (NP (NP (NN case) (NN report) (CC and) (NN review)) (PP (IN of) (NP (DT the) (NN literature)))) (. .)))
20552622	1	(S1 (S (NP (DT A) (JJ 49-year-old) (NN patient)) (VP (VBD experienced) (NP (NN chest) (NN discomfort)) (SBAR (IN while) (S (VP (VBG swallowing))))) (. .)))
20552622	2	(S1 (S (PP (IN On) (NP (NN electrocardiogram))) (, ,) (NP (NP (NNS episodes)) (PP (IN of) (NP (NNP Doc_20552622_218_240_Disease)))) (VP (AUX were) (VP (VBN recorded) (ADVP (RB immediately)) (PP (IN after) (S (VP (VBG swallowing) (NP (NP (: ;) (JJ 24-hour) (NN Holter)) (VP (VBG monitoring) (NP (JJ recorded) (JJ several) (NNS events))))))))) (. .)))
20552622	3	(S1 (S (NP (DT The) (NNP Doc_20552622_340_350_Disease)) (VP (VP (VBD resolved) (PP (IN after) (NP (NP (NN therapy)) (PP (IN with) (NP (NNP Doc_20552622_379_387_Chemical)))))) (, ,) (CC but) (VP (VBD recurred) (NP (DT a) (NN year)) (ADVP (RB later)))) (. .)))
20552622	4	(S1 (S (NP (DT The) (NN patient)) (VP (VBD noticed) (SBAR (IN that) (S (PP (IN before) (NP (DT these) (NNS episodes))) (NP (PRP he)) (VP (AUX had) (VP (AUX been) (S (VP (VBG using) (NP (NP (DT an) (NN inhalator)) (PP (IN of) (NP (NN Doc_20552622_497_507_Chemical))))))))))) (. .)))
20552622	5	(S1 (S (PP (PP (IN After) (S (VP (VBG stopping) (NP (DT the) (NN beta-agonist))))) (, ,) (CC and) (PP (IN after) (NP (NP (DT a) (NN week)) (PP (IN with) (NP (DT the) (NNP Doc_20552622_568_576_Chemical)))))) (, ,) (NP (DT the) (NNP Doc_20552622_582_592_Disease)) (VP (VBD disappeared)) (. .)))
20552622	6	(S1 (S (NP (NP (NN Doc_20552622_618_659_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_20552622_661_665_Disease)) (-RRB- -RRB-))) (VP (AUX is) (NP (DT a) (JJ rare) (NN phenomenon))) (. .)))
20552622	7	(S1 (S (NP (NP (QP (JJR Fewer) (IN than) (CD 50)) (NNS cases)) (PP (IN of) (NP (NNP Doc_20552622_712_716_Disease)))) (VP (AUX have) (VP (AUX been) (VP (VBN described) (PP (IN in) (NP (DT the) (NN literature)))))) (. .)))
20552622	8	(S1 (S (NP (DT This) (NN article)) (VP (VBZ summarizes) (NP (NP (PDT all) (DT the) (NNS cases)) (VP (VBN published))) (, ,) (S (VP (VBG creating) (NP (NP (NP (DT a) (JJ comprehensive) (NN review)) (PP (IN of) (NP (DT the) (JJ current) (NN knowledge)))) (CC and) (NP (NP (NN approach)) (PP (TO to) (NP (NNP Doc_20552622_878_882_Disease)))))))) (. .)))
20552622	9	(S1 (S (NP (PRP It)) (VP (VBZ discusses) (NP (NP (NNS demographics)) (, ,) (NP (NP (JJ clinical) (NNS characteristics) (CC and) (NNS types)) (PP (IN of) (NP (NNP Doc_20552622_949_959_Disease)))) (, ,) (NP (NP (JJ postulated) (NNS mechanisms)) (PP (IN of) (NP (NNP Doc_20552622_986_990_Disease)))) (, ,) (CC and) (NP (NP (JJ different) (NN treatment) (NNS possibilities)) (PP (JJ such) (IN as) (NP (NP (NNS medications)) (, ,) (NP (NN surgery)) (, ,) (CC and) (NP (NP (NN radiofrequency) (NN catheter) (NN ablation)) (PRN (-LRB- -LRB-) (NP (NNP RFCA)) (-RRB- -RRB-)))))))) (. .)))
20552622	10	(S1 (S (NP (NN Doc_20552622_1117_1127_Chemical)) (VP (AUX is) (VP (VBN presented) (ADVP (RB here)) (PP (IN as) (NP (NP (DT a) (JJ possible) (NN trigger)) (PP (IN for) (NP (NNP Doc_20552622_1172_1176_Disease))))))) (. .)))
20552622	11	(S1 (S (SBAR (IN Although) (S (NP (PRP it)) (VP (AUX is) (ADJP (JJ difficult) (SBAR (S (VP (TO to) (VP (VB define) (NP (NN causality)) (PP (IN in) (NP (DT a) (NN case) (NN report))))))))))) (, ,) (NP (PRP it)) (VP (AUX is) (ADJP (JJ logical) (S (VP (TO to) (VP (VB think) (SBAR (SBAR (IN that) (S (NP (NP (DT a) (NN beta-agonist)) (PP (IN like) (NP (NNP Doc_20552622_1289_1299_Chemical))) (PRN (-LRB- -LRB-) (VP (VBN known) (S (VP (TO to) (VP (VB induce) (NP (NNP Doc_20552622_1317_1328_Disease)))))) (-RRB- -RRB-))) (VP (MD may) (VP (AUX be) (NP (NP (DT the) (NN trigger)) (PP (IN of) (NP (NP (JJ adrenergic) (NNS reflexes)) (VP (VBG originating) (PP (IN in) (NP (DT the) (NN esophagus))))))) (SBAR (IN while) (S (VP (VBG swallowing)))))))) (CC and) (SBAR (IN that) (S (NP (NP (DT a) (NN beta-blocker)) (PP (JJ such) (IN as) (NP (NNP Doc_20552622_1450_1458_Chemical))) (PRN (-LRB- -LRB-) (PP (IN that) (NP (NNS blocks)) (NP (DT the) (JJ adrenergic) (NN activity))) (-RRB- -RRB-))) (VP (MD may) (VP (VB relieve) (NP (PRP it)))))))))))) (. .)))
2055425	0	(S1 (S (NP (NP (DT The) (NN ability)) (PP (IN of) (NP (NN insulin) (NN treatment))) (S (VP (TO to) (VP (VP (VB reverse)) (CC or) (VP (VB prevent) (NP (NP (DT the) (NNS changes)) (PP (IN in) (NP (JJ urinary) (NN bladder) (NN function))))))))) (VP (VBD caused) (PP (IN by) (NP (JJ Doc_2055425_105_119_Chemical-induced) (NNP Doc_2055425_128_145_Disease.) (CD 1)))) (. .)))
2055425	1	(S1 (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NN insulin) (NN treatment))) (PP (IN on) (PP (IN in) (NP (NN vivo))) (CC and) (PP (IN in) (NP (NP (NN vitro) (NN urinary) (NN bladder) (NN function)) (PP (IN in) (NP (JJ Doc_2055425_235_249_Chemical-Doc_2055425_250_258_Disease) (NNS rats))))))) (VP (AUX were) (VP (VBN investigated.) (NP (CD 2)))) (. .)))
2055425	2	(S1 (S (NP (NP (NN Doc_2055425_286_294_Disease)) (PP (IN of) (NP (QP (CD 2) (NNS months)) (NN duration)))) (VP (VBD resulted) (PP (IN in) (NP (NP (NP (NNS decreases)) (PP (IN in) (NP (NN body) (NN weight)))) (CC and) (NP (NP (NNS increases)) (PP (IN in) (NP (NP (NN fluid) (NN consumption)) (, ,) (NP (NN urine) (NN volume)) (, ,) (NP (NP (NN frequency)) (PP (IN of) (NP (NN micturition)))) (, ,) (CC and) (NP (NP (JJ average) (NN volume)) (PP (IN per) (NP (NP (NN micturition)) (: ;) (NP (NP (NNS effects)) (SBAR (WHNP (WDT which)) (S (VP (AUX were) (VP (VBN prevented) (PP (IN by) (NP (NN insulin) (NN treatment.) (CD 3))))))))))))))))) (. .)))
2055425	3	(S1 (S (NP (NN Insulin) (NN treatment)) (ADVP (RB also)) (VP (VBD prevented) (NP (NP (DT the) (NNS increases)) (PP (IN in) (NP (NP (JJ contractile) (NNS responses)) (PP (IN of) (NP (NN bladder) (NN body) (NNS strips)))))) (PP (PP (IN from) (NP (JJ Doc_2055425_619_627_Disease) (NNS rats))) (PP (TO to) (NP (NN nerve) (NN stimulation)))) (, ,) (NP (NP (NNP Doc_2055425_655_658_Chemical)) (, ,) (CC and) (NP (NNP Doc_2055425_664_675_Chemical.) (CD 4)))) (. .)))
2055425	4	(S1 (S (NP (NP (NN Doc_2055425_680_688_Disease)) (PP (IN of) (NP (QP (CD 4) (NNS months)) (NN duration)))) (ADVP (RB also)) (VP (VBD resulted) (PP (IN in) (NP (NP (NP (NNS decreases)) (PP (IN in) (NP (NN body) (NN weight)))) (, ,) (CC and) (NP (NP (NNS increases)) (PP (IN in) (NP (NP (NN fluid) (NN consumption)) (, ,) (NP (NN urine) (NN volume)) (, ,) (NP (NP (NN frequency)) (PP (IN of) (NP (NN micturition)))) (, ,) (CC and) (NP (NP (JJ average) (NN volume)) (PP (IN per) (NP (NN micturition)))) (, ,) (NP (NP (NNS effects)) (SBAR (WHNP (WDT which)) (S (VP (AUX were) (VP (VBN reversed) (PP (IN by) (NP (NP (NN insulin) (NN treatment)) (PP (IN for) (NP (NP (DT the) (JJ final) (CD 2) (NNS months)) (PP (IN of) (NP (DT the) (NN study.) (CD 5)))))))))))))))))) (. .)))
2055425	5	(S1 (S (NP (NN Insulin) (NN treatment)) (VP (VBD reversed) (NP (NP (DT the) (NNS increases)) (PP (IN in) (NP (NP (NP (JJ contractile) (NNS responses)) (PP (IN of) (NP (NP (NN bladder) (NN body) (NNS strips)) (PP (IN from) (NP (NNP Doc_2055425_1048_1056_Disease) (NNS rats))))) (PP (TO to) (NP (NN nerve) (NN stimulation)))) (, ,) (NP (NP (NNP Doc_2055425_1084_1087_Chemical)) (, ,) (CC and) (NP (NNP Doc_2055425_1093_1104_Chemical.) (CD 6))))))) (. .)))
2055425	6	(S1 (S (NP (DT The) (NNS data)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NNP Doc_2055425_1147_1161_Chemical-induced) (NNP Doc_2055425_1170_1178_Disease))) (PP (IN on) (NP (JJ urinary) (NN bladder) (NN function)))) (VP (AUX are) (DT both) (VP (VP (VBN prevented)) (CC and) (VP (VBN reversed) (PP (IN by) (NP (NN insulin) (NN treatment))))))))) (. .)))
20558148	0	(S1 (S (NP (NP (JJ Glutamatergic) (NN neurotransmission)) (VP (VBN mediated) (PP (IN by) (NP (JJ Doc_20558148_44_48_Chemical) (NNS receptors))) (PP (IN in) (NP (DT the) (JJ inferior) (NNS colliculus))))) (VP (MD can) (VP (VBP modulate) (NP (JJ Doc_20558148_99_110_Chemical-induced) (NN Doc_20558148_119_128_Disease)))) (. .)))
20558148	1	(S1 (S (S (NP (NP (DT The) (JJ inferior) (NN colliculus)) (PRN (-LRB- -LRB-) (NP (NN IC)) (-RRB- -RRB-))) (VP (AUX is) (ADVP (RB primarily)) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (NN processing)) (PP (IN of) (NP (JJ auditory) (NN information)))))))) (, ,) (CC but) (S (NP (PRP it)) (VP (AUX is) (VP (VBN distinguished) (PP (IN from) (NP (NP (JJ other) (JJ auditory) (NNS nuclei)) (PP (IN in) (NP (DT the) (NN brainstem))))) (PP (IN by) (NP (NP (PRP$ its) (NNS connections)) (PP (IN with) (NP (NP (NNS structures)) (PP (IN of) (NP (DT the) (NN motor) (NN system)))))))))) (. .)))
20558148	2	(S1 (S (NP (NP (JJ Functional) (NN evidence)) (VP (VBG relating) (NP (DT the) (NNS IC)) (PP (TO to) (NP (NN motor) (NN behavior))))) (VP (VBZ derives) (PP (IN from) (NP (NP (NNS experiments)) (VP (VBG showing) (SBAR (IN that) (S (NP (NP (NN activation)) (PP (IN of) (NP (DT the) (NNS IC))) (PP (IN by) (NP (NP (JJ electrical) (NN stimulation)) (CC or) (NP (JJ excitatory) (JJ Doc_20558148_501_511_Chemical) (NN microinjection))))) (VP (VBZ causes) (NP (NP (NN freezing)) (, ,) (NP (JJ escape-like) (NN behavior)) (, ,) (CC and) (NP (NN immobility)))))))))) (. .)))
20558148	3	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (NN nature)) (PP (IN of) (NP (DT this) (NN immobility)))) (VP (AUX is) (ADVP (RB still)) (ADJP (JJ unclear))) (. .)))
20558148	4	(S1 (S (NP (DT The) (JJ present) (NN study)) (VP (VBD examined) (NP (NP (DT the) (NN influence)) (PP (IN of) (NP (NP (JJ excitatory) (JJ Doc_20558148_694_704_Chemical-mediated) (NNS mechanisms)) (PP (IN in) (NP (DT the) (NN IC))))) (PP (IN on) (NP (NP (DT the) (NNP Doc_20558148_742_751_Disease)) (VP (VBN induced) (PP (IN by) (NP (NP (DT the) (NNP Doc_20558148_767_775_Chemical) (NN receptor) (NN blocker) (NNP Doc_20558148_793_804_Chemical)) (VP (VBN administered) (ADVP (RB systemically)) (PRN (-LRB- -LRB-) (NP (QP (CD 1) (CC or) (CD 0.5)) (NN mg/kg)) (-RRB- -RRB-)) (PP (IN in) (NP (NNS rats))))))))))) (. .)))
20558148	5	(S1 (S (NP (JJ Doc_20558148_857_868_Chemical-induced) (NNP Doc_20558148_877_886_Disease)) (VP (AUX was) (VP (VBN challenged) (PP (PP (IN with) (NP (NP (NP (JJ prior) (JJ intracollicular) (NNS microinjections)) (PP (IN of) (NP (NNP Doc_20558148_948_957_Chemical) (NNP Doc_20558148_958_962_Chemical) (NN receptor) (NNS antagonists)))) (, ,) (NP (NP (NP (NNP Doc_20558148_985_991_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 15) (CC or) (CD 30) (CD mmol/0.5)) (NN microl)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_20558148_1023_1026_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 10) (CC or) (CD 20) (CD nmol/0.5)) (NN microl)) (-RRB- -RRB-)))))) (, ,) (CC or) (PP (IN of) (NP (NP (DT the) (JJ Doc_20558148_1065_1069_Chemical) (NN receptor) (NN agonist) (NNP Doc_20558148_1087_1107_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_20558148_1109_1113_Chemical)) (, ,) (NP (QP (CD 20) (CC or) (CD 30) (CD nmol/0.5)) (NN microl)) (-RRB- -RRB-))))))) (. .)))
20558148	6	(S1 (S (NP (DT The) (NNS results)) (VP (VBD showed) (NP (NP (DT that) (JJ intracollicular) (NN microinjection)) (PP (IN of) (NP (NNP Doc_20558148_1200_1206_Chemical) (CC and) (NNP Doc_20558148_1211_1214_Chemical) (JJ previous)))) (PP (TO to) (NP (NP (JJ systemic) (NNS injections)) (PP (IN of) (NP (NP (NNP Doc_20558148_1250_1261_Chemical)) (VP (ADVP (RB significantly)) (VBN attenuated) (NP (DT the) (NNP Doc_20558148_1291_1300_Disease))))))) (, ,) (SBAR (IN as) (S (VP (VBN indicated) (PP (IN by) (NP (NP (DT a) (JJ reduced) (NN latency)) (SBAR (S (VP (TO to) (VP (VB step) (PRT (RP down)) (PP (IN from) (NP (DT a) (JJ horizontal) (NN bar))))))))))))) (. .)))
20558148	7	(S1 (S (ADVP (RB Accordingly)) (, ,) (NP (NP (NN intracollicular) (NN microinjection)) (PP (IN of) (NP (NNP Doc_20558148_1419_1423_Chemical)))) (VP (VBD increased) (NP (DT the) (NN latency)) (PP (TO to) (NP (NN step))) (PP (IN down) (NP (DT the) (NN bar)))) (. .)))
20558148	8	(S1 (S (NP (DT These) (NNS findings)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (JJ Doc_20558148_1496_1505_Chemical-mediated) (NNS mechanisms)) (PP (IN in) (NP (DT the) (JJ neural) (NNS circuits))) (PP (IN at) (NP (DT the) (JJ IC) (NN level)))) (VP (VP (VBP influence) (NP (JJ Doc_20558148_1575_1586_Chemical-induced) (NNP Doc_20558148_1595_1604_Disease))) (CC and) (VP (VB participate) (PP (IN in) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (NN motor) (NN activity)))))))))) (. .)))
20635749	0	(S1 (NP (NP (NP (JJ Severe) (JJ Doc_20635749_7_31_Disease) (NN patient)) (PP (IN on) (NP (NNP Doc_20635749_43_53_Chemical) (VBG presenting))) (PP (IN with) (NP (NNP Doc_20635749_70_84_Disease)))) (: :) (NP (DT a) (NN case) (NN report)) (. .)))
20635749	1	(S1 (S (NP (DT This)) (VP (AUX is) (NP (NP (DT a) (NN case) (NN report)) (PP (IN of) (NP (NNP Doc_20635749_126_139_Disease) (JJ secondary))) (PP (TO to) (NP (NP (NNP Doc_20635749_153_163_Chemical-induced) (NNP Doc_20635749_172_186_Disease)) (PP (IN in) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (NP (JJ severe) (NNP Doc_20635749_212_236_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_20635749_238_241_Disease)) (-RRB- -RRB-)))))))))) (. .)))
20635749	2	(S1 (S (PP (TO To) (NP (PRP$ our) (NN knowledge))) (CC and) (PP (IN after) (S (VP (VBG reviewing) (NP (DT the) (NN literature))))) (NP (EX there)) (VP (AUX is) (NP (NP (CD one) (NN case) (VB report)) (PP (IN of) (NP (NNP Doc_20635749_324_337_Disease))) (PP (IN during) (NP (JJ long) (NN term) (JJ Doc_20635749_355_365_Chemical) (NN therapy))))) (. .)))
20635749	3	(S1 (S (NP (NN Doc_20635749_375_388_Disease)) (VP (AUX is) (NP (NP (DT a) (NN life) (VBG threatening) (NN condition)) (SBAR (WHNP (WDT that)) (S (VP (VBZ carries) (NP (NP (DT a) (NN mortality)) (VP (VBG reaching) (NP (QP (RB as) (JJ high) (IN as) (CD 20)) (NN %)) (PP (IN with) (NP (NN treatment)))))))))) (. .)))
20635749	4	(S1 (S (NP (DT The) (NN condition)) (VP (AUX is) (VP (VBN treated) (PP (IN with) (NP (NP (NP (JJ intravenous) (NNP Doc_20635749_528_537_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP T4)) (-RRB- -RRB-))) (CC or) (NP (NP (JJ intravenous) (NNP Doc_20635749_558_576_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP T3)) (-RRB- -RRB-))))))) (. .)))
20635749	5	(S1 (S (S (NP (NP (NNS Patients)) (PP (IN with) (NP (NNP Doc_20635749_597_600_Disease))) (PP (IN on) (NP (NNP Doc_20635749_604_614_Chemical)))) (VP (MD may) (VP (VB suffer) (NP (NP (JJ serious) (NN morbidity)) (CC and) (NP (NN mortality))) (PP (IN from) (NP (NNP Doc_20635749_663_677_Disease)))))) (, ,) (CC and) (S (ADVP (RB thus)) (VP (MD may) (VP (VB deserve) (ADVP (RBR closer)) (VP (VB follow) (PRT (RP up)) (PP (IN for) (NP (JJ thyroid) (JJ stimulating) (NN hormone) (PRN (-LRB- -LRB-) (NP (NNP TSH)) (-RRB- -RRB-)) (NNS levels))))))) (. .)))
20635749	6	(S1 (S (NP (DT This) (NN case) (NN report)) (VP (VBZ carries) (NP (NP (DT an) (JJ important) (JJ clinical) (NN application)) (VP (VBN given) (NP (NP (DT the) (JJ frequent) (NN usage)) (PP (IN of) (NP (NNP Doc_20635749_850_860_Chemical))) (PP (IN among) (NP (NNP Doc_20635749_867_870_Disease) (NNS patients))))))) (. .)))
20635749	7	(S1 (S (NP (NP (DT The) (JJ myriad) (JJ clinical) (NN presentation)) (PP (IN of) (NP (NP (NNP Doc_20635749_917_930_Disease)) (CC and) (NP (NP (PRP$ its) (JJ serious) (NN morbidity)) (CC and) (NP (NN mortality)))))) (VP (VBZ stresses) (NP (DT the) (NN need) (S (VP (TO to) (VP (VB suspect) (NP (DT this) (JJ clinical) (NN syndrome)) (PP (IN among) (NP (NP (JJ Doc_20635749_1029_1032_Disease) (NNS patients)) (VP (VBG presenting) (PP (IN with) (NP (NP (NNP Doc_20635749_1058_1069_Disease)) (, ,) (NP (NNP Doc_20635749_1071_1079_Disease)) (CC or) (NP (JJ other) (JJ unexplained) (NNS symptoms)))))))))))) (. .)))
20683499	0	(S1 (NP (NP (NNS Effects)) (PP (IN of) (NP (NP (JJ active) (NNS constituents)) (PP (IN of) (NP (NNP Crocus) (NNS sativus) (NNP L.) (, ,) (NNP Doc_20683499_53_59_Chemical))))) (PP (IN on) (NP (NP (JJ Doc_20683499_63_75_Chemical-induced) (NN model)) (PP (IN of) (NP (JJ sporadic) (NNP Doc_20683499_102_121_Disease))) (PP (IN in) (NP (JJ male) (NNS rats))))) (. .)))
20683499	1	(S1 (S (NP (NP (DT The) (NN involvement)) (PP (IN of) (NP (NP (JJ water-soluble) (NNS carotenoids)) (, ,) (NP (NP (NNP Doc_20683499_194_201_Chemical)) (, ,) (SBAR (IN as) (S (NP (NP (DT the) (JJ main) (CC and) (JJ active) (NNS components)) (PP (IN of) (NP (NNP Crocus) (FW sativus) (NNP L.)))) (VP (VB extract) (PP (IN in) (NP (NN learning))))))) (CC and) (NP (NN memory) (NNS processes))))) (VP (AUX has) (VP (AUX been) (VP (VBN proposed)))) (. .)))
20683499	2	(S1 (S (PP (IN In) (NP (DT the) (JJ present) (NN study))) (, ,) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NNP Doc_20683499_354_361_Chemical))) (PP (IN on) (NP (NP (JJ sporadic) (NN Doc_20683499_374_393_Disease)) (VP (VBN induced) (PP (IN by) (NP (NP (JJ intracerebroventricular) (PRN (-LRB- -LRB-) (NP (NN icv)) (-RRB- -RRB-)) (NNP Doc_20683499_435_447_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_20683499_449_452_Chemical)) (-RRB- -RRB-)))) (PP (IN in) (NP (JJ male) (NNS rats))))))) (VP (AUX was) (VP (VBN investigated))) (. .)))
20683499	3	(S1 (S (NP (NP (JJ Male) (NN adult) (NN Wistar) (NNS rats)) (PRN (-LRB- -LRB-) (NP (NNP n) (QP (SYM =) (CD 90) (CC and) (CD 260-290))) (NP (NNP g)) (-RRB- -RRB-))) (VP (AUX were) (VP (VBN divided) (PP (IN into) (NP (NP (NP (CD 1)) (, ,) (NP (NP (NN control)) (: ;) (NP (NP (CD 2) (CC and) (CD 3)) (, ,) (NP (NP (NNP Doc_20683499_579_586_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 15) (CC and) (CD 30)) (NN mg/kg)) (-RRB- -RRB-)))) (: ;) (NP (NP (CD 4)) (, ,) (NP (NNP Doc_20683499_609_612_Chemical))) (: ;) (NP (CD 5) (CC and) (CD 6))) (, ,)) (NNP Doc_20683499_623_626_Chemical) (NNP +) (NNP Doc_20683499_629_636_Chemical) (PRN (-LRB- -LRB-) (NP (QP (CD 15) (CC and) (CD 30)) (NNS mg/kg)) (-RRB- -RRB-)) (NNS groups))))) (. .)))
20683499	4	(S1 (S (PP (IN In) (NP (JJ Doc_20683499_666_685_Disease) (NNS groups))) (, ,) (S (NP (NNS rats)) (VP (AUX were) (VP (VBN injected) (PP (IN with) (NP (NP (JJ Doc_20683499_718_721_Chemical-icv) (NN bilaterally)) (PRN (-LRB- -LRB-) (NP (CD 3) (NN mg/kg)) (-RRB- -RRB-)))) (PP (IN in) (NP (JJ first) (NN day)))))) (CC and) (S (ADVP (NP (CD 3) (NNS days)) (RB later)) (, ,) (NP (DT a) (JJ similar) (JJ Doc_20683499_789_792_Chemical-icv) (NN application)) (VP (AUX was) (VP (VBN repeated)))) (. .)))
20683499	5	(S1 (S (PP (IN In) (NP (NNP Doc_20683499_826_829_Chemical) (NNP +) (NNP Doc_20683499_832_838_Chemical) (NN animal) (NNS groups))) (, ,) (NP (NNP Doc_20683499_854_860_Chemical)) (VP (AUX was) (VP (VBN applied) (PP (IN in) (NP (NP (NNS doses)) (PP (IN of) (NP (NP (QP (CD 15) (CC and) (CD 30)) (NNS mg/kg)) (, ,) (NP (NNP i.p.)) (, ,) (UCP (ADJP (NP (CD one) (NN day)) (JJ pre-surgery)) (CC and) (VP (VBN continued) (PP (IN for) (NP (CD three) (NNS weeks))))))))))) (. .)))
20683499	6	(S1 (S (NP (NP (NN Prescription)) (PP (IN of) (NP (NNP Doc_20683499_975_981_Chemical))) (PP (IN in) (NP (DT each) (NN dose)))) (VP (AUX was) (VP (VBN repeated) (ADVP (RB once)) (PP (IN for) (NP (CD two) (NNS days))))) (. .)))
20683499	7	(S1 (S (S (ADVP (RB However)) (, ,) (NP (DT the) (NN learning) (CC and) (NN memory) (NN performance)) (VP (AUX was) (VP (VBN assessed) (S (VP (VBG using) (NP (JJ passive) (NN avoidance) (NNS paradigm))))))) (, ,) (CC and) (S (PP (IN for) (NP (JJ spatial) (NN cognition) (NN evaluation))) (, ,) (NP (JJ Y-maze) (NN task)) (VP (AUX was) (VP (VBN used)))) (. .)))
20683499	8	(S1 (S (NP (PRP It)) (VP (AUX was) (VP (VBN found) (PRT (RP out)) (SBAR (IN that) (S (NP (NP (NNP Doc_20683499_1210_1216_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 30) (NN mg/kg)) (-RRB- -RRB-))) (VP (VBD -treated) (SBAR (S (NP (JJ Doc_20683499_1236_1239_Chemical-injected) (NNS rats)) (VP (VBP show) (NP (NP (NP (JJR higher) (JJ correct) (NNS choices)) (CC and) (NP (NP (JJR lower) (NNS errors)) (PP (IN in) (NP (NN Y-maze))))) (PP (IN than) (NP (JJ vehicle-treated) (JJ Doc_20683499_1330_1333_Chemical-injected) (NNS rats)))))))))))) (. .)))
20683499	9	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (NNP Doc_20683499_1362_1368_Chemical)) (PP (IN in) (NP (DT the) (VBN mentioned) (NN dose)))) (VP (MD could) (ADVP (RB significantly)) (VP (VBD attenuated) (NP (NNP Doc_20683499_1422_1452_Disease)) (PP (IN in) (NP (NP (VBN treated) (JJ Doc_20683499_1464_1467_Chemical-injected) (NN group)) (PP (IN in) (NP (JJ passive) (NN avoidance) (NN test))))))) (. .)))
20683499	10	(S1 (S (ADVP (RB Therefore)) (, ,) (NP (DT these) (NNS results)) (VP (VBP demonstrate) (NP (NP (DT the) (NN effectiveness)) (PP (IN of) (NP (NP (NNP Doc_20683499_1580_1586_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 30) (NN mg/kg)) (-RRB- -RRB-))))) (PP (IN in) (S (VP (VBG antagonizing) (NP (NP (DT the) (NN Doc_20683499_1618_1636_Disease)) (VP (VBN caused) (PP (IN by) (NP (NNP Doc_20683499_1647_1650_Chemical-icv))))) (PP (IN in) (NP (NP (NNS rats)) (CC and) (NP (NP (PRP$ its) (NN potential)) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (NNP Doc_20683499_1701_1727_Disease)) (PP (JJ such) (IN as) (NP (NNP Doc_20683499_1736_1755_Disease)))))))))))))) (. .)))
20705401	0	(S1 (S (NP (NN Doc_20705401_0_9_Chemical) (CD 6) (NN receptor) (NN gene)) (VP (AUX is) (VP (VBN associated) (PP (IN with) (NP (NP (NNP Doc_20705401_45_60_Chemical-induced) (NNP Doc_20705401_69_78_Disease)) (PP (IN in) (NP (DT a) (JJ Japanese) (NN population))))))) (. .)))
20705401	1	(S1 (S (NP (JJ Altered) (JJ serotonergic) (NN neural) (NN transmission)) (VP (AUX is) (VP (VBN hypothesized) (S (VP (TO to) (VP (AUX be) (NP (NP (DT a) (JJ susceptibility) (NN factor)) (PP (IN for) (NP (NP (NNP Doc_20705401_208_227_Disease)) (PP (JJ such) (IN as) (NP (NN Doc_20705401_236_249_Disease))))))))))) (. .)))
20705401	2	(S1 (S (S (NP (DT The) (JJ Doc_20705401_255_264_Chemical) (CD 6) (-LRB- -LRB-) (NN 5-HT6) (-RRB- -RRB-) (NN receptor)) (VP (AUX is) (ADVP (RB therapeutically)) (VP (VBN targeted) (PP (IN by) (NP (NP (JJ several) (JJ second) (NN generation) (NNS antipsychotics)) (, ,) (PP (JJ such) (IN as) (NP (NP (NNP Doc_20705401_365_374_Chemical)) (CC and) (NP (NNP Doc_20705401_379_389_Chemical))))))))) (, ,) (CC and) (S (NP (NP (NNP Doc_20705401_395_408_Chemical-induced) (NNP Doc_20705401_417_430_Disease)) (PP (IN in) (NP (NNS rats)))) (VP (AUX is) (VP (VBN corrected) (PP (IN with) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (DT a) (JJ selective) (JJ 5-HT6) (NN receptor) (NN antagonist)))))))) (. .)))
20705401	3	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (DT the) (VBN disrupted) (NN prepulse) (NN inhibition)) (VP (VBN induced) (PP (IN by) (NP (NP (NNP Doc_20705401_565_578_Chemical)) (CC or) (NP (NNP Doc_20705401_582_595_Chemical)))))) (VP (AUX was) (VP (VBN restored) (PP (IN by) (NP (NP (JJ 5-HT6) (NN receptor) (NN antagonist)) (PP (IN in) (NP (NP (DT an) (NN animal) (NN study)) (VP (VBG using) (NP (NNS rats))))))))) (. .)))
20705401	4	(S1 (S (S (NP (DT These) (NN animal) (NNS models)) (VP (AUX were) (VP (VBN considered) (S (VP (TO to) (VP (VB reflect) (NP (NP (DT the) (JJ positive) (NNS symptoms)) (PP (IN of) (NP (NN Doc_20705401_741_754_Disease)))))))))) (, ,) (CC and) (S (NP (DT the) (JJ above) (NN evidence)) (VP (VBZ suggests) (SBAR (IN that) (S (NP (JJ altered) (NNP Doc_20705401_801_805_Chemical6) (NNS receptors)) (VP (AUX are) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (NN pathophysiology)) (PP (IN of) (NP (NNP Doc_20705401_856_875_Disease))))))))))) (. .)))
20705401	5	(S1 (S (NP (NP (DT The) (NNS symptoms)) (PP (IN of) (NP (NNP Doc_20705401_893_908_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_20705401_910_914_Chemical)) (-RRB- -RRB-)) (JJ -induced) (NNP Doc_20705401_924_933_Disease)))) (VP (AUX are) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT those)) (PP (IN of) (NP (NNP Doc_20705401_958_985_Disease))))))) (. .)))
20705401	6	(S1 (S (ADVP (RB Therefore)) (, ,) (NP (PRP we)) (VP (VBD conducted) (NP (NP (DT an) (NN analysis)) (PP (IN of) (NP (NP (DT the) (NN association)) (PP (IN of) (NP (DT the) (JJ Doc_20705401_1049_1053_Chemical6) (NN gene))))) (PRN (-LRB- -LRB-) (NP (NNP HTR6)) (-RRB- -RRB-)) (PP (IN with) (NP (JJ Doc_20705401_1072_1076_Chemical-induced) (NNP Doc_20705401_1085_1094_Disease))))) (. .)))
20705401	7	(S1 (S (S (VP (VBG Using) (NP (NP (CD five) (NN tagging) (NNS SNPs)) (PRN (-LRB- -LRB-) (NP (CD rs6693503) (, ,) (CD rs1805054) (, ,) (CD rs4912138) (, ,) (CD rs3790757) (CC and) (CD rs9659997)) (-RRB- -RRB-))))) (, ,) (NP (PRP we)) (VP (VBD conducted) (NP (NP (DT a) (JJ genetic) (NN association) (NN analysis)) (PP (IN of) (NP (NP (JJ case-control) (NNS samples)) (PRN (-LRB- -LRB-) (NP (NP (CD 197) (JJ Doc_20705401_1261_1265_Chemical-induced) (NNP Doc_20705401_1274_1283_Disease) (NNS patients)) (CC and) (NP (CD 337) (NNS controls))) (-RRB- -RRB-)))) (PP (IN in) (NP (DT the) (JJ Japanese) (NN population))))) (. .)))
20705401	8	(S1 (S (NP (NP (DT The) (NN age) (CC and) (NN sex)) (PP (IN of) (NP (DT the) (NN control) (NNS subjects)))) (VP (AUX did) (RB not) (VP (VB differ) (PP (IN from) (NP (NP (DT those)) (PP (IN of) (NP (DT the) (JJ Doc_20705401_1412_1427_Chemical) (NN dependence) (NNS patients))))))) (. .)))
20705401	9	(S1 (S (NP (CD rs6693503)) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (JJ Doc_20705401_1488_1492_Chemical-induced) (JJ Doc_20705401_1501_1510_Disease) (NNS patients)) (PP (IN in) (NP (DT the) (JJ allele/genotype-wise) (NN analysis))))))) (. .)))
20705401	10	(S1 (S (ADVP (RB Moreover)) (, ,) (NP (DT this) (NN association)) (VP (VBD remained) (ADJP (JJ significant)) (PP (IN after) (NP (NNP Bonferroni) (NN correction)))) (. .)))
20705401	11	(S1 (S (PP (IN In) (NP (DT the) (JJ haplotype-wise) (NN analysis))) (, ,) (NP (PRP we)) (VP (VBD detected) (NP (NP (DT an) (NN association)) (PP (IN between) (NP (NP (NP (CD two) (NNS markers)) (PRN (-LRB- -LRB-) (NP (CD rs6693503) (CC and) (CD rs1805054)) (-RRB- -RRB-))) (CC and) (NP (NP (CD three) (NNS markers)) (PRN (-LRB- -LRB-) (NP (CD rs6693503) (, ,) (CD rs1805054) (CC and) (CD rs4912138)) (-RRB- -RRB-)))))) (PP (IN in) (NP (NP (NNS HTR6)) (CC and) (NP (JJ Doc_20705401_1807_1811_Chemical-induced) (NN Doc_20705401_1820_1829_Disease) (NNS patients)))) (, ,) (ADVP (RB respectively))) (. .)))
20705401	12	(S1 (S (NP (NN HTR6)) (VP (MD may) (VP (VB play) (NP (DT an) (JJ important) (NN role)) (PP (IN in) (NP (NP (DT the) (NN pathophysiology)) (PP (IN of) (NP (NP (NNP Doc_20705401_1924_1928_Chemical-induced) (NNP Doc_20705401_1937_1946_Disease)) (PP (IN in) (NP (DT the) (JJ Japanese) (NN population))))))))) (. .)))
20727411	0	(S1 (S (NP (NP (JJ Neural) (NNS correlates)) (PP (IN of) (NP (NNP Doc_20727411_21_31_Chemical)))) (VP (VBN induced) (NP (NNP Doc_20727411_40_49_Disease)) (PP (IN during) (NP (JJ overt) (JJ continuous) (JJ verbal) (NN fluency)))) (. .)))
20727411	1	(S1 (S (NP (DT The) (JJ glutamatergic) (NNP Doc_20727411_108_128_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_20727411_130_134_Chemical)) (-RRB- -RRB-)) (NN receptor)) (VP (AUX has) (VP (AUX been) (VP (VBN implicated) (PP (IN in) (NP (NP (DT the) (NN pathophysiology)) (PP (IN of) (NP (NNP Doc_20727411_191_204_Disease)))))))) (. .)))
20727411	2	(S1 (S (PP (VBN Administered) (PP (TO to) (NP (JJ healthy) (NNS volunteers)))) (, ,) (NP (NP (DT a) (JJ subanesthetic) (NN dose)) (PP (IN of) (NP (DT the) (JJ non-competitive) (JJ Doc_20727411_286_290_Chemical) (NN receptor)))) (VP (VBP antagonist) (NP (NP (JJ Doc_20727411_311_319_Chemical) (NNS leads)) (PP (TO to) (NP (NP (JJ psychopathological) (NNS symptoms)) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT those)) (VP (VBN observed) (PP (IN in) (NP (NNP Doc_20727411_386_399_Disease))))))))))) (. .)))
20727411	3	(S1 (S (PP (IN In) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_20727411_418_431_Disease))))) (, ,) (NP (NNP Doc_20727411_433_441_Chemical)) (VP (VBZ exacerbates) (NP (NP (DT the) (JJ core) (NNS symptoms)) (PP (IN of) (NP (NN illness)))) (, ,) (S (VP (VBG supporting) (NP (NP (DT the) (NN hypothesis)) (PP (IN of) (NP (DT a) (NN Doc_20727411_515_540_Disease))))))) (. .)))
20727411	4	(S1 (S (PP (IN In) (NP (DT a) (JJ counterbalanced) (, ,) (JJ placebo-controlled) (, ,) (JJ double-blind) (NN study) (NN design))) (, ,) (NP (JJ healthy) (NNS subjects)) (VP (AUX were) (VP (VBN administered) (NP (DT a) (JJ continuous) (JJ subanesthetic) (JJ Doc_20727411_673_683_Chemical) (NN infusion)) (SBAR (IN while) (S (NP (NP (NNS differences)) (PP (IN in) (NP (NP (JJ BOLD) (NNS responses)) (VP (VBN measured) (PP (IN with) (NP (NN fMRI))))))) (VP (AUX were) (VP (VBN detected))))))) (. .)))
20727411	5	(S1 (S (PP (IN During) (NP (DT the) (VBG scanning) (NN period))) (, ,) (NP (NNS subjects)) (VP (VBD performed) (NP (NP (JJ continuous) (JJ overt) (JJ verbal) (NN fluency) (NNS tasks)) (PRN (-LRB- -LRB-) (ADJP (JJ phonological) (, ,) (JJ lexical) (CC and) (JJ semantic)) (-RRB- -RRB-)))) (. .)))
20727411	6	(S1 (S (NP (JJ Doc_20727411_886_894_Chemical-induced) (NN psychopathological) (NNS symptoms)) (VP (AUX were) (VP (VBN assessed) (PP (IN with) (NP (NP (DT the) (ADJP (JJ Positive) (CC and) (JJ Negative)) (NN Syndrome) (NN Scale)) (PRN (-LRB- -LRB-) (NP (NN PANSS)) (-RRB- -RRB-)))))) (. .)))
20727411	7	(S1 (S (NP (NN Doc_20727411_1000_1008_Chemical)) (VP (VBD elicited) (NP (NNP Doc_20727411_1018_1027_Disease)) (PP (IN like) (NP (NN psychopathology)))) (. .)))
20727411	8	(S1 (S (NP (JJ Post-hoc) (NNS t-tests)) (VP (VBD revealed) (NP (NP (JJ significant) (NNS differences)) (PP (IN between) (NP (NP (NN placebo)) (CC and) (NP (NNP Doc_20727411_1120_1128_Chemical))))) (PP (IN for) (NP (NP (DT the) (NNS amounts)) (PP (IN of) (NP (NP (NNS words)) (VP (VBN generated) (PP (IN during) (NP (NP (NN lexical)) (CC and) (NP (JJ semantic) (JJ verbal) (NN fluency))))))))) (, ,) (SBAR (IN while) (S (NP (DT the) (JJ phonological) (NN domain)) (VP (VBD remained) (ADJP (JJ unaffected)))))) (. .)))
20727411	9	(S1 (S (NP (NN Doc_20727411_1259_1267_Chemical)) (VP (VBD led) (PP (TO to) (NP (NP (JJ enhanced) (JJ cortical) (NNS activations)) (PP (IN in) (NP (NP (JJ supramarginal) (CC and) (JJ frontal) (NN brain) (NNS regions)) (PP (PP (IN for) (NP (NP (NN phonological)) (CC and) (NP (JJ lexical) (JJ verbal) (NN fluency)))) (, ,) (CC but) (RB not) (PP (IN for) (NP (JJ semantic) (JJ verbal) (NN fluency))))))))) (. .)))
20727411	10	(S1 (S (NP (NN Doc_20727411_1430_1438_Chemical)) (VP (VBZ induces) (NP (NP (NN activation) (NNS changes)) (PP (IN in) (NP (NP (JJ healthy) (NNS subjects)) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT those)) (VP (VBN observed) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_20727411_1529_1542_Disease))))) (, ,) (PP (ADVP (RB particularly)) (IN in) (NP (JJ frontal) (CC and) (JJ temporal) (NN brain) (NNS regions))))))))))) (. .)))
20727411	11	(S1 (S (NP (PRP$ Our) (NNS results)) (VP (VBP provide) (NP (NP (JJ further) (NN support)) (PP (IN for) (NP (NP (DT the) (NNS hypothesis)) (PP (IN of) (NP (NP (DT an) (JJ Doc_20727411_1657_1661_Chemical) (NN receptor) (NN dysfunction)) (PP (IN in) (NP (NP (DT the) (NN pathophysiology)) (PP (IN of) (NP (NNP Doc_20727411_1709_1722_Disease))))))))))) (. .)))
20735774	0	(S1 (NP (NP (JJ Long-term) (NN prognosis)) (PP (IN for) (NP (NP (JJ transplant-free) (NNS survivors)) (PP (IN of) (NP (NNP Doc_20735774_53_64_Chemical-induced) (NNP Doc_20735774_73_92_Disease))))) (. .)))
20735774	1	(S1 (S (NP (NP (DT The) (NN prognosis)) (PP (IN for) (NP (NP (JJ transplant-free) (NNS survivors)) (PP (IN of) (NP (NNP Doc_20735774_153_164_Chemical-induced) (NNP Doc_20735774_173_192_Disease)))))) (VP (VBZ remains) (NP (NN unknown))) (. .)))
20735774	2	(S1 (S (S (VP (TO To) (VP (VB examine) (SBAR (IN whether) (S (NP (NNP Doc_20735774_234_245_Chemical-induced) (NNP Doc_20735774_254_273_Disease)) (VP (VBZ increases) (NP (JJ long-term) (NN mortality)))))))) (. .)))
20735774	3	(S1 (S (NP (PRP We)) (VP (VBD followed) (PRT (RP up)) (NP (NP (DT all) (JJ transplant-free) (NNS survivors)) (PP (IN of) (NP (NNP Doc_20735774_362_373_Chemical-induced) (NNP Doc_20735774_382_400_Disease))) (, ,) (VP (VBN hospitalized) (PP (IN in) (NP (DT a) (JJ Danish) (JJ national) (NN referral))) (NP (NNP centre)) (PP (IN during) (NP (CD 1984-2004)))))) (. .)))
20735774	4	(S1 (S (NP (PRP We)) (VP (VBD compared) (NP (NP (JJ age-specific) (NN mortality) (NNS rates)) (PP (IN from) (NP (CD 1) (NN year) (NN post-discharge)))) (PP (IN through) (NP (CD 2008))) (PP (IN between) (NP (NP (NP (DT those)) (SBAR (WHPP (IN in) (WHNP (WP whom))) (S (NP (DT the) (NNP Doc_20735774_577_589_Disease)) (VP (VBD led) (PP (TO to) (NP (DT an) (NN Doc_20735774_600_619_Disease))))))) (CC and) (NP (NP (DT those)) (SBAR (WHPP (IN in) (WHNP (WP whom))) (S (NP (PRP it)) (VP (AUX did) (RB not)))))))) (. .)))
20735774	5	(S1 (S (NP (PRP We)) (VP (VBD included) (NP (CD 641) (NNS patients))) (. .)))
20735774	6	(S1 (S (PP (IN On) (NP (NN average))) (, ,) (S (NP (JJ age-specific) (NN mortality) (NNS rates)) (VP (AUX were) (ADJP (RB slightly) (JJR higher)) (PP (IN for) (NP (NP (DT the) (CD 101) (NNS patients)) (SBAR (WHNP (WP$ whose) (JJ Doc_20735774_774_785_Chemical-induced) (NN Doc_20735774_794_806_Disease)) (S (VP (AUX had) (VP (VBN caused) (NP (NP (DT an) (NN Doc_20735774_821_840_Disease)) (PRN (-LRB- -LRB-) (NP (NP (JJ adjusted) (NN mortality) (NN rate) (NN ratio) (SYM =) (CD 1.70)) (, ,) (NP (CD 95) (NN %) (QP (CD CI) (CD 1.02-2.85)))) (-RRB- -RRB-))))))))))) (, ,) (CC but) (S (NP (DT the) (NN association)) (VP (AUX was) (ADJP (JJ age-dependent)))) (, ,) (CC and) (S (NP (NP (DT no) (NNS survivors)) (PP (IN of) (NP (NNP Doc_20735774_958_977_Disease)))) (VP (VBD died) (PP (IN of) (NP (NNP Doc_20735774_986_999_Disease))) (, ,) (SBAR (IN whereas) (S (NP (NNS suicides)) (VP (AUX were) (ADJP (JJ frequent)) (PP (IN in) (NP (DT both) (NNS groups)))))))) (. .)))
20735774	7	(S1 (S (NP (DT These) (NNS observations)) (VP (VBP speak) (PP (IN against) (NP (NP (JJ long-term) (NNS effects)) (PP (IN of) (NP (NNP Doc_20735774_1102_1121_Disease)))))) (. .)))
20735774	8	(S1 (S (ADVP (RBR More) (JJ likely)) (, ,) (NP (DT the) (JJ elevated) (NN mortality) (NN rate) (NN ratio)) (VP (VBD resulted) (PP (IN from) (NP (NP (JJ incomplete) (NN adjustment)) (PP (IN for) (NP (NP (DT the) (JJR greater) (NN prevalence)) (PP (IN of) (NP (NNP Doc_20735774_1236_1251_Disease))) (PP (IN among) (NP (NP (NNS survivors)) (PP (IN of) (NP (NNP Doc_20735774_1271_1290_Disease)))))))))) (. .)))
20735774	9	(S1 (S (NP (JJ Doc_20735774_1305_1316_Chemical-induced) (NNP Doc_20735774_1325_1344_Disease)) (VP (AUX did) (RB not) (VP (VB affect) (NP (JJ long-term) (NN mortality)))) (. .)))
20735774	10	(S1 (S (NP (JJ Clinical) (NN follow-up)) (VP (MD may) (VP (AUX be) (VP (VBN justified) (PP (PP (IN by) (NP (NP (DT the) (NN cause)) (PP (IN of) (NP (DT the) (NNP Doc_20735774_1437_1450_Disease))))) (, ,) (CC but) (RB not) (PP (IN by) (NP (DT the) (NN Doc_20735774_1467_1480_Disease) (PRP itself))))))) (. .)))
20973483	0	(S1 (FRAG (PP (IN In) (NP (NP (NN vivo) (NN characterization)) (PP (IN of) (NP (NP (DT a) (JJ dual) (JJ Doc_20973483_35_48_Chemical/A1) (NN receptor) (NN antagonist)) (PP (IN in) (NP (NP (JJ animal) (NNS models)) (PP (IN of) (NP (NNP Doc_20973483_92_111_Disease))))))))) (. .)))
20973483	1	(S1 (S (NP (NP (DT The)) (PP (IN in) (NP (NP (NN vivo) (NN characterization)) (PP (IN of) (NP (NP (DT a) (JJ dual) (NNP Doc_20973483_152_167_Chemical/A) (PRN (-LRB- -LRB-) (NP (CD 1)) (-RRB- -RRB-)) (NN receptor) (NN antagonist)) (PP (IN in) (NP (NP (JJ several) (NN animal) (NNS models)) (PP (IN of) (NP (NNP Doc_20973483_221_240_Disease)))))))))) (VP (AUX is) (VP (VBN described))) (. .)))
20973483	2	(S1 (S (NP (NP (NN Discovery) (CC and) (NN scale-up) (NNS syntheses)) (PP (IN of) (NP (NN compound) (CD 1)))) (VP (AUX are) (VP (VBN described) (PP (IN in) (NP (NN detail))) (, ,) (S (VP (VBG highlighting) (NP (NP (NN optimization) (NNS steps)) (SBAR (WHNP (WDT that)) (S (VP (VBD increased) (NP (NP (DT the) (JJ overall) (NN yield)) (PP (IN of) (NP (QP (CD 1) (IN from) (CD 10.0)) (NN %)))) (PP (TO to) (NP (CD 30.5) (NN %))))))))))) (. .)))
20973483	3	(S1 (S (NP (NN Compound) (CD 1)) (VP (AUX is) (NP (NP (DT a) (JJ potent) (DT A) (PRN (-LRB- -LRB-) (NP (CD 2A)) (-RRB- -RRB-)) (NN /A) (PRN (-LRB- -LRB-) (NP (CD 1)) (-RRB- -RRB-)) (NN receptor) (NN antagonist)) (PP (IN in) (NP (NP (NN vitro)) (PRN (-LRB- -LRB-) (NP (NP (NP (DT A) (-LRB- -LRB-) (CD 2A) (-RRB- -RRB-) (NNP K) (S (-LRB- -LRB-) (NP (PRP i)) (-RRB- -RRB-) (NP (QP (SYM =) (CD 4.1) (CD nM))))) (: ;) (NP (DT A) (PRN (-LRB- -LRB-) (NP (CD 1)) (-RRB- -RRB-)) (NNP K))) (-LRB- -LRB-) (NP (PRP i)) (-RRB- -RRB-) (NP (SYM =)) (CD 17.0) (CD nM)) (-RRB- -RRB-)))) (SBAR (WHNP (WDT that)) (S (VP (AUX has) (NP (JJ excellent) (NN activity)) (, ,) (PP (IN after) (NP (NP (JJ oral) (NN administration) (PRN (, ,) (PP (IN across) (NP (NP (DT a) (NN number)) (PP (IN of) (NP (NP (NN animal) (NNS models)) (PP (IN of) (NP (NNP Doc_20973483_616_635_Disease))))) (VP (VBG including) (NP (NP (NN mouse) (CC and) (NN rat) (NNS models)) (PP (IN of) (NP (JJ Doc_20973483_670_681_Chemical-induced) (NNP Doc_20973483_690_699_Disease))))))) (, ,)) (NN mouse) (NN model)) (PP (IN of) (NP (JJ Doc_20973483_716_725_Chemical-induced) (NNP Doc_20973483_734_742_Disease))))) (, ,) (VP (VB rat) (NP (NP (NNP Doc_20973483_748_765_Chemical) (PRN (-LRB- -LRB-) (NNP Doc_20973483_767_773_Chemical) (-RRB- -RRB-)) (NN lesion) (NN model)) (PP (IN of) (NP (NP (JJ drug-induced) (NN rotation)) (, ,) (CC and) (NP (JJ Doc_20973483_818_822_Chemical-treated) (JJ non-human) (NN primate) (NN model))))))))))) (. .)))
21294084	0	(S1 (NP (NP (NP (NNS Effects)) (PP (IN of) (NP (DT the) (JJ hippocampal) (JJ deep) (NN brain) (NN stimulation))) (PP (IN on) (NP (NP (JJ cortical) (JJ Doc_21294084_62_71_Disease) (NNS discharges)) (PP (IN in) (NP (NNP Doc_21294084_86_96_Chemical)))))) (: -) (NP (NP (VBN induced) (JJ Doc_21294084_107_115_Disease) (NN model)) (PP (IN in) (NP (NNS rats)))) (. .)))
21294084	1	(S1 (S (S (NP (JJ Experimental) (CC and) (JJ clinical) (NNS studies)) (VP (AUX have) (VP (VBN revealed) (SBAR (IN that) (S (NP (JJ hippocampal) (NNS DBS)) (VP (MD can) (VP (VB control) (NP (JJ Doc_21294084_217_226_Disease) (NN activity))))))))) (, ,) (CC but) (S (S (NP (NP (DT the) (NN mechanism)) (PP (IN of) (NP (NN action)))) (VP (AUX is) (ADJP (JJ obscure)))) (CC and) (S (NP (JJ optimal) (NN stimulation) (NNS parameters)) (VP (AUX are) (RB not) (ADVP (RB clearly)) (VP (VBN defined))))) (. .)))
21294084	2	(S1 (S (NP (DT The) (NN aim)) (VP (AUX was) (S (VP (TO to) (VP (VB evaluate) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (JJ high) (NN frequency) (NN hippocampal) (NN stimulation))) (PP (IN on) (NP (NP (JJ cortical) (JJ Doc_21294084_426_435_Disease) (NN activity)) (PP (IN in) (NP (JJ Doc_21294084_448_458_Chemical-induced) (JJ Doc_21294084_467_475_Disease) (NN model)))))))))) (. .)))
21294084	3	(S1 (S (NP (NP (NN MATERIAL) (CC AND) (NNS METHODS)) (: :) (NP (CD Twenty-five) (JJ Sprague-Dawley) (NNS rats))) (VP (AUX were) (VP (VBN implanted) (NP (NNS DBS) (NNS electrodes)))) (. .)))
21294084	4	(S1 (S (SBAR (IN In) (S (NP (JJ group-1) (PRN (-LRB- -LRB-) (CD n=10) (-RRB- -RRB-)) (JJ hippocampal) (NNS DBS)) (VP (AUX was) (UCP (ADVP (RB off)) (CC and) (PP (IN in) (NP (DT the) (JJ group-2) (PRN (-LRB- -LRB-) (CD n=10) (-RRB- -RRB-)) (JJ hippocampal) (NNS DBS))))))) (VP (AUX was) (PP (IN on) (S (-LRB- -LRB-) (NP (NP (CD 185) (NNP Hz) (, ,) (NN 0.5V) (, ,) (NN 1V) (, ,) (NN 2V) (, ,) (CC and) (NN 5V)) (PP (IN for) (NP (CD 60) (NNP sec)))) (-RRB- -RRB-) (VP (VBG following) (NP (JJ Doc_21294084_711_723_Chemical) (NN injection)) (ADVP (RB intracortically)))))) (. .)))
21294084	5	(S1 (S (PP (IN In) (NP (DT the) (NN control) (NN group) (NN hippocampal))) (NP (NNP DBS)) (VP (AUX was) (PP (IN on) (S (VP (VBG following) (NP (CD 8) (NN l) (NN saline) (NN injection)) (ADVP (RB intracortically)))))) (. .)))
21294084	6	(S1 (S (NP (NNP EEG) (NNS recordings)) (VP (AUX were) (VP (VBN obtained) (PP (PP (IN before) (CC and) (NP (NP (CD 15) (NNS minutes)) (VP (VBG following) (NP (NNP Doc_21294084_905_917_Chemical) (NN injection))))) (, ,) (CC and) (PP (IN at) (NP (NP (JJ 10th) (NNS minutes)) (VP (VBG following) (NP (NP (DT each) (NN stimulus)) (PP (IN for) (NP (NN analysis)))) (PP (IN in) (NP (NP (NNS terms)) (PP (IN of) (NP (NP (NN frequency)) (, ,) (NP (NN amplitude)) (, ,) (CC and) (NP (NN power) (NN spectrum)))))))))))) (. .)))
21294084	7	(S1 (S (NP (JJ High) (NN frequency) (NN hippocampal) (NNS DBS)) (VP (VBD suppressed) (NP (NP (DT the) (JJ acute) (JJ Doc_21294084_1101_1111_Chemical-induced) (NN cortical) (NN Doc_21294084_1129_1138_Disease) (NN activity)) (ADJP (JJ independent) (PP (IN from) (NP (NN stimulus) (NN intensity)))))) (. .)))
21294084	8	(S1 (S (PP (IN In) (NP (DT the) (NN control) (NN group))) (, ,) (NP (JJ hippocampal) (NN stimulation)) (ADVP (RB alone)) (VP (VBP lead) (S (ADVP (RB only)) (VP (TO to) (VP (VB diffuse) (NP (NP (NN slowing)) (PP (IN of) (NP (JJ cerebral) (NN bioelectrical) (NN activity)))) (PP (IN at) (NP (CD 5V) (NN stimulation))))))) (. .)))
21294084	9	(S1 (S (NP (PRP$ Our) (NNS results)) (VP (VBD revealed) (SBAR (IN that) (S (NP (NP (JJ continuous) (JJ high) (NN frequency) (NN stimulation)) (PP (IN of) (NP (DT the) (NN hippocampus)))) (VP (VBD suppressed) (NP (JJ acute) (JJ cortical) (NN Doc_21294084_1441_1450_Disease) (NN activity)) (ADVP (RB effectively)) (PP (IN without) (S (VP (VBG causing) (NP (JJ secondary) (JJ Doc_21294084_1498_1507_Disease) (NNS discharges))))))))) (. .)))
21294084	10	(S1 (S (NP (DT These) (NNS results)) (VP (AUX are) (ADJP (JJ important)) (PP (IN in) (NP (NP (NNS terms)) (PP (IN of) (S (VP (VBG defining) (NP (NP (DT the) (JJ optimal) (NNS parameters)) (PP (IN of) (NP (JJ hippocampal) (NNS DBS))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_21294084_1628_1636_Disease)))))))))))) (. .)))
21418164	0	(S1 (NP (NP (NP (NNP Doc_21418164_0_4_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_21418164_6_15_Chemical)) (-RRB- -RRB-)) (NNP Doc_21418164_17_25_Disease)) (PP (IN in) (NP (NNS dogs)))) (: :) (NP (NP (DT a) (JJ retrospective) (NN study)) (PRN (-LRB- -LRB-) (NP (CD 2002-07)) (-RRB- -RRB-))) (. .)))
21418164	1	(S1 (FRAG (S (VP (TO To) (VP (VB describe) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NNP Doc_21418164_108_170_Disease))) (PP (IN in) (NP (NP (JJ tumour-bearing) (NNS dogs)) (VP (VBG receiving) (NP (NP (NNP Doc_21418164_204_248_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_21418164_250_254_Chemical)) (-RRB- -RRB-)))))))))) (. .)))
21418164	2	(S1 (S (NP (NP (DT The) (JJ medical) (NNS records)) (PP (IN of) (NP (NP (CD 206) (NNS dogs)) (SBAR (WHNP (WDT that)) (S (VP (AUX were) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_21418164_320_324_Chemical))) (PP (IN at) (NP (DT the) (NNP Melbourne) (JJ Veterinary) (NN Specialist) (NNP Centre))))))))) (PP (IN between) (NP (NP (NNP February) (CD 2002)) (CC and) (NP (NNP December) (CD 2007))))) (VP (AUX were) (VP (ADVP (RB retrospectively)) (VBN evaluated))) (. .)))
21418164	3	(S1 (S (PP (IN Of) (NP (NP (DT the) (CD 206) (NNS dogs)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_21418164_481_485_Chemical)))))) (, ,) (NP (CD 185)) (VP (VBD met) (NP (NP (DT the) (NN inclusion) (NNS criteria)) (PP (IN for) (NP (NP (QP (IN at) (JJS least) (CD one)) (NN class)) (PP (IN of) (NP (NNP Doc_21418164_544_552_Disease))))))) (. .)))
21418164	4	(S1 (S (NP (NN Doc_21418164_554_558_Chemical)) (VP (AUX was) (VP (VBN used) (ADVP (RBS most) (RB commonly)) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NNP Doc_21418164_602_610_Disease) (, ,) (NNP Doc_21418164_612_628_Disease) (, ,) (NNP Doc_21418164_630_642_Disease) (, ,) (NNP Doc_21418164_644_663_Disease) (CC and) (NNP Doc_21418164_668_692_Disease))))))) (. .)))
21418164	5	(S1 (S (PP (IN Throughout) (NP (NN treatment))) (, ,) (NP (NP (CD 56.9) (NN %)) (PP (IN of) (NP (NNS dogs)))) (VP (VBD experienced) (NP (NP (NNP Doc_21418164_742_753_Disease)) (, ,) (NP (NP (NP (CD 34.2) (NN %)) (VP (VBN experienced) (NP (NNP Doc_21418164_773_780_Disease)))) (CC and) (NP (NP (CD 14.2) (NN %)) (VP (VBN experienced) (NP (NNP Doc_21418164_803_819_Disease))))))) (. .)))
21418164	6	(S1 (S (S (NP (NN Doc_21418164_821_847_Disease)) (VP (AUX was) (VP (VBN detected) (PP (IN in) (NP (NP (CD 37.8) (NN %)) (PP (IN of) (NP (NNS dogs)))))))) (, ,) (S (NP (NP (DT the) (ADJP (RBS most) (JJ common)) (NN sign)) (PP (IN of) (NP (WDT which)))) (VP (AUX was) (NP (NP (NNP Doc_21418164_913_921_Disease)) (PRN (-LRB- -LRB-) (NP (CD 24.3) (NN %)) (-RRB- -RRB-))))) (. .)))
21418164	7	(S1 (S (NP (NP (JJ Potential) (JJ renal) (NN Doc_21418164_947_955_Disease)) (CC and) (NP (JJ elevated) (JJ Doc_21418164_969_976_Chemical) (NN transaminase) (PRN (-LRB- -LRB-) (NNP ALT) (-RRB- -RRB-)) (NN concentration))) (VP (AUX were) (VP (VBN reported) (PP (IN in) (NP (NP (CD 12.2) (NN %)) (CC and) (NP (NP (CD 48.8) (NN %)) (PP (IN of) (NP (NNS dogs)))) (, ,) (ADVP (RB respectively)))))) (. .)))
21418164	8	(S1 (S (NP (NP (DT The) (NN incidence)) (PP (IN of) (NP (NNP Doc_21418164_1083_1098_Disease)))) (VP (AUX was) (NP (CD 1.2) (NN %))) (. .)))
21418164	9	(S1 (S (NP (NP (JJ Doc_21418164_1122_1126_Chemical-associated) (NN Doc_21418164_1138_1146_Disease)) (PP (IN in) (NP (NNS dogs)))) (VP (VP (AUX is) (ADJP (JJ common))) (, ,) (CC but) (VP (AUX is) (ADJP (RB usually) (RB not) (NN life) (JJ threatening)))) (. .)))
2220369	0	(S1 (NP (NP (NP (NNP Central) (NNP Doc_2220369_8_23_Disease)) (CC and) (NP (JJ topical) (NNP Doc_2220369_36_57_Chemical))) (. .)))
2220369	1	(S1 (S (NP (DT A) (NN report)) (VP (AUX is) (VP (VBN given) (PP (IN on) (NP (NP (DT an) (JJ 83-year-old) (NN female)) (SBAR (WHNP (WP who)) (S (VP (VBD acquired) (NP (JJ central) (NNP Doc_2220369_123_138_Disease)) (PP (IN in) (NP (PRP$ her) (VBG seeing) (NN eye) (CD one) (NN day))) (PP (IN after) (S (VP (AUXG having) (VP (VBN started) (NP (JJ topical) (NN medication)) (PP (IN with) (NP (NNP Doc_2220369_210_231_Chemical))) (PP (IN for) (NP (NP (VBN advanced) (NN Doc_2220369_245_253_Disease)) (VP (VBN discovered) (PP (IN in) (NP (DT the) (JJ other) (NN eye))))))))))))))))) (. .)))
2220369	2	(S1 (S (PP (IN From) (NP (NP (JJ present) (NN knowledge)) (PP (IN about) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (JJ adrenergic) (NN eye) (NNS drops))) (PP (IN on) (NP (JJ ocular) (NN blood) (NN circulation))))))) (, ,) (NP (PRP it)) (VP (AUX is) (ADJP (JJ difficult) (SBAR (S (VP (TO to) (VP (VB suggest) (NP (NP (DT an) (NN association)) (PP (IN between) (NP (DT the) (CD two) (NNS events))))))))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (AUX be) (ADJP (JJ coincidental)) (ADVP (RB only))))))) (. .)))
2257294	0	(S1 (S (NP (NN Doc_2257294_0_19_Chemical)) (VP (VBZ reverses) (NP (JJ Doc_2257294_29_43_Chemical-induced) (NN Doc_2257294_52_70_Disease)) (PP (IN without) (NP (NP (NN impairment)) (PP (IN of) (NP (JJ anti-human) (JJ Doc_2257294_104_120_Disease) (NN virus) (NN activity)))))) (. .)))
2257294	1	(S1 (S (NP (NP (JJ Increased) (JJ extracellular) (NNS concentrations)) (PP (IN of) (NP (NP (NNP Doc_2257294_179_186_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2257294_188_191_Chemical)) (-RRB- -RRB-))))) (VP (AUX have) (VP (AUX been) (VP (VBN reported) (S (VP (TO to) (VP (VB reduce)))) (, ,) (PP (IN in) (NP (NP (NN vitro)) (, ,) (NP (NP (NNP Doc_2257294_233_247_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2257294_249_252_Chemical)) (-RRB- -RRB-)) (NP (NP (JJ -induced) (NN inhibition)) (PP (IN of) (NP (JJ human) (JJ granulocyte-macrophage) (NN progenitor) (NNS cells))) (PP (IN without) (NP (NP (NN impairment)) (PP (IN of) (NP (PRP$ its) (JJ antihuman) (JJ Doc_2257294_358_374_Disease) (NN virus) (PRN (-LRB- -LRB-) (NNP HIV) (-RRB- -RRB-)) (NN activity)))))))))))) (. .)))
2257294	2	(S1 (S (PP (IN Because) (IN of) (NP (NP (DT the) (JJ clinical) (NN Doc_2257294_421_431_Disease)) (VP (VBN associated) (PP (IN with) (NP (JJ chronic) (JJ Doc_2257294_456_459_Chemical) (NN administration)))))) (, ,) (NP (NP (DT the) (NN ability)) (PP (IN of) (NP (NP (NNP Doc_2257294_491_510_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2257294_512_515_Chemical)) (-RRB- -RRB-)))) (PP (TO to) (NP (NN effect)))) (, ,) (PP (IN in) (NP (NN vivo))) (, ,) (NP (NNP Doc_2257294_537_540_Chemical-induced) (NNP Doc_2257294_549_555_Disease) (CC and) (NNP Doc_2257294_560_570_Disease)) (VP (AUX was) (VP (VBN assessed))) (. .)))
2257294	3	(S1 (S (NP (DT This) (NN agent)) (VP (VP (VBZ inhibits) (NP (JJ Doc_2257294_605_608_Chemical) (NN catabolism))) (CC and) (PRN (, ,) (PP (IN in) (NP (NN vivo))) (, ,)) (VP (VBZ increases) (NP (NP (DT the) (NN plasma) (NN concentration)) (PP (IN of) (NP (NNP Doc_2257294_672_675_Chemical)))) (PP (IN in) (NP (DT a) (JJ dose-dependent) (NN manner))) (, ,) (PP (IN without) (NP (JJ Doc_2257294_712_715_Chemical-related) (NN Doc_2257294_724_732_Disease))))) (. .)))
2257294	4	(S1 (S (PP (IN In) (NP (NP (NNS mice)) (VP (VBN rendered) (S (ADJP (JJ anemic) (CC and) (JJ leukopenic))) (PP (IN by) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NP (NP (NP (NP (NNP Doc_2257294_798_801_Chemical)) (PP (IN for) (NP (NP (CD 28) (NNS days)) (PP (IN in) (NP (NN drinking) (NN water))) (PRN (-LRB- -LRB-) (NP (CD 1.5) (NNS mg/mL)) (-RRB- -RRB-))))) (, ,) (NP (NP (DT the) (JJ continued) (NN administration)) (PP (IN of) (NP (NNP Doc_2257294_877_880_Chemical)))) (CC plus) (NP (NP (JJ daily) (NNP Doc_2257294_892_895_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 300) (NNS mg/kg)) (, ,) (ADVP (RB orally)) (-RRB- -RRB-)))) (VP (ADVP (RB partially)) (VBN reversed) (NP (JJ Doc_2257294_935_938_Chemical-induced) (NNP Doc_2257294_947_953_Disease)))) (CC and) (NP (NNP Doc_2257294_958_968_Disease)))) (PRN (-LRB- -LRB-) (ADVP (RB P)) (NP (QP (JJR less) (IN than) (CD .05))) (-RRB- -RRB-))))))) (, ,) (NP (NP (VBN increased) (JJ peripheral) (NNS reticulocytes)) (PRN (-LRB- -LRB-) (PP (TO to) (NP (CD 4.9) (NN %))) (, ,) (NP (NNP P) (QP (JJR less) (IN than) (CD .01))) (-RRB- -RRB-)) (, ,)) (VP (VP (VBD increased) (NP (NN cellularity)) (PP (IN in) (NP (DT the) (NN marrow)))) (, ,) (CC and) (VP (VBN improved) (NP (NN megaloblastosis)))) (. .)))
2257294	5	(S1 (S (SBAR (WHADVP (WRB When)) (S (VP (VBN coadministered) (PP (IN with) (NP (NNP Doc_2257294_1143_1146_Chemical))) (PP (IN from) (NP (NP (DT the) (NN onset)) (PP (IN of) (NP (NN drug) (NN administration)))))))) (, ,) (NP (NNP Doc_2257294_1186_1189_Chemical)) (VP (VBD reduced) (NP (JJ Doc_2257294_1198_1201_Chemical-induced) (NN Doc_2257294_1210_1225_Disease))) (. .)))
2257294	6	(S1 (S (PP (IN In) (NP (NN vitro))) (, ,) (PP (IN at) (NP (NP (DT a) (NN concentration)) (PP (IN of) (NP (CD 100) (CD mumol/L))))) (, ,) (NP (NNP BAU)) (VP (VP (VBZ possesses) (NP (JJ minimal) (JJ anti-HIV) (NN activity))) (CC and) (VP (AUX has) (NP (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (DT the) (NN ability)) (PP (IN of) (NP (NNP Doc_2257294_1348_1351_Chemical))) (S (VP (TO to) (VP (VB reverse) (NP (NP (DT the) (JJ HIV-induced) (JJ cytopathic) (NN effect)) (PP (IN in) (NP (JJ MT4) (NNS cells)))))))))))) (. .)))
2257294	7	(S1 (S (NP (NP (DT The) (JJ clinical) (CC and) (JJ biochemical) (NNS implications)) (PP (IN of) (NP (DT these) (NNS findings)))) (VP (AUX are) (VP (VBN discussed))) (. .)))
2320800	0	(S1 (S (NP (NNP Lethal) (NNP Doc_2320800_7_13_Disease)) (VP (VBD complicating) (NP (JJ high) (NN dose) (JJ Doc_2320800_37_47_Chemical) (NN chemotherapy)) (PP (IN in) (NP (NP (DT a) (JJ Doc_2320800_66_79_Disease) (NN patient)) (PP (IN with) (NP (DT an) (NNP Doc_2320800_96_119_Disease)))))) (. .)))
2320800	1	(S1 (S (NP (NP (DT A) (JJ sixty-year-old) (NN woman)) (PP (IN with) (NP (JJ advanced) (NNP Doc_2320800_158_171_Disease))) (, ,) (VP (ADVP (RB previously)) (VBN treated) (PP (IN with) (NP (NNP Doc_2320800_197_206_Chemical)))) (, ,)) (VP (VBD developed) (NP (NP (DT an) (JJ irreversible) (JJ lethal) (NN Doc_2320800_241_254_Disease)) (PP (IN with) (NP (NP (NNP Doc_2320800_260_266_Disease)) (, ,) (NP (NP (DT the) (NN day)) (PP (IN after) (NP (CD 5) (JJ g/m2) (JJ bolus) (NN Doc_2320800_295_305_Chemical)))))))) (. .)))
2320800	2	(S1 (S (NP (NN Doc_2320800_307_324_Disease)) (VP (AUX was) (VP (VBN excluded) (PP (IN by) (NP (NN echography))))) (. .)))
2320800	3	(S1 (S (NP (DT A) (JJ prerenal) (NN component)) (VP (MD could) (VP (AUX have) (VP (VBN contributed) (PP (TO to) (NP (NNP Doc_2320800_400_413_Disease))) (PP (IN because) (IN of) (NP (DT a) (JJ transient) (NN Doc_2320800_437_448_Disease))) (, ,) (PP (JJ due) (PP (TO to) (NP (NP (DT an) (VBG increasing) (NN ascitis)) (, ,) (VP (VBG occurring) (ADVP (RB just)) (PP (IN before) (NP (NNP Doc_2320800_502_508_Disease)))))))))) (. .)))
2320800	4	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (NN correction)) (PP (IN of) (NP (DT the) (JJ hemodynamic) (NNS parameters)))) (VP (AUX did) (RB not) (VP (VB improve) (NP (JJ renal) (NN function)))) (. .)))
2320800	5	(S1 (S (NP (NN Doc_2320800_592_602_Chemical)) (VP (AUX is) (NP (NP (DT a) (JJ known) (JJ nephrotoxic) (NN drug)) (PP (IN with) (NP (VBN demonstrated) (NN Doc_2320800_649_662_Disease))))) (. .)))
2320800	6	(S1 (S (NP (PRP We)) (ADVP (RB strongly)) (VP (VBP suspect) (SBAR (IN that) (S (NP (DT this) (JJ lethal) (NN Doc_2320800_701_707_Disease)) (VP (AUX was) (ADJP (RB mainly) (JJ due) (PP (TO to) (NP (NNP Doc_2320800_726_736_Chemical)))) (, ,) (S (VP (VBG occurring) (PP (PP (IN in) (NP (NP (DT a) (NN patient)) (VP (AUXG having) (VP (VBN received) (NP (JJ previous) (JJ Doc_2320800_786_795_Chemical) (NN chemotherapy)))))) (CC and) (PP (IN with) (NP (NP (JJ poor) (NN kidney) (NNS perfusion)) (ADJP (JJ due) (PP (TO to) (NP (JJ transient) (NNP Doc_2320800_857_868_Disease))))))))))))) (. .)))
2320800	7	(S1 (S (NP (PRP We)) (VP (VBP recommend) (NP (NP (JJ careful) (NN use)) (PP (IN of) (NP (NNP Doc_2320800_898_908_Chemical))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBN pretreated) (PP (IN with) (NP (NP (JJ nephrotoxic) (NN chemotherapy)) (CC and) (NP (JJ inadequate) (JJ renal) (NN perfusion))))))))) (. .)))
2322844	0	(S1 (S (NP (JJ Nociceptive) (NNS effects)) (VP (VBN induced) (PP (IN by) (NP (NP (JJ intrathecal) (NN administration)) (PP (IN of) (NP (NP (NNP Doc_2322844_61_77_Chemical)) (, ,) (NP (NNP E2)) (, ,) (CC or) (NP (NNP F2) (NNP alpha)))) (PP (TO to) (NP (JJ conscious) (NNS mice)))))) (. .)))
2322844	1	(S1 (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NP (NN intrathecal) (NN administration)) (PP (IN of) (NP (NNP Doc_2322844_159_173_Chemical))))) (PP (IN on) (NP (JJ Doc_2322844_177_181_Disease) (NNS responses))) (PP (IN in) (NP (JJ conscious) (NNS mice)))) (VP (AUX were) (VP (VBN evaluated) (PP (IN by) (S (VP (VBG using) (NP (NP (JJ hot) (NN plate)) (CC and) (NP (JJ Doc_2322844_248_259_Chemical) (VBG writhing) (NNS tests)))))))) (. .)))
2322844	2	(S1 (S (NP (NP (NNP Doc_2322844_276_292_Chemical)) (PRN (-LRB- -LRB-) (NP (JJ 0.5-3) (NN ng/mouse)) (-RRB- -RRB-))) (VP (AUX had) (NP (NP (DT a) (NNP Doc_2322844_316_328_Disease) (NN action)) (PP (IN on) (NP (NP (DT the) (NN response)) (PP (TO to) (NP (NP (DT a) (JJ hot) (NN plate)) (PP (IN during) (NP (NP (DT a) (JJ 3-60) (NN min) (NN period)) (PP (IN after) (NP (NN injection))))))))))) (. .)))
2322844	3	(S1 (S (S (NP (NN Doc_2322844_409_425_Chemical)) (VP (VBD showed) (NP (DT a) (JJ Doc_2322844_435_447_Disease) (NN effect)) (PP (IN at) (NP (NP (NNS doses)) (PP (IN of) (NP (QP (CD 1) (NNS pg) (TO to) (CD 10)) (NN ng/mouse))))))) (, ,) (CC but) (S (NP (DT the) (NN effect)) (VP (VBD lasted) (NP (NP (JJR shorter) (PRN (-LRB- -LRB-) (NP (CD 3-30) (NN min)) (-RRB- -RRB-))) (PP (IN than) (NP (NP (DT that)) (PP (IN of) (NP (NNP Doc_2322844_542_558_Chemical)))))))) (. .)))
2322844	4	(S1 (S (NP (JJ Similar) (NNS results)) (VP (AUX were) (VP (VBN obtained) (PP (IN by) (NP (JJ Doc_2322844_593_604_Chemical) (VBG writhing) (NNS tests))))) (. .)))
2322844	5	(S1 (S (NP (NP (DT The) (JJ Doc_2322844_625_637_Disease) (NN effect)) (PP (IN of) (NP (NNP Doc_2322844_648_664_Chemical)))) (VP (AUX was) (VP (VBN blocked) (PP (PP (IN by) (NP (NP (JJ simultaneous) (NN injection)) (PP (IN of) (NP (NP (DT a) (NN substance)) (ADJP (ADJP (RB P) (JJ antagonist)) (PRN (-LRB- -LRB-) (ADVP (JJR greater) (IN than) (CC or) (JJ equal) (PP (TO to) (NP (CD 100) (CD ng)))) (-RRB- -RRB-))))))) (CC but) (PP (RB not) (IN by) (NP (NP (NNP Doc_2322844_776_782_Chemical)) (, ,) (NP (DT a) (JJ prostanoid) (NN EP1-receptor) (NN antagonist))))))) (. .)))
2322844	6	(S1 (S (ADVP (RB Conversely)) (, ,) (NP (NNP Doc_2322844_834_850_Chemical-induced) (NNP Doc_2322844_859_871_Disease)) (VP (AUX was) (VP (VBN blocked) (PP (PP (IN by) (NP (NNP Doc_2322844_887_893_Chemical))) (PRN (-LRB- -LRB-) (ADJP (ADJP (JJR greater) (PP (IN than))) (CC or) (ADJP (JJ equal) (PP (TO to) (NP (QP (CD 500) (CD ng)))))) (-RRB- -RRB-)) (CC but) (RB not) (PP (IN by) (NP (DT the) (NN substance) (NN P) (NN antagonist)))))) (. .)))
2322844	7	(S1 (S (NP (NN Doc_2322844_967_989_Chemical)) (VP (AUX had) (NP (NP (JJ little) (NN effect)) (PP (IN on) (NP (JJ Doc_2322844_1011_1015_Disease) (NNS responses))))) (. .)))
2322844	8	(S1 (S (NP (DT These) (NNS results)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP (DT both) (NNP Doc_2322844_1063_1079_Chemical) (CC and) (NNP Doc_2322844_1084_1100_Chemical)) (VP (VBP exert) (NP (NNP Doc_2322844_1107_1119_Disease)) (PP (PP (IN in) (NP (DT the) (JJ spinal) (NN cord))) (, ,) (CC but) (PP (IN in) (NP (JJ different) (NNS ways)))))))) (. .)))
2334179	0	(S1 (NP (NP (NN Doc_2334179_0_15_Chemical)) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NNP Doc_2334179_36_57_Disease))))) (. .)))
2334179	1	(S1 (S (NP (NN Doc_2334179_59_80_Disease)) (VP (VP (AUX has) (NP (DT no) (VBN recognized) (JJ internal) (NN organ) (NN involvement))) (CC but) (VP (MD may) (VP (AUX be) (VP (VP (VBG disfiguring)) (CC and) (VP (VBG disabling) (SBAR (WHADVP (WRB when)) (S (NP (DT the) (JJ cutaneous) (NNS lesions)) (VP (VP (AUX are) (ADJP (JJ extensive))) (CC or) (VP (VBP affect) (NP (NNS children))))))))))) (. .)))
2334179	2	(S1 (S (NP (EX There)) (VP (AUX is) (ADVP (RB no)) (VP (VP (VBN accepted)) (CC or) (VP (VBN proven) (NP (NN treatment)) (PP (IN for) (NP (NNP Doc_2334179_269_290_Disease)))))) (. .)))
2334179	3	(S1 (S (NP (NP (NN Case) (NNS reports)) (PP (IN of) (NP (CD 11) (NNS patients))) (PP (IN with) (NP (NP (JJ severe) (, ,) (JJ extensive) (NNP Doc_2334179_343_364_Disease)) (SBAR (WHNP (WP who)) (S (VP (AUX were) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_2334179_387_402_Chemical)))))))))) (VP (AUX are) (VP (VBD summarized) (PP (IN in) (NP (DT this) (NN article))))) (. .)))
2334179	4	(S1 (S (NP (DT This) (NN drug)) (VP (AUX was) (VP (VBN judged) (S (VP (TO to) (VP (AUX have) (NP (NP (DT a) (JJ favorable) (NN effect)) (PP (IN on) (NP (NP (DT the) (NN disease) (NN course)) (PP (IN in) (NP (CD 7))))) (PRN (-LRB- -LRB-) (NP (CD 64) (NN %)) (-RRB- -RRB-)) (PP (IN of) (NP (CD 11) (NNS patients))))))))) (. .)))
2334179	5	(S1 (S (NP (NN Improvement)) (VP (VP (VBD began) (PP (IN within) (NP (QP (CD 3) (TO to) (CD 6)) (NNS months)))) (CC and) (VP (VBD consisted) (PP (IN of) (NP (NP (NP (NN cessation)) (PP (IN of) (NP (JJ active) (JJ cutaneous) (NNS lesions))) (PP (IN in) (NP (DT all) (CD 7) (NNS patients)))) (, ,) (NP (NP (NN skin)) (VP (VBG softening) (PP (IN in) (NP (CD 5))))) (, ,) (CC and) (NP (NP (ADJP (RBR more) (JJ normal)) (NN growth)) (PP (IN of) (NP (DT the) (VBN affected) (NN limb))) (PP (IN in) (NP (QP (CD 2) (IN of) (CD 3)) (NNS children)))))))) (. .)))
2334179	6	(S1 (S (NP (NP (JJ Joint) (NN stiffness)) (CC and) (NP (NN Doc_2334179_750_762_Disease))) (ADVP (RB also)) (VP (VBD improved)) (. .)))
2334179	7	(S1 (S (NP (NP (DT The) (NN dose)) (PP (IN of) (NP (NNP Doc_2334179_790_805_Chemical))) (VP (VBN associated) (PP (IN with) (NP (DT a) (JJ favorable) (NN response))))) (VP (AUX was) (ADJP (RB as) (JJ low) (PP (IN as) (NP (QP (CD 2) (TO to) (CD 5)) (NN mg/kg)))) (PP (IN per) (NP (NP (NN day)) (VP (VBN given) (PP (IN over) (NP (NP (DT a) (NN period)) (VP (VBG ranging) (PP (IN from) (NP (QP (CD 15) (TO to) (CD 53)) (NNS months)))))))))) (. .)))
2334179	8	(S1 (S (S (NP (NNP Doc_2334179_928_943_Chemical)) (VP (VBD caused) (NP (NNP Doc_2334179_951_969_Disease)) (PP (IN in) (NP (NP (NP (CD 1) (NN patient)) (CC and) (NP (JJR milder) (JJ reversible) (NN Doc_2334179_1005_1016_Disease))) (PP (IN in) (NP (CD 3) (JJ other) (NNS patients))))))) (: ;) (S (NP (NN none)) (VP (VBD developed) (NP (NNP Doc_2334179_1053_1072_Disease)))) (. .)))
2334179	9	(S1 (S (NP (DT These) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NNP Doc_2334179_1098_1113_Chemical)) (VP (MD may) (VP (AUX be) (ADJP (JJ effective)) (PP (IN in) (NP (NP (JJ severe) (NNS cases)) (PP (IN of) (NP (NNP Doc_2334179_1150_1171_Disease)))))))))) (. .)))
2339463	0	(S1 (NP (NP (NN Doc_2339463_0_25_Disease)) (PP (IN as) (NP (NP (DT a) (JJ potential) (NN hazard)) (PP (IN of) (NP (NP (JJ antifibrinolytic) (NN treatment)) (PP (IN in) (NP (NNP Doc_2339463_81_92_Disease))))))) (. .)))
2339463	1	(S1 (S (NP (PRP We)) (VP (VBP describe) (NP (NP (DT a) (JJ 42-year-old) (NN woman)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NP (JJ superior) (NN Doc_2339463_149_194_Disease)) (VP (VBN associated) (PP (IN with) (NP (NP (JJ prolonged) (JJ Doc_2339463_221_246_Chemical) (NN therapy)) (PP (IN for) (NP (NNP Doc_2339463_259_270_Disease)))))))))))) (. .)))
2339463	2	(S1 (S (NP (DT This) (JJ antifibrinolytic) (NN agent)) (VP (AUX has) (VP (AUX been) (VP (VBN used) (PP (IN in) (NP (NP (NNS women)) (PP (IN with) (NP (NNP Doc_2339463_328_339_Disease))))) (S (VP (TO to) (VP (VP (VB promote) (NP (NN clotting))) (CC and) (VP (VB reduce) (NP (NN Doc_2339463_371_381_Disease))))))))) (. .)))
2339463	3	(S1 (S (SBAR (IN Although) (S (NP (NP (JJ increased) (NN risk)) (PP (IN of) (NP (NNP Doc_2339463_410_432_Disease)))) (VP (AUX has) (VP (AUX been) (VP (VBN reported) (PP (IN during) (NP (NP (NN treatment)) (PP (IN with) (NP (NNP Doc_2339463_473_498_Chemical)))))))))) (, ,) (NP (NNP Doc_2339463_500_525_Disease)) (VP (AUX has) (RB not) (VP (AUX been) (VP (ADVP (RB previously)) (VBN described)))) (. .)))
2339463	4	(S1 (S (NP (NP (JJ Careful) (NN use)) (PP (IN of) (NP (JJ Doc_2339463_576_601_Chemical) (NN therapy)))) (VP (AUX is) (VP (VBN recommended))) (. .)))
2343592	0	(S1 (NP (NP (NP (NN Doc_2343592_0_7_Disease) (NN activity)) (PP (IN with) (NP (JJ Doc_2343592_22_30_Chemical) (NN therapy)))) (: :) (NP (NP (NN incidence)) (CC and) (NP (NN risk) (NNS factors))) (. .)))
2343592	1	(S1 (S (NP (NP (CD Two) (JJ elderly) (NNS patients)) (PP (IN with) (NP (NP (NP (DT a) (NN history)) (PP (IN of) (NP (CC either) (NP (NP (NNP Doc_2343592_114_140_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2343592_142_145_Disease)) (-RRB- -RRB-))) (CC or) (NP (NNP Doc_2343592_150_161_Disease))))) (CC and) (NP (NP (DT no) (NN evidence)) (PP (IN of) (NP (NNP Doc_2343592_181_194_Disease))))))) (VP (VBD developed) (NP (NNP Doc_2343592_205_213_Disease)) (SBAR (IN while) (S (VP (VBG receiving) (NP (NP (JJ maximum) (NNS doses)) (PP (IN of) (NP (NNP Doc_2343592_247_255_Chemical/Doc_2343592_256_266_Chemical)))))))) (. .)))
2343592	2	(S1 (S (NP (DT Neither) (NN patient)) (VP (VP (AUX had) (VP (VBN reported) (NP (NP (JJ previous) (NN Doc_2343592_306_314_Disease)) (CC or) (NP (JJ Doc_2343592_318_325_Disease-like) (NN activity))))) (CC nor) (VP (AUX was) (VP (VBG receiving) (NP (JJ anticonvulsant) (NNS agents))))) (. .)))
2343592	3	(S1 (S (NP (DT All) (NNP Doc_2343592_385_393_Disease)) (VP (AUX were) (VP (VBN controlled) (PP (IN with) (NP (NP (JJ therapeutic) (NNS doses)) (PP (IN of) (NP (NNP Doc_2343592_436_445_Chemical))))))) (. .)))
2343592	4	(S1 (S (NP (DT Both) (NNS patients)) (VP (AUX had) (VP (VBN received) (NP (NP (JJ maximum) (NNS doses)) (PP (IN of) (NP (JJ other) (JJ Doc_2343592_497_508_Chemical) (NNS antibiotics)))) (PP (IN without) (NP (NP (NN evidence)) (PP (IN of) (NP (JJ Doc_2343592_541_548_Disease) (NN activity))))))) (. .)))
2422478	0	(S1 (S (NP (NP (NNP Midline) (NNP B3) (NNP Doc_2422478_11_20_Chemical) (NNS nerves)) (PP (IN in) (NP (NN rat) (NN medulla)))) (VP (AUX are) (VP (VBN involved) (PP (IN in) (NP (NP (JJ Doc_2422478_59_70_Disease) (NN effect)) (PP (IN of) (NP (NNP Doc_2422478_81_91_Chemical))))))) (. .)))
2422478	1	(S1 (S (NP (NP (JJ Previous) (NNS experiments)) (PP (IN in) (NP (DT this) (NN laboratory)))) (VP (AUX have) (VP (VBN shown) (SBAR (IN that) (S (NP (NP (NN microinjection)) (PP (IN of) (NP (NP (NNP Doc_2422478_167_177_Chemical)) (PP (IN onto) (NP (NP (DT the) (JJ ventrolateral) (NNS cells)) (PP (IN of) (NP (NP (DT the) (NNP B3) (NNP Doc_2422478_217_226_Chemical) (NNS neurons)) (PP (IN in) (NP (DT the) (NN medulla)))))))))) (VP (VBZ elicits) (NP (NP (DT a) (JJ Doc_2422478_260_271_Disease) (NN response)) (VP (VBN mediated) (PP (IN by) (NP (NP (DT a) (NN projection)) (VP (VBG descending) (PP (IN into) (NP (DT the) (JJ spinal) (NN cord))))))))))))) (. .)))
2422478	2	(S1 (S (NP (DT The) (JJ present) (NNS experiments)) (VP (AUX were) (VP (VBN designed) (S (VP (TO to) (VP (VB investigate) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NP (DT the) (JJ midline) (NNS cells)) (PP (IN of) (NP (DT the) (NNP B3) (NNP Doc_2422478_432_441_Chemical) (NNS neurons)))))) (PP (IN in) (NP (DT the) (NN medulla))) (, ,) (S (VP (VBG coinciding) (PP (IN with) (NP (DT the) (NNP raphe) (NNP magnus)))))))))) (. .)))
2422478	3	(S1 (S (PP (IN In) (NP (ADJP (RB spontaneously) (JJ Doc_2422478_517_529_Disease)) (, ,) (JJ Doc_2422478_531_537_Disease-prone) (NNS rats))) (, ,) (NP (NP (NN microinjection)) (PP (IN of) (NP (NNP Doc_2422478_568_578_Chemical))) (PP (IN into) (NP (NP (DT the) (NN area)) (PP (IN of) (NP (DT the) (JJ midline) (NNP B3) (NNP Doc_2422478_611_620_Chemical) (NN cell) (NN group))) (PP (IN in) (NP (DT the) (JJ ventral) (NN medulla)))))) (VP (VBD caused) (NP (NP (DT a) (JJ potent) (NN Doc_2422478_671_682_Disease)) (PP (IN of) (NP (NP (JJ 30-40) (NN mm) (NNP Hg)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VP (AUX was) (ADJP (JJ maximal) (NP (CD 2-3) (NNP h))) (PP (IN after) (NP (NN administration)))) (CC and) (VP (AUX was) (VP (VBN abolished) (PP (IN by) (NP (NP (DT the) (JJ Doc_2422478_769_778_Chemical) (NN neurotoxin)) (SBAR (S (NP (NP (NNP Doc_2422478_790_813_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2422478_815_822_Chemical)) (-RRB- -RRB-))) (VP (VBD injected) (ADVP (RB intracerebroventricularly)))))))))))))))) (. .)))
2422478	4	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (JJ intraspinal) (NN injection)) (PP (IN of) (NP (NNP Doc_2422478_894_901_Chemical))) (SBAR (S (VP (TO to) (VP (VB produce) (NP (NP (DT a) (ADJP (RBR more) (JJ selective)) (NN lesion)) (PP (IN of) (NP (JJ only) (VBG descending) (NNP Doc_2422478_956_965_Chemical) (NNS projections)))) (PP (IN in) (NP (DT the) (JJ spinal) (NN cord)))))))) (VP (AUX did) (RB not) (VP (VB affect) (NP (DT this) (NN Doc_2422478_1017_1028_Disease)))) (. .)))
2422478	5	(S1 (S (NP (NP (JJ Further) (, ,) (JJ Doc_2422478_1039_1046_Chemical) (NN lesion)) (PP (IN of) (NP (NP (JJ Doc_2422478_1057_1066_Chemical) (NNS nerves)) (VP (VBG travelling) (PP (IN in) (NP (NP (DT the) (JJ median) (NN forebrain) (NN bundle)) (, ,) (NP (NP (CD one)) (PP (IN of) (NP (NP (DT the) (JJ main) (VBG ascending) (NNS pathways)) (PP (IN from) (NP (DT the) (NNP B3) (NNP Doc_2422478_1164_1173_Chemical) (NNS cells)))))) (, ,))))))) (VP (AUX did) (RB not) (VP (VB affect) (NP (NP (DT the) (NN fall)) (PP (IN in) (NP (NP (NN blood) (NN pressure)) (VP (VBN associated) (PP (IN with) (NP (DT a) (JJ midline) (NNP B3) (NNP Doc_2422478_1252_1261_Chemical) (NNP Doc_2422478_1262_1272_Chemical) (NN injection))))))))) (. .)))
2422478	6	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (VBN concluded) (ADVP (RB therefore)) (SBAR (IN that) (, ,) (PP (PP (IN unlike) (NP (NP (DT the) (JJ ventrolateral) (NNP B3) (NNS cells)) (SBAR (WHNP (WDT which)) (S (VP (VB mediate) (NP (NP (NP (DT a) (JJ Doc_2422478_1366_1376_Chemical-induced) (NNP Doc_2422478_1385_1396_Disease)) (PP (IN via) (NP (VBG descending) (NNS projections)))) (, ,) (NP (NP (DT the) (JJ midline) (NN serotonin)) (SBAR (S (NP (NP (NNP B3) (NNS cells)) (PP (IN in) (NP (DT the) (NN medulla)))) (VP (VBP contribute) (PP (TO to) (NP (NP (DT the) (NNP Doc_2422478_1489_1500_Disease) (NN action)) (PP (IN of) (NP (NNP Doc_2422478_1511_1521_Chemical))))))))))))))) (, ,) (CC either) (PP (IN by) (NP (NP (NN way)) (PP (IN of) (NP (NP (DT an) (VBG ascending) (NN projection)) (SBAR (WHNP (WDT which)) (S (VP (AUX does) (RB not) (VP (VB pass) (PP (IN through) (NP (DT the) (JJ median) (NN forebrain) (NN bundle))))))))))) (, ,) (CC or) (PP (IN through) (NP (NP (DT a) (NN projection)) (VP (VBN restricted) (PP (TO to) (NP (DT the) (JJ caudal) (NN brainstem)))))))))) (. .)))
2435991	0	(S1 (S (NP (NP (JJ Antiarrhythmic) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NNP Doc_2435991_40_51_Chemical))) (PP (IN on) (NP (NN canine)))) (VP (VBP Doc_2435991_62_85_Disease)) (. .)))
2435991	1	(S1 (S (S (S (VP (VBG Using) (NP (NP (JJ two-stage) (JJ coronary) (NN ligation-)) (, ,) (NP (NN Doc_2435991_123_132_Chemical-)) (, ,) (CC and) (NP (JJ Doc_2435991_139_149_Chemical-induced) (NN canine) (NN Doc_2435991_165_188_Disease))))) (, ,) (NP (NP (JJ antiarrhythmic) (NNS effects)) (PP (IN of) (NP (NNP Doc_2435991_216_227_Chemical)))) (VP (AUX were) (VP (VBN examined)))) (CC and) (S (NP (NP (DT the) (JJ minimum) (JJ effective) (NN plasma) (NN concentration)) (PP (IN for) (NP (DT each) (NNP Doc_2435991_298_308_Disease) (NN model)))) (VP (AUX was) (VP (VBN determined)))) (. .)))
2435991	2	(S1 (S (S (NP (NNP Doc_2435991_331_342_Chemical)) (VP (VBD suppressed) (NP (PDT all) (DT the) (NN Doc_2435991_362_373_Disease)))) (, ,) (CC and) (S (NP (NP (DT the) (JJ minimum) (JJ effective) (NN plasma) (NNS concentrations)) (PP (IN for) (NP (NNP Doc_2435991_427_438_Disease))) (VP (VBN induced) (PP (IN by) (NP (NP (JJ 24-h) (JJ coronary) (NN ligation)) (, ,) (NP (JJ 48-h) (JJ coronary) (NN ligation)) (, ,) (NP (NNP Doc_2435991_498_507_Chemical)) (, ,) (CC and) (NP (NNP Doc_2435991_513_523_Chemical)))))) (VP (AUX were) (NP (NP (NP (QP (CD 1.9) (CD +/-)) (CD 0.9)) (PRN (-LRB- -LRB-) (PP (IN by) (NP (QP (CD 8) (CD mg/kg)) (NNS i.v.))) (-RRB- -RRB-))) (, ,) (NP (NP (CD 1.6) (NN +/-)) (NP (NP (CD 0.5)) (PRN (-LRB- -LRB-) (PP (IN by) (NP (QP (CD 8) (CD mg/kg)) (NNS i.v.))) (-RRB- -RRB-)))) (, ,) (NP (NP (CD 0.6) (NN +/-)) (NP (NP (CD 0.2)) (PRN (-LRB- -LRB-) (PP (IN by) (NP (QP (CD 2) (CD mg/kg)) (NNS i.v.))) (-RRB- -RRB-)))) (, ,) (CC and) (NP (NP (NP (CD 3.5) (NN +/-)) (NP (NP (NP (CD 1.3)) (PRN (-LRB- -LRB-) (PP (IN by) (NP (QP (CD 5) (CD mg/kg)) (NNS i.v.))) (-RRB- -RRB-))) (NP (NN micrograms/ml)) (, ,) (ADVP (RB respectively)))) (PRN (-LRB- -LRB-) (NP (JJ mean) (JJ +/-) (NNS SDM)) (, ,) (NP (NNP n) (SYM =) (JJ 6-7)) (-RRB- -RRB-)))))) (. .)))
2435991	3	(S1 (S (NP (NP (DT The) (NN concentration)) (PP (IN for) (NP (NNP Doc_2435991_731_741_Chemical-induced) (NNP Doc_2435991_750_760_Disease)))) (VP (AUX was) (ADJP (ADJP (RB significantly) (JJR higher)) (PP (IN than) (NP (NP (DT those)) (PP (IN for) (NP (NP (DT the) (JJ other) (NNS types)) (PP (IN of) (NP (NNP Doc_2435991_820_831_Disease))))))))) (. .)))
2435991	4	(S1 (S (S (NP (DT This) (JJ pharmacological) (NN profile)) (VP (AUX is) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT those)) (PP (IN of) (NP (NP (NNP Doc_2435991_885_895_Chemical)) (CC and) (NP (NNP Doc_2435991_900_909_Chemical))))))))) (, ,) (CC and) (S (NP (DT all) (CD three) (NNS drugs)) (VP (AUX have) (NP (ADJP (JJ central) (JJ nervous)) (NN system) (PRN (-LRB- -LRB-) (NP (NNP CNS)) (-RRB- -RRB-)) (NN stimulant) (NN action)))) (. .)))
2435991	5	(S1 (S (SBAR (IN Because) (S (NP (NNP Doc_2435991_991_1002_Chemical)) (VP (VP (AUX had) (NP (NP (JJ only) (JJ weak) (NN Doc_2435991_1017_1028_Disease)) (CC and) (NP (JJ sinus) (JJ node) (NNP Doc_2435991_1044_1054_Disease) (NNS effects)))) (CC and) (VP (AUX was) (VP (VBN found) (S (VP (TO to) (VP (AUX be) (ADJP (RB orally) (JJ active)) (SBAR (WHADVP (WRB when)) (S (VP (VBN given) (PP (TO to) (NP (JJ coronary) (JJ ligation) (NNP Doc_2435991_1129_1139_Disease) (NNS dogs)))))))))))))) (, ,) (NP (PRP$ its) (JJ clinical) (NN usefulness)) (VP (AUX is) (VP (VBN expected))) (. .)))
2466960	0	(S1 (NP (NP (NP (JJ Continuous) (JJ ambulatory) (NNS ECG)) (VP (VBG monitoring) (PP (IN during) (NP (JJ Doc_2466960_44_56_Chemical) (NN therapy))))) (: :) (NP (DT a) (JJ prospective) (NN study)) (. .)))
2466960	1	(S1 (S (SBAR (IN Although) (S (NP (EX there)) (VP (AUX have) (VP (AUX been) (NP (NP (JJ anecdotal) (NNS reports)) (PP (IN of) (NP (NNP Doc_2466960_133_149_Disease))) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_2466960_166_178_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_2466960_180_184_Chemical)) (-RRB- -RRB-)) (NN therapy))))))))) (, ,) (NP (DT this) (NN phenomenon)) (VP (AUX has) (RB not) (VP (AUX been) (VP (VBN studied) (PP (IN in) (NP (DT a) (JJ systematic) (NN fashion)))))) (. .)))
2466960	2	(S1 (S (NP (PRP We)) (ADVP (RB prospectively)) (VP (VBD performed) (NP (JJ continuous) (JJ ambulatory) (NN ECG) (NN monitoring)) (PP (IN on) (NP (NP (CD 25) (NNS patients)) (VP (VBG undergoing) (NP (JJ Doc_2466960_347_351_Chemical) (NN infusion)) (PP (IN for) (NP (NP (NN treatment)) (PP (IN of) (NP (JJ solid) (NNP Doc_2466960_384_390_Disease)))))))) (SBAR (IN in) (NN order) (S (VP (TO to) (VP (VB assess) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NNP Doc_2466960_427_435_Disease) (NNP ST) (NNS changes))))))))) (. .)))
2466960	3	(S1 (S (NP (NNS Patients)) (VP (AUX were) (VP (VBN monitored) (PP (IN for) (NP (NP (NP (CD 23) (JJ +/-) (CD 4) (NNS hours)) (PP (IN before) (NP (JJ Doc_2466960_498_502_Chemical) (NN infusion)))) (, ,) (CC and) (NP (NP (CD 98) (JJ +/-) (CD 9) (NNS hours)) (PP (IN during) (NP (JJ Doc_2466960_539_543_Chemical) (NN infusion)))))))) (. .)))
2466960	4	(S1 (S (S (NP (JJ Anginal) (NNS episodes)) (VP (AUX were) (ADJP (JJ rare)))) (: :) (S (NP (QP (RB only) (CD one)) (NN patient)) (VP (AUX had) (NP (NP (NN Doc_2466960_603_609_Disease)) (PRN (-LRB- -LRB-) (PP (IN during) (NP (JJ Doc_2466960_618_622_Chemical) (NN infusion))) (-RRB- -RRB-))))) (. .)))
2466960	5	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (JJ asymptomatic) (NNP ST) (NNS changes)) (PRN (-LRB- -LRB-) (ADVP (JJR greater) (IN than) (CC or) (JJ equal) (PP (TO to) (NP (CD 1) (JJ mm) (NNP ST) (NN deviation)))) (-RRB- -RRB-))) (VP (AUX were) (ADJP (JJ common)) (PRN (: :) (NP (NP (NP (CD six)) (PP (IN of) (NP (NP (CD 25) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 24) (NN %)) (-RRB- -RRB-)))) (VP (AUX had) (NP (NNP ST) (NNS changes)) (SBAR (IN before) (S (NP (JJ Doc_2466960_772_776_Chemical) (NN infusion)) (VP (VBD v) (NP (NP (CD 17)) (PRN (-LRB- -LRB-) (NP (CD 68) (NN %)) (-RRB- -RRB-))) (PP (IN during) (NP (JJ Doc_2466960_804_808_Chemical) (NN infusion)))))))) (-LRB- -LRB-) (NP (CD P) (JJR less)) (PP (IN than) (NP (CD .002)))) (-RRB- -RRB-))) (. .)))
2466960	6	(S1 (S (S (NP (NP (DT The) (NN incidence)) (PP (IN of) (NP (NP (NNP Doc_2466960_855_863_Disease) (NNS episodes)) (PP (IN per) (NP (NN patient))) (PP (IN per) (NP (NN hour)))))) (VP (AUX was) (NP (NP (NP (CD 0.05) (NN +/-)) (NP (CD 0.02))) (VP (ADVP (RB prior) (PP (TO to) (NP (JJ Doc_2466960_921_925_Chemical) (NN infusion)))) (VBG v) (NP (NP (NP (CD 0.13) (NN +/-)) (NP (NP (CD 0.03)) (PP (IN during) (NP (JJ Doc_2466960_958_962_Chemical) (NN infusion))))) (PRN (-LRB- -LRB-) (NP (NNP P) (QP (JJR less) (IN than) (CD .001))) (-RRB- -RRB-))))))) (: ;) (S (NP (NP (DT the) (NN duration)) (PP (IN of) (NP (JJ ECG) (NNS changes)))) (VP (AUX was) (NP (NP (NP (CD 0.6) (NN +/-)) (NP (CD 0.3) (NNS minutes))) (PP (IN per) (NP (NN patient)))) (PP (IN per) (NP (NN hour))) (SBAR (IN before) (S (NP (NNP Doc_2466960_1072_1076_Chemical)) (VP (VBD v) (NP (NP (CD 1.9) (JJ +/-) (CD 0.5) (NNS minutes)) (PP (IN per) (NP (NN patient))) (PP (IN per) (NP (NN hour)))) (PP (IN during) (NP (NP (NNP Doc_2466960_1127_1131_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP P) (QP (JJR less) (IN than) (CD .01))) (-RRB- -RRB-))))))))) (. .)))
2466960	7	(S1 (S (NP (JJ ECG) (NNS changes)) (VP (AUX were) (ADJP (RBR more) (JJ common)) (PP (IN among) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ known) (NNP Doc_2466960_1206_1229_Disease)))))) (. .)))
2466960	8	(S1 (S (NP (EX There)) (VP (AUX were) (NP (NP (CD two) (NNS cases)) (PP (IN of) (NP (NNP Doc_2466960_1255_1267_Disease))) (, ,) (SBAR (WHNP (DT both) (WHPP (IN of) (WHNP (WDT which)))) (S (VP (VBD occurred) (PP (IN at) (NP (NP (DT the) (NN end)) (PP (IN of) (NP (DT the) (JJ chemotherapy) (NN course)))))))))) (. .)))
2466960	9	(S1 (S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (S (NP (JJ Doc_2466960_1348_1352_Chemical) (NN infusion)) (VP (AUX is) (VP (VBN associated) (PP (IN with) (NP (NP (DT a) (JJ significant) (NN increase)) (PP (IN in) (NP (NP (JJ silent) (NNP ST) (NN segment) (NN deviation) (NN suggestive)) (PP (IN of) (NP (NNP Doc_2466960_1449_1457_Disease))))) (, ,) (PP (ADVP (RB particularly)) (IN among) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_2466960_1492_1515_Disease)))))))))))) (. .)))
2466960	10	(S1 (S (NP (NP (NP (DT The) (NN mechanism)) (CC and) (NP (JJ clinical) (NN significance))) (PP (IN of) (NP (DT these) (JJ ECG) (NNS changes)))) (VP (VBP remain) (S (VP (TO to) (VP (AUX be) (VP (VBN determined)))))) (. .)))
2528969	0	(S1 (NP (NP (NP (NP (NN Nature)) (, ,) (NP (NN time) (NN course)) (CC and) (NP (NN dose) (NN dependence))) (PP (IN of) (NP (JJ Doc_2528969_43_53_Chemical-related) (NN side) (NNS effects)))) (: :) (NP (NP (NNS results)) (PP (IN from) (NP (DT the) (NNP Multicenter) (NNP Canadian) (NNP Doc_2528969_114_128_Chemical) (NN Trial)))) (. .)))
2528969	1	(S1 (S (S (VP (TO To) (VP (VB characterize) (NP (NP (NP (DT the) (NN nature)) (, ,) (NP (NN time) (NN course)) (CC and) (NP (NN dose) (NN dependency))) (PP (IN of) (NP (JJ Doc_2528969_199_209_Chemical-related) (NN side) (NNS effects))))))) (, ,) (NP (PRP we)) (VP (VBD undertook) (NP (DT a) (JJ multicenter) (, ,) (JJ prospective) (, ,) (JJ dose-range) (NN finding) (NN study))) (. .)))
2528969	2	(S1 (S (NP (PRP$ Our) (NN study) (NN group)) (VP (VBD consisted) (PP (IN of) (NP (NP (CD 74) (JJ HIV-positive) (JJ homosexual) (NNS men)) (VP (VBG belonging) (PP (TO to) (NP (NP (NNS groups)) (NP (NP (NNP II) (NNP B)) (, ,) (NP (NNP III)) (CC and) (NP (NNP IV) (NNP C2))) (PP (IN from) (NP (NP (DT the) (NNPS Centers)) (PP (IN for) (NP (NP (NP (NP (NNP Disease) (NNP Control)) (PRN (-LRB- -LRB-) (NP (NNP CDC)) (-RRB- -RRB-))) (NN classification)) (PP (IN of) (NP (NNP Doc_2528969_460_471_Disease))))))))))))) (. .)))
2528969	3	(S1 (S (PP (VBG Following) (NP (DT a) (JJ 3-week) (NN observation) (NN period))) (, ,) (NP (NNS volunteers)) (VP (AUX were) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_2528969_541_551_Chemical) (CD 600) (NN mg/day))) (PP (IN for) (NP (NP (CD 18) (NNS weeks)) (, ,) (NP (NP (NP (CD 900) (NN mg/day)) (PP (IN for) (NP (CD 9) (NNS weeks)))) (CC and) (NP (NP (CD 1200) (NN mg/day)) (PP (IN for) (NP (CD 9) (NNS weeks))))) (, ,) (VP (VBN followed) (PP (IN by) (NP (NP (DT a) (JJ washout) (NN period)) (PP (IN of) (NP (CD 6) (NNS weeks))) (SBAR (WHPP (IN after) (WHNP (WDT which))) (S (NP (PRP they)) (VP (AUX were) (VP (VBN re-started) (PP (IN on) (NP (NP (CD 1200) (NN mg/day)) (CC or) (NP (NP (DT the) (JJS highest) (JJ tolerated) (NN dose)) (PP (IN at) (NP (JJ 8-hourly) (NNS intervals))))))))))))))))) (. .)))
2528969	4	(S1 (S (NP (NNS Subjects)) (VP (AUX were) (ADVP (RB randomly)) (VP (VBN assigned) (PP (TO to) (NP (ADJP (JJ 4-hourly) (CC or) (JJ 8-hourly)) (NNS regimens))) (PP (IN within) (NP (NNP CDC) (NNS groups))) (SBAR (IN while) (S (VP (VBG taking) (NP (QP (CD 600) (CC and) (CD 1200)) (NN mg/day))))))) (. .)))
2528969	5	(S1 (S (NP (JJ Clinical) (CC and) (NN laboratory) (NNS evaluations)) (VP (AUX were) (VP (VBN performed) (PP (IN at) (NP (JJ 3-week) (NNS intervals))))) (. .)))
2528969	6	(S1 (S (NP (JJ Symptomatic) (JJ adverse) (NNS effects)) (VP (AUX were) (ADJP (JJ present) (PP (IN in) (NP (NP (CD 96) (NN %)) (PP (IN of) (NP (NP (NNS subjects)) (, ,) (ADVP (RBS most) (RB commonly)) (NP (NP (NP (NNP Doc_2528969_1034_1040_Disease)) (PRN (-LRB- -LRB-) (NP (CD 64) (NN %)) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Doc_2528969_1048_1055_Disease)) (PRN (-LRB- -LRB-) (NP (CD 55) (NN %)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_2528969_1066_1074_Disease)) (PRN (-LRB- -LRB-) (NP (CD 49) (NN %)) (-RRB- -RRB-)))))))))) (. .)))
2528969	7	(S1 (S (NP (DT These)) (VP (AUX were) (ADVP (RB generally)) (ADJP (JJ self-limited)) (, ,) (S (VP (VBG reappearing) (ADVP (RB briefly)) (PP (IN at) (NP (DT each) (NN dose) (NN increment)))))) (. .)))
2528969	8	(S1 (S (NP (NP (DT A) (NN decrease)) (PP (IN in) (NP (NN hemoglobin)))) (VP (VBD occurred) (ADVP (RB shortly)) (PP (IN after) (NP (NP (NN initiation)) (PP (IN of) (NP (NN therapy)))))) (. .)))
2528969	9	(S1 (S (NP (DT This)) (VP (VP (AUX was) (RB not) (ADJP (NN dose) (JJ dependent))) (CC and) (VP (VBD reversed) (ADVP (RB rapidly)) (PP (IN upon) (NP (NP (NN discontinuation)) (PP (IN of) (NP (NN treatment))))))) (. .)))
2528969	10	(S1 (S (NP (NP (DT A) (JJ red) (NN blood) (NN cell) (NN count) (NN decrease)) (, ,) (NP (DT a) (JJ mean) (NN cell) (NN volume) (NN increase)) (CC and) (NP (DT a) (JJ granulocyte) (NN count) (NN decrease))) (VP (VBD developed) (ADVP (RB early)) (PP (IN in) (NP (DT a) (JJ dose-independent) (NN fashion))) (, ,) (S (VP (VBG reverting) (ADVP (ADVP (IN at) (JJS least)) (RB partially)) (PP (IN during) (NP (DT the) (JJ washout) (NN phase)))))) (. .)))
2528969	11	(S1 (S (NP (NP (DT The) (NN decrease)) (PP (IN in) (NP (JJ reticulocyte) (NN count)))) (VP (AUX was) (ADJP (NN dose) (VBN related)) (NP (QP (IN between) (CD 600) (CC and) (CD 900)) (NN mg/day)) (PP (IN with) (NP (NP (DT no) (JJ further) (NN change)) (SBAR (WHADVP (WRB when)) (S (NP (DT the) (NN dose)) (VP (AUX was) (VP (VBN escalated) (PP (TO to) (NP (CD 1200) (NN mg/day)))))))))) (. .)))
2528969	12	(S1 (S (NP (NN Bone) (NN marrow) (NNS changes)) (VP (VBD occurred) (ADVP (RB rapidly)) (SBAR (IN as) (S (VP (VBN demonstrated) (PP (IN by) (NP (NN megaloblastosis))) (PP (IN in) (NP (NP (CD 95) (NN %)) (PP (IN of) (NP (CD 65) (NNS specimens))))) (PP (IN at) (NP (NP (NN week) (NNS 18.)) (PRN (-LRB- -LRB-) (NP (NP (JJ ABSTRACT)) (VP (VBN TRUNCATED) (PP (IN AT) (NP (CD 250) (NNS WORDS))))) (-RRB- -RRB-))))))))))
2533791	0	(S1 (NP (NP (JJ National) (NN project)) (PP (IN on) (NP (NP (DT the) (NN prevention)) (PP (IN of) (NP (NP (JJ mother-to-infant) (NNP Doc_2533791_55_85_Disease)) (PP (IN in) (NP (NNP Japan))))))) (. .)))
2533791	1	(S1 (S (PP (IN In) (NP (NNP Japan))) (, ,) (NP (NP (DT a) (JJ nationwide) (NN prevention) (NN program)) (PP (IN against) (NP (NP (JJ mother-to-infant) (NNP Doc_2533791_163_193_Disease)) (PRN (-LRB- -LRB-) (NP (NNP HBV)) (-RRB- -RRB-))))) (VP (VBD started) (PP (IN in) (NP (CD 1985)))) (. .)))
2533791	2	(S1 (S (NP (DT This) (NN program)) (VP (VBZ consists) (PP (IN of) (NP (NP (JJ double) (NNS screenings)) (PP (IN of) (NP (NP (JJ pregnant) (NNS women)) (CC and) (NP (JJ prophylactic) (NN treatment)))) (PP (TO to) (NP (NP (DT the) (NNS infants)) (VP (VBN born) (PP (TO to) (NP (NP (NP (NP (DT both) (NNP Doc_2533791_333_360_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP HBsAg)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_2533791_373_394_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2533791_396_401_Chemical)) (-RRB- -RRB-)))) (JJ positive) (NNS mothers))))))))) (. .)))
2533791	3	(S1 (S (NP (DT These) (NNS infants)) (VP (AUX are) (VP (VBN treated) (PP (IN with) (NP (NP (NP (CD two) (NNS injections)) (PP (IN of) (NP (NP (JJ Doc_2533791_470_481_Disease) (JJ immune) (NN globulin)) (PRN (-LRB- -LRB-) (NP (NNP HBIG)) (-RRB- -RRB-))))) (CC and) (NP (NP (QP (IN at) (JJS least) (CD three)) (NNS injections)) (PP (IN of) (NP (NN plasma) (VBN derived) (NNP Doc_2533791_553_564_Disease) (NN vaccine)))))))) (. .)))
2533791	4	(S1 (S (S (NP (PRP We)) (VP (VBD sent) (NP (NP (NNS questionnaires)) (PP (IN about) (NP (NP (DT the) (NNS numbers)) (PP (IN of) (NP (DT each) (NN procedure) (CC or) (NN examination)))))) (PP (IN during) (NP (NP (CD nine) (NNS months)) (PP (IN of) (NP (NN investigation) (NN period))))) (PP (TO to) (NP (NP (NP (DT each) (JJ local) (NN government)) (PP (IN in) (NP (CD 1986)))) (CC and) (NP (NP (QP (CD 1987.) (CD 93.4)) (NN %)) (SBAR (S (NP (JJ pregnant) (NNS women)) (VP (AUX had) (NP (DT the) (NN chance) (S (VP (TO to) (VP (AUX be) (VP (VBN examined) (PP (IN for) (NP (NN HBsAg)))))))))))))))) (, ,) (CC and) (S (NP (DT the) (JJ positive) (NN rate)) (VP (AUX was) (NP (QP (CD 1.4) (TO to) (CD 1.5)) (NN %)))) (. .)))
2533791	5	(S1 (S (NP (NP (DT The) (JJ Doc_2533791_839_844_Chemical) (JJ positive) (NN rate)) (PP (IN in) (NP (NN HBsAg) (NN positive)))) (VP (AUX was) (NP (QP (CD 23) (TO to) (CD 26)) (NN %))) (. .)))
2533791	6	(S1 (S (NP (NP (DT The) (NNP HBsAg) (JJ positive) (NN rate)) (PP (PP (IN in) (NP (NNS neonates))) (CC and) (PP (IN in) (NP (NNS infants)))) (PP (IN before) (NP (CD two) (NNS months)))) (VP (AUX were) (ADVP (NP (NP (CD 3) (NN %)) (CC and) (NP (CD 2) (NN %))) (RB respectively))) (. .)))
2533791	7	(S1 (S (NP (DT Some) (NNS problems)) (VP (MD may) (VP (VB arise) (, ,) (SBAR (IN because) (S (NP (NP (QP (CD 27) (TO to) (CD 30)) (NN %)) (PP (IN of) (NP (NNS infants)))) (VP (AUX need) (NP (NP (DT the) (JJ fourth) (NN vaccination)) (PP (IN in) (NP (DT some) (VBN restricted) (NNS areas))))))))) (. .)))
2557556	0	(S1 (NP (NP (NN Involvement)) (PP (IN of) (NP (DT the) (JJ mu-opiate) (NN receptor))) (PP (IN in) (NP (JJ peripheral) (NNP Doc_2557556_52_61_Disease))) (. .)))
2557556	1	(S1 (S (NP (NP (DT The) (JJ intradermal) (NN injection)) (PP (IN of) (NP (NP (NP (NNS mu)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2557556_96_104_Chemical) (, ,) (NNP Doc_2557556_106_109_Chemical-Doc_2557556_110_134_Chemical) (CC and) (NNP Doc_2557556_139_151_Chemical)) (-RRB- -RRB-))) (, ,) (NP (NP (NN kappa)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2557556_161_236_Chemical)) (-RRB- -RRB-))) (CC and) (NP (JJ delta) (PRN (-LRB- -LRB-) (NP (NP (CD -LSB-D-Pen2.5) (JJ -RSB-) (NN -enkephalin)) (CC and) (NP (NNP Doc_2557556_275_303_Chemical))) (-RRB- -RRB-)) (JJ selective) (NNS opioid-agonists))))) (, ,) (PP (IN by) (NP (PRP themselves))) (, ,) (VP (AUX did) (ADVP (RB not) (RB significantly)) (VP (VB affect) (NP (NP (DT the) (JJ mechanical) (NN nociceptive) (NN threshold)) (PP (IN in) (NP (NP (DT the) (NN hindpaw)) (PP (IN of) (NP (DT the) (NN rat)))))))) (. .)))
2557556	2	(S1 (S (NP (NP (JJ Intradermal) (NN injection)) (PP (IN of) (NP (NP (NNS mu)) (, ,) (CONJP (CC but) (RB not)) (NP (NN delta) (CC or) (NN kappa) (NNS opioid-agonists))))) (, ,) (ADVP (RB however)) (, ,) (VP (VBD produced) (NP (NP (JJ dose-dependent) (NN inhibition)) (PP (IN of) (NP (NNP Doc_2557556_556_572_Chemical-induced) (NNP Doc_2557556_581_593_Disease))))) (. .)))
2557556	3	(S1 (S (NP (NP (DT The) (JJ analgesic) (NN effect)) (PP (IN of) (NP (DT the) (JJ mu-agonist) (NNP Doc_2557556_634_642_Chemical)))) (VP (AUX was) (ADVP (RB dose-dependently)) (VP (VP (VBN antagonized) (PP (IN by) (NP (NNP Doc_2557556_679_687_Chemical)))) (CC and) (VP (VBN prevented) (PP (IN by) (NP (NP (NN co-injection)) (PP (IN of) (NP (NN pertussis) (NN toxin)))))))) (. .)))
2557556	4	(S1 (S (NP (NNP Doc_2557556_738_746_Chemical)) (VP (AUX did) (RB not) (, ,) (ADVP (RB however)) (, ,) (VP (VB alter) (NP (NP (DT the) (NN Doc_2557556_775_787_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_2557556_799_837_Chemical))))))) (. .)))
2557556	5	(S1 (S (NP (PRP We)) (VP (VBP conclude) (SBAR (SBAR (IN that) (S (NP (NP (DT the) (JJ analgesic) (NN action)) (PP (IN of) (NP (NNS opioids))) (PP (IN on) (NP (NP (DT the) (JJ peripheral) (NNS terminals)) (PP (IN of) (NP (JJ primary) (NNS afferents)))))) (VP (AUX is) (PP (IN via) (NP (NP (DT a) (JJ binding) (NN site)) (PP (IN with) (NP (NP (NNS characteristics)) (PP (IN of) (NP (DT the) (JJ mu-opioid) (NN receptor)))))))))) (CC and) (SBAR (IN that) (S (NP (DT this) (NN action)) (VP (AUX is) (VP (VBN mediated) (PP (IN by) (NP (NP (NN inhibition)) (PP (IN of) (NP (DT the) (JJ Doc_2557556_1060_1090_Chemical) (JJ second) (NN messenger) (NN system))))))))))) (. .)))
2564649	0	(S1 (NP (NP (NN Involvement)) (PP (IN of) (NP (NP (JJ locus) (NN coeruleus)) (CC and) (NP (JJ noradrenergic) (NN neurotransmission)))) (PP (IN in) (NP (NP (NNP Doc_2564649_70_78_Chemical-induced) (NNP Doc_2564649_87_104_Disease)) (PP (IN in) (NP (DT the) (NN rat))))) (. .)))
2564649	1	(S1 (S (SBAR (IN Whereas) (S (NP (NNP Doc_2564649_125_142_Disease)) (VP (AUX is) (NP (NP (DT a) (JJ well-known) (NN side) (NN effect)) (SBAR (WHNP (WDT that)) (S (VP (AUX is) (VP (VBN associated) (PP (IN with) (NP (JJ high-dose) (JJ Doc_2564649_205_213_Chemical) (NNS anesthesia))))))))))) (, ,) (NP (NP (DT a) (NN paucity)) (PP (IN of) (NP (NN information)))) (VP (VBZ exists) (PP (IN with) (NP (NP (NN regard)) (PP (TO to) (NP (NP (PRP$ its) (JJ underlying) (NN mechanism)) (PRN (-LRB- -LRB-) (PRP s) (-RRB- -RRB-))))))) (. .)))
2564649	2	(S1 (S (NP (PRP We)) (VP (VBD investigated) (PP (IN in) (NP (DT this) (NN study))) (NP (NP (DT the) (JJ possible) (NN engagement)) (PP (IN of) (NP (NP (JJ locus) (NNS coeruleus)) (PP (IN of) (NP (NP (DT the) (NNP pons)) (PP (IN in) (NP (DT this) (NN phenomenon)))))))) (, ,) (S (VP (VBG using) (NP (NP (JJ male) (JJ Sprague-Dawley) (NNS rats)) (ADJP (JJ anesthetized) (PP (IN with) (NP (NNP Doc_2564649_456_464_Chemical)))))))) (. .)))
2564649	3	(S1 (S (PP (IN Under) (NP (NP (JJ proper) (NN control)) (PP (IN of) (NP (NP (NN respiration)) (, ,) (NP (NN body) (NN temperature)) (CC and) (NP (JJ end-tidal) (NNP Doc_2564649_534_537_Chemical)))))) (, ,) (NP (NP (JJ intravenous) (NN administration)) (PP (IN of) (NP (NNP Doc_2564649_569_577_Chemical))) (PRN (-LRB- -LRB-) (NP (QP (CD 50) (CC or) (CD 100)) (NNS micrograms/kg)) (-RRB- -RRB-))) (VP (ADVP (RB consistently)) (VBD promoted) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (JJ electromyographic) (NN activity))) (PP (VBN recorded) (PP (IN from) (NP (DT the) (JJ gastrocnemius) (CC and) (JJ abdominal) (JJ rectus) (NNS muscles)))))) (. .)))
2564649	4	(S1 (S (NP (NP (PDT Such) (DT an) (VBN induced) (NN Doc_2564649_746_763_Disease)) (PP (IN by) (NP (DT the) (JJ narcotic) (NN agent)))) (VP (AUX was) (VP (VP (ADVP (RB significantly)) (VBN antagonized)) (CC or) (VP (ADVP (RB even)) (VBN reduced) (PP (IN by) (NP (NP (JJ prior) (JJ electrolytic) (NNS lesions)) (PP (IN of) (NP (DT the) (JJ locus) (NN coeruleus) (CC or) (NN pretreatment))) (PP (IN with) (NP (NP (DT the) (NN alpha-adrenoceptor) (NN blocker)) (, ,) (NP (NNP Doc_2564649_938_946_Chemical))))))))) (. .)))
2564649	5	(S1 (S (NP (NP (NN Microinjection)) (PP (IN of) (NP (NP (NP (NNP Doc_2564649_966_974_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 2.5) (CD micrograms/50)) (NNP nl)) (-RRB- -RRB-))) (ADVP (RB directly) (PP (IN into) (NP (DT this) (JJ pontine) (NN nucleus))))))) (, ,) (PP (IN on) (NP (DT the) (JJ other) (NN hand))) (, ,) (VP (VBD elicited) (NP (JJ discernible) (JJ electromyographic) (NN excitation))) (. .)))
2564649	6	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (VBN speculated) (SBAR (IN that) (S (NP (NP (DT the) (NN induction)) (PP (IN of) (NP (NNP Doc_2564649_1143_1160_Disease))) (PP (IN by) (NP (NNP Doc_2564649_1164_1172_Chemical)))) (VP (MD may) (VP (VB involve) (NP (NP (DT the) (JJ coerulospinal) (NN noradrenergic) (NNS fibers)) (PP (TO to) (NP (DT the) (JJ spinal) (NNS motoneurons)))))))))) (. .)))
2569282	0	(S1 (S (NP (NP (NN Doc_2569282_0_15_Chemical)) (, ,) (VP (VBG acting) (PP (IN through) (NP (JJ central) (JJ alpha-2) (NNS adrenoceptors)))) (, ,)) (VP (VBZ prevents) (NP (JJ opiate-induced) (NN Doc_2569282_87_102_Disease)) (PP (IN in) (NP (DT the) (NN rat)))) (. .)))
2569282	1	(S1 (S (NP (NP (DT The) (JJ highly-selective) (JJ alpha-2) (JJ adrenergic) (NN agonist) (NNP Doc_2569282_163_178_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2569282_180_185_Chemical)) (-RRB- -RRB-))) (VP (AUX is) (ADJP (JJ capable) (PP (IN of) (S (VP (VBG inducing) (NP (NP (NP (NN Doc_2569282_210_227_Disease)) (CC and) (NP (NN anesthesia))) (PP (IN in) (NP (NNS rats) (CC and) (NNS dogs))))))))) (. .)))
2569282	2	(S1 (S (NP (JJ Intense) (JJ generalized) (NN Doc_2569282_281_296_Disease)) (VP (AUX is) (NP (NP (DT an) (JJ undesirable) (NN side) (NN effect)) (PP (IN of) (NP (JJ potent) (NN opiate) (NNS agonists))))) (. .)))
2569282	3	(S1 (S (SBAR (IN Although) (S (NP (NP (DT the) (NN neurochemistry)) (PP (IN of) (NP (JJ opiate-induced) (NNP Doc_2569282_400_408_Disease)))) (VP (AUX has) (ADVP (RB yet)) (S (VP (TO to) (VP (AUX be) (VP (ADVP (RB fully)) (VBN elucidated)))))))) (, ,) (NP (JJ recent) (NN work)) (VP (VBZ suggests) (NP (NP (DT a) (NN role)) (PP (IN for) (NP (DT a) (JJ central) (NN adrenergic) (NN mechanism))))) (. .)))
2569282	4	(S1 (S (PP (IN In) (NP (DT the) (JJ present) (NN study))) (, ,) (NP (DT the) (NNS authors)) (VP (VBD determined) (SBAR (IN if) (S (NP (NP (NN treatment)) (PP (IN with) (NP (NNP Doc_2569282_568_573_Chemical)))) (VP (VBZ prevents) (NP (NP (DT the) (NN Doc_2569282_587_602_Disease)) (VP (VBN caused) (PP (IN by) (NP (NP (JJ high-dose) (JJ Doc_2569282_623_633_Chemical) (NNS anesthesia)) (PP (IN in) (NP (DT the) (NN rat))))))))))) (. .)))
2569282	5	(S1 (S (S (NP (NP (NNS Animals)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 42)) (-RRB- -RRB-))) (VP (AUX were) (VP (VBN treated) (ADVP (RB intraperitoneally)) (PP (IN with) (NP (NP (NP (CD one)) (PP (IN of) (NP (DT the) (JJ following) (CD six) (NNS regimens)))) (: :) (NP (NP (LST (LS 1) (-RRB- -RRB-)) (NP (NNP L-MED)) (PRN (-LRB- -LRB-) (NP (NP (DT the) (JJ inactive) (NNP L-isomer)) (PP (IN of) (NP (NNP Doc_2569282_780_792_Chemical)))) (-RRB- -RRB-)) (, ,) (NP (CD 30) (NN micrograms/kg))) (: ;) (NP (LST (LS 2) (-RRB- -RRB-)) (NP (NNP D-MED)) (, ,) (NP (CD 10) (NN micrograms/kg))) (: ;) (NP (LST (LS 3) (-RRB- -RRB-)) (NP (NNP Doc_2569282_844_849_Chemical)) (, ,) (NP (CD 30) (NN micrograms/kg))) (: ;) (NP (LST (LS 4) (-RRB- -RRB-)) (NP (JJ Doc_2569282_872_877_Chemical) (JJ -LSB-30) (NN micrograms/kg) (NN -RSB-)) (CC and) (NP (NP (DT the) (JJ central-acting) (JJ alpha-2) (NN antagonist)) (, ,) (NP (JJ Doc_2569282_940_948_Chemical) (JJ -LSB-10) (JJ mg/kg) (NNS -RSB-)))))))))) (: ;) (S (NP (CD 5) (-RRB- -RRB-) (NNP Doc_2569282_964_969_Chemical) (CD -LSB-30)) (VP (VBD micrograms/kg) (NP (NP (NP (NN -RSB-)) (CC and) (NP (DT the) (JJ peripheral-acting) (JJ alpha-2) (NN antagonist) (NNP Doc_2569282_1034_1041_Chemical) (JJ -LSB-10) (NN mg/kg) (NN -RSB-))) (, ,) (CC or) (PRN (: ;) (CD 6) (-RRB- -RRB-)) (NP (NN saline))))) (. .)))
2569282	6	(S1 (S (NP (JJ Baseline) (NN electromyographic) (NN activity)) (VP (AUX was) (VP (VBN recorded) (PP (IN from) (NP (DT the) (JJ gastrocnemius) (NN muscle))) (PP (IN before) (CC and) (IN after) (NP (NN drug) (NN treatment))))) (. .)))
2569282	7	(S1 (S (NP (DT Each) (NN rat)) (VP (AUX was) (ADVP (RB then)) (VP (VBN injected) (PP (IN with) (NP (NP (NNP Doc_2569282_1213_1223_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (NNP Doc_2569282_1225_1228_Chemical)) (, ,) (NP (CD 0.5) (NN mg/kg) (NN sc))) (-RRB- -RRB-)))))) (. .)))
2569282	8	(S1 (S (NP (JJ Doc_2569282_1245_1248_Chemical) (NN injection)) (VP (VBD resulted) (PP (IN in) (NP (NP (DT a) (JJ marked) (NN increase)) (PP (IN in) (NP (NP (JJ hindlimb) (NN EMG) (NN activity)) (PP (IN in) (NP (NP (DT the) (JJ L-MED) (NN treatment) (NN group)) (SBAR (WHNP (WDT which)) (S (VP (AUX was) (ADJP (JJ indistinguishable) (PP (IN from) (NP (NP (DT that)) (VP (VBN seen) (PP (IN in) (NP (NP (NNS animals)) (VP (VBN treated) (PP (IN with) (NP (NN saline)))))))))))))))))))) (. .)))
2569282	9	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NNP Doc_2569282_1431_1436_Chemical)) (VP (VBD prevented) (NP (JJ Doc_2569282_1447_1457_Chemical-induced) (NNP Doc_2569282_1466_1481_Disease)) (PP (IN in) (NP (DT a) (JJ dose-dependent) (NN fashion)))) (. .)))
2569282	10	(S1 (S (NP (NP (DT The) (JJ small) (NN EMG) (NNS values)) (VP (VBN obtained) (PP (IN in) (NP (DT the) (JJ high-dose) (JJ Doc_2569282_1558_1563_Chemical) (NN group))))) (VP (AUX were) (ADJP (JJ comparable) (PP (IN with) (NP (NP (DT those)) (VP (VBN recorded) (PP (IN in) (NP (NP (JJR earlier) (NNS studies)) (PP (IN from) (NP (NP (NN control) (NNS animals)) (SBAR (S (RB not) (VP (VBN given) (NP (DT any) (NN opiate)))))))))))))) (. .)))
2569282	11	(S1 (S (NP (DT The) (JJ high-dose) (JJ Doc_2569282_1682_1687_Chemical) (NNS animals)) (VP (AUX were) (UCP (ADJP (JJ flaccid)) (, ,) (ADJP (JJ Doc_2569282_1710_1718_Disease)) (, ,) (CC and) (VP (VBD lacked) (NP (DT a) (JJ Doc_2569282_1733_1740_Disease) (NN response)) (PP (IN during) (NP (NP (DT the) (JJ entire) (JJ experimental) (NN period.)) (PRN (-LRB- -LRB-) (NP (NP (JJ ABSTRACT)) (VP (VBN TRUNCATED) (PP (IN AT) (NP (CD 250) (NNS WORDS))))) (-RRB- -RRB-)))))))))
2576810	0	(S1 (NP (NP (DT Some) (JJ central) (NNS effects)) (PP (IN of) (NP (VBN repeated) (NN treatment))) (PP (IN with) (NP (NNP Doc_2576810_48_59_Chemical))) (. .)))
2576810	1	(S1 (S (NP (PRP We)) (VP (VBD investigated) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (JJ repeated) (NN treatment)) (PP (IN with) (NP (NP (NNP Doc_2576810_115_126_Chemical)) (, ,) (NP (DT a) (JJ selective) (JJ Doc_2576810_140_149_Chemical) (NN uptake) (NN inhibitor)) (, ,))))) (PP (PP (IN on) (NP (NP (JJ behavioral) (NNS effects)) (PP (IN of) (NP (NNS dopaminomimetics) (CC and) (NNP Doc_2576810_214_225_Chemical))))) (CC and) (PP (IN on) (NP (NP (DT the) (NN animal) (NN behavior)) (PP (IN in) (NP (DT the) (`` ``) (JJ behavioral) (NN despair) ('' '') (NN test)))))))) (. .)))
2576810	2	(S1 (S (NP (NP (DT A) (VBN repeated) (NN treatment)) (PP (IN with) (NP (NP (NNP Doc_2576810_313_324_Chemical)) (PRN (-LRB- -LRB-) (ADJP (RB twice) (JJ daily) (PP (IN for) (NP (CD 14) (NNS days)))) (-RRB- -RRB-))))) (VP (VBD potentiated) (PP (PP (IN in) (NP (NNS mice))) (CC and) (PP (IN in) (NP (NNS rats))) (PRN (-LRB- -LRB-) (JJR weaker) (-RRB- -RRB-))) (NP (DT the) (JJ Doc_2576810_396_407_Chemical-induced) (NNP Doc_2576810_416_429_Disease))) (. .)))
2576810	3	(S1 (S (NP (NP (DT The) (NNP Doc_2576810_435_448_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_2576810_460_471_Chemical))) (PP (IN in) (NP (NNS mice))))) (VP (VBD remained) (ADJP (JJ unaffected)) (PP (IN by) (NP (NNP Doc_2576810_503_514_Chemical)))) (. .)))
2576810	4	(S1 (S (NP (NP (DT The) (NN stimulation)) (PP (IN of) (NP (NN locomotor) (NN activity))) (PP (IN by) (NP (ADJP (RB intracerebroventricularly) (VBN administered)) (NNP Doc_2576810_596_607_Chemical)))) (VP (AUX was) (RB not) (VP (VBN affected) (PP (IN by) (NP (NP (JJ repeated) (NN treatment)) (PP (IN with) (NP (NNP Doc_2576810_652_663_Chemical))))))) (. .)))
2576810	5	(S1 (S (S (VP (VBN Given) (NP (CD three) (NNS times)))) (NP (NNP Doc_2576810_683_694_Chemical)) (VP (AUX had) (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (DT the) (JJ immobilization) (NN time)) (PP (IN in) (NP (NP (DT the) (`` ``) (JJ behavioral) (NN despair) ('' '') (NN test)) (PP (IN in) (NP (NNS rats)))))))) (. .)))
2576810	6	(S1 (S (NP (DT The) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (NNP Doc_2576810_804_815_Chemical)) (VP (VBN given) (ADVP (RB repeatedly)))) (VP (VP (VBZ acts) (ADVP (RB differently)) (PP (IN than) (NP (NP (NNP Doc_2576810_855_865_Chemical)) (, ,) (NP (DT another) (JJ selective) (NNP Doc_2576810_885_894_Chemical) (NN uptake) (NN inhibitor)) (, ,)))) (CC and) (VP (VBZ differs) (ADVP (RB also)) (PP (IN from) (NP (JJ other) (NN antidepressant) (NNS drugs)))))))) (. .)))
2594614	0	(S1 (NP (NP (JJ Protective) (NN effect)) (PP (IN of) (NP (NP (DT a) (JJ specific) (JJ platelet-activating) (NN factor) (NN antagonist)) (, ,) (NP (NNP Doc_2594614_71_79_Chemical)) (, ,))) (PP (IN on) (NP (NP (NNP Doc_2594614_84_95_Chemical-induced) (NNP Doc_2594614_104_130_Disease)) (PP (IN in) (NP (NNS rats))))) (. .)))
2594614	1	(S1 (S (NP (NP (NN Administration)) (PP (IN of) (NP (NP (DT the) (JJ local) (JJ anaesthetic) (NNP Doc_2594614_180_191_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 1.5) (CC or) (CD 2)) (NN mg/kg)) (, ,) (NP (CD i.v.)) (-RRB- -RRB-)))) (PP (TO to) (NP (NNS rats)))) (VP (VBD elicited) (NP (NP (DT a) (JJ marked) (NN decrease)) (PP (IN of) (NP (NP (NP (JJ mean) (JJ arterial) (NN blood) (NN pressure)) (PRN (-LRB- -LRB-) (NP (NNP MBP)) (-RRB- -RRB-))) (CC and) (NP (NP (NN heart) (NN rate)) (PRN (-LRB- -LRB-) (NP (NNP HR)) (-RRB- -RRB-)))))) (PP (VBG leading) (PP (TO to) (NP (NP (NN death)) (PRN (-LRB- -LRB-) (PP (IN in) (NP (NP (CD 67) (NN %)) (CC or) (NP (NP (CD 90) (NN %)) (PP (IN of) (NP (NNS animals))))) (ADVP (RB respectively))) (-RRB- -RRB-)))))) (. .)))
2594614	2	(S1 (S (NP (NP (JJ Intravenous) (NN injection)) (PP (IN of) (NP (NP (NP (DT the) (JJ specific) (JJ platelet-activating) (NN factor) (PRN (-LRB- -LRB-) (NP (NNP PAF)) (-RRB- -RRB-)) (NN antagonist) (NNP Doc_2594614_448_456_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 10) (NN mg/kg)) (-RRB- -RRB-))) (, ,) (NP (NP (CD 30) (NN min)) (PP (IN before) (NP (NNP Doc_2594614_483_494_Chemical) (NN administration)))))) (PRN (-LRB- -LRB-) (NP (QP (CD 2) (CD mg/kg)) (NNS i.v.)) (-RRB- -RRB-))) (VP (VBD suppressed) (NP (PDT both) (DT the) (NNP Doc_2594614_545_567_Disease))) (. .)))
2594614	3	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NP (NNS doses)) (PP (IN of) (NP (CD 1) (NN mg/kg) (NNP Doc_2594614_599_607_Chemical)))) (VP (VBN given) (NP (CD 30) (NN min)) (SBAR (IN before) (S (NP (NP (QP (CC or) (CD 10)) (NNS mg/kg)) (VP (VBN administered) (NP (CD 5) (NN min)) (PP (IN before) (NP (NP (CD i.v.) (NN injection)) (PP (IN of) (NP (NNP Doc_2594614_684_695_Chemical))))))) (VP (AUX were) (ADJP (JJ ineffective)))))) (. .)))
2594614	4	(S1 (S (SBAR (WHADVP (WRB When)) (S (NP (NP (NNP Doc_2594614_719_727_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 20) (CD mg/kg)) (NN i.v.)) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN injected) (ADVP (RB immediately)) (PP (IN after) (NP (NP (NNP Doc_2594614_775_786_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 2) (NN mg/kg)) (-RRB- -RRB-)))))))) (, ,) (NP (NP (DT a) (JJ partial) (NN reversion)) (PP (IN of) (NP (DT the) (NNP Doc_2594614_825_847_Disease)))) (VP (AUX was) (ADJP (JJ observed)) (, ,) (SBAR (IN whereas) (S (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (CD 10) (NNS mg/kg)))) (VP (AUX was) (ADJP (JJ ineffective)))))) (. .)))
2594614	5	(S1 (S (NP (NP (DT A) (JJ partial) (NN recovery)) (PP (IN of) (NP (JJ Doc_2594614_930_941_Chemical-induced) (NN ECG) (NNS alterations)))) (VP (AUX was) (VP (VBN observed) (PP (IN after) (NP (NP (NN pretreatment)) (PP (IN of) (NP (NP (DT the) (NNS rats)) (PP (IN with) (NP (NNP Doc_2594614_1015_1023_Chemical))))))))) (. .)))
2594614	6	(S1 (S (SBAR (IN Since) (S (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NNP Doc_2594614_1053_1061_Chemical)))) (, ,) (PP (IN at) (NP (NP (DT all) (NNS doses)) (VP (VBN studied)))) (, ,) (VP (AUX did) (RB not) (VP (VB alter) (NP (NNS MBP) (CC and) (NNS HR)) (PP (IN at) (NP (NP (DT the) (NNS doses)) (VP (VBN used)))))))) (, ,) (NP (NP (DT the) (NN bulk)) (PP (IN of) (NP (DT these) (NNS results)))) (ADVP (RB clearly)) (VP (VBP demonstrate) (NP (NP (DT a) (JJ protective) (NN action)) (PP (IN of) (NP (NP (NNP Doc_2594614_1198_1206_Chemical)) (, ,) (NP (NP (DT a) (JJ specific) (NN antagonist)) (PP (IN of) (NP (NN PAF)))) (, ,))) (PP (IN against) (NP (NNP Doc_2594614_1246_1257_Chemical-induced) (NNP Doc_2594614_1266_1289_Disease))))) (. .)))
2594614	7	(S1 (S (ADVP (RB Thus)) (, ,) (NP (ADJP (JJ consistent) (PP (IN with) (NP (NP (PRP$ its) (JJ direct) (NN effect)) (PP (IN on) (NP (NN heart)))))) (, ,) (NN PAF)) (VP (VBZ appears) (S (VP (TO to) (VP (AUX be) (VP (VBN implicated) (PP (IN in) (NP (JJ Doc_2594614_1373_1384_Chemical-induced) (NN Doc_2594614_1393_1419_Disease)))))))) (. .)))
2598570	0	(S1 (NP (NP (DT The) (NN epidemiology)) (PP (IN of) (NP (DT the) (JJ acute) (JJ Doc_2598570_30_40_Disease) (NN syndrome))) (PP (IN from) (NP (NNP Doc_2598570_55_63_Chemical))) (. .)))
2598570	1	(S1 (S (NP (NP (NNP Doc_2598570_65_73_Chemical)) (, ,) (NP (DT a) (JJ new) (JJ nonsteroidal) (JJ anti-inflammatory) (NN drug)) (, ,)) (VP (AUX was) (VP (VBN marketed) (PP (IN in) (NP (JJ early) (CD 1986))) (PP (IN as) (NP (DT an) (JJ analgesic) (NN agent))))) (. .)))
2598570	2	(S1 (S (SBAR (IN Until) (S (NP (NNS physicians)) (VP (VBD began) (S (VP (VBG reporting) (NP (NP (DT an) (JJ unusual) (JJ acute) (NN Doc_2598570_218_228_Disease) (NN syndrome)) (PP (TO to) (NP (DT the) (JJ spontaneous) (NN reporting) (NN system))))))))) (, ,) (NP (CD 700,000) (NNS persons)) (VP (VBD used) (NP (DT the) (NN drug)) (PP (IN in) (NP (DT the) (NNP United) (NNPS States)))) (. .)))
2598570	3	(S1 (S (PP (IN Through) (NP (NNP August) (CD 1986))) (, ,) (NP (NP (DT a) (NN total)) (PP (IN of) (NP (NP (CD 163) (NNS cases)) (PP (IN of) (NP (DT this) (NN syndrome)))))) (VP (AUX were) (VP (VBN reported))) (. .)))
2598570	4	(S1 (S (S (VP (TO To) (VP (VB elucidate) (NP (NP (DT the) (NN epidemiology)) (PP (IN of) (NP (DT the) (NN syndrome))))))) (, ,) (NP (DT a) (JJ case-control) (NN study)) (VP (AUX was) (VP (VBN performed) (, ,) (S (VP (VBG comparing) (NP (NP (CD 62)) (PP (IN of) (NP (NP (DT the) (NN case) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX had) (VP (AUX been) (VP (VBN reported) (PP (TO to) (NP (NP (DT the) (JJ spontaneous) (NN reporting) (NN system)) (PP (TO to) (NP (NP (CD 185) (JJ Doc_2598570_583_591_Chemical-exposed) (NN control) (NNS subjects)) (SBAR (WHNP (WP who)) (S (VP (AUX did) (RB not) (VP (AUX have) (NP (DT the) (NN syndrome)))))))))))))))))))))) (. .)))
2598570	5	(S1 (S (NP (NN Case) (NNS patients)) (VP (AUX were) (ADJP (RBR more) (JJ likely) (S (VP (VP (TO to) (VP (AUX be) (NP (NP (NNS men)) (PRN (-LRB- -LRB-) (NP (NP (NNS odds) (NN ratio)) (, ,) (NP (CD 3.8))) (: ;) (NP (NP (ADJP (CD 95) (NN %)) (NN confidence) (NN interval)) (, ,) (NP (CD 1.2-12.1))) (-RRB- -RRB-))))) (, ,) (VP (VB suffer) (PP (IN from) (NP (NP (NNP Doc_2598570_755_764_Disease) (CC and) (NNP Doc_2598570_769_775_Disease)) (PRN (-LRB- -LRB-) (NP (NP (NNS odds) (NN ratio)) (, ,) (NP (CD 3.4))) (: ;) (NP (NP (ADJP (CD 95) (NN %)) (NN confidence) (NN interval)) (, ,) (NP (CD 1.0-11.9))) (-RRB- -RRB-))))) (: ;) (VP (TO to) (VP (VB participate) (PP (IN in) (NP (NP (JJ regular) (NN exercise)) (PRN (-LRB- -LRB-) (NP (NP (NNS odds) (NN ratio)) (, ,) (NP (NP (CD 5.9)) (: ;) (NP (ADJP (CD 95) (NN %)) (NN confidence) (NN interval)))) (, ,) (NP (CD 1.1-30.7)) (-RRB- -RRB-)))) (, ,) (PP (ADVP (RB especially)) (IN in) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NP (JJ Nautilus) (NN equipment)) (PRN (-LRB- -LRB-) (NP (NNP p) (SYM =) (CD 0.02)) (-RRB- -RRB-)))))))) (: ;) (CC and) (VP (TO to) (VP (VB use) (NP (NNP Doc_2598570_986_993_Chemical))))))) (PRN (-LRB- -LRB-) (NP (NP (NNS odds) (NN ratio)) (, ,) (NP (NP (CD 4.4)) (: ;) (NP (ADJP (CD 95) (NN %)) (NN confidence) (NN interval)))) (, ,) (NP (CD 1.1-17.5)) (-RRB- -RRB-))) (. .)))
2598570	6	(S1 (S (NP (JJ Possible) (NN risk) (NNS factors)) (VP (VBD included) (NP (NP (JJ young) (NN age)) (, ,) (NP (NP (JJ concurrent) (NN use)) (PP (IN of) (NP (NP (NP (JJ other) (JJ analgesic) (NNS agents)) (PRN (-LRB- -LRB-) (ADVP (RB especially)) (NP (NNP Doc_2598570_1143_1152_Chemical)) (-RRB- -RRB-))) (, ,) (NP (JJ preexisting) (NNP Doc_2598570_1167_1180_Disease))))) (, ,) (NP (NP (DT a) (NN history)) (PP (IN of) (NP (NNP Doc_2598570_1195_1208_Disease)))) (, ,) (NP (NP (DT a) (NN history)) (PP (IN of) (NP (NNP Doc_2598570_1223_1227_Disease)))) (, ,) (NP (NP (DT a) (JJ recent) (NN increase)) (PP (IN in) (NP (NN activity)))) (, ,) (NP (NP (DT a) (JJ recent) (NN increase)) (PP (IN in) (NP (NN sun) (NN exposure)))) (, ,) (CC and) (NP (NP (NN residence)) (PP (IN in) (NP (DT the) (NNP Sunbelt)))))) (. .)))
2598570	7	(S1 (S (NP (DT These)) (VP (AUX were) (NP (NP (NNS findings)) (SBAR (WHNP (WDT that)) (S (VP (VP (AUX were) (ADJP (JJ suggestive))) (CC but) (VP (AUX did) (RB not) (VP (VB reach) (NP (JJ conventional) (JJ statistical) (NN significance))))))))) (. .)))
2598570	8	(S1 (S (NP (DT These) (NNS findings)) (VP (AUX are) (ADJP (JJ consistent) (PP (IN with) (NP (NP (DT the) (JJ postulated) (NN mechanism)) (PP (IN for) (NP (NP (DT this) (JJ unusual) (NN syndrome)) (: :) (NP (NP (JJ acute) (NN diffuse) (NN crystallization)) (PP (IN of) (NP (NNP Doc_2598570_1543_1552_Chemical))) (PP (IN in) (NP (JJ renal) (NNS tubules)))))))))) (. .)))
2709684	0	(S1 (S (NP (JJ Doc_2709684_0_9_Chemical-induced) (NNP Doc_2709684_18_28_Disease)) (VP (AUX does) (RB not) (VP (VB prevent) (NP (NP (JJ Doc_2709684_46_56_Chemical) (NN nephrotoxicity)) (PP (IN in) (NP (NNS rats)))))) (. .)))
2709684	1	(S1 (S (SBAR (IN Because) (S (NP (NP (NNS rats)) (PP (IN with) (NP (NP (NNP Doc_2709684_99_113_Chemical-induced) (NNP Doc_2709684_122_139_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2709684_141_143_Disease)) (-RRB- -RRB-))))) (VP (AUX have) (NP (NP (DT a) (JJ high) (NN solute) (NN diuresis)) (PRN (-LRB- -LRB-) (NP (NP (NNP Doc_2709684_174_184_Disease)) (PP (IN of) (NP (QP (CD 10) (TO to) (CD 12)) (NN g/day)))) (-RRB- -RRB-)))))) (, ,) (NP (PRP we)) (VP (AUX have) (VP (VBN suggested) (SBAR (IN that) (S (NP (DT this)) (VP (MD may) (PP (IN in) (NP (NN part))) (VP (AUX be) (ADJP (JJ responsible) (PP (IN for) (NP (NP (PRP$ their) (NN resistance)) (PP (TO to) (NP (NP (JJ Doc_2709684_284_294_Chemical-induced) (NNP Doc_2709684_303_322_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2709684_324_327_Disease)) (-RRB- -RRB-))))))))))))) (. .)))
2709684	2	(S1 (S (NP (NP (DT The) (NN protection)) (PP (IN from) (NP (JJ Doc_2709684_350_360_Chemical) (NN nephrotoxicity)))) (VP (AUX was) (VP (VBN studied) (PP (IN in) (NP (NP (JJ non-Doc_2709684_395_403_Disease) (NNS rats)) (PP (IN with) (NP (NP (JJ chronic) (JJ solute) (NNS diuresis)) (VP (VBN induced) (PP (IN by) (NP (NP (NN blockage)) (PP (IN of) (NP (NP (JJ tubular) (JJ Doc_2709684_469_476_Chemical) (NN reabsorption)) (PP (IN with) (NP (NP (NNP Doc_2709684_495_504_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP P)) (-RRB- -RRB-))))))))))))))) (. .)))
2709684	3	(S1 (S (NP (NP (JJ Doc_2709684_510_512_Disease) (NNS rats)) (PP (IN with) (NP (NP (JJ mild) (NNP Doc_2709684_528_538_Disease)) (PRN (-LRB- -LRB-) (ADJP (JJ similar) (PP (IN in) (NP (NN degree))) (PP (TO to) (NP (NP (DT that)) (PP (IN of) (NP (DT the) (JJ P) (VBN treated) (NNS animals)))))) (-RRB- -RRB-))))) (VP (AUX were) (ADVP (RB also)) (VP (VBN studied))) (. .)))
2709684	4	(S1 (S (NP (JJ Unanesthetized) (NN adult) (NN female) (, ,) (JJ Sprague-Dawley) (NNS rats)) (VP (AUX were) (VP (VP (VBN divided) (PP (IN in) (NP (CD four) (NNS groups)))) (CC and) (VP (VBN studied) (PP (IN for) (NP (CD 15) (NNS days)))))) (. .)))
2709684	5	(S1 (S (NP (NP (NNP Group) (CD 1)) (PRN (-LRB- -LRB-) (NP (NNP P) (RB alone)) (-RRB- -RRB-))) (VP (VBD received) (NP (NP (NP (NNP Doc_2709684_740_741_Chemical)) (, ,) (NP (CD 360) (NN mg/day)) (, ,) (PP (IN for) (NP (CD 15) (NNS days)))) (: ;) (NP (NP (NNP Group) (NNP II)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2709684_778_779_Chemical) (NNP +) (NNP Doc_2709684_782_792_Chemical)) (-RRB- -RRB-))) (: ;) (NP (NP (NNP Group) (NNP III)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2709684_806_816_Chemical) (RB alone)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Group) (NNP IV)) (PRN (-LRB- -LRB-) (NP (JJ mild) (NNP Doc_2709684_843_845_Disease) (NNP +) (NNP Doc_2709684_848_858_Chemical)) (-RRB- -RRB-))))) (. .)))
2709684	6	(S1 (S (NP (NP (NP (JJ Nephrotoxic) (NNS doses)) (PRN (-LRB- -LRB-) (NP (QP (CD 40) (CD mg/kg)) (NN body) (NN wt/day)) (-RRB- -RRB-))) (PP (IN of) (NP (NNP Doc_2709684_905_915_Chemical)))) (VP (AUX were) (VP (VBN injected) (PP (IN during) (NP (NP (DT the) (JJ last) (CD nine) (NNS days)) (PP (IN of) (NP (NN study))))) (PP (TO to) (NP (NP (DT the) (NNS animals)) (PP (IN of) (NP (NP (NNS groups)) (VP (NNP II) (PP (TO to) (NP (NNP IV)))))))))) (. .)))
2709684	7	(S1 (S (PP (IN In) (NP (NNP Group) (NNP I))) (, ,) (NP (NNS P)) (VP (VP (VBN induced) (NP (NP (DT a) (ADJP (JJ moderate) (CC and) (JJ stable)) (NN Doc_2709684_1044_1054_Disease)) (PRN (-LRB- -LRB-) (NP (NP (CD 3.9) (NN +/-)) (NP (CD 0.1) (NN g/day))) (, ,) (FW SE) (-RRB- -RRB-)))) (, ,) (NP (CC and) (NP (NP (DT no) (ADJP (JJ functional) (CC or) (JJ morphologic)) (NN evidence)) (PP (IN of) (NP (NNP Doc_2709684_1125_1142_Disease))) (PRN (-LRB- -LRB-) (NP (JJ baseline) (NNP CCr) (CD 2.1) (NN +/-) (CD 0.1) (NN ml/min)) (, ,) (NP (JJ undetectable) (NN lysozymuria)) (-RRB- -RRB-))) (CC or) (NP (NP (NN damage)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2709684_1214_1230_Disease) (NN score) (NN -LSB-maximum) (CD 4) (NN -RSB-)) (, ,) (NP (CD zero)) (-RRB- -RRB-))))) (. .)))
2709684	8	(S1 (S (PP (IN In) (NP (NNP Group) (NNP II))) (, ,) (NP (NNP Doc_2709684_1270_1271_Chemical)) (VP (AUX did) (RB not) (VP (VB prevent) (NP (NP (NNP Doc_2709684_1288_1298_Chemical-Doc_2709684_1299_1302_Disease)) (PRN (-LRB- -LRB-) (NP (NP (NP (JJ maximal) (NN decrease)) (PP (IN in) (NP (NNP CCr)))) (PP (IN at) (NP (NN day))) (ADJP (CD 9.89) (NN %)) (, ,) (VP (VBG P) (NP (QP (JJR less) (IN than) (CD 0.001)))) (: ;) (NP (NP (JJ peak) (NN lysozymuria)) (, ,) (NP (NP (CD 1863) (NN +/-)) (NP (CD 321) (NN micrograms/day)))) (: ;) (CC and) (NP (JJ Doc_2709684_1412_1428_Disease) (NN score))) (, ,) (NP (QP (CD 3.9) (CD +/-)) (CD 0.1)) (-RRB- -RRB-))))) (. .)))
2709684	9	(S1 (S (NP (DT These) (NNS values)) (VP (AUX were) (RB not) (ADJP (JJ different) (PP (IN from) (NP (NP (NP (DT those)) (PP (IN of) (NP (NNP Group) (NNP III)))) (: :) (NP (NP (NP (JJ maximal) (NN decrease)) (PP (IN in) (NP (NNP CCr))) (NP (CD 73) (NN %)) (PRN (-LRB- -LRB-) (NP (NNP P) (QP (JJR less) (IN than) (CD 0.001))) (-RRB- -RRB-))) (: ;) (NP (NP (NN lysozymuria)) (, ,) (NP (NP (CD 2147) (NN +/-)) (NP (CD 701) (NN micrograms/day)))) (: ;) (NP (NP (JJ Doc_2709684_1598_1614_Disease) (NN score)) (, ,) (NP (QP (CD 3.8) (CD +/-)) (NNS 0.1.)) (PRN (-LRB- -LRB-) (NP (NP (JJ ABSTRACT)) (VP (VBN TRUNCATED) (PP (IN AT) (NP (CD 250) (NNS WORDS))))) (-RRB- -RRB-))))))))))
2716967	0	(S1 (NP (NP (NP (NN Doc_2716967_0_9_Disease)) (VP (VBN induced) (PP (IN by) (NP (NP (NNS combinations)) (PP (IN of) (NP (NNP Doc_2716967_37_45_Chemical) (CC and) (NNP Doc_2716967_50_58_Chemical))))))) (: :) (NP (NP (NP (NN potentiation)) (, ,) (NP (NN antagonism)) (, ,) (NP (NN tolerance)) (CC and) (NP (NN cross-tolerance))) (PP (IN in) (NP (DT the) (NN rat)))) (. .)))
2716967	1	(S1 (S (NP (JJ Previous) (NNS studies)) (VP (VBD demonstrated) (SBAR (IN that) (S (NP (DT both) (NNP Doc_2716967_168_176_Chemical) (CC and) (NNP Doc_2716967_181_189_Chemical)) (VP (VBN induced) (NP (NP (NNP Doc_2716967_198_207_Disease)) (CC and) (NP (NNP Doc_2716967_212_221_Disease))) (PP (IN in) (NP (DT the) (NN rat))))))) (. .)))
2716967	2	(S1 (S (S (NP (NP (NN Pre-treatment)) (PP (IN with) (NP (NNP Doc_2716967_253_261_Chemical)))) (VP (VBD produced) (NP (NN cross-tolerance)) (PP (TO to) (NP (NNP Doc_2716967_290_298_Chemical))) (, ,) (SBAR (IN whereas) (S (NP (NP (NN pretreatment)) (PP (IN with) (NP (NNP Doc_2716967_326_334_Chemical)))) (VP (VP (AUX did) (RB not) (VP (VB induce) (NP (NN cross-tolerance)) (PP (TO to) (NP (NNP Doc_2716967_369_377_Chemical))))) (CC but) (VP (ADVP (RB rather)) (VBD augmented) (NP (DT the) (JJ Doc_2716967_403_413_Disease) (NN response)))))))) (: ;) (S (NP (DT this) (NN augmentation)) (VP (AUX was) (VP (VBN attributed) (PP (TO to) (NP (NP (JJ residual) (NNP Doc_2716967_469_477_Chemical)) (PP (IN in) (NP (DT the) (NN brain)))))))) (. .)))
2716967	3	(S1 (S (NP (DT The) (JJ present) (NNS studies)) (VP (VBD explored) (NP (NP (DT the) (NN duration)) (PP (IN of) (NP (NP (DT the) (NN loss)) (PP (IN of) (S (VP (VBG righting) (NP (NP (JJ reflex)) (VP (VBN induced) (PP (IN by) (NP (NP (JJ sub-effective) (NNS doses)) (PP (IN of) (NP (NP (NNP Doc_2716967_599_607_Chemical)) (CC and) (NP (NNP Doc_2716967_612_620_Chemical))))))))))) (, ,) (VP (VBN administered) (ADVP (RB simultaneously))))))) (. .)))
2716967	4	(S1 (S (S (NP (EX There)) (VP (AUX was) (NP (NP (JJ mutual) (NN potentiation)) (PP (IN between) (NP (NP (JJ sub-effective) (NNS doses)) (PP (IN of) (NP (NP (NNP Doc_2716967_712_720_Chemical)) (CC and) (NP (NNP Doc_2716967_725_733_Chemical))))))))) (, ,) (CC but) (S (NP (NP (JJ sub-effective) (NNS doses)) (PP (IN of) (NP (NNP Doc_2716967_762_770_Chemical)))) (VP (ADVP (RB partly)) (VBN antagonized) (NP (NP (JJ fully-effective) (NNS doses)) (PP (IN of) (NP (NNP Doc_2716967_815_823_Chemical)))))) (. .)))
2716967	5	(S1 (S (NP (NP (NN Latency)) (PP (TO to) (NP (NP (DT the) (NN loss)) (PP (IN of) (NP (JJ righting) (JJ reflex) (, ,) (NN Doc_2716967_865_873_Disease) (CC and) (NN behavior))) (PP (IN on) (NP (NN recovery))))) (, ,)) (VP (VBD reflected) (NP (NP (DT the) (JJ relative) (NN predominance)) (PP (IN of) (NP (NP (NNP Doc_2716967_939_947_Chemical)) (CC or) (NP (NNP Doc_2716967_951_959_Chemical)))) (PP (IN in) (NP (DT each) (NN combination))))) (. .)))
2716967	6	(S1 (S (NP (NN Doc_2716967_981_989_Chemical)) (VP (VBD inhibited) (NP (DT the) (VBN induced) (NNP Doc_2716967_1012_1022_Disease) (NNS effects))) (. .)))
2716967	7	(S1 (S (NP (NP (DT The) (NN degree) (CC and) (NN time) (NN course)) (PP (IN of) (NP (NP (NN development)) (PP (IN of) (NP (NN tolerance))))) (PP (TO to) (NP (NP (JJ daily) (NN administration)) (PP (IN of) (NP (NP (JJ sub-effective) (NN dose) (NNS combinations)) (PP (IN of) (NP (NNP Doc_2716967_1149_1157_Chemical) (CC and) (NNP Doc_2716967_1162_1170_Chemical)))))))) (VP (AUX were) (ADJP (JJ similar))) (. .)))
2716967	8	(S1 (S (NP (NP (NNS Rats)) (, ,) (ADJP (JJ tolerant) (PP (TO to) (NP (JJ Doc_2716967_1203_1211_Chemical-dominant) (NNS combinations)))) (, ,)) (VP (AUX were) (ADJP (JJ cross-tolerant) (PP (TO to) (NP (DT both) (NNS drugs)))) (, ,) (SBAR (IN while) (S (NP (NP (DT those) (JJ tolerant)) (PP (TO to) (NP (JJ Doc_2716967_1294_1302_Chemical-dominant) (NNS combinations)))) (VP (VP (AUX were) (ADJP (JJ cross-tolerant) (PP (TO to) (NP (NNP Doc_2716967_1348_1356_Chemical))))) (CC but) (VP (VBD showed) (NP (CC either) (NP (DT no) (NN cross-tolerance)) (CC or) (NP (NP (DT an) (JJ augmented) (NN response)) (PP (TO to) (NP (NNP Doc_2716967_1422_1430_Chemical)))))))))) (. .)))
2716967	9	(S1 (S (SBAR (IN While) (S (NP (DT the) (JJ mutual) (NN potentiation) (, ,) (NN antagonism) (CC and) (NN tolerance)) (VP (VBP suggest) (NP (JJ common) (NNS mechanisms)) (PP (IN for) (NP (DT the) (VBN induced) (NNP Doc_2716967_1530_1539_Disease)))))) (, ,) (NP (NP (NP (NNS differences)) (PP (IN in) (NP (NN latency) (, ,) (NN Doc_2716967_1565_1573_Disease) (CC and) (NN behavior)))) (, ,) (NP (NP (NN asymmetry)) (PP (IN of) (NP (NN cross-tolerance)))) (CC and) (NP (NP (DT a) (JJ widely-different) (NN ID50)) (PP (IN for) (NP (NNP Doc_2716967_1649_1657_Chemical))))) (VP (MD would) (VP (VB argue) (PP (IN against) (NP (NP (DT an) (NN action)) (PP (IN at) (NP (DT a) (JJ single) (NN opioid) (NN site))))))) (. .)))
2722224	0	(S1 (NP (NP (NP (JJ Doc_2722224_0_14_Chemical-induced) (NN Doc_2722224_23_35_Disease)) (PP (IN in) (NP (NNS humans)))) (: :) (NP (NP (JJ pressor) (NN responsiveness)) (CC and) (NP (JJ sympathetic) (NN function))) (. .)))
2722224	1	(S1 (S (NP (JJ Oral) (NN Doc_2722224_101_115_Chemical)) (VP (VP (VBZ increases) (NP (NN blood) (NN pressure))) (CC and) (VP (VBZ enhances) (NP (NP (NN pressor) (NN responsiveness)) (PP (IN in) (NP (JJ normal) (JJ human) (NNS subjects)))))) (. .)))
2722224	2	(S1 (S (NP (PRP We)) (VP (VBD studied) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (CD 1) (NN week)) (PP (IN of) (NP (NP (JJ oral) (NNP Doc_2722224_244_258_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 200) (NN mg/day)) (-RRB- -RRB-)))))) (PP (IN on) (NP (NP (NN blood) (NN pressure)) (, ,) (NP (JJ cardiac) (NN output)) (, ,) (NP (JJ total) (JJ peripheral) (NN resistance)) (, ,) (NP (JJ forearm) (JJ vascular) (NN resistance)) (, ,) (CC and) (NP (JJ Doc_2722224_369_383_Chemical) (NN spillover))))) (PP (TO to) (NP (NN plasma))) (PP (IN in) (NP (CD eight) (JJ healthy) (NN male) (NNS volunteers)))) (. .)))
2722224	3	(S1 (S (SBAR (IN Although) (S (NP (JJ diastolic) (NN blood) (NN pressure)) (VP (VBD remained) (ADJP (JJ unchanged))))) (, ,) (NP (JJ systolic) (NN blood) (NN pressure)) (VP (VBN increased) (PP (IN from) (NP (CD 119))) (PP (TO to) (NP (NP (CD 135) (NNS mm)) (NP (NP (NNP Hg)) (PRN (-LRB- -LRB-) (NP (JJ SED) (NN +/-) (CD 3.4)) (, ,) (NP (NNP p) (QP (JJR less) (IN than) (CD 0.01))) (-RRB- -RRB-))) (, ,) (VP (VBN associated) (PP (IN with) (NP (NP (DT an) (NNP Doc_2722224_600_624_Disease)) (PRN (-LRB- -LRB-) (NP (NP (CD 5.85-7.73) (NN l/min)) (, ,) (NP (JJ SED) (JJ +/-) (NN 0.46))) (, ,) (NP (NNP p) (QP (JJR less) (IN than) (CD 0.01))) (-RRB- -RRB-)))))))) (. .)))
2722224	4	(S1 (S (NP (JJ Total) (JJ peripheral) (NN vascular) (NN resistance)) (VP (VBD fell) (PP (IN from) (NP (NP (QP (CD 15.1) (TO to) (CD 12.2) (CD mm)) (NNP Hg/l/min)) (PRN (-LRB- -LRB-) (NP (NNP SED) (CD +/-) (CD 1.03)) (, ,) (NP (NNP p) (QP (JJR less) (IN than) (CD 0.05))) (-RRB- -RRB-))))) (. .)))
2722224	5	(S1 (S (S (NP (JJ Resting) (NN forearm) (NN vascular) (NN resistance)) (VP (VBD remained) (ADJP (JJ unchanged)))) (, ,) (CC but) (S (NP (NP (DT the) (JJ reflex) (NN response)) (PP (TO to) (NP (DT the) (JJ cold) (NN pressor) (NN test)))) (VP (AUX was) (VP (VBN accentuated) (, ,) (NP (NP (DT the) (NN rise)) (PP (IN in) (NP (NP (NN resistance) (VBG increasing)) (PP (IN from) (NP (NP (CD 10.5) (JJ mm) (NNP Hg/ml/100) (NN ml/min)) (PRN (-LRB- -LRB-) (NP (NN R) (NNS units)) (-RRB- -RRB-)))))) (PP (IN before) (NP (NN treatment))) (PP (TO to) (NP (CD 32.6) (NN R) (NNS units))) (PP (IN after) (NP (NN treatment))) (PRN (-LRB- -LRB-) (NP (JJ SED) (NN +/-) (CD 6.4)) (, ,) (NP (NNP p) (QP (JJR less) (IN than) (CD 0.025))) (-RRB- -RRB-)))))) (. .)))
2722224	6	(S1 (S (NP (NP (DT The) (NN rise)) (PP (IN in) (NP (NP (JJ forearm) (JJ vascular) (NN resistance) (VBG accompanying) (JJ intra-arterial) (NNP Doc_2722224_1129_1143_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 25)) (, ,) (NP (CD 50)) (, ,) (CC and) (NP (CD 100) (NN ng/min))) (-RRB- -RRB-))))) (VP (AUX was) (ADVP (RB also)) (ADJP (ADJP (RB significantly) (JJR greater)) (PP (IN after) (NP (NNP Doc_2722224_1206_1220_Chemical)))) (, ,) (S (VP (VBG increasing) (PP (PP (IN from) (NP (NP (DT an) (NN average)) (PP (IN of) (NP (NP (QP (CD 14.9) (CD +/-)) (ADJP (CD 2.4) (NN R)) (NNS units)) (PP (IN before) (NP (NN treatment))))))) (PP (TO to) (NP (NP (QP (CD 35.1) (CD +/-)) (ADJP (CD 5.5) (NN R)) (NNS units)) (PP (IN after) (NP (NP (NNP Doc_2722224_1320_1334_Chemical)) (PRN (-LRB- -LRB-) (NP (JJ SED) (JJ +/-) (NN 6.0)) (, ,) (NP (NNP p) (QP (JJR less) (IN than) (CD 0.05))) (-RRB- -RRB-)))))))))) (. .)))
2722224	7	(S1 (S (NP (NP (NP (DT A) (NN shift)) (PP (TO to) (NP (DT the) (NN left))) (PP (IN in) (NP (DT the) (JJ dose-response) (NN relation)))) (CC and) (NP (NP (NN fall)) (PP (IN in) (NP (NN threshold))))) (VP (VBD suggested) (NP (JJ increased) (NN sensitivity)) (PP (TO to) (NP (NNP Doc_2722224_1475_1489_Chemical))) (PP (IN after) (NP (NN treatment)))) (. .)))
2722224	8	(S1 (S (NP (NP (NN Measurement)) (PP (IN of) (S (VP (VBG resting) (NP (JJ Doc_2722224_1530_1544_Chemical) (NN spillover) (NN rate)) (PP (TO to) (NP (NP (NN plasma)) (CC and) (NP (JJ Doc_2722224_1574_1588_Chemical) (NN uptake)))))))) (VP (VBD indicated) (SBAR (IN that) (S (NP (JJ overall) (JJ resting) (ADJP (JJ sympathetic) (JJ nervous)) (NN system) (NN activity)) (VP (AUX was) (RB not) (VP (VBN increased)))))) (. .)))
2722224	9	(S1 (S (NP (NP (DT The) (NNP Doc_2722224_1686_1716_Disease)) (PP (IN with) (NP (NNP Doc_2722224_1722_1736_Chemical)))) (VP (AUX is) (VP (VBN associated) (PP (IN with) (NP (NP (NP (DT an) (NNP Doc_2722224_1759_1783_Disease)) (PRN (-LRB- -LRB-) (ADJP (RB presumably) (JJ due) (PP (TO to) (NP (JJ increased) (NN blood) (NN volume)))) (-RRB- -RRB-)) (. .)) (PRN (-LRB- -LRB-) (NP (NP (JJ ABSTRACT)) (VP (VBN TRUNCATED) (PP (IN AT) (NP (CD 250) (NNS WORDS))))) (-RRB- -RRB-))))))))
2750819	0	(S1 (NP (NP (NN Doc_2750819_0_22_Disease)) (PP (IN with) (NP (NP (NNP Doc_2750819_28_45_Chemical)) (CC and) (NP (NNP Doc_2750819_50_60_Chemical)))) (. .)))
2750819	1	(S1 (S (NP (NP (DT A) (NN patient)) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (NN tocolysis)) (PP (IN with) (NP (NNP Doc_2750819_100_110_Chemical))))))) (VP (VBD developed) (NP (NNP Doc_2750819_121_143_Disease)) (SBAR (IN after) (S (NP (NP (CD 500) (NN mg)) (PP (IN of) (NP (NNP Doc_2750819_160_177_Chemical)))) (VP (AUX was) (VP (VBN administered)))))) (. .)))
2750819	2	(S1 (S (NP (DT This) (NN reaction)) (VP (VBZ demonstrates) (SBAR (IN that) (S (NP (NNP Doc_2750819_228_238_Chemical)) (VP (MD can) (ADVP (RB seriously)) (VP (VB potentiate) (NP (NP (DT the) (NN Doc_2750819_268_276_Disease)) (PP (IN of) (NP (NN Doc_2750819_280_289_Chemical))))))))) (. .)))
2750819	3	(S1 (S (NP (NN Caution)) (VP (MD should) (VP (AUX be) (VP (VBN exercised) (SBAR (WHADVP (WRB when)) (S (NP (DT these) (CD two) (NNS tocolytics)) (VP (AUX are) (VP (VBN combined)))))))) (. .)))
2790457	0	(S1 (S (NP (JJ Chronic) (NNP Doc_2790457_8_21_Chemical)) (VP (VBZ inhibits) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NP (JJ local) (JJ anesthetic) (NN Doc_2790457_67_75_Disease)) (VP (VBN kindled) (PP (IN by) (NP (NP (NNP Doc_2790457_87_94_Chemical)) (CC and) (NP (NNP Doc_2790457_99_108_Chemical))))))))) (. .)))
2790457	1	(S1 (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NNP Doc_2790457_125_138_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_2790457_140_143_Chemical)) (-RRB- -RRB-)) (NN treatment))) (PP (IN on) (NP (NP (JJ local) (JJ anesthetic-kindled) (NN Doc_2790457_183_191_Disease)) (CC and) (NP (NN lethality))))) (VP (AUX were) (VP (VBN evaluated) (PP (PP (IN in) (NP (NP (JJ different) (NNS stages)) (PP (IN of) (NP (DT the) (JJ kindling) (NN process))))) (CC and) (PP (IN under) (NP (NP (JJ different) (NNS methods)) (PP (IN of) (NP (NNP Doc_2790457_296_299_Chemical) (NN administration)))))))) (. .)))
2790457	2	(S1 (S (NP (JJ Chronic) (JJ oral) (NN Doc_2790457_329_332_Chemical)) (VP (VP (VBD inhibited) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (DT both) (NNP Doc_2790457_367_376_Chemical-) (CC and) (NNP Doc_2790457_382_389_Chemical-induced) (NNP Doc_2790457_398_406_Disease))))) (, ,) (CC but) (VP (AUX had) (NP (NP (JJ little) (NN effect)) (PP (IN on) (NP (DT the) (ADJP (RB fully) (VBN developed)) (JJ local) (JJ anesthetic) (NN Doc_2790457_470_478_Disease)))))) (. .)))
2790457	3	(S1 (S (NP (JJ Chronic) (NN Doc_2790457_488_491_Chemical)) (ADVP (RB also)) (VP (VBD decreased) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (JJ Doc_2790457_524_531_Disease-related) (NN mortality))) (PP (IN in) (NP (DT the) (JJ Doc_2790457_557_564_Chemical-injected) (NNS rats))))) (. .)))
2790457	4	(S1 (S (NP (NP (JJ Acute) (NN Doc_2790457_586_589_Chemical)) (PP (IN over) (NP (NP (DT a) (NN range)) (PP (IN of) (NP (NP (NNS doses)) (PRN (-LRB- -LRB-) (NP (CD 15-50) (NNS mg/kg)) (-RRB- -RRB-))))))) (VP (AUX had) (NP (NP (DT no) (NN effect)) (PP (IN on) (NP (VBN completed) (ADJP (JJ Doc_2790457_653_662_Chemical-kindled) (CC or) (JJ acute)) (JJ Doc_2790457_680_687_Chemical-induced) (NN Doc_2790457_696_704_Disease))))) (. .)))
2790457	5	(S1 (S (NP (NP (VBN Repeated) (NN i.p.) (NN injection)) (PP (IN of) (NP (NP (NNP Doc_2790457_733_736_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 15) (NN mg/kg)) (-RRB- -RRB-))))) (ADVP (RB also)) (VP (AUX was) (PP (IN without) (NP (NN effect))) (PP (IN on) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_2790457_794_803_Chemical-) (CC or) (NNP Doc_2790457_808_815_Chemical-kindled) (NNP Doc_2790457_824_832_Disease)))))) (. .)))
2790457	6	(S1 (S (NP (NP (DT The) (NN differential) (NNS effects)) (PP (IN of) (NP (NNP Doc_2790457_862_865_Chemical))) (PP (VBG depending) (PP (IN upon) (NP (NN stage)))) (PP (IN of) (NP (JJ Doc_2790457_890_897_Disease) (NN development)))) (VP (VBP suggest) (SBAR (IN that) (S (NP (JJ distinct) (NNS mechanisms)) (VP (VB underlie) (NP (NP (DT the) (NN development) (CC versus) (NN maintenance)) (PP (IN of) (NP (JJ local) (JJ anesthetic-kindled) (NN Doc_2790457_1015_1023_Disease)))))))) (. .)))
2790457	7	(S1 (S (NP (NP (DT The) (NN effectiveness)) (PP (IN of) (NP (NP (ADJP (ADJP (JJ chronic)) (CC but) (ADJP (RB not) (JJ repeated))) (, ,) (JJ intermittent) (NNS injections)) (PP (IN of) (NP (NNP Doc_2790457_1099_1102_Chemical)))))) (VP (VBZ suggests) (SBAR (IN that) (S (NP (JJ different) (JJ biochemical) (NNS consequences)) (VP (VBP result) (PP (IN from) (NP (DT the) (JJ different) (NN treatment) (NNS regimens))))))) (. .)))
2790457	8	(S1 (S (NP (NP (DT The) (JJ possible) (NN utility)) (PP (IN of) (NP (JJ chronic) (NNP Doc_2790457_1230_1233_Chemical))) (PP (IN in) (S (VP (VBG preventing) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (JJ toxic) (NN side) (NNS effects))) (PP (IN in) (NP (JJ human) (JJ Doc_2790457_1295_1302_Chemical) (NNS users)))))))) (VP (VP (AUX is) (VP (VBN suggested) (PP (IN by) (NP (DT these) (NNS data))))) (, ,) (CC but) (VP (VBZ remains) (S (VP (TO to) (VP (AUX be) (VP (ADVP (RB directly)) (VBN evaluated))))))) (. .)))
2819587	0	(S1 (S (NP (NP (JJ Magnetic) (NN resonance) (NN imaging)) (PP (IN of) (NP (JJ cerebral) (NNP Doc_2819587_39_56_Disease)))) (ADJP (JJ secondary) (PP (TO to) (NP (`` ``) (JJ low-dose) ('' '') (NN birth) (NN control) (NNS pills)))) (. .)))
2819587	1	(S1 (S (NP (NP (DT The) (ADJP (ADJP (JJ clinical)) (CC and) (ADJP (JJ radiographic))) (NNS features)) (PP (IN of) (NP (JJ cerebral) (NNP Doc_2819587_153_175_Disease))) (PP (IN in) (NP (DT a) (JJ 21-year-old) (JJ white) (NN woman)))) (VP (AUX are) (VP (VBN presented))) (. .)))
2819587	2	(S1 (S (NP (DT This) (JJ nulliparous) (NN patient)) (VP (VBD presented) (PP (IN with) (NP (NP (ADJP (RB relatively) (JJ mild)) (JJ clinical) (NNS symptoms)) (CC and) (NP (VBG progressing) (JJ mental) (NN status) (NNS changes))))) (. .)))
2819587	3	(S1 (S (NP (DT The) (JJ only) (JJ known) (NN risk) (NN factor)) (VP (AUX was) (NP (`` ``) (JJ low-dose) ('' '') (JJ Doc_2819587_375_393_Chemical) (NNS pills))) (. .)))
2819587	4	(S1 (S (NP (NP (DT The) (JJ magnetic) (NN resonance) (NN image)) (PRN (-LRB- -LRB-) (NP (NNP MRI)) (-RRB- -RRB-))) (VP (VBD showed) (NP (NP (NP (VBN increased) (NN signal) (NN intensity)) (PP (IN from) (NP (DT the) (JJ internal) (JJ cerebral) (NNS veins)))) (, ,) (NP (NP (NN vein)) (PP (IN of) (NP (NNP Galen)))) (, ,) (CC and) (NP (JJ straight) (NN sinus)))) (. .)))
2819587	5	(S1 (S (NP (DT The) (NN diagnosis)) (VP (AUX was) (VP (VBN confirmed) (PP (IN by) (NP (JJ arterial) (NN angiography))))) (. .)))
2826064	0	(S1 (NP (NP (NP (JJ Beta-2-adrenoceptor-mediated) (NN Doc_2826064_29_40_Disease)) (CC and) (NP (NP (PRP$ its) (NN abolishment)) (PP (IN by) (NP (NNP Doc_2826064_64_74_Chemical))))) (. .)))
2826064	1	(S1 (S (NP (NP (NP (DT The) (NN time) (NN course)) (CC and) (NP (JJ concentration-effect) (NN relationship))) (PP (IN of) (NP (NNP Doc_2826064_133_144_Chemical-induced) (NNP Doc_2826064_153_164_Disease)))) (VP (AUX was) (VP (VBN studied) (, ,) (S (VP (VBG using) (NP (JJ computer-aided) (JJ pharmacokinetic-dynamic) (NN modeling)))))) (. .)))
2826064	2	(S1 (S (ADVP (RB Subsequently)) (NP (PRP we)) (VP (VBD investigated) (NP (NP (DT the) (NN efficacy)) (PP (IN of) (NP (NNP Doc_2826064_278_288_Chemical)))) (PP (IN in) (S (VP (VBG antagonizing) (NP (JJ such) (NN Doc_2826064_310_321_Disease))))) (, ,) (ADVP (RB together)) (PP (IN with) (NP (NP (DT the) (JJ pharmacokinetic) (NN interaction)) (PP (IN between) (NP (DT both) (NNS drugs)))))) (. .)))
2826064	3	(S1 (S (NP (CD Six) (JJ healthy) (NNS subjects)) (VP (AUX were) (VP (VBN given) (NP (NP (DT a) (ADJP (CD 0.5) (NN mg)) (JJ subcutaneous) (NN dose)) (PP (IN of) (NP (NNP Doc_2826064_451_462_Chemical))) (PP (IN on) (NP (NP (CD two) (NNS occasions)) (: :) (NP (NP (NP (CD 1) (NN hour)) (PP (IN after) (NP (NP (JJ oral) (NN administration)) (PP (IN of) (NP (DT a) (NN placebo)))))) (CC and) (NP (NP (CD 1) (NN hour)) (PP (IN after) (NP (CD 80) (JJ mg) (NNP Doc_2826064_550_560_Chemical) (NN orally)))))))))) (. .)))
2826064	4	(S1 (S (PP (IN In) (NP (NP (DT the) (JJ 7-hour) (NN period)) (PP (IN after) (NP (NNP Doc_2826064_596_607_Chemical) (NN administration))))) (, ,) (NP (NN plasma) (NNS samples)) (VP (AUX were) (VP (VBN taken) (PP (IN for) (NP (NP (NN determination)) (PP (IN of) (NP (NP (NN plasma) (NN Doc_2826064_678_687_Chemical) (NNS levels)) (CC and) (NP (NN drug) (NNS concentrations)))))))) (. .)))
2826064	5	(S1 (S (NP (DT The) (JJ sigmoid) (JJ Emax) (NN model)) (VP (VBD offered) (NP (NP (DT a) (JJ good) (NN description)) (PP (IN of) (NP (DT the) (NN relation))) (PP (IN between) (NP (NP (JJ Doc_2826064_794_805_Chemical) (NNS concentrations)) (CC and) (NP (JJ Doc_2826064_825_834_Chemical) (NNS effects)))))) (. .)))
2826064	6	(S1 (S (NP (NN Doc_2826064_844_854_Chemical)) (VP (VBD caused) (NP (NP (NP (NNS decreases)) (PP (IN of) (NP (NP (CD 65) (NN %)) (CC and) (NP (NP (CD 56) (NN %)) (PP (IN of) (NP (NP (JJ Doc_2826064_890_901_Chemical) (NN volume)) (PP (IN of) (NP (NN distribution) (CC and) (NN clearance)))))) (, ,) (ADVP (RB respectively)) (, ,)))) (CC and) (NP (NP (DT an) (NN increase)) (PP (IN of) (NP (NP (CD 130) (NN %)) (PP (IN of) (NP (PRP$ its) (NNS AUC)))))))) (. .)))
2826064	7	(S1 (S (PP (IN In) (NP (NP (NN spite)) (PP (IN of) (NP (JJR higher) (NNP Doc_2826064_1009_1020_Chemical) (NNS concentrations))) (PP (IN after) (NP (JJ Doc_2826064_1042_1052_Chemical) (NN pretreatment))))) (, ,) (NP (DT the) (NNP Doc_2826064_1071_1082_Disease)) (VP (AUX was) (ADVP (RB almost) (RB completely)) (VP (VBN antagonized) (PP (IN by) (NP (DT the) (JJ beta) (JJ 2-blocking) (NN action))))) (. .)))
2840807	0	(S1 (NP (NP (DT A) (JJ Doc_2840807_2_10_Disease-like) (NN syndrome)) (PP (IN after) (NP (NP (JJ neuropeptide) (PRN (-LRB- -LRB-) (NP (NNP MSH/ACTH)) (-RRB- -RRB-)) (NN stimulation)) (PP (IN of) (NP (DT the) (NN rat) (NN locus) (NN ceruleus))))) (. .)))
2840807	1	(S1 (S (S (NP (NP (DT The) (NNP Doc_2840807_98_115_Disease)) (VP (VBN investigated) (PP (IN in) (NP (DT these) (NNS studies))))) (VP (AUX has) (NP (DT some) (NNS features)) (PP (IN in) (NP (NP (NN common)) (PP (IN with) (NP (JJ human) (JJ idiopathic) (NN Doc_2840807_196_204_Disease))))))) (, ,) (CC and) (S (NP (NP (NN information)) (VP (VBN obtained) (PP (IN in) (NP (DT these) (NNS studies))))) (VP (MD may) (VP (AUX be) (PP (IN of) (NP (JJ potential) (JJ clinical) (NN benefit)))))) (. .)))
2840807	2	(S1 (S (NP (DT The) (JJ present) (JJ experimental) (NNS results)) (VP (VBD indicated) (SBAR (S (NP (NP (DT that) (JJ peptidergic) (NN stimulation)) (PP (IN of) (NP (DT the) (NNS LC)))) (VP (VBD resulted) (PP (IN in) (NP (NP (DT a) (JJ NE-mediated) (NN inhibition)) (PP (IN of) (NP (NP (JJ cerebellar) (NNP Purkinje) (NNS cells)) (VP (VBN located) (PP (IN at) (NP (NP (NNS terminals)) (PP (IN of) (NP (DT the) (JJ ceruleo-cerebellar) (NN pathway)))))))))))))) (. .)))
2840807	3	(S1 (S (ADVP (RB However)) (, ,) (NP (PRP it)) (VP (AUX is) (RB not) (ADJP (JJ certain) (SBAR (IN as) (FRAG (PP (TO to) (NP (DT the) (NN following))) (: :) (PRN (-LRB- -LRB-) (NP (DT a)) (-RRB- -RRB-)) (WHNP (WP what)) (S (NP (NNS receptors)) (VP (AUX were) (VP (VBN stimulated) (PP (IN by) (NP (NP (DT the) (JJ ACTH) (JJ N-terminal) (NNS fragments)) (PP (IN at) (NP (NP (DT the) (NN LC)) (SBAR (WHNP (WDT that)) (S (VP (VBD resulted) (PP (IN in) (NP (NP (DT this) (NN disorder)) (PRN (: ;) (-LRB- -LRB-) (NP (NNP b)) (-RRB- -RRB-)) (PP (IN whether) (NP (NNP NE))) (, ,) (VP (VBN released) (PP (IN onto) (NP (NP (NNP Purkinje) (NN cell) (NNS synapses)) (VP (VBN located) (PP (IN at) (NP (NP (NNS terminals)) (PP (IN of) (NP (NP (DT the) (JJ ceruleo-cerebellar) (NN pathway)) (, ,) (SBAR (S (VP (AUX did) (RB indeed) (VP (VB cause) (NP (DT the) (JJ long-term) (NNP Doc_2840807_788_798_Disease)) (PP (IN at) (NP (NP (NP (NNP Purkinje) (NN cell) (NNS synapses)) (PRN (-LRB- -LRB-) (VP (ADVP (RB previously)) (VBN described) (PP (IN by) (NP (NNS others)))) (-RRB- -RRB-)) (SBAR (WHNP (WDT that)) (S (VP (VBD resulted) (PP (IN in) (NP (NP (NP (NP (DT the) (JJ long) (NN duration)) (PP (IN of) (NP (NP (DT the) (NNP Doc_2840807_900_917_Disease)) (PRN (: ;) (-LRB- -LRB-) (NP (NNP c)) (-RRB- -RRB-)) (PP (IN whether) (NP (NP (DT the) (NN inhibition)) (PP (IN of) (NP (JJ inhibitory) (NNP Purkinje) (NNS cells))))))) (VP (VBD resulted) (PP (IN in) (NP (NN disinhibition))))) (CC or) (NP (VBN increased) (NN excitability))) (PP (IN of) (NP (DT the) (JJ unilateral) (NN cerebellar) (NN fastigial))))))))) (CC or) (JJ interpositus) (FW nuclei) (, ,) (NP (NP (DT the) (NN output) (NNS targets)) (PP (IN of) (NP (NP (DT the) (NNP Purkinje) (NN cell) (NNS axons)) (, ,) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (AUX have) (VP (AUX been) (NP (NP (DT an) (JJ important) (JJ contributing) (NN factor)) (PP (TO to) (NP (DT this) (NN disorder)))))))))))))))))))))))))))))))))))))))))) (. .)))
2840807	4	(S1 (S (NP (DT These) (NNS questions)) (VP (AUX are) (ADVP (RB currently)) (VP (AUXG being) (VP (VBN investigated)))) (. .)))
2886572	0	(S1 (S (NP (NP (JJ Enhanced) (JJ stimulus-induced) (NN neurotransmitter) (NN overflow)) (PP (IN in) (NP (JJ Doc_2886572_55_66_Chemical-induced) (JJ Doc_2886572_75_87_Disease) (NNS rats)))) (VP (AUX is) (RB not) (VP (VBN mediated) (PP (IN by) (NP (JJ prejunctional) (NN beta-adrenoceptor) (NN activation))))) (. .)))
2886572	1	(S1 (S (NP (DT The) (JJ present) (NN study)) (VP (VBZ examines) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (JJ 6-day) (JJ Doc_2886572_203_214_Chemical) (NN treatment)) (PRN (-LRB- -LRB-) (NP (NP (CD 100) (NNS micrograms/kg)) (PP (IN per) (NP (NP (NNP h)) (, ,) (NP (NNP s.c.))))) (-RRB- -RRB-)))) (PP (IN on) (NP (NP (JJ stimulus-induced) (PRN (-LRB- -LRB-) (NP (CD 1) (NNPS Hz)) (-RRB- -RRB-)) (JJ endogenous) (NN neurotransmitter) (NN overflow)) (PP (IN from) (NP (NP (DT the) (VBN isolated) (JJ perfused) (NN kidney)) (PP (IN of) (NP (ADJP (JJ vehicle-) (CC and) (JJ Doc_2886572_371_382_Chemical-treated)) (NNS rats))))))))) (. .)))
2886572	2	(S1 (S (NP (NP (NP (JJ Renal) (JJ Doc_2886572_403_416_Chemical) (NNS stores)) (CC and) (NP (JJ stimulus-induced) (NN overflow))) (PP (IN in) (NP (DT the) (JJ vehicle-treated) (NN group)))) (VP (VBD consisted) (PP (IN of) (NP (NNP Doc_2886572_496_510_Chemical) (RB only)))) (. .)))
2886572	3	(S1 (S (ADVP (RB However)) (, ,) (NP (JJ Doc_2886572_526_537_Chemical) (NN treatment)) (VP (VBD resulted) (PP (IN in) (NP (NP (DT the) (NN incorporation)) (PP (IN of) (NP (NNP Doc_2886572_581_592_Chemical))))) (PP (IN into) (NP (NP (JJ renal) (JJ Doc_2886572_604_617_Chemical) (NNS stores)) (ADJP (JJ such) (SBAR (IN that) (S (NP (NP (QP (RB approximately) (CD 40)) (NN %)) (PP (IN of) (NP (DT the) (JJ Doc_2886572_660_673_Chemical) (NN present)))) (VP (AUX was) (ADJP (JJ Doc_2886572_686_697_Chemical)) (SBAR (IN while) (S (NP (DT the) (JJ Doc_2886572_708_722_Chemical) (NN content)) (VP (AUX was) (VP (VBN reduced) (PP (IN by) (NP (DT a) (JJ similar) (NN degree)))))))))))))) (. .)))
2886572	4	(S1 (S (NP (NP (JJ Total) (NN tissue) (NN Doc_2886572_777_790_Chemical) (NN content)) (PP (IN of) (NP (DT the) (NN kidney))) (PP (IN on) (NP (DT a) (JJ molar) (NN basis)))) (VP (AUX was) (ADJP (JJ unchanged))) (. .)))
2886572	5	(S1 (S (NP (NP (JJ Stimulus-induced) (JJ fractional) (NN overflow)) (PP (IN of) (NP (NN neurotransmitter))) (PP (IN from) (NP (DT the) (JJ Doc_2886572_911_922_Chemical-treated) (NNS kidneys)))) (VP (VP (AUX was) (ADJP (RB approximately) (RB twice) (JJ normal))) (CC and) (VP (VBD consisted) (PP (IN of) (NP (DT both) (NNP Doc_2886572_992_1006_Chemical) (CC and) (NNP Doc_2886572_1011_1022_Chemical))) (PP (IN in) (NP (NP (NNS proportions)) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT those)) (VP (VBN found) (PP (IN in) (NP (DT the) (NN kidney))))))))))) (. .)))
2886572	6	(S1 (S (NP (NP (DT This) (NN difference)) (PP (IN in) (NP (JJ fractional) (NN overflow))) (PP (IN between) (NP (NNS groups)))) (VP (AUX was) (RB not) (VP (VBN affected) (PP (IN by) (NP (NP (NN neuronal)) (CC and) (NP (JJ extraneuronal) (JJ uptake) (NN blockade)))))) (. .)))
2886572	7	(S1 (S (NP (NN Doc_2886572_1194_1205_Chemical)) (VP (AUX had) (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (JJ stimulus-induced) (NN overflow)) (PP (IN in) (NP (DT either) (NN group)))))) (. .)))
2886572	8	(S1 (S (NP (NN Doc_2886572_1266_1278_Chemical)) (VP (VBD increased) (NP (JJ stimulus-induced) (NN overflow)) (PP (IN in) (NP (DT both) (NNS groups))) (SBAR (IN although) (S (NP (NP (DT the) (NN increment)) (PP (IN in) (NP (NN overflow)))) (VP (AUX was) (ADJP (JJR greater)) (PP (IN in) (NP (DT the) (JJ Doc_2886572_1384_1395_Chemical-treated) (NN group))))))) (. .)))
2886572	9	(S1 (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (JJ chronic) (JJ Doc_2886572_1434_1445_Chemical) (NN treatment)) (VP (VBZ results) (PP (IN in) (NP (JJ enhanced) (JJ fractional) (NN neurotransmitter) (NN overflow)))) (. .)))
2886572	10	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (DT neither) (NNS alterations)) (PP (IN in) (NP (NP (JJ prejunctional) (JJ beta-adrenoceptor) (NNS influences)) (CC nor) (NP (NP (NNS alterations)) (PP (IN in) (NP (NP (NN neuronal)) (CC and) (NP (JJ extraneuronal) (JJ uptake) (NNS mechanisms)))))))) (VP (VBP appear) (S (VP (TO to) (VP (AUX be) (ADJP (JJ responsible) (PP (IN for) (NP (DT this) (NN alteration)))))))) (. .)))
2886572	11	(S1 (S (ADVP (RB Furthermore)) (, ,) (NP (NP (NNS data)) (VP (VBN obtained) (PP (IN with) (NP (NNP Doc_2886572_1731_1743_Chemical))))) (ADVP (RB alone)) (VP (AUX do) (RB not) (VP (VB suggest) (NP (NN alpha-adrenoceptor) (NN desensitization)) (PP (IN as) (NP (NP (DT the) (NN cause)) (PP (IN of) (NP (NP (DT the) (JJ enhanced) (NN neurotransmitter) (NN overflow)) (PP (IN after) (NP (JJ Doc_2886572_1861_1872_Chemical) (NN treatment))))))))) (. .)))
2893236	0	(S1 (S (NP (NP (JJ Doc_2893236_0_4_Chemical) (NN involvement)) (PP (IN in) (NP (NP (JJ Doc_2893236_20_28_Chemical) (VBN induced) (NN reversal)) (PP (IN of) (NP (NNP Doc_2893236_49_70_Disease)))))) (VP (VBD produced) (PP (IN by) (NP (NNP Doc_2893236_83_93_Chemical)))) (. .)))
2893236	1	(S1 (S (NP (DT No) (NN agent)) (VP (AUX is) (ADVP (RB yet)) (ADJP (JJ available)) (S (VP (TO to) (VP (VB reverse) (NP (NP (NN Doc_2893236_132_153_Disease)) (VP (VBN produced) (PP (IN by) (NP (NP (JJ CNS) (NNS depressants)) (, ,) (PP (JJ such) (IN as) (NP (JJ general) (NNS anesthetics))))))))))) (. .)))
2893236	2	(S1 (S (PP (IN In) (NP (DT this) (NN study))) (NP (NNP Doc_2893236_226_234_Chemical)) (VP (VP (VBD reversed) (S (NP (NNP Doc_2893236_244_265_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_2893236_277_287_Chemical))) (PP (IN in) (NP (NN rats.) (CD 25) (NN mg/kg))) (, ,) (S (VP (VBG i.v.) (NP (JJ Doc_2893236_312_322_Chemical) (VBN produced) (NN anesthesia)) (PP (IN without) (S (VP (VBG altering) (NP (NN respiratory) (NN rate)))))))))) (, ,) (VP (VBD increased) (NP (NNP Doc_2893236_388_392_Chemical))) (, ,) (VP (VBD decreased) (NP (NNP Doc_2893236_404_413_Chemical))) (, ,) (CC and) (VP (AUX had) (NP (NP (DT no) (NN effect)) (PP (IN on) (NP (NNP Doc_2893236_436_445_Chemical) (CC or) (NNP Doc_2893236_449_456_Chemical) (NNS levels)))) (PP (VBN compared) (PP (TO to) (NP (NNS controls)))) (PP (IN in) (NP (NP (NN rat) (NN cortex)) (CC and) (NP (NN brain) (NN stem)))))) (. .)))
2893236	3	(S1 (S (S (NP (NP (NN Pretreatment)) (PP (IN of) (NP (NP (NNS rats)) (PP (IN with) (NP (NNP Doc_2893236_541_558_Chemical))))) (PP (IN for) (NP (CD 30) (NNS minutes)))) (VP (VBD abolished) (NP (NP (DT the) (JJ anesthetic) (NN action)) (CONJP (RB as) (RB well) (IN as)) (NP (NP (DT the) (JJ respiratory) (NN depressant) (NN action)) (PP (IN of) (NP (NNP Doc_2893236_654_664_Chemical.))))) (NP (CD 50) (NN mg/kg)))) (, ,) (CC i.v.) (S (NP (NNP Doc_2893236_681_691_Chemical)) (VP (VBD produced) (NP (NNP Doc_2893236_701_719_Disease)) (PP (IN with) (NP (NP (NP (JJR further) (NN increase)) (PP (IN in) (NP (NNP Doc_2893236_745_749_Chemical)))) (CC and) (NP (NP (NN decrease)) (PP (IN in) (NP (NNP Doc_2893236_766_775_Chemical)))))) (PP (ADVP (RB again)) (IN in) (NP (NP (NN cortex)) (CC and) (NP (NN brain) (NN stem)))) (PP (IN without) (S (VP (VBG affecting) (NP (NP (DT any)) (PP (IN of) (NP (NP (DT the) (NNP Doc_2893236_836_847_Chemical)) (VP (VBN studied) (PP (IN in) (NP (NP (CD four) (NNS regions)) (PP (IN of) (NP (NN rat) (NN brain)))))))))))))) (. .)))
2893236	4	(S1 (S (NP (NP (NNP Doc_2893236_886_894_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 2.5) (CD mg/kg))) (, ,) (NP (NNP i.v.)) (-RRB- -RRB-))) (VP (VBD reversed) (NP (NNP Doc_2893236_922_943_Disease) (, ,) (NNP Doc_2893236_945_954_Chemical) (CC and) (NNP Doc_2893236_959_963_Chemical) (NNS levels)) (PP (TO to) (NP (NN control) (NNS values))) (PP (IN in) (NP (NP (NN brain) (NN stem) (CC and) (NN cortex)) (PP (IN with) (NP (NP (DT no) (NNS changes)) (PP (IN in) (NP (NN caudate) (CC or) (NN cerebellum)))))))) (. .)))
2893236	5	(S1 (S (NP (DT These) (NNS data)) (VP (VBP suggest) (SBAR (S (NP (NNP Doc_2893236_1075_1083_Chemical)) (VP (VP (VBZ reverses) (NP (NP (NNP Doc_2893236_1093_1114_Disease)) (VP (VBN produced) (PP (IN by) (NP (NNP Doc_2893236_1127_1137_Chemical)))))) (CC and) (VP (VBZ involves) (NP (NP (NN Doc_2893236_1151_1155_Chemical)) (PP (IN in) (NP (PRP$ its) (NN action))))))))) (. .)))
2894433	0	(S1 (S (NP (NN Doc_2894433_0_8_Chemical)) (VP (VBZ facilitates) (NP (NP (JJ reflex) (NN Doc_2894433_28_39_Disease)) (PP (IN in) (NP (JJ conscious) (NNS rats))))) (. .)))
2894433	1	(S1 (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NNP Doc_2894433_74_82_Chemical))) (PP (IN on) (NP (JJ cardiovascular) (NN function)))) (VP (AUX were) (VP (VBN assessed) (PP (IN in) (NP (JJ conscious) (NNS rats))))) (. .)))
2894433	2	(S1 (S (NP (NP (JJ Intravenous) (NN administration)) (PP (IN of) (NP (NP (NNP Doc_2894433_173_181_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 1-30) (CD mg)) (NN kg-1)) (-RRB- -RRB-))))) (VP (VBD produced) (NP (NP (DT a) (JJ dose-dependent) (NN decrease)) (PP (IN in) (NP (NP (PDT both) (DT the) (JJ mean) (JJ arterial) (NN pressure)) (CC and) (NP (DT the) (NN heart) (NN rate)))))) (. .)))
2894433	3	(S1 (S (ADVP (RB Also)) (, ,) (NP (JJ reflex) (NN Doc_2894433_300_311_Disease)) (VP (AUX was) (VP (VBN produced) (PP (IN in) (NP (NNS rats))) (PP (IN by) (NP (NP (JJ intravenous) (NN infusion)) (PP (IN of) (NP (NP (NNP Doc_2894433_360_370_Chemical)) (PRN (-LRB- -LRB-) (ADJP (NP (CD 1.25-2.5) (NNS micrograms)) (JJ kg-1)) (-RRB- -RRB-)))))))) (. .)))
2894433	4	(S1 (S (NP (NP (JJ Intravenous) (NN pretreatment)) (PP (IN of) (NP (DT the) (NNS rats))) (PP (IN with) (NP (NNP Doc_2894433_441_449_Chemical)))) (, ,) (SBAR (IN although) (S (VP (VBG causing) (NP (NP (DT no) (NN change)) (PP (IN in) (NP (DT the) (JJ Doc_2894433_485_495_Chemical-induced) (NN pressor) (NN effect))))))) (, ,) (VP (AUX did) (VP (VB enhance) (NP (DT the) (JJ Doc_2894433_536_546_Chemical-induced) (JJ reflex) (NN Doc_2894433_562_573_Disease)))) (. .)))
2894433	5	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (JJ Doc_2894433_588_596_Chemical) (NN enhancement)) (PP (IN of) (NP (JJ Doc_2894433_612_622_Chemical-induced) (JJ reflex) (NN Doc_2894433_638_649_Disease)))) (VP (AUX was) (VP (VBN antagonized) (PP (IN by) (NP (NP (NN pretreatment)) (PP (IN of) (NP (NNS rats))) (PP (IN with) (NP (NP (DT an) (JJ intravenous) (NN dose)) (PP (IN of) (NP (NP (NNP Doc_2894433_718_728_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (DT an) (NN agent)) (VP (NNS blocks) (NP (JJ Doc_2894433_746_754_Chemical) (NNS channels)) (PP (IN by) (S (VP (VBG binding) (PP (TO to) (NP (NP (NNS sites)) (VP (VBN associated) (PP (IN with) (NP (DT the) (JJ Doc_2894433_804_818_Chemical-Doc_2894433_819_823_Chemical-Doc_2894433_824_832_Chemical) (NN channel) (NN macromolecular) (NN complex))))))))))) (-RRB- -RRB-)))))))))) (. .)))
2894433	6	(S1 (S (NP (DT The) (NNS data)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NNP Doc_2894433_889_897_Chemical)) (VP (VBZ acts) (PP (IN through) (NP (NP (DT the) (JJ Doc_2894433_915_929_Chemical-Doc_2894433_930_934_Chemical-Doc_2894433_935_943_Chemical) (NN channel) (NN macromolecular) (NN complex)) (PP (IN within) (NP (NP (DT the) (ADJP (JJ central) (JJ nervous)) (NN system)) (SBAR (S (VP (TO to) (VP (VB facilitate) (NP (NP (JJ reflex) (NN Doc_2894433_1030_1041_Disease)) (VP (VBN mediated) (PP (IN through) (NP (NN baroreceptor) (NNS reflexes))) (PP (IN in) (NP (NP (NN response)) (PP (TO to) (NP (NP (DT an) (JJ acute) (NN increase)) (PP (IN in) (NP (JJ arterial) (NN pressure))))))))))))))))))))) (. .)))
28952	0	(S1 (NP (NP (NP (NP (JJ Initial) (JJ Doc_28952_8_17_Chemical) (NN loss)) (CC and) (NP (NP (NN hypokalaemia)) (PP (IN during) (NP (NNP Doc_28952_47_61_Chemical) (NN administration))))) (PP (IN in) (NP (NNS patients))) (PP (IN with) (NP (JJ essential) (NNP Doc_28952_104_116_Disease)))) (: :) (NP (NP (DT the) (NN influence)) (PP (IN of) (NP (JJ dietary) (JJ Doc_28952_143_149_Chemical) (NN restriction)))) (. .)))
28952	1	(S1 (S (S (VP (TO To) (VP (VB investigate) (NP (NP (DT the) (JJ initial) (JJ Doc_28952_190_199_Chemical) (NN loss) (CC and) (NN development)) (PP (IN of) (NP (NN hypokalaemia)))) (PP (IN during) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (DT an) (JJ oral) (NN diuretic)))))))) (, ,) (NP (JJ metabolic) (NN balance) (NNS studies)) (VP (AUX were) (VP (VBN performed) (PP (IN in) (NP (NP (CD ten) (NNS patients)) (PP (IN with) (NP (JJ essential) (NNP Doc_28952_356_368_Disease))) (SBAR (WHNP (WP who)) (S (VP (AUX had) (VP (VBN shown) (NP (NN hypokalaemia)) (PP (IN under) (NP (JJ prior) (JJ oral) (JJ diuretic) (NN treatment))))))))))) (. .)))
28952	2	(S1 (S (NP (NP (NN Doc_28952_433_447_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 50) (CD mg)) (NN daily)) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN given) (PP (IN for) (NP (CD 14) (NNS days))))) (. .)))
28952	3	(S1 (S (NP (CD Six) (NNS patients)) (VP (VBD received) (NP (NP (DT a) (JJ normal-Doc_28952_516_522_Chemical) (NN diet)) (CC and) (NP (NP (CD four)) (NP (DT a) (JJ low-Doc_28952_543_549_Chemical) (PRN (-LRB- -LRB-) (NP (CD 17) (NN mmol/day)) (-RRB- -RRB-)) (NN diet))))) (. .)))
28952	4	(S1 (S (NP (DT All) (NNS patients)) (VP (AUX had) (NP (NP (DT a) (JJ normal) (JJ initial) (JJ total) (NN body) (NN Doc_28952_615_624_Chemical)) (PRN (-LRB- -LRB-) (NP (NN 40K)) (-RRB- -RRB-)))) (. .)))
28952	5	(S1 (S (NP (NP (DT The) (JJ electrolyte) (NNS balances)) (, ,) (NP (NN weight)) (, ,) (NP (JJ bromide) (NN space)) (, ,) (NP (NN plasma) (NN renin) (NN activity)) (, ,) (CC and) (NP (JJ Doc_28952_708_719_Chemical) (NN secretion) (NN rate))) (VP (AUX were) (VP (VBN measured))) (. .)))
28952	6	(S1 (S (PP (IN In) (NP (DT both) (NNS groups))) (NP (DT a) (JJ Doc_28952_767_776_Chemical) (NN deficit)) (VP (VBD developed) (, ,) (PP (IN with) (NP (NP (ADJP (RB proportionally) (JJR larger)) (NNS losses)) (PP (IN from) (NP (DT the) (NN extracellular))))) (PP (IN than) (PP (IN from) (NP (DT the) (JJ intracellular) (NN compartment))))) (. .)))
28952	7	(S1 (S (S (PP (IN In) (NP (DT the) (JJ normal-Doc_28952_908_914_Chemical) (NN group))) (NP (DT the) (JJS highest) (JJ mean) (JJ Doc_28952_938_947_Chemical) (NN deficit)) (VP (AUX was) (NP (NP (CD 176) (NN mmol)) (PP (IN on) (NP (NN day) (CD 9))) (, ,) (SBAR (WHPP (IN after) (WHNP (WDT which))) (S (NP (DT some) (NNP Doc_28952_996_1005_Chemical)) (VP (AUX was) (VP (VBN regained)))))))) (: ;) (S (PP (IN in) (NP (DT the) (JJ low-Doc_28952_1031_1037_Chemical) (NN group))) (NP (DT the) (JJS highest) (NN deficit)) (VP (AUX was) (NP (CD 276) (NN mmol)) (PP (IN on) (NP (NN day) (CD 13))))) (. .)))
28952	8	(S1 (S (S (NP (DT The) (JJ normal-Doc_28952_1099_1105_Chemical) (NN group)) (VP (VBD showed) (NP (NP (DT an) (ADJP (ADJP (JJ immediate)) (CC but) (ADJP (JJ temporary))) (NN rise)) (PP (IN of) (NP (DT the) (JJ renin) (CC and) (JJ Doc_28952_1168_1179_Chemical) (NNS levels)))))) (: ;) (S (PP (IN in) (NP (NP (DT the) (JJ low-Doc_28952_1199_1205_Chemical) (NN group) (NN renin)) (CC and) (NP (NNP Doc_28952_1222_1233_Chemical)))) (VP (VP (VBD increased) (ADVP (RBR more) (RB slowly))) (CC but) (VP (VBD remained) (ADJP (JJ elevated))))) (. .)))
28952	9	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (VBN concluded) (SBAR (IN that) (S (NP (JJ dietary) (JJ Doc_28952_1308_1314_Chemical) (NN restriction)) (VP (VBZ increases) (NP (JJ diuretic-induced) (JJ Doc_28952_1354_1363_Chemical) (NN loss)) (, ,) (PP (ADVP (RB presumably)) (IN by) (NP (NP (DT an) (JJ increased) (NN activity)) (PP (IN of) (NP (DT the) (JJ renin-angiotensin-Doc_28952_1431_1442_Chemical) (NN system))))) (, ,) (SBAR (IN while) (S (NP (NP (JJ Doc_28952_1457_1463_Chemical) (NN delivery)) (PP (TO to) (NP (DT the) (JJ distal) (JJ renal) (NNS tubules)))) (VP (VBZ remains) (ADJP (RB sufficiently) (JJ high) (SBAR (S (VP (TO to) (VP (VB allow) (NP (VBN increased) (JJ Doc_28952_1546_1555_Chemical) (NN secretion))))))))))))))) (. .)))
2907585	0	(S1 (NP (NP (NN Reversal)) (PP (IN of) (NP (JJ neuroleptic-induced) (NNP Doc_2907585_32_41_Disease))) (PP (IN by) (NP (JJ novel) (JJ Doc_2907585_51_66_Chemical) (JJ anxiolytic) (NNS drugs))) (. .)))
2907585	1	(S1 (S (NP (NP (DT The) (JJ novel) (JJ anxiolytic) (NN drug)) (, ,) (NP (NNP Doc_2907585_112_121_Chemical)) (, ,)) (VP (VBZ reverses) (NP (NP (NNP Doc_2907585_132_141_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_2907585_153_164_Chemical)))))) (. .)))
2907585	2	(S1 (S (NP (NP (DT A) (NN series)) (PP (IN of) (NP (NP (JJ Doc_2907585_178_193_Chemical) (NNS analogues)) (PP (IN of) (NP (NP (NNP Doc_2907585_207_216_Chemical)) (CC and) (NP (JJ other) (NNP Doc_2907585_227_259_Chemical))))))) (VP (AUX were) (VP (VBN tested) (PP (IN for) (NP (PRP$ their) (NN ability) (S (VP (TO to) (VP (VB reverse) (NP (JJ Doc_2907585_301_312_Chemical) (VBN induced) (NN Doc_2907585_321_330_Disease))))))))) (. .)))
2907585	3	(S1 (S (NP (NP (DT Those) (NNS drugs)) (PP (IN with) (NP (JJ strong) (NN affinity))) (PP (IN for) (NP (JJ Doc_2907585_369_388_Chemical1a) (NNS receptors)))) (VP (AUX were) (ADJP (JJ able) (S (VP (TO to) (VP (VB reverse) (NP (NN Doc_2907585_422_431_Disease))))))) (. .)))
2907585	4	(S1 (S (NP (NP (NNS Drugs)) (PP (IN with) (NP (NN affinity))) (PP (IN for) (NP (NP (JJ other) (JJ Doc_2907585_463_467_Chemical) (NNS receptors)) (CC or) (NP (JJ weak) (NN affinity))))) (VP (AUX were) (ADJP (JJ ineffective))) (. .)))
2907585	5	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (NN inhibition)) (PP (IN of) (NP (JJ postsynaptic) (JJ Doc_2907585_549_553_Chemical) (NNS receptors)))) (VP (CC neither) (VP (VBD inhibited) (CC nor) (VBD potentiated) (NP (NP (NN reversal)) (PP (IN of) (NP (NNP Doc_2907585_610_619_Disease))))) (CC and) (VP (VBZ leaves) (NP (JJ open) (DT the) (NN question)) (PP (IN as) (PP (TO to) (NP (NP (DT the) (NN site) (CC or) (NN mechanism)) (PP (IN for) (NP (DT this) (NN effect)))))))) (. .)))
2917114	0	(S1 (NP (NP (JJ Doc_2917114_0_14_Chemical) (NNS requirements)) (PP (IN for) (NP (NP (NN antagonism)) (PP (IN of) (NP (NP (DT the) (JJ muscarinic) (NN side) (NNS effects)) (PP (IN of) (NP (NNP Doc_2917114_77_88_Chemical))))))) (. .)))
2917114	1	(S1 (S (NP (PRP We)) (VP (AUX have) (VP (VBN compared) (, ,) (PP (IN in) (NP (CD 60) (NN adult) (NNS patients))) (, ,) (NP (NP (DT the) (JJ cardiovascular) (NNS effects)) (PP (IN of) (NP (NP (NNP Doc_2917114_160_174_Chemical) (CD 5) (NNS micrograms)) (ADJP (ADJP (JJ kg-1)) (CC and) (ADJP (NP (CD 10) (NNS micrograms)) (JJ kg-1))) (VP (VBN given) (UCP (DT either) (ADVP (RB simultaneously)) (CC or) (NP (NP (CD 1) (NN min)) (PP (IN before) (NP (NNP Doc_2917114_260_271_Chemical) (CD 1))) (NP (CD mg) (NN kg-1)))))))))) (. .)))
2917114	2	(S1 (S (NP (NP (JJ Significant) (NNS differences)) (PP (IN between) (NP (DT the) (CD four) (NNS groups)))) (VP (AUX were) (VP (VBN detected) (PRN (-LRB- -LRB-) (NP (NP (NN P)) (QP (JJR less) (IN than) (CD 0.001))) (-RRB- -RRB-)))) (. .)))
2917114	3	(S1 (S (NP (NP (DT Both) (NNS groups)) (VP (VBG receiving) (NP (CD 10) (NNS micrograms) (JJ kg-1)))) (VP (VBD showed) (NP (NP (NNS increases)) (PP (IN in) (NP (NP (NN heart) (NN rate)) (PP (IN of) (NP (NP (QP (IN up) (TO to) (CD 30) (NN beat)) (NN min-1)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 95) (NN %)) (NP (NN confidence) (NNS limits))) (ADJP (CD 28-32) (NN beat) (JJ min-1))) (-RRB- -RRB-)))))))) (. .)))
2917114	4	(S1 (S (NP (NP (NN Use)) (PP (IN of) (NP (NNP Doc_2917114_510_524_Chemical) (CD 5) (NN micrograms) (NN kg-1)))) (VP (VP (VBD provided) (NP (JJR greater) (JJ cardiovascular) (NN stability))) (CC and) (VP (, ,) (PP (VBN given) (NP (NP (CD 1) (NN min)) (PP (IN before) (NP (DT the) (NNP Doc_2917114_613_624_Chemical))))) (, ,) (AUX was) (ADJP (JJ sufficient) (S (VP (TO to) (VP (VB minimize) (NP (JJ early) (, ,) (JJ Doc_2917114_660_671_Chemical-induced) (NNP Doc_2917114_680_692_Disease)))))))) (. .)))
2917114	5	(S1 (S (NP (NP (DT This) (JJ low) (NN dose)) (PP (IN of) (NP (NNP Doc_2917114_711_725_Chemical)))) (VP (VBD provided) (NP (NP (JJ good) (NN control)) (PP (IN of) (NP (JJ oropharyngeal) (NNS secretions))))) (. .)))
2980315	0	(S1 (NP (NP (JJ Selective) (NN injection)) (PP (IN of) (NP (NP (NNP Doc_2980315_23_31_Chemical)) (, ,) (NP (NNP Doc_2980315_33_40_Chemical)) (CC and) (NP (NNP Doc_2980315_45_55_Chemical)))) (PP (IN into) (NP (NP (DT the) (JJ left) (JJ coronary) (NN artery)) (PP (IN of) (NP (DT the) (NN dog))))) (. .)))
2980315	1	(S1 (NP (NP (NP (NP (NN Induction)) (PP (IN of) (NP (NNP Doc_2980315_111_135_Disease)))) (CC and) (NP (NP (NN decrease)) (PP (IN of) (NP (JJ aortic) (NN pressure))))) (. .)))
2980315	2	(S1 (S (PP (IN In) (NP (CD twenty) (JJ beagle) (NNS dogs))) (NP (JJ selective) (NNS injections)) (VP (AUX were) (VP (VBN made) (PP (IN into) (NP (NP (DT the) (JJ left) (JJ coronary) (NN artery)) (PP (IN with) (NP (NP (NNP Doc_2980315_257_265_Chemical) (, ,) (NNP Doc_2980315_267_274_Chemical) (CC and) (NNP Doc_2980315_279_289_Chemical)) (PP (IN in) (NP (NP (NNS doses)) (PP (IN of) (NP (NP (QP (CD 4) (CD ml))) (, ,) (NP (QP (CD 8) (CD ml))) (CC and) (NP (QP (CD 16) (CD ml))))))))))))) (. .)))
2980315	3	(S1 (S (NP (NP (JJ Thirty-six) (JJ Doc_2980315_335_343_Chemical) (NNS injections)) (, ,) (NP (CD 35) (JJ Doc_2980315_359_366_Chemical) (NNS injections)) (CC and) (NP (CD 37) (JJ Doc_2980315_385_395_Chemical) (NNS injections))) (VP (AUX were) (VP (VBN made))) (. .)))
2980315	4	(S1 (S (NP (NP (NNS Frequencies)) (PP (IN of) (NP (NNP Doc_2980315_433_457_Disease)))) (VP (AUX were) (ADJP (ADJP (RB significantly) (JJR lower)) (PRN (-LRB- -LRB-) (NP (NP (QP (CD p) (JJR less))) (PP (IN than) (NP (CD 0.05)))) (-RRB- -RRB-))) (PP (IN after) (NP (NP (NP (NNP Doc_2980315_508_516_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 0) (NN %)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_2980315_526_533_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 3) (NN %)) (-RRB- -RRB-))))) (PP (IN than) (PP (IN after) (NP (NP (NNP Doc_2980315_550_560_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 22) (NN %)) (-RRB- -RRB-)))))) (. .)))
2980315	5	(S1 (S (NP (NP (NNP Doc_2980315_568_576_Chemical)) (CC and) (NP (NNP Doc_2980315_581_588_Chemical))) (ADVP (RB also)) (VP (VBD produced) (NP (NP (ADJP (RB significantly) (JJR less)) (NN decrease)) (PP (IN in) (NP (JJ aortic) (NN blood) (NN pressure))) (PP (IN than) (NP (NNP Doc_2980315_661_671_Chemical)))) (PP (IN at) (NP (DT the) (JJ different) (NNS doses)))) (. .)))
3001299	0	(S1 (NP (NP (NP (JJ Thyroid) (NN function)) (CC and) (NP (JJ urine-concentrating) (NN ability))) (PP (IN during) (NP (JJ Doc_3001299_56_63_Chemical) (NN treatment))) (. .)))
3001299	1	(S1 (S (NP (PRP It)) (VP (AUX has) (VP (AUX been) (VP (VBN suggested) (SBAR (IN that) (S (NP (JJ Doc_3001299_102_111_Chemical) (NN cyclase) (NN inhibition)) (VP (MD may) (VP (AUX be) (ADJP (JJ important)) (PP (IN in) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (DT both) (NNP Doc_3001299_175_205_Disease) (CC and) (NNP Doc_3001299_210_224_Disease))))) (PP (IN during) (NP (JJ Doc_3001299_232_239_Chemical) (NN treatment)))))))))) (. .)))
3001299	2	(S1 (S (NP (PRP We)) (VP (VBD measured) (NP (NP (NP (JJ serum) (NN Doc_3001299_269_278_Chemical)) (CC and) (NP (JJ urine-concentrating) (NN ability))) (PRN (-LRB- -LRB-) (NP (NNP Umax)) (-RRB- -RRB-))) (PP (IN in) (NP (NP (NN response)) (PP (TO to) (NP (NP (NNP Doc_3001299_333_345_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP DDAVP)) (-RRB- -RRB-)))))) (PP (IN in) (NP (NP (CD 85) (NNS patients)) (VP (VBG receiving) (NP (NNP Doc_3001299_379_386_Chemical)))))) (. .)))
3001299	3	(S1 (S (NP (NN Doc_3001299_388_402_Disease)) (VP (VBD developed) (PP (IN in) (NP (CD eight) (NNS patients))) (SBAR (IN while) (S (NP (PRP they)) (VP (AUX were) (VP (VBG taking) (NP (NN Doc_3001299_454_461_Chemical))))))) (. .)))
3001299	4	(S1 (S (NP (VBN Impaired) (NN Umax)) (VP (AUX was) (VP (VBN found) (PP (IN in) (NP (DT both) (NN euthyroid) (CC and) (NN Doc_3001299_509_520_Disease) (NNS patients))) (SBAR (IN while) (S (NP (DT some) (NNP Doc_3001299_541_552_Disease) (NNS patients)) (VP (VBD concentrated) (NP (PRP$ their) (NN urine)) (ADVP (RB well))))))) (. .)))
3001299	5	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (VBN concluded) (SBAR (IN that) (S (NP (NP (DT the) (JJ dominant) (NNS mechanisms)) (SBAR (WHPP (IN by) (WHNP (WDT which))) (S (NP (NNP Doc_3001299_647_654_Chemical)) (VP (VBZ exerts) (NP (DT these) (CD two) (NNS effects)))))) (VP (AUX are) (ADJP (JJ different))))))) (. .)))
3015327	0	(S1 (NP (NP (NN Remodelling)) (PP (IN of) (NP (NN nerve) (NN structure))) (PP (IN in) (NP (NP (JJ experimental) (NNP Doc_3015327_47_56_Chemical) (NNP Doc_3015327_57_67_Disease)) (PP (IN in) (NP (DT the) (NN rat))))) (. .)))
3015327	1	(S1 (S (NP (NP (DT The) (NN Doc_3015327_84_94_Disease)) (VP (VBN caused) (PP (IN by) (NP (NP (DT a) (JJ single) (NN dose)) (PP (IN of) (NP (NNP Doc_3015327_122_131_Chemical))) (PP (IN in) (NP (NNS rats))))))) (VP (AUX was) (VP (VBN studied) (PP (IN with) (NP (DT a) (JJ computer-assisted) (NN morphometric) (NN method))))) (. .)))
3015327	2	(S1 (S (NP (NP (NN Scatter) (NNS diagrams)) (PP (IN of) (NP (NP (DT the) (NNP g) (NN ratio)) (PRN (-LRB- -LRB-) (NP (JJ quotient) (NN fibre) (NN diameter/axon) (NN diameter)) (-RRB- -RRB-))))) (VP (VB define) (NP (NP (JJ regenerating) (NNS fibres)) (PP (IN as) (NP (NP (DT a) (JJ distinct) (NN population)) (, ,) (ADJP (JJ distinguishable) (PP (IN from) (NP (NP (DT the) (VBG surviving) (NNS fibres)) (PP (IN by) (NP (NP (VBN reduced) (NN sheath) (NN thickness)) (CC and) (NP (VBN reduced) (NN axon) (NN calibre))))))))))) (. .)))
3015327	3	(S1 (S (NP (EX There)) (VP (AUX was) (ADVP (RB also)) (NP (NP (NN evidence)) (PP (IN of) (NP (NP (DT a) (JJ subtle) (JJ direct) (JJ toxic) (NN effect)) (PP (IN on) (NP (DT the) (JJ entire) (NN fibre) (NN population)))))) (, ,) (S (VP (VBG causing) (NP (NP (NN axon) (NN shrinkage)) (VP (VBN masked) (PP (IN by) (NP (NP (NN readjustment)) (PP (IN of) (NP (DT the) (JJ myelin) (NN sheath)))))))))) (. .)))
3057041	0	(S1 (S (NP (NP (NNP Multicenter)) (, ,) (ADJP (JJ double-blind) (, ,) (JJ multiple-dose)) (, ,)) (VP (VBZ parallel-groups) (NP (NP (NP (NP (NN efficacy)) (CC and) (NP (NN safety) (NN trial))) (PP (IN of) (NP (NP (NNP Doc_3057041_87_97_Chemical)) (, ,) (NP (NNP Doc_3057041_99_115_Chemical)) (, ,)))) (CC and) (NP (NP (NN placebo)) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NNP Doc_3057041_149_173_Disease)))))))) (. .)))
3057041	1	(S1 (S (NP (NP (NNP Doc_3057041_175_185_Chemical)) (, ,) (NP (DT a) (JJ novel) (JJ antiallergic) (NN medication)) (, ,)) (VP (AUX was) (PP (VBN compared) (PP (IN with) (NP (NP (NNP Doc_3057041_238_262_Chemical)) (CC and) (NP (NP (NN placebo)) (PP (IN for) (NP (NP (NP (NN efficacy)) (CC and) (NP (NN safety))) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (NNP Doc_3057041_319_343_Disease)) (PP (IN in) (NP (DT a) (JJ multicenter) (, ,) (JJ double-blind) (, ,) (JJ multiple-dose) (, ,) (JJ parallel-groups) (NN study)))))))))))))) (. .)))
3057041	2	(S1 (S (NP (QP (CD One) (CD hundred)) (JJ fifty-five) (NNS subjects)) (VP (VBD participated)) (. .)))
3057041	3	(S1 (S (NP (NNS Subjects)) (VP (VP (VBD ranged) (PP (IN in) (NP (NN age))) (PP (IN from) (NP (NP (QP (CD 18) (TO to) (CD 60)) (NNS years)) (PP (IN of) (NP (NN age)))))) (CC and) (VP (AUX had) (NP (NP (ADVP (IN at) (JJS least)) (DT a) (JJ 2-year) (NN history)) (PP (IN of) (NP (NNP Doc_3057041_547_571_Disease))) (, ,) (VP (VBN confirmed) (PP (IN by) (NP (NP (JJ positive) (NN skin) (NN test)) (PP (TO to) (NP (NN spring) (NNS aeroallergens))))))))) (. .)))
3057041	4	(S1 (S (S (NP (NNS Medications)) (VP (AUX were) (VP (VBN given) (NP (CD four) (NNS times)) (ADVP (RB daily))))) (: ;) (S (NP (DT the) (JJ Doc_3057041_675_685_Chemical) (NNS groups)) (VP (VBD received) (NP (NP (CD 0.5)) (, ,) (NP (CD 1.0)) (, ,) (CC or) (NP (NP (QP (CD 2.0) (CD mg))) (PP (IN in) (NP (DT the) (NN morning) (CC and) (NN evening))))) (PP (IN with) (NP (NN placebo))) (PP (IN in) (NP (DT the) (JJ early) (CC and) (JJ late) (NN afternoon))))) (: ;) (S (NP (DT the) (NNP Doc_3057041_799_815_Chemical) (NN group)) (VP (VBD received) (NP (CD 4.0) (NN mg)) (ADVP (NP (CD four) (NNS times)) (RB daily)))) (. .)))
3057041	5	(S1 (S (NP (JJ Daily) (NN subject) (NN symptom) (NNS cards)) (VP (AUX were) (VP (VBN completed) (PP (IN during) (NP (NP (DT a) (NN screening) (NN period)) (SBAR (S (VP (TO to) (VP (VB assess) (NP (JJ pretreatment) (NNS symptoms)) (PP (CC and) (PP (IN during) (NP (NP (DT a) (JJ 4-week) (NN treatment) (NN period)) (SBAR (WHNP (IN while)) (S (NP (NNS subjects)) (VP (VBD received) (NP (NN study) (NNS medications)))))))))))))))) (. .)))
3057041	6	(S1 (S (NP (NP (JJ Individual) (NNS symptoms)) (, ,) (NP (JJ total) (NNS symptoms)) (, ,) (CC and) (NP (JJ major) (NNS symptoms))) (VP (AUX were) (VP (VBN compared) (S (VP (TO to) (VP (VB determine) (NP (NP (NN efficacy)) (PP (IN of) (NP (NN medication))))))))) (. .)))
3057041	7	(S1 (S (VP (VP (VBD Elicited)) (, ,) (VP (VBD volunteered)) (, ,) (CC and) (VP (VBD observed) (SBAR (S (NP (JJ adverse) (NNS experiences)) (VP (AUX were) (VP (VP (VBN recorded) (PP (IN for) (NP (DT each) (NN subject)))) (CC and) (VP (VBN compared) (PP (IN among) (NP (NNS groups)))))))))) (. .)))
3057041	8	(S1 (S (NP (NP (JJ Vital) (NNS signs)) (, ,) (NP (NN body) (NNS weights)) (, ,) (NP (NN serum) (NN chemistry) (NNS values)) (, ,) (NP (JJ complete) (NN blood) (NN cell) (NNS counts)) (, ,) (NP (NN urine) (NNS studies)) (, ,) (CC and) (NP (NNS electrocardiograms))) (VP (AUX were) (VP (VP (VBN obtained) (PP (IN for) (NP (DT each) (NN subject)))) (CC and) (VP (VBN compared) (PP (IN among) (NP (NNS groups)))))) (. .)))
3057041	9	(S1 (S (NP (NP (NNS Symptoms) (NN relief)) (PP (IN in) (NP (NP (DT the) (NN group)) (VP (VBG receiving) (NP (NP (DT the) (JJS highest) (NN concentration)) (PP (IN of) (NP (NNP Doc_3057041_1501_1511_Chemical))))))) (PRN (-LRB- -LRB-) (ADJP (QP (CD 2.0) (CD mg)) (RB twice) (JJ daily)) (-RRB- -RRB-))) (VP (AUX was) (ADJP (ADJP (RB statistically) (JJR greater)) (PP (IN than) (PP (IN in) (NP (DT the) (NN placebo) (NN group))))) (PP (IN during) (NP (NP (DT all) (NNS weeks)) (PP (IN of) (NP (DT the) (NN study)))))) (. .)))
3057041	10	(S1 (S (NP (NP (JJR Lower) (NNS doses)) (PP (IN of) (NP (NNP Doc_3057041_1631_1641_Chemical)))) (VP (AUX were) (ADJP (RB statistically) (RBR more) (JJ effective)) (PP (IN than) (NP (NN placebo))) (PP (ADVP (RB only)) (IN during) (NP (NP (NNS portions)) (PP (IN of) (NP (NP (DT the) (JJ first) (CD 3) (NNS weeks)) (PP (IN of) (NP (DT the) (NN study)))))))) (. .)))
3057041	11	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (SBAR (IN although) (S (NP (DT the) (JJ Doc_3057041_1771_1787_Chemical) (NN group)) (VP (AUX did) (VP (AUX have) (NP (JJR fewer) (NNS symptoms)) (PP (IN than) (NP (DT the) (NN placebo) (NN group))) (PP (IN during) (NP (DT the) (NN study))))))) (, ,) (NP (DT the) (NN difference)) (ADVP (RB never)) (VP (VBD reached) (NP (JJ statistical) (NN significance)) (PP (IN during) (NP (NP (DT any) (NN week)) (PP (IN of) (NP (DT the) (NN study)))))) (. .)))
3057041	12	(S1 (S (NP (EX There)) (VP (AUX were) (NP (DT no) (JJ serious) (NN side) (NNS effects)) (PP (IN in) (NP (NP (DT any)) (PP (IN of) (NP (DT the) (NN treatment) (NNS groups)))))) (. .)))
3057041	13	(S1 (S (NP (NP (NNP Drowsiness)) (CC and) (NP (NNP Doc_3057041_2025_2049_Disease))) (VP (AUX were) (VP (VBN increased) (ADVP (RB significantly)) (PP (IN over) (NP (NN placebo))) (PP (ADVP (RB only)) (IN in) (NP (DT the) (JJ high-dose) (JJ Doc_3057041_2114_2124_Chemical) (NN group))))) (. .)))
3057041	14	(S1 (S (NP (NN Doc_3057041_2132_2142_Chemical)) (VP (VBZ appears) (S (VP (TO to) (VP (AUX be) (NP (NP (DT a) (JJ safe) (, ,) (JJ efficacious) (NN medication)) (PP (IN for) (NP (NN Doc_3057041_2192_2218_Disease)))))))) (. .)))
3084782	0	(S1 (S (VP (VBP Doc_3084782_0_8_Disease) (ADJP (JJ due) (PP (TO to) (NP (NP (JJ remission) (VBG inducing) (NNS drugs)) (PP (IN in) (NP (NNP Doc_3084782_44_64_Disease))))))) (. .)))
3084782	1	(S1 (S (NP (NP (NN Association)) (PP (IN with) (NP (NP (NNP HLA-B35)) (CC and) (NP (NNP Cw4))))) (VP (VBZ antigens)) (. .)))
3084782	2	(S1 (S (NP (NP (NP (CD Twenty-five) (NNS patients)) (PP (IN with) (NP (NP (NNP Doc_3084782_135_155_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_3084782_157_159_Disease)) (-RRB- -RRB-)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NNP Doc_3084782_175_183_Disease)) (SBAR (IN while) (S (VP (VBG taking) (NP (JJ remission) (VBG inducing) (NNS drugs))))))))))) (CC and) (NP (NP (CD 30)) (PP (IN without) (NP (NNP Doc_3084782_237_245_Disease))))) (VP (AUX were) (VP (VBN studied) (PP (IN for) (NP (JJ possible) (NNS associations))) (PP (IN with) (NP (NP (NN class) (NN I)) (CC and) (NP (NNP II) (NNP HLA) (NNS antigens)))))) (. .)))
3084782	3	(S1 (S (NP (DT A) (JJ strong) (NN association)) (VP (AUX has) (VP (AUX been) (VP (VBN found) (PP (PP (IN between) (NP (NP (NNP Doc_3084782_363_372_Disease) (CC and) (NNP Doc_3084782_377_387_Disease) (ADJP (JJ due) (PP (TO to) (NP (NP (NP (NNP Doc_3084782_395_404_Chemical)) (PRN (-LRB- -LRB-) (NP (DT a) (JJ Doc_3084782_408_423_Chemical) (JJ like) (NN compound)) (-RRB- -RRB-))) (CC and) (NP (NN class) (NN I))))) (NNS antigens)) (ADJP (JJ B35-Cw4)))) (, ,) (CC and) (PP (IN between) (NP (NNP Doc_3084782_481_491_Disease))) (PP (JJ due) (TO to) (NP (NP (NNP Doc_3084782_499_516_Chemical)) (CC and) (NP (NNP B35)))))))) (. .)))
3084782	4	(S1 (S (PP (VBN Compared) (PP (TO to) (NP (JJ healthy) (NNS controls)))) (NP (DT a) (JJR lower) (NN DR5) (NN frequency)) (VP (AUX was) (VP (VBN observed) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_3084782_607_609_Disease))))) (PP (IN except) (PP (IN for) (NP (DT the) (JJ Doc_3084782_625_634_Chemical) (JJ related) (NN Doc_3084782_643_652_Disease) (NN group)))))) (. .)))
3088349	0	(S1 (S (NP (NP (JJ Transient) (NN Doc_3088349_10_32_Disease)) (VP (VBG following) (NP (JJ unilateral) (NNP Doc_3088349_54_77_Disease)))) (VP (VBZ reflects) (NP (NP (NN susceptibility)) (PP (IN of) (NP (DT the) (JJ nigrostriatal) (NN system))) (PP (TO to) (NP (NN exhaustion))) (PP (IN by) (NP (NNP Doc_3088349_147_158_Chemical))))) (. .)))
3088349	1	(S1 (S (PP (VBG Following) (NP (JJ unilateral) (JJ Doc_3088349_181_187_Chemical) (VBN induced) (NN Doc_3088349_196_205_Disease))) (, ,) (NP (NP (DT a) (JJ transient) (NN period)) (PP (IN of) (NP (NNP Doc_3088349_229_251_Disease)))) (VP (AUX has) (VP (AUX been) (VP (VBN reported) (S (VP (TO to) (VP (VB precede) (NP (DT the) (JJ predominant) (NN Doc_3088349_297_317_Disease)))))))) (. .)))
3088349	2	(S1 (S (SBAR (IN In) (NN order) (S (VP (TO to) (VP (VB clarify) (NP (NP (DT the) (NN nature)) (PP (IN of) (NP (DT this) (JJ initial) (NN Doc_3088349_366_388_Disease)))))))) (NP (PRP we)) (VP (VBD examined) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (DT the) (NN duration)) (PP (IN of) (NP (NN recovery) (NN period)))))) (PP (IN after) (NP (DT the) (NN lesion))) (, ,) (PP (IN on) (NP (NNP Doc_3088349_468_479_Chemical-induced) (NNP Doc_3088349_488_507_Disease)))) (. .)))
3088349	3	(S1 (S (NP (NP (CD Three) (NNS days)) (PP (IN post) (NP (NN lesion) (, ,) (JJS most) (NNS rats)))) (VP (VBD circled) (ADVP (RB predominantly)) (ADVP (RB contralaterally)) (PP (TO to) (NP (DT the) (NN lesion)))) (. .)))
3088349	4	(S1 (S (NP (JJ Such) (NN Doc_3088349_601_623_Disease)) (VP (MD may) (VP (VB result) (PP (IN from) (NP (NP (NP (DT either) (JJ degeneration-induced) (NN breakdown)) (PP (IN of) (NP (DT the) (NN DA) (NN pool)))) (, ,) (CC or) (NP (NP (JJ lesion-induced) (NN increase)) (PP (IN of) (NP (NN DA) (NN turnover)))))) (PP (IN in) (NP (DT the) (VBN spared) (NNS neurons))))) (. .)))
3088349	5	(S1 (S (NP (NP (DT A) (JJ substantial) (NN degree)) (PP (IN of) (NP (JJ contralateral) (NN preference)))) (VP (AUX was) (ADVP (RB still)) (ADJP (JJ evident)) (SBAR (WHADVP (WRB when)) (S (NP (NNP Doc_3088349_831_842_Chemical)) (VP (AUX was) (VP (VBN administered) (PP (IN for) (NP (NP (NP (DT the) (JJ first) (NN time)) (NP (CD 24) (NNS days))) (PP (IN after) (NP (NN lesioning))))) (, ,) (S (VP (VBG indicating) (NP (NP (NN involvement)) (PP (IN of) (NP (NP (VBN spared) (NNS cells)) (PP (IN in) (NP (DT the) (NNP Doc_3088349_950_972_Disease))))))))))))) (. .)))
3088349	6	(S1 (S (ADVP (RB However)) (, ,) (ADVP (RB regardless) (PP (IN of) (NP (NP (DT the) (NN duration)) (PP (IN of) (NP (NP (NN recovery)) (PRN (-LRB- -LRB-) (CC and) (NP (NP (NP (RB irrespective)) (PP (IN of) (NP (DT either) (NN lesion) (NN volume)))) (, ,) (NP (JJ Doc_3088349_1065_1076_Chemical) (NN dose)) (, ,) (CC or) (NP (NN post-lesion) (NN motor) (NN exercise))) (-RRB- -RRB-))))))) (, ,) (NP (NNP Doc_3088349_1115_1126_Chemical-induced) (NNP Doc_3088349_1135_1143_Disease)) (VP (VBD tended) (S (VP (TO to) (VP (VB become) (ADJP (ADVP (RB gradually) (RBR more)) (JJ ipsilateral)) (SBAR (IN as) (S (S (NP (DT the) (NN observation) (NN session)) (VP (VBD progressed))) (, ,) (CC and) (S (NP (DT all) (NNS rats)) (VP (VBD circled) (ADVP (RB ipsilaterally)) (PP (TO to) (NP (DT the) (NN lesion))) (PP (IN in) (NP (NP (NN response)) (PP (TO to) (NP (JJ further) (JJ Doc_3088349_1299_1310_Chemical) (NNS injections))))))))))))) (. .)))
3088349	7	(S1 (S (NP (DT These) (NNS findings)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NNP Doc_3088349_1351_1362_Chemical)) (VP (AUX has) (NP (NP (DT an) (JJ irreversible) (NN effect)) (PP (IN on) (NP (NP (DT the) (JJ post-lesion) (NN DA) (NN pool)) (VP (VBG contributing) (PP (TO to) (NP (NN Doc_3088349_1433_1455_Disease))))))))))) (. .)))
3108839	0	(S1 (S (NP (NN Doc_3108839_0_11_Chemical)) (VP (VBN associated) (NP (NNP Doc_3108839_23_48_Disease))) (. .)))
3108839	1	(S1 (S (NP (NP (JJ Doc_3108839_50_61_Chemical) (JJ associated) (NNP Doc_3108839_73_98_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_3108839_100_103_Disease)) (-RRB- -RRB-))) (VP (AUX is) (NP (NP (DT a) (ADJP (RB potentially) (JJ fatal) (CC but) (JJ uncommon)) (NN condition)) (SBAR (WHNP (WDT that)) (S (VP (AUX is) (RB not) (ADVP (RB yet)) (VP (ADVP (RB widely)) (VBN recognised))))))) (. .)))
3108839	2	(S1 (S (NP (PRP It)) (VP (VP (VBZ consists) (PP (IN of) (NP (NP (JJ microangiopathic) (NN Doc_3108839_218_234_Disease)) (, ,) (NP (NNP Doc_3108839_236_252_Disease)) (CC and) (NP (NP (JJ progressive) (NN Doc_3108839_269_282_Disease)) (VP (VBN associated) (PP (IN with) (NP (JJ Doc_3108839_299_310_Chemical) (NN treatment)))))))) (CC and) (VP (VBZ affects) (NP (NP (QP (RB about) (CD 10)) (NN %)) (PP (IN of) (NP (NP (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (DT this) (NN agent))))))))) (. .)))
3108839	3	(S1 (S (S (NP (DT The) (NNP Doc_3108839_384_397_Disease)) (ADVP (RB usually)) (VP (VBZ develops) (PP (IN about) (NP (CD 8-10) (NN mth))) (PP (IN after) (NP (NP (NN start)) (PP (IN of) (NP (JJ Doc_3108839_445_456_Chemical) (NN treatment))))))) (CC and) (S (NP (DT the) (NN mortality)) (VP (AUX is) (NP (NP (QP (RB approximately) (CD 60)) (NN %)) (PP (IN from) (NP (NP (NNP Doc_3108839_511_524_Disease)) (CC or) (NP (NNP Doc_3108839_528_543_Disease))))))) (. .)))
3108839	4	(S1 (S (NP (NN Doc_3108839_545_558_Disease)) (VP (VP (AUX are) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT those)) (VP (VBN seen) (PP (IN in) (NP (JJ idiopathic) (NNP Doc_3108839_599_602_Disease)))))))) (CC and) (VP (VBP include) (NP (NP (JJ arteriolar) (NN fibrin) (NNS thrombi)) (, ,) (NP (NP (VBN expanded) (NN subendothelial) (NNS zones)) (PP (IN in) (NP (JJ glomerular) (NN capillary) (NNS walls)))) (, ,) (NP (NP (NNP Doc_3108839_703_711_Disease) (NN wrinkling)) (PP (IN of) (NP (JJ glomerular) (NN basement) (NNS membranes)))) (CC and) (NP (NNS mesangiolysis))))) (. .)))
3108839	5	(S1 (S (NP (NP (DT The) (NN mechanism)) (PP (IN of) (NP (NN action)))) (VP (AUX is) (VP (VBN postulated) (PP (IN as) (NP (JJ Doc_3108839_815_826_Chemical-induced) (JJ endothelial) (NN cell) (NN damage))))) (. .)))
3108839	6	(S1 (S (NP (PRP We)) (VP (VBP describe) (NP (NP (DT the) (JJ clinical) (NN course)) (CC and) (NP (JJ pathological) (NNS findings))) (PP (IN in) (NP (NP (DT a) (CD 65) (JJ yr-old) (NN man)) (PP (IN with) (NP (NP (NNP Doc_3108839_942_964_Disease)) (SBAR (WHNP (WP who)) (S (VP (VP (VBD developed) (NP (NNP Doc_3108839_979_992_Disease) (CC and) (NNP Doc_3108839_997_1013_Disease) (NN while)) (PP (IN on) (NP (NN treatment))) (PP (IN with) (NP (NNP Doc_3108839_1038_1049_Chemical)))) (CC and) (VP (VBD died) (PP (IN in) (NP (NNP Doc_3108839_1062_1077_Disease)))))))))))) (. .)))
3115150	0	(S1 (S (NP (JJ Doc_3115150_0_10_Chemical) (NN pretreatment)) (VP (VBZ reverses) (NP (JJ Doc_3115150_33_43_Chemical-induced) (NN Doc_3115150_52_67_Disease))) (. .)))
3115150	1	(S1 (S (NP (NP (JJ Systemic) (NN pretreatment)) (PP (IN with) (NP (NP (NNP Doc_3115150_96_106_Chemical)) (, ,) (NP (DT a) (ADJP (RB relatively) (JJ specific)) (JJ type-2) (JJ Doc_3115150_137_146_Chemical) (NN receptor) (NN antagonist)) (, ,)))) (ADVP (RB significantly)) (VP (VBD attenuated) (NP (NP (DT the) (NNP Doc_3115150_197_212_Disease)) (VP (VBN produced) (PP (IN in) (NP (NNS rats))) (PP (IN by) (NP (DT the) (JJ potent) (JJ short-acting) (NN opiate) (NN agonist) (NNP Doc_3115150_272_282_Chemical)))))) (. .)))
3115150	2	(S1 (S (PP (VBG Following) (NP (NP (NN placement)) (PP (IN of) (NP (JJ subcutaneous) (NNS electrodes))) (PP (IN in) (NP (NP (DT each) (NN animal) (POS 's)) (JJ left) (JJ gastrocnemius) (NN muscle))))) (, ,) (NP (NNP Doc_3115150_375_383_Disease)) (VP (AUX was) (VP (VBN assessed) (PP (IN by) (S (VP (VBG analyzing) (NP (JJ root-mean-square) (JJ electromyographic) (NN activity))))))) (. .)))
3115150	3	(S1 (S (NP (NP (JJ Intraperitoneal) (JJ Doc_3115150_471_481_Chemical) (NN administration)) (PP (IN at) (NP (NP (NNS doses)) (PP (IN of) (NP (CD 0.63) (CC and) (CD 2.5) (NN mg/kg)))))) (VP (VBD prevented) (NP (NP (DT the) (JJ Doc_3115150_542_552_Chemical-induced) (NN increase)) (PP (IN in) (NP (JJ electromyographic) (NN activity)))) (PP (VBN compared) (PP (IN with) (NP (NP (NNS animals)) (VP (VBN pretreated) (PP (IN with) (NP (NN saline)))))))) (. .)))
3115150	4	(S1 (S (NP (NP (NN Doc_3115150_646_662_Chemical)) (PP (IN at) (NP (QP (NNS doses) (IN up) (TO to) (CD 10)) (NNS mg/kg)))) (VP (VBD failed) (S (VP (TO to) (VP (ADVP (RB significantly)) (VB influence) (NP (NP (DT the) (NN Doc_3115150_725_733_Disease)) (VP (VBN produced) (PP (IN by) (NP (NNP Doc_3115150_746_756_Chemical))))))))) (. .)))
3115150	5	(S1 (S (PP (IN Despite) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (NNP Doc_3115150_781_789_Disease))))) (, ,) (NP (NP (NNS animals)) (SBAR (WHNP (WDT that)) (S (VP (VBD received) (NP (NP (NNP Doc_3115150_813_823_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (JJR greater) (IN than) (CD 0.31) (CD mg/kg)) (NN i.p.)) (-RRB- -RRB-)) (VP (VBN followed) (PP (IN by) (NP (NNP Doc_3115150_867_877_Chemical))))))))) (VP (AUX were) (ADJP (ADJP (JJ motionless)) (, ,) (ADJP (JJ flaccid)) (, ,) (CC and) (ADJP (RBR less) (JJ responsive) (PP (TO to) (NP (JJ external) (NNS stimuli)))) (SBAR (IN than) (S (VP (AUX were) (NP (NP (NNS animals)) (VP (VBG receiving) (NP (NNP Doc_3115150_972_982_Chemical)) (ADVP (RB alone))))))))) (. .)))
3115150	6	(S1 (S (NP (NP (NNS Rats)) (SBAR (WHNP (WDT that)) (S (VP (VBD received) (NP (NP (NNP Doc_3115150_1009_1019_Chemical)) (CC and) (NP (NNP Doc_3115150_1024_1034_Chemical))))))) (VP (VBD exhibited) (NP (JJR less) (NN rearing) (CC and) (JJ exploratory) (NN behavior)) (PP (IN at) (NP (NP (DT the) (NN end)) (PP (IN of) (NP (NP (DT the) (JJ 60-min) (NN recording) (NN period)) (SBAR (IN than) (S (VP (AUX did) (NP (NP (NNS animals)) (SBAR (WHNP (WDT that)) (S (VP (VBD received) (NP (NP (NNP Doc_3115150_1156_1166_Chemical)) (ADVP (RB alone))))))))))))))) (. .)))
3115150	7	(S1 (S (NP (DT These) (NNS results)) (, ,) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (JJ previous) (NN work))))) (, ,) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NNP Doc_3115150_1237_1252_Disease)) (, ,) (NP (NP (DT a) (ADJP (RB clinically) (JJ relevant)) (NN side-effect)) (PP (IN of) (NP (JJ parenteral) (JJ narcotic) (NN administration)))) (, ,)) (VP (MD may) (VP (AUX be) (ADVP (RB partly)) (VP (VBN mediated) (PP (IN via) (NP (JJ serotonergic) (NNS pathways))))))))) (. .)))
3115150	8	(S1 (S (NP (NP (NN Pretreatment)) (PP (IN with) (NP (JJ type-2) (JJ Doc_3115150_1402_1411_Chemical) (NNS antagonists)))) (VP (MD may) (VP (AUX be) (ADJP (RB clinically) (JJ useful) (PP (IN in) (S (VP (VBG attenuating) (NP (JJ opiate-induced) (NNP Doc_3115150_1479_1487_Disease)))))) (, ,) (SBAR (IN although) (S (NP (JJ further) (NNS studies)) (VP (MD will) (VP (AUX be) (ADJP (JJ necessary) (S (VP (TO to) (VP (VB assess) (NP (NP (DT the) (NN interaction)) (PP (IN of) (NP (NP (RB possibly) (JJ enhanced) (NNS CNS)) (, ,) (NP (NNP Doc_3115150_1584_1626_Disease))))))))))))))) (. .)))
3120485	0	(S1 (NP (NP (NN Antagonism)) (PP (IN of) (NP (JJ Doc_3120485_14_22_Chemical-induced) (JJ sedative) (NNS effects))) (PP (IN by) (NP (NNP Doc_3120485_51_60_Chemical))) (PP (IN in) (NP (NNS patients))) (PP (IN after) (NP (NN surgery))) (PP (IN under) (NP (JJ lumbar) (JJ epidural) (NN block))) (. .)))
3120485	1	(S1 (NP (NP (DT A) (JJ double-blind) (JJ placebo-controlled) (NN investigation)) (PP (IN of) (NP (NP (NN efficacy)) (CC and) (NP (NN safety)))) (. .)))
3120485	2	(S1 (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX was) (S (S (VP (TO to) (VP (VB assess) (NP (NP (NP (DT the) (NN efficacy)) (PP (IN of) (NP (NNP Doc_3120485_240_249_Chemical)))) (CC and) (NP (NP (DT a) (NN placebo)) (PP (IN in) (S (VP (VBG reversing) (NP (JJ Doc_3120485_277_285_Chemical-induced) (NNS effects)) (PP (IN after) (NP (NN surgery))) (PP (IN under) (NP (JJ epidural) (NN block))))))))))) (, ,) (CC and) (S (VP (TO to) (VP (VB evaluate) (NP (NP (DT the) (JJ local) (UCP (NN tolerance) (CC and) (JJ general)) (NN safety)) (PP (IN of) (NP (NNP Doc_3120485_396_405_Chemical))))))))) (. .)))
3120485	3	(S1 (S (NP (JJ Fifty-seven) (NNS patients)) (VP (AUX were) (VP (VBN sedated) (PP (IN with) (NP (NNP Doc_3120485_446_454_Chemical))) (PP (IN for) (NP (NN surgery))) (PP (IN under) (NP (JJ epidural) (NNS anaesthesia))))) (. .)))
3120485	4	(S1 (S (NP (NP (NN Antagonism)) (PP (IN of) (NP (JJ Doc_3120485_509_517_Chemical-induced) (NNS effects))) (PP (IN by) (NP (NNP Doc_3120485_537_546_Chemical)))) (VP (AUX was) (VP (VBN investigated) (ADVP (RB postoperatively)) (PP (IN in) (NP (DT a) (JJ double-blind) (JJ placebo-controlled) (NN trial))))) (. .)))
3120485	5	(S1 (S (NP (NP (NP (NP (DT The) (NN patient) (POS 's)) (JJ subjective) (NN assessment)) (PP (IN of) (NP (NP (NN mood) (NN rating)) (, ,) (NP (NP (DT an) (JJ objective) (NN test)) (PP (IN of) (NP (NN performance)))) (, ,) (NP (NP (DT a) (NN test)) (PP (IN for) (NP (NNP Doc_3120485_721_728_Disease)))) (, ,)))) (CC and) (NP (JJ vital) (NNS signs))) (VP (AUX were) (VP (VBN recorded) (PP (IN for) (NP (QP (IN up) (TO to) (CD 300)) (NN min))) (PP (IN after) (NP (NP (NN administration)) (PP (IN of) (NP (DT the) (NN trial) (NN drug))))))) (. .)))
3120485	6	(S1 (S (NP (NP (DT No) (JJ significant) (NNS differences)) (PP (IN between) (NP (DT the) (CD two) (NNS groups)))) (VP (AUX were) (VP (VBN observed) (PP (IN for) (NP (NP (NN mood) (NN rating)) (, ,) (NP (NN Doc_3120485_899_906_Disease)) (, ,) (CC or) (NP (JJ vital) (NNS signs)))))) (. .)))
3120485	7	(S1 (S (NP (DT The) (NNP Doc_3120485_928_937_Chemical) (NN group)) (VP (VBD showed) (NP (NP (DT a) (JJ significant) (NN improvement)) (PP (IN in) (NP (DT the) (NN performance) (NN test)))) (ADVP (RB up)) (PP (TO to) (NP (CD 120) (NN min))) (PP (IN after) (NP (NP (NN administration)) (PP (IN of) (NP (DT the) (NN drug)))))) (. .)))
3120485	8	(S1 (S (NP (EX There)) (VP (AUX was) (NP (NP (DT no) (NN evidence)) (PP (IN of) (NP (NN reaction)))) (PP (IN at) (NP (DT the) (NN injection) (NN site)))) (. .)))
3123611	0	(S1 (S (NP (NN Doc_3123611_0_6_Disease)) (VP (VBN associated) (PP (IN with) (NP (JJ oral) (NN contraception)))) (. .)))
3123611	1	(S1 (S (NP (CD Three) (NNS patients)) (VP (VBD developed) (NP (NN Doc_3123611_68_74_Disease)) (SBAR (IN while) (S (VP (VBG receiving) (NP (NN Doc_3123611_91_110_Chemical)))))) (. .)))
3123611	2	(S1 (S (NP (CD Two)) (VP (AUX were) (NP (NP (JJ young) (NNS patients)) (SBAR (WHNP (WP$ whose) (NN Doc_3123611_142_148_Disease)) (S (VP (VP (VBD developed) (SBAR (ADVP (RB long)) (IN after) (S (NP (NN treatment)) (VP (AUX had) (VP (AUX been) (VP (VBN started))))))) (CC and) (VP (VBD disappeared) (SBAR (ADVP (RB soon)) (IN after) (S (NP (PRP it)) (VP (AUX had) (VP (AUX been) (VP (VBN discontinued)))))))))))) (. .)))
3123611	3	(S1 (S (NP (DT The) (JJ third) (NN patient)) (VP (AUX had) (NP (JJ acute) (JJ Doc_3123611_278_289_Chemical-induced) (NN Doc_3123611_298_304_Disease)) (PP (IN after) (NP (JJ prolonged) (NN Doc_3123611_321_339_Chemical)))) (. .)))
3123611	4	(S1 (S (NP (NP (VBN Prolonged) (NN administration)) (PP (IN of) (NP (JJ female) (NN sex) (NNS hormones)))) (VP (AUX is) (NP (NP (DT a) (JJ possible) (NN cause)) (PP (IN of) (NP (NNP Doc_3123611_412_418_Disease))) (PP (IN in) (NP (NP (NNS women)) (SBAR (WHNP (WP who)) (S (VP (AUX have) (RB not) (ADVP (RB previously)) (VP (AUX had) (NP (NP (NNP Doc_3123611_456_462_Disease)) (CC or) (NP (NNP Doc_3123611_466_481_Disease))))))))))) (. .)))
3131282	0	(S1 (NP (NP (JJ Doc_3131282_0_2_Chemical-carcinogenic) (NN effect)) (PP (IN of) (NP (NNP Doc_3131282_26_41_Chemical))) (PP (IN on) (NP (NP (NNP Doc_3131282_45_71_Disease)) (PP (IN of) (NP (JJ male) (JJ F344) (NNS rats))) (VP (VBN induced) (PP (IN with) (NP (NNP Doc_3131282_103_127_Chemical)))))) (. .)))
3131282	1	(S1 (S (NP (NP (DT The) (JJ potential) (NN modifying) (NN effect)) (PP (IN of) (NP (NP (NNP Doc_3131282_163_178_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_3131282_180_182_Chemical)) (-RRB- -RRB-)))) (PP (IN on) (NP (NP (NNP Doc_3131282_187_211_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_3131282_213_216_Chemical)) (-RRB- -RRB-)))) (NP (JJ -induced) (NN rat) (NN Doc_3131282_230_255_Disease))) (VP (AUX was) (VP (VBN examined))) (. .)))
3131282	2	(S1 (S (NP (NP (JJ Male) (NNP F344) (NNS rats)) (, ,) (NP (NP (CD 5) (NNS weeks)) (PP (IN of) (NP (NN age)))) (, ,)) (VP (VP (AUX were) (VP (VBN maintained) (PP (IN on) (NP (NP (NN diet)) (VP (VBG containing) (NP (ADJP (QP (CD 1) (NN %) (CC or) (CD 2) (NN %))) (NNP Doc_3131282_346_349_Chemical))))) (PP (IN by) (NP (NN weight))))) (CC and) (VP (ADVP (RB simultaneously) (PP (IN on) (NP (NN drinking) (NN water)))) (VBD supplemented) (PP (IN with) (NP (NNP RA))) (PP (IN at) (NP (JJ various) (NNS concentrations))) (PRN (-LRB- -LRB-) (JJ w/v) (-RRB- -RRB-)) (PP (IN for) (NP (CD 52) (NNS weeks))))) (. .)))
3131282	3	(S1 (S (PP (IN In) (NP (NP (NNS groups)) (VP (VBN given) (NP (ADJP (CD 2) (NN %)) (NNP Doc_3131282_483_486_Chemical))))) (, ,) (SBAR (IN although) (S (NP (NP (JJ marked) (JJ hyperplastic) (NNS changes)) (PP (IN of) (NP (DT the) (JJ forestomach) (NN epithelium)))) (VP (AUX were) (VP (VBN observed) (PP (IN in) (NP (DT all) (NNS animals))))))) (, ,) (NP (NP (NN co-administration)) (PP (IN of) (NP (ADJP (CD 0.25) (NN %)) (NNP RA))) (ADJP (ADVP (RB significantly)) (-LRB- -LRB-) (NP (CD P)) (JJR less) (SBAR (IN than) (S (NP (CD 0.05)) (-RRB- -RRB-) (VP (VBD increased) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NP (NNP Doc_3131282_675_693_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_3131282_695_718_Disease) (CC and) (NNP Doc_3131282_723_732_Disease)) (-RRB- -RRB-))))) (PP (TO to) (NP (CD 60) (NN %))) (PRN (-LRB- -LRB-) (NP (CD 9/15)) (, ,) (NP (NP (CD 2) (NNS rats)) (PP (IN with) (NP (NNP Doc_3131282_760_769_Disease)))) (-RRB- -RRB-)) (PP (IN from) (NP (CD 15) (NN %))) (PRN (-LRB- -LRB-) (NP (CD 3/20)) (, ,) (NP (NP (CD one) (NN rat)) (PP (IN with) (NP (NNP Doc_3131282_800_809_Disease)))) (-RRB- -RRB-)) (PP (IN in) (NP (DT the) (NN group)))))))) (VP (VBN given) (NP (JJ RA-free) (NN water))) (. .)))
3131282	4	(S1 (S (PP (IN In) (NP (NP (NNS rats)) (VP (VBN given) (NP (ADJP (CD 1) (NN %)) (NNP Doc_3131282_862_865_Chemical))))) (, ,) (NP (NNP RA) (JJ co-administered) (PP (IN at) (NP (NP (DT a) (NN dose)) (PP (IN of) (NP (CD 0.05) (, ,) (CD 0.1) (, ,) (CD 0.2) (CC or) (CD 0.25) (NN %)))))) (VP (VBD showed) (NP (NP (DT a) (JJ dose-dependent) (VBG enhancing) (NN effect)) (PP (IN on) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (DT the) (JJ Doc_3131282_990_993_Chemical-induced) (NNP Doc_3131282_1002_1024_Disease))))))) (. .)))
3131282	5	(S1 (S (NP (NP (NN Doc_3131282_1026_1032_Disease)) (, ,) (NP (DT all) (NNP Doc_3131282_1038_1048_Disease)) (, ,)) (VP (AUX were) (VP (VBN induced) (PP (PP (IN in) (NP (NP (CD 3) (NNS rats)) (PRN (-LRB- -LRB-) (NP (CD 17) (NN %)) (-RRB- -RRB-)) (PP (IN with) (NP (ADJP (CD 0.25) (NN %)) (NNP RA))))) (CC and) (PP (IN in) (NP (NP (CD one) (NN rat)) (PRN (-LRB- -LRB-) (NP (CD 10) (NN %)) (-RRB- -RRB-))))) (PP (IN with) (NP (ADJP (CD 0.05) (NN %)) (JJ Doc_3131282_1125_1127_Chemical) (NN co-administration))))) (. .)))
3131282	6	(S1 (S (NP (NP (NN Doc_3131282_1147_1149_Chemical)) (ADVP (RB alone))) (VP (AUX did) (RB not) (VP (VB induce) (NP (NP (JJ hyperplastic) (NNS changes)) (PP (IN in) (NP (DT the) (NN forestomach)))))) (. .)))
3131282	7	(S1 (S (NP (DT These) (NNS findings)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NNP RA)) (VP (VBD acted) (PP (IN as) (NP (NP (DT a) (NN co-carcinogen)) (PP (IN in) (NP (NP (DT the) (NNP Doc_3131282_1276_1279_Chemical) (NNP Doc_3131282_1280_1306_Disease)) (PP (IN of) (NP (DT the) (NN rat))))))))))) (. .)))
3137399	0	(S1 (NP (NP (DT A) (JJ prospective) (NN study)) (PP (IN on) (NP (NP (DT the) (NN dose) (NN dependency)) (PP (IN of) (NP (NNP Doc_3137399_46_60_Disease))) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_3137399_72_83_Chemical)))))) (. .)))
3137399	1	(S1 (S (PP (IN Since) (NP (CD 1975))) (NP (NP (NNP Doc_3137399_96_107_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_3137399_109_112_Chemical)) (-RRB- -RRB-))) (VP (AUX has) (VP (AUX been) (VP (VBN suggested) (S (VP (TO to) (VP (AUX be) (ADJP (JJ Doc_3137399_139_150_Disease))))) (, ,) (SBAR (ADVP (RB especially)) (WHADVP (WRB when)) (S (VP (VBN combined) (PP (IN with) (CC or) (PP (VBN given) (NP (JJ following) (NNP Doc_3137399_201_212_Chemical)))))))))) (. .)))
3137399	2	(S1 (S (NP (NP (NNS Data)) (PP (IN on) (NP (NP (NN dose) (NN dependency) (CC or) (NN incidence)) (VP (VBG concerning) (NP (DT this) (NN side) (NN effect)))))) (VP (AUX were) (RB not) (VP (VBN known))) (. .)))
3137399	3	(S1 (S (NP (PRP We)) (VP (AUX have) (VP (VBN initiated) (NP (NP (DT a) (JJ prospective) (NN study)) (SBAR (S (VP (TO to) (VP (VB obtain) (NP (NP (DT some) (JJR more) (NNS data)) (PP (IN on) (NP (DT these) (NNS subjects))))))))))) (. .)))
3137399	4	(S1 (S (S (NP (JJ Forty-four) (JJ Doc_3137399_388_391_Chemical-treated) (NNS patients)) (VP (AUX were) (VP (VBN studied)))) (, ,) (S (NP (NP (CD 37)) (PP (IN of) (NP (PRP them)))) (VP (MD could) (VP (AUX be) (VP (VBN evaluated))))) (. .)))
3137399	5	(S1 (S (NP (DT All) (NNS patients)) (VP (AUX were) (VP (VBN studied) (PP (IN by) (NP (NP (VBN repeated) (JJ physical) (NNS examinations)) (, ,) (NP (NN chest) (NNS X-rays)) (, ,) (NP (ADJP (JJ electro-) (CC and) (JJ echocardiography) (CC and) (JJ radionuclide)) (JJ left) (NN ventricular) (NN ejection) (NN fraction) (-LRB- -LRB-) (NN EF) (-RRB- -RRB-) (NNS determinations)))))) (. .)))
3137399	6	(S1 (S (NP (DT The) (NNS results)) (VP (AUX were) (VP (VBN evaluated) (PP (IN per) (NP (JJ cumulative) (NN dose) (NN level))))) (. .)))
3137399	7	(S1 (S (NP (NP (CD One)) (PP (IN of) (NP (DT the) (NNS patients)))) (VP (VBD developed) (NP (NN Doc_3137399_716_731_Disease)) (PP (IN after) (NP (NP (ADJP (NP (CD 30) (NNS mg)) (JJ m-2)) (NNP Doc_3137399_748_751_Chemical)) (CC and) (NP (ADJP (NP (QP (RB only) (CD 150)) (NNS mg)) (JJ m-2)) (NNP Doc_3137399_772_783_Chemical))))) (. .)))
3137399	8	(S1 (S (NP (DT The) (NNP Doc_3137399_789_804_Disease)) (VP (AUX was) (VP (VBN predicted) (PP (IN by) (NP (NP (DT a) (NN drop)) (PP (IN in) (NP (NP (NNS EF)) (VP (VBN determined) (PP (IN during) (NP (DT a) (JJ cold) (NN pressor) (NN test)))))))))) (. .)))
3137399	9	(S1 (S (S (NP (NP (NN None)) (PP (IN of) (NP (DT the) (JJ other) (NNS patients)))) (VP (VBD developed) (NP (JJ clinical) (NN Doc_3137399_920_934_Disease)))) (, ,) (CC nor) (SINV (AUX did) (NP (DT the) (VBN studied) (NNS parameters)) (VP (VB change))) (. .)))
3137399	10	(S1 (S (NP (NP (DT The) (NN literature)) (PP (IN on) (NP (DT this) (NN subject)))) (VP (AUX was) (ADVP (RB also)) (VP (VBN reviewed))) (. .)))
3137399	11	(S1 (S (PP (VBN Based) (PP (IN on) (NP (NP (DT the) (VBN combined) (NNS data)) (PP (IN from) (NP (NP (DT the) (JJ present) (NN study)) (CC and) (NP (DT the) (NN literature))))))) (, ,) (NP (PRP we)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NNP Doc_3137399_1111_1114_Chemical-related) (NNP Doc_3137399_1123_1137_Disease)) (VP (AUX is) (ADJP (NN dose) (JJ dependent)) (, ,) (S (VP (VBG occurring) (PP (IN at) (NP (NP (JJ cumulative) (NN dose) (NNS levels)) (PP (IN of) (NP (CD 30) (NNS mg))) (ADJP (JJ m-2) (CC or) (JJR more)) (, ,) (PP (ADVP (RB mainly)) (IN in) (NP (NP (NNS patients)) (VP (ADVP (RB also) (PRN (-LRB- -LRB-) (ADVP (ADVP (RB previously)) (CC or) (ADVP (RB simultaneously))) (-RRB- -RRB-))) (VBN treated) (PP (IN with) (NP (NNP Doc_3137399_1283_1294_Chemical)))))))))))))) (. .)))
3137399	12	(S1 (S (NP (DT The) (NN incidence)) (VP (AUX is) (ADJP (JJ likely) (S (VP (TO to) (VP (AUX be) (NP (QP (JJR less) (IN than) (CD 10)) (NN %)))))) (ADVP (RB even)) (PP (IN for) (NP (DT this) (NN risk) (NN group)))) (. .)))
3183120	0	(S1 (NP (NP (NP (JJ Reversible) (NN Doc_3183120_11_27_Disease)) (VP (VBN associated) (PP (IN with) (NP (JJ Doc_3183120_44_54_Chemical) (NN usage))))) (: :) (NP (NNP MR) (NN demonstration)) (. .)))
3183120	1	(S1 (S (NP (NN Doc_3183120_80_90_Chemical)) (VP (AUX is) (NP (NP (DT an) (JJ experimental) (NN chemotherapeutic) (NN agent)) (VP (ADVP (RB currently)) (VBG undergoing) (NP (JJ clinical) (NN evaluation))))) (. .)))
3183120	2	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (PRP$ our) (NNS results)) (PP (IN with) (NP (NP (JJ magnetic) (NN resonance)) (PRN (-LRB- -LRB-) (NP (NNP MR)) (-RRB- -RRB-))))) (PP (IN in) (S (VP (VBG demonstrating) (NP (NP (JJ reversible) (NN Doc_3183120_254_276_Disease)) (ADJP (JJ concurrent) (PP (IN with) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (DT this) (NN drug))))))))))) (. .)))
3183120	3	(S1 (S (NP (NP (DT The) (NNS abnormalities)) (PP (IN on) (NP (NNP MR)))) (VP (AUX were) (VP (VBN correlated) (PP (IN with) (NP (NNS findings))) (PP (PP (IN on) (NP (NN CT))) (CONJP (RB as) (RB well) (IN as)) (PP (IN with) (NP (JJ cerebral) (NN angiography)))))) (. .)))
3183120	4	(S1 (S (NP (NP (DT The) (NN utility)) (PP (IN of) (NP (NNP MR))) (PP (IN in) (NP (NP (DT the) (NN evaluation)) (PP (IN of) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (DT this) (JJ new) (NN agent)))))))) (VP (AUX is) (VP (VBN illustrated))) (. .)))
3220106	0	(S1 (NP (NP (NN Receptor) (NNS mechanisms)) (PP (IN of) (NP (NP (NNP Doc_3220106_23_31_Chemical-induced) (NNP Doc_3220106_40_63_Disease)) (PP (IN in) (NP (JJ chronic) (JJ Doc_3220106_75_83_Chemical-treated) (NNS rats))))) (. .)))
3220106	1	(S1 (S (NP (NNS Rats)) (VP (AUX were) (VP (VBN pretreated) (PP (IN with) (NP (NP (NN saline)) (CC or) (NP (NP (NNP Doc_3220106_134_142_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 1.5) (NN mg/kg)) (PP (IN per) (NP (NN day)))) (-RRB- -RRB-))))) (PP (IN by) (S (ADVP (RB subcutaneously)) (VP (VBG implanting) (NP (DT each) (JJ animal)) (PP (IN with) (NP (NP (DT an) (NNP Alzet) (JJ osmotic) (NN mini-pump)) (SBAR (WHNP (WDT which)) (S (ADVP (RB continuously)) (VP (VBD released) (NP (NP (NN saline)) (CC or) (NP (NNP Doc_3220106_274_282_Chemical))) (PP (IN for) (NP (CD 1) (, ,) (CD 5) (CC and) (CD 14) (NNS days))))))))))))) (. .)))
3220106	2	(S1 (S (PP (IN At) (NP (NP (DT the) (NN end)) (PP (IN of) (NP (DT each) (JJ pretreatment) (NN period))))) (, ,) (NP (NNS animals)) (VP (AUX were) (VP (VBN used) (PP (IN for) (S (-LRB- -LRB-) (NP (PRP i)) (-RRB- -RRB-) (VP (VBG determining) (NP (NP (PRP$ their) (JJ locomotor) (NN response)) (PP (TO to) (S (ADVP (RB acutely)) (VP (VBN injected) (NP (NP (NP (NNP Doc_3220106_428_436_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 0.2) (NNS mg/kg)) (, ,) (NP (NNP s.c.)) (-RRB- -RRB-))) (CC and) (NP (-LRB- -LRB-) (NNP ii) (-RRB- -RRB-))) (S (VP (VBG measuring) (NP (NP (NP (DT the) (NN density)) (PP (IN of) (NP (NNP Doc_3220106_489_503_Chemical)))) (CC and) (NP (NP (JJ -LSB-3H) (JJ -RSB-) (JJ Doc_3220106_512_521_Chemical) (JJ binding) (NNS sites)) (PP (IN in) (NP (DT the) (NN striatum)))))))))))))))) (. .)))
3220106	3	(S1 (S (NP (PRP We)) (VP (VBD observed) (NP (NP (DT no) (NNS changes)) (PP (IN in) (NP (NP (JJ Doc_3220106_579_587_Chemical-induced) (NN locomotor) (NN response)) (, ,) (NP (JJ striatal) (JJ L--LSB-3H) (JJ -RSB-) (NN Doc_3220106_631_639_Chemical)) (CC and) (NP (JJ -LSB-3H) (JJ -RSB-) (NN Doc_3220106_648_657_Chemical) (VBG binding)))) (PP (IN in) (NP (DT the) (NNS animals)))) (PP (VBN pretreated) (PP (IN with) (NP (NNP Doc_3220106_697_705_Chemical)))) (PP (IN for) (NP (CD 1) (NN day)))) (. .)))
3220106	4	(S1 (S (PP (IN In) (NP (NP (NNS rats)) (SBAR (WHNP (WDT which)) (S (VP (AUX were) (VP (VBN pretreated) (PP (IN with) (NP (NNP Doc_3220106_752_760_Chemical))) (PP (IN for) (NP (CD 5) (NNS days))))))))) (, ,) (NP (EX there)) (VP (AUX was) (NP (NP (DT a) (JJ significant) (NN increase)) (PP (IN in) (NP (NP (DT the) (JJ Doc_3220106_813_821_Chemical-stimulated) (NN locomotor) (NN response)) (SBAR (WHNP (WDT which)) (S (VP (AUX was) (VP (VBN associated) (PP (PP (IN with) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (DT the) (NN number)) (PP (IN of) (NP (JJ L--LSB-3H) (JJ -RSB-) (NNP Doc_3220106_913_921_Chemical) (VBG binding) (NNS sites))))))) (CC and) (PP (ADVP (RB also)) (IN with) (NP (NP (DT an) (JJ elevated) (NNP Doc_3220106_962_970_Chemical) (PRN (-LRB- -LRB-) (NNP DA) (-RRB- -RRB-)) (NN level)) (PP (IN in) (NP (DT the) (NN striatum)))))))))))))) (. .)))
3220106	5	(S1 (S (NP (NP (DT The) (NN number)) (PP (IN of) (NP (JJ striatal) (JJ -LSB-3H) (NN -RSB-) (NN Doc_3220106_1026_1035_Chemical) (VBG binding) (NNS sites)))) (VP (AUX was) (RB not) (VP (VBN affected))) (. .)))
3220106	6	(S1 (S (PP (IN In) (NP (NP (NNS animals)) (VP (VBN pretreated) (PP (IN with) (NP (NNP Doc_3220106_1095_1103_Chemical))) (PP (IN for) (NP (CD 14) (NNS days)))))) (, ,) (NP (DT the) (JJ Doc_3220106_1121_1129_Chemical-induced) (JJ locomotor) (NN response)) (VP (VBD remained) (S (VP (TO to) (VP (AUX be) (VP (VBN potentiated)))))) (. .)))
3220106	7	(S1 (S (ADVP (RB However)) (, ,) (NP (DT this) (NN response)) (VP (AUX was) (VP (VBN correlated) (PP (IN with) (NP (NP (DT an) (JJ elevated) (NN number)) (PP (IN of) (NP (JJ striatal) (JJ -LSB-3H) (NN -RSB-) (NNP Doc_3220106_1263_1272_Chemical) (JJ binding) (NNS sites))))) (, ,) (SBAR (IN whereas) (S (NP (NP (DT the) (NN number)) (PP (IN of) (NP (NP (JJ striatal) (JJ L--LSB-3H) (JJ -RSB-) (JJ Doc_3220106_1325_1333_Chemical) (JJ binding) (NNS sites)) (CC and) (NP (DT the) (JJ striatal) (NN DA) (NN level))))) (VP (AUX were) (ADJP (JJ normal))))))) (. .)))
3220106	8	(S1 (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (JJ chronic) (JJ Doc_3220106_1422_1430_Chemical-treated) (NNS rats)) (VP (VBP develop) (NP (NN Doc_3220106_1452_1475_Disease)) (PP (IN in) (NP (NP (NN response)) (PP (TO to) (NP (NNP Doc_3220106_1491_1499_Chemical))) (PP (ADVP (RB initially)) (JJ due) (PP (TO to) (NP (NP (NNS increases)) (PP (IN of) (NP (NP (PDT both) (DT the) (NN density)) (PP (IN of) (NP (NP (JJ nicotinic) (NNS receptors)) (CC and) (NP (NN DA) (NN concentration)))) (, ,) (VP (VBN followed) (PP (IN by) (S (VP (VBG inducing) (NP (NP (NN DA) (NN receptor) (NN supersensitivity)) (PP (IN in) (NP (DT the) (NN striatum))))))))))))))))))) (. .)))
326460	0	(S1 (NP (NP (NN Amelioration)) (PP (IN of) (NP (NNP Doc_326460_16_30_Chemical-induced) (NNP Doc_326460_39_50_Disease))) (PP (IN by) (NP (NNP Doc_326460_54_61_Chemical))) (. .)))
326460	1	(S1 (S (S (NP (NP (DT The) (JJ beta) (JJ adrenergic) (VBG blocking) (NN drug)) (, ,) (NP (NNP Doc_326460_98_105_Chemical)) (, ,)) (VP (VBD tended) (S (VP (TO to) (VP (VB correct) (NP (NP (DT the) (NN Doc_326460_129_140_Disease)) (PP (IN of) (NP (NP (JJ short-term) (JJ Doc_326460_155_169_Chemical) (NN treatment)) (PP (IN in) (NP (ADJP (CD 6) (JJ healthy) (NN male)) (NNS subjects))))))))))) (CC and) (S (SBAR (IN although) (S (NP (DT the) (NN effect)) (VP (AUX was) (ADJP (JJ small))))) (NP (PRP it)) (VP (AUX was) (ADJP (JJ significant)))) (. .)))
326460	2	(S1 (S (NP (NNP Doc_326460_261_268_Chemical)) (ADVP (RB also)) (VP (VP (VBD reduced) (NP (NP (DT the) (NN rise)) (PP (IN in) (NP (NP (NN plasma) (NN Doc_326460_301_312_Chemical)) (CC and) (NP (NN urine) (JJ Doc_326460_323_332_Chemical) (NN excretion)))) (PP (VBG following) (NP (NNP Doc_326460_353_367_Chemical))))) (CC and) (VP (VBD increased) (NP (DT the) (NN urine) (NN Doc_326460_392_398_Chemical/Doc_326460_399_408_Chemical) (NN ratio)))) (. .)))
326460	3	(S1 (S (NP (EX There)) (VP (AUX was) (NP (NP (DT no) (NN evidence)) (PP (IN of) (NP (NP (DT a) (NN shift)) (PP (IN of) (NP (NNP Doc_326460_452_461_Chemical))) (PP (IN from) (NP (DT the) (NN intracellular))) (PP (TO to) (NP (DT the) (NN extracellular) (NN space))))))) (. .)))
3300918	0	(S1 (NP (NP (NP (NNP St.) (NNP Doc_3300918_4_18_Disease)) (, ,) (ADVP (ADVP (RB then)) (CC and) (ADVP (RB now)))) (: :) (NP (NP (DT a) (NN case) (NN report)) (CC and) (NP (JJ historical) (NN review))) (. .)))
3300918	1	(S1 (S (NP (NP (DT A) (JJ rare) (NN case)) (PP (IN of) (NP (JJ morbid) (NNP Doc_3300918_93_102_Disease)))) (, ,) (PP (ADVP (RB together)) (IN with) (NP (JJ striking) (JJ angiographic) (NNS findings))) (, ,) (VP (AUX is) (VP (VBN described) (PP (JJ secondary) (TO to) (NP (NP (DT the) (NN ingestion)) (PP (IN of) (NP (NNP Doc_3300918_193_205_Chemical))))) (PP (IN by) (NP (DT a) (JJ 48-year-old) (NN woman))))) (. .)))
3300918	2	(S1 (S (NP (NP (DT A) (JJ brief) (NN review)) (PP (IN of) (NP (NP (DT the) (NN literature)) (PP (IN on) (NP (JJ similar) (NNS cases)))))) (VP (AUX is) (VP (VBN presented))) (. .)))
3300918	3	(S1 (S (NP (NP (DT A) (NN discussion)) (PP (IN of) (NP (NP (DT the) (NN history)) (PP (IN of) (NP (NN ergot)))))) (VP (VBZ includes) (NP (NP (PRP$ its) (JJ original) (NN discovery)) (, ,) (NP (NP (DT the) (NNS epidemics)) (PP (IN of) (NP (NP (NN gangrene)) (SBAR (WHNP (WDT that)) (S (NP (PRP it)) (VP (AUX has) (VP (VBN caused) (PP (IN through) (NP (DT the) (NNS ages)))))))))) (CC and) (NP (NP (PRP$ its) (ADJP (JJ past) (CC and) (JJ present)) (NN role)) (PP (IN in) (NP (NP (DT the) (NN management)) (PP (IN of) (NP (NNP Doc_3300918_477_485_Disease) (NNP Doc_3300918_486_494_Disease)))))))) (. .)))
3300918	4	(S1 (S (PP (IN Despite) (NP (NP (DT the) (NN advent)) (PP (IN of) (NP (NP (JJ Doc_3300918_518_525_Chemical) (NN channel) (NNS blockers)) (CC and) (NP (JJ beta-adrenergic) (NNS antagonists)))))) (, ,) (NP (NN ergot) (NNS preparations)) (VP (VBP continue) (S (VP (TO to) (VP (VB play) (NP (DT a) (JJ major) (NN role)) (PP (IN in) (NP (JJ Doc_3300918_628_636_Disease) (NN therapy)))))) (, ,) (SBAR (IN so) (IN that) (S (NP (NP (DT the) (NN danger)) (PP (IN of) (NP (NNP St.) (NNP Doc_3300918_672_686_Disease)))) (VP (VBZ persists))))) (. .)))
3311455	0	(S1 (NP (NP (JJ Cardiac) (NN transplantation)) (: :) (NP (NP (VBN improved) (NN quality)) (PP (IN of) (NP (NN survival))) (PP (IN with) (NP (DT a) (VBN modified) (NN immunosuppressive) (NN protocol)))) (. .)))
3311455	1	(S1 (S (NP (NP (DT The) (NNS effects)) (PP (IN on) (NP (JJ renal) (NN function))) (PP (IN on) (NP (CD two) (JJ different) (NN immunosuppressive) (NNS protocols)))) (VP (AUX were) (VP (VBN evaluated) (ADVP (RB retrospectively)) (PP (IN in) (NP (NP (CD two) (JJ subsequent) (NNS groups)) (PP (IN of) (NP (NN heart) (NN transplant) (NNS recipients))))))) (. .)))
3311455	2	(S1 (S (PP (IN In) (NP (NN group))) (NP (PRP I)) (, ,) (NP (NNP Doc_3311455_273_285_Chemical)) (VP (VP (AUX was) (VP (VBN given) (PP (IN before) (NP (DT the) (NN procedure))) (PP (IN at) (NP (NP (DT a) (NN loading) (NN dose)) (PP (IN of) (NP (CD 17.5) (NN mg/kg))))))) (CC and) (VP (ADVP (RB then)) (VBD continued) (PP (IN after) (NP (DT the) (NN procedure))) (S (VP (TO to) (VP (VB keep) (NP (DT a) (JJ whole) (NN blood) (NN level)) (PP (IN about) (NP (CD 1000) (NN ng/ml)))))))) (. .)))
3311455	3	(S1 (S (PP (IN In) (NP (NN group) (NNP II))) (, ,) (NP (NNP Doc_3311455_447_459_Chemical)) (VP (VP (AUX was) (VP (VBN started) (ADVP (RB only)) (PP (IN after) (NP (DT the) (NN procedure))) (PP (IN at) (NP (DT a) (JJR lower) (NN dosage))))) (CC and) (VP (AUX was) (VP (VBN complemented) (PP (IN by) (NP (NP (NNP Doc_3311455_539_551_Chemical)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX was) (VP (VBN used) (PP (IN for) (NP (DT the) (JJ first) (JJ postoperative) (NN week)))))))))))) (. .)))
3311455	4	(S1 (S (NP (NNP Group) (NNP II)) (VP (VBD showed) (NP (NP (DT a) (ADJP (RBR better) (JJ perioperative)) (JJ renal) (NN function)) (SBAR (IN as) (S (VP (VBN determined) (PP (IN by) (NP (JJ serum) (UCP (JJ Doc_3311455_679_698_Chemical) (CC and) (NN serum)) (JJ Doc_3311455_709_719_Chemical) (NNS levels)))))))) (. .)))
3311455	5	(S1 (S (NP (NNP Group) (NNP II)) (ADVP (RB also)) (VP (VBD showed) (NP (NP (DT a) (JJ significant) (NN decrease)) (PP (IN of) (NP (NN chronic) (NN nephrotoxicity))) (ADJP (JJ secondary) (PP (TO to) (NP (NP (JJ long-term) (NN therapy)) (PP (IN with) (NP (NNP Doc_3311455_834_846_Chemical)))))))) (. .)))
3311455	6	(S1 (S (PP (IN Despite) (NP (NP (DT this) (NN improvement)) (PP (IN in) (NP (JJ late) (JJ renal) (NN function))))) (, ,) (NP (NNP group) (NNP II)) (ADVP (RB still)) (VP (VBZ shows) (NP (NP (DT a) (JJ slow) (NN rise)) (PP (IN in) (NP (JJ serum) (NNP Doc_3311455_939_949_Chemical))))) (. .)))
3311455	7	(S1 (S (NP (PRP We)) (VP (VBP think) (SBAR (SBAR (IN that) (S (NP (NP (RB even) (DT these) (JJR lower) (NNS dosages)) (PP (IN of) (NP (NNP Doc_3311455_993_1005_Chemical)))) (VP (MD can) (VP (VB cause) (NP (JJ chronic) (NN nephrotoxicity)))))) (CC and) (SBAR (IN that) (S (NP (NP (JJ further) (NN modification)) (PP (IN of) (NP (DT the) (JJ immunosuppressive) (NN regimen)))) (VP (AUX is) (VP (VBN required) (S (VP (TO to) (VP (ADVP (RB completely)) (VB abolish) (NP (DT this) (JJ toxic) (NN side) (NN effect))))))))))) (. .)))
33969	0	(S1 (NP (NP (NP (NNP Doc_33969_0_13_Chemical)) (CC and) (NP (NNP Doc_33969_18_29_Chemical))) (PP (IN in) (NP (JJ neuroleptic-induced) (NNP Doc_33969_53_65_Disease))) (. .)))
33969	1	(S1 (S (PP (IN In) (NP (DT a) (JJ 12-week) (JJ controlled) (NN study))) (NP (NNP Doc_33969_97_110_Chemical)) (VP (AUX was) (PP (VBN compared) (PP (TO to) (NP (NP (NNP Doc_33969_127_138_Chemical)) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NNP Doc_33969_159_171_Disease))) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_33969_183_205_Chemical))) (PP (IN in) (NP (CD 60) (JJ Doc_33969_212_225_Disease) (NNS outpatients)))))))))) (. .)))
33969	2	(S1 (S (NP (NP (NNP Doc_33969_239_252_Chemical)) (CC and) (NP (NNP Doc_33969_257_268_Chemical))) (VP (VP (AUX were) (VP (VBN found) (S (VP (TO to) (VP (AUX be) (ADJP (RB equally) (JJ effective) (PP (IN in) (S (VP (VBG controlling) (NP (NNP Doc_33969_319_340_Disease))))))))))) (CC and) (VP (AUX were) (ADJP (RB as) (JJ efficacious) (PP (IN as) (NP (NP (NNP Doc_33969_368_380_Chemical)) (, ,) (NP (PRP$ their) (JJ previous) (JJ antiparkinsonian) (NN drug))))))) (. .)))
33969	3	(S1 (S (ADVP (RB However)) (, ,) (NP (NNP Doc_33969_429_440_Chemical)) (VP (VP (VBD treated) (SBAR (S (NP (NNS patients)) (VP (AUX had) (NP (NP (DT a) (JJ significant) (NN increase)) (PP (IN in) (NP (NNP Doc_33969_488_506_Disease))) (PP (VBN compared) (PP (TO to) (NP (PRP$ their) (NN condition))))) (PP (IN during) (NP (JJ Doc_33969_542_555_Chemical) (NN treatment))))))) (, ,) (CC and) (VP (ADVP (RB significantly) (RBR more)) (NP (NP (NNP Doc_33969_590_597_Disease)) (CC and) (NP (NNP Doc_33969_602_612_Disease))) (PP (IN than) (NP (JJ Doc_33969_618_631_Chemical) (VBN treated) (NNS patients))))) (. .)))
33969	4	(S1 (S (NP (DT This)) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NNP Doc_33969_669_680_Chemical)) (VP (AUX is) (RB not) (NP (NP (DT the) (JJ anticholinergic) (NN drug)) (PP (IN of) (NP (NN choice))) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (JJ neuroleptic-induced) (NNP Doc_33969_763_784_Disease)))))) (, ,) (PP (IN because) (IN of) (NP (PRP$ its) (ADJP (RBR more) (JJ toxic)) (ADJP (JJ central) (CC and) (JJ peripheral)) (JJ atropinic) (NN effect))))))) (. .)))
3411101	0	(S1 (FRAG (NP (JJ Doc_3411101_0_32_Chemical-induced) (NN fulminant) (NN Doc_3411101_51_60_Disease)) (PP (IN in) (NP (DT a) (JJ pregnant) (NN woman))) (. .)))
3411101	1	(S1 (S (NP (DT A) (NN case)) (VP (VBP report)) (. .)))
3411101	2	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT the) (NN case)) (PP (IN of) (NP (NP (DT a) (JJ 19-year-old) (JJ Laotian) (NN patient)) (VP (VBN affected) (PP (IN by) (NP (JJ fulminant) (NNP Doc_3411101_171_180_Disease))) (PP (IN during) (NP (NP (DT the) (JJ third) (NN trimester)) (PP (IN of) (NP (PRP$ her) (NN pregnancy))) (PP (IN after) (NP (NP (DT a) (JJ 1-month) (NN administration)) (PP (IN of) (NP (NNP Doc_3411101_259_291_Chemical)))))))))))) (. .)))
3411101	3	(S1 (S (PP (IN After) (NP (NN delivery))) (, ,) (NP (DT the) (NN patient)) (VP (VBD underwent) (NP (JJ orthotopic) (NN liver) (NN transplantation))) (. .)))
3411101	4	(S1 (S (NP (DT The) (NN patient)) (VP (AUX was) (PP (IN in) (NP (JJ good) (NN condition))) (PP (NP (CD 16) (NNS months)) (IN after) (NP (NN liver) (NN transplantation)))) (. .)))
3411101	5	(S1 (S (NP (NP (NP (NN Doc_3411101_438_447_Chemical)) (NP (PRP itself))) (CC or) (NP (NNP Doc_3411101_458_480_Chemical))) (VP (MD may) (VP (AUX be) (ADJP (JJ responsible) (PP (IN for) (NP (NP (JJ fulminant) (NN Doc_3411101_514_523_Disease)) (PP (IN in) (NP (DT this) (NN patient)))))))) (. .)))
3413271	0	(S1 (NP (NP (NP (NNPS Mechanisms)) (PP (IN of) (NP (NNP Doc_3413271_14_33_Disease))) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_3413271_45_56_Chemical))))) (: :) (NP (NP (NN comparison)) (PP (IN with) (NP (JJ exercise-induced) (NNP Doc_3413271_91_99_Disease)))) (. .)))
3413271	1	(S1 (S (NP (NP (DT The) (NN role)) (PP (IN of) (NP (NNP Doc_3413271_113_124_Chemical))) (PP (IN in) (S (VP (VBG eliciting) (NP (NNP Doc_3413271_138_157_Disease)))))) (VP (AUX was) (VP (VBN examined) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_3413271_188_211_Disease))))))) (. .)))
3413271	2	(S1 (S (NP (NP (NP (JJ Objective) (NNS signs)) (PP (IN of) (NP (NNP Doc_3413271_232_240_Disease)))) (CC and) (NP (NP (NNS factors)) (VP (VBG increasing) (NP (JJ myocardial) (JJ Doc_3413271_275_281_Chemical) (NN consumption))))) (VP (AUX were) (VP (VBN compared) (PP (IN during) (NP (NP (JJ Doc_3413271_315_326_Chemical) (NN infusion)) (CC and) (NP (JJ supine) (NN bicycle) (NN exercise)))))) (. .)))
3413271	3	(S1 (S (CC Both) (NP (NP (NNP Doc_3413271_370_381_Chemical)) (CC and) (NP (NN exercise))) (VP (VBD produced) (NP (NNP Doc_3413271_404_423_Disease)) (SBAR (IN as) (S (VP (VBN evidenced) (PP (IN by) (NP (NNP ST) (NN segment) (NNP Doc_3413271_451_461_Disease) (CC and) (NNP Doc_3413271_466_472_Disease))))))) (. .)))
3413271	4	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (NNS mechanisms)) (PP (IN of) (NP (NNP Doc_3413271_501_520_Disease))) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_3413271_532_543_Chemical))))) (VP (AUX were) (ADJP (RB significantly) (JJ different) (PP (IN from) (NP (NP (DT those)) (PP (IN of) (NP (NN exercise))))))) (. .)))
3413271	5	(S1 (S (NP (JJ Exercise-induced) (NNP Doc_3413271_614_633_Disease)) (VP (AUX was) (VP (VBN marked) (ADVP (RB predominantly)) (PP (IN by) (NP (NP (VBN increased) (NN heart) (NN rate)) (CC and) (NP (JJ rate-pressure) (NN product)))) (PP (IN with) (NP (NP (DT a) (JJ minor) (NN contribution)) (PP (IN of) (NP (JJ end-diastolic) (NN volume))))) (, ,) (SBAR (IN while) (S (NP (NNP Doc_3413271_766_777_Chemical-induced) (NNP Doc_3413271_786_794_Disease)) (VP (AUX was) (VP (VBN characterized) (PP (IN by) (NP (NP (NP (DT a) (JJ marked) (NN increase)) (PP (IN in) (NP (NN contractility)))) (CC and) (NP (NP (DT a) (ADJP (RBR less) (JJ pronounced)) (NN increase)) (PP (IN in) (NP (NP (NN heart) (NN rate)) (CC and) (NP (NN rate-pressure) (NN product))))))))))))) (. .)))
3413271	6	(S1 (S (NP (DT These) (NNS findings)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (NNP Doc_3413271_952_960_Disease)) (VP (VBN produced) (PP (IN by) (NP (NNP Doc_3413271_973_984_Chemical))))) (, ,) (SBAR (IN as) (S (VP (MD may) (VP (VB occur) (PP (IN during) (NP (NP (NNS states)) (PP (IN of) (NP (JJ emotional) (NN distress))))))))) (, ,) (VP (AUX has) (NP (NP (DT a) (NN mechanism)) (ADJP (JJ distinct) (PP (IN from) (NP (NP (DT that)) (ADJP (JJ due) (PP (TO to) (NP (JJ physical) (NN exertion)))))))))))) (. .)))
3431591	0	(S1 (S (NP (NP (JJ Recent) (JJ preclinical) (CC and) (JJ clinical) (NNS studies)) (PP (IN with) (NP (DT the) (JJ thymidylate) (NN synthase)))) (VP (VBP inhibitor) (NP (NP (NNP Doc_3431591_80_115_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_3431591_117_124_Chemical)) (-RRB- -RRB-)))) (. .)))
3431591	1	(S1 (S (NP (NP (NN Doc_3431591_127_134_Chemical)) (, ,) (NP (NNP Doc_3431591_136_171_Chemical)) (, ,)) (VP (AUX is) (NP (NP (DT a) (JJ tight-binding) (NN inhibitor)) (PP (IN of) (NP (NP (JJ thymidylate) (NN synthase)) (-LRB- -LRB-) (NP (NNP TS)) (-RRB- -RRB-) (SBAR (WHNP (WP$ whose) (NN Doc_3431591_237_249_Disease)) (S (VP (AUX is) (VP (VBN mediated) (ADVP (RB solely)) (PP (IN through) (NP (NP (DT the) (NN inhibition)) (PP (IN of) (NP (DT this) (NN enzyme))))))))))))) (. .)))
3431591	2	(S1 (S (NP (JJ Recent) (NN preclinical) (NNS studies)) (VP (AUX have) (VP (VBN focused) (PP (IN on) (NP (NP (DT the) (JJ intracellular) (NN formation)) (PP (IN of) (NP (JJ Doc_3431591_382_389_Chemical) (NNS polyglutamates))))))) (. .)))
3431591	3	(S1 (S (PP (VBG Following) (NP (NP (DT a) (JJ 12-hour) (NN exposure)) (PP (IN of) (NP (JJ L1210) (NNS cells))) (PP (TO to) (NP (ADJP (CD 50) (NN microM)) (JJ -LSB-3H) (JJ -RSB-) (NN Doc_3431591_467_474_Chemical))))) (, ,) (NP (NP (CD 30) (NN %)) (PP (IN of) (NP (DT the) (JJ extractable) (NN radioactivity)))) (VP (MD could) (VP (AUX be) (VP (VBN accounted) (PP (IN for) (NP (NP (RB as) (JJ Doc_3431591_539_546_Chemical) (NN tetra-)) (CC and) (NP (NNP Doc_3431591_558_572_Chemical)))) (, ,) (SBAR (IN as) (S (VP (VBN determined) (PP (IN by) (NP (JJ high-pressure) (NN liquid) (NN chromatography) (PRN (-LRB- -LRB-) (NP (NNP HPLC)) (-RRB- -RRB-)) (NNS analyses))))))))) (. .)))
3431591	4	(S1 (S (PP (IN As) (NP (NP (NNS inhibitors)) (PP (IN of) (NP (JJ isolated) (JJ L1210) (NNS TS))))) (, ,) (S (NP (NNP Doc_3431591_680_687_Chemical)) (ADJP (JJ di-) (, ,) (JJ tri-) (, ,) (JJ tetra-))) (CC and) (S (NP (NNP Doc_3431591_710_724_Chemical)) (VP (AUX are) (ADJP (JJ 26-) (, ,) (JJ 87-) (, ,) (JJ 119-) (CC and) (JJ 114-fold) (ADJP (RBR more) (JJ potent)) (PP (IN than) (NP (NNP Doc_3431591_774_781_Chemical)))) (, ,) (ADVP (RB respectively)))) (, ,) (CC and) (S (NP (PRP$ their) (NN formation)) (VP (MD may) (, ,) (ADVP (RB therefore)) (, ,) (VP (AUX be) (NP (NP (DT an) (JJ important) (NN determinant)) (PP (IN of) (NP (NNP Doc_3431591_864_871_Chemical) (NNP Doc_3431591_872_884_Disease))))))) (. .)))
3431591	5	(S1 (S (PP (IN In) (NP (NP (JJ early) (JJ clinical) (NNS studies)) (PP (IN with) (NP (NNP Doc_3431591_917_924_Chemical))))) (, ,) (NP (NN activity)) (VP (AUX has) (VP (AUX been) (VP (VBN seen) (PP (IN in) (NP (NP (NNP Doc_3431591_952_965_Disease)) (, ,) (NP (NNP Doc_3431591_967_981_Disease)) (, ,) (NP (NNP Doc_3431591_983_991_Disease)) (, ,) (CC and) (NP (NNP Doc_3431591_997_1009_Disease))))))) (. .)))
3431591	6	(S1 (S (NP (NN Doc_3431591_1011_1021_Disease)) (VP (VBD included) (NP (NP (NN hepatotoxicity)) (, ,) (NP (NN malaise)) (, ,) (CC and) (NP (JJ dose-limiting) (NN nephrotoxicity)))) (. .)))
3431591	7	(S1 (S (NP (DT This) (JJ latter) (NN effect)) (VP (AUX is) (VP (VBN thought) (S (VP (TO to) (VP (AUX be) (ADVP (RB due) (PP (TO to) (NP (NN drug) (NN precipitation)))) (PP (IN within) (NP (NP (DT the) (JJ renal) (NN tubule)) (PP (IN as) (NP (NP (DT a) (NN result)) (PP (IN of) (NP (NP (DT the) (JJ poor) (NN solubility)) (PP (IN of) (NP (NNP Doc_3431591_1214_1221_Chemical))) (PP (IN under) (NP (JJ acidic) (NNS conditions)))))))))))))) (. .)))
3431591	8	(S1 (S (PP (IN In) (NP (DT an) (NN attempt) (S (VP (TO to) (VP (VB overcome) (NP (DT this) (NN problem))))))) (, ,) (NP (NP (DT a) (JJ clinical) (NN trial)) (PP (IN of) (NP (NNP Doc_3431591_1307_1314_Chemical))) (VP (VBN administered) (PP (IN with) (NP (JJ alkaline) (NNS diuresis))))) (VP (AUX is) (PP (IN under) (NP (NN way)))) (. .)))
3431591	9	(S1 (S (NP (NP (JJ Preliminary) (NNS results)) (PP (IN at) (NP (QP (CD 400) (CC and) (CD 500)) (NNS mg/m2)))) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (DT a) (NN reduction)) (PP (IN in) (NP (NN nephrotoxicity)))) (VP (MD may) (VP (AUX have) (VP (AUX been) (VP (VBN achieved) (PP (IN with) (NP (NP (QP (RB only) (CD 1)) (NN instance)) (PP (IN of) (NP (NNP Doc_3431591_1496_1510_Disease))) (PP (IN in) (NP (CD 10) (NNS patients)))))))))))) (. .)))
3431591	10	(S1 (S (NP (NP (NN Hepatotoxicity)) (CC and) (NP (NN malaise))) (VP (AUX are) (ADVP (RB again)) (NP (DT the) (RBS most) (JJ frequent) (NN side) (NNS effects))) (. .)))
3431591	11	(S1 (S (NP (NP (NN Evidence)) (PP (IN of) (NP (NN antitumor) (NN activity)))) (VP (AUX has) (VP (AUX been) (VP (VBN seen) (PP (IN in) (NP (CD 3) (NNS patients)))))) (. .)))
3431591	12	(S1 (S (NP (JJ Pharmacokinetic) (NNS investigations)) (VP (AUX have) (VP (VBN shown) (SBAR (SBAR (IN that) (S (NP (NN alkaline) (NN diuresis)) (VP (AUX does) (RB not) (VP (VB alter) (NP (NP (JJ Doc_3431591_1736_1743_Chemical) (NN plasma) (NNS levels)) (CC or) (NP (JJ urinary) (NN excretion))))))) (CC and) (SBAR (IN that) (S (NP (JJ satisfactory) (NN urinary) (NN alkalinization)) (VP (MD can) (VP (AUX be) (ADVP (RB readily)) (VP (VBN achieved))))))))) (. .)))
343678	0	(S1 (NP (NP (NP (NN Doc_343678_0_16_Disease)) (PP (IN after) (NP (NN needle-stick) (NN exposure)))) (: :) (NP (NP (NN prevention)) (PP (IN with) (NP (JJ Doc_343678_62_73_Disease) (JJ immune) (NN globulin)))) (. .)))
343678	1	(S1 (NP (NP (NP (JJ Final) (NN report)) (PP (IN of) (NP (DT the) (NNP Veterans) (NNP Administration)))) (NP (NNP Cooperative) (NNP Study)) (. .)))
343678	2	(S1 (S (NP (NP (NP (JJ Doc_343678_154_165_Disease) (JJ immune) (NN globulin)) (PRN (-LRB- -LRB-) (NP (NNP HBIG)) (-RRB- -RRB-))) (CC and) (NP (NP (JJ immune) (NN serum) (NN globulin)) (PRN (-LRB- -LRB-) (NP (NNP ISG)) (-RRB- -RRB-)))) (VP (AUX were) (VP (VBN examined) (PP (IN in) (NP (NP (DT a) (JJ randomized) (, ,) (JJ double-blind) (NN trial)) (SBAR (S (VP (TO to) (VP (VB assess) (NP (PRP$ their) (JJ relative) (NNS efficacies)) (PP (IN in) (S (VP (VBG preventing) (NP (NNP Doc_343678_321_337_Disease)) (PP (IN after) (NP (NP (JJ needle-stick) (NN exposure)) (PP (TO to) (NP (NNP Doc_343678_369_396_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_343678_398_403_Chemical)) (-RRB- -RRB-)) (JJ -positive) (NNS donors)))))))))))))))) (. .)))
343678	3	(S1 (S (S (NP (JJ Clinical) (NNP Doc_343678_431_440_Disease)) (VP (VBD developed) (PP (PP (IN in) (NP (NP (CD 1.4) (NN %)) (PP (IN of) (NP (NNP HBIG))))) (CC and) (PP (IN in) (NP (NP (CD 5.9) (NN %)) (PP (IN of) (NP (NP (JJ ISG) (NNS recipients)) (PRN (-LRB- -LRB-) (NP (NNP P) (SYM =) (CD 0.016)) (-RRB- -RRB-))))))))) (, ,) (CC and) (S (NP (NP (NN seroconversion)) (PRN (-LRB- -LRB-) (NP (NNS anti-HBs)) (-RRB- -RRB-))) (VP (VBD occurred) (PP (IN in) (NP (NP (CD 5.6) (NN %)) (CC and) (NP (NP (NP (CD 20.7) (NN %)) (PP (IN of) (NP (PRP them))) (ADVP (RB respectively))) (PRN (-LRB- -LRB-) (NP (NP (RB P) (JJR less)) (PP (IN than) (NP (CD 0.001)))) (-RRB- -RRB-))))))) (. .)))
343678	4	(S1 (S (NP (JJ Mild) (CC and) (JJ transient) (NNS side-effects)) (VP (AUX were) (VP (VBN noted) (PP (PP (IN in) (NP (NP (CD 3.0) (NN %)) (PP (IN of) (NP (NNP ISG))))) (CC and) (PP (IN in) (NP (NP (CD 3.2) (NN %)) (PP (IN of) (NP (NN HBIG) (NNS recipients)))))))) (. .)))
343678	5	(S1 (S (NP (JJ Available) (NN donor) (NNS sera)) (VP (AUX were) (VP (VBN examined) (PP (IN for) (NP (NP (NP (NN DNA) (NN polymerase)) (PRN (-LRB- -LRB-) (NP (NN DNAP)) (-RRB- -RRB-))) (CC and) (NP (NP (NP (NN e) (NN antigen)) (CC and) (NP (NN antibody))) (PRN (-LRB- -LRB-) (NP (NNP Doc_343678_788_793_Chemical)) (: ;) (NP (NN anti-HBE)) (-RRB- -RRB-))))))) (. .)))
343678	6	(S1 (S (CC Both) (NP (NP (NNP DNAP)) (CC and) (NP (NNP Doc_343678_820_825_Chemical))) (VP (VBD showed) (NP (NP (DT a) (ADJP (RB highly) (RB statistically) (JJ significant)) (NN correlation)) (PP (IN with) (NP (NP (DT the) (NN infectivity)) (PP (IN of) (NP (JJ Doc_343678_904_909_Chemical-positive) (NNS donors))))))) (. .)))
343678	7	(S1 (S (NP (JJ Doc_343678_927_938_Disease) (JJ immune) (NN globulin)) (VP (VBD remained) (ADJP (RB significantly) (JJ superior) (PP (TO to) (NP (NNP ISG)))) (PP (IN in) (S (VP (VBG preventing) (NP (NNP Doc_343678_1008_1024_Disease)) (ADVP (RB even))))) (SBAR (WHADVP (WRB when)) (S (NP (DT the) (NN analysis)) (VP (AUX was) (VP (VBN confined) (PP (TO to) (NP (DT these) (CD two) (JJ high-risk) (NNS subgroups)))))))) (. .)))
343678	8	(S1 (S (NP (NP (DT The) (NN efficacy)) (PP (IN of) (NP (NNP ISG))) (PP (IN in) (S (VP (VBG preventing) (NP (JJ Doc_343678_1129_1145_Disease) (NN cannot)))))) (VP (AUX be) (VP (VBN ascertained) (SBAR (IN because) (S (NP (DT a) (JJ true) (NN placebo) (NN group)) (VP (AUX was) (RB not) (VP (VBN included))))))) (. .)))
3461217	0	(S1 (NP (NP (NN Production)) (PP (IN of) (NP (NP (JJ autochthonous) (NN Doc_3461217_28_43_Disease)) (PP (IN in) (NP (JJ Lobund-Wistar) (NNS rats))))) (PP (IN by) (NP (NP (NNS treatments)) (PP (IN with) (NP (NP (NNP Doc_3461217_85_107_Chemical)) (CC and) (NP (NNP Doc_3461217_112_124_Chemical)))))) (. .)))
3461217	1	(S1 (S (S (NP (NP (QP (JJR More) (IN than) (CD 50)) (NN %)) (PP (IN of) (NP (NNP Lobund-Wistar) (PRN (-LRB- -LRB-) (NP (NNP L-W)) (-RRB- -RRB-)) (NN strain) (NNS rats)))) (VP (VBD developed) (NP (JJ large) (, ,) (JJ palpable) (NNP Doc_3461217_201_225_Disease) (PRN (-LRB- -LRB-) (NNP Doc_3461217_227_230_Disease) (-RRB- -RRB-)) (JJ following) (NNS treatments)) (PP (IN with) (NP (NP (NP (NNP Doc_3461217_258_280_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP CAS)) (: :) (NP (CD 684-93-5)) (-RRB- -RRB-))) (CC and) (NP (JJ Doc_3461217_301_324_Chemical) (JJ -LSB-) (PRN (-LRB- -LRB-) (NP (NNP TP)) (-RRB- -RRB-)) (NNP CAS)))) (: :) (NP (JJ 57-85-2) (NN -RSB-)))) (, ,) (CC and) (S (NP (NP (JJS most)) (PP (IN of) (NP (DT the) (JJ Doc_3461217_362_367_Disease-bearing) (NNS rats)))) (VP (VBD manifested) (NP (JJ metastatic) (NNS lesions)))) (. .)))
3461217	2	(S1 (S (NP (DT The) (JJ incubation) (NNS periods)) (VP (VBD averaged) (NP (CD 10.6) (NNS months))) (. .)))
3461217	3	(S1 (S (PP (IN Within) (NP (DT the) (JJ same) (NN timeframe))) (, ,) (NP (DT no) (JJ L-W) (NN rat)) (VP (VBD developed) (NP (DT a) (JJ similar) (NN palpable) (NN Doc_3461217_524_526_Disease)) (SBAR (WHADVP (WRB when)) (S (VP (VBN treated) (ADVP (RB only)) (PP (IN with) (NP (NN TP))))))) (. .)))
3461217	4	(S1 (S (PP (IN In) (NP (JJ L-W) (NNS rats))) (, ,) (NP (NNP TP)) (VP (VBD acted) (PP (IN as) (NP (DT a) (JJ Doc_3461217_581_586_Disease) (NN enhancement) (NN agent))) (, ,) (PP (IN with) (NP (NP (JJ primary) (NN emphasis)) (PP (IN on) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_3461217_650_665_Disease)))))))) (. .)))
3535719	0	(S1 (NP (NP (NP (JJ Relative) (NN efficacy)) (CC and) (NP (NN Doc_3535719_22_30_Disease))) (PP (IN of) (NP (NP (NNP Doc_3535719_34_44_Chemical)) (CC and) (NP (NNP Doc_3535719_49_59_Chemical)))) (PP (IN in) (NP (NN oncology) (NNS patients))) (. .)))
3535719	1	(S1 (S (NP (PRP We)) (ADVP (RB prospectively)) (VP (VBD compared) (NP (NP (DT the) (NN efficacy) (CC and) (NN safety)) (PP (IN of) (NP (NNP Doc_3535719_135_153_Chemical) (CC or) (NNP Doc_3535719_157_175_Chemical)))) (PP (IN in) (NP (NP (NN conjunction)) (PP (IN with) (NP (NNP Doc_3535719_196_215_Chemical))) (PP (IN in) (NP (CD 118) (JJ immunocompromised) (NNS patients))) (PP (IN with) (NP (JJ presumed) (JJ severe) (NN Doc_3535719_271_281_Disease)))))) (. .)))
3535719	2	(S1 (S (NP (DT The) (CD two) (NN treatment) (NNS regimens)) (VP (AUX were) (ADJP (RB equally) (JJ efficacious))) (. .)))
3535719	3	(S1 (S (NP (NN Nephrotoxicity)) (VP (VBD occurred) (PP (IN in) (NP (NP (DT a) (JJ similar) (NN proportion)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NP (NP (NNP Doc_3535719_409_419_Chemical)) (CC and) (NP (NNP Doc_3535719_424_434_Chemical))) (PRN (-LRB- -LRB-) (NP (NP (CD 17) (NN %)) (NNP vs) (CD 11) (NN %)) (-RRB- -RRB-)))))))))) (. .)))
3535719	4	(S1 (S (NP (NN Doc_3535719_449_460_Disease)) (VP (VBD occurred) (PP (PP (IN in) (NP (NP (NP (CD four)) (PRN (-LRB- -LRB-) (NP (CD 9.5) (NN %)) (-RRB- -RRB-))) (PP (IN of) (NP (CD 42) (NNP Doc_3535719_491_501_Chemical) (CC and) (NNP Doc_3535719_506_518_Chemical))))) (CC and) (PP (IN in) (NP (NP (NP (CD 12)) (PRN (-LRB- -LRB-) (NP (CD 22) (NN %)) (-RRB- -RRB-))) (PP (IN of) (NP (CD 54) (ADJP (JJ Doc_3535719_541_551_Chemical) (CC and) (JJ Doc_3535719_556_568_Chemical-treated)) (NNS patients))))))) (. .)))
3535719	5	(S1 (S (PP (IN Of) (NP (NP (DT those)) (VP (VBN evaluated) (PP (IN with) (NP (JJ posttherapy) (NNS audiograms)))))) (, ,) (NP (NP (CD three)) (PP (IN of) (NP (CD four) (UCP (NNP Doc_3535719_649_659_Chemical) (CC and) (JJ Doc_3535719_664_676_Chemical-treated)) (NNS patients)))) (VP (AUX had) (S (NP (NN auditory) (NNS thresholds)) (VP (VB return) (PP (TO to) (NP (NN baseline))) (PP (VBN compared) (PP (IN with) (NP (NP (CD one)) (PP (IN of) (NP (CD nine) (UCP (NNP Doc_3535719_763_773_Chemical) (CC and) (JJ Doc_3535719_778_790_Chemical-treated)) (NNS patients))))))))) (. .)))
3535719	6	(S1 (S (NP (NP (DT The) (NN number)) (PP (IN of) (ADVP (JJR greater) (IN than) (CC or) (JJ equal) (PP (TO to) (NP (NP (JJ 15-dB) (NNS increases)) (PP (IN in) (NP (JJ auditory) (NN threshold))) (PP (IN as) (NP (NP (DT a) (NN proportion)) (PP (IN of) (NP (NP (JJ total)) (ADJP (JJR greater) (IN than) (CC or) (ADJP (JJ equal) (PP (TO to) (NP (NP (JJ 15-dB) (NNS changes)) (PRN (-LRB- -LRB-) (NP (NP (NNS increases)) (CC and) (NP (NNS decreases))) (-RRB- -RRB-))))))))))))))) (VP (AUX was) (ADJP (RB significantly) (JJR lower)) (PP (IN in) (NP (NP (NNP Doc_3535719_1003_1013_Chemical) (CC and) (NNP Doc_3535719_1018_1030_Chemical-) (NNP vs) (NNP Doc_3535719_1035_1045_Chemical)) (CC and) (NP (NP (JJ Doc_3535719_1050_1062_Chemical-treated) (NNS patients)) (PRN (-LRB- -LRB-) (NP (NP (QP (CD 18) (IN of) (CD 78)) (NNP vs) (CD 67)) (PP (IN of) (NP (CD 115)))) (-RRB- -RRB-)))))) (. .)))
3535719	7	(S1 (S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (S (NP (NNP Doc_3535719_1122_1136_Chemical-associated) (NNP Doc_3535719_1148_1159_Disease)) (VP (AUX was) (ADJP (ADJP (RBR less) (JJ severe)) (CC and) (ADJP (RBR more) (RB often) (JJ reversible) (PP (IN with) (NP (NNP Doc_3535719_1207_1217_Chemical)))) (PP (IN than) (PP (IN with) (NP (NNP Doc_3535719_1228_1238_Chemical))))))))) (. .)))
3653576	0	(S1 (NP (NP (NP (NN Urinary) (NNS enzymes)) (CC and) (NP (NN protein) (NNS patterns))) (PP (IN as) (NP (NP (NNS indicators)) (PP (IN of) (NP (NNP Doc_3653576_54_95_Disease))))) (. .)))
3653576	1	(S1 (S (NP (NP (NN Doc_3653576_97_138_Disease)) (PP (TO to) (NP (NP (DT the) (JJ proximal) (JJ tubular) (, ,) (NN glomerular) (, ,) (CC and) (NN papillary) (NNS regions)) (PP (IN of) (NP (DT the) (NN rat)))))) (VP (AUX were) (VP (VBN produced) (PP (IN by) (NP (NP (NN administration)) (PP (IN of) (NP (NP (NP (NNP Doc_3653576_244_268_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_3653576_270_274_Chemical)) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Doc_3653576_277_302_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_3653576_304_307_Chemical)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NNP Doc_3653576_314_331_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_3653576_333_336_Chemical)) (-RRB- -RRB-))) (, ,) (ADVP (RB respectively)))))))) (. .)))
3653576	2	(S1 (S (NP (NP (NP (JJ Several) (JJ routine) (NNS indicators)) (PP (IN of) (NP (NP (NN nephrotoxicity)) (, ,) (NP (DT the) (NNS enzymes) (NN alkaline) (NN phosphatase)) (CC and) (NP (NN Doc_3653576_436_444_Chemical-beta-glucosaminidase))))) (, ,) (CC and) (NP (NP (DT the) (JJ molecular) (NN weight)) (PP (IN of) (NP (NNP Doc_3653576_495_512_Disease))))) (VP (AUX were) (VP (VBN determined) (PP (IN on) (NP (NN urine) (NNS samples))))) (. .)))
3653576	3	(S1 (S (NP (NP (JJ Tubular) (NN damage)) (VP (VBN produced) (PP (IN by) (NP (NP (NNP Doc_3653576_574_578_Chemical)) (CC or) (NP (NNP Doc_3653576_582_585_Chemical)))))) (VP (AUX was) (VP (VBN discriminated) (ADVP (DT both) (RB quantitatively) (CC and) (RB qualitatively)) (PP (IN from) (NP (NP (NNP Doc_3653576_647_664_Disease)) (VP (VBN produced) (PP (IN by) (NP (NNP Doc_3653576_677_680_Chemical)))))))) (. .)))
3653576	4	(S1 (S (NP (DT The) (NN latter)) (VP (AUX was) (VP (VBN characterized) (PP (IN by) (NP (NP (DT a) (JJ pronounced) (NN increase)) (PP (IN in) (NP (NP (NNP Doc_3653576_739_756_Disease)) (, ,) (NP (NP (RB especially) (NNS proteins)) (PP (IN with) (NP (JJ molecular) (NN weight))) (ADJP (QP (JJR greater) (IN than) (CD 40,000)) (NN Da))))))))) (. .)))
3653576	5	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NP (NN Doc_3653576_837_854_Disease)) (PP (IN in) (NP (JJ tubular) (NN damage)))) (VP (AUX was) (VP (VP (VBN raised) (ADVP (RB only) (RB slightly))) (CC and) (VP (VBN characterized) (PP (IN by) (NP (NP (NNP Doc_3653576_919_940_Disease)) (PP (IN of) (NP (NP (DT a) (JJ wide) (NN range)) (PP (IN of) (NP (JJ molecular) (NNS weights)))))))))) (. .)))
3653576	6	(S1 (S (S (NP (JJ Proximal) (JJ tubular) (NN damage)) (VP (VBN caused) (PP (IN by) (NP (NNP Doc_3653576_1013_1017_Chemical))))) (CC and) (S (NP (NP (JJ papillary) (NN damage)) (VP (VBN caused) (PP (IN by) (NP (NNP Doc_3653576_1049_1052_Chemical))))) (VP (AUX were) (VP (VBN distinguished) (PP (DT both) (PP (IN by) (NP (NP (JJ conventional) (NNS urinalysis)) (PRN (-LRB- -LRB-) (NP (NP (NN volume)) (CC and) (NP (JJ specific) (NN gravity))) (-RRB- -RRB-)))) (CC and) (PP (IN by) (NP (NP (NN measurement)) (PP (IN of) (NP (DT the) (CD two) (JJ urinary) (NNS enzymes))))))))) (. .)))
3653576	7	(S1 (S (S (NP (NP (JJ Alkaline) (NN phosphatase)) (CC and) (NP (NNP Doc_3653576_1206_1213_Chemical))) (VP (AUX were) (ADVP (RB markedly) (CC and) (RB transiently)) (ADJP (JJ elevated)) (PP (IN in) (NP (JJ proximal) (JJ tubular) (NN damage))))) (CC and) (S (NP (NNP Doc_3653576_1284_1292_Chemical-beta-glucosaminidase)) (VP (VBD showed) (NP (DT a) (JJ sustained) (NN elevation)) (PP (IN in) (NP (JJ papillary) (NN damage))))) (. .)))
3653576	8	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (VBN concluded) (SBAR (IN that) (S (S (NP (DT both) (JJ selective) (NN urinary)) (VP (VBZ enzymes))) (CC and) (S (NP (NP (DT the) (JJ molecular) (NN weight) (NN pattern)) (PP (IN of) (NP (JJ urinary) (NNS proteins)))) (VP (MD can) (VP (AUX be) (VP (VBN used) (S (VP (TO to) (VP (VB provide) (NP (NP (JJ diagnostic) (NN information)) (PP (IN about) (NP (NP (DT the) (JJ possible) (NN site)) (PP (IN of) (NP (NNP Doc_3653576_1542_1554_Disease))))))))))))))))) (. .)))
3670965	0	(S1 (FRAG (NP (DT A) (NN catch)) (PP (IN in) (NP (DT the) (NNP Doc_3670965_15_19_Disease))) (. .)))
3670965	1	(S1 (S (NP (NP (JJ Twenty-six) (NNS cases)) (PP (IN of) (NP (NP (NP (NNP Doc_3670965_41_54_Disease)) (PP (IN from) (NP (NP (DT The) (NNS Children) (POS 's)) (NNP Hospital)))) (, ,) (NP (NNP Camperdown)) (, ,) (NP (NNP Australia)) (, ,))) (VP (VBG occurring) (PP (IN between) (NP (CD 1973) (CC and) (CD 1982))))) (VP (AUX were) (VP (VBN reviewed))) (. .)))
3670965	2	(S1 (S (PP (IN Of) (NP (DT these))) (, ,) (NP (CD 20) (NNS cases)) (VP (VBD met) (NP (DT the) (NNP US) (NNP Public) (NNP Health) (NNP Service) (NNPS Centers)) (PP (IN for) (NP (NNP Disease) (NNP Control))) (NP (NP (NNS criteria)) (PP (IN for) (NP (NP (DT the) (NN diagnosis)) (PP (IN of) (NP (NNP Doc_3670965_265_278_Disease))))))) (. .)))
3670965	3	(S1 (S (S (NP (NNP Doc_3670965_280_287_Chemical) (CC or) (NNP Doc_3670965_291_301_Chemical) (NN ingestion)) (VP (AUX had) (VP (VBN occurred) (PP (IN in) (NP (NP (RB only) (CD one)) (PP (IN of) (NP (NP (DT the) (CD 20) (NNS cases)) (PRN (-LRB- -LRB-) (NP (CD 5) (NN %)) (-RRB- -RRB-))))))))) (, ,) (CC and) (S (NP (NP (NNP Doc_3670965_363_374_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_3670965_376_389_Chemical)) (-RRB- -RRB-))) (VP (AUX had) (VP (AUX been) (VP (VBN administered) (PP (IN in) (NP (NP (RB only) (CD six)) (PP (IN of) (NP (DT the) (NNS cases))))) (PRN (-LRB- -LRB-) (NP (CD 30) (NN %)) (-RRB- -RRB-)))))) (. .)))
3670965	4	(S1 (S (NP (NP (JJ Pathologic) (NN confirmation)) (PP (IN of) (NP (NP (DT the) (NN diagnosis)) (PP (IN of) (NP (NNP Doc_3670965_489_502_Disease)))))) (VP (AUX was) (VP (VBN accomplished) (PP (IN in) (NP (NP (CD 90) (NN %)) (PP (IN of) (NP (DT the) (NNS cases))))))) (. .)))
3670965	5	(S1 (S (NP (NP (DT The) (NN incidence)) (PP (IN of) (NP (NNP Doc_3670965_558_571_Disease))) (PP (IN in) (NP (NP (NNP New) (NNP South) (NNP Wales)) (, ,) (NP (NNP Australia)) (, ,)))) (VP (AUX is) (VP (VBN estimated) (PP (IN from) (NP (DT this) (NN study) (S (VP (TO to) (VP (AUX be) (NP (NP (QP (RB approximately) (CD nine)) (NNS cases)) (PP (IN per) (NP (NP (QP (CD 1) (CD million)) (NNS children)) (PP (VBN compared) (PP (IN with) (NP (JJ recent) (NNP US) (NNS data)))))) (PP (IN of) (NP (QP (CD ten) (TO to) (CD 20)) (NNS cases))) (PP (IN per) (NP (NP (QP (CD 1) (CD million)) (NNS children)) (CC and) (NP (NP (QP (CD three) (TO to) (CD seven)) (NNS cases)) (PP (IN per) (NP (NP (QP (CD 1) (CD million)) (NNS children)) (PP (IN in) (NP (NNP Great) (NNP Britain)))))))))))))))) (. .)))
3670965	6	(S1 (S (NP (NP (DT The) (NN mortality)) (PP (IN for) (NP (DT these) (NNP Doc_3670965_847_860_Disease) (NNS cases))) (PP (IN in) (NP (NNP Australia)))) (VP (AUX was) (NP (CD 45) (NN %)) (SBAR (IN as) (S (VP (VBN compared) (PP (IN with) (NP (NP (DT a) (ADJP (CD 32) (NN %)) (JJ case-fatality) (NN rate)) (PP (IN in) (NP (DT the) (NNP United) (NNPS States))))))))) (. .)))
3670965	7	(S1 (S (PP (IN In) (NP (NNP Australia))) (, ,) (NP (NP (DT the) (JJ pediatric) (NN usage)) (PP (IN of) (NP (NNP Doc_3670965_989_996_Chemical)))) (VP (AUX has) (VP (AUX been) (ADJP (RB extremely) (JJ low)) (PP (IN for) (NP (NP (DT the) (JJ past) (CD 25) (NNS years)) (PRN (-LRB- -LRB-) (NP (NP (QP (JJR less) (IN than) (CD 1)) (NN %)) (PP (IN of) (NP (JJ total) (NN dosage) (NNS units))) (VP (VBN sold))) (-RRB- -RRB-)))) (, ,) (SBAR (IN with) (S (NP (NP (NNP Doc_3670965_1090_1101_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_3670965_1103_1116_Chemical)) (-RRB- -RRB-))) (VP (VBG dominating) (NP (DT the) (JJ pediatric) (JJ analgesic) (CC and) (JJ antipyretic) (NN market))))))) (. .)))
3670965	8	(S1 (S (NP (NN Doc_3670965_1177_1190_Disease)) (VP (MD may) (VP (AUX be) (VP (VBG disappearing) (PP (IN from) (NP (NNP Australia))) (PP (IN despite) (NP (NP (DT a) (JJ total) (NN lack)) (PP (IN of) (NP (NN association))) (PP (IN with) (NP (NNP Doc_3670965_1267_1278_Chemical) (CC or) (NNP Doc_3670965_1282_1289_Chemical) (NN ingestion))))) (, ,) (SBAR (IN since) (S (NP (EX there)) (VP (AUX were) (NP (NP (DT no) (NNS cases)) (VP (VBN found) (PP (IN at) (NP (NP (NP (DT The) (NNP Children) (POS 's)) (NNP Hospital)) (PP (IN in) (NP (NP (CD 1983)) (, ,) (NP (CD 1984)) (, ,) (CC or) (NP (CD 1985)))))))))))))) (. .)))
3686155	0	(S1 (S (NP (NNP Postpartum) (NNP Doc_3686155_11_20_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_3686155_32_45_Chemical)))) (. .)))
3686155	1	(S1 (S (NP (NP (CD Two) (NN multigravida) (NNS patients)) (PP (IN with) (NP (DT no) (JJ prior) (JJ Doc_3686155_87_98_Disease) (NN history)))) (VP (AUX were) (VP (VBN seen) (PP (IN with) (NP (NN postpartum) (NN Doc_3686155_133_142_Disease))) (, ,) (S (VP (AUXG having) (VP (VBN received) (NP (NNP Doc_3686155_160_173_Chemical)) (PP (IN for) (NP (NNP Doc_3686155_178_201_Disease)))))))) (. .)))
3686155	2	(S1 (S (NP (NP (NN Doc_3686155_203_216_Chemical)) (VP (VBN given) (PP (IN in) (NP (JJ high) (NNS doses))))) (VP (AUX has) (VP (AUX been) (VP (VBN associated) (PP (IN with) (NP (NP (NNP Doc_3686155_262_271_Disease)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (DT the) (NN drug)) (PP (IN for) (NP (NN Doc_3686155_307_326_Disease))))))))))) (. .)))
3686155	3	(S1 (S (NP (DT These) (NNS cases)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP (NNP Doc_3686155_357_370_Chemical)) (VP (MD may) (VP (VB cause) (NP (NN Doc_3686155_381_390_Disease)) (SBAR (ADVP (RB even)) (WHADVP (WRB when)) (S (VP (VBN given) (PP (IN in) (NP (JJ low) (NNS doses))))))))))) (. .)))
3703509	0	(S1 (NP (NP (NP (NN Doc_3703509_0_27_Disease)) (CC and) (NP (NN death))) (PP (IN in) (NP (NNP Doc_3703509_41_62_Disease))) (. .)))
3703509	1	(S1 (S (NP (DT This) (NN paper)) (VP (VBZ presents) (NP (NP (DT the) (ADJP (JJ clinical) (CC and) (JJ metabolic)) (NNS findings)) (PP (IN in) (NP (NP (CD two) (JJ young) (NNS boys)) (PP (IN with) (NP (JJ long-standing) (NN Doc_3703509_157_178_Disease))))))) (. .)))
3703509	2	(S1 (S (PP (VBG Following) (NP (NP (JJ short) (NN exposure)) (PP (TO to) (NP (JJ oral) (NNP Doc_3703509_213_223_Chemical))))) (, ,) (NP (DT both) (NNS boys)) (VP (VBD developed) (NP (NN Doc_3703509_245_253_Disease)) (, ,) (S (VP (VBG increasing) (NP (NP (NNP Doc_3703509_266_276_Disease)) (, ,) (NP (NNP Doc_3703509_278_288_Disease)) (, ,) (NP (NNP Doc_3703509_290_300_Disease)) (, ,) (CC and) (NP (NNP Doc_3703509_306_314_Disease)))))) (. .)))
3703509	3	(S1 (S (NP (DT Both)) (VP (VBD presented) (PP (IN in) (NP (DT the) (NN emergency) (NN room))) (PP (IN with) (NP (NP (JJ profound) (NNP Doc_3703509_367_371_Disease)) (, ,) (NP (NNP Doc_3703509_373_384_Disease)) (, ,) (NP (JJ severe) (NNP Doc_3703509_393_406_Disease)) (, ,) (CC and) (NP (NNP Doc_3703509_412_420_Disease))))) (. .)))
3703509	4	(S1 (S (S (NP (NNP Nonketotic) (NNP Doc_3703509_433_448_Disease)) (VP (AUX was) (ADJP (JJ present) (PP (IN in) (NP (CD one)))))) (CC and) (S (NP (NP (NNP Doc_3703509_472_479_Disease)) (PP (IN without) (NP (DT a) (JJ known) (NN serum) (JJ Doc_3703509_502_509_Chemical) (NN level)))) (VP (AUX was) (ADJP (JJ present) (PP (IN in) (NP (DT the) (JJ other)))))) (. .)))
3703509	5	(S1 (S (S (NP (NN Doc_3703509_542_561_Disease)) (ADVP (RB rapidly)) (VP (VBD ensued))) (CC and) (S (NP (DT both) (NNS patients)) (VP (VBD expired) (PP (IN in) (NP (NP (NN spite)) (PP (IN of) (NP (NP (NNS efforts)) (PP (IN at) (NP (NN resuscitation))))))))) (. .)))
3703509	6	(S1 (S (NP (PRP We)) (VP (VBP believe) (SBAR (S (NP (DT these) (CD two) (NNS cases)) (VP (VBP represent) (NP (NP (DT a) (ADJP (ADJP (RB newly) (VBN described)) (CC and) (ADJP (JJ catastrophic))) (NN Doc_3703509_713_740_Disease)) (PP (IN in) (NP (DT the) (NNP Doc_3703509_748_769_Disease)))))))) (. .)))
3708922	0	(S1 (NP (NP (JJ Experimental) (JJ Doc_3708922_13_25_Chemical) (NN nephrotoxicity)) (: :) (NP (NP (NN risk)) (PP (IN of) (NP (JJ concomitant) (NNS chemotherapy)))) (. .)))
3708922	1	(S1 (S (NP (NP (DT The) (NN role)) (PP (IN of) (NP (NP (NNP Doc_3708922_88_100_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_3708922_102_105_Chemical)) (-RRB- -RRB-)))) (UCP (ADVP (RB alone)) (CC or) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NP (JJ various) (NNS chemotherapeutics)) (PP (IN in) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_3708922_184_198_Disease))))))))))) (VP (AUX was) (VP (VBN evaluated) (PP (IN in) (NP (NNS rats))))) (. .)))
3708922	2	(S1 (S (NP (NP (NN Administration)) (PP (IN of) (NP (CD 20) (NN mg/kg/day) (NNP Doc_3708922_253_256_Chemical))) (PP (IN for) (NP (CD 4) (NNS weeks)))) (VP (VBD caused) (NP (NP (JJ renal) (JJ functional) (CC and) (JJ structural) (NNS changes)) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT those)) (VP (VBN reported) (PP (IN in) (NP (NN man))))))))) (. .)))
3708922	3	(S1 (S (NP (NP (DT The) (VBN combined) (NN administration)) (PP (IN of) (NP (NP (NNP Doc_3708922_381_384_Chemical) (CC and) (JJ various) (JJ chemotherapeutic) (NNS drugs)) (PP (IN with) (NP (DT a) (JJ nephrotoxic) (NN potential))) (, ,) (PP (JJ such) (IN as) (NP (NP (NP (NNP Doc_3708922_458_468_Chemical)) (PRN (-LRB- -LRB-) (PP (IN at) (NP (JJ therapeutic) (NNS doses))) (-RRB- -RRB-))) (, ,) (NP (NNP Doc_3708922_493_508_Chemical)) (CC and) (NP (NNP Doc_3708922_513_525_Chemical)))))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX are) (ADVP (RB frequently)) (VP (VBN used) (PP (IN in) (NP (JJ immunosuppressed) (NNS patients))))))) (, ,)) (VP (AUX did) (RB not) (VP (VB aggravate) (S (NP (DT the) (NNP Doc_3708922_605_608_Chemical)) (VP (VBN induced) (S (NP (NNP Doc_3708922_617_625_Disease)) (PP (IN in) (NP (DT the) (NN rat) (NN model)))))))) (. .)))
3708922	4	(S1 (S (NP (NP (NN Doc_3708922_644_654_Chemical)) (PP (IN at) (NP (JJ toxic) (NNS doses)))) (, ,) (ADVP (RB however)) (, ,) (VP (VBD increased) (NP (JJ Doc_3708922_690_693_Chemical) (NN nephrotoxicity))) (. .)))
3708922	5	(S1 (S (ADVP (RB Thus)) (, ,) (NP (NP (DT the) (NN nephrotoxicity)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_3708922_746_749_Chemical))))) (VP (AUX has) (NP (DT a) (JJ different) (JJ pathogenetic) (NN mechanism))) (. .)))
3732088	0	(S1 (NP (NP (NP (NNP Diuretics)) (, ,) (NP (NNP Doc_3732088_11_20_Chemical)) (CC and) (NP (NNP Doc_3732088_25_36_Disease))) (PP (IN in) (NP (NNP Doc_3732088_40_52_Disease) (NNP Doc_3732088_53_69_Disease))) (. .)))
3732088	1	(S1 (S (NP (PRP It)) (VP (AUX has) (VP (AUX been) (VP (VBN proposed) (SBAR (IN that) (S (NP (NP (JJ modest) (NNS changes)) (PP (IN in) (NP (NN plasma) (NN Doc_3732088_122_131_Chemical)))) (VP (MD can) (VP (VB alter) (NP (DT the) (NN tendency)) (PP (IN towards) (NP (NN Doc_3732088_163_182_Disease)))))))))) (. .)))
3732088	2	(S1 (S (SBAR (IN If) (S (NP (DT this)) (VP (AUX were) (ADVP (RB so))))) (, ,) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_3732088_215_238_Disease)))) (VP (MD might) (VP (AUX be) (ADJP (RB especially) (JJ susceptible)))) (. .)))
3732088	3	(S1 (S (ADVP (RB Thus)) (, ,) (NP (JJ myocardial) (JJ electrical) (NN excitability)) (VP (VP (AUX was) (VP (VBN measured) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ mild) (JJ essential) (NN Doc_3732088_358_370_Disease))))))) (CC and) (VP (VBN known) (NP (NNP Doc_3732088_381_404_Disease)) (PP (IN after) (NP (NP (CD 8) (NNS weeks)) (PP (IN of) (NP (NP (NN treatment)) (PP (IN with) (NP (NP (NP (DT a) (JJ Doc_3732088_439_448_Chemical-conserving) (NN diuretic)) (PRN (-LRB- -LRB-) (NP (NNP Doc_3732088_470_479_Chemical)) (-RRB- -RRB-))) (CC and) (NP (NP (DT a) (JJ similar) (NN period)) (PP (IN on) (NP (NP (DT a) (JJ Doc_3732088_507_516_Chemical-losing) (NN diuretic)) (PRN (-LRB- -LRB-) (NP (NNP Doc_3732088_534_548_Chemical)) (-RRB- -RRB-)))) (PP (IN in) (NP (DT a) (JJ randomised) (NN study)))))))))))) (. .)))
3732088	4	(S1 (S (NP (NN Plasma) (NN Doc_3732088_580_589_Chemical) (NNS concentrations)) (VP (AUX were) (PP (IN on) (NP (NN average))) (ADVP (NP (CD 1) (CD mmol/L)) (JJR lower)) (PP (IN during) (NP (DT the) (JJ Doc_3732088_647_661_Chemical) (NN phase))) (PP (VBN compared) (PP (TO to) (NP (JJ Doc_3732088_680_689_Chemical) (NN therapy))))) (. .)))
3732088	5	(S1 (S (NP (NP (NN Blood) (NN pressure)) (CC and) (NP (NN volume) (NNS states))) (SBAR (IN as) (S (VP (VBN assessed) (PP (IN by) (NP (NP (NN bodyweight)) (, ,) (NP (NN plasma) (NN renin)) (CC and) (NP (NP (NNP Doc_3732088_776_789_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_3732088_791_805_Chemical)) (-RRB- -RRB-)))))))) (NP (NNS concentrations)) (VP (AUX were) (ADJP (JJ similar) (PP (IN on) (NP (DT the) (CD 2) (NNS regimens))))) (. .)))
3732088	6	(S1 (S (PP (VBN Compared) (PP (TO to) (NP (JJ Doc_3732088_866_875_Chemical) (NN treatment)))) (, ,) (NP (DT the) (JJ Doc_3732088_891_905_Chemical) (NN phase)) (VP (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (DT an) (VBN increased) (NN frequency)) (PP (IN of) (NP (NP (NP (NNP Doc_3732088_958_983_Disease)) (PRN (-LRB- -LRB-) (NP (JJ 24-hour) (NNP Holter) (NN monitoring)) (-RRB- -RRB-))) (CC and) (NP (NP (DT a) (JJR higher) (NNP Lown) (NN grading)) (, ,) (NP (NP (VBN increased) (NN upslope) (CC and) (NN duration)) (PP (IN of) (NP (DT the) (JJ monophasic) (NN action) (NN potential)))) (, ,) (NP (JJ prolonged) (JJ ventricular) (JJ effective) (JJ refractory) (NN period)) (, ,)))))))) (CC and) (VP (VBD increased) (NP (JJ electrical) (NN instability)) (PP (IN during) (NP (JJ programmed) (NN ventricular) (NN stimulation))))) (. .)))
3732088	7	(S1 (S (NP (DT The) (JJ above) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (SBAR (IN because) (S (NP (JJ Doc_3732088_1277_1286_Chemical-losing) (JJ diuretic) (NN therapy)) (VP (MD can) (VP (VB increase) (NP (JJ myocardial) (JJ electrical) (NN excitability)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_3732088_1376_1399_Disease))))))))) (, ,) (NP (NP (ADJP (RB even) (JJ minor)) (VBZ falls)) (PP (IN in) (NP (NN plasma) (NNP Doc_3732088_1428_1437_Chemical) (NNS concentrations)))) (VP (AUX are) (ADVP (RB probably)) (VP (ADVP (RBS best)) (VBN avoided) (PP (IN in) (NP (JJ such) (NNS patients)))))))) (. .)))
3762968	0	(S1 (NP (NP (NN Transketolase) (NN abnormality)) (PP (IN in) (NP (NNP Doc_3762968_29_39_Chemical-induced) (NNP Doc_3762968_48_73_Disease))) (. .)))
3762968	1	(S1 (S (NP (PRP We)) (VP (VBD studied) (NP (NP (DT a) (JJ Doc_3762968_88_96_Chemical-dependent) (NN enzyme)) (, ,) (NP (NN transketolase)) (, ,)) (PP (IN from) (NP (NP (NNS fibroblasts)) (PP (IN of) (NP (NP (DT a) (NNP Doc_3762968_152_160_Disease) (NN patient)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NNP Doc_3762968_183_208_Disease)) (SBAR (WHADVP (WRB when)) (S (VP (VBN treated) (PP (IN with) (NP (NNP Doc_3762968_227_237_Chemical))) (, ,) (SBAR (IN in) (NN order) (S (VP (TO to) (VP (VB delineate) (SBAR (IN if) (S (NP (DT this) (NN patient)) (ADVP (RB also)) (VP (AUX had) (NP (JJ transketolase) (JJ abnormality) (JJ -LSB-high) (NNS Km)) (PP (IN for) (NP (NNP Doc_3762968_325_347_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_3762968_349_352_Chemical)) (-RRB- -RRB-)) (NN -RSB-))) (, ,) (SBAR (IN as) (S (ADVP (RB previously)) (VP (VBN reported) (PP (IN in) (NP (JJ postalcoholic) (NNP Doc_3762968_396_423_Disease)))))))))))))))))))))))) (. .)))
3762968	2	(S1 (S (PP (IN In) (NP (NP (NN addition)) (PP (TO to) (NP (DT this) (NN patient))))) (, ,) (NP (PRP we)) (ADVP (RB also)) (VP (VBD studied) (NP (DT this) (NN enzyme)) (PP (IN from) (NP (CD three) (JJ Doc_3762968_493_501_Disease) (NNS kindreds))) (PP (PP (IN without) (NP (NP (DT any) (NN history)) (PP (IN of) (NP (NNP Doc_3762968_534_559_Disease))))) (CC and) (PP (IN from) (NP (CD four) (JJ normal) (NNS controls))))) (. .)))
3762968	3	(S1 (S (NP (PRP We)) (VP (VBD found) (SBAR (IN that) (S (NP (NP (NP (DT the) (JJ above-mentioned) (NN patient)) (CC and) (NP (NP (CD one)) (PP (IN of) (NP (DT the) (JJ Doc_3762968_648_656_Disease) (NNS kindreds))))) (PP (IN with) (NP (NP (DT no) (NN history)) (PP (IN of) (NP (NNP Doc_3762968_685_710_Disease)))))) (VP (AUX had) (NP (JJ abnormal) (NN transketolase)) (SBAR (IN as) (S (VP (VBN determined) (PP (IN by) (NP (NP (PRP$ its) (NN Km)) (PP (IN for) (NP (NNP Doc_3762968_766_769_Chemical)))))))))))) (. .)))
3762968	4	(S1 (S (NP (DT These) (NNS data)) (VP (VBP suggest) (NP (NP (DT a) (NN similarity)) (PP (IN between) (NP (NP (JJ postalcoholic) (NN Doc_3762968_825_852_Disease)) (CC and) (NP (NP (DT the) (NN patient)) (PP (IN with) (NP (JJ Doc_3762968_874_884_Chemical-induced) (NNP Doc_3762968_893_918_Disease))) (PP (IN from) (NP (NP (DT the) (NN standpoint)) (PP (IN of) (NP (NN transketolase) (NN abnormality)))))))))) (. .)))
3769769	0	(S1 (NP (NP (NN Doc_3769769_0_11_Disease)) (ADJP (JJ due) (PP (TO to) (NP (NNP Doc_3769769_19_48_Chemical)))) (. .)))
3769769	1	(S1 (S (NP (DT A) (JJ chronic) (NN Doc_3769769_60_73_Disease) (NN patient)) (VP (AUX was) (VP (VBN treated) (PP (IN with) (NP (NP (DT an) (JJ anticholinergic) (NN drug)) (, ,) (NP (NNP Doc_3769769_124_153_Chemical)))))) (. .)))
3769769	2	(S1 (S (NP (DT The) (NN patient)) (VP (VBD developed) (, ,) (ADVP (RB paradoxically)) (, ,) (NP (JJ sinus) (NN Doc_3769769_199_210_Disease))) (. .)))
3769769	3	(S1 (S (NP (DT The) (NN reaction)) (VP (AUX was) (UCP (ADJP (JJ specific) (PP (TO to) (NP (NNP Doc_3769769_241_256_Chemical)))) (CC and) (RB not) (PP (TO to) (NP (JJ other) (JJ anticholinergic) (NNS drugs))))) (. .)))
3769769	4	(S1 (S (S (NP (DT This) (JJ antidyskinetic) (NN drug)) (VP (AUX is) (ADVP (RB widely)) (VP (VBN used) (PP (IN in) (NP (JJ clinical) (JJ Doc_3769769_349_360_Disease) (NN practice)))))) (CC and) (S (NP (NNS physicians)) (VP (MD should) (VP (AUX be) (ADJP (JJ aware) (PP (IN of) (NP (DT this) (NN side) (NN effect))))))) (. .)))
3780697	0	(S1 (NP (NP (JJ Post-operative) (NN Doc_3780697_15_23_Disease)) (PP (IN after) (NP (NNP Doc_3780697_30_38_Chemical) (NN administration))) (. .)))
3780697	1	(S1 (S (NP (NP (DT A) (NN case)) (PP (IN of) (NP (JJ thoraco-abdominal) (NNP Doc_3780697_83_91_Disease))) (VP (VBG leading) (PP (TO to) (NP (NNP Doc_3780697_103_122_Disease))))) (VP (AUX is) (VP (VBN described) (PP (IN in) (NP (DT the) (JJ post-operative) (NN period))) (PP (IN in) (NP (NP (DT an) (JJ elderly) (NN patient)) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (NP (DT a) (JJ moderate) (NN dose)) (PP (IN of) (NP (NN Doc_3780697_219_227_Chemical))))))))))) (. .)))
3780697	2	(S1 (S (NP (DT This)) (VP (AUX was) (ADVP (RB successfully)) (VP (VBN reversed) (PP (IN by) (NP (NNP Doc_3780697_263_271_Chemical))))) (. .)))
3780697	3	(S1 (S (NP (NP (DT The) (NNS mechanisms)) (VP (ADVP (RB possibly)) (VBN implicated) (PP (IN in) (NP (DT this) (NN accident))))) (VP (AUX are) (VP (VBN discussed))) (. .)))
3780814	0	(S1 (S (NP (NP (JJ Anti-carcinogenic) (NN action)) (PP (IN of) (NP (NNP Doc_3780814_28_41_Chemical)))) (VP (VBN given) (ADVP (RB simultaneously)) (PP (IN with) (NP (NNP Doc_3780814_68_86_Chemical))) (PP (IN in) (NP (DT the) (NN rat)))) (. .)))
3780814	1	(S1 (S (NP (DT The) (JJ present) (NN work)) (VP (AUX has) (VP (AUX been) (VP (VBN planned) (PP (IN in) (NP (NN order))) (S (VP (TO to) (VP (VB elucidate) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (NNP Doc_3780814_169_182_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (NNP PB)) (: :) (NP (NP (CD 15) (NNS mg)) (PP (IN per) (NP (NP (NN rat)) (PP (IN of) (NP (JJ ingested) (NN dose))))))) (-RRB- -RRB-)))) (PP (IN on) (NP (NNP Doc_3780814_223_237_Disease)))) (SBAR (WHADVP (WRB when)) (S (NP (PRP it)) (VP (AUX is) (VP (VBN administered) (ADVP (RB simultaneously)) (PP (IN with) (NP (NP (NNP Doc_3780814_282_300_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (NNP Doc_3780814_302_305_Chemical)) (: :) (NP (CD 10) (NN mg/kg/day))) (-RRB- -RRB-)))))))))))))) (. .)))
3780814	2	(S1 (S (NP (NP (JJ Wistar) (NNS rats)) (PRN (-LRB- -LRB-) (NP (CD 180) (NNP g)) (-RRB- -RRB-))) (VP (AUX were) (VP (VBN treated) (PP (PP (IN by) (NP (NP (NNP Doc_3780814_358_361_Chemical)) (ADVP (RB alone)))) (CC or) (PP (IN by) (NP (NNP Doc_3780814_374_377_Chemical) (NNP +) (NNP Doc_3780814_380_382_Chemical)))) (PP (IN during) (NP (CD 2) (, ,) (CD 4) (CC and) (CD 6) (NNS weeks))) (PP (VBG according) (PP (TO to) (NP (NP (PRP$ our) (NN schedule)) (PP (IN for) (NP (NNS hepatocarcinogenesis)))))))) (. .)))
3780814	3	(S1 (S (PP (IN After) (NP (NP (DT the) (NN end)) (PP (IN of) (NP (DT the) (NN treatment))))) (, ,) (NP (NP (DT the) (NN number)) (CC and) (NP (NP (DT the) (NN size)) (PP (IN of) (NP (VBN induced) (NNP PAS) (JJ positive) (NN Doc_3780814_539_557_Disease))))) (VP (AUX was) (VP (ADVP (RB significantly)) (VBN reduced) (SBAR (WHADVP (WRB when)) (S (NP (NN PB)) (VP (AUX was) (VP (VBN given) (ADVP (RB simultaneously)) (PP (IN with) (NP (NNP Doc_3780814_622_625_Chemical))) (PP (IN for) (NP (QP (CD 4) (CC and) (CD 6)) (NNS weeks))))))))) (. .)))
3780814	4	(S1 (S (NP (NP (NP (DT The) (JJ mitotic) (NN inhibition)) (CC and) (NP (NP (DT the) (NN production)) (PP (IN of) (NP (FW micronuclei))))) (VP (ADVP (RB normally)) (VBN observed) (PP (IN after) (NP (JJ partial) (NN hepatectomy))) (PP (IN in) (NP (NN DEN) (VBN treated) (NNS rats))))) (VP (AUX were) (ADVP (RB also)) (VP (ADVP (RB significantly)) (VBN decreased) (PP (IN in) (NP (NNP Doc_3780814_803_806_Chemical) (NNP +) (JJ Doc_3780814_809_811_Chemical) (VBN treated) (NNS rats))))) (. .)))
3780814	5	(S1 (S (SBAR (WHADVP (WRB When)) (S (NP (DT the) (NN treatment)) (VP (VB last) (NP (QP (RB only) (CD 2)) (NNS weeks))))) (, ,) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NNS PB)))) (VP (AUX did) (RB not) (VP (NN change) (ADVP (RB significantly)) (NP (DT the) (JJ last) (NNS parameters)))) (. .)))
3780814	6	(S1 (S (PP (IN In) (NP (JJ Doc_3780814_936_939_Chemical) (JJ +) (JJ Doc_3780814_942_944_Chemical) (VBN treated) (NNS rats))) (, ,) (S (NP (DT the) (NN survival)) (VP (AUX was) (VP (VBN prolonged)))) (CC and) (S (NP (DT the) (NNP Doc_3780814_994_999_Disease) (NN incidence)) (VP (VBD decreased) (SBAR (IN as) (S (VP (VBN compared) (PP (IN with) (NP (NP (DT the) (NNS results)) (VP (VBN obtained) (PP (IN by) (NP (NP (NNP Doc_3780814_1061_1064_Chemical)) (ADVP (RB alone)))))))))))) (. .)))
3780814	7	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (VBN concluded) (SBAR (IN that) (S (NP (NP (NN PB)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ promotes) (NP (NN Doc_3780814_1112_1126_Disease)) (SBAR (WHADVP (WRB when)) (S (VP (VBN administered) (PP (IN after) (NP (DT the) (JJ Doc_3780814_1155_1158_Chemical) (NN treatment))))))))) (, ,)) (VP (VBZ reduces) (NP (DT the) (NN carcinogen) (NN effect)) (SBAR (WHADVP (WRB when)) (S (VP (VBN given) (ADVP (RB simultaneously)) (PP (IN with) (NP (NNP Doc_3780814_1231_1234_Chemical))))))))))) (. .)))
3780814	8	(S1 (S (S (NP (DT This)) (VP (POS ') (ADJP (JJ anti-carcinogen)))) (: ') (S (NP (NN effect)) (VP (VBZ acts) (PP (PP (IN on) (NP (DT the) (NN initiation))) (CONJP (RB as) (RB well) (IN as)) (PP (IN on) (NP (NP (DT the) (NN promotion)) (PP (IN of) (NP (DT the) (NNP Doc_3780814_1324_1344_Disease)))))))) (. .)))
3780814	9	(S1 (S (NP (JJ Biochemical) (NNS investigations)) (VP (AUX are) (PP (IN in) (NP (NN progress))) (S (VP (TO to) (VP (VB obtain) (NP (NP (JJR more) (NN information)) (PP (IN about) (NP (NP (DT this)) (: ') (NP (NP (NN paradoxical) (POS ')) (NN PB) (NN effect))))))))) (. .)))
384871	0	(S1 (S (VP (VB Doc_384871_0_26_Disease) (ADVP (RB due)) (PP (TO to) (NP (JJ combined) (NNP Doc_384871_43_53_Chemical) (CC and) (NNP Doc_384871_58_67_Chemical) (NN treatment)))) (. .)))
384871	1	(S1 (S (NP (NP (DT The) (NN case)) (PP (IN of) (NP (NP (DT a) (JJ 40-year-old) (NN patient)) (SBAR (WHNP (WP who)) (S (VP (VP (VBD underwent) (NP (DT an) (JJ unsuccessful) (NN cadaver) (NN kidney) (NN transplantation))) (CC and) (VP (AUX was) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_384871_195_205_Chemical)) (CC and) (NP (NNP Doc_384871_210_219_Chemical)))))))))))) (VP (AUX is) (VP (VBN reported))) (. .)))
384871	2	(S1 (S (NP (NP (DT A) (NN Doc_384871_235_267_Disease)) (PP (IN with) (NP (DT an) (JJ unusual) (JJ central) (NN bitemporal) (NN hemianopic) (NN Doc_384871_314_321_Disease)))) (VP (AUX was) (VP (VBN found))) (. .)))
384871	3	(S1 (S (S (NP (NN Doc_384871_333_343_Chemical)) (VP (AUX was) (VP (VBN stopped)))) (CC and) (S (NP (NP (JJ only) (JJ small) (NN improvement)) (PP (IN of) (NP (DT the) (JJ visual) (NN acuity)))) (VP (VBD followed))) (. .)))
384871	4	(S1 (S (NP (NN Doc_384871_414_423_Chemical)) (VP (AUX was) (VP (VBN discontinued) (ADVP (RB later)) (, ,) (S (VP (VBN followed) (PP (IN by) (NP (NP (DT a) (JJ dramatic) (NN improvement)) (PP (IN in) (NP (DT the) (JJ visual) (NN acuity))))))))) (. .)))
384871	5	(S1 (S (NP (NP (DT The) (NNS hazards)) (PP (IN of) (NP (JJ optic) (NN nerve) (NN Doc_384871_532_540_Disease))) (PP (JJ due) (TO to) (NP (NNP Doc_384871_548_558_Chemical)))) (VP (AUX are) (VP (VBN known))) (. .)))
384871	6	(S1 (S (NP (PRP We)) (VP (VB emphasize) (NP (DT the) (JJ potential) (NN danger)) (PP (IN in) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NP (NNP Doc_384871_618_628_Chemical)) (CC and) (NP (NNP Doc_384871_633_642_Chemical))))))) (. .)))
3934126	0	(S1 (NP (NP (DT A) (JJ prospective) (NN study)) (PP (IN of) (NP (JJ adverse) (NNS reactions))) (VP (VBN associated) (PP (IN with) (NP (JJ Doc_3934126_57_67_Chemical) (NN therapy)))) (. .)))
3934126	1	(S1 (S (NP (NP (NP (DT A) (JJ prospective) (NN evaluation)) (PP (IN of) (NP (DT the) (NN efficacy)))) (CC and) (NP (NP (NN safety)) (PP (IN of) (NP (NNP Doc_3934126_132_142_Chemical))))) (VP (AUX was) (VP (VBN conducted) (PP (IN in) (NP (CD 54) (JJ consecutive) (NNS patients))) (PP (IN over) (NP (DT a) (JJ 16-month) (NN period))))) (. .)))
3934126	2	(S1 (S (NP (NN Doc_3934126_208_218_Chemical)) (VP (AUX was) (ADJP (JJ curative)) (PP (IN in) (NP (NP (CD 95) (NN %)) (PP (IN of) (NP (NP (CD 43) (NNS patients)) (PP (IN with) (NP (JJ proven) (NNP Doc_3934126_266_275_Disease)))))))) (. .)))
3934126	3	(S1 (S (S (NP (NNS Drugs)) (VP (AUX were) (VP (VBN ceased) (PP (IN in) (NP (CD six) (NNS patients))) (PP (IN because) (IN of) (NP (JJ adverse) (NNS reactions)))))) (: ;) (S (NP (NP (IN in) (CD three)) (PP (IN of) (NP (DT these) (NNP Doc_3934126_359_369_Chemical)))) (VP (AUX was) (VP (VBN considered) (S (NP (DT the) (JJ likely) (NN cause)))))) (. .)))
3934126	4	(S1 (S (NP (NNS Reactions)) (VP (VBD included) (NP (NP (NP (NNP Doc_3934126_422_438_Disease)) (PRN (-LRB- -LRB-) (NP (NP (CD 20)) (PP (IN of) (NP (CD 54) (NNS patients)))) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Doc_3934126_460_464_Disease)) (PRN (-LRB- -LRB-) (NP (NP (CD 4)) (PP (IN of) (NP (CD 54)))) (-RRB- -RRB-))) (, ,) (NP (NP (NN nephrotoxicity)) (PRN (-LRB- -LRB-) (NP (NP (CD 4)) (PP (IN of) (NP (CD 50)))) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Doc_3934126_502_513_Disease)) (PRN (-LRB- -LRB-) (NP (NP (CD 1)) (PP (IN of) (NP (CD 50)))) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_3934126_528_539_Disease)) (PRN (-LRB- -LRB-) (NP (NP (CD 1)) (PP (IN of) (NP (NP (CD 11) (NNS patients)) (VP (VBN tested) (PP (IN by) (NP (NN audiometry))))))) (-RRB- -RRB-))))) (. .)))
3934126	5	(S1 (S (S (NP (NN Doc_3934126_581_597_Disease)) (VP (VBD occurred) (ADVP (RB only)) (PP (IN with) (NP (NN infusion))) (PP (IN through) (NP (JJ peripheral) (NNS cannulae))))) (: ;) (S (NP (NP (NN nephrotoxicity)) (CC and) (NP (NN Doc_3934126_674_685_Disease))) (VP (AUX were) (VP (VBN confined) (PP (TO to) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (DT an) (NNP Doc_3934126_725_739_Chemical) (IN plus) (NNP Doc_3934126_745_755_Chemical)))))))) (. .)))
3934126	6	(S1 (S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (S (NP (NP (NNP Doc_3934126_774_784_Chemical)) (, ,) (VP (VBN administered) (ADVP (RB appropriately))) (, ,)) (VP (VBZ constitutes) (NP (NP (JJ safe) (, ,) (JJ effective) (NN therapy)) (PP (IN for) (NP (NP (NNP Doc_3934126_854_864_Disease)) (VP (VBN caused) (PP (IN by) (NP (JJ susceptible) (NNS bacteria))))))))))) (. .)))
3950060	0	(S1 (S (NP (NNS Factors)) (VP (VBN associated) (PP (IN with) (NP (NP (NP (NN nephrotoxicity)) (CC and) (NP (JJ clinical) (NN outcome))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NNP Doc_3950060_82_90_Chemical)))))))) (. .)))
3950060	1	(S1 (S (NP (NP (NNS Data)) (PP (IN from) (NP (NP (CD 60) (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_3950060_127_135_Chemical))))))) (VP (AUX were) (VP (VBN analyzed) (PP (IN for) (NP (NP (NNS factors)) (VP (VBN associated) (PP (IN with) (NP (NN nephrotoxicity)))))))) (. .)))
3950060	2	(S1 (S (PP (IN In) (NP (NP (CD 42)) (PP (IN of) (NP (DT these) (NNS patients))))) (, ,) (NP (NNS data)) (VP (AUX were) (VP (VBN examined) (PP (IN for) (NP (NP (NNS factors)) (VP (VBN associated) (PP (IN with) (NP (JJ clinical) (NN outcome)))))))) (. .)))
3950060	3	(S1 (S (NP (NP (NNS Variables)) (VP (VBN evaluated))) (VP (VBD included) (SBAR (S (NP (NP (JJ patient) (NN weight) (, ,) (NN age) (, ,) (NN sex) (, ,) (JJ serum) (NNP Doc_3950060_345_355_Chemical) (NN level)) (, ,) (NP (NNP Doc_3950060_363_373_Chemical) (NN clearance)) (, ,) (NP (NP (NN duration)) (PP (IN of) (NP (NN therapy)))) (, ,) (NP (JJ total) (NN dose)) (, ,)) (VP (VBP mean) (S (NP (NP (JJ daily) (NN dose)) (, ,) (NP (NN organism) (NN minimum) (NN inhibitory) (NN concentration)) (PRN (-LRB- -LRB-) (NP (NNP MIC)) (-RRB- -RRB-)) (, ,)) (VP (VP (VB mean) (NP (NN peak) (NNS levels))) (, ,) (VP (VB mean) (NP (NN trough) (NNS levels))) (, ,) (VP (VB mean) (NP (NN area)) (PP (IN under) (NP (NP (NP (DT the) (NN serum)) (JJ concentration-time) (NN curve)) (PRN (-LRB- -LRB-) (NP (NNP AUC)) (-RRB- -RRB-)) (, ,) (NP (JJ total) (NNP AUC))))) (, ,) (VP (VB mean) (S (NP (NNP AUC)) (ADJP (JJR greater) (PP (IN than) (NP (NP (JJ MIC) (, ,) (JJ total) (NNS AUC)) (ADJP (ADJP (JJR greater) (PP (IN than) (NP (JJ MIC) (PRN (, ,) (S (VP (VB mean) (NP (NP (NP (NNP Schumacher) (POS 's)) (NN intensity) (NN factor)) (PRN (-LRB- -LRB-) (IN IF) (-RRB- -RRB-))))) (, ,)) (NN total)))) (SBAR (IN IF) (, ,) (PP (IN In) (PRN (-LRB- -LRB-) (VP (VB mean) (NP (NN maximum) (NN concentration)) (NP (JJ -LSB-Cmax) (JJ -RSB-) (NN /MIC))) (-RRB- -RRB-)))))))))))))))) (. .)))
3950060	4	(S1 (S (NP (JJ Model-dependent) (JJ pharmacokinetic) (NNS parameters)) (VP (AUX were) (VP (VBN calculated) (PP (IN by) (NP (NN computer))) (PP (VBN based) (PP (IN on) (NP (DT a) (JJ one-compartment) (NN model)))))) (. .)))
3950060	5	(S1 (S (SBAR (WHADVP (WRB When)) (S (NP (DT the) (NNS parameters)) (VP (AUX were) (VP (VBN examined) (ADVP (RB individually)))))) (, ,) (NP (NP (NN duration)) (PP (IN of) (NP (NN therapy) (CC and) (NN total) (NN AUC)))) (VP (VBD correlated) (ADVP (RB significantly)) (PRN (-LRB- -LRB-) (NP (NNP P) (QP (JJR less) (IN than) (CD .05))) (-RRB- -RRB-)) (PP (IN with) (NP (NN nephrotoxicity)))) (. .)))
3950060	6	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (DT a) (JJ stepwise) (NN discriminant) (NN function) (NN analysis)) (VP (VBD identified) (NP (NP (JJ only) (NN duration)) (PP (IN of) (NP (NN therapy))) (PRN (-LRB- -LRB-) (NP (NNP P) (QP (JJR less) (IN than) (CD .001))) (-RRB- -RRB-))) (PP (IN as) (NP (DT an) (JJ important) (NN factor)))) (. .)))
3950060	7	(S1 (S (PP (VBN Based) (PP (IN on) (NP (DT this) (NN model))) (CC and) (PP (IN on) (NP (NP (NNP Bayes) (POS ')) (NN theorem)))) (, ,) (NP (NP (DT the) (JJ predictive) (NN accuracy)) (PP (IN of) (S (VP (VBG identifying) (NP (`` ``) (JJ nephrotoxic) ('' '') (NNS patients)))))) (VP (VBD increased) (PP (IN from) (NP (CD 0.17))) (PP (TO to) (NP (CD 0.39)))) (. .)))
3950060	8	(S1 (S (SBAR (WHADVP (WRB When)) (S (VP (VBN examined) (ADVP (RB individually))))) (, ,) (VP (VB mean) (SBAR (IN IF) (, ,) (S (NP (NP (JJ MIC) (, ,) (JJ total) (NN dose)) (, ,) (NP (JJ mean) (JJ daily) (NN dose)) (, ,) (CC and) (NP (NP (NNS ln)) (PRN (-LRB- -LRB-) (NP (JJ mean) (NNP Cmax/MIC)) (-RRB- -RRB-)))) (VP (VBD correlated) (ADVP (RB significantly)) (PRN (-LRB- -LRB-) (NP (NNP P) (QP (JJR less) (IN than) (CD .05))) (-RRB- -RRB-)) (PP (IN with) (NP (NN cure))))))) (. .)))
3950060	9	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (DT a) (JJ simultaneous) (JJ multivariable) (NN analysis)) (VP (VBN identified) (SBAR (IN IF) (, ,) (S (NP (NP (NN MIC)) (, ,) (CC and) (NP (JJ total) (NN dose)) (PP (VBG according) (PP (TO to) (NP (NP (CD one) (NN model)) (CC and) (NP (NP (NNS ln)) (PRN (-LRB- -LRB-) (NP (JJ mean) (NNP Cmax/MIC)) (-RRB- -RRB-))))))) (PP (VBG according) (PP (TO to) (NP (NP (DT a) (JJ second) (JJ statistical) (NN model)) (PP (IN of) (NP (NP (NNS parameters)) (VP (VBN selected) (S (VP (TO to) (VP (AUX have) (NP (DT the) (JJS greatest) (JJ prospective) (NN value)))))))))))))) (. .)))
3950060	10	(S1 (S (PP (VBN Based) (PP (IN on) (NP (NP (NP (NNP Bayes) (POS ')) (NN theorem)) (CC and) (NP (DT the) (JJ first) (NN model))))) (, ,) (NP (NP (DT the) (JJ predictive) (NN accuracy)) (PP (IN of) (NP (NP (VBG identifying) (NNS patients)) (VP (RB not) (VBN cured))))) (VP (VBD increased) (PP (IN from) (NP (CD 0.19))) (PP (TO to) (NP (CD 0.83)))) (. .)))
3950060	11	(S1 (S (PP (IN For) (NP (DT the) (JJ second) (NN model))) (, ,) (NP (DT the) (JJ predictive) (NN accuracy)) (VP (VBD increased) (PP (IN from) (NP (CD 0.19))) (PP (TO to) (NP (CD 0.50.))) (PRN (-LRB- -LRB-) (NP (NP (JJ ABSTRACT)) (VP (VBN TRUNCATED) (PP (IN AT) (NP (CD 250) (NNS WORDS))))) (-RRB- -RRB-)))))
3952818	0	(S1 (NP (NP (NN Doc_3952818_0_16_Disease)) (PP (IN of) (NP (NNP Doc_3952818_20_34_Chemical))) (. .)))
3952818	1	(S1 (NP (NP (NN Report)) (PP (IN of) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (JJ spontaneous) (NNP Doc_3952818_68_74_Disease))))) (. .)))
3952818	2	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (NP (NNP Doc_3952818_111_126_Disease)) (CC and) (NP (NN liver) (NN Doc_3952818_137_147_Disease)))) (SBAR (WHNP (WP who)) (S (VP (VBD presented) (NP (NNP Doc_3952818_162_172_Disease)) (PP (IN after) (NP (NNP Doc_3952818_179_193_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_3952818_195_199_Chemical)) (-RRB- -RRB-)) (NN administration)))))))))) (. .)))
3952818	3	(S1 (S (S (NP (JJ Clinical) (JJ electrocardiographic) (NN evolution)) (VP (AUX was) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT that)) (VP (VBN observed) (PP (IN in) (NP (NNP Doc_3952818_289_308_Disease))))))))) (, ,) (CC and) (S (NP (NNP Doc_3952818_314_324_Disease)) (VP (ADVP (RB promptly)) (VBN resolved) (PP (IN with) (NP (NNP Doc_3952818_348_358_Chemical))))) (. .)))
3952818	4	(S1 (S (NP (DT These) (NNS data)) (VP (VBP suggest) (SBAR (SBAR (IN that) (S (NP (NNP Doc_3952818_384_398_Disease)) (VP (MD may) (VP (AUX be) (NP (NP (DT the) (NN cause)) (PP (IN of) (NP (NNP Doc_3952818_419_433_Disease))) (PP (JJ due) (TO to) (NP (NNP Doc_3952818_441_445_Chemical)))))))) (, ,) (CC and) (SBAR (IN that) (S (NP (NNP Doc_3952818_456_463_Chemical) (NNS antagonists)) (VP (MD may) (ADVP (RB probably)) (VP (AUX be) (VP (VBN used) (PP (IN in) (NP (NP (DT the) (NN prevention) (CC or) (NN treatment)) (PP (IN of) (NP (NNP Doc_3952818_531_535_Chemical) (NNP Doc_3952818_536_550_Disease)))))))))))) (. .)))
3961813	0	(S1 (NP (NP (JJ Dose-related) (JJ beneficial) (CC and) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ dietary) (NNP Doc_3961813_55_69_Chemical))) (PP (IN on) (NP (NP (JJ Doc_3961813_73_89_Chemical-induced) (JJ delayed) (NN Doc_3961813_106_116_Disease)) (PP (IN in) (NP (NNS chickens))))) (. .)))
3961813	1	(S1 (S (S (NP (NP (NNP Doc_3961813_130_155_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_3961813_157_161_Chemical)) (-RRB- -RRB-)) (, ,) (NP (CD 360) (NN mg/kg)) (, ,)) (VP (VBD po))) (, ,) (CC and) (S (NP (NP (NP (NNP Doc_3961813_183_219_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_3961813_221_224_Chemical)) (-RRB- -RRB-))) (, ,) (NP (QP (CD 1) (CD mg/kg)) (NN sc)) (, ,)) (VP (AUX were) (VP (VBN administered) (PP (TO to) (NP (JJ adult) (NNP White) (NNP Leghorn) (NNS chickens))) (SBAR (NP (CD 24) (NNS hr)) (IN after) (S (NP (PRP they)) (VP (AUX were) (VP (VBN placed) (PP (IN on) (NP (NP (NNS diets)) (VP (VBG containing) (NP (QP (CD 0) (TO to) (CD 300) (CD ppm)) (NNP Doc_3961813_351_365_Chemical)))))))))))) (. .)))
3961813	2	(S1 (S (NP (JJ Supplemented) (NNS diets)) (VP (AUX were) (VP (VBN continued) (SBAR (IN until) (S (NP (NP (JJ clinical) (NNS signs)) (CC and) (NP (NP (NNS lesions)) (PP (IN of) (NP (JJ delayed) (NNP Doc_3961813_445_455_Disease))))) (VP (VBD appeared)))))) (. .)))
3961813	3	(S1 (S (SBAR (IN Although) (S (NP (NP (NP (JJ low) (NNS concentrations)) (PRN (-LRB- -LRB-) (ADVP (RBR less) (IN than) (CC or) (JJ equal) (PP (TO to) (NP (CD 50) (NN ppm)))) (-RRB- -RRB-))) (PP (IN of) (NP (NNP Doc_3961813_528_542_Chemical)))) (VP (AUX had) (NP (NP (JJ beneficial) (NNS effects)) (PP (IN on) (NP (NNP Doc_3961813_569_573_Chemical-induced) (NNP Doc_3961813_582_592_Disease))))))) (, ,) (ADVP (JJR greater) (IN than) (CC or) (JJ equal) (PP (TO to) (NP (QP (CD 200) (CD ppm))))) (VP (VBD exacerbated) (NP (NP (JJ clinical) (NNS signs)) (PP (IN in) (NP (NP (NNS chickens)) (VP (VBN given) (NP (DT either) (NNP Doc_3961813_679_683_Chemical) (CC or) (NNP Doc_3961813_687_690_Chemical))))))) (. .)))
3961813	4	(S1 (S (NP (JJ Doc_3961813_692_702_Disease) (NN esterase) (NNS activities)) (PP (NP (CD 24) (NNS hr)) (IN after) (NP (NP (NNP Doc_3961813_735_739_Chemical)) (CC or) (NP (NNP Doc_3961813_743_746_Chemical)))) (VP (AUX were) (NP (NP (QP (JJR less) (IN than) (CD 20)) (NN %)) (PP (IN of) (NP (NP (NNS values)) (VP (VBN measured) (PP (IN in) (NP (NP (NNS chickens)) (SBAR (S (RB not) (VP (VBN given) (NP (JJ Doc_3961813_807_824_Chemical) (NNS compounds)))))))))))) (. .)))
3961813	5	(S1 (S (NP (NP (NNS Chickens)) (VP (VBN given) (NP (QP (CD 200) (CD ppm)) (NNP Doc_3961813_859_873_Chemical)) (PP (IN without) (NP (NNP Doc_3961813_882_886_Chemical) (CC or) (NNP Doc_3961813_890_893_Chemical))))) (VP (VP (AUX had) (NP (NP (ADJP (RB significantly) (JJ elevated)) (NN activity)) (PP (IN of) (NP (NN plasma) (NN cholinesterase))))) (CC and) (VP (ADVP (RB significantly)) (VBD inhibited) (NP (NP (NN activity)) (PP (IN of) (NP (NN liver) (NN carboxylesterase)))))) (. .)))
3961813	6	(S1 (S (NP (NN Doc_3961813_1019_1049_Disease)) (VP (AUX were) (ADVP (RB also)) (ADJP (JJ evident)) (PP (IN in) (NP (NP (JJ distal) (NNS levels)) (PP (IN of) (NP (NP (DT the) (JJ peripheral) (NNS nerves)) (PP (IN of) (NP (NP (NNS chickens)) (VP (VBN given) (NP (NNP Doc_3961813_1128_1132_Chemical) (CC or) (NNP Doc_3961813_1136_1139_Chemical)))))))))) (. .)))
3962737	0	(S1 (NP (NP (NN Hepatotoxicity)) (PP (IN of) (NP (NNP Doc_3962737_18_28_Chemical))) (. .)))
3962737	1	(S1 (S (NP (NN Doc_3962737_30_40_Chemical)) (VP (AUX has) (VP (VBN proved) (ADJP (RB very) (JJ effective)) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (ADJP (RB otherwise) (JJ resistant)) (JJ cardiac) (NN Doc_3962737_115_131_Disease))))))) (. .)))
3962737	2	(S1 (S (NP (NP (DT The) (NN use)) (PP (IN of) (NP (NNP Doc_3962737_144_154_Chemical)))) (VP (AUX has) (, ,) (ADVP (RB however)) (, ,) (VP (AUX been) (VP (VBN limited) (PP (JJ due) (TO to) (NP (PRP$ its) (JJ serious) (NNS side-effects)))))) (. .)))
3962737	3	(S1 (S (S (NP (NP (DT A) (NN patient)) (PP (IN with) (NP (NNP Doc_3962737_230_251_Disease))) (PP (JJ due) (TO to) (NP (JJ Doc_3962737_259_269_Chemical) (NN treatment)))) (VP (AUX is) (VP (VBN presented) (ADVP (RB below))))) (CC and) (S (NP (NP (DT a) (NN review)) (PP (IN of) (NP (NP (DT the) (NN hepatotoxicity)) (PP (IN of) (NP (NNP Doc_3962737_337_347_Chemical)))))) (VP (AUX is) (VP (VBN given)))) (. .)))
3962737	4	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (VBN concluded) (SBAR (IN that) (S (NP (NP (JJ solid) (NN evidence) (VBZ exists)) (PP (IN of) (NP (NNP Doc_3962737_404_418_Disease))) (ADJP (JJ due) (PP (TO to) (NP (JJ Doc_3962737_426_436_Chemical) (NN treatment)))) (, ,) (VP (VBG including) (NP (NNP Doc_3962737_458_467_Disease))) (, ,)) (VP (VBZ alterations) (S (VP (VBG resembling) (NP (NP (NNP Doc_3962737_492_511_Disease)) (, ,) (NP (NNP Doc_3962737_513_534_Disease)) (CC and) (NP (JJ micronodular) (NNP Doc_3962737_552_574_Disease)))))))))) (. .)))
3962737	5	(S1 (S (NP (NP (NNS Patients)) (VP (VBG receiving) (NP (NNP Doc_3962737_595_605_Chemical)))) (VP (MD should) (VP (AUX be) (ADVP (RB regularly)) (VP (VBN screened) (PP (IN with) (NP (NP (NN respect)) (PP (TO to) (NP (JJ hepatic) (JJ enzyme) (NNS levels)))))))) (. .)))
3962737	6	(S1 (S (NP (NN Therapy)) (VP (MD should) (VP (AUX be) (VP (VBN discontinued) (PP (IN on) (NP (NP (DT the) (NN suspicion)) (PP (IN of) (NP (NP (NNP Doc_3962737_725_743_Disease)) (CC or) (NP (NNP Doc_3962737_747_759_Disease))))))))) (. .)))
3969369	0	(S1 (S (NP (NP (NP (JJ Promotional) (NNS effects)) (PP (IN of) (NP (NNP Doc_3969369_23_35_Chemical)))) (CC and) (NP (NP (NN dietary) (NN fat)) (PP (IN on) (NP (NN prostate))))) (VP (VBP Doc_3969369_64_78_Disease) (PP (IN in) (NP (ADJP (RB genetically) (JJ susceptible)) (NNS rats)))) (. .)))
3969369	1	(S1 (S (NP (NP (NNP Germfree) (PRN (-LRB- -LRB-) (NP (NNP GF)) (-RRB- -RRB-)) (NNP Lobund) (NN strain) (NNP Wistar) (PRN (-LRB- -LRB-) (NP (NNP LW)) (-RRB- -RRB-)) (NNS rats)) (, ,) (VP (VBN fed) (NP (NN vegetable) (NN diet) (CD L-485))) (, ,)) (VP (AUX have) (VP (VBN developed) (NP (NNP Doc_3969369_199_223_Disease)) (ADVP (RB spontaneously)) (PRN (-LRB- -LRB-) (NP (CD 10) (NN %) (NN incidence)) (-RRB- -RRB-)) (PP (IN at) (NP (NP (JJ average) (NN age)) (NP (CD 34) (NNS months)))))) (. .)))
3969369	2	(S1 (S (S (NP (NP (JJ Conventional) (NN LW) (NNS rats)) (, ,) (VP (VBN implanted) (PP (IN with) (NP (NNP Doc_3969369_317_329_Chemical))) (PP (IN at) (NP (NP (NN age)) (NP (CD 4) (NNS months))))) (, ,)) (VP (VBD developed) (NP (NP (DT a) (JJR higher) (NN incidence)) (PP (IN of) (NP (NNP Doc_3969369_379_394_Disease)))) (PP (IN after) (NP (NP (DT an) (JJ average) (NN interval)) (PP (IN of) (NP (CD 14) (NNS months))))))) (: :) (S (NP (CD 24) (NN %)) (VP (AUX had) (VP (VBN developed) (NP (NP (JJ gross) (NN Doc_3969369_459_465_Disease)) (, ,) (CC and) (NP (CD 40) (NN %))) (SBAR (WHADVP (WRB when)) (S (NP (PRP it)) (VP (VBD included) (NP (JJ microscopic) (NN Doc_3969369_504_510_Disease)))))))) (. .)))
3969369	3	(S1 (S (NP (JJ Preliminary) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (NP (JJ Doc_3969369_546_558_Chemical-treated) (NN LW) (NNS rats)) (SBAR (WHNP (WDT that)) (S (VP (AUX were) (VP (VBN fed) (NP (DT the) (JJ same) (NN diet))))))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX was) (VP (VBN supplemented) (PP (IN with) (NP (NN corn) (NN oil))) (ADVP (RB up) (PP (TO to) (NP (ADJP (CD 20) (NN %)) (NN fat)))))))) (, ,)) (VP (VBD developed) (NP (NNP Doc_3969369_666_681_Disease)) (PP (IN after) (NP (NP (NNS intervals)) (PP (IN of) (NP (CD 6-12) (NNS months))))))))) (. .)))
3969369	4	(S1 (S (NP (VBN Aged) (NNP GF) (NNP Sprague-Dawley) (PRN (-LRB- -LRB-) (NP (NNP SD)) (-RRB- -RRB-)) (NNS rats)) (VP (AUX have) (RB not) (VP (VBN developed) (NP (NN Doc_3969369_766_781_Disease)) (ADVP (RB spontaneously)))) (. .)))
3969369	5	(S1 (S (NP (NP (JJ Conventional) (NN SD) (NNS rats)) (VP (VP (VBN fed) (NP (NN diet) (CD L-485))) (CC and) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_3969369_850_862_Chemical)))))) (VP (VBD developed) (NP (RB only) (NNP Doc_3969369_878_889_Disease))) (. .)))
3969369	6	(S1 (S (NP (JJ Experimental) (NNS designs)) (VP (MD should) (VP (VB consider) (NP (JJ genetic) (NN susceptibility)) (PP (IN as) (NP (NP (DT a) (JJ basic) (NN prerequisite)) (PP (IN for) (NP (NP (NNS studies)) (PP (IN on) (NP (JJ experimental) (NN Doc_3969369_1003_1018_Disease))))))))) (. .)))
3973521	0	(S1 (S (NP (NP (NN Time) (NN course) (NNS alterations)) (PP (IN of) (NP (NNP QTC)))) (VP (VB interval) (ADJP (JJ due) (PP (TO to) (NP (NNP Doc_3973521_47_57_Chemical))))) (. .)))
3973521	1	(S1 (S (NP (NP (JJ Sequential) (NN measurement)) (PP (IN of) (NP (CD QT) (NN interval))) (PP (IN during) (NP (JJ left) (NN ventricular) (NN angiography)))) (VP (AUX was) (VP (VBN made) (NP (NP (CD 30) (NNS seconds)) (CC and) (NP (NP (CD one) (, ,) (CD three) (, ,) (CD five) (CC and) (CD ten) (NNS minutes)) (PP (IN after) (NP (NP (NN injection)) (PP (IN of) (NP (NNP Doc_3973521_209_219_Chemical))))))))) (. .)))
3973521	2	(S1 (S (NP (DT The) (NNS subjects)) (VP (AUX were) (NP (NP (CD ten) (NNS patients)) (VP (VBN found) (S (VP (TO to) (VP (AUX have) (NP (NP (JJ normal) (NN left) (NNS ventricles)) (CC and) (NP (JJ coronary) (NNS arteries))))))))) (. .)))
3973521	3	(S1 (S (NP (JJ Significant) (NN Doc_3973521_324_340_Disease)) (VP (VBD occurred) (PP (IN in) (NP (CD 30) (NNS seconds))) (PP (TO to) (NP (CD one) (NN minute))) (PP (IN in) (NP (NP (NN association)) (PP (IN with) (NP (NP (JJ marked) (NN Doc_3973521_405_416_Disease)) (CC and) (NP (NP (NN elevation)) (PP (IN of) (NP (JJ cardiac) (NN output))))))))) (. .)))
4038130	0	(S1 (NP (NN Rat) (NN extraocular) (NN muscle) (NN regeneration) (. .)))
4038130	1	(S1 (NP (NP (NN Repair)) (PP (IN of) (NP (JJ local) (JJ anesthetic-induced) (NN damage))) (. .)))
4038130	2	(S1 (S (NP (NP (JJ Local) (NNS anesthetics)) (SBAR (WHNP (WDT that)) (S (VP (AUX are) (ADVP (RB commonly)) (VP (VBN used) (PP (IN in) (NP (NP (JJ ophthalmic) (NN surgery)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 0.75) (NN %)) (NP (NNP Doc_4038130_150_175_Chemical))) (, ,) (NP (NP (CD 2.0) (NN %)) (NP (NNP Doc_4038130_182_207_Chemical))) (, ,) (CC and) (NP (NP (NP (CD 2.0) (NN %)) (NP (NNP Doc_4038130_218_241_Chemical))) (PP (CC plus) (NP (CD 1:100,000) (NN Doc_4038130_257_268_Chemical))))) (-RRB- -RRB-))))))))) (VP (AUX were) (VP (VBN injected) (PP (IN into) (NP (NP (DT the) (JJ retrobulbar) (NN area)) (PP (IN of) (NP (NN rat) (NNS eyes))))))) (. .)))
4038130	3	(S1 (S (NP (NNS Controls)) (VP (AUX were) (VP (VBN injected) (PP (IN with) (NP (JJ physiological) (NN saline))))) (. .)))
4038130	4	(S1 (S (NP (DT All) (CD three) (NNS anesthetics)) (VP (VBD produced) (NP (NP (JJ massive) (NN degeneration)) (PP (IN of) (NP (DT the) (JJ extraocular) (NNS muscles))))) (. .)))
4038130	5	(S1 (S (NP (NN Doc_4038130_453_472_Disease)) (VP (AUX is) (VP (VBN followed) (PP (IN by) (NP (NP (NN regeneration)) (PP (IN of) (NP (DT the) (VBN damaged) (NN muscle) (NNS fibers))))))) (. .)))
4038130	6	(S1 (S (PP (IN In) (NP (NP (NN addition)) (PP (TO to) (NP (NNP Doc_4038130_546_559_Disease))))) (, ,) (NP (JJ severe) (NN damage)) (VP (AUX was) (ADVP (RB also)) (VP (VBN seen) (PP (IN in) (NP (JJ harderian) (NNS glands))) (, ,) (PP (ADVP (RB especially)) (IN after) (NP (NP (NN exposure)) (PP (TO to) (NP (NP (NNP Doc_4038130_639_650_Chemical)) (CC and) (NP (NP (NNP Doc_4038130_655_664_Chemical)) (CC plus) (NP (NNP Doc_4038130_670_681_Chemical))))))))) (. .)))
4038130	7	(S1 (S (PP (IN With) (NP (NP (DT these) (NNS findings)) (PP (IN in) (NP (NNS rats))))) (, ,) (NP (PRP it)) (VP (AUX is) (VP (VBN hypothesized) (SBAR (IN that) (S (NP (NP (DT the) (JJ temporary) (NN Doc_4038130_750_758_Disease)) (VP (ADVP (RB sometimes)) (VBN seen) (PP (IN in) (NP (NNS patients))) (PP (IN after) (NP (JJ ophthalmic) (NN surgery))))) (VP (MD might) (VP (AUX be) (ADJP (JJ due) (PP (TO to) (NP (NP (JJ anesthetic-induced) (NN damage)) (PP (TO to) (NP (DT the) (JJ extraocular) (NNS muscles)))))))))))) (. .)))
4069770	0	(S1 (NP (NP (NNP Doc_4069770_0_10_Chemical) (NNP Doc_4069770_11_22_Disease)) (PP (IN in) (NP (DT a) (NN neonate))) (. .)))
4069770	1	(S1 (S (NP (NP (DT The) (JJ clinical) (CC and) (JJ autopsy) (NNS findings)) (PP (IN in) (NP (DT a) (JJ premature) (NN baby))) (SBAR (WHNP (WP who)) (S (VP (VBD died) (PP (IN of) (NP (NNP Doc_4069770_103_122_Disease))) (PP (IN after) (NP (NN therapy))) (PP (IN with) (NP (NP (NP (NNP Doc_4069770_142_152_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 5) (NN mg/kg/day)) (-RRB- -RRB-))) (CC and) (NP (NNP Doc_4069770_171_181_Chemical)))))))) (VP (AUX are) (VP (VBN presented))) (. .)))
4069770	2	(S1 (S (NP (DT The) (NN serum) (NN Doc_4069770_207_217_Chemical) (NN concentration)) (VP (AUX had) (VP (VBN reached) (NP (JJ toxic) (NNS levels)) (SBAR (WHADVP (WRB when)) (S (NP (NNP Doc_4069770_262_268_Disease)) (VP (VBD developed)))))) (. .)))
4069770	3	(S1 (S (NP (NP (JJ Numerous) (NNP Doc_4069770_289_302_Chemical) (NNP Schiff) (PRN (-LRB- -LRB-) (NP (NNP PAS)) (-RRB- -RRB-)) (JJ positive) (, ,) (JJ diastase) (JJ resistant) (JJ cytoplasmic) (NN inclusion) (NNS bodies)) (SBAR (WHNP (WDT which)) (S (VP (VBD appeared) (PP (IN as) (NP (NN myelin) (NNS figures))) (PP (IN in) (NP (NP (NNS cytosegresomes)) (PP (IN under) (NP (DT the) (NNP electron) (NN microscope))))))))) (VP (AUX were) (VP (VBN identified) (PP (IN in) (NP (DT the) (JJ proximal) (JJ convoluted) (NNS tubules))))) (. .)))
4069770	4	(S1 (S (NP (NP (DT The) (JJ pathological) (NNS changes)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_4069770_543_553_Chemical))) (PP (IN in) (NP (DT the) (JJ human) (JJ neonatal) (NNS kidneys))))) (VP (AUX have) (RB not) (VP (AUX been) (ADVP (RB previously)) (VP (VBN reported)))) (. .)))
4090988	0	(S1 (NP (NP (NN Induction)) (PP (IN by) (NP (NP (NNP Doc_4090988_13_24_Chemical)) (PP (IN of) (NP (NNP Doc_4090988_28_53_Disease))))) (PP (IN in) (NP (DT the) (NN rat))) (. .)))
4090988	1	(S1 (NP (NP (NNS Effects)) (PP (IN on) (NP (JJ hepatocyte) (NN fine) (NN structure))) (. .)))
4090988	2	(S1 (S (NP (NP (NNS Groups)) (PP (IN of) (NP (ADJP (JJ male) (CC and) (JJ female)) (JJ inbred) (NNS Leeds)))) (VP (VBP strain) (SBAR (S (NP (NNS rats)) (VP (AUX were) (VP (VBN fed) (NP (NP (NNS diets)) (VP (VBG containing) (NP (DT either) (ADJP (ADJP (CD 0.5) (NN %)) (CC or) (ADJP (CD 1.0) (NN %))) (NNP Doc_4090988_201_212_Chemical)))) (PP (IN by) (NP (NN weight))) (PP (IN for) (NP (QP (IN up) (TO to) (CD 18)) (NNS months)))))))) (. .)))
4090988	3	(S1 (S (PP (IN At) (NP (DT the) (ADJP (CD 1.0) (NN %)) (NN dosage) (NN level))) (, ,) (NP (NP (CD 20) (NN %)) (PP (IN of) (NP (NP (NNS rats)) (PP (IN of) (NP (DT both) (NNS sexes)))))) (VP (VBD developed) (NP (NP (NP (JJ neoplastic) (NNS nodules)) (PP (IN of) (NP (DT the) (NN liver)))) (, ,) (NP (DT a) (ADJP (RB statistically) (JJ significant)) (NN incidence)))) (. .)))
4090988	4	(S1 (S (NP (DT These) (NNS rats)) (ADVP (RB also)) (VP (VBD showed) (NP (NP (NP (JJ gross) (NN enlargement)) (PP (IN of) (NP (PRP$ their) (NNS livers)))) (CC and) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (NNS foci)) (PP (IN of) (NP (JJ cellular) (NN alteration))))))) (, ,) (S (NP (DT the) (NN latter)) (ADVP (RB also)) (VP (AUXG being) (VP (VBN observed) (PP (IN in) (NP (DT the) (JJ low) (NN dosage) (NN male) (NNS rats))))))) (. .)))
4090988	5	(S1 (S (S (NP (NP (NN Doc_4090988_543_553_Disease)) (PP (IN of) (NP (NP (DT the) (JJ transitional) (NN epithelium)) (PP (IN of) (NP (DT the) (NN bladder)))))) (VP (VBD developed) (PP (IN in) (NP (DT all) (JJ Doc_4090988_617_628_Chemical-treated) (NNS groups))))) (, ,) (CC and) (S (NP (CD three) (NNS rats)) (VP (VBD bore) (NP (NN Doc_4090988_665_683_Disease)))) (. .)))
4090988	6	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (JJ significant) (NNS yields)) (PP (IN of) (NP (NNP Doc_4090988_716_731_Disease)))) (VP (AUX were) (ADVP (RB only)) (VP (VBN obtained) (PP (IN from) (NP (NP (JJ low) (NN dosage) (NNS females)) (CC and) (NP (JJ high) (NN dosage) (NNS males)))))) (. .)))
4090988	7	(S1 (S (ADVP (RB Additionally)) (, ,) (NP (NP (QP (CD 20) (TO to) (CD 25)) (NN %)) (PP (IN of) (NP (JJ Doc_4090988_825_836_Chemical-treated) (NNS rats)))) (VP (VBD developed) (NP (NP (NNP Doc_4090988_860_871_Disease)) (PP (IN of) (NP (DT the) (NN bladder) (NN epithelium))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX was) (RB not) (ADJP (JJ coincident) (PP (IN with) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NNP Doc_4090988_945_960_Disease))))))))))) (. .)))
4090988	8	(S1 (S (NP (NP (DT A) (JJ low) (NN yield)) (PP (IN of) (NP (NNP Doc_4090988_977_984_Disease))) (PP (IN at) (NP (JJ various) (JJ other) (NNS sites)))) (ADVP (RB also)) (VP (VBD arose) (PP (VBG following) (NP (JJ Doc_4090988_1029_1040_Chemical) (NN feeding)))) (. .)))
4090988	9	(S1 (S (NP (NP (DT An) (NNP electron) (NN microscope) (NN study)) (PP (IN of) (NP (NP (DT the) (NNS livers)) (PP (IN of) (NP (JJ Doc_4090988_1096_1107_Chemical-treated) (NNS rats)))))) (VP (VBD revealed) (NP (NP (JJ ultrastructural) (NNS changes)) (PP (IN in) (NP (NP (DT the) (NNS hepatocytes)) (SBAR (WHNP (WDT that)) (S (VP (VBP resemble) (NP (NP (DT those)) (SBAR (WHNP (WDT that)) (S (VP (VBP result) (PP (PP (IN from) (NP (NN exposure))) (PP (TO to) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (JJ known) (NNS hepatocarcinogens))))))))))))))))) (. .)))
430165	0	(S1 (NP (NP (JJ Transient) (NN Doc_430165_10_21_Disease)) (: :) (NP (NP (DT a) (JJ rare) (NN manifestation)) (PP (IN of) (NP (NNP Doc_430165_47_64_Chemical) (NNP Doc_430165_65_73_Disease)))) (. .)))
430165	1	(S1 (NP (NP (NN Report)) (PP (IN of) (NP (CD two) (NNS cases))) (. .)))
430165	2	(S1 (S (PP (IN Among) (NP (NP (DT the) (JJ common) (NN side) (NNS effects)) (PP (IN of) (NP (NNP Doc_430165_129_146_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_430165_148_151_Chemical)) (-RRB- -RRB-)) (NNP Doc_430165_153_161_Disease))))) (, ,) (NP (DT the) (ADJP (ADVP (RBS most) (RB frequently)) (VBN encountered)) (JJ neurological) (NNS signs)) (VP (AUX are) (NP (NP (DT those)) (PP (IN of) (NP (NNP Doc_430165_227_249_Disease))))) (. .)))
430165	3	(S1 (S (ADVP (RB Very) (RB rarely)) (, ,) (NP (NP (DT the) (JJ toxic) (JJ neurological) (NNS manifestations)) (PP (IN of) (NP (DT this) (NN drug)))) (VP (AUX are) (PP (IN of) (NP (JJ cerebral) (NN origin)))) (. .)))
430165	4	(S1 (S (NP (CD Two) (NNS patients)) (VP (AUX are) (VP (VBN presented) (SBAR (WHNP (WP who)) (S (VP (VBD suffered) (NP (JJ progressive) (NNP Doc_430165_391_402_Disease)) (PP (JJ due) (PP (TO to) (NP (NNP Doc_430165_410_413_Chemical) (NNP Doc_430165_414_422_Disease))))))))) (. .)))
430165	5	(S1 (S (NP (DT Both)) (VP (AUX had) (NP (NN brain) (NN surgery)) (PP (IN before) (NP (JJ Doc_430165_454_457_Chemical) (NN treatment)))) (. .)))
430165	6	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (VBN assumed) (SBAR (IN that) (S (NP (NP (NNS patients)) (PP (IN with) (NP (DT some) (NN Doc_430165_507_522_Disease)))) (VP (AUX are) (ADJP (JJ liable) (PP (TO to) (NP (JJ manifest) (NNP Doc_430165_546_549_Chemical) (NNP Doc_430165_550_558_Disease)))) (PP (IN as) (NP (JJ focal) (JJ neurological) (NNS signs)))))))) (. .)))
458486	0	(S1 (NP (NP (NN Doc_458486_0_8_Chemical)) (PP (IN in) (NP (NNP Doc_458486_12_20_Chemical-induced) (NNP Doc_458486_29_50_Disease))) (. .)))
458486	1	(S1 (S (NP (NP (NNP Doc_458486_52_60_Chemical)) (, ,) (NP (NP (DT a) (VBN substituted) (JJ Doc_458486_76_85_Chemical) (NN derivative)) (ADJP (RB closely) (JJ related) (PP (TO to) (NP (NNP Doc_458486_116_130_Chemical))))) (, ,)) (VP (VBD reduced) (NP (NP (JJ Doc_458486_140_148_Chemical-induced) (JJ peak) (NN dose) (NN Doc_458486_167_188_Disease)) (PP (IN in) (NP (NP (CD 16) (NNS patients)) (PP (IN with) (NP (NNP Doc_458486_209_239_Disease))))))) (. .)))
458486	2	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (DT an) (JJ unacceptable) (NN increase)) (PP (IN in) (NP (NN disability))) (PP (IN from) (NP (NNP Doc_458486_294_306_Disease))) (PP (IN with) (NP (NP (NN aggravation)) (PP (IN of) (NP (JJ end-of-dose) (NN Doc_458486_339_347_Disease)))))) (VP (VBD led) (PP (TO to) (NP (NP (PRP$ its) (NN cessation)) (PP (IN in) (NP (CD 14) (NNS patients)))))) (. .)))
458486	3	(S1 (S (NP (NN Doc_458486_385_393_Chemical)) (VP (AUX had) (NP (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (JJ Doc_458486_411_419_Chemical-induced) (JJ early) (NN morning)) (PP (IN of) (NP (`` ``) (JJ off-period) ('' '') (NN segmental) (NN Doc_458486_468_476_Disease))))))) (. .)))
458486	4	(S1 (S (NP (DT These) (NNS results)) (VP (VBP fail) (S (VP (TO to) (VP (VB support) (NP (DT the) (NN notion) (SBAR (IN that) (S (NP (NNP Doc_458486_524_532_Chemical-induced) (NNP Doc_458486_541_552_Disease)) (VP (AUX are) (VP (VBN caused) (PP (IN by) (NP (NP (NN overstimulation)) (PP (IN of) (NP (NP (DT a) (JJ separate) (NN group)) (PP (IN of) (NP (JJ Doc_458486_606_614_Chemical) (NNS receptors)))))))))))))))) (. .)))
48362	0	(S1 (NP (NNP Doc_48362_0_9_Chemical) (NNP Doc_48362_10_19_Disease) (. .)))
48362	1	(S1 (S (NP (NP (JJ Long-term) (NN administration)) (PP (IN of) (NP (NNP Doc_48362_49_58_Chemical)))) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (JJ persistent) (NN elevation)) (PP (IN of) (NP (NP (JJ serum) (NNS concentrations)) (PP (IN of) (NP (NP (NN SGOT)) (, ,) (NP (JJ Doc_48362_133_144_Chemical) (NN dehydrogenase)) (, ,) (CC and) (NP (JJ alkaline) (NN phosphatase)))))))))) (. .)))
48362	2	(S1 (S (NP (NN Liver) (NNS biopsy)) (VP (VBD showed) (NP (JJ active) (NN Doc_48362_213_222_Disease))) (. .)))
48362	3	(S1 (S (NP (NP (NN Discontinuance)) (PP (IN of) (NP (JJ Doc_48362_242_251_Chemical) (NN therapy)))) (VP (VBD led) (PP (TO to) (NP (NP (NN normalization)) (PP (IN of) (NP (NN liver) (NN function) (NNS tests)))))) (. .)))
48362	4	(S1 (S (NP (NP (DT A) (NN challenge) (NN dose)) (PP (IN of) (NP (NNP Doc_48362_326_335_Chemical)))) (VP (VBD caused) (NP (NP (NP (JJ clinical) (NNS symptoms)) (CC and) (NP (JJ abrupt) (NN elevation))) (PP (IN of) (NP (NP (NN SGOT)) (, ,) (NP (NN alkaline) (NN phosphatase)) (, ,) (CC and) (NP (JJ Doc_48362_417_428_Chemical) (NN dehydrogenase) (NNS values)))))) (. .)))
48362	5	(S1 (S (NP (PRP We)) (VP (VBD concluded) (SBAR (IN that) (S (NP (DT this) (NN patient)) (VP (VP (AUX had) (NP (JJ Doc_48362_486_495_Chemical) (NN hepatotoxicity))) (CC and) (VP (VB believe) (SBAR (IN that) (S (NP (DT this)) (VP (AUX is) (NP (NP (DT the) (JJ first) (NN case)) (VP (VBN reported) (PP (IN with) (NP (NN liver) (JJ biopsy) (NN documentation))))))))))))) (. .)))
48362	6	(S1 (S (NP (DT This) (NN report)) (ADVP (RB also)) (VP (VBZ suggests) (SBAR (IN that) (S (, ,) (PP (ADVP (RB even)) (IN after) (NP (JJ long-term) (NN administration))) (, ,) (NP (DT the) (NNP Doc_48362_666_682_Disease)) (VP (AUX is) (ADJP (JJ reversible)))))) (. .)))
591536	0	(S1 (NP (NP (NP (JJ Arterial) (NN Doc_591536_9_24_Disease)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (JJ systemic) (NN Doc_591536_56_63_Chemical) (NN therapy)))))) (: :) (NP (NP (DT a) (NN complication)) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_591536_104_111_Chemical-induced) (NNP Doc_591536_120_136_Disease))))) (. .)))
591536	1	(S1 (S (NP (NNP Arterial) (NNP Doc_591536_147_162_Disease)) (VP (AUX is) (NP (NP (DT a) (VBN recognized) (NN complication)) (PP (IN of) (NP (JJ systemic) (JJ Doc_591536_204_211_Chemical) (NN therapy))))) (. .)))
591536	2	(S1 (S (NP (NP (NN Characteristic)) (PP (IN of) (NP (DT the) (NN entity)))) (VP (AUX is) (VP (JJ Doc_591536_253_271_Disease) (PP (IN by) (NP (JJ platelet-fibrin) (NNS thrombi))) (PP (IN with) (S (NP (JJ distal) (NNP Doc_591536_311_319_Disease)) (VP (VBG occurring) (NP (QP (CD four) (TO to) (CD twenty)) (NNS days)) (PP (IN after) (NP (NP (DT the) (NN initiation)) (PP (IN of) (NP (JJ Doc_591536_374_381_Chemical) (NN therapy))) (, ,) (VP (VBN preceded) (PP (IN by) (NP (JJ profound) (NNP Doc_591536_412_428_Disease))) (PP (IN with) (NP (NP (JJ platelet) (NNS counts)) (PP (IN in) (NP (NP (DT the) (NN range)) (PP (IN of) (NP (NP (QP (CD 30,000) (TO to) (CD 40,000))) (PP (IN per) (NP (JJ cubic) (NN millimeter))))))))))))))))) (. .)))
591536	3	(S1 (S (NP (DT The) (ADJP (RB clinically) (JJ apparent)) (NN occlusion)) (VP (VP (MD may) (VP (AUX be) (VP (VBN preceded) (PP (IN by) (NP (NNP Doc_591536_558_603_Disease))) (SBAR (IN that) (S (VP (VBP appear) (S (VP (TO to) (VP (AUX be) (ADJP (JJ Doc_591536_622_630_Disease)) (PP (IN in) (NP (NN origin)))))))))))) (, ,) (CC and) (VP (MD might) (VP (VB serve) (S (VP (TO to) (VP (VB warn) (NP (NP (DT the) (NN clinician)) (PP (IN of) (NP (DT these) (NNS complications)))))))))) (. .)))
591536	4	(S1 (S (NP (NP (NP (JJ Previous) (NNS reports)) (PP (IN of) (NP (DT these) (NNS phenomena)))) (CONJP (RB as) (RB well) (IN as)) (NP (NP (JJ recent) (NNS studies)) (PP (IN of) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NNP Doc_591536_783_790_Chemical))))))) (VP (AUX are) (VP (VBN reviewed))) (. .)))
591536	5	(S1 (S (NP (NP (DT The) (JJ common) (NN factor)) (VP (VBG relating) (NP (NP (NNP Doc_591536_832_847_Disease)) (CC and) (NP (NNP Doc_591536_852_868_Disease))))) (VP (AUX is) (NP (JJ Doc_591536_872_879_Chemical-induced) (NN Doc_591536_888_908_Disease))) (. .)))
591536	6	(S1 (S (NP (JJ Appropriate) (NN treatment)) (VP (VBZ consists) (PP (IN of) (NP (NP (NP (NN discontinuation)) (PP (IN of) (NP (NNP Doc_591536_963_970_Chemical)))) (, ,) (CC and) (NP (NP (NN anticoagulation)) (PP (IN with) (NP (NNP Doc_591536_997_1012_Chemical)))))) (SBAR (IN if) (FRAG (ADJP (JJ necessary))))) (. .)))
591536	7	(S1 (S (NP (JJ Vascular) (NNS procedures)) (VP (AUX are) (VP (VBN performed) (SBAR (IN as) (S (VP (VBN indicated)))))) (. .)))
6111982	0	(S1 (NP (NP (NP (NNP Pharmacology)) (PP (IN of) (NP (NNP Doc_6111982_16_27_Chemical))) (PRN (-LRB- -LRB-) (NP (NNP Doc_6111982_29_42_Chemical)) (, ,) (NP (NNP Doc_6111982_44_51_Chemical)) (-RRB- -RRB-))) (NP (DT a) (JJ new) (JJ potent) (JJ beta-adrenergic) (NN antagonist)) (. .)))
6111982	1	(S1 (S (NP (DT The) (NN compound) (NN Doc_6111982_107_118_Chemical)) (, ,) (PP (IN as) (NP (DT a) (JJ beta-adrenergic) (NN antagonist))) (, ,) (VP (AUX is) (NP (NP (JJ 3-8) (NNS times)) (ADJP (RBR more) (JJ potent) (PP (PP (IN than) (NP (NNP Doc_6111982_183_194_Chemical))) (PP (IN in) (NP (NN vitro))) (CC and) (PP (IN in) (NP (NN vivo))))))) (. .)))
6111982	2	(S1 (S (NP (PRP$ Its) (JJ antiarrhythmic) (NN effectiveness)) (VP (VBZ surpasses) (NP (NP (DT that)) (PP (IN of) (NP (NP (NNP Doc_6111982_268_279_Chemical)) (CC and) (NP (NNP Doc_6111982_284_292_Chemical))))) (S (VP (VBG inhibiting) (NP (DT the) (NNP Doc_6111982_308_315_Chemical) (NNP Doc_6111982_316_326_Disease)) (PP (IN in) (NP (NNS dogs) (CC and) (NNS cats)))))) (. .)))
6111982	3	(S1 (S (S (NP (NN Doc_6111982_345_356_Chemical)) (VP (AUX has) (NP (DT a) (JJ negligible) (NN cardiodepressant) (NN activity)))) (: ;) (S (NP (PRP it)) (VP (AUX is) (RB not) (ADJP (JJ cardioselective)))) (. .)))
6111982	4	(S1 (S (NP (DT The) (NN compound)) (VP (VBZ shows) (NP (DT a) (ADJP (ADJP (JJ rapid)) (CC and) (ADJP (JJ long))) (JJ lasting) (NN effect))) (. .)))
6111982	5	(S1 (S (NP (EX There)) (VP (AUX was) (NP (NP (DT a) (JJ prolonged) (NN elimination)) (PP (IN of) (NP (DT the) (NN radioactivity)))) (PP (IN after) (NP (NP (DT the) (NN injection)) (PP (IN of) (NP (NNP Doc_6111982_558_568_Chemical))) (PP (TO to) (NP (NNS rats) (CC and) (NNS dogs)))))) (. .)))
6111982	6	(S1 (S (NP (NP (DT The) (JJ half) (NN life)) (PP (IN of) (NP (DT the) (VBN unlabeled) (NN substance))) (PP (IN in) (NP (NNS humans)))) (VP (AUX was) (NP (QP (JJR more) (IN than) (CD 10)) (NNS hours))) (. .)))
6115999	0	(S1 (NP (NP (JJ Adverse) (NNS reactions)) (PP (TO to) (NP (NP (NNP Doc_6115999_21_35_Chemical)) (CC and) (NP (NNP Doc_6115999_40_51_Chemical)))) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (JJ mild) (NNP Doc_6115999_78_90_Disease))))) (. .)))
6115999	1	(S1 (NP (NP (NN Report)) (PP (IN of) (NP (NNP Medical) (NNP Research) (NNP Council) (NNP Working) (NNP Party))) (PP (IN on) (NP (ADJP (JJ Mild) (TO to) (JJ Moderate)) (NNP Doc_6115999_161_173_Disease))) (. .)))
6115999	2	(S1 (S (NP (NP (NNS Participants)) (PP (IN in) (NP (NP (DT the) (NNP Medical) (NNP Research) (NNP Council) (NN treatment) (NN trial)) (PP (IN for) (NP (JJ mild) (NN Doc_6115999_245_257_Disease)))))) (VP (AUX are) (ADVP (RB randomly)) (VP (VBN allocated) (PP (TO to) (NP (NP (NP (CD one)) (PP (IN of) (NP (CD four) (NN treatment) (NNS groups)))) (: :) (NP (NP (NP (NNP Doc_6115999_314_328_Chemical)) (, ,) (NP (NNP Doc_6115999_330_341_Chemical)) (, ,)) (CC or) (NP (NP (DT a) (NN placebo)) (PP (IN for) (NP (NP (DT either)) (PP (IN of) (NP (DT these) (NNS drugs))))))))))) (. .)))
6115999	3	(S1 (S (NP (DT The) (NN trial)) (VP (AUX is) (VP (VBN single-blind.) (SBAR (S (NP (NP (QP (CD 23) (CD 582)) (NNS patient-years)) (PP (IN of) (NP (NN observation)))) (VP (AUX have) (VP (AUX been) (VP (VBN completed) (ADVP (RB so) (RB far)) (, ,) (NP (NP (NP (QP (CD 10) (CD 684))) (PP (IN on) (NP (JJ active) (NNS drugs)))) (CC and) (NP (NP (QP (CD 12) (CD 898))) (PP (IN on) (NP (NNS placebos)))))))))))) (. .)))
6115999	4	(S1 (S (NP (DT The) (NNS results)) (VP (VBP show) (SBAR (S (NP (NP (DT an) (NN association)) (PP (IN between) (NP (NP (NNP Doc_6115999_561_575_Chemical) (NNP treatment) (CC and) (NNP Doc_6115999_590_599_Disease)) (, ,) (CC and) (NP (NNP Doc_6115999_605_614_Disease))))) (ADVP (RB also)) (VP (VBD occurred) (ADVP (RBR more) (RB frequently)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG taking) (NP (NNP Doc_6115999_664_675_Chemical)) (PP (IN than) (PP (IN in) (NP (NP (DT those)) (VP (VBG taking) (NP (NNS placebos))))))))))))) (. .)))
6115999	5	(S1 (S (NP (NP (JJ Other) (JJ adverse) (NNS reactions)) (VP (ADVP (RB significantly)) (VBN linked) (PP (IN with) (NP (JJ active) (NNS drugs))))) (VP (VBP include) (NP (NP (NP (VBN impaired) (JJ Doc_6115999_787_794_Chemical) (NN tolerance)) (PP (IN in) (NP (NNS men) (CC and) (NNS women)))) (CC and) (NP (NP (NP (NP (NN Doc_6115999_826_830_Disease)) (PP (IN in) (NP (NNS men))) (, ,) (VP (VBN associated) (PP (IN with) (NP (JJ Doc_6115999_855_869_Chemical) (NN treatment)))) (, ,)) (CC and) (NP (NN Doc_6115999_885_905_Disease) (CC and) (NN dyspnoea))) (PP (IN in) (NP (NP (NNS men) (CC and) (NNS women)) (VP (VBG taking) (NP (NNP Doc_6115999_943_954_Chemical)))))))) (. .)))
6115999	6	(S1 (S (NP (DT No) (NN Doc_6115999_959_974_Disease)) (VP (AUX is) (VP (VBN known) (S (VP (TO to) (VP (AUX have) (VP (VBN occurred) (PP (IN in) (NP (DT the) (JJ Doc_6115999_1008_1019_Chemical) (NN group))))))))) (. .)))
6115999	7	(S1 (S (S (NP (JJ Mean) (NN serum) (JJ Doc_6115999_1038_1047_Chemical) (NN level)) (VP (VBD fell))) (, ,) (CC and) (S (NP (NNP Doc_6115999_1064_1068_Chemical) (CC and) (NNP Doc_6115999_1073_1082_Chemical) (NNS levels)) (VP (VBD rose) (, ,) (PP (IN in) (NP (NP (NNS men) (CC and) (NNS women)) (VP (VBG taking) (NP (NNP Doc_6115999_1120_1134_Chemical))))))) (. .)))
6115999	8	(S1 (S (PP (IN In) (NP (DT the) (NNP Doc_6115999_1143_1154_Chemical) (NN group))) (, ,) (S (NP (NP (NN serum) (NN Doc_6115999_1168_1177_Chemical)) (CC and) (NP (JJ Doc_6115999_1182_1191_Chemical) (NNS levels))) (VP (VBD rose) (PP (IN in) (NP (DT both) (NNS sexes))))) (, ,) (CC but) (S (NP (DT the) (NNP Doc_6115999_1227_1231_Chemical) (NN level)) (VP (VBD rose) (ADVP (RB significantly)) (PP (IN in) (NP (NNS women)) (ADVP (RB only))))) (. .)))
6118280	0	(S1 (S (NP (NP (JJ Serotonergic) (NNS drugs)) (, ,) (NP (NP (NNP Doc_6118280_20_35_Chemical)) (CC and) (NP (NNP Doc_6118280_40_48_Chemical)))) (VP (VBP block) (NP (JJ Doc_6118280_55_63_Chemical-induced) (NN Doc_6118280_72_87_Disease)) (PP (IN in) (NP (NP (DT a) (NN strain)) (PP (IN of) (NP (NNS mice)))))) (. .)))
6118280	1	(S1 (S (PP (IN In) (NP (JJ male) (JJ Swiss) (NNS mice))) (, ,) (NP (NNP Doc_6118280_129_137_Chemical)) (VP (VBD produced) (NP (NN Doc_6118280_147_162_Disease))) (. .)))
6118280	2	(S1 (S (S (NP (NP (DT A) (ADJP (ADJP (CD 3) (NN mg/kg)) (PRN (-LRB- -LRB-) (JJ i.p.) (-RRB- -RRB-))) (NN dose)) (VP (VBN induced) (NP (DT this) (NN response)) (PP (IN in) (NP (NP (DT all)) (PP (IN of) (NP (DT the) (NNS mice))))))) (VP (VBD tested))) (CC and) (S (NP (NP (DT the) (JJ peak) (NN response)) (PP (IN of) (NP (NP (CD 73) (NNS jerks)) (PP (IN per) (NP (NN min)))))) (VP (AUX was) (VP (VBN observed) (PP (IN between) (NP (CD 27) (CC and) (CD 45) (NN min)))))) (. .)))
6118280	3	(S1 (S (S (VP (VBG Increasing) (NP (DT the) (NN brain) (NN Doc_6118280_333_342_Chemical) (NNS levels)) (PP (IN by) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NP (NNP Doc_6118280_375_394_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 80-160) (NN mg/kg)) (-RRB- -RRB-)))))) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (DT a) (JJ peripheral) (NN decarboxylase) (NN inhibitor))))))) (VP (VBD resulted) (PP (IN in) (NP (NP (DT an) (NN inhibition)) (PP (IN of) (NP (DT the) (JJ Doc_6118280_500_508_Chemical) (NN effect)))))) (. .)))
6118280	4	(S1 (S (ADVP (RB However)) (, ,) (PP (IN in) (NP (DT a) (JJ similar) (NN experiment))) (NP (NP (NNP Doc_6118280_550_556_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 80-160) (NN mg/kg)) (-RRB- -RRB-))) (VP (AUX was) (PP (IN without) (NP (NN effect)))) (. .)))
6118280	5	(S1 (S (PP (IN In) (NP (NP (NNS doses)) (PP (IN of) (NP (JJ 3-10) (NNS mg/kg))))) (, ,) (NP (DT the) (JJ Doc_6118280_620_629_Chemical) (NN receptor) (NN agonist) (NN Doc_6118280_647_653_Chemical)) (VP (VBD caused) (NP (NP (DT a) (JJ dose-dependent) (NN blockade)) (PP (IN of) (NP (NP (DT the) (NN response)) (PP (IN of) (NP (NNP Doc_6118280_706_714_Chemical))))))) (. .)))
6118280	6	(S1 (S (PP (IN Of) (NP (DT the) (NNP Doc_6118280_723_738_Chemical))) (, ,) (NP (NP (NNP Doc_6118280_740_750_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 0.1-0.3) (NN mg/kg)) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN found) (S (VP (TO to) (VP (AUX be) (JJ several) (S (VP (VB fold) (ADJP (ADJP (RBR more) (JJ potent)) (PP (IN than) (NP (NP (NNP Doc_6118280_813_821_Chemical)) (PRN (-LRB- -LRB-) (NP (JJ 0.3-3) (NN mg/kg)) (-RRB- -RRB-)))) (PP (IN in) (S (VP (VBG blocking) (NP (DT the) (NNP Doc_6118280_852_867_Disease))))))))))))) (. .)))
6118280	7	(S1 (S (SBAR (IN While) (S (LST (-LRB- -LRB-) (: -) (-RRB- -RRB-)) (NP (NP (JJ -Doc_6118280_879_887_Chemical)) (PRN (-LRB- -LRB-) (NP (JJ 1-3) (NN mg/kg)) (-RRB- -RRB-))) (VP (VBD proved) (S (VP (TO to) (VP (AUX be) (NP (NP (DT an) (JJ effective) (NN antagonist)) (PP (IN of) (NP (NP (NNP Doc_6118280_940_948_Chemical) (, ,) (PRP$ its) (-LRB- -LRB-) (NNP +) (-RRB- -RRB-) (NN -isomer)) (PRN (-LRB- -LRB-) (NP (CD 5-20) (NNS mg/kg)) (-RRB- -RRB-))))))))))) (VP (VBD lacked) (NP (DT this) (NN property))) (. .)))
6118280	8	(S1 (S (S (VP (VBG Considering) (NP (DT the) (NN fact) (SBAR (IN that) (S (NP (NP (NNP Doc_6118280_1026_1031_Chemical)) (CC and) (NP (DT the) (NNP Doc_6118280_1040_1055_Chemical))) (VP (AUX have) (VP (AUX been) (VP (VBN found) (S (VP (TO to) (VP (AUX be) (ADJP (JJ beneficial)) (PP (IN in) (NP (NP (DT the) (NN management)) (PP (IN of) (NP (JJ clinical) (NNP Doc_6118280_1119_1128_Disease)))))))))))))))) (, ,) (NP (DT the) (JJ Doc_6118280_1134_1142_Chemical-induced) (NN Doc_6118280_1151_1160_Disease)) (VP (VBZ seems) (S (VP (TO to) (VP (AUX be) (NP (NP (DT a) (JJ satisfactory) (NN animal) (NN model)) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VB prove) (ADJP (JJ useful) (PP (IN for) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NP (JJ new) (NN drug) (NNS treatments)) (PP (IN for) (NP (DT this) (NN condition))))))))))))))))) (. .)))
6118280	9	(S1 (S (NP (PRP$ Our) (JJ present) (NN study)) (VP (VBD indicated) (NP (NP (DT the) (JJ possible) (NN value)) (PP (IN of) (NP (NP (NNP Doc_6118280_1336_1342_Chemical)) (CC and) (NP (LST (-LRB- -LRB-) (: -) (-RRB- -RRB-)) (NP (NN -Doc_6118280_1351_1359_Chemical)) (PP (IN in) (NP (NP (DT the) (NN management)) (PP (IN of) (NP (JJ clinical) (NNP Doc_6118280_1390_1399_Disease)))))))))) (. .)))
6127992	0	(S1 (NP (NP (JJ Adverse) (NN interaction)) (PP (IN between) (NP (NP (NP (NNP Doc_6127992_28_58_Chemical)) (CC and) (NP (NNP Doc_6127992_63_72_Chemical--report))) (PP (IN of) (NP (CD three) (NNS cases))))) (. .)))
6127992	1	(S1 (S (NP (NP (CD Three) (NNS patients)) (PP (IN with) (NP (NNP Doc_6127992_117_140_Disease)))) (VP (VBD developed) (NP (NP (JJ profound) (NNP Doc_6127992_160_175_Disease)) (, ,) (NP (NNP Doc_6127992_177_188_Disease)) (CC and) (NP (NNP Doc_6127992_193_204_Disease))) (PP (IN during) (NP (NP (JJ combined) (NN therapy)) (PP (IN with) (NP (NP (NNP Doc_6127992_234_243_Chemical)) (CC and) (NP (NNP Doc_6127992_248_278_Chemical))))))) (. .)))
6127992	2	(S1 (S (NP (DT This) (JJ clinical) (NN picture)) (VP (VBD resolved) (ADVP (RB completely)) (PP (IN with) (NP (NP (NN cessation)) (PP (IN of) (NP (DT the) (VBN combined) (NN therapy)))))) (. .)))
6127992	3	(S1 (S (NP (NN Baseline)) (VP (VP (VBD left) (NP (NN ventricular) (NN function))) (, ,) (VP (VBN assessed) (PP (IN by) (NP (NP (JJ cardiac) (NN catheterisation)) (CC or) (NP (JJ nuclear) (NN angiography))))) (, ,) (VP (AUX was) (ADVP (RB normal)) (PP (IN in) (NP (CD two) (NNS patients)))) (CC and) (VP (ADVP (RB only) (RB mildly)) (VBN reduced) (PP (IN in) (NP (DT the) (JJ other))))) (. .)))
6127992	4	(S1 (S (ADVP (RB Simultaneously)) (NP (NP (NN administration)) (PP (IN of) (NP (NP (NNP Doc_6127992_556_586_Chemical)) (CC and) (NP (NNP Doc_6127992_591_600_Chemical))))) (VP (VP (MD may) (VP (VB result) (PP (IN in) (NP (JJ profound) (JJ adverse) (NNS interactions))))) (CC and) (VP (MD should) (ADVP (RB only)) (VP (AUX be) (VP (VBN administered) (PP (IN with) (NP (JJ great) (NN caution))))))) (. .)))
6150641	0	(S1 (NP (NP (NN Comparison)) (PP (IN of) (NP (NP (DT the) (NN effectiveness)) (PP (IN of) (NP (NNP Doc_6150641_35_45_Chemical) (CC and) (NNP Doc_6150641_50_60_Chemical))))) (PP (IN in) (S (VP (VBG inhibiting) (NP (NN acid) (NN secretion)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ gastric) (JJ hypersecretory) (NNS states)))))))) (. .)))
6150641	1	(S1 (S (NP (NP (DT The) (JJ H2-Doc_6150641_145_154_Chemical) (NN receptor) (NNS antagonists)) (ADJP (JJ Doc_6150641_176_186_Chemical) (CC and) (JJ Doc_6150641_191_201_Chemical))) (VP (AUX were) (VP (VBN compared) (SBAR (IN for) (S (NP (PRP$ their) (NNS abilities)) (VP (TO to) (VP (VB control) (NP (JJ gastric) (NN acid) (NN hypersecretion)) (PP (IN on) (NP (NP (DT a) (ADJP (JJ short-) (CC and) (JJ long-term)) (NN basis)) (PP (IN in) (NP (NP (CD 22) (NNS patients)) (PP (IN with) (NP (JJ gastric) (NN acid) (NN hypersecretory) (NNS states))))))))))))) (. .)))
6150641	2	(S1 (S (S (NP (JJ Nineteen) (NNS patients)) (VP (AUX had) (NP (NN Doc_6150641_385_411_Disease)))) (, ,) (S (NP (CD one) (NN patient)) (VP (AUX had) (NP (NN Doc_6150641_429_450_Disease)))) (, ,) (CC and) (S (NP (CD two) (NNS patients)) (VP (AUX had) (NP (JJ idiopathic) (NN hypersecretion)))) (. .)))
6150641	3	(S1 (S (NP (NP (DT The) (NNS rates)) (PP (IN of) (NP (NP (NN onset)) (PP (IN of) (NP (NP (DT the) (NN action)) (PP (IN of) (NP (NP (NNP Doc_6150641_536_546_Chemical)) (CC and) (NP (NNP Doc_6150641_551_561_Chemical))))))))) (VP (AUX were) (NP (DT the) (JJ same))) (. .)))
6150641	4	(S1 (S (S (NP (NP (DT The) (NNS actions)) (PP (IN of) (NP (DT both) (NNS drugs)))) (VP (AUX were) (VP (VBN increased) (PP (IN by) (NP (JJ anticholinergic) (NNS agents)))))) (, ,) (CC and) (S (NP (EX there)) (VP (AUX was) (NP (NP (DT a) (JJ close) (NN correlation)) (PP (IN between) (NP (NP (DT the) (JJ daily) (NN maintenance) (NN dose)) (PP (IN of) (NP (DT each) (NN drug))) (VP (VBN needed) (S (VP (TO to) (VP (VB control) (NP (NN acid) (NN secretion))))))))))) (. .)))
6150641	5	(S1 (S (ADVP (RB However)) (, ,) (NP (NNP Doc_6150641_770_780_Chemical)) (VP (AUX was) (ADJP (ADVP (RB threefold) (RBR more)) (JJ potent) (PP (IN than) (NP (NNP Doc_6150641_812_822_Chemical)))) (PP (DT both) (PP (IN in) (NP (JJ acute) (NN inhibition) (NNS studies))) (CC and) (PP (IN in) (NP (NP (DT the) (JJ median) (NN maintenance) (NN dose)) (VP (VBN needed) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 1.2)) (NP (NNP g)) (PP (IN per) (NP (NN day))) (PP (IN for) (NP (NNP Doc_6150641_917_927_Chemical)))) (CC and) (NP (NP (CD 3.6) (NNP g)) (PP (IN per) (NP (NN day))) (PP (IN for) (NP (NNP Doc_6150641_950_960_Chemical))))) (-RRB- -RRB-))))))) (. .)))
6150641	6	(S1 (S (NP (NP (CD Sixty) (NN percent)) (PP (IN of) (NP (DT the) (NNS males)))) (VP (VP (VBD developed) (NP (NP (NN breast) (NNS changes)) (CC or) (NP (NN Doc_6150641_1018_1027_Disease))) (SBAR (IN while) (S (VP (VBG taking) (NP (NNP Doc_6150641_1041_1051_Chemical)))))) (CC and) (VP (PP (IN in) (NP (DT all) (NNS cases))) (NP (DT these) (NNS changes)) (VBD disappeared) (SBAR (WHADVP (WRB when)) (S (NP (NNP Doc_6150641_1100_1110_Chemical)) (VP (AUX was) (VP (VBN replaced) (PP (IN by) (NP (NNP Doc_6150641_1127_1137_Chemical))))))))) (. .)))
6150641	7	(S1 (S (S (NP (NP (NN Treatment)) (PP (IN with) (NP (NP (JJ high) (NNS doses)) (PP (IN of) (NP (NP (NP (NNP Doc_6150641_1168_1178_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD one) (TO to) (CD 60)) (NNS months)) (: ;) (NP (NP (NN median)) (, ,) (NP (CD 11) (NNS months))) (-RRB- -RRB-))) (CC or) (NP (NP (NNP Doc_6150641_1220_1230_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD two) (TO to) (CD 31)) (NNS months)) (: ;) (NP (NP (NN median)) (, ,) (NP (CD 14) (NNS months))) (-RRB- -RRB-)))))))) (VP (VP (AUX was) (RB not) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_6150641_1293_1324_Disease))))) (CC or) (VP (VBZ alterations) (PP (IN of) (NP (NN serum) (NN gastrin) (NNS concentrations)))))) (, ,) (CC but) (S (NP (JJ Doc_6150641_1377_1387_Chemical) (NN therapy)) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (DT a) (ADJP (RB significantly) (JJR lower)) (NN serum) (JJ Doc_6150641_1444_1454_Chemical) (NN level)) (SBAR (IN than) (S (VP (VBN seen) (PP (IN with) (NP (JJ Doc_6150641_1476_1486_Chemical) (NN therapy))))))))))) (. .)))
6150641	8	(S1 (S (NP (DT The) (NNS results)) (VP (VBP show) (SBAR (IN that) (S (NP (DT both) (NNS drugs)) (VP (MD can) (ADVP (RB adequately)) (VP (VB inhibit) (NP (NN acid) (NN secretion)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ gastric) (JJ hypersecretory) (NNS states)))))))))) (. .)))
6150641	9	(S1 (S (S (NP (DT Both)) (VP (AUX are) (ADJP (JJ safe)) (PP (IN at) (NP (JJ high) (NNS doses))))) (, ,) (CC but) (S (NP (NNP Doc_6150641_1648_1658_Chemical)) (VP (VP (AUX is) (ADVP (RB threefold)) (ADJP (RBR more) (JJ potent))) (CC and) (VP (AUX does) (RB not) (VP (VB cause) (NP (NP (DT the) (JJ antiandrogen) (NN side) (NNS effects)) (VP (ADVP (RB frequently)) (VBN seen) (PP (IN with) (NP (NP (JJ high) (NNS doses)) (PP (IN of) (NP (NNP Doc_6150641_1768_1778_Chemical))))))))))) (. .)))
6153967	0	(S1 (NP (NP (NP (NP (JJ Epileptogenic) (NNS properties)) (PP (IN of) (NP (NNP Doc_6153967_28_37_Chemical)))) (CC and) (NP (PRP$ their) (JJ clinical) (NN interpretation))) (. .)))
6153967	1	(S1 (S (NP (NP (CD Three) (NNS cases)) (PP (IN of) (NP (NNP EEG) (NNS changes))) (VP (VBN induced) (PP (IN by) (NP (NP (JJ single) (NN exposure)) (PP (TO to) (NP (JJ Doc_6153967_130_139_Chemical) (NNS anesthesia))))))) (VP (AUX are) (VP (VBN reported))) (. .)))
6153967	2	(S1 (S (PP (IN In) (NP (CD one) (NN patient))) (, ,) (NP (NNP Doc_6153967_181_190_Chemical)) (VP (VBN administered) (PP (IN during) (NP (NP (DT a) (NN donor) (NN nephrectomy)) (VP (VBN resulted) (PP (IN in) (NP (JJ unexpected) (JJ partial) (NN motor) (NN Doc_6153967_268_276_Disease))))))) (. .)))
6153967	3	(S1 (S (SBAR (IN Until) (S (NP (NP (DT the) (NN cause)) (PP (IN of) (NP (DT the) (NNP Doc_6153967_301_309_Disease)))) (VP (AUX was) (ADVP (RB correctly)) (VP (VBN identified))))) (, ,) (NP (DT the) (NN patient)) (VP (AUX was) (ADVP (RB inappropriately)) (VP (VBN treated) (PP (IN with) (NP (NNS anticonvulsants))))) (. .)))
6153967	4	(S1 (S (NP (CD Two) (JJ other) (NNS patients)) (VP (VBD suffered) (PP (IN from) (NP (JJ partial) (, ,) (ADJP (JJ complex) (CC and) (JJ generalized)) (JJ Doc_6153967_464_472_Disease) (JJ uncontrolled))) (PP (IN by) (NP (NN medication)))) (. .)))
6153967	5	(S1 (S (S (NP (NP (JJ Doc_6153967_501_510_Disease) (NNS foci)) (VP (VP (VBN delineated)) (CC and) (VP (VBN activated) (PP (IN by) (NP (NNP Doc_6153967_544_553_Chemical)))))) (VP (AUX were) (ADVP (RB surgically)) (VP (VBN ablated)))) (CC and) (S (NP (DT the) (NNS patients)) (VP (AUX are) (ADVP (RB now)) (ADJP (JJ Doc_6153967_603_610_Disease-free)))) (. .)))
6153967	6	(S1 (S (NP (NP (JJ Previous) (NNS exposures)) (PP (TO to) (NP (NNP Doc_6153967_639_648_Chemical)))) (VP (AUX have) (S (VP (TO to) (VP (AUX be) (VP (VBN disclosed) (S (VP (TO to) (VP (VB avoid) (NP (NNS mistakes)) (PP (IN in) (NP (NP (JJ clinical) (NN interpretation)) (PP (IN of) (NP (DT the) (NNP EEG))))))))))))) (. .)))
6153967	7	(S1 (S (PP (IN On) (NP (DT the) (JJ other) (NN hand))) (, ,) (NP (NNP Doc_6153967_746_755_Chemical)) (VP (MD may) (VP (VB prove) (S (VP (TO to) (VP (AUX be) (NP (NP (DT a) (JJ safe) (JJ fast) (JJ acting) (NN activator)) (PP (IN of) (NP (NNP Doc_6153967_804_813_Disease) (CD foci)))) (PP (IN during) (NP (NP (NN corticography)) (CC or) (NP (NN depth) (NN electrode) (NN intraoperative) (NNS recordings))))))))) (. .)))
6203632	0	(S1 (NP (NP (NN Development)) (PP (IN of) (NP (NNP Doc_6203632_15_28_Chemical-induced) (NNP Doc_6203632_37_56_Disease))) (. .)))
6203632	1	(S1 (S (NP (NP (DT The) (NN development)) (PP (IN of) (NP (NNP Doc_6203632_77_96_Disease)))) (VP (AUX was) (VP (VBN studied) (PP (IN in) (NP (NP (JJ adult) (JJ female) (JJ Wistar) (NNS rats)) (VP (VBG following) (NP (NP (JJ daily) (JJ subcutaneous) (NNS injections)) (PP (IN of) (NP (NP (NP (NNP Doc_6203632_180_193_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_6203632_195_198_Chemical)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (CD 0.3) (NN mg/kg) (NN body) (NN weight)) (-RRB- -RRB-)))))))))) (. .)))
6203632	2	(S1 (S (NP (DT A) (NN time) (NN course)) (VP (AUX was) (VP (VBN established) (PP (IN for) (NP (NP (NP (DT the) (NN change)) (PP (IN in) (NP (NP (NN tissue) (NN mass)) (, ,) (NP (NNP RNA)) (CC and) (NP (NN DNA) (NN content))))) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (JJ Doc_6203632_318_332_Chemical) (NN content)))))) (. .)))
6203632	3	(S1 (S (NP (NN Heart) (NN weight)) (VP (VBD increased) (NP (CD 44) (NN %)) (PP (IN after) (NP (NP (CD 8) (NNS days)) (PP (IN of) (NP (NN treatment))))) (PP (IN with) (NP (NP (DT a) (JJ half) (NN time)) (PP (IN of) (NP (CD 3.4) (NN days)))))) (. .)))
6203632	4	(S1 (S (NP (JJ Ventricular) (NNP RNA) (NN content)) (VP (AUX was) (VP (VBD elevated) (NP (CD 26) (NN %)) (PP (IN after) (NP (NP (CD 24) (NNP h)) (PP (IN of) (NP (DT a) (JJ single) (NN injection)))))) (CC and) (VP (VBD reached) (NP (DT a) (JJ maximal) (NN level)) (PP (VBG following) (NP (NP (CD 8) (NN days)) (PP (IN of) (NP (NN therapy))))))) (. .)))
6203632	5	(S1 (S (NP (NP (DT The) (JJ half) (NN time)) (PP (IN for) (NP (NNP RNA) (NN accumulation)))) (VP (AUX was) (NP (CD 2.0) (NNS days))) (. .)))
6203632	6	(S1 (S (NP (NP (DT The) (JJ total) (NN content)) (PP (IN of) (NP (NNP Doc_6203632_626_640_Chemical)))) (VP (VP (VBD remained) (ADJP (JJ stable)) (PP (IN during) (NP (NP (DT the) (JJ first) (CD 2) (NNS days)) (PP (IN of) (NP (NN treatment)))))) (CC but) (VP (VBD increased) (NP (CD 46) (NN %)) (PP (IN after) (NP (NP (CD 4) (NNS days)) (PP (IN of) (NP (NN therapy))))))) (. .)))
6203632	7	(S1 (S (NP (JJ Ventricular) (NN DNA) (NN content)) (VP (VP (AUX was) (ADJP (JJ unchanged)) (PP (IN during) (NP (NP (NP (DT the) (JJ early) (NN stage)) (PRN (-LRB- -LRB-) (NP (JJ 1-4) (NNS days)) (-RRB- -RRB-))) (PP (IN of) (NP (NNP Doc_6203632_812_824_Disease) (NN growth)))))) (CC but) (VP (VBD increased) (PP (TO to) (NP (DT a) (JJ new) (JJ steady-state) (NN level))) (NP (CD 19) (NN %)) (PP (IN above) (NP (DT the) (NNS controls))) (PP (IN after) (NP (NP (CD 8) (NNS days)) (PP (IN of) (NP (NN treatment))))))) (. .)))
6203632	8	(S1 (S (NP (NP (JJ Intraventricular) (NNS pressures)) (CC and) (NP (JJ coronary) (NN flow) (NNS measures))) (VP (AUX were) (ADJP (JJ similar) (PP (IN for) (NP (NP (NN control)) (CC and) (NP (JJ experimental) (NNS animals))))) (PP (VBG following) (NP (NP (CD 4) (NN days)) (PP (IN of) (NP (JJ developed) (NNP Doc_6203632_1058_1069_Disease)))))) (. .)))
6203632	9	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (NN dP/dt)) (PP (IN in) (NP (DT the) (JJ Doc_6203632_1093_1096_Chemical-treated) (NNS hearts)))) (VP (AUX was) (ADJP (ADVP (RB slightly) (CC but) (RB significantly)) (PRN (-LRB- -LRB-) (NP (QP (RB P) (JJR less) (IN than) (CD 0.05))) (-RRB- -RRB-)) (JJ elevated))) (. .)))
6203632	10	(S1 (S (NP (DT These) (NNS data)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (DT the) (JJ adaptive) (NN response)) (PP (TO to) (NP (NNP Doc_6203632_1222_1225_Chemical)))) (VP (VBZ shows) (NP (NP (DT an) (JJ early) (NN Doc_6203632_1241_1253_Disease) (NN phase)) (PRN (-LRB- -LRB-) (NP (JJ 1-4) (NNS days)) (-RRB- -RRB-)) (VP (VBN characterized) (PP (IN by) (NP (NP (NP (DT a) (JJ substantial) (NN increase)) (PP (IN in) (NP (NNP RNA) (NN content)))) (CC and) (NP (NP (JJ cardiac) (NN mass)) (PP (IN in) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (NP (NNS changes)) (PP (IN in) (NP (NNP DNA)))))))))))))))) (. .)))
6203632	11	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (JJ prolonged) (NN stimulation)) (PRN (-LRB- -LRB-) (NP (CD 8-12) (NNS days)) (-RRB- -RRB-))) (VP (VBZ appears) (S (VP (TO to) (VP (VB represent) (NP (NP (DT a) (JJ complex) (NN integration)) (PP (IN of) (NP (NP (DT both) (JJ cellular) (NNP Doc_6203632_1480_1491_Disease) (CC and) (NNP Doc_6203632_1496_1507_Disease)) (PP (IN within) (NP (DT the) (NN heart)))))))))) (. .)))
6216862	0	(S1 (NP (NP (JJ Multiple) (JJ side) (NNS effects)) (PP (IN of) (NP (JJ Doc_6216862_25_38_Chemical) (NN therapy))) (PP (IN in) (NP (NP (CD one) (NN patient)) (PP (IN with) (NP (NNP Doc_6216862_67_87_Disease))))) (. .)))
6216862	1	(S1 (S (NP (NNP Doc_6216862_89_100_Disease) (, ,) (NNP Doc_6216862_102_113_Disease) (, ,) (NNP Doc_6216862_115_143_Disease) (, ,) (NNP Doc_6216862_145_157_Disease) (CC and) (NNP Doc_6216862_162_179_Disease)) (VP (AUX have) (DT all) (VP (AUX been) (VP (VBN recorded) (PP (IN as) (NP (NP (NNS complications)) (PP (IN of) (NP (NP (JJ Doc_6216862_223_236_Chemical) (NN therapy)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_6216862_262_282_Disease)))))))))))) (. .)))
6216862	2	(S1 (S (NP (NP (DT A) (NN patient)) (SBAR (WHNP (WP who)) (S (VP (AUX had) (VP (VBN developed) (NP (QP (DT all) (CD 5)))))))) (VP (AUX is) (ADVP (RB now)) (VP (VBN described))) (. .)))
6216862	3	(S1 (S (NP (DT The) (NNP Doc_6216862_340_351_Disease)) (VP (VBD resembled) (NP (NP (NNP Doc_6216862_362_393_Disease)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX has) (VP (AUX been) (VP (VBN reported) (PP (IN as) (NP (NP (DT a) (JJ rare) (NN side) (NN effect)) (PP (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_6216862_458_474_Disease))))) (CC but) (PP (RB not) (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NNP Doc_6216862_500_520_Disease)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_6216862_534_547_Chemical)))))))))))))))))) (. .)))
625456	0	(S1 (NP (NP (ADJP (JJ Obsolete) (CC but) (JJ dangerous)) (NN antacid) (NNS preparations)) (. .)))
625456	1	(S1 (S (NP (NP (NP (CD One) (NN case)) (PP (IN of) (NP (JJ acute) (NNS hypercalcaemia)))) (CC and) (NP (NP (CD two)) (PP (IN of) (NP (JJ recurrent) (NNP Doc_625456_99_114_Disease))))) (VP (AUX are) (VP (VBN reported) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX had) (ADVP (RB regularly)) (VP (VBN consumed) (NP (NP (JJ large) (NNS amounts)) (PP (IN of) (NP (JJ Doc_625456_184_202_Chemical-Doc_625456_203_221_Chemical) (NNS powders)))) (PP (IN for) (NP (QP (JJR more) (IN than) (CD 20)) (NNS years))))))))))) (. .)))
625456	2	(S1 (S (NP (DT The) (NNS powders)) (VP (AUX had) (VP (AUX been) (VP (VBN obtained) (PP (IN from) (NP (NP (NNS pharmacists)) (ADJP (JJ unknown) (PP (TO to) (NP (NP (DT the) (NNS patients) (POS ')) (JJ medical) (NNS practitioners))))))))) (. .)))
625456	3	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (VBN suggested) (SBAR (SBAR (IN that) (S (NP (DT these) (NNS preparations)) (VP (AUX were) (ADJP (JJ responsible) (PP (IN for) (NP (NP (DT the) (NN patient) (POS 's)) (NNS problems))))))) (, ,) (CC and) (SBAR (IN that) (S (NP (JJ such) (NNS powders)) (VP (MD should) (ADVP (RB no) (RB longer)) (VP (AUX be) (ADJP (RB freely) (JJ obtainable))))))))) (. .)))
6292680	0	(S1 (NP (NP (NNP Doc_6292680_0_11_Chemical) (NNP Doc_6292680_12_26_Disease)) (PP (IN in) (NP (NP (NNS children)) (PP (IN with) (NP (JJ left-sided) (NNP Doc_6292680_55_66_Disease))))) (. .)))
6292680	1	(S1 (S (NP (NP (CD Two) (NNS children)) (PP (IN with) (NP (NP (NNP Doc_6292680_86_97_Disease)) (PP (IN of) (NP (DT the) (VBN left) (NN kidney)))))) (VP (VBD experienced) (NP (JJ severe) (NNP Doc_6292680_136_149_Chemical) (NNP Doc_6292680_150_164_Disease)) (PP (IN after) (NP (NP (NP (NN irradiation)) (PP (TO to) (NP (DT the) (NNP Doc_6292680_190_195_Disease) (NN bed)))) (CC and) (NP (NP (JJ conventional) (NN dosage)) (PP (IN of) (NP (NNP Doc_6292680_227_238_Chemical))))))) (. .)))
6292680	2	(S1 (S (NP (DT The) (NNP Doc_6292680_244_258_Disease)) (VP (AUX is) (VP (VBN attributed) (NP (CD 1)) (-RRB- -RRB-) (PP (TO to) (NP (DT the) (NN fact) (SBAR (IN that) (S (NP (NP (NN radiation) (NNS fields)) (PP (IN for) (NP (JJ left) (NNP Doc_6292680_319_330_Disease)))) (VP (VB include) (NP (NP (DT the) (JJR lower) (NN portion)) (PP (IN of) (NP (DT the) (NN heart) (CC and) (CD 2)))) (-RRB- -RRB-) (PP (TO to) (NP (NP (NP (DT the) (NN interaction)) (PP (IN of) (NP (NNP Doc_6292680_399_410_Chemical)))) (CC and) (NP (NP (NN irradiation)) (PP (IN on) (NP (JJ cardiac) (NN muscle))))))))))))) (. .)))
6292680	3	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (VBN recommended) (SBAR (IN that) (S (NP (JJ Doc_6292680_469_480_Chemical) (NN dosage)) (VP (AUX be) (VP (ADVP (RB sharply)) (VBN restricted) (PP (IN in) (NP (NP (NNS children)) (PP (IN with) (NP (NP (NNP Doc_6292680_527_538_Disease)) (PP (IN of) (NP (NP (DT the) (JJ left) (NN kidney)) (SBAR (WHNP (WP who)) (S (VP (VBP receive) (NP (JJ postoperative) (NN irradiation))))))))))))))))) (. .)))
6293644	0	(S1 (NP (NP (NP (NNS Effects)) (PP (IN of) (NP (NNP Doc_6293644_11_21_Chemical))) (PP (IN on) (NP (NN rat) (JJ extrapyramidal) (NN motor) (NN system)))) (: :) (NP (JJ behavioral) (CC and) (JJ biochemical) (NNS data)) (. .)))
6293644	1	(S1 (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NP (JJ i.v.c.) (NN injection)) (PP (IN of) (NP (NN human) (CC and) (NN salmon) (NN calcitonin))))) (PP (IN on) (NP (NP (JJ biochemical) (CC and) (JJ behavioral) (NNS parameters)) (VP (VBN related) (PP (TO to) (NP (DT the) (JJ extrapyramidal) (NN motor) (NN system))) (, ,))))) (VP (AUX were) (VP (VBN investigated) (PP (IN in) (NP (JJ male) (NNS rats))))) (. .)))
6293644	2	(S1 (S (NP (JJ Doc_6293644_271_281_Chemical) (NN injection)) (VP (VBD resulted) (PP (IN in) (NP (NP (NP (DT a) (NN potentiation)) (PP (IN of) (NP (JJ Doc_6293644_322_333_Chemical-induced) (NN Doc_6293644_342_351_Disease)))) (CC and) (NP (NP (DT a) (JJ partial) (NN prevention)) (PP (IN of) (NP (NNP Doc_6293644_380_391_Chemical-induced) (NNP Doc_6293644_400_413_Disease))))))) (. .)))
6293644	3	(S1 (S (ADVP (RB Moreover)) (NP (NN calcitonin)) (VP (VBN induced) (NP (NP (NP (DT a) (JJ significant) (NN decrease)) (PP (IN in) (NP (JJ nigral) (NN GAD) (NN activity)))) (CC but) (NP (NP (DT no) (NN change)) (PP (IN in) (NP (JJ striatal) (NN DA) (CC and) (JJ Doc_6293644_522_527_Chemical) (NN concentration) (CC or) (NN GAD) (NN activity)))))) (. .)))
6293644	4	(S1 (S (NP (DT The) (NNS results)) (VP (AUX are) (VP (VBN discussed) (PP (IN in) (NP (NP (NN view)) (PP (IN of) (NP (NP (DT a) (JJ primary) (NN action)) (PP (IN of) (NP (NN calcitonin))) (PP (IN on) (NP (NP (DT the) (JJ striatonigral) (JJ GABAergic) (NN pathway)) (VP (VBG mediating) (NP (NP (DT the) (JJ Doc_6293644_680_682_Chemical-related) (JJ behavioral) (NNS messages)) (PP (IN of) (NP (JJ striatal) (NN origin))))))))))))) (. .)))
6308526	0	(S1 (S (NP (JJ Doc_6308526_0_10_Chemical) (NN pretreatment)) (VP (VBZ modifies) (NP (NP (NN cardiorespiratory)) (, ,) (NP (NN temperature)) (, ,) (CC and) (NP (NP (JJ behavioral) (NNS effects)) (PP (IN of) (NP (NNP Doc_6308526_91_99_Chemical)))))) (. .)))
6308526	1	(S1 (S (NP (NP (JJ Behavioral) (CC and) (JJ cardiorespiratory) (NNS responses)) (PP (TO to) (NP (NP (DT a) (JJ lethal) (NN dose)) (PP (IN of) (NP (NNP Doc_6308526_164_172_Chemical)))))) (VP (AUX were) (VP (VBN evaluated) (PP (IN in) (NP (NP (NNS rats)) (VP (VBN pretreated) (PP (IN with) (NP (NP (NN saline)) (CC or) (NP (NP (NNP Doc_6308526_222_232_Chemical)) (, ,) (NP (NP (DT an) (NN antagonist)) (PP (IN of) (NP (QP (JJ high-affinity) (CD mu) (CD 1)) (JJ opioid) (NNS receptors)))))))))))) (. .)))
6308526	2	(S1 (S (NP (NP (NN Pretreatment)) (PP (IN with) (NP (NNP Doc_6308526_306_316_Chemical)))) (ADVP (RB significantly)) (VP (VBD blocked) (NP (NP (NNP Doc_6308526_339_347_Chemical) (NNP Doc_6308526_348_357_Disease)) (, ,) (NP (NNP Doc_6308526_359_368_Disease)) (CC and) (NP (NNP Doc_6308526_373_384_Disease))) (PP (IN at) (NP (NP (DT a) (NN dose)) (SBAR (WHNP (WDT which)) (S (ADVP (RB completely)) (VP (VBD eliminated) (NP (NP (NN high-affinity)) (VP (VBG binding) (PP (IN in) (NP (NN brain) (NNS membranes))))))))))) (. .)))
6308526	3	(S1 (S (ADVP (RB Moreover)) (, ,) (NP (NNP Doc_6308526_475_485_Chemical)) (ADVP (RB significantly)) (VP (VBD attenuated) (NP (DT the) (NNP Doc_6308526_515_523_Chemical-induced) (NNP Doc_6308526_532_543_Disease) (CC and) (NNP Doc_6308526_548_570_Disease)) (, ,) (SBAR (IN whereas) (S (NP (NNP Doc_6308526_580_588_Chemical-induced) (NNP Doc_6308526_597_608_Disease)) (VP (AUX was) (ADJP (RBR less) (JJ affected)))))) (. .)))
6308526	4	(S1 (S (NP (NNS Results)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (NNS subpopulations)) (PP (IN of) (NP (NN mu) (NNS receptors)))) (VP (MD may) (VP (VB mediate) (NP (NP (JJ selective) (JJ behavioral) (CC and) (JJ cardiorespiratory) (NNS responses)) (PP (TO to) (NP (NNP Doc_6308526_749_757_Chemical))))))))) (. .)))
6323692	0	(S1 (NP (NP (NN Modification)) (PP (IN of) (NP (NN drug) (NN action))) (PP (IN by) (NP (NNP Doc_6323692_31_45_Disease))) (. .)))
6323692	1	(S1 (S (S (NP (NP (NN Pretreatment)) (PP (IN with) (NP (NP (NP (NNP Doc_6323692_65_81_Chemical)) (PRN (-LRB- -LRB-) (NNP Doc_6323692_83_88_Chemical) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (NP (CD 6) (NN mmol/kg)) (NP (NNP s.c.))) (-RRB- -RRB-))))) (VP (ADVP (RB approximately)) (VBD doubled) (NP (NP (DT the) (NN time)) (SBAR (S (NP (JJ Doc_6323692_138_146_Chemical-treated) (NNS mice)) (VP (VP (VBD remained) (PP (IN on) (NP (DT a) (JJ hot) (NN surface)))) (CC and) (VP (ADVP (RB similarly)) (VBD increased) (NP (JJ muscular) (NNP Doc_6323692_219_233_Disease)) (PP (IN by) (NP (NNP Doc_6323692_237_245_Chemical)))))))))) (, ,) (CC but) (S (NP (NP (JJ Doc_6323692_251_256_Chemical) (NN treatment)) (ADVP (RB alone))) (VP (AUX had) (NP (DT no) (NN effect)))) (. .)))
6323692	2	(S1 (S (ADVP (RB Thus)) (, ,) (NP (NNP Doc_6323692_294_308_Disease)) (VP (VP (AUX is) (ADJP (JJ capable) (PP (IN of) (S (VP (VBG altering) (NP (NN drug) (NN action))))))) (CC and) (VP (MD must) (VP (AUX be) (VP (VBN considered) (PRT (RP along)) (PP (IN with) (NP (NP (VBN impaired) (NN drug) (NN metabolism)) (PP (IN in) (NP (NP (JJ enhanced) (NN drug) (NNS responses)) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_6323692_446_459_Disease)))))))))))) (. .)))
6323692	3	(S1 (S (NP (NP (NNS Experiments)) (PP (IN in) (NP (NN vitro)))) (VP (VBD showed) (SBAR (IN that) (S (NP (NP (JJ Doc_6323692_494_507_Chemical-induced) (JJ Doc_6323692_516_529_Chemical) (NN release)) (PP (IN from) (NP (JJ bovine) (JJ adrenal) (NN medulla)))) (VP (AUX is) (VP (VBN depressed) (NP (QP (RB as) (JJ much) (IN as) (CD 50)) (NN %)) (PP (IN by) (NP (NP (CD 0.3) (NN mM)) (SBAR (S (NP (NP (NNP Doc_6323692_604_609_Chemical)) (CC and) (NP (NP (JJ Doc_6323692_614_617_Chemical-induced) (NNS contractions)) (PP (IN of) (NP (NN guinea-pig) (NN ileum))))) (VP (AUX were) (VP (VBD inhibited) (NP (CD 20) (NN %)) (PP (IN by) (NP (CD 5) (NN mM) (NNP Doc_6323692_686_691_Chemical)))))))))))))) (. .)))
6323692	4	(S1 (S (S (NP (NP (NN Addition)) (PP (IN of) (NP (JJ excess) (NNP Doc_6323692_712_719_Chemical)))) (VP (VBD reversed) (NP (DT the) (NN Doc_6323692_733_743_Disease)) (PP (IN in) (NP (DT both) (NNS tissues))))) (, ,) (CC but) (S (NP (NP (JJ Doc_6323692_765_772_Chemical-independent) (JJ Doc_6323692_785_798_Chemical) (NN release)) (PP (IN by) (NP (NNP Doc_6323692_810_822_Chemical)))) (VP (AUX was) (RB not) (VP (VBN blocked) (PP (IN by) (NP (NNP Doc_6323692_842_847_Chemical)))))) (. .)))
6323692	5	(S1 (S (NP (DT These) (NNS results)) (VP (VBD suggested) (SBAR (IN that) (S (NP (NNP Doc_6323692_878_885_Chemical)) (VP (NNS blocks) (NP (JJ Doc_6323692_893_900_Chemical) (NNS channels)))))) (. .)))
6323692	6	(S1 (S (NP (NP (NP (NNS Parallels)) (PP (IN in) (NP (NP (DT the) (NNS actions)) (PP (IN of) (NP (NNP Doc_6323692_939_944_Chemical)))))) (CC and) (NP (NP (DT the) (JJ Doc_6323692_953_960_Chemical) (NN channel) (NN blocker)) (NP (NNP Doc_6323692_977_986_Chemical)))) (VP (VBP support) (NP (DT this) (NN concept))) (. .)))
6323692	7	(S1 (S (S (NP (NP (NP (DT Both) (NNP Doc_6323692_1014_1023_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 10) (CD mg/kg)) (NN i.p.)) (-RRB- -RRB-))) (CC and) (NP (JJ Doc_6323692_1044_1049_Chemical) (NN pretreatment))) (VP (VP (VBD enhanced) (NP (NP (NNP Doc_6323692_1072_1080_Chemical) (NNP Doc_6323692_1081_1090_Disease-)) (CC and) (NP (JJ Doc_6323692_1096_1104_Chemical-induced) (JJ muscular) (NN Doc_6323692_1122_1136_Disease)))) (CC and) (VP (VBD antagonized) (NP (JJ Doc_6323692_1153_1164_Chemical-induced) (NN motor) (NN activity))))) (, ,) (CC and) (S (NP (DT neither) (NNP Doc_6323692_1201_1210_Chemical) (CC nor) (NNP Doc_6323692_1215_1220_Chemical)) (VP (VBD affected) (NP (NP (DT the) (JJ convulsant) (NN action)) (PP (IN of) (NP (NNP Doc_6323692_1255_1263_Chemical)))))) (. .)))
6323692	8	(S1 (S (NP (DT The) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NNP Doc_6323692_1287_1301_Disease)) (VP (VBZ exerts) (NP (NP (DT a) (JJ Doc_6323692_1311_1318_Chemical) (NN channel)) (VP (VBG blocking) (NP (NN action))) (SBAR (WHNP (WDT which)) (S (VP (VBZ enhances) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (JJ central) (JJ nervous) (NN system) (NNS depressants)) (CC and) (NP (JJ certain) (NN opioid) (NNS analgesics))))))))))))) (. .)))
6381653	0	(S1 (NP (NP (NP (JJ Doc_6381653_0_8_Chemical-induced) (NN Doc_6381653_17_27_Disease)) (CC and) (NP (NN thalamotomy))) (. .)))
6381653	1	(S1 (S (NP (NP (JJ Doc_6381653_45_53_Chemical-induced) (NNP Doc_6381653_62_72_Disease)) (PP (IN of) (NP (NP (DT the) (NNS limbs)) (PP (IN in) (NP (NP (JJ thirteen) (NNS cases)) (PP (IN of) (NP (NNP Doc_6381653_107_119_Disease))))))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX was) (ADJP (JJ choreic) (, ,) (JJ ballistic) (CC or) (JJ Doc_6381653_153_161_Disease)) (PP (IN in) (NP (NN type)))))) (, ,)) (VP (VP (AUX was) (VP (VBN alleviated) (ADVP (RB almost) (RB completely)) (PP (IN by) (NP (JJ stereotaxic) (NN surgery))) (S (VP (VBG using) (NP (NP (DT a) (JJ microelectrode) (NN technique)) (PP (IN for) (NP (NP (DT the) (FW ventralis) (FW oralis) (NNP anterior)) (CC and) (NP (NP (JJ posterior) (NNS nuclei)) (PP (IN of) (NP (DT the) (NN thalamus))))))))))) (, ,) (CC but) (VP (ADJP (RB much) (JJR less)) (PP (IN by) (NP (DT the) (NN ventralis) (JJ intermedius) (NN nucleus))))) (. .)))
6381653	2	(S1 (S (NP (NP (NN Control)) (PP (IN of) (NP (NNP Doc_6381653_395_403_Chemical-induced) (NNP Doc_6381653_412_423_Disease))) (PP (IN by) (NP (NNP Doc_6381653_427_443_Disease))) (PP (IN in) (NP (NP (DT the) (NN course)) (PP (IN of) (NP (NP (JJ routine) (NN treatment)) (PP (IN of) (NP (NNP Doc_6381653_482_494_Disease)))))))) (VP (AUX is) (VP (VBN discussed))) (. .)))
6402369	0	(S1 (NP (NP (NN Treatment)) (PP (IN of) (NP (NNP Doc_6402369_13_23_Chemical-induced) (NNP Doc_6402369_32_51_Disease))) (PP (IN by) (NP (NP (JJ oral) (NN administration)) (PP (IN of) (NP (NP (NNP Doc_6402369_78_112_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_6402369_114_119_Chemical)) (-RRB- -RRB-)))) (PP (TO to) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ inoperable) (NNP Doc_6402369_149_160_Disease))))))) (. .)))
6402369	1	(S1 (S (NP (NP (DT The) (JJ protective) (NN effect)) (PP (IN of) (NP (NP (JJ oral) (NN administration)) (PP (IN of) (NP (NP (DT the) (NNP Doc_6402369_214_219_Chemical) (NN compound) (NNP Doc_6402369_229_263_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_6402369_265_270_Chemical)) (-RRB- -RRB-)))) (PP (IN against) (NP (NP (NNP Doc_6402369_280_299_Disease)) (VP (VBN induced) (PP (IN by) (NP (NP (NNP Doc_6402369_311_321_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_6402369_323_325_Chemical)) (-RRB- -RRB-)))))))))) (VP (AUX was) (VP (VBN tested) (PP (IN in) (NP (NP (DT a) (NN group)) (PP (IN of) (NP (NP (CD 45) (NNS patients)) (PP (IN with) (NP (JJ inoperable) (NNP Doc_6402369_380_391_Disease))))))) (PP (IN under) (NP (NN treatment))) (PP (IN with) (NP (NNP Doc_6402369_413_415_Chemical))) (PRN (-LRB- -LRB-) (NP (NP (CD 2250) (NN mg/m2)) (PP (IN on) (NP (NNS days)))) (NP (CD 2-5)) (-RRB- -RRB-)) (PP (IN as) (NP (NP (NN part)) (PP (IN of) (NP (NP (DT a) (JJ polychemotherapy) (NN regimen)) (VP (VBN repeated) (PP (IN in) (NP (DT a) (JJ 4-week) (NN cycle)))))))))) (. .)))
6402369	2	(S1 (S (NP (NNP Doc_6402369_507_512_Chemical)) (VP (AUX was) (VP (VBN given) (ADVP (RB orally)) (PP (IN on) (NP (NP (DT the) (NNS days)) (PP (IN of) (NP (NN treatment))))) (PP (IN with) (NP (IN IF))) (PP (IN in) (NP (NP (CD 3) (NNS doses)) (PP (IN of) (NP (NP (CD 840) (NNS mg/m2)) (, ,) (NP (NP (DT each)) (VP (VBN administered) (PP (IN at) (NP (NP (NP (CD 0) (NN hr)) (PRN (-LRB- -LRB-) (FRAG (X (SYM =)) (NP (NN injection)) (PP (IN of) (PP (IN IF)))) (-RRB- -RRB-))) (, ,) (NP (CD 4) (NN hr)) (CC and) (NP (NP (QP (CD 8) (CD hr)) (NN p.i.)) (PP (IN Out) (PP (IN of) (NP (NP (DT a) (NN total)) (PP (IN of) (NP (NP (CD 88) (NNS courses)) (PP (IN of) (NP (NP (DT this) (NN treatment)) (SBAR (S (NP (PRP we)) (VP (VBD observed) (NP (NP (CD 10) (NNS episodes)) (PP (IN of) (NP (NP (JJ asymptomatic) (JJ microscopic) (NNS haematuria)) (CC and) (NP (NP (DT no) (NNS episodes)) (PP (IN of) (NP (JJ gross) (NN haematuria)))))))))))))))))))))))))))) (. .)))
6402369	3	(S1 (S (PP (IN In) (NP (NP (DT this) (NN group)) (PP (IN of) (NP (NP (CD 45) (NNS patients)) (PP (IN under) (NP (NP (NN protection)) (PP (IN with) (NP (NNP Doc_6402369_852_857_Chemical))))))))) (NP (EX there)) (VP (AUX were) (NP (NP (NP (CD 5) (JJ complete) (NNS remissions)) (CC and) (NP (CD 9) (JJ partial) (NNS remissions))) (PRN (-LRB- -LRB-) (NP (QP (JJ total) (CD 31)) (NN %)) (-RRB- -RRB-)))) (. .)))
6402369	4	(S1 (S (NP (NP (DT A) (JJ further) (NN group)) (PP (IN of) (NP (NP (CD 25) (NNS patients)) (PP (IN under) (NP (NN polychemotherapy))) (PP (IN with) (NP (NNP Doc_6402369_988_990_Chemical)))))) (VP (AUX were) (VP (VBN treated) (PP (IN by) (NP (NP (JJ conventional) (JJ prophylactic) (NNS measures)) (PRN (-LRB- -LRB-) (NP (NP (VBN raised) (NN fluid) (NN intake)) (CC and) (NP (JJ forced) (NNS diuresis))) (-RRB- -RRB-)))))) (. .)))
6402369	5	(S1 (S (S (PP (IN In) (NP (DT this) (NN group))) (NP (EX there)) (VP (AUX were) (NP (NP (CD 1) (JJ complete) (CC and) (CD 5) (JJ partial) (NNS remissions)) (PRN (-LRB- -LRB-) (NP (JJ total) (CD 24) (NN %)) (-RRB- -RRB-))))) (, ,) (CC but) (S (NP (QP (RB nearly) (PDT all)) (NNS patients)) (VP (VBD developed) (NP (NP (DT either) (JJ gross) (NN haematuria) (NN and/or) (NNS symptoms)) (PP (IN of) (NP (NP (NNP Doc_6402369_1236_1254_Disease)) (PRN (-LRB- -LRB-) (NP (NP (NNP Doc_6402369_1256_1264_Disease)) (CC and) (NP (NNS pollakisuria))) (-RRB- -RRB-))))))) (. .)))
6402369	6	(S1 (S (NP (EX There)) (VP (AUX were) (NP (NP (DT no) (JJ appreciable) (NNS differences)) (PP (IN between) (NP (NP (DT the) (JJ Doc_6402369_1334_1339_Chemical) (NN series)) (CC and) (NP (DT the) (JJ conventional) (NN prophylaxis) (NNS series)))) (PP (IN with) (NP (NP (NN respect)) (PP (TO to) (NP (NP (DT either) (ADJP (JJ haematological) (CC or) (JJ systemic)) (NN Doc_6402369_1437_1445_Disease)) (PP (IN of) (NP (DT the) (JJ cytostatic) (NN treatment))))))))) (. .)))
6402369	7	(S1 (S (NP (PRP$ Our) (NNS results)) (VP (VBP support) (NP (DT the) (NN view) (SBAR (IN that) (S (NP (NP (NNP Doc_6402369_1509_1514_Chemical)) (, ,) (VP (VBN given) (ADVP (RB orally)) (PP (IN in) (NP (NP (NN conjunction)) (PP (IN with) (NP (NP (JJ combined) (JJ cytostatic) (NNS regimens)) (SBAR (WHNP (WDT which)) (S (VP (VBP include) (NP (NNP Doc_6402369_1592_1594_Chemical)))))))))) (, ,)) (VP (VP (VBZ simplifies) (NP (DT the) (NN treatment))) (CC and) (VP (VBZ provides) (NP (NP (JJ optimum) (NN protection)) (PP (IN for) (NP (DT the) (JJ urinary) (NN epithelium)))))))))) (. .)))
6402369	8	(S1 (S (NP (NP (NN Protection)) (PP (IN with) (NP (JJ oral) (NNP Doc_6402369_1702_1707_Chemical)))) (VP (AUX is) (ADJP (RB particularly) (JJ suitable) (PP (IN for) (NP (NNS outpatients))))) (. .)))
6415512	0	(S1 (S (VP (VBP Doc_6415512_0_39_Disease) (NP (NP (JJ following) (NN institution)) (PP (IN of) (NP (JJ Doc_6415512_65_78_Chemical) (NN therapy))) (PP (IN in) (NP (NNS children))))) (. .)))
6415512	1	(S1 (S (NP (NP (CD Five) (NNS children)) (, ,) (VP (VBN aged) (NP (QP (CD 3) (TO to) (CD 11)) (NNS years))) (, ,) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_6415512_148_161_Chemical))) (PP (IN for) (NP (NNP Doc_6415512_166_174_Disease)))) (, ,)) (VP (AUX had) (NP (NP (DT an) (JJ acute) (NN aberrant) (NN reaction)) (VP (VBN characterized) (PP (IN by) (NP (NP (DT the) (NN onset)) (PP (IN of) (NP (NNP Doc_6415512_237_301_Disease))))) (PP (IN within) (NP (DT a) (JJ few) (NNS days)))))) (. .)))
6415512	2	(S1 (S (SBAR (WHADVP (WRB When)) (S (NP (DT the) (NNP Doc_6415512_330_343_Chemical)) (VP (AUX was) (VP (VBN discontinued))))) (, ,) (NP (NP (CD two)) (PP (IN of) (NP (DT the) (NNS children)))) (VP (VBD returned) (PP (TO to) (NP (PRP$ their) (JJ former) (NN state))) (ADVP (RB very) (RB quickly)) (, ,) (SBAR (S (S (NP (CD two)) (VP (AUX had) (NP (NP (DT the) (JJ minor) (NN motor) (NN Doc_6415512_451_459_Disease) (NN resolve)) (PP (IN in) (NP (QP (CD 3) (CC and) (CD 6)) (NNS months)))))) (, ,) (CC and) (S (NP (NN one)) (VP (AUX had) (S (NP (DT the) (NNP Doc_6415512_503_511_Disease)) (VP (VB persist)))))))) (. .)))
6415512	3	(S1 (S (NP (NP (DT The) (NN child)) (SBAR (WHPP (IN in) (WHNP (WP whom))) (S (NP (DT the) (NNP Doc_6415512_543_551_Disease)) (VP (VBD persisted))))) (VP (AUX was) (ADVP (RB later)) (VP (VBN found) (S (VP (TO to) (VP (AUX have) (NP (NN Doc_6415512_586_607_Disease))))))) (. .)))
6415512	4	(S1 (S (NP (DT The) (JJ other) (NNS children)) (VP (AUX are) (VP (VBG doing) (ADVP (RB well)) (PP (IN on) (NP (JJ other) (NNS anticonvulsants))))) (. .)))
6433367	0	(S1 (NP (NP (NN Effect)) (PP (IN of) (NP (JJ Doc_6433367_10_23_Chemical) (JJ synthetase) (NNS inhibitors))) (PP (IN on) (NP (NP (ADJP (RB experimentally) (VBN induced)) (NNP Doc_6433367_72_83_Disease)) (PP (IN in) (NP (NNS rats))))) (. .)))
6433367	1	(S1 (S (S (VP (TO To) (VP (VB investigate) (NP (NP (DT the) (NN relationship)) (PP (IN of) (NP (NP (NNP Doc_6433367_128_142_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_6433367_144_147_Chemical)) (-RRB- -RRB-))))) (PP (TO to) (NP (NNP Doc_6433367_152_159_Disease) (NN induction)))))) (, ,) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (CD six) (JJ PG) (NN synthetase) (NNS inhibitors))) (PP (IN on) (NP (NP (NP (NP (NNP Doc_6433367_218_229_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_6433367_241_250_Chemical) (, ,) (NNP Doc_6433367_252_262_Chemical) (, ,) (NNP Doc_6433367_264_275_Chemical))))) (PRN (-LRB- -LRB-) (NP (NNP Doc_6433367_277_280_Chemical)) (-RRB- -RRB-))) (, ,) (NP (NN electroshock)) (CC or) (NP (NNP Doc_6433367_299_310_Chemical))))) (VP (AUX were) (VP (VBN evaluated))) (. .)))
6433367	2	(S1 (S (S (NP (NP (NNP Doc_6433367_327_336_Chemical) (, ,) (NNP Doc_6433367_338_346_Chemical) (, ,) (NNP Doc_6433367_348_362_Chemical) (, ,) (CC and) (JJ low) (NN dose)) (NP (NNP Doc_6433367_377_394_Chemical))) (VP (VBD increased) (NP (NP (DT the) (NN latency-to-onset)) (PP (IN in) (NP (DT the) (JJ Doc_6433367_433_442_Chemical) (JJ and/or) (NNP Doc_6433367_450_453_Chemical) (NNS models)))))) (: ;) (S (NP (DT the) (NN electroshock) (, ,) (NNP Doc_6433367_480_490_Chemical) (CC and) (NNP Doc_6433367_495_506_Chemical) (NNS models)) (VP (AUX were) (RB not) (VP (ADVP (RB significantly)) (VBN affected) (PP (IN by) (NP (NP (DT any)) (PP (IN of) (NP (DT the) (JJ pretreatment) (NNS agents)))))))) (. .)))
6433367	3	(S1 (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NNP Doc_6433367_608_611_Chemical)) (VP (AUX are) (VP (VBN involved) (PP (IN in) (NP (DT the) (NN mechanism) (PRN (-LRB- -LRB-) (PRP s) (-RRB- -RRB-)) (S (VP (VBG underlying) (UCP (JJ Doc_6433367_656_665_Chemical-) (CC and) (NNP Doc_6433367_671_674_Chemical-induced) (NNP Doc_6433367_683_694_Disease) (, ,) (CC but) (RB not) (ADJP (JJ Doc_6433367_704_714_Chemical-)) (, ,) (ADJP (JJ electroshock-)) (, ,) (CC or) (NP (JJ Doc_6433367_735_746_Chemical-induced) (NN Doc_6433367_755_766_Disease)))))))))))) (. .)))
6436733	0	(S1 (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN Doc_6436733_23_30_Chemical)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (NNP Doc_6436733_73_86_Chemical)))))) (. .)))
6436733	1	(S1 (S (NP (NP (NNP Doc_6436733_88_101_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_6436733_103_106_Chemical)) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ Doc_6436733_124_133_Disease) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX were) (ADVP (RB already)) (VP (AUXG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs)))))))))))) (. .)))
6436733	2	(S1 (S (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP Doc_6436733_237_240_Chemical)))) (VP (AUX was) (VP (VBN administered)))) (, ,) (CC and) (S (NP (JJ venous) (NN blood)) (VP (AUX was) (VP (VBN sampled) (PP (IN at) (NP (CD 0) (, ,) (CD 1) (, ,) (CD 2) (, ,) (CD 3) (, ,) (CC and) (CD 4) (NNS hours)))))) (. .)))
6436733	3	(S1 (S (NP (NP (NNP Doc_6436733_316_323_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_6436733_325_328_Chemical)) (-RRB- -RRB-))) (VP (AUX was) (ADJP (ADJP (JJR higher) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))))))))) (PP (IN than) (PP (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (AUX were) (ADJP (JJ symptom-free)) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-))))))))) (, ,) (SBAR (IN although) (S (NP (NNP Doc_6436733_483_486_Chemical) (NN plasma) (NNS levels)) (VP (AUX were) (ADJP (JJ similar)) (PP (IN in) (NP (DT both) (NNS groups))))))) (. .)))
6436733	4	(S1 (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ Doc_6436733_543_546_Chemical-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (JJ Doc_6436733_572_575_Chemical) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (AUX be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP Doc_6436733_660_663_Chemical)) (VP (AUX is) (VP (VBN given) (ADVP (RB chronically)))))))) (. .)))
6454943	0	(S1 (NP (NP (NN Effect)) (PP (IN of) (NP (NNP Doc_6454943_10_19_Chemical))) (PP (IN on) (NP (NP (JJ pre-existing) (CC and) (JJ Doc_6454943_40_55_Chemical-induced) (NN Doc_6454943_64_75_Disease)) (PP (IN in) (NP (ADJP (RB spontaneously) (JJ Doc_6454943_93_105_Disease)) (NNS rats))))) (. .)))
6454943	1	(S1 (S (NP (NN Doc_6454943_112_123_Disease)) (VP (AUX is) (NP (NP (DT a) (NN side) (NN effect)) (PP (IN of) (NP (NP (JJ Doc_6454943_144_153_Chemical) (NN treatment)) (PP (IN in) (NP (JJ Doc_6454943_167_179_Disease) (NNS patients))))))) (. .)))
6454943	2	(S1 (S (NP (NP (DT The) (NN possibility)) (PP (IN of) (S (VP (VBG reproducing) (NP (NP (DT the) (JJ same) (NN Doc_6454943_230_247_Disease)) (PP (IN with) (NP (NNP Doc_6454943_253_262_Chemical)))))))) (VP (AUX was) (VP (VBN examined) (PP (IN in) (NP (NNP SHR))))) (. .)))
6454943	3	(S1 (S (NP (NP (JJ Oral) (NN administration)) (PP (IN of) (NP (NNP Doc_6454943_307_316_Chemical))) (PP (IN at) (NP (CD 100) (CD mg/kg))) (PP (IN for) (NP (CD 14) (NNS days)))) (VP (VBD failed) (S (VP (TO to) (VP (VB aggravate) (NP (NP (JJ Doc_6454943_362_373_Disease) (NN pre-existing)) (PP (IN in) (NP (NNP SHR)))))))) (. .)))
6454943	4	(S1 (S (ADVP (RB Also)) (, ,) (NP (JJ Doc_6454943_401_410_Chemical) (NN treatment)) (VP (VBD failed) (S (VP (TO to) (VP (VB potentiate) (CC or) (VB facilitate) (NP (NP (NN development)) (PP (IN of) (NP (NP (JJ massive) (NN Doc_6454943_479_490_Disease)) (VP (VBN invoked) (PP (IN by) (NP (NNP Doc_6454943_502_527_Chemical))) (PP (IN in) (NP (NNP SHR))))))))))) (. .)))
6454943	5	(S1 (S (NP (NNP Doc_6454943_536_545_Chemical)) (VP (AUX had) (NP (NP (ADJP (JJ little) (CC or) (DT no)) (JJ demonstrable) (NNS effects)) (PP (IN on) (NP (NP (NN serum) (NN electrolyte) (NNS concentrations)) (, ,) (NP (NP (NP (NN excretion)) (PP (IN of) (NP (NN urine)))) (, ,) (NP (NNP Doc_6454943_641_647_Chemical) (CC and) (NNP Doc_6454943_652_661_Chemical)) (, ,) (NP (JJ endogenous) (JJ Doc_6454943_674_684_Chemical) (NN clearance)) (, ,) (NP (NN body) (NN weight)) (, ,) (CC and) (NP (NN food) (CC and) (NN water) (NN consumption))))))) (. .)))
6454943	6	(S1 (S (ADVP (RB However)) (, ,) (NP (NNP Doc_6454943_750_756_Chemical) (NNS bodies)) (VP (AUX were) (ADJP (RB consistently) (JJ present) (PP (IN in) (NP (NP (NN urine)) (CC and) (NP (NP (JJ several) (NNS lethalities)) (VP (VBN occurred) (PP (IN during) (NP (NP (JJ multiple) (NN dosing)) (PP (IN of) (NP (NP (NNP Doc_6454943_858_867_Chemical)) (PP (IN in) (NP (NNP SHR))))))))))))) (. .)))
6496797	0	(S1 (S (VP (VB Complete) (NP (NNP Doc_6496797_9_20_Disease)) (PP (VBG following) (NP (NP (DT a) (JJ single) (NN dose)) (PP (IN of) (NP (NNP Doc_6496797_48_57_Chemical)))))) (. .)))
6496797	1	(S1 (S (PP (NP (CD Forty) (NNS minutes)) (IN after) (S (VP (VBG receiving) (NP (NP (DT a) (JJ single) (NN starting) (NN dose)) (PP (IN of) (NP (NNP Doc_6496797_115_124_Chemical))))))) (, ,) (NP (DT a) (NN patient)) (VP (VBD developed) (NP (JJ complete) (NN Doc_6496797_155_166_Disease))) (. .)))
6496797	2	(S1 (S (NP (DT The) (NN case)) (VP (VBZ illustrates) (SBAR (IN that) (S (, ,) (PP (IN despite) (NP (NP (DT the) (NNS results)) (PP (IN of) (NP (JJR earlier) (NNS studies))))) (, ,) (NP (NP (NP (NNP Doc_6496797_235_244_Chemical) (POS 's)) (NN effect)) (PP (IN on) (NP (JJ cardiac) (NN conduction)))) (VP (MD may) (VP (AUX be) (ADJP (JJ severe)) (PP (IN in) (NP (NNS individuals))) (PP (IN at) (NP (NP (NN risk)) (PP (IN for) (NP (NN conduction) (NN delay)))))))))) (. .)))
6504332	0	(S1 (NP (NP (JJ Doc_6504332_0_13_Chemical-induced) (NNP Doc_6504332_22_32_Disease)) (PP (IN in) (NP (DT a) (JJ Doc_6504332_38_61_Disease) (NN child))) (. .)))
6504332	1	(S1 (S (NP (NP (DT A) (JJ 2-year-old) (NN child)) (PP (IN with) (NP (JJ known) (NN Doc_6504332_99_120_Disease)))) (VP (VBD developed) (NP (DT a) (NN Doc_6504332_133_143_Disease)) (PP (ADVP (RB soon)) (IN after) (S (VP (VBG starting) (NP (NP (JJ Doc_6504332_164_177_Chemical) (NN therapy)) (PP (IN for) (NP (NNP Doc_6504332_190_198_Disease)))))))) (. .)))
6504332	2	(S1 (S (NP (NP (JJ Known) (NNS causes)) (PP (IN of) (NP (NNP Doc_6504332_216_234_Disease)))) (VP (AUX were) (VP (VBN eliminated) (PP (IN after) (NP (NN evaluation))))) (. .)))
6504332	3	(S1 (S (PP (IN On) (NP (NP (NN repeat) (NN challenge)) (PP (IN with) (NP (NNP Doc_6504332_294_307_Chemical))))) (, ,) (NP (DT the) (NNP Doc_6504332_313_323_Disease)) (VP (VBD recurred)) (. .)))
6504332	4	(S1 (S (NP (NN Doc_6504332_334_347_Chemical)) (VP (MD should) (VP (AUX be) (VP (VBN added) (PP (TO to) (NP (NP (DT the) (NN list)) (PP (IN of) (NP (NP (JJ anticonvulsant) (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (VB cause) (NP (NN Doc_6504332_415_433_Disease))))))))))))) (. .)))
6540303	0	(S1 (S (NP (NP (NNS Effects)) (PP (IN of) (NP (NNP Doc_6540303_11_16_Chemical)))) (VP (VBP pretreatment) (PP (IN on) (NP (NP (NNP Doc_6540303_33_41_Chemical) (NNP Doc_6540303_42_51_Disease)) (PP (IN in) (NP (UCP (JJ pinealectomized) (CC or) (JJ hypophysectomized)) (NNS animals)))))) (. .)))
6540303	1	(S1 (S (NP (DT The) (JJ present) (NNS studies)) (VP (AUX were) (VP (VBN designed) (S (VP (TO to) (VP (VB clarify) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (UCP (NNP Doc_6540303_158_172_Chemical) (CC and) (JJ pineal)) (NNS idolamines))) (PP (IN on) (NP (NP (NNP Doc_6540303_198_206_Chemical-induced) (NNP Doc_6540303_215_224_Disease)) (PP (IN in) (NP (DT the) (ADJP (JJ intact) (, ,) (JJ pinealectomized) (CC or) (JJ hypophysectomized)) (NN chick) (CC and) (NN rat))))))))))) (. .)))
6540303	2	(S1 (S (PP (IN In) (NP (DT the) (VBN pinealectomized) (NN chick))) (, ,) (S (NP (NP (NN pretreatment)) (PP (IN with) (NP (NNP Doc_6540303_340_348_Chemical)))) (VP (VBD increased) (NP (NP (DT the) (NN duration)) (PP (IN of) (NP (NP (NNP Doc_6540303_375_384_Disease)) (PRN (-LRB- -LRB-) (NP (NNP DOC)) (-RRB- -RRB-))))) (PP (IN after) (NP (NNP Doc_6540303_397_405_Chemical))))) (, ,) (CC but) (S (NP (NP (NN pretreatment)) (PP (IN with) (NP (NNP Doc_6540303_429_443_Chemical)))) (VP (AUX did) (RB not))) (. .)))
6540303	3	(S1 (S (NP (DT The) (JJ pineal) (NNP Doc_6540303_464_475_Chemical)) (VP (VBD exhibited) (NP (JJ mixed) (NNS actions))) (. .)))
6540303	4	(S1 (S (NP (NP (NP (NNP Doc_6540303_501_510_Chemical)) (CC and) (NP (NNP Doc_6540303_515_533_Chemical))) (SBAR (WHNP (WDT which)) (S (VP (VBD augmented) (NP (NNP Doc_6540303_550_558_Chemical) (NNP DOC))))) (, ,)) (VP (AUX did) (RB not) (VP (AUX do) (ADVP (RB so)) (PP (IN in) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (DT the) (JJ pineal) (NN gland))))) (, ,) (SBAR (IN whereas) (S (NP (NNP Doc_6540303_622_631_Chemical)) (VP (VBD potentiated) (NP (DT the) (NNP Doc_6540303_648_656_Chemical) (NNP DOC)) (PP (IN in) (NP (PDT both) (DT the) (ADJP (JJ intact) (CC and) (JJ pinealectomized)) (NN chick)))))))) (. .)))
6540303	5	(S1 (S (S (S (NP (NN Doc_6540303_707_715_Chemical)) (VP (AUX was) (ADJP (RBR more) (JJ potent)) (PP (IN in) (NP (DT the) (VBN hypophysectomized) (NN chick))))) (CC and) (S (NP (NP (DT the) (JJ circadian) (NN rhythm)) (VP (VBN noted) (PP (IN in) (NP (DT the) (JJ intact) (NN chick))))) (VP (AUX was) (ADJP (JJ absent))))) (: ;) (S (ADVP (RB furthermore)) (, ,) (NP (NNP Doc_6540303_839_848_Chemical)) (VP (AUX did) (RB not) (VP (VB augment) (NP (DT the) (NNP Doc_6540303_869_877_Chemical) (NNP DOC)) (SBAR (IN whereas) (S (NP (NNP Doc_6540303_890_898_Chemical)) (VP (VBD continued) (S (VP (TO to) (VP (AUX do) (ADVP (RB so))))))))))) (. .)))
6540303	6	(S1 (S (NP (DT This) (NN study)) (VP (AUX did) (RB not) (VP (VB demonstrate) (NP (NP (DT a) (NNS species) (NN difference)) (VP (VBG regarding) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (DT the) (NNP Doc_6540303_997_1003_Chemical))) (PP (IN on) (NP (NP (NP (DT the) (NN pineal)) (PP (IN in) (NP (NP (NN spite)) (PP (IN of) (NP (NP (DT the) (JJ immature) (JJ blood-brain) (NN barrier)) (PP (IN in) (NP (DT the) (JJ young) (NN chick)))))))) (CC and) (NP (NP (DT the) (JJ intact) (NN barrier)) (PP (IN in) (NP (DT the) (NN rat))))))))))) (. .)))
6540303	7	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (DT these) (NNS data)) (VP (VBP indicate) (NP (NP (DT a) (JJ direct) (NN role)) (PP (IN of) (NP (DT the) (NN pituitary))) (PP (IN in) (NP (NP (DT the) (NN augmentation)) (PP (IN of) (NP (NNP Doc_6540303_1204_1212_Chemical) (NNP DOC))) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_6540303_1228_1237_Chemical)))))))) (. .)))
6540303	8	(S1 (S (ADVP (RB Furthermore)) (, ,) (NP (NNP Doc_6540303_1252_1260_Chemical)) (VP (VBD appeared) (S (VP (TO to) (VP (VP (VB act) (PP (IN on) (NP (NP (NNS systems)) (VP (ADVP (RBR more) (RB closely)) (VBN involved) (PP (IN with) (NP (NP (DT the) (NN induction)) (PP (IN of) (NP (NNP Doc_6540303_1332_1340_Chemical) (NNP Doc_6540303_1341_1350_Disease))))))))) (CONJP (RB rather) (IN than)) (ADVP (RB directly)) (PP (IN on) (NP (DT the) (NN pituitary))))))) (. .)))
6615052	0	(S1 (NP (NP (JJ Doc_6615052_0_7_Chemical-induced) (NNP Doc_6615052_16_32_Disease)) (, ,) (NP (NNP Doc_6615052_34_44_Disease)) (, ,) (CC and) (NP (NNP Doc_6615052_50_60_Disease)) (. .)))
6615052	1	(S1 (S (NP (NP (JJ Sixty-two) (NNS patients)) (PP (IN with) (NP (DT a) (JJ Doc_6615052_88_95_Chemical-induced) (NN Doc_6615052_104_120_Disease)))) (VP (AUX are) (VP (VBN reported))) (. .)))
6615052	2	(S1 (S (NP (NP (JJ Clinical) (NNS manifestations)) (PP (IN of) (NP (DT this) (NN disorder)))) (VP (VBP include) (NP (NP (NNP Doc_6615052_184_194_Disease)) (CC or) (, ,) (ADVP (RBR more) (RB frequently)) (, ,) (NP (NP (JJ Doc_6615052_216_230_Disease) (NNS events)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN heparin)))))))) (. .)))
6615052	3	(S1 (S (NP (NN Laboratory) (NN testing)) (VP (AUX has) (VP (VBN revealed) (NP (NP (NN Doc_6615052_301_325_Disease)) (, ,) (NP (NP (VBN increased) (NN resistance)) (PP (TO to) (NP (NNP Doc_6615052_351_358_Chemical)))) (, ,) (CC and) (NP (NP (NN aggregation)) (PP (IN of) (NP (NNS platelets))))) (PP (IN by) (NP (NP (DT the) (NN patient) (POS 's)) (NN plasma))) (SBAR (WHADVP (WRB when)) (S (NP (NN heparin)) (VP (AUX is) (VP (VBN added))))))) (. .)))
6615052	4	(S1 (S (NP (JJ Immunologic) (NN testing)) (VP (AUX has) (VP (VBN demonstrated) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (DT a) (JJ heparin-dependent) (NN platelet) (NN membrane) (NN antibody)))))) (. .)))
6615052	5	(S1 (S (NP (NP (NP (DT The) (CD 20) (NNS deaths)) (, ,) (NP (CD 52) (NN Doc_6615052_555_599_Disease))) (, ,) (CC and) (NP (NP (CD 21) (JJ surgical) (NNS procedures)) (VP (TO to) (VP (VB manage) (NP (DT the) (NNS complications)))))) (VP (VBP confirm) (NP (NP (DT the) (NN seriousness)) (PP (IN of) (NP (DT the) (NN disorder))))) (. .)))
6615052	6	(S1 (S (S (NP (JJ Specific) (NN risk) (NNS factors)) (VP (AUX have) (RB not) (VP (AUX been) (VP (VBN identified))))) (: ;) (S (ADVP (RB therefore)) (, ,) (NP (NP (DT all) (NNS patients)) (VP (VBG receiving) (NP (NN heparin)))) (VP (MD should) (VP (AUX be) (VP (VBN monitored))))) (. .)))
6615052	7	(S1 (S (SBAR (IN If) (S (NP (DT the) (NN platelet) (NN count)) (VP (VBZ falls) (PP (TO to) (NP (QP (JJR less) (IN than) (CD 100,000/mm3)))) (, ,) (SBAR (IN while) (S (NP (DT the) (NN patient)) (VP (AUX is) (VP (VBG receiving) (NP (JJ Doc_6615052_893_900_Chemical) (, ,) (JJ Doc_6615052_902_922_Disease) (NN testing))))))))) (, ,) (S (VP (VBG using) (NP (NP (DT the) (NN patient) (POS 's)) (NN plasma)))) (, ,) (VP (AUX is) (VP (VBN indicated))) (. .)))
6615052	8	(S1 (S (NP (NN Management)) (VP (VBZ consists) (PP (IN of) (NP (NP (NN cessation)) (PP (IN of) (NP (NP (NNP Doc_6615052_1010_1017_Chemical)) (, ,) (NP (JJ platelet) (JJ anti-aggregating) (NNS agents)) (, ,) (CC and) (NP (NP (JJ alternate) (NNS forms)) (PP (IN of) (NP (NN anticoagulation)))))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN indicated))))) (. .)))
663266	0	(S1 (NP (NP (NN Doc_663266_0_24_Disease)) (PP (IN from) (NP (NNP Doc_663266_30_41_Chemical))) (PP (PP (IN with)) (CC and) (PP (IN without) (NP (JJ chelating) (NNS agents)))) (. .)))
663266	1	(S1 (S (NP (NP (DT The) (NN Doc_663266_81_89_Disease)) (PP (IN of) (NP (NNP Doc_663266_93_103_Chemical) (CD 76) (NN %)))) (VP (AUX was) (VP (VBN compared) (PP (IN with) (NP (NP (DT that)) (PP (IN of) (NP (JJ Doc_663266_134_144_Chemical) (NN %))))) (PP (IN by) (NP (NP (JJ selective) (NN injection)) (PP (IN of) (NP (DT each))) (PP (IN into) (NP (NP (DT the) (JJ right) (JJ coronary) (NN artery)) (PP (IN of) (NP (NNS dogs))))))))) (. .)))
663266	2	(S1 (S (NP (NN Doc_663266_217_227_Chemical)) (VP (VBZ contains) (NP (NP (DT the) (NN chelating) (NNS agents)) (ADJP (JJ Doc_663266_258_272_Chemical) (CC and) (JJ Doc_663266_277_293_Chemical))) (, ,) (SBAR (IN while) (S (NP (NNP Hypaque)) (VP (VBZ contains) (NP (NP (NNP Doc_663266_318_342_Chemical)) (CC and) (NP (DT no) (NNP Doc_663266_350_364_Chemical))))))) (. .)))
663266	3	(S1 (S (NP (NN Doc_663266_366_390_Disease)) (VP (VBD occurred) (ADVP (RB significantly) (ADVP (RBR more) (RB often))) (PP (IN with) (NP (NNP Doc_663266_430_440_Chemical))) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP (NN chelating) (NNS agents)) (VP (VBP contribute) (S (VP (TO to) (VP (VB Doc_663266_489_497_Disease) (PP (IN in) (NP (JJ coronary) (NN angiography)))))))))))) (. .)))
6637851	0	(S1 (NP (NP (NP (JJ Long-term) (NN efficacy)) (CC and) (NP (NN Doc_6637851_23_31_Disease))) (PP (IN of) (NP (JJ high-dose) (JJ Doc_6637851_45_55_Chemical) (NN therapy))) (PP (IN for) (NP (NP (NNP Doc_6637851_68_91_Disease)) (CC or) (NP (NNP Doc_6637851_95_119_Disease)))) (. .)))
6637851	1	(S1 (S (NP (NN Doc_6637851_121_131_Chemical)) (VP (AUX was) (VP (VBN administered) (PP (TO to) (NP (NP (CD 154) (NNS patients)) (SBAR (SBAR (WHNP (WP who)) (S (VP (AUX had) (VP (VBN sustained) (, ,) (NP (NP (NP (NP (JJ symptomatic) (NNP Doc_6637851_196_219_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_6637851_221_223_Disease)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 118)) (-RRB- -RRB-))) (CC or) (NP (NP (DT a) (NNP Doc_6637851_240_254_Disease)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 36)) (-RRB- -RRB-)))))))) (CC and) (SBAR (WHNP (WP who)) (S (VP (AUX were) (ADJP (JJ refractory) (PP (TO to) (NP (JJ conventional) (JJ antiarrhythmic) (NNS drugs)))))))))))) (. .)))
6637851	2	(S1 (S (S (NP (DT The) (NN loading) (NN dose)) (VP (AUX was) (NP (NP (CD 800) (NN mg/day)) (PP (IN for) (NP (CD 6) (NNS weeks)))))) (CC and) (S (NP (DT the) (NN maintenance) (NN dose)) (VP (AUX was) (NP (CD 600) (NN mg/day)))) (. .)))
6637851	3	(S1 (S (NP (NP (JJ Sixty-nine) (NN percent)) (PP (IN of) (NP (NNS patients)))) (VP (VP (VBD continued) (NP (NN treatment)) (PP (IN with) (NP (NNP Doc_6637851_467_477_Chemical)))) (CC and) (VP (AUX had) (NP (NP (DT no) (NN recurrence)) (PP (IN of) (NP (NP (JJ symptomatic) (NNP Doc_6637851_515_517_Disease)) (CC or) (NP (NP (NNP Doc_6637851_521_545_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_6637851_547_549_Disease)) (-RRB- -RRB-)))))) (PP (IN over) (NP (NP (DT a) (NN follow-up)) (PP (IN of) (NP (QP (CD 6) (TO to) (CD 52)) (NNS months))))) (PRN (-LRB- -LRB-) (S (VP (VB mean) (NP (CD +/-) (JJ standard) (NN deviation)) (NP (CD 14.2) (NN +/-) (CD 8.2)))) (-RRB- -RRB-)))) (. .)))
6637851	4	(S1 (S (NP (NP (CD Six) (NN percent)) (PP (IN of) (NP (DT the) (NNS patients)))) (VP (VP (AUX had) (NP (NP (DT a) (JJ nonfatal) (NN recurrence)) (PP (IN of) (NP (NNP Doc_6637851_687_689_Disease))))) (CC and) (VP (AUX were) (ADVP (RB successfully)) (VP (VBN managed) (PP (IN by) (S (VP (VBG continuing) (NP (NNP Doc_6637851_734_744_Chemical)) (PP (PP (IN at) (NP (DT a) (JJR higher) (NN dose))) (CC or) (PP (IN by) (NP (NP (DT the) (NN addition)) (PP (IN of) (NP (DT a) (JJ conventional) (JJ antiarrhythmic) (NN drug)))))))))))) (. .)))
6637851	5	(S1 (S (NP (QP (CD One) (CC or) (JJR more)) (JJ adverse) (NN drug) (NNS reactions)) (VP (VBD occurred) (PP (IN in) (NP (NP (CD 51) (NN %)) (PP (IN of) (NP (NNS patients)))))) (. .)))
6637851	6	(S1 (S (NP (JJ Adverse) (NNS effects)) (VP (VBD forced) (NP (NP (NP (DT a) (NN reduction)) (PP (IN in) (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (NNP Doc_6637851_934_944_Chemical))))) (PP (IN in) (NP (CD 41) (NN %)))) (CC and) (NP (NP (NN discontinuation)) (PP (IN of) (NP (NNP Doc_6637851_975_985_Chemical))) (PP (IN in) (NP (NP (CD 10) (NN %)) (PP (IN of) (NP (NNS patients)))))))) (. .)))
6637851	7	(S1 (S (NP (DT The) (ADJP (RBS most) (JJ common)) (JJ symptomatic) (JJ adverse) (NNS reactions)) (VP (AUX were) (NP (NP (NP (NNP Doc_6637851_1057_1063_Disease) (CC or) (NNP Doc_6637851_1067_1073_Disease)) (PRN (-LRB- -LRB-) (NP (CD 35) (NN %)) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Doc_6637851_1081_1087_Disease) (CC and) (NNP Doc_6637851_1092_1100_Disease) (PRN (-LRB- -LRB-) (NP (CD 8) (NN %)) (-RRB- -RRB-) (, ,)) (NNP Doc_6637851_1107_1131_Disease)) (PRN (-LRB- -LRB-) (NP (CD 6) (NN %)) (-RRB- -RRB-))) (, ,) (NP (NNP Doc_6637851_1138_1168_Disease) (PRN (-LRB- -LRB-) (NP (CD 6) (NN %)) (-RRB- -RRB-))) (CC and) (NP (NNP Doc_6637851_1178_1212_Disease) (PRN (-LRB- -LRB-) (NP (CD 5) (NN %)) (-RRB- -RRB-))))) (. .)))
6637851	8	(S1 (S (SBAR (IN Although) (S (NP (JJ large-dose) (NNP Doc_6637851_1239_1249_Chemical)) (VP (AUX is) (ADJP (RB highly) (JJ effective) (PP (IN in) (NP (NP (DT the) (JJ long-term) (NN treatment)) (PP (IN of) (NP (NNP Doc_6637851_1300_1302_Disease) (CC or) (NNP Doc_6637851_1306_1308_Disease))) (ADJP (JJ refractory) (PP (TO to) (NP (JJ conventional) (JJ antiarrhythmic) (NNS drugs)))))))))) (, ,) (NP (PRP it)) (VP (VBZ causes) (NP (JJ significant) (NN Doc_6637851_1380_1388_Disease)) (PP (IN in) (NP (NP (QP (RB approximately) (CD 50)) (NN %)) (PP (IN of) (NP (NNS patients)))))) (. .)))
6637851	9	(S1 (S (ADVP (RB However)) (, ,) (SBAR (WHADVP (WRB when)) (S (NP (DT the) (NN dose)) (VP (AUX is) (VP (VBN adjusted) (PP (VBN based) (PP (IN on) (NP (NP (JJ clinical) (NN response)) (CC or) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (JJ adverse) (NNS effects))))))))))) (, ,) (NP (NP (CD 75) (NN %)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NNP Doc_6637851_1545_1547_Disease)) (CC or) (NP (NNP Doc_6637851_1551_1553_Disease))))))) (VP (MD can) (VP (AUX be) (ADVP (RB successfully)) (VP (VBN managed) (PP (IN with) (NP (NNP Doc_6637851_1587_1597_Chemical)))))) (. .)))
6674249	0	(S1 (SBARQ (WHADVP (WRB Why)) (SQ (MD may) (NP (NP (NNP Doc_6674249_8_33_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_6674249_35_39_Chemical)) (-RRB- -RRB-))) (VP (VB induce) (NP (NNP Doc_6674249_48_56_Disease)) (PP (IN in) (NP (NN man))))) (. ?)))
6674249	1	(S1 (NP (NP (NN Report)) (PP (IN of) (NP (NP (DT a) (NN case)) (CC and) (NP (NN literature) (NN review)))) (. .)))
6674249	2	(S1 (S (NP (NP (DT A) (NN case)) (PP (IN of) (NP (NNP Doc_6674249_115_135_Disease))) (ADJP (JJ due) (PP (TO to) (NP (NP (DT a) (JJ short) (NNP Doc_6674249_151_176_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_6674249_178_182_Chemical)) (-RRB- -RRB-)) (NN treatment)) (PP (IN in) (NP (NP (DT a) (CD 72) (JJ year-old) (NN patient)) (PP (IN with) (NP (NP (NNP Doc_6674249_224_248_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_6674249_250_253_Disease)) (-RRB- -RRB-)))))))))) (VP (AUX is) (VP (VBN described))) (. .)))
6674249	3	(S1 (S (NP (JJ Pathogenetic) (NNS hypotheses)) (VP (AUX are) (VP (VBN discussed))) (. .)))
6695415	0	(S1 (S (NP (NN Doc_6695415_0_19_Disease)) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_6695415_36_55_Chemical))) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NNP Doc_6695415_76_84_Chemical)))))) (. .)))
6695415	1	(S1 (S (NP (NP (NNP Doc_6695415_86_105_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_6695415_107_110_Chemical)) (-RRB- -RRB-))) (VP (AUX is) (NP (NP (DT a) (NN drug)) (SBAR (WHNP (WDT that)) (S (VP (AUX has) (VP (AUX been) (VP (VBN associated) (PP (IN with) (NP (NP (JJ serious) (JJ side) (NNS effects)) (PP (VBG including) (NP (NN Doc_6695415_183_189_Disease)))))))))))) (. .)))
6695415	2	(S1 (S (NP (PRP It)) (VP (AUX is) (ADVP (RB often)) (VP (VBN combined) (PP (IN with) (NP (NNP Doc_6695415_217_225_Chemical))) (PP (IN in) (NP (NP (NN diet) (NNS preparations)) (CC and) (NP (`` ``) (JJ look-alike) ('' '') (NNS pills)))))) (. .)))
6695415	3	(S1 (S (SBAR (IN In) (S (NP (NN order)) (VP (TO to) (VP (VB determine) (SBAR (IN if) (S (NP (NNP Doc_6695415_296_299_Chemical/Doc_6695415_300_308_Chemical)) (VP (MD can) (VP (VB lead) (PP (TO to) (NP (NP (NNP Doc_6695415_321_327_Disease)) (PP (IN in) (NP (JJ normotensive) (JJ and/or) (NNP Doc_6695415_351_363_Disease) (NNS rats))))))))))))) (, ,) (NP (PRP we)) (VP (VBN administered) (NP (NP (DT the) (NN combination)) (PP (IN in) (NP (NP (NP (CD six) (NNS times)) (NP (DT the) (JJ allowed) (JJ human) (NN dose))) (VP (VBN calculated) (PP (IN on) (NP (NP (DT a) (FW per) (NN weight) (NN basis)) (PP (IN for) (NP (DT the) (NNS rats))))))))) (NP (CD two) (NNS times)) (PP (IN per) (NP (NN day))) (PP (IN for) (NP (CD five) (NNS days)))) (. .)))
6695415	4	(S1 (S (NP (NN Doc_6695415_517_553_Disease)) (VP (AUX was) (VP (VBN noted) (PP (IN in) (NP (NP (CD 18) (NN %)) (PP (IN of) (NP (DT the) (JJ Doc_6695415_578_590_Disease) (NNS rats))))))) (. .)))
6695415	5	(S1 (S (NP (NP (DT A) (JJ single) (NNP Doc_6695415_606_609_Chemical/Doc_6695415_610_618_Chemical) (NN administration)) (PRN (-LRB- -LRB-) (NP (JJ same) (NN dose)) (-RRB- -RRB-))) (VP (VBP lead) (PP (TO to) (NP (NP (JJ acute) (NN Doc_6695415_660_672_Disease)) (PP (IN in) (NP (DT both) (DT the) (JJ normotensive) (CC and) (JJ Doc_6695415_702_714_Disease) (NNS animals)))))) (. .)))
6695415	6	(S1 (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NNP Doc_6695415_751_754_Chemical/Doc_6695415_755_763_Chemical)) (VP (MD can) (VP (VB lead) (PP (TO to) (NP (NP (NNP Doc_6695415_776_795_Disease)) (PP (IN in) (NP (ADJP (RB previously) (JJ Doc_6695415_810_822_Disease)) (NNS animals))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN administered) (PP (IN in) (NP (NP (JJR greater)) (PP (IN than) (NP (DT the) (JJ allowed) (NN dosage))))))))))))) (. .)))
6695415	7	(S1 (S (NP (NP (DT An) (JJ acute) (NN elevation)) (PP (IN in) (NP (NN blood) (NN pressure)))) (VP (MD may) (VP (AUX be) (NP (DT a) (JJ contributing) (NN factor)))) (. .)))
6699841	0	(S1 (NP (NP (NN Doc_6699841_0_24_Disease)) (ADJP (JJ due) (PP (TO to) (NP (NNP Doc_6699841_32_40_Chemical)))) (. .)))
6699841	1	(S1 (S (NP (NP (DT A) (JJ 31-year-old) (NN man)) (PP (IN with) (NP (NP (NNP Doc_6699841_65_85_Disease)) (, ,) (SBAR (WHNP (WP who)) (S (VP (AUX had) (ADVP (RB previously)) (VP (AUX been) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_6699841_124_132_Chemical)) (, ,) (NP (NNP Doc_6699841_134_152_Chemical)) (, ,) (NP (JJ high) (NN dose) (NNP Doc_6699841_164_175_Chemical)) (CC and) (NP (NNP Doc_6699841_180_190_Chemical))))))))) (, ,)))) (VP (VBD developed) (NP (NP (NNP Doc_6699841_202_226_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_6699841_228_231_Disease)) (-RRB- -RRB-))) (PP (NP (CD 4) (NNS months)) (IN after) (NP (NP (NN institution)) (PP (IN of) (NP (JJ Doc_6699841_263_271_Chemical) (NN therapy)))))) (. .)))
6699841	2	(S1 (S (NP (NP (DT No) (JJ other) (NN factor)) (VP (VBG predisposing) (PP (TO to) (NP (NNP Doc_6699841_313_316_Disease))))) (VP (MD could) (VP (AUX be) (VP (VBN discovered)))) (. .)))
6699841	3	(S1 (S (S (NP (NN Doc_6699841_338_346_Chemical)) (VP (AUX was) (VP (VBN substituted) (PP (IN for) (NP (NNP Doc_6699841_367_375_Chemical)))))) (CC and) (S (NP (DT no) (JJ further) (JJ adverse) (JJ renal) (NNS effects)) (VP (VBD occurred) (PP (IN over) (NP (DT the) (JJ next) (CD 12) (NNS months))))) (. .)))
6699841	4	(S1 (S (NP (PRP We)) (VP (VP (VBP review) (NP (NP (JJ previous) (NNS reports)) (VP (VBG linking) (NP (NNP Doc_6699841_482_485_Disease)) (PP (TO to) (NP (JJ antiinflammatory) (NN drug) (NN use)))))) (CC and) (VP (VB discuss) (NP (NP (JJ possible) (NNS advantages)) (PP (IN of) (NP (NNP Doc_6699841_550_558_Chemical)))) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX have) (VP (VBN experienced) (NP (NNP Doc_6699841_592_606_Disease)) (PP (IN from) (NP (JJ other) (NN antiinflammatory) (NNS agents))))))))))) (. .)))
6728084	0	(S1 (NP (NP (JJ Nephrotoxic) (NNS effects)) (PP (IN of) (NP (JJ Doc_6728084_23_37_Chemical) (NN treatment))) (PP (IN on) (NP (NP (JJ renal) (NN protein) (NN reabsorption)) (CC and) (NP (NN accumulation)))) (. .)))
6728084	1	(S1 (S (S (VP (TO To) (VP (VB quantify) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NNP Doc_6728084_123_133_Chemical) (, ,) (NNP Doc_6728084_135_144_Chemical) (CC and) (NNP Doc_6728084_149_159_Chemical))) (PP (IN on) (NP (NP (JJ renal) (NN protein) (NN reabsorption)) (CC and) (NP (NN accumulation)))))))) (, ,) (NP (DT these) (NNS drugs)) (VP (AUX were) (VP (VBN administered) (PP (TO to) (NP (NNS rats))) (ADVP (RB intraperitoneally)) (PRN (-LRB- -LRB-) (NP (CD 30) (NN mg/kg/day)) (-RRB- -RRB-)) (PP (IN for) (NP (CD 7) (, ,) (CD 14) (CC or) (CD 21) (NNS days))))) (. .)))
6728084	2	(S1 (S (PP (VBG Scanning) (NP (NP (NNP electron) (NN microscopy)) (PP (IN of) (NP (DT the) (JJ glomerular) (NN endothelia))))) (, ,) (NP (NP (JJ urinary) (NNS measurements)) (PP (IN of) (NP (NP (NNP Doc_6728084_384_390_Chemical)) (, ,) (NP (NNP Doc_6728084_392_401_Chemical)) (, ,) (NP (JJ endogenous) (NN lysozyme)) (, ,) (NP (NNP N-acetyl-beta-D-glucosaminidase) (PRN (-LRB- -LRB-) (NNP NAG) (-RRB- -RRB-)) (PP (IN as) (PP (ADVP (RB well)) (IN as) (NP (NP (NN clearance) (CC and) (NN accumulation) (NNS experiments)) (PP (IN after) (NP (NP (NN i.v.) (NN administration)) (PP (IN of) (NP (NP (JJ egg-white) (NN lysozyme) (CC and) (NNS measurements)) (PP (IN of) (NP (NP (NN inulin) (NN clearance)) (PRN (-LRB- -LRB-) (NP (NNP GFR)) (-RRB- -RRB-))))))))))))))) (VP (AUX were) (VP (AUX done) (PP (IN in) (NP (DT each) (NN treatment) (NN group))))) (. .)))
6728084	3	(S1 (S (NP (JJ Doc_6728084_638_648_Chemical) (NN administration)) (VP (VBD decreased) (NP (NP (NP (NN diameter)) (, ,) (NP (NN density)) (CC and) (NP (NN shape))) (PP (IN of) (NP (JJ endothelial) (NNS fenestrae))))) (. .)))
6728084	4	(S1 (S (NP (NP (NNP Doc_6728084_728_737_Chemical)) (CC and) (NP (NNP Doc_6728084_742_752_Chemical))) (VP (VBD appeared) (S (VP (TO to) (VP (AUX have) (NP (DT no) (NN effect)) (PP (IN at) (NP (NP (DT the) (NN dose)) (VP (VBN used)))))))) (. .)))
6728084	5	(S1 (S (NP (DT All) (CD three) (NNP Doc_6728084_808_823_Chemical)) (VP (VP (VBD decreased) (NP (NN GFR))) (CC and) (VP (VBD increased) (NP (NP (JJ urinary) (NN excretion)) (PP (IN of) (NP (NNP Doc_6728084_873_879_Chemical) (CC and) (NNP Doc_6728084_884_893_Chemical)))))) (. .)))
6728084	6	(S1 (S (SBAR (IN While) (S (NP (NP (NNP Doc_6728084_901_911_Chemical)) (CC and) (NP (NNP Doc_6728084_916_925_Chemical))) (VP (VBD decreased) (NP (NP (DT the) (NN percentage) (NN reabsorption) (CC and) (NN accumulation)) (PP (IN of) (NP (NN lysozyme)))) (PP (IN after) (NP (NP (NN i.v.) (NN administration)) (PP (IN of) (NP (JJ egg-white) (NN lysozyme)))))))) (NP (NNP Doc_6728084_1041_1051_Chemical)) (VP (AUX had) (NP (DT no) (NN effect))) (. .)))
6728084	7	(S1 (S (NP (NP (JJ Daily) (NN excretion)) (PP (IN of) (NP (NP (JJ total) (NN protein)) (, ,) (NP (JJ endogenous) (NN lysozyme)) (CC and) (NP (NN NAG))))) (VP (VBD increased) (ADVP (RB only)) (PP (IN after) (NP (NN treatment))) (PP (IN with) (NP (NP (NNP Doc_6728084_1165_1174_Chemical)) (CC and) (NP (NNP Doc_6728084_1179_1189_Chemical))))) (. .)))
6728084	8	(S1 (S (ADVP (RB Thus)) (, ,) (NP (NNP Doc_6728084_1197_1212_Chemical)) (VP (MD may) (VP (VB act) (PP (IN as) (NP (NNS nephrotoxicants))) (PP (IN at) (NP (NP (JJ glomerular) (NN and/or) (JJ tubular) (NN level)) (VP (VBG inducing) (NP (NP (NN Doc_6728084_1284_1316_Disease) (CC and) (NN accumulation)) (PP (IN of) (NP (NNS proteins))))))))) (. .)))
6732043	0	(S1 (NP (NP (NN Induction)) (PP (IN of) (NP (NP (DT the) (NNP Doc_6732043_17_49_Disease)) (PP (IN in) (NP (DT a) (NN woman))))) (PP (IN by) (NP (JJ exogenous) (JJ Doc_6732043_74_82_Chemical) (NN administration))) (. .)))
6732043	1	(S1 (S (NP (PRP We)) (VP (VBN documented) (NP (JJ airway) (NN occlusion)) (PP (IN during) (NP (NP (NN sleep)) (CC and) (NP (DT an) (ADJP (RB abnormally) (JJ high)) (NN supraglottic) (NN resistance)))) (SBAR (IN while) (S (ADJP (JJ awake) (PP (IN in) (NP (NP (DT a) (JJ 54-yr-old) (NN woman)) (SBAR (WHNP (WP who)) (S (VP (AUX had) (VP (VBN developed) (NP (NP (JJ physical) (NNS changes)) (CC and) (NP (DT the) (NN Doc_6732043_266_301_Disease))) (SBAR (IN while) (S (VP (AUXG being) (VP (VBN administered) (NP (JJ exogenous) (NNP Doc_6732043_337_346_Chemical)))))))))))))))) (. .)))
6732043	2	(S1 (S (SBAR (WHADVP (WRB When)) (S (NP (DT the) (NNP Doc_6732043_357_366_Chemical)) (VP (AUX were) (VP (VBN withdrawn))))) (, ,) (NP (NP (NP (DT the) (NN patient) (POS 's)) (JJ physical) (NNS changes)) (, ,) (NP (NNS symptoms)) (, ,) (NP (NN sleep) (NN study)) (, ,) (CC and) (NP (JJ supraglottic) (NN resistance))) (ADVP (RB all)) (VP (VBN returned) (PP (TO to) (NP (JJ normal)))) (. .)))
6732043	3	(S1 (S (NP (NP (DT A) (NN rechallenge)) (PP (IN with) (NP (NNP Doc_6732043_509_517_Chemical)))) (VP (VBD produced) (NP (NP (NNS symptoms)) (PP (IN of) (NP (NNP Doc_6732043_539_562_Disease))) (SBAR (WHNP (WDT that)) (S (VP (VBD abated) (PP (IN upon) (NP (NP (NN withdrawal)) (PP (IN of) (NP (DT the) (NN hormone)))))))))) (. .)))
6732043	4	(S1 (S (NP (JJ Previous) (NNS reports)) (VP (AUX have) (VP (VBN favored) (NP (NP (DT a) (NN role)) (PP (IN of) (NP (NNP Doc_6732043_647_656_Chemical))) (PP (IN in) (NP (NP (DT the) (NNS pathogenesis)) (PP (IN of) (NP (NNP Doc_6732043_680_691_Disease)))))))) (. .)))
6732043	5	(S1 (S (NP (PRP$ Our) (NN report)) (VP (VBZ provides) (NP (JJ direct) (NN evidence)) (PP (IN for) (NP (DT this) (NN role)))) (. .)))
6732043	6	(S1 (S (NP (ADJP (JJ Structural) (CC and) (JJ functional)) (NNS measurements)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NNP Doc_6732043_797_806_Chemical)) (VP (VBP exert) (NP (NP (DT a) (ADJP (JJ permissive) (CC or) (JJ necessary)) (NN action)) (PP (IN on) (NP (NP (DT the) (JJ structural) (NN configuration)) (PP (IN of) (NP (NP (DT the) (NN oropharynx)) (SBAR (WHNP (WDT that)) (S (VP (VBZ predisposes) (PP (TO to) (NP (NN obstruction))) (PP (IN during) (NP (NN sleep))))))))))))))) (. .)))
6732043	7	(S1 (S (NP (NP (NN Development)) (PP (IN of) (NP (DT the) (NNP Doc_6732043_961_993_Disease)))) (VP (MD must) (VP (AUX be) (VP (VBN considered) (S (NP (NP (DT a) (JJ possible) (NN side) (NN effect)) (PP (IN of) (NP (JJ Doc_6732043_1039_1047_Chemical) (NN therapy)))))))) (. .)))
6769133	0	(S1 (S (NP (NNP Doc_6769133_0_11_Disease)) (S (CC and) (NP (NP (JJ possible) (JJ leukemogenic) (NNS effects)) (PP (IN of) (NP (NP (NNP Doc_6769133_49_59_Chemical)) (PP (IN in) (NP (NP (JJ nonhuman) (NN primates.)) (SBAR (S (NP (NP (CD 10) (NNS monkeys)) (PRN (-LRB- -LRB-) (NP (NNS macaques)) (-RRB- -RRB-))) (VP (VBD received) (NP (NNP Doc_6769133_113_123_Chemical)) (PP (IN by) (NP (NP (JJ monthly) (JJ intravenous) (NNS injections)) (PP (IN at) (NP (NP (CD 12) (NNS mg/m2)) (PRN (-LRB- -LRB-) (NP (CD 1) (NNS mg/kg)) (-RRB- -RRB-))))))))))) (. .) (CD 8))) (PP (IN of) (NP (DT the) (CD 10) (NNS monkeys)))) (VP (VBD developed) (NP (NNP Doc_6769133_211_235_Disease)) (PP (IN at) (NP (NP (NP (DT an) (JJ average) (JJ cumulative) (JJ Doc_6769133_261_271_Chemical) (NN dose)) (PRN (-LRB- -LRB-) (NP (CD 310) (NNS mg/m2)) (-RRB- -RRB-))) (RB well) (RB below) (IN that) (VP (VBN considered) (S (NP (NP (DT the) (JJ safe) (JJ upper) (NN limit)) (PRN (-LRB- -LRB-) (NP (CD 550) (NNS mg/m2)) (-RRB- -RRB-))) (PP (IN in) (NP (NN man))))))))) (. .)))
6769133	1	(S1 (S (S (ADVP (RB Histologically)) (, ,) (NP (DT the) (NNP Doc_6769133_377_395_Disease)) (VP (VBD resembled) (SBAR (S (NP (NP (DT those)) (VP (VBN found) (PP (IN in) (NP (NP (JJ human) (JJ Doc_6769133_427_440_Chemical-induced) (NNP Doc_6769133_449_463_Disease.) (CD 1)) (PP (IN of) (NP (DT the) (CD 10) (NNS monkeys))))))) (VP (VBD developed) (NP (NN Doc_6769133_495_522_Disease)) (PP (IN after) (S (VP (VBG receiving) (NP (NP (CD 324) (NN mg/m2)) (PP (IN of) (NP (NNP Doc_6769133_552_562_Chemical)))))))))))) (: ;) (S (NP (DT the) (JJ 10th) (NN monkey)) (VP (AUX is) (ADJP (JJ alive) (CC and) (RB well)) (PP (NP (CD 26) (NNS months)) (IN after) (NP (NP (DT the) (JJ last) (NN dose)) (PP (IN of) (NP (NN drug))))))) (. .)))
6769133	2	(S1 (S (NP (PRP$ Our) (NNS results)) (VP (VBP suggest) (SBAR (SBAR (IN that) (S (NP (NNP Doc_6769133_662_672_Chemical)) (VP (AUX is) (NP (NP (DT a) (ADJP (RBR more) (JJ potent)) (NN cardiotoxin)) (PP (IN in) (NP (NNS monkeys)))) (PP (IN than) (PP (IN in) (NP (NN man))))))) (, ,) (CC and) (SBAR (IN that) (S (NP (NNP Doc_6769133_735_743_Disease)) (VP (MD may) (VP (AUX be) (NP (NP (DT a) (NN consequence)) (PP (IN of) (NP (VBN prolonged) (NN treatment))) (PP (IN with) (NP (DT this) (NN drug)))))))))) (. .)))
6794356	0	(S1 (NP (NP (NP (NN Doc_6794356_0_29_Disease)) (CC and) (NP (NNP Doc_6794356_34_51_Chemical) (NNP Doc_6794356_52_60_Disease))) (PP (IN in) (NP (DT a) (JJ newborn) (NN infant))) (. .)))
6794356	1	(S1 (S (NP (NP (DT A) (JJ newborn)) (PP (IN with) (NP (NP (JJ massive) (NNP Doc_6794356_105_128_Disease)) (, ,) (NP (NNP Doc_6794356_130_144_Disease)) (, ,) (NP (NNP Doc_6794356_146_170_Disease)) (, ,) (CC and) (NP (DT a) (JJ high) (JJ serum) (NNP Doc_6794356_189_196_Chemical) (NN level))))) (VP (AUX is) (VP (VBN described))) (. .)))
6794356	2	(S1 (S (S (NP (DT This)) (VP (AUX is) (NP (NP (DT the) (JJ first) (NN patient)) (PP (TO to) (NP (RB initially) (JJ manifest) (NNP Doc_6794356_265_288_Disease) (CC and) (NNP Doc_6794356_293_307_Disease)))))) (, ,) (CC and) (S (NP (NP (DT the) (JJ 11th) (VBN described) (NN patient)) (PP (IN with) (NP (NNP Doc_6794356_345_360_Disease))) (PP (IN among) (NP (NNS infants)))) (VP (VBD exposed) (PP (TO to) (NP (JJ Doc_6794356_386_393_Chemical) (NNS compounds))) (PP (IN in) (NP (NP (DT the) (JJ first) (NN trimester)) (PP (IN of) (NP (NN pregnancy))))))) (. .)))
6794356	3	(S1 (S (NP (NP (JJ Sixty-three) (NN percent)) (PP (IN of) (NP (DT these) (NNS infants)))) (VP (AUX had) (VP (VBN tricuspid) (NP (NN valve) (NN involvement)))) (. .)))
6794356	4	(S1 (S (NP (NN Doc_6794356_511_528_Chemical)) (VP (MD may) (VP (AUX be) (NP (NP (DT a) (NN factor)) (PP (IN in) (NP (NP (DT the) (VBG increasing) (NN incidence)) (PP (IN of) (NP (NNP Doc_6794356_576_600_Disease)))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN taken) (PP (IN during) (NP (JJ early) (NN pregnancy)))))))) (. .)))
6794356	5	(S1 (S (NP (PRP It)) (ADVP (RB also)) (VP (VBZ causes) (NP (NP (NNP Doc_6794356_651_672_Disease)) (, ,) (NP (NNP Doc_6794356_674_682_Disease)) (, ,) (CC and) (NP (NNP Doc_6794356_688_706_Disease))) (SBAR (WHADVP (WRB when)) (S (VP (VBN consumed) (ADVP (RB prior) (PP (TO to) (NP (NN delivery)))))))) (. .)))
6817363	0	(S1 (S (NP (NP (NNS Effects)) (PP (IN of) (NP (DT the) (NN novel)))) (VP (VB compound) (NP (NP (NNP Doc_6817363_30_40_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_6817363_42_52_Chemical)) (-RRB- -RRB-))) (PP (IN upon) (NP (NP (NNP Doc_6817363_59_87_Disease)) (PP (IN in) (NP (NNS rodents)))))) (. .)))
6817363	1	(S1 (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NP (NNP Doc_6817363_114_124_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_6817363_126_136_Chemical)) (, ,) (NP (NNP Doc_6817363_138_163_Chemical)) (-RRB- -RRB-))))) (VP (AUX was) (VP (VP (VBN studied) (PP (IN on) (NP (NP (JJ various) (NNS forms)) (PP (IN of) (NP (NP (RB experimentally) (NNP Doc_6817363_212_240_Disease)) (PRN (-LRB- -LRB-) (NP (NN learning) (CC and) (NN memory)) (-RRB- -RRB-)))))) (PP (IN in) (NP (NNS rodents)))) (CC and) (VP (VBN produced) (NP (NP (DT the) (VBG following) (NNS effects)) (: :) (NP (NP (ADJP (PRN (-LRB- -LRB-) (NP (CD 1)) (-RRB- -RRB-)) (RB almost) (JJ complete)) (NN prevention)) (PP (IN of) (NP (DT the) (NN incapacity) (S (VP (TO to) (VP (VB learn) (NP (DT a) (JJ discrete) (NN escape) (NN response)) (PP (IN in) (NP (NP (NNS rats)) (VP (VBN exposed) (PP (TO to) (NP (JJ sublethal) (NNP Doc_6817363_424_435_Disease))) (S (NP (NP (ADVP (RB immediately) (PP (IN before) (NP (NP (DT the) (NN acquisition) (NN session)) (PRN (: ;) (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-)) (NP (JJ partial) (-LRB- -LRB-) (NNS rats) (-RRB- -RRB-)) (CC or) (NP (JJ complete) (PRN (-LRB- -LRB-) (NP (NNS mice)) (-RRB- -RRB-)) (NN prevention)))) (IN of)) (DT the) (JJ Doc_6817363_536_547_Chemical-induced) (JJ short-term) (NNP Doc_6817363_567_574_Disease)) (PP (IN for) (NP (NP (DT a) (JJ passive) (NN avoidance) (NN task) (PRN (: ;) (-LRB- -LRB-) (NP (CD 3)) (-RRB- -RRB-)) (JJ complete) (NN protection)) (PP (IN against) (NP (NNP Doc_6817363_637_644_Disease))) (PP (IN for) (NP (NP (DT a) (JJ passive) (NN avoidance) (NN task)) (PP (IN in) (NP (NNS rats))) (VP (VBN submitted) (S (VP (TO to) (VP (VB electroconvulsive) (PP (NN shock) (PP (ADVP (RB immediately)) (IN after) (NP (NP (NN avoidance) (NN acquisition) (PRN (: ;) (-LRB- -LRB-) (NP (CD 4)) (-RRB- -RRB-)) (NN prevention)) (PP (IN of) (NP (NP (DT the) (JJ long-term) (ADJP (JJ retention-) (CC or) (JJ retrieval-deficit) (PP (IN for) (NP (NP (DT a) (JJ passive) (NN avoidance) (NN task)) (VP (VBN induced) (PP (IN in) (NP (NNS rats) (CC and) (NNS mice))) (PP (IN by) (NP (NNP Doc_6817363_881_896_Chemical) (CC or) (NNP Doc_6817363_900_913_Chemical)))) (VP (VBN administered) (PP (ADVP (RB immediately)) (IN after) (NP (NN acquisition))))))) (PRN (: ;) (-LRB- -LRB-) (NP (CD 5)) (-RRB- -RRB-)) (NN reversal)) (, ,) (SBAR (WHADVP (WRB when)) (S (VP (VBN administered) (PP (IN as) (ADJP (JJ late) (PP (IN as) (NP (NP (CD 1) (NNP h)) (PP (IN before) (NP (DT the) (NN retention) (NN test))) (, ,) (PP (IN of) (NP (NP (DT the) (NN deficit)) (PP (IN in) (NP (NP (NN retention) (CC or) (NN retrieval)) (PP (IN of) (NP (NP (DT a) (JJ passive) (NN avoidance) (NN task)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_6817363_1112_1125_Chemical))) (SBAR (S (VP (VBD injected) (NP (CD 2) (NNS days)) (ADVP (RB previously)) (: ;) (S (S (NP (NP (PRN (-LRB- -LRB-) (NP (CD 6)) (-RRB- -RRB-)) (NN prevention)) (PP (IN of) (NP (DT the) (NN deficit))) (PP (IN in) (NP (NP (DT the) (NN retrieval)) (PP (IN of) (NP (DT an) (JJ active) (NN avoidance) (NN task)))))) (VP (VBN induced) (PP (IN in) (NP (NNS mice))) (PP (IN by) (NP (JJ subconvulsant) (NN electroshock))))) (CC or) (S (NP (NNP Doc_6817363_1278_1289_Disease)) (VP (VBD applied) (ADVP (RB immediately)) (PP (IN before) (NP (NP (NN retrieval) (NN testing)) (PRN (-LRB- -LRB-) (NP (NP (CD 24) (NNP h)) (PP (IN after) (NP (NN acquisition)))) (-RRB- -RRB-)))))))))))))))))))))))))))))))))))))))))))))))))))) (. .)))
6817363	2	(S1 (S (NP (NP (DT These) (NNS improvements) (CC or) (NNS normalizations)) (PP (IN of) (NP (NNP Doc_6817363_1401_1429_Disease)))) (VP (AUX were) (VP (VBN seen) (PP (IN at) (NP (NP (JJ oral) (JJ Doc_6817363_1448_1458_Chemical) (NNS doses)) (PP (IN of) (NP (CD 10-100) (NN mg/kg))))))) (. .)))
6817363	3	(S1 (S (ADVP (RB Generally)) (, ,) (NP (DT the) (JJ dose-response) (NNS curves)) (VP (AUX were) (ADJP (JJ bell-shaped))) (. .)))
6817363	4	(S1 (S (NP (NP (NP (DT The) (NNS mechanisms)) (VP (VBG underlying) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (NNP Doc_6817363_1578_1588_Chemical)))))) (CC and) (NP (PRP$ its) (POS ') (JJ therapeutic) (NN window) ('' '))) (VP (AUX are) (ADJP (JJ unknown))) (. .)))
6817363	5	(S1 (S (ADVP (JJ Doc_6817363_1631_1640_Chemical)) (, ,) (NP (DT another) (JJ Doc_6817363_1650_1663_Chemical) (NN derivative)) (VP (AUX was) (VP (VBN used) (PP (IN for) (NP (NN comparison))))) (. .)))
6817363	6	(S1 (S (NP (PRP It)) (VP (VP (AUX was) (ADJP (JJ active)) (PP (RB only) (IN in) (NP (QP (CD six) (IN of) (CD nine)) (NNS tests)))) (CC and) (VP (AUX had) (PP (IN about) (NP (NN one-tenth))) (NP (NP (DT the) (NN potency)) (PP (IN of) (NP (NNP Doc_6817363_1779_1789_Chemical)))))) (. .)))
6817363	7	(S1 (S (NP (DT The) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NNP Doc_6817363_1817_1827_Chemical)) (VP (VBZ improves) (NP (NP (JJ cognitive) (NNS functions)) (SBAR (WHNP (WDT which)) (S (VP (AUX are) (VP (VBN impaired) (PP (PP (IN by) (NP (JJ different) (NN procedure))) (CC and) (PP (IN in) (NP (NP (JJ different) (NNS phases)) (PP (IN of) (NP (DT the) (NN learning) (CC and) (NN memory) (NN process))))))))))))))) (. .)))
6892185	0	(S1 (NP (NP (NN Effect)) (PP (IN of) (NP (NNP Doc_6892185_10_26_Chemical))) (PP (IN on) (NP (JJ gross) (JJ behavioural) (NNS changes))) (VP (VBN produced) (PP (IN by) (NP (NP (NNP Doc_6892185_68_77_Chemical)) (CC and) (NP (NNP Doc_6892185_82_89_Chemical)))) (PP (IN in) (NP (NNS cats)))) (. .)))
6892185	1	(S1 (S (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NNP Doc_6892185_113_129_Chemical)))) (VP (VBD injected) (PP (IN into) (NP (NP (DT the) (JJ cerebral) (NNS ventricles)) (PP (IN of) (NP (JJ group-housed) (JJ unanaesthetized) (NNS cats))))) (PP (IN upon) (NP (NP (NN vocalization)) (PRN (-LRB- -LRB-) (NP (NN rage)) (, ,) (NP (VBG hissing) (CC and) (VBG snarling)) (-RRB- -RRB-)))) (, ,) (S (VP (VBG fighting) (PRN (-LRB- -LRB-) (NP (NP (NP (NN attack)) (PP (IN with) (NP (NNS paws) (CC and) (NNS claws)))) (, ,) (NP (NP (NN defense)) (PP (IN with) (NP (NNS paws) (CC and) (NNS claws)))) (CC and) (NP (VBG biting))) (-RRB- -RRB-)))))) (, ,) (NP (NP (NNP Doc_6892185_332_341_Disease) (, ,) (NNP Doc_6892185_343_349_Disease) (CC and) (NNP Doc_6892185_354_378_Disease)) (VP (VBN produced) (PP (IN by) (NP (NP (NNP Doc_6892185_391_400_Chemical)) (CC and) (NP (NNP Doc_6892185_405_412_Chemical)))))) (VP (VBD injected) (SBAR (S (RB similarly) (VP (AUX was) (VP (VBN investigated)))))) (. .)))
6892185	2	(S1 (S (NP (NNP Doc_6892185_450_466_Chemical)) (VP (VP (VBD depressed)) (CC or) (VP (ADVP (RB almost) (RB completely)) (VBD abolished) (NP (NP (DT the) (NN vocalization) (CC and) (NN fighting)) (ADJP (JJ due) (PP (TO to) (NP (NP (NNP Doc_6892185_545_554_Chemical)) (CC and) (NP (NNP Doc_6892185_559_566_Chemical)))))))) (. .)))
6892185	3	(S1 (S (PP (IN On) (NP (DT the) (JJ other) (NN hand))) (, ,) (NP (NP (NNP Doc_6892185_587_596_Disease) (, ,) (NNP Doc_6892185_598_604_Disease) (CC and) (NNP Doc_6892185_609_633_Disease)) (VP (VBN evoked) (PP (IN by) (NP (NP (NNP Doc_6892185_644_653_Chemical)) (CC and) (NP (NNP Doc_6892185_658_665_Chemical)))))) (VP (AUX were) (RB not) (VP (ADVP (RB significantly)) (VBN changed) (PP (IN by) (NP (NNP Doc_6892185_700_716_Chemical))))) (. .)))
6892185	4	(S1 (S (NP (PRP It)) (VP (AUX is) (ADJP (JJ apparent)) (SBAR (IN that) (S (NP (NNP Doc_6892185_738_754_Chemical)) (VP (MD can) (VP (`` ``) (VB dissociate) ('' '') (NP (NN vocalization) (CC and) (NN fighting)) (PP (IN from) (NP (NP (NN autonomic) (CC and) (NN motor) (NNS phenomena)) (PP (JJ such) (IN as) (NP (NP (NNP Doc_6892185_841_850_Disease) (, ,) (NNP Doc_6892185_852_858_Disease) (CC and) (NNP Doc_6892185_863_887_Disease)) (VP (VBD caused) (PP (IN by) (NP (NP (NNP Doc_6892185_898_907_Chemical)) (CC and) (NP (NNP Doc_6892185_912_919_Chemical)))))))))))))) (. .)))
6892185	5	(S1 (S (NP (NNP Doc_6892185_921_937_Chemical)) (VP (VBD inhibited) (NP (NP (DT the) (NN vocalization) (CC and) (NN fighting)) (VP (VBN produced) (PP (IN by) (NP (NP (NNP Doc_6892185_990_999_Chemical)) (CC and) (NP (NNP Doc_6892185_1004_1011_Chemical)))) (PP (ADVP (RBS most) (RB probably)) (IN by) (NP (NP (DT a) (JJ nonspecific) (VBG stabilizing) (NN action)) (PP (IN on) (NP (JJ central) (JJ muscarinic) (NN cholinoceptive) (NNS sites)))))))) (. .)))
6892185	6	(S1 (S (NP (DT These) (NNS results)) (ADVP (RB further)) (VP (VBP support) (NP (DT the) (NN view) (SBAR (IN that) (S (NP (NP (JJ Doc_6892185_1150_1157_Chemical) (NNS ions)) (PP (IN in) (NP (NN excess)))) (VP (AUX have) (NP (DT an) (JJ Doc_6892185_1181_1189_Chemical-like) (NN action)) (ADVP (RB also)) (PP (IN in) (NP (DT the) (JJ central) (JJ nervous) (NN system)))))))) (. .)))
6942642	0	(S1 (NP (NP (JJ Doc_6942642_0_8_Chemical) (NNS diuretics)) (, ,) (NP (NP (NNP Doc_6942642_20_31_Disease)) (CC and) (NP (NNP Doc_6942642_36_55_Disease))) (. .)))
6942642	1	(S1 (S (NP (JJ Doc_6942642_57_65_Chemical) (NNS diuretics)) (VP (AUX are) (ADVP (RB widely)) (VP (VBN accepted) (PP (IN as) (NP (NP (DT the) (NN cornerstone)) (PP (IN of) (NP (JJ antihypertensive) (NN treatment) (NNS programs))))))) (. .)))
6942642	2	(S1 (S (NP (NN Doc_6942642_155_166_Disease)) (VP (AUX is) (NP (NP (DT a) (ADJP (RB commonly) (VBN encountered)) (NN metabolic) (NN consequence)) (PP (IN of) (NP (JJ chronic) (JJ Doc_6942642_226_234_Chemical) (NN therapy))))) (. .)))
6942642	3	(S1 (S (NP (PRP We)) (VP (VBN treated) (NP (NP (CD 38) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 22) (JJ low) (NN renin)) (, ,) (NP (CD 16) (JJ normal) (NN renin)) (-RRB- -RRB-))) (PP (IN with) (NP (NP (JJ moderate) (NN Doc_6942642_313_335_Disease)) (PP (IN with) (NP (NP (NNP Doc_6942642_341_360_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_6942642_362_366_Chemical)) (-RRB- -RRB-)))) (VP (VBN administered) (PP (IN on) (NP (DT a) (RB twice) (JJ daily) (NN schedule))))))) (. .)))
6942642	4	(S1 (S (S (NP (JJ Initial) (NN dose)) (VP (AUX was) (NP (CD 50) (NN mg)))) (CC and) (S (NP (DT the) (NN dose)) (VP (AUX was) (VP (VBN increased) (PP (IN at) (NP (JJ monthly) (NNS intervals))) (PP (TO to) (NP (CD 100) (CD mg))) (, ,) (ADVP (NP (QP (CD 150) (CD mg) (CC and) (CD 200)) (NNS mg)) (RB daily)) (SBAR (IN until) (S (NP (NN blood) (NN pressure)) (VP (VBD normalized))))))) (. .)))
6942642	5	(S1 (S (NP (NP (DT The) (NN serum) (NN K)) (PP (IN during) (NP (DT the) (NN control) (NN period)))) (VP (AUX was) (NP (NP (CD 4.5) (NN +/-)) (NP (CD 0.2) (NN mEq/l))) (NP (NP (NP (DT an) (ADJP (ADVP (IN on) (NP (CD 50) (, ,) (CD 100) (, ,) (CD 150) (CC and) (CD 200) (NNS mg))) (JJ Doc_6942642_637_641_Chemical)) (JJ daily) (CD 3.9) (NN +/-) (CD 0.3) (, ,) (CD 3.4)) (JJ +/-) (CD 0.2)) (, ,) (NP (NP (CD 2.9) (NN +/-)) (NP (CD 0.2))) (, ,) (CC and) (NP (NP (CD 2.4) (NN +/-)) (NP (CD 0.3) (NNS mEq/l)))) (, ,) (ADVP (RB respectively))) (. .)))
6942642	6	(S1 (S (NP (NP (JJ Corresponding) (NNS figures)) (PP (IN for) (NP (JJ whole) (NN body) (NN K)))) (VP (AUX were) (NP (NP (NP (CD 4107)) (ADJP (JJ +/-) (NP (CD 208)))) (, ,) (NP (CD 3722) (JJ +/-) (CD 319)) (, ,) (NP (CD 3628) (JJ +/-) (CD 257)) (, ,) (NP (CD 3551) (JJ +/-) (CD 336)) (, ,) (CC and) (NP (NP (CD 3269) (NN +/-)) (NP (CD 380) (NNS mEq))) (, ,) (ADVP (RB respectively)))) (. .)))
6942642	7	(S1 (S (PP (IN In) (NP (CD 13) (NNS patients))) (NP (PRP we)) (VP (VP (VBD observed) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (JJ Doc_6942642_902_906_Chemical) (NN therapy)) (PRN (-LRB- -LRB-) (NP (QP (CD 100) (CD mg)) (NN daily)) (-RRB- -RRB-)))) (PP (IN on) (NP (NP (DT the) (NN occurrence)) (PP (IN of) (NP (NNP PVC) (POS 's)))))) (PP (IN during) (NP (NN rest)))) (CONJP (RB as) (RB well) (IN as)) (PP (IN during) (NP (NP (JJ static)) (CC and) (NP (JJ dynamic) (NN exercise))))) (. .)))
6942642	8	(S1 (S (PP (IN During) (NP (NN rest))) (NP (PRP we)) (VP (VBD observed) (NP (CD 0.6) (NN +/-)) (UCP (NP (CD 0.08) (NNP PVC) (JJ beats/min) (JJ +/-) (NN SEM)) (CC and) (PP (IN during) (NP (NP (JJ static) (CC and) (JJ dynamic) (NN exercise) (CD 0.6) (NN +/-)) (NP (CD 0.06) (CC and) (CD 0.8) (NN +/-) (CD 0.15)) (, ,) (ADVP (RB respectively)))))) (. .)))
6942642	9	(S1 (S (NP (NP (JJ Corresponding) (NNS figures)) (PP (IN during) (NP (JJ Doc_6942642_1188_1192_Chemical) (NN therapy)))) (ADVP (NP (CD 100) (NNS mg)) (RB daily)) (VP (AUX were) (NP (CD 1.4) (NX (NX (JJ +/-) (CD 0.1)) (, ,) (NX (CD 3.6) (JJ +/-) (CD 0.7)) (CC and) (NX (CD 5.7) (JJ 4/-) (CD 0.8)))) (, ,) (ADVP (RB respectively))) (. .)))
6942642	10	(S1 (S (NP (NP (DT The) (NN occurrence)) (PP (IN of) (NP (NNP PVC) (POS 's)))) (VP (VBD correlated) (ADVP (RB significantly)) (PP (IN with) (NP (NP (DT the) (NN fall)) (PP (IN in) (NP (NN serum) (NNP K+) (JJ observed) (NN r)) (X (SYM =)) (NP (CD 0.72))))) (, ,) (S (VP (VBG p) (NP (QP (JJR less) (IN than) (CD 0.001)))))) (. .)))
6942642	11	(S1 (S (PP (IN In) (NP (NN conclusion))) (NP (PRP we)) (VP (VBD found) (SBAR (IN that) (S (NP (JJ Doc_6942642_1416_1424_Chemical) (NNS diuretics)) (VP (VBP cause) (NP (NP (NP (NN Doc_6942642_1441_1452_Disease)) (CC and) (NP (NN depletion))) (PP (IN of) (NP (NN body) (NN Doc_6942642_1475_1484_Chemical)))))))) (. .)))
6942642	12	(S1 (X (NP (DT The) (ADJP (RBR more) (JJ profound)) (NN Doc_6942642_1504_1515_Disease)) (, ,) (X (DT the) (JJR greater)) (NP (NP (DT the) (NN propensity)) (PP (IN for) (NP (NP (DT the) (NN occurrence)) (PP (IN of) (NP (NNP PVC) (POS 's)))))) (. .)))
7007443	0	(S1 (FRAG (S (VP (VBG Circulating) (NP (NP (JJ lysosomal) (NNS enzymes)) (CC and) (NP (NNP Doc_7007443_34_56_Disease))))) (. .)))
7007443	1	(S1 (S (NP (NP (DT The) (NNS activities)) (PP (IN of) (NP (NP (DT the) (JJ lysosomal) (NNS enzymes) (NN acid)) (CC and) (NP (NP (JJ neutral) (NN protease)) (, ,) (NP (NN N-acetylglucosaminidase)) (, ,) (CC and) (NP (NN acid) (NN phosphatase)))))) (VP (AUX were) (VP (VBN measured) (PP (IN in) (NP (NP (DT the) (NN serum)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_7007443_215_240_Disease))))))))) (. .)))
7007443	2	(S1 (S (NP (NN Acid) (NN protease) (PRN (-LRB- -LRB-) (NNP cathepsin) (NNP D) (-RRB- -RRB-)) (NN activity)) (VP (AUX was) (VP (VP (VBN increased) (ADVP (IN about) (RB tenfold)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD died))))))) (CC and) (VP (ADVP (RB nearly)) (VBN fourfold) (PP (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD survived) (NP (NNP Doc_7007443_370_395_Disease)) (PP (IN after) (NP (NNP Doc_7007443_402_413_Chemical) (NNP Doc_7007443_414_422_Disease))) (, ,) (SBAR (IN whereas) (S (NP (NNS activities)) (VP (AUX were) (VP (VBN increased) (ADVP (RB equally)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_7007443_483_508_Disease))))) (PP (JJ due) (TO to) (NP (NNP Doc_7007443_516_531_Disease))) (SBAR (IN whether) (CC or) (RB not) (S (NP (PRP they)) (VP (VBD survived)))))))))))))))) (. .)))
7007443	3	(S1 (S (S (NP (DT A) (NN correlation)) (VP (AUX was) (VP (VBN found) (PP (IN between) (NP (NP (NN serum) (NN acid) (NN protease) (NN activity)) (CC and) (NP (NN prothrombin) (NN time))))))) (, ,) (CC and) (S (NP (NP (DT the) (NN increase)) (PP (IN in) (NP (JJ cathepsin) (NNP D) (NN activity)))) (VP (AUX was) (VP (VBN sustained) (PP (IN over) (NP (JJ several) (NNS days))) (PP (VBN compared) (PP (IN with) (NP (NP (JJ Doc_7007443_732_741_Chemical) (NN aminotransferase)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD showed) (NP (NP (DT a) (JJ sharp) (JJ early) (NN peak)) (CC and) (ADVP (RB then)) (NP (DT a) (NN fall)))))))))))) (. .)))
7007443	4	(S1 (S (S (NP (VBG Circulating) (JJ lysosomal) (NNS proteases)) (VP (MD can) (VP (VB damage) (NP (JJ other) (NNS organs))))) (, ,) (CC and) (S (NP (NP (NN measurement)) (PP (IN of) (NP (PRP$ their) (NN activity)))) (VP (MD may) (ADVP (RB therefore)) (VP (AUX be) (PP (IN of) (NP (JJ added) (NN value))) (PP (IN in) (S (VP (VBG assessing) (NP (NN prognosis)) (PP (IN in) (NP (DT this) (NN condition))))))))) (. .)))
7053705	0	(S1 (S (NP (NN Doc_7053705_0_30_Disease)) (VP (VBN caused) (PP (IN by) (NP (NNP Doc_7053705_41_54_Chemical)))) (. .)))
7053705	1	(S1 (S (NP (ADJP (RB Clinically) (JJ reversible)) (NNP Doc_7053705_78_113_Disease)) (VP (VBD developed) (PP (IN in) (NP (NP (DT a) (JJ 23-year-old) (NN man)) (PP (IN with) (NP (NNP Doc_7053705_150_176_Disease))))) (PP (IN after) (NP (NP (CD 10) (NNS months)) (PP (IN of) (NP (NP (NN maintenance) (NN therapy)) (PP (IN with) (NP (NNP Doc_7053705_221_234_Chemical)))))))) (. .)))
7053705	2	(S1 (S (NP (JJ Serial) (NN liver) (NNS biopsies)) (VP (VBD showed) (NP (NP (DT the) (NN development) (CC and) (NN resolution)) (PP (IN of) (NP (JJ intense) (JJ sinusoidal) (NN engorgement))))) (. .)))
7053705	3	(S1 (S (SBAR (IN Although) (S (NP (DT this) (NN disease)) (VP (AUX was) (RB clinically) (ADJP (JJ reversible))))) (, ,) (NP (NP (DT some) (JJ subintimal) (NN Doc_7053705_396_404_Disease)) (PP (IN about) (NP (DT the) (JJ terminal) (JJ hepatic) (NNS veins)))) (VP (VBD persisted)) (. .)))
7053705	4	(S1 (S (NP (DT This) (NN case)) (VP (VP (VBD presented) (NP (DT a) (JJ unique) (NN opportunity) (S (VP (TO to) (VP (VB observe) (NP (NP (DT the) (JJ histologic) (NNS features)) (PP (IN of) (NP (ADJP (RB clinically) (JJ reversible)) (NN Doc_7053705_550_580_Disease)))) (PP (IN over) (NP (NN time)))))))) (, ,) (CC and) (VP (MD may) (VP (AUX be) (NP (NP (DT the) (JJ first) (NN case)) (PP (IN of) (NP (NP (NN veno-occlusive)) (VP (VBN related) (PP (ADVP (RB solely)) (TO to) (NP (NNP Doc_7053705_654_667_Chemical)))))))))) (. .)))
7059267	0	(S1 (NP (JJ Doc_7059267_0_14_Chemical-induced) (NN Doc_7059267_23_39_Disease) (. .)))
7059267	1	(S1 (S (NP (NP (DT A) (JJ 65-year-old) (NN woman)) (PP (IN with) (NP (NNP Doc_7059267_66_86_Disease))) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_7059267_100_114_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_7059267_116_125_Chemical)) (-RRB- -RRB-)))))) (VP (AUX had) (NP (NP (DT a) (NN Doc_7059267_133_155_Disease)) (SBAR (WHNP (WDT that)) (S (VP (VBD resolved) (PP (IN with) (NP (NP (NN discontinuation)) (PP (IN of) (NP (JJ Doc_7059267_194_208_Chemical) (NN therapy)))))))))) (. .)))
7059267	2	(S1 (S (S (NP (NN Doc_7059267_218_229_Disease)) (VP (VBZ occurs) (PP (IN in) (NP (NNP Doc_7059267_240_249_Disease))) (PP (IN for) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (NNS reasons))))))) (, ,) (CC and) (S (NP (JJ accurate) (NN diagnosis)) (VP (AUX is) (ADJP (JJ necessary)) (S (VP (TO to) (VP (VB institute) (NP (JJ appropriate) (NN therapy))))))) (. .)))
7059267	3	(S1 (S (NP (NP (DT The) (NN possibility)) (PP (IN of) (NP (DT a) (JJ drug-induced) (NN Doc_7059267_380_396_Disease)))) (VP (MD should) (VP (AUX be) (VP (VBN considered) (PP (IN in) (NP (NP (DT the) (NN differential) (NN diagnosis)) (PP (IN of) (NP (NNP Doc_7059267_451_462_Disease))) (PP (IN in) (NP (NNP Doc_7059267_466_475_Disease)))))))) (. .)))
7066357	0	(S1 (NP (NP (NP (NN Plasma) (CC and) (NN urinary) (NNS lipids)) (CC and) (NP (NP (NNS lipoproteins)) (PP (IN during) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_7066357_69_87_Disease))))))) (VP (VBN induced) (PP (IN in) (NP (DT the) (NN rat))) (PP (IN by) (NP (NNP Doc_7066357_110_135_Chemical)))) (. .)))
7066357	1	(S1 (S (NP (DT This) (NN study)) (VP (AUX was) (VP (VBN undertaken) (S (VP (TO to) (VP (VB ascertain) (SBAR (IN whether) (S (NP (NP (DT the) (NNS alterations)) (PP (IN of) (NP (NP (NN plasma) (NNS lipoproteins)) (VP (VBN found) (PP (IN in) (NP (NNP Doc_7066357_232_250_Disease)))))) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_7066357_262_287_Chemical))))) (VP (AUX were) (ADJP (JJ due) (PP (PP (TO to) (NP (NNP Doc_7066357_300_318_Disease) (FW per) (FW se))) (, ,) (CC or) (PP (, ,) (PP (ADVP (IN at) (JJS least)) (IN in) (NP (NN part))) (, ,) (TO to) (NP (DT the) (NNP Doc_7066357_356_371_Chemical))))))))))))) (. .)))
7066357	2	(S1 (S (NP (NP (DT The) (NN purpose)) (PP (IN of) (NP (DT the) (JJ present) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB investigate) (NP (NP (NP (DT the) (NNS changes)) (PP (IN in) (NP (NP (NN plasma) (CC and) (NN urinary) (NNS lipoproteins)) (PP (IN during) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NP (NNP Doc_7066357_501_526_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 20) (NN mg/kg)) (PP (IN for) (NP (CD 7) (NNS days)))) (-RRB- -RRB-))))))))) (CC and) (NP (NP (DT the) (JJ subsequent) (NN development)) (PP (IN of) (NP (NNP Doc_7066357_583_601_Disease))))))))) (. .)))
7066357	3	(S1 (S (SBAR (IN Since) (S (NP (JJ massive) (NN Doc_7066357_617_628_Disease)) (VP (VBD occurred) (PP (IN after) (NP (NP (CD 6) (NNS days)) (PP (IN of) (NP (NN treatment)))))))) (, ,) (NP (DT the) (JJ time-course) (NN study)) (VP (AUX was) (VP (VBN divided) (PP (IN into) (NP (NP (CD two) (NNS stages)) (: :) (NP (NP (NP (JJ pre-Doc_7066357_720_729_Disease) (NN stage)) (PRN (-LRB- -LRB-) (NP (NN day) (CD 1-5)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_7066357_750_759_Disease) (NN stage)) (PRN (-LRB- -LRB-) (NN day) (NN 6-11) (-RRB- -RRB-)))))))) (. .)))
7066357	4	(S1 (S (PP (IN In) (NP (JJ pre-Doc_7066357_785_794_Disease) (NN stage))) (NP (NP (DT the) (NN plasma) (NN level)) (PP (IN of) (NP (NP (NNP Doc_7066357_821_832_Chemical)) (, ,) (NP (NNP Doc_7066357_834_849_Chemical)) (CC and) (NP (NNP VLDL))))) (VP (VBD decreased) (SBAR (IN while) (S (NP (NP (DT that)) (PP (IN of) (NP (NN phospholipid) (, ,) (NNP Doc_7066357_897_915_Chemical) (CC and) (NNP HDL)))) (VP (VBD remained) (ADJP (JJ constant)))))) (. .)))
7066357	5	(S1 (S (NP (NN Plasma) (NN apolipoprotein) (NNS A-I)) (VP (VBD tended) (S (VP (TO to) (VP (VB increase) (PRN (-LRB- -LRB-) (NP (NP (ADJP (CD 40) (NN %)) (NN increase)) (PP (IN at) (NP (NN day) (CD 5)))) (-RRB- -RRB-)))))) (. .)))
7066357	6	(S1 (S (PP (IN At) (NP (NP (DT the) (NN beginning)) (PP (IN of) (NP (NNP Doc_7066357_1033_1042_Disease) (NN stage))))) (PRN (-LRB- -LRB-) (NP (NN day) (CD 6)) (-RRB- -RRB-)) (NP (NP (DT the) (NN concentration)) (PP (IN of) (NP (NN plasma) (NN albumin)))) (VP (VBD dropped) (PP (TO to) (NP (DT a) (ADJP (RB very) (JJ low)) (NN level))) (, ,) (SBAR (IN while) (S (NP (NP (DT that)) (PP (IN of) (NP (JJ apolipoprotein) (NNP A-I)))) (VP (VP (VBD increased) (ADVP (RB abruptly)) (PRN (-LRB- -LRB-) (NP (JJ 4-fold) (NN increase)) (-RRB- -RRB-))) (CC and) (VP (VBD continued) (S (VP (TO to) (VP (VB rise) (PRN (, ,) (PP (IN although) (NP (NP (JJR less)) (ADVP (RB steeply)))) (, ,)) (PP (IN in) (NP (DT the) (VBG following) (NNS days))))))))))) (. .)))
7066357	7	(S1 (S (NP (NP (DT The) (NN plasma) (NN concentration)) (PP (IN of) (NP (NNS HDL)))) (VP (VBD followed) (NP (DT the) (JJ same) (NN pattern))) (. .)))
7066357	8	(S1 (S (NP (NP (NN Plasma) (NNS VLDL)) (CC and) (NP (NNS LDL))) (VP (VBN increased) (PP (IN at) (NP (NP (DT a) (JJ later) (NN stage)) (PRN (-LRB- -LRB-) (NP (NN day) (CD 9)) (-RRB- -RRB-))))) (. .)))
7066357	9	(S1 (S (NP (NN Plasma) (NN apolipoprotein) (NNP A-I)) (VP (AUX was) (VP (VBN found) (PP (RB not) (PP (ADVP (RB only)) (IN in) (NP (NP (NNP HDL)) (PRN (-LRB- -LRB-) (NP (JJ 1.063-1.210) (NN g/ml)) (-RRB- -RRB-)))) (CC but) (PP (ADVP (RB also)) (IN in) (NP (NP (DT the) (NNP LDL) (NN density) (NN class)) (PRN (-LRB- -LRB-) (NP (CD 1.025-1.050) (NN g/ml)) (-RRB- -RRB-))))))) (. .)))
7066357	10	(S1 (S (PP (IN In) (NP (DT the) (JJ pre-Doc_7066357_1512_1521_Disease) (NN stage))) (NP (NN lipoproteinuria)) (VP (AUX was) (ADJP (JJ negligible)) (, ,) (SBAR (IN while) (S (PP (IN in) (NP (DT the) (JJ early) (NN Doc_7066357_1579_1588_Disease) (NN stage))) (NP (NP (DT the) (JJ urinary) (NN loss)) (PP (IN of) (NP (NN plasma) (NNS lipoproteins)))) (VP (VBD consisted) (PP (ADVP (RB mainly)) (IN of) (NP (NN HDL))))))) (. .)))
7066357	11	(S1 (S (NP (DT These) (NNS observations)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NNP Doc_7066357_1693_1718_Chemical)) (VP (VBZ alters) (NP (NN plasma) (NNS lipoproteins)) (PP (IN by) (S (VP (VP (VBG lowering) (NP (NN VLDL))) (CC and) (VP (VBG increasing) (NP (NN HDL)))))))))) (. .)))
7066357	12	(S1 (S (NP (PRP It)) (VP (AUX is) (ADJP (JJ likely)) (SBAR (IN that) (S (NP (NP (DT the) (ADJP (JJ early) (CC and) (JJ striking)) (NN increase)) (PP (IN of) (NP (NP (NN plasma) (NNS HDL)) (VP (VBN found) (PP (IN in) (NP (JJ Doc_7066357_1856_1865_Disease) (NNS rats))))))) (VP (AUX is) (VP (VBN related) (PP (TO to) (NP (NP (DT a) (JJ direct) (NN effect)) (PP (IN of) (NP (DT the) (NN drug))) (PP (IN on) (NP (CD HDL) (NN metabolism)))))))))) (. .)))
7072798	0	(S1 (S (NP (JJ Fatal) (NNP Doc_7072798_6_21_Disease)) (VP (VBG following) (NP (NP (JJ topical) (NN administration)) (PP (IN of) (NP (JJ ophthalmic) (NNP Doc_7072798_69_84_Chemical))))) (. .)))
7072798	1	(S1 (S (NP (DT A) (JJ 73-year-old) (NN woman)) (VP (VBD died) (PP (IN of) (NP (NNP Doc_7072798_114_129_Disease))) (PP (NP (QP (JJR less) (IN than) (CD two)) (NNS months)) (IN after) (S (VP (VP (VBG undergoing) (NP (JJ Doc_7072798_168_176_Disease) (NN extraction))) (CC and) (VP (VBG beginning) (NP (NP (JJ topical) (NN therapy)) (PP (IN with) (NP (NNP Doc_7072798_223_238_Chemical))))))))) (. .)))
7072798	2	(S1 (S (NP (NP (DT The) (JJ first) (NNS signs)) (PP (IN of) (NP (NNP Doc_7072798_259_271_Disease)))) (VP (VBD began) (PP (IN within) (NP (NP (CD one) (NN month)) (PP (IN of) (NP (DT the) (NN surgery)))))) (. .)))
7072798	3	(S1 (S (NP (NP (DT The) (NN pattern)) (PP (IN of) (NP (DT the) (NNP Doc_7072798_330_345_Disease)))) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (DT an) (JJ idiosyncratic) (NN response)) (PP (TO to) (NP (NNP Doc_7072798_395_410_Chemical))))))) (. .)))
7072798	4	(S1 (S (NP (DT This)) (VP (AUX was) (NP (NP (DT the) (JJ second) (NN report)) (PP (IN of) (NP (JJ fatal) (NN Doc_7072798_448_463_Disease)))) (PP (IN after) (NP (NP (JJ topical) (NN treatment)) (PP (IN with) (NP (NNP Doc_7072798_493_508_Chemical))) (PP (IN for) (NP (JJ ocular) (NNS conditions))))) (, ,) (SBAR (IN although) (S (NP (NP (CD two) (NNS cases)) (PP (IN of) (NP (JJ reversible) (NNP Doc_7072798_565_587_Disease)))) (VP (AUX have) (ADVP (RB also)) (VP (AUX been) (VP (VBN reported))))))) (. .)))
7072798	5	(S1 (S (NP (NP (DT Any) (JJ other) (VBN suspected) (NNS cases)) (PP (IN of) (NP (NNP Doc_7072798_642_657_Disease))) (VP (VBN associated) (PP (IN with) (NP (ADJP (RB topically) (VBN applied)) (NNP Doc_7072798_692_707_Chemical))))) (VP (MD should) (VP (AUX be) (VP (VBN reported) (PP (TO to) (NP (NP (DT the) (NNP National) (NNP Registry)) (PP (IN of) (NP (NP (JJ Drug-Induced) (JJ Ocular) (NN Side) (NNS Effects)) (, ,) (NP (NP (NP (NNP Oregon) (NNP Health) (NNPS Sciences) (NNP University)) (, ,) (NP (NNP Portland)) (, ,)) (CC OR) (NP (CD 97201)))))))))) (. .)))
7102237	0	(S1 (S (NP (NN Doc_7102237_0_9_Chemical)) (VP (VBN compared) (PP (IN with) (NP (NNP Doc_7102237_24_35_Chemical))) (PP (IN as) (NP (DT an) (NN induction) (NN agent)))) (. .)))
7102237	1	(S1 (S (PP (IN In) (NP (NP (NNS patients)) (VP (VBN premedicated) (PP (IN with) (NP (NP (NNP Doc_7102237_89_100_Chemical) (NNP +) (NNP Doc_7102237_103_111_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD +5) (NN mg) (NNP Doc_7102237_119_129_Chemical)) (NP (DT the) (NN evening))) (PP (IN before) (NP (NN surgery)))) (-RRB- -RRB-))))))) (, ,) (NP (NP (DT the) (JJ sleep-inducing) (NN effect)) (PP (IN of) (NP (NNP Doc_7102237_188_197_Chemical) (CD 0.15) (NN mg/kg) (NNS i.v.)))) (VP (AUX was) (ADJP (ADJP (RB clearly) (JJR slower) (PP (IN in) (NP (NN onset)))) (PP (IN than) (NP (NP (DT that)) (PP (IN of) (NP (NNP Doc_7102237_255_266_Chemical))) (SBAR (S (S (NP (CD 4.67) (NN mg/kg)) (VP (VBD i.v.) (SBAR (S (NP (ADJP (RB Somewhat) (JJR fewer)) (JJ cardiovascular) (CC and) (JJ local) (NNS sequelae)) (VP (AUX were) (VP (VBN found) (PP (IN in) (NP (DT the) (NNP Doc_7102237_350_359_Chemical) (NN group))))))))) (, ,) (CC but) (, ,) (S (SBAR (IN although) (S (NP (NN apnoea)) (VP (VBD occurred) (ADVP (RBR less) (RB often)) (PP (IN in) (NP (DT the) (NNP Doc_7102237_415_424_Chemical) (NN group)))))) (NP (PRP it)) (VP (VBD lasted) (ADVP (RBR longer)))))))))) (. .)))
7102237	2	(S1 (S (PP (IN On) (NP (DT the) (NN whole))) (, ,) (NP (NP (DT the) (NNS differences)) (PP (IN between) (NP (NP (NNP Doc_7102237_487_496_Chemical)) (CC and) (NP (NNP Doc_7102237_501_512_Chemical))))) (VP (AUX had) (NP (DT no) (JJ apparent) (JJ clinical) (NNS consequences))) (. .)))
7102237	3	(S1 (S (NP (NN Doc_7102237_552_561_Chemical)) (VP (AUX is) (NP (NP (DT a) (JJ new) (NN alternative) (NN agent)) (PP (IN for) (NP (NP (NN induction)) (PP (IN in) (NP (NN combination) (NNS anaesthesia))))))) (. .)))
7161250	0	(S1 (NP (NP (NP (JJ Extrapyramidal) (NN side) (NNS effects)) (CC and) (NP (JJ oral) (NN Doc_7161250_37_48_Chemical))) (: :) (NP (NP (DT an) (NN analysis)) (PP (IN of) (NP (JJ explanatory) (NN patient) (CC and) (NN treatment) (NNS characteristics)))) (. .)))
7161250	1	(S1 (S (NP (NP (DT The) (NN incidence)) (PP (IN of) (NP (NP (JJ extrapyramidal) (NN side) (NNS effects)) (PRN (-LRB- -LRB-) (NP (NNS EPS)) (-RRB- -RRB-))))) (VP (AUX was) (VP (VBN evaluated) (PP (IN in) (NP (NP (CD 98) (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_7161250_209_220_Chemical)))))))) (. .)))
7161250	2	(S1 (S (NP (NP (DT The) (NN incidence)) (PP (IN of) (NP (NNP Doc_7161250_239_251_Disease)))) (VP (AUX was) (ADJP (JJR higher)) (PP (PP (IN at) (NP (NP (JJR higher) (NNS doses)) (PP (IN of) (NP (NNP Doc_7161250_282_293_Chemical))))) (CC and) (PP (IN in) (NP (JJR younger) (NNS patients))))) (. .)))
7161250	3	(S1 (S (NP (JJ Prophylactic) (NN antiparkinsonian) (NN medication)) (VP (AUX was) (UCP (ADJP (JJ effective) (PP (IN in) (NP (JJR younger)))) (CC but) (PP (RB not) (IN in) (NP (JJR older) (NNS patients))))) (. .)))
7161250	4	(S1 (S (ADVP (RB However)) (, ,) (NP (DT these) (NNS medications)) (VP (AUX were) (ADJP (RBR more) (JJ effective)) (PP (IN in) (NP (DT both) (JJ young) (CC and) (JJ old) (NNS patients))) (SBAR (WHADVP (WRB when)) (S (VP (VBN given) (SBAR (IN after) (S (NP (NNP Doc_7161250_507_519_Disease)) (VP (VBD developed)))))))) (. .)))
7161250	5	(S1 (S (NP (NN Doc_7161250_531_540_Disease)) (VP (AUX was) (VP (VBN controlled) (PP (IN by) (NP (NP (DT the) (NNP Doc_7161250_563_577_Chemical) (NNP Doc_7161250_578_587_Chemical)) (PP (IN in) (NP (NP (CD 14) (NN out)) (PP (IN of) (NP (CD 16) (NNS patients))))))) (, ,) (SBAR (IN while) (S (NP (JJ prophylactic) (NNS antiparkinsonians)) (VP (AUX were) (ADJP (JJ ineffective))))))) (. .)))
7161250	6	(S1 (S (NP (DT The) (JJ present) (NN study)) (VP (VBZ points) (PP (TO to) (NP (NP (JJ patient) (NNS characteristics)) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (AUX be) (PP (IN of) (NP (NN significance))) (PP (IN in) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NP (NNS EPS)) (ADJP (JJ due) (PP (TO to) (NP (NNP Doc_7161250_782_793_Chemical))))))))))))))) (. .)))
7189975	0	(S1 (NP (NP (NNS Deaths)) (PP (IN from) (NP (NP (JJ local) (JJ anesthetic-induced) (NN Doc_7189975_37_48_Disease)) (PP (IN in) (NP (NNS mice))))) (. .)))
7189975	1	(S1 (S (NP (NP (NP (NP (JJ Median) (NN convulsant)) (PRN (-LRB- -LRB-) (NP (CD CD50)) (-RRB- -RRB-))) (CC and) (NP (JJ median) (JJ lethal) (PRN (-LRB- -LRB-) (CD LD50) (-RRB- -RRB-)) (NNS doses))) (PP (IN of) (NP (CD three) (JJ representative) (JJ local) (NNS anesthetics)))) (VP (AUX were) (VP (VBN determined) (PP (IN in) (NP (NN adult) (NNS mice))) (S (VP (TO to) (VP (VB evaluate) (NP (NP (DT the) (NN threat)) (PP (TO to) (NP (NP (NN life)) (PP (IN of) (NP (JJ local) (JJ anesthetic-induced) (NN Doc_7189975_245_256_Disease))))))))))) (. .)))
7189975	2	(S1 (S (NP (DT The) (CD CD50) (CC and) (CD LD50)) (, ,) (ADVP (RB respectively)) (, ,) (VP (AUX were) (NP (NP (NP (QP (CD 57.7) (CC and) (CD 58.7)) (NNS mg/kg)) (PP (IN for) (NP (NNP Doc_7189975_320_331_Chemical)))) (, ,) (NP (NP (QP (CD 111.0) (CC and) (CD 133.1)) (NNS mg/kg)) (PP (IN for) (NP (NNP Doc_7189975_359_368_Chemical)))) (, ,) (CC and) (NP (NP (QP (CD 243.4) (CC and) (CD 266.5)) (NNS mg/kg)) (PP (IN for) (NP (NNP Doc_7189975_400_414_Chemical)))))) (. .)))
7189975	3	(S1 (S (SBAR (WHADVP (WRB When)) (S (VP (VBN given) (ADVP (RB intraperitoneally))))) (, ,) (NP (NNP Doc_7189975_446_457_Chemical)) (ADVP (RB thus)) (VP (AUX was) (ADVP (RB only)) (PP (IN about) (NP (NP (NP (QP (RB twice) (IN as) (JJ toxic))) (PP (IN as) (NP (NNP Doc_7189975_496_505_Chemical)))) (CC and) (NP (NP (QP (CD four) (NNS times) (IN as) (JJ toxic))) (PP (IN as) (NP (NNP Doc_7189975_533_547_Chemical))))))) (. .)))
7189975	4	(S1 (S (NP (NN Doc_7189975_549_560_Disease)) (ADVP (RB always)) (VP (VBN preceded) (NP (NN death)) (, ,) (PP (IN except) (PP (IN after) (NP (NP (JJ precipitous) (NN Doc_7189975_609_631_Disease)) (PP (IN from) (NP (JJ extreme) (NNS doses))))))) (. .)))
7189975	5	(S1 (S (NP (NP (DT A) (CD CD50) (NN dose)) (PP (IN of) (NP (JJ local) (NN anesthetic))) (PRN (-LRB- -LRB-) (VP (VBG causing) (NP (NNP Doc_7189975_693_704_Disease)) (PP (IN in) (NP (NP (CD 50) (NN %)) (PP (IN of) (NP (NNS mice)))))) (-RRB- -RRB-))) (VP (AUX was) (ADJP (JJ fatal)) (PP (IN in) (NP (NP (CD 90) (NN %)) (PP (IN of) (NP (NNP Doc_7189975_741_752_Chemical-induced) (NNP Doc_7189975_761_769_Disease))))) (, ,) (PP (IN in) (NP (NP (NP (CD 57) (NN %)) (PP (IN of) (NP (DT the) (NNP Doc_7189975_785_799_Chemical) (NN group)))) (, ,) (CC and) (NP (NP (QP (IN in) (CD 6)) (NN %)) (PP (IN of) (NP (DT the) (NNP Doc_7189975_824_833_Chemical) (NN group))))))) (. .)))
7189975	6	(S1 (S (NP (NP (DT The) (JJ narrow) (NN gap)) (PP (IN between) (NP (NP (JJ convulsant) (CC and) (JJ lethal) (NNS doses)) (PP (IN of) (NP (JJ local) (NNS anesthetics)))))) (VP (VBZ indicates) (NP (NP (DT that) (JJ untreated) (NNP Doc_7189975_938_949_Disease) (NN present)) (ADJP (ADJP (RB much) (JJR more) (PP (IN of) (NP (NP (DT a) (NN threat)) (PP (TO to) (NP (NN life)))))) (PP (IN than) (ADJP (RB heretofore) (VBN appreciated)))))) (. .)))
7197363	0	(S1 (S (NP (NN Doc_7197363_0_21_Disease)) (VP (VBZ changes) (NP (NP (JJ behavioral) (NN response)) (PP (TO to) (NP (NP (NN catecholaminergic)) (CC and) (NP (NP (JJ serotonergic) (NN receptor) (NN activation)) (PP (IN in) (NP (NNS rats)))))))) (. .)))
7197363	1	(S1 (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NP (NNP Doc_7197363_132_153_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_7197363_155_159_Disease)) (-RRB- -RRB-)))) (PP (IN on) (NP (NP (NP (NNP Doc_7197363_164_175_Chemical-induced) (NNP Doc_7197363_184_198_Disease)) (CC and) (NP (NNP Doc_7197363_203_212_Chemical-induced) (NNP Doc_7197363_221_234_Disease))) (PP (IN in) (NP (NNS rats)))))) (VP (AUX were) (VP (VBN determined))) (. .)))
7197363	2	(S1 (S (NP (NP (JJ Forty-eight) (NNS hr)) (PP (IN of) (NP (NNP Doc_7197363_278_282_Disease)))) (VP (VP (VBN increased) (NP (JJ Doc_7197363_293_304_Chemical-induced) (NNP Doc_7197363_313_327_Disease))) (, ,) (CC and) (VP (VBN reduced)) (PRN (-LRB- -LRB-) (PP (ADVP (RB immediately)) (IN after) (NP (NP (VBG completing)) (PP (IN of) (NP (NNP Doc_7197363_374_378_Disease))))) (-RRB- -RRB-)) (CC or) (VP (VBD increased) (S (-LRB- -LRB-) (NP (NP (CD 96) (NN hr)) (PP (IN after) (NP (NP (VBG completing)) (PP (IN of) (NP (NNP Doc_7197363_420_424_Disease)))))) (-RRB- -RRB-) (NP (NNP Doc_7197363_426_435_Chemical-induced) (NNP Doc_7197363_444_457_Disease))))) (. .)))
7197363	3	(S1 (S (NP (NNS Results)) (VP (AUX are) (VP (VBN discussed) (PP (IN in) (NP (NP (NNS terms)) (PP (IN of) (NP (NN similarity))))) (PP (TO to) (NP (NP (JJ pharmacological) (NNS effects)) (PP (IN of) (NP (JJ other) (JJ antidepressive) (NNS treatments))))))) (. .)))
7263204	0	(S1 (S (NP (JJ Fatal) (NNP Doc_7263204_6_21_Disease)) (VP (NNS due) (PP (TO to) (NP (JJ Doc_7263204_29_41_Chemical--lymphocyte) (NN transformation) (NNS tests))) (PP (IN in) (NP (NN vitro)))) (. .)))
7263204	1	(S1 (S (SBAR (IN Although) (S (NP (NNP Doc_7263204_94_106_Chemical)) (VP (AUX has) (VP (AUX been) (VP (VBN implicated) (PP (IN as) (NP (NP (DT a) (JJ possible) (NN cause)) (PP (IN of) (NP (NNP Doc_7263204_150_165_Disease))))) (PP (IN on) (NP (NP (DT the) (NN basis)) (PP (IN of) (NP (DT a) (JJ few) (JJ clinical) (NNS observations)))))))))) (, ,) (NP (PRP$ its) (NN role)) (VP (AUX has) (RB not) (VP (AUX been) (ADVP (RB definitely)) (VP (VBN established)))) (. .)))
7263204	2	(S1 (S (NP (NP (DT A) (NN case)) (PP (IN of) (NP (JJ fatal) (NNP Doc_7263204_273_288_Disease)))) (VP (AUX is) (VP (VBN described) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (DT no) (NNS drugs)) (ADVP (JJ other) (PP (IN than) (NP (NP (NNP Doc_7263204_331_342_Chemical)) (CC and) (NP (NNP Doc_7263204_347_359_Chemical))))) (VP (AUX were) (VP (VBN given))))))) (. .)))
7263204	3	(S1 (S (NP (NN Doc_7263204_372_384_Chemical)) (VP (AUX was) (ADVP (RB first)) (VP (VBN given) (ADVP (NP (CD four) (NNS weeks)) (RB prior)) (PP (TO to) (NP (NP (DT the) (NN onset)) (PP (IN of) (NP (NNS symptoms))))))) (. .)))
7263204	4	(S1 (S (NP (NP (DT A) (JJ positive) (JJ lymphocyte) (NN transformation) (NN test)) (PP (IN with) (NP (NP (NNP Doc_7263204_491_503_Chemical)) (PP (IN in) (NP (NN vitro)))))) (ADVP (RB further)) (VP (VBZ substantiates) (NP (NP (DT the) (JJ potential) (NN role)) (PP (IN of) (NP (DT this) (NN drug))) (PP (IN in) (S (VP (VBG causing) (NP (NN Doc_7263204_578_593_Disease)) (PP (IN in) (NP (DT a) (JJ susceptible) (NN patient)))))))) (. .)))
7263204	5	(S1 (S (ADVP (RB Fortunately)) (, ,) (NP (DT this)) (VP (VBZ seems) (S (VP (TO to) (VP (AUX be) (NP (DT a) (ADJP (RB very) (JJ rare)) (NN complication)))))) (. .)))
7282516	0	(S1 (NP (NP (NP (NN Dose-effect)) (CC and) (NP (JJ structure-function) (NNS relationships))) (PP (IN in) (NP (NNP Doc_7282516_52_63_Chemical) (NNP Doc_7282516_64_78_Disease))) (. .)))
7282516	1	(S1 (S (NP (NP (DT The) (NNP Doc_7282516_84_98_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_7282516_100_102_Disease)) (-RRB- -RRB-)) (VP (VBN produced) (PP (IN by) (NP (NP (DT the) (NN anticancer) (NN drug)) (NP (NP (NP (NNP Doc_7282516_136_147_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_7282516_149_152_Chemical)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (NNP Doc_7282516_155_165_Chemical)) (-RRB- -RRB-))))))) (VP (VBZ provides) (NP (DT a) (JJ unique) (NN opportunity) (S (VP (TO to) (VP (VB analyze) (NP (UCP (JJ dose-effect) (CC and) (NN structure-function)) (NNS relationships)) (PP (IN during) (NP (NP (NN development)) (PP (IN of) (NP (NNP Doc_7282516_279_297_Disease)))))))))) (. .)))
7282516	2	(S1 (S (NP (PRP We)) (VP (VBN measured) (NP (NP (DT the) (NN degree)) (PP (IN of) (NP (JJ morphologic) (NN damage)))) (PP (IN by) (NP (NP (NP (JJ ultrastructural) (NN examination)) (PP (IN of) (NP (JJ endomyocardial) (NN biopsy)))) (CC and) (NP (NP (DT the) (NN degree)) (PP (IN of) (NP (NN performance)))))) (PP (ADVP (RB abnormally)) (IN by) (NP (NP (JJ right) (NN heart) (NN catheterization)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NNP Doc_7282516_494_497_Chemical)))))))) (. .)))
7282516	3	(S1 (S (NP (JJ Morphologic) (NN damage)) (VP (VP (AUX was) (ADJP (JJ variable))) (CC but) (VP (AUX was) (ADJP (JJ proportional) (PP (TO to) (NP (NP (DT the) (JJ total) (JJ cumulative) (JJ Doc_7282516_576_579_Chemical) (NN dose)) (PP (IN between) (NP (QP (CD 100) (CC and) (CD 600) (CD mg/m2))))))))) (. .)))
7282516	4	(S1 (S (NP (NN Performance) (NNS abnormalities)) (VP (VP (VBD correlated) (ADVP (RB weakly)) (PP (IN with) (NP (NN dose)))) (, ,) (VP (VBD exhibited) (NP (DT a) (JJ curvilinear) (NN relationship))) (, ,) (CC and) (VP (AUX had) (NP (NP (DT a) (`` ``) (NN threshold) ('' '')) (PP (IN for) (NP (NN expression)))))) (. .)))
7282516	5	(S1 (S (S (NP (NN Catheterization) (NNS abnormalities)) (VP (VBD correlated) (ADVP (RB well)) (PP (IN with) (NP (NP (JJ morphologic) (NN damage)) (PRN (-LRB- -LRB-) (NP (QP (SYM r) (SYM =) (CD 0.57) (TO to) (CD 0.78))) (-RRB- -RRB-)))) (PP (IN in) (NP (NP (DT a) (NN subgroup)) (PP (IN of) (NP (NP (NNS patients)) (SBAR (WHPP (IN in) (WHNP (WP whom))) (S (NP (NN exercise) (NNS hemodynamics)) (VP (AUX were) (VP (VBN measured))))))))))) (, ,) (CC and) (S (NP (DT this) (NN relationship)) (ADVP (RB also)) (VP (VBD exhibited) (NP (NP (DT a) (NN curvilinear)) (, ,) (NP (NN threshold) (NN configuration))))) (. .)))
7282516	6	(S1 (S (PP (IN In) (NP (NNP DXR-Doc_7282516_987_989_Disease) (NNP Doc_7282516_990_1007_Disease))) (VP (AUX is) (ADJP (JJ proportional) (PP (TO to) (NP (NP (DT the) (NN degree)) (PP (IN of) (NP (JJ cytotoxic) (NN insult)))))) (PRN (-LRB- -LRB-) (NP (JJ Doc_7282516_1059_1062_Chemical) (NN dose)) (-RRB- -RRB-)) (SBAR (IN while) (S (NP (JJ myocardial) (NN function)) (VP (AUX is) (VP (VBN preserved) (SBAR (IN until) (S (NP (NP (DT a) (JJ critical) (NN dose)) (CC or) (NP (NP (NN degree)) (PP (IN of) (NP (NN damage))))) (VP (AUX is) (VP (VBN reached) (, ,) (SBAR (WHPP (IN after) (WHNP (WDT which))) (S (NP (JJ myocardial) (NN performance)) (VP (VBZ deteriorates) (ADVP (RB rapidly)))))))))))))) (. .)))
7337133	0	(S1 (NP (NP (NP (JJ Massive) (NN Doc_7337133_8_22_Disease)) (VP (VBN associated) (PP (IN with) (NP (NP (NNP Doc_7337133_39_64_Disease)) (PP (IN in) (NP (NNP Doc_7337133_68_81_Chemical) (NNP Doc_7337133_82_90_Disease))))))) (: :) (NP (NP (JJ possible) (NN role)) (PP (IN of) (NP (JJ cranial) (NN decompression)))) (. .)))
7337133	1	(S1 (S (NP (NN Doc_7337133_132_146_Disease)) (VP (MD may) (VP (VB complicate) (NP (NP (DT the) (NN course)) (PP (IN of) (NP (NNP Doc_7337133_176_201_Disease)))))) (. .)))
7337133	2	(S1 (S (NP (NP (NN Response)) (PP (TO to) (NP (JJ conventional) (NN therapy)))) (VP (AUX has) (VP (AUX been) (ADJP (JJ disappointing)))) (. .)))
7337133	3	(S1 (S (NP (PRP We)) (VP (VBP present) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (JJ fatal) (JJ Doc_7337133_292_305_Chemical-induced) (NN Doc_7337133_314_339_Disease))) (, ,) (PP (IN with) (NP (NP (NNS signs)) (CC and) (NP (NP (NNS symptoms)) (PP (IN of) (NP (NNP Doc_7337133_368_382_Disease)))))) (, ,) (ADJP (JJ unresponsive) (PP (TO to) (NP (JJ conventional) (JJ medical) (NN therapy)))))) (. .)))
7337133	4	(S1 (S (NP (JJ Cranial) (NN decompression)) (VP (AUX was) (VP (VBN carried) (PRT (RP out)))) (. .)))
7337133	5	(S1 (S (NP (NP (DT A) (NN justification)) (PP (IN of) (NP (DT the) (NN need))) (PP (IN for) (NP (NP (JJ further) (NN evaluation)) (PP (IN of) (NP (JJ cranial) (NN decompression))))) (PP (IN in) (NP (JJ such) (NNS patients)))) (VP (AUX is) (VP (VBN presented))) (. .)))
7416947	0	(S1 (NP (NP (JJ Subjective) (NN assessment)) (PP (IN of) (NP (NP (NNP Doc_7416947_25_43_Disease)) (PP (IN of) (NP (NNS patients))))) (PP (IN on) (NP (NP (JJ long-term) (NN administration)) (PP (IN of) (NP (NNP Doc_7416947_87_94_Chemical))))) (. .)))
7416947	1	(S1 (S (NP (JJ Various) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (JJ male) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX have) (VP (VBN received) (NP (NNP Doc_7416947_154_161_Chemical)) (PP (IN on) (NP (DT a) (JJ longterm) (NN basis)))))))) (VP (AUX have) (VP (VP (VBN increased) (NP (NP (NNS levels)) (PP (IN of) (NP (JJ serum) (NNP Doc_7416947_213_221_Chemical))))) (CC and) (VP (VBN decreased) (NP (NP (NNS levels)) (PP (IN of) (NP (NP (NN plasma) (NN Doc_7416947_253_265_Chemical)) (CC and) (NP (NP (JJ luteinizing) (NN hormone)) (PRN (-LRB- -LRB-) (NP (NNP LH)) (-RRB- -RRB-)))))))))))) (. .)))
7416947	2	(S1 (S (NP (DT This) (NN study)) (VP (VP (AUX was) (VP (VBN undertaken) (S (VP (TO to) (VP (VB investigate) (NP (NP (DT the) (NNS links)) (PP (IN between) (NP (NP (DT the) (JJ long-term) (NN administration)) (PP (IN of) (NP (JJ Doc_7416947_387_394_Chemical) (NN therapy) (CC and) (JJ sexual) (NN behavior))))))))))) (, ,) (CC and) (VP (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NNP Doc_7416947_442_449_Chemical)))) (PP (IN on) (NP (NP (NN plasma) (NNS levels)) (PP (IN of) (NP (NP (NNP Doc_7416947_470_479_Chemical)) (, ,) (NP (NNP Doc_7416947_481_493_Chemical)) (, ,) (CC and) (NP (NNP LH)))))))) (. .)))
7416947	3	(S1 (S (NP (NP (DT The) (NNS patients)) (PP (IN of) (NP (DT the) (NN study) (CC and) (NN control) (NN group))) (PRN (-LRB- -LRB-) (PP (IN without) (NP (NNP Doc_7416947_556_563_Chemical))) (-RRB- -RRB-))) (VP (VP (AUX were) (PP (IN of) (NP (NP (JJ similar) (JJ cardiac) (JJ functional) (NN capacity)) (CC and) (NP (NP (NN age)) (PRN (-LRB- -LRB-) (NP (JJ 25-40) (NNS years)) (-RRB- -RRB-)))))) (CC and) (VP (AUX were) (ADJP (RB randomly) (VBN selected)) (PP (IN from) (NP (DT the) (JJ Doc_7416947_667_690_Disease) (NNS patients))))) (. .)))
7416947	4	(S1 (S (NP (NP (NP (DT A) (JJ subjective) (NN assessment)) (PP (IN of) (NP (JJ sexual) (NN behavior))) (PP (IN in) (NP (DT the) (NN study)))) (CC and) (NP (NN control) (NNS groups))) (VP (AUX was) (VP (VBN carried) (ADVP (RB out)) (, ,) (S (VP (VBG using) (NP (NP (NNS parameters)) (PP (JJ such) (IN as) (NP (NP (JJ sexual) (NN desire)) (, ,) (NP (JJ sexual) (NN excitement)) (, ,) (CC and) (NP (NP (NN frequency)) (PP (IN of) (NP (JJ sexual) (NNS relations))))))))))) (. .)))
7416947	5	(S1 (S (NP (NP (JJ Personal) (NNS interviews)) (CC and) (NP (DT a) (NN questionnaire))) (VP (AUX were) (ADVP (RB also)) (VP (VBN used) (PP (IN for) (NP (NP (DT the) (NN evaluation)) (PP (IN of) (NP (JJ sexual) (NN behavior))))))) (. .)))
7416947	6	(S1 (S (NP (DT The) (NNS findings)) (VP (VBP support) (NP (NP (DT the) (NNS reports)) (VP (VBG concerning) (NP (NP (JJ Doc_7416947_1025_1032_Chemical) (NN effect)) (PP (IN on) (NP (NP (NN plasma) (NNP Doc_7416947_1050_1059_Chemical)) (, ,) (NP (NNP Doc_7416947_1061_1073_Chemical)) (, ,) (CC and) (NP (NNP LH)))))))) (. .)))
7416947	7	(S1 (S (NP (NP (DT The) (NNS differences)) (PP (IN in) (NP (DT the) (NNS means)))) (VP (AUX were) (ADJP (JJ significant))) (. .)))
7416947	8	(S1 (S (NP (NP (NNS Tests)) (VP (VBN used) (S (VP (TO to) (VP (VB evaluate) (NP (NP (DT the) (NNS changes)) (PP (IN in) (NP (JJ sexual) (NN behavior))))))))) (VP (VBD showed) (NP (NP (DT a) (JJ significant) (NN Doc_7416947_1205_1230_Disease)) (, ,) (NP (NP (JJ sexual) (NN excitement) (NN phase)) (PRN (-LRB- -LRB-) (NP (NN erection)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NN frequency)) (PP (IN of) (NP (JJ sexual) (NNS relations))) (PP (IN in) (NP (DT the) (NN study) (NN group)))))) (. .)))
7421734	0	(S1 (NP (NP (NN Doc_7421734_0_21_Disease)) (PP (IN after) (NP (NP (NNP Doc_7421734_28_43_Disease)) (PP (IN in) (NP (NN childhood))))) (. .)))
7421734	1	(S1 (S (NP (DT A) (JJ 34-year-old) (NN patient)) (VP (VBD developed) (NP (JJ metastic) (NN Doc_7421734_99_120_Disease)) (PP (IN after) (NP (NNP Doc_7421734_127_142_Disease))) (PP (IN in) (NP (NN childhood)))) (. .)))
7421734	2	(S1 (S (NP (PRP She)) (VP (VP (AUX had) (ADJP (JJ Doc_7421734_165_180_Disease)) (PP (IN after) (NP (NP (JJ abdominal) (NN irradiation)) (CC and) (NP (NP (NN chemotherapy)) (PP (IN for) (NP (NNP Doc_7421734_230_245_Disease))))))) (, ,) (CC and) (VP (VBD received) (NP (NN exogenous)) (NP (NP (NNP Doc_7421734_270_279_Chemical)) (, ,) (NP (NP (DT a) (NN treatment)) (VP (VBN implicated) (PP (IN in) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_7421734_326_344_Disease))) (PP (IN in) (NP (JJ menopausal) (NNS women)))))))))) (. .)))
7421734	3	(S1 (S (NP (NP (JJ Young) (NNS women)) (PP (IN on) (NP (NP (NN replacement) (NN Doc_7421734_393_402_Chemical)) (PP (IN for) (NP (NNP Doc_7421734_407_422_Disease))) (PP (IN after) (NP (JJ Doc_7421734_429_435_Disease) (NN therapy)))))) (VP (VP (MD may) (ADVP (RB also)) (VP (AUX have) (VP (VBN increased) (NP (NP (NN risk)) (PP (IN of) (NP (NNP Doc_7421734_476_497_Disease))))))) (CC and) (VP (MD should) (VP (AUX be) (VP (VBN examined) (ADVP (RB periodically)))))) (. .)))
7437994	0	(S1 (NP (NP (NP (JJ Long-term) (JJ Doc_7437994_10_17_Chemical) (NN treatment)) (CC and) (NP (DT the) (NN kidney))) (. .)))
7437994	1	(S1 (NP (NP (JJ Interim) (NN report)) (PP (IN on) (NP (NN fifty) (NNS patients))) (. .)))
7437994	2	(S1 (S (NP (DT This)) (VP (AUX is) (NP (NP (DT a) (NN report)) (PP (IN on) (NP (NP (DT the) (JJ first) (NN part)) (PP (IN of) (NP (NP (PRP$ our) (NN study)) (PP (IN of) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (JJ long-term) (JJ Doc_7437994_154_161_Chemical) (NN treatment))) (PP (IN on) (NP (DT the) (NN kidney))))))))))) (. .)))
7437994	3	(S1 (S (NP (NP (JJ Doc_7437994_187_197_Chemical) (NN clearance)) (, ,) (NP (NN maximum) (NN urinary) (NN osmolality)) (CC and) (NP (ADJP (CD 24) (NN hour)) (NN urine) (NN volume))) (VP (AUX have) (VP (AUX been) (VP (VBN tested) (PP (IN in) (NP (NP (CD 50) (JJ affectively) (JJ ill) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX have) (VP (AUX been) (PP (IN on) (NP (JJ long-term) (NNP Doc_7437994_336_343_Chemical))) (PP (IN for) (NP (QP (JJR more) (IN than) (CD one)) (NN year)))))))))))) (. .)))
7437994	4	(S1 (S (NP (DT These) (NNS findings)) (VP (AUX have) (VP (AUX been) (VP (VBN compared) (PP (PP (IN with) (NP (NNS norms))) (CC and) (PP (IN with) (NP (NP (NNS values)) (PP (IN of) (NP (NP (DT the) (JJ same) (NNS tests)) (PP (IN from) (S (VP (VBG screening) (ADVP (RB prior)) (PP (TO to) (NP (NNP Doc_7437994_471_478_Chemical)))))) (, ,) (ADJP (JJ available) (PP (IN for) (NP (NP (JJS most)) (PP (IN of) (NP (PRP$ our) (NNS patients)))))))))))))) (. .)))
7437994	5	(S1 (S (NP (DT No) (NN evidence)) (VP (AUX was) (VP (VBN found) (PP (IN for) (NP (NP (DT any) (NN reduction)) (PP (IN of) (NP (JJ glomerular) (NN filtration))) (PP (IN during) (NP (JJ Doc_7437994_588_595_Chemical) (NN treatment))))))) (. .)))
7437994	6	(S1 (S (NP (NP (JJ Low) (NN clearance) (NNS values)) (VP (VBN found) (PP (IN in) (NP (JJ several) (NNS patients))))) (VP (MD could) (VP (AUX be) (VP (VBN accounted) (PP (IN for)) (PP (IN by) (NP (NP (PRP$ their) (NN age)) (CC and) (NP (PRP$ their) (JJ pre-Doc_7437994_704_711_Chemical) (NNS values))))))) (. .)))
7437994	7	(S1 (S (S (NP (JJ Urinary) (NN concentration) (NN defect)) (VP (VBD appeared) (ADJP (JJ frequent)))) (CC but) (S (NP (NP (DT the) (NN extent)) (PP (IN of) (NP (DT the) (NN impairment)))) (VP (AUX is) (ADJP (JJ difficult) (SBAR (S (VP (TO to) (VP (VB assess) (PP (IN because) (IN of) (NP (NP (DT the) (NN uncertainty)) (PP (IN about) (NP (NP (DT the) (NNS norms)) (ADJP (JJ applicable) (PP (TO to) (NP (NP (DT this) (NN group)) (PP (IN of) (NP (NNS patients))))))))))))))))) (. .)))
7437994	8	(S1 (S (NP (DT The) (NN concentration) (NN defect)) (VP (VBD appeared) (ADJP (JJ reversible)) (, ,) (PP (ADVP (IN at) (JJS least)) (IN in) (NP (NN part)))) (. .)))
7437994	9	(S1 (S (NP (NP (NN Doc_7437994_968_976_Disease)) (PP (IN above) (NP (QP (CD 3) (CD litres/24)) (NNS hours)))) (VP (AUX was) (VP (VBN found) (PP (IN in) (NP (NP (CD 10) (NN %)) (PP (IN of) (NP (NNS patients))))))) (. .)))
7437994	10	(S1 (S (NP (DT An) (NN attempt)) (VP (AUX is) (VP (VBN made) (S (VP (TO to) (VP (VB draw) (NP (JJ practical) (NNS conclusions)) (PP (IN from) (NP (DT the) (JJ preliminary) (NNS findings)))))))) (. .)))
7542793	0	(S1 (NP (NP (NP (NN Nephrotoxicity)) (PP (IN of) (NP (NP (NNP Doc_7542793_18_31_Chemical)) (CC and) (NP (NNP Doc_7542793_36_41_Chemical))))) (: :) (NP (NP (NN inhibition)) (PP (IN of) (NP (NN calcineurin) (NN phosphatase)))) (. .)))
7542793	1	(S1 (S (NP (NP (NP (NP (NP (NNP Doc_7542793_82_95_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (NNP Doc_7542793_97_100_Chemical)) (: ;) (NP (CD 50) (NNS mg/kg))) (-RRB- -RRB-))) (CC and) (NP (NNP Doc_7542793_116_126_Chemical))) (PRN (-LRB- -LRB-) (NP (NP (NNP Doc_7542793_128_133_Chemical)) (: ;) (NP (CD 5) (NN mg/kg))) (-RRB- -RRB-))) (, ,) (CONJP (CC but) (RB not)) (NP (NP (DT the) (JJ related) (JJ Doc_7542793_165_174_Chemical) (NN immunosuppressant) (NNP Doc_7542793_193_202_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 5) (NN mg/kg)) (-RRB- -RRB-))) (, ,)) (VP (VBD caused) (NP (NP (DT a) (NN reduction)) (PP (IN of) (NP (NP (JJ glomerular) (NN filtration) (NN rate)) (, ,) (NP (NP (JJ degenerative) (NNS changes)) (PP (IN of) (NP (JJ proximal) (JJ tubular) (NN epithelium)))) (, ,) (CC and) (NP (NP (NNP Doc_7542793_321_332_Disease)) (PP (IN of) (NP (NP (DT the) (JJ juxtaglomerular) (NN apparatus)) (PP (IN in) (NP (JJ male) (NNP Wistar) (NNS rats))))))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN given) (PP (IN for) (NP (CD 10) (NNS days))))))) (. .)))
7542793	2	(S1 (S (NP (NP (DT The) (JJ molecular) (NNS mechanisms)) (PP (IN of) (NP (NNP Doc_7542793_438_441_Chemical) (CC and) (NNP Doc_7542793_446_451_Chemical) (NNP Doc_7542793_452_460_Disease)))) (VP (AUX were) (VP (VBN investigated))) (. .)))
7542793	3	(S1 (S (NP (NP (NNP Cyclophilin) (NNP A)) (CC and) (NP (NP (JJ Doc_7542793_498_503_Chemical-binding) (NN protein)) (, ,) (NP (NP (DT the) (JJ main) (JJ intracytoplasmic) (NNS receptors)) (PP (IN for) (NP (NP (NNP Doc_7542793_561_564_Chemical)) (CC and) (NP (NNP Doc_7542793_569_574_Chemical)) (, ,) (ADVP (RB respectively))))) (, ,))) (VP (AUX were) (DT each) (VP (VBN detected) (PP (IN in) (NP (JJ renal) (NN tissue) (VB extract))))) (. .)))
7542793	4	(S1 (S (PP (IN In) (NP (DT the) (NN kidney))) (, ,) (NP (NP (JJ high) (NNS levels)) (PP (IN of) (NP (NP (NN immunoreactive)) (CC and) (NP (JJ enzymatically) (JJ active) (NN calcineurin))))) (VP (AUX were) (VP (VBN found) (SBAR (WHNP (WDT which)) (S (VP (AUX were) (VP (VBD inhibited) (PP (PP (IN by) (NP (DT the) (NNS immunosuppressants) (NNP Doc_7542793_774_777_Chemical) (CC and) (NNP Doc_7542793_782_787_Chemical))) (, ,) (CC but) (RB not) (PP (IN by) (NP (NNP Doc_7542793_800_809_Chemical)))))))))) (. .)))
7542793	5	(S1 (S (ADVP (RB Finally)) (, ,) (NP (JJ specific) (NN immunophilin-drug-calcineurin) (NNS complexes)) (VP (VBN formed) (PP (RB only) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (NNP Doc_7542793_900_903_Chemical)) (CC and) (NP (NNP Doc_7542793_908_913_Chemical)))))) (, ,) (CC but) (RB not) (ADJP (JJ Doc_7542793_923_932_Chemical)))) (. .)))
7542793	6	(S1 (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (DT the) (JJ nephrotoxic) (NNS effects)) (PP (IN of) (NP (NNP Doc_7542793_988_991_Chemical) (CC and) (NNP Doc_7542793_996_1001_Chemical)))) (VP (AUX is) (ADVP (RB likely)) (VP (VBN mediated) (PP (IN through) (S (VP (VBG binding) (PP (TO to) (NP (NP (JJ renal) (NN immunophilin)) (CC and) (NP (NN inhibiting) (NN calcineurin) (NN phosphatase)))))))))))) (. .)))
7565311	0	(S1 (NP (NP (NN Doc_7565311_0_19_Disease)) (PP (IN in) (NP (NP (JJ high) (NN dose)) (ADJP (NNP Doc_7565311_33_44_Chemical) (JJ chemotherapy)))) (. .)))
7565311	1	(S1 (S (NP (NN Doc_7565311_59_70_Chemical)) (VP (AUX has) (VP (AUX been) (VP (VBN reported) (S (VP (TO to) (VP (VB cause) (NP (NN Doc_7565311_98_117_Disease)) (SBAR (WHADVP (WRB when)) (S (VP (VBN administered) (PP (IN in) (NP (NP (JJ high) (NNS doses)) (PP (TO to) (NP (NN adult) (NNS patients)))))))))))))) (. .)))
7565311	2	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT a) (ADJP (CD 4) (NN 1/2-year-old)) (NN girl)) (SBAR (WHNP (WP who)) (S (VP (AUX was) (VP (VBN treated) (PP (IN with) (NP (JJ high-dose) (NN Doc_7565311_232_243_Chemical))) (PP (IN for) (NP (JJ metastatic) (JJ parameningeal) (NN Doc_7565311_273_299_Disease))))))))) (. .)))
7565311	3	(S1 (S (NP (NN Doc_7565311_301_320_Disease)) (VP (VBD developed) (VP (VBN followed) (PP (IN by) (NP (NP (DT a) (JJ slow) (JJ partial) (NN recovery)) (PP (IN of) (NP (JJ renal) (NN function))))))) (. .)))
7565311	4	(S1 (S (NP (JJ Possible) (JJ contributing) (NNS factors)) (VP (AUX are) (VP (VBN discussed))) (. .)))
7596955	0	(S1 (NP (NP (JJ Clinical) (NN evaluation)) (PP (IN on) (NP (NP (VBN combined) (NN administration)) (PP (IN of) (NP (NP (JJ oral) (JJ Doc_7596955_55_67_Chemical) (NN analogue) (NNP Doc_7596955_77_86_Chemical)) (CC and) (NP (NN phosphodiesterase) (NN inhibitor) (NNP Doc_7596955_119_129_Chemical)))))) (. .)))
7596955	1	(S1 (S (PP (IN Among) (NP (JJ various) (JJ oral) (NNS antiplatelets))) (, ,) (NP (NP (DT a) (NN combination)) (PP (IN of) (NP (NP (NP (DT a) (JJ novel) (JJ Doc_7596955_190_202_Chemical) (NN analogue) (NNP Doc_7596955_212_221_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_7596955_223_226_Chemical)) (-RRB- -RRB-))) (CC and) (NP (NP (DT a) (JJ potent) (NN phosphodiesterase) (NN inhibitor) (NNP Doc_7596955_269_279_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_7596955_281_284_Chemical)) (-RRB- -RRB-)))))) (VP (MD may) (VP (VB result) (PP (IN in) (NP (NP (JJ untoward) (JJ clinical) (NNS effects)) (ADJP (JJ due) (PP (TO to) (NP (NP (JJ possible) (JJ synergistic) (NN elevation)) (PP (IN of) (NP (NP (JJ intracellular) (NNP Doc_7596955_381_385_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_7596955_387_423_Chemical)) (-RRB- -RRB-))))))))))) (. .)))
7596955	2	(S1 (S (ADVP (RB Thereby)) (, ,) (NP (NP (DT a) (JJ clinical) (NN study)) (PP (IN of) (NP (NP (DT the) (VBN combined) (NN administration)) (PP (IN of) (NP (DT the) (CD two) (NNS agents)))))) (VP (AUX was) (VP (VBN attempted))) (. .)))
7596955	3	(S1 (S (S (NP (CD Twelve) (JJ healthy) (NNS volunteers)) (VP (AUX were) (VP (VBN assigned) (S (VP (TO to) (VP (VB take) (NP (NP (NP (NNP Doc_7596955_564_567_Chemical/Doc_7596955_568_571_Chemical)) (PP (IN in) (NP (DT the) (JJ following) (NN schedule)))) (: ;) (NP (NP (NNP Doc_7596955_599_602_Chemical)) (: :) (NP (NP (NP (CD 40) (NNS micrograms)) (PP (IN at) (NP (NN day) (CD 1)))) (CC and) (NP (NP (CD 120) (NNS micrograms)) (VP (VBN t.i.d.) (PP (IN from) (NP (NN day) (CD 7))) (PP (TO to) (NP (CD 14))))))) (, ,) (NP (NNP Doc_7596955_671_674_Chemical))))))))) (: :) (S (NP (CD 200) (NNS mg)) (VP (VBN t.i.d.) (PP (PP (IN from) (NP (NN day) (CD 3))) (PP (TO to) (NP (CD 14)))))) (. .)))
7596955	4	(S1 (S (PP (IN At) (NP (JJ various) (NN time) (NNS intervals))) (, ,) (NP (NP (NP (JJ physical) (NN examination)) (CC and) (NP (NN blood) (NN collection))) (PP (IN for) (NP (NP (FW ex) (NN vivo) (NN Doc_7596955_789_809_Disease)) (CC and) (NP (NP (NN determination)) (PP (IN of) (NP (JJ intraplatelet) (NNP Doc_7596955_845_849_Chemical))))))) (VP (AUX were) (VP (VBN performed))) (. .)))
7596955	5	(S1 (S (PP (IN Throughout) (NP (DT the) (JJ observation) (NN period))) (, ,) (NP (NP (DT no) (JJ significant) (NN alteration)) (PP (IN in) (NP (JJ vital) (NNS signs)))) (VP (AUX was) (VP (VBN observed))) (. .)))
7596955	6	(S1 (S (NP (NP (CD Seven)) (PP (IN out) (PP (IN of) (NP (CD 12) (NNS subjects))))) (VP (VBD experienced) (NP (NP (NP (NNP Doc_7596955_993_1001_Disease)) (PP (IN of) (NP (NP (DT a) (JJ short) (NN duration)) (VP (VBG accompanying) (NP (NNP Doc_7596955_1035_1047_Disease)) (PP (IN in) (NP (CD one))))))) (CC and) (NP (NP (NNP Doc_7596955_1059_1065_Disease)) (PP (IN in) (NP (CD one))))) (, ,) (PP (ADVP (RB especially)) (IN after) (NP (NP (NN ingestion)) (PP (IN of) (NP (NNP Doc_7596955_1104_1107_Chemical)))))) (. .)))
7596955	7	(S1 (S (S (NP (NP (DT All)) (PP (IN of) (NP (DT these) (NNS symptoms))) (, ,) (VP (ADVP (RB probably)) (VBN caused) (PP (IN by) (NP (NP (DT the) (JJ vasodilating) (NN effect)) (PP (IN of) (NP (DT the) (CD two) (NNS agents)))))) (, ,)) (VP (AUX were) (PP (IN of) (NP (JJ mild) (NN degree))))) (CC and) (S (NP (DT no) (JJ special) (NN treatment)) (VP (AUX was) (VP (VBN required)))) (. .)))
7596955	8	(S1 (S (NP (JJ Intraplatelet) (JJ Doc_7596955_1267_1271_Chemical) (NN content)) (VP (VP (AUX was) (ADVP (RB gradually))) (CC but) (VP (ADVP (RB significantly)) (VBD increased) (PP (TO to) (NP (CD 9.84) (NN +/-))) (SBAR (S (NP (NP (CD 4.59) (NN pmol)) (PP (IN per) (NP (NP (CD 10)) (PRN (-LRB- -LRB-) (NP (CD 9)) (-RRB- -RRB-))))) (VP (VBZ platelets) (PP (IN at) (NP (NN day) (CD 14))) (PP (IN in) (NP (NP (NN comparison)) (PP (IN with) (NP (NP (DT the) (JJ initial) (NN value)) (PRN (-LRB- -LRB-) (NP (NP (CD 6.87) (NN +/-)) (NP (CD 2.25) (NN pmol))) (-RRB- -RRB-))))))))))) (. .)))
7596955	9	(S1 (S (S (NP (DT The) (NN platelet) (NN aggregability)) (VP (AUX was) (ADVP (RB significantly)) (VP (VBN suppressed) (PP (IN at) (NP (JJ various) (NN time) (NNS intervals)))))) (CC but) (S (NP (NP (DT no) (ADJP (JJ additive) (CC or) (JJ synergistic)) (JJ inhibitory) (NN effect)) (PP (IN by) (NP (DT the) (VBN combined) (NN administration)))) (VP (AUX was) (VP (VBN noted)))) (. .)))
7596955	10	(S1 (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NP (DT the) (VBN combined) (NN administration)) (PP (IN of) (NP (NNP Doc_7596955_1652_1655_Chemical/Doc_7596955_1656_1659_Chemical)))) (VP (AUX is) (ADJP (JJ safe)) (PP (IN at) (NP (NP (NNS doses)) (VP (VBN used) (PP (IN in) (NP (DT the) (NN study)))))) (, ,) (SBAR (IN though) (S (NP (NP (DT the) (JJ beneficial) (JJ clinical) (NN effect)) (PP (IN of) (NP (DT the) (VBN combined) (NN administration)))) (VP (AUX has) (ADVP (RB yet)) (S (VP (TO to) (VP (AUX be) (VP (VBN elucidated))))))))) (. .)))
7604176	0	(S1 (NP (JJ Doc_7604176_0_11_Chemical-associated) (NN Doc_7604176_23_31_Disease) (. .)))
7604176	1	(S1 (NP (NP (NN Report)) (PP (IN of) (NP (DT a) (NN case))) (. .)))
7604176	2	(S1 (S (NP (NP (DT A) (NN case)) (PP (IN of) (NP (JJ acute) (NNP Doc_7604176_67_88_Disease))) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NP (NNP Doc_7604176_116_127_Chemical)) (, ,) (NP (NP (DT a) (JJ new) (JJ hydrophilic) (JJ 3-hydroxy-3) (NN methylglutaril) (NN coenzyme)) (NP (DT A) (JJ reductase) (NN inhibitor))) (, ,))))))) (VP (AUX is) (VP (VBN reported))) (. .)))
7604176	3	(S1 (S (NP (DT The) (NN patient)) (, ,) (NP (DT a) (JJ 69-year-old) (NN man)) (VP (AUX was) (VP (VBN affected) (PP (IN by) (NP (NP (NNP Doc_7604176_266_305_Disease)) (CC and) (NP (NNP Doc_7604176_310_322_Disease)))))) (. .)))
7604176	4	(S1 (S (NP (PRP He)) (VP (VBD assumed) (NP (NP (NNP Doc_7604176_335_346_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 20) (NN mg/day)) (-RRB- -RRB-))) (PP (IN because) (IN of) (NP (NN Doc_7604176_370_390_Disease)))) (. .)))
7604176	5	(S1 (S (NP (PRP He)) (VP (AUX was) (VP (VBN admitted) (PP (IN with) (NP (NP (JJ acute) (NN Doc_7604176_419_427_Disease)) (PP (IN of) (NP (NP (DT the) (JJR lower) (NNS limbs)) (SBAR (WHNP (WDT which)) (S (VP (VBD resolved) (PP (IN in) (NP (DT a) (JJ few) (NNS days))) (PP (IN after) (NP (JJ Doc_7604176_482_493_Chemical) (NN discontinuation)))))))))))) (. .)))
7604176	6	(S1 (S (NP (NP (DT A) (ADJP (RB previously) (JJ unknown)) (NN Doc_7604176_532_546_Disease)) (, ,) (ADJP (RB probably) (JJ due) (PP (TO to) (NP (NN chronic) (NN Doc_7604176_572_594_Disease)))) (, ,)) (VP (AUX was) (VP (VBN evidenced))) (. .)))
7604176	7	(S1 (S (NP (NP (NN Muscle) (NN biopsy)) (PRN (-LRB- -LRB-) (NP (JJ left) (NN gastrocnemius)) (-RRB- -RRB-))) (VP (VBD revealed) (NP (NP (DT a) (ADJP (JJ perimysial) (CC and) (JJ endomysial)) (JJ inflammatory) (VB infiltrate)) (PP (IN with) (NP (NP (DT a) (NN prevalence)) (PP (IN of) (NP (JJ CD4+) (NNS lymphocytes))))))) (. .)))
7604176	8	(S1 (S (SBAR (IN While) (S (NP (NP (NNP Doc_7604176_752_762_Chemical)) (CC and) (NP (NNP Doc_7604176_767_778_Chemical))) (VP (AUX have) (VP (AUX been) (VP (VBN associated) (PP (IN with) (NP (JJ toxic) (NN Doc_7604176_811_819_Disease)))))))) (, ,) (NP (NNP Doc_7604176_821_832_Chemical-associated) (NNP Doc_7604176_844_852_Disease)) (VP (MD could) (VP (VB represent) (NP (DT a) (JJ distinct) (, ,) (JJ inflammatory) (NN entity)))) (. .)))
761833	0	(S1 (NP (NP (NP (NN Reversal)) (PP (IN of) (NP (NNP Doc_761833_12_19_Chemical) (NNP Doc_761833_20_24_Disease))) (PP (IN in) (NP (NNS rats))) (PP (IN by) (NP (NNP Doc_761833_36_42_Chemical)))) (: :) (NP (DT a) (JJ peripheral) (NN effect)) (. .)))
761833	1	(S1 (S (NP (NN Ammonia) (NN Doc_761833_73_77_Disease)) (VP (AUX was) (VP (VBN produced) (PP (IN in) (NP (NNS rats))) (PP (IN within) (NP (NP (QP (CD 10) (TO to) (CD 15)) (NNS minutes)) (PP (IN of) (NP (NP (DT an) (NN intraperitonealinjection)) (PP (IN of) (NP (CD 1.7) (JJ mmol) (NN Doc_761833_166_171_Chemical))))))))) (. .)))
761833	2	(S1 (S (NP (DT This) (NN Doc_761833_178_182_Disease)) (VP (AUX was) (VP (VBN prevented) (PP (IN with) (NP (NP (CD 1.68) (JJ mmol) (NN Doc_761833_212_218_Chemical)) (VP (VBN given) (PP (IN by) (NP (JJ gastric) (NN intubation))) (PP (NP (CD 15) (NNS minutes)) (IN before) (NP (DT the) (NNP Doc_761833_269_282_Chemical) (NN injection)))))))) (. .)))
761833	3	(S1 (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NNP Doc_761833_308_314_Chemical)))) (VP (AUX was) (VP (VBN correlated) (PP (IN with) (NP (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (NP (NN blood)) (CC and) (NP (NN brain) (NN Doc_761833_365_372_Chemical))))) (, ,) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NN brain) (NN Doc_761833_395_403_Chemical)))) (, ,) (CC and) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (JJ renal) (NN excretion)) (PP (IN of) (NP (NNP Doc_761833_443_450_Chemical) (CC and) (NNP Doc_761833_455_459_Chemical)))))))))) (. .)))
761833	4	(S1 (S (NP (NP (JJ Intraventricular) (NN infusion)) (PP (IN of) (NP (NNP Doc_761833_490_498_Chemical))) (ADJP (JJ sufficient) (S (VP (TO to) (VP (VB raise) (NP (DT the) (NN brain) (NN Doc_761833_529_537_Chemical)) (PP (TO to) (NP (DT the) (JJ same) (NN extent)))))))) (VP (AUX did) (RB not) (VP (VP (VB prevent) (NP (DT the) (NNP Doc_761833_577_584_Chemical) (NNP Doc_761833_585_589_Disease))) (CC nor) (VP (VB affect) (NP (DT the) (NN blood) (CC and) (NN brain) (NN Doc_761833_621_628_Chemical) (NNS concentrations))))) (. .)))
761833	5	(S1 (S (S (NP (JJ Bilateral) (NN nephrectomy)) (VP (VBD eliminated) (NP (NP (DT the) (JJ beneficial) (NN effect)) (PP (IN of) (NP (NNP Doc_761833_703_709_Chemical))) (PP (IN on) (NP (NN blood) (CC and) (NN brain) (NN Doc_761833_729_736_Chemical)))))) (CC and) (S (NP (DT the) (NNP Doc_761833_745_752_Chemical) (NNP Doc_761833_753_757_Disease)) (VP (AUX was) (RB not) (VP (VBN prevented)))) (. .)))
761833	6	(S1 (S (ADVP (RB Thus)) (, ,) (NP (NP (NP (DT the) (NN reduction)) (PP (IN in) (NP (NN blood) (CC and) (NN brain) (NN Doc_761833_816_823_Chemical)))) (CC and) (NP (NP (DT the) (NN prevention)) (PP (IN of) (NP (NNP Doc_761833_846_853_Chemical) (NNP Doc_761833_854_858_Disease))) (PP (IN after) (NP (NNP Doc_761833_865_871_Chemical)))) (, ,)) (VP (MD can) (VP (AUX be) (VP (VBN accounted) (PP (IN for)) (PP (IN by) (NP (NP (DT the) (JJ peripheral) (NN effect)) (PP (IN of) (NP (NNP Doc_761833_922_930_Chemical))) (PP (IN on) (NP (NP (JJ renal) (NN function)) (CONJP (RB rather) (IN than)) (NP (PRP$ its) (JJ central) (NN action))))))))) (. .)))
761833	7	(S1 (S (NP (DT These) (NNS results)) (VP (VBP provide) (NP (NP (DT a) (JJ reasonable) (NN explanation)) (PP (IN for) (NP (NP (DT the) (JJ beneficial) (NNS effects)) (VP (VBN observed) (PP (IN in) (NP (NP (DT some) (JJ encephalopathic) (NNS patients)) (VP (VBG receiving) (NP (NN Doc_761833_1107_1113_Chemical)))))))))) (. .)))
7619765	0	(S1 (NP (JJ Doc_7619765_0_9_Chemical-related) (NN Doc_7619765_18_39_Disease) (. .)))
7619765	1	(S1 (S (NP (NP (DT The) (NN occurrence)) (PP (IN of) (NP (DT a) (NN Doc_7619765_61_82_Disease)))) (VP (AUX is) (VP (VBN reported) (PP (IN after) (NP (NP (NNS chemotherapy)) (VP (VBG containing) (NP (NNP Doc_7619765_125_134_Chemical))))) (, ,) (PP (IN in) (NP (NP (DT a) (NN man)) (PP (IN with) (NP (NP (DT no) (NN risk) (NNS factors)) (PP (IN for) (NP (NNP Doc_7619765_170_192_Disease))))))))) (. .)))
7619765	2	(S1 (S (NP (JJ Possible) (NN causal) (NNS mechanisms)) (VP (AUX are) (VP (VBN discussed))) (. .)))
7647582	0	(S1 (S (NP (VBD Halogenated) (NNS anesthetics)) (VP (VBP form) (NP (NP (NP (NN liver) (NNS adducts)) (CC and) (NP (NNS antigens))) (SBAR (WHNP (WDT that)) (S (VP (VBP cross-react) (PP (IN with) (NP (JJ Doc_7647582_78_87_Chemical-induced) (NNS antibodies)))))))) (. .)))
7647582	1	(S1 (S (NP (NP (CD Two) (VBD halogenated) (NNS anesthetics)) (, ,) (NP (NP (NNP Doc_7647582_137_146_Chemical)) (CC and) (NP (NNP Doc_7647582_151_161_Chemical))) (, ,)) (VP (AUX have) (VP (AUX been) (VP (VBN associated) (PP (IN with) (NP (NP (DT an) (JJ allergic-type) (UCP (NNP Doc_7647582_206_220_Disease) (CC both) (JJ alone) (CC and) (VBG following)) (JJ previous) (NN exposure)) (PP (TO to) (NP (NNP Doc_7647582_267_276_Chemical)))))))) (. .)))
7647582	2	(S1 (S (NP (NNP Doc_7647582_278_287_Chemical) (NNP Doc_7647582_288_297_Disease)) (VP (VBZ appears) (S (VP (TO to) (VP (VB involve) (NP (DT an) (JJ aberrant) (JJ immune) (NN response)))))) (. .)))
7647582	3	(S1 (S (NP (NP (DT An) (NN antibody) (NN response)) (PP (TO to) (NP (NP (DT a) (JJ protein-bound) (NN biotransformation) (NN product)) (PRN (-LRB- -LRB-) (NP (JJ Doc_7647582_413_428_Chemical) (NN adduct)) (-RRB- -RRB-))))) (VP (AUX has) (VP (AUX been) (VP (VBN detected) (PP (IN on) (NP (NNP Doc_7647582_458_467_Chemical) (NNP Doc_7647582_468_477_Disease) (NNS patients)))))) (. .)))
7647582	4	(S1 (S (NP (DT This) (NN study)) (VP (AUX was) (VP (VBN performed) (S (VP (TO to) (VP (VB determine) (NP (NP (NN cross-reactivity)) (PP (IN between) (NP (NP (NNP Doc_7647582_551_560_Chemical)) (CC and) (NP (NNP Doc_7647582_565_575_Chemical)))) (PP (IN with) (NP (NP (DT the) (NNP Doc_7647582_585_601_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_7647582_613_622_Chemical)))))))))))) (. .)))
7647582	5	(S1 (S (S (NP (NP (DT The) (ADJP (JJ subcellular) (CC and) (JJ lobular)) (NN production)) (PP (IN of) (NP (JJ hepatic) (NNS neoantigens)))) (VP (VBD recognized) (PP (IN by) (NP (JJ Doc_7647582_700_709_Chemical-induced) (NNS antibodies))) (PP (VBG following) (NP (NP (NNP Doc_7647582_739_748_Chemical)) (CC and) (NP (NNP Doc_7647582_753_763_Chemical)))))) (, ,) (CC and) (S (NP (NP (DT the) (JJ biochemical) (NN nature)) (PP (IN of) (NP (DT these) (NNS neoantigens)))) (VP (AUX was) (VP (VBN investigated) (PP (IN in) (NP (CD two) (NN animal) (NNS models)))))) (. .)))
7647582	6	(S1 (S (NP (JJ Doc_7647582_852_861_Chemical) (NN administration)) (VP (VBD resulted) (PP (IN in) (NP (NP (NNS neoantigens)) (VP (VBN detected) (PP (PP (IN in) (NP (NP (PDT both) (DT the) (JJ microsomal) (CC and) (JJ cytosolic) (NN fraction)) (PP (IN of) (NP (NN liver) (NNS homogenates))))) (CC and) (PP (IN in) (NP (NP (DT the) (JJ centrilobular) (NN region)) (PP (IN of) (NP (DT the) (NN liver)))))))))) (. .)))
7647582	7	(S1 (S (PP (IN In) (NP (DT the) (JJ same) (NN liver))) (, ,) (NP (JJ biochemical) (NN analysis)) (VP (VBD detected) (NP (NP (JJ fluorinated) (NN liver) (NNS adducts)) (SBAR (WHNP (WDT that)) (S (VP (AUX were) (ADVP (RB up) (PP (TO to) (NP (NN 20-fold)))) (ADJP (JJR greater) (PP (IN in) (NP (NN guinea) (NNS pigs))) (PP (IN than) (PP (IN in) (NP (NNS rats)))))))))) (. .)))
7647582	8	(S1 (S (NP (DT This)) (VP (VP (VBZ supports)) (CC and) (VP (VBZ extends) (NP (NP (JJ previous) (NN evidence)) (PP (IN for) (NP (NP (DT a) (NN mechanism)) (SBAR (WHPP (IN by) (WHNP (WDT which))) (S (NP (NNP Doc_7647582_1228_1237_Chemical) (FW and/or) (NNP Doc_7647582_1245_1255_Chemical)) (VP (MD could) (VP (VB produce) (NP (NP (DT a) (JJ Doc_7647582_1272_1288_Disease) (NN condition)) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT that)) (PP (IN of) (NP (NNP Doc_7647582_1318_1327_Chemical) (NNP Doc_7647582_1328_1337_Disease)))))))))))))) (ADVP (RB either)) (UCP (ADVP (RB alone)) (CC or) (ADJP (JJ subsequent) (PP (TO to) (NP (NNP Doc_7647582_1368_1377_Chemical) (NN administration))))))) (. .)))
7647582	9	(S1 (S (NP (DT The) (NN guinea) (NN pig)) (VP (MD would) (VP (VB appear) (S (VP (TO to) (VP (AUX be) (NP (NP (DT a) (JJ useful) (NN model)) (PP (IN for) (NP (NP (JJ further) (NNS investigations)) (PP (IN of) (NP (NP (DT the) (JJ immunological) (NN response)) (PP (TO to) (NP (DT these) (NNS antigens))))))))))))) (. .)))
7650771	0	(S1 (S (NP (NNP Cholinergic) (NNP Doc_7650771_12_20_Disease)) (VP (VBG resulting) (PP (IN from) (NP (NP (JJ ocular) (NN instillation)) (PP (IN of) (NP (JJ Doc_7650771_59_79_Chemical) (NN eye) (NNS drops)))))) (. .)))
7650771	1	(S1 (S (NP (DT A) (NN patient)) (VP (VP (VBD developed) (NP (DT a) (JJ severe) (JJ cholinergic) (NN syndrome)) (PP (IN from) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NP (JJ Doc_7650771_157_177_Chemical) (JJ ophthalmic) (NNS drops)) (, ,) (VP (VBN presented) (PP (IN with) (NP (JJ profound) (NN Doc_7650771_220_235_Disease))))))))) (CC and) (VP (AUX was) (ADVP (RB initially)) (VP (VBN given) (NP (NP (DT the) (NN diagnosis)) (PP (IN of) (NP (NNP Doc_7650771_277_294_Disease))))))) (. .)))
7650771	2	(S1 (S (S (NP (JJ Red) (NN blood) (NN cell) (CC and) (NN serum) (NN cholinesterase) (NNS levels)) (VP (AUX were) (ADVP (RB severely)) (VP (VBN depressed)))) (CC and) (S (NP (NNS symptoms)) (VP (VBD resolved) (ADVP (RB spontaneously)) (PP (VBG following) (NP (NP (NN discontinuation)) (PP (IN of) (NP (DT the) (NN eye) (NNS drops))))))) (. .)))
7651879	0	(S1 (NP (NP (NN Doc_7651879_0_7_Disease)) (PP (IN after) (NP (NNP Doc_7651879_14_24_Chemical) (NN administration))) (PP (IN in) (NP (DT a) (JJ pediatric) (NN patient))) (. .)))
7651879	1	(S1 (S (S (NP (NN Doc_7651879_64_74_Chemical)) (VP (AUX is) (NP (NP (DT a) (JJ Doc_7651879_80_94_Chemical) (NN receptor) (NN antagonist)) (VP (VBN used) (S (VP (TO to) (VP (VB reverse) (NP (NN sedation))))))))) (CC and) (S (NP (NNP Doc_7651879_144_166_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_7651879_178_193_Chemical))))) (. .)))
7651879	2	(S1 (S (NP (NP (NNP Doc_7651879_195_203_Disease)) (CC and) (NP (NNP Doc_7651879_208_227_Disease))) (VP (AUX have) (VP (VBN complicated) (NP (NP (PRP$ its) (NN use)) (PP (IN in) (NP (NN adult) (NNS patients)))))) (. .)))
7651879	3	(S1 (S (NP (NP (JJ Doc_7651879_272_280_Disease) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX have) (VP (VBN coingested) (NP (JJ tricyclic) (NNS antidepressants))))))) (VP (AUX have) (NP (NP (DT a) (JJR higher) (NN risk)) (PP (IN of) (NP (DT these) (NNS complications))))) (. .)))
7651879	4	(S1 (S (NP (JJ Little) (NN information)) (VP (VBZ exists) (S (VP (VBG concerning) (NP (NP (JJ adverse) (NNS effects)) (PP (IN of) (NP (NP (NNP Doc_7651879_435_445_Chemical)) (PP (IN in) (NP (NNS children))))))))) (. .)))
7651879	5	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT the) (NN occurrence)) (PP (IN of) (NP (DT a) (JJ generalized) (NN Doc_7651879_501_521_Disease)))) (PP (IN in) (NP (NP (DT a) (JJ pediatric) (NN patient)) (PP (VBG following) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NNP Doc_7651879_577_587_Chemical)))))))) (. .)))
7707116	0	(S1 (S (VP (VB Phase) (S (NP (PRP I)) (NP (NP (NN trial)) (PP (IN of) (NP (NNP Doc_7707116_17_37_Chemical))) (PP (IN in) (NP (NP (NNS children)) (PP (IN with) (NP (NNP Doc_7707116_55_68_Disease) (JJ following) (NN bone) (NN marrow) (NN transplantation)))))))) (. .)))
7707116	1	(S1 (S (NP (NP (NN Treatment)) (PP (IN of) (NP (NP (JJ Doc_7707116_130_143_Disease) (NN cell) (NNS lines)) (PP (IN with) (NP (NP (NNP Doc_7707116_160_180_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_7707116_182_188_Chemical)) (-RRB- -RRB-))))))) (VP (MD can) (VP (VB cause) (NP (NP (JJ sustained) (NN inhibition)) (PP (IN of) (NP (NN proliferation)))))) (. .)))
7707116	2	(S1 (S (SBAR (IN Since) (S (NP (NNP Doc_7707116_245_251_Chemical)) (VP (AUX has) (VP (VBN demonstrated) (NP (JJ clinical) (NNS responses)) (PP (IN in) (NP (NNP Doc_7707116_291_304_Disease) (NNS patients))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (AUX be) (ADJP (JJ effective) (PP (IN in) (S (VP (VBG preventing) (NP (NN relapse)) (PP (IN after) (NP (JJ cytotoxic) (NN therapy))))))))) (. .)))
7707116	3	(S1 (S (S (NP (DT This) (NN phase) (NN I) (NN trial)) (VP (AUX was) (VP (VBN designed) (S (VP (TO to) (VP (VB determine) (NP (NP (NP (DT the) (JJ maximal-tolerated) (NN dosage)) (PRN (-LRB- -LRB-) (NP (NNP MTD)) (-RRB- -RRB-))) (, ,) (NP (NNP Doc_7707116_463_473_Disease))))))))) (, ,) (CC and) (S (NP (NP (NNS pharmacokinetics)) (PP (IN of) (NP (NNP Doc_7707116_499_505_Chemical)))) (VP (VBN administered) (PP (IN on) (NP (DT an) (JJ intermittent) (NN schedule))) (PP (IN in) (NP (NP (NNS children)) (PP (IN with) (NP (NNP Doc_7707116_564_577_Disease))))) (PP (VBG following) (NP (NP (NN bone) (NN marrow) (NN transplantation)) (PRN (-LRB- -LRB-) (NP (NNP BMT)) (-RRB- -RRB-)))))) (. .)))
7707116	4	(S1 (S (NP (NNS PATIENTS) (CC AND) (NNS METHODS)) (: :) (NP (NP (JJ Fifty-one) (JJ assessable) (NNS patients)) (, ,) (NP (NP (QP (CD 2) (TO to) (CD 12)) (NNS years)) (PP (IN of) (NP (NN age)))) (, ,)) (VP (AUX were) (VP (VBN treated) (PP (IN with) (NP (NP (JJ oral) (NN Doc_7707116_721_727_Chemical)) (VP (VBN administered) (PP (IN in) (NP (NP (CD two) (ADJP (RB equally) (VBN divided)) (NNS doses)) (ADJP (JJ daily) (PP (IN for) (NP (CD 2) (NNS weeks)))) (, ,) (VP (VBN followed) (PP (IN by) (NP (DT a) (JJ 2-week) (NN rest) (NN period)))) (, ,)))))) (PP (IN for) (NP (QP (IN up) (TO to) (CD 12)) (NNS courses))))) (. .)))
7707116	5	(S1 (S (NP (DT The) (NN dose)) (VP (AUX was) (VP (VBN escalated) (PP (IN from) (NP (QP (CD 100) (TO to) (CD 200)) (NNS mg/m2/d))) (SBAR (IN until) (S (NP (NP (JJ dose-limiting) (NNP Doc_7707116_912_920_Disease)) (PRN (-LRB- -LRB-) (NP (NNP DLT)) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN observed))))))) (. .)))
7707116	6	(S1 (S (NP (DT A) (JJ single) (NN intrapatient) (NN dose) (NN escalation)) (VP (AUX was) (VP (VBN permitted))) (. .)))
7707116	7	(S1 (S (NP (NP (DT The) (NN MTD)) (PP (IN of) (NP (NNP Doc_7707116_1014_1020_Chemical)))) (VP (AUX was) (NP (CD 160) (NN mg/m2/d))) (. .)))
7707116	8	(S1 (S (NP (NP (JJ Dose-limiting) (NN Doc_7707116_1052_1062_Disease)) (PP (IN in) (NP (NP (QP (CD six) (IN of) (CD nine)) (NNS patients)) (PP (IN at) (NP (CD 200) (NNS mg/m2/d)))))) (VP (VBD included) (NP (NP (NP (NNP Doc_7707116_1111_1124_Disease)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 3)) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Doc_7707116_1134_1138_Disease)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 2)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NNP Doc_7707116_1152_1158_Disease/Doc_7707116_1159_1175_Disease/Doc_7707116_1176_1182_Disease/Doc_7707116_1183_1187_Disease)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 1)) (-RRB- -RRB-))))) (. .)))
7707116	9	(S1 (S (NP (NP (DT All) (NN Doc_7707116_1201_1211_Disease)) (VP (VBN resolved) (PP (IN after) (NP (NNP Doc_7707116_1227_1233_Chemical))))) (VP (AUX was) (VP (VBN discontinued))) (. .)))
7707116	10	(S1 (S (NP (CD Three) (JJ complete) (NNS responses)) (VP (AUX were) (VP (VBN observed) (PP (IN in) (NP (NN marrow) (NN Doc_7707116_1301_1311_Disease))))) (. .)))
7707116	11	(S1 (S (NP (NP (NN Serum) (NNS levels)) (PP (IN of) (NP (NP (NP (NP (CD 7.4) (NN +/-)) (NP (CD 3.0) (NNS mumol/L))) (PRN (-LRB- -LRB-) (NP (NN peak)) (-RRB- -RRB-))) (CC and) (NP (NP (CD 4.0) (NN +/-) (QP (CD 2.8) (CD mumol/L))) (PRN (-LRB- -LRB-) (NP (NN trough)) (-RRB- -RRB-))))) (PP (IN at) (NP (DT the) (NN MTD)))) (VP (AUX were) (VP (VBN maintained) (PP (IN during) (NP (NP (CD 14) (NNS days)) (PP (IN of) (NP (NN therapy))))))) (. .)))
7707116	12	(S1 (S (NP (NP (DT The) (NN DLT)) (VP (VBN correlated) (PP (IN with) (NP (JJ serum) (NNS levels))))) (VP (VBD >) (NP (QP (CC or) (SYM =) (CD 10) (CD mumol/L)))) (. .)))
7707116	13	(S1 (S (NP (NP (DT The) (NN MTD)) (PP (IN of) (NP (NNP Doc_7707116_1522_1528_Chemical))) (VP (VBN given) (PP (IN on) (NP (DT this) (JJ intermittent) (NN schedule))))) (VP (AUX was) (NP (CD 160) (NN mg/m2/d))) (. .)))
7707116	14	(S1 (S (NP (NP (NN Serum) (NNS levels)) (VP (VBN known) (S (VP (TO to) (VP (AUX be) (ADJP (JJ effective))))) (PP (IN against) (NP (NNP Doc_7707116_1625_1638_Disease))) (PP (IN in) (NP (NN vitro))))) (VP (AUX were) (VP (VBN achieved) (PP (IN at) (NP (DT this) (NN dose))))) (. .)))
7707116	15	(S1 (S (NP (DT The) (NN DLT)) (VP (VP (VBD included) (NP (NNP Doc_7707116_1693_1706_Disease))) (, ,) (CC and) (VP (MD may) (VP (AUX be) (VP (VBN predicted) (PP (IN by) (NP (JJ serum) (JJ Doc_7707116_1738_1744_Chemical) (NNS levels))))))) (. .)))
7707116	16	(S1 (S (NP (NP (NN Monitoring)) (PP (IN of) (NP (JJ serum) (UCP (NNP Doc_7707116_1773_1780_Chemical) (CC and) (NNP Doc_7707116_1785_1791_Chemical)) (NNS levels)))) (VP (AUX is) (VP (VBN indicated) (PP (IN in) (NP (JJ future) (NNS trials))))) (. .)))
7710775	0	(S1 (NP (NP (NN Time) (NN dependence)) (PP (IN of) (NP (NP (NN plasma) (NNP Doc_7710775_26_41_Chemical)) (, ,) (NP (NNP Doc_7710775_43_53_Chemical)) (, ,) (CC and) (NP (NNP Doc_7710775_59_70_Chemical)))) (PP (IN during) (NP (NP (JJ incomplete) (NN Doc_7710775_89_106_Disease)) (PP (IN in) (NP (DT the) (NN rat))))) (. .)))
7710775	1	(S1 (S (NP (NP (JJ Incomplete) (NN Doc_7710775_130_147_Disease)) (PRN (-LRB- -LRB-) (NP (CD 30) (NN min)) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN induced) (PP (IN in) (NP (DT the) (NN rat))) (PP (IN by) (S (ADVP (RB bilaterally)) (VP (VBG clamping) (NP (DT the) (JJ common) (JJ carotid) (NNS arteries))))))) (. .)))
7710775	2	(S1 (S (NP (JJ Peripheral) (JJ venous) (NN blood) (NNS samples)) (VP (AUX were) (VP (VBN withdrawn) (PP (IN from) (NP (DT the) (JJ femoral) (NN vein))) (NP (CD four) (NNS times)) (PRN (-LRB- -LRB-) (PP (IN once) (NP (DT every) (CD 5) (NN min))) (-RRB- -RRB-)) (PP (IN before) (NP (NP (NP (NNP Doc_7710775_339_347_Disease)) (PRN (-LRB- -LRB-) (NP (CD 0) (NN time)) (-RRB- -RRB-))) (CC and) (NP (NP (CD 5)) (, ,) (NP (CD 15)) (, ,) (CC and) (NP (NP (CD 30) (NN min)) (PP (IN after) (NP (NNP Doc_7710775_385_393_Disease))))))))) (. .)))
7710775	3	(S1 (S (NP (NN Plasma) (NNS extracts)) (VP (AUX were) (VP (VBN analyzed) (PP (IN by) (NP (NP (DT a) (ADJP (RB highly) (JJ sensitive)) (NN high-performance) (NN liquid) (NN chromatographic) (NN method)) (PP (IN for) (NP (NP (DT the) (JJ direct) (NN determination)) (PP (IN of) (NP (NP (NNP Doc_7710775_526_541_Chemical)) (, ,) (NP (NNP Doc_7710775_543_553_Chemical)) (, ,) (CC and) (NP (NNP Doc_7710775_559_570_Chemical)))))))))) (. .)))
7710775	4	(S1 (S (PP (IN During) (NP (NNP Doc_7710775_579_587_Disease))) (, ,) (NP (NP (DT a) (JJ time-dependent) (NN increase)) (PP (IN of) (NP (NN plasma)))) (NP (NP (NNP Doc_7710775_625_635_Chemical)) (CC and) (NP (NNP Doc_7710775_640_651_Chemical))) (VP (AUX was) (VP (VBN observed))) (. .)))
7710775	5	(S1 (S (NP (NP (NN Plasma) (NN Doc_7710775_673_688_Chemical)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX was) (ADJP (JJ present)) (PP (IN in) (NP (JJ minimal) (NN amount))) (PP (IN at) (NP (NP (CD zero) (NN time)) (PRN (-LRB- -LRB-) (NP (NP (CD 0.058) (NN mumol/liter) (NN plasma)) (: ;) (NP (NNP SD) (CD 0.015))) (-RRB- -RRB-))))))) (, ,)) (VP (VBN increased) (PP (IN after) (NP (NP (CD 5) (NN min)) (PP (IN of) (NP (NNP Doc_7710775_802_810_Disease))))) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (NP (DT a) (ADJP (RB fivefold)) (NN increase)) (PP (IN after) (NP (NP (CD 30) (NN min)) (PP (IN of) (NP (NP (JJ carotid) (NN occlusion)) (PRN (-LRB- -LRB-) (NP (NP (CD 0.298) (NN mumol/liter) (NN plasma)) (: ;) (NP (NNP SD) (CD 0.078))) (-RRB- -RRB-))))))))))) (. .)))
7710775	6	(S1 (S (NP (VBN Increased) (NN plasma) (NN Doc_7710775_934_949_Chemical)) (VP (AUX was) (ADVP (RB also)) (VP (VBN recorded) (PP (IN in) (NP (NP (CD two) (JJ other) (NNS groups)) (PP (IN of) (NP (NP (NNS animals)) (VP (VBN subjected) (PP (TO to) (NP (NP (DT the) (JJ same) (JJ experimental) (NN model)) (, ,) (NP (NP (CD one)) (VP (VBG receiving) (NP (NP (QP (CD 20) (CD mg/kg)) (NNS b.w.)) (PP (IN of) (NP (DT the) (NN cyclooxygenase) (NN inhibitor) (NNP Doc_7710775_1101_1117_Chemical)))) (ADVP (RB intravenously) (RB immediately)) (PP (IN before) (NP (NNP Doc_7710775_1151_1159_Disease))))) (, ,))) (NP (DT the) (JJ other) (S (VP (VBG receiving) (NP (NP (QP (CD 650) (CD micrograms/kg)) (NNS b.w.)) (PP (IN of) (NP (NP (DT the) (NNP Doc_7710775_1211_1222_Disease) (NN drug) (NNP Doc_7710775_1228_1241_Chemical)) (PP (IN at) (NP (NP (DT a) (NN flow) (NN rate)) (PP (IN of) (NP (CD 103) (NN microliters/min)))))))) (ADVP (RB intravenously)) (PP (IN during) (NP (NNP Doc_7710775_1301_1309_Disease))))))))))) (, ,) (SBAR (IN although) (S (PP (IN in) (NP (DT this) (JJ latter) (NN group))) (NP (NNP Doc_7710775_1341_1356_Chemical)) (VP (AUX was) (ADJP (RB significantly) (JJR higher))))))) (. .)))
7710775	7	(S1 (S (NP (DT The) (JJ present) (NNS data)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (DT the) (NN determination)) (PP (IN of) (NP (NP (NNP Doc_7710775_1435_1450_Chemical)) (, ,) (NP (NNP Doc_7710775_1452_1462_Chemical)) (, ,) (CC and) (NP (NP (NNP Doc_7710775_1468_1479_Chemical)) (PP (IN in) (NP (JJ peripheral) (NN blood)))) (, ,)))) (VP (MD may) (VP (AUX be) (VP (VBN used) (S (VP (TO to) (VP (VB monitor) (NP (NP (DT the) (JJ metabolic) (NNS alterations)) (PP (IN of) (NP (NP (NNS tissues)) (VP (VBG occurring) (PP (IN during) (NP (NP (JJ Doc_7710775_1578_1586_Disease) (NNS phenomena.)) (PRN (-LRB- -LRB-) (NP (NP (JJ ABSTRACT)) (VP (VBN TRUNCATED) (PP (IN AT) (NP (CD 250) (NNS WORDS))))) (-RRB- -RRB-)))))))))))))))))))
7724492	0	(S1 (S (NP (NP (JJ Acute) (NN Doc_7724492_6_20_Disease)) (PP (IN of) (NP (NP (NNP Doc_7724492_24_35_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_7724492_37_47_Chemical)) (-RRB- -RRB-))))) (VP (VBD -loaded) (NP (JJ Doc_7724492_56_69_Chemical) (NNS nanoparticles))) (. .)))
7724492	1	(S1 (S (NP (JJ Acute) (JJ Doc_7724492_91_102_Chemical-loaded) (FW nanoparticle) (PRN (-LRB- -LRB-) (NP (NNP DXNP)) (-RRB- -RRB-)) (NNP Doc_7724492_130_144_Disease)) (VP (AUX was) (VP (VBN explored) (PP (IN in) (NP (DT both) (JJ normal) (NNS rats) (CC and) (NNS rats))) (PP (IN with) (NP (JJ experimental) (NN Doc_7724492_205_223_Disease))))) (. .)))
7724492	2	(S1 (S (PP (IN In) (NP (JJ normal) (NNS rats))) (, ,) (S (NP (NN 2/6) (NNS rats)) (VP (VBN given) (NP (NP (NP (JJ free) (NNP Doc_7724492_261_272_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_7724492_274_276_Chemical)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (CD 5) (NN mg/kg)) (-RRB- -RRB-)) (VP (VBN died) (PP (IN within) (NP (CD one) (NN week)))) (, ,)) (PP (IN whereas) (NP (DT all) (NN control) (NNS animals))))) (CC and) (S (NP (DT all) (NNS rats)) (VP (AUXG having) (VP (VBN received) (NP (JJ free) (NN NP))))) (CC or) (S (NP (NNS DXNP)) (VP (VBN survived))) (. .)))
7724492	3	(S1 (S (NP (DT A) (ADJP (QP (CD 3) (NNS times)) (JJR higher)) (NN Doc_7724492_410_421_Disease)) (VP (VBD appeared) (PP (IN in) (NP (NP (NNS animals)) (VP (VBN treated) (PP (IN with) (S (VP (VBG DXNP) (PP (IN than) (PP (IN in) (NP (NP (DT those)) (VP (VBN treated) (PP (IN with) (NP (NN DX)))))))))))))) (. .)))
7724492	4	(S1 (S (NP (JJ Free) (NNS NP)) (VP (AUX did) (RB not) (VP (VB provoke) (NP (DT any) (NN Doc_7724492_519_530_Disease)))) (. .)))
7724492	5	(S1 (S (NP (NP (QP (CD Two) (CD hr)) (NN post-injection)) (, ,) (NP (NNP DXNP))) (VP (AUX was) (ADJP (ADJP (QP (CD 2.7) (NNS times)) (RBR more) (JJ concentrated)) (PP (IN in) (NP (NNS kidneys))) (PP (IN than) (NP (NP (JJ free) (JJ Doc_7724492_613_615_Chemical)) (PRN (-LRB- -LRB-) (NP (QP ($ p) (CD <) (CD 0.025))) (-RRB- -RRB-)))))) (. .)))
7724492	6	(S1 (S (PP (IN In) (NP (NP (NNS rats)) (PP (IN with) (NP (JJ immune) (JJ experimental) (NN Doc_7724492_662_680_Disease))))) (, ,) (NP (NP (JJ 5/6) (NNS rats)) (VP (VBN given) (NP (NNP Doc_7724492_697_699_Chemical)))) (VP (VBD died) (PP (IN within) (NP (CD 7) (NNS days))) (, ,) (PP (IN in) (NP (NP (NN contrast)) (PP (TO to) (NP (NP (NNS animals)) (VP (VBN treated) (PP (IN by) (NP (NP (NN DXNP)) (, ,) (ADJP (JJ NP) (, ,) (CC or) (JJ untreated)) (, ,) (SBAR (WHNP (WDT which)) (S (ADVP (RB all)) (VP (VBD survived)))))))))))) (. .)))
7724492	7	(S1 (S (S (NP (NN Doc_7724492_798_809_Disease)) (VP (VBD appeared) (PP (IN in) (NP (DT all) (NN series))))) (, ,) (CC but) (S (VP (AUX was) (ADJP (ADJP (QP (CD 2-5) (NNS times)) (RBR more) (JJ intense)) (PRN (-LRB- -LRB-) (NP (QP (CD p) (CD >)) (CD 0.001)) (-RRB- -RRB-)) (CC and) (ADJP (JJ prolonged))) (PP (IN after) (NP (NP (JJ Doc_7724492_897_908_Chemical) (NN treatment)) (PRN (-LRB- -LRB-) (NP (CD 400-700) (NN mg/day)) (-RRB- -RRB-)))) (, ,) (PP (IN without) (NP (NP (JJ significant) (NN difference)) (PP (IN between) (NP (CD DXNP) (CC and) (CD DX))))))) (. .)))
7724492	8	(S1 (S (NP (NP (NNS Rats)) (VP (VBN treated) (PP (IN by) (NP (JJ unloaded) (NNS NP))))) (VP (VBD behaved) (PP (IN as) (NP (NNS controls)))) (. .)))
7724492	9	(S1 (S (NP (DT These) (NNS results)) (VP (VBP demonstrate) (SBAR (IN that) (S (, ,) (PP (IN in) (NP (DT these) (JJ experimental) (NNS conditions))) (, ,) (ADVP (RB DXNP)) (VP (VBD killed) (NP (JJR less) (NNS animals)) (PP (IN than) (NP (JJ free) (NNS DX))) (, ,) (PP (IN despite) (IN of) (NP (NP (DT an) (JJ enhanced) (NN Doc_7724492_1166_1180_Disease)) (PP (IN of) (NP (DT the) (JJ former))))))))) (. .)))
7724492	10	(S1 (S (NP (NP (DT Both) (NNS effects)) (PRN (-LRB- -LRB-) (NP (NP (JJR better) (NN survival)) (CC and) (NP (NNP Doc_7724492_1230_1239_Disease))) (-RRB- -RRB-))) (VP (AUX are) (ADJP (ADVP (RBS most) (RB probably)) (VBN related) (PP (TO to) (NP (NP (DT an) (JJ enhanced) (NN capture)) (PP (IN of) (NP (NN DXNP))) (PP (IN by) (NP (NP (NNS cells)) (PP (IN of) (NP (DT the) (JJ mononuclear) (NN phagocyte) (NN system))) (, ,) (PP (VBG including) (NP (JJ mesangial) (NNS cells))))))))) (. .)))
7752389	0	(S1 (NP (NP (NP (JJ Doc_7752389_0_16_Chemical-induced) (NN Doc_7752389_25_46_Disease)) (PP (IN in) (NP (JJ normal) (, ,) (JJ conscious) (NNS rats)))) (: :) (NP (NP (NN involvement)) (PP (IN of) (NP (NNP Doc_7752389_89_100_Chemical)))) (. ?)))
7752389	1	(S1 (S (PP (IN In) (NP (NP (JJ normal) (JJ conscious) (NNS rats)) (VP (VBN investigated) (PP (IN by) (NP (JJ continuous) (NN cystometry)))))) (, ,) (NP (ADJP (RB intravesically) (VBN instilled)) (NNP Doc_7752389_191_212_Chemical)) (VP (VP (VBD facilitated) (NP (NN micturition))) (CC and) (VP (VBD increased) (NP (JJ basal) (JJ intravesical) (NN pressure)))) (. .)))
7752389	2	(S1 (S (NP (DT The) (NN effect)) (VP (AUX was) (VP (VBN attenuated) (PP (IN by) (NP (PDT both) (NP (DT the) (ADJP (CD NK1) (NN receptor)) (JJ selective) (NN antagonist) (NN Doc_7752389_352_361_Chemical)) (CC and) (NP (DT the) (ADJP (CD NK2) (NN receptor)) (JJ selective) (NN antagonist) (NN Doc_7752389_404_413_Chemical)))) (, ,) (S (VP (VBN given) (ADVP (RB intra-arterially)) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP (PRP it)) (VP (AUX was) (VP (VBN mediated) (PP (IN by) (NP (NP (NN stimulation)) (PP (IN of) (NP (DT both) (NNP NK1) (CC and) (NNP NK2) (NNS receptors))))))))))))))) (. .)))
7752389	3	(S1 (S (NP (ADJP (RB Intra-arterially) (VBN given)) (NNP Doc_7752389_540_544_Chemical)) (VP (VBD produced) (NP (NP (DT a) (JJ distinct) (NN increase)) (PP (IN in) (NP (NN bladder) (NN pressure)))) (PP (IN before) (S (VP (VBG initiating) (NP (DT a) (NN micturition) (JJ reflex))))) (, ,) (S (VP (VBG indicating) (SBAR (IN that) (S (NP (DT the) (NNS PG)) (VP (AUX had) (NP (NP (DT a) (JJ direct) (JJ contractant) (NN effect)) (PP (IN on) (NP (DT the) (JJ detrusor) (JJ smooth) (NN muscle)))))))))) (. .)))
7752389	4	(S1 (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (JJ intra-arterial) (NNP Doc_7752389_749_753_Chemical)))) (VP (MD could) (RB not) (VP (AUX be) (VP (VBN blocked) (PP (IN by) (NP (NP (NP (JJ intra-arterial) (NNP Doc_7752389_793_802_Chemical)) (CC or) (NP (NNP SR) (CD 48,968))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ opens) (NP (DT the) (NN possibility) (SBAR (IN that) (S (NP (NP (DT the) (JJ micturition) (JJ reflex) (NN elicited)) (PP (IN by) (NP (JJ intra-arterial) (NNP Doc_7752389_900_904_Chemical)))) (VP (AUX was) (VP (VBN mediated) (PP (IN by) (NP (NP (NNS pathways)) (ADJP (JJ other) (PP (IN than) (NP (NP (DT the) (JJ reflex)) (VP (VBN initiated) (SBAR (WHADVP (WRB when)) (S (NP (DT the) (NN PG)) (VP (AUX was) (VP (VBN given) (ADVP (RB intravesically))))))))))))))))))))))))) (. .)))
7752389	5	(S1 (S (NP (DT The) (JJ present) (NNS results)) (ADVP (RB thus)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (JJ intra-arterial) (NNP Doc_7752389_1053_1057_Chemical)) (, ,) (VP (VBN given) (PP (IN near) (NP (DT the) (NN bladder)))) (, ,)) (VP (MD may) (VP (VB initiate) (NP (NP (NN micturition)) (PP (IN in) (NP (DT the) (JJ normal) (NN rat)))) (ADVP (RB chiefly)) (PP (IN by) (S (VP (ADVP (RB directly)) (VBG contracting) (NP (NP (DT the) (JJ smooth) (NN muscle)) (PP (IN of) (NP (DT the) (NN detrusor)))))))))))) (. .)))
7752389	6	(S1 (S (ADVP (RB However)) (, ,) (SBAR (WHADVP (WRB when)) (S (VP (VBN given) (ADVP (RB intravesically))))) (, ,) (NP (NNP Doc_7752389_1229_1233_Chemical)) (VP (MD may) (VP (VB stimulate) (NP (NN micturition)) (PP (IN by) (S (VP (VBG releasing) (NP (NNP Doc_7752389_1273_1284_Chemical)) (PP (IN from) (NP (NNS nerves))) (PP (IN in) (NP (NN and/or))) (PP (ADVP (RB immediately)) (IN below) (NP (DT the) (NN urothelium)))))))) (. .)))
7752389	7	(S1 (S (NP (DT These) (NNP Doc_7752389_1347_1358_Chemical)) (, ,) (PP (IN in) (NP (NN turn))) (, ,) (VP (VB initiate) (NP (NP (DT a) (NN micturition)) (ADJP (JJ reflex) (PP (IN by) (NP (NP (JJ stimulating) (NNS NK1)) (CC and) (NP (JJ NK2) (NNS receptors))))))) (. .)))
7752389	8	(S1 (S (S (NP (NN Doc_7752389_1437_1448_Chemical)) (VP (MD may) (, ,) (PP (IN via) (NP (NP (NN release)) (PP (IN of) (NP (NNP Doc_7752389_1469_1480_Chemical))))) (, ,) (VP (VB contribute) (PP (TO to) (NP (DT both) (NN urge)))))) (CC and) (S (NP (NNP Doc_7752389_1510_1531_Disease)) (VP (VBN seen) (PP (IN in) (NP (NP (JJ inflammatory) (NNS conditions)) (PP (IN of) (NP (DT the) (JJR lower) (NN urinary) (NN tract))))))) (. .)))
7785794	0	(S1 (NP (NP (NP (JJ Refractory) (NN Doc_7785794_11_28_Disease)) (CC and) (NP (JJ complete) (NN Doc_7785794_42_53_Disease))) (PP (IN after) (NP (NNP Doc_7785794_60_69_Chemical) (NNP SR) (CC and) (NNP Doc_7785794_77_87_Chemical) (NN treatment))) (. .)))
7785794	1	(S1 (S (NP (DT A) (NN case)) (VP (VBP report)) (. .)))
7785794	2	(S1 (S (NP (DT A) (JJ seventy-eight-year-old) (NN woman)) (VP (VBD presented) (PP (IN with) (NP (NP (JJ complete) (NNP Doc_7785794_169_180_Disease)) (CC and) (NP (JJ refractory) (NNP Doc_7785794_196_207_Disease)))) (PP (NP (CD two) (NNS days)) (IN after) (NP (NP (DT a) (JJ therapeutic) (NN dose)) (PP (IN of) (NP (JJ sustained-release) (NNP Doc_7785794_263_272_Chemical))) (PP (IN with) (NP (NP (JJ concomitant) (NN use)) (PP (IN of) (NP (NNP Doc_7785794_297_307_Chemical)))))))) (. .)))
7785794	3	(S1 (S (NP (DT The) (NN patient)) (VP (VBD continued) (S (VP (TO to) (VP (VB remain) (NP (NNP Doc_7785794_341_352_Disease)) (PP (PP (IN with) (NP (JJ complete) (NNP Doc_7785794_367_378_Disease))) (, ,) (RB even) (PP (IN with) (NP (NP (NP (JJ multiple) (NNS uses)) (PP (IN of) (NP (JJ intravenous) (NNP Doc_7785794_419_427_Chemical)))) (CONJP (RB as) (RB well) (IN as)) (NP (NP (JJ high) (NNS doses)) (PP (IN of) (NP (NN pressor) (NNS agents))) (PP (JJ such) (IN as) (NP (NP (NNP Doc_7785794_476_484_Chemical)) (CC and) (NP (NNP Doc_7785794_489_499_Chemical)))))))))))) (. .)))
7785794	4	(S1 (S (ADVP (RB However)) (, ,) (PP (ADVP (RB shortly)) (IN after) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (JJ intravenous) (NNP Doc_7785794_547_563_Chemical))))) (, ,) (NP (NP (DT the) (JJ refractory) (NN Doc_7785794_580_591_Disease)) (CC and) (NP (JJ complete) (NN Doc_7785794_605_616_Disease))) (VP (VBD resolved)) (. .)))
7791169	0	(S1 (NP (NP (JJ Protective) (NN effect)) (PP (IN of) (NP (NNP Doc_7791169_21_32_Chemical))) (PP (IN on) (NP (NNP Doc_7791169_36_48_Chemical))) (VP (VBN induced) (NP (NNP Doc_7791169_57_74_Disease)) (PP (IN in) (NP (JJ elderly) (NNS patients)))) (. .)))
7791169	1	(S1 (FRAG (S (VP (TO To) (VP (VB evaluate) (NP (NP (DT the) (JJ possible) (JJ protective) (NNS effects)) (PP (IN of) (NP (NNP Doc_7791169_154_165_Chemical))) (PP (IN on) (NP (NP (JJ renal) (NN function)) (PP (IN in) (NP (NP (VBN hospitalized) (JJ elderly) (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_7791169_230_242_Chemical)))))))))))) (. .)))
7791169	2	(S1 (S (NP (NP (NP (JJ Forty-five) (VBN hospitalized) (JJ elderly) (NNS patients)) (PRN (-LRB- -LRB-) (NP (NP (QP (CD >) (CD 65)) (NNS years)) (ADJP (JJ old))) (-RRB- -RRB-))) (SBAR (WHNP (WP who)) (S (VP (VBD required) (NP (NP (NN therapy)) (PP (IN with) (NP (NP (JJ nonsteroidal) (JJ antiinflammatory) (NNS drugs)) (PRN (-LRB- -LRB-) (NP (NNP NSAID)) (-RRB- -RRB-))))))))) (VP (AUX were) (ADVP (RB randomly)) (VP (VBN assigned) (S (VP (TO to) (VP (VB receive) (NP (NP (DT either) (NP (NP (NP (NNP Doc_7791169_422_434_Chemical)) (, ,) (NP (CD 150) (NN mg/day)) (PRN (-LRB- -LRB-) (NP (NNP Group) (NNP A)) (-RRB- -RRB-))) (, ,) (CC or) (NP (NNP Doc_7791169_461_473_Chemical) (CD 150))) (NN mg/day)) (PP (IN plus) (NP (NNP Doc_7791169_490_501_Chemical)))) (PP (IN at) (NP (NP (CD 0.6) (NN mg/day)) (-LRB- -LRB-) (NP (NNP Group) (NNP B)) (-RRB- -RRB-)))))))) (. .)))
7791169	3	(S1 (S (NP (NP (NP (NN Laboratory) (NNS variables)) (PP (IN of) (NP (NP (JJ renal) (NN function) (NN -LSB-serum) (NNP Doc_7791169_573_583_Chemical)) (, ,) (NP (NP (NN blood) (NNP Doc_7791169_591_595_Chemical) (NNP Doc_7791169_596_604_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP BUN)) (-RRB- -RRB-)))))) (CC and) (NP (NNS electrolytes) (NNS -RSB-))) (VP (AUX were) (VP (VBN evaluated) (PP (IN before) (NP (NP (NN initiation)) (PP (IN of) (NP (NP (NN therapy)) (CC and) (NP (NP (DT every) (CD 2) (NNS days)) (PRN (, ,) (PP (IN until) (NP (NP (NN termination)) (PP (IN of) (NP (DT the) (NN study))))) (-LRB- -LRB-) (NP (NP (DT a) (NN period)) (PP (IN of) (NP (QP (IN at) (JJS least) (CD 6)) (NNS days)))) (-RRB- -RRB-))))))))) (. .)))
7791169	4	(S1 (S (NP (NP (NN Response)) (PP (TO to) (NP (NN treatment)))) (VP (AUX was) (VP (VBN estimated) (PP (IN by) (NP (NP (DT the) (JJ visual) (NN analog) (NN scale)) (PP (IN for) (NP (NP (NN severity)) (PP (IN of) (NP (NNP Doc_7791169_832_836_Disease))))))))) (. .)))
7791169	5	(S1 (S (NP (NP (NP (JJ Forty-two) (NNS patients)) (VP (VBN completed) (NP (DT the) (NN study)))) (, ,) (NP (NP (CD 22)) (PP (IN in) (NP (NNP Group) (NNP A)))) (CC and) (NP (NP (CD 20)) (PP (IN in) (NP (NP (NNP Group) (NNP B.) (NNP BUN)) (CC and) (NP (NNP Doc_7791169_928_938_Chemical)))))) (VP (VBD increased) (PP (IN by) (NP (NP (NP (NP (NP (QP (CD >) (CD 50)) (NN %)) (PP (IN of) (NP (NP (NN baseline) (NNS levels)) (PP (IN in) (NP (CD 54)))))) (CC and) (NP (NP (CD 45) (NN %)) (PP (IN of) (NP (NNP Group))))) (NP (DT A) (NNS patients))) (, ,) (ADVP (RB respectively)))) (, ,) (PP (VBN compared) (PP (TO to) (NP (NP (QP (RB only) (CD 20) (CC and) (CD 10) (NN %))) (PP (IN of) (NP (NP (NNP Group) (NNP B) (NNS patients)) (PRN (-LRB- -LRB-) (NP (NNP p) (NNP <) (CD 0.05)) (-RRB- -RRB-)))))))) (. .)))
7791169	6	(S1 (S (NP (NP (JJ Doc_7791169_1086_1095_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_7791169_1097_1098_Chemical)) (-RRB- -RRB-)) (NN increment)) (PP (IN of) (NP (QP (CD 0.6) (CD mEq/l) (CC or) (JJR more))))) (VP (AUX was) (VP (VBN observed) (PP (PP (IN in) (NP (NP (CD 50) (NN %)) (PP (IN of) (NP (NNP Group) (NNP A))))) (, ,) (CC but) (PP (IN in) (NP (NP (QP (RB only) (CD 15)) (NN %)) (PP (IN of) (NP (NP (NNP Group) (NNP B) (NNS patients)) (PRN (-LRB- -LRB-) (NP (QP ($ p) (CD <) (CD 0.05))) (-RRB- -RRB-))))))))) (. .)))
7791169	7	(S1 (S (NP (NP (DT The) (JJ mean) (NNS increments)) (PP (IN in) (NP (NP (NNP BUN)) (, ,) (NP (NNP Doc_7791169_1239_1249_Chemical)) (, ,) (CC and) (NP (NNP K))))) (VP (AUX were) (VP (VBN reduced) (PP (IN by) (NP (NP (CD 63)) (, ,) (NP (CD 80)) (, ,) (CC and) (NP (CD 42) (NN %)) (, ,) (ADVP (RB respectively)))) (, ,) (SBAR (IN in) (S (NP (NNP Group) (NNP B) (NNS patients)) (PP (VBN compared) (PP (TO to) (NP (NP (NNP Group) (NNP A.) (NNP Response)) (PP (TO to) (NP (NN treatment)))))) (VP (AUX did) (RB not) (VP (VB differ) (ADVP (RB significantly)) (PP (IN between) (NP (DT the) (CD 2) (NNS groups))))))))) (. .)))
7791169	8	(S1 (S (NP (VBN Hospitalized) (JJ elderly) (NNS patients)) (VP (AUX are) (PP (IN at) (NP (NN risk))) (PP (IN for) (S (VP (VBG developing) (NP (JJ Doc_7791169_1487_1499_Chemical) (JJ related) (NN Doc_7791169_1508_1525_Disease)))))) (. .)))
7791169	9	(S1 (S (NP (NP (NN Addition)) (PP (IN of) (NP (NNP Doc_7791169_1539_1550_Chemical)))) (VP (MD can) (VP (VB minimize) (NP (DT this) (NN Doc_7791169_1569_1585_Disease)) (PP (IN without) (S (VP (VBG affecting) (NP (JJ Doc_7791169_1604_1608_Disease) (NN control))))))) (. .)))
7803371	0	(S1 (NP (NP (NP (NN Doc_7803371_0_23_Disease)) (PP (IN from) (NP (NP (JJ long-term) (NN abuse)) (PP (IN of) (NP (NNP Doc_7803371_48_64_Chemical)))))) (: :) (NP (DT a) (NN case) (NN report)) (. .)))
7803371	1	(S1 (S (NP (NP (NP (NNP Doc_7803371_81_97_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP DM)) (-RRB- -RRB-))) (, ,) (NP (NP (DT the) (JJ dextrorotatory) (NN isomer)) (PP (IN of) (NP (NNP Doc_7803371_133_160_Chemical)))) (, ,)) (VP (AUX is) (NP (NP (DT the) (JJ main) (NN ingredient)) (PP (IN in) (NP (NP (DT a) (NN number)) (PP (IN of) (NP (ADJP (RB widely) (JJ available)) (, ,) (JJ over-the-counter) (NNS antitussives))))))) (. .)))
7803371	2	(S1 (S (NP (NP (JJ Initial) (NNS studies)) (PRN (-LRB- -LRB-) (NP (NNP Bornstein) (CD 1968)) (-RRB- -RRB-))) (VP (VBD showed) (SBAR (IN that) (S (NP (PRP it)) (VP (VBN possessed) (NP (NP (DT no) (JJ respiratory) (NN suppressant) (NNS effects)) (CC and) (NP (DT no) (NN addiction) (NN liability))))))) (. .)))
7803371	3	(S1 (S (ADVP (RB Subsequently)) (, ,) (ADVP (RB however)) (, ,) (NP (NP (JJ several) (NNS articles)) (VP (VBG reporting) (NP (NP (NN abuse)) (PP (IN of) (NP (DT this) (NN drug)))))) (VP (AUX have) (VP (VBN appeared) (PP (IN in) (NP (DT the) (NN literature))))) (. .)))
7803371	4	(S1 (S (NP (DT The) (NN drug)) (VP (AUX is) (VP (VBN known) (S (VP (TO to) (VP (VB cause) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (NP (JJ acute) (JJ toxic) (NNS effects)) (, ,) (VP (VBG ranging) (PP (IN from) (NP (NP (NNP Doc_7803371_546_552_Disease) (, ,) (NNP Doc_7803371_554_566_Disease) (, ,) (NNP Doc_7803371_568_576_Disease) (, ,) (NNP Doc_7803371_578_584_Disease) (, ,)) (VBN slurred) (NN speech) (CC and) (NP (NNP Doc_7803371_605_614_Disease) (PRN (PP (TO to) (NP (NP (NN mood) (NNS changes)) (, ,) (NP (JJ perceptual) (NNS alterations)) (, ,) (NP (NN inattention)) (, ,) (NP (NN disorientation)) (CC and) (NP (NNP Doc_7803371_688_707_Disease)))) (-LRB- -LRB-) (NP (NNP Rammer) (FW et) (NNP al) (CD 1988)) (: ;) (NP (NP (NP (NP (NNP Katona)) (CC and) (NP (NNP Watson) (CD 1986))) (: ;) (NP (NP (NNP Isbell)) (CC and) (NP (NNP Fraser) (CD 1953))) (: ;) (NP (NNP Devlin) (FW et) (NNP al) (CD 1985)) (: ;) (NP (NNP McCarthy) (CD 1971)) (: ;) (NP (NNP Dodds)) (CC and) (NP (NNP Revai) (CD 1967))) (: ;) (NP (NNP Degkwitz) (CD 1964)) (: ;) (NP (NNP Hildebrand) (FW et) (NNP al) (CD 1989))) (-RRB- -RRB-)))))))))))))) (. .)))
7803371	5	(S1 (S (NP (EX There)) (VP (AUX have) (ADVP (RB also)) (VP (AUX been) (NP (NP (CD two) (JJ reported) (NNS fatalities)) (PP (IN from) (NP (JJ DM) (NNS overdoses)))) (PRN (-LRB- -LRB-) (NP (NNP Fleming) (CD 1986)) (-RRB- -RRB-)))) (. .)))
7803371	6	(S1 (S (ADVP (RB However)) (, ,) (NP (EX there)) (VP (AUX are) (NP (NP (DT no) (NNS reports)) (VP (VBG describing) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NN chronic) (NN abuse))))))) (. .)))
7803371	7	(S1 (S (NP (DT This) (NN report)) (VP (VBZ describes) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NNP Doc_7803371_1053_1076_Disease))) (VP (VBG resulting) (PP (IN from) (NP (NP (JJ prolonged) (NN use)) (PP (IN of) (NP (NN DM)))))))) (. .)))
783197	0	(S1 (NP (NP (NNS Effects)) (PP (IN of) (NP (NNP Doc_783197_11_18_Chemical))) (PP (IN on) (NP (NP (JJ myocardial) (JJ Doc_783197_33_39_Chemical) (NN supply)) (CC and) (NP (NP (NN demand)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ chronic) (NNP Doc_783197_83_106_Disease)))))))) (. .)))
783197	1	(S1 (NP (NP (DT A) (ADJP (ADJP (JJ hemodynamic)) (, ,) (ADJP (JJ volumetric)) (, ,) (CC and) (ADJP (JJ metabolic))) (NN study)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN without) (NP (NNP Doc_783197_175_188_Disease))))) (. .)))
783197	2	(S1 (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NNP Doc_783197_205_225_Chemical))) (PP (IN on) (NP (NP (JJ myocardial) (JJ Doc_783197_240_246_Chemical) (NN supply)) (CC and) (NP (NN demand))))) (VP (VP (AUX are) (PP (IN of) (NP (NP (JJ particular) (NN interest)) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (JJ obstructive) (NNP Doc_783197_323_346_Disease)))))))) (, ,) (CC but) (VP (AUX have) (RB not) (VP (AUX been) (VP (VBN measured) (ADVP (RB previously)) (PP (IN in) (NP (NN man))))))) (. .)))
783197	3	(S1 (S (NP (PRP We)) (VP (VBD assessed) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (NNP Doc_783197_421_428_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 0.015) (CD mg/kg)) (NN body) (NN weight)) (-RRB- -RRB-)))) (PP (IN on) (NP (NP (ADJP (JJ hemodynamic) (, ,) (JJ volumetric) (, ,) (CC and) (JJ metabolic)) (NNS parameters)) (PP (IN in) (NP (NP (CD 11) (NNS patients)) (PP (IN with) (NP (NP (JJ severe) (NN chronic) (NN Doc_783197_543_566_Disease)) (PP (IN without) (NP (JJ clinical) (NNP Doc_783197_584_608_Disease))))))))))) (. .)))
783197	4	(S1 (S (SBAR (IN Because) (S (NP (DT the) (NN protocol)) (VP (VP (AUX was) (ADVP (RB long))) (CC and) (VP (VBN involved) (NP (NP (NNS interventions)) (SBAR (WHNP (WDT which)) (S (VP (MD might) (VP (VB affect) (NP (DT the) (NNS determinations))))))))))) (, ,) (NP (PRP we)) (ADVP (RB also)) (VP (VBD studied) (PP (IN in) (NP (CD nine) (NNS patients))) (S (VP (VBG using) (NP (NP (DT an) (JJ identical) (NN protocol)) (SBAR (WHNP (IN except)) (S (NP (DT that) (NNP Doc_783197_779_786_Chemical) (NN administration)) (VP (AUX was) (VP (VBN omitted))))))))) (. .)))
783197	5	(S1 (S (NP (NP (JJ Left) (JJ ventricular) (JJ end-diastolic) (NN pressure)) (CC and) (NP (JJ left) (JJ ventricular) (JJ end-diastolic) (NN volume))) (VP (VBD fell) (PP (IN in) (NP (NP (DT each) (NN patient)) (VP (VBN given) (NP (NNP Doc_783197_924_931_Chemical))))) (, ,) (SBAR (RB even) (IN though) (S (NP (PRP they)) (VP (AUX were) (ADVP (RB initially)) (ADJP (JJ elevated)) (PP (IN in) (NP (QP (RB only) (CD two)) (NNS patients))))))) (. .)))
783197	6	(S1 (S (NP (JJ Left) (JJ ventricular) (JJ end-diastolic) (NN pressure)) (VP (VP (VBD fell) (PP (IN from) (NP (NP (CD 11.5+/-1.4)) (PRN (-LRB- -LRB-) (JJ mean+/-SE) (-RRB- -RRB-)))) (PP (TO to) (NP (NP (CD 5.6+/-0.9) (JJ mm) (NNP Hg)) (PRN (-LRB- -LRB-) (NP (NNP P) (QP (JJR less) (IN than) (CD 0.001))) (-RRB- -RRB-))))) (CC and) (VP (VBD left) (SBAR (S (NP (JJ ventricular) (JJ end-diastolic) (NN volume)) (VP (VBD fell) (PP (IN from) (NP (NP (QP (CD 100+/-17) (TO to) (CD 82+/-12)) (NNS ml/m2)) (PRN (-LRB- -LRB-) (NP (NNP P) (QP (JJR less) (IN than) (CD 0.01))) (-RRB- -RRB-)) (NP (CD 1) (NNP h)))) (SBAR (IN after) (S (NP (JJ Doc_783197_1215_1222_Chemical) (NN infusion)) (VP (AUX was) (VP (VBN completed)))))))))) (. .)))
783197	7	(S1 (S (NP (NP (DT The) (JJ maximum) (NN velocity)) (PP (IN of) (NP (JJ contractile) (NN element) (NN shortening)))) (VP (VP (VBD increased) (PP (IN from) (NP (CD 1.68+/-0.11) (NN ml/s))) (PP (TO to) (NP (NP (JJ 2.18+/-0.21) (NNS muscle-lengths/s)) (PRN (-LRB- -LRB-) (NP (NNP P) (QP (JJR less) (IN than) (CD 0.05))) (-RRB- -RRB-))))) (CC and) (VP (AUX is) (ADJP (JJ consistent) (PP (IN with) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NN contractility)))))))) (. .)))
783197	8	(S1 (S (NP (NP (DT No) (JJ significant) (NN change)) (PP (IN in) (NP (DT these) (NNS parameters)))) (VP (VBD occurred) (PP (IN in) (NP (DT the) (JJ control) (NNS patients)))) (. .)))
783197	9	(S1 (S (S (NP (NP (DT No) (JJ significant) (NN change)) (PP (IN in) (NP (JJ myocardial) (JJ Doc_783197_1550_1556_Chemical) (NN consumption)))) (VP (VBD occurred) (PP (IN after) (NP (NNP Doc_783197_1584_1591_Chemical) (NN administration))))) (CC but) (S (NP (DT this)) (VP (MD may) (VP (AUX be) (ADJP (JJ related) (PP (TO to) (NP (NP (DT a) (JJR greater) (NN decrease)) (PP (IN in) (NP (NP (JJ mean) (JJ arterial) (NN pressure)) (PP (IN in) (NP (DT the) (JJ ouabain) (NNS patients)))))))) (PP (IN than) (PP (IN in) (NP (DT the) (NN control) (NNS patients))))))) (. .)))
783197	10	(S1 (S (NP (PRP We)) (VP (VBP conclude) (NP (DT that)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ chronic) (NNP Doc_783197_1775_1798_Disease))) (SBAR (WHNP (WP who)) (S (VP (AUX are) (RB not) (PP (IN in) (NP (JJ clinical) (NNP Doc_783197_1823_1847_Disease) (NNP Doc_783197_1848_1891_Disease))) (PP (IN after) (NP (NNP Doc_783197_1898_1905_Chemical) (NN administration))) (SBAR (RB even) (WHADVP (WRB when)) (S (NP (PRP it)) (VP (AUX is) (ADVP (RB initially)) (ADJP (JJ normal))))))))))) (. .)))
783197	11	(S1 (S (SBAR (IN Though) (S (NP (DT this) (NN fall)) (VP (VP (MD would) (VP (AUX be) (VP (VBN associated) (PP (IN with) (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (NN wall) (NN tension)))))))) (, ,) (CC and) (, ,) (ADVP (RB therefore)) (, ,) (PP (IN of) (NP (JJ myocardial) (JJ Doc_783197_2055_2061_Chemical) (NN consumption)))))) (, ,) (NP (PRP it)) (VP (MD may) (RB not) (VP (AUX be) (PP (IN of) (NP (JJ sufficient) (NN magnitude))) (S (VP (TO to) (VP (VB prevent) (NP (NP (DT a) (JJ net) (NN increase)) (PP (IN in) (NP (JJ myocardial) (JJ Doc_783197_2153_2159_Chemical) (NN consumption))))))))) (. .)))
783197	12	(S1 (S (ADVP (RB Nevertheless)) (, ,) (NP (JJ compensatory) (NNS mechanisms)) (VP (VBP prevent) (NP (NP (DT a) (NN deterioration)) (PP (IN of) (NP (JJ resting) (JJ myocardial) (NN metabolism))))) (. .)))
7843916	0	(S1 (NP (NP (JJ Doc_7843916_0_13_Chemical-induced) (NN Doc_7843916_22_41_Disease)) (PP (IN in) (NP (JJ perfusion-cultured) (JJ human) (NNS eyes))) (. .)))
7843916	1	(S1 (S (NP (JJ Glucocorticoid) (NN administration)) (VP (MD can) (VP (VB lead) (PP (TO to) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NP (NNP Doc_7843916_146_165_Disease)) (CC and) (NP (NNP Doc_7843916_170_193_Disease)))) (PP (IN in) (NP (NP (DT a) (NN subset)) (PP (IN of) (NP (NP (DT the) (NN population)) (PP (IN through) (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (DT the) (JJ aqueous) (NN humor) (NN outflow) (NN facility))))))))))))) (. .)))
7843916	2	(S1 (S (NP (NP (DT The) (NN purpose)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB determine) (SBAR (IN whether) (S (NP (JJ glucocorticoid) (NN treatment)) (VP (MD can) (ADVP (RB directly)) (VP (VB affect) (NP (NP (DT the) (NN outflow) (NN facility)) (PP (IN of) (NP (JJ isolated) (, ,) (JJ perfusion-cultured) (JJ human) (NNS eyes)))))))))))) (. .)))
7843916	3	(S1 (S (NP (NP (DT The) (NNP anterior) (NNS segments)) (PP (IN of) (NP (NP (JJ human) (NN donor) (NNS eyes)) (PP (IN from) (NP (JJ regional) (NN eye) (NNS banks)))))) (VP (AUX were) (VP (VBN placed) (PP (IN in) (NP (DT a) (JJ constant) (NN flow) (, ,) (JJ variable) (NN pressure) (NN perfusion) (NN culture) (NN system))))) (. .)))
7843916	4	(S1 (S (NP (VBN Paired) (NNS eyes)) (VP (AUX were) (VP (VBN perfused) (PP (IN in) (NP (NP (JJ serum-free) (NNS media)) (PP (IN with) (NP (QP (CC or) (IN without) (CD 10)) (PRN (-LRB- -LRB-) (NP (NN -7)) (-RRB- -RRB-)) (NNP M) (NNP Doc_7843916_665_678_Chemical))))) (PP (IN for) (NP (CD 12) (NNS days))))) (. .)))
7843916	5	(S1 (S (NP (JJ Intraocular) (NN pressure)) (VP (AUX was) (VP (VBN monitored) (ADVP (RB daily)))) (. .)))
7843916	6	(S1 (S (PP (IN After) (NP (NN incubation))) (, ,) (NP (DT the) (NNS eyes)) (VP (AUX were) (RB morphologically) (VP (VBN characterized) (PP (IN by) (NP (NP (JJ light) (NN microscopy)) (, ,) (NP (NN transmission) (CC and) (VBG scanning) (NNP electron) (NN microscopy)) (, ,) (CC and) (NP (VBG scanning) (NN laser) (JJ confocal) (NN microscopy)))))) (. .)))
7843916	7	(S1 (S (NP (NP (DT A) (JJ significant) (NN increase)) (PP (IN in) (NP (NP (JJ intraocular) (NN pressure)) (VP (VBN developed) (PP (IN in) (NP (NP (CD 13)) (PP (IN of) (NP (NP (DT the) (CD 44) (NNS pairs)) (PP (IN of) (NP (NNS eyes))))))))))) (VP (VBD perfused) (PP (IN with) (NP (NNP Doc_7843916_1014_1027_Chemical))) (PP (IN with) (NP (NP (DT an) (JJ average) (NN pressure) (NN rise)) (PP (IN of) (NP (CD 17.5) (NN +/-))) (NP (CD 3.8) (NN mm)))) (NP (NNP Hg)) (PP (IN after) (NP (NP (CD 12) (NNS days)) (PP (IN of) (NP (NNP Doc_7843916_1097_1110_Chemical) (NN exposure)))))) (. .)))
7843916	8	(S1 (S (NP (NP (DT The) (JJ contralateral) (NN control) (NNS eyes)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX did) (RB not) (VP (VB receive) (NP (NN Doc_7843916_1175_1188_Chemical)))))) (, ,)) (VP (VBD maintained) (NP (DT a) (JJ stable) (NN intraocular) (NN pressure)) (PP (IN during) (NP (DT the) (JJ same) (NN period)))) (. .)))
7843916	9	(S1 (S (NP (NP (DT The) (NN outflow) (NN pathway)) (PP (IN of) (NP (DT the) (JJ untreated) (NNS eyes)))) (VP (VBD appeared) (ADJP (RB morphologically) (JJ normal))) (. .)))
7843916	10	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (DT the) (JJ Doc_7843916_1347_1360_Chemical-treated) (NNP Doc_7843916_1369_1386_Disease)) (VP (AUX had) (NP (NP (JJ thickened) (NN trabecular) (VBZ beams)) (, ,) (VP (VP (VBN decreased) (NP (NN intertrabecular) (NNS spaces))) (, ,) (VP (VBN thickened) (NP (JJ juxtacanalicular) (NN tissue))) (, ,) (VP (VBN activated) (NP (JJ trabecular) (NN meshwork) (NNS cells))) (, ,) (CC and) (VP (VBN increased) (NP (NP (NNS amounts)) (PP (IN of) (NP (JJ amorphogranular) (JJ extracellular) (NN material)))))) (, ,) (PP (RB especially) (PP (IN in) (NP (DT the) (JJ juxtacanalicular) (NN tissue))) (CC and) (PP (IN beneath) (NP (NP (DT the) (JJ endothelial) (NN lining)) (PP (IN of) (NP (NP (DT the) (NN canal)) (PP (IN of) (NP (NNP Schlemm)))))))))) (. .)))
7843916	11	(S1 (S (NP (DT The) (JJ Doc_7843916_1696_1709_Chemical-treated) (NN nonresponder) (NNS eyes)) (VP (VBD appeared) (S (VP (TO to) (VP (AUX be) (ADJP (RB morphologically) (JJ similar) (PP (TO to) (NP (DT the) (JJ untreated) (NNS eyes))))))) (, ,) (SBAR (IN although) (S (NP (JJ several) (JJ subtle) (JJ Doc_7843916_1822_1835_Chemical-induced) (NN morphologic) (NNS changes)) (VP (AUX were) (ADJP (JJ evident)))))) (. .)))
7843916	12	(S1 (S (NP (NP (JJ Doc_7843916_1890_1903_Chemical) (NN treatment)) (PP (IN of) (NP (JJ isolated) (, ,) (JJ perfusion-cultured) (JJ human) (NNS eyes)))) (VP (VBD led) (PP (TO to) (NP (NP (DT the) (NN generation)) (PP (IN of) (NP (NNP Doc_7843916_1982_2001_Disease))))) (PP (IN in) (NP (NP (QP (RB approximately) (CD 30)) (NN %)) (PP (IN of) (NP (DT the) (JJ Doc_7843916_2030_2043_Chemical-treated) (NNS eyes)))))) (. .)))
7843916	13	(S1 (S (NP (JJ Doc_7843916_2058_2065_Chemical) (NN treatment)) (VP (VBD resulted) (PP (IN in) (NP (NP (JJ morphologic) (NNS changes)) (PP (IN in) (NP (NP (DT the) (JJ trabecular) (NN meshwork)) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT those)) (VP (VBN reported) (PP (IN for) (NP (NP (NNP Doc_7843916_2165_2188_Disease)) (CC and) (NP (NNP Doc_7843916_2193_2212_Disease))))))))))))) (. .)))
7843916	14	(S1 (S (NP (DT This) (NN system)) (VP (MD may) (VP (VB provide) (NP (NP (DT an) (JJ acute) (NN model)) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (VP (TO to) (VP (VB study) (NP (NP (DT the) (JJ pathogenic) (NNS mechanisms)) (VP (VBN involved) (PP (IN in) (NP (NP (NNP Doc_7843916_2309_2325_Disease)) (CC and) (NP (NNP Doc_7843916_2330_2357_Disease))))))))))))) (. .)))
7880714	0	(S1 (S (NP (JJ Auditory) (NN disturbance)) (VP (VBN associated) (PP (IN with) (NP (JJ interscalene) (JJ brachial) (NN plexus) (NN block)))) (. .)))
7880714	1	(S1 (S (NP (PRP We)) (VP (VBD performed) (NP (NP (DT an) (JJ audiometric) (NN study)) (PP (IN in) (NP (NP (CD 20) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD underwent) (NP (NP (NN surgery)) (PP (IN of) (NP (DT the) (NN shoulder) (NN region)))) (PP (IN under) (NP (NP (DT an) (JJ interscalene) (JJ brachial) (NN plexus) (NN block)) (PRN (-LRB- -LRB-) (NP (NNP IBPB)) (-RRB- -RRB-))))))))))) (. .)))
7880714	2	(S1 (S (NP (NP (NN Doc_7880714_219_230_Chemical) (CD 0.75) (NN %)) (PP (IN with) (NP (NNP Doc_7880714_242_252_Chemical)))) (VP (AUX was) (VP (VBN given) (PP (VBN followed) (PP (IN by) (NP (NP (DT a) (JJ 24-hr) (JJ continuous) (NN infusion)) (PP (IN of) (NP (ADJP (CD 0.25) (NN %)) (NNP Doc_7880714_312_323_Chemical)))))))) (. .)))
7880714	3	(S1 (S (NP (NP (CD Three) (JJ audiometric) (NN threshold) (NNS measurements)) (PRN (-LRB- -LRB-) (NP (CD 0.25-18) (NN kHz)) (-RRB- -RRB-))) (VP (AUX were) (VP (VBN made) (: :) (NP (NP (NP (DT the) (JJ first)) (PP (IN before) (NP (NP (NNP IBPB)) (, ,) (NP (NP (NP (DT the) (JJ second) (NN 2-6)) (NP (NNP h))) (PP (IN after) (NP (NN surgery))))))) (CC and) (NP (NP (DT the) (JJ third)) (PP (IN on) (NP (NP (DT the) (JJ first) (NN day)) (PP (IN after) (NP (NN operation))))))))) (. .)))
7880714	4	(S1 (S (PP (IN In) (NP (CD four) (NNS patients))) (NP (NP (NNP Doc_7880714_510_528_Disease)) (PP (IN on) (NP (NP (DT the) (NN side)) (PP (IN of) (NP (DT the) (NN block)))))) (VP (AUX was) (VP (VBN demonstrated) (PP (IN after) (NP (NN operation))) (, ,) (PP (PP (IN in) (NP (CD three) (NNS measurements))) (PP (IN on) (NP (NP (DT the) (NN day)) (PP (IN of) (NP (NN surgery))))) (CC and) (PP (IN in) (NP (NP (CD one)) (PP (IN on) (NP (DT the) (JJ following) (NN day)))))))) (. .)))
7880714	5	(S1 (S (NP (NP (DT The) (NNS frequencies)) (SBAR (WHPP (IN at) (WHNP (WDT which))) (S (NP (DT the) (NN impairment)) (VP (VBD occurred) (VP (VBN varied) (PP (IN between) (NP (NNS patients)))))))) (: ;) (PP (IN in) (NP (CD one))) (NP (NP (RB only) (JJ low) (NNS frequencies)) (PRN (-LRB- -LRB-) (NP (CD 0.25-0.5) (NNS kHz)) (-RRB- -RRB-))) (VP (AUX were) (VP (VBN involved))) (. .)))
7880714	6	(S1 (S (NP (NP (DT The) (NN maximum) (NN change)) (PP (IN in) (NP (NN threshold)))) (VP (AUX was) (NP (CD 35) (NN dB)) (PP (IN at) (NP (NP (CD 6) (NN kHz)) (VP (VBN measured) (PP (IN at) (NP (NP (DT the) (NN end)) (PP (IN of) (NP (NP (DT the) (JJ continuous) (NN infusion)) (PP (IN of) (NP (NNP Doc_7880714_898_909_Chemical))))))))))) (. .)))
7880714	7	(S1 (S (NP (DT This) (NN patient)) (VP (AUX had) (NP (NP (NN hearing) (NN threshold) (NNS changes)) (PRN (-LRB- -LRB-) (NP (CD 15-20) (NNS dB)) (-RRB- -RRB-))) (PP (IN at) (NP (NP (JJ 6-10) (NNS kHz)) (PP (IN on) (NP (DT the) (JJ opposite) (NN side))))) (ADVP (RB also))) (. .)))
7880714	8	(S1 (S (NP (NNS IBPB)) (VP (MD may) (VP (VB cause) (NP (JJ transient) (NN Doc_7880714_1029_1049_Disease)) (PP (IN in) (NP (DT the) (JJ ipsilateral) (NN ear))) (, ,) (PP (ADVP (RB possibly)) (IN via) (NP (NP (DT an) (NN effect)) (PP (IN on) (NP (JJ sympathetic) (NN innervation))))))) (. .)))
7905523	0	(S1 (S (NP (NP (DT The) (NN safety) (CC and) (NN efficacy)) (PP (IN of) (NP (NP (NP (NN combination) (NNP Doc_7905523_39_63_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_7905523_65_73_Chemical)) (-RRB- -RRB-))) (CC and) (NP (NNP Doc_7905523_79_89_Chemical)))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NNP Doc_7905523_107_122_Disease)) (CC and) (NP (CD 200-500) (NNS CD4))))))) (VP (VBZ cells/mm3)) (. .)))
7905523	1	(S1 (S (NP (PRP We)) (VP (VBD conducted) (NP (NP (DT a) (JJ double-blind) (, ,) (JJ randomized) (NN phase) (NNP II) (NN study)) (SBAR (S (VP (TO to) (VP (VB evaluate) (NP (NP (DT the) (NN safety) (CC and) (NN activity)) (PP (IN of) (NP (NP (NN combination) (NN therapy)) (PP (IN with) (NP (NP (NP (NNP Doc_7905523_269_293_Chemical) (-LRB- -LRB-) (NNP Doc_7905523_295_303_Chemical) (-RRB- -RRB-)) (PRN (-LRB- -LRB-) (NP (DT an) (JJ alpha-glucosidase) (NN I) (NN inhibitor)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_7905523_344_354_Chemical) (CC versus) (NNP Doc_7905523_362_372_Chemical)) (ADVP (RB alone)))))))))))))) (. .)))
7905523	2	(S1 (S (NP (NP (NNS Patients)) (PP (IN with) (NP (NP (NP (QP (CD 200) (TO to) (CD 500)) (JJ CD4) (NNS cells/mm3)) (SBAR (WHNP (WP who)) (S (VP (VBD tolerated) (NP (CD <)))))) (CC or) (NP (NP (NP (SYM =)) (NP (CD 12) (NNS weeks))) (PP (IN of) (NP (JJ prior) (JJ Doc_7905523_458_468_Chemical) (NN therapy))))))) (VP (VBD received) (NP (NP (NP (NP (NP (NNP Doc_7905523_486_494_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 1000) (NN mg)) (NP (DT every) (CD 8) (NNP h))) (-RRB- -RRB-))) (CC and) (NP (NNP Doc_7905523_519_529_Chemical))) (PRN (-LRB- -LRB-) (NP (QP (CD 100) (CD mg)) (DT every) (CD 8) (NNP h)) (-RRB- -RRB-))) (CC or) (NP (NP (NNP Doc_7905523_552_562_Chemical)) (CC and) (NP (NN placebo))))) (. .)))
7905523	3	(S1 (S (NP (CD Sixty) (NNS patients)) (VP (VBD received) (NP (NP (NN combination) (NN therapy)) (CC and) (NP (NP (CD 58)) (, ,) (NP (NP (NN Doc_7905523_628_638_Chemical)) (CC and) (NP (NN placebo)))))) (. .)))
7905523	4	(S1 (S (NP (NP (NP (JJ Twenty-three) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 38) (NN %)) (-RRB- -RRB-))) (CC and) (NP (NP (CD 15)) (PRN (-LRB- -LRB-) (NP (CD 26) (NN %)) (-RRB- -RRB-)))) (, ,) (PP (IN in) (NP (NP (DT the) (NN combination)) (CC and) (NP (JJ Doc_7905523_717_727_Chemical) (NNS groups)))) (, ,) (ADVP (RB respectively)) (, ,) (VP (VBN discontinued) (NP (NP (NN therapy)) (PRN (-LRB- -LRB-) (NP (NNP p) (SYM =) (CD 0.15)) (-RRB- -RRB-)))) (. .)))
7905523	5	(S1 (S (NP (NP (DT The) (JJ mean) (JJ Doc_7905523_792_800_Chemical) (JJ steady-state) (NN trough) (NN level)) (PRN (-LRB- -LRB-) (NP (NP (CD 4.04) (NN +/-)) (NP (CD 0.99) (NNS micrograms/ml))) (-RRB- -RRB-))) (VP (AUX was) (PP (IN below) (NP (NP (DT the) (ADJP (IN in) (NN vitro)) (NN inhibitory) (NN concentration)) (PP (IN for) (NP (NP (JJ human) (JJ Doc_7905523_915_931_Disease) (NN virus)) (PRN (-LRB- -LRB-) (NP (NNP HIV)) (-RRB- -RRB-))))))) (. .)))
7905523	6	(S1 (S (NP (NP (DT The) (JJ mean) (NN increase)) (PP (IN in) (NP (NP (JJ CD4) (NNS cells)) (PP (IN at) (NP (NN week) (CD 4)))))) (VP (AUX was) (NP (NP (QP (CD 73.8) (NN cells/mm3) (CC and) (CD 52.4) (CD cells/mm3))) (PP (IN for) (NP (NP (DT the) (NN combination)) (CC and) (NP (JJ Doc_7905523_1048_1058_Chemical) (NNS groups))))) (, ,) (ADVP (RB respectively)) (PRN (-LRB- -LRB-) (NP (QP (CD p) (CD >)) (CD 0.36)) (-RRB- -RRB-))) (. .)))
7905523	7	(S1 (S (PP (IN For) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ prior) (JJ Doc_7905523_1116_1126_Chemical) (NN therapy))))) (, ,) (NP (NP (DT the) (JJ mean) (NN change)) (PP (IN in) (NP (JJ CD4) (NNS cells))) (PP (IN in) (NP (NP (DT the) (NN combination)) (CC and) (NP (JJ Doc_7905523_1188_1198_Chemical) (NNS groups))))) (VP (AUX was) (NP (NP (CD 63.7) (NN cells/mm3)) (CC and) (NP (NP (CD 4.9) (NN cells/mm3)) (PP (IN at) (NP (NN week))) (NP (QP (CD 8) (CC and) (CD 6.8) (NN cells/mm3) (CC and) (CD -45.1) (NN cells/mm3))))) (PP (IN at) (NP (NN week) (CD 16))) (, ,) (ADVP (RB respectively))) (. .)))
7905523	8	(S1 (S (NP (NP (DT The) (NN number)) (PP (IN of) (NP (NNS patients)))) (VP (PP (IN with) (NP (NN suppression))) (SBAR (IN of) (S (NP (NNP HIV) (CD p24) (NN antigenemia)) (PP (IN in) (NP (NP (DT the) (NN combination)) (CC and) (NP (NNP Doc_7905523_1403_1413_Chemical) (NNS groups)))) (VP (AUX was) (NP (NP (NP (NP (NP (NP (CD six)) (PRN (-LRB- -LRB-) (NP (CD 40) (NN %)) (-RRB- -RRB-))) (CC and) (NP (NP (CD two)) (PRN (-LRB- -LRB-) (NP (CD 11) (NN %)) (-RRB- -RRB-)))) (PP (IN at) (NP (NN week) (CD 4)))) (-LRB- -LRB-) (NP (NNP p) (SYM =) (CD 0.10)) (-RRB- -RRB-)) (CC and) (NP (NP (NP (CD five)) (PRN (-LRB- -LRB-) (NP (CD 45) (NN %)) (-RRB- -RRB-))) (CC and) (NP (NP (CD two)) (PRN (-LRB- -LRB-) (NP (CD 14) (NN %)) (-RRB- -RRB-))))) (PP (IN at) (NP (NP (NN week) (CD 24)) (PRN (-LRB- -LRB-) (NP (NNP p) (SYM =) (CD 0.08)) (-RRB- -RRB-)))) (, ,) (ADVP (RB respectively)))))) (. .)))
7905523	9	(S1 (S (NP (NP (NNP Doc_7905523_1536_1544_Disease)) (, ,) (NP (NNP Doc_7905523_1546_1556_Disease)) (, ,) (NP (NNP Doc_7905523_1558_1572_Disease)) (, ,) (CC and) (NP (NNP Doc_7905523_1578_1589_Disease))) (VP (AUX were) (ADJP (JJ common) (PP (IN for) (NP (NN combination) (NN recipients.)))) (PRN (-LRB- -LRB-) (NP (NP (JJ ABSTRACT)) (VP (VBN TRUNCATED) (PP (IN AT) (NP (CD 250) (NNS WORDS))))) (-RRB- -RRB-)))))
7910951	0	(S1 (S (VP (VBN Prolonged) (ADVP (NNP Doc_7910951_10_19_Disease) (JJ due)) (PP (TO to) (NP (NP (JJ nondepolarizing) (NN neuromuscular)) (VP (VBG blocking) (NP (NNS agents) (CC and) (NNP Doc_7910951_77_92_Chemical)))))) (. .)))
7910951	1	(S1 (S (NP (NP (DT The) (JJ long-term) (NN use)) (PP (IN of) (S (VP (VBG nondepolarizing) (NP (NP (JJ neuromuscular) (VBG blocking) (NNS agents)) (PRN (-LRB- -LRB-) (NP (NNP Doc_7910951_162_169_Chemical)) (-RRB- -RRB-))))))) (VP (AUX has) (ADVP (RB recently)) (VP (AUX been) (VP (VBN implicated) (PP (IN as) (NP (NP (DT a) (NN cause)) (PP (IN of) (NP (JJ prolonged) (NNP Doc_7910951_224_239_Disease))))) (, ,) (SBAR (IN although) (S (NP (NP (NP (DT the) (NN site)) (PP (IN of) (NP (DT the) (NN lesion)))) (CC and) (NP (DT the) (JJ predisposing) (NNS factors))) (VP (AUX have) (VP (AUX been) (ADJP (JJ unclear))))))))) (. .)))
7910951	2	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (NP (CD 3) (NNS patients)) (PRN (-LRB- -LRB-) (NP (NP (NN age)) (NP (CD 37-52) (NNS years))) (-RRB- -RRB-))) (PP (IN with) (NP (JJ acute) (NNP Doc_7910951_371_396_Disease))) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (JJ prolonged) (NN Doc_7910951_421_429_Disease)) (PP (VBG following) (NP (NP (DT the) (NN discontinuation)) (PP (IN of) (NP (NNP Doc_7910951_463_471_Chemical)))))))))) (. .)))
7910951	3	(S1 (S (NP (CD Two) (NNS patients)) (ADVP (RB also)) (VP (VBD received) (NP (JJ intravenous) (NNP Doc_7910951_512_527_Chemical))) (. .)))
7910951	4	(S1 (S (S (NP (JJ Renal) (NN function)) (VP (AUX was) (ADJP (JJ normal)))) (CC but) (S (NP (JJ hepatic) (NN function)) (VP (AUX was) (VP (VBN impaired) (PP (IN in) (NP (DT all) (NNS patients)))))) (, ,) (CC and) (S (NP (DT all)) (VP (AUX had) (NP (NN Doc_7910951_618_626_Disease)))) (. .)))
7910951	5	(S1 (S (NP (JJ Electrophysiologic) (NNS studies)) (VP (VBD revealed) (NP (NP (JJ low) (JJ amplitude) (NN compound) (NN motor) (NN action) (NNS potentials)) (, ,) (NP (JJ normal) (JJ sensory) (NNS studies)) (, ,) (CC and) (NP (NNS fibrillations)))) (. .)))
7910951	6	(S1 (S (NP (NP (JJ Repetitive) (NN stimulation)) (PP (IN at) (NP (CD 2) (NN Hz)))) (VP (VBD showed) (NP (DT a) (JJ decremental) (NN response)) (PP (IN in) (NP (CD 2) (NNS patients)))) (. .)))
7910951	7	(S1 (S (NP (NP (DT The) (NN serum) (JJ Doc_7910951_841_851_Chemical) (NN level)) (VP (VBN measured) (PP (IN in) (NP (CD 1) (NN patient))) (SBAR (NP (CD 14) (NNS days)) (IN after) (S (NP (DT the) (NN drug)) (VP (AUX had) (VP (AUX been) (VP (VBN discontinued)))))))) (VP (AUX was) (NP (CD 172) (NN ng/mL))) (. .)))
7910951	8	(S1 (S (NP (NP (DT A) (NN muscle) (NN biopsy)) (PP (IN in) (NP (DT this) (NN patient)))) (VP (VBD showed) (NP (NN Doc_7910951_979_1010_Disease))) (. .)))
7910951	9	(S1 (S (NP (NP (DT The) (NN Doc_7910951_1016_1024_Disease)) (PP (IN in) (NP (DT these) (NNS patients)))) (VP (AUX is) (ADJP (ADJP (ADJP (JJ due) (PP (TO to) (NP (NNP Doc_7910951_1053_1097_Disease)))) (PRN (-LRB- -LRB-) (ADVP (RBS most) (RB likely)) (ADJP (JJ due) (PP (TO to) (NP (NNP Doc_7910951_1118_1125_Chemical)))) (-RRB- -RRB-)) (CC and) (NN muscle)) (PRN (-LRB- -LRB-) (ADVP (RBS most) (RB likely)) (ADJP (JJ due) (PP (TO to) (NP (NNP Doc_7910951_1158_1173_Chemical)))) (-RRB- -RRB-)))) (. .)))
7910951	10	(S1 (S (NP (NP (NN Doc_7910951_1176_1195_Disease)) (CC and) (NP (NN Doc_7910951_1200_1208_Disease))) (VP (AUX are) (NP (JJ contributing) (NN risk) (NNS factors))) (. .)))
8012887	0	(S1 (NP (NP (NN Failure)) (PP (IN of) (NP (NN ancrod))) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (JJ Doc_8012887_38_45_Chemical-induced) (JJ arterial) (NN Doc_8012887_63_73_Disease))))) (. .)))
8012887	1	(S1 (S (NP (NP (DT The) (NN morbidity) (CC and) (NN mortality)) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_8012887_119_126_Chemical-induced) (NNP Doc_8012887_135_145_Disease))))) (VP (VBP remain) (ADJP (JJ high)) (PP (IN despite) (NP (JJ numerous) (JJ empirical) (NNS therapies)))) (. .)))
8012887	2	(S1 (S (S (NP (NNP Ancrod)) (VP (AUX has) (VP (AUX been) (VP (VBN used) (ADVP (RB successfully)) (PP (IN for) (NP (NN prophylaxis))) (PP (IN against) (NP (NP (NN development)) (PP (IN of) (NP (NNP Doc_8012887_269_279_Disease))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_8012887_297_304_Chemical) (VBN induced) (NN Doc_8012887_313_333_Disease))) (SBAR (WHNP (WP who)) (S (VP (VBP require) (NP (JJ brief) (NN reexposure)) (PP (TO to) (NP (NNP Doc_8012887_366_373_Chemical)))))))))))))) (, ,) (CC but) (S (NP (NP (PRP$ its) (NN success)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX have) (VP (VBN developed) (NP (DT the) (NNP Doc_8012887_426_436_Disease) (NN syndrome))))))))) (VP (AUX is) (RB not) (VP (ADVP (RB well)) (VBN defined)))) (. .)))
8012887	3	(S1 (S (NP (DT The) (NNS authors)) (VP (VBP present) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NP (NN failure)) (PP (IN of) (NP (NN ancrod) (NN treatment)))))) (PP (IN in) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (NNP Doc_8012887_543_550_Chemical-induced) (NNP Doc_8012887_559_569_Disease)))))) (. .)))
803783	0	(S1 (S (NP (NN Doc_803783_0_18_Disease)) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_803783_35_43_Chemical) (NN administration))) (PP (IN during) (NP (JJ saline-induced) (NN Doc_803783_81_89_Disease)))) (. .)))
803783	1	(S1 (S (NP (NP (CD Four) (NNS cases)) (PP (IN of) (NP (NNP Doc_803783_105_123_Disease))) (PP (IN in) (NP (NP (NN connection)) (PP (IN with) (NP (NNP Doc_803783_143_151_Chemical) (NN administration))))) (PP (IN during) (NP (JJ saline-induced) (NN Doc_803783_189_198_Disease)))) (VP (AUX are) (VP (VBN described))) (. .)))
803783	2	(S1 (S (NP (NP (DT The) (NN mechanism)) (PP (IN of) (NP (NNP Doc_803783_231_249_Disease)))) (VP (AUX is) (VP (VBN discussed) (PP (IN in) (NP (NP (NN regard)) (PP (TO to) (NP (DT these) (NNS cases))))))) (. .)))
803783	3	(S1 (S (NP (NP (JJ Doc_803783_289_297_Chemical) (NN administration)) (PP (IN during) (NP (JJ midtrimester-induced) (NNP Doc_803783_341_350_Disease)))) (VP (AUX is) (VP (VBN advocated) (SBAR (RB only) (IN if) (S (NP (PRP it)) (VP (MD can) (VP (AUX be) (VP (VP (VBN carried) (PRT (RP out)) (PP (IN under) (NP (NP (JJ careful) (NNS observations)) (PP (IN of) (NP (DT an) (JJ alert) (NN nursing) (NN staff))))) (, ,) (ADJP (JJ aware) (PP (IN of) (NP (NP (DT the) (NNS symptoms)) (PP (IN of) (NP (NNP Doc_803783_473_491_Disease))))))) (CC and) (VP (VBN instructed) (S (VP (TO to) (VP (VP (VB watch) (NP (DT the) (NN diuresis))) (CC and) (VP (VB report) (NP (NP (JJ such) (JJ early) (NNS signs)) (PP (IN of) (NP (DT the) (NN syndrome)))))))) (PP (IN as) (NP (NP (NNP Doc_803783_576_584_Disease)) (, ,) (NP (JJ muscular) (NNP Doc_803783_595_607_Disease)) (, ,) (CC or) (NP (NNP Doc_803783_612_621_Disease)))))))))))) (. .)))
803783	4	(S1 (S (NP (DT The) (NNP Doc_803783_627_635_Chemical)) (VP (MD should) (VP (VP (AUX be) (VP (VBN given) (ADVP (RB only)) (PP (IN in) (NP (NNP Ringers) (NNP Doc_803783_668_675_Chemical))))) (CC or) (, ,) (ADVP (RB alternately)) (, ,) (PP (IN in) (NP (NP (NNP Ringers) (NNP Doc_803783_704_711_Chemical)) (CC and) (NP (NP (DT a) (CD 5)) (PP (IN per) (NP (NP (NN cent) (NN Doc_803783_729_737_Chemical)) (CC and) (NP (NN water) (NNS solutions))))))))) (. .)))
803783	5	(S1 (S (S (NP (DT The) (JJ urinary) (NN output)) (VP (MD should) (VP (AUX be) (VP (VBN monitored))))) (CC and) (S (NP (NP (DT the) (NNP Doc_803783_806_814_Chemical) (NN administration) (VBN discontinued)) (CC and) (NP (DT the) (JJ serum) (NNS electrolytes))) (VP (VBD checked) (SBAR (IN if) (S (NP (DT the) (JJ urinary) (NN output)) (VP (VBZ decreases)))))) (. .)))
803783	6	(S1 (S (NP (DT The) (NNP Doc_803783_915_923_Chemical)) (VP (MD should) (RB not) (VP (AUX be) (VP (VBN administered) (PP (IN in) (NP (NP (NN excess)) (PP (IN of) (NP (CD 36) (NNS hours)))))))) (. .)))
803783	7	(S1 (S (SBAR (IN If) (S (NP (DT the) (NN patient)) (VP (AUX has) (RB not) (VP (VBN aborted) (PP (IN by) (NP (RB then))))))) (NP (DT the) (NNP Doc_803783_1017_1025_Chemical)) (VP (MD should) (VP (AUX be) (VP (VBN discontinued) (PP (IN for) (NP (QP (CD 10) (TO to) (CD 12)) (NNS hours))) (PP (IN in) (NP (NN order))) (S (VP (TO to) (VP (VP (VB perform) (NP (NN electrolyte) (NNS determinations))) (CC and) (VP (VB correct) (NP (DT any) (JJ electrolyte) (NN imbalance))))))))) (. .)))
804391	0	(S1 (S (NP (NP (NP (JJ Light) (NN chain) (NN Doc_804391_12_23_Disease)) (CC and) (NP (JJ cellular) (JJ mediated) (NN immunity))) (PP (IN in) (NP (NNP Doc_804391_58_66_Chemical)))) (VP (VBD treated) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_804391_89_101_Disease))))) (. .)))
804391	1	(S1 (S (NP (JJ Light) (NN chain) (NN Doc_804391_115_126_Disease)) (VP (AUX was) (VP (VBN found) (PP (IN in) (NP (NP (QP (CD 9) (IN of) (CD 17)) (JJ Doc_804391_148_160_Disease) (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_804391_183_191_Chemical)))))))) (. .)))
804391	2	(S1 (S (NP (NP (NP (JJ Concomitant) (NN assay)) (PP (IN of) (NP (NP (JJ cellular) (JJ mediated) (NN immunity)) (PP (IN in) (NP (NP (DT these) (NNS patients)) (VP (VBG using) (NP (NN skin) (NN test) (NN antigen)))))))) (CC and) (NP (NP (DT a) (NN lymphokine)) (PP (IN in) (NP (NN vitro) (NN test))))) (VP (VBD provided) (NP (NP (NNS results)) (SBAR (WHNP (WDT that)) (S (VP (AUX were) (ADJP (JJ different))))))) (. .)))
804391	3	(S1 (S (NP (NP (NN Response)) (PP (TO to) (NP (NNP Varidase) (NN skin) (NN test) (NN antigen)))) (VP (AUX was) (ADJP (JJ negative) (SBAR (IN for) (S (S (NP (DT all) (CD eight) (NNP Doc_804391_418_430_Disease) (NNS patients)) (VP (VBN tested))) (, ,) (CC but) (S (NP (EX there)) (VP (VBN occurred) (NP (NP (DT a) (NN hyper-responsiveness)) (PP (IN of) (NP (NP (DT the) (NNS lymphocytes)) (PP (IN of) (NP (DT these) (CD eight) (NNS patients))))) (SBAR (S (VP (TO to) (VP (VB phytomitogen) (PRN (-LRB- -LRB-) (NP (NNP Doc_804391_550_555_Chemical)) (-RRB- -RRB-))))))))) (. .))) (RB as) (PP (RB well) (IN as) (IN of) (NP (NP (DT those)) (PP (IN of) (NP (CD seven) (JJ other) (NNP Doc_804391_593_604_Disease) (NNS patients))))))) (. .)))
804391	4	(S1 (S (NP (DT This) (JJ last) (NN finding)) (VP (MD may) (VP (AUX be) (ADJP (VBN related) (PP (TO to) (NP (NP (NN time)) (PP (IN of) (S (VP (VBG testing) (NP (NP (NN and/or) (JJ endogenous) (NN serum) (VBG binding)) (PP (IN of) (NP (NNP Doc_804391_702_710_Chemical))) (SBAR (WHNP (WDT which)) (S (VP (MD could) (VP (AUX have) (VP (VBD inhibited) (NP (CD mitogen) (NN activity)) (PP (IN for) (NP (DT the) (NN lymphocyte))))))))))))))))) (. .)))
8045270	0	(S1 (NP (NP (NN Doc_8045270_0_7_Chemical)) (: :) (NP (NP (DT a) (JJ novel) (JJ selective) (NNP Doc_8045270_27_36_Chemical) (NNP A2A) (NN receptor) (NN antagonist)) (PP (IN with) (NP (JJ anticataleptic) (NN activity)))) (. .)))
8045270	1	(S1 (S (NP (NN Doc_8045270_91_98_Chemical)) (VP (AUX is) (NP (DT a) (JJ novel) (JJ selective) (NNP Doc_8045270_120_129_Chemical) (NNP A2A) (NN receptor) (NN antagonist))) (. .)))
8045270	2	(S1 (S (NP (NP (JJ Oral) (NN administration)) (PP (IN of) (NP (NP (NNP Doc_8045270_178_185_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 2.5) (, ,) (CD 10.0) (CC and) (CD 30.0) (NN mg/kg)) (-RRB- -RRB-))))) (ADVP (RB significantly)) (VP (VBD ameliorated) (NP (NP (DT the) (JJ Doc_8045270_243_253_Disease) (NNS responses)) (VP (VBN induced) (PP (IN by) (NP (NP (NN intracerebroventricular) (NN administration)) (PP (IN of) (NP (NP (DT an) (NNP Doc_8045270_320_329_Chemical) (NNP A2A) (NN receptor) (NN agonist)) (, ,) (NP (NP (NNP Doc_8045270_352_361_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 10) (NNS micrograms)) (-RRB- -RRB-))) (, ,))))))) (PP (IN in) (NP (DT a) (JJ dose-dependent) (NN manner)))) (. .)))
8045270	3	(S1 (S (NP (NN Doc_8045270_407_414_Chemical)) (ADVP (RB also)) (VP (VBD reduced) (NP (NP (DT the) (NN Doc_8045270_432_441_Disease)) (VP (VBN induced) (PP (PP (IN by) (NP (NP (NNP Doc_8045270_453_464_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 1) (CD mg/kg)) (NN i.p.)) (-RRB- -RRB-)))) (CC and) (PP (IN by) (NP (NP (NNP Doc_8045270_487_496_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 5) (CD mg/kg)) (NN i.p.)) (-RRB- -RRB-)))))))) (. .)))
8045270	4	(S1 (S (NP (DT These) (JJ anticataleptic) (NNS effects)) (VP (AUX were) (VP (VBN exhibited) (S (VP (NN dose) (ADVP (RB dependently)) (PP (IN at) (NP (NNS doses))) (PP (IN from) (NP (QP (CD 0.625) (CC and) (CD 2.5) (CD mg/kg)) (NNS p.o.))) (, ,) (ADVP (RB respectively)))))) (. .)))
8045270	5	(S1 (S (ADVP (RB Moreover)) (, ,) (NP (NP (NNP Doc_8045270_638_645_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 0.625) (CD mg/kg)) (NN p.o.)) (-RRB- -RRB-))) (VP (VBD potentiated) (NP (NP (DT the) (JJ anticataleptic) (NNS effects)) (PP (IN of) (NP (NP (DT a) (JJ subthreshold) (NN dose)) (PP (IN of) (NP (NP (NP (NNP Doc_8045270_730_758_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (NNP Doc_8045270_760_766_Chemical)) (: ;) (NP (CD 25) (JJ mg/kg) (NNS i.p.))) (-RRB- -RRB-))) (CC plus) (NP (NP (NNP Doc_8045270_788_799_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 6.25) (JJ mg/kg) (NNS i.p.)) (-RRB- -RRB-))))))))) (. .)))
8045270	6	(S1 (S (NP (DT These) (NNS results)) (VP (VBD suggested) (SBAR (SBAR (IN that) (S (NP (NNP Doc_8045270_848_855_Chemical)) (VP (AUX is) (NP (DT a) (ADJP (RB centrally) (JJ active)) (NNP Doc_8045270_878_887_Chemical) (NNP A2A) (NN receptor) (NN antagonist))))) (CC and) (SBAR (IN that) (S (NP (NP (DT the) (JJ dopaminergic) (NN function)) (PP (IN of) (NP (DT the) (JJ nigrostriatal) (NN pathway)))) (VP (AUX is) (VP (VBN potentiated) (PP (IN by) (NP (NNP Doc_8045270_994_1003_Chemical) (NNP A2A) (NN receptor) (NNS antagonists))))))))) (. .)))
8045270	7	(S1 (S (ADVP (RB Furthermore)) (, ,) (NP (NNP Doc_8045270_1043_1050_Chemical)) (VP (MD may) (VP (AUX be) (NP (DT a) (JJ useful) (NN drug)) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NNP Doc_8045270_1092_1104_Disease))))))) (. .)))
8106150	0	(S1 (NP (NP (NN Effect)) (PP (IN of) (NP (JJ nondopaminergic) (NNS drugs))) (PP (IN on) (NP (NP (NNP Doc_8106150_35_41_Chemical-induced) (NNP Doc_8106150_50_61_Disease)) (PP (IN in) (NP (JJ Doc_8106150_65_69_Chemical-treated) (NNS monkeys))))) (. .)))
8106150	1	(S1 (S (NP (NP (DT A) (NN group)) (PP (IN of) (NP (CD four) (NNS monkeys)))) (VP (AUX was) (VP (VBN rendered) (NP (NNP Doc_8106150_124_136_Disease)) (PP (IN with) (NP (DT the) (NN toxin) (NN Doc_8106150_152_156_Chemical))))) (. .)))
8106150	2	(S1 (S (NP (PRP They)) (VP (AUX were) (ADVP (RB then)) (VP (VBN treated) (ADVP (RB chronically)) (PP (IN with) (NP (NNP Doc_8106150_198_204_Chemical/Doc_8106150_205_216_Chemical) (CD 50/12.5))) (SBAR (IN mg/kg) (S (VP (VBN given) (ADVP (RB orally) (RB daily)) (PP (IN for) (NP (CD 2) (NNS months)))))))) (. .)))
8106150	3	(S1 (S (S (NP (DT This) (NN dose)) (VP (VBD produced) (NP (DT a) (JJ striking) (NN antiparkinsonian) (NN effect)))) (, ,) (CC but) (S (NP (DT all) (NNS animals)) (VP (VBD manifested) (NP (NN Doc_8106150_346_356_Disease)))) (. .)))
8106150	4	(S1 (S (NP (NP (DT A) (NN series)) (PP (IN of) (NP (NP (NNS agents)) (VP (VBG acting) (ADVP (RB primarily)) (PP (IN on) (NP (NP (NNS neurotransmitters)) (ADJP (JJ other) (PP (IN than) (NP (NNP Doc_8106150_426_434_Chemical)))))))))) (VP (AUX were) (ADVP (RB then)) (VP (VBN tested) (PP (IN in) (NP (NN combination))) (PP (IN with) (NP (NNP Doc_8106150_472_478_Chemical))) (S (VP (TO to) (VP (VB see) (SBAR (IN if) (S (NP (DT the) (NNP Doc_8106150_493_503_Disease) (NNS movements)) (VP (MD would) (VP (AUX be) (VP (VBN modified))))))))))) (. .)))
8106150	5	(S1 (S (NP (NP (JJ Several) (NNS drugs)) (, ,) (PP (VBG including) (NP (NNP Doc_8106150_558_567_Chemical) (, ,) (NNP Doc_8106150_569_582_Chemical) (, ,) (NNP Doc_8106150_584_596_Chemical) (, ,) (NNP Doc_8106150_598_604_Chemical) (, ,) (NNP Doc_8106150_606_617_Chemical) (, ,) (CC and) (NNP Doc_8106150_623_629_Chemical))) (, ,)) (VP (VP (ADVP (RB markedly)) (VBD reduced) (NP (DT the) (JJ Doc_8106150_652_662_Disease) (NNS movements))) (CC but) (VP (PP (IN at) (NP (NP (DT the) (NN cost)) (PP (IN of) (NP (NP (DT a) (NN return)) (PP (IN of) (NP (JJ Doc_8106150_704_716_Disease) (NN symptomatology))))))))) (. .)))
8106150	6	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (NNP Doc_8106150_742_751_Chemical)) (CC and) (NP (NNP Doc_8106150_756_766_Chemical))) (VP (VBD reduced) (ADVP (RB predominantly)) (NP (DT the) (JJ Doc_8106150_793_803_Disease) (NNS movements))) (. .)))
8106150	7	(S1 (S (NP (NN Doc_8106150_815_823_Chemical)) (VP (AUX was) (ADVP (RB also)) (ADJP (JJ useful)) (PP (IN in) (NP (NP (CD one) (NN monkey)) (PP (IN against) (NP (NP (DT a) (ADJP (RBR more) (JJ Doc_8106150_869_877_Disease)) (NN form)) (PP (IN of) (NP (NNP Doc_8106150_886_896_Disease)))))))) (. .)))
8106150	8	(S1 (S (NP (NN Doc_8106150_898_906_Chemical)) (VP (VBD converted) (NP (DT the) (JJ Doc_8106150_921_929_Disease) (NNS movements)) (PP (IN into) (NP (NN Doc_8106150_945_951_Disease)))) (. .)))
8111719	0	(S1 (NP (NNP Doc_8111719_0_14_Disease) (CC and) (NNP Doc_8111719_19_29_Chemical-induced) (NNP Doc_8111719_38_51_Disease) (. .)))
8111719	1	(S1 (S (NP (NP (NN Doc_8111719_65_79_Disease)) (PP (IN as) (NP (NP (DT a) (NN symptom)) (PP (IN of) (NP (JJ central) (NNP Doc_8111719_104_117_Disease)))))) (VP (AUX are) (NP (NP (DT a) (ADJP (ADJP (VBN known)) (CC but) (ADJP (RB poorly) (VBN described))) (NN side) (NN effect)) (PP (IN of) (NP (NNP Doc_8111719_166_176_Chemical))))) (. .)))
8111719	2	(S1 (S (NP (NP (JJS Most) (NNS cases)) (PP (IN of) (NP (NNP Doc_8111719_192_202_Chemical-induced) (NNP Doc_8111719_211_225_Disease)))) (VP (AUX have) (VP (AUX been) (VP (VBN reported) (PP (IN with) (NP (JJ other) (JJ mental) (NN status) (NNS changes)))))) (. .)))
8111719	3	(S1 (S (NP (DT The) (NNS authors)) (VP (VBD interviewed) (NP (CD six) (NNS persons)) (PP (IN with) (NP (NNP Doc_8111719_329_339_Chemical-induced) (NNP Doc_8111719_348_362_Disease))) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (DT a) (JJ clear) (NN sensorium)))))) (. .)))
8111719	4	(S1 (S (NP (DT All) (NNS patients)) (VP (AUX were) (S (VP (VBG receiving) (NP (JJ high-dose) (NN Doc_8111719_439_449_Chemical)) (PP (IN as) (NP (NP (NN part)) (PP (IN of) (NP (PRP$ their) (NN bone) (NN marrow) (NN transplant) (NN procedure)))))))) (. .)))
8111719	5	(S1 (S (NP (NN Doc_8111719_510_524_Disease)) (VP (VBD occurred) (ADVP (RB only)) (SBAR (WHADVP (WRB when)) (S (NP (NP (DT the) (NN patient) (POS 's)) (NNS eyes)) (VP (VP (AUX were) (ADJP (JJ closed))) (CC and) (PRN (, ,) (PP (IN in) (NP (NP (DT all)) (PP (CC but) (NP (CD one) (NN case))))) (, ,)) (VP (AUX were) (VP (VBN reported) (PP (IN as) (ADJP (ADJP (JJ disturbing)) (CC or) (ADJP (JJ frightening)))))))))) (. .)))
8111719	6	(S1 (S (NP (NP (NN Underreporting)) (PP (IN of) (NP (DT these) (NNP Doc_8111719_669_683_Disease))) (PP (IN by) (NP (NNS patients)))) (VP (AUX is) (ADJP (JJ likely))) (. .)))
8111719	7	(S1 (S (NP (NN Doc_8111719_720_734_Disease)) (VP (MD may) (VP (AUX be) (NP (NP (DT the) (JJ sole) (CC or) (JJ first) (NN manifestation)) (PP (IN of) (NP (NN Doc_8111719_777_790_Disease)))))) (. .)))
8111719	8	(S1 (S (NP (DT The) (NN incidence)) (VP (MD may) (VP (AUX be) (ADJP (NP (NP (NN dose)) (CC and) (NP (NN infusion-time))) (VBN related)))) (. .)))
8111719	9	(S1 (S (NP (DT The) (NN clinician)) (VP (MD should) (VP (AUX be) (VP (VBD alerted) (PP (IN for) (NP (NP (JJ possible) (JJ Doc_8111719_890_900_Chemical-induced) (NN Doc_8111719_909_923_Disease)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VB occur) (SBAR (IN without) (S (NP (NP (JJ other) (NNS signs)) (PP (IN of) (NP (NNP Doc_8111719_964_977_Disease.) (`` ``) (NNP Eyes-closed) ('' '') (NN hallucinatory) (NNS experiences)))) (VP (VBP appear) (S (VP (TO to) (VP (AUX be) (NP (NP (DT an) (JJ unusual) (NN feature)) (PP (IN of) (NP (DT this) (NN presentation))))))))))))))))))) (. .)))
8111719	10	(S1 (S (NP (NP (NNS Patients)) (ADJP (JJ anxious) (PP (IN about) (NP (DT this) (NN experience))))) (VP (VB respond) (ADVP (RB well)) (PP (TO to) (NP (NP (NN support)) (CC and) (NP (NN education)))) (PP (IN about) (NP (DT this) (NN occurrence)))) (. .)))
8111719	11	(S1 (S (NP (NP (JJ Optimal) (JJ pharmacologic) (NN management)) (PP (IN of) (NP (JJ disturbed) (NNS patients)))) (VP (AUX is) (ADJP (JJ unclear))) (. .)))
8111719	12	(S1 (S (SBAR (IN If) (S (NP (NNP Doc_8111719_1243_1252_Disease)) (VP (VBZ becomes) (ADJP (JJ marked))))) (, ,) (NP (NP (JJ high-potency) (NNS neuroleptics)) (PRN (-LRB- -LRB-) (FW i.e.) (, ,) (NP (NNP Doc_8111719_1302_1313_Chemical)) (-RRB- -RRB-))) (VP (MD may) (VP (AUX be) (ADJP (JJ effective)))) (. .)))
8251368	0	(S1 (FRAG (NP (JJ Photodistributed) (JJ Doc_8251368_17_27_Chemical-induced) (JJ facial) (NN Doc_8251368_43_57_Disease)) (. .)))
8251368	1	(S1 (S (PP (NP (CD Five) (NNS months)) (IN after) (S (VP (VBG starting) (NP (NP (NNP Doc_8251368_86_96_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_8251368_98_104_Chemical)) (-RRB- -RRB-)))))) (, ,) (NP (CD two) (NNS patients)) (VP (VBD developed) (NP (NP (JJ photodistributed) (JJ facial) (NN Doc_8251368_154_168_Disease)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD became) (ADJP (RBR more) (JJ noticeable)) (PP (IN with) (NP (NN time)))))))) (. .)))
8251368	2	(S1 (S (NP (DT Neither) (NN patient)) (VP (VBD complained) (PP (IN of) (NP (NP (NN photosensitivity)) (CC or) (NP (NN Doc_8251368_260_268_Disease))))) (. .)))
8251368	3	(S1 (S (NP (DT Both) (NNS patients)) (VP (VBD reported) (NP (DT a) (JJ significant) (NN cosmetic) (NN improvement)) (PP (IN after) (S (VP (VBG discontinuing) (NP (DT the) (NN drug)))))) (. .)))
8251368	4	(S1 (S (NP (NN One)) (VP (VBD commenced) (NP (DT the) (ADJP (RB closely) (JJ related)) (NN drug) (NN Doc_8251368_397_407_Chemical)) (ADVP (NP (CD 3) (NNS years)) (RB later)) (, ,) (PP (IN with) (NP (NP (NN recurrence)) (PP (IN of) (NP (NNP Doc_8251368_442_456_Disease)))))) (. .)))
8251368	5	(S1 (S (NP (NP (DT The) (NN photodistribution)) (PP (IN of) (NP (DT the) (NNP Doc_8251368_487_501_Disease)))) (VP (VBZ suggests) (NP (DT a) (JJ significant) (NN drug/light) (NN interaction))) (. .)))
8267029	0	(S1 (NP (NP (JJ Doc_8267029_0_13_Chemical-induced) (NN Doc_8267029_22_60_Disease)) (PP (IN in) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (NNP Doc_8267029_79_99_Disease))))) (. .)))
8267029	1	(S1 (S (NP (NP (DT A) (JJ 67-year-old) (NN woman)) (PP (IN with) (NP (NNP Doc_8267029_126_146_Disease)))) (VP (VBD presented) (NP (NP (NNP Doc_8267029_157_195_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_8267029_197_201_Disease)) (-RRB- -RRB-))) (PP (IN after) (NP (NP (CD 5) (NNS months)) (PP (IN of) (NP (NNP Doc_8267029_221_236_Chemical) (PRN (-LRB- -LRB-) (NP (CD 250) (NN mg/day)) (-RRB- -RRB-)) (NN treatment)))))) (. .)))
8267029	2	(S1 (S (NP (JJ Light) (JJ microscopy) (NN study)) (VP (VBD showed) (NP (JJ severe) (NN Doc_8267029_298_316_Disease)) (PP (IN with) (NP (NN crescent) (NN formation))) (PP (IN in) (NP (NP (NP (CD 60) (NN %)) (PP (IN of) (NP (DT the) (NNS glomeruli)))) (CC and) (NP (NP (NN infiltration)) (PP (IN of) (NP (JJ inflammatory) (NNS cells)))))) (PP (IN in) (NP (NP (DT the) (NN wall)) (PP (IN of) (NP (DT an) (NN arteriole)))))) (. .)))
8267029	3	(S1 (S (NP (NN Immunofluorescence)) (VP (VBD revealed) (NP (CD scanty) (JJ granular) (NNP IgG) (, ,) (NNP IgA) (CC and) (NNP C3) (NNS deposits)) (PP (IN along) (NP (NP (DT the) (JJ capillary) (NNS walls)) (CC and) (NP (NN mesangium))))) (. .)))
8267029	4	(S1 (S (NP (DT The) (NN patient)) (VP (AUX was) (VP (VBN treated) (PP (IN with) (NP (NP (JJ Doc_8267029_572_579_Chemical) (NN pulse)) (, ,) (NP (NN plasmapheresis)) (, ,) (NP (NN Doc_8267029_603_619_Chemical)) (CC and) (NP (NN antiplatelet) (NNS agents)))))) (. .)))
8267029	5	(S1 (S (NP (NP (DT A) (JJ complete) (NN recovery)) (PP (IN of) (NP (JJ renal) (NN function)))) (VP (AUX was) (VP (VBN achieved) (PP (IN in) (NP (DT a) (JJ few) (NNS weeks))))) (. .)))
8267029	6	(S1 (S (NP (NP (DT This) (JJ new) (NN case)) (PP (IN of) (NP (NP (NNP Doc_8267029_729_733_Disease)) (PP (IN in) (NP (NP (DT the) (NN course)) (PP (IN of) (NP (JJ Doc_8267029_751_766_Chemical) (NN treatment)))))))) (VP (VBZ emphasizes) (NP (NP (DT the) (NN need)) (PP (IN for) (NP (NP (NP (JJ frequent) (NN monitoring)) (PP (IN of) (NP (NP (JJ renal) (NN function) (CC and) (NN evaluation)) (PP (IN of) (NP (JJ urinary) (NN sediment)))))) (CC and) (NP (NP (NNP Doc_8267029_878_889_Disease)) (PP (IN in) (NP (DT these) (NNS patients)))))))) (. .)))
8267029	7	(S1 (S (NP (NP (DT The) (JJ prompt) (NN discontinuation)) (PP (IN of) (NP (NP (NNP Doc_8267029_939_954_Chemical)) (CC and) (NP (JJ vigorous) (NN treatment) (NNS measures))))) (VP (MD could) (VP (VB allow) (PP (IN for) (NP (NP (DT a) (JJ good) (NN prognosis)) (PP (IN as) (PP (IN in) (NP (DT this) (NN case)))))))) (. .)))
8268147	0	(S1 (NP (NP (DT A) (NN case)) (PP (IN of) (NP (NNP Doc_8268147_10_22_Disease))) (PP (IN in) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (NNP Doc_8268147_41_66_Disease))) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_8268147_80_95_Chemical)))))) (. .)))
8268147	1	(S1 (S (SBAR (IN Although) (S (NP (NNP Doc_8268147_106_121_Chemical)) (VP (AUX has) (VP (AUX been) (VP (VBN used) (PP (IN for) (NP (JJ many) (NN Doc_8268147_145_167_Disease)))))))) (, ,) (NP (NNP Doc_8268147_169_177_Disease)) (VP (VBZ limits) (NP (NP (PRP$ its) (NN usefulness)) (PP (IN in) (NP (JJ many) (NNS patients))))) (. .)))
8268147	2	(S1 (S (S (NP (NN Doc_8268147_218_230_Disease/Doc_8268147_231_246_Disease)) (VP (MD can) (VP (VB develop) (PP (IN as) (NP (NP (CD one)) (PP (IN of) (NP (NP (DT the) (JJ autoimmune) (NNS complications)) (PP (IN of) (NP (JJ Doc_8268147_301_316_Chemical) (NN treatment)))))))))) (, ,) (CC but) (S (NP (PRP$ its) (JJ exact) (NN pathogenesis)) (VP (VBZ remains) (ADJP (JJ unclear)))) (. .)))
8268147	3	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (NP (NNP Doc_8268147_397_422_Disease)) (, ,) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NN Doc_8268147_438_450_Disease)) (PP (IN while) (S (VP (VBG receiving) (NP (JJ Doc_8268147_467_482_Chemical) (NN therapy)))))))))))) (. .)))
8268147	4	(S1 (S (NP (PRP We)) (VP (VBD described) (NP (NP (DT the) (JJ special) (JJ clinical) (NN course)) (PP (IN of) (NP (DT the) (NN patient))))) (. .)))
8268147	5	(S1 (S (NP (NP (NNS Patients)) (VP (VBG receiving) (NP (JJ Doc_8268147_568_583_Chemical) (NN therapy)))) (VP (MD should) (VP (AUX be) (VP (VBN followed) (ADVP (RB carefully)) (PP (IN for) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NP (JJ autoimmune) (NNS complications)) (PP (IN like) (NP (NNP Doc_8268147_674_686_Disease/Doc_8268147_687_702_Disease)))))))))) (. .)))
8278214	0	(S1 (S (NP (NP (NP (NNP Doc_8278214_0_12_Disease)) (CC and) (NP (NNP Doc_8278214_17_26_Disease))) (PP (IN in) (NP (JJ terminal) (NNP Doc_8278214_39_45_Disease) (NNS patients)))) (VP (VBN treated) (PP (IN with) (NP (JJ continuous) (JJ intravenous) (NNP Doc_8278214_91_99_Chemical)))) (. .)))
8278214	1	(S1 (S (NP (NP (CD Eight) (JJ Doc_8278214_107_113_Disease) (NNS patients)) (PP (IN in) (NP (NP (DT the) (JJ terminal) (NNS stages)) (PP (IN of) (NP (DT the) (NN disease)))))) (VP (VBN treated) (PP (IN with) (NP (NP (JJ high) (NNS doses)) (PP (IN of) (NP (JJ intravenous) (JJ Doc_8278214_200_208_Chemical) (VBN developed) (NN Doc_8278214_219_231_Disease)))))) (. .)))
8278214	2	(S1 (S (NP (DT All) (NNS cases)) (VP (AUX were) (ADVP (RB retrospectively)) (VP (VBN sampled) (PP (IN from) (NP (CD three) (JJ different) (NNS hospitals))) (PP (IN in) (NP (NNP Copenhagen))))) (. .)))
8278214	3	(S1 (S (NP (CD Five) (NNS patients)) (VP (VBD developed) (NP (NP (NP (JJ universal) (NN Doc_8278214_352_364_Disease)) (CC and) (NP (NN Doc_8278214_369_382_Disease))) (SBAR (WHNP (WDT which)) (S (PP (IN in) (NP (CD 2) (NNS cases))) (VP (AUX were) (VP (VBN accompanied) (PP (IN by) (NP (NNP Doc_8278214_420_429_Disease))))))))) (. .)))
8278214	4	(S1 (S (PP (PP (IN In) (NP (NP (CD 3) (NNS patients)) (SBAR (S (NP (DT a) (JJ pre-existing) (NN Doc_8278214_460_469_Disease)) (VP (VBD increased) (PP (TO to) (NP (JJ excruciating) (NN intensity)))))))) (CC and) (PP (IN in) (NP (NP (CD 2)) (PP (IN of) (NP (DT these) (NNS cases)))))) (NP (NNP Doc_8278214_530_539_Disease)) (VP (VBD occurred) (ADVP (RB simultaneously))) (. .)))
8278214	5	(S1 (S (SBAR (IN Although) (S (NP (NP (QP (RB only) (JJ few)) (JJ clinical) (NNS descriptions)) (PP (IN of) (NP (NP (DT the) (NN relationship)) (PP (IN between) (NP (NP (NNP Doc_8278214_633_645_Disease/Doc_8278214_646_655_Disease)) (CC and) (NP (NP (JJ high) (NNS doses)) (PP (IN of) (NP (NNP Doc_8278214_674_682_Chemical))))))))) (VP (AUX are) (ADJP (JJ available))))) (, ,) (NP (NP (JJ experimental) (NN support)) (PP (IN from) (NP (NN animal) (NNS studies)))) (VP (VBZ indicates) (SBAR (IN that) (S (NP (NP (NNP Doc_8278214_754_762_Chemical)) (, ,) (CC or) (NP (PRP$ its) (NNS metabolites)) (, ,)) (VP (VBZ plays) (NP (NP (DT a) (JJ causative) (NN role)) (PP (IN for) (NP (DT the) (JJ observed) (JJ behavioural) (NN syndrome)))))))) (. .)))
8278214	6	(S1 (S (S (NP (DT The) (JJ possible) (NNS mechanisms)) (VP (AUX are) (VP (VBN discussed)))) (CC and) (S (NP (NN treatment) (NNS proposals)) (VP (VBN given) (S (VP (VBG suggesting) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (ADJP (RBR more) (JJ efficacious)) (NNS opioids)))) (PP (IN with) (NP (NP (ADJP (RBR less) (JJ excitatory)) (NN potency)) (PP (IN in) (NP (DT these) (NNS situations))))))))) (. .)))
8305357	0	(S1 (NP (NP (NP (NNP Liposomal) (NNP Doc_8305357_10_22_Chemical)) (PP (IN in) (NP (JJ advanced) (NN Doc_8305357_35_51_Disease)))) (: :) (NP (DT a) (NN phase) (NNP II) (NN study)) (. .)))
8305357	1	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT a) (JJ non-randomized) (NN Phase)) (SBAR (S (NP (NNP II) (JJ clinical) (NN trial)) (VP (TO to) (VP (VB assess) (NP (NP (DT the) (NN efficacy) (CC and) (NN safety)) (PP (IN of) (NP (NP (JJ liposomal) (NNP Doc_8305357_169_181_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP DaunoXome)) (-RRB- -RRB-))))) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (JJ Doc_8305357_214_218_Disease) (JJ related) (NN Doc_8305357_227_243_Disease))))))))))) (. .)))
8305357	2	(S1 (S (NP (NP (CD Eleven) (JJ homosexual) (NNS men)) (PP (IN with) (NP (JJ advanced) (NN Doc_8305357_281_297_Disease)))) (VP (AUX were) (VP (VBN entered) (PP (IN in) (NP (DT the) (NN trial))))) (. .)))
8305357	3	(S1 (S (NP (NP (NNS Changes)) (PP (IN in) (NP (NP (NP (NN size)) (, ,) (NP (NN colour)) (CC and) (NP (JJ associated) (NN Doc_8305357_364_370_Disease))) (PP (IN of) (NP (NP (VBN selected) ('' ') (NN target) (POS ')) (NNS lesions)))))) (VP (AUX were) (VP (VBN measured))) (. .)))
8305357	4	(S1 (S (NP (JJ Clinical) (, ,) (ADJP (ADJP (JJ biochemical)) (CC and) (ADJP (JJ haematological))) (NNP Doc_8305357_456_466_Disease)) (VP (AUX were) (VP (VBN assessed))) (. .)))
8305357	5	(S1 (S (NP (CD Ten) (NNS subjects)) (VP (AUX were) (VP (VBN evaluated))) (. .)))
8305357	6	(S1 (S (NP (DT A) (JJ partial) (NN response)) (VP (AUX was) (VP (VBN achieved) (PP (IN in) (NP (NP (CD four)) (, ,) (SBAR (WHPP (IN of) (WHNP (WP whom))) (S (NP (CD two)) (ADVP (RB subsequently)) (VP (VBD relapsed)))))))) (. .)))
8305357	7	(S1 (S (NP (NP (NN Stabilization)) (PP (IN of) (NP (NNP Doc_8305357_604_620_Disease)))) (VP (VBD occurred) (PP (IN in) (NP (DT the) (JJ remaining) (CD six))) (, ,) (S (VP (VBN maintained) (PP (IN until) (NP (NP (DT the) (NN end)) (PP (IN of) (NP (NP (DT the) (NN trial) (NN period)) (PP (IN in) (NP (CD four)))))))))) (. .)))
8305357	8	(S1 (S (NP (DT The) (NN drug)) (VP (AUX was) (ADVP (RB generally)) (VP (ADVP (RB well)) (VBN tolerated) (, ,) (PP (IN with) (NP (NP (JJ few) (JJ mild) (NNS symptoms)) (PP (IN of) (NP (NNP Doc_8305357_771_779_Disease))))))) (. .)))
8305357	9	(S1 (S (NP (NP (DT The) (JJ main) (NN problem)) (VP (VBN encountered))) (VP (AUX was) (NP (JJ haematological) (NNP Doc_8305357_829_837_Disease)) (, ,) (PP (IN with) (NP (NP (CD three) (NNS subjects)) (VP (VBG experiencing) (NP (NP (JJ severe) (NN Doc_8305357_879_890_Disease)) (PRN (-LRB- -LRB-) (NP (NP (NN neutrophil) (NN count)) (SBAR (S (NP (NP (QP (CD <) (CD 0.5)) (NNP x) (CD 10)) (PRN (-LRB- -LRB-) (NP (CD 9)) (-RRB- -RRB-))) (VP (VBZ /l))))) (-RRB- -RRB-))))))) (. .)))
8305357	10	(S1 (S (NP (EX There)) (VP (AUX was) (NP (NP (DT no) (NN evidence)) (PP (IN of) (NP (NNP Doc_8305357_952_966_Disease))))) (. .)))
8305357	11	(S1 (S (PP (IN In) (NP (DT this) (JJ small) (NN patient) (NN sample))) (, ,) (NP (JJ liposomal) (NNP Doc_8305357_1008_1020_Chemical)) (VP (AUX was) (NP (NP (DT an) (ADJP (ADJP (JJ effective)) (CC and) (ADJP (RB well) (JJ tolerated))) (NN agent)) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NNP Doc_8305357_1083_1099_Disease))))))) (. .)))
8384253	0	(S1 (NP (NP (JJ Long-term) (NNS effects)) (PP (IN of) (NP (NNP Doc_8384253_21_32_Chemical))) (PP (IN on) (NP (DT the) (JJ peripheral) (JJ nervous) (NN system))) (. .)))
8384253	1	(S1 (S (NP (NP (CD Forty) (NNS patients)) (PP (IN with) (NP (NNP Doc_8384253_87_109_Disease))) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_8384253_123_134_Chemical))) (PP (IN between) (NP (NP (CD 1984)) (CC and) (NP (CD 1990))))) (PRN (-LRB- -LRB-) (NP (NP (NP (JJ cumulative) (NN dose)) (NP (CD 12) (NNS mg))) (PP (IN in) (NP (CD 18-24) (NNS weeks)))) (-RRB- -RRB-))) (VP (AUX were) (VP (VBN investigated) (SBAR (IN in) (NN order) (S (VP (TO to) (VP (VB evaluate) (NP (NP (DT the) (JJ long) (NN term) (NNS effects)) (PP (IN of) (NP (NNP Doc_8384253_260_271_Chemical))) (PP (IN on) (NP (DT the) (JJ peripheral) (JJ nervous) (NN system)))))))))) (. .)))
8384253	2	(S1 (S (NP (DT The) (NNS patients)) (VP (AUX were) (VP (VBN interviewed) (PP (IN with) (NP (NN emphasis))) (PP (IN on) (NP (NN Doc_8384253_353_373_Disease))))) (. .)))
8384253	3	(S1 (S (NP (NP (JJ Physical) (CC and) (JJ quantitative) (JJ sensory) (NN examination)) (PP (IN with) (NP (NP (NN determination)) (PP (IN of) (NP (NP (JJ vibratory) (NN perception)) (CC and) (NP (JJ thermal) (NN discrimination) (NNS thresholds))))))) (VP (AUX were) (VP (VBN performed) (, ,) (PP (NP (NP (QP (CD four) (TO to) (CD 77)) (NNS months)) (PRN (-LRB- -LRB-) (NP (JJ median) (CD 34) (NNS months)) (-RRB- -RRB-))) (IN after) (NP (JJ Doc_8384253_561_572_Chemical) (NN treatment))))) (. .)))
8384253	4	(S1 (S (NP (JJ Twenty-seven) (NNS patients)) (VP (VBD reported) (NP (NN Doc_8384253_615_635_Disease))) (. .)))
8384253	5	(S1 (S (PP (IN In) (NP (NP (CD 13)) (PP (IN of) (NP (DT these) (CD 27) (NNS patients))))) (NP (NNS symptoms)) (VP (AUX were) (ADVP (RB still)) (ADJP (JJ present)) (PP (IN at) (NP (NP (DT the) (NN time)) (PP (IN of) (NP (NN examination)))))) (. .)))
8384253	6	(S1 (S (PP (IN In) (NP (DT these) (NNS patients))) (NP (JJ sensory) (NNS signs) (CC and) (NNS symptoms)) (VP (VBD predominated)) (. .)))
8384253	7	(S1 (S (PP (IN In) (NP (DT the) (JJ other) (CD 14) (NNS patients))) (NP (NNS symptoms)) (VP (AUX had) (VP (AUX been) (ADJP (JJ present) (PP (IN in) (NP (DT the) (NN past)))))) (. .)))
8384253	8	(S1 (S (NP (NNS Symptoms)) (VP (VBD persisted) (NP (QP (RB maximally) (CD 40)) (NNS months)) (PP (IN since) (NP (NP (NN cessation)) (PP (IN of) (NP (NN therapy)))))) (. .)))
8384253	9	(S1 (S (NP (EX There)) (VP (AUX was) (NP (NP (DT no) (NN age) (NN difference)) (PP (IN between) (NP (NP (NNS patients)) (PP (PP (IN with)) (CC and) (PP (IN without) (NP (NP (NNS complaints)) (PP (IN at) (NP (NP (DT the) (NN time)) (PP (IN of) (NP (NN examination)))))))))))) (. .)))
8384253	10	(S1 (S (NP (JJ Normal) (NNS reflexes)) (VP (AUX were) (VP (VBN found) (PP (IN in) (NP (NP (CD two) (NN third)) (PP (IN of) (NP (NNS patients))))))) (. .)))
8384253	11	(S1 (S (NP (JJ Neuropathic) (NNS complaints)) (VP (AUX were) (RB not) (ADJP (RB very) (JJ troublesome) (PP (IN on) (NP (DT the) (JJ long) (NN term))))) (. .)))
8384253	12	(S1 (S (S (NP (PRP It)) (VP (AUX is) (VP (VBN concluded) (SBAR (IN that) (S (PP (IN with) (NP (DT the) (ADJP (RB above) (VBN mentioned)) (JJ Doc_8384253_1177_1188_Chemical) (NN dose) (NN schedule))) (NP (NP (NNS signs) (CC and) (NNS symptoms)) (PP (IN of) (NP (NNP Doc_8384253_1225_1236_Chemical) (NNP Doc_8384253_1237_1247_Disease)))) (VP (AUX are) (ADJP (JJ reversible) (PP (IN for) (NP (DT a) (JJ great) (NN deal)))))))))) (CC and) (S (NP (NN prognosis)) (VP (AUX is) (ADJP (RB fairly) (JJ good)))) (. .)))
839274	0	(S1 (NP (NP (NP (NNP Hepatic) (NNP Doc_839274_8_16_Disease) (CC and) (NNP Doc_839274_21_46_Disease)) (PP (IN of) (NP (DT the) (NN liver))) (PP (IN in) (NP (JJ young) (NNS women))) (PP (IN on) (NP (NNP Doc_839274_78_97_Chemical)))) (: :) (NP (NN case) (NNS reports)) (. .)))
839274	1	(S1 (S (NP (NP (NP (NP (CD Two) (NNS cases)) (PP (IN of) (NP (JJ hepatic) (NNP Doc_839274_134_141_Disease)))) (CC and) (NP (NP (CD one)) (PP (IN of) (NP (NNP Doc_839274_153_178_Disease))))) (VP (ADVP (RB presumably)) (VBN associated) (PP (IN with) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NNP Doc_839274_217_236_Chemical))))) (, ,))) (VP (AUX are) (VP (VBN reported))) (. .)))
839274	2	(S1 (S (NP (JJ Special) (NN reference)) (VP (AUX is) (VP (VBN made) (PP (TO to) (NP (NP (PRP$ their) (JJ clinical) (NN presentation)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (AUX be) (ADJP (RB totally) (NN asymptomatic)))))))))) (. .)))
839274	3	(S1 (S (S (NP (NN Liver-function) (NNS tests)) (VP (AUX are) (PP (IN of) (NP (JJ little) (JJ diagnostic) (NN value))))) (, ,) (CC but) (S (NP (JJ valuable) (NN information)) (VP (MD may) (VP (AUX be) (VP (VBN obtained) (PP (IN from) (NP (DT both) (NN liver) (VBG scanning) (CC and) (NN hepatic) (NN angiography))))))) (. .)))
839274	4	(S1 (S (NP (NP (NP (JJ Histologic) (NNS differences)) (CC and) (NP (JJ clinical) (NNS similarities))) (PP (IN between) (NP (NP (NNP hepatic) (NNP Doc_839274_554_561_Disease) (CC and) (NNP Doc_839274_566_591_Disease)) (PP (IN of) (NP (DT the) (NN liver)))))) (VP (AUX are) (VP (VBN discussed))) (. .)))
8410199	0	(S1 (S (NP (NP (NN Loss)) (PP (IN of) (NP (NNP Doc_8410199_8_17_Chemical)))) (VP (VBP decarboxylase) (NP (NP (JJ mRNA-containing) (NNS neurons)) (PP (IN in) (NP (NP (DT the) (NN rat) (NN dentate) (NNS gyrus)) (VP (VBG following) (NP (JJ Doc_8410199_91_102_Chemical-induced) (NNP Doc_8410199_111_119_Disease))))))) (. .)))
8410199	1	(S1 (FRAG (SBAR (IN In) (S (NP (JJ situ) (NN hybridization) (NNS methods)) (VP (AUX were) (VP (VBN used) (S (VP (TO to) (VP (VB determine) (SBAR (IN if) (S (NP (NP (NNP Doc_8410199_177_190_Chemical) (FW decarboxylase) (PRN (-LRB- -LRB-) (NP (NNP GAD)) (-RRB- -RRB-)) (NN mRNA-containing) (NNS neurons)) (PP (IN within) (NP (NP (DT the) (NN hilus)) (PP (IN of) (NP (DT the) (JJ dentate) (NN gyrus)))))) (VP (AUX are) (ADJP (JJ vulnerable) (PP (TO to) (NP (NP (JJ Doc_8410199_291_298_Disease-induced) (NN damage)) (PP (IN in) (NP (NP (DT a) (NN model)) (PP (IN of) (NP (JJ chronic) (NNP Doc_8410199_336_344_Disease)))))))))))))))))) (. .)))
8410199	2	(S1 (S (S (NP (JJ Sprague-Dawley) (NNS rats)) (VP (AUX were) (VP (VBN injected) (ADVP (RB intraperitoneally)) (PP (IN with) (NP (NNP Doc_8410199_403_414_Chemical)))))) (, ,) (CC and) (S (NP (DT the) (JJ hippocampal) (NN formation)) (VP (AUX was) (VP (VBN studied) (ADVP (RB histologically)) (PP (IN at) (NP (CD 1) (, ,) (CD 2) (, ,) (CD 4) (, ,) (CC and) (CD 8) (NN week) (NNS intervals))) (PP (IN after) (NP (NNP Doc_8410199_512_523_Chemical-induced) (NNP Doc_8410199_532_540_Disease)))))) (. .)))
8410199	3	(S1 (S (PP (IN In) (NP (JJ situ) (NN hybridization) (NN histochemistry))) (, ,) (S (VP (VBG using) (NP (DT a) (JJ Doc_8410199_588_599_Chemical-labeled) (NNP GAD) (NN cRNA) (NN probe)))) (, ,) (VP (VBD demonstrated) (NP (NP (DT a) (JJ substantial) (NN decrease)) (PP (IN in) (NP (NP (DT the) (NN number)) (PP (IN of) (NP (JJ GAD) (JJ mRNA-containing) (NNS neurons))))) (PP (IN in) (NP (NP (DT the) (NN hilus)) (PP (IN of) (NP (NP (DT the) (JJ dentate) (NNS gyrus)) (PP (IN in) (NP (DT the) (JJ Doc_8410199_746_757_Chemical-treated) (NNS rats)))))))) (SBAR (IN as) (S (VP (VBN compared) (PP (TO to) (NP (NNS controls))) (PP (IN at) (NP (DT all) (NN time) (NNS intervals))))))) (. .)))
8410199	4	(S1 (S (NP (NP (JJ Additional) (JJ neuronanatomical) (NNS studies)) (, ,) (PP (VBG including) (NP (NP (JJ Doc_8410199_865_878_Chemical) (NN staining)) (, ,) (NP (JJ Doc_8410199_889_910_Disease) (NNS methods)) (, ,) (CC and) (NP (NP (JJ histochemical) (NN localization)) (PP (IN of) (NP (JJ glial) (JJ fibrillary) (JJ acidic) (NN protein)))))) (, ,)) (VP (VBD suggested) (SBAR (IN that) (S (NP (NP (DT the) (NN decrease)) (PP (IN in) (NP (NP (DT the) (NN number)) (PP (IN of) (NP (JJ GAD) (JJ mRNA-containing) (NNS neurons)))))) (VP (AUX was) (VP (VP (VBN related) (PP (TO to) (NP (NNP Doc_8410199_1075_1088_Disease)))) (CONJP (RB rather) (IN than)) (PP (TO to) (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (JJ GAD) (NN mRNA) (NNS levels)))))))))) (. .)))
8410199	5	(S1 (S (NP (NP (DT The) (NN loss)) (PP (IN of) (NP (JJ GAD) (JJ mRNA-containing) (NNS neurons))) (PP (IN in) (NP (DT the) (NN hilus)))) (VP (VBN contrasted) (PP (IN with) (NP (NP (DT the) (JJ relative) (NN preservation)) (PP (IN of) (NP (VBN labeled) (JJ putative) (NN basket) (NNS cells))) (PP (IN along) (NP (NP (DT the) (JJ inner) (NN margin)) (PP (IN of) (NP (DT the) (JJ granule) (NN cell) (NN layer)))))))) (. .)))
8410199	6	(S1 (S (NP (NP (JJ Quantitative) (NNS analyses)) (PP (IN of) (NP (NP (VBN labeled) (NNS neurons)) (PP (IN in) (NP (NP (CD three) (NNS regions)) (PP (IN of) (NP (NP (DT the) (JJ dentate) (NN gyrus)) (PP (IN in) (NP (DT the) (ADJP (CD 1) (CC and) (CD 2)) (NN week) (NNS groups)))))))))) (VP (VBD showed) (NP (NP (ADJP (RB statistically) (JJ significant)) (NNS decreases)) (PP (IN in) (NP (NP (DT the) (JJ mean) (NN number)) (PP (IN of) (NP (NP (JJ GAD) (JJ mRNA-containing) (NNS neurons)) (PP (IN in) (NP (NP (DT the) (NNS hilus)) (PP (IN of) (NP (NP (DT both) (NNS groups)) (PP (IN of) (NP (JJ experimental) (NNS animals))))))))))))) (. .)))
8410199	7	(S1 (S (NP (DT No) (JJ significant) (NNS differences)) (VP (AUX were) (VP (VBN found) (PP (IN in) (NP (NP (NP (DT the) (JJ molecular) (NN layer)) (CC or) (NP (DT the) (JJ granule) (NN cell) (NN layer))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD included) (NP (VBN labeled) (NNS neurons)) (PP (IN along) (NP (NP (DT the) (JJR lower) (NN margin)) (PP (IN of) (NP (DT the) (JJ granule) (NN cell) (NN layer)))))))))))) (. .)))
8410199	8	(S1 (S (NP (DT The) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (, ,) (PP (IN in) (NP (DT this) (NN model))) (, ,) (NP (NP (DT a) (NN subpopulation)) (PP (IN of) (NP (NP (JJ GAD) (JJ mRNA-containing) (NNS neurons)) (PP (IN within) (NP (DT the) (JJ dentate) (NNS gyrus)))))) (VP (AUX is) (ADJP (RB selectively) (JJ vulnerable) (PP (TO to) (NP (JJ Doc_8410199_1877_1884_Disease-induced) (NN damage)))))))) (. .)))
8410199	9	(S1 (S (NP (JJ Such) (NN differential) (NN vulnerability)) (VP (VBZ appears) (S (VP (TO to) (VP (AUX be) (NP (NP (DT another) (NN indication)) (PP (IN of) (NP (NP (DT the) (NN heterogeneity)) (PP (IN of) (NP (JJ Doc_8410199_1990_1994_Chemical) (NNS neurons)))))))))) (. .)))
8424298	0	(S1 (NP (NP (NNS Effects)) (PP (IN of) (NP (JJ deliberate) (NNP Doc_8424298_22_33_Disease))) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_8424298_45_54_Chemical))) (PP (IN with) (NP (NNP Doc_8424298_60_70_Chemical))) (PP (IN on) (NP (JJ neuropsychological) (NN function)))) (. .)))
8424298	1	(S1 (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (JJ deliberate) (NN Doc_8424298_128_139_Disease))) (PP (IN on) (NP (NP (NN brain) (NN function)) (VP (VBN measured) (PP (IN by) (NP (JJ neuropsychological) (NNS tests))))))) (VP (AUX was) (VP (VBN studied) (PP (IN in) (NP (CD 41) (NN adult) (NNS patients))))) (. .)))
8424298	2	(S1 (S (NP (JJ Twenty-four) (NNS patients)) (VP (AUX were) (VP (VBN anaesthetized) (PP (IN for) (NP (NP (JJ middle-ear) (NN surgery)) (PP (IN with) (NP (NP (JJ deliberate) (NNP Doc_8424298_308_319_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_8424298_331_340_Chemical))) (PP (IN with) (NP (NP (NNP Doc_8424298_346_356_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_8424298_358_369_Disease) (NN group)) (-RRB- -RRB-))))))))))) (. .)))
8424298	3	(S1 (S (NP (NP (CD Seventeen) (NNS patients)) (PP (IN without) (NP (NNP Doc_8424298_405_416_Disease)))) (VP (VBD served) (PP (IN as) (NP (DT a) (NN control) (NN group)))) (. .)))
8424298	4	(S1 (S (NP (DT The) (JJ mean) (JJ arterial) (NN pressure)) (VP (AUX was) (NP (NP (NP (NP (CD 77) (NN +/-) (QP (CD 2) (CD mmHg))) (PRN (-LRB- -LRB-) (NP (NP (CD 10.3) (NN +/-)) (NP (CD 0.3) (NN kPa))) (-RRB- -RRB-))) (PP (IN before) (NP (NP (NNP Doc_8424298_515_526_Disease)) (CC and) (NP (NP (CD 50) (JJ +/-) (CD 0) (NNS mmHg)) (PRN (-LRB- -LRB-) (NP (NP (CD 6.7) (NN +/-)) (NP (CD 0.0) (NN kPa))) (-RRB- -RRB-))))) (PP (IN during) (NP (NNP Doc_8424298_570_581_Disease))) (PP (IN in) (NP (DT the) (NNP Doc_8424298_589_600_Disease) (NN group)))) (, ,) (CC and) (NP (NP (CD 86) (NN +/-) (QP (CD 2) (CD mmHg))) (PRN (-LRB- -LRB-) (NP (NP (CD 11.5) (NN +/-)) (NP (CD 0.3) (NN kPa))) (-RRB- -RRB-)))) (PP (IN during) (NP (NP (NN anaesthesia)) (PP (IN in) (NP (DT the) (NN control) (NN group)))))) (. .)))
8424298	5	(S1 (S (S (NP (DT The) (JJ following) (JJ psychological) (NNS tests)) (VP (AUX were) (VP (VBN performed)))) (: :) (S (NP (NP (CD four) (NNS subtests)) (PP (IN of) (NP (NP (DT the) (NNP Wechsler) (NN Adult) (NNP Intelligence) (NNP Scale)) (PRN (-LRB- -LRB-) (NP (NNS similarities) (, ,) (NN digit) (NN span) (, ,) (NN vocabulary) (CC and) (NN digit) (NN symbol)) (-RRB- -RRB-))))) (, ,) (NP (JJ Trail-Making) (NNS tests)) (VP (NP (NP (NP (DT A)) (CC and) (NP (NN B))) (, ,) (NP (NP (JJ Zung) (NNS tests)) (PRN (-LRB- -LRB-) (NP (NP (JJ self-rating) (JJ Doc_8424298_900_907_Disease) (NN scale)) (CC and) (NP (JJ self-rating) (JJ Doc_8424298_930_940_Disease) (NN scale))) (-RRB- -RRB-))) (CC and) (NP (JJ two-part) (NN memory) (NN test) (NN battery))) (PP (IN with) (NP (JJ immediate) (CC and) (JJ delayed) (NN recall))))) (. .)))
8424298	6	(S1 (S (NP (DT The) (NNS tests)) (VP (VP (AUX were) (VP (VBN performed) (ADVP (RB preoperatively)))) (CC and) (VP (NP (CD 2) (NNS days)) (ADVP (RB postoperatively)))) (. .)))
8424298	7	(S1 (S (NP (EX There)) (VP (AUX were) (NP (NP (DT no) (ADJP (RB statistically) (JJ significant)) (NNS differences)) (PP (IN between) (NP (NP (DT the) (NNS groups)) (PP (IN in) (NP (NP (DT any)) (PP (IN of) (NP (NP (DT the) (NNS tests)) (PP (IN in) (NP (NP (DT the) (NNS changes)) (PP (IN from) (NP (JJ preoperative) (NN value))) (PP (TO to) (NP (NN postoperative) (NN value))))))))))))) (. .)))
8424298	8	(S1 (S (NP (DT The) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (NNP Doc_8424298_1264_1275_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_8424298_1287_1296_Chemical))) (PP (IN with) (NP (NNP Doc_8424298_1302_1312_Chemical))))) (VP (AUX has) (NP (NP (DT no) (JJ significant) (JJ harmful) (NNS effects)) (PP (IN on) (NP (NP (JJ mental) (NNS functions)) (VP (VBN compared) (S (VP (TO to) (VP (VB normotensive) (NP (NN anaesthesia))))))))))))) (. .)))
8441146	0	(S1 (NP (NP (JJ Apparent) (NN cure)) (PP (IN of) (NP (NNP Doc_8441146_17_37_Disease))) (PP (IN by) (NP (NN bone) (NN marrow) (NN transplantation))) (. .)))
8441146	1	(S1 (S (NP (PRP We)) (VP (VBP describe) (NP (NP (NP (DT the) (NN induction)) (PP (IN of) (NP (JJ sustained) (NNS remissions)))) (CC and) (NP (NP (JJ possible) (NN cure)) (PP (IN of) (NP (NP (JJ severe) (JJ erosive) (NNP Doc_8441146_156_176_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_8441146_178_180_Disease)) (-RRB- -RRB-)))))) (PP (IN by) (NP (NP (NN bone) (NN marrow) (NN transplantation)) (PRN (-LRB- -LRB-) (NP (NNP BMT)) (-RRB- -RRB-)))) (PP (IN in) (NP (CD 2) (NNS patients)))) (. .)))
8441146	2	(S1 (S (NP (NN BMT)) (VP (AUX was) (VP (VBN used) (S (VP (TO to) (VP (VB treat) (NP (NP (JJ severe) (NN Doc_8441146_263_278_Disease)) (SBAR (WHNP (WDT which)) (S (VP (AUX was) (VP (VP (VBN caused) (PP (IN by) (NP (NN gold))) (PP (IN in) (NP (CD one) (NN case)))) (CC and) (VP (ADJP (JJ Doc_8441146_320_335_Chemical)) (PP (IN in) (NP (DT the) (JJ other)))))))))))))) (. .)))
8441146	3	(S1 (S (PP (IN In) (NP (NP (DT the) (QP (CD 8) (CC and) (CD 6)) (NNS years)) (PP (IN since) (NP (NP (DT the) (NNS transplants)) (PRN (-LRB- -LRB-) (VP (VBG representing) (NP (QP (CD 8) (CC and) (CD 4)) (NNS years)) (PP (IN since) (NP (NP (NN cessation)) (PP (IN of) (NP (DT all) (JJ immunosuppressive) (NN therapy))))) (, ,) (ADVP (RB respectively))) (-RRB- -RRB-)))))) (, ,) (NP (NP (DT the) (NNP Doc_8441146_490_492_Disease)) (PP (IN in) (NP (DT each) (NN case)))) (VP (AUX has) (VP (AUX been) (ADJP (RB completely) (JJ quiescent)))) (. .)))
8441146	4	(S1 (S (SBAR (IN Although) (S (NP (NP (JJ short) (NN term) (NN remission)) (PP (IN of) (NP (JJ severe) (JJ Doc_8441146_577_579_Disease) (JJ following) (NNS BMT)))) (VP (AUX has) (VP (AUX been) (VP (VBN reported)))))) (, ,) (NP (DT these)) (VP (AUX are) (NP (NP (DT the) (JJ first) (NNS cases)) (SBAR (WHPP (IN for) (WHNP (WDT which))) (S (NP (JJ prolonged) (NN followup)) (VP (AUX has) (VP (AUX been) (ADJP (JJ available)))))))) (. .)))
8441146	5	(S1 (S (NP (DT This) (NN experience)) (VP (VBZ raises) (NP (NP (DT the) (NN question)) (PP (IN of) (NP (NP (DT the) (NN role)) (PP (IN of) (S (VP (VBG BMT) (NP (PRP itself)) (PP (IN as) (NP (NP (DT a) (JJ therapeutic) (NN option)) (PP (IN for) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ uncontrolled) (JJ destructive) (NN Doc_8441146_817_826_Disease)))))))))))))) (. .)))
8473723	0	(S1 (S (NP (NN Doc_8473723_0_8_Disease)) (VP (VBN induced) (PP (IN by) (NP (JJ combined) (JJ Doc_8473723_29_44_Chemical-Doc_8473723_45_56_Chemical) (NN treatment)))) (. .)))
8473723	1	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (JJ combined) (JJ Doc_8473723_97_112_Chemical-Doc_8473723_113_124_Chemical) (JJ treatment-induced) (NN Doc_8473723_143_151_Disease))))) (. .)))
8473723	2	(S1 (S (NP (PRP It)) (VP (VBZ seems) (SBAR (IN that) (S (NP (NP (JJ combined) (NN treatment)) (PP (IN of) (NP (NNP Doc_8473723_189_200_Chemical))) (PP (IN with) (NP (NNP Doc_8473723_206_220_Chemical)))) (VP (MD may) (VP (VB possess) (NP (JJ proconvulsive) (NN activity))))))) (. .)))
8475949	0	(S1 (NP (NP (NN Case) (NN report)) (: :) (NP (ADJP (JJ Doc_8475949_13_24_Chemical) (CC and) (JJ polymorphic)) (NNP Doc_8475949_41_64_Disease) (NNP revisited)) (. .)))
8475949	1	(S1 (S (NP (NN Doc_8475949_76_99_Chemical)) (VP (AUX has) (VP (AUX been) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_8475949_125_153_Disease))) (, ,) (PP (VBG including) (NP (NN Doc_8475949_165_183_Disease)))))) (. .)))
8475949	2	(S1 (S (NP (DT This) (NN article)) (VP (VP (VBZ reports) (NP (NP (CD two) (NNS cases)) (PP (IN of) (NP (DT this) (NN complication))))) (CC and) (VP (VBZ reviews) (NP (NP (DT all) (VBN reported) (NNS cases)) (PP (TO to) (NP (NN date)))))) (. .)))
8475949	3	(S1 (S (S (NP (JJ Doc_8475949_277_288_Chemical-induced) (NNP Doc_8475949_297_315_Disease)) (VP (MD may) (VP (AUX be) (ADJP (JJ related) (PP (TO to) (NP (JJ serum) (JJ Doc_8475949_340_349_Chemical) (NNS levels))))))) (CC and) (S (NP (NNP Doc_8475949_361_375_Disease)) (VP (MD may) (ADVP (RB synergistically)) (VP (VB induce) (NP (NN torsade))))) (. .)))
8475949	4	(S1 (S (NP (NN Doc_8475949_412_430_Disease)) (VP (VBD occurred) (PP (IN after) (NP (NP (DT an) (NN average)) (PP (IN of) (NP (NP (CD 10) (NNS days)) (PP (IN of) (NP (NN treatment))) (PP (IN with) (NP (NNP Doc_8475949_486_497_Chemical)))))))) (. .)))
8475949	5	(S1 (S (PP (IN In) (NP (DT these) (NNS patients))) (, ,) (NP (NP (DT no) (JJ other) (JJ acute) (NN side) (NNS effects)) (PP (IN of) (NP (NNP Doc_8475949_549_560_Chemical)))) (VP (AUX were) (VP (VBN observed))) (. .)))
8475949	6	(S1 (S (NP (NN Doc_8475949_576_594_Disease)) (VP (MD can) (VP (AUX be) (VP (VBN treated) (SBAR (WHADVP (WRB when)) (S (VP (VBD recognized) (ADVP (RB early))))) (, ,) (PP (ADVP (RB possibly)) (IN without) (NP (NP (NN discontinuation)) (PP (IN of) (NP (NNP Doc_8475949_669_680_Chemical)))))))) (. .)))
8475949	7	(S1 (S (SBAR (WHADVP (WRB When)) (S (NP (NNP Doc_8475949_687_712_Disease)) (VP (AUX is) (ADJP (JJ observed))))) (, ,) (NP (JJ early) (JJ Doc_8475949_732_741_Chemical) (NN supplementation)) (VP (AUX is) (VP (VBN advocated))) (. .)))
8480959	0	(S1 (NP (NP (NP (NN Efficacy)) (CC and) (NP (NN tolerability))) (PP (IN of) (NP (NNP Doc_8480959_29_39_Chemical))) (PP (IN in) (NP (NP (CD 3390) (NNS women)) (PP (IN with) (NP (JJ moderate) (NNP Doc_8480959_68_88_Disease))))) (. .)))
8480959	1	(S1 (FRAG (S (VP (TO To) (VP (VB evaluate) (NP (NP (DT the) (NN efficacy) (CC and) (NN safety)) (PP (IN of) (NP (NNP Doc_8480959_140_150_Chemical))) (PP (IN in) (NP (NP (NNS women)) (PP (IN with) (NP (JJ moderate) (NNP Doc_8480959_174_194_Disease))))))))) (. .)))
8480959	2	(S1 (NP (NP (NP (DT The) (JJ Expanded) (JJ Clinical) (NN Evaluation)) (PP (IN of) (NP (NNP Doc_8480959_240_250_Chemical) (PRN (-LRB- -LRB-) (NP (NNP EXCEL)) (-RRB- -RRB-)) (NNP Study)))) (, ,) (NP (NP (DT a) (ADJP (JJ multicenter) (, ,) (JJ double-blind) (, ,) (JJ diet-) (CC and) (JJ placebo-controlled)) (NN trial)) (, ,) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (NNS participants)) (VP (AUX were) (ADVP (RB randomly)) (VP (VBN assigned) (S (VP (TO to) (VP (VB receive) (NP (NP (NN placebo)) (CC or) (NP (NP (NNP Doc_8480959_398_408_Chemical)) (PP (IN at) (NP (NP (NNS doses)) (PP (IN of) (NP (NP (NP (QP (CD 20) (CC or) (CD 40)) (NNS mg)) (ADJP (RB once) (JJ daily))) (, ,) (CC or) (NP (NP (QP (CD 20) (CC or) (CD 40)) (NNS mg)) (ADJP (RB twice) (JJ daily))))))))) (PP (IN for) (NP (CD 48) (NNS weeks))))))))))) (. .)))
8480959	3	(S1 (S (NP (JJ Ambulatory) (NNS patients)) (VP (VBD recruited) (PP (IN by) (NP (CD 362) (VBG participating) (NNS centers))) (PP (IN throughout) (NP (DT the) (NNP United) (NNPS States)))) (. .)))
8480959	4	(S1 (NP (NP (NP (NNS Women)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 3390)) (-RRB- -RRB-))) (PP (IN from) (NP (NP (DT the) (JJ total) (NN cohort)) (PP (IN of) (NP (CD 8245) (NNS volunteers))))) (. .)))
8480959	5	(S1 (S (NP (NP (NN Plasma) (NN total)) (, ,) (NP (NN low-density) (NN lipoprotein)) (PRN (-LRB- -LRB-) (NP (NNP LDL)) (-RRB- -RRB-)) (, ,) (CC and) (NP (JJ high-density) (FW lipoprotein) (PRN (-LRB- -LRB-) (NP (NNP HDL)) (-RRB- -RRB-)) (NNP Doc_8480959_747_758_Chemical)) (, ,) (CC and) (NP (NNP Doc_8480959_764_777_Chemical)) (: ;) (CC and) (NP (NP (NN laboratory)) (CC and) (NP (NP (JJ clinical) (NN evidence)) (PP (IN of) (NP (JJ adverse) (NNS events)))))) (VP (VBD monitored) (ADVP (RB periodically)) (PP (IN throughout) (NP (DT the) (NN study)))) (. .)))
8480959	6	(S1 (S (PP (IN Among) (NP (NNS women))) (, ,) (NP (NP (NNP Doc_8480959_901_911_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 20) (TO to) (CD 80)) (NN mg/d)) (-RRB- -RRB-))) (VP (VBD produced) (NP (NP (NP (JJ sustained) (PRN (-LRB- -LRB-) (ADJP (JJ 12-) (TO to) (JJ 48-week)) (-RRB- -RRB-) (, ,)) (JJ dose-related) (NNS changes)) (-LRB- -LRB-) (NP (NNP P) (NNP <) (CD 0.001)) (-RRB- -RRB-)) (: :) (NP (NP (NP (NP (NNS decreases)) (PP (IN in) (NP (NP (NP (NNP LDL) (NNP Doc_8480959_1016_1027_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 24) (NN %) (TO to) (CD 40)) (NN %)) (-RRB- -RRB-))) (CC and) (NP (NNP Doc_8480959_1045_1058_Chemical) (PRN (-LRB- -LRB-) (NP (NP (CD 9) (NN %)) (PP (TO to) (NP (CD 18) (NN %)))) (-RRB- -RRB-)))))) (, ,) (CC and) (NP (NNS increases))) (PP (IN in) (NP (NP (NNP HDL) (NNP Doc_8480959_1093_1104_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 6.7) (NN %)) (PP (TO to) (NP (CD 8.6) (NN %)))) (-RRB- -RRB-))))))) (. .)))
8480959	7	(S1 (S (PP (VBG Depending) (PP (IN on) (NP (DT the) (NN dose)))) (, ,) (S (NP (NP (QP (IN from) (CD 82) (NN %) (TO to) (CD 95) (NN %))) (PP (IN of) (NP (JJ Doc_8480959_1163_1173_Chemical-treated) (NNS women)))) (VP (VBD achieved) (NP (NP (NP (NP (DT the) (NNP National) (NNP Doc_8480959_1210_1221_Chemical) (NNP Education) (NN Program) (NN goal)) (PP (IN of) (NP (NNP LDL) (NNP Doc_8480959_1252_1263_Chemical) (NNS levels)))) (NP (QP (JJR less) (IN than) (CD 4.14)) (NNS mmol/L))) (PRN (-LRB- -LRB-) (NP (CD 160) (NNS mg/dL)) (-RRB- -RRB-))))) (, ,) (CC and) (S (NP (NP (CD 40) (NN %)) (PP (TO to) (NP (CD 87) (NN %)))) (VP (VBD achieved) (NP (NP (DT the) (NN goal)) (PP (IN of) (NP (NP (CD 3.36) (NNS mmol/L)) (PRN (-LRB- -LRB-) (NP (CD 130) (NNS mg/dL)) (-RRB- -RRB-))))))) (. .)))
8480959	8	(S1 (S (NP (JJ Successive) (NN transaminase) (NNS elevations)) (NP (NP (QP (JJR greater) (IN than) (CD three) (NNS times)) (DT the) (JJ upper) (NN limit)) (PP (IN of) (NP (JJ normal)))) (VP (VP (VBD occurred) (PP (IN in) (NP (NP (CD 0.1) (NN %)) (PP (IN of) (NP (NNS women)))))) (CC and) (VP (AUX were) (ADJP (NN dose) (JJ dependent)) (PP (IN above) (NP (DT the) (JJ 20-mg) (NN dose))))) (. .)))
8480959	9	(S1 (S (NP (NP (NN Doc_8480959_1525_1533_Disease)) (, ,) (VP (VBN defined) (PP (IN as) (NP (NP (NN muscle) (NNS symptoms)) (PP (IN with) (NP (JJ Doc_8480959_1567_1575_Chemical) (NN kinase) (NNS elevations))))) (NP (NP (QP (JJR greater) (IN than) (CD 10) (NNS times)) (DT the) (JJ upper) (NN limit)) (PP (IN of) (NP (JJ normal))))) (, ,)) (VP (VP (AUX was) (ADJP (JJ rare))) (CC and) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (JJS highest) (JJ recommended) (JJ daily) (NN dose)) (PP (IN of) (NP (NNP Doc_8480959_1710_1720_Chemical))))) (PRN (-LRB- -LRB-) (NP (CD 80) (NN mg)) (-RRB- -RRB-)))) (. .)))
8480959	10	(S1 (S (NP (JJ Doc_8480959_1730_1738_Chemical-replacement) (NN therapy)) (VP (VBD appeared) (S (VP (TO to) (VP (AUX have) (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (CC either) (DT the) (NN efficacy) (CC or) (NN safety) (NN profile)) (PP (IN of) (NP (NNP Doc_8480959_1830_1840_Chemical))))))))) (. .)))
8480959	11	(S1 (S (NP (NN Doc_8480959_1854_1864_Chemical)) (VP (AUX is) (ADJP (ADJP (RB highly) (JJ effective)) (CC and) (ADJP (RB generally) (RB well) (JJ tolerated) (PP (IN as) (NP (NN therapy)))) (PP (IN for) (NP (NP (JJ primary) (NN Doc_8480959_1937_1957_Disease)) (PP (IN in) (NP (NNS women))))))) (. .)))
8492347	0	(S1 (S (NP (NP (NNP Doc_8492347_0_6_Disease)) (CC and) (NP (NNP Doc_8492347_11_25_Disease))) (VP (JJ due) (PP (TO to) (NP (NP (JJ surreptitious) (NN Doc_8492347_47_57_Chemical--importance)) (PP (IN of) (NP (JJ Doc_8492347_73_82_Chemical) (NN supplementation)))))) (. .)))
8492347	1	(S1 (S (NP (NNS Diuretics)) (VP (MD may) (VP (VB induce) (NP (NP (NNP Doc_8492347_121_132_Disease)) (, ,) (NP (NNP Doc_8492347_134_146_Disease)) (CC and) (NP (NNP Doc_8492347_151_165_Disease))))) (. .)))
8492347	2	(S1 (S (SBAR (IN While) (S (NP (JJ severe) (NNP Doc_8492347_180_191_Disease)) (VP (MD may) (VP (VB cause) (NP (NNP Doc_8492347_202_217_Disease)))))) (, ,) (NP (JJ severe) (NNP Doc_8492347_226_240_Disease)) (VP (AUX is) (VP (VBN associated) (PP (IN with) (NP (NP (NNP Doc_8492347_260_273_Disease) (CC and) (NNP Doc_8492347_278_284_Disease)) (SBAR (WHNP (WDT which)) (S (VP (VBP cannot) (VP (AUX be) (VP (VBN corrected) (PP (IN by) (NP (NP (NNP Doc_8492347_314_323_Chemical) (CC and) (NNP Doc_8492347_328_335_Chemical) (NN supplementation)) (ADVP (RB alone)) (PRN (-LRB- -LRB-) (NP (NN 1,2)) (-RRB- -RRB-))))))))))))) (. .)))
8492347	3	(S1 (S (NP (JJ Surreptitious) (JJ diuretic) (NN ingestion)) (VP (AUX has) (VP (AUX been) (VP (VBN described) (, ,) (PP (ADVP (RB mainly)) (IN in) (NP (NP (NNS women)) (SBAR (WHNP (WP who)) (S (VP (AUX are) (ADJP (JJ concerned) (SBAR (IN that) (S (NP (PRP they)) (VP (AUX are) (NP (NP (NNP Doc_8492347_466_471_Disease)) (CC or) (NP (NNP Doc_8492347_475_484_Disease))))))))))))))) (. .)))
8492347	4	(S1 (S (S (NP (NNP Symptomatic) (NNP Doc_8492347_498_509_Disease)) (VP (AUX has) (VP (AUX been) (VP (VBN reported) (PP (IN in) (NP (NP (JJ such) (NNS patients)) (PRN (-LRB- -LRB-) (JJ 3-7) (-RRB- -RRB-)))))))) (CC and) (S (PP (IN in) (NP (CD one) (NN case))) (S (NP (NNP Doc_8492347_567_579_Disease)) (VP (AUX was) (VP (VBN observed) (PRN (-LRB- -LRB-) (NP (CD 8)) (-RRB- -RRB-))))) (, ,) (CC but) (S (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (JJ Doc_8492347_617_626_Chemical) (NN depletion)))) (VP (AUX were) (RB not) (VP (VBN noted) (PP (IN in) (NP (DT these) (NNS patients))))))) (. .)))
8494478	0	(S1 (NP (NP (JJ Doc_8494478_0_13_Chemical-induced) (NN nephrotoxicity)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_8494478_54_60_Disease))))) (. .)))
8494478	1	(S1 (S (NP (NP (NN Nephrotoxicity)) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_8494478_93_106_Chemical))))) (VP (AUX is) (ADJP (JJ uncommon))) (. .)))
8494478	2	(S1 (S (S (NP (NP (CD Five) (NNS patients)) (PP (IN with) (NP (NP (NNP Doc_8494478_139_145_Disease)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NN Doc_8494478_160_179_Disease))))))) (SBAR (WHNP (WDT that)) (S (VP (VBD followed) (NP (NN treatment)) (PP (IN with) (NP (NNP Doc_8494478_209_222_Chemical))))))) (VP (AUX are) (VP (VBN described)))) (CC and) (S (NP (NP (DT an) (JJ additional) (CD 15) (NNS cases)) (VP (VBN reported) (PP (IN in) (NP (DT the) (NN literature))))) (VP (AUX are) (VP (VBN reviewed)))) (. .)))
8494478	3	(S1 (S (NP (ADJP (JJ Other) (PP (IN than) (NP (NP (NN elevation)) (PP (IN of) (NP (NP (JJ serum) (JJ Doc_8494478_335_345_Chemical) (NNS levels)) (, ,) (NP (JJ characteristic) (JJ clinical) (NNS manifestations)) (CC and) (NP (JJ abnormal) (NN laboratory))))))) (NNS findings)) (VP (AUX are) (RB not) (ADVP (RB frequently)) (ADJP (JJ present))) (. .)))
8494478	4	(S1 (S (NP (JJ Allergic) (NN Doc_8494478_463_485_Disease)) (VP (AUX is) (VP (VBN believed) (S (VP (TO to) (VP (AUX be) (NP (DT the) (JJ underlying) (NN pathological-process))))))) (. .)))
8494478	5	(S1 (S (NP (JJ Definitive) (NN diagnosis)) (VP (VBZ requires) (NP (NP (NN performance)) (PP (IN of) (NP (JJ renal) (NN biopsy)))) (, ,) (SBAR (IN although) (S (NP (DT this)) (VP (AUX is) (RB not) (ADVP (RB always)) (ADJP (JJ feasible)))))) (. .)))
8494478	6	(S1 (NP (NP (DT An) (NN improvement)) (PP (IN in) (NP (NP (JJ renal) (NN function)) (SBAR (WHNP (WDT that)) (S (VP (VBD followed) (NP (NP (DT the) (NN discontinuation)) (PP (IN of) (NP (DT the) (VBG offending) (JJ antibiotic) (NNS supports)))) (NP (NP (DT the) (JJ presumptive) (NN diagnosis)) (PP (IN of) (NP (NNP Doc_8494478_771_784_Chemical-induced) (NNP Doc_8494478_793_812_Disease))))))))) (. .)))
8514073	0	(S1 (NP (NP (NN Doc_8514073_0_20_Disease)) (PP (IN of) (NP (NP (NNP Doc_8514073_24_33_Chemical)) (CC versus) (NP (NNP Doc_8514073_41_49_Chemical)))) (. .)))
8514073	1	(S1 (S (SBAR (IN Although) (S (NP (DT some) (NNS studies)) (VP (AUX have) (VP (VBN suggested) (NP (NP (JJR fewer) (NNP Doc_8514073_94_114_Disease) (AUX are)) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_8514073_135_144_Chemical))))) (ADVP (IN than) (PP (IN with) (NP (NNP Doc_8514073_155_163_Chemical)))) (PP (IN for) (NP (JJ endoscopic) (NNS procedures))))))) (, ,) (NP (DT this) (NN variable)) (VP (AUX has) (RB not) (VP (AUX been) (ADVP (RB well)) (VP (VBN documented)))) (. .)))
8514073	2	(S1 (S (NP (PRP We)) (ADVP (RB prospectively)) (VP (VBN evaluated) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NNP Doc_8514073_279_299_Disease)))) (PP (IN after) (NP (NP (JJ intravenous) (NN injection)) (PP (IN of) (NP (NP (NNP Doc_8514073_331_339_Chemical)) (CC or) (NP (NNP Doc_8514073_343_352_Chemical)))))) (PP (IN in) (NP (NP (CD 122) (JJ consecutive) (NNS patients)) (VP (VBG undergoing) (ADJP (JJ colonoscopy) (CC and) (JJ esophagogastroduodenoscopy)))))) (. .)))
8514073	3	(S1 (S (ADVP (JJ Overall)) (, ,) (NP (NNP Doc_8514073_445_465_Disease)) (VP (AUX were) (ADJP (ADJP (RBR more) (JJ frequent)) (PP (IN with) (NP (NNP Doc_8514073_490_498_Chemical)))) (PRN (-LRB- -LRB-) (NP (NP (CD 22)) (PP (IN of) (NP (CD 62) (NNS patients)))) (-RRB- -RRB-)) (PP (IN than) (PP (IN with) (NP (NP (NP (NNP Doc_8514073_529_538_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 4)) (PP (IN of) (NP (CD 60) (NNS patients)))) (-RRB- -RRB-))) (-LRB- -LRB-) (NP (NNP p) (NNP <) (CD 0.001)) (-RRB- -RRB-))))) (. .)))
8514073	4	(S1 (S (NP (DT A) (JJ palpable) (JJ venous) (NN cord)) (VP (AUX was) (ADJP (JJ present) (PP (IN in) (NP (NP (NP (CD 23) (NN %)) (PRN (-LRB- -LRB-) (NP (NP (CD 14)) (PP (IN of) (NP (CD 62)))) (-RRB- -RRB-))) (PP (IN of) (NP (NP (NNS patients)) (PP (IN in) (NP (DT the) (NNP Doc_8514073_643_651_Chemical) (NN group)))))))) (, ,) (PP (VBN compared) (PP (IN with) (NP (NP (NP (CD 2) (NN %)) (PRN (-LRB- -LRB-) (NP (NP (CD 1)) (PP (IN of) (NP (CD 60) (NNS patients)))) (-RRB- -RRB-))) (PP (IN in) (NP (NP (DT the) (JJ Doc_8514073_702_711_Chemical) (NN group)) (PRN (-LRB- -LRB-) (NP (NNP p) (NNP <) (CD 0.002)) (-RRB- -RRB-)))))))) (. .)))
8514073	5	(S1 (S (NP (NP (NN Doc_8514073_731_735_Disease)) (PP (IN at) (NP (DT the) (NN injection) (NN site)))) (VP (VBD occurred) (PP (IN in) (NP (NP (NP (CD 35) (NN %)) (PRN (-LRB- -LRB-) (NP (NP (CD 22)) (PP (IN of) (NP (CD 62)))) (-RRB- -RRB-))) (PP (IN of) (NP (NP (NNS patients)) (PP (IN in) (NP (DT the) (NNP Doc_8514073_804_812_Chemical) (NN group))))))) (PP (VBN compared) (PP (IN with) (NP (NP (CD 7) (NN %)) (PRN (-LRB- -LRB-) (NP (NP (CD 4)) (PP (IN of) (NP (CD 60) (NNS patients)))) (-RRB- -RRB-))))) (PP (IN in) (NP (NP (DT the) (JJ Doc_8514073_862_871_Chemical) (NN group)) (PRN (-LRB- -LRB-) (NP (NNP p) (NNP <) (CD 0.001)) (-RRB- -RRB-))))) (. .)))
8514073	6	(S1 (S (NP (NP (NP (NN Doc_8514073_891_899_Disease)) (CC and) (NP (NN warmth))) (PP (IN at) (NP (DT the) (NN injection) (NN site)))) (VP (AUX were) (RB not) (ADJP (RB significantly) (JJ different) (PP (IN between) (NP (DT the) (CD two) (NNS groups))))) (. .)))
8514073	7	(S1 (S (NP (NP (NP (NP (NN Smoking)) (, ,) (NP (JJ nonsteroidal) (JJ anti-inflammatory) (NN drug) (NN use)) (, ,) (NP (JJ intravenous) (NN catheter) (NN site)) (, ,) (NP (NN dwell) (NN time))) (PP (IN of) (NP (DT the) (NN needle)))) (, ,) (NP (JJ Doc_8514073_1093_1100_Chemical) (NN use)) (, ,) (CC and) (NP (NNP Doc_8514073_1110_1114_Disease))) (PP (IN during) (NP (DT the) (NN injection))) (VP (AUX had) (NP (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NNP Doc_8514073_1170_1190_Disease))))))) (. .)))
8546130	0	(S1 (NP (NP (JJ Doc_8546130_0_14_Chemical-associated) (NN Doc_8546130_26_47_Disease)) (PP (IN in) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (NNP Doc_8546130_66_87_Disease))))) (PP (IN on) (NP (JJ continuous) (JJ ambulatory) (JJ peritoneal) (NN dialysis))) (. .)))
8546130	1	(S1 (S (NP (NN Doc_8546130_134_155_Disease)) (VP (VP (AUX are) (NP (NP (DT a) (JJ rare) (NN event)) (PP (IN in) (NP (NNP Doc_8546130_176_197_Disease))))) (CC and) (RB not) (VP (VBN related) (S (VP (TO to) (VP (VB Doc_8546130_217_223_Disease) (ADVP (FW per) (FW se))))))) (. .)))
8546130	2	(S1 (SINV (ADJP (JJ Unreported) (PP (IN in) (NP (DT the) (NN literature)))) (VP (AUX is)) (NP (NP (NNP Doc_8546130_264_285_Disease)) (VP (VBG occurring) (PP (IN in) (NP (NP (NN association)) (PP (IN with) (NP (NP (DT the) (JJ new) (JJ Doc_8546130_324_333_Chemical) (JJ antibiotic)) (, ,) (NP (NNP Doc_8546130_346_360_Chemical)))))))) (. .)))
8546130	3	(S1 (S (NP (PRP We)) (VP (VBP describe) (NP (PDT such) (DT a) (NN case)) (PP (IN in) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (NP (NNP Doc_8546130_404_427_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_8546130_429_433_Disease)) (-RRB- -RRB-)))) (VP (VBN maintained) (PP (IN on) (NP (NP (JJ continuous) (JJ ambulatory) (JJ peritoneal) (NN dialysis)) (PRN (-LRB- -LRB-) (NP (NNP CAPD)) (-RRB- -RRB-)))))))) (. .)))
8546130	4	(S1 (S (NP (NP (DT The) (NN combination)) (PP (IN of) (NP (NP (DT a) (ADJP (RB relatively) (JJ high)) (NN dose)) (PP (IN of) (NP (NNP Doc_8546130_544_558_Chemical))) (PP (IN in) (NP (NP (NN face)) (PP (IN of) (NP (NP (NNP Doc_8546130_570_591_Disease)) (PP (IN in) (NP (DT a) (ADJP (RB functionally) (JJ anephric)) (NN patient)))))))))) (, ,) (PP (IN with) (NP (JJ underlying) (JJ Doc_8546130_644_652_Chemical) (NN intoxication))) (, ,) (VP (MD may) (VP (AUX have) (VP (VBN facilitated) (NP (NP (DT the) (NN appearance)) (PP (IN of) (NP (DT this) (NNP Doc_8546130_711_721_Disease) (NN side) (NN effect))))))) (. .)))
8546130	5	(S1 (S (NP (PRP It)) (VP (AUX is) (ADJP (JJ important) (S (VP (TO to) (VP (VB understand) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NNS medications)))) (PP (IN in) (NP (NP (NN face)) (PP (IN of) (NP (NP (NNP Doc_8546130_812_833_Disease)) (, ,) (NP (NP (DT the) (NN possibility)) (PP (IN of) (NP (NN drug) (NNS interactions)))) (, ,))))))))) (SBAR (CC and) (WHADVP (WRB how)) (S (NP (DT these) (NNS factors)) (VP (MD should) (VP (VB help) (VP (VB guide) (NP (NN medication) (NN therapy)) (PP (IN in) (NP (DT the) (NNP Doc_8546130_939_943_Disease) (NN patient))))))))) (. .)))
85485	0	(S1 (NP (NP (NNS Changes)) (PP (IN in) (NP (NP (NNS peroxisomes)) (PP (IN in) (NP (NP (JJ preneoplastic) (NN liver) (CC and) (NN Doc_85485_50_58_Disease)) (PP (IN of) (NP (NP (NNS mice)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_85485_78_104_Chemical)))))))))) (. .)))
85485	1	(S1 (S (NP (NP (NNS Peroxisomes)) (PP (IN in) (NP (NP (NNP Doc_85485_121_130_Disease)) (CC and) (NP (JJ hyperplastic) (JJ preneoplastic) (NNP Doc_85485_162_175_Disease)))) (VP (VBN induced) (PP (IN in) (NP (NNS mice))) (PP (IN by) (NP (CD 500) (NN ppm) (NNP Doc_85485_203_229_Chemical))))) (VP (AUX were) (VP (VP (VBN examined) (ADVP (RB histochemically))) (CC and) (VP (NP (NNP electron)) (ADVP (RB microscopically))))) (. .)))
85485	2	(S1 (S (SBAR (IN Although) (S (NP (NP (JJS most)) (PP (IN of) (NP (DT the) (NNP Doc_85485_311_320_Disease)))) (VP (AUX were) (VP (VP (VBN well-differentiated) (NP (NNP Doc_85485_346_352_Disease))) (CC and) (VP (VBN contained) (NP (NP (DT a) (JJ considerable) (NN number)) (PP (IN of) (NP (NNS peroxisomes))))))))) (, ,) (NP (DT the) (JJ Doc_85485_409_414_Disease) (NNS cells)) (VP (AUX did) (RB not) (VP (VB respond) (PP (TO to) (NP (NNP Doc_85485_440_478_Chemical))) (PP (IN with) (NP (NP (NN proliferation)) (PP (IN of) (NP (NNS peroxisomes))))))) (. .)))
85485	3	(S1 (S (PP (IN At) (NP (NP (DT the) (JJ 16th) (NN week)) (PP (IN of) (NP (NN carcinogen) (NN feeding))))) (, ,) (NP (JJ hyperplastic) (NNS nodules)) (VP (VP (VBD appeared)) (CC and) (VP (VBD advanced) (PP (TO to) (NP (JJ further) (NNS stages))))) (. .)))
85485	4	(S1 (S (NP (NP (DT A) (NN majority)) (PP (IN of) (NP (DT the) (NNS nodules)))) (VP (VBD showed) (NP (NP (NP (DT a) (JJ considerable) (NN number)) (PP (IN of) (NP (NNS peroxisomes)))) (CC and) (NP (NP (DT the) (JJ inductive) (NN proliferation)) (PP (IN of) (NP (NNS peroxisomes)))))) (. .)))
85485	5	(S1 (S (PP (IN Within) (NP (DT the) (NNS nodules))) (, ,) (NP (NP (NNS foci)) (PP (IN of) (NP (NP (NN proliferation)) (PP (IN of) (NP (NP (DT the) (NNS cells)) (SBAR (WHNP (WDT that)) (S (VP (VBD showed) (NP (NP (DT no) (NN inducibility)) (PP (IN of) (NP (NP (NN proliferation)) (PP (IN of) (NP (NNS peroxisomes)))))))))))))) (VP (VBD appeared)) (. .)))
85485	6	(S1 (S (S (NP (DT These) (NNS cells)) (VP (VBN proliferated) (ADVP (RB further)) (, ,) (S (VP (VBG replacing) (NP (NP (DT the) (JJS most) (NN part)) (PP (IN of) (NP (DT the) (NNS nodules)))))))) (, ,) (CC and) (S (PP (IN with) (NP (DT this) (NN process))) (NP (NNP Doc_85485_955_964_Disease)) (VP (VBD appeared) (S (VP (TO to) (VP (AUX have) (VP (AUX been) (VP (VBN formed)))))))) (. .)))
85485	7	(S1 (S (NP (NP (DT No) (JJ abnormal) (JJ matrical) (NNS inclusions)) (PP (IN of) (NP (NNS peroxisomes)))) (VP (AUX were) (VP (VBN formed) (PP (IN in) (NP (NP (DT the) (NNS cells)) (PP (IN of) (NP (JJ hyperplastic) (NNS nodules))))) (PP (IN by) (NP (NP (NNP Doc_85485_1094_1132_Chemical)) (ADJP (IN unlike) (PP (IN in) (NP (NP (DT the) (NN case)) (PP (IN of) (NP (NNS rats)))))))))) (. .)))
8586822	0	(S1 (S (NP (NP (NN Contribution)) (PP (IN of) (NP (DT the) (JJ sympathetic) (JJ nervous) (NN system))) (PP (TO to) (NP (NN salt-sensitivity))) (PP (IN in) (NP (NN lifetime)))) (VP (VBD Doc_8586822_79_88_Chemical-treated) (ADVP (RB spontaneously)) (NP (NNP Doc_8586822_111_123_Disease) (NNS rats))) (. .)))
8586822	1	(S1 (S (S (VP (TO To) (VP (VB test) (NP (DT the) (NN hypothesis) (SBAR (IN that) (, ,) (PP (IN in) (NP (NP (NN lifetime) (JJ Doc_8586822_182_191_Chemical-treated) (RB spontaneously) (JJ Doc_8586822_214_226_Disease) (NNS rats)) (PRN (-LRB- -LRB-) (NP (NNP SHR)) (-RRB- -RRB-))))))))) (, ,) (NP (DT the) (JJ sympathetic) (JJ nervous) (NN system)) (VP (VBZ contributes) (ADVP (RB importantly)) (PP (TO to) (NP (NP (DT the) (JJ Doc_8586822_301_313_Disease) (NN effect)) (PP (IN of) (NP (JJ Doc_8586822_324_347_Chemical) (NN supplementation)))))) (. .)))
8586822	2	(S1 (S (NP (NP (JJ Male) (NNS SHR)) (PRN (-LRB- -LRB-) (NP (VBN aged) (CD 6) (NNS weeks)) (-RRB- -RRB-)) (SBAR (WHNP (WDT that)) (S (VP (AUX had) (VP (AUX been) (VP (VBN treated) (PP (IN from) (NP (NN conception))))))))) (ADVP (RB onward) (PP (IN with) (NP (DT either) (NN Doc_8586822_455_464_Chemical) (CC or) (NN vehicle)))) (VP (VP (VBD remained) (PP (IN on) (NP (DT a) (JJ basal) (JJ Doc_8586822_496_511_Chemical) (NN diet)))) (CC or) (VP (AUX were) (VP (VBN fed) (NP (DT a) (JJ high) (JJ Doc_8586822_536_551_Chemical) (NN diet))))) (. .)))
8586822	3	(S1 (S (PP (IN After) (NP (CD 2) (NNS weeks))) (, ,) (NP (DT the) (NNS rats)) (VP (AUX were) (VP (VBN subjected) (PP (TO to) (NP (NP (JJ ganglionic) (NN blockade)) (CC and) (ADVP (NP (CD 2) (NNS days)) (RB later)) (, ,) (NP (NP (DT an) (NN infusion)) (PP (IN of) (NP (NNP Doc_8586822_653_662_Chemical)))))))) (. .)))
8586822	4	(S1 (S (NP (NN Lifetime) (JJ Doc_8586822_682_691_Chemical) (NN treatment)) (ADVP (RB significantly)) (VP (VBD lowered) (NP (JJ mean) (JJ arterial) (NN pressure)) (PP (IN in) (NP (DT both) (NNS groups)))) (. .)))
8586822	5	(S1 (S (NP (NP (JJ Intravenous) (NN infusion)) (PP (IN of) (NP (DT the) (JJ ganglionic) (NN blocker) (NN Doc_8586822_810_823_Chemical)))) (VP (VBD resulted) (PP (IN in) (NP (NP (DT a) (JJ rapid) (NN decline)) (PP (IN in) (NP (NN MAP))) (SBAR (WHNP (WDT that)) (S (VP (VBD eliminated) (NP (NP (DT the) (JJ dietary) (JJ Doc_8586822_887_902_Chemical-induced) (NN increase)) (PP (IN in) (NP (NN MAP))) (PP (IN in) (NP (DT both) (NNS groups)))))))))) (. .)))
8586822	6	(S1 (S (NP (NP (NN Infusion)) (PP (IN of) (NP (DT the) (JJ central) (JJ nervous) (NN system) (NNP Doc_8586822_982_1016_Chemical) (NNP Doc_8586822_1017_1026_Chemical)))) (ADVP (RB also)) (VP (VBD resulted) (PP (IN in) (NP (NP (DT a) (JJR greater) (NN reduction)) (PP (IN in) (NP (NN MAP))) (PP (IN in) (NP (NP (DT both) (NNS groups)) (PP (IN of) (NP (NNP SHR))) (SBAR (WHNP (WDT that)) (S (VP (AUX were) (VP (VBN fed) (NP (DT the) (JJ high) (PRN (-LRB- -LRB-) (VP (VBN compared) (PP (IN with) (NP (DT the) (NN basal)))) (-RRB- -RRB-)) (JJ Doc_8586822_1142_1157_Chemical) (NN diet))))))))))) (. .)))
8586822	7	(S1 (S (PP (IN In) (NP (DT both) (NN lifetime) (UCP (JJ Doc_8586822_1194_1203_Chemical-treated) (CC and) (NN control)) (NN SHR))) (, ,) (NP (DT the) (JJ sympathetic) (JJ nervous) (NN system)) (VP (VBZ contributes) (PP (TO to) (NP (NP (DT the) (JJ pressor) (NNS effects)) (PP (IN of) (NP (DT a) (JJ high) (JJ Doc_8586822_1305_1320_Chemical) (NN diet)))))) (. .)))
8599504	0	(S1 (S (NP (NN Doc_8599504_0_10_Disease)) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_8599504_27_37_Chemical) (NN administration)))) (. .)))
8599504	1	(S1 (S (NP (NP (NN Doc_8599504_54_64_Disease)) (, ,) (VP (ADVP (RB also)) (VBN known) (PP (IN as) (NP (NP (NNP Doc_8599504_80_99_Disease)) (CC or) (NP (NNP Doc_8599504_103_120_Disease))))) (, ,)) (VP (AUX is) (NP (NP (DT a) (JJ well-demarcated) (, ,) (JJ localized) (NN Doc_8599504_154_159_Disease)) (VP (VBG involving) (NP (NP (DT the) (JJ subcutaneous) (NNS tissues)) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VB cause) (NP (NN Doc_8599504_210_234_Disease)))))))))) (. .)))
8599504	2	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT the) (NN case)) (PP (IN of) (NP (NP (DT a) (ADJP (RB previously) (JJ healthy)) (JJ 19-year-old) (NN man)) (PP (IN with) (NP (NP (DT no) (JJ known) (NN Doc_8599504_309_323_Disease)) (SBAR (WHPP (IN in) (WHNP (WP whom))) (S (NP (NP (NNP Doc_8599504_332_342_Disease)) (PP (IN with) (NP (NP (JJ significant) (NN Doc_8599504_360_375_Disease)) (CC and) (NP (NN protrusion))))) (VP (VBD developed) (PP (IN within) (NP (NP (CD 10) (NNS minutes)) (PP (IN of) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NP (DT a) (JJ single) (NNP IV) (NN dose)) (PP (IN of) (NP (NNP Doc_8599504_464_474_Chemical)))))))))))))))))) (. .)))
8600333	0	(S1 (NP (NP (JJ Late) (NN Doc_8600333_5_19_Disease)) (PP (IN after) (NP (NN treatment))) (PP (IN for) (NP (DT a) (JJ malignant) (NN Doc_8600333_52_62_Disease))) (. .)))
8600333	1	(S1 (S (NP (JJ Cardiac) (NN function)) (VP (AUX was) (VP (VBN assessed) (PP (IN in) (NP (NP (NP (JJ long-term) (NNS survivors)) (PP (IN of) (NP (JJ malignant) (NNP Doc_8600333_130_141_Disease))) (SBAR (WHNP (WP who)) (S (VP (AUX were) (VP (VBN treated) (PP (VBG according) (PP (TO to) (NP (NP (NNP Rosen) (POS 's)) (NNP T5) (CC or) (NNP T10) (NN protocol))))))))) (, ,) (NP (NP (DT both)) (PP (VBG including) (NP (NNP Doc_8600333_215_226_Chemical)))))))) (. .)))
8600333	2	(S1 (S (NP (NP (JJ Thirty-one) (NNS patients)) (, ,) (NP (NN age) (JJ 10-45) (NNS years)) (PRN (-LRB- -LRB-) (NP (NP (JJ median) (NN age)) (NP (CD 17.8) (NNS years))) (-RRB- -RRB-))) (VP (AUX were) (VP (VBN evaluated) (NP (NP (CD 2.3-14.1) (NNS years)) (PRN (-LRB- -LRB-) (NP (JJ median) (CD 8.9) (NNS years)) (-RRB- -RRB-)) (VP (VBG following) (NP (NP (NN completion)) (PP (IN of) (NP (NN treatment)))))))) (. .)))
8600333	3	(S1 (S (NP (NP (JJ Cumulative) (NNS doses)) (PP (IN of) (NP (NNP Doc_8600333_393_404_Chemical)))) (VP (AUX were) (NP (NP (JJ 225-550) (NNS mg/m2)) (PRN (-LRB- -LRB-) (NP (NN median) (NN dose) (CD 360)) (-RRB- -RRB-)))) (. .)))
8600333	4	(S1 (S (S (NP (DT The) (NN evaluation)) (VP (VBD consisted) (PP (IN of) (NP (NP (DT a) (NN history)) (, ,) (NP (JJ physical) (NN examination)) (, ,) (NP (NP (NN electrocardiogram)) (PRN (-LRB- -LRB-) (NP (NNP ECG)) (-RRB- -RRB-))))))) (, ,) (NP (NN signal)) (VP (VBD averaged) (NP (NP (NN ECG)) (, ,) (NP (JJ 24-hour) (JJ ambulatory) (NN ECG)) (, ,) (NP (NN echocardiography)) (CC and) (NP (NN radionuclide) (NN angiography)))) (. .)))
8600333	5	(S1 (S (S (NP (NP (CD Eighteen)) (PP (IN of) (NP (CD 31) (PRN (-LRB- -LRB-) (NP (CD 58) (NN %)) (-RRB- -RRB-)) (NNS patients)))) (VP (VBD showed) (NP (NP (NNP Doc_8600333_658_674_Disease)) (, ,) (VP (VBN defined) (PP (IN as) (S (VP (AUXG having) (NP (NP (QP (CD one) (CC or) (JJR more))) (PP (IN of) (NP (DT the) (JJ following) (NNS abnormalities))))))))))) (: :) (S (NP (NP (JJ late) (NNS potentials)) (, ,) (NP (JJ complex) (NNP Doc_8600333_763_786_Disease)) (, ,)) (VP (VP (VBD left) (NP (NNP Doc_8600333_793_813_Disease))) (, ,) (VP (VBD decreased) (NP (NN shortening) (NN fraction))) (, ,) (CC or) (VP (VBD decreased) (NP (JJ ejection) (NN fraction))))) (. .)))
8600333	6	(S1 (S (NP (NP (DT The) (NN incidence)) (PP (IN of) (NP (NNP Doc_8600333_895_916_Disease)))) (VP (VBN increased) (PP (IN with) (NP (NP (NN length)) (PP (IN of) (NP (NN follow-up))))) (PRN (-LRB- -LRB-) (NP (NNP P<) (CC or) (SYM =) (CD .05)) (-RRB- -RRB-))) (. .)))
8600333	7	(S1 (S (NP (DT No) (NN correlation)) (VP (MD could) (VP (AUX be) (VP (VBN demonstrated) (PP (IN between) (NP (NP (NP (JJ cumulative) (NN dose)) (PP (IN of) (NP (NNP Doc_8600333_1031_1042_Chemical)))) (CC and) (NP (JJ cardiac) (NN status)))) (, ,) (PP (IN except) (PP (IN for) (NP (NN heart) (NN rate) (NN variability))))))) (. .)))
8600333	8	(S1 (S (SBAR (WHADVP (WRB When)) (S (VP (VBN adjusted) (PP (TO to) (NP (NP (NN body) (NN surface) (NN area)) (, ,) (NP (NP (DT the) (JJ left) (JJ ventricular) (NN posterior) (NN wall) (NN thickness)) (PRN (-LRB- -LRB-) (NP (CD LVPW) (NN index)) (-RRB- -RRB-)))))))) (VP (AUX was) (VP (VBN decreased) (PP (IN in) (NP (DT all) (NNS patients))))) (. .)))
8600333	9	(S1 (S (NP (NP (DT The) (NN incidence)) (PP (IN of) (NP (NNP Doc_8600333_1241_1252_Chemical-induced) (NNP Doc_8600333_1261_1275_Disease)))) (VP (VP (AUX is) (ADJP (JJ high))) (CC and) (VP (VBZ increases) (PP (IN with) (NP (NN follow-up))) (, ,) (ADVP (RB irrespective) (PP (IN of) (NP (JJ cumulative) (NN dose)))))) (. .)))
8600333	10	(S1 (S (NP (NP (JJ Life-long) (JJ cardiac) (NN follow-up)) (PP (IN in) (NP (DT these) (NNS patients)))) (VP (AUX is) (VP (VBN warranted))) (. .)))
8600333	11	(S1 (S (NP (NP (DT The) (NNS results)) (PP (IN of) (NP (PRP$ our) (NN study)))) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NN heart) (NN rate) (NN variability)) (CC and) (NP (JJ LVPW) (NN index))) (VP (MD could) (VP (AUX be) (NP (NP (JJ sensitive) (NNS indicators)) (PP (IN for) (NP (NN Doc_8600333_1517_1531_Disease))))))))) (. .)))
8607407	0	(S1 (S (NP (JJ Acute) (NN blood) (NN pressure)) (VP (NNS elevations) (PP (IN with) (NP (NNP Doc_8607407_37_45_Chemical))) (PP (IN in) (NP (NP (NNS men)) (PP (IN with) (NP (JJ borderline) (JJ systemic) (NN Doc_8607407_78_90_Disease)))))) (. .)))
8607407	1	(S1 (S (SBAR (IN Whether) (S (NP (NP (DT the) (JJ vasoconstrictive) (NNS actions)) (PP (IN of) (NP (NNP Doc_8607407_132_140_Chemical)))) (VP (AUX are) (VP (VBN enhanced) (PP (IN in) (NP (JJ Doc_8607407_157_169_Disease) (NNS persons))))))) (VP (AUX has) (RB not) (VP (AUX been) (VP (VBN demonstrated)))) (. .)))
8607407	2	(S1 (S (ADVP (RB Thus)) (, ,) (NP (NP (NP (NNP Doc_8607407_211_219_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 3.3) (NN mg/kg)) (-RRB- -RRB-))) (CC versus) (NP (NN placebo))) (VP (AUX was) (VP (VBN tested) (PP (IN in) (NP (NP (NP (CD 48) (JJ healthy) (NNS men)) (PRN (-LRB- -LRB-) (VP (VBN aged) (NP (QP (CD 20) (TO to) (CD 35)) (NNS years))) (-RRB- -RRB-))) (VP (VBN selected) (PP (IN after) (S (VP (VBG screening) (PP (IN on) (NP (CD 2) (JJ separate) (NNS occasions))))))))))) (. .)))
8607407	3	(S1 (S (NP (NNP Borderline) (NNP Doc_8607407_359_371_Disease) (NNS men)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 24)) (-RRB- -RRB-)) (VP (AUX were) (VP (VBN selected) (PP (IN with) (S (VP (VBG screening) (NP (NP (JJ systolic) (NN blood) (NN pressure)) (PRN (-LRB- -LRB-) (NP (NNP BP)) (-RRB- -RRB-)) (PP (IN of) (NP (QP (CD 140) (TO to) (CD 160)) (NNS mm)))) (S (NP (NNP Hg) (NN and/or)) (ADJP (JJ diastolic) (NP (NNP BP) (CD 90)) (PP (TO to) (NP (CD 99) (NN mm) (NNP Hg)))))))))) (. .)))
8607407	4	(S1 (S (NP (NP (JJ Low-risk) (NNS controls)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 24)) (-RRB- -RRB-))) (VP (VP (VBD reported) (NP (NP (DT no) (JJ parental) (NN history)) (PP (IN of) (NP (NNP Doc_8607407_558_570_Disease))))) (CC and) (VP (AUX had) (S (NP (NN screening) (NNP BP) (NNP <) (CD 130/85)) (VP (VBG mm) (NP (NNP Hg)))))) (. .)))
8607407	5	(S1 (S (S (NP (NNS Participants)) (VP (AUX were) (ADVP (RB then)) (VP (VBN tested) (PP (IN on) (NP (CD 2) (NNS occasions))) (PP (IN after) (NP (NP (JJ 12-hour) (NN abstinence)) (PP (IN from) (NP (NNP Doc_8607407_683_691_Chemical))))) (PP (IN in) (NP (NP (DT each)) (PP (IN of) (NP (CD 2) (NNS protocols)))))))) (: ;) (S (NP (DT this)) (VP (VBD required) (NP (NP (DT a) (NN total)) (PP (IN of) (NP (CD 4) (NN laboratory) (NNS visits)))))) (. .)))
8607407	6	(S1 (S (NP (NP (JJ Doc_8607407_762_770_Chemical-induced) (NNS changes)) (PP (IN in) (NP (JJ diastolic) (NNP BP)))) (VP (VP (AUX were) (ADJP (ADJP (QP (CD 2) (TO to) (CD 3) (NNS times)) (JJR larger) (PP (IN in) (NP (JJ borderline) (NNS subjects)))) (PP (IN than) (PP (IN in) (NP (NP (NNS controls)) (PRN (-LRB- -LRB-) (NP (NP (CD +8.4) (NNP vs) (CD +3.8)) (VP (VBG mm) (NP (NNP Hg)))) (, ,) (NP (NNP p) (QP (CD <) (CD 0.0001))) (-RRB- -RRB-))))))) (, ,) (CC and) (VP (AUX were) (ADJP (JJ attributable) (PP (TO to) (NP (NP (JJR larger) (NNS changes)) (PP (IN in) (NP (NP (JJ impedance-derived) (NNS measures)) (PP (IN of) (NP (NP (JJ systemic) (JJ vascular) (NN resistance)) (PRN (-LRB- -LRB-) (NP (NP (CD +135) (NNP vs) (CD +45) (NN dynes.s.cm-5)) (, ,) (NP (NNP p) (NNP <) (CD 0.004))) (-RRB- -RRB-))))))))))) (. .)))
8607407	7	(S1 (S (NP (DT These) (NNS findings)) (VP (VP (AUX were) (ADJP (JJ consistent))) (CC and) (VP (VBD reached) (NP (NN significance)) (PP (IN in) (NP (DT both) (NNS protocols))))) (. .)))
8607407	8	(S1 (S (NP (NP (DT The) (NN percentage)) (PP (IN of) (NP (JJ borderline) (NNS subjects))) (SBAR (WHPP (IN in) (WHNP (WP whom))) (S (NP (JJ diastolic) (NNP BP) (NNS changes)) (VP (VBD exceeded) (NP (DT the) (JJ median) (NN control) (NN response)))))) (VP (AUX was) (NP (CD 96) (NN %))) (. .)))
8607407	9	(S1 (S (ADVP (RB Consequently)) (, ,) (SBAR (IN whereas) (S (NP (DT all) (NNS participants)) (VP (VBD exhibited) (NP (NN normotensive) (NNS levels)) (PP (IN during) (NP (DT the) (JJ resting) (NN predrug) (NN baseline)))))) (, ,) (NP (NP (CD 33) (NN %)) (PP (IN of) (NP (JJ borderline) (NNS subjects)))) (VP (VBD achieved) (NP (NNP Doc_8607407_1373_1385_Disease) (NNP BP) (NNS levels)) (PP (IN after) (NP (JJ Doc_8607407_1402_1410_Chemical) (NN ingestion)))) (. .)))
8607407	10	(S1 (S (ADVP (RB Thus)) (, ,) (PP (IN in) (NP (JJ borderline) (JJ Doc_8607407_1442_1454_Disease) (NNS men))) (, ,) (NP (NP (JJ exaggerated) (NNS responses)) (PP (TO to) (NP (NNP Doc_8607407_1485_1493_Chemical)))) (VP (AUX were) (UCP (: :) (ADJP (ADJP (JJ selective) (PP (IN for) (NP (JJ diastolic) (NNP BP)))) (, ,) (ADJP (JJ consistent) (PP (IN with) (NP (NP (JJR greater) (NN vasoconstriction)) (, ,) (VP (VBN replicated) (PP (IN in) (NP (CD 2) (NNS protocols)))) (, ,)))) (CC and) (ADJP (JJ representative) (PP (IN of) (NP (NP (RB nearly) (DT all)) (VP (VBN borderline) (NP (NNP Doc_8607407_1641_1654_Disease))))))))) (. .)))
8607407	11	(S1 (S (NP (PRP We)) (VP (VBP suspect) (SBAR (IN that) (S (NP (NP (DT the) (NN potential)) (PP (IN for) (NP (NNP Doc_8607407_1690_1698_Chemical))) (S (VP (TO to) (VP (VB stabilize) (NP (NP (JJ high) (NN resistance) (NNS states)) (PP (IN in) (NP (JJ susceptible) (NNS persons)))))))) (VP (VBZ suggests) (SBAR (IN that) (S (NP (PRP$ its) (NN use)) (VP (MD may) (VP (VP (VB facilitate) (NP (PRP$ their) (NN disease) (NN progression))) (, ,) (CONJP (RB as) (RB well) (IN as)) (VP (VB hinder) (NP (JJ accurate) (NN diagnosis) (CC and) (NN treatment))))))))))) (. .)))
8617710	0	(S1 (NP (NP (NN Absence)) (PP (IN of) (NP (NN effect))) (PP (IN of) (NP (NNP Doc_8617710_21_31_Chemical))) (PP (IN on) (NP (NP (JJ time-based) (NN sensitization)) (PP (IN of) (NP (NNP Doc_8617710_63_83_Disease))) (PP (IN with) (NP (NNP Doc_8617710_89_100_Chemical))))) (. .)))
8617710	1	(S1 (S (NP (DT This) (JJ double-blind) (, ,) (JJ randomized) (, ,) (JJ placebo-controlled) (NN study)) (VP (VBN evaluated) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (NP (NNP Doc_8617710_183_194_Chemical)) (ADVP (RB alone))) (CC and) (NP (NNP Doc_8617710_205_216_Chemical) (CC plus) (NNP Doc_8617710_222_232_Chemical))))) (PP (IN on) (NP (NP (NN cognitive)) (CC and) (NP (NN psychomotor) (NN function)))) (PP (IN in) (NP (CD 24) (JJ healthy) (NN male) (NNS subjects)))) (. .)))
8617710	2	(S1 (S (NP (DT All) (NNS subjects)) (VP (VBD received) (NP (NN placebo)) (PP (IN on) (NP (NP (NNP Day) (CD 1)) (CC and) (NP (NNP Doc_8617710_351_362_Chemical) (CD 2)))) (S (VP (VBG mg) (PP (IN on) (NP (NNS Days) (CD 2) (CC and) (CD 25)))))) (. .)))
8617710	3	(S1 (S (S (PP (IN From) (NP (NNS Days) (CD 9) (TO to) (CD 25))) (, ,) (NP (NNS subjects)) (VP (AUX were) (ADVP (RB randomly)) (VP (VBN assigned) (PP (TO to) (NP (DT either) (NP (NP (NNP Doc_8617710_447_457_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 12) (NNS subjects)) (-RRB- -RRB-))) (CC or) (NP (NP (NN placebo)) (PRN (-LRB- -LRB-) (NP (CD 12) (NNS subjects)) (-RRB- -RRB-)))))))) (: ;) (S (NP (DT the) (JJ Doc_8617710_502_512_Chemical) (NN dose)) (VP (VP (AUX was) (VP (VBN titrated) (PP (IN from) (NP (NP (QP (CD 50) (TO to) (CD 200)) (NN mg/day)) (PP (IN from) (NP (NNS Days) (CD 9) (TO to) (CD 16))))))) (, ,) (CC and) (VP (VBD remained) (PP (IN at) (NP (CD 200) (NN mg/day))) (PP (IN for) (NP (NP (DT the) (JJ final) (CD 10) (NNS days)) (PP (IN of) (NP (DT the) (NN drug) (NN administration) (NN period)))))))) (. .)))
8617710	4	(S1 (S (NP (JJ Cognitive) (NN function) (NN testing)) (VP (AUX was) (VP (VBN performed) (PP (PP (IN before) (NP (NN dosing))) (CC and) (PP (IN over) (NP (DT a) (JJ 24-hour) (NN period)))) (PP (IN after) (S (VP (VBG dosing) (PP (IN on) (NP (NNS Days))) (NP (CD 1) (, ,) (CD 2) (, ,) (CC and) (CD 25))))))) (. .)))
8617710	5	(S1 (S (NP (NN Doc_8617710_781_813_Disease)) (VP (AUX was) (VP (VBD observed) (NP (QP (CD 6) (TO to) (CD 8)) (NNS hours)) (PP (IN after) (NP (NP (NN administration)) (PP (IN of) (NP (NNP Doc_8617710_864_875_Chemical))))) (PP (IN on) (NP (NNP Day) (CD 2)))) (CC but) (VP (AUX was) (RB not) (ADJP (JJ evident)) (PP (NP (CD 23) (NNS hours)) (IN after) (NP (NN dosing))))) (. .)))
8617710	6	(S1 (S (SBAR (WHADVP (WRB When)) (S (NP (JJ single-dose) (NNP Doc_8617710_945_956_Chemical)) (VP (AUX was) (VP (VBN given) (ADVP (RB again)) (ADVP (NP (CD 25) (NNS days)) (RB later)))))) (, ,) (NP (NP (JJR greater) (NN impairment)) (PP (IN with) (NP (JJR earlier) (NN onset)))) (VP (AUX was) (VP (VBN noted) (PP (IN in) (NP (NP (JJ several) (NNS tests)) (PP (IN in) (NP (DT both) (NN treatment) (NNS groups))))) (, ,) (S (VP (VBG suggesting) (NP (NP (NN enhancement)) (PP (IN of) (NP (DT this) (NN effect)))))))) (. .)))
8617710	7	(S1 (S (NP (EX There)) (VP (AUX was) (NP (DT no) (NN indication) (SBAR (IN that) (S (NP (NNP Doc_8617710_1147_1157_Chemical)) (VP (VBD exacerbated) (SBAR (S (NP (NP (DT the) (NN impairment)) (VP (VBN produced) (PP (IN by) (NP (NNP Doc_8617710_1197_1208_Chemical))) (PP (IN since) (NP (DT an) (JJ equivalent) (NN effect))))) (ADVP (RB also)) (VP (VBD occurred) (PP (IN in) (NP (DT the) (NN placebo) (NN group))))))))))) (. .)))
8617710	8	(S1 (S (NP (NP (CD Three) (NNS subjects)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 2)) (PP (IN on) (NP (NNP Doc_8617710_1293_1303_Chemical)))) (CC and) (NP (NP (CD 1)) (PP (IN on) (NP (NN placebo))))) (-RRB- -RRB-))) (VP (VBD withdrew) (PP (IN from) (NP (DT the) (NN study))) (PP (IN because) (IN of) (NP (NN side) (NNS effects)))) (. .)))
8617710	9	(S1 (S (NP (NP (CD Ten) (NNS subjects)) (PP (IN in) (NP (DT each) (NN group)))) (VP (VBD reported) (NP (NP (JJ side) (NNS effects)) (VP (VBN related) (PP (TO to) (NP (NN treatment)))))) (. .)))
8617710	10	(S1 (S (NP (NP (DT The) (JJ side) (NN effect) (NNS profiles)) (PP (PP (IN of) (NP (NNP Doc_8617710_1470_1480_Chemical))) (CC and) (PP (IN of) (NP (NN placebo))))) (VP (AUX were) (ADJP (JJ similar))) (. .)))
8617710	11	(S1 (S (NP (NN Doc_8617710_1522_1533_Chemical)) (VP (VBD produced) (NP (NP (DT a) (JJ clear) (NN profile)) (PP (IN of) (NP (NNP Doc_8617710_1562_1582_Disease))) (SBAR (WHNP (WDT that)) (S (VP (AUX was) (RB not) (VP (VBN worsened) (PP (IN by) (NP (JJ concomitant) (JJ Doc_8617710_1620_1630_Chemical) (NN administration))))))))) (. .)))
8638876	0	(S1 (NP (NP (NN Coexistence)) (PP (IN of) (NP (NNP Doc_8638876_15_75_Disease))) (VP (VBN associated) (PP (IN with) (NP (JJ exogenous) (NN sex) (NNS hormones)))) (. .)))
8638876	1	(S1 (S (NP (DT A) (NN case)) (VP (VBP report)) (. .)))
8638876	2	(S1 (S (NP (DT A) (JJ forty-six) (JJ year-old) (JJ premenopausal) (NN woman)) (VP (VBD developed) (SBAR (S (NP (NP (NNP Doc_8638876_182_190_Disease)) (, ,) (NP (NNP Doc_8638876_192_198_Disease) (CC and) (NNP Doc_8638876_203_211_Disease)) (, ,)) (VP (VBD left) (NP (NNP Doc_8638876_218_229_Disease) (CC and) (NNP Doc_8638876_234_241_Disease) (CD two) (NNS days)) (PP (IN after) (NP (NP (JJ parenteral) (NN use)) (PP (IN of) (NP (NP (NNP Doc_8638876_275_287_Chemical)) (CC and) (NP (NNP Doc_8638876_292_301_Chemical)))))))))) (. .)))
8638876	3	(S1 (S (NP (NP (NN Doc_8638876_303_320_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_8638876_322_324_Disease)) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN found) (PP (IN during) (NP (NN admission))))) (. .)))
8638876	4	(S1 (S (NP (JJ Computed) (NN tomography)) (VP (VP (VBD showed) (NP (DT a) (NN Doc_8638876_383_402_Disease)) (PP (IN in) (NP (DT the) (JJ right) (JJ frontal) (NN lobe)))) (CC and) (VP (VBD increased) (NP (NN density)) (PP (IN in) (NP (NP (DT the) (JJ superior) (NN sagittal) (NN sinus)) (PRN (-LRB- -LRB-) (NP (NN SSS)) (-RRB- -RRB-)))))) (. .)))
8638876	5	(S1 (S (NP (JJ Left) (JJ carotid) (NN angiography)) (VP (VBD found) (NP (NP (NNP Doc_8638876_520_565_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_8638876_567_570_Chemical)) (-RRB- -RRB-)))) (. .)))
8638876	6	(S1 (S (NP (JJ Right) (NN carotid) (NNS angiograms)) (VP (VBD failed) (S (VP (TO to) (VP (VB show) (NP (NP (DT the) (ADJP (JJ SSS) (CC and) (JJ inferior)) (NN sagittal) (NN sinus)) (, ,) (NP (NP (NN suggestive)) (PP (IN of) (NP (NNP Doc_8638876_664_687_Disease))))))))) (. .)))
8638876	7	(S1 (S (NP (NP (NN Coexistence)) (PP (IN of) (NP (DT the) (NNP Doc_8638876_708_754_Disease)))) (VP (AUX has) (VP (AUX been) (VP (VBN described) (ADVP (RB infrequently))))) (. .)))
8638876	8	(S1 (S (PP (IN In) (NP (DT this) (NN case))) (, ,) (NP (DT the) (NNS authors)) (VP (VBP postulate) (SBAR (IN that) (S (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NP (NNP Doc_8638876_840_849_Chemical) (CC and) (NNP Doc_8638876_854_866_Chemical)) (CC and) (NP (DT the) (VBG underlying) (NNP Doc_8638876_886_888_Disease))))) (VP (VBD increased) (NP (NP (JJ vascular) (NN thrombogenicity)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD provided) (NP (NP (DT a) (JJ common) (NN denominator)) (PP (IN for) (NP (NP (NNS thrombosis)) (PP (IN of) (NP (NP (PDT both) (DT the) (NNP Doc_8638876_988_991_Chemical)) (CC and) (NP (DT the) (JJ venous) (NN sinus))))))))))))))) (. .)))
8643966	0	(S1 (NP (NP (NP (NN Chemotherapy)) (PP (IN of) (NP (JJ advanced) (JJ inoperable) (NN Doc_8643966_36_62_Disease))) (PP (IN with) (NP (NNP Doc_8643966_68_78_Chemical)))) (: :) (NP (DT a) (NN phase) (NNP II) (NN trial)) (. .)))
8643966	1	(S1 (S (NP (NP (NNP Doc_8643966_98_108_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (NNP Doc_8643966_110_115_Chemical)) (: ;) (NP (NP (NNP Bristol-Myers) (NNP Squibb) (NNP Company)) (, ,) (NP (NNP Princeton)))) (, ,) (NP (NNP NJ)) (-RRB- -RRB-))) (VP (AUX has) (VP (VBN demonstrated) (NP (JJ significant) (JJ antineoplastic) (NN activity)) (PP (IN against) (NP (NP (JJ different) (JJ Doc_8643966_233_238_Disease) (NNS types)) (, ,) (ADVP (RB notably)) (NP (NNP Doc_8643966_254_282_Disease)))))) (. .)))
8643966	2	(S1 (S (NP (NP (NP (CD Two) (NN phase)) (NP (NNP II) (NNS trials))) (PP (IN of) (NP (NP (JJ 24-hour) (JJ Doc_8643966_315_325_Chemical) (NNS infusions)) (PP (IN in) (NP (NP (JJ chemotherapy-naive) (NNS patients)) (PP (IN with) (NP (NP (NN stage) (NN IIIB)) (CC or) (NP (NP (NNP IV) (NNP Doc_8643966_389_415_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_8643966_417_422_Disease)) (-RRB- -RRB-)))))))))) (VP (VBD reported) (NP (NP (NN response) (NNS rates)) (PP (IN of) (NP (NP (CD 21) (NN %)) (CC and) (NP (CD 24) (NN %)))))) (. .)))
8643966	3	(S1 (S (S (NP (NN Doc_8643966_464_474_Disease)) (VP (AUX was) (ADJP (NN dose) (VBG limiting)))) (: :) (S (NP (NP (QP (RB as) (JJ many) (IN as) (CD 62.5)) (NN %)) (PP (IN of) (NP (NNS patients)))) (VP (VBD experienced) (NP (NN grade) (CD 4) (NN Doc_8643966_543_553_Disease)))) (. .)))
8643966	4	(S1 (S (NP (PRP We)) (VP (VBD investigated) (NP (NP (DT the) (NN efficacy) (CC and) (NN Doc_8643966_588_596_Disease)) (PP (IN of) (NP (DT a) (JJ 3-hour) (JJ Doc_8643966_609_619_Chemical) (NN infusion))) (PP (IN in) (NP (NP (DT a) (NN phase) (NNP II) (NN trial)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ inoperable) (NN stage) (NNP IIIB) (CC or) (NNP IV) (NNP Doc_8643966_694_699_Disease))))))))) (. .)))
8643966	5	(S1 (S (NP (DT The) (CD 58) (NNS patients)) (VP (VBD treated) (SBAR (S (-LRB- -LRB-) (NP (NP (CD 41) (NNS men)) (CC and) (NP (CD 17) (NNS women))) (-RRB- -RRB-) (VP (AUX had) (NP (NP (NP (DT a) (JJ median) (NN age)) (PP (IN of) (NP (NP (CD 59) (NNS years)) (PRN (-LRB- -LRB-) (NP (NN age) (NN range)) (, ,) (NP (QP (CD 25) (TO to) (CD 75))) (-RRB- -RRB-))))) (CC and) (NP (NP (DT a) (NN performance) (NN status)) (PP (IN of) (NP (NP (CD 0)) (PP (IN through) (NP (CD 2))))))))))) (. .)))
8643966	6	(S1 (S (NP (NP (JJS Most) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 72.4) (NN %)) (-RRB- -RRB-))) (VP (AUX had) (VP (VB stage) (NP (NNP IV) (NNP Doc_8643966_874_879_Disease)))) (. .)))
8643966	7	(S1 (S (NP (NN Doc_8643966_881_891_Chemical) (CD 225) (NN mg/m2)) (VP (AUX was) (VP (VBN infused) (PP (IN over) (NP (NP (CD 3) (NNS hours)) (NP (NP (DT every) (CD 3) (NNS weeks)) (PP (IN with) (NP (JJ standard) (JJ prophylactic) (NN premedication)))))))) (. .)))
8643966	8	(S1 (S (PP (IN Of) (NP (NP (CD 50) (NNS patients)) (ADJP (JJ evaluable) (PP (IN for) (NP (NP (NN response)) (, ,) (SBAR (S (NP (NP (CD 12)) (PRN (-LRB- -LRB-) (NP (CD 24) (NN %)) (-RRB- -RRB-))) (VP (AUX had) (NP (JJ partial) (NN remission)))))))))) (, ,) (S (NP (NP (CD 26)) (PRN (-LRB- -LRB-) (NP (CD 52) (NN %)) (-RRB- -RRB-))) (VP (AUX had) (NP (DT no) (NN change)))) (, ,) (CC and) (S (NP (CD 12)) (VP (AUX had) (NP (NP (NN disease) (NN progression)) (PRN (-LRB- -LRB-) (NP (CD 24) (NN %)) (-RRB- -RRB-))))) (. .)))
8643966	9	(S1 (S (S (NP (NNP Hematologic) (NNP Doc_8643966_1128_1138_Disease)) (VP (AUX were) (ADJP (JJ mild)))) (: :) (S (NP (NP (QP (RB only) (CD one)) (NN patient)) (PRN (-LRB- -LRB-) (NP (CD 2) (NN %)) (-RRB- -RRB-))) (VP (VBD developed) (NP (NN grade)) (NP (QP (CD 3) (CC or) (CD 4)) (NN Doc_8643966_1195_1206_Disease)) (, ,) (SBAR (IN while) (S (NP (CD 29) (NN %)) (VP (AUX had) (NP (NN grade)) (NP (CD 1) (CC or) (CD 2))))))) (. .)))
8643966	10	(S1 (S (NP (NP (NN Grade) (CD 1)) (CC or) (NP (CD 2) (NN Doc_8643966_1249_1263_Disease))) (VP (VBD affected) (NP (NP (CD 56) (NN %)) (PP (IN of) (NP (NNS patients)))) (SBAR (IN while) (S (NP (NP (RB only) (CD one)) (PRN (-LRB- -LRB-) (NP (CD 2) (NN %)) (-RRB- -RRB-))) (VP (VBD experienced) (NP (JJ severe) (NN Doc_8643966_1328_1342_Disease)))))) (. .)))
8643966	11	(S1 (S (ADVP (RB Similarly)) (, ,) (S (NP (ADJP (NN grade) (CD 1) (CC or) (CD 2)) (NNP Doc_8643966_1368_1375_Disease/Doc_8643966_1376_1386_Disease)) (VP (AUX was) (VP (VBN observed) (PP (IN in) (NP (NP (CD 63.2) (NN %)) (PP (IN of) (NP (NNS patients)))))))) (, ,) (CC but) (S (NP (QP (RB only) (CD 14.3)) (NN %)) (VP (VBD experienced) (NP (NN grade) (CD 3) (CC or) (CD 4)))) (. .)))
8643966	12	(S1 (S (NP (NP (NNP Doc_8643966_1463_1469_Disease)) (CC and) (NP (NNP Doc_8643966_1474_1482_Disease))) (VP (AUX were) (ADJP (JJ infrequent)) (, ,) (PP (IN with) (NP (NP (NP (CD 14) (NN %)) (PP (IN of) (NP (NP (NNS patients)) (VP (VBG experiencing) (NP (NN grade)) (NP (CD 1) (CC or) (CD 2)))))) (CC and) (NP (NP (QP (RB only) (CD 2)) (NN %)) (VP (VBG experiencing) (NP (NN grade) (CD 3) (CC or) (CD 4))))))) (. .)))
8643966	13	(S1 (S (NP (NNP Doc_8643966_1586_1596_Chemical)) (VP (AUX is) (ADVP (RB thus)) (NP (NP (DT an) (JJ active) (JJ single) (NN agent)) (PP (IN in) (NP (DT this) (JJ patient) (NN population))) (, ,) (PP (IN with) (NP (NP (DT a) (JJ 3-hour) (NN infusion) (NN proving)) (ADJP (ADJP (RB comparably) (JJ effective) (PP (TO to) (NP (DT a) (JJ 24-hour) (NN infusion)))) (CC and) (ADJP (JJ superior) (PP (IN in) (NP (NP (NNS terms)) (PP (IN of) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (ADJP (JJ hematologic) (CC and) (JJ nonhematologic)) (NNP Doc_8643966_1803_1811_Disease))))))))))))) (. .)))
8643966	14	(S1 (S (S (NP (NP (JJ Further) (NN phase) (NNP II) (NNS studies)) (PP (IN with) (NP (NNP Doc_8643966_1843_1853_Chemical))) (VP (VBN combined) (PP (IN with) (NP (NP (JJ other) (NNS drugs)) (PP (JJ active) (IN against) (NP (NNP Doc_8643966_1895_1900_Disease))))))) (VP (AUX are) (VP (VBN indicated)))) (, ,) (CC and) (S (NP (NP (NN phase) (NNP III) (NNS studies)) (VP (VBG comparing) (NP (NNP Doc_8643966_1948_1958_Chemical)) (PP (IN with) (NP (JJ standard) (NN chemotherapy))))) (VP (VBP remain) (S (VP (TO to) (VP (AUX be) (VP (VBN completed))))))) (. .)))
8643973	0	(S1 (S (NP (NN Doc_8643973_0_10_Chemical)) (VP (VBD combined) (PP (IN with) (NP (NNP Doc_8643973_25_36_Chemical))) (PP (IN in) (NP (NP (DT the) (JJ first-line) (NN treatment)) (PP (IN of) (NP (JJ advanced) (NN Doc_8643973_77_91_Disease)))))) (. .)))
8643973	1	(S1 (S (PP (IN In) (NP (NP (DT a) (NN phase)) (SBAR (S (NP (PRP I)) (VP (VBP study) (S (VP (TO to) (VP (VB determine) (NP (NP (DT the) (JJ maximum) (JJ tolerated) (NN dose)) (PP (IN of) (NP (NP (NNP Doc_8643973_155_165_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (NNP Doc_8643973_167_172_Chemical)) (: ;) (NP (NNP Bristol-Myers) (NNP Squibb) (NNP Company))) (, ,) (NP (NNP Princeton)) (, ,) (NP (NNP NJ)) (-RRB- -RRB-)))) (VP (VBN given) (PP (IN as) (NP (DT a) (JJ 3-hour) (NN infusion))) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NNP Doc_8643973_266_277_Chemical))) (VP (VBN administered) (NP (DT every) (CD 21) (NNS days)) (PP (TO to) (NP (NP (NNS women)) (PP (IN with) (NP (JJ advanced) (NNP Doc_8643973_328_342_Disease)))))))))))))))))) (, ,) (NP (NNP Doc_8643973_344_354_Chemical) (NNS doses)) (VP (AUX were) (VP (VBN escalated) (SBAR (IN as) (S (VP (VBZ follows) (: :) (NP (NP (NN level) (CD 1)) (, ,) (NP (NP (CD 135) (NN mg/m2)) (: ;) (NP (NP (NN level) (CD 2)) (, ,) (NP (CD 160) (NNS mg/m2))) (: ;) (NP (NP (NN level) (CD 3)) (, ,) (NP (CD 185) (NN mg/m2))) (: ;) (CC and) (NP (NP (NN level)) (NP (CD 4,210) (NNS mg/m2)))))))))) (. .)))
8643973	2	(S1 (S (NP (NP (DT The) (JJ fixed) (NN dose)) (PP (IN of) (NP (NNP Doc_8643973_489_500_Chemical))) (PP (IN at) (NP (NNS levels) (CD 1) (IN through) (CD 4)))) (VP (AUX was) (VP (VBN given) (S (VP (TO to) (VP (VB achieve) (NP (DT an) (NN area)) (PP (IN under) (NP (NP (DT the) (JJ concentration-time) (NN curve)) (PRN (-LRB- -LRB-) (NP (NNP AUC)) (-RRB- -RRB-)) (PP (IN of) (NP (CD 5))))) (S (VP (VBG using) (NP (DT the) (NNP Calvert) (NN formula))))))))) (. .)))
8643973	3	(S1 (S (PP (IN In) (NP (NNS levels) (CD 5) (CC and) (CD 6))) (NP (DT the) (NNP Doc_8643973_647_658_Chemical) (NN dose)) (VP (AUX was) (VP (VBN targeted) (PP (IN at) (NP (NP (NNS AUCs)) (PP (IN of) (NP (NP (CD 6)) (CC and) (NP (CD 7.5)))))) (, ,) (ADVP (RB respectively)) (, ,) (PP (VBN combined) (PP (IN with) (NP (NP (DT a) (VBN fixed) (JJ Doc_8643973_735_745_Chemical) (NN dose)) (PP (IN of) (NP (QP (CD 185) (CD mg/m2))))))))) (. .)))
8643973	4	(S1 (S (PP (TO To) (NP (NN date))) (, ,) (NP (NP (CD 30) (ADJP (RB previously) (JJ untreated)) (NNS patients)) (, ,) (NP (NP (DT all)) (PP (IN with) (NP (NP (DT a) (JJ good) (NN performance) (NN status)) (PRN (-LRB- -LRB-) (NP (NP (NNP Eastern) (NNP Cooperative) (NNP Oncology) (NNP Group)) (QP (CD 0) (TO to) (CD 2))) (-RRB- -RRB-)))))) (VP (AUX have) (VP (AUX been) (VP (VBN entered) (PP (IN into) (NP (DT this) (JJ ongoing) (NN study)))))) (. .)))
8643973	5	(S1 (S (NP (NP (DT The) (JJ dose-limiting) (NN Doc_8643973_948_956_Disease)) (PP (IN of) (NP (DT the) (NN combination)))) (VP (AUX was) (NP (NP (NN myelosuppression)) (PRN (-LRB- -LRB-) (NP (NP (NNP Doc_8643973_998_1008_Disease)) (, ,) (NP (NNP Doc_8643973_1010_1026_Disease)) (, ,) (CC and) (NP (NNP Doc_8643973_1032_1048_Disease))) (-RRB- -RRB-)))) (. .)))
8643973	6	(S1 (S (NP (NN Doc_8643973_1051_1064_Disease)) (VP (AUX was) (ADJP (RB largely) (JJ moderate))) (. .)))
8643973	7	(S1 (S (S (ADVP (RB So) (RB far)) (, ,) (NP (CD 14) (NNS patients)) (VP (AUX are) (ADJP (JJ evaluable)) (PP (IN for) (NP (NN response))))) (: ;) (S (PP (IN of) (NP (DT these))) (, ,) (NP (NP (CD eight)) (PRN (-LRB- -LRB-) (NP (CD 57) (NN %)) (-RRB- -RRB-))) (VP (VBD showed) (SBAR (S (NP (NP (JJ objective) (PRN (-LRB- -LRB-) (ADJP (JJ complete) (CC or) (JJ partial)) (-RRB- -RRB-)) (NN response)) (CC and) (NP (NN disease))) (VP (VBD stabilized) (PP (IN in) (NP (CD six) (NNS patients)))))))) (. .)))
8643973	8	(S1 (S (NP (DT No) (NN patient)) (VP (AUX had) (NP (NN disease) (NN progression))) (. .)))
8643973	9	(S1 (S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (S (NP (NP (DT the) (NN combination)) (PP (IN of) (NP (NP (NNP Doc_8643973_1317_1327_Chemical) (CD 185) (NNS mg/m2)) (VP (VBN administered) (PP (IN as) (NP (NP (DT a) (JJ 3-hour) (NN infusion)) (VP (VBN followed) (ADVP (RB immediately)) (PP (IN by) (NP (NP (DT a) (JJ 1-hour) (NN infusion)) (PP (IN of) (NP (NNP Doc_8643973_1417_1428_Chemical))))) (PP (IN at) (NP (NP (DT an) (NN AUC)) (PP (IN of) (NP (CD 6)))))))))))) (VP (MD can) (VP (AUX be) (VP (VBN administered) (ADVP (RB safely)) (PP (IN in) (NP (DT a) (JJ 21-day) (NN schedule))) (PP (IN in) (NP (DT the) (NN outpatient) (NN setting))))))))) (. .)))
8643973	10	(S1 (S (NP (NP (DT The) (VBN recommended) (NN dose)) (PP (IN for) (NP (NN phase) (NNP III) (NNS studies)))) (VP (AUX is) (NP (NP (NNP Doc_8643973_1565_1575_Chemical) (CD 185) (NN mg/m2)) (CC and) (NP (NNP Doc_8643973_1590_1601_Chemical) (NNP AUC) (CD 6)))) (. .)))
8665051	0	(S1 (NP (NP (NNS Effects)) (PP (IN of) (NP (JJ acute) (JJ Doc_8665051_17_24_Chemical) (NN administration))) (PP (IN on) (NP (NP (JJ ventilatory) (CC and) (JJ peripheral) (NNS muscles)) (PP (IN in) (NP (NNS rats))))) (. .)))
8665051	1	(S1 (S (NP (JJ Occasional) (NN case) (NNS reports)) (VP (AUX have) (VP (VBN shown) (SBAR (IN that) (S (NP (JJ acute) (NN Doc_8665051_133_141_Disease)) (VP (MD may) (VP (VB occur) (PP (IN in) (NP (NP (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NP (JJ massive) (NNS doses)) (PP (IN of) (NP (NNP Doc_8665051_194_209_Chemical)))))))))))))) (. .)))
8665051	2	(S1 (S (NP (NP (DT The) (NN mechanism)) (PP (IN of) (NP (DT this) (NN Doc_8665051_233_241_Disease)))) (VP (AUX is) (ADVP (RB poorly)) (VP (VBN understood))) (. .)))
8665051	3	(S1 (S (ADVP (RB Therefore)) (, ,) (NP (CD 60) (JJ male) (NNS rats)) (VP (AUX were) (ADVP (RB randomly)) (VP (VBN assigned) (S (VP (TO to) (VP (VB receive) (NP (NP (JJ daily) (NN injection)) (PP (IN of) (NP (NP (NN saline)) (PRN (-LRB- -LRB-) (NP (NNP C)) (-RRB- -RRB-)) (, ,) (NP (NP (NP (NNP Doc_8665051_353_371_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP M)) (-RRB- -RRB-))) (, ,) (CC or) (NP (NP (NNP Doc_8665051_380_393_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_8665051_395_396_Chemical)) (-RRB- -RRB-)))))))))) (SBAR (S (NP (NP (CD 80) (NN mg/kg/d)) (PP (IN for) (NP (CD 5) (NNP d.) (NNP Nutritional) (NN intake))) (, ,) (VP (VBN measured) (ADVP (RB daily)) (PP (IN in) (NP (CD 15) (NNS animals)))) (, ,)) (VP (VBD showed) (NP (DT a) (JJ significant) (NN Doc_8665051_489_513_Disease)) (PP (IN in) (NP (NP (DT the) (JJ Doc_8665051_521_528_Chemical-treated) (NNS groups)) (PRN (-LRB- -LRB-) (NP (NP (QP (CD -50) (CC and) (CD -79)) (NN %)) (PP (IN in) (NP (NNP M) (CC and) (NNP T)))) (, ,) (RB respectively) (-RRB- -RRB-))))))))) (. .)))
8665051	4	(S1 (S (NP (DT This)) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (DT a) (JJ similar) (NN Doc_8665051_620_639_Disease))))) (. .)))
8665051	5	(S1 (S (PP (IN In) (NP (DT the) (CD 45) (JJ remaining) (NNS animals))) (, ,) (NP (NP (NP (JJ diaphragm) (NN contractility)) (CC and) (NP (JJ histopathologic) (NNS features))) (PP (IN of) (NP (JJ several) (NNS muscles)))) (VP (AUX were) (VP (VBN studied))) (. .)))
8665051	6	(S1 (S (NP (NP (NNS Weights)) (PP (IN of) (NP (NP (NN respiratory)) (CC and) (NP (JJ peripheral) (NNS muscles))))) (VP (AUX were) (ADVP (RB similarly)) (VP (VBN decreased) (PP (IN after) (NP (JJ Doc_8665051_833_840_Chemical) (NN treatment))))) (. .)))
8665051	7	(S1 (S (NP (NP (JJ Maximal) (NNS twitches)) (PP (IN of) (NP (DT the) (NNS diaphragm)))) (VP (AUX were) (ADJP (JJR lower)) (PP (IN in) (NP (NP (NP (DT the) (NNP C) (NN group)) (PRN (-LRB- -LRB-) (NP (NP (CD 653) (JJ +/-) (CD 174) (JJ g/cm) (PRN (-LRB- -LRB-) (CD 2) (-RRB- -RRB-) (-RRB- -RRB-) (PP (IN than) (PP (IN in) (NP (NP (DT the) (NNP M) (NN group)) (PRN (-LRB- -LRB-) (NP (CD 837) (JJ +/-) (CD 171) (NNS g/cm)) (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-))))) (: ;)) (NNS p)) (NP (NNP <) (CD 0.05))) (-RRB- -RRB-))) (CC and) (NP (NP (DT the) (JJ T) (NN group)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 765) (JJ +/-) (CD 145) (NNS g/cm)) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-))) (, ,) (NP (NNP NS))) (-RRB- -RRB-)))))) (. .)))
8665051	8	(S1 (S (S (NP (JJ Half-relaxation) (NN time)) (VP (AUX was) (VP (VBN prolonged) (PP (IN in) (NP (DT both) (JJ Doc_8665051_1072_1079_Chemical) (NNS groups)))))) (, ,) (CC and) (S (NP (NP (NN time)) (PP (TO to) (NP (JJ peak) (NN tension)))) (VP (AUX was) (ADVP (RB longer)) (PP (IN with) (NP (NNP M))) (, ,) (SBAR (IN whereas) (S (NP (JJ tetanic) (NNS tensions)) (VP (AUX were) (ADJP (JJ similar))))))) (. .)))
8665051	9	(S1 (S (NP (JJ Doc_8665051_1171_1178_Chemical) (NN treatment)) (ADVP (RB also)) (VP (VBN induced) (NP (NP (DT a) (JJ leftward) (NN shift)) (PP (IN of) (NP (DT the) (NN force-frequency) (NN curve)))) (PP (IN at) (NP (CD 25) (CC and) (CD 50) (NN Hz))) (SBAR (WHADVP (WRB when)) (S (VP (VBN compared) (PP (IN with) (NP (NP (JJ saline) (NN treatment)) (PRN (-LRB- -LRB-) (NP (QP (CD p) (CD <)) (CD 0.05)) (-RRB- -RRB-)))))))) (. .)))
8665051	10	(S1 (S (NP (NP (JJ ATPase) (NN staining)) (PP (IN of) (NP (NP (DT the) (JJ diaphragm) (, ,) (JJ scalenus) (NNS medius)) (, ,) (CC and) (NP (NNS gastrocnemius))))) (VP (VBD showed) (NP (NP (NP (NN type) (NNP IIb) (NN fiber) (NNP Doc_8665051_1403_1410_Disease)) (PP (IN in) (NP (DT the) (NNP Doc_8665051_1418_1425_Chemical) (NNS groups)))) (CC and) (ADVP (RB also)) (NP (JJ diaphragmatic) (NN type) (NNP IIa) (NNP Doc_8665051_1465_1472_Disease))) (PP (IN with) (NP (NNP T))) (, ,) (SBAR (IN whereas) (S (NP (JJ histologic) (NNS examinations)) (VP (VBD revealed) (NP (NP (DT a) (JJ normal) (JJ muscular) (NN pattern)) (PP (IN with) (NP (NP (NN absence)) (PP (IN of) (NP (NNP Doc_8665051_1564_1572_Disease)))))))))) (. .)))
8665051	11	(S1 (S (ADVP (RB Finally)) (, ,) (NP (NP (DT a) (JJ pair-fed) (PRN (-LRB- -LRB-) (NP (NNP PF)) (-RRB- -RRB-)) (NN study)) (, ,) (VP (VBN performed) (PP (IN in) (NP (NP (CD 18) (NNS rats)) (PRN (-LRB- -LRB-) (NP (NNP C)) (, ,) (NP (NP (NNS T)) (, ,) (CC and) (NP (NNS PF))) (-RRB- -RRB-))))) (, ,)) (VP (VBD showed) (SBAR (IN that) (S (NP (NNP Doc_8665051_1655_1669_Disease)) (VP (AUX was) (ADJP (ADJP (ADVP (RB considerably) (RBR less)) (JJ pronounced)) (PP (IN in) (NP (JJ PF) (NNS animals))) (PP (IN than) (PP (IN in) (NP (JJ T-treated) (NNS animals))))))))) (. .)))
8665051	12	(S1 (S (NP (PRP We)) (VP (VBP conclude) (SBAR (SBAR (S (NP (IN that) (NP (NP (PRN (-LRB- -LRB-) (NP (CD 1)) (-RRB- -RRB-)) (JJ short-term) (NN treatment)) (PP (IN with) (NP (NP (JJ massive) (NNS doses)) (PP (IN of) (NP (NNP Doc_8665051_1808_1816_Chemical))) (VP (VBN induced) (NP (NP (JJ severe) (NN respiratory) (CC and) (NN limb) (NN muscle) (NN wasting)) (: ;) (NP (LST (-LRB- -LRB-) (LS 2) (-RRB- -RRB-)) (NP (DT both) (NNS types)) (PP (IN of) (NP (NNP Doc_8665051_1887_1895_Chemical))) (VP (VBN induced) (ADVP (RB predominantly)) (NP (NN type) (NNP IIb) (NNP Doc_8665051_1927_1934_Disease)))))))) (, ,) (VP (VBG resulting) (PP (IN in) (NP (NP (DT the) (VBN expected) (NNS alterations)) (PP (IN in) (NP (NP (JJ diaphragm) (JJ contractile) (NNS properties)) (PRN (: ;) (-LRB- -LRB-) (NP (CD 3)) (-RRB- -RRB-)))))))) (CC neither) (NP (NNP Doc_8665051_2023_2030_Chemical))) (VP (VBD caused) (NP (NN muscle) (NNP Doc_8665051_2045_2053_Disease))))) (: ;) (PRN (-LRB- -LRB-) (NP (CD 4)) (-RRB- -RRB-)) (NN type) (S (NP (NNP IIb) (NNP Doc_8665051_2068_2075_Disease)) (VP (AUX was) (RB not) (VP (VBN caused) (PP (IN by) (NP (JJ acute) (JJ nutritional) (NN deprivation)) (ADVP (RB alone)))))))) (. .)))
8677458	0	(S1 (S (NP (NP (JJ Continuous) (JJ subcutaneous) (NN administration)) (PP (IN of) (NP (NNP Doc_8677458_42_47_Chemical)))) (VP (TO to) (VP (VB prevent) (NP (JJ Doc_8677458_59_69_Chemical-induced) (NNP Doc_8677458_78_98_Disease)))) (. .)))
8677458	1	(S1 (S (NP (NN Doc_8677458_100_120_Disease)) (VP (AUX is) (NP (NP (DT a) (JJ major) (JJ potential) (NN Doc_8677458_142_150_Disease)) (PP (IN of) (NP (NNP Doc_8677458_154_164_Chemical))) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (AUX be) (VP (VBN prevented) (PP (IN by) (S (VP (VBG administering) (NP (NNP Doc_8677458_204_209_Chemical)) (ADVP (RB along)) (PP (IN with) (NP (DT the) (JJ cytotoxic) (NN agent))))))))))))) (. .)))
8677458	2	(S1 (S (NP (NN Doc_8677458_242_247_Chemical)) (VP (AUX is) (ADVP (RB generally)) (VP (VBN administered) (PP (IN by) (NP (DT the) (JJ intravenous) (NN route))) (, ,) (SBAR (IN although) (S (NP (NP (NN experience)) (PP (IN with) (NP (NP (JJ oral) (NN delivery)) (PP (IN of) (NP (DT the) (NN drug)))))) (VP (AUX has) (VP (VBN increased))))))) (. .)))
8677458	3	(S1 (S (NP (NP (DT The) (JJ continuous) (JJ subcutaneous) (NN administration)) (PP (IN of) (NP (NNP Doc_8677458_412_417_Chemical)))) (VP (AUX has) (NP (NP (DT the) (NN advantage)) (PP (IN of) (S (VP (RB not) (VBG requiring) (NP (JJ intravenous) (NN access))))))) (. .)))
8677458	4	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (JJ subcutaneous) (NN delivery)) (PP (IN of) (NP (DT the) (VBG neutralizing) (NN agent)))) (VP (MD will) (RB not) (VP (AUX be) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NP (JJ inadequate) (JJ urinary) (JJ Doc_8677458_593_598_Chemical) (NNS concentrations)) (, ,) (PP (JJ such) (IN as) (PP (IN in) (NP (NP (DT a) (NN patient)) (VP (VBG taking) (NP (NP (JJ oral) (NNP Doc_8677458_648_653_Chemical)) (SBAR (WHNP (WP who)) (S (VP (VP (VBZ experiences) (NP (JJ severe) (JJ Doc_8677458_677_687_Chemical-induced) (NN Doc_8677458_696_702_Disease))) (CC and) (VP (AUX is) (ADJP (JJ unable) (S (VP (TO to) (VP (VB absorb) (NP (DT the) (NN drug)))))))))))))))))))))) (. .)))
8677458	5	(S1 (S (NP (NP (VBN Limited) (JJ clinical) (NN experience)) (PP (IN with) (NP (JJ continuous) (JJ subcutaneous) (NNP Doc_8677458_794_799_Chemical) (NN administration)))) (VP (VBZ suggests) (SBAR (S (NP (PRP it)) (VP (AUX is) (NP (NP (DT a) (ADJP (ADJP (JJ safe)) (, ,) (ADJP (JJ practical)) (, ,) (CC and) (ADJP (JJ economic))) (NN method)) (PP (IN of) (NP (NN drug) (NN delivery))) (SBAR (WHNP (WDT that)) (S (VP (VBZ permits) (S (NP (NNP Doc_8677458_899_909_Chemical)) (VP (TO to) (VP (AUX be) (VP (VBN administered) (ADVP (RB successfully)) (PP (IN in) (NP (DT the) (NN outpatient) (NN setting))))))))))))))) (. .)))
8686832	0	(S1 (NP (NP (NN Doc_8686832_0_17_Disease)) (PP (IN after) (NP (NP (JJ spinal) (NNS anaesthesia)) (VP (VBG involving) (NP (JJ hyperbaric) (ADJP (CD 5) (NN %)) (NN Doc_8686832_67_77_Chemical))))) (. .)))
8686832	1	(S1 (S (NP (NP (JJ Fifty-four) (NNS patients)) (, ,) (VP (VBN aged) (NP (CD 27-90) (NNS years))) (, ,) (SBAR (WHNP (WP who)) (S (VP (AUX were) (VP (VBN given) (NP (NNP Doc_8686832_133_143_Chemical)) (NP (CD 5) (NN %)) (PP (IN in) (NP (NP (ADJP (CD 6.8) (NN %)) (JJ Doc_8686832_155_162_Chemical) (NN solution)) (PP (IN for) (NP (JJ spinal) (NNS anaesthesia)))))))))) (VP (AUX were) (VP (VBN studied))) (. .)))
8686832	2	(S1 (S (NP (NP (NNS Thirteen)) (PP (IN of) (NP (DT these) (NNS patients)))) (VP (VBD experienced) (NP (NNP Doc_8686832_248_276_Disease)) (PP (IN after) (NP (NP (NN recovery)) (PP (IN from) (NP (NN anaesthesia)))))) (. .)))
8686832	3	(S1 (S (S (NP (NP (DT The) (NNS patients)) (VP (VBN affected))) (VP (AUX were) (ADJP (JJR younger)))) (PRN (-LRB- -LRB-) (VP (VBN p) (NP (NNP <) (CD 0.05))) (-RRB- -RRB-)) (CC and) (S (NP (NP (DT the) (NN site)) (PP (IN of) (NP (DT the) (JJ dural) (NN puncture)))) (VP (AUX was) (ADJP (ADJP (ADJP (JJR higher)) (PRN (-LRB- -LRB-) (NP (QP (CD p) (CD <)) (CD 0.01)) (-RRB- -RRB-))) (PP (IN than) (NP (NP (DT those) (NNS individuals)) (PP (IN without) (NP (NNP Doc_8686832_444_448_Disease)))))))) (. .)))
8686832	4	(S1 (S (NP (NP (NP (CD Five)) (PP (IN of) (NP (NP (DT the) (CD 13) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 38) (NN %)) (-RRB- -RRB-)))) (PP (IN with) (NP (NNP Doc_8686832_485_489_Disease)))) (CC and) (NP (NP (CD seven)) (PP (IN of) (NP (NP (DT the) (CD 41) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 17) (NN %)) (-RRB- -RRB-)))) (PP (IN without) (NP (NNP Doc_8686832_533_537_Disease))))) (VP (VBD admitted) (PP (TO to) (NP (NP (DT a) (JJ high) (JJ Doc_8686832_557_564_Chemical) (NN intake)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD might) (VP (AUX be) (NP (DT a) (JJ contributing) (NN factor))))))))) (. .)))
8686832	5	(S1 (S (NP (NN Doc_8686832_611_631_Disease)) (VP (AUX is) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (JJ intrathecal) (NN use)) (PP (IN of) (NP (JJ hyperbaric) (ADJP (CD 5) (NN %)) (NN Doc_8686832_688_698_Chemical))))))) (. .)))
871943	0	(S1 (S (NP (NP (DT The) (NN use)) (PP (IN of) (NP (NN serum)))) (VP (VBP cholinesterase) (PP (IN in) (NP (JJ Doc_871943_35_50_Chemical) (NN apnoea)))) (. .)))
871943	1	(S1 (S (NP (NP (JJ Fifteen) (NNS patients)) (VP (VBG demonstrating) (NP (NP (JJ unexpected) (JJ prolonged) (NN apnoea)) (VP (VBG lasting) (NP (JJ several) (NNS hours)) (PP (IN after) (NP (NNP Doc_871943_146_161_Chemical))))))) (VP (AUX have) (VP (AUX been) (VP (VBN treated) (PP (IN by) (NP (NP (DT a) (JJ new) (NN preparation)) (PP (IN of) (NP (JJ human) (NN serum) (NN cholinesterase)))))))) (. .)))
871943	2	(S1 (S (NP (JJ Adequate) (JJ spontaneous) (NN respiration)) (VP (AUX was) (VP (VBN re-established) (PP (IN in) (NP (NP (DT an) (JJ average) (NN period)) (PP (IN of) (NP (CD ten) (NNS minutes))) (PP (IN after) (NP (DT the) (NN injection))))))) (. .)))
871943	3	(S1 (S (PP (IN In) (NP (CD 12) (NNS patients))) (NP (JJ biochemical) (JJ genetic) (NNS examinations)) (VP (VBD confirmed) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (DT an) (JJ atypical) (NN serum) (NN cholinesterase))))) (. .)))
871943	4	(S1 (S (PP (IN In) (NP (CD three) (NNS patients))) (NP (NP (NN none)) (PP (IN of) (NP (DT the) (JJ usual) (NNS variants)))) (VP (AUX were) (VP (VBN found))) (. .)))
871943	5	(S1 (S (NP (PRP It)) (VP (AUX is) (ADVP (RB therefore)) (VP (VBN supposed) (SBAR (IN that) (S (NP (NP (JJ other) (JJ unknown) (NNS variants)) (PP (IN of) (NP (NN serum) (NN cholinesterase)))) (VP (VBP exist) (SBAR (WHNP (WDT which)) (S (ADVP (RB cannot)) (VP (VBP hydrolyze) (NP (NNP Doc_871943_612_627_Chemical)))))))))) (. .)))
871943	6	(S1 (S (NP (NP (DT The) (NN use)) (PP (IN of) (NP (NP (NN serum) (NN cholinesterase)) (PP (IN in) (NP (JJ Doc_871943_664_679_Chemical) (NN apnoea)))))) (VP (VBD provided) (NP (JJ considerable) (NN relief)) (PP (TO to) (NP (PDT both) (NP (NN patient)) (CC and) (NP (NN anaesthetist))))) (. .)))
873132	0	(S1 (S (VP (VP (VBN Increased) (NP (NN sulfation))) (CC and) (VP (VBD decreased) (NP (NP (NN 7alpha-hydroxylation)) (PP (IN of) (NP (NNP Doc_873132_58_74_Chemical)))) (PP (IN in) (NP (NP (NNP Doc_873132_78_95_Chemical-induced) (NNP Doc_873132_104_115_Disease)) (PP (IN in) (NP (NNS rats))))))) (. .)))
873132	1	(S1 (S (NP (NP (NN Doc_873132_125_141_Chemical) (NN conjugation)) (, ,) (NP (NN transport) (NN capacity)) (, ,) (CC and) (NP (NN metabolism))) (VP (AUX were) (VP (VBN compared) (PP (IN in) (NP (NP (NN control)) (CC and) (NP (JJ Doc_873132_219_236_Chemical-treated) (NNS rats)))))) (. .)))
873132	2	(S1 (S (S (NP (NN Control) (NNS rats)) (VP (AUX were) (VP (VBN found) (S (VP (TO to) (VP (AUX have) (NP (NP (DT a) (JJR lower) (NN capacity)) (SBAR (S (VP (TO to) (VP (VB transport) (NP (NNP Doc_873132_313_329_Chemical)) (PP (IN than) (NP (NNP Doc_873132_335_356_Chemical)))))))))))))) (, ,) (CC and) (S (NP (DT both)) (VP (AUX were) (VP (VBN decreased) (PP (IN by) (NP (JJ Doc_873132_385_402_Chemical) (NN treatment)))))) (. .)))
873132	3	(S1 (S (PP (IN During) (NP (JJ -LSB-24-14C) (JJ -RSB-) (JJ Doc_873132_429_448_Chemical) (NN infusion))) (, ,) (S (NP (JJ -LSB-14C) (JJ -RSB-) (NN biliary) (NN Doc_873132_472_481_Chemical) (NN secretion)) (VP (VBD increased))) (, ,) (CC but) (S (NP (JJ bile) (NN flow)) (VP (AUX did) (RB not) (VP (VB change) (ADVP (RB significantly)) (PP (IN in) (NP (UCP (DT either) (NN control) (CC or) (JJ Doc_873132_567_584_Chemical-treated)) (NNS rats)))))) (. .)))
873132	4	(S1 (S (NP (JJ Doc_873132_599_616_Chemical-treated) (NNS animals)) (VP (VBD excreted) (NP (ADJP (RB significantly) (JJR less)) (NN 14C)) (PP (IN as) (NP (NNP Doc_873132_668_684_Chemical))) (SBAR (IN than) (S (VP (AUX did) (VP (VB control) (NP (NP (NNS animals)) (, ,) (ADJP (JJ consistent) (PP (IN with) (NP (NP (DT an) (NN impairment)) (PP (IN of) (NP (NP (NN 7alpha-hydroxylation)) (PP (IN of) (NP (NNP Doc_873132_768_789_Chemical)))))))))))))) (. .)))
873132	5	(S1 (S (NP (JJ Doc_873132_791_808_Chemical) (NN treatment)) (VP (VP (AUX did) (RB not) (VP (VB impair) (NP (NP (NN conjugation)) (PP (IN of) (NP (NNP Doc_873132_849_865_Chemical)))))) (, ,) (CC but) (VP (AUX did) (VP (VB result) (PP (IN in) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (NN sulfation)) (PP (IN of) (NP (NNP Doc_873132_913_934_Chemical))))) (PP (PP (IN from) (NP (NP (CD 1.5) (NN %)) (PP (IN in) (NP (NNS controls))))) (PP (TO to) (NP (QP (RB nearly) (CD 4.0)) (NN %)))))) (PRN (-LRB- -LRB-) (NP (NNP P) (QP (JJR less) (IN than) (CD 0.01))) (-RRB- -RRB-))))) (. .)))
873132	6	(S1 (S (NP (DT These) (NNS results)) (VP (AUX are) (ADJP (JJ consistent) (PP (IN with) (NP (NP (DT the) (NNS hypothesis)) (SBAR (WHNP (WDT that)) (S (NP (DT the) (NN rat)) (VP (AUX has) (NP (NP (DT a) (JJR poorer) (NN tolerance)) (PP (IN for) (NP (NNP Doc_873132_1081_1097_Chemical))) (SBAR (IN than) (SINV (AUX do) (NP (JJ certain) (JJ other) (NNS species)))))))))))) (. .)))
873132	7	(S1 (S (ADVP (RB Furthermore)) (, ,) (NP (DT the) (NN rat)) (VP (VBZ converts) (NP (NP (NNP Doc_873132_1159_1175_Chemical)) (, ,) (NP (DT a) (JJ poor) (NN choleretic)) (, ,)) (PP (TO to) (NP (NP (NNP Doc_873132_1199_1215_Chemical)) (, ,) (NP (DT a) (JJ good) (NN choleretic))))) (. .)))
873132	8	(S1 (S (SBAR (WHADVP (WRB When)) (S (NP (DT this) (NN conversion)) (VP (AUX is) (VP (VBN impaired) (PP (IN with) (NP (JJ Doc_873132_1274_1291_Chemical) (NN treatment))))))) (, ,) (NP (NN sulfation)) (VP (MD may) (VP (AUX be) (NP (NP (DT an) (JJ important) (JJ alternate) (NN pathway)) (PP (IN for) (NP (NP (NN excretion)) (PP (IN of) (NP (DT this) (ADJP (RB potentially) (JJ harmful)) (NN Doc_873132_1393_1402_Chemical)))))))) (. .)))
8742498	0	(S1 (NP (NP (NN Influence)) (PP (IN of) (NP (NP (NN diet) (JJ free)) (PP (IN of) (NP (NNP Doc_8742498_26_29_Chemical-precursors))))) (PP (IN on) (NP (NP (JJ Doc_8742498_44_57_Chemical) (NN hepatotoxicity)) (PP (IN in) (NP (NNS mice))))) (. .)))
8742498	1	(S1 (S (ADVP (RB Recently)) (, ,) (NP (PRP we)) (VP (VBD demonstrated) (NP (NP (DT the) (JJ hepatoprotective) (NNS effects)) (PP (IN of) (NP (NP (NP (NNP Doc_8742498_140_160_Chemical)) (, ,) (NP (NP (DT a) (JJ selective) (NN inhibitor)) (PP (IN of) (NP (JJ Doc_8742498_187_203_Chemical) (NN polymerase))))) (PRN (-LRB- -LRB-) (NP (NP (NNP PARP)) (: ;) (NP (NNP EC) (CD 2.4.2.30))) (-RRB- -RRB-)))) (PP (IN on) (NP (NP (NNS mice)) (VP (VBG suffering) (PP (IN from) (NP (NNP Doc_8742498_258_271_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_8742498_273_276_Chemical)) (-RRB- -RRB-)) (NN -Doc_8742498_278_287_Disease))))))) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP (DT the) (JJ Doc_8742498_309_312_Chemical-induced) (NN Doc_8742498_321_333_Disease)) (VP (VBZ involves) (NP (NP (DT a) (NN step)) (SBAR (WHNP (WDT which)) (S (VP (VBZ depends) (PP (IN on) (NP (NN adenoribosylation))))))))))))) (. .)))
8742498	2	(S1 (S (NP (DT The) (JJ present) (NN study)) (VP (VP (VBZ investigates) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (DT a) (NN diet)) (ADJP (JJ free) (PP (IN of) (NP (NP (NNS precursors)) (PP (IN of) (NP (NP (NNP Doc_8742498_461_464_Chemical)) (, ,) (NP (NP (DT the) (NN substrate)) (SBAR (WHPP (IN on) (WHNP (WDT which))) (S (NP (NNP PARP)) (VP (VBZ acts))))) (, ,))) (PP (IN in) (NP (NP (JJ female) (NNP NMRI) (NNS mice)) (PP (IN with) (NP (NNP Doc_8742498_525_528_Chemical) (NNP Doc_8742498_529_538_Disease)))))))))))) (CC and) (VP (VBZ evaluates) (NP (NP (DT the) (NN influence)) (PP (IN of) (NP (JJ simultaneous) (JJ Doc_8742498_583_590_Chemical) (NN consumption))) (PP (IN in) (NP (DT these) (NNS animals)))))) (. .)))
8742498	3	(S1 (S (NP (NN Doc_8742498_621_635_Disease)) (VP (AUX were) (VP (VBN quantified) (PP (IN as) (NP (NP (JJ serum) (NNS activities)) (PP (IN of) (NP (NP (NP (JJ Doc_8742498_675_684_Chemical-Doc_8742498_685_697_Chemical) (NN transaminase)) (PRN (-LRB- -LRB-) (VP (VBD GOT)) (-RRB- -RRB-))) (CC and) (NP (NP (JJ Doc_8742498_721_730_Chemical-Doc_8742498_731_739_Chemical) (NN transaminase)) (PRN (-LRB- -LRB-) (NP (NN GPT)) (-RRB- -RRB-))))))))) (. .)))
8742498	4	(S1 (S (SBAR (IN While) (S (NP (NNP Doc_8742498_766_769_Chemical)) (VP (VBD caused) (NP (NP (DT a) (JJ 117-fold) (NN elevation)) (PP (IN of) (NP (NP (JJ serum) (NN transaminase) (NNS activities)) (PP (IN in) (NP (NP (NNS mice)) (VP (VBN kept) (PP (IN on) (NP (NP (DT a) (JJ standard) (NN laboratory) (NN diet)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VP (AUX was) (VP (ADVP (RB significantly)) (VBN exacerbated) (PP (IN by) (NP (NNP Doc_8742498_914_921_Chemical))))) (CC and) (VP (VBD inhibited) (PP (IN by) (NP (NP (NNP Doc_8742498_939_959_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_8742498_961_964_Chemical)) (-RRB- -RRB-))))))))))))))))))) (, ,) (NP (JJ adverse) (NNS effects)) (VP (AUX were) (VP (VBN noted) (PP (IN in) (NP (NP (NNS animals)) (VP (VBN fed) (NP (NP (DT a) (NN diet)) (ADJP (JJ free) (PP (IN of) (NP (NP (NNS precursors)) (PP (IN of) (NP (NNP Doc_8742498_1038_1041_Chemical)))))))))))) (. .)))
8742498	5	(S1 (S (S (PP (IN In) (NP (DT these) (NNS animals))) (, ,) (NP (NP (ADJP (RB only) (JJ minor)) (NNS increases)) (PP (IN of) (NP (NN serum) (NN transaminase) (NNS activities)))) (VP (AUX were) (VP (VBN measured) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NNP Doc_8742498_1148_1151_Chemical)))))))) (, ,) (CC and) (S (PP (IN unlike) (NP (NP (DT the) (NN exacerbation)) (VP (VBN caused) (PP (IN by) (NP (NNP Doc_8742498_1191_1198_Chemical))) (PP (IN in) (NP (NP (NNS mice)) (PP (IN on) (NP (DT a) (JJ standard) (NN diet)))))))) (, ,) (NP (DT the) (NNP Doc_8742498_1231_1243_Disease)) (VP (AUX was) (VP (VBD inhibited) (PP (IN by) (NP (CD 50) (NN %))) (PP (IN by) (NP (NNP Doc_8742498_1268_1275_Chemical)))))) (. .)))
8742498	6	(S1 (S (NP (NP (DT A) (JJ further) (ADJP (CD 64) (NN %)) (NN reduction)) (PP (IN of) (NP (NNP Doc_8742498_1304_1313_Disease)))) (VP (AUX was) (ADJP (JJ observed)) (, ,) (SBAR (WHADVP (WRB when)) (S (NP (NNP Doc_8742498_1333_1336_Chemical)) (VP (AUX was) (VP (VBN given) (PP (TO to) (NP (NN Doc_8742498_1350_1357_Chemical/AAP-mice)))))))) (. .)))
8742498	7	(S1 (S (NP (PRP$ Our) (NNS results)) (VP (VBP provide) (NP (NN evidence) (SBAR (IN that) (S (NP (NP (DT the) (JJ Doc_8742498_1406_1409_Chemical-induced) (NN Doc_8742498_1418_1427_Disease)) (CC and) (NP (NP (PRP$ its) (NN exacerbation)) (PP (IN by) (NP (NNP Doc_8742498_1452_1459_Chemical))))) (VP (MD can) (ADVP (RB either)) (VP (AUX be) (VP (VBN reduced) (PP (IN by) (NP (NP (JJ end-product) (NN inhibition)) (PP (IN of) (NP (NNP PARP))))) (PP (PP (IN by) (NP (NNP Doc_8742498_1519_1522_Chemical))) (CC or) (PP (IN by) (NP (NP (JJ dietary) (NN depletion)) (PP (IN of) (NP (NP (DT the) (NN enzyme) (POS 's)) (JJ substrate) (NN Doc_8742498_1573_1576_Chemical))))))))))))) (. .)))
8742498	8	(S1 (S (NP (PRP We)) (VP (VBP see) (NP (NP (DT the) (JJ main) (NN application)) (PP (IN of) (NP (NNP Doc_8742498_1609_1612_Chemical)))) (PP (IN as) (PP (IN for) (NP (NP (DT the) (JJ combinational) (NN use)) (PP (IN in) (NP (NP (JJ pharmaceutical) (NNS preparations)) (PP (IN of) (NP (NNP Doc_8742498_1676_1689_Chemical))) (PP (IN in) (NP (NN order))))) (S (VP (TO to) (VP (VB avoid) (NP (NNP Doc_8742498_1708_1722_Disease)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (DT this) (ADJP (RB widely) (VBN used)) (JJ analgesic))))))))))))) (. .)))
8766220	0	(S1 (S (NP (NP (NNS Nightmares)) (CC and) (NP (NN Doc_8766220_15_29_Disease))) (PP (IN after) (NP (NP (JJ long-term) (NN intake)) (PP (IN of) (NP (NNP Doc_8766220_56_64_Chemical))))) (VP (VBN combined) (PP (IN with) (NP (NNS antidepressants)))) (. .)))
8766220	1	(S1 (S (NP (NNP Doc_8766220_96_104_Chemical)) (VP (AUX is) (NP (NP (DT a) (JJ weak) (NN opioid)) (PP (IN with) (NP (NP (NNS effects)) (PP (IN on) (NP (NP (JJ adrenergic) (CC and) (JJ serotonergic) (NN neurotransmission)) (SBAR (WHNP (WDT that)) (S (VP (AUX is) (VP (VBN used) (S (VP (TO to) (VP (VB treat) (NP (NP (NNP Doc_8766220_206_212_Disease) (NNP Doc_8766220_213_217_Disease)) (CC and) (NP (JJ chronic) (JJ non) (JJ malignant) (NNP Doc_8766220_244_248_Disease)))))))))))))))) (. .)))
8766220	2	(S1 (S (NP (DT This) (NN drug)) (VP (AUX was) (VP (VBN initiated) (PP (IN in) (NP (NN association))) (PP (IN with) (NP (NP (NNP Doc_8766220_294_304_Chemical)) (CC and) (NP (NNP Doc_8766220_309_333_Chemical)))) (PP (IN in) (NP (NP (DT a) (JJ tetraparetic) (NN patient)) (PP (IN with) (NP (NNP Doc_8766220_365_377_Disease))))))) (. .)))
8766220	3	(S1 (S (NP (JJ Fifty-six) (NNS days)) (PP (IN after) (NP (NP (NN initiation)) (PP (IN of) (NP (DT the) (NN treatment))))) (NP (DT the) (NN patient)) (VP (VBD presented) (NP (NP (NN Doc_8766220_450_464_Disease)) (SBAR (WHNP (WDT that)) (S (ADVP (RB only)) (VP (VBD stopped) (PP (IN after) (NP (NP (DT the) (NN withdrawal)) (PP (IN of) (NP (NP (JJ psycho-active) (NNS drugs)) (CC and) (NP (NNP Doc_8766220_531_539_Chemical))))))))))) (. .)))
8766220	4	(S1 (S (NP (DT The) (NN case) (NN report)) (VP (VBZ questions) (NP (NP (DT the) (JJ long) (NN term) (NN use)) (PP (IN of) (NP (NP (JJ Doc_8766220_588_592_Disease) (NNS killers)) (VP (VBN combined) (PP (IN with) (NP (JJ psycho-active) (NNS drugs))) (PP (IN in) (NP (JJ chronic) (NN non))) (NP (JJ malignant) (NNP Doc_8766220_660_664_Disease)) (, ,) (SBAR (ADVP (RB especially)) (IN if) (S (NP (NNP Doc_8766220_680_684_Disease)) (VP (AUX is) (PP (IN under) (NP (NN control))))))))))) (. .)))
8800187	0	(S1 (NP (NP (NP (NP (NN Effect)) (PP (IN of) (NP (NNP Doc_8800187_10_26_Chemical)))) (CC and) (NP (JJ Doc_8800187_31_46_Chemical) (NN therapy))) (PP (IN on) (NP (NP (NNP Doc_8800187_58_69_Chemical) (NNP Doc_8800187_70_78_Disease)) (PP (IN in) (NP (NNS rats))))) (. .)))
8800187	1	(S1 (S (NP (NN Doc_8800187_100_111_Disease)) (VP (AUX is) (NP (NP (DT a) (JJ major) (NN contributor)) (PP (TO to) (NP (NN mortality))) (PP (IN in) (NP (JJ tricyclic) (JJ antidepressant) (NN Doc_8800187_176_184_Disease))))) (. .)))
8800187	2	(S1 (S (NP (JJ Recent) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (NP (JJ tricyclic) (NNS antidepressants)) (VP (VBP inhibit) (NP (JJ Doc_8800187_245_252_Chemical) (NN influx)) (PP (IN in) (NP (DT some) (NNS tissues))))))) (. .)))
8800187	3	(S1 (S (NP (DT This) (NN study)) (VP (VBD addressed) (NP (NP (DT the) (JJ potential) (NN role)) (PP (IN of) (NP (JJ Doc_8800187_320_327_Chemical) (NN channel) (NN blockade))) (PP (IN in) (NP (JJ tricyclic) (JJ antidepressant-induced) (NN Doc_8800187_381_392_Disease))))) (. .)))
8800187	4	(S1 (S (NP (CD Two) (NNS interventions)) (VP (AUX were) (VP (VBN studied) (SBAR (WHNP (WDT that)) (S (VP (AUX have) (VP (AUX been) (VP (VBN shown) (ADVP (RB previously)) (S (VP (TO to) (VP (VB improve) (NP (NN blood) (NN pressure)) (PP (IN with) (NP (NP (JJ Doc_8800187_497_504_Chemical) (NN channel) (NN blocker)) (NP (NNP Doc_8800187_521_529_Disease)))))))))))))) (. .)))
8800187	5	(S1 (NP (NNP Doc_8800187_531_536_Chemical) (CC and) (NNP Doc_8800187_541_556_Chemical) (. .)))
8800187	6	(S1 (S (NP (JJ Anesthetized) (NNS rats)) (VP (VBD received) (NP (DT the) (JJ tricyclic) (JJ antidepressant) (JJ Doc_8800187_614_625_Chemical) (NN IP)) (S (VP (TO to) (VP (VB produce) (NP (NP (NNP Doc_8800187_640_651_Disease)) (, ,) (NP (NNS QRS) (NN prolongation)) (, ,) (CC and) (NP (NNP Doc_8800187_675_686_Disease))))))) (. .)))
8800187	7	(S1 (S (ADVP (NP (CD Fifteen) (NN min)) (RB later)) (, ,) (NP (NNS animals)) (VP (VBD received) (NP (NP (NNP Doc_8800187_724_729_Chemical)) (, ,) (NP (NNP Doc_8800187_731_737_Chemical)) (, ,) (CC or) (NP (NN saline)))) (. .)))
8800187	8	(S1 (S (PP (IN In) (NP (DT a) (JJ second) (NN experiment))) (, ,) (NP (NNS rats)) (VP (VBD received) (NP (NP (JJ tricyclic) (JJ antidepressant) (JJ Doc_8800187_813_824_Chemical) (NNS IP)) (VP (VBN followed) (PP (IN in) (NP (CD 15) (NN min))) (PP (IN by) (NP (NP (NNP Doc_8800187_850_865_Chemical)) (CC or) (NP (NN saline))))))) (. .)))
8800187	9	(S1 (S (NP (NP (JJ Doc_8800187_886_892_Chemical) (NN briefly)) (PRN (-LRB- -LRB-) (NP (CD 5) (NN min)) (-RRB- -RRB-))) (VP (VP (VBD reversed) (NP (NN Doc_8800187_918_929_Disease))) (CC and) (VP (VBZ QRS) (NP (NN prolongation)))) (. .)))
8800187	10	(S1 (S (NP (NP (NNP Doc_8800187_952_957_Chemical)) (CC and) (NP (NNP Doc_8800187_962_977_Chemical))) (VP (VBD failed) (S (VP (TO to) (VP (VB improve) (NP (NN blood) (NN pressure)))))) (. .)))
8800187	11	(S1 (S (NP (NP (DT The) (NN incidence)) (PP (IN of) (NP (NP (NP (NNP Doc_8800187_1029_1052_Disease)) (PRN (-LRB- -LRB-) (S (NP (NN p)) (VP (SYM =) (NP (CD 0.004)))) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_8800187_1069_1077_Disease)) (PRN (-LRB- -LRB-) (S (NP (NN p)) (VP (SYM =) (NP (CD 0.03)))) (-RRB- -RRB-))))) (PP (IN in) (NP (DT the) (NNP Doc_8800187_1096_1101_Chemical) (NN group)))) (VP (AUX was) (ADJP (ADJP (JJR higher)) (PP (IN than) (NP (DT the) (JJ other) (NNS groups))))) (. .)))
8800187	12	(S1 (S (NP (NP (DT The) (NN administration)) (PP (IN of) (NP (NP (NNP Doc_8800187_1176_1181_Chemical)) (CC or) (NP (NNP Doc_8800187_1185_1200_Chemical))))) (VP (AUX did) (RB not) (VP (VB reverse) (NP (NP (JJ tricyclic) (JJ antidepressant-induced) (NN Doc_8800187_1250_1261_Disease)) (PP (IN in) (NP (NNS rats)))))) (. .)))
8800187	13	(S1 (S (NP (JJ Doc_8800187_1271_1276_Chemical) (NN therapy)) (VP (MD may) (ADVP (RB possibly)) (VP (VB worsen) (NP (DT both) (NNP Doc_8800187_1310_1360_Disease)))) (. .)))
8800187	14	(S1 (S (NP (DT These) (NNS findings)) (VP (AUX do) (RB not) (VP (VB support) (NP (NP (DT a) (NN role)) (PP (IN for) (NP (NP (JJ Doc_8800187_1403_1410_Chemical) (NN channel) (NN inhibition)) (PP (IN in) (NP (NP (DT the) (NNS pathogenesis)) (PP (IN of) (NP (JJ tricyclic) (JJ antidepressant-induced) (NN Doc_8800187_1486_1497_Disease)))))))))) (. .)))
8841157	0	(S1 (NP (NP (NP (NN Doc_8841157_0_9_Chemical)) (, ,) (NP (NP (DT a) (JJ new) (NN angiotensin) (NNP II) (NN antagonist)) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (JJ essential) (NNP Doc_8841157_74_86_Disease))))))) (: :) (NP (NP (DT a) (JJ comparative) (NN study)) (PP (IN of) (NP (NP (DT the) (NN efficacy) (CC and) (NN safety)) (PP (IN against) (NP (NNP Doc_8841157_143_153_Chemical)))))) (. .)))
8841157	1	(S1 (FRAG (S (VP (TO To) (VP (VB compare) (NP (NP (DT the) (JJ antihypertensive) (NN efficacy)) (PP (IN of) (NP (NP (DT a) (JJ new) (JJ Doc_8841157_216_230_Chemical) (NN antagonist)) (, ,) (NP (NNP Doc_8841157_243_252_Chemical)) (, ,)))) (PP (IN with) (NP (NP (DT a) (NN reference) (NN therapy)) (, ,) (NP (NNP Doc_8841157_280_290_Chemical))))))) (. .)))
8841157	2	(S1 (S (NP (NP (QP (CD One) (CD hundred)) (JJ sixty-eight) (NN adult) (NNS outpatients)) (PP (IN with) (NP (ADJP (JJ mild) (TO to) (JJ moderate)) (NNP Doc_8841157_365_377_Disease)))) (VP (AUX were) (ADVP (RB randomly)) (VP (VBN allocated) (PP (IN in) (NP (NP (JJ double-blind) (NN fashion)) (CC and) (NP (JJ equal) (NN number)))) (S (VP (TO to) (VP (VB receive) (NP (QP (CD 80) (CD mg) (NN Doc_8841157_460_469_Chemical) (CC or) (CD 5) (CD mg)) (NN Doc_8841157_478_488_Chemical)) (PP (IN for) (NP (CD 12) (NNS weeks)))))))) (. .)))
8841157	3	(S1 (S (PP (IN After) (NP (NP (CD 8) (NNS weeks)) (PP (IN of) (NP (NN therapy))))) (, ,) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP$ whose) (NN blood) (NN pressure)) (S (VP (VBD remained) (ADJP (JJ uncontrolled))))))) (, ,) (NP (CD 5) (JJ mg) (NN Doc_8841157_590_600_Chemical)) (VP (AUX was) (VP (VBN added) (PP (TO to) (NP (DT the) (JJ initial) (NN therapy))))) (. .)))
8841157	4	(S1 (S (NP (NNS Patients)) (VP (AUX were) (VP (VBN assessed) (PP (IN at) (NP (NP (CD 4)) (, ,) (NP (CD 8)) (, ,) (CC and) (NP (CD 12) (NNS weeks)))))) (. .)))
8841157	5	(S1 (S (NP (DT The) (JJ primary) (NN efficacy) (NN variable)) (VP (AUX was) (NP (NP (NN change)) (PP (IN from) (NP (NN baseline))) (PP (IN in) (NP (NP (NN mean)) (VP (VBG sitting) (NP (JJ diastolic) (NN blood) (NN pressure)) (PP (IN at) (NP (CD 8) (NNS weeks)))))))) (. .)))
8841157	6	(S1 (S (NP (JJ Secondary) (NNS variables)) (VP (VBD included) (NP (NN change)) (PP (IN in) (S (VP (VBG sitting) (NP (NP (JJ systolic) (NN blood) (NN pressure)) (CC and) (NP (NN responder) (NNS rates))))))) (. .)))
8841157	7	(S1 (S (NP (PDT Both) (NP (NNP Doc_8841157_895_904_Chemical)) (CC and) (NP (NNP Doc_8841157_909_919_Chemical))) (VP (AUX were) (ADJP (JJ effective) (PP (IN at) (S (VP (VBG lowering) (NP (NN blood) (NN pressure)) (PP (IN at) (NP (NP (CD 4)) (, ,) (NP (CD 8)) (, ,) (CC and) (NP (CD 12) (NNS weeks))))))))) (. .)))
8841157	8	(S1 (S (NP (JJ Similar) (NNS decreases)) (VP (AUX were) (VP (VBN observed) (PP (IN in) (NP (DT both) (NNS groups))) (, ,) (PP (IN with) (NP (NP (DT no) (ADJP (RB statistically) (JJ significant)) (NNS differences)) (PP (IN between) (NP (NP (DT the) (NNS groups)) (PP (IN for) (NP (NP (DT any) (NN variable)) (VP (VBD analyzed)))))))))) (. .)))
8841157	9	(S1 (S (PP (IN For) (NP (DT the) (JJ primary) (NN variable))) (NP (DT the) (NN difference)) (VP (VP (AUX was) (NP (CD 0.5) (NN mm)) (NP (NNP Hg)) (PP (IN in) (NP (NP (NN favor)) (PP (IN of) (NP (NNP Doc_8841157_1191_1200_Chemical)))))) (PRN (-LRB- -LRB-) (NP (NP (NNP p) (SYM =) (CD 0.68)) (: ;) (NP (ADJP (CD 95) (NN %)) (NN confidence) (NN interval))) (, ,) (NP (QP (CD -2.7) (TO to) (CD 1.7))) (-RRB- -RRB-))) (. .)))
8841157	10	(S1 (S (NP (NP (NN Responder) (NNS rates)) (PP (IN at) (NP (CD 8) (NNS weeks)))) (VP (AUX were) (NP (NP (NP (CD 66.7) (NN %)) (PP (IN for) (NP (NNP Doc_8841157_1293_1302_Chemical)))) (CC and) (NP (NP (CD 60.2) (NN %)) (PP (IN for) (NP (NP (NNP Doc_8841157_1317_1327_Chemical)) (PRN (-LRB- -LRB-) (S (NP (NN p)) (VP (SYM =) (NP (CD 0.39)))) (-RRB- -RRB-))))))) (. .)))
8841157	11	(S1 (S (NP (DT Both) (NNS treatments)) (VP (AUX were) (ADVP (RB well)) (VP (VBN tolerated))) (. .)))
8841157	12	(S1 (S (NP (NP (DT The) (NN incidence)) (PP (IN of) (NP (ADJP (JJ drug-related) (JJ dependent)) (NNP Doc_8841157_1417_1422_Disease)))) (VP (AUX was) (ADJP (RB somewhat) (JJR higher)) (PP (IN in) (NP (DT the) (NNP Doc_8841157_1450_1460_Chemical) (NN group))) (, ,) (PP (ADVP (RB particularly)) (IN at) (NP (NP (DT a) (NN dose)) (PP (IN of) (NP (NP (NP (CD 10) (NNS mg)) (PP (IN per) (NP (NN day)))) (-LRB- -LRB-) (NP (NP (NP (CD 2.4) (NN %)) (PP (IN for) (NP (NP (CD 80) (NNS mg)) (NP (NNP Doc_8841157_1524_1533_Chemical))))) (: ;) (NP (NP (CD 3.6) (NN %)) (PP (IN for) (NP (CD 5) (NN mg) (NNP Doc_8841157_1549_1559_Chemical)))) (: ;) (NP (NP (CD 0) (NN %)) (PP (IN for) (NP (NP (NNP Doc_8841157_1568_1577_Chemical)) (CC plus) (NP (CD 5) (JJ mg) (NNP Doc_8841157_1588_1598_Chemical))))) (: ;) (NP (NP (CD 14.3) (NN %)) (PP (IN for) (NP (CD 10) (NN mg) (NNP Doc_8841157_1616_1626_Chemical))))) (-RRB- -RRB-)))))) (. .)))
8841157	13	(S1 (S (NP (DT The) (NNS data)) (VP (VBP show) (SBAR (IN that) (S (NP (NNP Doc_8841157_1661_1670_Chemical)) (VP (AUX is) (ADJP (ADVP (IN at) (JJS least)) (RB as) (JJ effective)) (PP (IN as) (NP (NNP Doc_8841157_1699_1709_Chemical))) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (ADJP (JJ mild) (TO to) (JJ moderate)) (NNP Doc_8841157_1747_1759_Disease))))))))) (. .)))
8841157	14	(S1 (S (NP (DT The) (NNS results)) (ADVP (RB also)) (VP (VP (VBP show) (S (NP (NNP Doc_8841157_1783_1792_Chemical)) (VP (TO to) (VP (AUX be) (ADVP (RB well)) (VP (VBN tolerated)))))) (CC and) (VP (VBP suggest) (SBAR (IN that) (S (NP (PRP it)) (VP (AUX is) (RB not) (VP (VBN associated) (PP (IN with) (NP (NP (NP (JJ side) (NNS effects)) (ADJP (JJ characteristic) (PP (IN of) (NP (DT this) (JJ comparator) (NN class))))) (, ,) (NP (NNP Doc_8841157_1911_1926_Chemical) (NNP Doc_8841157_1927_1934_Chemical) (NNS antagonists)))))))))) (. .)))
8854309	0	(S1 (NP (NP (DT A) (NN measure)) (PP (IN of) (NP (NNP Doc_8854309_13_34_Disease))) (PP (IN as) (NP (NP (DT a) (NN marker)) (PP (IN of) (NP (NNP Doc_8854309_50_57_Chemical-induced) (NNP Doc_8854309_66_74_Disease))))) (. .)))
8854309	1	(S1 (S (NP (NP (JJ Doc_8854309_76_83_Chemical-induced) (NN paranoia)) (PRN (-LRB- -LRB-) (NP (NNP Doc_8854309_102_105_Disease)) (-RRB- -RRB-))) (VP (VBZ remains) (NP (NP (DT an) (JJ important) (JJ drug-induced) (NN model)) (PP (IN of) (NP (JJ idiopathic) (NNP Doc_8854309_161_169_Disease))) (SBAR (WHPP (IN for) (WHNP (WDT which))) (S (NP (DT no) (JJ psychophysiologic) (NN marker)) (VP (AUX has) (ADVP (RB yet)) (VP (VBN emerged))))))) (. .)))
8854309	2	(S1 (S (NP (NP (NNS Measures)) (PP (IN of) (NP (NNP Doc_8854309_237_258_Disease)))) (VP (AUX were) (ADJP (JJ able) (S (VP (TO to) (ADVP (RB significantly)) (VP (VB distinguish) (NP (NP (DT a) (NN group)) (PP (IN of) (NP (NP (JJ abstinent) (JJ Doc_8854309_319_332_Chemical) (NNS abusers)) (VP (VBG endorsing) (NP (JJ past) (NNP Doc_8854309_356_359_Disease)))))) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 32)) (-RRB- -RRB-)) (PP (IN from) (NP (NP (DT another) (NN group)) (PP (IN of) (NP (NP (NN crack) (NNS addicts)) (SBAR (WHNP (WP who)) (S (VP (VBD denied) (NP (JJ past) (NNP Doc_8854309_421_424_Disease))))))))) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 29)) (-RRB- -RRB-))))))) (. .)))
8888541	0	(S1 (NP (NP (JJ Doc_8888541_0_9_Chemical) (NN syndrome)) (PP (IN from) (NP (JJ Doc_8888541_24_35_Chemical-Doc_8888541_36_51_Chemical) (NN interaction))) (. .)))
8888541	1	(S1 (S (NP (NP (JJ Excessive) (NN stimulation)) (PP (IN of) (NP (JJ Doc_8888541_90_99_Chemical) (NN 5HT1A) (NNS receptors)))) (VP (VBZ causes) (NP (NP (DT a) (NN syndrome)) (PP (IN of) (NP (JJ Doc_8888541_137_146_Chemical) (NN excess))) (SBAR (WHNP (WDT that)) (S (VP (VBZ consists) (PP (IN of) (NP (VBG shivering) (, ,) (NNP Doc_8888541_182_197_Disease) (, ,) (NNP salivation) (, ,) (NNP Doc_8888541_211_220_Disease) (, ,) (NNP Doc_8888541_222_231_Disease) (CC and) (NNP Doc_8888541_236_248_Disease)))))))) (. .)))
8888541	2	(S1 (S (NP (NP (DT The) (ADJP (RBS most) (JJ common)) (NN cause)) (PP (IN of) (NP (DT this) (NN syndrome)))) (VP (AUX is) (NP (NP (DT an) (NN interaction)) (PP (IN between) (NP (NP (NP (DT a) (JJ Doc_8888541_317_326_Chemical) (NN oxidase) (NN inhibitor)) (PRN (-LRB- -LRB-) (NP (NNP MAOI)) (-RRB- -RRB-))) (CC and) (NP (DT a) (JJ specific) (JJ Doc_8888541_367_376_Chemical) (NN reuptake) (NN inhibitor)))))) (. .)))
8888541	3	(S1 (S (NP (NN Doc_8888541_397_408_Chemical)) (VP (AUX is) (NP (NP (DT a) (JJ new) (NN antidepressant) (NN agent)) (SBAR (WHNP (WDT that)) (S (VP (VBZ inhibits) (NP (NP (DT the) (NN reuptake)) (PP (IN of) (NP (NP (NNP Doc_8888541_469_478_Chemical)) (CC and) (NP (NNP Doc_8888541_483_497_Chemical)))))))))) (. .)))
8888541	4	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT a) (NNP Doc_8888541_511_522_Chemical-MAOI) (NN interaction)) (SBAR (WHNP (WDT that)) (S (VP (VBD resulted) (PP (IN in) (NP (DT the) (JJ Doc_8888541_561_570_Chemical) (NN syndrome))) (PP (IN in) (NP (NP (DT a) (JJ 23-y-old) (NN male)) (SBAR (WHNP (WP who)) (S (VP (AUX was) (VP (VBG taking) (NP (NNP Doc_8888541_614_629_Chemical)) (PP (IN for) (NP (NN Doc_8888541_634_644_Disease)))))))))))))) (. .)))
8888541	5	(S1 (S (NP (PRP He)) (VP (AUX had) (VP (AUX been) (ADVP (RB well)) (PP (IN until) (NP (NP (DT the) (NN morning)) (PP (IN of) (NP (NN presentation))))) (SBAR (WHADVP (WRB when)) (S (NP (PRP he)) (VP (VBD took) (NP (NP (CD 1/2) (NN tab)) (PP (IN of) (NP (NNP Doc_8888541_721_732_Chemical))))))))) (. .)))
8888541	6	(S1 (S (PP (IN Within) (NP (CD 2) (NNP h))) (NP (PRP he)) (VP (VBD became) (VP (VBN confused) (PP (IN with) (S (VP (VBG jerking) (NP (NP (NNS movements)) (PP (IN of) (NP (NP (PRP$ his) (NNS extremities)) (, ,) (NP (NP (NNP Doc_8888541_807_814_Disease)) (CC and) (NP (NNP Doc_8888541_819_827_Disease))))))))))) (. .)))
8888541	7	(S1 (S (NP (PRP He)) (VP (AUX was) (VP (VBN brought) (ADVP (RB directly)) (PP (TO to) (NP (NP (DT a) (NN hospital)) (SBAR (WHADVP (WRB where)) (S (NP (PRP he)) (VP (AUX was) (VP (VBN found) (S (VP (TO to) (VP (AUX be) (VP (VBN agitated) (CC and) (VBN confused) (PP (IN with) (NP (NP (VBG shivering)) (, ,) (NP (NNP Doc_8888541_930_945_Disease) (, ,) (NNP Doc_8888541_947_955_Disease) (, ,) (NN salivation) (CC and) (NN diaphoresis)))))))))))))))) (. .)))
8888541	8	(S1 (S (NP (PRP$ His) (NNS pupils)) (VP (VP (AUX were) (NP (CD 7) (NN mm))) (CC and) (VP (ADVP (RB sluggishly)) (VBP reactive) (S (VP (TO to) (VP (VB light)))))) (. .)))
8888541	9	(S1 (S (S (NP (JJ Vital) (NNS signs)) (VP (AUX were))) (: :) (S (NP (NN blood) (NN pressure) (CD 120/67)) (VP (VBD mm) (NP (NP (NNP Hg)) (, ,) (NP (NP (NN heart) (NN rate) (NN 127/min)) (, ,) (NP (NN respiratory) (NN rate) (NN 28/min)) (, ,) (CC and) (NP (NN temperature) (CD 97) (NN F)))))) (. .)))
8888541	10	(S1 (S (PP (IN After) (NP (NP (CD 180) (NN mg)) (PP (IN of) (NP (JJ Doc_8888541_1170_1178_Chemical) (NNS i.v.))))) (NP (PRP he)) (VP (VBD remained) (ADJP (JJ tremulous) (PP (IN with) (NP (UCP (NNP Doc_8888541_1211_1226_Disease) (CC and) (JJ clenched)) (NNS jaws))))) (. .)))
8888541	11	(S1 (S (NP (PRP He)) (VP (VP (AUX was) (VP (VBN intubated) (PP (IN for) (NP (NP (JJ airway) (NN protection)) (CC and) (NP (NP (IN because)) (PP (IN of) (NP (NNP Doc_8888541_1300_1315_Disease)))))))) (, ,) (CC and) (VP (AUX was) (VP (VBN paralyzed) (S (VP (TO to) (VP (VB control) (NP (NNP Doc_8888541_1346_1361_Disease)))))))) (. .)))
8888541	12	(S1 (S (NP (PRP$ His) (JJ subsequent) (NN course)) (VP (AUX was) (ADJP (JJ remarkable) (PP (IN for) (NP (NP (JJ non-immune) (NN Doc_8888541_1415_1431_Disease)) (SBAR (WHNP (WDT which)) (S (VP (VBD resolved)))))))) (. .)))
8888541	13	(S1 (S (S (NP (NP (DT The) (NN patient) (POS 's)) (JJ maximal) (NN temperature)) (VP (AUX was) (NP (CD 101.2) (NN F)))) (CC and) (S (NP (PRP$ his) (NN CPK)) (VP (VBD remained) (S (VP (VBG <) (NP (CD 500) (NN units/L)) (PP (IN with) (NP (NP (DT no) (JJ other) (NN evidence)) (PP (IN of) (NP (NNP Doc_8888541_1555_1569_Disease))))))))) (. .)))
8888541	14	(S1 (S (S (NP (JJ Doc_8888541_1571_1574_Chemical) (JJ mental) (NN status)) (VP (VBD normalized))) (CC and) (S (NP (PRP he)) (VP (AUX was) (VP (VBN transferred) (PP (TO to) (NP (DT a) (NN psychiatry) (NN ward)))))) (. .)))
8888541	15	(S1 (S (NP (DT This) (NN patient)) (VP (VBD survived) (PP (IN without) (NP (NP (NNS sequelae)) (ADJP (JJ due) (PP (TO to) (NP (NP (DT the) (JJ aggressive) (NN sedation)) (CC and) (NP (NN neuromuscular) (NN Doc_8888541_1733_1742_Disease)))))))) (. .)))
8911359	0	(S1 (NP (NP (JJ Doc_8911359_0_16_Chemical) (JJ associated) (JJ Doc_8911359_28_42_Disease--a) (ADJP (RB highly) (JJ aggressive)) (NN disease)) (: :) (NP (NP (NN analysis)) (PP (IN of) (NP (CD 12) (NNS cases)))) (. .)))
8911359	1	(S1 (S (NP (PRP We)) (VP (VBD gained) (NP (NP (NN knowledge)) (PP (IN of) (NP (NP (DT the) (NN etiology) (, ,) (NN treatment) (CC and) (NN prevention)) (PP (IN of) (NP (NNP Doc_8911359_169_185_Chemical) (NNP associated) (NNP Doc_8911359_197_214_Disease))))))) (. .)))
8911359	2	(S1 (S (NP (NNS MATERIALS) (CC AND) (NNS METHODS)) (: :) (NP (NP (DT The) (JJ medical) (NNS records)) (PP (IN of) (NP (NP (NP (CD 6) (NNS men)) (CC and) (NP (CD 6) (NNS women))) (PRN (-LRB- -LRB-) (NP (NP (JJ mean) (NN age)) (NP (CD 55) (NNS years))) (-RRB- -RRB-)))) (PP (IN with) (NP (NNP Doc_8911359_305_321_Chemical) (NNP associated) (NNP Doc_8911359_333_347_Disease)))) (VP (AUX were) (VP (VBN reviewed))) (. .)))
8911359	3	(S1 (S (NP (DT All) (NNP Doc_8911359_376_382_Disease)) (VP (AUX were) (NP (NP (NN grade) (CD 3)) (CC or) (NP (CD 4) (JJ transitional) (NN cell) (NN Doc_8911359_419_428_Disease)))) (. .)))
8911359	4	(S1 (S (PP (IN Of) (NP (NP (DT the) (CD 5) (NNS patients)) (VP (ADVP (RB initially)) (VBN treated) (PP (IN with) (NP (JJ endoscopic) (NN resection)))))) (NP (RB alone) (QP (RB only) (CD 1))) (VP (AUX is) (ADJP (JJ alive)) (PP (IN without) (NP (NN disease)))) (. .)))
8911359	5	(S1 (S (NP (NP (IN Of) (DT the) (CD 6) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD underwent) (NP (JJ early) (JJ cystectomy) (CD 4)))))) (VP (AUX were) (ADJP (JJ alive)) (PP (IN at) (NP (QP (CD 24) (TO to) (CD 111)) (NNS months)))) (. .)))
8911359	6	(S1 (S (NP (NP (DT The) (VBG remaining) (NN patient)) (PP (IN with) (NP (JJ extensive) (NN Doc_8911359_651_657_Disease)))) (VP (VP (VBD underwent) (NP (JJ partial) (NN cystectomy)) (PP (IN for) (NP (NN palliation)))) (CC and) (VP (VBD died) (ADVP (NP (CD 3) (NNS months)) (RB later)))) (. .)))
8911359	7	(S1 (S (NP (JJ Doc_8911359_740_756_Chemical) (JJ associated) (NN Doc_8911359_768_781_Disease)) (VP (AUX is) (NP (DT an) (JJ aggressive) (NN disease))) (. .)))
8911359	8	(S1 (S (ADVP (RB However)) (, ,) (NP (JJ long-term) (NN survival)) (VP (AUX is) (ADJP (JJ possible)) (SBAR (WHADVP (WRB when)) (S (NP (JJ radical) (NN cystectomy)) (VP (AUX is) (VP (VBN performed) (PP (IN for) (NP (NNP Doc_8911359_889_903_Disease))) (PP (PP (IN with) (NP (NP (DT any) (NN sign)) (PP (IN of) (NP (NN invasion))))) (CC and) (PP (IN for) (NP (JJ recurrent) (JJ high) (NN grade) (NN disease)))) (, ,) (SBAR (WHADVP (RB even) (WRB when)) (S (VP (VBP noninvasive))))))))) (. .)))
8958188	0	(S1 (S (NP (NP (DT A) (NN phase) (NN I) (JJ clinical) (NN study)) (PP (IN of) (NP (NP (DT the) (NNP Doc_8958188_32_42_Chemical) (NN antifolate) (NNP Doc_8958188_54_64_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_8958188_66_72_Chemical)) (-RRB- -RRB-))))) (VP (VBN given) (PP (IN with) (NP (JJ oral) (NNP Doc_8958188_90_100_Chemical)))) (. .)))
8958188	1	(S1 (S (NP (NN Doc_8958188_102_112_Chemical)) (VP (AUX is) (NP (NP (DT an) (NN antifolate)) (SBAR (WHNP (WDT which)) (S (VP (VBZ inhibits) (NP (NP (JJ Doc_8958188_145_171_Chemical) (NN formyltransferase)) (PRN (-LRB- -LRB-) (NP (NN GARFT)) (-RRB- -RRB-))) (, ,) (S (NP (DT an) (NN enzyme)) (ADJP (JJ essential) (PP (IN for) (NP (FW de) (FW novo) (JJ Doc_8958188_231_237_Chemical) (NN synthesis)))))))))) (. .)))
8958188	2	(S1 (S (NP (JJ Extensive) (JJ experimental) (CC and) (JJ limited) (JJ clinical) (NNS data)) (VP (AUX have) (VP (VBN shown) (SBAR (IN that) (S (NP (NNP Doc_8958188_314_324_Chemical)) (VP (AUX has) (NP (NP (NN activity)) (PP (IN against) (NP (NP (NP (NNP Doc_8958188_346_353_Disease)) (SBAR (WHNP (WDT which)) (S (VP (AUX are) (ADJP (JJ refractory) (PP (TO to) (NP (JJ other) (NNS drugs)))))))) (, ,) (ADVP (RB notably)) (NP (NNP Doc_8958188_399_411_Chemical)))))))))) (. .)))
8958188	3	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (JJ initial) (JJ clinical) (NN development)) (PP (IN of) (NP (NNP Doc_8958188_458_468_Chemical)))) (VP (AUX was) (VP (VBN curtailed) (PP (IN because) (IN of) (NP (JJ severe) (CC and) (JJ cumulative) (NN antiproliferative) (NN Doc_8958188_534_544_Disease))))) (. .)))
8958188	4	(S1 (S (NP (JJ Preclinical) (NN murine) (NNS studies)) (VP (VBD demonstrated) (SBAR (IN that) (S (NP (NP (DT the) (NNP Doc_8958188_595_603_Disease)) (PP (IN of) (NP (NNP Doc_8958188_607_617_Chemical)))) (VP (MD can) (VP (AUX be) (VP (VBN prevented) (PP (IN by) (NP (NP (JJ low) (NN dose) (NNP Doc_8958188_647_657_Chemical) (NN administration)) (, ,) (NP (NP (FW i.e.)) (PP (IN for) (NP (NP (CD 7) (NNS days)) (ADVP (RB prior) (PP (TO to)))))) (CC and) (NP (NP (CD 7) (NNS days)) (PP (VBG following) (NP (DT a) (JJ single) (JJ bolus) (NN dose)))))))))))) (. .)))
8958188	5	(S1 (S (NP (DT This) (NN observation)) (VP (VBD prompted) (NP (NP (DT a) (NN Phase) (NN I) (JJ clinical) (NN study)) (PP (IN of) (NP (NNP Doc_8958188_795_805_Chemical))) (VP (VBN given) (PP (IN with) (NP (NP (JJ Doc_8958188_817_827_Chemical) (NN supplementation)) (SBAR (WHNP (WDT which)) (S (VP (AUX has) (VP (VBN confirmed) (SBAR (IN that) (S (NP (NP (DT the) (NN Doc_8958188_873_881_Disease)) (PP (IN of) (NP (NNP Doc_8958188_885_895_Chemical)))) (VP (MD can) (VP (AUX be) (VP (ADVP (RB markedly)) (VBN reduced) (PP (IN by) (NP (JJ Doc_8958188_923_933_Chemical) (NN supplementation))))))))))))))))) (. .)))
8958188	6	(S1 (S (NP (NP (NN Doc_8958188_951_967_Disease)) (CC and) (NP (NN Doc_8958188_972_981_Disease))) (VP (AUX were) (NP (DT the) (JJ major) (NN Doc_8958188_997_1007_Disease))) (. .)))
8958188	7	(S1 (S (NP (EX There)) (VP (AUX was) (NP (NP (DT no) (JJ clear) (NN relationship)) (PP (IN between) (NP (NP (JJ clinical) (NN Doc_8958188_1058_1066_Disease)) (CC and) (NP (NP (DT the) (NN extent)) (PP (IN of) (NP (NN plasma) (JJ Doc_8958188_1092_1098_Chemical) (NN elevation)))))))) (. .)))
8958188	8	(S1 (S (NP (JJ Associated) (NNS studies)) (VP (VBD demonstrated) (SBAR (IN that) (S (NP (JJ Doc_8958188_1147_1157_Chemical) (NN plasma) (NNS pharmacokinetics)) (VP (AUX were) (RB not) (VP (VBN altered) (PP (IN by) (NP (NP (JJ Doc_8958188_1202_1212_Chemical) (NN administration)) (VP (VBG indicating) (SBAR (IN that) (S (NP (NN supplementation)) (VP (AUX is) (ADJP (JJ unlikely) (S (VP (TO to) (VP (VB reduce) (NP (NNP Doc_8958188_1282_1290_Disease)) (PP (IN by) (S (VP (VBG enhancing) (NP (JJ Doc_8958188_1304_1314_Chemical) (NN plasma) (NN clearance)))))))))))))))))))) (. .)))
8958188	9	(S1 (S (NP (NP (DT The) (NN work)) (VP (VBN described) (PP (IN in) (NP (DT this) (NN report))))) (VP (AUX has) (VP (VBN identified) (PP (IN for) (NP (DT the) (JJ first) (NN time))) (NP (NP (DT a) (ADJP (RB clinically) (JJ acceptable)) (NN schedule)) (PP (IN for) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (DT a) (JJ GARFT) (NN inhibitor)))))))) (. .)))
8958188	10	(S1 (S (NP (DT This) (NN information)) (VP (MD will) (VP (VB facilitate) (NP (NP (DT the) (JJ future) (NN evaluation)) (PP (IN of) (NP (NP (DT this) (NN class)) (PP (IN of) (NP (NP (NNS compounds)) (PP (IN in) (NP (JJ Doc_8958188_1564_1570_Disease) (NN therapy)))))))))) (. .)))
8988571	0	(S1 (S (S (NP (JJ Fatal)) (VP (VBN excited) (NP (NNP Doc_8988571_14_22_Disease)) (PP (VBG following) (NP (JJ Doc_8988571_33_40_Chemical) (NN use))))) (: :) (S (NP (JJ epidemiologic) (NNS findings)) (VP (VBP provide) (NP (NP (JJ new) (NN evidence)) (PP (IN for) (NP (NP (NNS mechanisms)) (PP (IN of) (NP (NNP Doc_8988571_108_115_Chemical) (NNP Doc_8988571_116_124_Disease)))))))) (. .)))
8988571	1	(S1 (S (NP (PRP We)) (VP (VBP describe) (NP (NP (DT an) (NN outbreak)) (PP (IN of) (NP (NP (NNS deaths)) (PP (IN from) (NP (NP (JJ Doc_8988571_165_172_Chemical-induced) (JJ excited) (NNP Doc_8988571_189_197_Disease)) (PRN (-LRB- -LRB-) (NP (NNP EDDs)) (-RRB- -RRB-)))))) (PP (IN in) (NP (NP (NNP Dade) (NNP County)) (, ,) (NP (NNP Florida)))) (PP (IN between) (NP (CD 1979) (CC and) (CD 1990))))) (. .)))
8988571	2	(S1 (S (PP (IN From) (NP (NP (DT a) (NN registry)) (PP (IN of) (NP (NP (DT all) (JJ Doc_8988571_275_282_Chemical-related) (NNS deaths)) (PP (IN in) (NP (NP (NNP Dade) (NNP County)) (, ,) (NP (NNP Florida)) (, ,))) (PP (IN from) (NP (CD 1969-1990))))))) (, ,) (NP (CD 58) (NNS EDDs)) (VP (AUX were) (VP (VBN compared) (PP (IN with) (NP (NP (CD 125) (NNS victims)) (PP (IN of) (NP (JJ accidental) (NNP Doc_8988571_392_399_Chemical) (NNP Doc_8988571_400_408_Disease))))) (PP (IN without) (NP (VBN excited) (NN Doc_8988571_425_433_Disease))))) (. .)))
8988571	3	(S1 (S (PP (VBN Compared) (PP (IN with) (NP (NNS controls)))) (, ,) (NP (NNS EDDs)) (VP (AUX were) (ADVP (RBR more) (RB frequently)) (ADJP (JJ black) (, ,) (JJ male) (, ,) (CC and) (JJR younger))) (. .)))
8988571	4	(S1 (S (NP (PRP They)) (VP (AUX were) (ADJP (ADJP (RBR less) (JJ likely) (S (VP (TO to) (VP (AUX have) (NP (DT a) (JJ low) (NN body) (NN mass) (NN index)))))) (, ,) (CC and) (ADJP (RBR more) (JJ likely) (S (VP (VP (TO to) (VP (AUX have) (VP (VBN died) (PP (IN in) (NP (NN police) (NN custody)))))) (, ,) (VP (TO to) (VP (AUX have) (VP (VBN received) (NP (JJ medical) (NN treatment)) (ADVP (RB immediately)) (PP (IN before) (NP (NN death)))))) (, ,) (VP (TO to) (VP (AUX have) (VP (VBN survived) (PP (IN for) (NP (DT a) (JJR longer) (NN period)))))) (, ,) (VP (TO to) (VP (AUX have) (VP (VBN developed) (NP (NNP Doc_8988571_729_741_Disease))))) (, ,) (CC and) (VP (TO to) (VP (AUX have) (VP (VBN died) (PP (IN in) (NP (NN summer) (NNS months))))))))))) (. .)))
8988571	5	(S1 (S (NP (NNS EDDs)) (VP (AUX had) (NP (NP (NNS concentrations)) (PP (IN of) (NP (NP (NP (NNP Doc_8988571_805_812_Chemical)) (CC and) (NP (NNP Doc_8988571_817_832_Chemical))) (PP (IN in) (NP (JJ autopsy) (NN blood))))) (SBAR (WHNP (WDT that)) (S (VP (AUX were) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT those)) (PP (IN for) (NP (NNS controls))))))))))) (. .)))
8988571	6	(S1 (S (NP (DT The) (JJ epidemiologic) (NNS findings)) (VP (AUX are) (ADJP (RBS most) (JJ consistent) (PP (IN with) (NP (NP (DT the) (NN hypothesis)) (SBAR (WHNP (WDT that)) (S (NP (JJ chronic) (JJ Doc_8988571_971_978_Chemical) (NN use) (NNS disrupts)) (ADVP (RB dopaminergic)) (VP (VBP function) (SBAR (S (CC and) (, ,) (SBAR (WHADVP (WRB when)) (S (VP (VBN coupled) (PP (IN with) (NP (JJ recent) (JJ Doc_8988571_1044_1051_Chemical) (NN use)))))) (, ,) (VP (MD may) (VP (VB precipitate) (NP (NP (NNP Doc_8988571_1073_1082_Disease)) (, ,) (NP (NNP Doc_8988571_1084_1092_Disease)) (, ,) (NP (NN aberrant) (NN thermoregulation)) (, ,) (NP (NNP Doc_8988571_1121_1135_Disease)) (, ,) (CC and) (NP (NNP Doc_8988571_1141_1153_Disease)))))))))))))) (. .)))
9022662	0	(S1 (NP (NP (JJ Doc_9022662_0_8_Chemical) (VBN induced) (JJ acute) (NN Doc_9022662_23_38_Disease)) (: :) (NP (NP (NN case) (NN report) (CC and) (NN review)) (PP (IN of) (NP (DT the) (NN literature)))) (. .)))
9022662	1	(S1 (S (NP (NN Doc_9022662_94_102_Chemical)) (VP (AUX is) (NP (NP (DT an) (JJ Doc_9022662_109_120_Chemical) (NN derivative)) (SBAR (WHNP (WDT that)) (S (VP (VP (AUX is) (ADJP (RB structurally) (JJ different) (PP (IN from) (NP (NNP Doc_9022662_168_180_Chemical))))) (CC and) (VP (VBD used) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NNP Doc_9022662_210_236_Disease))))))))))) (. .)))
9022662	2	(S1 (S (NP (NN Doc_9022662_238_246_Chemical)) (VP (AUX has) (RB not) (VP (AUX been) (ADVP (RB commonly)) (VP (VBN associated) (PP (IN in) (NP (DT the) (NN literature))) (PP (IN as) (NP (NP (DT a) (NN cause)) (PP (IN of) (NP (JJ acute) (NNP Doc_9022662_318_336_Disease)))))))) (. .)))
9022662	3	(S1 (S (NP (DT The) (JJ following) (NN case)) (VP (VBZ describes) (NP (NP (CD two) (NNS children)) (VP (ADVP (RB acutely)) (VBN poisoned) (PP (IN with) (NP (NP (NNP Doc_9022662_402_410_Chemical)) (SBAR (WHNP (WP who)) (S (VP (VBD experienced) (NP (JJ profound) (NN Doc_9022662_436_451_Disease)))))))))) (. .)))
9022662	4	(S1 (NP (NP (NN CASE) (NN REPORT)) (: :) (NP (NP (CD Two) (, ,) (JJ 3-year-old) (JJ male) (, ,) (JJ identical) (JJ twin) (NNS siblings)) (VP (VBN presented) (PP (TO to) (NP (NP (DT the) (NN emergency) (NN department)) (PP (IN after) (NP (NP (VBN found) (VBG playing)) (PP (IN with) (NP (NP (DT a) (DT an) (JJ empty) (NN bottle)) (PP (IN of) (NP (NNP Doc_9022662_596_604_Chemical))) (VP (ADVP (RB originally)) (VBG containing) (NP (CD 59) (NNS tablets))))))))))) (. .)))
9022662	5	(S1 (S (NP (DT The) (NNS children)) (VP (AUX had) (NP (NP (DT a) (JJ medical) (NN history)) (ADJP (JJ significant) (PP (IN for) (NP (NNP Doc_9022662_690_716_Disease))))) (ADVP (RB previously)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_9022662_741_756_Chemical))) (PP (IN without) (NP (NN success))))) (. .)))
9022662	6	(S1 (S (NP (DT This)) (VP (AUX was) (NP (NP (PRP$ their) (JJ first) (NN day)) (PP (IN of) (NP (JJ Doc_9022662_802_810_Chemical) (NN therapy))))) (. .)))
9022662	7	(S1 (S (NP (DT The) (JJ choreoathetoid) (NNS movements)) (VP (VBD began) (NP (QP (CD 45) (NN min) (TO to) (CD 1))) (NP (NNP h)) (PP (IN after) (NP (NN ingestion)))) (. .)))
9022662	8	(S1 (S (NP (DT The) (NNS children)) (VP (VP (VBD gave) (NP (NP (DT no) (NN history)) (PP (IN of) (NP (JJ prior) (NN Doc_9022662_924_942_Disease))))) (CC and) (VP (ADVP (RB there)) (AUX was) (NP (NP (DT no) (NN family) (NN history)) (PP (IN of) (NP (NNP Doc_9022662_978_996_Disease)))))) (. .)))
9022662	9	(S1 (S (NP (DT The) (NNS children)) (VP (VBD received) (NP (NP (JJ gastrointestinal) (NN decontamination)) (CC and) (NP (NP (JJ high) (NNS doses)) (PP (IN of) (NP (JJ intravenous) (NNP Doc_9022662_1083_1098_Chemical))))) (PP (IN in) (NP (DT an) (NN attempt) (S (VP (TO to) (VP (VB control) (NP (DT the) (JJ choreoathetoid) (NNS movements)))))))) (. .)))
9022662	10	(S1 (S (PP (IN Despite) (NP (NN treatment))) (, ,) (NP (DT the) (NNS children)) (VP (VBD continued) (S (VP (TO to) (VP (AUX have) (NP (NN Doc_9022662_1204_1219_Disease)) (PP (IN for) (NP (QP (RB approximately) (CD 24)) (NNS hours))))))) (. .)))
9022662	11	(S1 (S (PP (NP (JJ Forty-eight) (NNS hours)) (IN after) (NP (NN admission))) (, ,) (NP (DT the) (NNS children)) (VP (VP (VBD appeared) (S (VP (TO to) (VP (AUX be) (PP (IN at) (NP (PRP$ their) (NN baseline))))))) (CC and) (VP (AUX were) (VP (VBN discharged) (NP (NN home))))) (. .)))
9022662	12	(S1 (S (NP (JJ Doc_9022662_1367_1375_Chemical) (JJ associated) (NN Doc_9022662_1387_1404_Disease)) (VP (AUX has) (VP (AUX been) (ADVP (RB rarely)) (VP (VBN reported) (PP (IN in) (NP (DT the) (JJ acute) (NN toxicology) (NN literature)))))) (. .)))
9022662	13	(S1 (S (NP (NP (DT The) (NN possibility)) (PP (IN of) (NP (NN choreoathetoid) (NNS movements)))) (VP (MD should) (VP (AUX be) (VP (VBN considered) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG presenting) (PP (IN after) (NP (NNP Doc_9022662_1560_1568_Chemical) (NNP Doc_9022662_1569_1577_Disease))))))))) (. .)))
9041081	0	(S1 (NP (NP (NN Effect)) (PP (IN of) (NP (JJ myopic) (NN excimer) (NN laser) (NN photorefractive) (NN keratectomy))) (PP (IN on) (NP (NP (DT the) (JJ electrophysiologic) (NN function)) (PP (IN of) (NP (DT the) (ADJP (JJ retina) (CC and) (JJ optic)) (NN nerve))))) (. .)))
9041081	1	(S1 (FRAG (S (VP (TO To) (VP (VB assess) (PP (IN by) (NP (JJ electrophysiologic) (NN testing))) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (JJ photorefractive) (NN keratectomy)) (PRN (-LRB- -LRB-) (NP (NNP PRK)) (-RRB- -RRB-)))) (PP (IN on) (NP (DT the) (NN retina) (CC and) (JJ optic) (NN nerve))))))) (. .)))
9041081	2	(S1 (NP (NP (NP (NNP Eye) (NNP Clinic)) (, ,) (NP (NNP S.) (NNP Salvatore) (NNP Hospital)) (, ,)) (NP (NP (NNP L') (NNP Aquila) (NNP University)) (, ,) (NP (NNP Italy))) (. .)))
9041081	3	(S1 (S (NP (NP (NP (JJ Standard) (NN pattern) (NNS electroretinograms)) (PRN (-LRB- -LRB-) (NP (NNP P-ERGs)) (-RRB- -RRB-))) (CC and) (NP (NP (JJ standard) (NN pattern) (JJ visual) (JJ evoked) (NNS potentials)) (PRN (-LRB- -LRB-) (NP (NNP P-VEPs)) (-RRB- -RRB-)))) (VP (AUX were) (VP (AUX done) (PP (IN in) (NP (NP (CD 25) (NNS eyes)) (PP (IN of) (NP (NP (CD 25) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX had) (NP (NP (JJ myopic) (NN PRK)) (PP (IN for) (NP (NP (DT an) (VBN attempted) (NN correction)) (PP (IN between) (NP (NP (CD 5.00) (CC and) (CD 15.00) (NNS diopters)) (-LRB- -LRB-) (NP (NNP D)) (-RRB- -RRB-) (-LRB- -LRB-) (VP (VB mean) (NP (CD 8.00) (NNP D))) (-RRB- -RRB-))))))))))))))) (. .)))
9041081	4	(S1 (S (NP (NN Testing)) (VP (VP (AUX was) (VP (AUX done) (ADVP (RB preoperatively)))) (CC and) (VP (NP (NP (CD 3)) (, ,) (NP (CD 6)) (, ,) (NP (CD 12)) (, ,) (CC and) (NP (CD 18) (NNS months))) (ADVP (RB postoperatively)))) (. .)))
9041081	5	(S1 (S (NP (DT The) (JJ contralateral) (NNS eyes)) (VP (VBD served) (PP (IN as) (NP (NNS controls)))) (. .)))
9041081	6	(S1 (S (PP (IN During) (NP (DT the) (NN follow-up))) (, ,) (NP (NP (CD 3) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 12) (NN %)) (-RRB- -RRB-))) (VP (VBD developed) (NP (NP (JJ Doc_9041081_737_744_Chemical-induced) (NN Doc_9041081_753_782_Disease)) (PRN (-LRB- -LRB-) (NP (NN IOP)) (-RRB- -RRB-)) (SBAR (WHNP (WDT that)) (S (VP (VBD resolved) (SBAR (IN after) (S (NP (JJ Doc_9041081_809_823_Chemical) (NN therapy)) (VP (AUX was) (VP (VBN discontinued)))))))))) (. .)))
9041081	7	(S1 (S (NP (DT No) (ADJP (RB statistically) (JJ significant)) (NNS differences)) (VP (AUX were) (VP (VBN seen) (PP (PP (IN between) (NP (NP (VBN treated)) (CC and) (NP (NN control) (NNS eyes)))) (CC nor) (PP (IN between) (NP (NP (VBN treated) (NNS eyes)) (ADVP (RB preoperatively) (CC and) (RB postoperatively))))))) (. .)))
9041081	8	(S1 (S (NP (JJ Myopic) (NN excimer) (NN laser) (NN PRK)) (VP (AUX did) (RB not) (VP (VB seem) (S (VP (TO to) (VP (VB affect) (NP (DT the) (NN posterior) (NN segment))))))) (. .)))
9041081	9	(S1 (S (NP (DT The) (JJ transient) (JJ Doc_9041081_1101_1108_Chemical-induced) (NN Doc_9041081_1117_1125_Disease)) (VP (AUX did) (RB not) (VP (VB seem) (S (VP (TO to) (VP (VB cause) (NP (JJ functional) (NN impairment))))))) (. .)))
9061311	0	(S1 (NP (NP (NNP Neutrophil) (NNP Doc_9061311_11_21_Chemical) (CC and) (NNP Doc_9061311_26_43_Chemical) (NN production)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_9061311_72_91_Disease))))) (. .)))
9061311	1	(S1 (S (NP (NP (NNS Defects)) (PP (IN in) (NP (NNP Doc_9061311_104_114_Chemical) (CC and) (NNP Doc_9061311_119_136_Chemical) (NN production)))) (VP (MD may) (VP (AUX be) (VP (VBN implicated) (PP (IN in) (NP (NP (DT the) (JJ high) (NN incidence)) (PP (IN of) (NP (NNP Doc_9061311_191_211_Disease))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NNP Doc_9061311_229_248_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9061311_250_253_Disease)) (-RRB- -RRB-))))))))))) (. .)))
9061311	2	(S1 (S (PP (IN In) (NP (DT the) (JJ present) (NN study))) (, ,) (NP (NP (JJ Doc_9061311_278_284_Chemical) (JJ radical) (NN production)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_9061311_321_324_Disease))) (ADJP (JJ due) (PP (TO to) (NP (NNP Doc_9061311_332_343_Chemical) (NNP Doc_9061311_344_352_Disease))))))) (VP (AUX was) (VP (VBN compared) (PP (IN with) (NP (NP (DT that)) (PP (IN of) (NP (JJ healthy) (NNS volunteers))))))) (. .)))
9061311	3	(S1 (S (NP (NP (NNS Neutrophils)) (PP (IN from) (NP (CD 14) (NNP Doc_9061311_419_422_Disease) (NNS patients)))) (VP (AUX were) (VP (VBN stimulated) (PP (IN via) (NP (NP (DT the) (VB complement) (NNS receptors)) (VP (VBG using) (NP (NP (NN zymosan)) (VP (VBN opsonized) (PP (IN with) (NP (NP (NN Doc_9061311_506_509_Disease)) (CC or) (NP (NN control) (NN serum))))))))))) (. .)))
9061311	4	(S1 (S (NP (NP (ADJP (JJ Doc_9061311_528_538_Chemical) (CC and) (JJ Doc_9061311_543_560_Chemical)) (NN production)) (PP (IN by) (NP (NP (JJ Doc_9061311_575_578_Disease) (NNS neutrophils)) (VP (VBN stimulated) (PP (IN with) (NP (NN zymosan))) (PP (VBN opsonized) (PP (IN with) (NP (JJ Doc_9061311_630_633_Disease) (NN serum)))))))) (VP (AUX was) (VP (ADVP (RB significantly)) (VBN reduced) (PP (VBN compared) (PP (IN with) (NP (NP (DT the) (NN control) (NNS subjects)) (PRN (-LRB- -LRB-) (NP (QP ($ P) (CD <) (CD 0.01))) (-RRB- -RRB-))))))) (. .)))
9061311	5	(S1 (S (NP (DT This) (NN defect)) (VP (VBD persisted) (SBAR (WHADVP (WRB when)) (S (NP (NP (NN zymosan)) (VP (VBN opsonized) (PP (IN by) (NP (NN control) (NN serum))))) (VP (AUX was) (VP (VBN used) (PRN (-LRB- -LRB-) (S (NP (NNS P)) (VP (VBD <) (NP (CD 0.05)))) (-RRB- -RRB-))))))) (. .)))
9061311	6	(S1 (S (NP (NP (ADJP (JJ Doc_9061311_796_806_Chemical) (CC and) (JJ Doc_9061311_811_828_Chemical)) (NN production)) (PP (IN in) (NP (NP (NNS neutrophils)) (VP (VBN stimulated) (PP (IN with) (NP (NP (NNP Doc_9061311_871_908_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9061311_910_914_Chemical)) (-RRB- -RRB-)))) (PP (IN from) (NP (DT a) (JJ further) (CD 18) (JJ Doc_9061311_934_937_Disease) (NNS patients))))))) (VP (AUX was) (ADJP (JJ unaffected)) (PP (VBN compared) (PP (IN with) (NP (NN control) (NNS neutrophils))))) (. .)))
9061311	7	(S1 (S (NP (NNP Serum) (NNP C3)) (VP (VB complement) (SBAR (S (NP (NNS levels)) (VP (AUX were) (VP (ADVP (RB significantly)) (VBN reduced) (PP (IN in) (NP (JJ Doc_9061311_1054_1057_Disease) (NNS patients))) (PP (VBN compared) (PP (IN with) (NP (NP (NN control) (NNS subjects)) (PRN (-LRB- -LRB-) (NP (QP ($ P) (CD <) (CD 0.0005))) (-RRB- -RRB-)))))))))) (. .)))
9061311	8	(S1 (S (NP (DT These) (NNS results)) (VP (VBP demonstrate) (NP (NP (DT a) (JJ neutrophil) (NN defect)) (PP (IN in) (NP (NNP Doc_9061311_1161_1164_Disease))) (PP (JJ due) (TO to) (NP (NNP Doc_9061311_1172_1183_Chemical) (NNP Doc_9061311_1184_1192_Disease))) (, ,) (SBAR (WHNP (WDT that)) (S (VP (AUX is) (S (VP (VB complement) (ADJP (JJ dependent) (CC but) (JJ independent) (PP (IN of) (NP (NP (NN serum)) (VP (VB complement) (, ,) (ADVP (RB possibly)) (VBN connected) (PP (TO to) (NP (DT the) (VB complement) (NN receptor)))))))))))))) (. .)))
9067481	0	(S1 (S (NP (JJ Doc_9067481_0_25_Chemical) (NN treatment)) (VP (VBZ protects) (NP (NNS rodents)) (PP (IN from) (NP (NP (DT the) (JJ toxic) (NNS effects)) (PP (IN of) (NP (NNP Doc_9067481_79_92_Chemical) (, ,) (NNP Doc_9067481_94_104_Chemical) (, ,) (NNP Doc_9067481_106_126_Chemical) (, ,) (NNP Doc_9067481_128_138_Chemical) (CC and) (NNP Doc_9067481_143_156_Chemical)))))) (. .)))
9067481	1	(S1 (S (PP (IN In) (NP (NP (NN addition)) (PP (TO to) (NP (NP (PRP$ its) (NN use)) (PP (IN as) (NP (NP (DT a) (NN stabilizer/rigidifier)) (PP (IN of) (NP (NNS membranes))))))))) (, ,) (NP (NNP Doc_9067481_222_247_Chemical) (, ,) (NNP Doc_9067481_249_258_Chemical) (PRN (-LRB- -LRB-) (NP (NNP CS)) (-RRB- -RRB-)) (NN administration)) (VP (AUX has) (ADVP (RB also)) (VP (AUX been) (VP (VBN shown) (S (VP (TO to) (VP (VB protect) (NP (NNS rats)) (PP (IN from) (NP (NP (DT the) (JJ hepatotoxic) (NNS effects)) (PP (IN of) (NP (NP (NNP Doc_9067481_347_367_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9067481_369_373_Chemical)) (-RRB- -RRB-)))))))))))) (. .)))
9067481	2	(S1 (S (S (VP (TO To) (VP (VB further) (NP (NP (PRP$ our) (NN understanding)) (PP (IN of) (NP (NP (DT the) (NN mechanism)) (PP (IN of) (NP (NNP CS) (NN cytoprotection))))))))) (, ,) (NP (PRP we)) (VP (VBD examined) (PP (IN in) (NP (NNS rats) (CC and) (NNS mice))) (NP (NP (DT the) (JJ protective) (NNS abilities)) (PP (IN of) (NP (NP (NNP CS)) (CC and) (NP (NP (DT the) (JJ non-hydrolyzable) (NN ether) (NN form)) (PP (IN of) (NP (NP (NNP CS) (, ,) (NNP Doc_9067481_547_579_Chemical) (, ,) (NNP Doc_9067481_581_590_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP CSE)) (-RRB- -RRB-)))) (PP (IN against) (NP (NNP Doc_9067481_605_618_Chemical-) (, ,) (NNP Doc_9067481_621_631_Chemical-) (, ,) (NNP Doc_9067481_634_654_Chemical-) (, ,) (NNP Doc_9067481_657_667_Chemical-) (CC and) (NNP Doc_9067481_673_686_Chemical-induced) (NNP Doc_9067481_695_703_Disease)))))))) (. .)))
9067481	3	(S1 (S (NP (NP (DT The) (NNS results)) (PP (IN of) (NP (DT these) (NNS studies)))) (VP (VBD demonstrated) (SBAR (IN that) (S (NP (JJ CS-mediated) (NN protection)) (VP (AUX is) (RB not) (ADJP (JJ selective)) (PP (IN for) (NP (NP (DT a) (JJ particular) (NNS species)) (, ,) (NP (NN organ) (NN system)) (CC or) (NP (NN toxic) (NN chemical)))))))) (. .)))
9067481	4	(S1 (S (NP (NP (DT A) (JJ 24-h) (NN pretreatment)) (PP (IN of) (NP (NP (DT both) (NNS rats) (CC and) (NNS mice)) (PP (IN with) (NP (NP (DT a) (JJ single) (NN dose)) (PP (IN of) (NP (NNP CS))) (PRN (-LRB- -LRB-) (NP (NN 100mg/kg)) (, ,) (NP (CD i.p.)) (-RRB- -RRB-)) (, ,)))))) (VP (VBD resulted) (PP (IN in) (NP (NP (JJ significant) (NN protection)) (PP (PP (IN against) (NP (NP (DT the) (JJ hepatotoxic) (NNS effects)) (PP (IN of) (NP (NNP Doc_9067481_1005_1009_Chemical) (, ,) (NNP Doc_9067481_1011_1016_Chemical) (, ,) (NNP Doc_9067481_1018_1031_Chemical) (CC and) (NNP Doc_9067481_1036_1049_Chemical))))) (CC and) (PP (IN against) (NP (NP (DT the) (JJ lethal) (PRN (-LRB- -LRB-) (CC and) (ADVP (RB presumably)) (NP (NNP Doc_9067481_1089_1100_Disease)) (-RRB- -RRB-)) (NN effect)) (PP (IN of) (NP (NNP Doc_9067481_1112_1122_Chemical) (NN administration))))))))) (. .)))
9067481	5	(S1 (S (NP (JJ Maximal) (JJ CS-mediated) (NN protection)) (VP (AUX was) (VP (VBN observed) (PP (IN in) (NP (NP (JJ experimental) (NNS animals)) (VP (VBN pretreated) (NP (CD 24) (NNP h)) (PP (ADVP (RB prior)) (TO to) (NP (DT the) (JJ toxic) (NN insult)))))))) (. .)))
9067481	6	(S1 (S (NP (DT These) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NNP Doc_9067481_1274_1276_Chemical)) (VP (VBZ intervenes) (PP (IN in) (NP (NP (DT a) (JJ critical) (JJ cellular) (NN event)) (SBAR (WHNP (WDT that)) (S (VP (AUX is) (NP (NP (DT an) (JJ important) (JJ common) (NN pathway)) (PP (TO to) (NP (JJ toxic) (NN cell) (NN death))))))))))))) (. .)))
9067481	7	(S1 (S (NP (NP (DT The) (NN mechanism)) (PP (IN of) (NP (NNP CS) (NN protection)))) (VP (AUX does) (RB not) (VP (VB appear) (S (VP (TO to) (VP (AUX be) (ADJP (JJ dependent) (PP (IN on) (NP (NP (DT the) (NN inhibition)) (PP (IN of) (NP (NN chemical) (NN bioactivation))) (PP (TO to) (NP (NP (DT a) (JJ toxic) (NN reactive)) (ADJP (ADJP (JJ intermediate)) (PRN (-LRB- -LRB-) (PP (IN in) (NP (NP (NN light)) (PP (IN of) (NP (NP (DT the) (NN protection)) (VP (VBN observed) (PP (IN against) (NP (JJ Doc_9067481_1559_1572_Chemical) (NN hepatotoxicity)))))))) (-RRB- -RRB-))))))))))))) (. .)))
9067481	8	(S1 (S (ADVP (RB However)) (, ,) (PP (VBN based) (PP (IN on) (NP (NP (DT the) (NNS data)) (VP (VBN presented))))) (, ,) (NP (PRP we)) (VP (MD can) (RB not) (VP (VB exclude) (NP (DT the) (NN possibility) (SBAR (IN that) (S (NP (NNP CS) (NN administration)) (VP (VBZ inhibits) (NP (NN chemical) (NN bioactivation)))))))) (. .)))
9067481	9	(S1 (S (NP (PRP$ Our) (NNS findings)) (VP (AUX do) (VP (VB suggest) (SBAR (IN that) (S (NP (JJ CS-mediated) (NN protection)) (VP (AUX is) (ADJP (JJ dependent) (PP (IN on) (NP (NP (DT the) (NN action)) (PP (IN of) (NP (NP (DT the) (JJ intact) (JJ anionic) (NNP CS) (NN molecule)) (PRN (-LRB- -LRB-) (S (NP (JJ non-hydrolyzable) (NN CSE)) (VP (AUX was) (ADJP (RB as) (JJ protective) (PP (IN as) (NP (NNP CS)))))) (-RRB- -RRB-)))) (, ,) (SBAR (WHNP (WP$ whose) (NN mechanism)) (S (VP (AUX has) (ADVP (RB yet)) (S (VP (TO to) (VP (AUX be) (VP (VBN defined)))))))))))))))) (. .)))
9098464	0	(S1 (NP (NP (NP (DT A) (JJ murine) (NN model)) (PP (IN of) (NP (NNP Doc_9098464_18_29_Disease)))) (: :) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NNP Doc_9098464_46_64_Disease))) (VP (VBN induced) (PP (IN by) (NP (NP (NNP Doc_9098464_76_100_Chemical)) (, ,) (NP (DT a) (JJ selective) (JJ Doc_9098464_114_123_Chemical) (NN reuptake) (NN inhibitor)) (, ,))) (PP (IN on) (NP (NP (JJ Doc_9098464_147_158_Disease) (NN induction)) (PP (IN in) (NP (NNP Wistar) (NN albino) (NNS rats))))))) (. .)))
9098464	1	(S1 (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB investigate) (SBAR (IN whether) (S (NP (NNP Doc_9098464_252_262_Chemical)) (VP (VBN given) (PP (TO to) (NP (NP (NP (ADJP (JJ castrated) (CC and) (JJ noncastrated)) (NNS rats)) (VP (VBN caused) (NP (NNP Doc_9098464_311_329_Disease)))) (CC and) (NP (NP (PRP$ its) (NNS effects)) (PP (IN with) (NP (NP (NN respect)) (PP (TO to) (NP (NNP Doc_9098464_362_373_Disease))))))))))))))) (. .)))
9098464	2	(S1 (S (NP (NP (NNP Doc_9098464_383_393_Chemical)) (, ,) (NP (DT a) (JJ Doc_9098464_397_406_Chemical) (NN reuptake) (NN inhibitor)) (, ,)) (VP (AUX was) (VP (VBN given) (PP (TO to) (NP (NNP Wistar) (NNP Albino) (NNS rats))) (PP (IN for) (NP (NP (CD 98) (NNS days)) (SBAR (S (VP (TO to) (VP (VB produce) (NP (NN Doc_9098464_482_500_Disease)))))))))) (. .)))
9098464	3	(S1 (S (NP (DT The) (NN drug)) (VP (AUX was) (VP (VBN given) (PP (PP (TO to) (NP (NP (CD two) (NNS groups)) (VP (VBG consisting) (PP (IN of) (NP (ADJP (JJ castrated) (CC and) (JJ noncastrated)) (NNS rats)))))) (CC and) (PP (VBN compared) (PP (TO to) (NP (NP (CD two) (NNS groups)) (PP (IN of) (NP (ADJP (JJ castrated) (CC and) (JJ noncastrated)) (NNS controls))))))))) (. .)))
9098464	4	(S1 (S (S (NP (NN Prolactin) (NNS levels)) (VP (AUX were) (VP (VBN measured)))) (CC and) (S (NP (NP (DT the) (NN uteri)) (PP (IN of) (NP (DT the) (NNS rats)))) (VP (AUX were) (VP (VBN removed) (PP (IN for) (NP (JJ histopathological) (NN analysis))) (PP (IN at) (NP (NP (DT the) (NN end)) (PP (IN of) (NP (CD 98) (NN days)))))))) (. .)))
9098464	5	(S1 (NP (NP (NP (NNP Marmara) (NNP University) (NNP School)) (PP (IN of) (NP (NNP Medicine)))) (, ,) (NP (NP (NP (NNP Department)) (PP (IN of) (NP (NP (NNP Histology)) (CC and) (NP (NNP Embryology))))) (, ,) (NP (NNP Zeynep) (NNP Kamil) (NNP Women)) (CC and) (NP (NP (NNP Children) (POS 's)) (NNP Hospital))) (. .)))
9098464	6	(S1 (NP (NP (JJ MAIN) (NN OUTCOME) (NNS MEASURES)) (: :) (NP (NP (NNP Serum) (JJ prolactin) (NNS levels)) (, ,) (NP (NN uterine) (NN histopathology))) (. .)))
9098464	7	(S1 (S (NP (NP (DT The) (JJ prolactin) (NNS levels)) (PP (IN of) (NP (NP (ADJP (VBN castrated) (CC and) (VBN noncastrated)) (NNS groups)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_9098464_1055_1065_Chemical))))))) (VP (AUX were) (ADJP (RB statistically) (RB significantly) (JJR higher)) (SBAR (WHADVP (WRB when)) (S (VP (VBD compared) (PP (TO to) (NP (PRP$ their) (JJ respective) (NN control) (NNS groups))))))) (. .)))
9098464	8	(S1 (S (NP (JJ Histological) (NNS studies)) (VP (VBD revealed) (NP (NP (NP (CD 11) (NNS cases)) (PP (IN of) (NP (NNP Doc_9098464_1198_1209_Disease)))) (, ,) (NP (NP (DT all)) (PP (IN within) (NP (DT the) (JJ noncastrated) (NN group) (NN receiving) (NNP Doc_9098464_1255_1265_Chemical)))))) (. .)))
9098464	9	(S1 (S (NP (PRP It)) (VP (AUX was) (VP (VBN suggested) (SBAR (IN that) (S (NP (JJ high) (NN serum) (NN prolactin) (NNS levels)) (VP (VBP cause) (NP (NP (NN degeneration)) (PP (IN of) (NP (JJ myometrial) (NNS cells)))) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (JJ ovarian) (NNP Doc_9098464_1395_1403_Chemical))) (SBAR (WHNP (WDT that)) (S (VP (VBZ results) (PP (IN in) (NP (NP (DT a) (JJ myometrial) (NN invasion)) (PP (IN by) (NP (JJ endometrial) (NN stroma))))))))))))))) (. .)))
9098464	10	(S1 (S (NP (DT This) (NN invasion)) (ADVP (RB eventually)) (VP (VBZ progresses) (S (VP (TO to) (VP (VB Doc_9098464_1504_1515_Disease))))) (. .)))
9105126	0	(S1 (S (NP (NNP Postinfarction) (NNP Doc_9105126_15_40_Disease)) (VP (VBN associated) (PP (IN with) (NP (JJ long-term) (JJ Doc_9105126_67_74_Chemical) (NN therapy)))) (. .)))
9105126	1	(S1 (S (S (NP (NP (CD Two) (NNS cases)) (PP (IN of) (NP (NP (NN postinfarction) (NN Doc_9105126_112_138_Disease)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN on) (NP (JJ long-term) (JJ Doc_9105126_164_171_Chemical) (NN therapy)))))))) (VP (AUX are) (VP (VBN presented)))) (CC and) (S (NP (NP (DT the) (JJ favourable) (NN outcome)) (PP (IN in) (NP (DT both) (NNS cases)))) (VP (VBD described))) (. .)))
9105126	2	(S1 (S (NP (NP (DT A) (JJ possible) (NN association)) (PP (IN between) (NP (NP (JJ Doc_9105126_277_284_Chemical) (NN therapy)) (CC and) (NP (JJ subsequent) (NN postinfarction) (NN Doc_9105126_323_337_Disease))))) (VP (AUX is) (VP (VBN discussed))) (. .)))
9121607	0	(S1 (S (NP (NNP Neuroactive) (NNP Doc_9121607_12_20_Chemical)) (VP (VB protect) (PP (IN against) (NP (NP (NNP Doc_9121607_37_48_Chemical-)) (CC and) (NP (JJ Doc_9121607_54_65_Chemical-induced) (JJ limbic) (NNP Doc_9121607_81_89_Disease) (CC and) (NNP Doc_9121607_94_112_Disease)))) (PP (IN in) (NP (NNS mice)))) (. .)))
9121607	1	(S1 (S (NP (NP (NP (JJ Several) (ADJP (RB structurally) (VBN related)) (NNS metabolites)) (PP (IN of) (NP (NP (NP (NNP Doc_9121607_166_178_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9121607_180_212_Chemical)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_9121607_218_237_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9121607_239_279_Chemical)) (-RRB- -RRB-)))))) (CC and) (NP (PRP$ their) (CD 3) (NNS beta-epimers))) (VP (AUX were) (VP (VBN evaluated) (PP (IN for) (NP (NP (JJ protective) (NN activity)) (PP (IN against) (NP (NP (NNP Doc_9121607_353_364_Chemical-) (, ,) (NNP Doc_9121607_367_378_Chemical-) (CC and) (NNP Doc_9121607_384_404_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9121607_406_410_Chemical)) (-RRB- -RRB-)))) (VP (VBN -induced) (NP (NNP Doc_9121607_420_428_Disease)) (PP (IN in) (NP (NNS mice)))))))) (. .)))
9121607	2	(S1 (S (NP (NP (NP (NNP Doc_9121607_438_446_Chemical)) (PP (IN with) (NP (NP (DT the) (JJ Doc_9121607_456_465_Chemical) (NN group)) (PP (IN in) (NP (DT the) (NN alpha-position)))))) (CC and) (NP (NP (NNP Doc_9121607_498_501_Chemical)) (PP (IN in) (NP (DT the) (NNS alpha-) (CC or) (NNS beta-configurations))))) (VP (AUX were) (ADJP (RB highly) (JJ effective) (PP (IN in) (S (VP (VBG protecting) (PP (IN against) (NP (NP (NP (NNP Doc_9121607_583_594_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 416) (NN mg/kg)) (, ,) (NP (NNP s.c.))) (-RRB- -RRB-))) (NP (NP (JJ -induced) (JJ limbic) (NN motor) (NNP Doc_9121607_634_642_Disease) (CC and) (NNP Doc_9121607_647_665_Disease)) (PRN (-LRB- -LRB-) (NP (NP (CD ED50) (NNS values)) (, ,) (NP (CD 7.0-18.7) (NNS mg/kg))) (, ,) (NP (NNP i.p.)) (-RRB- -RRB-)))))))))) (. .)))
9121607	3	(S1 (S (NP (NP (DT The) (JJ corresponding) (NNS epimers)) (PP (IN with) (NP (DT the) (NNP Doc_9121607_738_747_Chemical) (NN group))) (PP (IN in) (NP (DT the) (NN beta-position)))) (VP (AUX were) (ADVP (RB also)) (ADJP (ADJP (JJ effective)) (CC but) (ADJP (ADJP (RBR less) (JJ potent)) (PRN (-LRB- -LRB-) (NP (NP (CD ED50) (NNS values)) (, ,) (NP (CD 33.8-63.5))) (, ,) (NP (CD i.p.)) (-RRB- -RRB-))))) (. .)))
9121607	4	(S1 (S (SBAR (IN Although) (S (NP (DT the) (JJ neuroactive) (NNP Doc_9121607_868_876_Chemical)) (VP (AUX were) (ADJP (ADVP (RB considerably) (RBR less)) (JJ potent) (PP (IN than) (NP (DT the) (NNP Doc_9121607_916_930_Chemical) (NNP Doc_9121607_931_941_Chemical)))) (PP (IN in) (S (VP (VBG protecting) (PP (IN against) (NP (NNP Doc_9121607_964_975_Chemical) (NNP Doc_9121607_976_984_Disease))))))))) (, ,) (NP (NP (NNP Doc_9121607_986_994_Chemical)) (PP (IN with) (NP (DT the) (CD 5) (NN alpha,3) (NN alpha-configuration)))) (VP (AUX had) (NP (NP (ADJP (JJ comparable) (CC or) (JJR higher)) (JJ protective) (NN index) (NNS values)) (PRN (-LRB- -LRB-) (NP (NP (CD TD50)) (PP (IN for) (NP (NN motor) (NN impairment))) (VP (VBN divided) (PP (IN by) (NP (NP (CD ED50)) (PP (IN for) (NP (NN Doc_9121607_1130_1137_Disease) (NN protection))))))) (-RRB- -RRB-)) (PP (IN than) (NP (NNP Doc_9121607_1155_1165_Chemical))) (, ,) (VP (VBG indicating) (SBAR (IN that) (S (NP (DT some) (JJ neuroactive) (NNP Doc_9121607_1200_1208_Chemical)) (VP (MD may) (VP (AUX have) (NP (JJR lower) (JJ relative) (NN Doc_9121607_1233_1241_Disease))))))))) (. .)))
9121607	5	(S1 (S (NP (NP (NN Doc_9121607_1243_1251_Chemical)) (PP (IN with) (NP (DT the) (QP (CD 5) (CD alpha,3) (NN alpha-) (CC or) (CD 5) (NN beta,3)) (NNS alpha-configurations)))) (ADVP (RB also)) (VP (VP (VBD produced) (NP (NP (DT a) (JJ dose-dependent) (NN delay)) (PP (IN in) (NP (NP (DT the) (NN onset)) (PP (IN of) (NP (NP (JJ limbic) (NNP Doc_9121607_1371_1379_Disease)) (VP (VBN induced) (PP (IN by) (NP (NP (NNP Doc_9121607_1391_1402_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 32) (NN mg/kg)) (, ,) (NP (NNP s.c.))) (-RRB- -RRB-))))))))))) (, ,) (CC but) (VP (AUX did) (RB not) (VP (ADVP (RB completely)) (VB protect) (PP (IN against) (NP (DT the) (NNP Doc_9121607_1464_1472_Disease)))))) (. .)))
9121607	6	(S1 (S (ADVP (RB However)) (, ,) (SBAR (WHADVP (WRB when)) (S (NP (NP (DT a) (JJ second) (NN dose)) (PP (IN of) (NP (DT the) (NNP Doc_9121607_1509_1516_Chemical)))) (VP (AUX was) (VP (VBN administered) (NP (CD 1) (NN hr)) (PP (IN after) (NP (DT the) (JJ first) (NN dose))))))) (, ,) (NP (NP (JJ complete) (NN protection)) (PP (IN from) (NP (NP (DT the) (JJ Doc_9121607_1590_1601_Chemical-induced) (JJ limbic) (NNP Doc_9121607_1617_1625_Disease)) (CC and) (NP (NNP Doc_9121607_1630_1648_Disease))))) (VP (AUX was) (VP (VBN obtained))) (. .)))
9121607	7	(S1 (S (NP (DT The) (NNP Doc_9121607_1667_1675_Chemical)) (ADVP (RB also)) (VP (VP (VBD caused) (NP (DT a) (JJ dose-dependent) (NN delay)) (PP (IN in) (NP (JJ Doc_9121607_1714_1718_Chemical) (PRN (-LRB- -LRB-) (NP (NP (CD 257) (NN mg/kg)) (, ,) (NP (NNP s.c.))) (-RRB- -RRB-)) (JJ -induced) (NN lethality)))) (, ,) (CC but) (VP (AUX did) (RB not) (VP (ADVP (RB completely)) (VB protect) (PP (IN against) (NP (NP (NNP Doc_9121607_1795_1799_Chemical) (NNP Doc_9121607_1800_1808_Disease)) (CC or) (NP (NN lethality))))))) (. .)))
9121607	8	(S1 (S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (S (NP (JJ neuroactive) (NNP Doc_9121607_1852_1860_Chemical)) (VP (VP (AUX are) (ADJP (RB highly) (JJ effective) (PP (IN in) (S (VP (VBG protecting) (PP (IN against) (NP (NP (NNP Doc_9121607_1904_1915_Chemical-)) (CC and) (NP (NNP Doc_9121607_1921_1932_Chemical-induced) (NNP Doc_9121607_1941_1949_Disease) (CC and) (NNP Doc_9121607_1954_1972_Disease)))) (PP (IN in) (NP (NNS mice)))))))) (, ,) (CC and) (VP (MD may) (VP (AUX be) (PP (IN of) (NP (NN utility))) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (DT some) (NNS forms)) (PP (IN of) (NP (NP (NNP Doc_9121607_2038_2056_Disease)) (PP (IN in) (NP (NNS humans))))))))))))))) (. .)))
9154656	0	(S1 (NP (NP (NP (NN Hepatic)) (CC and) (NP (JJ extrahepatic) (JJ angiotensinogen) (NN gene) (NN expression))) (PP (IN in) (NP (NP (NNS rats)) (PP (IN with) (NP (JJ acute) (NNP Doc_9154656_76_94_Disease))))) (. .)))
9154656	1	(S1 (S (NP (NP (NP (NN Plasma) (NN concentration)) (CC and) (NP (NN urine) (NN excretion))) (PP (IN of) (NP (DT the) (JJ renin-angiotensin) (NN system) (NNS proteins)))) (VP (AUX are) (VP (VBN altered) (PP (IN in) (NP (NP (NNS rats)) (PP (IN with) (NP (NP (NNP Doc_9154656_203_221_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9154656_223_225_Disease)) (-RRB- -RRB-)))))))) (. .)))
9154656	2	(S1 (S (PP (IN In) (NP (DT this) (NN work))) (NP (NP (DT the) (NN messenger) (NNP Doc_9154656_255_271_Chemical) (PRN (-LRB- -LRB-) (NN mRNA) (-RRB- -RRB-)) (NNS levels)) (PP (IN of) (NP (NP (NNS angiotensinogen)) (PRN (-LRB- -LRB-) (NP (NNP Ao)) (-RRB- -RRB-))))) (VP (AUX were) (VP (VBN analyzed) (PP (IN with) (NP (NP (NP (DT the) (JJ slot-blot) (NN hybridization) (NN technique)) (PP (IN in) (NP (NP (UCP (NN liver) (CC and) (JJ other)) (JJ extrahepatic) (NNS tissues)) (: :) (NP (NP (NN kidney)) (, ,) (NP (NN heart)) (, ,) (NP (NN brain)) (, ,) (CC and) (NP (NP (JJ adrenal) (NN gland)) (PP (IN from) (NP (NN control)))))))) (, ,) (NP (NNP Doc_9154656_462_471_Disease)) (, ,) (CC and) (NP (JJ pair-fed) (PRN (-LRB- -LRB-) (NP (NNP PF)) (-RRB- -RRB-)) (NNS rats)))))) (. .)))
9154656	3	(S1 (S (NP (NN Doc_9154656_497_499_Disease)) (VP (AUX was) (VP (VBN induced) (PP (IN by) (NP (NP (DT a) (JJ single) (NN injection)) (PP (IN of) (NP (NP (NNP Doc_9154656_537_563_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9154656_565_568_Chemical)) (-RRB- -RRB-)))))))) (. .)))
9154656	4	(S1 (S (SBAR (IN Although) (S (NP (NP (NP (DT a) (JJ great) (NN urinary) (NN excretion)) (CC and) (NP (JJ half-normal) (NN plasma) (NNS levels))) (PP (IN of) (NP (NNP Ao)))) (VP (AUX were) (VP (VBN observed) (PP (IN on) (NP (NN day) (CD 6))) (PP (IN after) (NP (JJ Doc_9154656_671_674_Chemical) (NN injection))))))) (, ,) (SBAR (WHADVP (WRB when)) (S (NP (NNP Doc_9154656_691_693_Disease)) (VP (AUX was) (ADVP (RB clearly)) (VP (VBN established))))) (, ,) (NP (JJ hepatic) (NNP Ao) (NN mRNA) (NNS levels)) (VP (AUX did) (RB not) (VP (VB change))) (. .)))
9154656	5	(S1 (S (ADVP (RB Furthermore)) (, ,) (NP (DT the) (JJ Ao) (NN mRNA) (NNS levels)) (VP (VP (AUX did) (RB not) (VP (VB change) (PP (IN in) (NP (NP (DT any)) (PP (IN of) (NP (NP (DT the) (JJ extrahepatic) (NNS tissues)) (VP (VBN studied) (PP (IN on) (NP (NN day) (CD 6)))))))))) (, ,) (CC nor) (VP (AUX did) (NP (PRP$ its) (JJ hepatic) (NNS levels)) (PP (IN at) (NP (NP (NNS days)) (VP (NP (CD 1) (, ,) (CD 3) (, ,) (CD 5) (, ,) (CC or) (CD 7)) (PP (IN after) (NP (JJ Doc_9154656_913_916_Chemical) (NN injection)))))))) (. .)))
9154656	6	(S1 (S (NP (DT These) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (NP (DT the) (ADJP (JJ hepatic) (CC and) (JJ extrahepatic)) (NN Ao) (NN mRNA) (NNS levels)) (VP (AUX are) (ADJP (JJ unaltered)) (PP (IN during) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NP (DT the) (JJ acute) (NN Doc_9154656_1046_1048_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_9154656_1060_1063_Chemical)))))))))))) (. .)))
9165568	0	(S1 (S (VP (VB Doc_9165568_0_30_Disease) (PP (IN with) (NP (NNP Doc_9165568_36_47_Chemical)))) (. .)))
9165568	1	(S1 (S (NP (NN Doc_9165568_49_79_Disease)) (VP (AUX is) (VP (VBN thought) (S (VP (TO to) (VP (AUX be) (NP (NP (DT a) (NN result)) (PP (IN of) (NP (NNP Doc_9165568_109_117_Chemical) (NNP D2) (NN receptor) (NN blockade)))) (PP (IN in) (NP (NP (DT the) (NN striatum)) (PP (IN of) (NP (DT the) (JJ basal) (NNS ganglia)))))))))) (. .)))
9165568	2	(S1 (S (NP (NP (NNP Doc_9165568_177_188_Chemical)) (, ,) (NP (DT a) (NNP Doc_9165568_192_205_Chemical) (NN derivative) (NN antipsychotic)) (, ,)) (VP (AUX has) (NP (NP (JJ high) (JJ Doc_9165568_241_250_Chemical) (JJ 5-HT2) (NN receptor) (NN blockade)) (CC and) (NP (JJ dose-related) (JJ D2) (NN receptor) (NN blockade)))) (. .)))
9165568	3	(S1 (S (NP (DT The) (JJ high) (NN ratio)) (VP (AUX is) (VP (VBN believed) (S (VP (TO to) (VP (VB impart) (NP (NP (DT the) (JJ low) (NN frequency)) (PP (IN of) (NP (NNP Doc_9165568_372_395_Disease))) (PP (IN with) (NP (NNP Doc_9165568_401_412_Chemical))) (PP (IN at) (NP (JJ low) (NNS dosages))))))))) (. .)))
9165568	4	(S1 (S (PP (IN With) (NP (NP (DT this) (JJ low) (NN frequency)) (PP (IN of) (NP (NNP Doc_9165568_456_479_Disease))))) (, ,) (NP (PRP it)) (VP (AUX was) (VP (VBN thought) (SBAR (S (NP (NP (DT the) (NN frequency)) (PP (IN of) (NP (NNP Doc_9165568_513_543_Disease)))) (VP (MD might) (ADVP (RB also)) (VP (AUX be) (VP (VBN lowered)))))))) (. .)))
9165568	5	(S1 (S (NP (DT A) (JJ 73-year-old) (NN woman)) (VP (VBD developed) (NP (NN Doc_9165568_597_627_Disease)) (PP (IN after) (S (VP (VBG monotherapy) (PP (IN with) (NP (NNP Doc_9165568_651_662_Chemical))))))) (. .)))
9165568	6	(S1 (S (NP (DT The) (NN syndrome)) (VP (VBD reversed) (PP (IN after) (S (VP (VP (VBG discontinuing) (NP (NNP Doc_9165568_706_717_Chemical))) (CC and) (VP (VBG starting) (NP (NP (NN treatment)) (PP (IN with) (NP (NP (NNP Doc_9165568_746_756_Chemical)) (CC and) (NP (NNP Doc_9165568_761_774_Chemical)))))))))) (. .)))
9165568	7	(S1 (S (NP (PRP It)) (VP (VBZ appears) (SBAR (IN that) (S (NP (NP (DT the) (NN protection)) (PP (IN from) (NP (JJ extrapyramidal) (NN side) (NNS effects))) (VP (VBN observed) (PP (IN with) (NP (NNP Doc_9165568_854_865_Chemical))))) (VP (AUX does) (RB not) (VP (VB ensure) (NP (NP (NN protection)) (PP (IN from) (NP (NN Doc_9165568_898_928_Disease))))))))) (. .)))
9201797	0	(S1 (NP (NP (DT The) (JJ attenuating) (NN effect)) (PP (IN of) (NP (NP (NNP Doc_9201797_26_49_Chemical)) (, ,) (NP (DT a) (JJ beta-adrenoceptor) (NN antagonist)) (, ,))) (PP (IN on) (NP (NP (JJ neuroleptic-induced) (NN Doc_9201797_106_115_Disease)) (PP (IN in) (NP (NNS rats))))) (. .)))
9201797	1	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (VBN known) (SBAR (IN that) (S (NP (NN beta-adrenoceptor) (NNS antagonists)) (VP (AUX are) (ADJP (JJ effective)) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (NNP Doc_9201797_206_215_Disease)) (, ,) (NP (NP (CD one)) (PP (IN of) (NP (DT the) (JJ extrapyramidal) (NN side) (NNS effects))) (SBAR (WHNP (WDT that)) (S (VP (VBP occur) (PP (IN during) (NP (JJ neuroleptic) (NN treatment)))))))))))))))) (. .)))
9201797	2	(S1 (S (NP (NP (JJ Neuroleptic-induced) (NNP Doc_9201797_317_326_Disease)) (, ,) (NP (NP (DT a) (NN model)) (PP (IN of) (NP (JJ neuroleptic-induced) (JJ extrapyramidal) (NN side) (NNS effects)))) (, ,)) (VP (AUX was) (VP (VBN considered) (S (ADJP (JJ suitable) (PP (IN as) (NP (NP (DT a) (NN model)) (PP (IN for) (S (VP (VBG predicting) (NP (NP (JJ neuroleptic-induced) (NN Doc_9201797_458_467_Disease)) (PP (IN in) (NP (NNS humans))))))))))) (, ,) (SBAR (IN although) (S (NP (JJ neuroleptic-induced) (NNP Doc_9201797_508_517_Disease)) (VP (AUX was) (RB not) (VP (VBN considered) (S (NP (NP (DT a) (JJ specific) (NN test)) (PP (IN for) (NP (JJ neuroleptic-induced) (NN Doc_9201797_577_586_Disease))))))))))) (. .)))
9201797	3	(S1 (S (ADVP (RB Therefore)) (, ,) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (NNP Doc_9201797_614_623_Chemical)) (, ,) (NP (DT a) (JJ beta-adrenoceptor) (NN antagonist)) (, ,))) (PP (IN on) (NP (NP (NNP Doc_9201797_660_671_Chemical-induced) (NNP Doc_9201797_680_689_Disease)) (PP (IN in) (NP (NNS rats)))))) (VP (VP (AUX were) (ADVP (RB behaviorally)) (VP (VBN studied))) (CC and) (VP (VBN compared) (PP (IN with) (NP (NP (DT those)) (PP (IN of) (NP (NP (NNP Doc_9201797_751_762_Chemical)) (CC and) (NP (NP (NNP Doc_9201797_767_776_Chemical)) (, ,) (NP (DT a) (JJ muscarinic) (NN receptor) (NN antagonist))))))))) (. .)))
9201797	4	(S1 (S (NP (NP (NNP Doc_9201797_812_821_Chemical)) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (NP (NNP Doc_9201797_834_845_Chemical)) (CC and) (NP (NNP Doc_9201797_850_859_Chemical))) (, ,)) (VP (VBD inhibited) (NP (DT the) (JJ Doc_9201797_875_886_Chemical-induced) (NN Doc_9201797_895_904_Disease))) (. .)))
9201797	5	(S1 (S (NP (NP (DT The) (JJ inhibitory) (NN effect)) (PP (IN of) (NP (NNP Doc_9201797_931_940_Chemical)))) (VP (VP (AUX was) (ADJP (RB almost) (JJ comparable) (PP (TO to) (NP (NP (DT that)) (PP (IN of) (NP (NNP Doc_9201797_974_985_Chemical))))))) (, ,) (CC but) (VP (AUX was) (ADJP (JJR weaker) (PP (IN than) (NP (NP (DT that)) (PP (IN of) (NP (NNP Doc_9201797_1015_1024_Chemical)))))))) (. .)))
9201797	6	(S1 (S (NP (NNP Doc_9201797_1026_1035_Chemical)) (VP (AUX did) (RB not) (VP (VB evoke) (NP (NP (JJ postsynaptic) (JJ Doc_9201797_1063_1071_Chemical) (JJ receptor-stimulating) (JJ behavioral) (NNS signs)) (PP (JJ such) (IN as) (NP (NP (NP (NN stereotypy)) (CC and) (NP (NN hyperlocomotion))) (PP (IN in) (NP (NNS rats)))))))) (. .)))
9201797	7	(S1 (S (NP (NNP Doc_9201797_1158_1167_Chemical)) (VP (AUX did) (RB not) (VP (VP (VB antagonize) (NP (NP (DT the) (JJ inhibitory) (NNS effects)) (PP (IN of) (NP (NNP Doc_9201797_1213_1224_Chemical))) (PP (IN on) (NP (JJ Doc_9201797_1228_1239_Chemical-induced) (NN stereotypy))))) (CC and) (VP (VB locomotor) (NP (NP (NN activity)) (PP (IN in) (NP (NNS rats))))))) (. .)))
9201797	8	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NNP Doc_9201797_1304_1313_Chemical)) (VP (VP (AUX did) (RB not) (VP (VP (VB evoke) (NP (NP (JJ 5-HT1A) (JJ receptor-stimulating) (JJ behavioral) (NNS signs)) (PP (JJ such) (IN as) (NP (JJ flat) (NN body) (NN posture))))) (CC and) (VP (VB forepaw) (NP (NN treading))))) (CC and) (VP (AUX did) (RB not) (VP (VB inhibit) (S (NP (JJ Doc_9201797_1440_1459_Chemical-induced) (NN head)) (VP (VB twitch) (PP (IN in) (NP (NNS rats)))))))) (. .)))
9201797	9	(S1 (S (ADVP (RB Finally)) (, ,) (NP (NNP Doc_9201797_1498_1507_Chemical)) (VP (AUX did) (RB not) (VP (VB inhibit) (NP (NP (JJ Doc_9201797_1524_1537_Chemical-induced) (NN lethality)) (PP (IN in) (NP (NNS rats)))))) (. .)))
9201797	10	(S1 (S (NP (DT These) (NNS results)) (VP (ADVP (RB strongly)) (VBP suggest) (SBAR (IN that) (S (NP (NNP Doc_9201797_1601_1610_Chemical)) (VP (VP (VBZ improves) (NP (NP (JJ Doc_9201797_1620_1631_Chemical-induced) (NN Doc_9201797_1640_1649_Disease)) (PP (IN via) (NP (PRP$ its) (JJ beta-adrenoceptor) (JJ antagonistic) (NN activity))))) (CC and) (VP (AUX is) (VP (VBN expected) (S (VP (TO to) (VP (AUX be) (ADJP (JJ effective) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NNP Doc_9201797_1750_1759_Disease)))))) (PP (IN without) (S (VP (VBG attenuating) (NP (NP (JJ neuroleptic-induced) (JJ antipsychotic) (NNS effects)) (ADJP (JJ due) (PP (TO to) (NP (PRP$ its) (JJ postsynaptic) (NNP Doc_9201797_1846_1854_Chemical) (NN receptor) (JJ antagonistic) (NN activity))))))))))))))))) (. .)))
9205462	0	(S1 (S (NP (NN Doc_9205462_0_33_Disease)) (VP (VBN associated) (PP (IN with) (NP (JJ antecedent) (JJ Doc_9205462_61_70_Chemical) (NN use)))) (. .)))
9205462	1	(S1 (S (NP (VBN Increased) (NN attention)) (VP (AUX has) (VP (AUX been) (VP (VBN focused) (ADVP (RB recently)) (PP (IN on) (NP (NP (DT the) (JJ estrogenic) (NNS effects)) (PP (IN of) (NP (NNP Doc_9205462_163_172_Chemical)))))))) (. .)))
9205462	2	(S1 (S (NP (NP (NN Review)) (PP (IN of) (NP (DT the) (NN literature)))) (VP (VBZ reveals) (NP (NP (DT an) (NN association)) (PP (IN between) (NP (NP (JJ Doc_9205462_230_239_Chemical) (NN use)) (CC and) (NP (JJ gynecologic) (NN Doc_9205462_260_266_Disease)))))) (. .)))
9205462	3	(S1 (S (NP (DT A) (JJ 52-year-old) (NN postmenopausal) (NN woman)) (VP (AUX was) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_9205462_326_335_Chemical))) (PP (IN for) (NP (NN stage) (NNP II) (JJ Doc_9205462_349_357_Chemical) (JJ receptor-positive) (NN Doc_9205462_376_392_Disease))))) (. .)))
9205462	4	(S1 (S (NP (PRP$ Her) (JJ Doc_9205462_398_407_Chemical) (ADJP (JJ transaminase) (CC and) (JJ Doc_9205462_425_432_Chemical)) (NN transaminase) (NNS levels)) (VP (VBP increase) (ADVP (RB markedly)) (PP (IN after) (NP (NP (CD 6) (NNS months)) (PP (IN of) (NP (JJ Doc_9205462_489_498_Chemical) (NN use)))))) (. .)))
9205462	5	(S1 (S (PP (IN After) (NP (NP (DT an) (JJ additional) (CD 17) (NNS months)) (PP (IN of) (NP (JJ elevated) (NN serum) (NNS transaminases))))) (, ,) (NP (DT the) (NN patient)) (VP (AUX was) (VP (VBN found) (S (VP (TO to) (VP (AUX have) (NP (DT a) (NN stage) (NNP Ic) (NN Doc_9205462_608_641_Disease))))))) (. .)))
9205462	6	(S1 (S (NP (NP (NNS Patients)) (PP (IN with) (NP (NNP Doc_9205462_669_678_Chemical-induced) (NNP Doc_9205462_687_704_Disease)))) (VP (MD may) (VP (AUX be) (PP (IN at) (NP (NP (JJ increased) (NN risk)) (PP (IN for) (NP (NNP Doc_9205462_734_755_Disease))))) (PP (IN because) (IN of) (NP (NP (NNS alterations)) (PP (IN in) (NP (JJ Doc_9205462_782_791_Chemical) (NN metabolism))))))) (. .)))
9209318	0	(S1 (S (NP (NP (NN Lifetime) (NN treatment)) (PP (IN of) (NP (NNS mice))) (PP (IN with) (NP (NP (NNP Doc_9209318_32_46_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9209318_48_51_Chemical)) (-RRB- -RRB-))))) (VP (VBZ produces) (NP (NN Doc_9209318_62_76_Disease))) (. .)))
9209318	1	(S1 (S (NP (NNP Doc_9209318_78_81_Chemical)) (VP (AUX has) (VP (VBN induced) (NP (NP (DT a) (NN Doc_9209318_96_113_Disease)) (PP (IN in) (NP (NP (JJ Doc_9209318_117_121_Disease) (NNS patients)) (PP (IN on) (NP (JJ long) (NN term) (JJ Doc_9209318_144_147_Chemical) (NN therapy)))))))) (. .)))
9209318	2	(S1 (S (NP (PRP It)) (VP (AUX is) (ADVP (RB generally)) (VP (VBN assumed) (SBAR (IN that) (S (NP (NN DNA) (NN elongation)) (VP (AUX is) (VP (VBN stopped) (PP (IN by) (S (NP (NP (DT the) (NN insertion)) (PP (IN of) (NP (NNP Doc_9209318_232_235_Chemical))) (PP (IN into) (NP (DT the) (NN chain))) (PP (IN in) (NP (NN place))) (PP (IN of) (NP (NNP Doc_9209318_263_272_Chemical)))) (ADVP (RB thus)) (VP (VP (VBG preventing) (NP (DT the) (JJ Doc_9209318_293_302_Chemical) (NN hydroxyl) (NNS linkages))) (CC and) (VP (ADVP (RB therefore)) (VBZ suppresses) (NP (JJ hemopoietic) (NN progenitor) (NN cell) (NN proliferation)) (PP (IN in) (NP (NP (DT an) (JJ early) (NN stage)) (PP (IN of) (NP (NN differentiation))))))))))))))) (. .)))
9209318	3	(S1 (S (NP (NNP Doc_9209318_426_429_Chemical/Ca) (NN male) (NNS mice)) (VP (VP (VBD started) (PP (IN on) (NP (NNP Doc_9209318_454_457_Chemical) (CD 0.75) (NN mg/ml))) (NP (NNP H2O)) (PP (IN at) (NP (NP (CD 84) (NNS days)) (PP (IN of) (NP (NN age)))))) (CC and) (VP (VBD kept) (PP (IN on) (NP (PRP it))) (PP (IN for) (NP (NP (CD 687) (NNS days)) (SBAR (WHADVP (WRB when)) (S (NP (NN dosage)) (VP (VBD reduced) (PP (TO to) (NP (CD 0.5) (NN mg/ml))) (SBAR (S (NP (NP (NNP Doc_9209318_552_555_Chemical)) (PP (IN for) (NP (NP (DT a) (NN group)) (, ,) (NP (NP (DT another) (NN group)) (VP (VBN removed) (PP (IN from) (NP (NNP Doc_9209318_596_599_Chemical))) (S (VP (TO to) (VP (VB see) (NP (NN recovery))))))) (, ,) (CC and) (NP (JJ third) (NN group))))) (VP (VBD remained) (PP (IN on) (NP (CD 0.75) (NN mg))))))))))))) (. .)))
9209318	4	(S1 (S (PP (IN At) (NP (CD 687) (NNS days))) (NP (NP (NNS mice)) (SBAR (WHNP (WDT that)) (S (VP (AUX had) (VP (AUX been) (PP (IN on) (NP (CD 0.75) (NN mg)))))))) (VP (AUX had) (NP (NP (JJ average) (NN platelet) (NNS counts)) (PP (IN of) (NP (NP (QP (CD 2.5) (SYM x) (CD 10))) (PRN (-LRB- -LRB-) (NP (CD 6)) (-RRB- -RRB-)))))) (. .)))
9209318	5	(S1 (S (NP (NP (JJ Histological) (NN examination)) (PP (IN on) (NP (NP (QP (CD 9) (IN of) (CD 10)) (NNS mice)) (PP (IN with) (NP (JJ such) (NN Doc_9209318_791_807_Disease)))))) (VP (VBD showed) (NP (NP (NNS changes)) (ADJP (JJ compatible) (PP (IN with) (NP (NP (NNP Doc_9209318_839_863_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9209318_865_868_Disease)) (-RRB- -RRB-))))))) (. .)))
9209318	6	(S1 (S (NP (NP (DT A) (NN variety)) (PP (IN of) (NP (JJ histological) (NNS patterns)))) (VP (AUX was) (VP (VBN observed))) (. .)))
9209318	7	(S1 (S (NP (EX There)) (VP (AUX were) (NP (NP (NP (CD two) (NNS cases)) (PP (IN of) (NP (JJ hypocellular) (NNP Doc_9209318_957_971_Disease)))) (, ,) (NP (NP (CD two) (NNS cases)) (PP (IN of) (NP (JJ hypersegmented) (NNP Doc_9209318_1001_1016_Disease) (NNS granulocytosis)))) (, ,) (NP (NP (CD two) (NNS cases)) (PP (IN of) (NP (NP (JJ hypercellular) (NN marrow)) (PP (IN with) (NP (NP (JJ abnormal) (NNS megakaryocytes)) (PP (IN with) (NP (NP (JJ bizarre) (NN nuclei)) (, ,) (NP (NP (CD one) (NN case)) (PP (IN of) (NP (NP (JJ megakaryocytic) (NNS myelosis)) (VP (VBN associated) (PP (IN with) (NP (DT a) (NNP Doc_9209318_1171_1190_Disease))))))) (, ,) (NP (NN dysmyelopoiesis)) (CC and) (NP (DT a) (NNP Doc_9209318_1214_1233_Disease))))))))) (CC and) (NP (NP (CD two) (NNS cases)) (PP (IN of) (NP (NNP Doc_9209318_1251_1265_Disease))))) (PP (IN with) (NP (NP (NNP Doc_9209318_1271_1288_Disease)) (, ,) (NP (NNP Doc_9209318_1290_1303_Disease)) (CC and) (NP (DT a) (NNP Doc_9209318_1310_1329_Disease))))) (. .)))
9209318	8	(S1 (S (IN Above) (NP (VBN mentioned) (JJ Doc_9209318_1347_1350_Chemical) (NN incorporation)) (VP (MD may) (VP (AUX have) (VP (VBN induced) (NP (DT an) (JJ ineffective) (NN hemopoiesis)) (PP (IN in) (NP (NP (DT the) (JJ primitive) (JJ hemopoietic) (NN progenitor) (NNS cells)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX is) (VP (VBN known) (S (VP (TO to) (VP (AUX be) (VP (VBN seen) (ADVP (RB commonly)) (PP (IN in) (NP (DT the) (NNP Doc_9209318_1498_1522_Disease)))))))))))))))) (. .)))
921394	0	(S1 (NP (NP (JJ Biphasic) (NN response)) (PP (IN of) (NP (NP (DT the) (NNP SA) (NN node)) (PP (IN of) (NP (DT the) (NN dog) (NN heart))) (PP (IN in) (NP (NN vivo))))) (PP (TO to) (NP (NP (JJ selective) (NN administration)) (PP (IN of) (NP (NNP Doc_921394_89_97_Chemical))))) (. .)))
921394	1	(S1 (S (NP (NP (NN Effect)) (PP (IN of) (NP (NNP Doc_921394_109_117_Chemical))) (PP (IN on) (NP (NP (DT the) (NNP SA) (NN node)) (PP (IN of) (NP (DT the) (NN dog) (NN heart)))))) (VP (AUX was) (VP (VBN studied) (PP (IN in) (NP (NP (NNS vivo)) (VP (VBG using) (NP (NP (DT a) (JJ selective) (NN perfusion) (NN technique)) (PP (IN of) (NP (DT the) (NNP SA) (NN node) (NN artery))))))))) (. .)))
921394	2	(S1 (S (NP (NP (NNS Injections)) (PP (IN of) (NP (NNP Doc_921394_245_253_Chemical))) (PP (IN in) (NP (NP (NNS doses)) (PP (IN from) (NP (NP (QP (CD 100) (NN microgram) (TO to) (CD 3) (NN mg))) (PP (IN into) (NP (DT the) (NN artery)))))))) (VP (VBD produced) (NP (NP (DT a) (NN Doc_921394_317_327_Disease)) (PP (IN of) (NP (DT the) (NNP SA) (NN nodal) (NN activity))) (PP (IN by) (NP (DT a) (JJ direct) (NN action))))) (. .)))
921394	3	(S1 (S (NP (DT This) (NN Doc_921394_378_388_Disease)) (VP (AUX was) (VP (VBN followed) (PP (IN by) (NP (NP (DT the) (JJ sudden) (NN appearance)) (PP (IN of) (NP (DT a) (JJ stimulatory) (NN phase))))))) (. .)))
921394	4	(S1 (S (NP (NP (JJ Bilateral) (NN vagotomy)) (CC and) (NP (NP (NP (NN sympathectomy)) (CC or) (NP (JJ prior) (NN administration))) (PP (IN of) (NP (DT a) (NN ganglion) (NN blocker))))) (VP (VBD failed) (S (VP (TO to) (VP (VB inhibit) (NP (NP (DT the) (NN occurrence)) (PP (IN of) (NP (DT the) (JJ Doc_921394_574_582_Chemical-induced) (NN Doc_921394_591_602_Disease))))))) (, ,) (SBAR (IN while) (S (NP (PRP it)) (VP (AUX was) (VP (ADVP (RB completely)) (VBN abolished) (PP (PP (IN in) (NP (DT the) (JJ reserpinized) (NNS dogs))) (CC or) (PP (IN by) (NP (NP (DT a) (JJ prior) (NN injection)) (PP (IN of) (NP (NP (DT a) (JJ beta-blocking) (NN agent)) (PP (IN into) (NP (DT the) (NNP SA) (NN node) (NN artery))))))))))))) (. .)))
921394	5	(S1 (S (NP (DT This)) (VP (MD may) (VP (VB indicate) (SBAR (IN that) (S (NP (NP (DT an) (NN activation)) (PP (IN of) (NP (DT the) (JJ peripheral) (NN adrenergic) (NN mechanism)))) (VP (VBZ plays) (NP (DT an) (JJ important) (NN role)) (PP (IN in) (NP (NP (DT the) (NN induction)) (PP (IN of) (NP (NP (DT the) (JJ excitatory) (NN effect)) (PP (IN of) (NP (NNP Doc_921394_882_890_Chemical))) (VP (VBN injected) (PP (IN in) (NP (DT the) (NNP SA) (NN node) (NN artery))))))))))))) (. .)))
9214597	0	(S1 (S (PP (IN Over) (NP (NP (NP (NN expression)) (PP (IN of) (NP (JJ vascular) (JJ endothelial) (NN growth) (NN factor)))) (CC and) (NP (NP (PRP$ its) (NN receptor)) (PP (IN during) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (JJ Doc_9214597_97_105_Chemical-induced) (NN rat)))))))) (NP (NNP Doc_9214597_118_134_Disease)) (VP (MD may) (VP (VB mediate) (NP (JJ Doc_9214597_147_155_Chemical-initiated) (JJ Doc_9214597_166_171_Disease) (NNS angiogenesis)))) (. .)))
9214597	1	(S1 (S (NP (NP (NN Doc_9214597_186_195_Chemical)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX have) (VP (AUX been) (VP (VBN associated) (PP (IN with) (NP (NP (JJ several) (NNS types)) (PP (IN of) (NP (ADJP (JJ human) (CC and) (JJ animal)) (NNP Doc_9214597_263_270_Disease)))))))))) (, ,)) (VP (MD can) (VP (VB induce) (NP (NNP Doc_9214597_283_288_Disease) (NNS angiogenesis)) (PP (IN in) (NP (NP (DT the) (NN pituitary)) (PP (IN of) (NP (NNP Fischer) (CD 344) (NNS rats))))))) (. .)))
9214597	2	(S1 (S (NP (NP (DT The) (JJ mechanistic) (NNS details)) (PP (IN of) (NP (NNP Doc_9214597_367_372_Disease) (NN angiogenesis) (NN induction)))) (, ,) (PP (IN during) (NP (NNP Doc_9214597_404_412_Chemical) (NNP Doc_9214597_413_427_Disease))) (, ,) (VP (AUX are) (ADVP (RB still)) (ADJP (JJ unknown))) (. .)))
9214597	3	(S1 (S (S (VP (TO To) (VP (VB elucidate) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NNP Doc_9214597_473_481_Chemical)))) (PP (IN in) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (NP (NNP Doc_9214597_503_508_Disease) (NNS angiogenesis)) (PP (IN in) (NP (NP (DT the) (NN pituitary)) (PP (IN of) (NP (JJ female) (NNS rats)))))))))))) (, ,) (NP (NP (DT the) (NN density)) (PP (IN of) (NP (NN blood) (NNS vessels)))) (VP (AUX was) (VP (VBN analysed) (S (VP (VBG using) (NP (NP (NN factor)) (SBAR (S (NP (NP (NP (NP (NNP VIII) (JJ related) (NN antigen) (PRN (-LRB- -LRB-) (NNP FVIIIRAg) (-RRB- -RRB-)) (NN immunohistochemistry)) (CC and) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (JJ vascular) (JJ endothelial) (NN growth))))) (JJ factor/vascular) (NN permeability) (NN factor)) (PRN (-LRB- -LRB-) (NP (NNP VEGF/VPF)) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN examined) (PP (IN by) (NP (NP (NNP Western) (NNP blot)) (CC and) (NP (JJ immunohistochemical) (NN analysis))))))))))))) (. .)))
9214597	4	(S1 (S (NP (NP (DT The) (NN expression)) (PP (IN of) (NP (NP (JJ VEGF) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NNP VEGFR-2/Flk-1/KDR)) (-RRB- -RRB-))))) (VP (AUX was) (ADVP (RB also)) (VP (VBN examined) (PP (IN by) (NP (NN immunohistochemistry))))) (. .)))
9214597	5	(S1 (S (NP (DT The) (NNS results)) (VP (VBD demonstrated) (SBAR (IN that) (S (NP (NP (NNP Doc_9214597_948_964_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP E2)) (-RRB- -RRB-))) (VP (VBZ induces) (NP (NP (NN neovascularization)) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (NP (DT the) (NN growth) (CC and) (NN enlargement)) (PP (IN of) (NP (NN blood) (NNS vessels))))) (PP (IN after) (NP (NP (CD 7) (NNS days)) (PP (IN of) (NP (NN exposure))))))))) (. .)))
9214597	6	(S1 (S (NP (DT The) (JJ high) (JJ Doc_9214597_1088_1093_Disease) (JJ angiogenic) (NN potential)) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (DT an) (JJ elevated) (NNP VEGF/VPF) (NN protein) (NN expression)) (PP (IN in) (NP (NP (DT the) (JJ E2) (VBN exposed) (NN pituitary)) (PP (IN of) (NP (JJ ovariectomized) (PRN (-LRB- -LRB-) (NP (NNP OVEX)) (-RRB- -RRB-)) (NNS rats))))))))) (. .)))
9214597	7	(S1 (S (NP (NNP VEGF/VPF) (CC and) (NNP FVIIIRAg) (JJ immunohistochemistry) (CC and) (JJ endothelial) (JJ specific) (NN lectin) (PRN (-LRB- -LRB-) (NP (NNP UEA1)) (-RRB- -RRB-)) (JJ binding) (NNS studies)) (, ,) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (DT the) (NN elevation)) (PP (IN of) (NP (JJ VEGF) (NN protein) (NN expression)))) (ADVP (RB initially)) (VP (VBD occurred) (PP (IN in) (NP (NP (DT both) (NN blood) (NNS vessels)) (CC and) (NP (JJ non-endothelial) (NNS cells)))))))) (. .)))
9214597	8	(S1 (S (PP (IN After) (NP (NP (CD 15) (NNS days)) (PP (IN of) (NP (NNP E2) (NN exposure))))) (, ,) (NP (NNP VEGF/VPF) (NN protein) (NN expression)) (, ,) (PP (IN in) (NP (DT the) (JJ non-endothelial) (NN cell) (NN population))) (, ,) (VP (VP (ADVP (RB sharply)) (VBN declined)) (CC and) (VP (AUX was) (VP (VBN restricted) (PP (TO to) (NP (DT the) (NN blood) (NNS vessels)))))) (. .)))
9214597	9	(S1 (S (NP (NP (DT The) (NN function)) (PP (IN of) (NP (JJ non-endothelial-derived) (NNS VEGF)))) (VP (AUX is) (RB not) (ADJP (JJ clear))) (. .)))
9214597	10	(S1 (S (ADVP (RB Furthermore)) (, ,) (NP (NN immunohistochemical) (NNS studies)) (VP (VBD demonstrated) (SBAR (S (NP (DT that) (JJ VEGFR-2) (PRN (-LRB- -LRB-) (JJ flk-1/KDR) (-RRB- -RRB-) (, ,)) (NN expression)) (VP (AUX was) (VP (VBD elevated) (ADVP (RB significantly)) (PP (IN in) (NP (NP (DT the) (JJ endothelial) (NNS cells)) (PP (IN of) (NP (NN microblood) (NNS vessels))))) (PP (IN after) (NP (NP (CD 7) (NNS days)) (PP (IN of) (NP (NNP E2) (NN exposure)))))))))) (. .)))
9214597	11	(S1 (S (NP (DT These) (NNS findings)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (IN over) (NN expression)) (PP (IN of) (NP (NP (NNS VEGF)) (CC and) (NP (NP (PRP$ its) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN VEGFR-2)) (-RRB- -RRB-)))))) (VP (MD may) (VP (VB play) (NP (DT an) (JJ important) (NN role)) (PP (IN in) (NP (NP (DT the) (JJ initial) (NN step)) (PP (IN of) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (NP (JJ Doc_9214597_2013_2021_Chemical) (VBN induced) (JJ Doc_9214597_2030_2035_Disease) (NNS angiogenesis)) (PP (IN in) (NP (DT the) (NN rat) (NN pituitary)))))))))))))) (. .)))
9226773	0	(S1 (S (NP (JJ Persistent) (NNP Doc_9226773_11_41_Disease)) (VP (VBG following) (NP (JJ Doc_9226773_52_59_Chemical) (NN therapy))) (. .)))
9226773	1	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT the) (NN case)) (PP (IN of) (NP (NP (DT a) (NN patient)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (JJ severe) (JJ hypernatraemic) (NN Doc_9226773_137_148_Disease)) (PP (VBG following) (NP (DT a) (NN Doc_9226773_161_172_Disease)))))))))) (. .)))
9226773	2	(S1 (S (S (ADVP (NP (CD Ten) (NNS years)) (RB previously)) (NP (PRP he)) (VP (AUX had) (VP (AUX been) (VP (VBN diagnosed) (S (VP (TO to) (VP (AUX have) (NP (JJ Doc_9226773_225_232_Chemical-induced) (NN Doc_9226773_241_271_Disease))))))))) (, ,) (CC and) (S (NP (JJ Doc_9226773_277_284_Chemical) (NN therapy)) (VP (AUX had) (VP (AUX been) (VP (VBN discontinued))))) (. .)))
9226773	3	(S1 (S (S (NP (PRP He)) (VP (VBD remained) (ADJP (JJ thirsty) (CC and) (JJ polyuric)) (PP (IN despite) (NP (NP (NN cessation)) (PP (IN of) (NP (NNP Doc_9226773_370_377_Chemical))))))) (CC and) (S (NP (NP (NNS investigations)) (PP (IN on) (NP (NN admission)))) (VP (VBD showed) (NP (PRP him)) (S (VP (TO to) (VP (AUX have) (NP (NP (JJ normal) (JJ osmoregulated) (NN thirst)) (CC and) (NP (JJ Doc_9226773_461_472_Chemical) (NN secretion)))))) (, ,) (PP (IN with) (NP (NP (JJ clear) (NN evidence)) (PP (IN of) (NP (NNP Doc_9226773_507_537_Disease))))))) (. .)))
9226773	4	(S1 (S (S (NP (NP (NN Doc_9226773_539_546_Chemical)) (VP (VBN induced) (NP (NNP Doc_9226773_555_585_Disease)))) (VP (AUX is) (VP (VBN considered) (S (VP (TO to) (VP (AUX be) (ADJP (JJ reversible)) (PP (IN on) (NP (NP (NN cessation)) (PP (IN of) (NP (NN therapy))))))))))) (CC but) (S (NP (NNP Doc_9226773_645_653_Disease)) (VP (VBD persisted) (PP (IN in) (NP (DT this) (NN patient))) (PP (IN for) (NP (CD ten) (NNS years))) (SBAR (IN after) (S (NP (NNP Doc_9226773_700_707_Chemical)) (VP (AUX was) (VP (VBN stopped))))))) (. .)))
9226773	5	(S1 (S (NP (PRP We)) (VP (VB discuss) (NP (NP (DT the) (JJ possible) (JJ renal) (NNS mechanisms)) (CC and) (NP (NP (DT the) (NNS implications)) (PP (IN for) (NP (NP (NN management)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_9226773_815_822_Chemical-induced) (NNP Doc_9226773_831_861_Disease)))))))))) (. .)))
9228650	0	(S1 (NP (NP (NNS Effects)) (PP (IN of) (NP (NNP Doc_9228650_11_18_Chemical))) (PP (IN on) (NP (NP (NN cholinesterase)) (CC and) (NP (JJ Doc_9228650_41_52_Chemical-induced) (NN Doc_9228650_61_68_Disease)))) (. .)))
9228650	1	(S1 (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NNP Doc_9228650_85_92_Chemical))) (PP (IN on) (NP (NP (NN cholinesterase)) (, ,) (NP (JJ Doc_9228650_112_123_Chemical-induced) (NN Doc_9228650_132_139_Disease)) (CC and) (NP (JJ spontaneous) (NN movement))))) (VP (VP (AUX were) (VP (VBN examined))) (CC and) (VP (VBN compared) (PP (IN with) (NP (NP (DT those)) (PP (IN of) (NP (NP (DT the) (JJ well-known) (NN cholinesterase) (NNS inhibitors)) (ADJP (JJ Doc_9228650_247_254_Chemical) (CC and) (JJ Doc_9228650_259_265_Chemical)))))))) (. .)))
9228650	2	(S1 (S (NP (NNP Doc_9228650_267_274_Chemical) (, ,) (NNP Doc_9228650_276_283_Chemical) (CC and) (NNP Doc_9228650_288_294_Chemical)) (ADVP (RB all) (RB strongly)) (VP (VBD inhibited) (NP (NP (NN acetylcholinesterase)) (PRN (-LRB- -LRB-) (NP (NNP AChE)) (-RRB- -RRB-))) (PP (IN in) (NP (NP (JJ human) (JJ red) (NN blood) (NNS cells)) (PRN (-LRB- -LRB-) (NP (NP (QP (CD IC50s) (SYM =) (CD 1.0) (SYM x) (CD 10) (PRN (-LRB- -LRB-) (JJ -6) (-RRB- -RRB-) (, ,)) (CD 2.9) (SYM x) (CD 10) (PRN (-LRB- -LRB-) (JJ -7) (-RRB- -RRB-)) (CC and) (CD 3.7)) (NNP x) (CD 10) (-LRB- -LRB-) (JJ -8) (-RRB- -RRB-) (NNP M)) (, ,) (NP (RB respectively))) (-RRB- -RRB-))))) (. .)))
9228650	3	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (NP (NNP Doc_9228650_455_462_Chemical)) (CC and) (NP (NNP Doc_9228650_467_474_Chemical))) (, ,) (CONJP (CC but) (RB not)) (NP (NNP Doc_9228650_484_490_Chemical)) (, ,)) (ADVP (RB strongly)) (VP (VBD inhibited) (NP (NP (NN butyrylcholinestrase)) (PRN (-LRB- -LRB-) (NP (NNP BuChE)) (-RRB- -RRB-))) (PP (IN in) (NP (JJ human) (NN serum)))) (. .)))
9228650	4	(S1 (S (NP (DT All) (CD three) (NNS drugs)) (VP (VBD produced) (NP (NP (VBN mixed) (NN inhibition)) (PP (IN of) (NP (NN AChE) (NN activity))))) (. .)))
9228650	5	(S1 (S (ADVP (RB Moreover)) (, ,) (NP (NP (DT the) (JJ inhibitory) (NN effect)) (PP (IN of) (NP (NNP Doc_9228650_651_658_Chemical))) (PP (IN on) (NP (NN AChE)))) (VP (AUX was) (ADJP (JJ reversible))) (. .)))
9228650	6	(S1 (S (NP (NP (DT All) (NNS compounds)) (PP (IN at) (NP (JJ 0.1-1) (NN mg/kg) (NNS p.o.)))) (VP (ADVP (RB significantly)) (VBN improved) (NP (NP (DT the) (NNP Doc_9228650_744_751_Disease)) (VP (VBN induced) (PP (IN by) (NP (NP (NNP Doc_9228650_763_774_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 0.5) (NN mg/kg)) (NP (NNP s.c.))) (-RRB- -RRB-)))) (PP (IN in) (NP (NP (NNS rats)) (VP (VBG performing) (NP (DT a) (JJ passive) (NN avoidance) (NN task)))))))) (. .)))
9228650	7	(S1 (S (NP (NP (DT The) (CD three) (NNS compounds)) (PP (IN at) (NP (QP (CD 1) (CC and) (CD 3) (CD mg/kg)) (NNS p.o.)))) (VP (AUX did) (RB not) (ADVP (RB significantly)) (VP (VB decrease) (NP (NP (JJ spontaneous) (NN movement)) (PP (IN by) (NP (NNS rats)))))) (. .)))
9228650	8	(S1 (S (NP (DT These) (NNS findings)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NN Doc_9228650_968_975_Chemical)) (PP (IN at) (NP (NP (DT a) (JJ low) (NN dose)) (PRN (-LRB- -LRB-) (NP (JJ 0.1-1) (NN mg/kg) (NN p.o.)) (-RRB- -RRB-))))) (VP (VP (VBZ improves) (NP (JJ Doc_9228650_1018_1029_Chemical-induced) (NN Doc_9228650_1038_1045_Disease))) (CC but) (VP (AUX does) (RB not) (VP (VB affect) (NP (JJ spontaneous) (NN movement)))))))) (. .)))
9228650	9	(S1 (S (NP (DT The) (NNS findings)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NNP Doc_9228650_1114_1121_Chemical)) (VP (MD may) (VP (AUX be) (NP (NP (DT a) (JJ useful) (NN drug)) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NN Doc_9228650_1164_1183_Disease))))))))))) (. .)))
9270571	0	(S1 (NP (NP (NP (NP (JJ Potential) (JJ therapeutic) (NN use)) (PP (IN of) (NP (DT the) (JJ selective) (NNP Doc_9270571_43_51_Chemical) (NNP D1) (NN receptor) (NN agonist)))) (, ,) (NP (NNP Doc_9270571_73_80_Chemical))) (: :) (NP (NP (DT an) (JJ acute) (NN study)) (PP (IN in) (NP (JJ Doc_9270571_100_112_Disease) (JJ Doc_9270571_113_121_Chemical-primed) (NNS monkeys)))) (. .)))
9270571	1	(S1 (S (NP (NP (DT The) (JJ clinical) (NN utility)) (PP (IN of) (NP (NNP Doc_9270571_162_170_Chemical) (PRN (-LRB- -LRB-) (NP (NNP DA)) (-RRB- -RRB-)) (NNP D1) (NN receptor) (NNS agonists))) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (NNP Doc_9270571_217_236_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9270571_238_240_Disease)) (-RRB- -RRB-))))))) (VP (AUX is) (ADVP (RB still)) (ADJP (JJ unclear))) (. .)))
9270571	2	(S1 (S (NP (NP (DT The) (JJ therapeutic) (NN use)) (PP (IN of) (NP (NP (JJ selective) (NNP DA) (NNP D1) (NN receptor) (NNS agonists)) (PP (JJ such) (IN as) (NP (NP (NP (NNP Doc_9270571_325_334_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9270571_336_425_Chemical)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_9270571_431_438_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9270571_440_535_Chemical)) (-RRB- -RRB-)))))))) (VP (VBZ seems) (VP (VBN limited) (PP (IN because) (IN of) (NP (NP (PRP$ their) (NN duration)) (PP (IN of) (NP (NN action))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX is) (ADJP (ADJP (RB too) (JJ short) (PP (IN for) (NP (NNP Doc_9270571_611_620_Chemical)))) (PRN (-LRB- -LRB-) (NP (QP (CD <) (CD 1)) (NNS hr)) (-RRB- -RRB-)) (CC and) (ADJP (ADJP (RB too) (JJ long)) (PP (IN for) (NP (NNP Doc_9270571_647_654_Chemical)))) (PRN (-LRB- -LRB-) (NP (QP (CD >) (CD 20)) (NN hr)) (, ,) (ADJP (JJ leading) (PP (TO to) (NP (JJ behavioral) (NN tolerance)))) (-RRB- -RRB-)))))))))) (. .)))
9270571	3	(S1 (S (NP (PRP We)) (ADVP (RB therefore)) (VP (VBD conducted) (NP (DT the) (JJ present) (JJ acute) (NN dose-response) (NN study)) (PP (IN in) (NP (NP (CD four) (JJ Doc_9270571_768_812_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_9270571_814_818_Chemical)) (-RRB- -RRB-)) (JJ -exposed) (NN cynomolgus) (NNS monkeys)) (VP (VBN primed) (S (VP (TO to) (VP (VB exhibit) (NP (JJ Doc_9270571_865_873_Chemical-induced) (NNP Doc_9270571_882_893_Disease)) (S (VP (TO to) (VP (VB evaluate) (NP (NP (DT the) (NN locomotor)) (CC and) (NP (NP (NP (NNP Doc_9270571_924_934_Disease) (NNS effects)) (PP (IN on) (NP (NN challenge))) (PP (IN with) (NP (CD four) (NNS doses))) (PRN (-LRB- -LRB-) (PP (IN from) (NP (QP (CD 0.03) (TO to) (CD 1.0)) (NNS mg/kg))) (-RRB- -RRB-))) (PP (IN of) (NP (NP (NP (NNP Doc_9270571_1000_1007_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9270571_1009_1114_Chemical)) (-RRB- -RRB-))) (, ,) (NP (NP (DT a) (ADJP (JJ selective) (CC and) (JJ full)) (NNP DA) (NNP D1-like) (NN receptor) (NN agonist)) (PP (IN with) (NP (NP (DT an) (JJ intermediate) (NN duration)) (PP (IN of) (NP (NN action)))))))))))))))))))) (. .)))
9270571	4	(S1 (S (NP (NP (NN Doc_9270571_1207_1215_Chemical)) (CC and) (NP (NP (DT the) (NNP DA) (JJ D2-like) (NN receptor) (NN agonist)) (, ,) (NP (NP (NNP Doc_9270571_1253_1262_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9270571_1264_1354_Chemical)) (-RRB- -RRB-))))) (VP (AUX were) (ADVP (RB also)) (VP (VBN used) (PP (IN for) (NP (NN comparison))))) (. .)))
9270571	5	(S1 (S (NP (NP (JJ Acute) (NN administration)) (PP (IN of) (NP (NNP Doc_9270571_1411_1418_Chemical)))) (VP (VP (AUX was) (ADJP (RB as) (JJ efficacious) (PP (IN in) (S (VP (VBG alleviating) (NP (JJ Doc_9270571_1453_1457_Chemical-induced) (NN Doc_9270571_1466_1478_Disease)) (PP (IN as) (NP (NNP Doc_9270571_1482_1490_Chemical) (CC and) (NNP Doc_9270571_1495_1504_Chemical)))))))) (, ,) (CC but) (VP (AUX was) (ADJP (ADJP (RBR less) (JJ likely) (S (VP (TO to) (VP (VB reproduce) (NP (DT the) (JJ Doc_9270571_1543_1551_Chemical-induced) (NN Doc_9270571_1560_1571_Disease)) (PP (IN in) (NP (DT these) (NNS animals))))))) (PP (IN than) (PP (IN with) (NP (NP (DT either) (JJ Doc_9270571_1606_1615_Chemical) (CC or) (JJ subsequent) (NN challenge)) (PP (IN of) (NP (NNP Doc_9270571_1643_1651_Chemical))))))))) (. .)))
9270571	6	(S1 (S (NP (NP (JJ Selective) (NN stimulation)) (PP (IN of) (NP (DT the) (NNP DA) (NNP D1) (NN receptor)))) (VP (MD may) (VP (VB provide) (NP (NP (JJR better) (NN integration)) (PP (IN of) (NP (NP (JJ neural) (NNS inputs)) (VP (VBN transmitted) (PP (TO to) (NP (NP (DT the) (JJ internal) (NN segment)) (PP (IN of) (NP (NP (DT the) (JJ globus) (NNS pallidus)) (PRN (-LRB- -LRB-) (VP (VBN referred) (PP (TO to)) (PP (IN as) (NP (DT the) (JJ basal) (NN ganglia) (NN output)))) (-RRB- -RRB-)))))))))) (PP (VBN compared) (PP (IN with) (NP (NP (NNP Doc_9270571_1860_1868_Chemical)) (CC and) (NP (JJ selective) (NNP DA) (NNP D2) (NN receptor) (NN agonist))))))) (. .)))
9270571	7	(S1 (S (NP (NP (JJ Potent) (NNP DA) (NNP D1) (NN receptor) (NNS agents)) (PP (IN with) (NP (NP (DT an) (JJ intermediate) (NN duration)) (PP (IN of) (NP (NN efficacy))))) (PP (JJ such) (IN as) (NP (NP (NNP Doc_9270571_1986_1993_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (QP (RB approximately) (CD 4)) (NN hr)) (PP (IN at) (NP (NP (JJR higher) (NNS doses)) (VP (VBN tested))))) (-RRB- -RRB-))))) (VP (VP (AUX are) (NP (NP (JJ potential) (JJ therapeutic) (NNS tools)) (PP (IN in) (NP (NNP Doc_9270571_2073_2075_Disease))))) (CC and) (VP (VBP merit) (NP (JJ further) (NN attention)))) (. .)))
9305828	0	(S1 (NP (NP (JJ Neuropeptide-Y) (NN immunoreactivity)) (PP (IN in) (NP (NP (DT the) (JJ Doc_9305828_39_50_Chemical) (NN model)) (PP (IN of) (NP (NNP Doc_9305828_60_82_Disease))))) (. .)))
9305828	1	(S1 (S (NP (NP (NNP Neuropeptide-Y)) (PRN (-LRB- -LRB-) (NP (NNP NPY)) (-RRB- -RRB-))) (VP (AUX is) (VP (VBN expressed) (PP (IN by) (NP (NP (JJ granule) (NNS cells)) (CC and) (NP (NP (JJ mossy) (NNS fibres)) (PP (IN of) (NP (DT the) (JJ hippocampal) (NN dentate) (NN gyrus))) (PP (IN during) (NP (NP (JJ experimental) (NNP Doc_9305828_205_227_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9305828_229_232_Disease)) (-RRB- -RRB-))))))))) (. .)))
9305828	2	(S1 (S (NP (DT This) (NN expression)) (VP (MD may) (VP (VB represent) (NP (NP (DT an) (JJ endogenous) (VBG damping) (NN mechanism)) (SBAR (IN since) (S (NP (NNP NPY)) (VP (AUX has) (VP (AUX been) (VP (VBN shown) (S (VP (TO to) (VP (VB block) (NP (JJ Doc_9305828_331_338_Disease-like) (NNS events)) (PP (VBG following) (NP (NP (NN high-frequency) (NN stimulation)) (PP (IN in) (NP (JJ hippocampal) (NNS slices)))))))))))))))) (. .)))
9305828	3	(S1 (S (NP (NP (DT The) (NNP Doc_9305828_415_426_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_9305828_428_432_Chemical)) (-RRB- -RRB-)) (NN model)) (PP (IN of) (NP (NNP Doc_9305828_443_451_Disease)))) (VP (AUX is) (VP (VBN characterized) (PP (IN by) (NP (NP (DT an) (JJ acute) (NN period)) (PP (IN of) (NP (NNP Doc_9305828_491_509_Disease))) (VP (VBN followed) (PP (IN by) (NP (NP (JJ spontaneous) (JJ recurrent) (NN Doc_9305828_544_552_Disease)) (CC and) (NP (JJ related) (NN Doc_9305828_565_577_Disease))))))))) (. .)))
9305828	4	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (JJ peroxidase-antiperoxidase) (NN immunostaining)) (PP (IN for) (NP (NN NPY)))) (PP (IN in) (NP (NP (JJ several) (NN brain) (NNS regions)) (PP (IN in) (NP (DT this) (NN model)))))) (. .)))
9305828	5	(S1 (S (NP (JJ Doc_9305828_678_682_Chemical-injected) (NNS animals)) (VP (VBD exhibited) (NP (JJ NPY) (NN immunoreactivity)) (PP (IN in) (NP (NP (DT the) (NN region)) (PP (IN of) (NP (DT the) (JJ mossy) (JJ fibre) (NNS terminals))))) (, ,) (PP (PP (IN in) (NP (DT the) (JJ dentate) (JJ gyrus) (JJ inner) (JJ molecular) (NN layer))) (CC and) (, ,) (PP (IN in) (NP (DT a) (JJ few) (NNS cases)))) (, ,) (PP (IN within) (NP (JJ presumed) (NN granule) (NNS cells)))) (. .)))
9305828	6	(S1 (S (NP (JJ NPY) (NN immunoreactivity)) (VP (AUX was) (ADVP (RB also)) (VP (ADVP (RB dramatically)) (VBN changed) (PP (IN in) (NP (NP (DT the) (JJ entorhinal) (NN cortex)) (, ,) (NP (NN amygdala)) (CC and) (NP (NN sensorimotor) (NNS areas)))))) (. .)))
9305828	7	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NNP Doc_9305828_993_997_Chemical)) (VP (VBD injected) (SBAR (S (NP (NNS animals)) (VP (VBD exhibited) (NP (NP (DT a) (NN reduction)) (PP (IN in) (NP (NP (DT the) (NN number)) (PP (IN of) (NP (JJ NPY-immunoreactive) (NNS interneurons)))))) (PP (VBN compared) (PP (IN with) (NP (NNS controls)))))))) (. .)))
9305828	8	(S1 (S (NP (DT The) (NNS results)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP (NP (NNS changes)) (PP (IN in) (NP (JJ NPY) (NN expression))) (, ,) (PP (VBG including) (NP (NP (NP (NN expression)) (PP (IN in) (NP (NP (DT the) (JJ granule) (NNS cells)) (CC and) (NP (JJ mossy) (NNS fibres))))) (CC and) (NP (NP (DT the) (NN loss)) (PP (IN of) (NP (JJ vulnerable) (JJ NPY) (NNS neurons)))))) (, ,)) (VP (AUX are) (ADJP (JJ present) (PP (IN in) (NP (NP (DT the) (JJ Doc_9305828_1284_1288_Chemical) (NN model)) (PP (IN of) (NP (NNP Doc_9305828_1298_1301_Disease)))))))))) (. .)))
9305828	9	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (NN significance)) (PP (IN of) (NP (NP (DT this) (JJ changed) (NN synthesis)) (PP (IN of) (NP (NN NPY)))))) (VP (VBZ remains) (S (VP (TO to) (VP (AUX be) (VP (VBN determined)))))) (. .)))
9321531	0	(S1 (NP (NP (JJ Posteroventral) (JJ medial) (NN pallidotomy)) (PP (IN in) (NP (JJ advanced) (NNP Doc_9321531_46_65_Disease))) (. .)))
9321531	1	(S1 (S (S (NP (JJ Posteroventral) (NN medial) (NN pallidotomy)) (ADVP (RB sometimes)) (VP (VBZ produces) (NP (NP (JJ striking) (NN improvement)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ advanced) (NNP Doc_9321531_179_198_Disease)))))))) (, ,) (CC but) (S (NP (NP (DT the) (NNS studies)) (PP (TO to) (NP (NN date)))) (VP (AUX have) (VP (VBN involved) (NP (NP (JJ small) (NNS numbers)) (PP (IN of) (NP (NP (NNS patients)) (CC and) (NP (JJ short-term) (NN follow-up)))))))) (. .)))
9321531	2	(S1 (S (NP (NP (CD Forty) (NNS patients)) (PP (IN with) (NP (NNP Doc_9321531_319_338_Disease)))) (VP (VBD underwent) (NP (JJ serial) (, ,) (JJ detailed) (NNS assessments)) (PP (DT both) (PP (IN after) (NP (NP (NN drug) (NN withdrawal)) (PRN (-LRB- -LRB-) (NP (`` ``) (JJ off) ('' '') (NN period)) (-RRB- -RRB-)))) (CC and) (PP (IN while) (S (VP (VBG taking) (NP (NP (PRP$ their) (JJ optimal) (JJ medical) (NNS regimens)) (PRN (-LRB- -LRB-) (`` ``) (PP (IN on) ('' '') (NP (NN period))) (-RRB- -RRB-)))))))) (. .)))
9321531	3	(S1 (S (S (S (NP (DT All) (NNS patients)) (VP (AUX were) (VP (VBN examined) (ADVP (RB preoperatively))))) (CC and) (S (NP (CD 39)) (VP (AUX were) (VP (VBN examined) (PP (IN at) (NP (CD six) (NNS months))))))) (: ;) (S (NP (NP (CD 27)) (PP (IN of) (NP (DT the) (NNS patients)))) (VP (VP (AUX were) (ADVP (RB also)) (VP (VBN examined) (PP (IN at) (NP (CD one) (NN year))))) (, ,) (CC and) (VP (NP (CD 11)) (PP (IN at) (NP (CD two) (NNS years)))))) (. .)))
9321531	4	(S1 (S (NP (NP (DT The) (NN percent) (NNS improvements)) (PP (IN at) (NP (CD six) (NNS months)))) (VP (AUX were) (UCP (RB as) (S (VP (VBZ follows))) (: :) (NP (NP (NP (JJ off-period) (NN score)) (PP (IN for) (NP (JJ overall) (NN motor) (NN function)))) (, ,) (NP (NP (ADJP (ADJP (CD 28) (NN percent)) (PRN (-LRB- -LRB-) (NP (CD 95) (NN percent) (NN confidence) (NN interval)) (, ,) (NP (QP (CD 19) (TO to) (CD 38)) (NN percent)) (-RRB- -RRB-)) (, ,) (PP (IN with) (NP (NP (JJS most)) (PP (IN of) (NP (NP (NP (DT the) (NN improvement)) (PP (IN in) (NP (DT the) (JJ contralateral) (NNS limbs)))) (: ;) (NP (NP (JJ off-period) (NN score)) (PP (IN for) (NP (NP (NNS activities)) (PP (IN of) (NP (NP (JJ daily) (NN living)) (, ,) (NP (NP (CD 29) (NN percent)) (PRN (-LRB- -LRB-) (NP (CD 95) (NN percent) (NN confidence) (NN interval)) (, ,) (NP (QP (CD 19) (TO to) (CD 39)) (NN percent)) (-RRB- -RRB-)))))))) (: ;))))) (NN on-period)) (NN score)) (PP (IN for) (NP (JJ contralateral) (NNP Doc_9321531_1009_1020_Disease)))) (, ,) (NP (NP (NP (NP (CD 82) (NN percent)) (PRN (-LRB- -LRB-) (NP (CD 95) (NN percent) (NN confidence) (NN interval)) (, ,) (NP (QP (CD 72) (TO to) (CD 91)) (NN percent)) (-RRB- -RRB-)) (: ;)) (CC and) (NP (JJ on-period) (NN score))) (PP (IN for) (NP (JJ ipsilateral) (NNP Doc_9321531_1121_1132_Disease)))) (, ,) (NP (NP (CD 44) (NN percent)) (PRN (-LRB- -LRB-) (NP (CD 95) (NN percent) (NN confidence) (NN interval)) (, ,) (NP (QP (CD 29) (TO to) (CD 59)) (NN percent)) (-RRB- -RRB-)))))) (. .)))
9321531	5	(S1 (S (NP (NP (NP (DT The) (NNS improvements)) (PP (IN in) (NP (NNP Doc_9321531_1217_1228_Disease)))) (CC and) (NP (NP (DT the) (JJ total) (NNS scores)) (PP (IN for) (NP (NP (JJ off-period) (NNP Doc_9321531_1265_1277_Disease)) (, ,) (NP (JJ contralateral) (NNP Doc_9321531_1293_1305_Disease)) (, ,) (CC and) (NP (NNP Doc_9321531_1311_1319_Disease)))))) (VP (AUX were) (VP (VBN sustained) (PP (IN in) (NP (NP (DT the) (CD 11) (NNS patients)) (VP (VBN examined) (PP (IN at) (NP (CD two) (NNS years)))))))) (. .)))
9321531	6	(S1 (S (S (NP (NP (DT The) (NN improvement)) (PP (IN in) (NP (JJ ipsilateral) (NNP Doc_9321531_1408_1419_Disease)))) (VP (AUX was) (VP (VBN lost) (PP (IN after) (NP (CD one) (NN year)))))) (, ,) (CC and) (S (NP (NP (DT the) (NNS improvements)) (PP (IN in) (NP (NP (JJ postural) (NN stability)) (CC and) (NP (NN gait))))) (VP (VBD lasted) (NP (QP (RB only) (CD three) (TO to) (CD six)) (NNS months)))) (. .)))
9321531	7	(S1 (S (NP (NP (QP (RB Approximately) (PDT half)) (DT the) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX had) (VP (AUX been) (ADJP (JJ dependent) (PP (IN on) (NP (NN assistance)))) (PP (IN in) (NP (NP (NNS activities)) (PP (IN of) (NP (NP (JJ daily) (NN living)) (PP (IN in) (NP (NP (DT the) (JJ off) (NN period)) (PP (IN before) (NP (NN surgery)))))))))))))) (VP (VBD became) (ADJP (JJ independent)) (PP (IN after) (NP (NN surgery)))) (. .)))
9321531	8	(S1 (S (S (NP (NP (DT The) (NNS complications)) (PP (IN of) (NP (NN surgery)))) (VP (AUX were) (ADVP (RB generally)) (VP (ADVP (RB well)) (VBN tolerated)))) (, ,) (CC and) (S (NP (EX there)) (VP (AUX were) (NP (NP (DT no) (JJ significant) (NNS changes)) (PP (IN in) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NN medication)))))))) (. .)))
9321531	9	(S1 (S (PP (IN In) (NP (JJ late-stage) (NNP Doc_9321531_1847_1866_Disease))) (, ,) (NP (NN pallidotomy)) (ADVP (RB significantly)) (VP (VBZ reduces) (NP (NP (JJ Doc_9321531_1902_1910_Chemical-induced) (NN Doc_9321531_1919_1930_Disease)) (CC and) (NP (JJ off-period) (NN disability)))) (. .)))
9321531	10	(S1 (S (NP (NP (RB Much)) (PP (IN of) (NP (DT the) (NN benefit)))) (VP (AUX is) (VP (VBN sustained) (PP (IN at) (NP (CD two) (NNS years))) (, ,) (SBAR (IN although) (S (NP (NP (DT some) (NNS improvements)) (, ,) (PP (JJ such) (IN as) (NP (NP (DT those)) (PP (PP (IN on) (NP (DT the) (JJ ipsilateral) (NN side))) (CC and) (PP (IN in) (NP (JJ axial) (NNS symptoms)))))) (, ,)) (VP (VBP wane) (PP (IN within) (NP (DT the) (JJ first) (NN year)))))))) (. .)))
9321531	11	(S1 (S (NP (NP (DT The) (JJ on-period) (NNS symptoms)) (SBAR (WHNP (WDT that)) (S (VP (AUX are) (ADJP (JJ resistant) (PP (TO to) (NP (JJ dopaminergic) (NN therapy)))))))) (VP (AUX do) (RB not) (VP (VB respond) (PP (TO to) (NP (NN pallidotomy))))) (. .)))
9326871	0	(S1 (NP (JJ Doc_9326871_0_14_Chemical-induced) (NN Doc_9326871_23_46_Disease) (. .)))
9326871	1	(S1 (S (NP (NN Doc_9326871_48_62_Chemical)) (VP (AUX is) (NP (NP (DT a) (ADJP (RB relatively) (JJ new)) (JJ Doc_9326871_83_92_Chemical) (JJ antibiotic)) (SBAR (WHNP (WDT that)) (S (VP (VBZ offers) (NP (JJ twice-daily) (NN dosing))))))) (. .)))
9326871	2	(S1 (S (NP (PRP It)) (VP (VBZ differs) (PP (IN from) (NP (NNP Doc_9326871_152_164_Chemical))) (PP (RB only) (IN in) (NP (NP (DT the) (NN methylation)) (PP (IN of) (NP (DT the) (NNP Doc_9326871_196_204_Chemical) (NN group))) (PP (IN at) (NP (NN position) (CD 6)))))) (. .)))
9326871	3	(S1 (S (SBAR (IN Although) (S (NP (NP (DT the) (JJ side-effect) (NN profile)) (PP (IN of) (NP (NNP Doc_9326871_262_274_Chemical)))) (VP (AUX is) (VP (VBN established))))) (, ,) (PP (VBG including) (NP (NP (NNP Doc_9326871_301_316_Disease)) (CC and) (NP (NP (NNS interactions)) (PP (IN with) (NP (NP (JJ other) (NNS drugs)) (ADJP (JJ subject) (PP (TO to) (NP (JJ hepatic) (NN mixed-function) (NN oxidase) (NN metabolism))))))))) (, ,) (NP (NP (NN experience)) (PP (IN with) (NP (DT the) (JJR newer) (NN Doc_9326871_431_441_Chemical)))) (VP (AUX is) (ADVP (RB still)) (VP (AUXG being) (VP (VBN recorded)))) (. .)))
9326871	4	(S1 (S (NP (NN Doc_9326871_467_481_Disease)) (VP (VP (AUX has) (VP (AUX been) (VP (VBN demonstrated) (PP (IN after) (NP (NP (DT both) (JJ intravenous) (CC and) (JJ oral) (NN administration)) (PP (IN of) (NP (NNP Doc_9326871_554_566_Chemical)))))))) (CC but) (VP (AUX has) (ADVP (RB never)) (VP (AUX been) (VP (VBN reported) (PP (IN with) (NP (DT the) (JJR newer) (NN Doc_9326871_610_620_Chemical))))))) (. .)))
9326871	5	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NNP Doc_9326871_642_666_Disease))) (SBAR (WHNP (WDT that)) (S (VP (VBD occurred) (PP (IN after) (NP (NP (CD six) (JJ therapeutic) (NNS doses)) (PP (IN of) (NP (NN Doc_9326871_712_726_Chemical)))))))))) (. .)))
9326871	6	(S1 (S (NP (DT The) (NNP Doc_9326871_732_744_Disease)) (VP (VBD resolved) (PP (IN after) (NP (NP (NN discontinuation)) (PP (IN of) (NP (DT the) (NN drug)))))) (. .)))
9431903	0	(S1 (S (NP (NP (NN Effect)) (PP (IN of) (NP (NNP Doc_9431903_10_29_Chemical))) (PP (IN on) (NP (DT the) (NNP Doc_9431903_37_60_Disease)))) (VP (VBN evoked) (PP (IN by) (NP (JJ Doc_9431903_71_82_Chemical-Doc_9431903_83_91_Chemical) (NN administration)))) (. .)))
9431903	1	(S1 (S (PP (IN In) (NP (DT this) (NN study))) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NNP Doc_9431903_147_166_Chemical))) (PP (IN on) (NP (DT the) (JJ Doc_9431903_174_185_Chemical-Doc_9431903_186_194_Chemical-induced) (NN Doc_9431903_203_226_Disease)))) (VP (AUX was) (VP (VBN evaluated) (PP (IN in) (NP (NP (CD nine) (JJ female) (NNS patients)) (PP (IN with) (NP (NNP Doc_9431903_270_298_Disease))))))) (. .)))
9431903	2	(S1 (S (NP (NN Doc_9431903_308_331_Disease)) (VP (AUX was) (VP (VP (VBN induced) (PP (IN by) (NP (NP (JJ Doc_9431903_347_358_Chemical-Doc_9431903_359_367_Chemical) (NN administration)) (PRN (-LRB- -LRB-) (NP (NP (CD 0.5) (JJ mg) (NNP Doc_9431903_391_402_Chemical) (NN intramuscularly)) (CC and) (NP (CD 10) (JJ mg) (NNP Doc_9431903_429_437_Chemical) (NN subcutaneously))) (-RRB- -RRB-))))) (CC and) (VP (VBN visualized) (PP (IN by) (NP (JJ quantitative) (NN hepatobiliary) (NN scintigraphy)))))) (. .)))
9431903	3	(S1 (S (NP (DT The) (JJ entire) (NN procedure)) (VP (AUX was) (VP (VBN repeated) (PP (IN during) (NP (NP (JJ Doc_9431903_554_573_Chemical) (NN infusion)) (PRN (-LRB- -LRB-) (NP (NP (NNP Nitrolingual) (CD 1)) (VP (VBN microg/kg/min) (PP (IN for) (NP (CD 120) (NN min))))) (-RRB- -RRB-)))))) (. .)))
9431903	4	(S1 (S (NP (JJ Doc_9431903_636_647_Chemical-Doc_9431903_648_656_Chemical) (NN provocation)) (VP (VBD caused) (NP (NP (NP (NP (JJ significant) (NNS increases)) (PP (PP (IN in) (NP (NP (NP (DT the) (NN time)) (S (VP (TO to) (VP (VB peak) (NP (NP (NN activity)) (PRN (-LRB- -LRB-) (NP (NNP Tmax)) (-RRB- -RRB-))) (PP (IN over) (NP (DT the) (JJ hepatic) (NN hilum)))))) (PRN (-LRB- -LRB-) (NP (NNP HH)) (: :) (NP (NP (CD 34.33) (NNS +/-)) (NP (CD 5.05) (CC vs.) (CD 22.77) (NN +/-) (CD 3.26))) (-RRB- -RRB-))) (CC and) (NP (NP (DT the) (JJ common) (JJ bile) (NN duct)) (PRN (-LRB- -LRB-) (NP (NNP CBD)) (: :) (NP (NP (CD 60.44) (NNS +/-)) (NP (CD 5.99) (CC vs.) (CD 40.0) (NN +/-) (CD 2.88))) (-RRB- -RRB-))))) (CC and) (PP (IN in) (NP (NP (DT the) (NN half-time)) (PP (IN of) (NP (NN excretion))))))) (PRN (-LRB- -LRB-) (NP (NNP T1/2)) (-RRB- -RRB-))) (PP (IN over) (NP (DT the) (NN liver) (NN parenchyma))) (PRN (-LRB- -LRB-) (NP (NNP LP)) (: :) (NP (NP (CD 120.04) (NN +/-)) (NP (CD 16.01) (CC vs.) (CD 27.37) (NN +/-) (CD 2.19))) (-RRB- -RRB-)) (, ,) (NP (NP (NP (NNP HH)) (PRN (-LRB- -LRB-) (NP (NP (CD 117.61) (NN +/-)) (NP (CD 14.71) (CC vs.) (CD 31.85) (NN +/-) (CD 3.99))) (-RRB- -RRB-))) (CC and) (NP (NNP CBD))) (PRN (-LRB- -LRB-) (NP (QP (CD 158.11) (CD +/-) (NN 9.18) (CC vs.) (CD 40.1) (NN +/-)) (CD 6.24)) (-RRB- -RRB-))) (, ,) (S (VP (VBG indicating) (NP (DT a) (JJ complete) (NN Doc_9431903_1080_1085_Disease)) (PP (IN at) (NP (NP (DT the) (NN level)) (PP (IN of) (NP (NP (DT the) (NN sphincter)) (PP (IN of) (NP (NNP Oddi)))))))))) (. .)))
9431903	5	(S1 (S (NP (JJ Doc_9431903_1125_1144_Chemical) (NN infusion)) (ADVP (RB completely)) (VP (VBD normalized) (NP (DT the) (JJ Doc_9431903_1180_1191_Chemical-Doc_9431903_1192_1200_Chemical-induced) (NNS alterations)) (PP (IN in) (NP (NP (DT these) (JJ quantitative) (NNS parameters)) (PRN (-LRB- -LRB-) (NP (NP (NP (JJ TmaX)) (PP (IN over) (NP (DT the) (NN LP)))) (: :) (NP (NP (CD 11.33) (NN +/-)) (NP (CD 1.13)) (: ;) (PP (PP (IN over) (NP (NP (DT the) (NN HH)) (: :) (NP (NP (CD 18.88) (NN +/-)) (NP (CD 1.48))) (: ;))) (CC and) (PP (IN over) (NP (NP (NP (NP (DT the) (VBG CBD)) (: :) (NP (NP (CD 36.22) (NNS +/-)) (NP (CD 1.92))) (: ;) (CC and) (NP (NNP T1/2))) (PP (IN over) (NP (DT the) (NN LP)))) (: :) (NP (NP (CD 28.21) (NNS +/-)) (NP (CD 1.83))) (: ;) (PP (IN over) (NP (DT the) (NN HH))) (: :) (NP (NP (CD 33.42) (NNS +/-)) (NP (CD 3.10))) (: ;))) (CC and) (PP (IN over) (NP (DT the) (NNP CBD))))) (: :) (NP (NP (CD 41.66) (NNS +/-)) (NP (CD 6.33)))) (-RRB- -RRB-)))) (, ,) (S (VP (VBG suggesting) (NP (NP (DT an) (JJ effective) (JJ sphincter-relaxing) (NN effect)) (PP (IN of) (NP (NNP Doc_9431903_1507_1526_Chemical))))))) (. .)))
9431903	6	(S1 (S (NP (DT These) (NNS results)) (VP (VBP provide) (NP (NP (DT the) (JJ first) (NN evidence)) (PP (IN of) (NP (NP (DT the) (NN effectiveness)) (PP (IN of) (NP (NNP Doc_9431903_1605_1624_Chemical))))) (PP (IN on) (NP (NP (DT the) (JJ Doc_9431903_1632_1640_Chemical-induced) (NN Doc_9431903_1649_1672_Disease)) (PP (IN in) (NP (NNS humans))))))) (. .)))
9431903	7	(S1 (S (SBAR (IN Since) (S (NP (NNP Doc_9431903_1690_1709_Chemical)) (VP (AUX is) (ADJP (JJ able) (S (VP (TO to) (VP (VB overcome) (ADVP (RB even)) (NP (NP (DT the) (JJ drastic) (NN effect)) (PP (IN of) (NP (NNP Doc_9431903_1757_1765_Chemical))))))))))) (, ,) (NP (PRP it)) (VP (MD might) (VP (AUX be) (PP (IN of) (NP (NN relevance))) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NNP Doc_9431903_1812_1840_Disease))))))) (. .)))
950631	0	(S1 (NP (NP (NN Immunopathology)) (PP (IN of) (NP (NNP Doc_950631_19_32_Chemical-induced) (NNP Doc_950631_41_59_Disease))) (. .)))
950631	1	(S1 (S (NP (NP (CD Four) (NNS patients)) (PP (IN with) (NP (NNP Doc_950631_80_100_Disease)))) (VP (VBD developed) (NP (JJ heavy) (NN Doc_950631_117_128_Disease)) (PP (IN after) (NP (NP (QP (CD five) (TO to) (CD 12)) (NNS months)) (PP (IN of) (NP (NP (NN treatment)) (PP (IN with) (NP (NNP Doc_950631_171_186_Chemical)))))))) (. .)))
950631	2	(S1 (S (NP (NP (JJ Light) (NN microscopy)) (PP (IN of) (NP (JJ renal) (NN biopsy) (NNS samples)))) (VP (VBD showed) (NP (NP (NP (JJ minimal) (JJ glomerular) (JJ capillary) (NN wall) (VBG thickening)) (CC and) (NP (JJ mesangial) (NNP matrix) (NN increase))) (, ,) (CC or) (NP (NP (DT no) (NN departure)) (PP (IN from) (NP (JJ normal)))))) (. .)))
950631	3	(S1 (S (NP (NNP Electron) (NN microscopy)) (, ,) (ADVP (RB however)) (, ,) (VP (VBD revealed) (NP (NP (JJ subepithelial) (JJ electron-dense) (NNS deposits)) (, ,) (NP (NP (NP (NN fusion)) (PP (IN of) (NP (JJ epithelial) (NN cell) (NN foot) (NNS processes)))) (, ,) (CC and) (NP (NP (NN evidence)) (PP (IN of) (NP (JJ mesangial) (NN cell) (NN hyperactivity))))))) (. .)))
950631	4	(S1 (S (NP (JJ Immunofluorescence) (NN microscopy)) (VP (VBD demonstrated) (NP (NP (JJ granular) (NN capillary) (NN wall) (NNS deposits)) (PP (IN of) (NP (NP (NNP IgG)) (CC and) (NP (NNP C3)))))) (. .)))
950631	5	(S1 (S (NP (DT The) (NNS findings)) (VP (AUX were) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT those)) (PP (IN in) (NP (JJ early) (NNP Doc_950631_642_671_Disease)))))) (, ,) (S (NP (NNS differences)) (VP (AUXG being) (VP (VBN observed) (ADVP (RB however)) (PP (IN in) (NP (NP (DT the) (NNS results)) (PP (IN of) (NP (NN staining))) (PP (IN for) (NP (DT the) (NN early-acting) (VB complement) (NNS components) (NNP C1q) (CC and) (NNP C4))))))))) (. .)))
950631	6	(S1 (S (NP (PRP It)) (VP (AUX is) (ADVP (RB tentatively)) (VP (VBN concluded) (SBAR (IN that) (S (VP (VB complement) (SBAR (S (VP (AUX was) (VP (VBN activated) (PP (IN by) (NP (DT the) (JJ classical) (NN pathway)))))))))))) (. .)))
9514561	0	(S1 (NP (NP (NP (JJ Experimental) (JJ cranial) (NN Doc_9514561_21_25_Disease)) (VP (VBN elicited) (PP (IN by) (NP (NNP Doc_9514561_38_47_Chemical))))) (: :) (NP (DT a) (JJ PET) (NN study)) (. .)))
9514561	1	(S1 (S (S (VP (VBG Using) (NP (DT a) (NN positron) (NN emission) (NN tomography) (-LRB- -LRB-) (NN PET) (-RRB- -RRB-) (NN study)))) (NP (PRP it)) (VP (AUX was) (VP (VBN shown) (ADVP (RB recently)) (SBAR (IN that) (S (PP (IN in) (NP (NNP Doc_9514561_141_149_Disease))) (PP (IN without) (NP (NN aura))) (NP (NP (JJ certain) (NNS areas)) (PP (IN in) (NP (DT the) (NN brain) (NN stem)))) (VP (AUX were) (UCP (VP (VBN activated) (PP (IN during) (NP (DT the) (NNP Doc_9514561_221_229_Disease) (NN state)))) (, ,) (CC but) (PP (RB not) (IN in) (NP (DT the) (JJ Doc_9514561_252_260_Disease) (JJ free) (NN interval))))))))) (. .)))
9514561	2	(S1 (S (NP (PRP It)) (VP (AUX was) (VP (VBN suggested) (SBAR (IN that) (S (NP (DT this) (NN brain) (NN stem) (NN activation)) (VP (VP (AUX is) (ADJP (JJ inherent) (PP (TO to) (NP (NP (DT the) (NNP Doc_9514561_344_352_Disease) (NN attack)) (NP (PRP itself)))))) (CC and) (VP (VBZ represents) (NP (DT the) (ADJP (RB so) (VBN called)) ('' ') (JJ Doc_9514561_397_405_Disease) (NN generator) (POS ')))))))) (. .)))
9514561	3	(S1 (S (S (VP (TO To) (VP (VB test) (NP (DT this) (NN hypothesis))))) (NP (PRP we)) (VP (VBD performed) (NP (DT an) (JJ experimental) (NN Doc_9514561_471_475_Disease) (NN study)) (PP (IN in) (NP (CD seven) (JJ healthy) (NNS volunteers))) (, ,) (S (VP (VBG using) (NP (NP (DT the) (JJ same) (NN positioning)) (PP (IN in) (NP (DT the) (JJ PET) (NN scanner)))) (PP (IN as) (PP (IN in) (NP (DT the) (JJ Doc_9514561_567_575_Disease) (NNS patients))))))) (. .)))
9514561	4	(S1 (S (NP (NP (DT A) (JJ small) (NN amount)) (PP (IN of) (NP (NNP Doc_9514561_604_613_Chemical)))) (VP (AUX was) (VP (VBN administered) (ADVP (RB subcutaneously)) (PP (IN in) (NP (DT the) (JJ right) (NN forehead))) (S (VP (TO to) (VP (VB evoke) (NP (DT a) (NN burning) (NN Doc_9514561_687_694_Disease) (NN sensation)) (PP (IN in) (NP (NP (DT the) (JJ first) (NN division)) (PP (IN of) (NP (DT the) (JJ trigeminal) (NN nerve)))))))))) (. .)))
9514561	5	(S1 (S (NP (NP (NNS Increases)) (PP (IN of) (NP (NP (JJ regional) (JJ cerebral) (NN blood) (NN flow)) (PRN (-LRB- -LRB-) (NP (NN rCBF)) (-RRB- -RRB-))))) (VP (AUX were) (VP (VBN found) (ADVP (RB bilaterally)) (PP (IN in) (NP (DT the) (NN insula))) (, ,) (PP (IN in) (NP (NP (DT the) (NNP anterior) (NN cingulate) (NN cortex)) (, ,) (NP (DT the) (JJ cavernous) (NN sinus)) (CC and) (NP (DT the) (NN cerebellum)))))) (. .)))
9514561	6	(S1 (S (S (VP (VBG Using) (NP (NP (DT the) (JJ same) (JJ stereotactic) (NN space) (NNS limits)) (PP (IN as) (PP (IN in) (NP (DT the) (ADJP (RB above) (VBN mentioned)) (NN Doc_9514561_980_988_Disease) (NN study))))) (NP (DT no) (NN brain) (NN stem) (NN activation)))) (VP (AUX was) (VP (VBN found) (PP (IN in) (NP (DT the) (JJ acute) (NNP Doc_9514561_1043_1047_Disease) (NN state))) (PP (VBN compared) (PP (TO to) (NP (DT the) (JJ Doc_9514561_1070_1074_Disease) (JJ free) (NN state)))))) (. .)))
9514561	7	(S1 (S (NP (NP (DT The) (NN increase)) (PP (IN of) (NP (NN activation))) (PP (IN in) (NP (NP (DT the) (NN region)) (PP (IN of) (NP (DT the) (JJ cavernous) (NN sinus)))))) (ADVP (RB however)) (, ,) (VP (VBZ suggests) (SBAR (IN that) (S (NP (DT this) (NN structure)) (VP (AUX is) (ADJP (RBR more) (JJ likely) (S (VP (TO to) (VP (AUX be) (VP (VBN involved) (PP (IN in) (NP (JJ trigeminal) (JJ transmitted) (NNP Doc_9514561_1245_1249_Disease))) (PP (PP (IN as) (NP (JJ such))) (, ,) (CONJP (RB rather) (IN than)) (PP (IN in) (NP (NP (DT a) (JJ specific) (NN type)) (PP (IN of) (NP (NNP Doc_9514561_1293_1301_Disease)))))) (SBAR (IN as) (S (VP (AUX was) (VP (VBN suggested) (PP (IN for) (NP (NNP Doc_9514561_1323_1339_Disease)))))))))))))))) (. .)))
9523850	0	(S1 (NP (NP (NP (NN Value)) (PP (IN of) (NP (NNP Doc_9523850_9_27_Chemical))) (PP (IN in) (NP (NP (NN prevention)) (PP (IN of) (NP (NP (DT the) (JJ Doc_9523850_49_59_Disease-Doc_9523850_60_67_Disease) (NN syndrome)) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (JJ total) (NN dose) (NN infusion)) (PP (IN of) (NP (NNP Doc_9523850_120_132_Chemical))))))))))) (: :) (NP (DT a) (JJ double) (JJ blind) (JJ randomized) (NN trial)) (. .)))
9523850	1	(S1 (S (NP (NP (DT The) (NN safety) (CC and) (NN efficacy)) (PP (IN of) (NP (JJ total) (NN dose) (NN infusion))) (PRN (-LRB- -LRB-) (NP (NNP TDI)) (-RRB- -RRB-)) (PP (IN of) (NP (NNP Doc_9523850_223_235_Chemical)))) (VP (AUX has) (VP (AUX been) (ADVP (RB well)) (VP (VBN documented)))) (. .)))
9523850	2	(S1 (S (PP (IN In) (NP (NP (CD 40) (NN %)) (PP (IN of) (NP (VBN treated) (NNS patients))))) (, ,) (NP (DT an) (JJ Doc_9523850_293_303_Disease-Doc_9523850_304_311_Disease) (NN syndrome)) (VP (VBZ develops)) (. .)))
9523850	3	(S1 (S (NP (NP (DT The) (NN purpose)) (PP (IN of) (NP (DT this) (JJ randomized) (, ,) (JJ double-blind) (, ,) (JJ prospective) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB investigate) (SBAR (S (NP (NP (IN whether) (JJ intravenous) (-LRB- -LRB-) (NN i.v.) (-RRB- -RRB-) (NN administration)) (PP (IN of) (NP (NP (NNP Doc_9523850_459_477_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9523850_479_481_Chemical)) (-RRB- -RRB-))))) (VP (VBZ prevents) (NP (DT this) (NN complication))))))))) (. .)))
9523850	4	(S1 (S (S (NP (NP (NP (JJ Sixty-five) (NNS patients)) (, ,) (NP (CD 34) (NNS women)) (CC and) (NP (CD 31) (NNS men))) (, ,) (NP (NP (NNS ages)) (NP (QP (CD 36) (TO to) (CD 80)) (NNS years))) (, ,)) (VP (VBD received) (NP (DT either) (JJ normal) (NN saline)) (PP (IN before) (CC and) (IN after) (NP (NP (NNP TDI)) (PRN (-LRB- -LRB-) (NP (NN group) (CD 1)) (-RRB- -RRB-)))))) (, ,) (NP (CD 125) (NN mg)) (VP (VBD i.v.) (NP (NNP MP)) (UCP (ADVP (RB before)) (CC and) (VP (VBN saline) (PP (IN after) (NP (NP (NP (NNP TDI)) (PRN (-LRB- -LRB-) (NP (NN group) (CD 2)) (-RRB- -RRB-))) (, ,) (CC or) (NP (CD 125) (NNS mg)))) (NP (JJ i.v.) (NNP MP)) (PP (IN before) (CC and) (IN after) (NP (NP (NNP TDI)) (PRN (-LRB- -LRB-) (NP (NN group) (CD 3)) (-RRB- -RRB-))))))) (. .)))
9523850	5	(S1 (S (S (NP (NNS Patients)) (VP (AUX were) (VP (VBN observed) (PP (IN for) (NP (CD 72) (NNS hours)))))) (CC and) (S (NP (NNS reactions)) (VP (AUX were) (VP (VBN recorded) (CC and) (VBN graded) (PP (VBG according) (PP (TO to) (NP (NN severity))))))) (. .)))
9523850	6	(S1 (S (NP (NP (NP (JJ Fifty-eight) (NN percent)) (PP (IN of) (NP (NN group) (CD 1) (NNS patients)))) (, ,) (NP (NP (CD 33) (NN %)) (PP (IN of) (NP (NN group) (CD 2)))) (, ,) (CC and) (NP (NP (CD 26) (NN %)) (PP (IN of) (NP (NN group) (CD 3))))) (VP (AUX had) (NP (NP (NNS reactions)) (PP (TO to) (NP (NNP TDI))))) (. .)))
9523850	7	(S1 (S (NP (NP (DT The) (NN severity)) (PP (IN of) (NP (NP (NNS reactions)) (PRN (-LRB- -LRB-) (ADJP (JJ minimal) (, ,) (JJ mild) (, ,) (CC and) (JJ moderate) (, ,) (ADVP (RB respectively))) (-RRB- -RRB-))))) (VP (AUX was) (UCP (RB as) (S (VP (VBZ follows))) (: :) (NP (NP (NP (NN group) (NN 1--6)) (, ,) (NP (NP (CD 6)) (, ,) (CC and) (NP (CD 2)))) (: ;) (NP (NP (NN group) (NN 2--1)) (, ,) (NP (NP (CD 5)) (, ,) (CC and) (NP (CD 0)))) (: ;) (NP (NN group) (NN 3--5)) (, ,) (NP (CD 1)) (, ,) (CC and) (NP (CD 0))))) (. .)))
9523850	8	(S1 (S (NP (NNS Data)) (VP (AUX were) (VP (VBN analyzed) (PP (IN by) (NP (NP (NP (DT the) (JJ two-sided) (NNP Fisher) (POS 's)) (JJ exact) (NN test)) (VP (VBG using) (NP (ADJP (CD 95) (NN %)) (NN confidence) (NNS intervals)) (PP (IN with) (NP (NP (DT the) (NN approximation)) (PP (IN of) (NP (NNP Woolf)))))))))) (. .)))
9523850	9	(S1 (S (NP (DT These) (NNS data)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP (NP (NN administration)) (PP (IN of) (NP (NNP MP))) (PP (IN before) (CC and) (IN after) (NP (NNP TDI)))) (VP (VBZ reduces) (NP (NP (DT the) (NN frequency) (CC and) (NN severity)) (PP (IN of) (NP (DT the) (JJ Doc_9523850_1320_1330_Disease-Doc_9523850_1331_1338_Disease) (NN syndrome)))))))) (. .)))
9523850	10	(S1 (S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (S (NP (NP (CD 125) (NN mg)) (PP (IN i.v.) (NP (NNP MP)))) (VP (MD should) (VP (AUX be) (VP (VBN given) (ADVP (RB routinely)) (PP (IN before) (CC and) (IN after) (NP (NP (NNP TDI)) (PP (IN of) (NP (NNP Doc_9523850_1431_1443_Chemical))))))))))) (. .)))
9545159	0	(S1 (S (NP (NN Doc_9545159_0_31_Disease)) (VP (VBD related) (PP (TO to) (NP (JJ Doc_9545159_43_52_Chemical-Doc_9545159_53_62_Chemical) (NN interaction)))) (. .)))
9545159	1	(S1 (S (NP (NP (NNP Doc_9545159_76_85_Chemical)) (, ,) (NP (DT a) (JJ cytochrome) (JJ P450) (NN 3A4) (PRN (-LRB- -LRB-) (NNP CYP3A4) (-RRB- -RRB-)) (NN substrate)) (, ,)) (VP (AUX is) (ADVP (RB widely)) (VP (VBN prescribed) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NNP Doc_9545159_171_206_Disease))))))) (. .)))
9545159	2	(S1 (S (NP (NNP Doc_9545159_208_235_Disease) (, ,) (NNP Doc_9545159_237_256_Disease) (, ,) (CC and) (NNP Doc_9545159_262_282_Disease)) (VP (AUX have) (VP (AUX been) (VP (VBN reported) (PP (IN after) (NP (NP (JJ concomitant) (NN administration)) (PP (PP (IN with) (NP (NNP Doc_9545159_340_352_Chemical) (CC or) (NNP Doc_9545159_356_361_Chemical) (NN antifungal) (NNS agents))) (, ,) (CC but) (RB not) (PP (IN with) (NP (JJ other) (JJ CYP3A4) (NNS inhibitors))))))))) (. .)))
9545159	3	(S1 (S (NP (DT A) (JJ possible) (NN drug) (NN interaction)) (VP (VBD occurred) (PP (IN in) (NP (NP (DT a) (JJ 45-year-old) (NN woman)) (SBAR (WHNP (WP who)) (S (VP (AUX was) (VP (VBG taking) (NP (NNP Doc_9545159_494_503_Chemical)) (PP (IN for) (NP (NP (NNP Doc_9545159_508_540_Disease)) (CC and) (NP (NP (NNP Doc_9545159_545_554_Chemical)) (, ,) (NP (NP (DT an) (NN agent)) (SBAR (WHNP (WDT that)) (S (VP (AUX has) (NP (NP (JJ inhibitory) (NN effect)) (PP (IN on) (NP (NNS CYP3A4)))))))) (, ,) (PP (IN for) (NP (NNP Doc_9545159_607_619_Disease))))))))))))) (. .)))
9545159	4	(S1 (S (NP (DT The) (NN patient)) (VP (VP (AUX was) (ADVP (RB in)) (PP (IN near) (NP (NNP Doc_9545159_645_652_Disease)))) (CC and) (VP (AUX had) (NP (NN Doc_9545159_661_685_Disease)))) (. .)))
9545159	5	(S1 (S (PP (IN After) (S (VP (VBG discontinuing) (NP (NNP Doc_9545159_707_716_Chemical))))) (, ,) (S (NP (DT the) (JJ QT) (NN interval)) (VP (VBD returned) (PP (TO to) (NP (JJ normal))))) (CC and) (S (NP (NNS symptoms)) (VP (AUX did) (RB not) (VP (VB recur)))) (. .)))
9545159	6	(S1 (S (NP (PRP We)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NN caution)) (VP (AUX be) (VP (VBN taken) (SBAR (WHADVP (WRB when)) (S (NP (NNP Doc_9545159_819_828_Chemical)) (VP (AUX is) (VP (VBN prescribed) (PP (IN with) (NP (NP (DT any) (JJ potent) (NN inhibitor)) (PP (IN of) (NP (NN CYP3A4))) (, ,) (PP (VBG including) (NP (NNP Doc_9545159_890_899_Chemical)))))))))))))) (. .)))
9549528	0	(S1 (NP (NP (JJ Cortical) (NN motor) (NN overactivation)) (PP (IN in) (NP (NP (JJ Doc_9549528_33_45_Disease) (NNS patients)) (PP (IN with) (NP (JJ Doc_9549528_60_66_Chemical-induced) (JJ peak-dose) (NN Doc_9549528_85_95_Disease))))) (. .)))
9549528	1	(S1 (S (NP (PRP We)) (VP (AUX have) (VP (VBN studied) (SBAR (S (NP (NP (DT the) (JJ regional) (JJ cerebral) (NN blood) (NN flow)) (PRN (-LRB- -LRB-) (NP (NN rCBF)) (-RRB- -RRB-))) (VP (VBZ changes) (S (VP (VBN induced) (PP (IN by) (NP (NP (DT the) (NN execution)) (PP (IN of) (NP (DT a) (JJ finger-to-thumb) (NN opposition) (NN motor) (NN task))) (PP (PP (IN in) (NP (NP (NP (DT the) (JJ supplementary) (CC and) (JJ primary) (NN motor) (NN cortex)) (PP (IN of) (NP (NP (NP (CD two) (NNS groups)) (PP (IN of) (NP (NP (JJ Doc_9549528_292_304_Disease) (NNS patients)) (PP (IN on) (NP (JJ Doc_9549528_317_323_Chemical) (NN medication)))))) (, ,) (NP (NP (DT the) (JJ first) (CD one)) (PP (IN without) (NP (NNP Doc_9549528_358_364_Chemical))) (VP (VBN induced) (NP (NNP Doc_9549528_373_383_Disease)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 23)) (-RRB- -RRB-))))))) (CC and) (NP (NP (DT the) (JJ other)) (PP (IN with) (NP (NP (JJ moderate) (JJ peak-dose) (NNP Doc_9549528_431_441_Disease)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 15)) (-RRB- -RRB-))))))) (, ,) (CC and) (PP (IN of) (NP (NP (DT a) (NN group)) (PP (IN of) (NP (CD 14) (JJ normal) (NNS subjects))))))))))))))) (. .)))
9549528	2	(S1 (S (NP (NP (JJ Single) (NN photon) (NN emission) (NN tomography)) (PP (IN with) (NP (JJ i.v.) (NNS 133Xe)))) (VP (AUX was) (VP (VBN used) (S (VP (TO to) (VP (VB measure) (NP (DT the) (JJ rCBF) (NNS changes))))))) (. .)))
9549528	3	(S1 (S (NP (DT The) (NNP Doc_9549528_582_592_Disease) (NNP Doc_9549528_593_605_Disease) (NNS patients)) (VP (VBD exhibited) (NP (NP (DT a) (NN pattern)) (PP (IN of) (NP (NP (NN response)) (SBAR (WHNP (WDT which)) (S (VP (AUX was) (ADJP (RB markedly) (JJ different) (PP (IN from) (NP (NP (DT those)) (PP (IN of) (NP (NP (DT the) (JJ normal) (NNS subjects)) (CC and) (NP (JJ non-Doc_9549528_718_728_Disease) (NN Doc_9549528_729_741_Disease) (NNS patients))))))))))))) (, ,) (PP (IN with) (NP (NP (DT a) (JJ significant) (NN overactivation)) (PP (IN in) (NP (NP (DT the) (JJ supplementary) (NN motor) (NN area)) (CC and) (NP (DT the) (ADJP (JJ ipsi-) (CC and) (JJ contralateral)) (JJ primary) (NN motor) (NNS areas))))))) (. .)))
9549528	4	(S1 (S (NP (DT These) (NNS results)) (VP (AUX are) (ADJP (JJ compatible) (PP (IN with) (NP (DT the) (NN hypothesis) (SBAR (IN that) (S (NP (NP (DT an) (NNP Doc_9549528_928_940_Disease) (NNP Doc_9549528_941_970_Disease)) (, ,) (PP (IN like) (NP (JJ Doc_9549528_977_983_Chemical-induced) (NN peak) (NN dose) (NNP Doc_9549528_1002_1012_Disease))) (, ,)) (VP (AUX is) (ADJP (JJ due) (PP (TO to) (NP (NP (DT a) (NN disinhibition)) (PP (IN of) (NP (NP (DT the) (JJ primary) (CC and) (JJ associated) (NN motor) (NN cortex)) (ADJP (JJ secondary) (PP (TO to) (NP (NP (DT an) (JJ excessive) (NN outflow)) (PP (IN of) (NP (DT the) (JJ pallidothalamocortical) (NN motor) (NN loop)))))))))))))))))) (. .)))
9564988	0	(S1 (NP (NP (JJ Open-label) (NN assessment)) (PP (IN of) (NP (NNP Doc_9564988_25_37_Chemical))) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (JJ acute) (JJ bacterial) (NN Doc_9564988_75_84_Disease)) (PP (IN in) (NP (NNS adults))))))) (. .)))
9564988	1	(S1 (FRAG (S (VP (TO To) (VP (VB evaluate) (NP (NP (DT the) (NN efficacy) (CC and) (NN safety)) (PP (IN of) (NP (NNP Doc_9564988_144_156_Chemical)))) (PRN (-LRB- -LRB-) (S (NP (CD 500)) (VP (VBG mg) (ADVP (RB orally) (RB once) (RB daily)) (PP (IN for) (NP (QP (CD 10) (TO to) (CD 14)) (NNS days))))) (-RRB- -RRB-)) (PP (IN in) (S (VP (VBG treating) (NP (NN adult) (NNS outpatients)) (PP (IN with) (NP (JJ acute) (JJ bacterial) (NN Doc_9564988_253_262_Disease))))))))) (. .)))
9564988	2	(S1 (NP (NP (NP (NNS PATIENTS)) (CC AND) (NP (NNS METHODS))) (: :) (NP (NP (DT A) (NN total)) (PP (IN of) (NP (CD 329) (NNS patients))) (VP (VBD enrolled) (PP (IN in) (NP (DT the) (NN study))) (PP (IN at) (NP (CD 24) (NNS centers))))) (. .)))
9564988	3	(S1 (S (NP (DT All) (NNS patients)) (VP (AUX had) (NP (NP (DT a) (JJ pre-therapy) (NN Gram)) (SBAR (S (VP (AUX 's) (NP (NP (NP (VB stain)) (CC and) (NP (NN culture))) (PP (IN of) (NP (NP (JJ sinus) (NN exudate)) (VP (VBN obtained) (PP (IN by) (NP (NP (JJ antral) (NN puncture)) (CC or) (NP (JJ nasal) (NN endoscopy))))))))))))) (. .)))
9564988	4	(S1 (S (NP (JJ Clinical) (NN response)) (VP (AUX was) (VP (VBN assessed) (PP (IN on) (NP (NP (DT the) (NN basis)) (PP (IN of) (NP (NP (NNS signs) (CC and) (NNS symptoms)) (CC and) (NP (NP (JJ sinus) (NN radiograph)) (CC or) (NP (JJ computed) (NN tomography) (NNS results))))))))) (. .)))
9564988	5	(S1 (S (NP (JJ Microbiologic) (NN cure) (NNS rates)) (VP (AUX were) (VP (VBN determined) (PP (IN on) (NP (NP (DT the) (NN basis)) (PP (IN of) (NP (NP (VBN presumed) (CC plus) (VBN documented) (NN eradication)) (PP (IN of) (NP (NP (DT the) (JJ pre-therapy) (NNS pathogen)) (PRN (-LRB- -LRB-) (NP (PRP s)) (-RRB- -RRB-)))))))))) (. .)))
9564988	6	(S1 (S (NP (DT The) (JJS most) (JJ common) (NNS pathogens)) (VP (AUX were) (NP (NP (JJ Haemophilus) (NNS influenzae)) (, ,) (NP (JJ Streptococcus) (NNS pneumoniae)) (, ,) (NP (NN Staphylococcus) (NN aureus)) (, ,) (CC and) (NP (NN Moraxella) (NN catarrhalis)))) (. .)))
9564988	7	(S1 (S (PP (IN Of) (NP (CD 300) (ADJP (RB clinically) (JJ evaluable)) (NNS patients))) (, ,) (S (NP (NP (CD 175)) (PRN (-LRB- -LRB-) (NP (CD 58) (NN %)) (-RRB- -RRB-))) (VP (AUX were) (VP (VBN cured)))) (CC and) (S (NP (NP (CD 90)) (PRN (-LRB- -LRB-) (NP (CD 30) (NN %)) (-RRB- -RRB-))) (VP (AUX were) (VP (VBN improved) (PP (IN at) (NP (NP (DT the) (JJ post-therapy) (NN evaluation)) (, ,) (VP (VBG resulting) (PP (IN in) (NP (NP (DT a) (JJ clinical) (NN success) (NN rate)) (PP (IN of) (NP (CD 88) (NN %))))))))))) (. .)))
9564988	8	(S1 (S (NP (NP (JJ Thirty-five) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 12) (NN %)) (-RRB- -RRB-))) (ADVP (RB clinically)) (VP (VBD failed) (NP (NN treatment))) (. .)))
9564988	9	(S1 (S (NP (NP (DT The) (JJ microbiologic) (NN eradication) (NN rate)) (PRN (-LRB- -LRB-) (ADJP (VBN presumed) (CC plus) (VBN documented)) (-RRB- -RRB-)) (PP (IN among) (NP (CD 138) (JJ microbiologically) (NN evaluable) (NNS patients)))) (VP (AUX was) (NP (CD 92) (NN %))) (. .)))
9564988	10	(S1 (S (NP (NP (NP (JJ Microbiologic) (NN eradication) (NNS rates)) (PRN (-LRB- -LRB-) (VP (VBN presumed) (CC plus) (VBN documented)) (-RRB- -RRB-))) (PP (IN of) (NP (DT the) (RBS most) (JJ common) (NNS pathogens)))) (VP (VBD ranged) (PP (PP (IN from) (NP (NP (CD 93) (NN %)) (PRN (-LRB- -LRB-) (NP (NNP M.) (NN catarrhalis)) (-RRB- -RRB-)))) (PP (TO to) (NP (NP (CD 100) (NN %)) (PRN (-LRB- -LRB-) (NP (NNP S.) (NNP pneumoniae)) (-RRB- -RRB-))))) (PP (IN at) (NP (DT the) (JJ post-therapy) (NN visit)))) (. .)))
9564988	11	(S1 (S (S (NP (NP (DT All)) (CC but) (NP (NP (NP (CD one)) (PP (IN of) (NP (NP (DT the) (CD 265) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX were) (VP (VBN cured) (CC or) (VBN improved) (PP (IN at) (NP (NP (JJ post-therapy)) (VP (VBN returned) (PP (IN for) (NP (DT a) (JJ long-term) (JJ follow-up) (NN visit))))))))))))) (: ;) (NP (CD 243)) (PRN (-LRB- -LRB-) (NP (CD 92) (NN %)) (-RRB- -RRB-)))) (VP (VBD remained) (ADVP (RB well) (NP (QP (CD 4) (TO to) (CD 6)) (NNS weeks))) (PP (IN after) (NP (NN therapy))))) (: ;) (CC and) (S (NP (NP (CD 21)) (PRN (-LRB- -LRB-) (NP (CD 8) (NN %)) (-RRB- -RRB-))) (VP (AUX had) (NP (NP (DT a) (NN relapse)) (PP (IN of) (NP (NNS symptoms)))))) (. .)))
9564988	12	(S1 (S (NP (NP (JJ Adverse) (NNS events)) (VP (VBN considered) (S (VP (TO to) (VP (AUX be) (VP (VBN related) (PP (TO to) (NP (NNP Doc_9564988_1613_1625_Chemical) (NN administration))))))))) (VP (AUX were) (VP (VBN reported) (PP (IN by) (NP (NP (CD 29) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 9) (NN %)) (-RRB- -RRB-)))))) (. .)))
9564988	13	(S1 (S (S (NP (DT The) (ADJP (RBS most) (JJ common)) (JJ drug-related) (JJ adverse) (NNS events)) (VP (AUX were) (NP (NP (NNP Doc_9564988_1725_1733_Disease)) (, ,) (NP (NNP Doc_9564988_1735_1745_Disease)) (, ,) (CC and) (NP (NNP Doc_9564988_1751_1757_Disease))))) (: ;) (S (NP (JJS most) (JJ adverse) (NNS events)) (VP (AUX were) (ADJP (JJ mild) (S (VP (TO to) (VP (VB moderate) (PP (IN in) (NP (NN severity))))))))) (. .)))
9564988	14	(S1 (S (NP (NP (DT The) (NNS results)) (PP (IN of) (NP (DT this) (NN study)))) (VP (VBP indicate) (SBAR (IN that) (S (NP (NNP Doc_9564988_1866_1878_Chemical) (CD 500)) (VP (VBD mg) (SBAR (IN once) (S (NP (NN daily)) (VP (AUX is) (NP (NP (DT an) (ADJP (ADJP (JJ effective)) (CC and) (ADJP (JJ safe))) (NN treatment)) (PP (IN for) (NP (JJ acute) (JJ bacterial) (NN Doc_9564988_1952_1961_Disease))))))))))) (. .)))
9579567	0	(S1 (S (NP (NP (JJ Iatrogenic) (NNS risks)) (PP (IN of) (NP (NNP Doc_9579567_20_41_Disease))) (PP (IN after) (NP (NN treatment))) (PP (IN for) (NP (NNP Doc_9579567_62_75_Disease))) (PP (IN in) (NP (DT a) (JJ large) (JJ French) (NN case-control)))) (VP (VBP study)) (. .)))
9579567	1	(S1 (NP (NP (NNP F) (NNP d) (FW ration) (NNP Nationale) (FW des) (NNP Centres) (FW de) (NNP Lutte) (NNP Contre) (FW le) (NNP Cancer)) (PRN (-LRB- -LRB-) (NP (NNP FNCLCC)) (-RRB- -RRB-)) (. .)))
9579567	2	(S1 (S (SBAR (IN Since) (S (NP (NNP Doc_9579567_191_200_Chemical)) (VP (VP (AUX is) (VP (ADVP (RB widely)) (VBN used) (PP (IN in) (NP (JJ Doc_9579567_219_232_Disease) (NN treatment))))) (CC and) (VP (AUX has) (VP (AUX been) (VP (VBN proposed) (PP (IN for) (NP (NP (DT the) (NN prevention)) (PP (IN of) (NP (NNP Doc_9579567_287_300_Disease))))))))))) (, ,) (NP (PRP$ its) (JJ endometrial) (JJ iatrogenic) (NNS effects)) (VP (MD must) (VP (AUX be) (VP (ADVP (RB carefully)) (VBN examined)))) (. .)))
9579567	3	(S1 (S (NP (PRP We)) (VP (AUX have) (VP (VBN investigated) (NP (NP (DT the) (NN association)) (PP (IN between) (NP (NP (NP (NNP Doc_9579567_410_428_Disease)) (CC and) (NP (NNP Doc_9579567_433_442_Chemical)) (NX (NX (NN use)) (CC or) (NX (JJ other) (NNS treatments)))) (PP (IN in) (NP (NP (NNS women)) (VP (VBN treated) (PP (IN for) (NP (NNP Doc_9579567_488_501_Disease))) (PP (IN in) (NP (DT a) (JJ case-control) (NN study))))))))))) (. .)))
9579567	4	(S1 (S (S (NP (NP (NNS Cases)) (PP (IN of) (NP (NNP Doc_9579567_536_554_Disease)))) (VP (VBD diagnosed) (PP (IN after) (NP (NNP Doc_9579567_571_584_Disease))))) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 135)) (-RRB- -RRB-)) (CC and) (S (NP (NP (CD 467) (NNS controls)) (VP (VBN matched) (PP (IN for) (NP (NP (NN age)) (, ,) (NP (NP (NN year)) (PP (IN of) (NP (NP (NN diagnosis)) (PP (IN of) (NP (NNP Doc_9579567_650_663_Disease)))))) (CC and) (NP (NP (NP (NN hospital)) (CC and) (NP (NN survival) (NN time))) (PP (IN with) (NP (DT an) (JJ intact) (NN uterus)))))))) (VP (AUX were) (VP (VBN included)))) (. .)))
9579567	5	(S1 (S (NP (NP (NNS Women)) (SBAR (WHNP (WP who)) (S (VP (AUX had) (VP (VBN received) (NP (NNP Doc_9579567_755_764_Chemical))))))) (VP (AUX were) (ADJP (ADVP (RB significantly) (RBR more)) (JJ likely) (S (VP (TO to) (VP (AUX have) (S (NP (NNP Doc_9579567_804_822_Disease)) (VP (VBN diagnosed) (PP (IN than) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (AUX had) (RB not)))))))))))) (PRN (-LRB- -LRB-) (FRAG (NP (NP (JJ crude) (JJ relative) (NN risk)) (NP (SYM =) (CD 4.9) (, ,) (CD p))) (X (SYM =)) (NP (CD 0.0001))) (-RRB- -RRB-))) (. .)))
9579567	6	(S1 (S (NP (NP (NNP Univariate)) (CC and) (NP (VBN adjusted) (NNS analyses))) (VP (VBD showed) (SBAR (IN that) (S (NP (DT the) (NN risk)) (VP (VBD increased) (PP (IN with) (NP (NP (NP (DT the) (NN length)) (PP (IN of) (NP (NN treatment))) (PRN (-LRB- -LRB-) (NP (NNP p) (SYM =) (CD 0.0001)) (-RRB- -RRB-))) (CC or) (NP (NP (DT the) (JJ cumulative) (NN dose)) (PP (IN of) (NP (NNP Doc_9579567_1029_1038_Chemical))) (VP (VBN received) (PRN (-LRB- -LRB-) (S (NP (NN p)) (VP (SYM =) (NP (CD 0.0001)))) (-RRB- -RRB-)))))) (, ,) (ADVP (RB irrespective) (PP (IN of) (NP (DT the) (JJ daily) (NN dose)))))))) (. .)))
9579567	7	(S1 (S (NP (NP (NNS Women)) (SBAR (WHNP (WP who)) (S (VP (AUX had) (VP (VBN undergone) (NP (JJ pelvic) (NN radiotherapy))))))) (ADVP (RB also)) (VP (AUX had) (NP (NP (DT a) (JJR higher) (NN risk)) (PRN (-LRB- -LRB-) (NP (JJ crude) (JJ relative) (NN risk) (SYM =) (CD 7.8)) (, ,) (NP (NNP p) (SYM =) (CD 0.0001)) (-RRB- -RRB-)))) (. .)))
9579567	8	(S1 (S (PP (IN After) (S (VP (VBG adjusting) (PP (IN for) (NP (JJ confounding) (NNS factors)))))) (, ,) (NP (DT the) (NN risk)) (VP (AUX was) (ADJP (JJR higher)) (PP (IN for) (NP (NP (JJ Doc_9579567_1267_1276_Chemical) (NNS users)) (PRN (-LRB- -LRB-) (NP (NNP p) (SYM =) (CD 0.0012)) (-RRB- -RRB-)))) (, ,) (NP (NP (NN treatment)) (PP (IN for) (NP (NP (NP (QP (JJR more) (IN than) (CD 3)) (NNS years)) (PRN (-LRB- -LRB-) (NP (DT all) (JJ p) (CD <) (CD 0.03)) (-RRB- -RRB-))) (CC and) (NP (NP (JJ pelvic) (NNS radiotherapy)) (PRN (-LRB- -LRB-) (S (NP (NN p)) (VP (SYM =) (NP (CD 0.012)))) (-RRB- -RRB-))))))) (. .)))
9579567	9	(S1 (S (NP (NP (NNS Women)) (SBAR (WHNP (WP who)) (S (VP (VP (AUX had) (NP (NN Doc_9579567_1395_1413_Disease))) (CC and) (VP (AUX had) (VP (VBN received) (NP (NNP Doc_9579567_1431_1440_Chemical)))))))) (VP (AUX had) (ADJP (ADJP (RBR more) (JJ Doc_9579567_1450_1466_Disease)) (CC and) (ADJP (JJR poorer) (NN prognosis) (PP (IN than) (NP (NP (DT those)) (PP (IN with) (NP (NNP Doc_9579567_1504_1522_Disease))) (SBAR (WHNP (WP who)) (S (VP (AUX had) (RB not) (VP (VBN received) (NP (DT this) (NN treatment))))))))))) (. .)))
9579567	10	(S1 (S (NP (PRP$ Our) (NNS results)) (VP (VBP suggest) (NP (NP (DT a) (JJ causal) (NN role)) (PP (IN of) (NP (NNP Doc_9579567_1597_1606_Chemical))) (PP (IN in) (NP (NP (NNP Doc_9579567_1610_1628_Disease)) (, ,) (SBAR (ADVP (RB particularly)) (WHADVP (WRB when)) (S (VP (VBN used) (SBAR (IN as) (S (ADVP (RB currently)) (VP (VBN proposed) (PP (IN for) (NP (NN Doc_9579567_1679_1692_Disease) (NN prevention))))))))))))) (. .)))
9579567	11	(S1 (S (NP (JJ Pelvic) (NN radiotherapy)) (VP (MD may) (VP (AUX be) (NP (NP (DT an) (JJ additional) (NN iatrogenic) (NN factor)) (PP (IN for) (NP (NP (NNS women)) (PP (IN with) (NP (NNP Doc_9579567_1779_1792_Disease)))))))) (. .)))
9579567	12	(S1 (S (NP (NP (NN Doc_9579567_1794_1813_Disease)) (VP (VBN diagnosed) (PP (IN in) (NP (NP (NNS women)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_9579567_1846_1855_Chemical)))))))) (VP (AUX have) (NP (JJR poorer) (NN prognosis))) (. .)))
9579567	13	(S1 (S (NP (NP (NNS Women)) (SBAR (WHNP (WP who)) (S (VP (VBP receive) (NP (NNP Doc_9579567_1897_1906_Chemical)) (PP (IN for) (NP (NNP Doc_9579567_1911_1924_Disease))))))) (VP (MD should) (VP (AUX be) (VP (VBN offered) (NP (NN gynaecological) (NN surveillance)) (PP (IN during) (CC and) (IN after) (NP (NN treatment)))))) (. .)))
9579567	14	(S1 (S (NP (NP (DT A) (JJ long-term) (NN evaluation)) (PP (IN of) (NP (NP (DT the) (JJ risk-benefit) (NN ratio)) (PP (IN of) (NP (NNP Doc_9579567_2051_2060_Chemical))) (PP (IN as) (NP (NP (DT a) (JJ preventive) (NN treatment)) (PP (IN for) (NP (NNP Doc_9579567_2091_2104_Disease)))))))) (VP (AUX is) (ADVP (RB clearly)) (VP (VBN warranted))) (. .)))
9630698	0	(S1 (NP (NP (NN Contribution)) (PP (IN of) (NP (NP (DT the) (JJ Doc_9630698_20_27_Chemical) (NN site)) (PP (IN of) (NP (JJ Doc_9630698_36_40_Chemical) (NNS receptors))) (PP (IN in) (NP (NP (JJ rostral) (CC and) (JJ intermediate-caudal) (NNS parts)) (PP (IN of) (NP (DT the) (NN striatum))))))) (PP (TO to) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (NP (NN muscle) (NN tone)) (PP (IN in) (NP (NNS rats))))))) (. .)))
9630698	1	(S1 (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT the) (JJ present) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB assess) (NP (NP (DT the) (NN contribution)) (PP (IN of) (NP (NP (DT the) (JJ Doc_9630698_217_224_Chemical) (NN site)) (PP (IN of) (NP (JJ Doc_9630698_233_237_Chemical) (NNS receptors))))) (PP (IN in) (NP (DT the) (NN striatum))) (PP (TO to) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (NN muscle) (NN tone)))))))))) (. .)))
9630698	2	(S1 (S (NP (NN Muscle) (NN tone)) (VP (AUX was) (VP (VBN examined) (S (VP (VBG using) (NP (NP (NP (DT a) (JJ combined) (NN mechanoand) (NN electromyographic) (NN method)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD measured) (ADVP (RB simultaneously)) (NP (NP (DT the) (NN muscle) (NN resistance)) (PRN (-LRB- -LRB-) (NP (NNP MMG)) (-RRB- -RRB-)) (PP (IN of) (NP (NP (DT the) (NN rat) (POS 's)) (JJ hind) (NN foot)))) (PP (TO to) (NP (NP (JJ passive) (NN extension)) (CC and) (NP (NP (NN flexion)) (PP (IN in) (NP (NP (NP (DT the) (JJ ankle) (NN joint)) (CC and) (NP (NP (DT the) (JJ electromyographic) (NN activity)) (PRN (-LRB- -LRB-) (NP (NNP EMG)) (-RRB- -RRB-)))) (PP (IN of) (NP (NP (DT the) (JJ antagonistic) (NNS muscles)) (PP (IN of) (NP (DT that) (NN joint)))))))))))))) (: :) (NP (NP (NN gastrocnemius) (CC and) (NN tibialis)) (NP (NNP anterior)))))))) (. .)))
9630698	3	(S1 (S (S (NP (NN Doc_9630698_631_646_Disease)) (VP (AUX was) (VP (VBN induced) (PP (IN by) (NP (NP (NP (NP (NNP Doc_9630698_662_673_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 2.5) (CD mg/kg)) (NN i.p.)) (-RRB- -RRB-)) (. .)) (NNP Doc_9630698_692_718_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9630698_720_728_Chemical)) (-RRB- -RRB-))))))) (, ,) (NP (NP (DT a) (JJ selective) (JJ Doc_9630698_743_750_Chemical) (NN site) (NN antagonist)) (, ,) (VP (VBN injected) (PP (IN in) (NP (NP (NNS doses)) (PP (IN of) (NP (QP (CD 2.5) (CC and) (CD 4.5) (CD microg/0.5)) (NN microl))))) (ADVP (RB bilaterally)) (, ,) (PP (IN into) (NP (NP (DT the) (JJ rostral) (NN region)) (PP (IN of) (NP (DT the) (NN striatum)))))) (, ,)) (VP (VBD decreased) (SBAR (S (NP (DT both) (NP (NP (NP (DT the) (JJ Doc_9630698_892_903_Chemical-induced) (NNP Doc_9630698_912_927_Disease)) (PRN (-LRB- -LRB-) (NP (NNP MMG)) (-RRB- -RRB-))) (CC and) (NP (NP (DT the) (JJ enhanced) (JJ electromyographic) (NN activity)) (PRN (-LRB- -LRB-) (NP (NNP EMG)) (-RRB- -RRB-)) (. .))) (NNP Doc_9630698_985_993_Chemical)) (VP (VP (VBD injected) (ADVP (RB bilaterally)) (PP (IN in) (NP (NP (DT a) (NN dose)) (PP (IN of) (NP (QP (CD 4.5) (CD microg/0.5)) (NN microl))))) (PP (IN into) (NP (NP (DT the) (JJ intermediate-caudal) (NN region)) (PP (IN of) (NP (NP (DT the) (NN striatum)) (PP (IN of) (NP (NNS rats)))))))) (RB not) (VP (VBN pretreated) (SBAR (IN with) (S (NP (NNP Doc_9630698_1130_1141_Chemical)) (VP (AUX had) (NP (NP (DT no) (NN effect)) (PP (IN on) (NP (DT the) (NN muscle) (NN tone)))))))))))) (. .)))
9630698	4	(S1 (S (NP (DT The) (JJ present) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NN blockade)) (PP (IN of) (NP (NP (DT the) (JJ Doc_9630698_1225_1232_Chemical) (NN site)) (PP (IN of) (NP (JJ Doc_9630698_1241_1245_Chemical) (NNS receptors))) (PP (IN in) (NP (NP (DT the) (JJ rostral) (NN part)) (PP (IN of) (NP (DT the) (NN striatum)))))))) (VP (MD may) (VP (AUX be) (ADJP (RB mainly) (JJ responsible) (PP (IN for) (NP (NP (DT the) (JJ antiparkinsonian) (NN action)) (PP (IN of) (NP (DT this) (NN drug))))))))))) (. .)))
9636837	0	(S1 (NP (NP (JJ Doc_9636837_0_11_Chemical) (JJ toxic) (NNS effects)) (PP (IN on) (NP (NP (DT the) (JJ peripheral) (JJ nervous) (NN system)) (PP (IN of) (NP (DT the) (NN rat))))) (. .)))
9636837	1	(S1 (S (NP (NP (DT The) (ADJP (RBS most) (JJ striking))) (PP (IN of) (NP (NP (NP (NP (NNP Doc_9636837_104_115_Chemical) (POS 's)) (NNS advantages)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9636837_130_135_Chemical)) (-RRB- -RRB-))) (PP (IN over) (NP (NP (NNP Doc_9636837_142_151_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9636837_153_157_Chemical)) (-RRB- -RRB-))))))) (VP (AUX is) (NP (NP (PRP$ its) (ADJP (RB markedly) (VBN reduced)) (NN rate)) (PP (IN of) (NP (JJ Doc_9636837_191_201_Disease) (NNS effects))))) (. .)))
9636837	2	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (NP (DT the) (NN use)) (PP (IN of) (NP (JJ Doc_9636837_231_236_Chemical) (NN higher-intensity) (NNS schedules)))) (CC and) (NP (NP (DT the) (NN association)) (PP (IN with) (NP (NP (JJ other) (JJ Doc_9636837_295_305_Disease) (NNS drugs)) (PP (IN in) (NP (NN polychemotherapy))))))) (VP (MD may) (VP (VB cause) (NP (NP (DT some) (NN concern)) (PP (IN about) (NP (PRP$ its) (NN safety)))) (PP (IN with) (NP (NP (NN respect)) (PP (TO to) (NP (NNP Doc_9636837_388_420_Disease))))))) (. .)))
9636837	3	(S1 (S (NP (NNS MATERIALS) (CC AND) (NNS METHODS)) (: :) (NP (NP (CD Two) (JJ different) (NNS schedules)) (PP (IN of) (NP (NNP Doc_9636837_472_477_Chemical) (NN administration))) (PRN (-LRB- -LRB-) (NP (NP (NP (QP (CD 10) (CD mg/kg) (CC and) (CD 15)) (JJ mg/kg) (NNS i.p.)) (NP (RB twice) (DT a) (NN week))) (PP (IN for) (NP (CD nine) (NNS times)))) (-RRB- -RRB-))) (VP (AUX were) (VP (VBN evaluated) (PP (IN in) (NP (JJ Wistar) (NNS rats))))) (. .)))
9636837	4	(S1 (S (NP (NN Doc_9636837_581_594_Disease)) (VP (AUX was) (VP (VBN assessed) (PP (IN for) (NP (NP (JJ behavioral) (-LRB- -LRB-) (JJ tail-flick) (NN test) (-RRB- -RRB-)) (, ,) (NP (NP (NN neurophysiological)) (PRN (-LRB- -LRB-) (NP (NP (NN nerve) (NN conduction) (NN velocity)) (PP (IN in) (NP (DT the) (NN tail) (NN nerve)))) (-RRB- -RRB-))) (, ,) (NP (NN morphological)) (, ,) (NP (NN morphometrical)) (CC and) (NP (JJ analytical) (NNS effects)))))) (. .)))
9636837	5	(S1 (S (NP (JJ Doc_9636837_771_776_Chemical) (NN administration)) (VP (VBN induced) (NP (JJ dose-dependent) (NNP Doc_9636837_815_839_Disease))) (. .)))
9636837	6	(S1 (S (NP (NP (NP (JJ Doc_9636837_841_845_Disease) (NN perception)) (CC and) (NP (NN nerve) (NN conduction) (NN velocity))) (PP (IN in) (NP (DT the) (NN tail)))) (VP (AUX were) (ADJP (RB significantly) (JJ impaired)) (, ,) (PP (ADVP (RB particularly)) (IN after) (NP (DT the) (JJ high-dose) (NN treatment)))) (. .)))
9636837	7	(S1 (S (NP (NP (DT The) (JJ dorsal) (NN root) (NN ganglia) (JJ sensory) (NNS neurons)) (CC and) (PRN (, ,) (PP (TO to) (NP (DT a) (JJR lesser) (NN extent))) (, ,)) (NP (NN satellite) (NNS cells))) (VP (VBD showed) (NP (NP (DT the) (JJ same) (NNS changes)) (PP (IN as) (NP (NP (DT those)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_9636837_1097_1101_Chemical))))))) (, ,) (S (ADVP (RB mainly)) (VP (VBG affecting) (NP (NP (DT the) (NN nucleus) (CC and) (NN nucleolus)) (PP (IN of) (NP (JJ ganglionic) (JJ sensory) (NNS neurons))))))) (. .)))
9636837	8	(S1 (S (ADVP (RB Moreover)) (, ,) (NP (NP (JJ significant) (NNS amounts)) (PP (IN of) (NP (NNP Doc_9636837_1210_1218_Chemical)))) (VP (AUX were) (VP (VBN detected) (PP (IN in) (NP (NP (DT the) (JJ dorsal) (NN root) (NN ganglia)) (CC and) (NP (NN kidney)))) (PP (IN after) (NP (JJ Doc_9636837_1277_1282_Chemical) (NN treatment))))) (. .)))
9636837	9	(S1 (S (S (NP (NN Doc_9636837_1307_1312_Chemical)) (VP (AUX is) (ADJP (JJ Doc_9636837_1316_1326_Disease)) (PP (IN in) (NP (PRP$ our) (NN model))))) (, ,) (CC and) (S (NP (NP (DT the) (NN type)) (PP (IN of) (NP (JJ pathological) (NNS changes)))) (NP (PRP it)) (VP (VBZ induces) (SBAR (S (VP (AUX are) (ADJP (ADJP (RB so) (RB closely) (JJ similar) (PP (TO to) (NP (NP (DT those)) (VP (VBN caused) (PP (IN by) (NP (NNP Doc_9636837_1431_1435_Chemical))))))) (SBAR (IN that) (S (NP (PRP it)) (VP (AUX is) (ADJP (JJ probable)) (SBAR (IN that) (S (NP (NNP Doc_9636837_1461_1474_Disease)) (VP (AUX is) (VP (VBN induced) (PP (IN in) (NP (DT the) (CD two) (NNS drugs))) (PP (IN by) (NP (DT the) (JJ same) (NN mechanism)))))))))))))))) (. .)))
9636837	10	(S1 (S (NP (DT This) (NN model)) (VP (MD can) (VP (AUX be) (VP (VBN used) (UCP (ADVP (RB alone)) (CC or) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NP (JJ other) (NNS drugs)) (SBAR (S (VP (TO to) (VP (VB explore) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NNP Doc_9636837_1615_1620_Chemical))) (PP (IN on) (NP (DT the) (JJ peripheral) (JJ nervous) (NN system)))))))))))))))) (. .)))
9669632	0	(S1 (NP (NP (NP (NP (NNS Effects)) (PP (IN of) (NP (NNP Doc_9669632_11_20_Chemical))) (PP (IN on) (NP (NNS symptoms)))) (CC and) (NP (JJ postcibal) (JJ small-bowel) (NN motor) (NN function))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_9669632_91_115_Disease))))) (. .)))
9669632	1	(S1 (S (NP (NN Doc_9669632_129_153_Disease)) (VP (VP (AUX is) (NP (NP (DT a) (JJ common) (NN cause)) (PP (IN of) (NP (NP (NN Doc_9669632_175_189_Disease)) (CC and) (NP (NN discomfort)))))) (CC and) (VP (MD may) (VP (AUX be) (VP (VBN related) (PP (TO to) (NP (NNP Doc_9669632_227_263_Disease))))))) (. .)))
9669632	2	(S1 (S (NP (PRP$ Our) (NN aim)) (VP (AUX was) (S (VP (TO to) (VP (VB assess) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (JJ long-term) (NN treatment)) (PP (IN with) (NP (NP (DT a) (JJ prokinetic) (NN agent)) (, ,) (NP (NNP Doc_9669632_347_356_Chemical)) (, ,))))) (PP (IN on) (NP (NP (JJ postprandial) (JJ jejunal) (NN motility)) (CC and) (NP (NP (NNS symptoms)) (PP (IN in) (NP (NP (DT the) (NNP Doc_9669632_411_435_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9669632_437_440_Disease)) (-RRB- -RRB-)))))))))))) (. .)))
9669632	3	(S1 (S (NP (NP (JJ Thirty-eight) (NNS patients)) (PP (IN with) (NP (NP (NNP Doc_9669632_479_482_Disease)) (PRN (-LRB- -LRB-) (NP (NP (NNP Doc_9669632_484_496_Disease-predominant)) (, ,) (NP (NNP n) (SYM =) (CD 17))) (: ;) (NP (NP (NNP Doc_9669632_518_527_Disease-predominant)) (, ,) (NP (NNP n) (SYM =) (CD 21))) (-RRB- -RRB-))))) (VP (VBD underwent) (NP (JJ 24-h) (JJ ambulatory) (JJ jejunal) (NN manometry)) (PP (IN before) (CC and) (IN after) (NP (NP (CD 12) (NN week) (POS 's)) (NN treatment) (NN -LSB-Doc_9669632_631_640_Chemical))) (, ,) (S (NP (NP (NP (NP (CD 5) (NN mg)) (NP (QP (CD three) (NNS times)) (NN daily))) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 19)) (-RRB- -RRB-))) (CC or) (NP (NP (NN placebo)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 19)) (-RRB- -RRB-)))) (ADJP (JJ -RSB-)))) (. .)))
9669632	4	(S1 (S (PP (IN In) (NP (JJ Doc_9669632_708_717_Disease-predominant) (NNS patients))) (NP (NP (JJ significant) (NNS differences)) (PP (IN in) (NP (NN contraction) (NNS characteristics)))) (VP (AUX were) (VP (VBN observed) (PP (IN between) (NP (DT the) (NN Doc_9669632_820_829_Chemical) (CC and) (NN placebo) (NNS groups))))) (. .)))
9669632	5	(S1 (S (IN In) (JJ Doc_9669632_853_862_Chemical-treated) (JJ Doc_9669632_871_880_Disease-predominant) (NNS patients) (DT the) (VB mean) (NN contraction) (NN amplitude) (AUX was) (JJR higher) (-LRB- -LRB-) (CD 29.3) (JJ +/-) (CD 3.2) (CC versus) (CD 24.9) (JJ +/-) (CD 2.6) (CD mm) (NNP Hg) (, ,) (NNP Doc_9669632_985_994_Chemical) (CC versus) (NN placebo) (-LRB- -LRB-) (NNP P) (NNP <) (CD 0.001) (-RRB- -RRB-) (: ;) (NN pretreatment) (, ,) (CD 25.7) (JJ +/-) (CD 6.0) (CD mm) (NNP Hg) (-RRB- -RRB-) (, ,) (DT the) (VB mean) (NN contraction) (NN duration) (RB longer) (-LRB- -LRB-) (CD 3.4) (JJ +/-) (CD 0.2) (CC versus) (CD 3.0) (JJ +/-) (CD 0.2) (NNP sec) (, ,) (NNP Doc_9669632_1132_1141_Chemical) (CC versus) (NN placebo) (-LRB- -LRB-) (NNP P) (NNP <) (CD 0.001) (-RRB- -RRB-) (: ;) (NN pretreatment) (, ,) (CD 3.1) (JJ +/-) (CD 0.5) (NNP sec) (-RRB- -RRB-) (, ,) (CC and) (DT the) (VB mean) (NN contraction) (NN frequency) (JJR lower) (-LRB- -LRB-) (CD 2.0) (JJ +/-) (CD 0.2) (CC versus) (CD 2.5) (JJ +/-) (CD 0.4) (NN cont./min) (, ,) (NNP Doc_9669632_1286_1295_Chemical) (CC versus) (NN placebo) (-LRB- -LRB-) (NNP P) (NNP <) (CD 0.001) (-RRB- -RRB-) (: ;) (NN pretreatment) (, ,) (CD 2.5) (JJ +/-) (CD 1.1) (NN cont./min) (JJ -RSB-) (IN than) (NNS patients) (VBN treated) (IN with) (NN placebo) (. .)))
9669632	6	(S1 (S (NP (NP (DT No) (JJ significant) (NNS differences)) (PP (IN in) (NP (JJ jejunal) (NN motility)))) (VP (AUX were) (VP (VBN found) (PP (IN in) (NP (DT the) (JJ Doc_9669632_1462_1474_Disease-predominant) (NN Doc_9669632_1487_1490_Disease) (NN group))))) (. .)))
9669632	7	(S1 (S (NP (NNS Symptoms)) (VP (AUX were) (VP (VBN assessed) (PP (IN by) (S (VP (VBG using) (NP (DT a) (JJ visual) (NN analogue) (NN scale)) (PP (IN before) (CC and) (IN after) (NP (NN treatment)))))))) (. .)))
9669632	8	(S1 (S (NP (NP (NN Symptom) (NNS scores)) (VP (VBG relating) (PP (TO to) (NP (NP (DT the) (NN severity)) (PP (IN of) (NP (NNP Doc_9669632_1625_1637_Disease))))))) (VP (AUX were) (ADJP (JJR lower)) (PP (IN in) (NP (NP (JJ Doc_9669632_1652_1661_Chemical-treated) (JJ Doc_9669632_1670_1682_Disease-predominant) (NNP Doc_9669632_1695_1698_Disease) (NNS patients) (NN -LSB-score)) (, ,) (NP (NP (CD 54) (NN +/-)) (NP (QP (CD 5) (CC versus) (CD 67)) (JJ +/-) (CD 14) (NNS mm))) (, ,) (NP (NNP Doc_9669632_1746_1755_Chemical)) (CC versus) (NP (NP (NN placebo)) (PRN (-LRB- -LRB-) (NP (QP ($ P) (CD <) (CD 0.05))) (-RRB- -RRB-)) (: ;) (NP (NN pretreatment)) (, ,) (NP (NP (CD 62) (NNS +/-)) (NP (CD 19) (CD mm) (NN -RSB-))))))) (. .)))
9669632	9	(S1 (S (NP (JJ Doc_9669632_1812_1821_Disease-predominant) (NNP Doc_9669632_1834_1837_Disease) (NNS patients)) (VP (AUX had) (NP (DT a) (JJR higher) (NN Doc_9669632_1860_1864_Disease) (NN score)) (PP (IN after) (NP (NP (JJ Doc_9669632_1877_1886_Chemical) (NN therapy) (NN -LSB-score)) (, ,) (NP (NP (CD 55) (NN +/-)) (NP (QP (CD 15) (CC versus) (CD 34)) (JJ +/-) (CD 12) (NNS mm))) (, ,) (NP (NNP Doc_9669632_1934_1943_Chemical)) (CC versus) (NP (NP (NN placebo)) (PRN (-LRB- -LRB-) (NP (QP ($ P) (CD <) (CD 0.05))) (-RRB- -RRB-)) (: ;) (NP (NN pretreatment)) (, ,) (NP (NP (CD 67) (NNS +/-)) (NP (QP (CD 19) (CD mm)) (NN -RSB-))))))) (. .)))
9669632	10	(S1 (S (NP (NN Doc_9669632_2012_2021_Chemical)) (VP (VBZ affects) (NP (NP (JJ jejunal) (NN contraction) (NNS characteristics)) (CC and) (NP (NP (DT some) (NNS symptoms)) (PP (IN in) (NP (NNP Doc_9669632_2087_2090_Disease)))))) (. .)))
9672273	0	(S1 (NP (NP (NP (NN Prevention)) (PP (IN of) (NP (NNP Doc_9672273_14_27_Disease))) (PP (IN with) (NP (NNP Doc_9672273_33_42_Chemical)))) (: :) (NP (NP (JJ preliminary) (NNS findings)) (PP (IN from) (NP (NP (DT the) (JJ Italian) (JJ randomised) (NN trial)) (PP (IN among) (NP (JJ hysterectomised) (NNS women)))))) (. .)))
9672273	1	(S1 (NP (NNP Italian) (NNP Doc_9672273_136_145_Chemical) (NNP Prevention) (NNP Study) (. .)))
9672273	2	(S1 (S (NP (NN Doc_9672273_176_185_Chemical)) (VP (AUX is) (NP (NP (DT a) (NN candidate) (JJ chemopreventive) (NN agent)) (PP (IN in) (NP (NNP Doc_9672273_226_239_Disease)))) (, ,) (SBAR (IN although) (S (NP (DT the) (NN drug)) (VP (MD may) (VP (AUX be) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NN Doc_9672273_301_319_Disease))))))))))) (. .)))
9672273	3	(S1 (S (ADVP (RB Therefore)) (NP (PRP we)) (VP (AUX did) (NP (DT a) (NN trial)) (PP (IN in) (NP (NP (JJ hysterectomised) (NNS women)) (PP (IN of) (NP (NNP Doc_9672273_374_383_Chemical))))) (PP (IN as) (NP (DT a) (NN chemopreventive)))) (. .)))
9672273	4	(S1 (S (PP (IN In) (NP (NP (NNP October)) (, ,) (NP (CD 1992)))) (, ,) (NP (PRP we)) (VP (VBD started) (NP (NP (DT a) (JJ double-blind) (JJ placebo-controlled) (, ,) (JJ randomised) (NN trial)) (PP (IN of) (NP (NNP Doc_9672273_499_508_Chemical))) (PP (IN in) (NP (NP (NP (NNS women)) (PRN (-LRB- -LRB-) (PP (ADVP (RB mainly)) (IN in) (NP (NNP Italy))) (-RRB- -RRB-))) (SBAR (SBAR (WHNP (WP who)) (S (VP (AUX did) (RB not) (VP (AUX have) (NP (NN Doc_9672273_553_566_Disease)))))) (CC and) (SBAR (WHNP (WP who)) (S (VP (AUX had) (VP (AUX had) (NP (DT a) (NN hysterectomy))))))))))) (. .)))
9672273	5	(S1 (S (NP (NNS Women)) (VP (AUX were) (VP (VBN randomised) (S (VP (TO to) (VP (VB receive) (NP (NP (NNP Doc_9672273_632_641_Chemical) (CD 20) (NNS mg)) (PP (IN per) (NP (NP (NN day)) (CC or) (NP (NN placebo)))))))) (, ,) (FRAG (CC both) (RB orally) (PP (IN for) (NP (CD 5) (NNS years)))))) (. .)))
9672273	6	(S1 (S (NP (DT The) (JJ original) (NN plan)) (VP (AUX was) (S (VP (TO to) (VP (VB follow) (NP (DT the) (NN intervention) (NN phase)) (PP (IN by) (NP (NP (CD 5) (NNS years) (POS ')) (NN follow-up))))))) (. .)))
9672273	7	(S1 (S (PP (IN In) (NP (NP (NNP June)) (, ,) (NP (CD 1997)))) (, ,) (NP (NP (DT the) (NNS trialists)) (CC and) (NP (DT the) (JJ data-monitoring) (NN committee))) (VP (VBD decided) (S (VP (TO to) (VP (VB end) (NP (NN recruitment)) (PP (ADVP (RB primarily)) (IN because) (IN of) (NP (NP (DT the) (NN number)) (PP (IN of) (NP (NNS women)))))))) (S (VP (VBG dropping) (PP (IN out) (PP (IN of) (NP (DT the) (NN study))))))) (. .)))
9672273	8	(S1 (S (S (NP (NN Recruitment)) (VP (VBD ended) (PP (IN on) (NP (NNP July) (CD 11) (, ,) (CD 1997))))) (, ,) (CC and) (S (NP (DT the) (NN study)) (VP (MD will) (VP (VB continue) (SBAR (IN as) (S (VP (VBN planned))))))) (. .)))
9672273	9	(S1 (S (NP (DT The) (JJ primary) (NNS endpoints)) (VP (AUX are) (NP (NP (DT the) (NN occurrence)) (PP (IN of) (CC and) (NP (NP (NNS deaths)) (PP (IN from) (NP (NNP Doc_9672273_1065_1078_Disease))))))) (. .)))
9672273	10	(S1 (S (NP (DT This) (JJ preliminary) (JJ interim) (NN analysis)) (VP (AUX is) (VP (VBN based) (PP (IN on) (NP (NN intention-to-treat))))) (. .)))
9672273	11	(S1 (S (S (NP (CD 5408) (NNS women)) (VP (AUX were) (VP (VBN randomised)))) (: ;) (S (NP (VBG participating) (NNS women)) (VP (AUX have) (NP (NP (DT a) (JJ median) (NN follow-up)) (PP (IN of) (NP (CD 46) (NNS months))) (PP (IN for) (NP (NP (JJ major) (CD endpoints.) (CD 41) (NNS cases)) (PP (IN of) (NP (NNP Doc_9672273_1274_1287_Disease)))))) (VP (VBN occurred) (ADVP (RB so) (RB far))))) (: ;) (S (NP (EX there)) (VP (AUX have) (VP (AUX been) (NP (NP (DT no) (NNS deaths)) (PP (IN from) (NP (NNP Doc_9672273_1336_1349_Disease))))))) (. .)))
9672273	12	(S1 (S (NP (EX There)) (VP (AUX is) (NP (NP (DT no) (NN difference)) (PP (IN in) (NP (JJ Doc_9672273_1377_1390_Disease) (NN frequency))) (PP (IN between) (NP (NP (NP (DT the) (NN placebo)) (PRN (-LRB- -LRB-) (NP (CD 22) (NNS cases)) (-RRB- -RRB-))) (CC and) (NP (NNP Doc_9672273_1436_1445_Chemical) (-LRB- -LRB-) (CD 19) (-RRB- -RRB-) (NNS arms)))))) (. .)))
9672273	13	(S1 (S (S (NP (EX There)) (VP (AUX is) (NP (NP (DT a) (ADJP (RB statistically) (JJ significant)) (NN reduction)) (PP (IN of) (NP (NP (NNP Doc_9672273_1507_1520_Disease)) (PP (IN among) (NP (NP (NNS women)) (VP (VBG receiving) (NP (NP (NNP Doc_9672273_1543_1552_Chemical)) (SBAR (WHNP (WP who)) (S (ADVP (RB also)) (VP (VBD used) (NP (JJ hormone-replacement) (NN therapy)) (PP (IN during) (NP (DT the) (NN trial)))))) (: :) (PP (IN among) (NP (CD 390) (NNS women)))) (PP (IN on) (NP (JJ such) (NN therapy))))))))))) (CC and) (S (S (VP (VBN allocated) (PP (TO to) (NP (NN placebo))))) (, ,) (NP (PRP we)) (VP (VBD found) (NP (NP (CD eight) (NNS cases)) (PP (IN of) (NP (NNP Doc_9672273_1695_1708_Disease)))) (PP (VBN compared) (PP (IN with) (NP (NP (CD one) (NN case)) (PP (IN among) (NP (NP (CD 362) (NNS women)) (VP (VBN allocated) (PP (TO to) (NP (NNP Doc_9672273_1761_1770_Chemical))))))))))) (. .)))
9672273	14	(S1 (S (PP (VBN Compared) (PP (IN with) (NP (DT the) (NN placebo) (NN group)))) (, ,) (NP (EX there)) (VP (AUX was) (NP (NP (NP (DT a) (ADJP (RB significantly) (JJ increased)) (NN risk)) (PP (IN of) (NP (NNP Doc_9672273_1849_1864_Disease)))) (CC and) (NP (NP (NN hypertriglyceridaemia)) (PP (IN among) (NP (NP (NNS women)) (PP (IN on) (NP (NNP Doc_9672273_1906_1915_Chemical)))))))) (. .)))
9672273	15	(S1 (S (SBAR (IN Although) (S (NP (DT this) (JJ preliminary) (NN analysis)) (VP (AUX has) (NP (JJ low) (NN power))))) (, ,) (PP (IN in) (NP (NP (DT this) (NN cohort)) (PP (IN of) (NP (NNS women))) (PP (IN at) (NP (NP (JJ low-to-normal) (NN risk)) (PP (IN of) (NP (NNP Doc_9672273_2032_2045_Disease))))))) (, ,) (NP (NP (DT the) (VBN postulated) (JJ protective) (NNS effects)) (PP (IN of) (NP (NNP Doc_9672273_2084_2093_Chemical)))) (VP (AUX are) (RB not) (ADVP (RB yet)) (ADJP (JJ apparent))) (. .)))
9672273	16	(S1 (S (NP (NP (NNS Women)) (VP (VBG using) (NP (JJ hormone-replacement) (NN therapy)))) (VP (VBP appear) (S (VP (TO to) (VP (AUX have) (VP (VBN benefited) (PP (IN from) (NP (NP (NN use)) (PP (IN of) (NP (NN Doc_9672273_2193_2202_Chemical)))))))))) (. .)))
9672273	17	(S1 (S (NP (EX There)) (VP (AUX were) (NP (NP (DT no) (NNS deaths)) (PP (IN from) (NP (NNP Doc_9672273_2230_2243_Disease))) (VP (VBN recorded) (PP (IN in) (NP (NP (NNS women)) (PP (IN in) (NP (DT the) (NN study)))))))) (. .)))
9672273	18	(S1 (S (NP (PRP It)) (VP (AUX is) (ADJP (JJ essential) (S (VP (TO to) (VP (VB continue) (S (NP (NN follow-up)) (VP (TO to) (VP (VB quantify) (NP (NP (DT the) (JJ long-term) (NNS risks)) (CC and) (NP (NP (NNS benefits)) (PP (IN of) (NP (JJ Doc_9672273_2362_2371_Chemical) (NN therapy))))))))))))) (. .)))
9758264	0	(S1 (S (NP (NP (JJ Epileptogenic) (NN activity)) (PP (IN of) (NP (NNP Doc_9758264_26_36_Chemical))) (PP (IN after) (NP (NN drug)))) (VP (VBZ induces) (NP (NP (NNP Doc_9758264_56_59_Disease)) (PRN (-LRB- -LRB-) (NP (NP (NNP Doc_9758264_61_71_Chemical)) (CC and) (NP (NNP Doc_9758264_76_84_Disease))) (-RRB- -RRB-))))))
9758264	1	(S1 (FRAG (S (VP (TO To) (VP (VB study) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (JJ Doc_9758264_120_130_Chemical-containing) (NN multivitamin) (NN supplementation)) (PP (IN in) (NP (JJ Doc_9758264_174_183_Disease) (NNS women)))))) (PP (IN before) (CC and) (IN during) (NP (NN pregnancy))) (SBAR (IN in) (NN order) (S (VP (TO to) (VP (VB determine) (NP (NP (DT the) (NN rate)) (PP (IN of) (NP (NP (JJ structural) (NN Doc_9758264_263_276_Disease)) (CC and) (NP (JJ Doc_9758264_281_289_Disease-related) (NN side) (NNS effects)))))))))))) (. .)))
9758264	2	(S1 (NP (NP (NN STUDY) (NN DESIGN)) (: :) (NP (NP (RB First) (DT a) (JJ randomised) (NN trial)) (, ,) (NP (NP (JJ later) (NN periconception) (NN care)) (VP (VBG including) (PP (IN in) (NP (JJ total) (CD 12225) (NNS females)))))) (. .)))
9758264	3	(S1 (S (PP (IN Of) (NP (NP (CD 60) (JJ Doc_9758264_427_436_Disease) (NNS women)) (PP (IN with) (NP (JJ periconceptional) (NNP Doc_9758264_465_475_Chemical) (PRN (-LRB- -LRB-) (NP (CD 0.8) (NN mg)) (-RRB- -RRB-)) (NN -containing) (NN multivitamin) (NN supplementation))))) (, ,) (NP (DT no) (CD one)) (VP (VBD developed) (NP (JJ Doc_9758264_543_551_Disease-related) (NN side) (NNS effects)) (PP (IN during) (NP (DT the) (JJ periconception) (NN period)))) (. .)))
9758264	4	(S1 (S (NP (CD One) (NNP Doc_9758264_611_620_Disease) (NN woman)) (VP (VBD delivered) (NP (NP (DT a) (JJ newborn)) (PP (IN with) (NP (NNP Doc_9758264_652_672_Disease))))) (. .)))
9758264	5	(S1 (S (NP (DT Another) (NN patient)) (VP (VBD exhibited) (PP (IN with) (NP (NP (DT a) (NN cluster)) (PP (IN of) (NP (NNP Doc_9758264_718_726_Disease))))) (PP (IN after) (NP (NP (DT the) (JJ periconception) (NN period)) (VP (VBG using) (NP (DT another) (NN multivitamin)))))) (. .)))
9758264	6	(S1 (S (NP (DT This) (JJ 22-year-old) (NNP Doc_9758264_804_813_Disease) (NN woman)) (VP (AUX was) (VP (VP (VBN treated) (ADVP (RB continuously)) (PP (IN by) (NP (NNP Doc_9758264_848_861_Chemical)))) (CC and) (VP (NP (DT a) (JJ Doc_9758264_868_878_Chemical) (PRN (-LRB- -LRB-) (NP (QP (CD 1) (CD mg))) (-RRB- -RRB-)) (JJ -containing) (NN multivitamin)) (PP (IN from) (NP (NP (DT the) (JJ 20th) (NN week)) (PP (IN of) (NP (NN gestation)))))))) (. .)))
9758264	7	(S1 (S (NP (PRP She)) (VP (VBD developed) (NP (NP (NP (NN Doc_9758264_957_975_Disease)) (CC and) (NP (JJ later) (NNS symptoms))) (PP (IN of) (NP (NNP Doc_9758264_998_1026_Disease))))) (. .)))
9758264	8	(S1 (S (NP (PRP$ Her) (NN pregnancy)) (VP (VBN ended) (PP (IN with) (NP (NNP Doc_9758264_1053_1063_Disease)))) (. .)))
9758264	9	(S1 (S (S (NP (NP (NP (DT The) (JJ Doc_9758264_1082_1091_Disease) (JJ pregnant) (NN patient) (POS 's)) (NNP Doc_9758264_1111_1129_Disease)) (PRN (-LRB- -LRB-) (NP (RB probably) (JJ drug-induced) (NNP Doc_9758264_1153_1158_Disease)) (-RRB- -RRB-))) (VP (MD could) (VP (VB damage) (NP (DT the) (JJ blood-brain) (NN barrier))))) (, ,) (RB therefore) (S (NP (NP (DT the) (JJ therapeutic) (NN dose)) (PRN (-LRB- -LRB-) (NP (QP (CD >) (CC or) (CD =1)) (NN mg)) (-RRB- -RRB-)) (PP (IN of) (NP (NNP Doc_9758264_1245_1255_Chemical)))) (VP (VBD triggered) (NP (NP (DT a) (NN cluster)) (PP (IN of) (NP (NNP Doc_9758264_1279_1287_Disease)))))) (. .)))
9758264	10	(S1 (S (NP (NP (NP (JJ Physiological) (NN dose)) (PRN (-LRB- -LRB-) (NP (CD <1) (NN mg)) (-RRB- -RRB-))) (PP (IN of) (NP (NNP Doc_9758264_1319_1329_Chemical) (CD both))) (PP (IN in) (NP (JJ healthy))) (CC and) (NP (NP (CD 60) (JJ Doc_9758264_1353_1362_Disease) (NNS women)) (, ,) (NP (NP (DT all)) (PP (IN without) (NP (DT any) (NN Doc_9758264_1386_1404_Disease)))) (, ,))) (VP (AUX did) (RB not) (VP (VB increase) (NP (NP (DT the) (NN risk)) (PP (IN for) (NP (NNP Doc_9758264_1436_1454_Disease)))))) (. .)))
9799166	0	(S1 (S (NP (NP (NNP Doc_9799166_0_6_Disease)) (CC and) (NP (NNP Doc_9799166_11_18_Chemical)) (CC or) (NP (NNP Doc_9799166_22_33_Chemical))) (VP (VBP use)) (. .)))
9799166	1	(S1 (S (NP (NP (DT The) (NN association)) (PP (IN of) (NP (NNP Doc_9799166_58_65_Chemical) (CC and) (NNP Doc_9799166_70_81_Chemical) (NN use))) (PP (IN with) (NP (NP (NN hemorrhagic)) (CC and) (NP (NNP Doc_9799166_107_115_Disease) (NNP Doc_9799166_116_122_Disease))))) (VP (AUX is) (VP (VBN based) (PP (ADVP (RB almost) (RB solely)) (IN on) (NP (NP (NNS data)) (PP (IN from) (NP (NN case) (NNS series))))))) (. .)))
9799166	2	(S1 (S (NP (NP (DT The) (JJ limited) (NN number)) (PP (IN of) (NP (NP (NP (JJ epidemiologic) (NNS studies)) (PP (IN of) (NP (NNP Doc_9799166_219_225_Disease)))) (CC and) (NP (NP (NN use)) (PP (IN of) (NP (NNP Doc_9799166_237_244_Chemical) (FW and/or) (NNP Doc_9799166_252_263_Chemical))))))) (VP (AUX have) (VP (AUX been) (VP (AUX done) (PP (IN in) (NP (NP (NNS settings)) (SBAR (WHNP (WDT that)) (S (VP (VBP serve) (ADVP (RB mostly)) (NP (DT the) (JJ poor) (NN and/or) (NNS minorities)))))))))) (. .)))
9799166	3	(S1 (S (NP (DT This) (JJ case-control) (NN study)) (VP (AUX was) (VP (VBN conducted) (PP (IN in) (NP (NP (DT the) (VBN defined) (NN population)) (VP (VBG comprising) (NP (NP (NNS members)) (PP (IN of) (NP (NP (NNP Kaiser) (NNP Permanente)) (PP (IN of) (NP (NNP Northern) (CC and) (NNP Southern) (NNP California))))))))))) (. .)))
9799166	4	(S1 (S (NP (PRP We)) (VP (VBD attempted) (S (VP (TO to) (VP (VB identify) (NP (DT all) (NN incident) (NN Doc_9799166_516_523_Disease)) (PP (IN in) (NP (NNS women) (NNS ages)))))) (NP (CD 15-44) (NNS years)) (PP (IN during) (NP (NP (DT a) (JJ 3-year) (NN period)) (VP (VBG using) (NP (NP (NN hospital) (NN admission) (CC and) (NN discharge) (NNS records)) (, ,) (NP (NN emergency) (NN department) (VBZ logs)) (, ,) (CC and) (NP (NP (NN payment) (NNS requests)) (PP (IN for) (NP (JJ out-of-plan) (NNS hospitalizations))))))))) (. .)))
9799166	5	(S1 (S (NP (PRP We)) (VP (VBD selected) (NP (NP (NNS controls)) (, ,) (VP (VBN matched) (PP (IN on) (NP (NP (NP (NN age)) (CC and) (NP (NN facility))) (PP (IN of) (NP (JJ usual) (NN care)))))) (, ,)) (PP (IN at) (NP (JJ random))) (PP (IN from) (NP (NP (JJ healthy) (NNS members)) (PP (IN of) (NP (DT the) (NN health) (NN plan)))))) (. .)))
9799166	6	(S1 (S (NP (PRP We)) (VP (VBD obtained) (NP (NN information)) (PP (IN in) (NP (JJ face-to-face) (NNS interviews)))) (. .)))
9799166	7	(S1 (S (NP (EX There)) (VP (AUX were) (NP (NP (CD 347) (VBN confirmed) (NN Doc_9799166_896_902_Disease) (NNS cases)) (CC and) (NP (JJ 1,021) (NNS controls)))) (. .)))
9799166	8	(S1 (S (NP (NP (DT The) (JJ univariate) (VBN matched) (NNS odds) (NN ratio)) (PP (IN for) (NP (NNP Doc_9799166_967_973_Disease))) (PP (IN in) (NP (NP (NNS women)) (SBAR (WHNP (WP who)) (S (VP (VBD admitted) (PP (TO to) (S (VP (VBG using) (NP (NNP Doc_9799166_1005_1012_Chemical) (FW and/or) (NNP Doc_9799166_1020_1031_Chemical))))))))))) (VP (AUX was) (NP (NP (CD 8.5)) (PRN (-LRB- -LRB-) (NP (NP (ADJP (CD 95) (NN %)) (NN confidence)) (JJ interval) (SYM =) (CD 3.6-20.0)) (-RRB- -RRB-)))) (. .)))
9799166	9	(S1 (S (PP (IN After) (NP (NP (JJ further) (NN adjustment)) (PP (IN for) (NP (JJ potential) (NNS confounders))))) (, ,) (NP (NP (DT the) (NNS odds) (NN ratio)) (PP (IN in) (NP (NP (NNS women)) (SBAR (WHNP (WP who)) (S (VP (VBD reported) (S (VP (VBG using) (NP (NNP Doc_9799166_1173_1180_Chemical) (FW and/or) (NNP Doc_9799166_1188_1199_Chemical)))))))))) (VP (AUX was) (NP (NP (CD 7.0)) (PRN (-LRB- -LRB-) (NP (NP (ADJP (CD 95) (NN %)) (NN confidence)) (JJ interval) (SYM =) (CD 2.8-17.9)) (-RRB- -RRB-)))) (. .)))
9799166	10	(S1 (S (NP (NP (DT The) (NN use)) (PP (IN of) (NP (NNP Doc_9799166_1257_1264_Chemical) (FW and/or) (NNP Doc_9799166_1272_1283_Chemical)))) (VP (AUX is) (NP (NP (DT a) (JJ strong) (NN risk) (NN factor)) (PP (IN for) (NP (NNP Doc_9799166_1312_1318_Disease))) (PP (IN in) (NP (DT this) (ADJP (RB socioeconomically) (JJ heterogeneous) (, ,) (JJ insured)) (JJ urban) (NN population))))) (. .)))
982002	0	(S1 (S (NP (NN Doc_982002_0_19_Disease)) (ADJP (JJ subsequent) (PP (TO to) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NNP Doc_982002_56_66_Chemical)))))) (. .)))
982002	1	(S1 (S (NP (NP (DT A) (JJ follow-up) (NN study)) (PP (IN of) (NP (NNS cases)))) (VP (VBD reported) (ADVP (RB earlier))) (. .)))
982002	2	(S1 (S (NP (DT A) (JJ clinical) (NN presentation)) (VP (AUX is) (VP (VBN made) (PP (IN of) (NP (NP (DT a) (CD 2-3) (NN year) (NN follow-up)) (PP (IN of) (NP (NP (CD six) (NNS cases)) (PP (IN of) (NP (NNP Doc_982002_185_204_Disease))))) (SBAR (WHNP (WDT that)) (S (VP (AUX have) (VP (AUX been) (VP (VBN reported) (ADVP (RB earlier))))))))))) (. .)))
982002	3	(S1 (S (NP (DT The) (NNS patients)) (VP (AUX had) (VP (VBN developed) (NP (JJ transient) (NN Doc_982002_275_288_Disease)) (PP (IN after) (NP (NP (DT the) (JJ intermittent) (NN administration)) (PP (IN of) (NP (NNP Doc_982002_330_340_Chemical))))))) (. .)))
982002	4	(S1 (S (S (NP (NP (DT The) (NN stage)) (PP (IN of) (NP (NN olig-Doc_982002_360_366_Disease)))) (VP (VBD lasted) (PP (IN for) (NP (JJ 1-3) (NNS weeks))))) (, ,) (CC and) (S (NP (NP (CD five)) (PP (IN of) (NP (DT the) (NNS patients)))) (VP (AUX were) (VP (VBN treated) (PP (IN by) (NP (NN hemodialysis)))))) (. .)))
982002	5	(S1 (S (NP (NP (CD Two)) (PP (IN of) (NP (DT the) (NNS patients)))) (VP (VBD died) (PP (JJ due) (TO to) (NP (JJ unrelated) (NNS causes))) (PP (IN during) (NP (DT the) (JJ follow-up) (NN period)))) (. .)))
982002	6	(S1 (S (NP (NP (DT The) (CD four) (NNS patients)) (VP (VBN re-examined))) (VP (AUX were) (ADVP (RB clinically)) (VP (VBN cured))) (. .)))
982002	7	(S1 (S (NP (NP (JJ Pathologic) (NNS findings)) (PP (IN by) (NP (NP (JJ light) (NN microscopy)) (CC and) (NP (NN immunofluorescence)))) (PP (IN at) (NP (NN biopsy)))) (VP (AUX were) (ADJP (JJ scarce))) (. .)))
982002	8	(S1 (S (NP (NN Nothing) (JJ abnormal)) (VP (AUX was) (VP (VBN seen) (PP (IN by) (NP (NNP electron) (CD microscopy))) (PP (IN in) (NP (NP (CD two)) (PP (IN of) (NP (NP (DT the) (NNS cases)) (VP (VBN studied)))))))) (. .)))
982002	9	(S1 (S (NP (JJ Renal) (NN function)) (VP (AUX was) (ADJP (JJ normal))) (. .)))
982002	10	(S1 (S (PP (IN In) (NP (CD three) (NNS cases))) (NP (NP (DT the) (NN excretion)) (PP (IN at) (NP (JJ 131I-hippuran) (NN renography)))) (VP (AUX was) (ADVP (RB slightly)) (VP (VBN slowed))) (. .)))
982002	11	(S1 (S (SBAR (IN Although) (S (PP (IN in) (NP (DT the) (JJ acute) (NN stage))) (NP (DT the) (NNP Doc_982002_876_889_Disease) (NN histologically)) (VP (VBD appeared) (ADJP (JJ toxic))))) (, ,) (NP (NP (NN evidence) (NN suggestive)) (PP (IN of) (NP (DT an) (JJ immunological) (NN mechanism)))) (ADVP (RB cannot)) (VP (AUX be) (VP (VBN excluded))) (. .)))
9848575	0	(S1 (NP (NP (JJ Chronic) (NNS effects)) (PP (IN of) (NP (NP (DT a) (JJ novel) (JJ synthetic) (JJ Doc_9848575_37_50_Chemical) (NN derivative)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9848575_63_70_Chemical)) (-RRB- -RRB-)))) (PP (IN on) (NP (NP (JJ normal) (NN heart)) (CC and) (NP (NP (JJ Doc_9848575_92_103_Chemical-induced) (NN Doc_9848575_112_126_Disease)) (PP (IN in) (NP (JJ beagle) (NNS dogs)))))) (. .)))
9848575	1	(S1 (S (NP (DT This) (NN study)) (VP (AUX was) (VP (VBN designed) (S (VP (TO to) (VP (VB investigate) (NP (NP (NP (DT the) (JJ chronic) (JJ Doc_9848575_194_205_Disease) (NN potential)) (PP (IN of) (NP (NNP Doc_9848575_219_226_Chemical)))) (CC and) (NP (NP (DT a) (JJ possible) (JJ deteriorating) (NN effect)) (PP (IN of) (NP (NNP Doc_9848575_266_273_Chemical))))) (PP (IN on) (NP (NP (JJ low-grade) (NN Doc_9848575_287_301_Disease)) (VP (VBN pre-induced) (PP (IN by) (NP (NNP Doc_9848575_317_328_Chemical))) (PP (IN in) (NP (JJ beagle) (NNS dogs))))))))))) (. .)))
9848575	2	(S1 (S (PP (IN In) (NP (DT the) (JJ chronic) (NN treatment))) (, ,) (NP (NP (JJ beagle) (NNS dogs)) (PP (IN of) (NP (DT each) (NN sex)))) (VP (AUX were) (VP (VBN given) (ADVP (RB intravenously)) (PP (IN once) (NP (DT every) (CD 3) (NNS weeks))) (, ,) (CC either) (NP (NP (DT a) (JJ sublethal) (NN dose)) (PP (IN of) (NP (NP (NP (NNP Doc_9848575_467_478_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 1.5) (NN mg/kg)) (-RRB- -RRB-))) (CC or) (NP (NP (NNP Doc_9848575_494_501_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 2.5) (NN mg/kg)) (-RRB- -RRB-)))))))) (. .)))
9848575	3	(S1 (S (NP (DT The) (NN experiment)) (VP (AUX was) (VP (VBN terminated) (NP (CD 3) (NNS weeks)) (PP (IN after) (NP (DT the) (JJ ninth) (NN dosing))))) (. .)))
9848575	4	(S1 (S (NP (NP (NNS Animals)) (SBAR (WHNP (WDT which)) (S (VP (VBD received) (PP (IN over) (NP (NP (CD six) (NNS courses)) (PP (IN of) (NP (NNP Doc_9848575_620_631_Chemical))))))))) (VP (VBD demonstrated) (NP (NP (DT the) (NN electrocardiogram) (-LRB- -LRB-) (NN ECG) (-RRB- -RRB-) (NNS changes)) (, ,) (NP (NP (NN decrease)) (PP (IN of) (NP (NN blood) (NN pressure)))) (CC and) (NP (JJ high-grade) (JJ histopathological) (NN Doc_9848575_742_756_Disease))) (, ,) (SBAR (IN while) (S (NP (NP (NNS animals)) (SBAR (WHNP (WDT which)) (S (VP (AUX were) (ADVP (RB terminally)) (VP (VBN sacrificed) (PP (IN after) (NP (DT the) (NNP Doc_9848575_815_822_Chemical) (NN administration)))))))) (VP (AUX did) (RB not) (VP (VB show) (NP (NP (DT any) (NNS changes)) (PP (IN in) (NP (NP (NN ECG)) (, ,) (NP (NN blood) (NN pressure)) (CC and) (NP (JJ histopathological) (NNS examinations)))))))))) (. .)))
9848575	5	(S1 (S (S (VP (TO To) (VP (VB examine) (NP (NP (DT a) (ADJP (RB possibly) (VBG deteriorating)) (NN Doc_9848575_958_969_Disease) (NN effect)) (PP (IN of) (NP (NNP Doc_9848575_980_987_Chemical))))))) (, ,) (NP (JJ low-grade) (NNP Doc_9848575_999_1013_Disease)) (VP (AUX was) (VP (VBN induced) (PP (IN in) (NP (NNS dogs))) (PP (IN by) (NP (NP (CD four) (NNS courses)) (PP (IN of) (NP (NP (NNP Doc_9848575_1053_1064_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 1.5) (NN mg/kg)) (-RRB- -RRB-)))))))) (. .)))
9848575	6	(S1 (S (S (NP (CD Nine) (NNS weeks)) (PP (IN after) (NP (NN pre-treatment)))) (, ,) (NP (NNS dogs)) (VP (AUX were) (VP (VBN given) (NP (NP (CD four) (NNS courses)) (PP (IN of) (NP (NP (NP (DT either) (NNP Doc_9848575_1149_1160_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 1.5) (NN mg/kg)) (-RRB- -RRB-))) (CC or) (NP (NP (NNP Doc_9848575_1176_1183_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 2.5) (NN mg/kg)) (-RRB- -RRB-)))))) (PP (IN once) (NP (DT every) (CD 3) (NNS weeks))))) (. .)))
9848575	7	(S1 (S (NP (DT The) (JJ low-grade) (NN Doc_9848575_1230_1241_Disease) (NNS changes)) (VP (AUX were) (VP (VBN enhanced) (PP (IN by) (NP (DT the) (JJ additional) (JJ Doc_9848575_1282_1293_Chemical) (NN treatment))))) (. .)))
9848575	8	(S1 (S (PP (IN On) (NP (DT the) (NN contrary))) (, ,) (NP (DT the) (JJ Doc_9848575_1326_1333_Chemical) (NN treatment)) (VP (AUX did) (RB not) (VP (VB progress) (NP (NP (DT the) (NN grade)) (PP (IN of) (NP (NNP Doc_9848575_1374_1388_Disease)))))) (. .)))
9848575	9	(S1 (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NNP Doc_9848575_1405_1412_Chemical)) (VP (AUX does) (RB not) (VP (AUX have) (NP (NP (NP (DT any) (NN potential)) (PP (IN of) (NP (JJ chronic) (NNP Doc_9848575_1452_1466_Disease)))) (CC and) (NP (NP (VBG deteriorating) (NN effect)) (PP (IN on) (NP (NP (NNP Doc_9848575_1495_1506_Chemical-induced) (NNP Doc_9848575_1515_1529_Disease)) (PP (IN in) (NP (NNS dogs))))))))) (. .)))
9867728	0	(S1 (NP (NP (NN Risk)) (PP (IN for) (NP (NNP Doc_9867728_9_31_Disease))) (PP (IN among) (NP (NP (NNS users)) (PP (IN of) (NP (NP (NNP Doc_9867728_47_59_Chemical)) (CC and) (NP (NNP Doc_9867728_64_79_Chemical)))) (SBAR (WHNP (WP who)) (S (VP (VBD underwent) (NP (NN echocardiography)) (PP (IN before) (NP (NP (NN use)) (PP (IN of) (NP (NN medication)))))))))) (. .)))
9867728	1	(S1 (S (SBAR (IN Because) (S (NP (JJ uncontrolled) (JJ echocardiographic) (NNS surveys)) (VP (VBD suggested) (SBAR (IN that) (S (NP (NP (QP (IN up) (TO to) (CD 30) (NN %) (TO to) (CD 38) (NN %))) (PP (IN of) (NP (NP (NNS users)) (PP (IN of) (NP (NP (NNP Doc_9867728_240_252_Chemical)) (CC and) (NP (NNP Doc_9867728_257_272_Chemical))))))) (VP (AUX had) (NP (NN Doc_9867728_277_293_Disease)))))))) (, ,) (NP (DT these) (NNS drugs)) (VP (AUX were) (VP (VBN withdrawn) (PP (IN from) (NP (DT the) (NN market))))) (. .)))
9867728	2	(S1 (FRAG (S (VP (TO To) (VP (VB determine) (NP (NP (DT the) (NN risk)) (PP (IN for) (NP (NP (ADJP (JJ new) (CC or) (VBG worsening)) (NN Doc_9867728_393_415_Disease)) (PP (IN among) (NP (NP (NNS users)) (PP (IN of) (NP (NNP Doc_9867728_431_443_Chemical) (CC or) (NNP Doc_9867728_447_462_Chemical))) (SBAR (WHNP (WP who)) (S (VP (VBD underwent) (NP (NN echocardiography)) (SBAR (IN before) (S (NP (PRP they)) (VP (VBD began) (S (VP (TO to) (VP (VB take) (NP (DT these) (NNS medications))))))))))))))))))) (. .)))
9867728	3	(S1 (S (NP (NNS Cohort)) (VP (VBP study)) (. .)))
9867728	4	(S1 (FRAG (NP (JJ Academic) (JJ primary) (NN care) (NNS practices)) (. .)))
9867728	5	(S1 (S (NP (NP (CD 46) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VP (VBD used) (NP (NP (NNP Doc_9867728_634_646_Chemical)) (CC or) (NP (NNP Doc_9867728_650_665_Chemical))) (PP (IN for) (NP (CD 14) (NNS days) (QP (CC or) (JJR more))))) (CC and) (VP (AUX had) (NP (NNS echocardiograms))))))) (VP (VBN obtained) (PP (IN before) (NP (NN therapy)))) (. .)))
9867728	6	(S1 (NP (JJ Follow-up) (NN echocardiography) (. .)))
9867728	7	(S1 (S (NP (DT The) (JJ primary) (NN outcome)) (VP (AUX was) (NP (NP (JJ new) (CC or) (VBG worsening) (NN valvulopathy)) (, ,) (VP (VBN defined) (PP (IN as) (NP (NP (NN progression)) (PP (IN of) (NP (DT either) (NNP Doc_9867728_865_895_Disease))))) (PP (IN by) (NP (NP (QP (IN at) (JJS least) (CD one)) (NN degree)) (PP (IN of) (NP (NP (NN severity) (CC and) (NN disease)) (SBAR (WHNP (WDT that)) (S (VP (VBD met) (NP (NNP U.S.) (NNP Food) (CC and) (NNP Drug) (NNP Administration)) (NP (NP (NNS criteria)) (PRN (-LRB- -LRB-) (PP (IN at) (NP (NP (ADJP (JJS least) (JJ mild)) (NNP Doc_9867728_1010_1030_Disease)) (CC or) (NP (JJ moderate) (NNP Doc_9867728_1043_1063_Disease)))) (-RRB- -RRB-))))))))))))) (. .)))
9867728	8	(S1 (S (NP (NP (CD Two) (NNS patients) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 4.3) (NN %)) (ADJP (CD -LSB-95) (NN %)) (NN CI)) (, ,) (NP (QP (CD 0.6) (NN %) (TO to) (CD 14.8) (NN %)) (NN -RSB-))) (-RRB- -RRB-))) (VP (VBG receiving) (NP (NNP Doc_9867728_1129_1141_Chemical-Doc_9867728_1142_1153_Chemical)))) (VP (VBD developed) (NP (NNP Doc_9867728_1164_1186_Disease))) (. .)))
9867728	9	(S1 (S (NP (NN One)) (VP (AUX had) (NP (NP (NP (JJ baseline) (NN Doc_9867728_1205_1226_Disease)) (CC and) (NP (JJ mild) (NN Doc_9867728_1236_1256_Disease))) (SBAR (WHNP (WDT that)) (S (VP (VBD progressed) (PP (TO to) (NP (JJ moderate) (NN regurgitation)))))))) (. .)))
9867728	10	(S1 (S (NP (DT The) (JJ second) (NN patient)) (VP (VBD developed) (NP (JJ new) (JJ moderate) (NN Doc_9867728_1342_1362_Disease))) (. .)))
9867728	11	(S1 (S (NP (NP (NNS Users)) (PP (IN of) (NP (NN diet) (NNS medications)))) (VP (AUX are) (PP (IN at) (NP (NP (NN risk)) (PP (IN for) (NP (NNP Doc_9867728_1418_1440_Disease)))))) (. .)))
9867728	12	(S1 (S (ADVP (RB However)) (, ,) (NP (DT the) (NN incidence)) (VP (MD may) (VP (AUX be) (ADJP (ADJP (JJR lower)) (PP (IN than) (NP (NP (DT that)) (VP (VBN reported) (ADVP (RB previously)))))))) (. .)))
9875685	0	(S1 (NP (NP (NP (JJ Therapeutic) (NN drug) (NN monitoring)) (PP (IN of) (NP (NNP Doc_9875685_31_41_Chemical)))) (: :) (NP (NP (NN once-daily)) (PP (IN versus) (NP (JJ twice-daily) (NN dosage) (NNS schedules)))) (. .)))
9875685	1	(S1 (FRAG (S (VP (TO To) (VP (VB evaluate) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN dosage) (NN regimen))) (PRN (-LRB- -LRB-) (ADJP (JJ once-daily) (CC vs.) (JJ twice-daily)) (-RRB- -RRB-)) (PP (IN of) (NP (NNP Doc_9875685_175_185_Chemical)))) (PP (IN on) (NP (NP (JJ steady-state) (NN serum) (NNS concentrations)) (CC and) (NP (NNP Doc_9875685_227_235_Disease))))))) (. .)))
9875685	2	(S1 (FRAG (NP (NNS MATERIALS) (CC AND) (NNS METHODS)) (: :) (S (NP (NP (NNPS Patients)) (VP (VBG undergoing) (NP (NN treatment)) (PP (IN with) (S (VP (VBG i.v.) (NP (NP (NNP Doc_9875685_300_310_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 4) (NN mg/kg/day)) (-RRB- -RRB-)))))))) (VP (AUX were) (VP (VBN randomised) (PP (TO to) (NP (CD two) (NNS groups)))))) (. .)))
9875685	3	(S1 (S (NP (NP (NNP Group) (NNP OD)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 22)) (-RRB- -RRB-))) (VP (VBD received) (SBAR (S (NP (NP (NP (DT a) (JJ once-daily) (NN dose)) (PP (IN of) (NP (NNP Doc_9875685_404_414_Chemical)))) (CC and) (NP (NP (NN group) (NN TD)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 21)) (-RRB- -RRB-)))) (VP (VBD received) (NP (NP (DT the) (JJ same) (NN dose)) (VP (VBN divided) (PP (IN into) (NP (CD two) (NNS doses))))) (ADVP (RB daily)))))) (. .)))
9875685	4	(S1 (S (NP (NP (JJ Doc_9875685_490_500_Chemical) (NN serum) (NNS concentrations)) (PRN (-LRB- -LRB-) (NP (NP (NN peak)) (CC and) (NP (NN trough))) (-RRB- -RRB-))) (VP (AUX were) (VP (VBN measured) (PP (IN by) (NP (ADJP (RB enzyme) (VBN multiplied)) (NN immunoassay))))) (. .)))
9875685	5	(S1 (S (NP (NP (DT The) (JJ renal) (CC and) (JJ auditory) (NNS functions)) (PP (IN of) (NP (DT the) (NNS patients)))) (VP (AUX were) (VP (VBN monitored) (ADVP (IN before)) (, ,) (PP (PP (IN during)) (CC and) (PP (ADVP (RB immediately)) (IN after) (NP (NN treatment)))))) (. .)))
9875685	6	(S1 (S (NP (DT The) (CD two) (NNS groups)) (VP (AUX were) (ADJP (JJ comparable) (PP (IN with) (NP (NP (NN respect)) (PP (TO to) (NP (NP (NN sex)) (, ,) (NP (NN age)) (, ,) (NP (NN body) (NN weight)) (CC and) (NP (JJ renal) (NN function)))))))) (. .)))
9875685	7	(S1 (S (NP (DT No) (ADJP (RB statistically) (JJ significant)) (NNS differences)) (VP (AUX were) (VP (VBN found) (PP (IN in) (NP (NP (JJ mean) (JJ daily) (NN dose)) (, ,) (NP (NP (NN duration)) (PP (IN of) (NP (NN treatment)))) (, ,) (CC or) (NP (JJ cumulative) (NN dose)))))) (. .)))
9875685	8	(S1 (S (NP (NN Trough) (NNS concentrations)) (VP (AUX were) (VP (VBN <) (NP (CD 2) (NN g/ml)) (PP (IN in) (NP (DT the) (CD two) (NNS groups))) (PRN (-LRB- -LRB-) (NP (CD 100) (NN %)) (-RRB- -RRB-)))) (. .)))
9875685	9	(S1 (S (NP (NN Peak) (NNS concentrations)) (VP (AUX were) (VP (VBG >) (NP (NP (CD 6) (NN microg/ml)) (PP (IN in) (NP (NP (NP (CD 100) (NN %)) (PP (IN of) (NP (DT the) (JJ OD) (NN group)))) (CC and) (NP (NP (QP (IN in) (CD 67)) (NN %)) (PP (IN of) (NP (DT the) (JJ TD) (NN group)))))) (PRN (-LRB- -LRB-) (NP (NNP P<) (CD 0.01)) (-RRB- -RRB-))))) (. .)))
9875685	10	(S1 (S (S (NP (JJ Mean) (NN peak) (NNS concentrations)) (VP (AUX were) (ADJP (RB markedly) (JJ different)))) (: :) (S (NP (NP (CD 11.00+/-2.89) (NN microg/ml)) (PP (IN in) (NP (CD OD) (CC vs.) (CD 6.53+/-1.45)))) (VP (VBD microg/ml) (PP (IN in) (NP (NP (NNP TD)) (PRN (-LRB- -LRB-) (NP (NNP P<) (CD 0.01)) (-RRB- -RRB-)))))) (. .)))
9875685	11	(S1 (S (NP (DT The) (JJ pharmacokinetics) (NNS parameters)) (VP (AUX were) (: :) (NP (NP (NNP Ke)) (, ,) (PRN (-LRB- -LRB-) (NP (NP (JJ 0.15+/-0.03/h)) (PP (IN in) (NP (CD OD) (CC vs.) (CD 0.24+/-0.06/h))) (PP (IN in) (NP (NNP TD)))) (-RRB- -RRB-)) (, ,) (NP (CD t1/2)) (PRN (, ,) (-LRB- -LRB-) (NP (NP (CD 4.95+/-1.41) (NAC (NNP h) (PP (IN in) (NP (CD OD) (CC vs.) (CD 3.07+/-0.71)))) (NNP h)) (PP (IN in) (NP (NNP TD)))) (-RRB- -RRB-)) (, ,) (NP (NNP Vd)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 0.35+/-0.11) (NN l/kg)) (PP (IN in) (NP (NNP OD)))) (CC vs.) (NP (NP (CD 0.33+/-0.09) (NN l/kg)) (PP (IN in) (NP (NNP TD))))) (-RRB- -RRB-)) (, ,) (NP (NNP Doc_9875685_1396_1398_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 0.86+/-0.29) (NN ml/min/kg)) (PP (IN in) (NP (NNP OD)))) (CC vs.) (NP (NP (CD 1.28+/-0.33) (NN ml/min/kg)) (PP (IN in) (NP (NNP TD))))) (-RRB- -RRB-)))) (. .)))
9875685	12	(S1 (S (NP (VBN Increased) (NN serum) (NN Doc_9875685_1478_1488_Chemical)) (VP (AUX was) (VP (VBN observed) (PP (IN in) (NP (NP (NP (CD 73) (NN %)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN in) (NP (NNP OD)))))) (CC versus) (NP (NP (CD 57) (NN %)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN in) (NP (NNP TD)))))))) (, ,) (PP (IN without) (NP (NP (NN evidence)) (PP (IN of) (NP (NN nephrotoxicity))))))) (. .)))
9875685	13	(S1 (S (PP (IN In) (NP (CD TD) (NN group))) (, ,) (NP (CD three) (NNS patients)) (VP (VBD developed) (NP (NP (NNP Doc_9875685_1631_1658_Disease)) (, ,) (SBAR (WHPP (IN of) (WHNP (WDT which))) (S (NP (PRP one)) (VP (VBD presented) (PP (IN with) (NP (NP (DT an) (NN Doc_9875685_1691_1704_Disease)) (PP (IN of) (NP (JJ -30) (NNS dB))))) (, ,) (SBAR (IN whereas) (S (PP (IN in) (NP (DT the) (NN OD) (NN group))) (NP (QP (RB only) (CD one)) (NN patient)) (VP (VBD presented) (NP (NNP Doc_9875685_1767_1794_Disease)))))))))) (. .)))
9875685	14	(S1 (S (NP (DT This) (JJ small) (NN study)) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NP (DT a) (JJ once-daily) (NN dosing) (NN regimen)) (PP (IN of) (NP (NNP Doc_9875685_1870_1880_Chemical)))) (VP (VP (AUX is) (ADJP (ADVP (IN at) (JJS least)) (RB as) (JJ effective) (RB as))) (CC and) (VP (AUX is) (ADJP (ADJP (ADJP (RB no) (JJR more)) (CC and) (ADJP (ADVP (RB possibly)) (RBR less) (JJ toxic))) (PP (IN than) (NP (DT the) (JJ twice-daily) (NN regimen))))))))) (. .)))
9875685	15	(S1 (S (S (S (VP (VBG Using) (NP (DT a) (JJ single-dose) (NN therapy)))) (, ,) (NP (JJ peak) (NN concentration) (NN determination)) (VP (AUX is) (RB not) (ADJP (JJ necessary)))) (, ,) (S (NP (JJ only) (NN trough) (NNS samples)) (VP (MD should) (VP (AUX be) (VP (VBN monitored) (S (VP (TO to) (VP (VB ensure) (NP (NP (NNS levels)) (PP (IN below) (NP (CD 2) (NN microg/ml))))))))))) (. .)))
9915601	0	(S1 (S (NP (JJ Enhanced) (NN Doc_9915601_9_20_Disease)) (VP (VBN induced) (PP (IN by) (NP (NP (JJ beta-adrenoceptor) (NNS antagonists)) (PP (IN in) (NP (NP (NNS rats)) (VP (VBN pretreated) (PP (IN with) (NP (NNP Doc_9915601_86_95_Chemical))))))))) (. .)))
9915601	1	(S1 (S (NP (NP (JJ High) (NNS doses)) (PP (IN of) (NP (NNP Doc_9915601_111_120_Chemical)))) (VP (VP (VB increase) (NP (NP (NN Doc_9915601_130_141_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNS vasodilators)))))) (CC and) (VP (VB change) (NP (NP (DT the) (JJ accompanying) (JJ reflex) (NN Doc_9915601_201_212_Disease)) (PP (TO to) (NP (NP (NNP Doc_9915601_216_227_Disease)) (, ,) (NP (NP (DT an) (NN interaction)) (VP (VBN attributed) (PP (TO to) (NP (NP (VBN decreased) (NN synthesis)) (PP (IN of) (NP (NP (NN brain) (NNP Doc_9915601_287_310_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9915601_312_316_Chemical)) (-RRB- -RRB-))))))))))))) (. .)))
9915601	2	(S1 (S (PP (IN In) (NP (DT the) (JJ present) (NN study))) (, ,) (NP (NP (DT the) (JJ possible) (NN enhancement)) (PP (IN by) (NP (NP (NNP Doc_9915601_369_378_Chemical)) (PP (IN of) (NP (NNP Doc_9915601_382_393_Disease))))) (VP (VBN induced) (PP (IN by) (NP (JJ beta-adrenoceptor) (NNS antagonists))))) (VP (AUX was) (VP (VBN determined) (PP (IN in) (NP (NP (NNS rats)) (VP (VBN anaesthetised) (PP (IN with) (NP (NNP Doc_9915601_477_487_Chemical-Doc_9915601_488_496_Chemical)))))))) (. .)))
9915601	3	(S1 (S (NP (NN Doc_9915601_498_507_Chemical)) (ADVP (RB significantly)) (VP (VBD increased) (NP (NNP Doc_9915601_532_543_Disease)) (PP (PP (IN after) (NP (NNP Doc_9915601_550_561_Chemical) (, ,) (NNP Doc_9915601_563_571_Chemical) (, ,) (NNP Doc_9915601_573_582_Chemical) (CC and) (NNP Doc_9915601_587_595_Chemical))) (, ,) (CONJP (RB as) (RB well) (IN as)) (PP (IN after) (NP (NNP Doc_9915601_614_623_Chemical))) (, ,) (CONJP (CC but) (RB not)) (PP (IN after) (NP (NP (NNP Doc_9915601_639_652_Chemical)) (CC or) (NP (NNP Doc_9915601_656_665_Chemical)))))) (. .)))
9915601	4	(S1 (S (NP (NN Enhancement)) (VP (AUX was) (RB not) (VP (VBN observed) (PP (IN in) (NP (NP (NNS rats)) (VP (VP (VBN pretreated) (PP (IN with) (NP (NNP Doc_9915601_720_734_Chemical)))) (CC or) (VP (ADVP (RB previously)) (VBN vagotomised))))))) (. .)))
9915601	5	(S1 (S (NP (DT These) (NNS results)) (VP (AUX are) (ADJP (JJ compatible) (PP (IN with) (NP (NP (NN interference)) (PP (IN by) (NP (NNP Doc_9915601_812_821_Chemical))) (PP (IN with) (NP (NP (JJ GABAergic) (NN inhibition)) (PP (IN of) (NP (JJ cardiac) (JJ parasympathetic) (NN tone))))))))) (. .)))
9915601	6	(S1 (S (NP (JJ Such) (NN interference)) (VP (MD could) (VP (AUX be) (VP (VBN exerted) (ADVP (RB centrally)) (, ,) (PP (ADVP (RB possibly)) (PP (IN at) (NP (DT the) (NN nucleus) (NN ambiguus))) (, ,) (CC or) (ADVP (RB peripherally)) (PP (IN at) (NP (DT the) (JJ sinus) (NN node))))))) (. .)))
9952311	0	(S1 (NP (NP (NP (NN Doc_9952311_0_52_Disease)) (PP (IN in) (NP (NP (NNP Doc_9952311_56_66_Chemical-induced) (NNP Doc_9952311_75_89_Disease)) (PP (IN in) (NP (NNS mice)))))) (: :) (NP (NP (NN suppression)) (PP (IN of) (NP (JJ cytochrome) (NNP c) (FW oxidase) (NNP II) (NN gene) (NN expression)))) (. .)))
9952311	1	(S1 (S (NP (NP (DT The) (NN use)) (PP (IN of) (NP (NP (NNP Doc_9952311_166_176_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9952311_178_181_Chemical)) (-RRB- -RRB-)))) (PP (IN in) (NP (NNP Doc_9952311_186_192_Disease) (CD chemotherapy)))) (VP (AUX has) (VP (AUX been) (VP (VBN limited) (PP (JJ due) (TO to) (NP (PRP$ its) (JJ cumulative) (NN Doc_9952311_245_268_Disease)))))) (. .)))
9952311	2	(S1 (S (NP (NP (JJR Earlier) (NNS observations)) (SBAR (WHNP (WDT that)) (S (NP (NNP Doc_9952311_296_299_Chemical)) (VP (VP (VBZ interacts) (PP (IN with) (NP (NP (JJ mitochondrial) (JJ cytochrome) (NN c) (NN oxidase)) (PRN (-LRB- -LRB-) (NP (NNP COX)) (-RRB- -RRB-))))) (CC and) (VP (VBZ suppresses) (NP (PRP$ its) (JJ enzyme) (NN activity))))))) (VP (VBD led) (S (NP (PRP us)) (VP (TO to) (VP (VB investigate) (NP (NP (NP (NNP ADR) (POS 's)) (NN action)) (PP (IN on) (NP (NP (DT the) (JJ cardiovascular) (NNS functions)) (CC and) (NP (NP (NN heart) (JJ mitochondrial) (NN morphology)) (PP (IN in) (NP (NP (JJ Balb-c) (NNS mice)) (VP (ADVP (RB i.p.)) (VBN treated) (PP (IN with) (NP (NNP Doc_9952311_526_529_Chemical))) (PP (IN for) (NP (JJ several) (NNS weeks)))))))))))))) (. .)))
9952311	3	(S1 (S (PP (IN At) (NP (NP (JJ various) (NNS times)) (PP (IN during) (NP (NN treatment))))) (, ,) (NP (DT the) (NNS animals)) (VP (AUX were) (VP (VBN assessed) (PP (PP (IN for) (NP (NP (JJ cardiovascular) (NNS functions)) (PP (IN by) (NP (NN electrocardiography))))) (CC and) (PP (IN for) (NP (NP (NN heart) (NN tissue) (NN damage)) (PP (IN by) (NP (NNP electron) (CD microscopy)))))))) (. .)))
9952311	4	(S1 (S (PP (IN In) (NP (NN parallel))) (, ,) (NP (JJ total) (NNP RNA)) (VP (VP (AUX was) (VP (VBN extracted) (PP (IN from) (NP (NP (NNS samples)) (PP (IN of) (NP (VBN dissected) (NN heart))))))) (CC and) (VP (VBD analyzed) (PP (IN by) (NP (NNP Northern) (NNP blot) (NN hybridization))) (S (VP (TO to) (VP (VB determine) (NP (NP (DT the) (JJ steady-state) (NN level)) (PP (IN of) (NP (NP (CD three) (NNP RNA) (NNS transcripts)) (VP (VBN encoded) (PP (IN by) (NP (DT the) (NNP COXII) (, ,) (NNP COXIII) (, ,) (CC and) (NNP COXIV) (NNS genes)))))))))))) (. .)))
9952311	5	(S1 (S (ADVP (RB Similarly)) (, ,) (NP (NP (NNS samples)) (VP (VBN obtained) (PP (IN from) (NP (NP (DT the) (NN liver)) (PP (IN of) (NP (DT the) (JJ same) (NNS animals))))))) (VP (AUX were) (VP (VBN analyzed) (PP (IN for) (NP (JJ comparative) (NNS studies))))) (. .)))
9952311	6	(S1 (S (NP (PRP$ Our) (NNS results)) (VP (VBD indicated) (SBAR (IN that) (S (NP (CD 1)) (-RRB- -RRB-) (S (NP (NP (NN treatment)) (PP (IN of) (NP (NP (NNS mice)) (PP (IN with) (NP (NNP Doc_9952311_1090_1093_Chemical)))))) (VP (VBD caused) (SBAR (S (NP (NNP Doc_9952311_1101_1127_Disease)) (VP (VBD characterized) (PP (IN by) (NP (NP (NNP Doc_9952311_1145_1156_Disease)) (, ,) (NP (NP (NN extension)) (PP (IN of) (NP (NP (JJ ventricular) (NN depolarization) (NN time)) (PRN (-LRB- -LRB-) (NP (NNS tQRS)) (-RRB- -RRB-)) (, ,) (CC and) (NP (NN failure)))) (PP (IN of) (NP (NNS QRS)))))) (PP (IN at) (NP (JJ high) (NNS concentrations))) (PRN (-LRB- -LRB-) (NP (QP (CD 10-14) (CD mg/kg)) (NN body) (NN weight)) (NP (JJ cumulative) (NN dose)) (-RRB- -RRB-))))))) (: ;) (S (LST (LS 2) (-RRB- -RRB-)) (NP (DT the) (NN heart) (NN mitochondria)) (VP (VBD underwent) (NP (NP (NNP Doc_9952311_1332_1340_Disease) (, ,) (NN fusion) (, ,) (NN dissolution) (, ,) (JJ and/or) (NN disruption)) (PP (IN of) (NP (JJ mitochondrial) (NNS cristae)))) (PP (IN after) (NP (NP (JJ several) (NNS weeks)) (PP (IN of) (NP (NN treatment)))))))))) (. .)))
9952311	7	(S1 (S (NP (JJ Such) (NNS abnormalities)) (VP (AUX were) (RB not) (VP (VBN observed) (PP (IN in) (NP (NP (DT the) (NN mitochondria)) (PP (IN of) (NP (NN liver) (NN tissue))))) (PRN (: ;) (CC and) (NP (CD 3)) (-RRB- -RRB-)) (SBAR (IN among) (S (NP (NP (DT the) (CD three) (NNS genes)) (PP (IN of) (NP (NNP COX) (NN enzyme)))) (VP (VBD examined) (, ,) (SBAR (S (NP (QP (RB only) (CD COXII)) (NN gene) (NN expression)) (VP (AUX was) (VP (VBN suppressed) (PP (IN by) (NP (JJ Doc_9952311_1612_1615_Chemical) (NN treatment))))))) (, ,) (PP (ADVP (RB mainly)) (IN after) (NP (NP (CD 8) (NNS weeks)) (PP (IN in) (NP (DT both) (NN heart) (CC and) (NN liver)))))))))) (. .)))
9952311	8	(S1 (S (S (VP (VBG Knowing) (SBAR (IN that) (S (NP (NN heart) (NNS mitochondria)) (VP (VBP represent) (NP (NP (QP (RB almost) (CD 40)) (NN %)) (PP (IN of) (NP (NN heart) (NN muscle)))) (PP (IN by) (NP (NN weight)))))))) (, ,) (NP (PRP we)) (VP (VBP conclude) (SBAR (IN that) (S (NP (NP (DT the) (JJ deteriorating) (NNS effects)) (PP (IN of) (NP (NNP Doc_9952311_1799_1802_Chemical))) (PP (IN on) (NP (JJ cardiovascular) (NN function)))) (VP (VBP involve) (NP (NN Doc_9952311_1838_1888_Disease)))))) (. .)))
